PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Anderluh, G; Dalla Serra, M; Viero, G; Guella, G; Macek, P; Menestrina, G				Anderluh, G; Dalla Serra, M; Viero, G; Guella, G; Macek, P; Menestrina, G			Pore formation by equinatoxin II, a eukaryotic protein toxin, occurs by induction of nonlamellar lipid structures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA-ANEMONE; FORMING TOXIN; INFRARED-SPECTROSCOPY; SECONDARY STRUCTURE; BILAYER-MEMBRANES; STICHOLYSIN-I; CYTOLYSIN; MECHANISM; VESICLES; PEPTIDE	Pore formation in the target cell membranes is a common mechanism used by many toxins in order to kill cells. Among various described mechanisms, a toroidal pore concept was described recently in the course of action of small antimicrobial peptides. Here we provide evidence that such mechanism may be used also by larger toxins. Membrane-destabilizing effects of equinatoxin II, a sea anemone cytolysin, were studied by various biophysical techniques. P-31 NMR showed an occurrence of an isotropic component when toxin was added to multilamellar vesicles and heated. This component was not observed with melittin, alpha-staphylococcal toxin, or myoglobin. It does not originate from isolated small lipid structures, since the size of the vesicles after the experiment was similar to the control without toxin. Electron microscopy shows occurrence of a honeycomb structure, previously observed only for some particular lipid mixtures. The analysis of FTIR spectra of the equinatoxin II-lipid complex showed lipid disordering that is consistent with isotropic component observed in NMR. Finally, the cation selectivity of the toxin-induced pores increased in the presence of negatively charged phosphatidic acid, indicating the presence of lipids in the conductive channel. The results are compatible with the toroidal pore concept that might be a general mechanism of pore formation for various membrane-interacting proteins or peptides.	ITC, CNR, Inst Biophys, Sect Trento, I-38050 Trento, Italy; Univ Ljubljana, Biotech Fac, Dept Biol, Ljubljana 1000, Slovenia; Univ Trent, Dept Phys, Bioorgan Chem Lab, I-38050 Trento, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biofisica (IBF-CNR); Istituto per le Tecnologie della Costruzione (ITC-CNR); University of Ljubljana; University of Trento	Menestrina, G (corresponding author), ITC, CNR, Inst Biophys, Sect Trento, Via Sommarive 18, I-38050 Trento, Italy.	menes@itc.it	Anderluh, Gregor/C-6905-2014; Viero, Gabriella/G-2096-2012; Graziano, Guella/A-6283-2010; Serra, Mauro Dalla/A-6218-2010; Maček, Peter/Y-9877-2019; Serra, Mauro Dalla/AAK-9299-2021; Maček, Peter/U-4662-2017	Anderluh, Gregor/0000-0002-9916-8465; Viero, Gabriella/0000-0002-6755-285X; Graziano, Guella/0000-0002-1799-0819; Serra, Mauro Dalla/0000-0003-1048-2739; Maček, Peter/0000-0001-6470-7759; Serra, Mauro Dalla/0000-0003-1048-2739; Maček, Peter/0000-0001-6470-7759				Anderluh G, 1997, PROTEIN ENG, V10, P751, DOI 10.1093/protein/10.7.751; Anderluh G, 1999, EUR J BIOCHEM, V263, P128, DOI 10.1046/j.1432-1327.1999.00477.x; Anderluh G, 2002, TOXICON, V40, P111, DOI 10.1016/S0041-0101(01)00191-X; Athanasiadis A, 2001, STRUCTURE, V9, P341, DOI 10.1016/S0969-2126(01)00592-5; Axelsen PH, 1995, BIOPHYS J, V69, P2770, DOI 10.1016/S0006-3495(95)80150-5; Basanez G, 2002, J BIOL CHEM, V277, P49360, DOI 10.1074/jbc.M206069200; Bechinger B, 1999, BIOPOLYMERS, V51, P174, DOI 10.1002/(SICI)1097-0282(1999)51:3<174::AID-BIP2>3.0.CO;2-7; BELMONTE G, 1994, BBA-BIOMEMBRANES, V1192, P197, DOI 10.1016/0005-2736(94)90119-8; BELMONTE G, 1993, J MEMBRANE BIOL, V131, P11, DOI 10.1007/BF02258530; Bonev BB, 2003, BIOPHYS J, V84, P2382, DOI 10.1016/S0006-3495(03)75044-9; Chugh JK, 2001, BIOCHEM SOC T, V29, P565, DOI 10.1042/BST0290565; de los Rios V, 1999, FEBS LETT, V455, P27, DOI 10.1016/S0014-5793(99)00846-7; DEKRUIJFF B, 1979, BIOCHIM BIOPHYS ACTA, V555, P200, DOI 10.1016/0005-2736(79)90160-3; DUFOURCQ J, 1986, BIOCHIM BIOPHYS ACTA, V859, P33, DOI 10.1016/0005-2736(86)90315-9; Epand RM, 1998, BBA-REV BIOMEMBRANES, V1376, P353, DOI 10.1016/S0304-4157(98)00015-X; Ferreras M, 1998, BBA-BIOMEMBRANES, V1414, P108, DOI 10.1016/S0005-2736(98)00160-6; FORTI S, 1989, EUR J BIOCHEM, V181, P767, DOI 10.1111/j.1432-1033.1989.tb14790.x; Goormaghtigh E, 1999, BBA-REV BIOMEMBRANES, V1422, P105, DOI 10.1016/S0304-4157(99)00004-0; Grigoriev PA, 2000, IUBMB LIFE, V50, P227; Harrick N.J., 1967, INTERNAL REFLECTION; Heller WT, 1998, BIOCHEMISTRY-US, V37, P17331, DOI 10.1021/bi981314q; Heuck AP, 2001, BIOCHEMISTRY-US, V40, P9065, DOI 10.1021/bi0155394; Hinds MG, 2002, J MOL BIOL, V315, P1219, DOI 10.1006/jmbi.2001.5321; Hong Q, 2002, J BIOL CHEM, V277, P41916, DOI 10.1074/jbc.M204625200; Hori Y, 1999, FEBS LETT, V455, P228, DOI 10.1016/S0014-5793(99)00881-9; HUBNER W, 1991, BIOPHYS J, V59, P1261, DOI 10.1016/S0006-3495(91)82341-4; KAYALAR C, 1986, BIOCHIM BIOPHYS ACTA, V860, P51, DOI 10.1016/0005-2736(86)90497-9; Lesieur C, 1997, MOL MEMBR BIOL, V14, P45, DOI 10.3109/09687689709068435; Liu F, 2001, BIOCHEMISTRY-US, V40, P760, DOI 10.1021/bi001942j; Lohner K, 1999, BIOCHEMISTRY-US, V38, P16514, DOI 10.1021/bi9913101; MACEK P, 1988, TOXICON, V26, P441, DOI 10.1016/0041-0101(88)90183-3; Malovrh P, 2000, BIOCHEM J, V346, P223, DOI 10.1042/0264-6021:3460223; Malovrh P, 2003, J BIOL CHEM, V278, P22678, DOI 10.1074/jbc.M300622200; Matsuzaki K, 1998, BBA-REV BIOMEMBRANES, V1376, P391, DOI 10.1016/S0304-4157(98)00014-8; Matsuzaki K, 1998, BIOCHEMISTRY-US, V37, P11856, DOI 10.1021/bi980539y; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; Menestrina G, 2000, METH MOL B, V145, P115; Menestrina G, 1999, BIOCHEM BIOPH RES CO, V254, P174, DOI 10.1006/bbrc.1998.9898; Menestrina G., 2003, PORE FORMING PEPTIDE; Muller E, 1996, BIOPHYS J, V71, P1400, DOI 10.1016/S0006-3495(96)79342-6; Pereira FB, 1999, CHEM PHYS LIPIDS, V103, P11, DOI 10.1016/S0009-3084(99)00087-0; Pott T, 1998, EUR BIOPHYS J BIOPHY, V27, P237, DOI 10.1007/s002490050130; RANCE M, 1983, J MAGN RESON, V52, P221, DOI 10.1016/0022-2364(83)90190-7; Santos NC, 1996, BIOPHYS J, V71, P1641, DOI 10.1016/S0006-3495(96)79369-4; SEDDON JM, 1990, BIOCHIM BIOPHYS ACTA, V1031, P1, DOI 10.1016/0304-4157(90)90002-T; Shai Y, 2001, PEPTIDES, V22, P1629, DOI 10.1016/S0196-9781(01)00498-3; SIEGEL DP, 1984, BIOPHYS J, V45, P399, DOI 10.1016/S0006-3495(84)84164-8; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; TAMM LK, 1993, BIOCHEMISTRY-US, V32, P7720, DOI 10.1021/bi00081a017; Tamm LK, 1997, Q REV BIOPHYS, V30, P365, DOI 10.1017/S0033583597003375; Tejuca M, 2001, J MEMBRANE BIOL, V183, P125, DOI 10.1007/s00232-001-0060-y; Tejuca M, 1996, BIOCHEMISTRY-US, V35, P14947, DOI 10.1021/bi960787z; Valcarcel CA, 2001, BIOPHYS J, V80, P2761, DOI 10.1016/S0006-3495(01)76244-3; van der Goot F, 2001, PORE FORMING TOXINS; VARANDA W, 1980, J MEMBRANE BIOL, V55, P203, DOI 10.1007/BF01869461; Yang L, 2001, BIOPHYS J, V81, P1475, DOI 10.1016/S0006-3495(01)75802-X; Yeagle PL, 1997, CURR TOP MEMBR, V44, P375; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a; [No title captured]	59	116	117	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45216	45223		10.1074/jbc.M305916200	http://dx.doi.org/10.1074/jbc.M305916200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12944411	hybrid			2022-12-25	WOS:000186452300022
J	Monleon, D; Moreno-Murciano, MP; Kovacs, H; Marcinkiewicz, C; Calvete, JJ; Celda, B				Monleon, D; Moreno-Murciano, MP; Kovacs, H; Marcinkiewicz, C; Calvete, JJ; Celda, B			Concerted motions of the integrin-binding loop and the C-terminal tail of the non-RGD disintegrin obtustatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-AGGREGATION INHIBITOR; CROSS-RELAXATION RATES; GLYCOPROTEIN-IIB-IIIA; HETERODIMERIC DISINTEGRIN; 3-DIMENSIONAL STRUCTURE; ALPHA-V-BETA-3 INTEGRINS; PROTEIN DYNAMICS; NMR RELAXATION; ECHISTATIN; VENOM	Obtustatin is a potent and selective inhibitor of the alpha(1)beta(1) integrin in vitro and of angiogenesis in vivo. It possesses an integrin recognition loop that harbors, in a lateral position, the inhibitory (KTS23)-K-21 motif. We report an analysis of the dynamics of the backbone and side-chain atoms of obtustatin by homonuclear NMR methods. Angular mobility has been calculated for 90 assigned cross-peaks from 22 off-resonance rotating frame nuclear Overhauser effect spectroscopy spectra recorded at three magnetic fields. Our results suggest that the integrin binding loop and the C-terminal tail display concerted motions, which can be interpreted by hinge effects. Among the integrin-binding motif, threonine 22 and serine 23 exhibit the lowest and the highest side-chain flexibility, respectively. It is noteworthy that the side chain of threonine 22 is not solvent-exposed, although based on synthetic peptides it appears to be the most critical residue for the inhibitory activity of obtustatin on the binding of integrin alpha(1)beta(1) to collagen IV. Instead, the side chain of threonine 22 is oriented toward the loop center and hydrogen-bonded to residues Thr(25) and Ser(26). This network of interactions explains the restrained mobility of threonine 22 and suggests that its functional importance lies in maintaining the active conformation of the alpha(1)beta(1) inhibitory loop.	Consejo Super Invest Cient, Inst Biomed Valencia, Valencia 46010, Spain; Univ Valencia, Dept Quim Fis, E-46100 Valencia, Spain; Univ Valencia, Serv Cent Soporte Invest Expt, E-46100 Valencia, Spain; Bruker Biospin AG, CH-8117 Fallanden, Switzerland; Temple Univ, Coll Sci & Technol, Ctr Biotechnol, Philadelphia, PA 19122 USA	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biomedicina de Valencia (IBV); University of Valencia; University of Valencia; Bruker Corporation; Bruker BioSpin GmbH; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Calvete, JJ (corresponding author), Consejo Super Invest Cient, Inst Biomed Valencia, Jaume Roig 11, Valencia 46010, Spain.		Calvete, Juan J/K-9619-2014; Monleon, Daniel/GNP-4083-2022; Moreno-Murciano, Paz/D-7871-2018; Monleon, Daniel/A-5078-2010; Moreno, Paz/K-6870-2012; Calvete, Juan/P-2555-2019	Calvete, Juan J/0000-0001-5026-3122; Monleon, Daniel/0000-0002-4803-1573; Monleon, Daniel/0000-0002-4803-1573; Calvete, Juan/0000-0001-5026-3122				ADLER M, 1991, SCIENCE, V253, P445, DOI 10.1126/science.1862345; ADLER M, 1992, BIOCHEMISTRY-US, V31, P1031, DOI 10.1021/bi00119a011; Bernado P, 2002, J BIOMOL NMR, V23, P139, DOI 10.1023/A:1016359412284; Birlirakis N., 1996, BRUKER REPORT, V142, P34; BROCKEL C, 1992, BIOCHIM BIOPHYS ACTA, V1122, P196, DOI 10.1016/0167-4838(92)90324-7; BRUSCHWEILER R, 1992, J AM CHEM SOC, V114, P2289, DOI 10.1021/ja00033a002; BURGEN ASV, 1975, NATURE, V253, P753, DOI 10.1038/253753a0; Calvete JJ, 2003, BIOCHEM J, V372, P725, DOI 10.1042/BJ20021739; Calvete JJ, 2002, BIOCHEMISTRY-US, V41, P2014, DOI 10.1021/bi015627o; CALVETE JJ, 1991, BIOCHEMISTRY-US, V30, P5225, DOI 10.1021/bi00235a016; CHEN Y, 1994, J BIOMOL NMR, V4, P307; DENNIS MS, 1993, PROTEINS, V15, P312, DOI 10.1002/prot.340150308; Fischer MWF, 1998, PROG NUCL MAG RES SP, V33, P207, DOI 10.1016/S0079-6565(98)00023-5; Goddard T. D., 1999, SPARKY 3; Kay LE, 1998, NAT STRUCT BIOL, V5, P513, DOI 10.1038/755; KINI RM, 1992, TOXICON, V30, P265, DOI 10.1016/0041-0101(92)90869-7; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Korzhnev DM, 2001, PROG NUCL MAG RES SP, V38, P197, DOI 10.1016/S0079-6565(00)00028-5; Kuwata K, 1997, J MAGN RESON, V128, P70, DOI 10.1006/jmre.1997.1212; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEMASTER DM, 1988, FEBS LETT, V236, P71, DOI 10.1016/0014-5793(88)80287-4; Malliavin TE, 1999, J MAGN RESON, V140, P189, DOI 10.1006/jmre.1999.1818; Marcinkiewicz C, 2003, CANCER RES, V63, P2020; Marcinkiewicz C, 1999, BIOCHEMISTRY-US, V38, P13302, DOI 10.1021/bi9906930; Marcinkiewicz C, 1999, J BIOL CHEM, V274, P12468, DOI 10.1074/jbc.274.18.12468; Marcinkiewicz C, 1997, BLOOD, V90, P1565, DOI 10.1182/blood.V90.4.1565.1565_1565_1575; McLane MA, 1996, FEBS LETT, V391, P139, DOI 10.1016/0014-5793(96)00716-8; Moreno-Murciano MP, 2003, J MOL BIOL, V329, P135, DOI 10.1016/S0022-2836(03)00371-1; Moreno-Murciano MP, 2003, PROTEIN SCI, V12, P366, DOI 10.1110/ps.0230203; Neuhaus D., 1989, NUCL OVERHAUSER EFFE; PFAFF M, 1994, J BIOL CHEM, V269, P20233; SAUDEK V, 1991, BIOCHEMISTRY-US, V30, P7369, DOI 10.1021/bi00244a003; Schleucher J, 2002, J AM CHEM SOC, V124, P5881, DOI 10.1021/ja012040o; SENN H, 1993, J MOL BIOL, V232, P907, DOI 10.1006/jmbi.1993.1439; Smith KJ, 1996, INT J PEPT PROT RES, V48, P220; WILLIAMS RJP, 1989, EUR J BIOCHEM, V183, P479, DOI 10.1111/j.1432-1033.1989.tb21076.x; WRIGHT PS, 1993, BIOCHEM J, V293, P263, DOI 10.1042/bj2930263; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040	38	34	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45570	45576		10.1074/jbc.M307030200	http://dx.doi.org/10.1074/jbc.M307030200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12947085	hybrid			2022-12-25	WOS:000186452300065
J	Sagara, J; Higuchi, T; Hattori, Y; Moriya, M; Sarvotham, H; Shima, H; Shirato, H; Kikuchi, K; Taniguchi, S				Sagara, J; Higuchi, T; Hattori, Y; Moriya, M; Sarvotham, H; Shima, H; Shirato, H; Kikuchi, K; Taniguchi, S			Scapinin, a putative protein phosphatase-1 regulatory subunit associated with the nuclear nonchromatin structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX PROTEINS; GENE-EXPRESSION; CANCER; CELLS; LEUKEMIA; DIFFERENTIATION; IDENTIFICATION; LOCALIZATION; ORGANIZATION; INTERPHASE	It is thought that the nuclear nonchromatin structures, such as the nuclear matrix and lamina, play regulatory roles in gene expression. In this study, we identified an insoluble protein that was associated with the chromatin-depleted nuclear structure of proliferating human leukemia HL-60 cells. Preparation of the chromatin-depleted nuclear structure, referred to as the nuclear matrix-intermediate filament scaffold (Fey, E., Krochmalnic, G., and Penman, S. (1986) J. Cell. Biol. 102, 1654-1665), involved cell extraction using a series of buffers containing Triton X-100, DNase I, and 2 M NaCl. A yeast two-hybrid assay revealed that this protein bound to the catalytic subunit of protein phosphatase-1 (PP1). Furthermore, it inhibited PP1 activity in vitro. We therefore named it scapinin ((s) under bar caffold-(a) under bar ssociated (P) under bar P1 (in) under bar hibiting prote (in) under bar). cDNA cloning revealed that scapinin had two splicing variants of 448 amino acids (scapinin-S) and 518 amino acids (scapinin-L). Scapinin was down-regulated by differentiation in HL-60 cells. These results suggest that scapinin is a putative regulatory subunit of PP1 and is involved in transformed or immature phenotypes of HL-60 cells. We also describe the presence of scapinin family proteins from worm to human.	Shinshu Univ, Grad Sch Med, Inst Aging & Adaptat, Dept Mol Oncol, Matsumoto, Nagano 3908621, Japan; Hokkaido Univ, Inst Med Genet, Div Biochem Oncol & Immunol, Kita Ku, Sapporo, Hokkaido 0600815, Japan	Shinshu University; Hokkaido University	Sagara, J (corresponding author), Shinshu Univ, Grad Sch Med, Inst Aging & Adaptat, Dept Mol Oncol, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.		Shirato, Hiroki/A-7068-2010					Andreassen PR, 1998, J CELL BIOL, V141, P1207, DOI 10.1083/jcb.141.5.1207; Ayukawa K, 2000, J BIOL CHEM, V275, P34465, DOI 10.1074/jbc.M003673200; BEREZNEY R, 1975, SCIENCE, V189, P291, DOI 10.1126/science.1145202; BIDWELL JP, 1994, CANCER RES, V54, P28; BOLLEN M, 1992, CRIT REV BIOCHEM MOL, V27, P227, DOI 10.3109/10409239209082564; Bollen M, 2001, TRENDS BIOCHEM SCI, V26, P426, DOI 10.1016/S0968-0004(01)01836-9; Boudrez A, 2000, J BIOL CHEM, V275, P25411, DOI 10.1074/jbc.M001676200; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; COHEN P, 1992, TRENDS BIOCHEM SCI, V17, P408, DOI 10.1016/0968-0004(92)90010-7; Cohen PTW, 2002, J CELL SCI, V115, P241; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; FEY EG, 1986, J CELL BIOL, V102, P1654, DOI 10.1083/jcb.102.5.1654; FEY EG, 1988, P NATL ACAD SCI USA, V85, P121, DOI 10.1073/pnas.85.1.121; Getzenberg RH, 1996, CANCER RES, V56, P1690; Holt MR, 2001, TRENDS CELL BIOL, V11, P38, DOI 10.1016/S0962-8924(00)01876-6; KAUFMANN SH, 1992, CANCER RES, V52, P847; KEESEE SK, 1994, P NATL ACAD SCI USA, V91, P1913, DOI 10.1073/pnas.91.5.1913; KHANUJA PS, 1993, CANCER RES, V53, P3394; LEES JF, 1988, EMBO J, V7, P1947, DOI 10.1002/j.1460-2075.1988.tb03032.x; Ma H, 1999, J CELL BIOL, V146, P531, DOI 10.1083/jcb.146.3.531; Ma ZG, 2001, NAT GENET, V28, P220, DOI 10.1038/90054; MACKAY AM, 1993, J CELL BIOL, V123, P373, DOI 10.1083/jcb.123.2.373; Mercher T, 2001, P NATL ACAD SCI USA, V98, P5776, DOI 10.1073/pnas.101001498; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; Oguchi M, 2002, BRIT J DERMATOL, V147, P853, DOI 10.1046/j.1365-2133.2002.04948.x; PAI CY, 1995, J CELL SCI, V108, P1911; PARTIN AW, 1993, CANCER RES, V53, P744; Shirato H, 2000, BIOCHEMISTRY-US, V39, P13848, DOI 10.1021/bi001326n; Steen RL, 2000, J CELL BIOL, V150, P1251, DOI 10.1083/jcb.150.6.1251; Stein GS, 2000, CANCER RES, V60, P2067; Sudol M, 2000, CELL, V103, P1001, DOI 10.1016/S0092-8674(00)00203-8; Tanji C, 2002, J BIOL CHEM, V277, P36955, DOI 10.1074/jbc.M206210200; Thompson LJ, 1997, J BIOL CHEM, V272, P29693, DOI 10.1074/jbc.272.47.29693; Wang DZ, 2001, CELL, V105, P851, DOI 10.1016/S0092-8674(01)00404-4	34	39	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45611	45619		10.1074/jbc.M305227200	http://dx.doi.org/10.1074/jbc.M305227200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12925532	hybrid			2022-12-25	WOS:000186452300070
J	Verrills, NM; Walsh, BJ; Cobon, GS; Hains, PG; Kavallaris, M				Verrills, NM; Walsh, BJ; Cobon, GS; Hains, PG; Kavallaris, M			Proteome analysis of Vinca alkaloid response and resistance in acute lymphoblastic leukemia reveals novel cytoskeletal alterations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2-DIMENSIONAL GEL-ELECTROPHORESIS; HEAT-SHOCK-PROTEIN; RADIATION-INDUCED APOPTOSIS; SCAFFOLD ATTACHMENT FACTOR; RNA DIFFERENTIAL DISPLAY; EPITHELIAL TUMOR-CELLS; NEURONAL PC12 CELLS; MASS-SPECTROMETRY; MULTIDRUG-RESISTANCE; MESSENGER-RNA	Vinca alkaloids are used widely in the treatment of both childhood and adult cancers. Their cellular target is the beta-tubulin subunit of alpha/beta-tubulin heterodimers, and they act to inhibit cell division by disrupting microtubule dynamics. Despite the effectiveness of these agents, drug resistance is a major clinical problem. To identify the underlying mechanisms behind vinca alkaloid resistance, we have performed high resolution differential proteome analysis. Treatment of drug-sensitive human leukemia cells (CCRF-CEM) with vincristine identified numerous proteins involved in the cellular response to vincristine. In addition, differential protein expression was analyzed in leukemia cell lines selected for resistance to vincristine (CEM/VCR R) and vinblastine (CEM/VLB100). This combined proteomic approach identified 10 proteins altered in both vinca alkaloid response and resistance: beta-tubulin, alpha-tubulin, actin, heat shock protein 90beta, 14-3-3tau, 14-3-3epsilon, L-plastin, lamin B1, heterogeneous nuclear ribonuclear protein-F, and heterogeneous nuclear ribonuclear protein-K. Several of these proteins have not previously been associated with drug resistance and are thus novel targets for elucidation of resistance mechanisms. In addition, seven of these proteins are associated with the tubulin and/or actin cytoskeletons. This study provides novel insights into the interrelationship between the microtubule and microfilament systems in vinca alkaloid resistance.	Childrens Canc Inst Australia Med Res, Randwick, NSW 2031, Australia; Macquarie Univ, Australian Proteome Anal Facil, Sydney, NSW 2109, Australia	Children's Cancer Institute; Macquarie University	Kavallaris, M (corresponding author), Childrens Canc Inst Australia Med Res, High St,POB 81, Randwick, NSW 2031, Australia.		Hains, Peter/HIK-2945-2022; Kavallaris, Maria/J-5240-2014; Hains, Peter G/E-6089-2015	Hains, Peter G/0000-0002-7276-1760; Walsh, Brad/0000-0003-3571-4399; Verrills, Nicole/0000-0002-7894-0137				AHMAD S, 1990, MOL CELL BIOL, V10, P5160, DOI 10.1128/MCB.10.10.5160; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BECK WT, 1986, CANCER RES, V46, P778; Beere HM, 2001, TRENDS CELL BIOL, V11, P6, DOI 10.1016/S0962-8924(00)01874-2; Bobinnec Y, 1998, J CELL BIOL, V143, P1575, DOI 10.1083/jcb.143.6.1575; BOGGS B, 1987, MOL CELL BIOL, V7, P2700, DOI 10.1128/MCB.7.8.2700; Bomsztyk K, 1997, FEBS LETT, V403, P113, DOI 10.1016/S0014-5793(97)00041-0; BOUCHER D, 1994, BIOCHEMISTRY-US, V33, P12471, DOI 10.1021/bi00207a014; Brockstedt E, 1998, J BIOL CHEM, V273, P28057, DOI 10.1074/jbc.273.43.28057; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Burkhart C.A., 2001, BIOCHIM BIOPHYS ACTA, V1471, P1; CABRAL F, 1981, P NATL ACAD SCI-BIOL, V78, P4388, DOI 10.1073/pnas.78.7.4388; CORDWELL SJ, 1995, ELECTROPHORESIS, V16, P438, DOI 10.1002/elps.1150160171; daSilva CP, 1996, BIOCHEM PHARMACOL, V51, P1331, DOI 10.1016/0006-2952(96)00041-X; Drukman S, 2002, INT J ONCOL, V21, P621; FOWLER VM, 1990, J CELL BIOL, V111, P471, DOI 10.1083/jcb.111.2.471; Gachet Y, 1999, J CELL SCI, V112, P1257; Galigniana MD, 2001, J BIOL CHEM, V276, P14884, DOI 10.1074/jbc.M010809200; Garnier C, 1998, BIOCHEM BIOPH RES CO, V250, P414, DOI 10.1006/bbrc.1998.9319; Garrido C, 2001, BIOCHEM BIOPH RES CO, V286, P433, DOI 10.1006/bbrc.2001.5427; Gohla A, 2002, CURR BIOL, V12, P1704, DOI 10.1016/S0960-9822(02)01184-3; Gohring F, 1997, EMBO J, V16, P7361, DOI 10.1093/emboj/16.24.7361; Goldberg M, 1999, CRIT REV EUKAR GENE, V9, P285, DOI 10.1615/CritRevEukarGeneExpr.v9.i3-4.130; Gotzmann J, 2000, CELL DEATH DIFFER, V7, P425, DOI 10.1038/sj.cdd.4400668; HABER M, 1989, CANCER RES, V49, P5281; Haber M, 1995, J BIOL CHEM, V270, P31269, DOI 10.1074/jbc.270.52.31269; Hashiguchi M, 2000, J BIOL CHEM, V275, P25247, DOI 10.1074/jbc.M003738200; Higuchi Y, 1998, BIOCHEM BIOPH RES CO, V248, P597, DOI 10.1006/bbrc.1998.8978; Hisano T, 1996, FEBS LETT, V397, P101, DOI 10.1016/S0014-5793(96)01150-7; Huang YH, 2002, PROTEOMICS, V2, P1220, DOI 10.1002/1615-9861(200209)2:9<1220::AID-PROT1220>3.0.CO;2-3; Ishikawa T, 2000, CLIN CHEM LAB MED, V38, P893, DOI 10.1515/CCLM.2000.130; JASMIN BJ, 1990, NATURE, V344, P673, DOI 10.1038/344673a0; Jordan A, 1998, MED RES REV, V18, P259, DOI 10.1002/(SICI)1098-1128(199807)18:4<259::AID-MED3>3.3.CO;2-T; JORDAN MA, 1985, CANCER RES, V45, P2741; Jordan MA, 1998, CURR OPIN CELL BIOL, V10, P123, DOI 10.1016/S0955-0674(98)80095-1; Kavallaris M, 1997, ANTI-CANCER DRUG, V8, P17, DOI 10.1097/00001813-199701000-00002; Kavallaris M, 2001, CANCER RES, V61, P5803; Kavallaris M, 1997, J CLIN INVEST, V100, P1282, DOI 10.1172/JCI119642; Khan IA, 2003, INVEST NEW DRUG, V21, P3, DOI 10.1023/A:1022946305242; Kipp M, 2000, J BIOL CHEM, V275, P5031, DOI 10.1074/jbc.275.7.5031; KIRBY BA, 1994, J NEUROSCI, V14, P5687; KOYASU S, 1986, P NATL ACAD SCI USA, V83, P8054, DOI 10.1073/pnas.83.21.8054; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; Kulms D, 2002, CELL DEATH DIFFER, V9, P598, DOI 10.1038/sj.cdd.4401002; Larsen MR, 2001, ELECTROPHORESIS, V22, P566, DOI 10.1002/1522-2683(200102)22:3<566::AID-ELPS566>3.0.CO;2-T; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; Liang P, 1997, J CELL SCI, V110, P1431; Lin CS, 1998, DNA CELL BIOL, V17, P1041, DOI 10.1089/dna.1998.17.1041; Littlefield R, 1998, ANNU REV CELL DEV BI, V14, P487, DOI 10.1146/annurev.cellbio.14.1.487; Littlefield R, 2001, NAT CELL BIOL, V3, P544, DOI 10.1038/35078517; Luduena RF, 1998, INT REV CYTOL, V178, P207; MACEJAK DG, 1991, VIRUS RES, V19, P31, DOI 10.1016/0168-1702(91)90092-A; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; Moller A, 2002, PROTEOMICS, V2, P697, DOI 10.1002/1615-9861(200206)2:6<697::AID-PROT697>3.0.CO;2-F; Ostareck-Lederer A, 2002, MOL CELL BIOL, V22, P4535, DOI 10.1128/MCB.22.13.4535-4543.2002; PEATTIE DA, 1992, P NATL ACAD SCI USA, V89, P10974, DOI 10.1073/pnas.89.22.10974; Percipalle P, 2002, NUCLEIC ACIDS RES, V30, P1725, DOI 10.1093/nar/30.8.1725; Percipalle P, 2001, J CELL BIOL, V153, P229, DOI 10.1083/jcb.153.1.229; PERROTAPPLANAT M, 1995, J CELL SCI, V108, P2037; Prasad S, 1998, INT J ONCOL, V13, P757; Prasad SC, 1999, ELECTROPHORESIS, V20, P1065, DOI 10.1002/(SICI)1522-2683(19990101)20:4/5<1065::AID-ELPS1065>3.3.CO;2-D; Prasad SC, 1998, BIOCHEM BIOPH RES CO, V249, P332, DOI 10.1006/bbrc.1998.9137; Pui CH, 1998, NEW ENGL J MED, V339, P605, DOI 10.1056/NEJM199808273390907; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; Rao S, 2001, BIOCHEMISTRY-US, V40, P2096, DOI 10.1021/bi002323d; Roach MC, 1998, CELL MOTIL CYTOSKEL, V39, P273; RONINSON IB, 1992, BIOCHEM PHARMACOL, V43, P95, DOI 10.1016/0006-2952(92)90666-7; Rosenbaum J, 2000, CURR BIOL, V10, pR801, DOI 10.1016/S0960-9822(00)00767-3; SANCHEZ C, 1994, ARCH BIOCHEM BIOPHYS, V310, P428, DOI 10.1006/abbi.1994.1188; Sinha P, 1998, J BIOCHEM BIOPH METH, V37, P105, DOI 10.1016/S0165-022X(98)00020-7; Sinha P, 2001, ELECTROPHORESIS, V22, P2990, DOI 10.1002/1522-2683(200108)22:14<2990::AID-ELPS2990>3.0.CO;2-F; Sinha P, 1999, ELECTROPHORESIS, V20, P2952, DOI 10.1002/(SICI)1522-2683(19991001)20:14<2952::AID-ELPS2952>3.0.CO;2-H; Sinha P, 2000, ELECTROPHORESIS, V21, P3048, DOI 10.1002/1522-2683(20000801)21:14<3048::AID-ELPS3048>3.0.CO;2-W; Suzuki T, 2001, CURR DRUG METAB, V2, P367, DOI 10.2174/1389200013338289; Takahashi A, 1999, INT J HEMATOL, V70, P226; Tan S, 2002, INT J CANCER, V98, P523, DOI 10.1002/ijc.10236; Thiede B, 2002, PROTEOMICS, V2, P996, DOI 10.1002/1615-9861(200208)2:8<996::AID-PROT996>3.0.CO;2-3; Vargas-Roig LM, 1998, INT J CANCER, V79, P468, DOI 10.1002/(SICI)1097-0215(19981023)79:5<468::AID-IJC4>3.0.CO;2-Z; Verdier-Pinard P, 2003, BIOCHEMISTRY-US, V42, P5349, DOI 10.1021/bi027293o; Verrills NM, 2003, CURR OPIN MOL THER, V5, P258; Verrills NM, 2000, ELECTROPHORESIS, V21, P3810, DOI 10.1002/1522-2683(200011)21:17<3810::AID-ELPS3810>3.0.CO;2-3; WALLACE W, 1993, MOL BRAIN RES, V19, P149, DOI 10.1016/0169-328X(93)90160-Q; Waterhouse N, 1996, J BIOL CHEM, V271, P29335, DOI 10.1074/jbc.271.46.29335; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Yamazaki Y, 2000, EXP CELL RES, V259, P64, DOI 10.1006/excr.2000.4970; Yarm FR, 2002, MOL CELL BIOL, V22, P6209, DOI 10.1128/MCB.22.17.6209-6221.2002; YENOFSKY R, 1983, MOL CELL BIOL, V3, P1197, DOI 10.1128/MCB.3.7.1197	87	68	76	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45082	45093		10.1074/jbc.M303378200	http://dx.doi.org/10.1074/jbc.M303378200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12949081	hybrid			2022-12-25	WOS:000186452300007
J	Gunaratnam, L; Morley, M; Franovic, A; de Paulsen, N; Mekhail, K; Parolin, DAE; Nakamura, E; Lorimer, IAJ; Lee, S				Gunaratnam, L; Morley, M; Franovic, A; de Paulsen, N; Mekhail, K; Parolin, DAE; Nakamura, E; Lorimer, IAJ; Lee, S			Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL-/- renal cell carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINDAU TUMOR-SUPPRESSOR; UBIQUITIN LIGASE COMPLEX; FACTOR-ALPHA; FAMILIAL PHEOCHROMOCYTOMA; PROLYL HYDROXYLATION/; GERMLINE MUTATIONS; TYROSINE KINASE; GENE-EXPRESSION; CANCER-CELLS; REGULATE HIF	Bi-allelic-inactivating mutations of the VHL tumor suppressor gene are found in the majority of clear cell renal cell carcinomas (VHL-/- RCC). VHL-/- RCC cells overproduce hypoxia-inducible genes as a consequence of constitutive, oxygen-independent activation of hypoxia inducible factor (HIF). While HIF activation explains the highly vascularized nature of VHL loss lesions, the relative role of HIF in oncogenesis and loss of growth control remains unknown. Here, we report that HIF plays a central role in promoting unregulated growth of VHL-/- RCC cells by activating the transforming growth factor-alpha (TGF-alpha)/epidermal growth factor receptor (EGF-R) pathway. Dominant-negative HIF and enzymatic inhibition of EGF-R were equally efficient at abolishing EGF-R activation and serum-independent growth of VHL-/- RCC cells. TGF-alpha is the only known EGF-R ligand that has a VHL-dependent expression profile and its overexpression by VHL-/- RCC cells is a direct consequence of HIF activation. In contrast to TGF-alpha, other HIF targets, including vascular endothelial growth factor ( VEGF), were unable to stimulate serum-independent growth of VHL-/- RCC cells. VHL-/- RCC cells expressing reintroduced type 2C mutants of VHL, and which retain the ability to degrade HIF, fail to overproduce TGF-alpha and proliferate in serum-free media. These data link HIF with the overproduction of a bona fide renal cell mitogen leading to activation of a pathway involved in growth of renal cancer cells. Moreover, our results suggest that HIF might be involved in oncogenesis to a much higher extent than previously appreciated.	Univ Ottawa, Fac Med, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada; Univ Ottawa, Fac Med, Kidney Res Ctr, Ottawa, ON K1H 8M5, Canada; Univ Ottawa, Fac Med, Dept Internal Med, Ottawa, ON K1H 8M5, Canada; Univ Ottawa, Fac Med, Ottawa Reg Canc Ctr, Ottawa, ON K1H 8M5, Canada; Univ Ottawa, Fac Med, Dept Biochem & Immunol, Ottawa, ON K1H 8M5, Canada; Harvard Univ, Dana Farber Canc Inst, Howard Hughes Med Inst, Boston, MA 02115 USA	University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Harvard University; Dana-Farber Cancer Institute; Howard Hughes Medical Institute	Lee, S (corresponding author), Univ Ottawa, Fac Med, Dept Cellular & Mol Med, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.		Gunaratnam, Lakshman/G-3299-2011; Vickers, Michael M/E-4095-2010	Gunaratnam, Lakshman/0000-0002-8845-1126; Mekhail, Karim/0000-0002-6084-020X				ATLAS I, 1992, CANCER RES, V52, P3335; Bonicalzi ME, 2001, J BIOL CHEM, V276, P1407, DOI 10.1074/jbc.M008295200; Bos M, 1997, CLIN CANCER RES, V3, P2099; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Chen F, 1996, J MED GENET, V33, P716, DOI 10.1136/jmg.33.8.716; Chen LN, 1996, SOMAT CELL MOLEC GEN, V22, P477, DOI 10.1007/BF02369439; Ciardiello F, 1998, JNCI-J NATL CANCER I, V90, P1087, DOI 10.1093/jnci/90.14.1087; Clifford SC, 2001, ONCOGENE, V20, P5067, DOI 10.1038/sj.onc.1204602; Clifford SC, 2001, HUM MOL GENET, V10, P1029, DOI 10.1093/hmg/10.10.1029; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; CROSSEY PA, 1995, J MED GENET, V32, P885, DOI 10.1136/jmg.32.11.885; de Paulsen N, 2001, P NATL ACAD SCI USA, V98, P1387, DOI 10.1073/pnas.031587498; DUAN DR, 1995, P NATL ACAD SCI USA, V92, P6459, DOI 10.1073/pnas.92.14.6459; ENG C, 1995, J MED GENET, V32, P934, DOI 10.1136/jmg.32.12.934; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Everitt JI, 1997, MOL CARCINOGEN, V19, P213, DOI 10.1002/(SICI)1098-2744(199707)19:3<213::AID-MC9>3.3.CO;2-W; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; GOMELLA LG, 1989, CANCER RES, V49, P6972; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; Groulx I, 2002, MOL CELL BIOL, V22, P5319, DOI 10.1128/MCB.22.15.5319-5336.2002; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harris RC, 2003, EXP CELL RES, V284, P2, DOI 10.1016/S0014-4827(02)00105-2; Hoffman MA, 2001, HUM MOL GENET, V10, P1019, DOI 10.1093/hmg/10.10.1019; HUMES HD, 1991, LAB INVEST, V64, P538; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Iliopoulos O, 1998, P NATL ACAD SCI USA, V95, P11661, DOI 10.1073/pnas.95.20.11661; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885; Kaelin WG, 1998, J INTERN MED, V243, P535; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Knebelmann B, 1998, CANCER RES, V58, P226; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kondo K, 2001, EXP CELL RES, V264, P117, DOI 10.1006/excr.2000.5139; KOVALENKO M, 1994, CANCER RES, V54, P6106; Koyama S, 1999, BRIT J PHARMACOL, V127, P537, DOI 10.1038/sj.bjp.0702564; Krieg M, 2000, ONCOGENE, V19, P5435, DOI 10.1038/sj.onc.1203938; LAGER DJ, 1994, MODERN PATHOL, V7, P544; Lee DC, 2003, ANN NY ACAD SCI, V995, P22, DOI 10.1111/j.1749-6632.2003.tb03207.x; LEE DC, 1995, PHARMACOL REV, V47, P51; LINEHAN WM, 1995, JAMA-J AM MED ASSOC, V273, P564; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; LOWDEN DA, 1994, J LAB CLIN MED, V124, P386; Luetteke N C, 1990, Semin Cancer Biol, V1, P265; Maemura K, 1999, J BIOL CHEM, V274, P31565, DOI 10.1074/jbc.274.44.31565; Maher ER, 1997, MEDICINE, V76, P381, DOI 10.1097/00005792-199711000-00001; Mandriota SJ, 2002, CANCER CELL, V1, P459, DOI 10.1016/S1535-6108(02)00071-5; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; MYDLO JH, 1989, CANCER RES, V49, P3407; NEUFELD TK, 1992, KIDNEY INT, V41, P1222, DOI 10.1038/ki.1992.184; NEUMANN HPH, 1995, BRAIN PATHOL, V5, P181, DOI 10.1111/j.1750-3639.1995.tb00592.x; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Pause A, 1998, P NATL ACAD SCI USA, V95, P993, DOI 10.1073/pnas.95.3.993; PETRIDES PE, 1990, CANCER RES, V50, P3934; Prewett M, 1998, CLIN CANCER RES, V4, P2957; REIFENBERGER G, 1995, AM J PATHOL, V147, P245; REYNOLDS FH, 1981, NATURE, V292, P259, DOI 10.1038/292259a0; Ritter MM, 1996, J CLIN ENDOCR METAB, V81, P1035, DOI 10.1210/jc.81.3.1035; ROSENTHAL A, 1986, CELL, V46, P301, DOI 10.1016/0092-8674(86)90747-6; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Siemeister G, 1996, CANCER RES, V56, P2299; SMITH JJ, 1987, P NATL ACAD SCI USA, V84, P7567, DOI 10.1073/pnas.84.21.7567; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; van der Harst E, 1998, INT J CANCER, V77, P337, DOI 10.1002/(SICI)1097-0215(19980729)77:3<337::AID-IJC5>3.3.CO;2-C; WATANABE S, 1987, P NATL ACAD SCI USA, V84, P1258, DOI 10.1073/pnas.84.5.1258; Weber KL, 2003, CANCER RES, V63, P2940; Weinberg RA, 1996, SCI AM, V275, P62, DOI 10.1038/scientificamerican0996-62; Wiesener MS, 2001, CANCER RES, V61, P5215; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498; Zbar B, 1996, HUM MUTAT, V8, P348, DOI 10.1002/(SICI)1098-1004(1996)8:4<348::AID-HUMU8>3.0.CO;2-3	80	148	165	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44966	44974		10.1074/jbc.M305502200	http://dx.doi.org/10.1074/jbc.M305502200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12944410	hybrid			2022-12-25	WOS:000186306700133
J	Iizuka, R; Yoshida, T; Shomura, Y; Miki, K; Maruyama, T; Odaka, M; Yohda, M				Iizuka, R; Yoshida, T; Shomura, Y; Miki, K; Maruyama, T; Odaka, M; Yohda, M			ATP binding is critical for the conformational change from an open to closed state in archaeal group II chaperonin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMOCOCCUS STRAIN KS-1; EUKARYOTIC CHAPERONIN; FUNCTIONAL-CHARACTERIZATION; HYPERTHERMOPHILIC ARCHAEUM; CYTOPLASMIC CHAPERONIN; THERMOSOME; TCP-1; HYDROLYSIS; SUBUNITS; DOMAINS	Group II chaperonins, found in archaea and in eukaryotic cytosol, do not have a co-chaperonin corresponding to GroES. Instead, it is suggested that the helical protrusion extending from the apical domain acts as a built-in lid for the central cavity and that the opening and closing of the lid is regulated by ATP binding and hydrolysis. However, details of this conformational change remain unclear. To investigate the conformational change associated with the ATP-driven cycle, we conducted protease sensitivity analyses and tryptophan fluorescence spectroscopy of alpha-chaperonin from a hyperthermophilic archaeum, Thermococcus strain KS-1. In the nucleotide-free or ADP-bound state, the chaperonin, especially in the helical protrusion region, was highly sensitive to proteases. Addition of ATP and ammonium sulfate induced the transition to the relatively protease-resistant form. The fluorescence intensity of the tryptophan residue introduced at the tip of the helical protrusion was enhanced by the presence of ATP or ammonium sulfate. We conclude that ATP binding induces the conformational change from the lid-open to lid-closed form in archaeal group II chaperonin.	Tokyo Univ Agr & Technol, Dept Biotechnol & Life Sci, Tokyo 1848588, Japan; Kyoto Univ, Inst Frontier Med Sci, Dept Mol & Cellular Biol, Sakyo Ku, Kyoto 6068397, Japan; Kyoto Univ, Grad Sch Sci, Dept Chem, Sakyo Ku, Kyoto 6068502, Japan; RIKEN Harima Inst SPring8, Mikazukicho, Hyogo 6795148, Japan; Japan Marine Sci & Technol Ctr, Marine Ecosyst Res Dept, Kanagawa 2370061, Japan; RIKEN, Bioengn Lab, Wako, Saitama 3510198, Japan	Tokyo University of Agriculture & Technology; Kyoto University; Kyoto University; RIKEN; Japan Agency for Marine-Earth Science & Technology (JAMSTEC); RIKEN	Yohda, M (corresponding author), Tokyo Univ Agr & Technol, Dept Biotechnol & Life Sci, 2-24-16 Naka Cho, Tokyo 1848588, Japan.	yohda@cc.tuat.ac.jp	Odaka, Masafumi/C-2378-2013; Yohda, Masafumi/A-5149-2013	Yohda, Masafumi/0000-0001-8307-9671; Iizuka, Ryo/0000-0002-9328-5628				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Ditzel L, 1998, CELL, V93, P125, DOI 10.1016/S0092-8674(00)81152-6; Gutsche I, 2000, CURR BIOL, V10, P405, DOI 10.1016/S0960-9822(00)00421-8; Gutsche I, 2000, J MOL BIOL, V300, P187, DOI 10.1006/jmbi.2000.3833; Gutsche I, 1999, J MOL BIOL, V293, P295, DOI 10.1006/jmbi.1999.3008; Gutsche I, 2001, J STRUCT BIOL, V135, P139, DOI 10.1006/jsbi.2001.4373; Horwich AL, 1998, NAT STRUCT BIOL, V5, P333, DOI 10.1038/nsb0598-333; Iizuka R, 2001, BIOCHEM BIOPH RES CO, V289, P1118, DOI 10.1006/bbrc.2001.6139; Klumpp M, 1998, FEBS LETT, V430, P73, DOI 10.1016/S0014-5793(98)00541-9; Klumpp M, 1997, CELL, V91, P263, DOI 10.1016/S0092-8674(00)80408-0; KUBOTA H, 1995, EUR J BIOCHEM, V230, P3, DOI 10.1111/j.1432-1033.1995.0003i.x; Kusmierczyk AR, 2001, FEBS LETT, V505, P343, DOI 10.1016/S0014-5793(01)02838-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Llorca O, 1999, NAT STRUCT BIOL, V6, P639; Llorca O, 2001, EMBO J, V20, P4065, DOI 10.1093/emboj/20.15.4065; Llorca O, 1998, J BIOL CHEM, V273, P10091, DOI 10.1074/jbc.273.17.10091; Melki R, 1997, BIOCHEMISTRY-US, V36, P5817, DOI 10.1021/bi962830o; Meyer AS, 2003, CELL, V113, P369, DOI 10.1016/S0092-8674(03)00307-6; Ranson NA, 1998, BIOCHEM J, V333, P233, DOI 10.1042/bj3330233; Sambrook J., 2002, MOL CLONING LAB MANU; Schoehn G, 2000, J MOL BIOL, V301, P323, DOI 10.1006/jmbi.2000.3952; Schoehn G, 2000, J MOL BIOL, V296, P813, DOI 10.1006/jmbi.2000.3505; Szpikowska BK, 1998, PROTEIN SCI, V7, P1524, DOI 10.1002/pro.5560070705; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; Yoshida T, 2000, J MOL BIOL, V299, P1399, DOI 10.1006/jmbi.2000.3847; Yoshida T, 2002, FEBS LETT, V514, P269, DOI 10.1016/S0014-5793(02)02377-3; Yoshida T, 2002, MOL MICROBIOL, V44, P761, DOI 10.1046/j.1365-2958.2002.02909.x; Yoshida T, 2002, J MOL BIOL, V315, P73, DOI 10.1006/jmbi.2001.5220; Yoshida T, 1997, J MOL BIOL, V273, P635, DOI 10.1006/jmbi.1997.1337; Yoshida T, 2001, MOL MICROBIOL, V39, P1406, DOI 10.1046/j.1365-2958.2001.02334.x	31	41	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44959	44965		10.1074/jbc.M305484200	http://dx.doi.org/10.1074/jbc.M305484200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12920124	hybrid			2022-12-25	WOS:000186306700132
J	Paul, AV; Yin, J; Mugavero, J; Rieder, E; Liu, Y; Wimmer, E				Paul, AV; Yin, J; Mugavero, J; Rieder, E; Liu, Y; Wimmer, E			A "slide-back" mechanism for the initiation of protein-primed RNA synthesis by the RNA polymerase of poliovirus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTING REPLICATION ELEMENT; GENOME-LINKED PROTEIN; IN-VITRO; VPG URIDYLYLATION; DNA-REPLICATION; SEQUENCE REQUIREMENTS; TERMINAL PROTEIN; STRUCTURAL BASIS; LINEAR TEMPLATE; 3 NUCLEOTIDE	Poliovirus RNA replication is initiated when a molecule of UMP is covalently linked to the hydroxyl group of a tyrosine in the terminal protein VPg. This reaction can be reproduced in vitro with an assay that utilizes two purified viral proteins, RNA polymerase 3D(pol) and viral protein 3CD(pro), synthetic VPg, UTP, and Mg2+. The template for the reaction is either poliovirus RNA or transcripts of a small RNA hairpin, termed cre(2C), located in the coding sequence of protein 2C(ATPase). The products of the reaction are VPgpU and VPgpUpU, the primers used by 3D(pol) for RNA synthesis. With mutant template RNAs in this assay we determined the precise initiation site. Our results indicate that 1) 3Dpol does not possess strict specificity toward the nucleotide it links to VPg, 2) A-5 of the conserved (1)GXXXAAAXXXXXXA(14) sequence in the loop is the template nucleotide for the linkage of both the first and second UMPs to VPg, 3) VPgpUpU is synthesized by a "slideback" mechanism, and 4) A-6 provides specificity to the reaction during the slide-back step and also modulates the uridylylation reaction. In additional experiments we determined the effect of mutations in the (5)AAA(7) sequence of cre( 2C) on viral growth, RNA replication, and on the activity of the 2CATPase protein. Furthermore, we observed that the spacing between G-1 and A-5 and the size of the loop affect the yield but not the nature of the VPg-linked products.	SUNY Stony Brook, Sch Med, Dept Mol Genet & Microbiol, Stony Brook, NY 11790 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Paul, AV (corresponding author), SUNY Stony Brook, Sch Med, Dept Mol Genet & Microbiol, Stony Brook, NY 11790 USA.	apaul@ms.cc.sunysb.edu	Liu, Ying/B-8752-2011		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI015122] Funding Source: NIH RePORTER; NIAID NIH HHS [R37 AIO15122-30] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agol VI, 1999, VIRUS RES, V62, P129, DOI 10.1016/S0168-1702(99)00037-4; AMBROS V, 1978, J BIOL CHEM, V253, P5263; ANDINO R, 1993, EMBO J, V12, P3587, DOI 10.1002/j.1460-2075.1993.tb06032.x; CALDENTEY J, 1993, NUCLEIC ACIDS RES, V21, P3725, DOI 10.1093/nar/21.16.3725; CRAWFORD NM, 1983, P NATL ACAD SCI-BIOL, V80, P7452, DOI 10.1073/pnas.80.24.7452; FLANEGAN JB, 1977, P NATL ACAD SCI USA, V74, P3677, DOI 10.1073/pnas.74.9.3677; Gerber K, 2001, J VIROL, V75, P10979, DOI 10.1128/JVI.75.22.10979-10990.2001; Gonzalez-Huici V, 2000, J BIOL CHEM, V275, P40547, DOI 10.1074/jbc.M007170200; Goodfellow I, 2000, J VIROL, V74, P4590, DOI 10.1128/JVI.74.10.4590-4600.2000; Goodfellow IG, 2003, RNA, V9, P124, DOI 10.1261/rna.2950603; Illana B, 1996, J MOL BIOL, V264, P453, DOI 10.1006/jmbi.1996.0653; Jiang HY, 1997, J VIROL, V71, P5345, DOI 10.1128/JVI.71.7.5345-5354.1997; JORE J, 1988, J GEN VIROL, V69, P1627, DOI 10.1099/0022-1317-69-7-1627; KING AJ, 1994, EMBO J, V13, P5786, DOI 10.1002/j.1460-2075.1994.tb06917.x; KITAMURA N, 1981, NATURE, V291, P547, DOI 10.1038/291547a0; Lobert PE, 1999, P NATL ACAD SCI USA, V96, P11560, DOI 10.1073/pnas.96.20.11560; Lyle JM, 2002, J BIOL CHEM, V277, P16324, DOI 10.1074/jbc.M112429200; Martin AC, 1996, J MOL BIOL, V260, P369, DOI 10.1006/jmbi.1996.0407; Mason PW, 2002, J VIROL, V76, P9686, DOI 10.1128/JVI.76.19.9686-9694.2002; McKnight KL, 1998, RNA, V4, P1569, DOI 10.1017/S1355838298981006; MENDEZ J, 1992, P NATL ACAD SCI USA, V89, P9579, DOI 10.1073/pnas.89.20.9579; MOLLA A, 1991, SCIENCE, V254, P1647, DOI 10.1126/science.1661029; Morasco BJ, 2003, J VIROL, V77, P5136, DOI 10.1128/JVI.77.9.5136-5144.2003; Murray KE, 2003, J VIROL, V77, P4739, DOI 10.1128/JVI.77.8.4739-4750.2003; NOMOTO A, 1977, NATURE, V268, P208, DOI 10.1038/268208a0; PATA JD, 1995, RNA, V1, P466; Paul Aniko V., 2002, P227; Paul AV, 2000, J VIROL, V74, P10359, DOI 10.1128/JVI.74.22.10359-10370.2000; Paul AV, 2003, J VIROL, V77, P891, DOI 10.1128/JVI.77.2.891-904.2003; Paul AV, 1998, NATURE, V393, P280, DOI 10.1038/30529; Pilipenko EV, 1996, EMBO J, V15, P5428, DOI 10.1002/j.1460-2075.1996.tb00926.x; Rieder E, 2000, J VIROL, V74, P10371, DOI 10.1128/JVI.74.22.10371-10380.2000; ROTHBERG PG, 1978, P NATL ACAD SCI USA, V75, P4868, DOI 10.1073/pnas.75.10.4868; SALAS M, 1996, DNA REPLICATION EUKA, P131; SEEGER C, 1996, DNA REPLICATION EUKA, P815; TAKEGAMI T, 1983, P NATL ACAD SCI-BIOL, V80, P7447, DOI 10.1073/pnas.80.24.7447; TOYODA H, 1987, J VIROL, V61, P2816, DOI 10.1128/JVI.61.9.2816-2822.1987; VANDERWERF S, 1986, P NATL ACAD SCI USA, V83, P2330; WIMMER E, 1982, CELL, V28, P199, DOI 10.1016/0092-8674(82)90335-X; WIMMER E, 1993, ANNU REV GENET, V27, P353, DOI 10.1146/annurev.ge.27.120193.002033; Xiang WK, 1998, J VIROL, V72, P6732, DOI 10.1128/JVI.72.8.6732-6741.1998; Yang Y, 2002, J VIROL, V76, P7485, DOI 10.1128/JVI.76.15.7485-7494.2002; Yin J, 2003, J VIROL, V77, P5152, DOI 10.1128/JVI.77.9.5152-5166.2003; Yin YW, 2002, SCIENCE, V298, P1387, DOI 10.1126/science.1077464; YPMAWONG MF, 1988, VIROLOGY, V166, P265, DOI 10.1016/0042-6822(88)90172-9	45	65	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					43951	43960		10.1074/jbc.M307441200	http://dx.doi.org/10.1074/jbc.M307441200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12937178	hybrid			2022-12-25	WOS:000186306700010
J	Ugarov, VI; Demidenko, AA; Chetverin, AB				Ugarov, VI; Demidenko, AA; Chetverin, AB			Q beta replicase discriminates between legitimate and illegitimate templates by having different mechanisms of initiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT RNA-POLYMERASE; CELL-FREE SYSTEM; PHAGE RNA; SECONDARY STRUCTURE; QBETA-REPLICASE; VIRAL RNA; RECOMBINATION; VITRO; ELONGATION; SEQUENCES	Qbeta replicase (RNA-directed RNA polymerase of bacteriophage Qbeta) exponentially amplifies certain RNAs (RQ RNAs) in vitro. Here we characterize template properties of the 5' and 3' fragments obtained by cleaving one of such RNAs at an internal site. We unexpectedly found that, besides the 3' fragment, Qbeta replicase can copy the 5' fragment and a number of its variants, although they lack the initiator region of RQ RNA. This copying can occur as a 3'-terminal elongation or through de novo initiation. In contradistinction to RQ RNA and its 3' fragment, initiation on these templates occurs without regard to the 3'-terminal or internal oligo(C) clusters, is GTP-independent, and does not result in a stable replicative complex capable of elongation in the presence of aurintricarboxylic acid. The results suggest that, although Qbeta replicase can initiate and elongate on a variety of RNAs, only some of them are recognized as legitimate templates. GTP-dependent initiation on a legitimate template drives the enzyme to a "closed" conformation that may be important for keeping the template and the complementary nascent strand unannealed, without which the exponential replication is impossible. Triggering the GTP-dependent conformational transition at the initiation step could serve as a discriminative feature of legitimate templates providing for the high template specificity of Qbeta replicase.	Russian Acad Sci, Inst Prot Res, Pushchino 142290, Moscow Region, Russia	Russian Academy of Sciences	Chetverin, AB (corresponding author), Russian Acad Sci, Inst Prot Res, Pushchino 142290, Moscow Region, Russia.	alexch@vega.protres.ru	Ugarov, Victor/AAC-6454-2022; Chetverin, Alexander B/AAA-6511-2022; Ugarov, Victor/AAC-6502-2022					Ackermann M, 2001, J BIOL CHEM, V276, P39926, DOI 10.1074/jbc.M104248200; AXELROD VD, 1991, VIROLOGY, V184, P595, DOI 10.1016/0042-6822(91)90430-J; BERESTOWSKAYA NH, 1988, FEBS LETT, V228, P263, DOI 10.1016/0014-5793(88)80012-7; BIEBRICHER CK, 1992, EMBO J, V11, P5129, DOI 10.1002/j.1460-2075.1992.tb05620.x; BIEBRICHER CK, 1993, BIOCHEMISTRY-US, V32, P4848, DOI 10.1021/bi00069a021; BIEBRICHER CK, 1982, J MOL BIOL, V154, P629, DOI 10.1016/S0022-2836(82)80019-3; BLUMENTHAL T, 1973, BIOCHEM BIOPH RES CO, V55, P680, DOI 10.1016/0006-291X(73)91198-4; BLUMENTHAL T, 1980, P NATL ACAD SCI-BIOL, V77, P2601, DOI 10.1073/pnas.77.5.2601; Blumenthal T, 1979, Methods Enzymol, V60, P628; BLUMENTHAL T, 1979, ANNU REV BIOCHEM, V48, P525, DOI 10.1146/annurev.bi.48.070179.002521; Brown D, 1996, P NATL ACAD SCI USA, V93, P11558, DOI 10.1073/pnas.93.21.11558; BROWN D, 1995, BIOCHEMISTRY-US, V34, P14765, DOI 10.1021/bi00045a018; BROWN D, 1995, BIOCHEMISTRY-US, V34, P14775, DOI 10.1021/bi00045a019; BROWN S, 1976, P NATL ACAD SCI USA, V73, P1131, DOI 10.1073/pnas.73.4.1131; Chetverin AB, 1997, CELL, V88, P503, DOI 10.1016/S0092-8674(00)81890-5; CHETVERIN AB, 1991, J MOL BIOL, V222, P3, DOI 10.1016/0022-2836(91)90729-P; CHETVERIN AB, 1995, PROG NUCLEIC ACID RE, V51, P225, DOI 10.1016/S0079-6603(08)60880-6; Chetverin AB, 1999, FEBS LETT, V460, P1, DOI 10.1016/S0014-5793(99)01282-X; Chetverina HV, 1999, FEBS LETT, V450, P89, DOI 10.1016/S0014-5793(99)00469-X; CHETVERINA HV, 1993, NUCLEIC ACIDS RES, V21, P2349, DOI 10.1093/nar/21.10.2349; De Rijk P, 2003, BIOINFORMATICS, V19, P299, DOI 10.1093/bioinformatics/19.2.299; FEIX G, 1975, EUR J BIOCHEM, V58, P59, DOI 10.1111/j.1432-1033.1975.tb02348.x; FEIX G, 1975, BIOCHEM BIOPH RES CO, V65, P503, DOI 10.1016/S0006-291X(75)80176-8; FEIX G, 1967, P NATL ACAD SCI USA, V57, P1401, DOI 10.1073/pnas.57.5.1401; GAILLARD C, 1990, NUCLEIC ACIDS RES, V18, P378, DOI 10.1093/nar/18.2.378; GILBERTOGONZALEZ R, 1980, BIOCHEMISTRY-US, V19, P4299, DOI 10.1021/bi00559a023; HARUNA I, 1965, P NATL ACAD SCI USA, V54, P579, DOI 10.1073/pnas.54.2.579; HORI K, 1967, P NATL ACAD SCI USA, V57, P1790, DOI 10.1073/pnas.57.6.1790; IGLOI GL, 1983, ANAL BIOCHEM, V134, P184, DOI 10.1016/0003-2697(83)90281-6; JAEGER JA, 1990, METHOD ENZYMOL, V183, P281; Kochetkov SN, 1998, FEBS LETT, V440, P264, DOI 10.1016/S0014-5793(98)01484-7; KUPPERS B, 1975, P NATL ACAD SCI USA, V72, P2640, DOI 10.1073/pnas.72.7.2640; Mooney RA, 1999, CELL, V98, P687, DOI 10.1016/S0092-8674(00)81483-X; MOROZOV IY, 1993, P NATL ACAD SCI USA, V90, P9325, DOI 10.1073/pnas.90.20.9325; MUNISHKIN AV, 1991, J MOL BIOL, V221, P463, DOI 10.1016/0022-2836(91)80067-5; PALASINGAM K, 1992, J VIROL, V66, P2435, DOI 10.1128/JVI.66.4.2435-2442.1992; PALMENBERG A, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1371, DOI 10.1073/pnas.71.4.1371; Preuss R, 1997, J MOL BIOL, V273, P600, DOI 10.1006/jmbi.1997.1343; RENSING U, 1969, NATURE, V224, P853, DOI 10.1038/224853a0; Sambrook J, 2001, MOL CLONING LAB MANU; SHAKLEE PN, 1988, VIROLOGY, V163, P209, DOI 10.1016/0042-6822(88)90250-4; SILVERMAN PM, 1973, ARCH BIOCHEM BIOPHYS, V157, P222, DOI 10.1016/0003-9861(73)90408-6; STEINSCHNEIDER A, 1966, BIOCHEMISTRY-US, V5, P2729, DOI 10.1021/bi00872a033; Tretheway DM, 2001, J VIROL, V75, P11373, DOI 10.1128/JVI.75.23.11373-11383.2001; van Duin J., 1988, BACTERIOPHAGES, P117; VOGT VM, 1973, EUR J BIOCHEM, V33, P192, DOI 10.1111/j.1432-1033.1973.tb02669.x; WEISSMANN C, 1973, ANNU REV BIOCHEM, V42, P303, DOI 10.1146/annurev.bi.42.070173.001511; WEISSMANN C, 1968, COLD SPRING HARB SYM, V33, P83, DOI 10.1101/SQB.1968.033.01.014; WEISSMANN C, 1974, FEBS LETT, V43, pS10; WERNER M, 1991, BIOCHEMISTRY-US, V30, P5832, DOI 10.1021/bi00238a004; Yoshinari S, 2000, VIROLOGY, V271, P363, DOI 10.1006/viro.2000.0334; Yoshinari S, 2000, RNA, V6, P698, DOI 10.1017/S1355838200992410; ZAMORA H, 1995, BIOCHEMISTRY-US, V34, P1261, DOI 10.1021/bi00004a020	53	20	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44139	44146		10.1074/jbc.M305992200	http://dx.doi.org/10.1074/jbc.M305992200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12947121	hybrid			2022-12-25	WOS:000186306700032
J	Stollar, EJ; Mayor, U; Lovell, SC; Federici, L; Freund, SMV; Fersht, AR; Luisi, BF				Stollar, EJ; Mayor, U; Lovell, SC; Federici, L; Freund, SMV; Fersht, AR; Luisi, BF			Crystal structures of engrailed homeodomain mutants - Implications for stability and dynamics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTENNAPEDIA HOMEODOMAIN; X-RAY; MOLECULAR REPLACEMENT; MATA1 HOMEODOMAIN; NMR-SPECTROSCOPY; NK-2 HOMEODOMAIN; DNA COMPLEX; PROTEIN; BINDING; CRYSTALLOGRAPHY	We report the crystal structures and biophysical characterization of two stabilized mutants of the Drosophila Engrailed homeodomain that have been engineered to minimize electrostatic repulsion. Four independent copies of each mutant occupy the crystal lattice, and comparison of these structures illustrates variation that can be partly ascribed to networks of correlated conformational adjustments. Central to one network is leucine 26 (Leu(26)), which occupies alternatively two side chain rotameric conformations (-gauche and trans) and different positions within the hydrophobic core. Similar sets of conformational substates are observed in other Engrailed structures and in another homeodomain. The pattern of structural adjustments can account for NMR relaxation data and sequence co-variation networks in the wider homeodomain family. It may also explain the dysfunction associated with a P26L mutation in the human ARX homeodomain protein. Finally, we observe a novel dipolar interaction between a conserved tryptophan and a water molecule positioned along the normal to the indole ring. This interaction may explain the distinctive fluorescent properties of the homeodomain family.	Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England; MRC, Ctr Prot Engn, Cambridge CB2 2QH, England	University of Cambridge; University of Cambridge	Luisi, BF (corresponding author), Univ Cambridge, Dept Biochem, 80 Tennis Court Rd, Cambridge CB2 1GA, England.	Ben@cryst.bioc.cam.ac.uk	Fersht, Alan R/B-2189-2008; Mayor, Ugo/F-5890-2011	Mayor, Ugo/0000-0003-2812-8287; Lovell, Simon/0000-0002-4092-8458				Anderson JS, 2000, BIOCHEMISTRY-US, V39, P10045, DOI 10.1021/bi000677z; Banerjee-Basu S, 2001, NUCLEIC ACIDS RES, V29, P3258, DOI 10.1093/nar/29.15.3258; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carra JH, 1997, BIOCHEMISTRY-US, V36, P526, DOI 10.1021/bi962206b; CLARKE ND, 1994, PROTEIN SCI, V3, P1779, DOI 10.1002/pro.5560031018; CLARKE ND, 1995, PROTEIN SCI, V4, P2269, DOI 10.1002/pro.5560041104; COX M, 1995, J BIOMOL NMR, V6, P23, DOI 10.1007/BF00417488; Delbruck H, 2001, J MOL BIOL, V313, P359, DOI 10.1006/jmbi.2001.5051; Esposito G, 1996, EUR J BIOCHEM, V241, P101, DOI 10.1111/j.1432-1033.1996.0101t.x; Fraenkel E, 1998, NAT STRUCT BIOL, V5, P692, DOI 10.1038/1382; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; Grant RA, 2000, BIOCHEMISTRY-US, V39, P8187, DOI 10.1021/bi000071a; GUYDOSH NR, 2002, THESIS U CAMBRIDGE C; Hirsch JA, 1995, EMBO J, V14, P6280, DOI 10.1002/j.1460-2075.1995.tb00318.x; HOROVITZ A, 1990, J MOL BIOL, V216, P1031, DOI 10.1016/S0022-2836(99)80018-7; Hovde S, 2001, BIOCHEMISTRY-US, V40, P12013, DOI 10.1021/bi0108148; HUANG GS, 1995, P NATL ACAD SCI USA, V92, P6878, DOI 10.1073/pnas.92.15.6878; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Ippel H, 1999, J MOL BIOL, V288, P689, DOI 10.1006/jmbi.1999.2718; Jackson SE, 1998, FOLD DES, V3, pR81, DOI 10.1016/S1359-0278(98)00033-9; Ke A, 2003, PROTEIN SCI, V12, P306, DOI 10.1110/ps.0219103; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; Kissinger CR, 2001, ACTA CRYSTALLOGR D, V57, P1474, DOI 10.1107/S0907444901012458; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Laurents DV, 2000, BIOCHEMISTRY-US, V39, P13963, DOI 10.1021/bi001388d; LEVITT M, 1988, J MOL BIOL, V201, P751, DOI 10.1016/0022-2836(88)90471-8; LI T, 1995, SCIENCE, V270, P262, DOI 10.1126/science.270.5234.262; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; Markley JL, 1998, EUR J BIOCHEM, V256, P1, DOI 10.1046/j.1432-1327.1998.2560001.x; Marshall SA, 2002, J MOL BIOL, V316, P189, DOI 10.1006/jmbi.2001.5326; Mayor U, 2000, P NATL ACAD SCI USA, V97, P13518, DOI 10.1073/pnas.250473497; Mayor U, 2003, NATURE, V421, P863, DOI 10.1038/nature01428; MAYOR U, 2003, THESIS U CAMBRIDGE C; MEIERING EM, 1992, J MOL BIOL, V225, P585, DOI 10.1016/0022-2836(92)90387-Y; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nanda V, 2000, PROTEINS, V40, P112, DOI 10.1002/(SICI)1097-0134(20000701)40:1<112::AID-PROT130>3.0.CO;2-C; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Phillips K, 2000, J MOL BIOL, V302, P1023, DOI 10.1006/jmbi.2000.4107; QIAN YQ, 1989, CELL, V59, P573, DOI 10.1016/0092-8674(89)90040-8; QIAN YQ, 1994, J MOL BIOL, V238, P333, DOI 10.1006/jmbi.1994.1296; Rejto PA, 1996, PROG BIOPHYS MOL BIO, V66, P167, DOI 10.1016/S0079-6107(97)85629-5; Remenyi A, 2001, MOL CELL, V8, P569, DOI 10.1016/S1097-2765(01)00336-7; RICHARDSON DC, 1994, TRENDS BIOCHEM SCI, V19, P135, DOI 10.1016/0968-0004(94)90207-0; SALI A, 1990, TRENDS BIOCHEM SCI, V15, P235, DOI 10.1016/0968-0004(90)90036-B; Scheffer IE, 2002, NEUROLOGY, V59, P348, DOI 10.1212/WNL.59.3.348; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; Stromme P, 2002, NAT GENET, V30, P441, DOI 10.1038/ng862; Subramaniam V, 2001, J BIOL CHEM, V276, P21506, DOI 10.1074/jbc.M102292200; Tang KS, 1999, J MOL BIOL, V285, P1869, DOI 10.1006/jmbi.1998.2420; Tjandra N, 1996, J AM CHEM SOC, V118, P6986, DOI 10.1021/ja960510m; TSAO DHH, 1995, J MOL BIOL, V251, P297, DOI 10.1006/jmbi.1995.0435; TSAO DHH, 1994, BIOCHEMISTRY-US, V33, P15053, DOI 10.1021/bi00254a014; Weiler S, 1998, J BIOL CHEM, V273, P10994, DOI 10.1074/jbc.273.18.10994; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9; Wilson MA, 2000, J MOL BIOL, V301, P1237, DOI 10.1006/jmbi.2000.4029; Word JM, 1999, J MOL BIOL, V285, P1735, DOI 10.1006/jmbi.1998.2401; Word JM, 1999, J MOL BIOL, V285, P1711, DOI 10.1006/jmbi.1998.2400; Xiao L, 1999, J MOL BIOL, V289, P1435, DOI 10.1006/jmbi.1999.2810; ZHANG XJ, 1995, J MOL BIOL, V250, P527, DOI 10.1006/jmbi.1995.0396	62	33	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43699	43708		10.1074/jbc.M308029200	http://dx.doi.org/10.1074/jbc.M308029200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12923178	hybrid			2022-12-25	WOS:000186157000119
J	Vergnes, L; Phan, J; Strauss, M; Tafuri, S; Reue, K				Vergnes, L; Phan, J; Strauss, M; Tafuri, S; Reue, K			Cholesterol and cholate components of an atherogenic diet induce distinct stages of hepatic inflammatory gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN LEVELS; HIGH-FAT DIETS; STELLATE CELLS; ATHEROSCLEROSIS; MOUSE; SUSCEPTIBILITY; FIBROSIS; MICE; HYPERCHOLESTEROLEMIA; FIBROGENESIS	Atherosclerosis in inbred mouse strains has been widely studied by using an atherogenic (Ath) diet containing cholesterol, cholic acid, and fat, but the effect of these components on gene expression has not been systematically examined. We employed DNA microarrays to interrogate gene expression levels in liver of C57BL/6J mice fed the following five diets: mouse chow, the Ath diet, or modified versions of the Ath diet in which either cholesterol, cholate, or fat were omitted. Dietary cholesterol and cholate produced discrete gene expression patterns. Cholesterol was required for induction of genes involved in acute inflammation, including three genes of the serum amyloid A family, three major histocompatibility class II antigen genes, and various cytokine-related genes. In contrast, cholate induced expression of genes involved in extracellular matrix deposition in hepatic fibrosis, including five collagen family members, collagen-interacting proteins, and connective tissue growth factor. The gene expression findings were confirmed by biochemical measurements showing that cholesterol was required for elevation of circulating serum amyloid A, and cholate was required for accumulation of collagen in the liver. The possibility that these gene expression changes are relevant to atherogenesis in C57BL/6J mice was supported by the observation that the closely related, yet atherosclerosis-resistant, C57BL/ 6ByJ strain was largely resistant to dietary induction of the inflammatory and fibrotic response genes. These results establish that cholesterol and cholate components of the Ath diet have distinct proatherogenic effects on gene expression and suggest a strategy to study the contribution of acute inflammatory response and fibrogenesis independently through dietary manipulation.	Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Human Genet, Los Angeles, CA 90095 USA; Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA; Pfizer Global Res & Dev, Ann Arbor Labs, Ann Arbor, MI 48105 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; Pfizer	Reue, K (corresponding author), 11301 Wilshire Blvd,Bldg 113,Rm 312, Los Angeles, CA 90073 USA.	Reuek@ucla.edu		vergnes, laurent/0000-0002-8804-589X; Phan, Jack/0000-0001-5977-6004	NHLBI NIH HHS [HL58627, HL28481] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058627, P01HL028481] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bailey DW, 1978, ORIGINS INBRED MICE, P197; Baroukh N, 2001, FEBS LETT, V502, P16, DOI 10.1016/S0014-5793(01)02621-7; Bissell DM, 1998, J GASTROENTEROL, V33, P295, DOI 10.1007/s005350050087; Brady LM, 1996, BIOCHEM J, V316, P765, DOI 10.1042/bj3160765; Canbay A, 2002, GASTROENTEROLOGY, V123, P1323, DOI 10.1053/gast.2002.35953; CARR TP, 1993, CLIN BIOCHEM, V26, P39, DOI 10.1016/0009-9120(93)90015-X; Cohen RD, 1997, J CLIN INVEST, V99, P1906, DOI 10.1172/JCI119358; Fazio S, 2001, FRONT BIOSCI-LANDMRK, V6, pD515, DOI 10.2741/Fazio; Friedman SL, 2000, J BIOL CHEM, V275, P2247, DOI 10.1074/jbc.275.4.2247; HEDRICK CC, 1993, J BIOL CHEM, V268, P20676; Higuchi H, 2003, AM J PHYSIOL-GASTR L, V284, pG734, DOI 10.1152/ajpgi.00491.2002; Huebert RC, 2002, J BIOL CHEM, V277, P22710, DOI 10.1074/jbc.M202394200; Kersten S, 2001, FASEB J, V15, P1971, DOI 10.1096/fj.01-0147com; Kmiec Z, 2001, ADV ANAT EMBRYOL CEL, V161, P1; KNOLLE P, 1995, Z GASTROENTEROL, V33, P613; Knowles JW, 2000, ARTERIOSCL THROM VAS, V20, P2336, DOI 10.1161/01.ATV.20.11.2336; LEBOEUF RC, 1990, J LIPID RES, V31, P91; Li D, 1999, J GASTROEN HEPATOL, V14, P618, DOI 10.1046/j.1440-1746.1999.01928.x; LIAO F, 1993, J CLIN INVEST, V91, P2572, DOI 10.1172/JCI116495; LIAO F, 1994, J CLIN INVEST, V94, P877, DOI 10.1172/JCI117409; Marra F, 1999, J HEPATOL, V31, P1120; Mouzeyan A, 2000, J LIPID RES, V41, P573; Neubauer K, 2001, CAN J GASTROENTEROL, V15, P187, DOI 10.1155/2001/870205; NISHINA PM, 1993, J LIPID RES, V34, P1413; NISHINA PM, 1990, J LIPID RES, V31, P859; PAIGEN B, 1987, P NATL ACAD SCI USA, V84, P3763, DOI 10.1073/pnas.84.11.3763; PAIGEN B, 1985, ATHEROSCLEROSIS, V57, P65, DOI 10.1016/0021-9150(85)90138-8; Phan J, 2002, J BIOL CHEM, V277, P469, DOI 10.1074/jbc.M107107200; Reardon CA, 2001, CURR OPIN LIPIDOL, V12, P167, DOI 10.1097/00041433-200104000-00010; Sheth SS, 2002, CURR OPIN LIPIDOL, V13, P181, DOI 10.1097/00041433-200204000-00010; THOMPSON JS, 1969, J ATHEROSCLER RES, V10, P113, DOI 10.1016/S0368-1319(69)80090-6; Tsukamoto H, 2001, FASEB J, V15, P1335, DOI 10.1096/fj.00-0650rev; Urizar NL, 2000, J BIOL CHEM, V275, P39313, DOI 10.1074/jbc.M007998200; Vergnes L, 2003, J LIPID RES, V44, P503, DOI 10.1194/jlr.M200399-JLR200; VESSELIN.D, 1968, J ATHEROSCLER RES, V8, P497, DOI 10.1016/S0368-1319(68)80105-X	35	149	156	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42774	42784		10.1074/jbc.M306022200	http://dx.doi.org/10.1074/jbc.M306022200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12923166	hybrid			2022-12-25	WOS:000186157000008
J	Zhao, Z; Peng, Y; Hao, SF; Zeng, ZH; Wang, CC				Zhao, Z; Peng, Y; Hao, SF; Zeng, ZH; Wang, CC			Dimerization by domain hybridization bestows chaperone and isomerase activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; PEPTIDE-BINDING; THIOREDOXIN; RESIDUES; FOLD; DSBC	Thioredoxin, DsbA, the N-terminal active-site domain a and the non-active-site domain b of protein-disulfide isomerase are all monomeric with a thioredoxin fold, and each exhibits low or no isomerase and chaperone activity. We have linked the N terminus of the above four monomers, individually, to the C terminus of the N-terminal domain of DsbC via the flexible linker helix of the latter to produce four domain hybrids, DsbCn-Trx, DsbCn-DsbA, DsbCn-PDIa, and DsbCn-PDIb. These four hybrid proteins form homodimers, and except for DsbCn-PDIb they exhibit new or greatly elevated isomerase as well as chaperone activity. Three-dimensional structure prediction indicates that all the four domain hybrids adopt DsbC-like V-shaped structure with a broad uncharged cleft between the two arms for binding of non-native protein folding intermediates. The results provide strong evidence that dimerization creates chaperone and isomerase activity for monomeric thiol-protein oxidases or reductases, and suggesting a pathway for proteins to acquire new functions and/or higher biological efficiency during evolution.	Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China; Chinese Acad Sci, Inst Biophys, Ctr Mol Biol, Beijing 100101, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS; Chinese Academy of Sciences; Institute of Biophysics, CAS	Wang, CC (corresponding author), Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, 15 Datun Rd, Beijing 100101, Peoples R China.	chihwang@sun5.ibp.ac.cn	Peng, Yi/G-5945-2010					Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bader MW, 2001, EMBO J, V20, P1555, DOI 10.1093/emboj/20.7.1555; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bessette PH, 1999, J BIOL CHEM, V274, P7784, DOI 10.1074/jbc.274.12.7784; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; CAI H, 1994, J BIOL CHEM, V269, P24550; Chen J, 1999, J BIOL CHEM, V274, P19601, DOI 10.1074/jbc.274.28.19601; Chivers PT, 1996, EMBO J, V15, P2659, DOI 10.1002/j.1460-2075.1996.tb00626.x; Edeling MA, 2002, STRUCTURE, V10, P973, DOI 10.1016/S0969-2126(02)00794-3; HAWKINS HC, 1991, BIOCHEM J, V275, P349, DOI 10.1042/bj2750349; Hiniker A, 2003, BIOCHEMISTRY-US, V42, P1179, DOI 10.1021/bi027141t; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; KATTI SK, 1990, J MOL BIOL, V212, P167, DOI 10.1016/0022-2836(90)90313-B; Katzen F, 2002, EMBO J, V21, P3960, DOI 10.1093/emboj/cdf405; Kemmink J, 1996, BIOCHEMISTRY-US, V35, P7684, DOI 10.1021/bi960335m; Kemmink J, 1999, J BIOMOL NMR, V13, P357, DOI 10.1023/A:1008341820489; Kemmink J, 1997, CURR BIOL, V7, P239, DOI 10.1016/S0960-9822(06)00119-9; LAMBERT N, 1983, BIOCHEM J, V213, P225, DOI 10.1042/bj2130225; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee S, 2002, J BIOL CHEM, V277, P21675, DOI 10.1074/jbc.M111075200; LIANG SJ, 1990, BIOCHIM BIOPHYS ACTA, V1038, P240, DOI 10.1016/0167-4838(90)90211-W; Liepinsh E, 2001, STRUCTURE, V9, P457, DOI 10.1016/S0969-2126(01)00607-4; Liu XQ, 1999, PROTEIN SCI, V8, P2085, DOI 10.1110/ps.8.10.2085; Lu GA, 1996, PROTEIN DATA BANK Q, V78, P10; LUNDSTROM J, 1992, J BIOL CHEM, V267, P9047; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; MARTIN JL, 1993, NATURE, V365, P464, DOI 10.1038/365464a0; MARTINEZGALISTEO E, 1993, BIOCHIMIE, V75, P803, DOI 10.1016/0300-9084(93)90131-B; McCarthy AA, 2000, NAT STRUCT BIOL, V7, P196; Missiakas D, 1997, J BACTERIOL, V179, P2465, DOI 10.1128/jb.179.8.2465-2471.1997; Mossner E, 1998, PROTEIN SCI, V7, P1233; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POWNALL HJ, 1977, BIOCHIM BIOPHYS ACTA, V488, P190, DOI 10.1016/0005-2760(77)90176-X; PUIG A, 1994, J BIOL CHEM, V269, P7764; Ruoppolo M, 2003, PROTEIN SCI, V12, P939, DOI 10.1110/ps.0242803; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sha BD, 2000, STRUCTURE, V8, P799, DOI 10.1016/S0969-2126(00)00170-2; Shao F, 2000, J BIOL CHEM, V275, P13349, DOI 10.1074/jbc.275.18.13349; Siegert R, 2000, CELL, V103, P621, DOI 10.1016/S0092-8674(00)00165-3; Sun XX, 2000, J BIOL CHEM, V275, P22743, DOI 10.1074/jbc.M002406200; Sun XX, 2000, BBA-PROTEIN STRUCT M, V1481, P45, DOI 10.1016/S0167-4838(00)00122-9; WANG CC, 1993, FASEB J, V7, P1515, DOI 10.1096/fasebj.7.15.7903263; Yao Y, 1997, EMBO J, V16, P651, DOI 10.1093/emboj/16.3.651	45	38	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43292	43298		10.1074/jbc.M306945200	http://dx.doi.org/10.1074/jbc.M306945200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12933788	hybrid			2022-12-25	WOS:000186157000072
J	Guimaraes, CA; Benchimol, M; Amarante-Mendes, GP; Linden, R				Guimaraes, CA; Benchimol, M; Amarante-Mendes, GP; Linden, R			Alternative programs of cell death in developing retinal tissue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							APOPTOSIS-INDUCING FACTOR; L-DNASE-II; PROTEIN-SYNTHESIS; CASPASE ACTIVATION; NEURONAL DEATH; GANGLION-CELLS; MEMBRANE PERMEABILIZATION; SPINAL-CORD; AUTOPHAGY; INHIBITION	We examined cell death in developing retinal tissue, following inhibition of protein synthesis, which kills undifferentiated post-mitotic cells. Ultrastructural features were found of both apoptosis and autophagy. Only approximately half of the degenerating cells were either terminal dUTP nick-end labeling (TUNEL)-positive or reacted with antibodies specific for activated caspases-3 or -9. Bongkrekic acid completely inhibited any appearance of cell death, whereas inhibitors of autophagy, caspases-9 or -3, prevented only TUNEL-positive cell death. Interestingly, inhibition of caspase-6 blocked TUNEL-negative cell death. Simultaneous inhibition of caspases-9 and -6 prevented cell death almost completely, but degeneration dependent on autophagy/ caspase-9 still occurred under inhibition of both caspases-3 and -6. Thus, inhibition of protein synthesis induces in the developing retina various post-translational, mitochondria-dependent pathways of cell death. Autophagy precedes sequential activation of caspases-9 and -3, and DNA fragmentation, whereas, in parallel, caspase-6 leads to a TUNEL-negative form of cell death. Additional mechanisms of cell death may be engaged upon selective caspase inhibition.	Univ Fed Rio de Janeiro, Inst Biofis, CCS, BR-21949900 Rio De Janeiro, Brazil; Univ Santa Ursula, Rio De Janeiro, Brazil; Univ Sao Paulo, Inst Ciencias Biomed, Dept Imunol, BR-05508 Sao Paulo, Brazil	Universidade Federal do Rio de Janeiro; Universidade de Sao Paulo	Linden, R (corresponding author), Univ Fed Rio de Janeiro, Inst Biofis, CCS, Bloco G,Cidade Univ, BR-21949900 Rio De Janeiro, Brazil.	rlinden@biof.ufrj.br	Mendes, Gustavo P Amarante/C-8187-2012; Sternberg, Cinthya/K-4038-2012; Linden, Rafael/F-2275-2011	Mendes, Gustavo P Amarante/0000-0002-7851-6205; Sternberg, Cinthya/0000-0002-4760-6339; Linden, Rafael/0000-0003-3287-336X				Allsopp TE, 2000, CELL DEATH DIFFER, V7, P984, DOI 10.1038/sj.cdd.4400733; Altairac S, 2001, NEUROSCI LETT, V303, P41, DOI 10.1016/S0304-3940(01)01706-2; Anglade P, 1997, HISTOL HISTOPATHOL, V12, P25; ARAKI T, 1990, ACTA NEUROPATHOL, V79, P501, DOI 10.1007/BF00296109; Bauvy C, 2001, EXP CELL RES, V268, P139, DOI 10.1006/excr.2001.5285; Bijl M, 2001, NETH J MED, V59, P66, DOI 10.1016/S0300-2977(01)00131-0; Boya P, 2003, ONCOGENE, V22, P3927, DOI 10.1038/sj.onc.1206622; Boya P, 2003, J EXP MED, V197, P1323, DOI 10.1084/jem.20021952; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; BULTZINGSLOWEN I, 2001, ORAL ONCOL, V37, P537; Bursch W, 2000, J CELL SCI, V113, P1189; Bursch W, 2001, CELL DEATH DIFFER, V8, P569, DOI 10.1038/sj.cdd.4400852; Bursch W, 1996, CARCINOGENESIS, V17, P1595, DOI 10.1093/carcin/17.8.1595; Cataldo AM, 1996, J NEUROSCI, V16, P186; Cecconi F, 2001, CELL MOL LIFE SCI, V58, P1688, DOI 10.1007/PL00000806; Chang SH, 2002, EXP CELL RES, V277, P15, DOI 10.1006/excr.2002.5539; Chaudhary P, 1999, MOL BRAIN RES, V67, P36, DOI 10.1016/S0169-328X(99)00032-7; Chua BT, 2000, J BIOL CHEM, V275, P5131, DOI 10.1074/jbc.275.7.5131; Clarke G, 2001, HUM MOL GENET, V10, P2269, DOI 10.1093/hmg/10.20.2269; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; De Basilio V, 2001, POULTRY SCI, V80, P29, DOI 10.1093/ps/80.1.29; DEARAUJO EG, 1993, EUR J NEUROSCI, V5, P1181; Delshad A, 2001, FOLIA NEUROPATHOL, V39, P125; Domen J, 2000, IMMUNOL RES, V22, P83, DOI 10.1385/IR:22:2-3:83; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Dumont RJ, 2001, CLIN NEUROPHARMACOL, V24, P254, DOI 10.1097/00002826-200109000-00002; DUNN WA, 1990, J CELL BIOL, V110, P1923, DOI 10.1083/jcb.110.6.1923; DUNN WA, 1990, J CELL BIOL, V110, P1935, DOI 10.1083/jcb.110.6.1935; Foghsgaard L, 2001, J CELL BIOL, V153, P999, DOI 10.1083/jcb.153.5.999; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; GARCIAPORRERO JA, 1979, EXPERIENTIA, V35, P375, DOI 10.1007/BF01964362; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Grossmann J, 1998, AM J PHYSIOL-GASTR L, V274, pG1117, DOI 10.1152/ajpgi.1998.274.6.G1117; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; Hisatomi T, 2001, AM J PATHOL, V158, P1271, DOI 10.1016/S0002-9440(10)64078-3; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; JEFFREY M, 1992, ACTA NEUROPATHOL, V84, P559, DOI 10.1007/BF00304476; Jia L, 1997, BRIT J HAEMATOL, V98, P673, DOI 10.1046/j.1365-2141.1997.2623081.x; Joaquin AM, 2001, J AM GERIATR SOC, V49, P1234, DOI 10.1046/j.1532-5415.2001.04990.x; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Katai N, 1999, INVEST OPHTH VIS SCI, V40, P2697; Kegel KB, 2000, J NEUROSCI, V20, P7268, DOI 10.1523/jneurosci.20-19-07268.2000; Kermer P, 2000, MOL BRAIN RES, V85, P144, DOI 10.1016/S0169-328X(00)00256-4; Kermer P, 1998, J NEUROSCI, V18, P4656; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Krajewski S, 1999, P NATL ACAD SCI USA, V96, P5752, DOI 10.1073/pnas.96.10.5752; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Linden R, 1999, PROG RETIN EYE RES, V18, P133, DOI 10.1016/S1350-9462(98)00020-2; Linden R, 2000, BRAIN RES REV, V32, P146, DOI 10.1016/S0165-0173(99)00073-9; LOCKSHIN RA, 1969, J INSECT PHYSIOL, V15, P1505, DOI 10.1016/0022-1910(69)90172-3; Lockshin RA, 2002, CURR OPIN CELL BIOL, V14, P727, DOI 10.1016/S0955-0674(02)00383-6; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; McKinnon SJ, 2002, INVEST OPHTH VIS SCI, V43, P1077; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Miyashita T, 1998, CELL DEATH DIFFER, V5, P1034, DOI 10.1038/sj.cdd.4400442; Monk CS, 2001, DEV NEUROPSYCHOL, V19, P211, DOI 10.1207/S15326942DN1902_5; MORIYA M, 1986, CELL TISSUE RES, V246, P607, DOI 10.1007/BF00215203; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakanishi K, 2001, J BIOL CHEM, V276, P41237, DOI 10.1074/jbc.M105648200; Namura S, 1998, J NEUROSCI, V18, P3659; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; O'Reilly LA, 2002, CELL DEATH DIFFER, V9, P832, DOI 10.1038/sj.cdd.4401033; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; Paglin S, 2001, CANCER RES, V61, P439; Petersen A, 2001, HUM MOL GENET, V10, P1243, DOI 10.1093/hmg/10.12.1243; Pru JK, 2001, MOL ENDOCRINOL, V15, P845, DOI 10.1210/me.15.6.845; QUIGLEY HA, 1995, INVEST OPHTH VIS SCI, V36, P774; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Read SH, 2002, J CELL BIOL, V159, P739, DOI 10.1083/jcb.200209004; Rehen SK, 1996, DEVELOPMENT, V122, P1439; Rehen SK, 1999, EUR J NEUROSCI, V11, P4349, DOI 10.1046/j.1460-9568.1999.00868.x; Reme CE, 1999, INVEST OPHTH VIS SCI, V40, P2398; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; SCHWARTZ LM, 1990, P NATL ACAD SCI USA, V87, P6594, DOI 10.1073/pnas.87.17.6594; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509; Singh M, 2001, J NEUROCHEM, V77, P466, DOI 10.1046/j.1471-4159.2001.00258.x; Sorimachi T, 2002, J NEUROSURG, V97, P104, DOI 10.3171/jns.2002.97.1.0104; Stefanis L, 2001, J NEUROSCI, V21, P9549, DOI 10.1523/JNEUROSCI.21-24-09549.2001; Stennicke HR, 1999, CELL DEATH DIFFER, V6, P1054, DOI 10.1038/sj.cdd.4400599; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; TATA JR, 1966, DEV BIOL, V13, P77, DOI 10.1016/0012-1606(66)90050-9; Tezel G, 1999, INVEST OPHTH VIS SCI, V40, P2660; THILMANN R, 1986, ACTA NEUROPATHOL, V71, P88, DOI 10.1007/BF00687967; Torriglia A, 2001, EXP EYE RES, V72, P443, DOI 10.1006/exer.2000.0969; Uchiyama Y, 2001, ARCH HISTOL CYTOL, V64, P233, DOI 10.1679/aohc.64.233; UCKER DS, 1989, J IMMUNOL, V143, P3461; van Loo G, 2001, CELL DEATH DIFFER, V8, P1136, DOI 10.1038/sj.cdd.4400944; Varella MH, 1997, NEUROCHEM INT, V31, P217, DOI 10.1016/S0197-0186(96)00151-9; WEBER R, 1965, EXPERIENTIA, V21, P665, DOI 10.1007/BF02144069; Wei YY, 2000, CHEM BIOL, V7, P423, DOI 10.1016/S1074-5521(00)00123-X; Xue LZ, 1999, MOL CELL NEUROSCI, V14, P180, DOI 10.1006/mcne.1999.0780; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; ZAKERI Z, 1995, CELL DEATH DIFFER, V2, P87; Zimmermann KC, 2001, PHARMACOL THERAPEUT, V92, P57, DOI 10.1016/S0163-7258(01)00159-0	101	65	65	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41938	41946		10.1074/jbc.M306547200	http://dx.doi.org/10.1074/jbc.M306547200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12917395	hybrid			2022-12-25	WOS:000185989500048
J	Lammering, G; Hewit, TH; Valerie, K; Contessa, JN; Amorino, GP; Dent, P; Schmidt-Ullrich, RK				Lammering, G; Hewit, TH; Valerie, K; Contessa, JN; Amorino, GP; Dent, P; Schmidt-Ullrich, RK			EGFRvIII-mediated radioresistance through a strong cytoprotective response	ONCOGENE			English	Article						radiation; EGFRvIII; EGFR; MAP kinase; PI3 kinase; AKT	GROWTH-FACTOR RECEPTOR; CONFERS ENHANCED TUMORIGENICITY; HUMAN GLIOBLASTOMA CELLS; MAMMARY-CARCINOMA CELLS; SIGNAL-TRANSDUCTION; TYROSINE PHOSPHORYLATION; EGF RECEPTOR; GLIOMA-CELLS; KINASE; GENE	The constitutively active, truncated epidermal growth factor receptor EGFRvII lacks the ability of EGF binding due to a deletion of the NH2-terminal domain. EGFRvIII confers increased tumorigenicity, is coexpressed with EGFR wild type (wt) in human carcinoma and malignant glioma cells when grown as xenografts, but is not expressed in vitro. The effects of EGFRvIII expression on cellular radiation responses were studied in Chinese hamster ovary (CHO) cells transfected with plasmids expressing EGFRvIII (CHO.EGFRvIII) or EGFRwt (CHO.EGFRwt). CHO cells expressing similar levels of either receptor were employed to define their roles in response to EGF and ionizing radiation. EGF activated EGFRwt with no effect on EGFRvIII. In contrast, a single radiation exposure of 2 Gy resulted in a 2.8- and 4.3-fold increase in Tyr phosphorylation of EGFRwt and EGFRvIII, respectively. Downstream consequences of this radiation-induced activation were examined by inhibiting EGFRwt and EGFRvIII with AG1478 (kinase inhibitor). The radiation-induced 8.5-fold activation of the pro-proliferative mitogen-activated protein kinase and the 3.2-fold stimulation of the antiapoptotic AKT/phosphatidylinositol-3-kinase pathways by EGFRvII far exceeded that in CHO.EGFR wt cells. Thus, based on colony formation and apoptosis assays, EGFRvIII expression conferred a stronger cytoprotective response to radiation than EGFRwt, resulting in relative radioresistance. Therefore, disabling EGFRvIII in addition to EGFRwt needs to be considered in any therapeutic approach aimed at targeting EGFR for tumor cell radiosensitization.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, Richmond, VA 23298 USA; Univ Dusseldorf, Dept Radiat Oncol, D-4000 Dusseldorf, Germany	Virginia Commonwealth University; Heinrich Heine University Dusseldorf	Schmidt-Ullrich, RK (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, POB 980058, Richmond, VA 23298 USA.		Valerie, Kristoffer/AAL-8299-2021		NATIONAL CANCER INSTITUTE [P01CA072955, R01CA065896] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA65896, P01 CA72955] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amorino GP, 2002, MOL BIOL CELL, V13, P2233, DOI 10.1091/mbc.01-12-0572; BATRA SK, 1995, CELL GROWTH DIFFER, V6, P1251; BIGNER SH, 1990, CANCER RES, V50, P8017; Bowers G, 2001, ONCOGENE, V20, P1388, DOI 10.1038/sj.onc.1204255; Chu CT, 1997, BIOCHEM J, V324, P855, DOI 10.1042/bj3240855; Contessa JN, 2002, ONCOGENE, V21, P4032, DOI 10.1038/sj.onc.1205500; Contessa JN, 1999, CLIN CANCER RES, V5, P405; Dent P, 1999, MOL BIOL CELL, V10, P2493, DOI 10.1091/mbc.10.8.2493; EKSTRAND AJ, 1994, ONCOGENE, V9, P2313; Frederick L, 2000, CANCER RES, V60, P1383; Han YC, 1996, CANCER RES, V56, P3859; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Lammering G, 2001, INT J RADIAT ONCOL, V51, P775, DOI 10.1016/S0360-3016(01)01714-X; Lammering G, 2001, J NATL CANCER I, V93, P921, DOI 10.1093/jnci/93.12.921; Lammering G, 2001, CLIN CANCER RES, V7, P682; Montgomery RB, 1995, J BIOL CHEM, V270, P30562, DOI 10.1074/jbc.270.51.30562; MOSCATELLO DK, 1995, CANCER RES, V55, P5536; Moscatello DK, 1998, J BIOL CHEM, V273, P200, DOI 10.1074/jbc.273.1.200; Moscatello DK, 1996, ONCOGENE, V13, P85; Nagane M, 1996, CANCER RES, V56, P5079; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; O'Rourke DM, 1998, ONCOGENE, V16, P1197, DOI 10.1038/sj.onc.1201635; O'Rourke DM, 1998, P NATL ACAD SCI USA, V95, P10842, DOI 10.1073/pnas.95.18.10842; ORourke DM, 1997, P NATL ACAD SCI USA, V94, P3250, DOI 10.1073/pnas.94.7.3250; Reardon DB, 1999, ONCOGENE, V18, P4756, DOI 10.1038/sj.onc.1202849; Schmidt-Ullrich RK, 2000, RADIAT RES, V153, P245, DOI 10.1667/0033-7587(2000)153[0245:STACRR]2.0.CO;2; Schmidt-Ullrich RK, 1999, RADIAT ONCOL INVESTI, V7, P321, DOI 10.1002/(SICI)1520-6823(1999)7:6<321::AID-ROI2>3.0.CO;2-Q; SchmidtUllrich RK, 1997, ONCOGENE, V15, P1191, DOI 10.1038/sj.onc.1201275; SchmidtUllrich RK, 1996, RADIAT RES, V145, P81, DOI 10.2307/3579199; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965	31	72	84	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2003	22	36					5545	5553		10.1038/sj.onc.1206788	http://dx.doi.org/10.1038/sj.onc.1206788			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944901				2022-12-25	WOS:000184865900002
J	Berton, TR; Matsumoto, T; Page, A; Conti, CJ; Deng, CX; Jorcano, JL; Johnson, DG				Berton, TR; Matsumoto, T; Page, A; Conti, CJ; Deng, CX; Jorcano, JL; Johnson, DG			Tumor formation in mice with conditional inactivation of Brca1 in epithelial tissues	ONCOGENE			English	Article						BRCA1; Cre-lox; epithelium; E2F1	SUPPRESSOR GENE BRCA1; DNA-DAMAGE RESPONSE; INTERACT IN-VIVO; CELL-CYCLE; TRANSCRIPTIONAL ACTIVATION; CENTROSOME AMPLIFICATION; MESSENGER-RNA; BREAST; EXPRESSION; P53	The BRCA1 tumor-suppressor protein has been implicated in the regulation of transcription, DNA repair, proliferation, and apoptosis. BRCA1 is expressed in many proliferative tissues and this is at least in part due to E2F-dependent transcriptional control. In this study, inactivation of a conditional murine Brca1 allele was achieved in a variety of epithelial tissues via expression of the Cre recombinase under the control of a keratin 5 (K5) promoter. The K5 Cre:Brca1 conditional knockout mice exhibited modest epidermal hyperproliferation, increased apoptosis, and were predisposed to developing tumors in the skin, the inner ear canal, and the oral epithelium after 1 year of age. Overexpression of the E2F1 transcription factor in K5 Cre:Brca1 conditional knockout mice dramatically accelerated tumor development. In addition, Brca1 heterozygous female mice that had elevated E2F1 expression developed tumors of the reproductive tract at high incidence. These findings demonstrate that in mice Brca1 functions as a tumor suppressor in other epithelial tissues in addition to the mammary gland. Moreover, inactivation of Brca1 is shown to cooperate with deregulation of the Rb-E2F1 pathway to promote tumorigenesis.	Univ Texas, Dept Carcinogenesis, MD Anderson Canc Ctr, Sci Pk Res Div, Smithville, TX 78957 USA; CIEMAT, E-28040 Madrid, Spain; NIDDKD, Biochem & Metab Lab, Bethesda, MD 20892 USA	University of Texas System; UTMD Anderson Cancer Center; Centro de Investigaciones Energeticas, Medioambientales Tecnologicas; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Johnson, DG (corresponding author), Univ Texas, Dept Carcinogenesis, MD Anderson Canc Ctr, Sci Pk Res Div, Smithville, TX 78957 USA.	djohnson@sprd1.mdacc.tmc.edu	deng, chuxia/N-6713-2016	Johnson, David/0000-0002-6223-1790; Page, Angustias/0000-0002-0231-8536	NCI NIH HHS [T-32 CA9480] Funding Source: Medline; NIEHS NIH HHS [U01 ES11047] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009480] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK056001, Z01DK056001] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [U01ES011047] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aprelikova ON, 1999, P NATL ACAD SCI USA, V96, P11866, DOI 10.1073/pnas.96.21.11866; Baldwin RL, 2000, CANCER RES, V60, P5329; Bianco T, 2000, CARCINOGENESIS, V21, P147, DOI 10.1093/carcin/21.2.147; Brakebusch C, 2000, EMBO J, V19, P3990, DOI 10.1093/emboj/19.15.3990; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen YM, 1996, CANCER RES, V56, P3168; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Couch FJ, 1996, HUM MUTAT, V8, P8, DOI 10.1002/humu.1380080102; Crook T, 1998, ONCOGENE, V17, P1681, DOI 10.1038/sj.onc.1202106; Crook T, 1997, LANCET, V350, P638, DOI 10.1016/S0140-6736(05)63327-2; Eisinger F, 1997, LANCET, V350, P1101, DOI 10.1016/S0140-6736(05)70461-X; Esteller M, 2001, CANCER RES, V61, P3225; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Gatei M, 2000, CANCER RES, V60, P3299; Gatei M, 2001, J BIOL CHEM, V276, P17276, DOI 10.1074/jbc.M011681200; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Gudas JM, 1996, CELL GROWTH DIFFER, V7, P717; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hill ADK, 1997, BRIT J SURG, V84, P1334; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; Huber LJ, 2001, MOL CELL BIOL, V21, P4005, DOI 10.1128/MCB.21.12.4005-4015.2001; Johannsson O, 1999, EUR J CANCER, V35, P1248, DOI 10.1016/S0959-8049(99)00135-5; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Ludwig T, 2001, GENE DEV, V15, P1188, DOI 10.1101/gad.879201; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; Pierce AM, 1999, MOL CELL BIOL, V19, P6408; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; Polager S, 2002, ONCOGENE, V21, P437, DOI 10.1038/sj.onc.1205102; RAMIREZ A, 1994, DIFFERENTIATION, V58, P53, DOI 10.1007/s002580050065; Randrianarison V, 2001, CANCER GENE THER, V8, P759, DOI 10.1038/sj.cgt.7700366; Rao VN, 1996, ONCOGENE, V12, P523; Rhei E, 1998, CANCER RES, V58, P3193; Rice JC, 2000, CARCINOGENESIS, V21, P1761, DOI 10.1093/carcin/21.9.1761; Ruffner H, 1999, MOL CELL BIOL, V19, P4843; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SMEDTS F, 1992, AM J PATHOL, V140, P601; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Tong D, 2000, INT J CANCER, V88, P319, DOI 10.1002/1097-0215(20001015)88:2<319::AID-IJC27>3.0.CO;2-X; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; Wang A, 2000, J BIOL CHEM, V275, P4532, DOI 10.1074/jbc.275.6.4532; Wang AJ, 1999, NUCLEIC ACIDS RES, V27, P4609, DOI 10.1093/nar/27.23.4609; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Weaver Z, 2002, ONCOGENE, V21, P5097, DOI 10.1038/sj.onc.1205636; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; Wilson CA, 1997, ONCOGENE, V14, P1, DOI 10.1038/sj.onc.1200924; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	74	29	30	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2003	22	35					5415	5426		10.1038/sj.onc.1206825	http://dx.doi.org/10.1038/sj.onc.1206825			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JC	12934101				2022-12-25	WOS:000184735000006
J	Yeh, CT; Lu, SC; Tseng, IC; Lai, HY; Tsao, ML; Huang, SF; Liaw, YF				Yeh, CT; Lu, SC; Tseng, IC; Lai, HY; Tsao, ML; Huang, SF; Liaw, YF			Antisense overexpression of BMAL2 enhances cell proliferation	ONCOGENE			English	Article						hepatocellular carcinoma; BMAL2; antisense; cell cycle; TNF-alpha; caspase-3	DIFFERENTIALLY EXPRESSED GENES; HEPATOCELLULAR-CARCINOMA; HEPATITIS-C; NUCLEAR-LOCALIZATION; IDENTIFICATION; PROTEIN; CLONING; CARCINOGENESIS; MICROARRAY; APOPTOSIS	To identify genes that are frequently downregulated in hepatocellular carcinoma (HCC), a panel of putative underexpressed genes was first established by an in-house cDNA macroarray method. Two different assays, semi-quantitative RT-PCR combined with Northern analysis and customized cDNA microarray analysis, were used to screen through these genes and the results were compared. Several genes, some with unknown function, were confirmed to be downregulated by both the methods. The effect of a downregulated gene, BMAL2, on cell proliferation was examined. Overexpression of antisense BMAL2 RNA in 293EBNA cells resulted in reduced cell cycle time, increased plating efficiency in soft agar, diminished TNF-alpha-induced increment of CPP32/caspase-3 activity, and a reduced proportion of cells in the G2 phase with a concomitantly increased proportion of cells in the S phase. In conclusion, by combining three different methods, we have obtained a panel of frequently down regulated genes in HCC, including BMAL2. Antisense overexpression of BMAL2 enhances cell proliferation.	Chang Gung Mem Hosp, Liver Res Unit, Taipei 10591, Taiwan; Chang Gung Univ, Coll Med, Dept Pathol, Taipei, Taiwan	Chang Gung Memorial Hospital; Chang Gung University	Yeh, CT (corresponding author), Chang Gung Mem Hosp, Liver Res Unit, 199 Tung Hwa N Rd, Taipei 10591, Taiwan.	chauting@adm.cgmh.org.tw	Liaw, Yun-Fan/B-4305-2009; Huang, Shiu-Feng Kathy/E-3977-2010; Tseng, I-Chu/C-1936-2013	Tseng, I-Chu/0000-0001-8522-6524				BEASLEY RP, 1984, SEMIN LIVER DIS, V4, P113, DOI 10.1055/s-2008-1040651; Boige V, 1997, CANCER RES, V57, P1986; CHISARI FV, 1989, CELL, V59, P1145, DOI 10.1016/0092-8674(89)90770-8; CREWS ST, 1988, CELL, V52, P143, DOI 10.1016/0092-8674(88)90538-7; DiBisceglie AM, 1997, HEPATOLOGY, V26, pS34, DOI 10.1002/hep.510260706; Elferink CJ, 2001, MOL PHARMACOL, V59, P664, DOI 10.1124/mol.59.4.664; Gerber AN, 1996, MOL CELL BIOL, V16, P3901; HAMBOR JE, 1988, P NATL ACAD SCI USA, V85, P4010, DOI 10.1073/pnas.85.11.4010; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Hogenesch JB, 2000, J NEUROSCI, V20, part. no.; Hung SC, 2001, P NATL ACAD SCI USA, V98, P1865, DOI 10.1073/pnas.031584698; Iizuka N, 2002, CANCER RES, V62, P3939; Ikeda M, 2000, BIOCHEM BIOPH RES CO, V275, P493, DOI 10.1006/bbrc.2000.3248; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kolluri SK, 1999, GENE DEV, V13, P1742, DOI 10.1101/gad.13.13.1742; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; Kusano N, 1999, HEPATOLOGY, V29, P1858, DOI 10.1002/hep.510290636; Luo X, 1996, P NATL ACAD SCI USA, V93, P1308, DOI 10.1073/pnas.93.3.1308; Marchio A, 1997, GENE CHROMOSOME CANC, V18, P59, DOI 10.1002/(SICI)1098-2264(199701)18:1<59::AID-GCC7>3.0.CO;2-0; Miyasaka Y, 2001, BRIT J CANCER, V85, P228, DOI 10.1054/bjoc.2001.1901; Moriya K, 1998, NAT MED, V4, P1065, DOI 10.1038/2053; Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136; Norton JD, 2000, J CELL SCI, V113, P3897; Okabe H, 2001, CANCER RES, V61, P2129; Okano T, 2001, GENES CELLS, V6, P825, DOI 10.1046/j.1365-2443.2001.00462.x; REDDY P, 1986, CELL, V46, P53, DOI 10.1016/0092-8674(86)90859-7; Scuric Z, 1998, HEPATOLOGY, V27, P943, DOI 10.1002/hep.510270408; Shirota Y, 2001, HEPATOLOGY, V33, P832, DOI 10.1053/jhep.2001.23003; Taylor BL, 1999, MICROBIOL MOL BIOL R, V63, P479, DOI 10.1128/MMBR.63.2.479-506.1999; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Wang ZX, 2001, BRIT J CANCER, V85, P1162, DOI 10.1054/bjoc.2001.2059; WU GS, 1995, LIFE SCI, V57, P1077, DOI 10.1016/0024-3205(95)02053-L; Xu XR, 2001, P NATL ACAD SCI USA, V98, P15089, DOI 10.1073/pnas.241522398; Yeh CT, 1998, J MED VIROL, V55, P42, DOI 10.1002/(SICI)1096-9071(199805)55:1<42::AID-JMV8>3.0.CO;2-O; Yeh CT, 2000, ONCOGENE, V19, P5213, DOI 10.1038/sj.onc.1203903; Yeh CT, 2001, J VIROL, V75, P11017, DOI 10.1128/JVI.75.22.11017-11024.2001; Yeh CT, 1997, J GEN VIROL, V78, P2761, DOI 10.1099/0022-1317-78-11-2761; YEH CT, 1993, P NATL ACAD SCI USA, V90, P6459, DOI 10.1073/pnas.90.14.6459	39	26	30	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2003	22	34					5306	5314		10.1038/sj.onc.1206674	http://dx.doi.org/10.1038/sj.onc.1206674			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JB	12917632				2022-12-25	WOS:000184734900010
J	Mulugeta, S; Beers, MF				Mulugeta, S; Beers, MF			Processing of surfactant protein C requires a type II transmembrane topology directed by juxtamembrane positively charged residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSIN-CONVERTING ENZYME; INTEGRAL MEMBRANE-PROTEIN; STRUCTURAL REQUIREMENTS; AGGRESOME FORMATION; I/D POLYMORPHISM; GENE; PALMITOYLATION; BIOSYNTHESIS; ORIENTATION; PROPROTEIN	Surfactant protein C (SP-C) is a lung-specific protein that is synthesized as a 21-kDa integral membrane propeptide (pro-SP-C) and proteolytically processed to a 3.7-kDa secretory product. Previous studies have shown that palmitoylation of pro-SP-C is dependent on two N-terminal juxtamembrane positively charged residues. We hypothesized that these residues influence modification of pro-SP-C by directing transmembrane orientation. Double substitution mutation of these juxtaposed residues from positive to neutral charged species resulted in complete reversal of transmembrane orientation of pro-SP-C and total abrogation of post-translational processing. Mutation of a single residue resulted in mixed orientation. Protein trafficking studies in A549 cells showed that while the double mutant was retained in the endoplasmic reticulum, single mutants produced a mixed pattern of both endoplasmic reticulum ( double mutant-like) and vesicular (wild type-like) expression. Our study demonstrates the crucial role juxtamembrane positively charged residues play in establishing membrane topology and their influence on the trafficking and processing of pro-SP-C. Moreover this study provides a likely precedent for a mechanism in disorders associated with mutations in the membrane-flanking region of integral membrane proteins.	Univ Penn, Abramson Res Ctr, Pulm & Crit Care Div, Sch Med,Lung Epithelial Cell Biol Labs, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Mulugeta, S (corresponding author), Univ Penn, Abramson Res Ctr, Pulm & Crit Care Div, Sch Med,Lung Epithelial Cell Biol Labs, Room 1015 Hb,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	mulugeta@mail.med.upenn.edu			NHLBI NIH HHS [HL-19737, HL74064, P50-HL56401] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL019737, R01HL074064, P50HL056401] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beers M. F., 1998, MED INTELL UNIT, P93; BELTZER JP, 1991, J BIOL CHEM, V266, P973; Carrell RW, 2002, NEW ENGL J MED, V346, P45, DOI 10.1056/NEJMra010772; Carter J., 2001, Current Molecular Medicine (Hilversum), V1, P733, DOI 10.2174/1566524013363177; Conkright JJ, 2001, J BIOL CHEM, V276, P14658, DOI 10.1074/jbc.M011770200; Davis RL, 2002, LANCET, V359, P2242, DOI 10.1016/S0140-6736(02)09293-0; FISHER JH, 1989, BIOCHIM BIOPHYS ACTA, V995, P225, DOI 10.1016/0167-4838(89)90040-X; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Goder V, 1999, J CELL BIOL, V147, P257, DOI 10.1083/jcb.147.2.257; Goder V, 2001, FEBS LETT, V504, P87, DOI 10.1016/S0014-5793(01)02712-0; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; Hooper NM, 2000, BIOCHEM SOC T, V28, P441, DOI 10.1042/0300-5127:0280441; ISHIGAMI T, 1995, CIRCULATION, V91, P951, DOI 10.1161/01.CIR.91.4.951; Johnson AL, 2001, AM J RESP CELL MOL, V24, P253, DOI 10.1165/ajrcmb.24.3.4312; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kabore AF, 2001, J CELL SCI, V114, P293; KABORE AF, 2000, AM J RESP CRIT CARE, V161, pA41; Manoil C, 1995, ANNU REV GENET, V29, P131; Monne M, 1998, J MOL BIOL, V284, P1177, DOI 10.1006/jmbi.1998.2218; Niu TH, 2002, DRUGS, V62, P977, DOI 10.2165/00003495-200262070-00001; Nogee LM, 2002, CHEST, V121, p20S, DOI 10.1378/chest.121.3_suppl.20S; Nogee LM, 2001, NEW ENGL J MED, V344, P573, DOI 10.1056/NEJM200102223440805; Notterpek L, 1999, NEUROBIOL DIS, V6, P450, DOI 10.1006/nbdi.1999.0274; Ott CM, 2002, J CELL SCI, V115, P2003; PARKS GD, 1993, J BIOL CHEM, V268, P19101; PARKS GD, 1991, CELL, V64, P777, DOI 10.1016/0092-8674(91)90507-U; PASTRANA B, 1991, BIOCHEMISTRY-US, V30, P10058, DOI 10.1021/bi00105a033; Russo SJ, 1999, AM J PHYSIOL-LUNG C, V277, pL1034, DOI 10.1152/ajplung.1999.277.5.L1034; Seidah NG, 1997, CURR OPIN BIOTECH, V8, P602, DOI 10.1016/S0958-1669(97)80036-5; Solarin KO, 1997, PEDIATR RES, V42, P356, DOI 10.1203/00006450-199709000-00017; Soto C, 2001, FEBS LETT, V498, P204, DOI 10.1016/S0014-5793(01)02486-3; Stefansson B, 2000, BLOOD PRESSURE, V9, P104, DOI 10.1080/080370500453429; Szolnoki Z, 2001, J NEUROL, V248, P756, DOI 10.1007/s004150170090; ten Brinke A, 2002, BIOCHEM BIOPH RES CO, V290, P532, DOI 10.1006/bbrc.2001.6223; ten Brinke A, 2001, AM J RESP CELL MOL, V25, P156, DOI 10.1165/ajrcmb.25.2.4423; Ten Brinke A, 2002, BIOCHEM J, V361, P663, DOI 10.1042/0264-6021:3610663; Thomas AQ, 2002, AM J RESP CRIT CARE, V165, P1322, DOI 10.1164/rccm.200112-123OC; Tobler AR, 1999, J NEUROSCI, V19, P2027; van Geest M, 2000, MICROBIOL MOL BIOL R, V64, P13, DOI 10.1128/MMBR.64.1.13-33.2000; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; VORBROKER DK, 1992, BIOCHIM BIOPHYS ACTA, V1105, P161, DOI 10.1016/0005-2736(92)90175-L; Wallin E, 1998, PROTEIN SCI, V7, P1029, DOI 10.1002/pro.5560070420; Wang WJ, 2003, J CELL SCI, V116, P683, DOI 10.1242/jcs.00267; Wang WJ, 2002, J BIOL CHEM, V277, P19929, DOI 10.1074/jbc.M201537200; WARR RG, 1987, P NATL ACAD SCI USA, V84, P7915, DOI 10.1073/pnas.84.22.7915; WETZEL R, 1994, TRENDS BIOTECHNOL, V12, P193, DOI 10.1016/0167-7799(94)90082-5	48	19	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47979	47986		10.1074/jbc.M308210200	http://dx.doi.org/10.1074/jbc.M308210200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12933801	hybrid			2022-12-25	WOS:000186731400076
J	Fitch, ME; Nakajima, S; Yasui, A; Ford, JM				Fitch, ME; Nakajima, S; Yasui, A; Ford, JM			In vivo recruitment of XPC to UV-induced cyclobutane pyrimidine dimers by the DDB2 gene product	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE; TRANSCRIBED STRAND; EXCISION; REPAIR; BINDING; PHOTOLYASE; IRRADIATION; CELLS; P48; RECOGNITION	The initial step in mammalian nucleotide excision repair (NER) of the major UV-induced photoproducts, cyclobutane pyrimidine dimers (CPDs) and 6-4 photoproducts (6-4PPs), requires lesion recognition. It is believed that the heterodimeric proteins XPC/hHR23B and UV-DDB (UV-damaged DNA binding factor, composed of the p48 and p127 subunits) perform this function in genomic DNA, but their requirement and lesion specificity in vivo remains unknown. Using repair-deficient xeroderma pigmentosum (XP)-A cells that stably express photoproduct-specific photolyases, we determined the binding characteristics of p48 and XPC to either CPDs or 6-4PPs in vivo. p48 localized to UV-irradiated sites that contained either CPDs or 6-4PPs. However, XPC localized only to UV-irradiated sites that contained 6-4PPs, suggesting that XPC does not efficiently recognize CPDs in vivo. XPC did localize to CPDs when p48 was overexpressed in the same cell, signifying that p48 activates the recruitment of XPC to CPDs and may be the initial recognition factor in the NER pathway.	Stanford Univ, Sch Med, Dept Med, Div Oncol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Tohoku Univ, Inst Dev Aging & Canc, Dept Mol Genet, Sendai, Miyagi 9808575, Japan	Stanford University; Stanford University; Tohoku University	Ford, JM (corresponding author), Stanford Univ, Sch Med, Dept Med, Div Oncol, 1115 CCSR Bldg,269 Campus Dr, Stanford, CA 94305 USA.	jmf@stanford.edu		Ford, James/0000-0002-2513-7025	NATIONAL CANCER INSTITUTE [R01CA083889] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 83889] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; Batty D, 2000, J MOL BIOL, V300, P275, DOI 10.1006/jmbi.2000.3857; Chigancas V, 2000, CANCER RES, V60, P2458; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; Fitch ME, 2003, CARCINOGENESIS, V24, P843, DOI 10.1093/carcin/bgg031; FITCH ME, 2003, DNA REPAIR AMST, P819; Ford JM, 1997, CURR TOP MICROBIOL, V221, P47; Fujiwara Y, 1999, J BIOL CHEM, V274, P20027, DOI 10.1074/jbc.274.28.20027; Groisman R, 2003, CELL, V113, P357, DOI 10.1016/S0092-8674(03)00316-7; Hey T, 2002, BIOCHEMISTRY-US, V41, P6583, DOI 10.1021/bi012202t; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; KEENEY S, 1993, J BIOL CHEM, V268, P21293; Kosmoski JV, 1999, BIOCHEMISTRY-US, V38, P9485, DOI 10.1021/bi990297h; Kusumoto R, 2001, MUTAT RES-DNA REPAIR, V485, P219, DOI 10.1016/S0921-8777(00)00082-3; LOMMEL L, 1993, MOL CELL BIOL, V13, P970, DOI 10.1128/MCB.13.2.970; Meijer M, 1999, BIOESSAYS, V21, P596, DOI 10.1002/(SICI)1521-1878(199907)21:7<596::AID-BIES8>3.0.CO;2-5; MITCHELL DL, 1985, MUTAT RES, V143, P109, DOI 10.1016/S0165-7992(85)80018-X; MORI T, 1991, PHOTOCHEM PHOTOBIOL, V54, P225, DOI 10.1111/j.1751-1097.1991.tb02010.x; Nakajima S, 1998, NUCLEIC ACIDS RES, V26, P638, DOI 10.1093/nar/26.2.638; NG JMY, 2003, GENE DEV; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Rapic-Otrin V, 2002, NUCLEIC ACIDS RES, V30, P2588, DOI 10.1093/nar/30.11.2588; SANCAR GB, 1990, MUTAT RES, V236, P147, DOI 10.1016/0921-8777(90)90002-M; SATOKATA I, 1992, MUTAT RES, V273, P193, DOI 10.1016/0921-8777(92)90080-M; Schieferstein U, 1998, EMBO J, V17, P306, DOI 10.1093/emboj/17.1.306; Schul W, 2002, EMBO J, V21, P4719, DOI 10.1093/emboj/cdf456; Smerdon MJ, 1999, PROG NUCLEIC ACID RE, V62, P227; Sugasawa K, 1998, MOL CELL, V2, P223, DOI 10.1016/S1097-2765(00)80132-X; Thoma F, 1999, EMBO J, V18, P6585, DOI 10.1093/emboj/18.23.6585; VENEMA J, 1991, MOL CELL BIOL, V11, P4128, DOI 10.1128/MCB.11.8.4128; Volker M, 2001, MOL CELL, V8, P213, DOI 10.1016/S1097-2765(01)00281-7; Wakasugi M, 2002, J BIOL CHEM, V277, P1637, DOI 10.1074/jbc.C100610200; Wakasugi M, 2001, J BIOL CHEM, V276, P15434, DOI 10.1074/jbc.M011177200; Wang QE, 2003, DNA REPAIR, V2, P483, DOI 10.1016/S1568-7864(03)00002-8; YASUI A, 1994, EMBO J, V13, P6143, DOI 10.1002/j.1460-2075.1994.tb06961.x; You YH, 2001, J BIOL CHEM, V276, P44688, DOI 10.1074/jbc.M107696200	36	191	198	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46906	46910		10.1074/jbc.M307254200	http://dx.doi.org/10.1074/jbc.M307254200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12944386				2022-12-25	WOS:000186569400084
J	Ghirlando, R; Trainor, CD				Ghirlando, R; Trainor, CD			Determinants of GATA-1 binding to DNA - The role of non-finger residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; PROTEIN-PROTEIN INTERACTION; IN-VIVO; ZINC-FINGER; MEGAKARYOCYTIC CELLS; REGULATORY ELEMENT; SELF-ASSOCIATION; CUTTING EDGE; N-FINGER; COMPLEX	Mammalian GATA transcription factors are expressed in various tissues in a temporally regulated manner. The prototypic member, GATA-1, is required for normal erythroid, megakaryocytic, and mast cell development. This family of DNA-binding proteins recognizes a consensus (A/T) GATA(A/G) motif and possesses homologous DNA binding domains consisting of two zinc fingers. The C-terminal finger of GATA-1 recognizes the consensus motif with nanomolar affinities, whereas the N-terminal finger shows a binding preference for a GATC motif, albeit with much reduced affinity (K(d)approximate tomuM). The N-terminal finger of GATA-2 also shows a preference for an AGATCT binding site, with an increased affinity attributed to N- and C-terminal flanking basic residues (K(d)approximate tonM). To understand the differences in the binding specificities of the N- and C-terminal zinc fingers of GATA-1, we have constructed a series of swapped domain peptides. We show that the specificity for AGATAA over AGATCT arises from the C-terminal non-finger basic domain. Thus, the N- terminal finger binds preferentially to AGATAA once appended to the C-terminal arm of the C-terminal finger. We further show that this specificity arises from the highly conserved QTRNRK residues. The converse is, however, untrue in the case of the C-terminal finger; swapping of QTRNRK with the corresponding LVSKRA does not switch the DNA binding specificity from AGATAA to AGATCT. These results highlight the important role of residues adjacent to the CXXCX(17)CNAC zinc finger motif (i.e. non-finger residues) in the specific recognition of DNA residues.	NIDDK, Mol Biol Lab, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Ghirlando, R (corresponding author), NIDDK, Mol Biol Lab, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA.		Ghirlando, Rodolfo/A-8880-2009		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK011005, ZIADK011005] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Boyes J, 1998, J MOL BIOL, V279, P529, DOI 10.1006/jmbi.1998.1783; Cantor AB, 2002, ONCOGENE, V21, P3368, DOI 10.1038/sj.onc.1205326; Chen ML, 2001, EUR J IMMUNOL, V31, P1696, DOI 10.1002/1521-4141(200106)31:6<1696::AID-IMMU1696>3.3.CO;2-E; Crispino JD, 1999, MOL CELL, V3, P219, DOI 10.1016/S1097-2765(00)80312-3; CROSSLEY M, 1995, MOL CELL BIOL, V15, P2448; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Eisbacher M, 2003, MOL CELL BIOL, V23, P3427, DOI 10.1128/MCB.23.10.3427-3441.2003; EVANS T, 1991, MOL CELL BIOL, V11, P843, DOI 10.1128/MCB.11.2.843; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; Fujiwara Y, 1996, P NATL ACAD SCI USA, V93, P12355, DOI 10.1073/pnas.93.22.12355; Ghirlando R, 2000, J BIOL CHEM, V275, P28152; HANNON R, 1991, P NATL ACAD SCI USA, V88, P3004, DOI 10.1073/pnas.88.8.3004; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; Lowry JA, 2000, J MOL EVOL, V50, P103, DOI 10.1007/s002399910012; Mackay JP, 1998, J BIOL CHEM, V273, P30560, DOI 10.1074/jbc.273.46.30560; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; Mead PE, 2001, DEVELOPMENT, V128, P2301; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; Migliaccio AR, 2003, J EXP MED, V197, P281, DOI 10.1084/jem.20021149; Newton A, 2001, J BIOL CHEM, V276, P35794, DOI 10.1074/jbc.M106256200; Nichols KE, 2000, NAT GENET, V24, P266, DOI 10.1038/73480; Ohneda K, 2002, GENES CELLS, V7, P1243, DOI 10.1046/j.1365-2443.2002.00595.x; Ohneda K, 2002, ACTA HAEMATOL-BASEL, V108, P237, DOI 10.1159/000065660; OMICHINSKI JG, 1993, P NATL ACAD SCI USA, V90, P1676, DOI 10.1073/pnas.90.5.1676; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; Pedone PV, 1997, EMBO J, V16, P2874, DOI 10.1093/emboj/16.10.2874; SCHWARTZBAUER G, 1992, NUCLEIC ACIDS RES, V20, P4429, DOI 10.1093/nar/20.17.4429; Shimizu R, 2001, EMBO J, V20, P5250, DOI 10.1093/emboj/20.18.5250; Shivdasani RA, 1997, EMBO J, V16, P3965, DOI 10.1093/emboj/16.13.3965; Starich MR, 1998, J MOL BIOL, V277, P605, DOI 10.1006/jmbi.1998.1625; Takahashi S, 1998, BLOOD, V92, P434, DOI 10.1182/blood.V92.2.434.414k24_434_442; Takemoto N, 2002, J IMMUNOL, V169, P4103, DOI 10.4049/jimmunol.169.8.4103; Trainor CD, 2000, J BIOL CHEM, V275, P28157; Trainor CD, 1996, MOL CELL BIOL, V16, P2238; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; Vyas P, 1999, DEVELOPMENT, V126, P2799; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; Waltzer L, 2002, EMBO J, V21, P5477, DOI 10.1093/emboj/cdf545; Weiss MJ, 1997, MOL CELL BIOL, V17, P1642, DOI 10.1128/MCB.17.3.1642; WHYATT DJ, 1993, EMBO J, V12, P4993, DOI 10.1002/j.1460-2075.1993.tb06193.x; YANG HY, 1995, MOL CELL BIOL, V15, P1353; Yu CN, 2002, J EXP MED, V195, P1387, DOI 10.1084/jem.20020656; Yu CN, 2002, BLOOD, V100, P2040, DOI 10.1182/blood-2002-02-0387; Zhang DH, 1998, J IMMUNOL, V161, P3817	46	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45620	45628		10.1074/jbc.M306410200	http://dx.doi.org/10.1074/jbc.M306410200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12941967	hybrid			2022-12-25	WOS:000186452300071
J	Huecas, S; Andreu, JM				Huecas, S; Andreu, JM			Energetics of the cooperative assembly of cell division protein FtsZ and the nucleotide hydrolysis switch	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-BETA-TUBULIN; ESCHERICHIA-COLI; GTP HYDROLYSIS; CRYSTAL-STRUCTURE; BINDING; ACTIN; POLYMERIZATION; ASSOCIATION; DYNAMICS; RECONSTITUTION	FtsZis the first protein recruited to the bacterial division site, where it forms the cytokinetic Z ring. We have determined the functional energetics of FtsZ assembly, employing FtsZ from the thermophilic Archaea Methanococcus jannaschii bound to GTP, GMPCPP, GDP, or GMPCP, under different solution conditions. FtsZ oligomerizes in a magnesium-insensitive manner. FtsZ cooperatively assembles with magnesium and GTP or GMPCPP into large polymers, following a nucleated condensation polymerization mechanism, under nucleotide hydrolyzing and non-hydrolyzing conditions. The effect of temperature on the critical concentration indicates polymer elongation with an apparent heat capacity change of -800 +/- 100 cal mol(-1) K-1 and positive enthalpy and entropy changes, compatible with axial hydrophobic contacts of each FtsZ in the polymer, and predicts optimal polymer stability near 75 degreesC. Assembly entails the binding of one medium affinity magnesium ion and the uptake of one proton per FtsZ. Interestingly, GDP- or GMPCP-liganded FtsZ cooperatively form helically curved polymers, with an elongation only 1-2 kcal mol(-1) more unfavorable than the straight polymers formed with nucleotide triphosphate, suggesting a physiological requirement for FtsZ polymerization inhibitors. This GTP hydrolysis switch should provide the basic properties for FtsZ polymer disassembly and its functional dynamics.	CSIC, Ctr Invest Biol, E-28040 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Huecas, S (corresponding author), CSIC, Ctr Invest Biol, Ramiro de Maeztu 9, E-28040 Madrid, Spain.	sonia@cib.csic.es; j.m.andreu@cib.csic.es	Huecas, Sonia/P-2542-2019; Huecas, Sonia/K-1754-2014	Huecas, Sonia/0000-0002-6419-441X; Huecas, Sonia/0000-0002-6419-441X; Andreu, Jose M/0000-0001-8064-6933				Alberts B, 1998, CELL, V92, P291, DOI 10.1016/S0092-8674(00)80922-8; ANDREU JM, 1986, METHOD ENZYMOL, V130, P47; Andreu JM, 2002, J BIOL CHEM, V277, P43262, DOI 10.1074/jbc.M206723200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Caplan MR, 2003, J BIOL CHEM, V278, P13784, DOI 10.1074/jbc.M300860200; CAPLOW M, 1994, J CELL BIOL, V127, P779, DOI 10.1083/jcb.127.3.779; CARLIER MF, 1991, J BIOL CHEM, V266, P12361; CARLIER MF, 1987, BIOCHEMISTRY-US, V26, P4428, DOI 10.1021/bi00388a036; Chacon P, 2002, J MOL BIOL, V317, P375, DOI 10.1006/jmbi.2002.5438; Cordell SC, 2003, P NATL ACAD SCI USA, V100, P7889, DOI 10.1073/pnas.1330742100; CORREIA JJ, 1988, J BIOL CHEM, V263, P10681; CORREIA JJ, 1987, J BIOL CHEM, V262, P17278; DEBOER P, 1992, NATURE, V359, P254, DOI 10.1038/359254a0; DIAZ JF, 1994, J MOL BIOL, V238, P214, DOI 10.1006/jmbi.1994.1282; Diaz JF, 2001, J BIOL CHEM, V276, P17307, DOI 10.1074/jbc.M010920200; DIAZ JF, 1993, BIOCHEMISTRY-US, V32, P10067, DOI 10.1021/bi00089a023; Erickson HP, 1996, P NATL ACAD SCI USA, V93, P519, DOI 10.1073/pnas.93.1.519; ERICKSON HP, 1989, J MOL BIOL, V206, P465, DOI 10.1016/0022-2836(89)90494-4; Gonzalez JM, 2003, J BIOL CHEM, V278, P37664, DOI 10.1074/jbc.M305230200; HOWARD WD, 1986, BIOCHEMISTRY-US, V25, P8292, DOI 10.1021/bi00373a025; HYMAN AA, 1992, MOL BIOL CELL, V3, P1155, DOI 10.1091/mbc.3.10.1155; Jaenicke R, 2000, ADV PROTEIN CHEM, V53, P329; JONES WJ, 1983, ARCH MICROBIOL, V136, P254, DOI 10.1007/BF00425213; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; LEE JC, 1975, BIOCHEMISTRY-US, V14, P5183, DOI 10.1021/bi00694a025; LEE JC, 1977, BIOCHEMISTRY-US, V16, P1754, DOI 10.1021/bi00627a037; Levin PA, 1999, P NATL ACAD SCI USA, V96, P9642, DOI 10.1073/pnas.96.17.9642; Lowe J, 1998, NATURE, V391, P203, DOI 10.1038/34472; Lowe J, 1999, EMBO J, V18, P2364, DOI 10.1093/emboj/18.9.2364; Lowe J, 2001, J MOL BIOL, V313, P1045, DOI 10.1006/jmbi.2001.5077; Lu CL, 1998, CELL MOTIL CYTOSKEL, V40, P71, DOI 10.1002/(SICI)1097-0169(1998)40:1<71::AID-CM7>3.3.CO;2-Z; Lu CL, 2000, J BACTERIOL, V182, P164, DOI 10.1128/JB.182.1.164-170.2000; Luque I, 1998, PROTEINS, V30, P74, DOI 10.1002/(SICI)1097-0134(199801)30:1<74::AID-PROT7>3.3.CO;2-G; Luque I, 1998, METHOD ENZYMOL, V295, P100; Lutkenhaus J, 2002, CURR OPIN MICROBIOL, V5, P548, DOI 10.1016/S1369-5274(02)00376-4; Meinhardt H, 2001, P NATL ACAD SCI USA, V98, P14202, DOI 10.1073/pnas.251216598; Menendez M, 1998, J BIOL CHEM, V273, P167, DOI 10.1074/jbc.273.1.167; Mingorance J, 2001, MOL MICROBIOL, V41, P83, DOI 10.1046/j.1365-2958.2001.02498.x; Minton A.P., 1994, MODERN ANAL ULTRACEN, P81; Mukherjee A, 1999, J BACTERIOL, V181, P823, DOI 10.1128/JB.181.3.823-832.1999; MUKHERJEE A, 1994, J BACTERIOL, V176, P2754, DOI 10.1128/JB.176.9.2754-2758.1994; MUKHERJEE A, 1993, P NATL ACAD SCI USA, V90, P1053, DOI 10.1073/pnas.90.3.1053; Mukherjee A, 1998, EMBO J, V17, P462, DOI 10.1093/emboj/17.2.462; Nogales E, 1999, CELL, V96, P79, DOI 10.1016/S0092-8674(00)80961-7; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; Nogales E, 2003, CURR OPIN STRUC BIOL, V13, P256, DOI 10.1016/S0959-440X(03)00029-0; Oliva MA, 2003, J BIOL CHEM, V278, P33562, DOI 10.1074/jbc.M303798200; OOSAWA F, 1962, J MOL BIOL, V4, P10, DOI 10.1016/S0022-2836(62)80112-0; Oosawa F., 1975, THERMODYNAMICS POLYM; PERRONE PA, 1984, J CHROMATOGR, V317, P301, DOI 10.1016/S0021-9673(01)91668-1; Philo JS, 1997, BIOPHYS J, V72, P435, DOI 10.1016/S0006-3495(97)78684-3; Pichoff S, 2001, J BACTERIOL, V183, P6630, DOI 10.1128/JB.183.22.6630-6635.2001; RAYCHAUDHURI D, 1992, NATURE, V359, P251, DOI 10.1038/359251a0; Record MT, 1998, TRENDS BIOCHEM SCI, V23, P190, DOI 10.1016/S0968-0004(98)01207-9; Rivas G, 2000, J BIOL CHEM, V275, P11740, DOI 10.1074/jbc.275.16.11740; Romberg L, 2001, J BIOL CHEM, V276, P11743, DOI 10.1074/jbc.M009033200; Scheffers DJ, 2002, MOL MICROBIOL, V43, P1517, DOI 10.1046/j.1365-2958.2002.02828.x; Scheffers DJ, 2001, FEBS LETT, V506, P6, DOI 10.1016/S0014-5793(01)02855-1; SECKLER R, 1990, J BIOL CHEM, V265, P7655; Shapiro L, 2002, SCIENCE, V298, P1942, DOI 10.1126/science.1072163; Shapiro L, 2000, CELL, V100, P89, DOI 10.1016/S0092-8674(00)81686-4; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; Stricker J, 2002, P NATL ACAD SCI USA, V99, P3171, DOI 10.1073/pnas.052595099; Sun Q, 1998, J BACTERIOL, V180, P2050, DOI 10.1128/JB.180.8.2050-2056.1998; van den Ent F, 2001, NATURE, V413, P39, DOI 10.1038/35092500; van den Ent F, 2002, EMBO J, V21, P6935, DOI 10.1093/emboj/cdf672; van den Ent F, 2000, EMBO J, V19, P5300, DOI 10.1093/emboj/19.20.5300; Vicente Miguel, 2003, EMBO Reports, V4, P655, DOI 10.1038/sj.embor.embor885; Vulevic B, 1997, BIOPHYS J, V72, P1357, DOI 10.1016/S0006-3495(97)78782-4; White EL, 2000, J BACTERIOL, V182, P4028, DOI 10.1128/JB.182.14.4028-4034.2000; Wyman J, 1990, BINDING LINKAGE FUNC; Yu XC, 1997, EMBO J, V16, P5455, DOI 10.1093/emboj/16.17.5455	73	46	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					46146	46154		10.1074/jbc.M307128200	http://dx.doi.org/10.1074/jbc.M307128200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12933789	hybrid, Green Published			2022-12-25	WOS:000186452300132
J	Le Gall, SM; Auger, R; Dreux, C; Mauduit, P				Le Gall, SM; Auger, R; Dreux, C; Mauduit, P			Regulated cell surface Pro-EGF ectodomain shedding is a zinc metalloprotease-dependent process	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; NECROSIS-FACTOR-ALPHA; ACTIVATED PROTEIN-KINASE; LACTATING MAMMARY-GLAND; TGF-ALPHA; CONVERTING-ENZYME; MEMBRANE-PROTEIN; FACTOR PRECURSOR; MESSENGER-RNA; FACTOR CDNA	Epidermal growth factor receptor (EGFR) ligands are synthesized as type I membrane protein precursors exposed at the cell surface. Shedding of the ectodomain of these proteins is the way cells regulate the equilibrium between cell-associated and diffusible forms of these growth factors. Whereas the regulated shedding of transforming growth factor-alpha, HB-EGF, and amphiregulin precursors have been clearly established, regulation of full-length pro-EGF shedding has not been clearly demonstrated. Here, using both wild-type and M2 mutant CHO-K1 as well as HeLa cell lines transiently transfected with epitope-tagged rat pro-EGF expression plasmid, we demonstrate that these cells synthesize EGF as a high molecular weight membrane-associated precursor glycoprotein expressed at the cell surface. All cell lines are able to release the entire ectodomain of pro-EGF in the extracellular medium following juxtamembrane cleavage of the precursor once it is present at the cell surface. More significantly we clearly established that CHO-M2 and HeLa cells only constitutively release low levels of pro-EGF. This shedding is a regulated phenomenon in wild-type CHO cells where it can be induced by different agents such as phorbol 12-myristate 13-acetate (PMA), pervanadate, and serum but not by calcium ionophores. Using specific inhibitors as well as protein kinase C (PKC) depletion, PMA stimulation was shown to be completely dependent on PKC activation whereas pervanadate and serum stimulation were not. Regulated ectodomain shedding involves the activity of a zinc metalloprotease as determined by inhibition with phenantrolin and TAPI-2 and by the results obtained with the CHO-M2 shedding defective mutant cell line. Comparison of the ability of CHO and HeLa cell lines to shed pro-EGF and pro-TNF-alpha upon stimulation greatly suggests that TACE (ADAM 17) may not be the ectoprotease involved in the secretion of pro-EGF ectodomain and that this protease, which remains to be identified, shows a restricted cellular expression pattern.	Univ Paris 11, UMR 819, Inst Biochim Biophys Mol & Cellulaire, F-91405 Orsay, France	UDICE-French Research Universities; Universite Paris Saclay	Mauduit, P (corresponding author), Univ Paris 11, UMR 819, Inst Biochim Biophys Mol & Cellulaire, F-91405 Orsay, France.	philippe.mauduit@bbmpc.u-psud.fr						Amour A, 2002, FEBS LETT, V524, P154, DOI 10.1016/S0014-5793(02)03047-8; ANKLESARIA P, 1990, P NATL ACAD SCI USA, V87, P3289, DOI 10.1073/pnas.87.9.3289; ARRIBAS J, 1995, J CELL BIOL, V128, P433, DOI 10.1083/jcb.128.3.433; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; BEARDMORE JM, 1983, J ENDOCRINOL, V96, P287, DOI 10.1677/joe.0.0960287; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Black RA, 1998, CURR OPIN CELL BIOL, V10, P654, DOI 10.1016/S0955-0674(98)80042-2; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; Borrell-Pages M, 2003, EMBO J, V22, P1114, DOI 10.1093/emboj/cdg111; Borroto A, 2003, J BIOL CHEM, V278, P25933, DOI 10.1074/jbc.M301673200; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; BREYER JA, 1990, J BIOL CHEM, V265, P16564; BROWN CF, 1989, MOL ENDOCRINOL, V3, P1077, DOI 10.1210/mend-3-7-1077; Brown CL, 1998, J BIOL CHEM, V273, P17258, DOI 10.1074/jbc.273.27.17258; BYYNY RL, 1974, ENDOCRINOLOGY, V95, P776, DOI 10.1210/endo-95-3-776; CARPENTER G, 1985, J CELL SCI, P1; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; COHEN S, 1962, J BIOL CHEM, V237, P1555; Davis-Fleischer KM, 2001, GROWTH FACTORS, V19, P127, DOI 10.3109/08977190109001081; DEMPSEY PJ, 1994, J BIOL CHEM, V269, P16878; Dempsey PJ, 1997, J CELL BIOL, V138, P747, DOI 10.1083/jcb.138.4.747; DERYNCK R, 1992, ADV CANCER RES, V58, P27, DOI 10.1016/S0065-230X(08)60289-4; Diaz-Rodriguez E, 2002, MOL BIOL CELL, V13, P2031, DOI 10.1091/mbc.01-11-0561; Dong JY, 2000, J BIOL CHEM, V275, P557, DOI 10.1074/jbc.275.1.557; Fan HZ, 1999, EMBO J, V18, P6962, DOI 10.1093/emboj/18.24.6962; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FISHER DA, 1990, ENDOCR REV, V11, P418, DOI 10.1210/edrv-11-3-418; FISHER DA, 1989, ANNU REV PHYSIOL, V51, P67, DOI 10.1146/annurev.physiol.51.1.67; Gechtman Z, 1999, J BIOL CHEM, V274, P28828, DOI 10.1074/jbc.274.40.28828; GRAY A, 1983, NATURE, V303, P722, DOI 10.1038/303722a0; HAMMERMAN MR, 1993, ANNU REV PHYSIOL, V55, P305, DOI 10.1146/annurev.physiol.55.1.305; HIGASHIYAMA S, 1995, J CELL BIOL, V128, P929, DOI 10.1083/jcb.128.5.929; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; JAHNKE GD, 1994, ENDOCRINOLOGY, V135, P2022, DOI 10.1210/en.135.5.2022; JORGENSEN PE, 1991, BIOCHIM BIOPHYS ACTA, V1074, P284, DOI 10.1016/0304-4165(91)90165-D; Journe F, 1997, BBA-MOL CELL RES, V1357, P18, DOI 10.1016/S0167-4889(97)00012-8; LAKSHMANAN J, 1992, AM J PHYSIOL, V263, pE142, DOI 10.1152/ajpendo.1992.263.1.E142; LAKSHMANAN J, 1990, BIOCHEM BIOPH RES CO, V173, P902, DOI 10.1016/S0006-291X(05)80871-X; LEE LS, 1981, P NATL ACAD SCI-BIOL, V78, P1042, DOI 10.1073/pnas.78.2.1042; Marechal H, 1999, AM J PHYSIOL-CELL PH, V276, pC734, DOI 10.1152/ajpcell.1999.276.3.C734; Marechal H, 1996, AM J PHYSIOL-CELL PH, V270, pC1164, DOI 10.1152/ajpcell.1996.270.4.C1164; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MAUDUIT P, 1998, P 13 INT C EY RES PA; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; Merlos-Suarez A, 1998, J BIOL CHEM, V273, P24955, DOI 10.1074/jbc.273.38.24955; Merlos-Suarez A, 2001, J BIOL CHEM, V276, P48510, DOI 10.1074/jbc.M103488200; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; MROCZKOWSKI B, 1989, MOL CELL BIOL, V9, P2771, DOI 10.1128/MCB.9.7.2771; Nakagawa T, 1996, J BIOL CHEM, V271, P30858, DOI 10.1074/jbc.271.48.30858; NEXO E, 1990, BIOCHIM BIOPHYS ACTA, V1037, P388, DOI 10.1016/0167-4838(90)90041-D; Nishi E, 2001, EMBO J, V20, P3342, DOI 10.1093/emboj/20.13.3342; OHASHI Y, 1989, INVEST OPHTH VIS SCI, V30, P1879; PANDIELLA A, 1991, J BIOL CHEM, V266, P5769; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; PARRIES G, 1995, J BIOL CHEM, V270, P27954, DOI 10.1074/jbc.270.46.27954; PASQUINI F, 1974, EXP CELL RES, V86, P233, DOI 10.1016/0014-4827(74)90708-3; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; RALL LB, 1985, NATURE, V313, P228, DOI 10.1038/313228a0; ROBERTS ML, 1978, BIOCHIM BIOPHYS ACTA, V540, P246, DOI 10.1016/0304-4165(78)90137-X; SAGGI SJ, 1992, DNA CELL BIOL, V11, P481, DOI 10.1089/dna.1992.11.481; SALIDO EC, 1991, HISTOCHEMISTRY, V96, P65, DOI 10.1007/BF00266763; SCHAUDIES RP, 1990, AM J PHYSIOL, V259, pG1056, DOI 10.1152/ajpgi.1990.259.6.G1056; SCHAUDIES RP, 1993, AM J PHYSIOL, V264, pF523, DOI 10.1152/ajprenal.1993.264.3.F523; SCOTT J, 1983, SCIENCE, V221, P236, DOI 10.1126/science.6602382; SCOTT J, 1985, J CELL SCI, P19; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SHOYAB M, 1989, SCIENCE, V269, P234; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; Toyoda H, 1995, FEBS LETT, V377, P403, DOI 10.1016/0014-5793(95)01403-9; TSUTSUMI O, 1988, J CLIN INVEST, V81, P1067, DOI 10.1172/JCI113418; VANSETTEN GB, 1989, GRAEFES ARCH CLIN EX, V227, P82; Vecchi M, 1998, J BIOL CHEM, V273, P20589, DOI 10.1074/jbc.273.32.20589; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3	74	63	65	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45255	45268		10.1074/jbc.M307745200	http://dx.doi.org/10.1074/jbc.M307745200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12947092	hybrid			2022-12-25	WOS:000186452300027
J	Rousset, S; Alves-Guerra, MC; Ouadghiri-Bencherif, S; Kozak, LP; Miroux, B; Richard, D; Bouillaud, F; Ricquier, D; Cassard-Doulcier, AM				Rousset, S; Alves-Guerra, MC; Ouadghiri-Bencherif, S; Kozak, LP; Miroux, B; Richard, D; Bouillaud, F; Ricquier, D; Cassard-Doulcier, AM			Uncoupling protein 2, but not uncoupling protein 1, is expressed in the female mouse reproductive tract	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENINE-NUCLEOTIDE TRANSLOCATOR; IN-VIVO; MEMBRANE; OBESITY; CELLS; GENE; UCP1; FAT; MITOCHONDRIA; OVULATION	Uncoupling proteins (UCPs) are transporters of the inner mitochondrial membrane. Whereas UCP1 is uniquely present in brown adipose tissue where it uncouples respiration from ATP synthesis and activates respiration and heat production, UCP2 is present in numerous tissues, and its exact function remains to be clarified. Two sets of data provided the rationale for this study: (i) the intriguing report that UCP1 is present in uterus of mice (Nibbelink, M., Moulin, K., Arnaud, E., Duval, C., Penicaud, L., and Casteilla, L. (2001) J. Biol. Chem. 276, 47291-47295); and (ii) an observation that Ucp2(-/-) female mice (homozygous matings) have smaller litters compared with Ucp2(+/+) animals (S. Rousset and A.-M. Cassard-Doulcier, unpublished observations). These data prompted us to examine the expression of UCP1 and UCP2 in the reproductive tract of female mice. Using wild type, Ucp1(-/-) mice, and Ucp2(-/-) mice, we were unable to detect UCP1 in uterus of mice with appropriate antibodies, and we conclude that the signal assigned to UCP1 by others was neither UCP1 nor UCP2. Using a polyclonal antibody against UCP2 and tissues from Ucp2(-/-) mice as controls, UCP2 was detected in ovary, oviduct, and uterus. Expression of Ucp2 mRNA was also observed in ovary and uterus using in situ hybridization analysis. Bone marrow transplantation experiments revealed that the UCP2 signal of the ovary was restricted to ovarian cells. UCP2 level in ovary decreased during follicular growth and increased during the pre-ovulatory period, during which aspects of an inflammatory process are known to exist. Because UCP2 down-regulates reactive oxygen species, a role in the regulation of inflammatory events linked to the preparation of ovulation is suggested.	Fac Med Necker Enfants Malad, CNRS, Unite Propre Rech 9078, F-75730 Paris 15, France; Univ Laval, Fac Med, Dept Anat & Physiol, Quebec City, PQ G1K 7P4, Canada; Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Laval University; Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center	Cassard-Doulcier, AM (corresponding author), Fac Med Necker Enfants Malad, CNRS, Unite Propre Rech 9078, 156 Rue Vaugirard, F-75730 Paris 15, France.	cassard-doulcier@necker.fr	Bouillaud, Frédéric R/L-3238-2017; CASSARD, Anne-Marie/B-6095-2019; Alves-Guerra, Marie-Clotilde/P-4356-2017; Miroux, Bruno/E-9267-2017	Bouillaud, Frédéric R/0000-0002-7518-9237; CASSARD, Anne-Marie/0000-0002-1813-5128; Alves-Guerra, Marie-Clotilde/0000-0002-7918-1216; Miroux, Bruno/0000-0002-3066-4700				AQUILA H, 1985, EMBO J, V4, P2369, DOI 10.1002/j.1460-2075.1985.tb03941.x; Arcuri F, 2001, BIOL REPROD, V64, P1200, DOI 10.1095/biolreprod64.4.1200; Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; Aten RF, 1998, BIOL REPROD, V59, P1069, DOI 10.1095/biolreprod59.5.1069; Blanc J, 2003, CIRCULATION, V107, P388, DOI 10.1161/01.CIR.0000051722.66074.60; Boss O, 2000, DIABETES, V49, P143, DOI 10.2337/diabetes.49.2.143; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; CANNON B, 1985, ESSAYS BIOCHEM, V20, P110; Cohen PE, 1999, J LEUKOCYTE BIOL, V66, P765, DOI 10.1002/jlb.66.5.765; Couplan E, 2002, J BIOL CHEM, V277, P26268, DOI 10.1074/jbc.M202535200; Echtay KS, 2001, P NATL ACAD SCI USA, V98, P1416, DOI 10.1073/pnas.98.4.1416; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; ESPEY LL, 1994, BIOL REPROD, V50, P233, DOI 10.1095/biolreprod50.2.233; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Gimeno RE, 1997, DIABETES, V46, P900, DOI 10.2337/diabetes.46.5.900; HIMMSHAGEN J, 1998, HDB OBESITY, P415; Hofmann WE, 2001, J BIOL CHEM, V276, P12460, DOI 10.1074/jbc.M100466200; Hunt J S, 1998, Dev Immunol, V6, P105, DOI 10.1155/1998/87527; Kizaki T, 2002, P NATL ACAD SCI USA, V99, P9392, DOI 10.1073/pnas.142206299; Kozak LP, 1999, INT J OBESITY, V23, pS33, DOI 10.1038/sj.ijo.0800941; Kozak LP, 2000, ANNU REV NUTR, V20, P339, DOI 10.1146/annurev.nutr.20.1.339; Krauss S, 2002, P NATL ACAD SCI USA, V99, P118, DOI 10.1073/pnas.012410699; Larrouy D, 1997, BIOCHEM BIOPH RES CO, V235, P760, DOI 10.1006/bbrc.1997.6852; LEDESMA A, 2002, GENOME BIOL; Machelon V, 1997, EUR CYTOKINE NETW, V8, P137; Mao WG, 1999, FEBS LETT, V443, P326, DOI 10.1016/S0014-5793(98)01713-X; Masaki T, 1999, BBA-MOL CELL BIOL L, V1440, P81, DOI 10.1016/S1388-1981(99)00104-3; Medvedev AV, 2002, J BIOL CHEM, V277, P42639, DOI 10.1074/jbc.M208645200; MIROUX B, 1992, J BIOL CHEM, V267, P13603; Nagase I, 1996, J CLIN INVEST, V97, P2898, DOI 10.1172/JCI118748; NegreSalvayre A, 1997, FASEB J, V11, P809, DOI 10.1096/fasebj.11.10.9271366; Nibbelink M, 2001, J BIOL CHEM, V276, P47291, DOI 10.1074/jbc.M105658200; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; Pecqueur C, 2001, J BIOL CHEM, V276, P8705, DOI 10.1074/jbc.M006938200; Rial E, 1999, EMBO J, V18, P5827, DOI 10.1093/emboj/18.21.5827; Richard D, 1998, J COMP NEUROL, V397, P549; Ricquier D, 2000, BIOCHEM J, V345, P161, DOI 10.1042/0264-6021:3450161; Sanchis D, 1998, J BIOL CHEM, V273, P34611, DOI 10.1074/jbc.273.51.34611; SCHULTHEISS HP, 1984, BIOCHIM BIOPHYS ACTA, V771, P235, DOI 10.1016/0005-2736(84)90538-8; Shabalina I, 2002, AM J PHYSIOL-GASTR L, V283, pG1107, DOI 10.1152/ajpgi.00193.2002; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; Skulachev VP, 1997, BIOSCIENCE REP, V17, P347, DOI 10.1023/A:1027344914565; Vyssokikh MY, 2001, BIOCHEM J, V358, P349, DOI 10.1042/0264-6021:3580349; Yu XX, 2000, FASEB J, V14, P1611, DOI 10.1096/fj.14.11.1611; Zhang CY, 2001, CELL, V105, P745, DOI 10.1016/S0092-8674(01)00378-6	45	28	33	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45843	45847		10.1074/jbc.M306980200	http://dx.doi.org/10.1074/jbc.M306980200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12941933	hybrid			2022-12-25	WOS:000186452300097
J	Shang, X; Zhou, YT; Low, BC				Shang, X; Zhou, YT; Low, BC			Concerted regulation of cell dynamics by BNIP-2 and Cdc42GAP Homology/Sec14p-like, Proline-rich, and GTPase-activating protein domains of a novel Rho GTPase-activating protein, BPGAP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST MOTILITY; ENA/VASP PROTEINS; BINDING; MIGRATION; ADHESION; FAMILY; RAC; IDENTIFICATION; CYTOSKELETON; STIMULATION	RhoA, Cdc42, and Rac1 are small GTPases that regulate cytoskeletal reorganization leading to changes in cell morphology and cell motility. Their signaling pathways are activated by guanine nucleotide exchange factors and inactivated by GTPase-activating proteins ( GAPs). We have identified a novel RhoGAP, BPGAP1 ( for (B) under bar NIP- 2 and Cdc42GAP Homology (BCH) domain-containing, (P) under bar roline-rich and Cdc42 (GAP) under bar -like protein subtype-(1) under bar), that is ubiquitously expressed and shares 54% sequence identity to Cdc42GAP/p50RhoGAP. BPGAP1 selectively enhanced RhoA GTPase activity in vivo although it also interacted strongly with Cdc42 and Rac1. "Pull- down" and co-immunoprecipitation studies indicated that it formed homophilic or heterophilic complexes with other BCH domain-containing proteins. Fluorescence studies of epitope-tagged BPGAP1 revealed that it induced pseudopodia and increased migration of MCF7 cells. Formation of pseudopodia required its BCH and GAP domains but not the proline-rich region, and was differentially inhibited by coexpression of the constitutively active mutant of RhoA, or dominant negative mutants of Cdc42 and Rac1. However, the mutant without the proline-rich region failed to confer any increase in cell migration despite the induction of pseudopodia. Our findings provide evidence that cell morphology changes and migration are coordinated via multiple domains in BPGAP1 and present a novel mode of regulation for cell dynamics by a RhoGAP protein.	Natl Univ Singapore, Dept Biol Sci, Cell Signaling & Dev Biol Lab, Singapore 117543, Singapore	National University of Singapore	Low, BC (corresponding author), Natl Univ Singapore, Dept Biol Sci, Cell Signaling & Dev Biol Lab, 14 Sci Dr 4, Singapore 117543, Singapore.		Low, Boon Chuan/AAU-7685-2021; Low, Boon Chuan/H-8049-2012	Low, Boon Chuan/0000-0003-0756-096X; Low, Boon Chuan/0000-0003-0756-096X; Zhou, Yi-Ting/0000-0003-4543-3099				Arthur WT, 2001, MOL BIOL CELL, V12, P2711, DOI 10.1091/mbc.12.9.2711; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; BARFOD ET, 1993, J BIOL CHEM, V268, P26059; Bear JE, 2000, CELL, V101, P717, DOI 10.1016/S0092-8674(00)80884-3; Bear JE, 2002, CELL, V109, P509, DOI 10.1016/S0092-8674(02)00731-6; Christerson LB, 2002, J CELL PHYSIOL, V192, P200, DOI 10.1002/jcp.10125; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Evers EE, 2000, EUR J CANCER, V36, P1269, DOI 10.1016/S0959-8049(00)00091-5; Fidyk NJ, 2002, BIOCHEMISTRY-US, V41, P15644, DOI 10.1021/bi026413p; Furman C, 2002, J BIOL CHEM, V277, P7962, DOI 10.1074/jbc.M109149200; Gamblin SJ, 1998, CURR OPIN STRUC BIOL, V8, P195, DOI 10.1016/S0959-440X(98)80038-9; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HOMMA Y, 1995, EMBO J, V14, P286, DOI 10.1002/j.1460-2075.1995.tb07002.x; Koo TH, 2002, ONCOGENE, V21, P4080, DOI 10.1038/sj.onc.1205514; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LANCASTER CA, 1994, J BIOL CHEM, V269, P1137; Lim J, 2000, J BIOL CHEM, V275, P32837, DOI 10.1074/jbc.M002156200; Low BC, 1999, J BIOL CHEM, V274, P33123, DOI 10.1074/jbc.274.46.33123; Low BC, 2000, J BIOL CHEM, V275, P14415, DOI 10.1074/jbc.275.19.14415; Low BC, 2000, J BIOL CHEM, V275, P37742, DOI 10.1074/jbc.M004897200; Macias MJ, 2002, FEBS LETT, V513, P30, DOI 10.1016/S0014-5793(01)03290-2; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Maddox AS, 2003, J CELL BIOL, V160, P255, DOI 10.1083/jcb.200207130; Miura K, 2002, MOL CELL, V9, P109, DOI 10.1016/S1097-2765(02)00428-8; Moon SY, 2003, J BIOL CHEM, V278, P4151, DOI 10.1074/jbc.M207789200; Moon SY, 2003, TRENDS CELL BIOL, V13, P13, DOI 10.1016/S0962-8924(02)00004-1; Nassar N, 1998, NAT STRUCT BIOL, V5, P1047, DOI 10.1038/4156; NOBES CD, 1995, BIOCHEM SOC T, V23, P456, DOI 10.1042/bst0230456; Peck J, 2002, FEBS LETT, V528, P27, DOI 10.1016/S0014-5793(02)03331-8; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Sambrook J, 2001, MOL CLONING LAB MANU, V3rd; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Sekimata M, 1999, J BIOL CHEM, V274, P17757, DOI 10.1074/jbc.274.25.17757; Sudol M, 2000, CELL, V103, P1001, DOI 10.1016/S0092-8674(00)00203-8; Wittmann T, 2001, J CELL SCI, V114, P3795; Wu G, 2000, PLANT PHYSIOL, V124, P1625, DOI 10.1104/pp.124.4.1625; Zhou YT, 2002, J BIOL CHEM, V277, P7483, DOI 10.1074/jbc.M109459200; Zondag GCM, 2000, J CELL BIOL, V149, P775, DOI 10.1083/jcb.149.4.775	40	41	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45903	45914		10.1074/jbc.M304514200	http://dx.doi.org/10.1074/jbc.M304514200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12944407	hybrid			2022-12-25	WOS:000186452300103
J	Gupta, M; Sueblinvong, V; Raman, J; Jeevanandam, V; Gupta, MP				Gupta, M; Sueblinvong, V; Raman, J; Jeevanandam, V; Gupta, MP			Single-stranded DNA-binding proteins PUR alpha and PUR beta bind to a purine-rich negative regulatory element of the alpha-myosin heavy chain gene and control transcriptional and translational regulation of the gene expression - Implications in the repression of alpha-myosin heavy chain during heart failure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VENTRICULAR SYSTOLIC RESISTANCE; Y-BOX PROTEIN; MESSENGER-RNA; CELL-CYCLE; PROMOTER; DOMAIN; HYPERTROPHY; SEQUENCE; SITES; MSY1	The alpha-myosin heavy chain is a principal molecule of the thick filament of the sarcomere, expressed primarily in cardiac myocytes. The mechanism for its cardiac-restricted expression is not yet fully understood. We previously identified a purine-rich negative regulatory (PNR) element in the first intron of the gene, which is essential for its cardiac-specific expression (Gupta, M., Zak, R., Libermann, T. A., and Gupta, M. P. (1998) Mol. Cell. Biol. 18, 7243-7258). In this study we cloned and characterized muscle and non-muscle factors that bind to this element. We show that two single-stranded DNA-binding proteins of the PUR family, PURalpha and PURbeta, which are derived from cardiac myocytes, bind to the plus strand of the PNR element. In functional assays, PURalpha and PURbeta repressed alpha-myosin heavy chain (alpha-MHC) gene expression in the presence of upstream regulatory sequences of the gene. However, from HeLa cells an Ets family of protein, Ets-related protein (ERP), binds to double-stranded PNR element. The ERP.PNR complex inhibited the activity of the basal transcription complex from homologous as well as heterologous promoters in a PNR position-independent manner, suggesting that ERP acts as a silencer of alpha-MHC gene expression in non-muscle cells. We also show that PUR proteins are capable of binding to alpha-MHC mRNA and attenuate its translational efficiency. Furthermore, we show robust expression of PUR proteins in failing hearts where alpha-MHC mRNA levels are suppressed. Together, these results reveal that (i) PUR proteins participate in transcriptional as well as translational regulation of alpha-MHC expression in cardiac myocytes and (ii) ERP may be involved in cardiac-restricted expression of the alpha-MHC gene by preventing its expression in nonmuscle cells.	Univ Chicago, Dept Surg, Cardiac & Thorac Div, Chicago, IL 60637 USA; Univ Chicago, Comm Mol Med, Chicago, IL 60637 USA; Univ Illinois, Dept Physiol & Biophys, Chicago, IL 60612 USA; Hope Childrens Hosp, Chicago, IL 60612 USA	University of Chicago; University of Chicago; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Gupta, MP (corresponding author), Univ Chicago, Dept Surg, Cardiac & Thorac Div, MC 5040,5841 S Maryland Ave, Chicago, IL 60637 USA.				NHLBI NIH HHS [R0-1 HL68083] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068083] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADOLPH EA, 1993, J BIOL CHEM, V268, P5349; Aikawa R, 2002, J BIOL CHEM, V277, P18979, DOI 10.1074/jbc.M201257200; ALTIOK S, 1994, MOL CELL BIOL, V14, P6004, DOI 10.1128/MCB.14.9.6004; Ayadi A, 2001, MECH DEVELOP, V102, P205, DOI 10.1016/S0925-4773(01)00289-1; BARANY M, 1967, J GEN PHYSIOL, V50, P197, DOI 10.1085/jgp.50.6.197; BOLUYT MO, 1994, CIRC RES, V75, P23, DOI 10.1161/01.RES.75.1.23; Carlini LE, 2002, J BIOL CHEM, V277, P8682, DOI 10.1074/jbc.M109754200; CHEN NN, 1995, P NATL ACAD SCI USA, V92, P1087, DOI 10.1073/pnas.92.4.1087; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; Darbinian N, 1999, ONCOGENE, V18, P6398, DOI 10.1038/sj.onc.1203011; Davis FJ, 2002, AM J PHYSIOL-HEART C, V282, pH1521, DOI 10.1152/ajpheart.00844.2001; Gallia GL, 2000, NUCLEIC ACIDS RES, V28, P3197, DOI 10.1093/nar/28.17.3197; GALLIA GL, 1999, J CELL BIOCHEM, V75, P1; Greenall A, 2001, J BIOL CHEM, V276, P16207, DOI 10.1074/jbc.M011582200; Gupta M, 1998, MOL CELL BIOL, V18, P7243, DOI 10.1128/MCB.18.12.7243; Gupta MP, 1997, MOL CELL BIOL, V17, P3924, DOI 10.1128/MCB.17.7.3924; GUPTA MP, 1994, J BIOL CHEM, V269, P29677; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; Itoh H, 1998, CELL GROWTH DIFFER, V9, P651; IVESTER CT, 1995, J BIOL CHEM, V270, P21950, DOI 10.1074/jbc.270.37.21950; JOHNSON EM, 1995, J BIOL CHEM, V270, P24352, DOI 10.1074/jbc.270.41.24352; Jones WK, 1996, J CLIN INVEST, V98, P1906, DOI 10.1172/JCI118992; Kelm RJ, 1999, J BIOL CHEM, V274, P14238, DOI 10.1074/jbc.274.20.14238; Kelm RJ, 1999, J BIOL CHEM, V274, P38268, DOI 10.1074/jbc.274.53.38268; Kelm RJ, 1997, J BIOL CHEM, V272, P26727, DOI 10.1074/jbc.272.42.26727; Kim SJ, 1999, AM J PHYSIOL-HEART C, V276, pH1780, DOI 10.1152/ajpheart.1999.276.5.H1780; Kuo CH, 1999, BIOCHEM BIOPH RES CO, V255, P406, DOI 10.1006/bbrc.1999.0218; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; Maira SM, 1996, EMBO J, V15, P5849, DOI 10.1002/j.1460-2075.1996.tb00972.x; Matsumoto K, 1996, J BIOL CHEM, V271, P22706, DOI 10.1074/jbc.271.37.22706; MERCADIER JJ, 1981, CIRC RES, V49, P525, DOI 10.1161/01.RES.49.2.525; Miyata S, 2000, CIRC RES, V86, P386, DOI 10.1161/01.RES.86.4.386; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P4947, DOI 10.1128/MCB.14.7.4947; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P5056, DOI 10.1128/MCB.14.8.5056; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; Nakao K, 1997, J CLIN INVEST, V100, P2362, DOI 10.1172/JCI119776; OJAMAA K, 1994, P NATL ACAD SCI USA, V91, P3468, DOI 10.1073/pnas.91.8.3468; OPREY J, 1995, NUCLEIC ACIDS RES, V23, P3664, DOI 10.1093/nar/23.18.3664; Sambrook J., 2002, MOL CLONING LAB MANU; Sanbe A, 2003, CIRC RES, V92, P609, DOI 10.1161/01.RES.0000065442.64694.9F; SHEN RQ, 1991, MOL CELL BIOL, V11, P1676, DOI 10.1128/MCB.11.3.1676; SHROFF SG, 1990, AM J PHYSIOL, V258, pH381, DOI 10.1152/ajpheart.1990.258.2.H381; SHROFF SG, 1989, AM J PHYSIOL, V257, pH386, DOI 10.1152/ajpheart.1989.257.2.H386; Stacey DW, 1999, ONCOGENE, V18, P4254, DOI 10.1038/sj.onc.1202795; STRIPECKE R, 1994, MOL CELL BIOL, V14, P5898, DOI 10.1128/MCB.14.9.5898; Sucharov CC, 2003, J BIOL CHEM, V278, P31233, DOI 10.1074/jbc.M301917200; TAFURI SR, 1993, J BIOL CHEM, V268, P12213; TANAKA N, 1992, ADV IMMUNOL, V52, P263, DOI 10.1016/S0065-2776(08)60877-9; WEISNER RJ, 1997, CIRCULATION, V95, P1253; Weiss A, 1996, ANNU REV CELL DEV BI, V12, P417, DOI 10.1146/annurev.cellbio.12.1.417; Zambrano N, 1997, BIOCHEM J, V328, P293, DOI 10.1042/bj3280293	52	57	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44935	44948		10.1074/jbc.M307696200	http://dx.doi.org/10.1074/jbc.M307696200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12933792	hybrid			2022-12-25	WOS:000186306700130
J	Hellmann, N; Weber, RE; Decker, H				Hellmann, N; Weber, RE; Decker, H			Nested allosteric interactions in extracellular hemoglobin of the leech Macrobdella decora	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUMBRICUS-TERRESTRIS; OXYGEN-BINDING; 3-DIMENSIONAL RECONSTRUCTION; HEMOCYANIN; SUBUNITS; PH; ERYTHROCRUORIN; COOPERATIVITY; TEMPERATURE; HIERARCHY	Hemoglobin from the leech Macrobdella decora belongs to the class of giant extracellular hexagonal bilayer globin structures found in annelid and vestimentiferan worms. These complexes consist of 144 heme-bearing subunits, exhibit a characteristic quaternary structure (2 x (6 x (3 x 4))), and contain tetramers as basic substructures that express cooperative oxygen binding and thus provide a structural basis for a hierarchy in allosteric interactions. A thorough analysis of the isolated tetramer indicates that it functions as a trimer of cooperatively interacting subunits and a noncooperative monomer rather than as four interacting subunits. A thermodynamic analysis of the whole molecule favors the application of a nested Monod-Wyman-Changeux model with six cooperatively interacting 12-mer allosteric units. In contrast to the isolated tetramers, all subunits of the tetramers seem to be coupled cooperatively within the oligomerized 144-mer. Thus, besides hemocyanins and GroEL, the hexagonal bilayer hemoglobins represent another class of proteins in which the hierarchical quaternary structure provides the basis for nested interaction in their functional properties.	Univ Mainz, Inst Mol Biophys, D-55128 Mainz, Germany; Aarhus Univ, Dept Zoophysiol, DK-8000 Aarhus, Denmark	Johannes Gutenberg University of Mainz; Aarhus University	Hellmann, N (corresponding author), Univ Mainz, Inst Mol Biophys, Jakob Welder Weg 26, D-55128 Mainz, Germany.							Dainese E, 1998, EUR J BIOCHEM, V256, P350, DOI 10.1046/j.1432-1327.1998.2560350.x; DECKER H, 1990, J MOL BIOL, V211, P281, DOI 10.1016/0022-2836(90)90027-J; Decker H., 1986, P383; DECKER H, 1990, BIOPHYS CHEM, V37, P257, DOI 10.1016/0301-4622(90)88025-N; deHaas F, 1996, BIOPHYS J, V70, P1973, DOI 10.1016/S0006-3495(96)79762-X; deHaas F, 1997, BIOCHEMISTRY-US, V36, P7330, DOI 10.1021/bi970131l; FUSHITANI K, 1986, J BIOL CHEM, V261, P8414; FUSHITANI K, 1988, J BIOL CHEM, V263, P6502; FUSHITANI K, 1991, J BIOL CHEM, V266, P10275; GIBSON QH, 1991, J BIOL CHEM, V266, P13097; GREEN DN, 2001, J MOL BIOL, V309, P563; Hellmann N, 2002, BBA-PROTEINS PROTEOM, V1599, P45, DOI 10.1016/S1570-9639(02)00399-0; ILAN E, 1993, BIOCHIM BIOPHYS ACTA, V1162, P77, DOI 10.1016/0167-4838(93)90130-J; KAPP OH, 1990, J MOL BIOL, V213, P141, DOI 10.1016/S0022-2836(05)80127-5; Krebs A, 1996, J BIOL CHEM, V271, P18695, DOI 10.1074/jbc.271.31.18695; Lamy JN, 1996, CHEM REV, V96, P3113, DOI 10.1021/cr9600058; MAKINO N, 1993, BIOCHIM BIOPHYS ACTA, V1162, P237, DOI 10.1016/0167-4838(93)90287-2; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; ROBERT CH, 1987, P NATL ACAD SCI USA, V84, P1891, DOI 10.1073/pnas.84.7.1891; Royer WE, 2000, P NATL ACAD SCI USA, V97, P7107, DOI 10.1073/pnas.97.13.7107; van Holde KE, 2001, J BIOL CHEM, V276, P15563, DOI 10.1074/jbc.R100010200; vanHolde KE, 1995, ADV PROTEIN CHEM, V47, P1, DOI 10.1016/S0065-3233(08)60545-8; WEBER RE, 1987, J COMP PHYSIOL B, V157, P145, DOI 10.1007/BF00692358; WEBER RE, 1995, J MOL BIOL, V251, P703, DOI 10.1006/jmbi.1995.0466; WEBER RE, 1981, NATURE, V292, P386, DOI 10.1038/292386a0; Weber RE, 2001, PHYSIOL REV, V81, P569, DOI 10.1152/physrev.2001.81.2.569; Wyman J., 1990, BINDING LINKAGE	27	9	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44355	44360		10.1074/jbc.M307810200	http://dx.doi.org/10.1074/jbc.M307810200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12944389	hybrid			2022-12-25	WOS:000186306700059
J	Tofaris, GK; Razzaq, A; Ghetti, B; Lilley, KS; Spillantini, MG				Tofaris, GK; Razzaq, A; Ghetti, B; Lilley, KS; Spillantini, MG			Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-BETA COMPONENT; PARKINSONS-DISEASE; PRECURSOR PROTEIN; HUMAN BRAIN; DEGRADATION; DEMENTIA; AGGREGATION; INCLUSIONS; FILAMENTS; MUTATION	Lewy bodies are intracellular fibrillar inclusions composed of alpha-synuclein. They constitute the pathological hallmark of Parkinson's disease, dementia with Lewy bodies, and other neurodegenerative diseases. Although the majority of Lewy bodies are stained for ubiquitin by immunohistochemistry, the substrate for this modification is poorly understood. Insoluble, urea-soluble alpha-synuclein was separated from soluble fractions and subjected to two-dimensional gel electrophoresis to further characterize pathogenic alpha-synuclein species from disease brains. By using this approach, we found that in sporadic Lewy body diseases a highly modified, disease-associated 22-24-kDa alpha-synuclein species is ubiquitinated. Conjugation of one, two, and, to a lesser extent, three ubiquitins was detected. This 22-24-kDa alpha-synuclein species represents partly phosphorylated protein. Furthermore, no generalized impairment of the proteolytic activity of the proteasome was detected in brain regions with Lewy body pathology. Because unmodified alpha-synuclein is degraded by the proteasome in a ubiquitin-independent manner, these data suggest that accumulation of modified 22-24-kDa alpha-synuclein is a disease-specific event which may overwhelm the proteolytic system, leading to aberrant ubiquitination. Accordingly, carboxyl-terminal-truncated alpha-synuclein, presumably the result of aberrant proteolysis, is found only in association with alpha-synuclein aggregates.	Cambridge Ctr Brain Repair, Cambridge CB2 2PY, England; Dept Neurol, Cambridge CB2 2PY, England; Cambridge Ctr Proteom, Cambridge CB2 1QW, England; Dept Biochem, Cambridge CB2 1QW, England; Indiana Univ, Sch Med, Dept Pathol & Lab Med, Div Neuropathol, Indianapolis, IN 46202 USA	University of Cambridge; University of Cambridge; Indiana University System; Indiana University-Purdue University Indianapolis	Spillantini, MG (corresponding author), Cambridge Ctr Brain Repair, Cambridge CB2 2PY, England.		Lilley, Kathryn/ABF-5787-2020	Lilley, Kathryn/0000-0003-0594-6543; Tofaris, George/0000-0002-9252-5933	NIA NIH HHS [P30AG10133] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P30AG010133] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ancolio K, 2000, NEUROSCI LETT, V285, P79, DOI 10.1016/S0304-3940(00)01049-1; Baba M, 1998, AM J PATHOL, V152, P879; Bennett MC, 1999, J BIOL CHEM, V274, P33855, DOI 10.1074/jbc.274.48.33855; Campbell BCV, 2001, J NEUROCHEM, V76, P87, DOI 10.1046/j.1471-4159.2001.00021.x; Culvenor JG, 1999, AM J PATHOL, V155, P1173, DOI 10.1016/S0002-9440(10)65220-0; Forno LS, 1996, J NEUROPATH EXP NEUR, V55, P259, DOI 10.1097/00005072-199603000-00001; Fujiwara H, 2002, NAT CELL BIOL, V4, P160, DOI 10.1038/ncb748; Giasson BI, 2001, J BIOL CHEM, V276, P2380, DOI 10.1074/jbc.M008919200; Gray DA, 2001, NEUROPATH APPL NEURO, V27, P89, DOI 10.1046/j.1365-2990.2001.00321.x; Grune T, 2001, J GERONTOL A-BIOL, V56, pB459, DOI 10.1093/gerona/56.11.B459; Hasegawa M, 2002, J BIOL CHEM, V277, P49071, DOI 10.1074/jbc.M208046200; Hochstrasser M, 2002, SCIENCE, V298, P549, DOI 10.1126/science.1078097; Hsu LJ, 1998, J NEUROCHEM, V71, P338; Irizarry MC, 1996, J NEUROPATH EXP NEUR, V55, P889, DOI 10.1097/00005072-199608000-00004; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Jakes R, 1999, NEUROSCI LETT, V269, P13, DOI 10.1016/S0304-3940(99)00411-5; Kisselev AF, 1999, J BIOL CHEM, V274, P3363, DOI 10.1074/jbc.274.6.3363; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Liu CW, 2003, SCIENCE, V299, P408, DOI 10.1126/science.1079293; Liu YC, 2002, CELL, V111, P209, DOI 10.1016/S0092-8674(02)01012-7; McNaught KSP, 2001, NEUROSCI LETT, V297, P191, DOI 10.1016/S0304-3940(00)01701-8; Miake H, 2002, J BIOL CHEM, V277, P19213, DOI 10.1074/jbc.M110551200; MORISHIMAKAWASHIMA M, 1993, NEURON, V10, P1151, DOI 10.1016/0896-6273(93)90063-W; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Rideout HJ, 2002, MOL CELL NEUROSCI, V21, P223, DOI 10.1006/mcne.2002.1173; Rideout HJ, 2001, J NEUROCHEM, V78, P899, DOI 10.1046/j.1471-4159.2001.00474.x; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Tofaris GK, 2001, FEBS LETT, V509, P22, DOI 10.1016/S0014-5793(01)03115-5; Touitou R, 2001, EMBO J, V20, P2367, DOI 10.1093/emboj/20.10.2367; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282	33	266	282	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44405	44411		10.1074/jbc.M308041200	http://dx.doi.org/10.1074/jbc.M308041200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12923179	hybrid			2022-12-25	WOS:000186306700066
J	Kikuchi, K; Kishino, A; Konishi, O; Kumagai, K; Hosotani, N; Saji, I; Nakayama, C; Kimura, T				Kikuchi, K; Kishino, A; Konishi, O; Kumagai, K; Hosotani, N; Saji, I; Nakayama, C; Kimura, T			In vitro and in vivo characterization of a novel semaphorin 3A inhibitor, SM-216289 or xanthofulvin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROOT GANGLION NEURONS; GROWTH CONE GUIDANCE; NEURITE GROWTH; AXON REGENERATION; NEUROPILIN; ADULT; CHEMOREPELLENT; EXPRESSION; PROTEIN; COLLAPSIN	SM-216289 (xanthofulvin) isolated from the fermentation broth of a fungal strain, Penicillium sp. SPF-3059, was identified as a strong semaphorin 3A (Sema3A) inhibitor. Sema3A-induced growth cone collapse of dorsal root ganglion neurons in vitro was completely abolished in the presence of SM-216289 at levels less than 2 muM (IC50=0.16 muM). When dorsal root ganglion explants were co-cultured with Sema3A-producing COS7 cells in a collagen gel matrix, SM-216289 enabled neurites to grow toward the COS7 cells. SM-216289 diminished the binding of Sema3A to its receptor neuropilin-1 in vitro, suggesting a direct interference of receptor-ligand association. Moreover, our data suggest that SM-216289 interacted with Sema3A directly and blocked the binding of Sema3A to its receptor. We examined the efficacy of SM-216289 in vivo using a rat olfactory nerve axotomy model, in which strong Sema3A induction has been reported around regenerating axons. The regeneration of olfactory nerves was significantly accelerated by a local administration of SM-216289 in the lesion site, suggesting the involvement of Sema3A in neural regeneration as an inhibitory factor. SM-216289 is an excellent molecular probe to investigate the function of Sema3A, in vitro and in vivo, and may be useful for the treatment of traumatic neural injuries.	Sumitomo Pharmaceut Co Ltd, Div Res, Konohana Ku, Osaka 5540022, Japan; Sumitomo Pharmaceut Co Ltd, Div Res, Takaraduka, Hyogo 6650051, Japan		Kimura, T (corresponding author), Sumitomo Pharmaceut Co Ltd, Div Res, Konohana Ku, 3-1-98 Kasugade Naka, Osaka 5540022, Japan.	tkimura@sumitomopharm.co.jp	Kumagai, Kazuo/D-7676-2016	Kumagai, Kazuo/0000-0003-2312-5765				Adams RH, 1997, EMBO J, V16, P6077, DOI 10.1093/emboj/16.20.6077; BAKER H, 1986, EXP BRAIN RES, V63, P461, DOI 10.1007/BF00237470; BREGMAN BS, 1995, NATURE, V378, P498, DOI 10.1038/378498a0; CARONI P, 1988, J CELL BIOL, V106, P1281, DOI 10.1083/jcb.106.4.1281; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; COSTANZO RM, 1985, BRAIN RES, V361, P258, DOI 10.1016/0006-8993(85)91297-1; De Winter F, 2002, EXP NEUROL, V175, P61, DOI 10.1006/exnr.2002.7884; Dickson BJ, 2002, SCIENCE, V298, P1959, DOI 10.1126/science.1072165; Encinas JA, 1999, P NATL ACAD SCI USA, V96, P2491, DOI 10.1073/pnas.96.5.2491; FAN JH, 1993, J CELL BIOL, V121, P867, DOI 10.1083/jcb.121.4.867; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; Flanagan JG, 2000, METHOD ENZYMOL, V327, P19, DOI 10.1016/S0076-6879(00)27264-9; Fournier AE, 2001, CURR OPIN NEUROBIOL, V11, P89, DOI 10.1016/S0959-4388(00)00178-1; Goshima Y, 2000, JPN J PHARMACOL, V82, P273, DOI 10.1254/jjp.82.273; GrandPre T, 2000, NATURE, V403, P439, DOI 10.1038/35000226; GUTHRIE S, 1994, NEUROPROTOCOLS, V4, P116; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Horner PJ, 2000, NATURE, V407, P963, DOI 10.1038/35039559; INAGAKI S, 1995, FEBS LETT, V370, P269, DOI 10.1016/0014-5793(95)00850-9; Kawakami A, 1996, J NEUROBIOL, V29, P1, DOI 10.1002/(SICI)1097-4695(199601)29:1<1::AID-NEU1>3.0.CO;2-F; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; Kikuchi K, 1999, MOL CELL NEUROSCI, V13, P9, DOI 10.1006/mcne.1998.0732; Kitsukawa T, 1997, NEURON, V19, P995, DOI 10.1016/S0896-6273(00)80392-X; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; Kumagai K, 2003, J ANTIBIOT, V56, P610, DOI 10.7164/antibiotics.56.610; LUO YL, 1995, NEURON, V14, P1131, DOI 10.1016/0896-6273(95)90261-9; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; Merkler D, 2001, J NEUROSCI, V21, P3665, DOI 10.1523/JNEUROSCI.21-10-03665.2001; MESSERSMITH EK, 1995, NEURON, V14, P949, DOI 10.1016/0896-6273(95)90333-X; Mueller BK, 1999, ANNU REV NEUROSCI, V22, P351, DOI 10.1146/annurev.neuro.22.1.351; Nakamura F, 2000, J NEUROBIOL, V44, P219, DOI 10.1002/1097-4695(200008)44:2<219::AID-NEU11>3.0.CO;2-W; Owesson C, 2000, EXP NEUROL, V165, P394, DOI 10.1006/exnr.2000.7477; Pasterkamp RJ, 1999, MOL CELL NEUROSCI, V13, P143, DOI 10.1006/mcne.1999.0738; Pasterkamp RJ, 2001, EUR J NEUROSCI, V13, P457, DOI 10.1046/j.0953-816X.2000.01398.x; Pasterkamp RJ, 1998, J NEUROSCI, V18, P9962; Polleux F, 1998, SCIENCE, V282, P1904, DOI 10.1126/science.282.5395.1904; PUSCHEL AW, 1995, NEURON, V14, P941, DOI 10.1016/0896-6273(95)90332-1; Qiu J, 2000, GLIA, V29, P166, DOI 10.1002/(SICI)1098-1136(20000115)29:2<166::AID-GLIA10>3.0.CO;2-G; Reza JN, 1999, MOL CELL NEUROSCI, V14, P317, DOI 10.1006/mcne.1999.0786; SHIMAMOTO A, 1993, FEBS LETT, V333, P61, DOI 10.1016/0014-5793(93)80375-5; Shirvan A, 2002, J BIOL CHEM, V277, P49799, DOI 10.1074/jbc.M204793200; Takahashi T, 1999, CELL, V99, P59, DOI 10.1016/S0092-8674(00)80062-8; Takahashi T, 1997, J NEUROSCI, V17, P9183; Tanelian DL, 1997, NAT MED, V3, P1398, DOI 10.1038/nm1297-1398; Taniguchi M, 1997, NEURON, V19, P519, DOI 10.1016/S0896-6273(00)80368-2; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; VACTOR DV, 1999, CURR BIOL, V9, pR201; WALTER J, 1990, J PHYSIOL-PARIS, V84, P104	50	70	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42985	42991		10.1074/jbc.M302395200	http://dx.doi.org/10.1074/jbc.M302395200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12933805	hybrid			2022-12-25	WOS:000186157000033
J	Marcheselli, VL; Hong, S; Lukiw, WJ; Tian, XH; Gronert, K; Musto, A; Hardy, M; Gimenez, JM; Chiang, N; Serhan, CN; Bazan, NG				Marcheselli, VL; Hong, S; Lukiw, WJ; Tian, XH; Gronert, K; Musto, A; Hardy, M; Gimenez, JM; Chiang, N; Serhan, CN; Bazan, NG			Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL CEREBRAL-ISCHEMIA; FREE FATTY-ACIDS; FACTOR-KAPPA-B; DOCOSAHEXAENOIC ACID; ARTERY OCCLUSION; INJURY; RAT; OMEGA-3-FATTY-ACIDS; CYCLOOXYGENASE-2; APOPTOSIS	Ischemic stroke triggers lipid peroxidation and neuronal injury. Docosahexaenoic acid released from membrane phospholipids during brain ischemia is a major source of lipid peroxides. Leukocyte infiltration and pro-inflammatory gene expression also contribute to stroke damage. In this study using lipidomic analysis, we have identified stereospecific messengers from docosahexaenoate-oxygenation pathways in a mouse stroke model. Aspirin, widely used to prevent cerebrovascular disease, activates an additional pathway, which includes the 17R-resolvins. The newly discovered brain messenger 10,17S-docosatriene potently inhibited leukocyte infiltration, NFkappaB, and cyclooxygenase-2 induction in experimental stroke and elicited neuroprotection. In addition, in neural cells in culture, this lipid messenger also inhibited both interleukin 1-beta-induced NFkappaB activation and cyclooxygenase-2 expression. Thus, the specific novel bioactive docosanoids generated in vivo counteract leukocyte-mediated injury as well as pro-inflammatory gene induction. These results challenge the view that docosahexaenoate only participates in brain damage and demonstrate that this fatty acid is also the endogenous precursor to a neuroprotective signaling response to ischemia-reperfusion.	Louisiana State Univ, Neurosci Ctr Excellence, Hlth Sci Ctr, New Orleans, LA 70112 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Ophthalmol, New Orleans, LA 70112 USA; Brigham & Womens Hosp, Dept Anesthesiol Periooperat & Pain Med, Ctr Expt Therapeut & Reperfus Injury, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Bazan, NG (corresponding author), Louisiana State Univ, Neurosci Ctr Excellence, Hlth Sci Ctr, 2020 Gravier St,Suite D, New Orleans, LA 70112 USA.		Chiang, Nan/ABA-4924-2021; Bazan, Nicolas/AAN-4121-2020	Chiang, Nan/0000-0003-1963-1585; Bazan, Nicolas/0000-0002-9243-5444	NCRR NIH HHS [P20 RR016816] Funding Source: Medline; NIA NIH HHS [AG18031] Funding Source: Medline; NIDCR NIH HHS [P01 DE13499] Funding Source: Medline; NIDDK NIH HHS [K01 DK060583-03] Funding Source: Medline; NIGMS NIH HHS [GM38765] Funding Source: Medline; NINDS NIH HHS [NS23002] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016816] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE013499] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK060583] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038765, R01GM038765, R29GM038765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023002] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG018031] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AVELDANO MI, 1975, BRAIN RES, V100, P99, DOI 10.1016/0006-8993(75)90244-9; Bazan N. G., 1990, NUTR BRAIN, V8, P1; Bazan NG, 2002, J BIOL CHEM, V277, P30359, DOI 10.1074/jbc.M203201200; BAZAN NG, 1970, BIOCHIM BIOPHYS ACTA, V218, P1, DOI 10.1016/0005-2760(70)90086-X; BAZAN NG, 1984, BIOCHEM BIOPH RES CO, V125, P741, DOI 10.1016/0006-291X(84)90601-6; BAZAN NG, 1998, CEREBROVASC DIS, P532; Beal MF, 1996, CURR OPIN NEUROBIOL, V6, P661, DOI 10.1016/S0959-4388(96)80100-0; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; Chopp M, 1996, J CEREBR BLOOD F MET, V16, P578, DOI 10.1097/00004647-199607000-00007; de Turco EBR, 2002, J NEUROCHEM, V83, P515, DOI 10.1046/j.1471-4159.2002.01121.x; Gamoh S, 1999, NEUROSCIENCE, V93, P237, DOI 10.1016/S0306-4522(99)00107-4; GAUDET RJ, 1980, STROKE, V11, P648, DOI 10.1161/01.STR.11.6.648; GORDON WC, 1990, J NEUROSCI, V10, P2190; Gronert K, 1999, METH MOL B, V120, P119; HALLENBECK JM, 1998, CEREBROVASC DIS, V1, P489; Hong S, 2003, J BIOL CHEM, V278, P14677, DOI 10.1074/jbc.M300218200; Huang J, 2000, STROKE, V31, P3047, DOI 10.1161/01.STR.31.12.3047; Kim HY, 2000, J BIOL CHEM, V275, P35215, DOI 10.1074/jbc.M004446200; Lauritzen I, 2000, EMBO J, V19, P1784, DOI 10.1093/emboj/19.8.1784; Lukiw WJ, 1998, J NEUROSCI RES, V53, P583, DOI 10.1002/(SICI)1097-4547(19980901)53:5<583::AID-JNR8>3.3.CO;2-B; Mabuchi T, 2000, STROKE, V31, P1735, DOI 10.1161/01.STR.31.7.1735; MATSUO Y, 1994, STROKE, V25, P1469, DOI 10.1161/01.STR.25.7.1469; Mattson MP, 2000, J NEUROCHEM, V74, P443, DOI 10.1046/j.1471-4159.2000.740443.x; McGahon BM, 1999, NEUROSCIENCE, V94, P305, DOI 10.1016/S0306-4522(99)00219-5; Mirnikjoo B, 2001, J BIOL CHEM, V276, P10888, DOI 10.1074/jbc.M008150200; MOSKOWITZ MA, 1984, SCIENCE, V224, P886, DOI 10.1126/science.6719118; Roberts LJ, 1998, J BIOL CHEM, V273, P13605, DOI 10.1074/jbc.273.22.13605; Rothwell NJ, 2000, TRENDS NEUROSCI, V23, P618, DOI 10.1016/S0166-2236(00)01661-1; Royo NC, 1999, NEUROREPORT, V10, P1363, DOI 10.1097/00001756-199904260-00038; Schneider A, 1999, NAT MED, V5, P554, DOI 10.1038/8432; SCOTT BL, 1989, P NATL ACAD SCI USA, V86, P2903, DOI 10.1073/pnas.86.8.2903; Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760; Serhan CN, 2000, J EXP MED, V192, P1197, DOI 10.1084/jem.192.8.1197; SHEAKIN DJ, 2000, HDB PARAMETRIC NONPA; YOSHIDA S, 1984, J NEUROCHEM, V42, P711, DOI 10.1111/j.1471-4159.1984.tb02741.x; Zhang RL, 2002, J BIOL CHEM, V277, P46116, DOI 10.1074/jbc.M209124200	37	611	651	2	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43807	43817		10.1074/jbc.M305841200	http://dx.doi.org/10.1074/jbc.M305841200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12923200	Green Published, hybrid			2022-12-25	WOS:000186157000131
J	Sugiyama, D; Kusuhara, H; Taniguchi, H; Ishikawa, S; Nozaki, Y; Aburatani, H; Sugiyama, Y				Sugiyama, D; Kusuhara, H; Taniguchi, H; Ishikawa, S; Nozaki, Y; Aburatani, H; Sugiyama, Y			Functional characterization of rat brain-specific organic anion transporter (Oatp14) at the blood-brain barrier - High affinity transporter for thyroxine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; CEREBROSPINAL-FLUID BARRIER; THYROID-HORMONES; EFFLUX TRANSPORT; CHOROID-PLEXUS; HUMAN LIVER; IDENTIFICATION; TAUROCHOLATE; XENOBIOTICS; POLYPEPTIDE	Oatp14/blood-brain barrier-specific anion transporter 1 (Slc21a14) is a novel member of the organic anion transporting polypeptide (Oatp/OATP) family. Northern blot analysis revealed predominant expression of Oatp14 in the brain, and Western blot analysis revealed its expression in the brain capillary and choroid plexus. Immunohistochemical staining indicated that Oatp14 is expressed in the border of the brain capillary endothelial cells. When expressed in human embryonic kidney 293 cells, Oatp14 transports thyroxine (T-4; prothyroid hormone) (K-m = 0.18 muM), as well as amphipathic organic anions such as 17beta estradiol-D-17beta-glucuronide (K-m = 10 muM), cerivastatin (K-m = 1.3 muM), and troglitazone sulfate (K-m = 0.76 muM). The uptake of triiodothyronine (T-3), an active form produced from T-4, was significantly greater in Oatp14-expressed cells than in vector-transfected cells, but the transport activity for T-3 was similar to 6-fold lower that for T-4. The efflux of T-4, preloaded into the cells, from Oatp14-expressed cells was more rapid than that from vector-transfected cells (0.032 versus 0.006 min(-1)). Therefore, Oatp14 can mediate a bidirectional transport of T-4. Sulfobromophthalein, taurocholate, and estrone sulfate were potent inhibitors for Oatp14, whereas digoxin, p-aminohippurate, or leukotriene C-4, or organic cations such as tetraetheylammonium or cimetidine had no effect. The expression levels of Oatp14 mRNA and protein were up- and down-regulated under hypo- and hyperthyroid conditions, respectively. Therefore, it may be speculated that Oatp14 plays a role in maintaining the concentration of T-4 and, ultimately, T-3 in the brain by transporting T-4 from the circulating blood to the brain.	Univ Tokyo, Dept Mol Pharmacokinet, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Adv Sci & Technol Res Ctr, Meguro Ku, Tokyo 1538904, Japan	University of Tokyo; University of Tokyo	Sugiyama, Y (corresponding author), Univ Tokyo, Dept Mol Pharmacokinet, Grad Sch Pharmaceut Sci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.							Abe T, 1998, J BIOL CHEM, V273, P22395, DOI 10.1074/jbc.273.35.22395; Akita H, 2001, BBA-BIOMEMBRANES, V1511, P7, DOI 10.1016/S0005-2736(00)00355-2; BANKS WA, 1985, LIFE SCI, V37, P2407, DOI 10.1016/0024-3205(85)90108-0; BOADO RJ, 1991, J NEUROCHEM, V57, P2136, DOI 10.1111/j.1471-4159.1991.tb06433.x; Burmeister LA, 1997, ENDOCRINOLOGY, V138, P5231, DOI 10.1210/en.138.12.5231; Dagenais C, 2001, NEUROSCI LETT, V301, P155, DOI 10.1016/S0304-3940(01)01640-8; DRATMAN MB, 1991, BRAIN RES, V554, P229, DOI 10.1016/0006-8993(91)90194-Z; Forrest D, 2002, CURR OPIN NEUROBIOL, V12, P49, DOI 10.1016/S0959-4388(02)00289-1; Gao B, 2000, J PHARMACOL EXP THER, V294, P73; Gao P, 1999, J HISTOCHEM CYTOCHEM, V47, P1255, DOI 10.1177/002215549904701005; Groothuis DR, 1997, J NEUROVIROL, V3, P387, DOI 10.3109/13550289709031185; HAGEN GA, 1974, ENDOCRINOLOGY, V95, P1398, DOI 10.1210/endo-95-5-1398; Izumi T, 1997, J PHARMACOL EXP THER, V280, P1392; JACQUEMIN E, 1994, P NATL ACAD SCI USA, V91, P133, DOI 10.1073/pnas.91.1.133; Kullak-Ublick GA, 2000, SEMIN LIVER DIS, V20, P273, DOI 10.1055/s-2000-9426; Kullak-Ublick GA, 2001, GASTROENTEROLOGY, V120, P525, DOI 10.1053/gast.2001.21176; KULLAKUBLICK GA, 1995, GASTROENTEROLOGY, V109, P1274, DOI 10.1016/0016-5085(95)90588-X; Kusuhara H, 2001, DRUG DISCOV TODAY, V6, P150, DOI 10.1016/S1359-6446(00)01632-9; Lee G, 2001, PHARMACOL REV, V53, P569; Li JY, 2001, J CEREBR BLOOD F MET, V21, P61, DOI 10.1097/00004647-200101000-00008; Li LQ, 2000, MOL PHARMACOL, V58, P335, DOI 10.1124/mol.58.2.335; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MINN A, 1991, BRAIN RES REV, V16, P65, DOI 10.1016/0165-0173(91)90020-9; Nishio T, 2000, BIOCHEM BIOPH RES CO, V275, P831, DOI 10.1006/bbrc.2000.3377; Noe B, 1997, P NATL ACAD SCI USA, V94, P10346, DOI 10.1073/pnas.94.19.10346; Oppenheimer JH, 1997, ENDOCR REV, V18, P462, DOI 10.1210/er.18.4.462; Pardridge W M, 1991, Semin Cell Biol, V2, P419; PARDRIDGE WM, 1979, ENDOCRINOLOGY, V105, P605, DOI 10.1210/endo-105-3-605; Pizzagalli F, 2002, MOL ENDOCRINOL, V16, P2283, DOI 10.1210/me.2001-0309; RAPOPORT SI, 1976, EXP NEUROL, V52, P467, DOI 10.1016/0014-4886(76)90218-1; Segal MB, 2000, CELL MOL NEUROBIOL, V20, P183, DOI 10.1023/A:1007045605751; Shi YB, 2002, PHARMACOL THERAPEUT, V94, P235, DOI 10.1016/S0163-7258(02)00219-X; Strazielle N, 1999, J NEUROSCI, V19, P6275; Sugiyama D, 2001, J PHARMACOL EXP THER, V298, P316; Suzuki H, 1997, ADV DRUG DELIVER REV, V25, P257, DOI 10.1016/S0169-409X(97)00503-6	35	229	235	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43489	43495		10.1074/jbc.M306933200	http://dx.doi.org/10.1074/jbc.M306933200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12923172	hybrid			2022-12-25	WOS:000186157000094
J	Yin, W; Mu, J; Birnbaum, MJ				Yin, W; Mu, J; Birnbaum, MJ			Role of AMP-activated protein kinase in cyclic AMP-dependent lipolysis in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-SENSITIVE LIPASE; FATTY-ACID OXIDATION; INSULIN-INDUCED PHOSPHORYLATION; SKELETAL-MUSCLE; GLUCOSE-TRANSPORT; 5-AMINOIMIDAZOLE-4-CARBOXAMIDE RIBONUCLEOSIDE; PHOSPHODIESTERASE 3B; CARDIAC-HYPERTROPHY; GAMMA(2) SUBUNIT; RAT ADIPOCYTES	AMP-activated protein kinase (AMPK) is a phylogenetically conserved intracellular energy sensor that has been implicated as a major regulator of glucose and lipid metabolism in mammals. However, its possible role in mediating or influencing the adrenergic control of lipolysis in adipocytes remains uncertain. In this study, we utilized the murine cultured preadipocyte line 3T3-L1 to examine this question. Treatment of adipocytes with isoproterenol or forskolin promoted the phosphorylation of AMPK at a critical activating Thr-172 residue in a dose- and time-dependent manner. This correlated well with a stimulation of the activity of AMPK, as measured in the immune complex. Analogs of cAMP mimicked the effect of isoproterenol and forskolin on AMPK phosphorylation. Treatment of adipocytes with insulin reduced both basal and forskolin-induced AMPK phosphorylation via a pathway dependent on phosphatidylinositol 3'-kinase. Overexpression of a dominant-inhibitory mutant of AMPK blocked isoproterenol-induced lipolysis by similar to50%. These data indicate that there exists a novel pathway by which cAMP can lead to the activation of AMPK, and in adipocytes, this is required for maximal activation of lipolysis.	Univ Penn, Sch Med, Dept Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania	Birnbaum, MJ (corresponding author), Univ Penn, Sch Med, Dept Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA.			Birnbaum, Morris/0000-0001-9972-8680; Mu, James/0000-0001-8081-2401	NIDDK NIH HHS [P30-DK-019525] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK019525] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anthonsen MW, 1998, J BIOL CHEM, V273, P215, DOI 10.1074/jbc.273.1.215; Bergeron R, 1999, AM J PHYSIOL-ENDOC M, V276, pE938, DOI 10.1152/ajpendo.1999.276.5.E938; Birnbaum MJ, 2003, J CELL BIOL, V161, P1011, DOI 10.1083/jcb.200306008; Blair E, 2001, HUM MOL GENET, V10, P1215, DOI 10.1093/hmg/10.11.1215; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Brasaemle DL, 2000, BBA-MOL CELL BIOL L, V1483, P251, DOI 10.1016/S1388-1981(99)00179-1; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; Daniel T, 2002, J BIOL CHEM, V277, P51017, DOI 10.1074/jbc.M207093200; EGAN JJ, 1992, P NATL ACAD SCI USA, V89, P8537, DOI 10.1073/pnas.89.18.8537; Fryer LGD, 2002, J BIOL CHEM, V277, P25226, DOI 10.1074/jbc.M202489200; GARTON AJ, 1989, EUR J BIOCHEM, V179, P249, DOI 10.1111/j.1432-1033.1989.tb14548.x; Garza LA, 2000, J BIOL CHEM, V275, P2560, DOI 10.1074/jbc.275.4.2560; Gollob MH, 2001, CIRCULATION, V104, P3030, DOI 10.1161/hc5001.102111; Hamilton SR, 2001, FEBS LETT, V500, P163, DOI 10.1016/S0014-5793(01)02602-3; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hawley SA, 2002, DIABETES, V51, P2420, DOI 10.2337/diabetes.51.8.2420; Hayashi T, 1997, AM J PHYSIOL-ENDOC M, V273, pE1039, DOI 10.1152/ajpendo.1997.273.6.E1039; Holm C, 2000, ANNU REV NUTR, V20, P365, DOI 10.1146/annurev.nutr.20.1.365; Kemp BE, 1999, TRENDS BIOCHEM SCI, V24, P22, DOI 10.1016/S0968-0004(98)01340-1; Kitamura T, 1999, MOL CELL BIOL, V19, P6286; Lawrence JTR, 2001, MOL CELL BIOL, V21, P5276, DOI 10.1128/MCB.21.15.5276-5285.2001; Londos C, 1999, ANN NY ACAD SCI, V892, P155, DOI 10.1111/j.1749-6632.1999.tb07794.x; Merrill GF, 1997, AM J PHYSIOL-ENDOC M, V273, pE1107, DOI 10.1152/ajpendo.1997.273.6.E1107; Milan D, 2000, SCIENCE, V288, P1248, DOI 10.1126/science.288.5469.1248; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Moule SK, 1998, FEBS LETT, V439, P287, DOI 10.1016/S0014-5793(98)01392-1; Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097-2765(01)00251-9; Musi N, 2002, DIABETES, V51, P2074, DOI 10.2337/diabetes.51.7.2074; Orlicky DJ, 2001, J LIPID RES, V42, P460; Salt IP, 2000, DIABETES, V49, P1649, DOI 10.2337/diabetes.49.10.1649; Stein SC, 2000, BIOCHEM J, V345, P437, DOI 10.1042/0264-6021:3450437; SU CL, 2003, J BIOL CHEM; SULLIVAN JE, 1994, FEBS LETT, V353, P33, DOI 10.1016/0014-5793(94)01006-4; Syu LJ, 1999, MOL CELL, V4, P109, DOI 10.1016/S1097-2765(00)80192-6; Sztalryd C, 2003, J CELL BIOL, V161, P1093, DOI 10.1083/jcb.200210169; Tomas E, 2002, P NATL ACAD SCI USA, V99, P16309, DOI 10.1073/pnas.222657499; Wijkander J, 1998, ENDOCRINOLOGY, V139, P219, DOI 10.1210/en.139.1.219; Winder WW, 1999, AM J PHYSIOL-ENDOC M, V277, pE1, DOI 10.1152/ajpendo.1999.277.1.E1; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI200113505; Zong HH, 2002, P NATL ACAD SCI USA, V99, P15983, DOI 10.1073/pnas.252625599	41	235	237	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43074	43080		10.1074/jbc.M308484200	http://dx.doi.org/10.1074/jbc.M308484200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12941946	hybrid			2022-12-25	WOS:000186157000045
J	Jensen, LT; Ajua-Alemanji, M; Culotta, VC				Jensen, LT; Ajua-Alemanji, M; Culotta, VC			The Saccharomyces cerevisiae high affinity phosphate transporter encoded by PHO84 also functions in manganese homeostasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SECRETORY PATHWAY; SUPEROXIDE-DISMUTASE; GENE ENCODES; COPPER TRANSPORTER; ZINC TRANSPORTER; ION-PUMP; PROTEIN; IRON; PERMEASE; SYSTEM	In the bakers' yeast Saccharomyces cerevisiae, high affinity manganese uptake and intracellular distribution involve two members of the Nramp family of genes, SMF1 and SMF2. In a search for other genes involved in manganese homeostasis, PHO84 was identified. The PHO84 gene encodes a high affinity inorganic phosphate transporter, and we find that its disruption results in a manganese-resistant phenotype. Resistance to zinc, cobalt, and copper ions was also demonstrated for pho84Delta yeast. When challenged with high concentrations of metals, pho84Delta yeast have reduced metal ion accumulation, suggesting that resistance is due to reduced uptake of metal ions. Pho84p accounted for virtually all the manganese accumulated under metal surplus conditions, demonstrating that this transporter is the major source of excess manganese accumulation. The manganese taken in via Pho84p is indeed biologically active and can not only cause toxicity but can also be incorporated into manganese-requiring enzymes. Pho84p is essential for activating manganese enzymes in smf2Delta mutants that rely on low affinity manganese transport systems. A role for Pho84p in manganese accumulation was also identified in a standard laboratory growth medium when high affinity manganese uptake is active. Under these conditions, cells lacking both Pho84p and the high affinity Smf1p transporter accumulated low levels of manganese, although there was no major effect on activity of manganese-requiring enzymes. We conclude that Pho84p plays a role in manganese homeostasis predominantly under manganese surplus conditions and appears to be functioning as a low affinity metal transporter.	Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biochem & Mol Biol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Jensen, LT (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, 615 N Wolfe St,Rm 7032, Baltimore, MD 21205 USA.			Jensen, Laran/0000-0003-3199-1743	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008996] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES 08996] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Andre B, 1995, YEAST, V11, P1575, DOI 10.1002/yea.320111605; ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUNYA M, 1991, MOL CELL BIOL, V11, P3229, DOI 10.1128/MCB.11.6.3229; CELLIER M, 1995, P NATL ACAD SCI USA, V92, P10089, DOI 10.1073/pnas.92.22.10089; Cohen A, 2000, J BIOL CHEM, V275, P33388, DOI 10.1074/jbc.M004611200; DANCIS A, 1994, J BIOL CHEM, V269, P25660; Dix D, 1997, J BIOL CHEM, V272, P11770, DOI 10.1074/jbc.272.18.11770; DIX DR, 1994, J BIOL CHEM, V269, P26092; Durr G, 1998, MOL BIOL CELL, V9, P1149, DOI 10.1091/mbc.9.5.1149; Finley JW, 1999, BIOFACTORS, V10, P15, DOI 10.1002/biof.5520100102; FLOHE L, 1984, METHOD ENZYMOL, V105, P93; Fristedt U, 1999, BIOCHEMISTRY-US, V38, P16010, DOI 10.1021/bi991545c; GABRIEL O, 1969, ANAL BIOCHEM, V27, P545, DOI 10.1016/0003-2697(69)90068-2; GIETZ RD, 1991, YEAST, V7, P253, DOI 10.1002/yea.320070307; HARRISON MJ, 1995, NATURE, V378, P626, DOI 10.1038/378626a0; Hassett R, 2000, BIOCHEM J, V351, P477, DOI 10.1042/0264-6021:3510477; Henderson PJF, 1993, CURR OPIN CELL BIOL, V5, P708, DOI 10.1016/0955-0674(93)90144-F; Jabalquinto AM, 1999, J PROTEIN CHEM, V18, P659, DOI 10.1023/A:1020602222808; Jensen LT, 2000, MOL CELL BIOL, V20, P3918, DOI 10.1128/MCB.20.11.3918-3927.2000; Kaiser J, 2003, SCIENCE, V300, P926, DOI 10.1126/science.300.5621.926; KINNETT DG, 1982, INT J BIOCHEM, V14, P977, DOI 10.1016/0020-711X(82)90058-1; Knight SAB, 1996, GENE DEV, V10, P1917, DOI 10.1101/gad.10.15.1917; KUHN NJ, 1991, EUR J BIOCHEM, V195, P243, DOI 10.1111/j.1432-1033.1991.tb15700.x; Liu XF, 1999, J BIOL CHEM, V274, P4863, DOI 10.1074/jbc.274.8.4863; Luk EEC, 2001, J BIOL CHEM, V276, P47556, DOI 10.1074/jbc.M108923200; Malecki EA, 2001, BRAIN RES BULL, V55, P225, DOI 10.1016/S0361-9230(01)00456-7; Mandal D, 2000, J BIOL CHEM, V275, P23933, DOI 10.1074/jbc.M002619200; MARRES CAM, 1985, EUR J BIOCHEM, V147, P153, DOI 10.1111/j.1432-1033.1985.tb08731.x; Muchhal US, 1996, P NATL ACAD SCI USA, V93, P10519, DOI 10.1073/pnas.93.19.10519; Nelissen B, 1995, FEBS LETT, V377, P232, DOI 10.1016/0014-5793(95)01380-6; OEHME FW, 1978, TOXICITY HEAVY METAL, V2, P547; Ooi CE, 1996, EMBO J, V15, P3515, DOI 10.1002/j.1460-2075.1996.tb00720.x; Pal PK, 1999, NEUROTOXICOLOGY, V20, P227; Petersson J, 1999, FEBS LETT, V462, P37, DOI 10.1016/S0014-5793(99)01471-4; Portnoy ME, 2000, MOL CELL BIOL, V20, P7893, DOI 10.1128/MCB.20.21.7893-7902.2000; PUTRAMENT A, 1973, MOL GEN GENET, V126, P357, DOI 10.1007/BF00269445; RAM BP, 1985, CRC CR REV BIOCH MOL, V17, P257, DOI 10.3109/10409238509113606; Rayner JC, 1998, J BIOL CHEM, V273, P26836, DOI 10.1074/jbc.273.41.26836; Sherman F., 1978, METHODS YEAST GENETI; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; Supek F, 1996, P NATL ACAD SCI USA, V93, P5105, DOI 10.1073/pnas.93.10.5105; VANLOON APGM, 1986, P NATL ACAD SCI USA, V83, P3820; VANVEEN HW, 1994, BIOCHEMISTRY-US, V33, P1766, DOI 10.1021/bi00173a020; VANVEEN HW, 1993, J BIOL CHEM, V268, P19377; Wedler FC., 1994, MANGANESE HLTH DIS, P1; WEISIGER RA, 1973, J BIOL CHEM, V248, P4793; WEST AH, 1992, J BIOL CHEM, V267, P24625; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; Wykoff DD, 2001, GENETICS, V159, P1491; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x; Zhao H, 1997, MOL CELL BIOL, V17, P5044, DOI 10.1128/MCB.17.9.5044; Zhao H, 1996, J BIOL CHEM, V271, P23203, DOI 10.1074/jbc.271.38.23203; Zhao H, 1996, P NATL ACAD SCI USA, V93, P2454, DOI 10.1073/pnas.93.6.2454	54	111	115	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42036	42040		10.1074/jbc.M307413200	http://dx.doi.org/10.1074/jbc.M307413200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12923174	hybrid			2022-12-25	WOS:000185989500059
J	Leung, SW; Harreman, MT; Hodel, MR; Hodel, AE; Corbett, AH				Leung, SW; Harreman, MT; Hodel, MR; Hodel, AE; Corbett, AH			Dissection of the karyopherin alpha nuclear localization signal (NLS)-binding groove - Functional requirements for NLS binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN IMPORTIN-ALPHA; SACCHAROMYCES-CEREVISIAE; PORE COMPLEX; NUCLEOCYTOPLASMIC TRANSPORT; CRYSTALLOGRAPHIC ANALYSIS; STRUCTURAL BASIS; PROTEIN IMPORT; YEAST; SEQUENCE; RECOGNITION	Classical protein import, mediated by the binding of a classical nuclear localization signal (NLS) to the NLS receptor, karyopherin/importin alpha, is the most well studied nuclear transport process. Classical NLSs are either monopartite sequences that contain a single cluster of basic amino acids (Lys/Arg) or bipartite sequences that contain two clusters of basic residues separated by an unconserved linker region. We have created mutations in conserved residues in each of the three NLS-binding sites/regions in Saccharomyces cerevisiae karyopherin alpha (SRP1). For each mutant we have analyzed binding to both a monopartite and a bipartite NLS cargo in vitro. We have also expressed each karyopherin alpha mutant in vivo as the only cellular copy of the NLS receptor and examined the impact on cell growth and import of both monopartite and bipartite NLS-containing cargoes. Our results reveal the functional significance of specific residues within karyopherin alpha for NLS cargo binding. A karyopherin alpha variant with a mutation in the major NLS-binding site exhibits decreased binding to both monopartite and bipartite NLS cargoes, and this protein is not functional in vivo. However, we also find that a karyopherin alpha variant with a mutation in the minor NLS-binding site, which shows decreased binding only to bipartite NLS-containing cargoes, is also not functional in vivo. This suggests that the cell is dependent on the function of at least one bipartite NLS cargo that is imported into the nucleus by karyopherin alpha. Our experiments also reveal functional importance for the linker-binding region. This study provides insight into how changes in binding to cellular NLS sequences could impact cellular function. In addition, this work has led to the creation of conditional alleles of karyopherin alpha with well characterized defects in NLS binding that will be useful for identifying and characterizing novel NLS cargoes.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Grad Program Biochem Cell & Dev Biol, Atlanta, GA 30322 USA	Emory University; Emory University	Corbett, AH (corresponding author), Emory Univ, Sch Med, Dept Biochem, 1510 Clifton Rd NE, Atlanta, GA 30322 USA.		Corbett, Anita/AAH-6106-2021	Corbett, Anita/0000-0002-0461-6895	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065442] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 065442-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams A, 1997, METHODS YEAST GENETI; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; Chook YM, 2001, CURR OPIN STRUC BIOL, V11, P703, DOI 10.1016/S0959-440X(01)00264-0; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Conti E, 2000, STRUCTURE, V8, P329, DOI 10.1016/S0969-2126(00)00107-6; Conti E, 2001, CURR OPIN CELL BIOL, V13, P310, DOI 10.1016/S0955-0674(00)00213-1; ENENKEL C, 1995, J BIOL CHEM, V270, P16499, DOI 10.1074/jbc.270.28.16499; Fanara P, 2000, J BIOL CHEM, V275, P21218, DOI 10.1074/jbc.M002217200; Fontes MRM, 2003, J BIOL CHEM, V278, P27981, DOI 10.1074/jbc.M303275200; Fontes MRM, 2000, J MOL BIOL, V297, P1183, DOI 10.1006/jmbi.2000.3642; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gruss OJ, 2001, CELL, V104, P83, DOI 10.1016/S0092-8674(01)00193-3; Harreman MT, 2003, J BIOL CHEM, V278, P5854, DOI 10.1074/jbc.M210951200; Herold A, 1998, J CELL BIOL, V143, P309, DOI 10.1083/jcb.143.2.309; Hodel MR, 2001, J BIOL CHEM, V276, P1317, DOI 10.1074/jbc.M008522200; Hood JK, 1998, J BIOL CHEM, V273, P35142, DOI 10.1074/jbc.273.52.35142; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kobe B, 1999, NAT STRUCT BIOL, V6, P388, DOI 10.1038/7625; LANFORD RE, 1984, CELL, V37, P801, DOI 10.1016/0092-8674(84)90415-X; Moroianu J, 1996, P NATL ACAD SCI USA, V93, P6572, DOI 10.1073/pnas.93.13.6572; Niedenthal RK, 1996, YEAST, V12, P773, DOI 10.1002/(SICI)1097-0061(19960630)12:8<773::AID-YEA972>3.3.CO;2-C; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Rout MP, 2001, J BIOL CHEM, V276, P16593, DOI 10.1074/jbc.R100015200; SIKORSKI RS, 1989, GENETICS, V122, P19; Suntharalingam M, 2003, DEV CELL, V4, P775, DOI 10.1016/S1534-5807(03)00162-X; Weis K, 2003, CELL, V112, P441, DOI 10.1016/S0092-8674(03)00082-5; Weis K, 1996, EMBO J, V15, P1818, DOI 10.1002/j.1460-2075.1996.tb00531.x; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107; YANO R, 1994, P NATL ACAD SCI USA, V91, P6880, DOI 10.1073/pnas.91.15.6880; YANO R, 1992, MOL CELL BIOL, V12, P5640, DOI 10.1128/MCB.12.12.5640	33	53	53	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41947	41953		10.1074/jbc.M307162200	http://dx.doi.org/10.1074/jbc.M307162200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12917403	hybrid			2022-12-25	WOS:000185989500049
J	Odriozola, L; Cruchaga, C; Andreola, M; Dolle, V; Nguyen, CH; Tarrago-Litvak, L; Perez-Mediavilla, A; Martinez-Irujo, JJ				Odriozola, L; Cruchaga, C; Andreola, M; Dolle, V; Nguyen, CH; Tarrago-Litvak, L; Perez-Mediavilla, A; Martinez-Irujo, JJ			Non-nucleoside inhibitors of HIV-1 reverse transcriptase inhibit phosphorolysis and resensitize the 3 '-azido-3 '-deoxythymidine (AZT)-resistant polymerase to AZT-5 '-triphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ANTIVIRAL ACTIVITY; IN-VITRO; PYRIDINONE DERIVATIVES; SYNERGISTIC INHIBITION; RESISTANCE; MECHANISM; AZT; REPLICATION; COMBINATION	Removal of 3'-azido-3'deoxythymidine (AZT) 3'-azido-3'-deoxythymidine-5'-monophosphate (AZTMP) from the terminated primer mediated by the human HIV-1 reverse transcriptase (RT) has been proposed as a relevant mechanism for the resistance of HIV to AZT. Here we compared wild type and AZT-resistant (D67N/K70R/T215Y/K219Q) RTs for their ability to unblock the AZTMP-terminated primer by phosphorolysis in the presence of physiological concentrations of pyrophosphate or ATP. The AZT-resistant enzyme, as it has been previously described, showed an increased ability to unblock the AZTMP-terminated primer by an ATP-dependent mechanism. We found that only mutations in the p66 subunit were responsible for this ability. We also found that three structurally divergent non-nucleoside reverse transcriptase inhibitor (NNRTI), nevirapine, TIBO, and a 4-arylmethylpyridinone derivative, were able to inhibit the phosphorolytic activity of the enzyme, rendering the AZT-resistant RT sensitive to AZTTP. The 4-arylmethylpyridinone derivative proved to be about 1000-fold more potent in inhibiting phosphorolysis than nevirapine or TIBO. Moreover, combinations of AZTTP with NNRTIs exhibited an exceptionally high degree of synergy in the inhibition of AZT-resistant enzyme only when ATP or PPi were present, indicating that inhibition of phosphorolysis was responsible for the synergy found in the combination. Our results not only demonstrate the importance of phosphorolysis concerning HIV-1 RT resistance to AZT but also point to the implication of this activity in the strong synergy found in some combinations of NNRTIs with AZT.	Univ Navarra, Dept Biochem & Mol Biol, Pamplona 31008, Spain; Univ Bordeaux 2, CNRS, UMR 5097, F-33076 Bordeaux, France; IFR 66 Pathol Infect, F-33076 Bordeaux, France; Inst Curie, Sect Rech, CNRS, UMR 176, F-91405 Orsay, France	University of Navarra; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS)	Martinez-Irujo, JJ (corresponding author), Univ Navarra, Dept Biochem & Mol Biol, Calle Irunlarrea S-N, Pamplona 31008, Spain.		Nguyen, Chi/GWR-1592-2022; Nguyen, Chi/GZG-5146-2022; Perez-Mediavilla, Alberto/A-5246-2011; Cruchaga, Carlos/ABF-4065-2020; Martinez-Irujo, Juan/N-3193-2014	Perez-Mediavilla, Alberto/0000-0003-1926-0972; Cruchaga, Carlos/0000-0002-0276-2899; Martinez-Irujo, Juan/0000-0003-4576-8139				Arion D, 1998, BIOCHEMISTRY-US, V37, P15908, DOI 10.1021/bi981200e; BABA M, 1994, ANTIMICROB AGENTS CH, V38, P688, DOI 10.1128/AAC.38.4.688; BALZARINI J, 1992, J BIOL CHEM, V267, P11831; BERENBAUM MC, 1977, CLIN EXP IMMUNOL, V28, P1; Borkow G, 1999, ANTIMICROB AGENTS CH, V43, P259, DOI 10.1128/AAC.43.2.259; BOYER PL, 1994, P NATL ACAD SCI USA, V91, P4882, DOI 10.1073/pnas.91.11.4882; Boyer PL, 2001, J VIROL, V75, P4832, DOI 10.1128/JVI.75.10.4832-4842.2001; BUCKHEIT RW, 1995, ANTIMICROB AGENTS CH, V39, P2718, DOI 10.1128/AAC.39.12.2718; BUCKHEIT RW, 1993, AIDS RES HUM RETROV, V9, P1097, DOI 10.1089/aid.1993.9.1097; BUCKHEIT RW, 1994, ANTIVIR RES, V25, P43, DOI 10.1016/0166-3542(94)90092-2; Cabodevilla JF, 2001, EUR J BIOCHEM, V268, P1163, DOI 10.1046/j.1432-1327.2001.01939.x; CARROLL SS, 1994, J BIOL CHEM, V269, P32351; CHATTOPADHYAY D, 1992, J BIOL CHEM, V267, P14227; CHONG KT, 1994, ANTIMICROB AGENTS CH, V38, P288, DOI 10.1128/AAC.38.2.288; Dolle V, 2000, J MED CHEM, V43, P3949, DOI 10.1021/jm0009437; GOLDMAN ME, 1991, P NATL ACAD SCI USA, V88, P6863, DOI 10.1073/pnas.88.15.6863; Gu ZX, 1995, J BIOL CHEM, V270, P31046, DOI 10.1074/jbc.270.52.31046; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; Martinez-Irujo JJ, 1998, BIOCHEM J, V329, P689, DOI 10.1042/bj3290689; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; Meyer PR, 2000, ANTIMICROB AGENTS CH, V44, P3465, DOI 10.1128/AAC.44.12.3465-3472.2000; Meyer PR, 1998, P NATL ACAD SCI USA, V95, P13471, DOI 10.1073/pnas.95.23.13471; PARKER WB, 1991, J BIOL CHEM, V266, P1754; PAUWELS R, 1992, BIOCHEM SOC T, V220, P509; Ren JS, 1998, P NATL ACAD SCI USA, V95, P9518, DOI 10.1073/pnas.95.16.9518; Richman D D, 1991, AIDS, V5 Suppl 2, pS189, DOI 10.1097/00002030-199101001-00027; Rigourd M, 2002, J BIOL CHEM, V277, P18611, DOI 10.1074/jbc.M110836200; SPENCE RA, 1995, SCIENCE, V267, P988, DOI 10.1126/science.7532321; TRAMONTANO E, 1992, BIOCHEM PHARMACOL, V43, P1371; Villahermosa ML, 1997, BIOCHEMISTRY-US, V36, P13223, DOI 10.1021/bi970852k	31	28	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42710	42716		10.1074/jbc.M212673200	http://dx.doi.org/10.1074/jbc.M212673200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12917424	hybrid			2022-12-25	WOS:000185989500138
J	Wada, Y; Ohya, H; Yamaguchi, Y; Koizumi, N; Sano, H				Wada, Y; Ohya, H; Yamaguchi, Y; Koizumi, N; Sano, H			Preferential de Novo methylation of cytosine residues in non-CpG sequences by a domains rearranged DNA methyltransferase from tobacco plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARABIDOPSIS-THALIANA; MOSAIC-VIRUS; GENES; RNA; DEMETHYLATION; MAINTENANCE; MAIZE; CELLS; CHROMOMETHYLASE3; TRANSFORMATION	In plant DNA, cytosines in symmetric CpG and CpNpG (N is A, T, or C) are thought to be methylated by DNA methyltransferases, MET1 and CMT3, respectively. Cytosines in asymmetric CpNpN are also methylated, and genetic analysis has suggested the responsible enzyme to be domains rearranged methyltransferase (DRM). We cloned a tobacco cDNA, encoding a novel protein consisting of 608 amino acids, that resembled DRMs found in maize and Arabidopsis and designated this as NtDRM1. The protein could be shown to be localized exclusively in the nucleus and exhibit methylation activity toward unmethylated synthetic as well as native DNA samples upon expression in Sf9 insect cells. It also methylated hemimethylated DNA, but the activity was lower than that for unmethylated substrates. Methylation mapping of a 962-bp DNA, treated with NtDRM1 in vitro, directly demonstrated methylation of similar to70% of the cytosines in methylatable CpNpN and CpNpG sequences but only 10% in CpG. Further analyses indicated that the enzyme apparently non-selectively methylates any cytosines except in CpG, regardless of the adjacent nucleotide at both 5' and 3' ends. Transcripts of NtDRM1 ubiquitously accumulated in all tissues and during the cell cycle in tobacco cultured BY2 cells. These results indicate that NtDRM1 is a de novo cytosine methyltransfease, which actively excludes CpG substrate.	Nara Inst Sci & Technol, Res & Educ Ctr Genet Inforamt, Nara 6300192, Japan	Nara Institute of Science & Technology	Sano, H (corresponding author), Nara Inst Sci & Technol, Res & Educ Ctr Genet Inforamt, Nara 6300192, Japan.		Hu, Ruogu/B-2203-2008; Yamaguchi, Yube/B-9594-2012					AN GH, 1985, PLANT PHYSIOL, V79, P568, DOI 10.1104/pp.79.2.568; BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Cao XF, 2002, CURR BIOL, V12, P1138, DOI 10.1016/S0960-9822(02)00925-9; Cao XF, 2002, P NATL ACAD SCI USA, V99, P16491, DOI 10.1073/pnas.162371599; Cao XF, 2000, P NATL ACAD SCI USA, V97, P4979, DOI 10.1073/pnas.97.9.4979; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Ehrlich M, 2003, J CELL BIOCHEM, V88, P899, DOI 10.1002/jcb.10464; Finnegan EJ, 2000, PLANT MOL BIOL, V43, P189, DOI 10.1023/A:1006427226972; FINNEGAN EJ, 1993, NUCLEIC ACIDS RES, V21, P2383, DOI 10.1093/nar/21.10.2383; Finnegan EJ, 1996, P NATL ACAD SCI USA, V93, P8449, DOI 10.1073/pnas.93.16.8449; Gong ZH, 2002, CELL, V111, P803, DOI 10.1016/S0092-8674(02)01133-9; Hara K, 2000, PLANT CELL PHYSIOL, V41, P684, DOI 10.1093/pcp/41.6.684; Hernandez A, 1998, BIOINFORMATICS, V14, P227, DOI 10.1093/bioinformatics/14.2.227; Hofmann K, 1996, TRENDS BIOCHEM SCI, V21, P172, DOI 10.1016/0968-0004(96)30015-7; HOLLIDAY R, 1975, SCIENCE, V187, P226, DOI 10.1126/science.1111098; HOOD EE, 1993, TRANSGENIC RES, V2, P208, DOI 10.1007/BF01977351; Jacobsen SE, 1997, SCIENCE, V277, P1100, DOI 10.1126/science.277.5329.1100; Jones L, 2001, CURR BIOL, V11, P747, DOI 10.1016/S0960-9822(01)00226-3; JOST JP, 1995, J BIOL CHEM, V270, P9734, DOI 10.1074/jbc.270.17.9734; Lindroth AM, 2001, SCIENCE, V292, P2077, DOI 10.1126/science.1059745; Miura A, 2001, NATURE, V411, P212, DOI 10.1038/35075612; MURRAY MG, 1980, NUCLEIC ACIDS RES, V8, P4321, DOI 10.1093/nar/8.19.4321; NAGATA T, 1981, MOL GEN GENET, V184, P161, DOI 10.1007/BF00272899; Nakano Y, 2000, PLANT CELL PHYSIOL, V41, P448, DOI 10.1093/pcp/41.4.448; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Papa CM, 2001, PLANT CELL, V13, P1919, DOI 10.1105/tpc.13.8.1919; RAIZIS AM, 1995, ANAL BIOCHEM, V226, P161, DOI 10.1006/abio.1995.1204; Ramsahoye BH, 2000, P NATL ACAD SCI USA, V97, P5237, DOI 10.1073/pnas.97.10.5237; Robertson KD, 2000, NAT REV GENET, V1, P11, DOI 10.1038/35049533; Ronemus MJ, 1996, SCIENCE, V273, P654, DOI 10.1126/science.273.5275.654; Selker EU, 2002, P NATL ACAD SCI USA, V99, P16485, DOI 10.1073/pnas.182427299; Steward N, 2000, NUCLEIC ACIDS RES, V28, P3250, DOI 10.1093/nar/28.17.3250; Steward N, 2002, J BIOL CHEM, V277, P37741, DOI 10.1074/jbc.M204050200; Tompa R, 2002, CURR BIOL, V12, P65, DOI 10.1016/S0960-9822(01)00622-4; Wakefield RID, 1999, J MOL BIOL, V291, P1055, DOI 10.1006/jmbi.1999.3023; Wassenegger M, 2000, PLANT MOL BIOL, V43, P203, DOI 10.1023/A:1006479327881; Wassenegger M, 1998, PLANT MOL BIOL, V37, P349, DOI 10.1023/A:1005946720438; Yoda H, 2002, MOL GENET GENOMICS, V267, P154, DOI 10.1007/s00438-002-0651-z; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5	41	54	66	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42386	42393		10.1074/jbc.M303892200	http://dx.doi.org/10.1074/jbc.M303892200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12917429	hybrid			2022-12-25	WOS:000185989500101
J	Wicksteed, B; Alarcon, C; Briaud, I; Lingohr, MK; Rhodes, CJ				Wicksteed, B; Alarcon, C; Briaud, I; Lingohr, MK; Rhodes, CJ			Glucose-induced translational control of proinsulin biosynthesis is proportional to preproinsulin mRNA levels in islet beta-cells but not regulated via a positive feedback of secreted insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT PANCREATIC-ISLETS; GENE-EXPRESSION; DIFFERENTIAL ACTIVATION; SIGNAL-TRANSDUCTION; PROTEIN-KINASE; RIN-5F CELLS; TRANSCRIPTION; RECEPTOR; INHIBITION; CALCIUM	Proinsulin biosynthesis is regulated in response to nutrients, most notably glucose. In the short term (less than or equal to2 h) this is due to increases in the translation of pre-existing mRNA. However, prolonging glucose stimulation (24 h) also increases preproinsulin mRNA levels. It has been proposed that secreted insulin from the pancreatic beta-cell regulates its own synthesis through a positive autocrine feedback mechanism. Here the comparative contributions of translation and mRNA levels on the levels of proinsulin biosynthesis were examined in isolated pancreatic islets. Also, the autocrine role of insulin upon four beta-cell functions (insulin secretion, proinsulin translation, preproinsulin mRNA levels, and total protein synthesis) was investigated in parallel. The results showed that proinsulin biosynthesis is regulated, in the short term (1 h), solely at the level of translation, through an similar to6-fold increase in response to glucose (2.8 mM versus 16.7 mM glucose). In the longer term, when preproinsulin mRNA levels have increased similar to2-fold, a corresponding increase was observed in the fold response of proinsulin translation to a stimulatory glucose concentration (greater than or equal to10-fold). Importantly, neither exogenously added nor secreted insulin were found to play any role in regulating insulin secretion, proinsulin translation, preproinsulin mRNA levels, or total protein synthesis. The results presented here indicate that long term nutritional state sets the preproinsulin mRNA level in the beta-cell at which translation control regulates short term changes in rates of proinsulin biosynthesis in response to glucose, but this is not mediated by any autocrine effect of insulin.	Pacific NW Res Inst, Seattle, WA 98122 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98122 USA	University of Washington; University of Washington Seattle	Rhodes, CJ (corresponding author), Pacific NW Res Inst, 720 Broadway, Seattle, WA 98122 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047919, R01DK050610, R56DK050610] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 47919, DK 50610, DK 55269] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALARCON C, 1993, J BIOL CHEM, V268, P4276; Alarcon C, 2002, DIABETES, V51, P2496, DOI 10.2337/diabetes.51.8.2496; ASHCROFT SJH, 1980, DIABETOLOGIA, V18, P5, DOI 10.1007/BF01228295; Benes C, 1999, BIOCHEM J, V340, P219, DOI 10.1042/0264-6021:3400219; BEST L, 1988, BIOCHEM PHARMACOL, V37, P4611, DOI 10.1016/0006-2952(88)90328-0; BODEN G, 1993, METABOLISM, V42, P786, DOI 10.1016/0026-0495(93)90250-R; Briaud I, 2000, HORM METAB RES, V32, P53, DOI 10.1055/s-2007-978588; Briaud I, 2003, DIABETES, V52, P974, DOI 10.2337/diabetes.52.4.974; Briaud I, 2002, DIABETES, V51, P662, DOI 10.2337/diabetes.51.3.662; BRUNSTEDT J, 1982, BIOCHEM BIOPH RES CO, V106, P1383, DOI 10.1016/0006-291X(82)91267-0; Clemens MJ, 1989, CURR OPIN CELL BIOL, V1, P1160, DOI 10.1016/S0955-0674(89)80067-5; CRETTAZ M, 1984, DIABETES, V33, P477, DOI 10.2337/diabetes.33.5.477; Dickson LM, 2001, J BIOL CHEM, V276, P21110, DOI 10.1074/jbc.M101257200; ELAHI D, 1982, NEW ENGL J MED, V306, P1196, DOI 10.1056/NEJM198205203062002; Gannon M, 2000, GENESIS, V26, P139, DOI 10.1002/(SICI)1526-968X(200002)26:2<139::AID-GENE12>3.0.CO;2-7; GERMAN MS, 1990, J BIOL CHEM, V265, P22063; GIDDINGS SJ, 1982, DIABETES, V31, P624, DOI 10.2337/diabetes.31.7.624; GIDDINGS SJ, 1981, J CLIN INVEST, V67, P952, DOI 10.1172/JCI110145; GIDDINGS SJ, 1985, DIABETES, V34, P235, DOI 10.2337/diabetes.34.3.235; Gilligan M, 1996, J BIOL CHEM, V271, P2121, DOI 10.1074/jbc.271.4.2121; Gomez E, 2002, J BIOL CHEM, V277, P48146, DOI 10.1074/jbc.M209165200; GUEST PC, 1989, BIOCHEM J, V257, P431, DOI 10.1042/bj2570431; GUEST PC, 1991, BIOCHEM J, V274, P73, DOI 10.1042/bj2740073; Hugl SR, 1998, J BIOL CHEM, V273, P17771, DOI 10.1074/jbc.273.28.17771; ITOH N, 1980, NATURE, V283, P100, DOI 10.1038/283100a0; Kitamura T, 2002, J CLIN INVEST, V110, P1839, DOI 10.1172/JCI200216857; KORANYI L, 1992, J CLIN INVEST, V89, P432, DOI 10.1172/JCI115602; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Laedtke T, 2000, AM J PHYSIOL-ENDOC M, V279, pE520, DOI 10.1152/ajpendo.2000.279.3.E520; Leibiger B, 2000, J BIOL CHEM, V275, P30153, DOI 10.1074/jbc.M005216200; Leibiger B, 1998, P NATL ACAD SCI USA, V95, P9307, DOI 10.1073/pnas.95.16.9307; Leibiger B, 2001, MOL CELL, V7, P559, DOI 10.1016/S1097-2765(01)00203-9; Leibiger IB, 2002, FEBS LETT, V532, P1, DOI 10.1016/S0014-5793(02)03627-X; Leibiger IB, 1998, MOL CELL, V1, P933, DOI 10.1016/S1097-2765(00)80093-3; Leibowitz G, 2002, ENDOCRINOLOGY, V143, P3214, DOI 10.1210/en.2002-220174; Leibowitz G, 2003, DIABETES, V52, P998, DOI 10.2337/diabetes.52.4.998; LEVY J, 1975, BIOCHEM PHARMACOL, V24, P235, DOI 10.1016/0006-2952(75)90282-8; LIN BJ, 1973, ENDOCRINOLOGY, V92, P735, DOI 10.1210/endo-92-3-735; Lingohr MK, 2002, DIABETES, V51, P966, DOI 10.2337/diabetes.51.4.966; LUZI L, 1992, DIABETES, V41, P1632, DOI 10.2337/diabetes.41.12.1632; MARSHALL S, 1980, J CLIN INVEST, V66, P763, DOI 10.1172/JCI109914; McDaniel ML, 2002, DIABETES, V51, P2877, DOI 10.2337/diabetes.51.10.2877; NIELSEN DA, 1985, J BIOL CHEM, V260, P3585; Obici S, 2002, NAT NEUROSCI, V5, P566, DOI 10.1038/nn861; Ohneda K, 2000, SEMIN CELL DEV BIOL, V11, P227, DOI 10.1006/scdb.2000.0171; OLSON SE, 1976, DIABETS METAB REV, V2, P199; ORLAND MJ, 1987, DIABETES, V36, P341, DOI 10.2337/diabetes.36.3.341; PERMUTT MA, 1984, J CLIN INVEST, V73, P1344, DOI 10.1172/JCI111337; Prentki M, 1996, EUR J ENDOCRINOL, V134, P272, DOI 10.1530/eje.0.1340272; Proud CG, 2002, EUR J BIOCHEM, V269, P5338, DOI 10.1046/j.1432-1033.2002.03292.x; Rhodes CJ, 2002, EUR J CLIN INVEST, V32, P3, DOI 10.1046/j.1365-2362.32.s3.2.x; Rhodes CJ., 2000, DIABETES MELLITUS FU, P20; Robey RB, 1998, BIOCHEMISTRY-US, V37, P9894, DOI 10.1021/bi980857x; ROHILLA AMK, 1991, BIOCHEM BIOPH RES CO, V175, P520, DOI 10.1016/0006-291X(91)91595-4; Rouault T, 1997, CURR TOP CELL REGUL, V35, P1, DOI 10.1016/S0070-2137(97)80001-5; Tillmar L, 2002, J BIOL CHEM, V277, P1099, DOI 10.1074/jbc.M108340200; WELSH M, 1986, BIOCHEM J, V235, P459, DOI 10.1042/bj2350459; WELSH M, 1985, J BIOL CHEM, V260, P3590; Wicksteed B, 2001, J BIOL CHEM, V276, P22553, DOI 10.1074/jbc.M011214200; Xavier GD, 2000, J BIOL CHEM, V275, P36269, DOI 10.1074/jbc.M006597200; Zawalich WS, 2002, J BIOL CHEM, V277, P26233, DOI 10.1074/jbc.M202291200	61	92	96	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42080	42090		10.1074/jbc.M303509200	http://dx.doi.org/10.1074/jbc.M303509200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12928442	hybrid			2022-12-25	WOS:000185989500065
J	Yao, YL; Yang, WM				Yao, YL; Yang, WM			The metastasis-associated proteins 1 and 2 form distinct protein complexes with histone deacetylase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMED-CELL DIFFERENTIATION; MAMMARY ADENOCARCINOMA; TRICHOSTATIN-A; BREAST-CANCER; BONE-MARROW; TRANSCRIPTIONAL REPRESSION; CHROMATIN STRUCTURE; CARCINOMA-CELLS; DNA METHYLATION; GASTRIC-CANCER	The metastasis-associated protein MTA1 has been shown to express differentially to high levels in metastatic cells. MTA2, which is homologous to MTA1, is a component of the NuRD ATP-dependent chromatin remodeling and histone deacetylase complex. Here we report evidence that although both human MTA1 and MTA2 repress transcription specifically, are located in the nucleus, and contain associated histone deacetylase activity, they exist in two biochemically distinct protein complexes and may perform different functions pertaining to tumor metastasis. Specifically, both MTA1 and MTA2 complexes exert histone deacetylase activity. However, the MTA1 complex contained HDAC1/2, RbAp46/48, and MBD3, but not Sin3 or Mi2, two important components of the MTA2 complex. Moreover, the MTA2 complex is similar to the HDAC1 complex, suggesting a housekeeping role of the MTA2 complex. The MTA1 complex could be further separated, resulting in a core MTA1-HDAC complex, showing that the histone deacetylase activity and transcriptional repression activity were integral properties of the MTA1 complex. Finally, MTA1, unlike MTA2, did not interact with the pleotropic transcription factor YY1 or the immunophilin FKBP25. We suggest that MTA1 associates with a different set of transcription factors from MTA2 and that this property may contribute to the metastatic potential of cells overexpressing MTA1. We also report the finding of human MTA3, which is highly homologous to both MTA1 and MTA2. However, MTA3 does not repress transcription to a significant level and appears to have a diffused pattern of subcellular localization, suggesting a biological role distinct from that of the other two MTA proteins.	Natl Chung Hsing Univ, Inst Mol Biol, Taichung 402, Taiwan; Acad Sinica, Inst Zool, Taipei 115, Taiwan	National Chung Hsing University; Academia Sinica - Taiwan	Yang, WM (corresponding author), Natl Chung Hsing Univ, Inst Mol Biol, 250 Kuo Kuang Rd, Taichung 402, Taiwan.	yangwm@mail.nchu.edu.tw		Yang, Wen-Ming/0000-0002-5871-5979				Aasland R, 1996, TRENDS BIOCHEM SCI, V21, P87, DOI 10.1016/S0968-0004(96)30009-1; Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; Andres ME, 1999, P NATL ACAD SCI USA, V96, P9873, DOI 10.1073/pnas.96.17.9873; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Callebaut I, 1999, FEBS LETT, V446, P189, DOI 10.1016/S0014-5793(99)00132-5; Choi JH, 2001, JPN J CANCER RES, V92, P1300, DOI 10.1111/j.1349-7006.2001.tb02153.x; CLARKE R, 1993, BREAST CANCER RES TR, V24, P227, DOI 10.1007/BF01833263; COLLINS AF, 1995, BLOOD, V85, P43, DOI 10.1182/blood.V85.1.43.bloodjournal85143; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; DEXTER DL, 1986, J CLIN ONCOL, V4, P244, DOI 10.1200/JCO.1986.4.2.244; Fenrick R, 1998, J CELL BIOCHEM, P194; FUTAMURA M, 1995, ONCOGENE, V10, P1119; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Goodwin GH, 2001, GENE, V268, P1, DOI 10.1016/S0378-1119(01)00428-0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Guenther MG, 2001, MOL CELL BIOL, V21, P6091, DOI 10.1128/MCB.21.18.6091-6101.2001; HARLOW E, 1999, USING ANTIBODIES LAB, P490; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Herman MA, 1999, DEVELOPMENT, V126, P1055; HONG L, 1993, J BIOL CHEM, V268, P305; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; KELLEY RI, 1973, BIOCHEM BIOPH RES CO, V54, P1588, DOI 10.1016/0006-291X(73)91168-6; Khochbin S, 2001, FEBS LETT, V494, P141, DOI 10.1016/S0014-5793(01)02327-4; KIJIMA M, 1993, J BIOL CHEM, V268, P22429; Kim Y, 2003, ONCOGENE, V22, P826, DOI 10.1038/sj.onc.1206068; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; KNEZETIC JA, 1986, CELL, V45, P95, DOI 10.1016/0092-8674(86)90541-6; KORNBERG RD, 1974, SCIENCE, V184, P868, DOI 10.1126/science.184.4139.868; KORNBERG RD, 1974, SCIENCE, V184, P865, DOI 10.1126/science.184.4139.865; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; Minucci S, 2001, ONCOGENE, V20, P3110, DOI 10.1038/sj.onc.1204336; Murata T, 2001, HUM MOL GENET, V10, P1071, DOI 10.1093/hmg/10.10.1071; Nawa A, 2000, J CELL BIOCHEM, V79, P202, DOI 10.1002/1097-4644(20001101)79:2<202::AID-JCB40>3.0.CO;2-L; Nicolas RH, 1996, GENE, V175, P233, DOI 10.1016/0378-1119(96)82845-9; NICOLSON GL, 1988, BIOCHIM BIOPHYS ACTA, V948, P175, DOI 10.1016/0304-419X(88)90010-8; PENCIL SD, 1993, BREAST CANCER RES TR, V25, P165, DOI 10.1007/BF00662141; Richon VM, 1996, P NATL ACAD SCI USA, V93, P5705, DOI 10.1073/pnas.93.12.5705; Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003; ROARK DE, 1974, BIOCHEM BIOPH RES CO, V59, P542, DOI 10.1016/S0006-291X(74)80014-8; RON D, 1992, BIOTECHNIQUES, V13, P866; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; Samid D, 1997, ADV EXP MED BIOL, V400, P501; SCHLIMOK G, 1991, EUR J CANCER, V27, P1461, DOI 10.1016/0277-5379(91)90032-9; SCHLIMOK G, 1995, EUR J CANCER, V31A, P1799, DOI 10.1016/0959-8049(95)00317-C; SHI Y, 1997, BIOCHIM BIOPHYS ACTA, V1332, P49; Solakoglu O, 2002, P NATL ACAD SCI USA, V99, P2246, DOI 10.1073/pnas.042372199; Solari F, 1999, DEVELOPMENT, V126, P2483; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; TOH Y, 1995, GENE, V159, P97, DOI 10.1016/0378-1119(94)00410-T; Toh Y, 1997, INT J CANCER, V74, P459, DOI 10.1002/(SICI)1097-0215(19970822)74:4<459::AID-IJC18>3.3.CO;2-H; Toh Y, 1999, BRIT J CANCER, V79, P1723, DOI 10.1038/sj.bjc.6690274; TOH Y, 1994, J BIOL CHEM, V269, P22958; Urnov FD, 2001, ONCOGENE, V20, P2991, DOI 10.1038/sj.onc.1204323; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Yang WM, 2001, EMBO J, V20, P4814, DOI 10.1093/emboj/20.17.4814; YANG WM, 1995, J BIOL CHEM, V270, P15187, DOI 10.1074/jbc.270.25.15187; Yao YL, 2001, MOL CELL BIOL, V21, P5979, DOI 10.1128/MCB.21.17.5979-5991.2001; YOSHIDA H, 1992, JPN J CANCER RES, V83, P324, DOI 10.1111/j.1349-7006.1992.tb00109.x; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; You A, 2001, P NATL ACAD SCI USA, V98, P1454, DOI 10.1073/pnas.98.4.1454; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4; Zhang Y, 1998, MOL CELL, V1, P1021, DOI 10.1016/S1097-2765(00)80102-1	70	114	126	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42560	42568		10.1074/jbc.M302955200	http://dx.doi.org/10.1074/jbc.M302955200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12920132	hybrid			2022-12-25	WOS:000185989500121
J	Tashiro, E; Minato, Y; Maruki, H; Asagiri, M; Imoto, M				Tashiro, E; Minato, Y; Maruki, H; Asagiri, M; Imoto, M			Regulation of FGF receptor-2 expression by transcription factor E2F-1	ONCOGENE			English	Article						FGFR-2; cell cycle; promoter; transcription; E2F-1; pRB	FIBROBLAST GROWTH-FACTORS; CYCLIN-E GENE; RETINOBLASTOMA PROTEIN; PROMOTER; RECEPTOR; FAMILY; PRB; TRANSACTIVATION; BINDING; MOUSE	Fibroblast growth factors (FGF) and their receptors play an important role in cell proliferation, angiogenesis and embryonal development. In this study, we show that expression of the FGF receptor-2 (FGFR-2) protein is induced in the mid-to-late G1 phase of the cell cycle in serum-starved mouse NIH3T3 cells released from starvation. Transcription of mouse FGFR-2 was activated by E2F-1. Analysis of various mouse FGFR-2 promoter mutant constructs showed that a sequence located +57/+64 downstream of the transcriptional initiation site, related to the consensus E2F-responsive sequence, is necessary for the activation. The promoter activity of the mouse FGFR-2 gene is also positively regulated by E2F-2 and E2F-3, but not by E2F-4 and E2F-5. Moreover, the E2F-1-induced activation of mouse FGFR-2 gene transcription is suppressed by pRB. Taken together, the results demonstrate that FGFR-2 is a new class of targets for E2F, and expression of mouse FGFR-2 in mid-to-late G1 phase would be mediated, at least in part, by the activation of a pRB/E2F pathway.	Keio Univ, Fac Sci & Technol, Dept Biosci & Informat, Yokohama, Kanagawa 2238522, Japan	Keio University	Imoto, M (corresponding author), Keio Univ, Fac Sci & Technol, Dept Biosci & Informat, Yokohama, Kanagawa 2238522, Japan.			Tashiro, Etsu/0000-0003-4533-623X				AVIVI A, 1992, ONCOGENE, V7, P1957; Black AR, 1999, GENE, V237, P281, DOI 10.1016/S0378-1119(99)00305-4; Botz J, 1996, MOL CELL BIOL, V16, P3401; DEGREGORI J, 1997, P NATL ACAD SCI USA, V94, P2443; Geng Y, 1996, ONCOGENE, V12, P1173; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Jones SM, 2001, NAT CELL BIOL, V3, P165, DOI 10.1038/35055073; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; Lukas J, 1996, MOL CELL BIOL, V16, P6917; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; PETERS K, 1993, DEV BIOL, V155, P423, DOI 10.1006/dbio.1993.1040; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; QIN XQ, 1995, MOL CELL BIOL, V15, P742; Ricol D, 1999, ONCOGENE, V18, P7234, DOI 10.1038/sj.onc.1203186; STARK KL, 1991, DEVELOPMENT, V113, P641; Takahashi Y, 2000, GENE DEV, V14, P804; Tashiro E, 2003, CANCER RES, V63, P424; Yamasaki L, 1998, Results Probl Cell Differ, V22, P199; ZHANG YH, 1995, ONCOGENE, V10, P2085	23	34	34	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2003	22	36					5630	5635		10.1038/sj.onc.1206636	http://dx.doi.org/10.1038/sj.onc.1206636			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944911				2022-12-25	WOS:000184865900012
J	van der Giessen, K; Di-Marco, S; Clair, E; Gallouzi, IE				van der Giessen, K; Di-Marco, S; Clair, E; Gallouzi, IE			RNAi-mediated HuR depletion leads to the inhibition of muscle cell differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY FACTOR PROTEINS; MYOSIN HEAVY-CHAIN; MYOD MESSENGER-RNA; BINDING PROTEINS; SKELETAL MYOGENESIS; GENE-EXPRESSION; KINASE-ACTIVITY; IN-VIVO; ELAV; STABILITY	The formation of muscle fibers involves the sequential expression of many proteins that regulate key steps during myoblast- to- myotube transition. MyoD, myogenin, and the cyclin- dependent kinase inhibitor p21(cip1) are major players in the initiation and maintenance of the differentiated state of mouse embryonic muscle cells ( C2C12). The messenger RNAs encoding these three proteins contain typical AU- rich elements ( AREs) in their 3 '- untranslated regions ( 3 '- UTRs), which are known to affect the half- life of many short- lived mRNAs. HuR, an RNA- binding protein that regulates both the stability and cellular movement of ARE- containing mRNAs, interacts and stabilizes the p21(cip1) message under UV stress in human RKO colorectal carcinoma cells. Here, by the use of gel shift experiments and immunoprecipitation followed by reverse transcription- PCR analysis, we show that HuR interacts with MyoD, myogenin, and p21cip1 mRNAs through specific sequences in their 3 '-UTRs. To demonstrate the implication of endogenous HuR in myogenesis, we knocked down its expression in myoblasts using RNA interference and observed a significant reduction of HuR expression, associated with complete inhibition of myogenesis. Moreover, the expression of MyoD and myogenin mRNAs, as well as proteins, is significantly reduced in the HuR knockdown C2C12 cells. We were able to completely re- establish the myogenic process of these defective cells by introducing back HuR protein conjugated to a cell- permeable peptide. Finally, HuR accumulates in the cytoplasm during myogenesis. Thus, our results clearly demonstrated that endogenous HuR plays a crucial role in muscle differentiation by regulating the expression and/ or the nuclear export of ARE- containing mRNAs that are essential for this process.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	McGill University	Gallouzi, IE (corresponding author), McGill Univ, Dept Biochem, McIntyre Bldg,Rm 904,3655 Promenade Sir William O, Montreal, PQ H3G 1Y6, Canada.			Di Marco, Sergio/0000-0002-4039-0600				Akamatsu W, 1999, P NATL ACAD SCI USA, V96, P9885, DOI 10.1073/pnas.96.17.9885; Antic D, 1999, GENE DEV, V13, P449, DOI 10.1101/gad.13.4.449; Antic D, 1997, AM J HUM GENET, V61, P273, DOI 10.1086/514866; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; Bakheet T, 2001, NUCLEIC ACIDS RES, V29, P246, DOI 10.1093/nar/29.1.246; Bisbal C, 2000, MOL CELL BIOL, V20, P4959, DOI 10.1128/MCB.20.14.4959-4969.2000; Brennan CM, 2000, J CELL BIOL, V151, P1, DOI 10.1083/jcb.151.1.1; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; CAMPOS AR, 1985, J NEUROGENET, V2, P197, DOI 10.3109/01677068509100150; Coletti D, 2002, EMBO J, V21, P631, DOI 10.1093/emboj/21.4.631; Di Marco S, 2001, NUCLEIC ACIDS RES, V29, P863, DOI 10.1093/nar/29.4.863; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Figueroa A, 2003, MOL CELL BIOL, V23, P4991, DOI 10.1128/MCB.23.14.4991-5004.2003; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gallouzi IE, 1998, MOL CELL BIOL, V18, P3956, DOI 10.1128/MCB.18.7.3956; Gallouzi IE, 2000, P NATL ACAD SCI USA, V97, P3073, DOI 10.1073/pnas.97.7.3073; Gallouzi IE, 2001, RNA, V7, P1348, DOI 10.1017/s1355838201016089; Gallouzi IE, 2001, SCIENCE, V294, P1895, DOI 10.1126/science.1064693; GOOD PJ, 1995, P NATL ACAD SCI USA, V92, P4557, DOI 10.1073/pnas.92.10.4557; GUO K, 1995, MOL CELL BIOL, V15, P3823; Guttridge DC, 2000, SCIENCE, V289, P2363, DOI 10.1126/science.289.5488.2363; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; Jain RG, 1997, MOL CELL BIOL, V17, P954, DOI 10.1128/MCB.17.2.954; Kasashima K, 1999, GENES CELLS, V4, P667, DOI 10.1046/j.1365-2443.1999.00292.x; Keene JD, 1999, P NATL ACAD SCI USA, V96, P5, DOI 10.1073/pnas.96.1.5; Kim S, 1999, J BIOL CHEM, V274, P33035, DOI 10.1074/jbc.274.46.33035; Lambermon MHL, 2002, MOL CELL BIOL, V22, P4346, DOI 10.1128/MCB.22.12.4346-4357.2002; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; LUDOLPH DC, 1994, DEV BIOL, V166, P18, DOI 10.1006/dbio.1994.1294; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; Myer VE, 1997, EMBO J, V16, P2130, DOI 10.1093/emboj/16.8.2130; Odelberg SJ, 2000, CELL, V103, P1099, DOI 10.1016/S0092-8674(00)00212-9; Okano HJ, 1997, J NEUROSCI, V17, P3024; Pederson T, 2002, J STRUCT BIOL, V140, P3, DOI 10.1016/S1047-8477(02)00528-2; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Polesskaya A, 2002, DEV CELL, V3, P757, DOI 10.1016/S1534-5807(02)00372-6; Reed R, 2002, CELL, V108, P523, DOI 10.1016/S0092-8674(02)00627-X; Reynaud EG, 1999, MOL CELL BIOL, V19, P7621; Rios R, 2001, BIOCHEM BIOPH RES CO, V280, P561, DOI 10.1006/bbrc.2000.4159; ROBINOW S, 1988, SCIENCE, V242, P1570, DOI 10.1126/science.3144044; Sabourin LA, 2000, CLIN GENET, V57, P16, DOI 10.1034/j.1399-0004.2000.570103.x; Seale P, 2001, DEV CELL, V1, P333, DOI 10.1016/S1534-5807(01)00049-1; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Shen X, 2003, DEV DYNAM, V226, P128, DOI 10.1002/dvdy.10200; Singh OP, 2001, INDIAN J BIOCHEM BIO, V38, P129; Siomi H, 1997, CURR OPIN GENET DEV, V7, P345, DOI 10.1016/S0959-437X(97)80148-7; SMITH TH, 1994, J CELL BIOL, V127, P95, DOI 10.1083/jcb.127.1.95; SMITH TH, 1993, DEVELOPMENT, V117, P1125; Tenenbaum SA, 2002, METHODS, V26, P191, DOI 10.1016/S1046-2023(02)00022-1; Torgan CE, 2001, MOL BIOL CELL, V12, P1499, DOI 10.1091/mbc.12.5.1499; Wakamatsu Y, 1997, DEVELOPMENT, V124, P3449; Weighardt F, 1996, BIOESSAYS, V18, P747, DOI 10.1002/bies.950180910; Wojciechowski W, 1999, J IMMUNOL, V163, P2688; YAMAGUCHI A, 1995, SEMIN CELL BIOL, V6, P165, DOI 10.1006/scel.1995.0023; Yan Z, 2001, J BIOL CHEM, V276, P17361, DOI 10.1074/jbc.M101251200	58	101	103	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					47119	47128		10.1074/jbc.M308889200	http://dx.doi.org/10.1074/jbc.M308889200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12944397	hybrid			2022-12-25	WOS:000186569400110
J	Arnesano, F; Banci, L; Benvenuti, M; Bertini, I; Calderone, V; Mangani, S; Viezzoli, MS				Arnesano, F; Banci, L; Benvenuti, M; Bertini, I; Calderone, V; Mangani, S; Viezzoli, MS			The evolutionarily conserved trimeric structure of CutA1 proteins suggests a role in signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; P-II; BRAIN ACETYLCHOLINESTERASE; CRYSTAL-STRUCTURE; COPPER; SEQUENCE; PROGRAM; GLNK	CutA1 are a protein family present in bacteria, plants, and animals, including humans. Escherichia coli CutA1 is involved in copper tolerance, whereas mammalian proteins are implicated in the anchoring of acetylcholinesterase in neuronal cell membranes. The x-ray structures of CutA1 from E. coli and rat were determined. Both proteins are trimeric in the crystals and in solution through an inter-subunit beta-sheet formation. Each subunit consists of a ferredoxin-like (beta1alpha1beta2beta3alpha2beta4) fold with an additional strand (beta5), a C-terminal helix (alpha3), and an unusual extended beta-hairpin involving strands beta2 and beta3. The bacterial CutA1 is able to bind copper(II) in vitro through His(2)Cys coordination in a type II water-accessible site, whereas the rat protein precipitates in the presence of copper(II). The evolutionarily conserved trimeric assembly of CutA1 is reminiscent of the architecture of PII signal transduction proteins. This similarity suggests an intriguing role of CutA1 proteins in signal transduction through allosteric communications between subunits.	Univ Florence, Magnet Resonance Ctr CERM, I-50019 Florence, Italy; Univ Florence, Dept Chem, I-50019 Florence, Italy; Univ Siena, Dept Chem, I-53100 Siena, Italy	University of Florence; University of Florence; University of Siena	Bertini, I (corresponding author), Univ Florence, Magnet Resonance Ctr CERM, Via Luigi Sacconi 6, I-50019 Florence, Italy.	bertini@cerm.unifi.it	Calderone, Vito/A-2917-2014; Arnesano, Fabio/C-3066-2016	Calderone, Vito/0000-0002-7963-6241; Arnesano, Fabio/0000-0002-8399-0964; BANCI, LUCIA/0000-0003-0562-5774				Arcondeguy T, 2001, MICROBIOL MOL BIOL R, V65, P80, DOI 10.1128/MMBR.65.1.80-105.2001; Arnesano F, 2002, GENOME RES, V12, P255, DOI 10.1101/gr.196802; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Banci L, 2003, ACCOUNTS CHEM RES, V36, P215, DOI 10.1021/ar010120r; Binsted N, 1996, J SYNCHROTRON RADIAT, V3, P185, DOI 10.1107/S0909049596005651; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bush AI, 2000, CURR OPIN CHEM BIOL, V4, P184, DOI 10.1016/S1367-5931(99)00073-3; Carr PD, 1996, ACTA CRYSTALLOGR D, V52, P93, DOI 10.1107/S0907444995007293; CHEAH E, 1994, STRUCTURE, V2, P981, DOI 10.1016/S0969-2126(94)00100-6; Coutts G, 2002, EMBO J, V21, P536, DOI 10.1093/emboj/21.4.536; Daugherty RG, 2002, INORG CHEM, V41, P2623, DOI 10.1021/ic010555a; Edeling MA, 2002, STRUCTURE, V10, P973, DOI 10.1016/S0969-2126(02)00794-3; Evans W, 1997, CHEM BRIT, V33, P22; FONG ST, 1995, MOL MICROBIOL, V15, P1127, DOI 10.1111/j.1365-2958.1995.tb02286.x; Haebel PW, 2002, EMBO J, V21, P4774, DOI 10.1093/emboj/cdf489; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; Katzen F, 2000, CELL, V103, P769, DOI 10.1016/S0092-8674(00)00180-X; Kinch LN, 2002, PROTEINS, V48, P75, DOI 10.1002/prot.10110; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Krupp R, 2001, J BIOL CHEM, V276, P3696, DOI 10.1074/jbc.M009500200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1991, CRYSTALLOGRAPHIC COM, V5, P50; Lever A. B. P., 1984, INORGANIC ELECT SPEC; Lieberman RL, 2001, BIOCHEMISTRY-US, V40, P5674, DOI 10.1021/bi0102611; LINDER MC, 1991, BIOCH COPPER, P1; Lo Conte L, 2000, NUCLEIC ACIDS RES, V28, P257, DOI 10.1093/nar/28.1.257; Lu Y, 1996, INORG CHEM, V35, P1692, DOI 10.1021/ic9513189; LYTLE FW, 1989, PHYS REV B, V11, P2795; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Mira H, 2001, BIOCHEM J, V357, P545, DOI 10.1042/0264-6021:3570545; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Navaratnam DS, 2000, J NEUROCHEM, V74, P2146, DOI 10.1046/j.1471-4159.2000.0742146.x; Ninfa AJ, 2000, TRENDS MICROBIOL, V8, P172, DOI 10.1016/S0966-842X(00)01709-1; Pena MMO, 1999, J NUTR, V129, P1251, DOI 10.1093/jn/129.7.1251; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Perrier AL, 2000, J BIOL CHEM, V275, P34260, DOI 10.1074/jbc.M004289200; Perrier AL, 2002, NEURON, V33, P275, DOI 10.1016/S0896-6273(01)00584-0; ROBERTS WL, 1991, J BIOL CHEM, V266, P7481; Rosenzweig AC, 2000, CURR OPIN CHEM BIOL, V4, P140, DOI 10.1016/S1367-5931(99)00066-6; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; van Heeswijk WC, 2000, P NATL ACAD SCI USA, V97, P3942, DOI 10.1073/pnas.97.8.3942; Xu YB, 1998, J MOL BIOL, V282, P149, DOI 10.1006/jmbi.1998.1979; Xu YB, 2001, EUR J BIOCHEM, V268, P2028, DOI 10.1046/j.1432-1327.2001.02074.x	44	49	54	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45999	46006		10.1074/jbc.M304398200	http://dx.doi.org/10.1074/jbc.M304398200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12949080	hybrid			2022-12-25	WOS:000186452300115
J	Griffitts, JS; Huffman, DL; Whitacre, JL; Barrows, BD; Marroquin, LD; Muller, R; Brown, JR; Hennet, T; Esko, JD; Aroian, RV				Griffitts, JS; Huffman, DL; Whitacre, JL; Barrows, BD; Marroquin, LD; Muller, R; Brown, JR; Hennet, T; Esko, JD; Aroian, RV			Resistance to a bacterial toxin is mediated by removal of a conserved glycosylation pathway required for toxin-host interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-THURINGIENSIS; DROSOPHILA-MELANOGASTER; PORE FORMATION; PROTEINS; SYNTHASE	Crystal (Cry) proteins made by the bacterium Bacillus thuringiensis are pore-forming toxins that specifically target insects and nematodes and are used around the world to kill insect pests. To better understand how pore-forming toxins interact with their host, we have screened for Caenorhabditis elegans mutants that resist Cry protein intoxication. We find that Cry toxin resistance involves the loss of two glycosyltransferase genes, bre-2 and bre-4. These glycosyltransferases function in the intestine to confer susceptibility to toxin. Furthermore, they are required for the interaction of active toxin with intestinal cells, suggesting they make an oligosaccharide receptor for toxin. Similarly, the bre-3 resistance gene is also required for toxin interaction with intestinal cells. Cloning of the bre-3 gene indicates it is the C. elegans homologue of the Drosophila egghead (egh) gene. This identification is striking given that the previously identified bre-5 has homology to Drosophila brainiac (brn) and that egh-brn likely function as consecutive glycosyltransferases in Drosophila epithelial cells. We find that, like in Drosophila, bre-3 and bre-5 act in a single pathway in C. elegans. bre-2 and bre-4 are also part of this pathway, thereby extending it. Consistent with its homology to brn, we demonstrate that C. elegans bre-5 rescues the Drosophila brn mutant and that BRE-5 encodes the dominant UDP-GlcNAc:Man GlcNAc transferase activity in C. elegans. Resistance to Cry toxins has uncovered a four component glycosylation pathway that is functionally conserved between nematodes and insects and that provides the basis of the dominant mechanism of resistance in C. elegans.	Univ Calif San Diego, Sect Cell & Dev Biol, La Jolla, CA 92093 USA; Univ Zurich, Inst Physiol, CH-8057 Zurich, Switzerland; Univ Calif San Diego, Glycobiol Res & Training Ctr, Dept Cellular & Mol Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of Zurich; University of California System; University of California San Diego	Aroian, RV (corresponding author), Univ Calif San Diego, Sect Cell & Dev Biol, 9500 Gilman Dr,Dept 0349,Bonner Hall 4430, La Jolla, CA 92093 USA.	raroian@ucsd.edu		Barrows, Brad/0000-0003-4069-525X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033063, R37GM033063] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33063] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Betz FS, 2000, REGUL TOXICOL PHARM, V32, P156, DOI 10.1006/rtph.2000.1426; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRENNER S, 1974, GENETICS, V77, P71; Britton C, 1998, J MOL BIOL, V283, P15, DOI 10.1006/jmbi.1998.2093; Carriere Y, 2003, P NATL ACAD SCI USA, V100, P1519, DOI 10.1073/pnas.0436708100; de Maagd RA, 2001, TRENDS GENET, V17, P193, DOI 10.1016/S0168-9525(01)02237-5; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; Gilbert RJC, 2002, CELL MOL LIFE SCI, V59, P832, DOI 10.1007/s00018-002-8471-1; Goode S, 1996, DEVELOPMENT, V122, P3863; Griffitts JS, 2001, SCIENCE, V293, P860, DOI 10.1126/science.1062441; Jurat-Fuentes JL, 2002, APPL ENVIRON MICROB, V68, P5711, DOI 10.1128/AEM.68.11.5711-5717.2002; Kawar ZS, 2002, J BIOL CHEM, V277, P34924, DOI 10.1074/jbc.M206112200; Kumaraswami NS, 2001, COMP BIOCHEM PHYS B, V129, P173, DOI 10.1016/S1096-4959(01)00327-X; Marroquin LD, 2000, GENETICS, V155, P1693; Muller R, 2002, J BIOL CHEM, V277, P32417, DOI 10.1074/jbc.C200381200; Nishikawa K, 2002, P NATL ACAD SCI USA, V99, P7669, DOI 10.1073/pnas.112058999; Panin VM, 1998, SEMIN CELL DEV BIOL, V9, P609, DOI 10.1006/scdb.1998.0263; PERRIMON N, 1989, GENETICS, V121, P333; Ramakrishnan B, 2002, BIOCHEM BIOPH RES CO, V291, P1113, DOI 10.1006/bbrc.2002.6506; Saxena IM, 2001, PHYTOCHEMISTRY, V57, P1135, DOI 10.1016/S0031-9422(01)00048-6; Schmitt CK, 1999, EMERG INFECT DIS, V5, P224, DOI 10.3201/eid0502.990206; Schwientek T, 2002, J BIOL CHEM, V277, P32421, DOI 10.1074/jbc.M206213200; Uawithya P, 1998, BIOCHEM MOL BIOL INT, V44, P825; Vachon V, 2002, BIOCHEMISTRY-US, V41, P6178, DOI 10.1021/bi011572e; Wandall HH, 2003, J BIOL CHEM, V278, P1411, DOI 10.1074/jbc.C200619200; Wei JZ, 2003, P NATL ACAD SCI USA, V100, P2760, DOI 10.1073/pnas.0538072100	26	99	118	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45594	45602		10.1074/jbc.M308142200	http://dx.doi.org/10.1074/jbc.M308142200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12944392	hybrid			2022-12-25	WOS:000186452300068
J	Huan, JN; Li, J; Han, YP; Chen, K; Wu, N; Zhao, AZ				Huan, JN; Li, J; Han, YP; Chen, K; Wu, N; Zhao, AZ			Adipocyte-selective reduction of the leptin receptors induced by antisense RNA leads to increased adiposity, dyslipidemia, and insulin resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; FATTY-ACID OXIDATION; IN-VIVO; TNF-ALPHA; BODY-WEIGHT; OB PROTEIN; OBESE GENE; EXPRESSION; MICE; ACTIVATION	Although recent evidence suggests that leptin can directly regulate a wide spectrum of peripheral functions, including fat metabolism, genetic examples are still needed to illustrate the physiological significance of direct actions of leptin in a given peripheral tissue. To this end, we used a technical knock-out approach to reduce the expression of leptin receptors specifically in white adipose tissue. The evaluation of leptin receptor reduction in adipocytes was based on real time PCR analysis of the mRNA levels, Western blot analysis of the proteins, and biochemical analysis of leptin signaling capability. Despite a normal level of leptin receptors in the hypothalamus and normal food intake, mutant mice developed increased adiposity, decreased body temperature, hyperinsulinemia, hypertriglyceridemia, impaired glucose tolerance and insulin sensitivity, as well as elevated hepatic and skeletal muscle triglyceride levels. In addition, a variety of genes involved in regulating fat and glucose metabolism were dysregulated in white adipose tissue. These include tumor necrosis factor-alpha, adiponectin, leptin, fatty acid synthase, sterol regulatory element-binding protein 1, glycerol kinase, and beta(3)-adrenergic receptor. Furthermore, the mutant mice are significantly more sensitive to high fat feeding with regard to developing obesity and severe insulin resistance. Thus, we provide a genetic model demonstrating the physiological importance of a peripheral effect of leptin in vivo. Importantly, this suggests the possibility that leptin resistance at the adipocyte level might be a molecular link between obesity and type 2 diabetes.	Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA; Univ So Calif, Norris Canc Res Inst, Dept Biochem, Los Angeles, CA 90033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Southern California	Zhao, AZ (corresponding author), Univ Pittsburgh, Dept Cell Biol & Physiol, S-326,3500 Terrace St, Pittsburgh, PA 15261 USA.							Ahima RS, 2000, ANNU REV PHYSIOL, V62, P413, DOI 10.1146/annurev.physiol.62.1.413; Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; Baskin DG, 1999, J HISTOCHEM CYTOCHEM, V47, P353, DOI 10.1177/002215549904700309; Bouloumie A, 1998, CIRC RES, V83, P1059, DOI 10.1161/01.RES.83.10.1059; Buettner R, 2000, AM J PHYSIOL-ENDOC M, V278, pE563, DOI 10.1152/ajpendo.2000.278.3.E563; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Chen GX, 1996, P NATL ACAD SCI USA, V93, P14795, DOI 10.1073/pnas.93.25.14795; Cohen P, 2001, J CLIN INVEST, V108, P1113, DOI 10.1172/JCI200113914; Degerman E, 1998, METHODS, V14, P43, DOI 10.1006/meth.1997.0564; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; Fruhbeck G, 1997, BIOCHEM BIOPH RES CO, V240, P590, DOI 10.1006/bbrc.1997.7716; GalvinParton PA, 1997, J BIOL CHEM, V272, P4335, DOI 10.1074/jbc.272.7.4335; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; HOTAMISLIGIL GS, 1994, DIABETES, V43, P1271, DOI 10.2337/diabetes.43.11.1271; Hotamisligil GS, 1999, J INTERN MED, V245, P621, DOI 10.1046/j.1365-2796.1999.00490.x; Hotta K, 2001, DIABETES, V50, P1126, DOI 10.2337/diabetes.50.5.1126; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; Kim YB, 2000, ENDOCRINOLOGY, V141, P2328, DOI 10.1210/en.141.7.2328; Kowalski TJ, 2001, DIABETES, V50, P425, DOI 10.2337/diabetes.50.2.425; Kulkarni RN, 1997, J CLIN INVEST, V100, P2729, DOI 10.1172/JCI119818; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Levin N, 1996, P NATL ACAD SCI USA, V93, P1726, DOI 10.1073/pnas.93.4.1726; Lord GM, 1998, NATURE, V394, P897, DOI 10.1038/29795; LOWELL BB, 1995, J CLIN INVEST, V95, P923, DOI 10.1172/JCI117798; Magni P, 1999, ENDOCRINOLOGY, V140, P1581, DOI 10.1210/en.140.4.1581; Matsuda J, 1999, ENDOCRINOLOGY, V140, P5233, DOI 10.1210/en.140.11.5233; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; MOXHAM CM, 1993, SCIENCE, V260, P991, DOI 10.1126/science.8493537; Moxham CM, 1996, NATURE, V379, P840, DOI 10.1038/379840a0; MURRAY JAH, 1992, ANTISENSE RNA DNA; Niswender KD, 2001, NATURE, V413, P794, DOI 10.1038/35101657; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Ruan H, 2002, DIABETES, V51, P3176, DOI 10.2337/diabetes.51.11.3176; Ruan H, 2002, DIABETES, V51, P1319, DOI 10.2337/diabetes.51.5.1319; Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683; Soukas A, 2000, GENE DEV, V14, P963; SUSULIC VS, 1995, J BIOL CHEM, V270, P29483, DOI 10.1074/jbc.270.49.29483; Valladares A, 2001, FEBS LETT, V493, P6, DOI 10.1016/S0014-5793(01)02264-5; VanHeek M, 1997, J CLIN INVEST, V99, P385, DOI 10.1172/JCI119171; WANG HY, 1996, INT J OBESITY, V20, P26; Wang MY, 1999, J BIOL CHEM, V274, P17541, DOI 10.1074/jbc.274.25.17541; Wang ZW, 1999, P NATL ACAD SCI USA, V96, P10373, DOI 10.1073/pnas.96.18.10373; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; Zhao AZ, 2000, J BIOL CHEM, V275, P11348, DOI 10.1074/jbc.275.15.11348; Zhao AZ, 2002, NAT NEUROSCI, V5, P727, DOI 10.1038/nn885; Zhao AZ, 1998, J CLIN INVEST, V102, P869, DOI 10.1172/JCI3920	48	82	89	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45638	45650		10.1074/jbc.M304165200	http://dx.doi.org/10.1074/jbc.M304165200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12925533	hybrid			2022-12-25	WOS:000186452300073
J	Kunz, M; Moeller, S; Koczan, D; Lorenz, P; Wenger, RH; Glocker, MO; Thiesen, HJ; Gross, G; Ibrahim, SM				Kunz, M; Moeller, S; Koczan, D; Lorenz, P; Wenger, RH; Glocker, MO; Thiesen, HJ; Gross, G; Ibrahim, SM			Mechanisms of hypoxic gene regulation of angiogenesis factor Cyr61 in melanoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY GENE; FIBROBLAST-GROWTH-FACTOR; HEPARAN-SULFATE PROTEOGLYCANS; HUMAN-MALIGNANT MELANOMA; VEIN ENDOTHELIAL-CELLS; INDUCED UP-REGULATION; TUMOR-GROWTH; INDUCIBLE FACTOR-1-ALPHA; NUDE-MICE; INTEGRIN ALPHA(6)BETA(1)	Hypoxia has a profound influence on progression and metastasis of malignant tumors. In the present report, we used the oligonucleotide microarray technique to identify new hypoxia-inducible genes in malignant melanoma with a special emphasis on angiogenesis factors. A commercially available Affymetrix(R) gene chip system was used to analyze five melanoma cell lines of different aggressiveness. A total of 160 hypoxia-inducible genes were identified, clustering in four different functional clusters. In search of putative angiogenesis and tumor progression factors within these clusters, Cyr61, a recently discovered angiogenesis factor, was identified. Cyr61 was hypoxia-inducible in low aggressive melanoma cells; however, it showed constitutive high expression in highly aggressive melanoma cells. Further analyses of transcriptional mechanisms underlying Cyr61 gene expression under hypoxia demonstrated that an AP-1 binding motif within the Cyr61 promoter plays a central role in the hypoxic regulation of Cyr61. It could be shown by use of in vitro luciferase assays, electrophoretic mobility shift assays, and immunoprecipitation that hypoxia-inducible factor-1alpha interacts with c-Jun/AP-1 and may thereby contribute to Cyr61 transcriptional regulation under hypoxia. Taken together, the presented data show that Cyr61 is a hypoxia-inducible angiogenesis factor in malignant melanoma with tumor stage-dependent expression. This may argue for a hypoxia-induced selection process during tumor progression toward melanoma cells with constitutive high Cyr61 expression.	Univ Rostock, Dept Dermatol & Venereol, D-18055 Rostock, Germany; Univ Rostock, Inst Immunol, D-18055 Rostock, Germany; Univ Rostock, Proteome Ctr, D-18055 Rostock, Germany; Univ Leipzig, Carl Ludwig Inst Physiol, D-04103 Leipzig, Germany	University of Rostock; University of Rostock; University of Rostock; Leipzig University	Kunz, M (corresponding author), Univ Rostock, Dept Dermatol & Venereol, Augusten Str 80, D-18055 Rostock, Germany.	manfred.kunz@med.uni-rostock.de	Ibrahim, Saleh/AAO-9541-2020; GROSS, Gerd/AAF-8938-2019; Wenger, Roland H./B-7953-2009	Wenger, Roland H./0000-0001-7592-4839; Lorenz, Peter A./0000-0001-7925-1002; Ibrahim, Saleh/0000-0001-7827-2290				Alfranca A, 2002, MOL CELL BIOL, V22, P12, DOI 10.1128/MCB.22.1.12-22.2002; Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; Beavon IRG, 1999, J CLIN PATHOL-MOL PA, V52, P179, DOI 10.1136/mp.52.4.179; Belperio JA, 2000, J LEUKOCYTE BIOL, V68, P1; Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chen NY, 2000, J BIOL CHEM, V275, P24953, DOI 10.1074/jbc.M003040200; Desbaillets I, 1997, J EXP MED, V186, P1201, DOI 10.1084/jem.186.8.1201; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Goldberg M, 1997, J CLIN INVEST, V99, P55, DOI 10.1172/JCI119133; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Grzeszkiewicz TM, 2002, ENDOCRINOLOGY, V143, P1441, DOI 10.1210/en.143.4.1441; Guillemin K, 1997, CELL, V89, P9, DOI 10.1016/S0092-8674(00)80176-2; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hartmann A, 1999, CANCER RES, V59, P1578; Helmlinger G, 1997, NAT MED, V3, P177, DOI 10.1038/nm0297-177; Hess AR, 2001, CANCER RES, V61, P3250; Hoffmeyer A, 1999, J BIOL CHEM, V274, P4319, DOI 10.1074/jbc.274.7.4319; Jedsadayanmata A, 1999, J BIOL CHEM, V274, P24321, DOI 10.1074/jbc.274.34.24321; Kireeva ML, 1996, MOL CELL BIOL, V16, P1326; Kireeva ML, 1998, J BIOL CHEM, V273, P3090, DOI 10.1074/jbc.273.5.3090; Kireeva ML, 1997, EXP CELL RES, V233, P63, DOI 10.1006/excr.1997.3548; Kolesnikova TV, 1998, ONCOGENE, V16, P747, DOI 10.1038/sj.onc.1201572; Kung AL, 2000, NAT MED, V6, P1335, DOI 10.1038/82146; Kunz M, 1999, AM J PATHOL, V155, P753, DOI 10.1016/S0002-9440(10)65174-7; KUWABARA K, 1995, P NATL ACAD SCI USA, V92, P4606, DOI 10.1073/pnas.92.10.4606; Laderoute KR, 1999, J BIOL CHEM, V274, P12890, DOI 10.1074/jbc.274.18.12890; Laderoute KR, 2002, MOL CELL BIOL, V22, P2515, DOI 10.1128/MCB.22.8.2515-2523.2002; Laderoute KR, 1997, CIRC RES, V80, P336, DOI 10.1161/01.RES.80.3.336; LINDEBRO MC, 1995, EMBO J, V14, P3528, DOI 10.1002/j.1460-2075.1995.tb07359.x; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Luca M, 1997, AM J PATHOL, V151, P1105; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; Perbal B, 2001, J CLIN PATHOL-MOL PA, V54, P57, DOI 10.1136/mp.54.2.57; Rak J, 2000, J INVEST DERM SYMP P, V5, P24, DOI 10.1046/j.1087-0024.2000.00012.x; Rofstad EK, 1998, BRIT J CANCER, V77, P897, DOI 10.1038/bjc.1998.148; RUPEC RA, 1995, EUR J BIOCHEM, V234, P632, DOI 10.1111/j.1432-1033.1995.632_b.x; Ryan HE, 2000, CANCER RES, V60, P4010; Schutze N, 2001, J CLIN PATHOL-MOL PA, V54, P170, DOI 10.1136/mp.54.3.170; Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Shimo T, 2001, CANCER LETT, V174, P57, DOI 10.1016/S0304-3835(01)00683-8; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SINGH RK, 1994, CANCER RES, V54, P3242; Straume O, 2002, AM J PATHOL, V160, P1009, DOI 10.1016/S0002-9440(10)64922-X; Tsai MS, 2000, CANCER RES, V60, P5603; VANMUIJEN GNP, 1991, INT J CANCER, V48, P85; VANMUIJEN GNP, 1991, CLIN EXP METASTAS, V9, P259, DOI 10.1007/BF01753729; Vaupel P, 2001, SEMIN ONCOL, V28, P29, DOI 10.1016/S0093-7754(01)90210-6; Wang YP, 1997, NAT MED, V3, P887, DOI 10.1038/nm0897-887; WENG HQ, 1995, J BIOL CHEM, V270, P13637, DOI 10.1074/jbc.270.23.13637; Wenger RH, 2000, J EXP BIOL, V203, P1253; WENGER RH, 1995, J BIOL CHEM, V270, P27865, DOI 10.1074/jbc.270.46.27865; Wenger RH, 1998, CANCER RES, V58, P5678; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; Westphal JR, 1997, BRIT J CANCER, V76, P561, DOI 10.1038/bjc.1997.427; Xie D, 2001, CANCER RES, V61, P8917; Xu L, 1999, CANCER RES, V59, P5822; Yancopoulos GD, 1998, CELL, V93, P661, DOI 10.1016/S0092-8674(00)81426-9; YOUNG SD, 1988, P NATL ACAD SCI USA, V85, P9533, DOI 10.1073/pnas.85.24.9533	65	88	96	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45651	45660		10.1074/jbc.M301373200	http://dx.doi.org/10.1074/jbc.M301373200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12939282	hybrid, Green Accepted			2022-12-25	WOS:000186452300074
J	Karsdal, MA; Hjorth, P; Henriksen, K; Kirkegaard, T; Nielsen, KL; Lou, H; Delaisse, JM; Foged, NT				Karsdal, MA; Hjorth, P; Henriksen, K; Kirkegaard, T; Nielsen, KL; Lou, H; Delaisse, JM; Foged, NT			Transforming growth factor-beta controls human osteoclastogenesis through the p38 MAPK and regulation of RANK expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B-LIGAND; ACTIVATED PROTEIN-KINASE; TGF-BETA; RECEPTOR ACTIVATOR; SIGNAL-TRANSDUCTION; BONE-RESORPTION; ACCELERATED OSTEOCLASTOGENESIS; PHOSPHATIDYLINOSITOL 3-KINASE; INHIBITORY FACTOR; GENE-EXPRESSION	Although RANK-L is essential for osteoclast formation, factors such as transforming growth factor-beta (TGF-beta) are potent modulators of osteoclastogenic stimuli. To systematically investigate the role of TGF-beta in human osteoclastogenesis, monocytes were isolated from peripheral blood by three distinct approaches, resulting in either a lymphocyte-rich, a lymphocyte-poor, or a pure osteoclast precursor (CD14-positive) cell population. In each of these osteoclast precursor populations, the effect of TGF-beta on proliferation, TRAP activity, and bone resorption was investigated with respect to time and length of exposure. When using the highly pure CD14 osteoclast precursor cell population, the effect of TGF-beta was strongly dependent on the stage of osteoclast maturation. When monocytes were exposed to TGF-beta during the initial culture period ( days 1 - 7), TRAP activity and bone resorption were increased by 40%, whereas the cell number was reduced by 25%. A similar decrease in cell number was observed when TGF-beta was present during the entire culture period ( days 1 - 21), but in direct contrast, TRAP activity, cell fusion, cathepsin K, and matrix metalloproteinase (MMP)-9 expression as well as bone resorption were almost completely abrogated. Moreover, we found that latent TGF-beta was strongly activated by incubation with MMP-9 and suggest this to be a highly relevant mechanism for regulating osteoclast activity. To further investigate the molecular mechanism responsible for the divergent effects of continuous versus discontinuous exposure to TGF-beta, we examined RANK expression and p38 MAPK activation. We found the TGF-beta strongly induced p38 MAPK in monocytes, but not in mature osteoclasts, and that continuous exposure of TGF-beta to monocytes down-regulated RANK expression. The current results suggest that TGF-beta promotes human osteoclastogenesis in monocytes through stimulation of the p38 MAPK, whereas continuous exposure to TGF-beta abrogates osteoclastogenesis through down-regulation of RANK expression and therefore attenuation of RANK-RANK-L signaling.	Nord Biosci AS, CCBR, DK-2730 Herlev, Denmark	Center Clinical & Basic Research; Nordic Bioscience; Synarc	Karsdal, MA (corresponding author), Nord Biosci AS, CCBR, Herlev Hovedgade 207, DK-2730 Herlev, Denmark.	mk@nordicbioscience.com	Foged, Niels T/AHA-2122-2022	Karsdal, Morten/0000-0001-5026-8740; Delaisse, Jean-Marie/0000-0001-7370-1500				Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Andrades JA, 1999, EXP CELL RES, V250, P485, DOI 10.1006/excr.1999.4528; Andresen JL, 1998, CURR EYE RES, V17, P79; Bonewald L. F., 1996, P647; BONEWALD LF, 1994, J CELL BIOCHEM, V55, P350, DOI 10.1002/jcb.240550312; BONEWALD LF, 1990, CLIN ORTHOP RELAT R, P261; Bonewald LF, 1997, ENDOCRINOLOGY, V138, P657, DOI 10.1210/en.138.2.657; Borton AJ, 2001, J BONE MINER RES, V16, P1754, DOI 10.1359/jbmr.2001.16.10.1754; Boyce Brendan F., 1996, P739; Cenci S, 2000, J CLIN INVEST, V106, P1229, DOI 10.1172/JCI11066; CENTRELLA M, 1994, ENDOCR REV, V15, P27, DOI 10.1210/er.15.1.27; Chambers TJ, 2000, J PATHOL, V192, P4; Chirgwin JM, 2000, CRIT REV EUKAR GENE, V10, P159; Dallas SL, 2002, J BIOL CHEM, V277, P21352, DOI 10.1074/jbc.M111663200; Engsig MT, 2000, J CELL BIOL, V151, P879, DOI 10.1083/jcb.151.4.879; Erlebacher A, 1998, MOL BIOL CELL, V9, P1903, DOI 10.1091/mbc.9.7.1903; Festuccia C, 1999, INT J CANCER, V81, P395, DOI 10.1002/(SICI)1097-0215(19990505)81:3<395::AID-IJC13>3.0.CO;2-V; Filvaroff E, 1999, DEVELOPMENT, V126, P4267; Fox SW, 2000, J IMMUNOL, V165, P4957, DOI 10.4049/jimmunol.165.9.4957; Fox SW, 2003, J IMMUNOL, V170, P3679, DOI 10.4049/jimmunol.170.7.3679; Fuller K, 2000, J CELL SCI, V113, P2445; Galvin RJS, 1999, BIOCHEM BIOPH RES CO, V265, P233, DOI 10.1006/bbrc.1999.1632; Geiser AG, 1998, BONE, V23, P87, DOI 10.1016/S8756-3282(98)00078-7; Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467; Gingery A, 2003, J CELL BIOCHEM, V89, P165, DOI 10.1002/jcb.10503; Hannigan M, 1998, BIOCHEM BIOPH RES CO, V246, P55, DOI 10.1006/bbrc.1998.8570; Heino TJ, 2002, J CELL BIOCHEM, V85, P185, DOI 10.1002/jcb.10109; Kaneda T, 2000, J IMMUNOL, V165, P4254, DOI 10.4049/jimmunol.165.8.4254; Kanematsu M, 2000, J BONE MINER RES, V15, P1321, DOI 10.1359/jbmr.2000.15.7.1321; Karsdal MA, 2002, J BIOL CHEM, V277, P44061, DOI 10.1074/jbc.M207205200; Karsdal MA, 2001, J BIOL CHEM, V276, P39350, DOI 10.1074/jbc.M008738200; KNIGHT CG, 1995, METHOD ENZYMOL, V248, P85; Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271; Koseki T, 2002, CELL SIGNAL, V14, P31, DOI 10.1016/S0898-6568(01)00221-2; Koyama S, 1998, AM J PHYSIOL-LUNG C, V275, pL223, DOI 10.1152/ajplung.1998.275.2.L223; Lakkakorpi PT, 2003, J BIOL CHEM, V278, P11502, DOI 10.1074/jbc.M206579200; Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756-3282(01)00657-3; Lee SP, 2001, J BIOL CHEM, V276, P29826, DOI 10.1074/jbc.M101822200; Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006-291X(03)00695-8; Li XT, 2002, ENDOCRINOLOGY, V143, P3105, DOI 10.1210/en.143.8.3105; LIND M, 1995, APMIS, V103, P140, DOI 10.1111/j.1699-0463.1995.tb01089.x; Manabe N, 2001, J IMMUNOL, V167, P2625, DOI 10.4049/jimmunol.167.5.2625; Massey HM, 2001, BONE, V28, P577, DOI 10.1016/S8756-3282(01)00432-X; Massey HM, 1999, BRIT J HAEMATOL, V106, P167; Matsumoto M, 2000, FEBS LETT, V486, P23, DOI 10.1016/S0014-5793(00)02231-6; Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200; MORODOMI T, 1992, BIOCHEM J, V285, P603, DOI 10.1042/bj2850603; Mundy GR, 1997, CANCER-AM CANCER SOC, V80, P1546, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1546::AID-CNCR4>3.3.CO;2-R; Mundy GR, 2001, SEMIN ONCOL, V28, P35, DOI 10.1053/sonc.2001.24158; Mundy GR, 1999, PRIMER METABOLIC BON, P30, DOI DOI 10.1080/10255840802136150; Murakami T, 1998, BIOCHEM BIOPH RES CO, V252, P747, DOI 10.1006/bbrc.1998.9723; Nicholson GC, 2000, CLIN SCI, V99, P133, DOI 10.1042/CS19990355; Onoe Y, 2000, J BONE MINER RES, V15, P541, DOI 10.1359/jbmr.2000.15.3.541; OURSLER MJ, 1994, J BONE MINER RES, V9, P443; Parfitt AM, 1996, J BONE MINER RES, V11, P150; PFEILSCHIFTER J, 1990, J BONE MINER RES, V5, P49, DOI 10.1002/jbmr.5650050109; Pilkington MF, 2001, J BONE MINER RES, V16, P1237, DOI 10.1359/jbmr.2001.16.7.1237; POSTLETHWAITE AE, 1995, J CELL PHYSIOL, V164, P587, DOI 10.1002/jcp.1041640317; Quinn JMW, 2001, J BONE MINER RES, V16, P1787, DOI 10.1359/jbmr.2001.16.10.1787; ROSIER RN, 1998, CLIN ORTHOP S, V355, P294; Sato K, 2000, J IMMUNOL, V164, P2285, DOI 10.4049/jimmunol.164.5.2285; Sato T, 2001, J BONE MINER RES, V16, P2215, DOI 10.1359/jbmr.2001.16.12.2215; Shalhoub V, 2000, BRIT J HAEMATOL, V111, P501, DOI 10.1046/j.1365-2141.2000.02379.x; Sugatani T, 2003, J BIOL CHEM, V278, P5001, DOI 10.1074/jbc.M209299200; Takai H, 1998, J BIOL CHEM, V273, P27091, DOI 10.1074/jbc.273.42.27091; Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477; Tanaka S, 2003, J BONE MINER METAB, V21, P123, DOI 10.1007/s007740300021; Tanaka S, 1996, NATURE, V383, P528, DOI 10.1038/383528a0; Thirunavukkarasu K, 2001, J BIOL CHEM, V276, P36241, DOI 10.1074/jbc.M104319200; Tong GM, 2002, ANTICANCER RES, V22, P103; Toyosaki-Maeda T, 2001, ARTHRITIS RES, V3, P306, DOI 10.1186/ar320; Van Wesenbeeck L, 2002, P NATL ACAD SCI USA, V99, P14303, DOI 10.1073/pnas.202332999; WAHL SM, 1993, P NATL ACAD SCI USA, V90, P4577, DOI 10.1073/pnas.90.10.4577; Wang RX, 2002, EUR J IMMUNOL, V32, P1090, DOI 10.1002/1521-4141(200204)32:4<1090::AID-IMMU1090>3.0.CO;2-P; Weitzmann MN, 2000, J CELL BIOCHEM, V78, P318, DOI 10.1002/(SICI)1097-4644(20000801)78:2<318::AID-JCB13>3.0.CO;2-N; Yan T, 2001, J CELL BIOCHEM, V83, P320, DOI 10.1002/jcb.1200; Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523; ZHENG MH, 1994, AM J PATHOL, V145, P1095	78	115	126	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44975	44987		10.1074/jbc.M303905200	http://dx.doi.org/10.1074/jbc.M303905200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12933809	hybrid			2022-12-25	WOS:000186306700134
J	Zhao, C; Fu, DC; Dave, V; Ma, J				Zhao, C; Fu, DC; Dave, V; Ma, J			A composite motif of the Drosophila morphogenetic protein bicoid critical to transcription control	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE COMPLEX; TERMINAL DOMAIN; MESSENGER-RNA; CO-REPRESSORS; GENE; IDENTIFICATION; HOMEODOMAIN; YEAST; RECRUITMENT; PROMOTERS	Bicoid is a molecular morphogen-controlling embryonic patterning in Drosophila. It is a homeodomain-containing protein that activates specific target genes during early embryogenesis. Our recent studies have identified a domain of Bcd located outside its homeodomain and referred to as a self-inhibitory domain that can dramatically repress its own ability to activate transcription. Here we present evidence that the self-inhibitory function is evolutionarily conserved. A systematic analysis of this domain reveals a composite 10-amino acid motif with interdigitating residues that regulate Bcd activity in opposite manners. Mutations within the Bcd motif can exert their respective effects when the self-inhibitory domain is grafted to an entirely heterologous activator, but they do not affect DNA binding in vitro or subcellular localization of Bcd in cells. We further show that the self-inhibitory domain of Bcd can interact with Sin3A, a component of the histone deacetylase co-repressor complex. Our study suggests that the activity of Bcd is intricately controlled by multiple mechanisms involving the actions of co-repressor proteins.	Childrens Hosp Res Fdn, Div Dev Biol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation	Ma, J (corresponding author), Childrens Hosp Res Fdn, Div Dev Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	jun.ma@cchmc.org	Zhao, Chen/A-9987-2011; Dave, Vrushank/K-5262-2012; Ma, Jun/GLT-4809-2022	Dave, Vrushank/0000-0003-4044-2658; Ma, Jun/0000-0002-1609-3294				Ayer DE, 1999, TRENDS CELL BIOL, V9, P193, DOI 10.1016/S0962-8924(99)01536-6; Bach I, 1999, NAT GENET, V22, P394, DOI 10.1038/11970; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; Bi WL, 1998, ANAL BIOCHEM, V256, P137, DOI 10.1006/abio.1997.2516; Brantjes H, 2002, BIOL CHEM, V383, P255, DOI 10.1515/BC.2002.027; Breiling A, 2001, NATURE, V412, P651, DOI 10.1038/35088090; Brubaker K, 2000, CELL, V103, P655, DOI 10.1016/S0092-8674(00)00168-9; Burke LJ, 2000, FASEB J, V14, P1876, DOI 10.1096/fj.99-0943rev; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; Driever W., 1992, TRANSCRIPTIONAL REGU, P1221; Fu DC, 2003, MOL CELL BIOL, V23, P4439, DOI 10.1128/MCB.23.13.4439-4448.2003; Gao Q, 1998, DEVELOPMENT, V125, P4185; Jenster G, 1997, P NATL ACAD SCI USA, V94, P7879, DOI 10.1073/pnas.94.15.7879; JOHNSON AD, 1995, CURR OPIN GENET DEV, V5, P552, DOI 10.1016/0959-437X(95)80022-0; Johnson KD, 2002, NUCLEIC ACIDS RES, V30, P1522, DOI 10.1093/nar/30.7.1522; Kioussi C, 2002, CELL, V111, P673, DOI 10.1016/S0092-8674(02)01084-X; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; Ma XG, 1996, DEVELOPMENT, V122, P1195; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; McKinsey TA, 2001, CURR OPIN GENET DEV, V11, P497, DOI 10.1016/S0959-437X(00)00224-0; Niessing D, 2002, GENE DEV, V16, P2576, DOI 10.1101/gad.240002; NUSSLEINVOLHARD C, 1991, DEVELOPMENT, P1; Saurin AJ, 2001, NATURE, V412, P655, DOI 10.1038/35088096; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; SEEGER MA, 1990, EMBO J, V9, P2977, DOI 10.1002/j.1460-2075.1990.tb07490.x; Senger K, 2000, MOL CELL, V6, P931, DOI 10.1016/S1097-2765(05)00081-X; Shaw PJ, 2002, EVOL DEV, V4, P265, DOI 10.1046/j.1525-142X.2002.02016.x; Shaw PJ, 2001, EVOL DEV, V3, P251, DOI 10.1046/j.1525-142x.2001.003004251.x; SMALL S, 1991, GENE DEV, V5, P827, DOI 10.1101/gad.5.5.827; Stauber M, 1999, P NATL ACAD SCI USA, V96, P3786, DOI 10.1073/pnas.96.7.3786; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Uesugi M, 1999, P NATL ACAD SCI USA, V96, P14801, DOI 10.1073/pnas.96.26.14801; Yamamoto KR, 1998, COLD SPRING HARB SYM, V63, P587, DOI 10.1101/sqb.1998.63.587; Yochum GS, 2001, MOL CELL BIOL, V21, P4110, DOI 10.1128/MCB.21.13.4110-4118.2001; Yuan D, 1996, J BIOL CHEM, V271, P21660, DOI 10.1074/jbc.271.35.21660; Zhang DY, 2002, NUCLEIC ACIDS RES, V30, P3078, DOI 10.1093/nar/gkf422; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0; Zhao C, 2000, MOL CELL BIOL, V20, P8112, DOI 10.1128/MCB.20.21.8112-8123.2000; Zhao C, 2002, DEVELOPMENT, V129, P1669; ZHAO C, 2003, IN PRESS RECENT DEV, V3; Zhu WC, 2000, GENE, V245, P329, DOI 10.1016/S0378-1119(00)00048-2; Zhu WC, 2001, DEV GENES EVOL, V211, P109, DOI 10.1007/s004270100135	45	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					43901	43909		10.1074/jbc.M302714200	http://dx.doi.org/10.1074/jbc.M302714200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12939280	hybrid			2022-12-25	WOS:000186306700005
J	Hunzicker-Dunn, M; Barisas, G; Song, JM; Roess, DA				Hunzicker-Dunn, M; Barisas, G; Song, JM; Roess, DA			Membrane organization of luteinizing hormone receptors differs between actively signaling and desensitized receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OVARIAN FOLLICULAR MEMBRANES; PROTEIN-COUPLED RECEPTORS; RESONANCE ENERGY-TRANSFER; DELTA-OPIOID RECEPTOR; ADENYLYL-CYCLASE; CELL-SURFACE; HORMONE/CHORIOGONADOTROPIN RECEPTOR; BETA-ARRESTIN; CHORIOGONADOTROPIN RECEPTOR; LEYDIG-CELLS	Signaling by the luteinizing hormone/choriogonadotropin receptor (LHR) is of considerable interest because of its requirement for successful reproduction. Time-resolved phosphorescence anisotropy and fluorescence resonance energy transfer were used to investigate the organization of endogenous LHRs in porcine follicular membranes in two distinct signaling states, active and desensitized. Desensitized LHRs exhibited similar to 3-fold slower rotational correlation times compared with active LHRs ( 59 +/- 4 and 21 +/- 9 mus, respectively), suggesting that with agonist-dependent desensitization the receptors are organized into larger protein complexes. Incubation of membranes with inhibitors of LHR desensitization, such as neutralizing anti-arrestin antibodies, a synthetic peptide corresponding to the third intracellular loop of the LHR but not the corresponding scrambled peptide, or catalytically inactive ARNO, resulted in faster rotational diffusion times equivalent to those of actively signaling LHRs. Furthermore, desensitized LHRs exhibited a 2.4-fold increase in fluorescence resonance energy transfer between LHRs suggesting that the larger protein aggregates formed during desensitization contain more self-associated LHRs. These results indicate that agonist-dependent LHR desensitization precedes organization of LHRs at the cells surface into larger protein aggregates.	Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Colorado State Univ, Dept Physiol, Ft Collins, CO 80523 USA; Colorado State Univ, Dept Chem, Ft Collins, CO 80523 USA	Northwestern University; Colorado State University; Colorado State University	Hunzicker-Dunn, M (corresponding author), Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA.				NICHD NIH HHS [R01 HD38060, HD23226] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD038060] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AMSTERDAM A, 1980, P NATL ACAD SCI-BIOL, V77, P3440, DOI 10.1073/pnas.77.6.3440; Angers S, 2001, LIFE SCI, V68, P2243, DOI 10.1016/S0024-3205(01)01012-8; Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605; BENDER FE, 1982, STAT METHODS FOOD AG; Bevington PR, 1969, DATA REDUCTION ERROR; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; CHAN SS, 1979, J HISTOCHEM CYTOCHEM, V27, P56, DOI 10.1177/27.1.374620; Cheng ZJ, 2001, J BIOL CHEM, V276, P48040, DOI 10.1074/jbc.M105668200; Cornea A, 2001, J BIOL CHEM, V276, P2153, DOI 10.1074/jbc.M007850200; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; EKSTROM RC, 1989, ENDOCRINOLOGY, V125, P2470, DOI 10.1210/endo-125-5-2470; EKSTROM RC, 1992, J BIOL CHEM, V267, P22183; EKSTROM RC, 1990, ENDOCRINOLOGY, V127, P2578, DOI 10.1210/endo-127-5-2578; EKSTROM RC, 1989, ENDOCRINOLOGY, V124, P956, DOI 10.1210/endo-124-2-956; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; GHINEA N, 1992, J CELL BIOL, V118, P1347, DOI 10.1083/jcb.118.6.1347; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Horvat RD, 2001, MOL ENDOCRINOL, V15, P534, DOI 10.1210/me.15.4.534; Horvat RD, 1999, BIOCHEM BIOPH RES CO, V255, P382, DOI 10.1006/bbrc.1999.0185; HUNZICKERDUNN M, 1976, ENDOCRINOLOGY, V99, P185, DOI 10.1210/endo-99-1-185; Issafras H, 2002, J BIOL CHEM, V277, P34666, DOI 10.1074/jbc.M202386200; JOHNSON GD, 1986, HDB EXPT IMMUNOLOGY; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Krupnick JG, 1997, J BIOL CHEM, V272, P18125, DOI 10.1074/jbc.272.29.18125; LAMM MLG, 1994, ENDOCRINOLOGY, V134, P1745, DOI 10.1210/en.134.4.1745; LAMM MLG, 1994, MOL ENDOCRINOL, V8, P1537, DOI 10.1210/me.8.11.1537; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; LUBORSKY JL, 1984, ENDOCRINOLOGY, V115, P2217, DOI 10.1210/endo-115-6-2217; MARSH JM, 1973, BIOCHIM BIOPHYS ACTA, V304, P197, DOI 10.1016/0304-4165(73)90128-1; McVey M, 2001, J BIOL CHEM, V276, P14092, DOI 10.1074/jbc.M008902200; Mellado M, 2001, CELL MOL BIOL, V47, P575; Mukherjee S, 1999, J BIOL CHEM, V274, P12984, DOI 10.1074/jbc.274.19.12984; Mukherjee S, 1999, P NATL ACAD SCI USA, V96, P493, DOI 10.1073/pnas.96.2.493; Mukherjee S, 2002, J BIOL CHEM, V277, P17916, DOI 10.1074/jbc.M110479200; Mukherjee S, 2001, J BIOL CHEM, V276, P6524, DOI 10.1074/jbc.C000725200; Mukherjee S, 2000, P NATL ACAD SCI USA, V97, P5901, DOI 10.1073/pnas.100127097; Ng GYK, 1996, BIOCHEM BIOPH RES CO, V227, P200, DOI 10.1006/bbrc.1996.1489; Pfeiffer M, 2001, J BIOL CHEM, V276, P14027, DOI 10.1074/jbc.M006084200; PHILPOTT CJ, 1995, BIOL REPROD, V53, P647, DOI 10.1095/biolreprod53.3.647; PODESTA EJ, 1983, P NATL ACAD SCI-BIOL, V80, P3986, DOI 10.1073/pnas.80.13.3986; Rodriguez-Frade JM, 1999, P NATL ACAD SCI USA, V96, P3628, DOI 10.1073/pnas.96.7.3628; Roess DA, 2000, ENDOCRINOLOGY, V141, P4518, DOI 10.1210/en.141.12.4518; ROESS DA, 1977, BIOCHIM BIOPHYS ACTA, V1357, P98; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; Salvador LM, 2001, J BIOL CHEM, V276, P33773, DOI 10.1074/jbc.M101498200; SPIEGEL AM, 1992, ENDOCR REV, V13, P536, DOI 10.1210/er.13.3.536; TSAI SC, 1991, J BIOL CHEM, V268, P8213; Wang Z, 1997, MOL ENDOCRINOL, V11, P183, DOI 10.1210/me.11.2.183; Wang Z, 1996, MOL ENDOCRINOL, V10, P748, DOI 10.1210/me.10.6.748; YOSHIMI T, 1969, J CLIN ENDOCR METAB, V29, P225, DOI 10.1210/jcem-29-2-225; YOUNG RM, 1994, BIOPHYS J, V67, P881, DOI 10.1016/S0006-3495(94)80549-1; ZHU X, 1993, J BIOL CHEM, V268, P1723	56	30	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42744	42749		10.1074/jbc.M306133200	http://dx.doi.org/10.1074/jbc.M306133200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12930832	hybrid			2022-12-25	WOS:000186157000004
J	Noda, Y; Kohjima, M; Izaki, T; Ota, K; Yoshinaga, S; Inagaki, F; Ito, T; Sumimoto, H				Noda, Y; Kohjima, M; Izaki, T; Ota, K; Yoshinaga, S; Inagaki, F; Ito, T; Sumimoto, H			Molecular recognition in dimerization between PB1 domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CELL-POLARITY; NADPH OXIDASE; EPITHELIAL TIGHT; PC MOTIF; COMPLEX; BINDING; APKC; CDC42; LINKS	The PB1 ( Phox and Bem 1) domain is a recently identified module that mediates formation of a heterodimeric complex with other PB1 domain, e. g. the complexes between the phagocyte oxidase activators p67(phox) and p40(phox) and between the yeast polarity proteins Bem1p and Cdc24p. These PB1 domains harbor either a conserved lysine residue on one side or an acidic OPCA (OPR/PC/AID) motif around the other side; the lysine of p67phox or Bem1p likely binds to the OPCA of p40phox or Cdc24p, respectively, via electrostatic interactions. To further understand molecular recognition by PB1 domains, here we investigate the interactions mediated by proteins presenting both the lysine and OPCA on a single PB1 domain, namely Par6, atypical protein kinase C ( aPKC), and ZIP. Par6 and aPKC form a complex via the interaction of the Par6 lysine with aPKC-OPCA but not via that between the aPKC lysine and Par6-OPCA, thereby localizing to the tight junction of epithelial cells. aPKC also uses its OPCA to interact with ZIP, another protein that has a PB1 domain presenting both the lysine and OPCA, whereas aPKC binds via the conserved lysine to MEK5 in the same manner as ZIP interacts with MEK5. In addition, ZIP can form a homotypic complex via the conserved electrostatic interactions. Thus the PB1 domain appears to be a protein module that fully exploits its two mutually interacting elements in molecular recognition to expand its repertoire of protein-protein interactions.	Kyushu Univ, Med Inst Bioregulat, Higashi Ku, Fukuoka 8128582, Japan; Kanazawa Univ, Canc Res Inst, Div Genome Biol, Kanazawa, Ishikawa 9200934, Japan; Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biol Struct, Sapporo, Hokkaido 0600812, Japan	Kyushu University; Kanazawa University; Hokkaido University	Sumimoto, H (corresponding author), Kyushu Univ, Med Inst Bioregulat, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	hsumi@bioreg.kyushu-u.ac.jp		Ito, Takashi/0000-0001-6097-2803				Ago T, 1999, J BIOL CHEM, V274, P33644, DOI 10.1074/jbc.274.47.33644; Betschinger J, 2003, NATURE, V422, P326, DOI 10.1038/nature01486; Bokoch GM, 2002, BLOOD, V100, P2692, DOI 10.1182/blood-2002-04-1149; Butty AC, 2002, EMBO J, V21, P1565, DOI 10.1093/emboj/21.7.1565; Clark RA, 1999, J INFECT DIS, V179, pS309, DOI 10.1086/513849; Diaz-Meco MT, 2001, MOL CELL BIOL, V21, P1218, DOI 10.1128/MCB.21.4.1218-1227.2001; Endo M, 2003, J BIOL CHEM, V278, P843, DOI 10.1074/jbc.M209714200; ENGLISH JM, 1995, J BIOL CHEM, V270, P28897, DOI 10.1074/jbc.270.48.28897; Etienne-Manneville S, 2003, CURR OPIN CELL BIOL, V15, P67, DOI 10.1016/S0955-0674(02)00005-4; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Gao L, 2002, CURR BIOL, V12, P221, DOI 10.1016/S0960-9822(01)00663-7; Gong JP, 1999, SCIENCE, V285, P1565, DOI 10.1126/science.285.5433.1565; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; Hurd TW, 2003, NAT CELL BIOL, V5, P137, DOI 10.1038/ncb923; Ito T, 2001, EMBO J, V20, P3938, DOI 10.1093/emboj/20.15.3938; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Joung I, 1996, P NATL ACAD SCI USA, V93, P5991, DOI 10.1073/pnas.93.12.5991; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Koga H, 1999, J BIOL CHEM, V274, P25051, DOI 10.1074/jbc.274.35.25051; Kohjima M, 2002, BIOCHEM BIOPH RES CO, V299, P641, DOI 10.1016/S0006-291X(02)02698-0; Kuribayashi F, 2002, EMBO J, V21, P6312, DOI 10.1093/emboj/cdf642; Letunic I, 2002, NUCLEIC ACIDS RES, V30, P242, DOI 10.1093/nar/30.1.242; Lin D, 2000, NAT CELL BIOL, V2, P540, DOI 10.1038/35019582; Mayer BJ, 2001, J CELL SCI, V114, P1253; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Moscat J, 2000, EMBO REP, V1, P399, DOI 10.1093/embo-reports/kvd098; Nakamura R, 1998, EUR J BIOCHEM, V251, P583, DOI 10.1046/j.1432-1327.1998.2510583.x; Nauseef WM, 1999, P ASSOC AM PHYSICIAN, V111, P373, DOI 10.1111/paa.1999.111.5.373; Noda Y, 2001, GENES CELLS, V6, P107, DOI 10.1046/j.1365-2443.2001.00404.x; Ohno S, 2001, CURR OPIN CELL BIOL, V13, P641, DOI 10.1016/S0955-0674(00)00264-7; Otomo T, 2000, NAT STRUCT BIOL, V7, P658, DOI 10.1038/77957; Pawson T, 2003, SCIENCE, V300, P445, DOI 10.1126/science.1083653; Plant PJ, 2003, NAT CELL BIOL, V5, P301, DOI 10.1038/ncb948; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; Ponting CP, 2002, TRENDS BIOCHEM SCI, V27, P10, DOI 10.1016/S0968-0004(01)02006-0; Puls A, 1997, P NATL ACAD SCI USA, V94, P6191, DOI 10.1073/pnas.94.12.6191; Qiu RG, 2000, CURR BIOL, V10, P697, DOI 10.1016/S0960-9822(00)00535-2; Sanz L, 1999, EMBO J, V18, P3044, DOI 10.1093/emboj/18.11.3044; Shiose A, 2000, J BIOL CHEM, V275, P13793, DOI 10.1074/jbc.275.18.13793; Suzuki A, 2001, J CELL BIOL, V152, P1183, DOI 10.1083/jcb.152.6.1183; TAKEUCHI K, 1994, J CELL BIOL, V125, P1371, DOI 10.1083/jcb.125.6.1371; Terasawa H, 2001, EMBO J, V20, P3947, DOI 10.1093/emboj/20.15.3947; Wodarz A, 2002, NAT CELL BIOL, V4, pE39, DOI 10.1038/ncb0202-e39; Yaffe MB, 2002, NAT REV MOL CELL BIO, V3, P177, DOI 10.1038/nrm759; Yamanaka T, 2003, CURR BIOL, V13, P734, DOI 10.1016/S0960-9822(03)00244-6; Yamanaka T, 2001, GENES CELLS, V6, P721, DOI 10.1046/j.1365-2443.2001.00453.x; YOSHINAGA S, 2003, IN PRESS EMBO J, V22; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	48	68	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43516	43524		10.1074/jbc.M306330200	http://dx.doi.org/10.1074/jbc.M306330200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12920115	hybrid			2022-12-25	WOS:000186157000097
J	Yuan, LP; Yu, WM; Qu, CK				Yuan, LP; Yu, WM; Qu, CK			DNA damage-induced G(2)/M checkpoint in SV40 large T antigen-immortalized embryonic fibroblast cells requires SHP-2 tyrosine phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; CYCLE ARREST; C-JUN; CELLULAR-RESPONSE; ERK ACTIVATION; MAP KINASE; IN-VITRO; PATHWAY; P53; RADIATION	DNA damage induced by radiation or DNA-damaging agents leads to apoptosis and cell cycle arrest. However, DNA damage-triggered signal transduction involved in these cellular responses is not well understood. We previously demonstrated an important role for SHP-2, a ubiquitously expressed SH2 domain-containing tyrosine phosphatase, in the DNA damage-induced apoptotic response. Here we report a potential role for SHP-2 in a DNA damage-activated cell cycle checkpoint. Cell cycle analysis and the mitotic index assay showed that following DNA damage induced by cisplatin or gamma-irradiation, the G(2) (but not S) arrest response was diminished in SV40 large T antigen-immortalized embryonic fibroblast cells lacking functional SHP-2. Notably, reintroduction of wild-type SHP-2 into the mutant cells fully restored the DNA damage-induced G(2) arrest response, suggesting a direct role of SHP-2 in the G(2)/M checkpoint. Further biochemical analysis revealed that SHP-2 constitutively associated with 14-3-3beta, and that Cdc25C cytoplasmic translocation induced by DNA damage was essentially blocked in SHP-2 mutant cells. Additionally, we showed that following DNA damage, activation of p38 kinase was significantly elevated, while Erk kinase activation was decreased in mutant cells, and treatment of SHP-2 mutant cells with SB203580, a selective inhibitor for p38 kinase, partially restored the DNA damage-induced G(2) arrest response. These results together provide the first evidence that SHP-2 tyrosine phosphatase enhances the DNA damage G(2)/M checkpoint in SV40 large T antigen immortalized murine embryonic fibroblast cells.	Amer Red Cross, Jerome H Holland Lab Biomed Sci, Dept Hematopoiesis, Rockville, MD 20855 USA; George Washington Univ, Med Ctr, Dept Anat & Cell Biol, Washington, DC 20037 USA	American Red Cross; George Washington University	Qu, CK (corresponding author), Amer Red Cross, Holland Lab, Dept Hematopoiesis, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.				NHLBI NIH HHS [R01HL68212-01A1] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068212] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Carter S, 1998, ONCOGENE, V16, P2787, DOI 10.1038/sj.onc.1201802; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Ghahremani MH, 2002, J BIOL CHEM, V277, P35586, DOI 10.1074/jbc.M204362200; Guadagno TM, 1998, SCIENCE, V282, P1312, DOI 10.1126/science.282.5392.1312; Hayakawa J, 1999, J BIOL CHEM, V274, P31648, DOI 10.1074/jbc.274.44.31648; Hayne C, 2000, J BIOL CHEM, V275, P31876, DOI 10.1074/jbc.M002766200; Heron-Milhavet L, 2001, J BIOL CHEM, V276, P18185, DOI 10.1074/jbc.M011490200; Jasani B, 2001, SEMIN CANCER BIOL, V11, P49, DOI 10.1006/scbi.2000.0346; Liu QH, 2000, GENE DEV, V14, P1448; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Persons DL, 2000, J BIOL CHEM, V275, P35778, DOI 10.1074/jbc.M004267200; Pipas JM, 2001, SEMIN CANCER BIOL, V11, P23, DOI 10.1006/scbi.2000.0343; Potapova O, 2001, J BIOL CHEM, V276, P28546, DOI 10.1074/jbc.M102075200; Qu CK, 1999, P NATL ACAD SCI USA, V96, P8528, DOI 10.1073/pnas.96.15.8528; Qu CK, 2002, BBA-MOL CELL RES, V1592, P297, DOI 10.1016/S0167-4889(02)00322-1; Qu CK, 1998, MOL CELL BIOL, V18, P6075, DOI 10.1128/MCB.18.10.6075; Qu CK, 1997, MOL CELL BIOL, V17, P5499, DOI 10.1128/MCB.17.9.5499; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sanchez-Prieto R, 2000, CANCER RES, V60, P2464; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Shi ZQ, 2000, MOL CELL BIOL, V20, P1526, DOI 10.1128/MCB.20.5.1526-1536.2000; Shi ZQ, 1998, J BIOL CHEM, V273, P4904, DOI 10.1074/jbc.273.9.4904; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Wang XF, 2000, MOL CELL BIOL, V20, P4543, DOI 10.1128/MCB.20.13.4543-4552.2000; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; Weinert T, 1997, SCIENCE, V277, P1450, DOI 10.1126/science.277.5331.1450; Wright JH, 1999, P NATL ACAD SCI USA, V96, P11335, DOI 10.1073/pnas.96.20.11335; You M, 2001, J EXP MED, V193, P101, DOI 10.1084/jem.193.1.101; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; Yuan LP, 2003, J BIOL CHEM, V278, P15208, DOI 10.1074/jbc.M211327200; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	45	31	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42812	42820		10.1074/jbc.M305075200	http://dx.doi.org/10.1074/jbc.M305075200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12937170	hybrid			2022-12-25	WOS:000186157000012
J	Garofano, A; Zwicker, K; Kerscher, S; Okun, P; Brandt, U				Garofano, A; Zwicker, K; Kerscher, S; Okun, P; Brandt, U			Two aspartic acid residues in the PSST-homologous NUKM subunit of complex I from Yarrowia lipolytica are essential for catalytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADH-UBIQUINONE OXIDOREDUCTASE; SULFUR CLUSTER N2; SITE-DIRECTED MUTAGENESIS; MITOCHONDRIAL NADH; ESCHERICHIA-COLI; 49-KDA SUBUNIT; CORE; HYDROGENASES; TYKY	Mitochondrial proton-translocating NADH: ubiquinone oxidoreductase ( complex I) couples the transfer of two electrons from NADH to ubiquinone to the translocation of four protons across the mitochondrial inner membrane. Subunit PSST is the most likely carrier of iron-sulfur cluster N2, which has been proposed to play a crucial role in ubiquinone reduction and proton pumping. To explore the function of this subunit we have generated site-directed mutants of all eight highly conserved acidic residues in the Yarrowia lipolytica homologue, the NUKM protein. Mutants D99N and D115N had only 5 and 8% of the wild type catalytic activity, respectively. In both cases complex I was stably assembled but electron paramagnetic resonance spectra of the purified enzyme showed a reduced N2 signal (about 50%). In terms of complex I catalytic activity, almost identical results were obtained when the aspartates were individually changed to glutamates or to glycines. Mutations of other conserved acidic residues had less dramatic effects on catalytic activity and did not prevent assembly of iron-sulfur cluster N2. This excludes all conserved acidic residues in the PSST subunit as fourth ligands of this redox center. The results are discussed in the light of the structural similarities to the homologous small subunit of water-soluble [NiFe] hydrogenases.	Univ Frankfurt, Fachbereich Med, Inst Biochem 1, Gustav Embden Zentrum Biol Chem, D-60590 Frankfurt, Germany	Goethe University Frankfurt	Brandt, U (corresponding author), Univ Frankfurt, Fachbereich Med, Inst Biochem 1, Gustav Embden Zentrum Biol Chem, Theodor Stern Kai 7,Haus 25B, D-60590 Frankfurt, Germany.		Brandt, Ulrich/GLV-1242-2022; Brandt, Ulrich/C-4406-2008	Brandt, Ulrich/0000-0003-1869-6811; Brandt, Ulrich/0000-0003-1869-6811				Ahlers PM, 2000, J BIOL CHEM, V275, P23577, DOI 10.1074/jbc.M002074200; Ahlers PM, 2000, BBA-BIOENERGETICS, V1459, P258, DOI 10.1016/S0005-2728(00)00160-2; ALBRACHT SPJ, 1993, BIOCHIM BIOPHYS ACTA, V1144, P221, DOI 10.1016/0005-2728(93)90176-G; Brandt U, 2003, FEBS LETT, V545, P9, DOI 10.1016/S0014-5793(03)00387-9; Carroll J, 2003, MOL CELL PROTEOMICS, V2, P117, DOI 10.1074/mcp.M300014-MCP200; Chevallet M, 2003, BBA-BIOENERGETICS, V1557, P51, DOI 10.1016/S0005-2728(02)00398-5; Djafarzadeh R, 2000, BBA-BIOENERGETICS, V1459, P230, DOI 10.1016/S0005-2728(00)00154-7; Duarte M, 2002, BIOCHEM J, V364, P833, DOI 10.1042/BJ20011750; Dutton P L, 1978, Methods Enzymol, V54, P411; Friedrich T, 1998, BBA-BIOENERGETICS, V1364, P134, DOI 10.1016/S0005-2728(98)00024-3; Kashani-Poor N, 2001, BBA-BIOENERGETICS, V1504, P363, DOI 10.1016/S0005-2728(00)00266-8; Kashani-Poor N, 2001, J BIOL CHEM, V276, P24082, DOI 10.1074/jbc.M102296200; Kerscher S, 2002, BBA-BIOENERGETICS, V1555, P83, DOI 10.1016/S0005-2728(02)00259-1; Kerscher S, 2001, J BIOENERG BIOMEMBR, V33, P187, DOI 10.1023/A:1010726818165; Kerscher SJ, 2001, J CELL SCI, V114, P3915; Magnitsky S, 2002, J BIOENERG BIOMEMBR, V34, P193, DOI 10.1023/A:1016083419979; Montet Y, 1997, NAT STRUCT BIOL, V4, P523, DOI 10.1038/nsb0797-523; Ohnishi T, 1998, BBA-BIOENERGETICS, V1364, P186, DOI 10.1016/S0005-2728(98)00027-9; PRIEUR L, 2001, BIOCHIM BIOPHYS ACTA, V1504, P173; Rasmussen T, 2001, BIOCHEMISTRY-US, V40, P6124, DOI 10.1021/bi0026977; Rousset M, 1998, P NATL ACAD SCI USA, V95, P11625, DOI 10.1073/pnas.95.20.11625; SAUTER M, 1992, MOL MICROBIOL, V6, P1523, DOI 10.1111/j.1365-2958.1992.tb00873.x; Schagger H., 2003, MEMBRANE PROTEIN PUR, P105, DOI DOI 10.1016/B978-012361776-7/50006-1; Schuler F, 1999, P NATL ACAD SCI USA, V96, P4149, DOI 10.1073/pnas.96.7.4149; SLED VD, 1993, BIOCHIM BIOPHYS ACTA, V1141, P262, DOI 10.1016/0005-2728(93)90051-G; Triepels RH, 1999, ANN NEUROL, V45, P787, DOI 10.1002/1531-8249(199906)45:6<787::AID-ANA13>3.0.CO;2-6; VOLBEDA A, 1995, NATURE, V373, P580, DOI 10.1038/373580a0; WIKSTROM M, 1984, FEBS LETT, V169, P300, DOI 10.1016/0014-5793(84)80338-5; Zickermann V, 2003, J BIOL CHEM, V278, P29072, DOI 10.1074/jbc.M302713200	29	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42435	42440		10.1074/jbc.M305819200	http://dx.doi.org/10.1074/jbc.M305819200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12930834	hybrid			2022-12-25	WOS:000185989500107
J	Krauskopf, A; Lhote, P; Mutter, M; Dufour, JF; Ruegg, UT; Buetler, TM				Krauskopf, A; Lhote, P; Mutter, M; Dufour, JF; Ruegg, UT; Buetler, TM			Vasopressin type 1A receptor up-regulation by cyclosporin A in vascular smooth muscle cells is mediated by superoxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; HYDROGEN-PEROXIDE; REACTIVE OXYGEN; OXIDATIVE STRESS; PROTEIN-KINASE; ENDOTHELIAL DYSFUNCTION; SIGNAL-TRANSDUCTION; ARACHIDONIC-ACID; GENE-EXPRESSION; FREE-RADICALS	Based on our previous results, we investigated whether cyclosporin A (CsA)-induced vasopressin type 1A receptor up-regulation was mediated by free radicals. We report that CsA analogues with different affinities for cyclophilin and calcineurin were able to upregulate vasopressin type 1A receptor and to generate free radicals in smooth muscle cells independently of calcineurin. Further, we demonstrate that the antioxidant N-acetyl-L-cysteine blocked the increase in vasopressin type 1A receptor mRNA and protein levels induced by CsA and that low concentrations of prooxidants were able to directly increase vasopressin type 1A receptor mRNA and protein levels. In addition, short exposure to CsA or pro-oxidants was sufficient to significantly increase vasopressin type 1A receptor mRNA and protein levels. Using cell-permeable forms of superoxide dismutase and catalase, we finally show that superoxide mediates the CsA-induced effects on vasopressin type 1A receptor. These results provide strong evidence that CsA-induced superoxide generation is causally involved in vasopressin type 1A receptor expression and demonstrate for the first time that low physiological concentrations of radicals, most probably superoxide, are able to directly affect cellular signaling to increase vasopressin type 1A receptor expression in rat aortic smooth muscle cells.	Univ Lausanne, Sch Pharm, Pharmacol Grp, CH-1015 Lausanne, Switzerland; Ecole Polytech Fed Lausanne, Inst Mol & Biol Chem, CH-1015 Lausanne, Switzerland; Univ Bern, Dept Clin Pharmacol, CH-3010 Bern, Switzerland	University of Lausanne; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; University of Bern	Ruegg, UT (corresponding author), Univ Lausanne, Sch Pharm, Pharmacol Grp, CH-1015 Lausanne, Switzerland.	urs.ruegg@dpharm.unil.ch	Dufour, Jean Francois Jacques/AAL-9866-2020	Dufour, Jean Francois Jacques/0000-0002-8062-1346; RUEGG, Urs/0000-0001-6078-8280				AHMED SS, 1993, J PHARMACOL EXP THER, V265, P1047; Allen RG, 2000, FREE RADICAL BIO MED, V28, P463, DOI 10.1016/S0891-5849(99)00242-7; Aramburu J, 2000, CURR TOP CELL REGUL, V36, P237; Avdonin PV, 1999, KIDNEY INT, V55, P2407, DOI 10.1046/j.1523-1755.1999.00481.x; BAUMANN G, 1991, NEW BIOL, V3, P270; BECKMAN JS, 1988, J BIOL CHEM, V263, P6884; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Borel J F, 1996, Adv Pharmacol, V35, P115, DOI 10.1016/S1054-3589(08)60276-8; Cai H, 2002, J BIOL CHEM, V277, P48311, DOI 10.1074/jbc.M208884200; Cai H, 2001, ARTERIOSCL THROM VAS, V21, P1571, DOI 10.1161/hq1001.097028; Chae HZ, 1999, METHOD ENZYMOL, V300, P219; Chen HW, 2002, BRIT J PHARMACOL, V137, P771, DOI 10.1038/sj.bjp.0704908; Cottet-Maire F, 2001, BRIT J PHARMACOL, V132, P909, DOI 10.1038/sj.bjp.0703878; Dalton TD, 1999, ANNU REV PHARMACOL, V39, P67, DOI 10.1146/annurev.pharmtox.39.1.67; deLema GP, 1997, TRANSPL P, V29, P1241; DIEDERICH D, 1994, HYPERTENSION, V23, P957, DOI 10.1161/01.HYP.23.6.957; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; FRANTZ B, 1994, EMBO J, V13, P861, DOI 10.1002/j.1460-2075.1994.tb06329.x; FRIDOVICH I, 1985, HARVEY LECT, V79, P51; Galle J, 2000, NEPHROL DIAL TRANSPL, V15, P339, DOI 10.1093/ndt/15.3.339; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; Hempel SL, 1999, FREE RADICAL BIO MED, V27, P146, DOI 10.1016/S0891-5849(99)00061-1; Huang WC, 2002, EXP CELL RES, V277, P192, DOI 10.1006/excr.2002.5546; Ischiropoulos H, 1999, METHOD ENZYMOL, V301, P367; KAHAN BD, 1989, NEW ENGL J MED, V321, P1725; Krauskopf A, 2002, BRIT J PHARMACOL, V135, P977, DOI 10.1038/sj.bjp.0704544; LAMB FS, 1987, LIFE SCI, V40, P2571, DOI 10.1016/0024-3205(87)90080-4; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; Liochev SI, 1999, MET IONS BIOL SYST, V36, P1; Lopez-Ongil S, 1998, BRIT J PHARMACOL, V124, P447, DOI 10.1038/sj.bjp.0701847; LoRusso A, 1996, BRIT J PHARMACOL, V118, P885; LoRusso A, 1997, J RECEPT SIGNAL TR R, V17, P149; LoRusso A, 1997, BRIT J PHARMACOL, V121, P248, DOI 10.1038/sj.bjp.0701102; MASON J, 1989, PHARMACOL REV, V41, P423; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; Namgaladze D, 2002, J BIOL CHEM, V277, P5962, DOI 10.1074/jbc.M111268200; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; RAO GN, 1993, ONCOGENE, V8, P2759; RAO GN, 1993, NUCLEIC ACIDS RES, V21, P1259, DOI 10.1093/nar/21.5.1259; RAO GN, 1995, BBA-MOL CELL RES, V1265, P67, DOI 10.1016/0167-4889(95)91997-Z; REGO A, 1990, J PHARMACOL EXP THER, V254, P799; ROSENKRANZ AR, 1992, J IMMUNOL METHODS, V156, P39, DOI 10.1016/0022-1759(92)90008-H; Schreck R, 1991, Trends Cell Biol, V1, P39, DOI 10.1016/0962-8924(91)90072-H; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SHIBATA N, 1988, EUR J CLIN PHARMACOL, V35, P443, DOI 10.1007/BF00561382; Sies H., 1991, OXIDATIVE STRESS OXI; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Sugimoto T, 1997, J BIOL CHEM, V272, P29415, DOI 10.1074/jbc.272.47.29415; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; TEXTOR SC, 1994, MAYO CLIN PROC, V69, P1182, DOI 10.1016/S0025-6196(12)65772-3; ULLMAN KS, 1993, GENE DEV, V7, P188, DOI 10.1101/gad.7.2.188; Ullrich V, 2001, BBA-MOL CELL BIOL L, V1532, P1, DOI 10.1016/S1388-1981(01)00126-3; WANG CY, 1995, KIDNEY INT, V47, P927, DOI 10.1038/ki.1995.138; Wang H, 1999, FREE RADICAL BIO MED, V27, P612, DOI 10.1016/S0891-5849(99)00107-0; WOLF A, 1994, TRANSPLANT P, V26, P2902; Wolin MS, 2002, J VASC RES, V39, P191, DOI 10.1159/000063685; Yang JQ, 1999, MOL CARCINOGEN, V26, P180; Yang JQ, 2002, MOL CARCINOGEN, V33, P206, DOI 10.1002/mc.10037; Zhang JH, 1998, AM J RESP CELL MOL, V19, P324, DOI 10.1165/ajrcmb.19.2.3209; Zimmerman MC, 2002, CIRC RES, V91, P1038, DOI 10.1161/01.RES.0000043501.47934.FA	61	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41685	41690		10.1074/jbc.M301181200	http://dx.doi.org/10.1074/jbc.M301181200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12923165	hybrid			2022-12-25	WOS:000185989500018
J	Yokoyama, K; Nagata, K; Imamura, H; Ohkuma, S; Yoshida, M; Tamakoshi, M				Yokoyama, K; Nagata, K; Imamura, H; Ohkuma, S; Yoshida, M; Tamakoshi, M			Subunit arrangement in V-ATPase from Thermus thermophilus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; PROTON-TRANSLOCATING ATPASE; MANDUCA-SEXTA MIDGUT; CROSS-LINKING; EXTREME THERMOPHILE; 100-KDA SUBUNIT; TERMINAL DOMAIN; GENE ENCODES; V-1 ATPASE; IN-VIVO	The V0V1-ATPase of Thermus thermophilus catalyzes ATP synthesis coupled with proton translocation. It consists of an ATPase-active V-1 part (ABDF) and a proton channel V-0 part (CLEGI), but the arrangement of each subunit is still largely unknown. Here we found that acid treatment of V0V1-ATPase induced its dissociation into two subcomplexes, one with subunit composition ABDFCL and the other with EGI. Exposure of the isolated V0 to acid or 8 M urea also produced two subcomplexes, EGI and CL. Thus, the C subunit (homologue of d subunit, yeast Vma6p) associates with the L subunit ring tightly, and I (homologue of 100-kDa subunit, yeast Vph1p), E, and G subunits constitute a stable complex. Based on these observations and our recent demonstration that D, F, and L subunits rotate relative to A(3)B(3) (Imamura, H., Nakano, M., Noji, H., Muneyuki, E., Ohkuma, S., Yoshida, M., and Yokoyama, K. (2003) Proc. Natl. Acad. Sci. U. S. A. 100, 2312-2315; Yokoyama, K., Nakano, M., Imamura, H., Yoshida, M., and Tamakoshi, M. (2003) J. Biol. Chem. 278, 24255-24258), we propose that C, D, F, and L subunits constitute the central rotor shaft and A, B, E, G, and I subunits comprise the surrounding stator apparatus in the V0V1-ATPase.	Japan Sci & Technol Corp, ERATO, ATP Syst Project, Midori Ku, Yokohama, Kanagawa 2260026, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Bunkyo Ku, Tokyo 1138657, Japan; Kanazawa Univ, Fac Pharmaceut Sci, Dept Mol & Cellular Biol, Kanazawa, Ishikawa 9200934, Japan; Tokyo Inst Technol, Chem Resources Lab, Midori Ku, Yokohama, Kanagawa 2268503, Japan; Tokyo Univ Pharm & Life Sci, Dept Mol Biol, Tokyo 1920392, Japan	Japan Science & Technology Agency (JST); University of Tokyo; Kanazawa University; Tokyo Institute of Technology; Tokyo University of Pharmacy & Life Sciences	Yokoyama, K (corresponding author), Japan Sci & Technol Corp, ERATO, ATP Syst Project, Midori Ku, 5800-3 Nagatsuta, Yokohama, Kanagawa 2260026, Japan.		Yokoyama, Ken/AAJ-3582-2020; Imamura, Hiromi/AAD-5109-2019	Yokoyama, Ken/0000-0002-6813-1096; Imamura, Hiromi/0000-0002-1896-0443; Nagata, Koji/0000-0002-4704-0603				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Arata Y, 2002, BIOCHEMISTRY-US, V41, P11301, DOI 10.1021/bi0262449; Arata Y, 2002, J BIOL CHEM, V277, P3357, DOI 10.1074/jbc.M109967200; BAUERLE C, 1993, J BIOL CHEM, V268, P12749; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; Chaban Y, 2002, EMBO REP, V3, P982, DOI 10.1093/embo-reports/kvf196; Fillingame RH, 1997, J EXP BIOL, V200, P217; Forgac M, 1999, J BIOENERG BIOMEMBR, V31, P57, DOI 10.1023/A:1005496530380; Gruber G, 2001, J EXP BIOL, V204, P2597; Gruber G, 2001, BIOCHEMISTRY-US, V40, P1890, DOI 10.1021/bi002195t; Gruber G, 2000, J BIOL CHEM, V275, P30082, DOI 10.1074/jbc.M002976200; Gruber G, 2000, BIOCHEMISTRY-US, V39, P8609, DOI 10.1021/bi000103u; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; Imamura H, 2003, P NATL ACAD SCI USA, V100, P2312, DOI 10.1073/pnas.0436796100; KANE PM, 1995, J BIOL CHEM, V270, P17025; Kawasaki-Nishi S, 2001, J BIOL CHEM, V276, P47411, DOI 10.1074/jbc.M108310200; Kawasaki-Nishi S, 2001, P NATL ACAD SCI USA, V98, P12397, DOI 10.1073/pnas.221291798; Leng XH, 1996, J BIOL CHEM, V271, P22487, DOI 10.1074/jbc.271.37.22487; Leng XH, 1998, J BIOL CHEM, V273, P6717, DOI 10.1074/jbc.273.12.6717; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Oster G, 2000, BBA-BIOENERGETICS, V1458, P482, DOI 10.1016/S0005-2728(00)00096-7; Parra KJ, 1998, MOL CELL BIOL, V18, P7064, DOI 10.1128/MCB.18.12.7064; Powell B, 2000, J BIOL CHEM, V275, P23654, DOI 10.1074/jbc.M004440200; RICHARD P, 1995, J BIOL CHEM, V270, P21571, DOI 10.1074/jbc.270.37.21571; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; SUMNER JP, 1995, J BIOL CHEM, V270, P5649, DOI 10.1074/jbc.270.10.5649; Suzuki T, 2000, J BIOL CHEM, V275, P37902, DOI 10.1074/jbc.M007075200; Tamakoshi M, 1998, GENE, V222, P125, DOI 10.1016/S0378-1119(98)00482-X; Tamakoshi M, 1999, FEMS MICROBIOL LETT, V173, P431, DOI 10.1016/S0378-1097(99)00101-9; Tamakoshi M, 1997, J BACTERIOL, V179, P4811, DOI 10.1128/jb.179.15.4811-4814.1997; Tomashek JJ, 1997, J BIOL CHEM, V272, P26787, DOI 10.1074/jbc.272.42.26787; Tomashek JJ, 1997, J BIOL CHEM, V272, P16618, DOI 10.1074/jbc.272.26.16618; Yokoyama K, 2003, J BIOL CHEM, V278, P24255, DOI 10.1074/jbc.M303104200; YOKOYAMA K, 1994, J BIOL CHEM, V269, P12248; YOKOYAMA K, 1990, J BIOL CHEM, V265, P21946; Yokoyama K, 1998, J BIOL CHEM, V273, P20504, DOI 10.1074/jbc.273.32.20504; Yokoyama K, 2000, J BIOL CHEM, V275, P13955, DOI 10.1074/jbc.275.18.13955; Yoshida M, 2001, NAT REV MOL CELL BIO, V2, P669, DOI 10.1038/35089509	41	52	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42686	42691		10.1074/jbc.M305853200	http://dx.doi.org/10.1074/jbc.M305853200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12913005	hybrid			2022-12-25	WOS:000185989500135
J	Gurrola-Diaz, C; Lacroix, J; Dihlmann, S; Becker, CM; Doeberitz, MV				Gurrola-Diaz, C; Lacroix, J; Dihlmann, S; Becker, CM; Doeberitz, MV			Reduced expression of the neuron restrictive silencer factor permits transcription of glycine receptor alpha 1 subunit in small-cell lung cancer cells	ONCOGENE			English	Article						glycine receptor alpha-1 subunit; GLRA1; NRSF; NRSE; neuroendocrine differentiation; small-cell lung cancer; SCLC; NSCLC	GENE-EXPRESSION; MAMMALIAN-CELLS; DNA-BINDING; REPRESSOR; PROTEIN; IDENTIFICATION; VARIANT; REST4; RAT	Small-cell lung cancer (SCLC) cells express various markers of neuronal differentiation associated with deficient activity of the neuron-restricted silencer factor (NRSF). Here, we characterize mechanisms by which NRSF target genes are upregulated in SCLC and their functional consequences for cell survival. Since the glycine receptor (GlyR) alpha1 subunit gene, GLRA1, contains a sequence motif for NRSF binding (NRSE) within its 5' UTR, it served as a cellular surrogate marker for NRSF activity. Expression of GLRA1 in nontransformed cells is largely restricted to cells in the spinal cord, retina and brain stem. In experiments described here, we detected GLRA1 transcripts in three out of four SCLC-derived cell lines and in three of five biopsy samples obtained from SCLCs. In contrast, no GLRA1 transcripts were found in 10 nonmalignant nor 15 non-small-cell lung cancer biopsies. Consistent with this observation, NRSF-mediated suppression of an expression construct harbouring the NRSE of the GLRA1 (GLRA1 NRSE) gene was impaired in three of four 'classic' SCLC cell lines, whereas exogenous overexpression of NRSF in NRSF-deficient SCLC cell lines reconstituted silencing of the reporter plasmid. The level of NRSF transcripts as well as the level of specifically bound NRSF to the NRSE correlated with the level of GLRA1 transcripts in SCLC cell lines. Splice variants encoding truncated NRSF proteins and expressed in some SCLC did not antagonize the repression of NRSE-containing genes. Most interestingly, reconstitution of NRSF expression induced apoptosis in SCLC cells, suggesting that inhibition of NRSF activity is a crucial step in the carcinogenesis of a subgroup of SCLC.	Heidelberg Univ, Inst Mol Pathol, D-69120 Heidelberg, Germany; Univ Erlangen Nurnberg, Emil Fischer Ctr, Inst Biochem, D-91054 Erlangen, Germany	Ruprecht Karls University Heidelberg; University of Erlangen Nuremberg	Doeberitz, MV (corresponding author), Heidelberg Univ, Inst Mol Pathol, Neuenheimer Feld 220, D-69120 Heidelberg, Germany.	knebel@med.uni-heidelberg.de		Dihlmann, Susanne/0000-0002-3737-7755; Gurrola-Diaz, Carmen Magdalena/0000-0002-9851-8961				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Betz H, 1999, ANN NY ACAD SCI, V868, P667, DOI 10.1111/j.1749-6632.1999.tb11343.x; Breitinger HG, 2002, CHEMBIOCHEM, V3, P1043, DOI 10.1002/1439-7633(20021104)3:11<1042::AID-CBIC1042>3.0.CO;2-7; CARNEY DN, 1985, CANCER RES, V45, P2913; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; Coulson JM, 1999, CANCER RES, V59, P5123; Coulson JM, 2000, CANCER RES, V60, P1840; ENZ R, 1995, VISUAL NEUROSCI, V12, P501, DOI 10.1017/S0952523800008403; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Heasley LE, 2001, ONCOGENE, V20, P1563, DOI 10.1038/sj.onc.1204183; Lawinger P, 2000, NAT MED, V6, P826, DOI 10.1038/77565; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; Magin A, 2002, NEUROCHEM INT, V40, P195, DOI 10.1016/S0197-0186(01)00091-2; Monani U, 1996, GENOME RES, V6, P1200, DOI 10.1101/gr.6.12.1200; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Palm K, 1999, MOL BRAIN RES, V72, P30, DOI 10.1016/S0169-328X(99)00196-5; Palm K, 1998, J NEUROSCI, V18, P1280; Pardo LA, 1999, EMBO J, V18, P5540, DOI 10.1093/emboj/18.20.5540; PARKIN DM, 1994, ANTICANCER RES, V14, P277; Quinn JP, 2002, REGUL PEPTIDES, V108, P135, DOI 10.1016/S0167-0115(02)00103-9; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; Schoenherr CJ, 1996, P NATL ACAD SCI USA, V93, P9881, DOI 10.1073/pnas.93.18.9881; Scholl T, 1996, J IMMUNOL, V156, P1448; Shimojo M, 1999, MOL CELL BIOL, V19, P6788; Shimojo M, 2001, J BIOL CHEM, V276, P13121, DOI 10.1074/jbc.M011193200	25	41	43	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2003	22	36					5636	5645		10.1038/sj.onc.1206790	http://dx.doi.org/10.1038/sj.onc.1206790			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944912				2022-12-25	WOS:000184865900013
J	Yang, G; Thompson, JA; Fang, BL; Liu, JS				Yang, G; Thompson, JA; Fang, BL; Liu, JS			Silencing of H-ras gene expression by retrovirus-mediated siRNA decreases transformation efficiency and tumorgrowth in a model of human ovarian cancer	ONCOGENE			English	Article						siRNA; H-ras; retrovirus; ovarian cancer	SMALL INTERFERING RNA; MAMMALIAN-CELLS; EPITHELIAL TUMORS; STABLE SUPPRESSION; HAIRPIN RNAS; MUTATIONS; ACTIVATION; PROTOONCOGENE; CARCINOMAS; ONCOGENES	To examine the role of H-ras in the development of human ovarian cancer, we used small inhibitory RNA (siRNA) to silence its expression in human ovarian cancer cell lines and assessed the effects of its silencing on proliferation, apoptosis, and tumorgrowth. First, we developed a retrovirus-based delivery system that allowed long-term stable expression of the desired siRNA. Retrovirus-mediated expression of siRNA against green fluorescence protein (GFP) reduced its expression more than 90% in four cancer cell lines. We then constructed three retroviruses that expressed siRNAs targeting the H-rasV(12) mutation (H1/siRNA) or either of two wild-type sequences of the H-ras gene (H2/siRNA and H3/siRNA) and used these retroviruses to infect T80H and SKOV-3 cells. In T80H cells (a genetically transformed human ovarian surface epithelial cell tine whose tumorigenicity depends on H-rasV(12) expression), infection with the H1/siRNA and H2/siRNA, but not with H3/siRNA, decreased T80H proliferation, increased G(0)/G(1) arrest and apoptosis, blocked transformation in vitro, and suppressed tumor growth in nude mice. In SKOV-3 cells (a human ovarian cancer cell line that contains high levels of wild-type H-ras protein but no H-rasV(12) mutation), introduction of the H2/siRNA construct, but not H1/siRNA or H3/siRNA, produced similar effects, demonstrating that the suppression of tumorgrowth by siRNA was sequence-specific. We conclude that H-ras is involved in maintenance of tumorgrowth of human ovarian cancer, and that retrovirus-mediated siRNA expression against H-Pas expression is a powerful toot to dissect ras-signaling pathways and may be used therapeutically against ovarian cancer.	Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Liu, JS (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Box 85,1515 Holcombe Blvd, Houston, TX 77030 USA.							ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Barton GM, 2002, P NATL ACAD SCI USA, V99, P14943, DOI 10.1073/pnas.242594499; BOS JL, 1987, BLOOD, V69, P1237; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BOS JL, 1989, CANCER RES, V49, P4682; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Cuatrecasas M, 1998, CANCER-AM CANCER SOC, V82, P1088; Cuatrecasas M, 1997, CANCER, V79, P1581, DOI 10.1002/(SICI)1097-0142(19970415)79:8<1581::AID-CNCR21>3.0.CO;2-T; Devroe Eric, 2002, BMC Biotechnol, V2, P15, DOI 10.1186/1472-6750-2-15; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; ENOMOTO T, 1991, AM J PATHOL, V139, P777; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; ICHIKAWA Y, 1994, CANCER RES, V54, P33; JACQUE JM, 2002, NATURE, V26, P26; LIU J, 2003, UNPUB; Liu JS, 2000, ONCOGENE, V19, P2767, DOI 10.1038/sj.onc.1203599; McCaffrey AP, 2002, NATURE, V418, P38, DOI 10.1038/418038a; Miyagishi M, 2002, NAT BIOTECHNOL, V20, P497, DOI 10.1038/nbt0502-497; MOK SCH, 1993, CANCER RES, V53, P1489; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Paddison PJ, 2002, CANCER CELL, V2, P17, DOI 10.1016/S1535-6108(02)00092-2; Paddison PJ, 2002, P NATL ACAD SCI USA, V99, P1443, DOI 10.1073/pnas.032652399; Patton SE, 1998, CANCER RES, V58, P2253; Paul CP, 2002, NAT BIOTECHNOL, V20, P505, DOI 10.1038/nbt0502-505; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Singer G, 2003, J NATL CANCER I, V95, P484, DOI 10.1093/jnci/95.6.484; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; TENERIELLO MG, 1993, CANCER RES, V53, P3103; Varras MN, 1999, ONCOLOGY-BASEL, V56, P89, DOI 10.1159/000011946; VISVANATHAN KV, 1988, ONCOGENE RES, V3, P77; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499	34	105	128	2	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2003	22	36					5694	5701		10.1038/sj.onc.1206858	http://dx.doi.org/10.1038/sj.onc.1206858			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944918				2022-12-25	WOS:000184865900019
J	Pan, W; Datta, A; Adami, GR; Raychaudhuri, P; Bagchi, S				Pan, W; Datta, A; Adami, GR; Raychaudhuri, P; Bagchi, S			P19ARF inhibits the functions of the HPV16 E7 oncoprotein	ONCOGENE			English	Article						ARF; HPV16 E7 oncoprotein; nucleolar localization; E7 relocalization; Rb proteolysis	HUMAN-PAPILLOMAVIRUS TYPE-16; E7 PROTEIN; DNA-REPLICATION; DIFFERENTIAL REGULATION; CARCINOMA-CELLS; GENE; P53; E2F; TRANSFORMATION; KERATINOCYTES	The E7 oncoprotein encoded by high-risk types of human papillomavirus (HPV) plays a significant role in the development of HPV-related cancers. E7 is a potent stimulator of S phase and host DNA replication. These functions of E7 are linked to the deregulation of the Rb family of proteins. For example, E7 binds and induces proteolysis of Rb through the ubiquitin-proteasome pathway. Despite advances in our understanding of E7, reagents that inhibit E7 with promise in therapy have not been developed or identified. Here, we provide evidence that the tumor suppressor ARF can inhibit E7. We show that the expression of ARF causes a relocalization of E7 from the nucleoplasm to the nucleolus. Two distinct regions in ARF overlapping with the MDM2-binding sites are necessary for the relocalization of E7. Furthermore, we show that ARF blocks the proteolysis of Rb induced by E7. In addition, ARF expression inhibits DNA replication induced by E7. Although it is not known whether the endogenous ARF, which is expressed at a low level, interferes with E7, our results suggest that ARF is an effective inhibitor of E7. We speculate that ARF or an ARF-derived molecule might have a significant impact in therapy against HPV-related tumors.	Univ Illinois, Coll Dent, Ctr Mol Biol Oral Dis, Chicago, IL 60612 USA; Univ Illinois, Dept Biochem & Mol Biol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Bagchi, S (corresponding author), Univ Illinois, Coll Dent, Ctr Mol Biol Oral Dis, M-C 860,801 S Paulina St, Chicago, IL 60612 USA.	sbagchi@uic.edu			NATIONAL CANCER INSTITUTE [R01CA076276] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012506] Funding Source: NIH RePORTER; NCI NIH HHS [CA76276] Funding Source: Medline; NIDCR NIH HHS [DE12506] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Berezutskaya E, 1997, CELL GROWTH DIFFER, V8, P1277; Berezutskaya E, 1997, J BIOL CHEM, V272, P30135, DOI 10.1074/jbc.272.48.30135; Bohl J, 2001, J VIROL, V75, P513, DOI 10.1128/JVI.75.1.513-521.2001; Boyer SN, 1996, CANCER RES, V56, P4620; CHANG FJ, 1991, J ORAL PATHOL MED, V20, P305, DOI 10.1111/j.1600-0714.1991.tb00936.x; CHENG S, 1995, GENE DEV, V9, P2335, DOI 10.1101/gad.9.19.2335; Datta A, 2002, MOL CELL BIOL, V22, P8398, DOI 10.1128/MCB.22.24.8398-8408.2002; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Flores ER, 2000, J VIROL, V74, P6622, DOI 10.1128/JVI.74.14.6622-6631.2000; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HICKMAN ES, 1994, ONCOGENE, V9, P2177; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Jian YC, 1999, CELL GROWTH DIFFER, V10, P101; Jiang M, 2002, ONCOGENE, V21, P6041, DOI 10.1038/sj.onc.1205878; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; LAIMINS LA, 1993, INFECT AGENT DIS, V2, P74; Lohrum MAE, 2000, CURR BIOL, V10, P539, DOI 10.1016/S0960-9822(00)00472-3; Martelli F, 2001, P NATL ACAD SCI USA, V98, P4455, DOI 10.1073/pnas.081061398; Morozov A, 1997, J VIROL, V71, P3451, DOI 10.1128/JVI.71.5.3451-3457.1997; MUNGER K, 1989, J VIROL, V63, P4417; NEVINS JR, 1992, SCIENCE, V258, P424; QUELLE DE, 1995, CELL, V83, P993; Ruesch MN, 1997, J VIROL, V71, P5570, DOI 10.1128/JVI.71.7.5570-5578.1997; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; SHILLITOE EJ, 1992, ANN NY ACAD SCI, V660, P286, DOI 10.1111/j.1749-6632.1992.tb21087.x; SHILLITOE EJ, 1994, CANCER GENE THER, V1, P193; STEELE C, 1992, CANCER RES, V52, P4706; Wang J, 2001, ONCOGENE, V20, P4740, DOI 10.1038/sj.onc.1204655; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Wettergreen MA, 2001, EUR J ORAL SCI, V109, P415, DOI 10.1034/j.1600-0722.2001.00105.x; Zatsepina O, 1997, ONCOGENE, V14, P1137, DOI 10.1038/sj.onc.1200946; ZURHAUSEN H, 1994, ANNU REV MICROBIOL, V48, P427, DOI 10.1146/annurev.micro.48.1.427	38	15	16	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2003	22	35					5496	5503		10.1038/sj.onc.1206857	http://dx.doi.org/10.1038/sj.onc.1206857			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JC	12934109				2022-12-25	WOS:000184735000014
J	Willis, AC; Pipes, T; Zhu, JH; Chen, XB				Willis, AC; Pipes, T; Zhu, JH; Chen, XB			p73 can suppress the proliferation of cells that express mutant p53	ONCOGENE			English	Article						p73; p53; p21; cell cycle arrest; apoptosis	INDUCIBLE GENE-EXPRESSION; MAMMALIAN-CELLS; DNA-DAMAGE; TUMOR-SUPPRESSOR; CODON-72 POLYMORPHISM; CYCLE ARREST; HEPATOCELLULAR-CARCINOMA; FUNCTIONAL DOMAINS; CHROMOSOME 1P36.3; COLORECTAL-CANCER	Mutation of the p53 tumor suppressor gene is the most common genetic alteration in human cancer. p73, a member of the p53 family, has been found to exhibit activity similar to that of p53, including the ability to induce growth arrest and apoptosis. p53 and p73 have a high percentage of similarity at several domains, including the DNA binding domain. This domain in p53 is the location of missense mutations in many human cancers. Mutant p53, which cannot suppress cell proliferation, has been found to have a dominant-negative activity that inactivates wild-type p53. To determine the effects of mutant p53 on wild-type p73, we have established cell lines expressing both mutant p53 and wild-type p73 in a dual-inducible system. This system expresses mutant p53 in a tetracycline-repressible system and p73beta in an ecdysone-inducible system in a p53-null lung carcinoma parental cell tine. We have found that wild-type p73beta, in the presence of mutant p53, retains the ability to transactivate p21 and suppresses cell growth through induction of both cell cycle arrest and apoptosis. In addition, in cell lines expressing wild-type p53 and wild-type p73beta, we have found that these proteins cooperate to additively transactivate p21 and suppress cell proliferation.	Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama, UAB Comprehens Canc Ctr, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Chen, XB (corresponding author), MCLM 660,1530 3rd Ave S, Birmingham, AL 35242 USA.			Amara, Amy/0000-0003-0762-9656	NATIONAL CANCER INSTITUTE [R01CA081237] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA81237] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Almog N, 1997, BBA-REV CANCER, V1333, pF1, DOI 10.1016/S0304-419X(97)00012-7; Brachmann RK, 1996, P NATL ACAD SCI USA, V93, P4091, DOI 10.1073/pnas.93.9.4091; Brunner HG, 2002, J MED GENET, V39, P377, DOI 10.1136/jmg.39.6.377; Calhoun ES, 2002, CLIN CHEM, V48, P1218; Celli J, 1999, CELL, V99, P143, DOI 10.1016/S0092-8674(00)81646-3; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Chen XB, 1999, MOL MED TODAY, V5, P387, DOI 10.1016/S1357-4310(99)01545-2; Chene P, 1998, J MOL BIOL, V281, P205, DOI 10.1006/jmbi.1998.1897; Chinery R, 1997, NAT MED, V3, P1233, DOI 10.1038/nm1197-1233; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; Davison TS, 1999, J BIOL CHEM, V274, P18709, DOI 10.1074/jbc.274.26.18709; De Laurenzi V, 2000, BIOCHEM BIOPH RES CO, V273, P342, DOI 10.1006/bbrc.2000.2932; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Dohn M, 2001, ONCOGENE, V20, P6503, DOI 10.1038/sj.onc.1204816; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Harvey DM, 1998, CURR OPIN CHEM BIOL, V2, P512; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kovalev S, 1998, CELL GROWTH DIFFER, V9, P897; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Levrero M, 2000, J CELL SCI, V113, P1661; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; McGregor JM, 2002, J INVEST DERMATOL, V119, P84, DOI 10.1046/j.1523-1747.2002.01655.x; Mihara M, 1999, BRIT J CANCER, V79, P164, DOI 10.1038/sj.bjc.6690027; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MIYASHITA T, 1995, CELL, V80, P293; Moll UM, 2001, BBA-REV CANCER, V1552, P47, DOI 10.1016/S0304-419X(01)00036-1; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Nicholls CD, 2002, J BIOL CHEM, V277, P12937, DOI 10.1074/jbc.M108815200; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; Nomoto S, 1998, CANCER RES, V58, P1380; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Robles AI, 2001, CANCER RES, V61, P6660; ROLLEY N, 1995, ONCOGENE, V11, P763; Rossi FMV, 1998, CURR OPIN BIOTECH, V9, P451, DOI 10.1016/S0958-1669(98)80028-1; Saez E, 1997, CURR OPIN BIOTECH, V8, P608, DOI 10.1016/S0958-1669(97)80037-7; Sambrook J., 2002, MOL CLONING LAB MANU; Saranath D, 2002, GYNECOL ONCOL, V86, P157, DOI 10.1006/gyno.2002.6735; Sasaki Y, 2001, GENE THER, V8, P1401, DOI 10.1038/sj.gt.3301538; Shinoura N, 2000, CANCER LETT, V160, P67, DOI 10.1016/S0304-3835(00)00564-4; Sifakis S, 2001, CLIN GENET, V60, P165, DOI 10.1034/j.1399-0004.2001.600301.x; Soulitzis N, 2002, CANCER LETT, V179, P175, DOI 10.1016/S0304-3835(01)00867-9; Storey A, 1998, NATURE, V393, P229, DOI 10.1038/30400; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Sunahara M, 1998, INT J ONCOL, V13, P319; Tannapfel A, 1999, J NATL CANCER I, V91, P1154, DOI 10.1093/jnci/91.13.1154; Toruner GA, 2001, UROL RES, V29, P393; VAN MEIR EG, 1994, NAT GENET, V8, P171, DOI 10.1038/ng1094-171; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yokomizo A, 1999, PROSTATE, V39, P94; Zhu JH, 2000, MOL CELL BIOL, V20, P5602, DOI 10.1128/MCB.20.15.5602-5618.2000; Zhu JH, 2000, J BIOL CHEM, V275, P39927, DOI 10.1074/jbc.M005676200; Zhu JH, 1998, CANCER RES, V58, P5061; Zhu KC, 1999, ONCOGENE, V18, P7740, DOI 10.1038/sj.onc.1203235	76	25	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 21	2003	22	35					5481	5495		10.1038/sj.onc.1206505	http://dx.doi.org/10.1038/sj.onc.1206505			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JC	12934108				2022-12-25	WOS:000184735000013
J	Guo, GL; Lambert, G; Negishi, M; Ward, JM; Brewer, HB; Kliewer, SA; Gonzalez, FJ; Sinal, CJ				Guo, GL; Lambert, G; Negishi, M; Ward, JM; Brewer, HB; Kliewer, SA; Gonzalez, FJ; Sinal, CJ			Complementary roles of farnesoid X receptor, pregnane X receptor, and constitutive androstane receptor in protection against bile acid toxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL INTRAHEPATIC CHOLESTASIS; NUCLEAR RECEPTOR; GENE-EXPRESSION; PROTEIN GENE; IDENTIFICATION; HOMEOSTASIS; CAR; DETOXIFICATION; TRANSCRIPTION; ACTIVATION	The nuclear receptors, farnesoid X receptor (FXR) and pregnane X receptor (PXR), are important in maintaining bile acid homeostasis. Deletion of both FXR and PXR in vivo by cross-breeding B6;129-Fxr(tm1Gonz) (FXR-null) and B6;129-Pxr(tm1Glaxo-Wellcome) (PXR-null) mice revealed a more severe disruption of bile acid, cholesterol, and lipid homeostasis in B6;129-Fxr(tm1Gonz) Pxr(tm1Glaxo-Wellcome) (FXR-PXR double null or FPXR-null) mice fed a 1% cholic acid (CA) diet. Hepatic expression of the constitutive androstane receptor (CAR) and its target genes was induced in FXR- and FPXR-null mice fed the CA diet. To test whether up-regulation of CAR represents a means of protection against bile acid toxicity to compensate for the loss of FXR and PXR, animals were pretreated with CAR activators, phenobarbital or 1,4- bis[2-(3,5-dichlorpyridyloxy)] benzene (TCPOBOP), followed by the CA diet. A role for CAR in protection against bile acid toxicity was confirmed by a marked reduction of serum bile acid and bilirubin concentrations, with an elevation of the expression of the hepatic genes involved in bile acid and/or bilirubin metabolism and excretion (CYP2B, CYP3A, MRP2, MRP3, UGT1A, and glutathione S-transferase alpha), following pretreatment with phenobarbital or TCPOBOP. In summary, the current study demonstrates a critical and combined role of FXR and PXR in maintaining not only bile acid but also cholesterol and lipid homeostasis in vivo. Furthermore, FXR, PXR, and CAR protect against hepatic bile acid toxicity in a complementary manner, suggesting that they serve as redundant but distinct layers of defense to prevent overt hepatic damage by bile acids during cholestasis.	NCI, Lab Metab, NIH, Bethesda, MD 20892 USA; INSERM, U539, F-44035 Nantes, France; NIEHS, Pharmacogenet Sect, Reprod & Dev Toxicol Lab, NIH, Res Triangle Pk, NC 27709 USA; NCI, Vet & Tumor Pathol Sect, Ctr Canc Res, Frederick, MD 21702 USA; NHLBI, Mol Dis Branch, NIH, Bethesda, MD 20892 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Institut National de la Sante et de la Recherche Medicale (Inserm); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gonzalez, FJ (corresponding author), NCI, Lab Metab, NIH, Bldg 37,Rm 2A19A,9000 Rockville Pike, Bethesda, MD 20892 USA.		Negishi, Masahiko/F-7805-2019	Negishi, Masahiko/0000-0002-2076-8928; Lambert, Gilles/0000-0001-5632-0685; Sinal, Christopher/0000-0001-8301-3349	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES080040, Z01ES080040, Z01ES071005] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BECKER M, 1984, EUR J PEDIATR, V143, P41, DOI 10.1007/BF00442746; BLOOMER JR, 1975, ANN INTERN MED, V82, P310, DOI 10.7326/0003-4819-82-3-310; CAPRON JP, 1975, DIGESTION, V12, P43, DOI 10.1159/000197653; CHEN CH, 1982, J LIPID RES, V23, P680; Elferink RO, 2002, BBA-MOL BASIS DIS, V1586, P129; Elferink RPJO, 1999, GASTROENTEROL CLIN N, V28, P59; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Grober J, 1999, J BIOL CHEM, V274, P29749, DOI 10.1074/jbc.274.42.29749; Guo GL, 2002, J PHARMACOL EXP THER, V300, P206, DOI 10.1124/jpet.300.1.206; HOFMANN AF, 1995, ITAL J GASTROENTEROL, V27, P106; Huang WD, 2003, P NATL ACAD SCI USA, V100, P4156, DOI 10.1073/pnas.0630614100; Kast HR, 2001, MOL ENDOCRINOL, V15, P1720, DOI 10.1210/me.15.10.1720; Lambert G, 2003, J BIOL CHEM, V278, P2563, DOI 10.1074/jbc.M209525200; Lambert G, 2000, J LIPID RES, V41, P667; Longo M, 2002, GUT, V51, P265, DOI 10.1136/gut.51.2.265; Maglich JM, 2002, MOL PHARMACOL, V62, P638, DOI 10.1124/mol.62.3.638; Makishima M, 2002, SCIENCE, V296, P1313, DOI 10.1126/science.1070477; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; MCINTYRE N, 1975, GUT, V16, P379, DOI 10.1136/gut.16.5.379; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Salen G, 1999, GASTROENTEROL CLIN N, V28, P173, DOI 10.1016/S0889-8553(05)70049-2; Schuetz EG, 2001, J BIOL CHEM, V276, P39411, DOI 10.1074/jbc.M106340200; SEOL WG, 1995, MOL ENDOCRINOL, V9, P72, DOI 10.1210/me.9.1.72; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; Sonoda J, 2002, P NATL ACAD SCI USA, V99, P13801, DOI 10.1073/pnas.212494599; Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698; Strautnieks SS, 1996, J MED GENET, V33, P833, DOI 10.1136/jmg.33.10.833; Strautnieks SS, 1997, AM J HUM GENET, V61, P630, DOI 10.1086/515501; Sueyoshi T, 2001, ANNU REV PHARMACOL, V41, P123, DOI 10.1146/annurev.pharmtox.41.1.123; Sugatani J, 2001, HEPATOLOGY, V33, P1232, DOI 10.1053/jhep.2001.24172; Urizar NL, 2000, J BIOL CHEM, V275, P39313, DOI 10.1074/jbc.M007998200; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Wang L, 2002, DEV CELL, V2, P721, DOI 10.1016/S1534-5807(02)00187-9; Xie W, 2003, P NATL ACAD SCI USA, V100, P4150, DOI 10.1073/pnas.0438010100; Xie W, 2000, GENE DEV, V14, P3014, DOI 10.1101/gad.846800; Xie W, 2001, P NATL ACAD SCI USA, V98, P3375, DOI 10.1073/pnas.051014398	37	235	241	2	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45062	45071		10.1074/jbc.M307145200	http://dx.doi.org/10.1074/jbc.M307145200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12923173	hybrid			2022-12-25	WOS:000186452300005
J	Johansson, K; Bourhis, JM; Campanacci, V; Cambillau, C; Canard, B; Longhi, S				Johansson, K; Bourhis, JM; Campanacci, V; Cambillau, C; Canard, B; Longhi, S			Crystal structure of the measles virus phosphoprotein domain responsible for the induced folding of the C-terminal domain of the nucleoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOCAPSID-LIKE STRUCTURES; P-PROTEIN; RNA-SYNTHESIS; PARAINFLUENZA VIRUS; GENOME REPLICATION; IN-VITRO; NP-P; BINDING; RECOGNITION; COMPLEX	Measles virus is a negative-sense, single-stranded RNA virus belonging to the Mononegavirales order which comprises several human pathogens such as Ebola, Nipah, and Hendra viruses. The phosphoprotein of measles virus is a modular protein consisting of an intrinsically disordered N-terminal domain (Karlin, D., Longhi, S., Receveur, V., and Canard, B. (2002) Virology 296, 251 - 262) and of a C-terminal moiety (PCT) composed of alternating disordered and globular regions. We report the crystal structure of the extreme C-terminal domain (XD) of measles virus phosphoprotein (aa 459 - 507) at 1.8 Angstrom resolution. We have previously reported that the C-terminal domain of measles virus nucleoprotein, N-TAIL, is intrinsically unstructured and undergoes induced folding in the presence of PCT ( Longhi, S., Receveur-Brechot, V., Karlin, D., Johansson, K., Darbon, H., Bhella, D., Yeo, R., Finet, S., and Canard, B. (2003) J. Biol. Chem. 278, 18638 - 18648). Using far-UV circular dichroism, we show that within PCT, XD is the region responsible for the induced folding of N-TAIL. The crystal structure of XD consists of three helices, arranged in an anti-parallel triple-helix bundle. The surface of XD formed between helices alpha2 and alpha3 displays a long hydrophobic cleft that might provide a complementary hydrophobic surface to embed and promote folding of the predicted alpha-helix of N-TAIL. We present a tentative model of the interaction between XD and N-TAIL. These results, beyond presenting the first measles virus protein structure, shed light both on the function of the phosphoprotein at the molecular level and on the process of induced folding.	CNRS, UMR Architecture & Fonct Macromol Biol 6098, ESIL, F-13288 Marseille 09, France; Univ Aix Marseille, F-13288 Marseille, France; Univ Aix Marseille, F-13402 Marseille, France; CNRS, UMR Architecture & Fonct Macromol Biol 6098, F-13402 Marseille 20, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Longhi, S (corresponding author), CNRS, UMR Architecture & Fonct Macromol Biol 6098, ESIL, Case 925,163 Av Luminy, F-13288 Marseille 09, France.		LONGHI, Sonia/M-5305-2014	LONGHI, Sonia/0000-0002-6829-6771; Canard, Bruno/0000-0003-4924-1991; Campanacci, Valerie/0000-0001-6407-6395				Bankamp B, 1996, VIROLOGY, V216, P272, DOI 10.1006/viro.1996.0060; Bhella D, 2002, J GEN VIROL, V83, P1831, DOI 10.1099/0022-1317-83-8-1831; BUCHHOLZ CJ, 1994, VIROLOGY, V204, P770, DOI 10.1006/viro.1994.1592; Coronel EC, 2001, J VIROL, V75, P1117, DOI 10.1128/JVI.75.3.1117-1123.2001; CURRAN J, 1991, EMBO J, V10, P3079, DOI 10.1002/j.1460-2075.1991.tb07860.x; Curran J, 1999, ADV VIRUS RES, V54, P403, DOI 10.1016/S0065-3527(08)60373-5; CURRAN J, 1995, J VIROL, V69, P849, DOI 10.1128/JVI.69.2.849-855.1995; CURRAN J, 1988, EMBO J, V7, P2869, DOI 10.1002/j.1460-2075.1988.tb03143.x; Curran J, 1998, J VIROL, V72, P4274, DOI 10.1128/JVI.72.5.4274-4280.1998; Curran J, 1996, VIROLOGY, V221, P130, DOI 10.1006/viro.1996.0359; CURRAN J, 1994, VIROLOGY, V202, P875, DOI 10.1006/viro.1994.1409; CURRAN J, 1995, VIROLOGY, V214, P139, DOI 10.1006/viro.1995.9946; Dauter Z, 2002, ACTA CRYSTALLOGR D, V58, P494, DOI 10.1107/S090744490200118X; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; FOOKS AR, 1993, J GEN VIROL, V74, P1439, DOI 10.1099/0022-1317-74-7-1439; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HARTY RN, 1995, J GEN VIROL, V76, P2863, DOI 10.1099/0022-1317-76-11-2863; HEGGENESS MH, 1981, VIROLOGY, V114, P555, DOI 10.1016/0042-6822(81)90235-X; HEGGENESS MH, 1980, P NATL ACAD SCI-BIOL, V77, P2631, DOI 10.1073/pnas.77.5.2631; Hogbom M, 2003, P NATL ACAD SCI USA, V100, P3191, DOI 10.1073/pnas.0436100100; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HORIKAMI SM, 1992, J VIROL, V66, P4901, DOI 10.1128/JVI.66.8.4901-4908.1992; HUBER M, 1991, VIROLOGY, V185, P299, DOI 10.1016/0042-6822(91)90777-9; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Karlin D, 2002, VIROLOGY, V302, P420, DOI 10.1006/viro.2002.1634; Karlin D, 2002, VIROLOGY, V296, P251, DOI 10.1006/viro.2001.1296; KARLIN D, 2003, IN PRESS J GEN VIROL, V84; Kleywegt GJ, 1996, STRUCTURE, V4, P1395, DOI 10.1016/S0969-2126(96)00147-5; LAMB R., 2001, FIELDS VIROLOGY, V1, P1305; Liston P, 1997, ARCH VIROL, V142, P305, DOI 10.1007/s007050050078; LISTON P, 1995, VIRUS RES, V38, P241, DOI 10.1016/0168-1702(95)00067-Z; Lo Conte L, 1999, J MOL BIOL, V285, P2177; Longhi S, 2003, J BIOL CHEM, V278, P18638, DOI 10.1074/jbc.M300518200; Marion D, 2001, J BIOMOL NMR, V21, P75, DOI 10.1023/A:1011990021282; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; Morris MC, 1999, J PEPT SCI, V5, P263, DOI 10.1002/(SICI)1099-1387(199906)5:6<263::AID-PSC191>3.3.CO;2-1; Morris RJ, 2002, ACTA CRYSTALLOGR D, V58, P968, DOI 10.1107/S0907444902005462; Nishio M, 1996, J GEN VIROL, V77, P2457, DOI 10.1099/0022-1317-77-10-2457; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; PRECIOUS B, 1995, J VIROL, V69, P8001, DOI 10.1128/JVI.69.12.8001-8010.1995; Rost B, 1996, METHOD ENZYMOL, V266, P525; RYAN KW, 1990, VIROLOGY, V174, P515, DOI 10.1016/0042-6822(90)90105-Z; SMALLWOOD S, 1994, VIROLOGY, V202, P154, DOI 10.1006/viro.1994.1331; Spehner D, 1997, VIROLOGY, V232, P260, DOI 10.1006/viro.1997.8568; SPEHNER D, 1991, J VIROL, V65, P6296, DOI 10.1128/JVI.65.11.6296-6300.1991; Sulzenbacher G, 2002, ACTA CRYSTALLOGR D, V58, P2109, DOI 10.1107/S0907444902013938; Tarbouriech N, 2000, NAT STRUCT BIOL, V7, P777; Terwilliger TC, 2001, ACTA CRYSTALLOGR D, V57, P1755, DOI 10.1107/S0907444901013737; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Turnbull AP, 2001, STRUCTURE, V9, P347, DOI 10.1016/S0969-2126(01)00595-0; VANGUNSTEREN WF, 1995, COMPUT PHYS COMMUN, V91, P305, DOI 10.1016/0010-4655(95)00055-K; Wahlberg E, 2003, P NATL ACAD SCI USA, V100, P3185, DOI 10.1073/pnas.0436086100; WARNES A, 1995, GENE, V160, P173, DOI 10.1016/0378-1119(95)00227-W; Zhang XS, 2002, J VIROL, V76, P8737, DOI 10.1128/JVI.76.17.8737-8746.2002	56	133	144	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44567	44573		10.1074/jbc.M308745200	http://dx.doi.org/10.1074/jbc.M308745200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12944395	hybrid			2022-12-25	WOS:000186306700086
J	Orlandini, M; Semboloni, S; Oliviero, S				Orlandini, M; Semboloni, S; Oliviero, S			beta-catenin inversely regulates vascular endothelial growth factor-D mRNA stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VEGF-D; TRANSCRIPTIONAL ACTIVATION; COLORECTAL-CANCER; FACTOR FAMILY; DISEASE PROGRESSION; PERMEABILITY FACTOR; SIGNALING PATHWAY; FACTOR EXPRESSION; TYROSINE KINASES; FACTOR GENE	The angiogenic and lymphangiogenic vascular endothelial growth factor (VEGF)-D is the only member of the VEGF family that is not induced by hypoxia or by serum factors, but its induction is mediated by direct cell-cell contact. Here we show that VEGF-D mRNA is down-modulated either by beta-catenin mobilization from the cell membrane, by activation of the Wnt signaling pathway, or by transfection with the beta-catenin stable mutant. Down-modulation of beta-catenin by means of RNA interference showed an increase of VEGF-D mRNA steady state in fibroblasts. The beta-catenin-dependent decrease of VEGF-D mRNA is indirect and mainly due to reduced VEGF- D mRNA stability, as demonstrated by experiments of mRNA decay in the presence of transcription or translation inhibitors. By transient transfection of chimeric constructs carrying fusion of VEGF- D sequences under the control of the cytomegalovirus early promoter, we demonstrated that beta-catenin negative regulation is on the VEGF- D mRNA 3'-untranslated region. We mapped the VEGF- D mRNA-destabilizing element to a sequence, conserved between mouse and human VEGF- D, which contains an AU-rich element of group I. These results unveiled a new regulatory pathway for VEGF- D, which explains, at least in part, VEGF- D regulation in tumor progression.	Univ Siena, Dipartimento Biol Mol, I-53100 Siena, Italy	University of Siena	Oliviero, S (corresponding author), Univ Siena, Dipartimento Biol Mol, Via Fiorentina 1, I-53100 Siena, Italy.		Orlandini, Maurizio/AAF-8247-2020; oliviero, salvatore/R-6657-2019	Orlandini, Maurizio/0000-0002-6112-4889; oliviero, salvatore/0000-0002-3405-765X				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Avantaggiato V, 1998, MECH DEVELOP, V73, P221, DOI 10.1016/S0925-4773(98)00049-5; Bankfalvi A, 2002, J PATHOL, V198, P343, DOI 10.1002/path.1204; Barker N, 2000, ADV CANCER RES, V77, P1; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; Bienz M, 2003, NAT CELL BIOL, V5, P179, DOI 10.1038/ncb0303-179; Bright-Thomas RM, 2003, EUR J SURG ONCOL, V29, P107, DOI 10.1053/ejso.2002.1331; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Chan SK, 2002, CELL, V111, P265, DOI 10.1016/S0092-8674(02)01037-1; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHOEN T, 1996, J BIOL CHEM, V271, P736; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Easwaran V, 2003, CANCER RES, V63, P3145; Enholm B, 1997, ONCOGENE, V14, P2475, DOI 10.1038/sj.onc.1201090; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; George ML, 2001, NEOPLASIA, V3, P420, DOI 10.1038/sj.neo.7900186; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Goruppi S, 2001, MOL CELL BIOL, V21, P902, DOI 10.1128/MCB.21.3.902-915.2001; Grimmond S, 1996, GENOME RES, V6, P124, DOI 10.1101/gr.6.2.124; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Henderson BR, 2002, EMBO REP, V3, P834, DOI 10.1093/embo-reports/kvf181; Huelsken J, 2002, J CELL SCI, V115, P3977, DOI 10.1242/jcs.00089; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; Ishikawa M, 2003, JPN J CLIN ONCOL, V33, P21, DOI 10.1093/jjco/hyg008; Jenkins NA, 1997, CHROMOSOME RES, V5, P502; Joukov V, 1996, EMBO J, V15, P290; Kageshita T, 2001, BRIT J DERMATOL, V145, P210, DOI 10.1046/j.1365-2133.2001.04336.x; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kurebayashi J, 1999, JPN J CANCER RES, V90, P977, DOI 10.1111/j.1349-7006.1999.tb00844.x; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; LI J, 1995, J BIOL CHEM, V270, P308, DOI 10.1074/jbc.270.1.308; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; Marikawa Y, 1998, MECH DEVELOP, V77, P75, DOI 10.1016/S0925-4773(98)00134-8; MINCHENKO A, 1994, LAB INVEST, V71, P374; Nakamura Y, 2003, CLIN CANCER RES, V9, P716; Nicosia RF, 1998, AM J PATHOL, V153, P11, DOI 10.1016/S0002-9440(10)65539-3; Niki T, 2000, CLIN CANCER RES, V6, P2431; O-charoenrat P, 2001, CANCER-AM CANCER SOC, V92, P556, DOI 10.1002/1097-0142(20010801)92:3<556::AID-CNCR1355>3.0.CO;2-Q; Ogawa S, 1998, J BIOL CHEM, V273, P31273, DOI 10.1074/jbc.273.47.31273; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; Orlandini M, 1996, P NATL ACAD SCI USA, V93, P11675, DOI 10.1073/pnas.93.21.11675; Orlandini M, 2001, J BIOL CHEM, V276, P6576, DOI 10.1074/jbc.M009573200; Osborne JE, 2002, BRIT J DERMATOL, V146, P1104, DOI 10.1046/j.1365-2133.2002.47322.x; PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271; Pokutta S, 2002, CURR OPIN STRUC BIOL, V12, P255, DOI 10.1016/S0959-440X(02)00318-4; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Ristimaki A, 1998, J BIOL CHEM, V273, P8413, DOI 10.1074/jbc.273.14.8413; Rocchigiani M, 1998, GENOMICS, V47, P207, DOI 10.1006/geno.1997.5079; Semplici F, 2002, ONCOGENE, V21, P3978, DOI 10.1038/sj.onc.1205574; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; Stacker SA, 2001, NAT MED, V7, P186, DOI 10.1038/84635; Stacker SA, 2002, NAT REV CANCER, V2, P573, DOI 10.1038/nrc863; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; White JD, 2002, CANCER RES, V62, P1669; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; Yamada Y, 1997, GENOMICS, V42, P483, DOI 10.1006/geno.1997.4774; Yokoyama Y, 2003, BRIT J CANCER, V88, P237, DOI 10.1038/sj.bjc.6600701; Young CS, 1998, MOL CELL BIOL, V18, P2474, DOI 10.1128/MCB.18.5.2474	64	32	33	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44650	44656		10.1074/jbc.M304255200	http://dx.doi.org/10.1074/jbc.M304255200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12920128	hybrid, Green Published			2022-12-25	WOS:000186306700097
J	Bezzi, M; Hasmim, M; Bieler, G; Dormond, O; Ruegg, C				Bezzi, M; Hasmim, M; Bieler, G; Dormond, O; Ruegg, C			Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death - Evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NITROGEN-CONTAINING BISPHOSPHONATES; BREAST-CANCER CELLS; FARNESYL DIPHOSPHATE SYNTHASE; TYROSINE-PHOSPHATASE SHP-2; IN-VITRO; BONE-RESORPTION; MEVALONATE PATHWAY; INDUCED APOPTOSIS; TNF-ALPHA	Bisphosphonates are potent inhibitors of osteoclast function widely used to treat conditions of excessive bone resorption, including tumor bone metastases. Recent evidence indicates that bisphosphonates have direct cytotoxic activity on tumor cells and suppress angiogenesis, but the associated molecular events have not been fully characterized. In this study we investigated the effects of zoledronate, a nitrogen-containing bisphosphonate, and clodronate, a non-nitrogen-containing bisphosphonate, on human umbilical vein endothelial cell (HUVEC) adhesion, migration, and survival, three events essential for angiogenesis. Zoledronate inhibited HUVEC adhesion mediated by integrin alpha(V)beta(3), but not alpha(5)beta(1), blocked migration and disrupted established focal adhesions and actin stress fibers without modifying cell surface integrin expression level or affinity. Zoledronate treatment slightly decreased HUVEC viability and strongly enhanced tumor necrosis factor (TNF)-induced cell death. HUVEC treated with zoledronate and TNF died without evidence of enhanced annexin-V binding, chromatin condensation, or nuclear fragmentation and caspase dependence. Zoledronate inhibited sustained phosphorylation of focal adhesion kinase (FAK) and in combination with TNF, with and without interferon (IFN) gamma, of protein kinase B (PKB/Akt). Constitutive active PKB/Akt protected HUVEC from death induced by zoledronate and TNF/IFNgamma. Phosphorylation of c-Src and activation of NF-kappaB were not affected by zoledronate. Clodronate had no effect on HUVEC adhesion, migration, and survival nor did it enhanced TNF cytotoxicity. Taken together these data demonstrate that zoledronate sensitizes endothelial cells to TNF-induced, caspase-independent programmed cell death and point to the FAK-PKB/Akt pathway as a novel zoledronate target. These results have potential implications to the clinical use of zoledronate as an anti-angiogenic or anti-cancer agent.	Swiss Inst Expt Canc Res, Lab Ctr Pluridisciplinaire Oncol, Natl Ctr Competence Res Mol Oncol, CH-1066 Epalinges, Switzerland; Univ Lausanne, Sch Med, Ctr Pluridisciplinaire Oncol, CH-1011 Lausanne, Switzerland	Swiss Institute Experimental Cancer Research; University of Lausanne	Ruegg, C (corresponding author), Swiss Inst Expt Canc Res, Lab Ctr Pluridisciplinaire Oncol, Natl Ctr Competence Res Mol Oncol, 155 Chemin Boveresses, CH-1066 Epalinges, Switzerland.	curzio.ruegg@isrec.unil.ch	Dormond, Olivier/B-5347-2017	Dormond, Olivier/0000-0002-6418-1782; Hasmim, Meriem/0000-0002-7920-2443				Abbi S, 2002, HISTOL HISTOPATHOL, V17, P1163, DOI 10.14670/HH-17.1163; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; Bartholomew PJ, 1998, J STEROID BIOCHEM, V67, P241, DOI 10.1016/S0960-0760(98)00098-3; Benford HL, 2001, BONE, V28, P465, DOI 10.1016/S8756-3282(01)00412-4; Bergstrom JD, 2000, ARCH BIOCHEM BIOPHYS, V373, P231, DOI 10.1006/abbi.1999.1502; Boissier S, 1997, CANCER RES, V57, P3890; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Brown DL, 1999, J CLIN PHARMACOL, V39, P651, DOI 10.1177/00912709922008272; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Chan PC, 1999, J BIOL CHEM, V274, P26901, DOI 10.1074/jbc.274.38.26901; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; DEALTRY GB, 1987, EUR J IMMUNOL, V17, P689, DOI 10.1002/eji.1830170517; Dormond O, 2001, NAT MED, V7, P1041, DOI 10.1038/nm0901-1041; Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235; Eliceiri BP, 2000, CANCER J, V6, pS245; Fang Y, 2001, EUR J BIOCHEM, V268, P4513, DOI 10.1046/j.1432-1327.2001.02376.x; Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80; Fleisch H, 2002, BREAST CANCER RES, V4, P30, DOI 10.1186/bcr414; Fournier P, 2002, CANCER RES, V62, P6538; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; Fromigue O, 2000, J BONE MINER RES, V15, P2211, DOI 10.1359/jbmr.2000.15.11.2211; Green JR, 2003, CANCER, V97, P840, DOI 10.1002/cncr.11128; Green JR, 2002, CURR OPIN ONCOL, V14, P609, DOI 10.1097/00001622-200211000-00004; Gupta S, 2002, J CLIN IMMUNOL, V22, P185, DOI 10.1023/A:1016089607548; Guvakova MA, 1999, EXP CELL RES, V251, P244, DOI 10.1006/excr.1999.4566; Hartman GD, 2000, EXPERT OPIN INV DRUG, V9, P1281, DOI 10.1517/13543784.9.6.1281; Hermann C, 2000, ARTERIOSCL THROM VAS, V20, P402, DOI 10.1161/01.ATV.20.2.402; Hiraga T, 2001, CANCER RES, V61, P4418; Honda O, 2000, INT J ONCOL, V16, P283; Hughes PE, 1998, TRENDS CELL BIOL, V8, P359, DOI 10.1016/S0962-8924(98)01339-7; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Hynes RO, 1999, THROMB HAEMOSTASIS, V82, P481; Jagdev SP, 2001, BRIT J CANCER, V84, P1126, DOI 10.1054/bjoc.2001.1727; Kabir J, 2002, BIOCHEM J, V367, P145, DOI 10.1042/BJ20020665; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Kasahara T, 2002, ANTIOXID REDOX SIGN, V4, P491, DOI 10.1089/15230860260196290; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kuroda J, 2003, BLOOD, V102, P2229, DOI 10.1182/blood-2003-01-0305; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; LASTER SM, 1988, J IMMUNOL, V141, P2629; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Lejeune FJ, 1998, CURR OPIN IMMUNOL, V10, P573, DOI 10.1016/S0952-7915(98)80226-4; Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581; Luckman SP, 1998, J BONE MINER RES, V13, P1668, DOI 10.1359/jbmr.1998.13.11.1668; Luque A, 1996, J BIOL CHEM, V271, P11067, DOI 10.1074/jbc.271.19.11067; Madge LA, 2000, J BIOL CHEM, V275, P15458, DOI 10.1074/jbc.M001237200; Magnetto S, 1999, INT J CANCER, V83, P263, DOI 10.1002/(SICI)1097-0215(19991008)83:2<263::AID-IJC19>3.0.CO;2-T; Manes S, 1999, MOL CELL BIOL, V19, P3125; Mariotti A, 2001, J CELL BIOL, V155, P447, DOI 10.1083/jcb.200105017; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Neville-Webbe HL, 2002, CANCER TREAT REV, V28, P305, DOI 10.1016/S0305-7372(02)00095-6; Oades GM, 2003, J UROLOGY, V170, P246, DOI 10.1097/01.ju.0000070685.34760.5f; Ouwens DM, 1996, BIOCHEM J, V318, P609, DOI 10.1042/bj3180609; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; PILLAY TS, 1995, J BIOL CHEM, V270, P991, DOI 10.1074/jbc.270.3.991; Reynolds LE, 2002, NAT MED, V8, P27, DOI 10.1038/nm0102-27; Riebeling C, 2002, BRIT J CANCER, V87, P366, DOI 10.1038/sj.bjc.6600476; Rodan GA, 1998, ANNU REV PHARMACOL, V38, P375, DOI 10.1146/annurev.pharmtox.38.1.375; Rogers Michael J., 2000, Cancer, V88, P2961, DOI 10.1002/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.3.CO;2-C; Rogers MJ, 1996, BIOCHEM BIOPH RES CO, V224, P863, DOI 10.1006/bbrc.1996.1113; Rogers MJ, 1997, CANCER, V80, P1652, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1652::AID-CNCR15>3.0.CO;2-Z; Ruegg C, 2003, CELL MOL LIFE SCI, V60, P1135, DOI 10.1007/s00018-003-2297-3; Ruegg C, 1998, NAT MED, V4, P408, DOI 10.1038/nm0498-408; Sawada K, 2002, CANCER RES, V62, P6015; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; Senaratne SG, 2002, BRIT J CANCER, V86, P1479, DOI 10.1038/sj.bjc.6600297; Shipman CM, 1998, CANCER RES, V58, P5294; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Tassone P, 2000, LEUKEMIA, V14, P841, DOI 10.1038/sj.leu.2401770; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Teitelbaum SL, 2000, J BONE MINER METAB, V18, P344, DOI 10.1007/s007740070007; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; VAN AD, 1996, SCIENCE, V274, P787; van Beek E, 1999, BIOCHEM BIOPH RES CO, V255, P491, DOI 10.1006/bbrc.1999.0224; van de Water B, 1999, J BIOL CHEM, V274, P13328, DOI 10.1074/jbc.274.19.13328; vanderPluijm G, 1996, J CLIN INVEST, V98, P698, DOI 10.1172/JCI118841; Varner JA, 1996, CURR OPIN CELL BIOL, V8, P724, DOI 10.1016/S0955-0674(96)80115-3; Viereck V, 2002, BIOCHEM BIOPH RES CO, V291, P680, DOI 10.1006/bbrc.2002.6510; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Webb DJ, 2002, NAT CELL BIOL, V4, pE97, DOI 10.1038/ncb0402-e97; Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yilmaz A, 1998, INT J CANCER, V77, P592; You ZB, 2001, J BIOL CHEM, V276, P26398, DOI 10.1074/jbc.M102464200; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; Zhang L, 2001, CELL DEATH DIFFER, V8, P528, DOI 10.1038/sj.cdd.4400838	90	129	131	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43603	43614		10.1074/jbc.M308114200	http://dx.doi.org/10.1074/jbc.M308114200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12933798	hybrid			2022-12-25	WOS:000186157000108
J	Goldberg, MS; Fleming, SM; Palacino, JJ; Cepeda, C; Lam, HA; Bhatnagar, A; Meloni, EG; Wu, NP; Ackerson, LC; Klapstein, GJ; Gajendiran, M; Roth, BL; Chesselet, MF; Maidment, NT; Levine, MS; Shen, J				Goldberg, MS; Fleming, SM; Palacino, JJ; Cepeda, C; Lam, HA; Bhatnagar, A; Meloni, EG; Wu, NP; Ackerson, LC; Klapstein, GJ; Gajendiran, M; Roth, BL; Chesselet, MF; Maidment, NT; Levine, MS; Shen, J			Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECESSIVE JUVENILE PARKINSONISM; UBIQUITIN-PROTEIN LIGASE; HUMAN ALPHA-SYNUCLEIN; BODY FORMATION; HUMAN BRAIN; GENE; DISEASE; MUTATIONS; SENSORIMOTOR; FAMILIES	Loss-of-function mutations in parkin are the major cause of early-onset familial Parkinson's disease. To investigate the pathogenic mechanism by which loss of parkin function causes Parkinson's disease, we generated a mouse model bearing a germline disruption in parkin. Parkin-/- mice are viable and exhibit grossly normal brain morphology. Quantitative in vivo microdialysis revealed an increase in extracellular dopamine concentration in the striatum of parkin-/- mice. Intracellular recordings of medium-sized striatal spiny neurons showed that greater currents are required to induce synaptic responses, suggesting a reduction in synaptic excitability in the absence of parkin. Furthermore, parkin-/- mice exhibit deficits in behavioral paradigms sensitive to dysfunction of the nigrostriatal pathway. The number of dopaminergic neurons in the substantia nigra of parkin-/- mice, however, is normal up to the age of 24 months, in contrast to the substantial loss of nigral neurons characteristic of Parkinson's disease. Steady-state levels of CDCrel-1, synphilin-1, and alpha-synuclein, which were identified previously as substrates of the E3 ubiquitin ligase activity of parkin, are unaltered in parkin-/- brains. Together these findings provide the first evidence for a novel role of parkin in dopamine regulation and nigrostriatal function, and a non-essential role of parkin in the survival of nigral neurons in mice.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA; Univ Calif Los Angeles, Mental Retardat Res Ctr, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Psychiat, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Neurosci, Cleveland, OH 44106 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Shen, J (corresponding author), Harvard Inst Med, Ctr Neurol Dis, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	jshen@rics.bwh.harvard.edu	Goldberg, Matthew/T-7827-2019; Roth, Bryan/ABE-7032-2020; Klapstein, Gloria J/AAQ-8614-2020; Shen, Jie/GXH-9449-2022; Roth, Bryan L/F-3928-2010	Roth, Bryan/0000-0002-0561-6520; Goldberg, Matthew/0000-0002-5172-9841				Abbas N, 1999, HUM MOL GENET, V8, P567, DOI 10.1093/hmg/8.4.567; Asakawa S, 2001, BIOCHEM BIOPH RES CO, V286, P863, DOI 10.1006/bbrc.2001.5490; Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; CALABRESI P, 1987, NEUROSCIENCE, V20, P757, DOI 10.1016/0306-4522(87)90239-9; Cepeda C, 2001, J NEUROPHYSIOL, V85, P659, DOI 10.1152/jn.2001.85.2.659; Chung KKK, 2001, NAT MED, V7, P1144, DOI 10.1038/nm1001-1144; Corti O, 2003, HUM MOL GENET, V12, P1427, DOI 10.1093/hmg/ddg159; Cosford RJO, 1996, J NEUROSCI METH, V68, P39, DOI 10.1016/0165-0270(96)00057-X; Dluzen DE, 2001, EXP NEUROL, V170, P121, DOI 10.1006/exnr.2001.7698; DRUCKERCOLIN R, 1991, J NEUROSCI METH, V39, P153, DOI 10.1016/0165-0270(91)90081-A; DUNHAM NW, 1957, J AM PHARM ASSOC, V46, P208, DOI 10.1002/jps.3030460322; FAHN S, 1992, ANN NEUROL, V32, P804, DOI 10.1002/ana.410320616; Fallon L, 2002, J BIOL CHEM, V277, P486, DOI 10.1074/jbc.M109806200; Farrer M, 2001, ANN NEUROL, V50, P293, DOI 10.1002/ana.1132; Finney N, 2003, J BIOL CHEM, V278, P16054, DOI 10.1074/jbc.C300051200; GARCIAHERNANDEZ F, 1993, PHYSIOL BEHAV, V54, P589, DOI 10.1016/0031-9384(93)90254-D; Giasson BI, 2002, NEURON, V34, P521, DOI 10.1016/S0896-6273(02)00682-7; Greene JC, 2003, P NATL ACAD SCI USA, V100, P4078, DOI 10.1073/pnas.0737556100; HADI AS, 1992, J ROY STAT SOC B MET, V54, P761; Hattori N, 1998, ANN NEUROL, V44, P935, DOI 10.1002/ana.410440612; Hayashi S, 2000, MOVEMENT DISORD, V15, P884, DOI 10.1002/1531-8257(200009)15:5<884::AID-MDS1019>3.0.CO;2-8; Hock B J Jr, 2001, Trends Genet, V17, pS7, DOI 10.1016/S0168-9525(01)02449-0; Imai Y, 2000, J BIOL CHEM, V275, P35661, DOI 10.1074/jbc.C000447200; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kitada T, 2000, NEUROGENETICS, V2, P207, DOI 10.1007/s100489900083; Kitada T, 2000, MAMM GENOME, V11, P417, DOI 10.1007/s003350010080; Klapstein GJ, 2001, J NEUROPHYSIOL, V86, P2667, DOI 10.1152/jn.2001.86.6.2667; Klein C, 2000, ANN NEUROL, V48, P65, DOI 10.1002/1531-8249(200007)48:1<65::AID-ANA10>3.0.CO;2-L; Kosel S, 1999, BIOL CHEM, V380, P865, DOI 10.1515/BC.1999.106; Kozak M, 2001, NUCLEIC ACIDS RES, V29, P5226, DOI 10.1093/nar/29.24.5226; Lee MK, 2002, P NATL ACAD SCI USA, V99, P8968, DOI 10.1073/pnas.132197599; Levine MS, 1996, SYNAPSE, V24, P65, DOI 10.1002/syn.890240102; LJUNGBERG T, 1976, EXP NEUROL, V53, P585, DOI 10.1016/0014-4886(76)90140-0; Lucking CB, 2000, NEW ENGL J MED, V342, P1560, DOI 10.1056/NEJM200005253422103; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Menalled LB, 2002, TRENDS PHARMACOL SCI, V23, P32, DOI 10.1016/S0165-6147(00)01884-8; Mori H, 1998, NEUROLOGY, V51, P890, DOI 10.1212/WNL.51.3.890; Murphy NP, 2001, J NEUROCHEM, V79, P626, DOI 10.1046/j.1471-4159.2001.00599.x; PARSONS LH, 1994, CRIT REV NEUROBIOL, V8, P189; Petrucelli L, 2002, NEURON, V36, P1007, DOI 10.1016/S0896-6273(02)01125-X; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Ren Y, 2003, J NEUROSCI, V23, P3316; Richfield EK, 2002, EXP NEUROL, V175, P35, DOI 10.1006/exnr.2002.7882; ROTH BL, 1987, J NEUROCHEM, V49, P1833, DOI 10.1111/j.1471-4159.1987.tb02444.x; Roth BL, 2002, P NATL ACAD SCI USA, V99, P11934, DOI 10.1073/pnas.182234399; SCHALLERT T, 1988, ANN NY ACAD SCI, V515, P108, DOI 10.1111/j.1749-6632.1988.tb32972.x; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; SCHALLERT T, 1983, PHARMACOL BIOCHEM BE, V18, P753, DOI 10.1016/0091-3057(83)90019-9; SCHALLERT T, 1982, PHARMACOL BIOCHEM BE, V16, P455, DOI 10.1016/0091-3057(82)90452-X; Schallert T, 2000, CONT NEUROS, P131; Shapiro DA, 2003, NEUROPSYCHOPHARMACOL, V28, P1400, DOI 10.1038/sj.npp.1300203; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Shimura H, 1999, ANN NEUROL, V45, P668, DOI 10.1002/1531-8249(199905)45:5<668::AID-ANA19>3.0.CO;2-Z; Solano SM, 2000, ANN NEUROL, V47, P201, DOI 10.1002/1531-8249(200002)47:2<201::AID-ANA10>3.0.CO;2-F; Staropoli JF, 2003, NEURON, V37, P735, DOI 10.1016/S0896-6273(03)00084-9; STERIO DC, 1984, J MICROSC-OXFORD, V134, P127, DOI 10.1111/j.1365-2818.1984.tb02501.x; TAKAHASHI H, 1994, NEUROLOGY, V44, P437, DOI 10.1212/WNL.44.3_Part_1.437; TANNER CM, 1990, NEUROLOGY, V40, P17; van de Warrenburg BPC, 2001, NEUROLOGY, V56, P555, DOI 10.1212/WNL.56.4.555; van der Putten H, 2000, J NEUROSCI, V20, P6021, DOI 10.1523/JNEUROSCI.20-16-06021.2000; WALSH SL, 1992, J PHARMACOL EXP THER, V263, P617; West A, 2002, AM J MED GENET, V114, P584, DOI 10.1002/ajmg.10525; Yang YF, 2003, NEURON, V37, P911, DOI 10.1016/S0896-6273(03)00143-0; Yu HK, 2000, GENESIS, V26, P5, DOI 10.1002/(SICI)1526-968X(200001)26:1<5::AID-GENE3>3.0.CO;2-8; Yu HK, 2001, NEURON, V31, P713, DOI 10.1016/S0896-6273(01)00417-2; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797	68	661	678	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43628	43635		10.1074/jbc.M308947200	http://dx.doi.org/10.1074/jbc.M308947200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12930822	Green Published, hybrid			2022-12-25	WOS:000186157000111
J	Higashi, K; Inagaki, Y; Fujimori, K; Nakao, A; Kaneko, H; Nakatsuka, I				Higashi, K; Inagaki, Y; Fujimori, K; Nakao, A; Kaneko, H; Nakatsuka, I			Interferon-gamma interferes with transforming growth factor-beta signaling through direct interaction of YB-1 with Smad3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN GENE-EXPRESSION; BOX-BINDING-PROTEIN; HUMAN SKIN FIBROBLASTS; MEDIATES TRANSCRIPTIONAL REPRESSION; NECROSIS-FACTOR-ALPHA; TGF-BETA; MESSENGER-RNA; INHIBITION; ELEMENT; STIMULATION	Transforming growth factor-beta (TGF-beta) and interferon-gamma ( IFN-gamma) exert antagonistic effects on collagen synthesis in human dermal fibroblasts. We have recently shown that Y box-binding protein YB-1 mediates the inhibitory effects of IFN-gamma on alpha2(I) procollagen gene (COL1A2) transcription through the IFN-gamma response element located between - 161 and - 150. Here we report that YB-1 counter-represses TGF-beta-stimulated COL1A2 transcription by interfering with Smad3 bound to the upstream sequence around - 265 and subsequently by interrupting the Smad3-p300 interaction. Western blot and immunofluorescence analyses using inhibitors for Janus kinases or casein kinase II suggested that the casein kinase II-dependent signaling pathway mediates IFN-gamma-induced nuclear translocation of YB-1. Down-regulation of endogenous YB-1 expression by double-stranded YB-1-specific RNA abrogated the transcriptional repression of COL1A2 by IFN-gamma in the absence and presence of TGF-beta. In transient transfection assays, overexpression of YB-1 in human dermal fibroblasts exhibited antagonistic actions against TGF-beta and Smad3. Physical interaction between Smad3 and YB- 1 was demonstrated by immunoprecipitation-Western blot analyses, and electrophoretic mobility shift assays using the recombinant Smad3 and YB- 1 proteins indicated that YB- 1 forms a complex with Smad3 bound to the Smad-binding element. Glutathione S-transferase pull-down assays showed that YB- 1 binds to the MH1 domain of Smad3, whereas the central and carboxyl-terminal regions of YB- 1 were required for its interaction with Smad3. YB- 1 also interferes with the Smad3-p300 interaction by its preferential binding to p300. Altogether, the results provide a novel insight into the mechanism by which IFN-gamma/ YB-1 counteracts TGF-beta/Smad3. They also indicate that IFN-gamma/YB-1 inhibits COL1A2 transcription by dual actions: via the IFN-gamma response element and through a cross-talk with the TGF-beta/Smad signaling pathway.	Sumitomo Chem Co Ltd, Environm Hlth Sci Lab, Konohana Ku, Osaka 5548558, Japan; Tokai Univ, Sch Med, Dept Community Hlth, Kanagawa 2591193, Japan; Juntendo Univ, Sch Med, Allergy Res Ctr, Bunkyo Ku, Tokyo 1138421, Japan	Sumitomo Chem Co Ltd; Tokai University; Juntendo University	Higashi, K (corresponding author), Sumitomo Chem Co Ltd, Environm Hlth Sci Lab, Konohana Ku, Osaka 5548558, Japan.	higashik2@sc.sumitomo-chem.co.jp	Fujimori, Ko/AAD-5428-2021	Fujimori, Ko/0000-0002-2506-0769; HIGASHI, KIYOSHI/0000-0003-3577-0526				Chen CW, 2002, BRIT J PHARMACOL, V137, P1011, DOI 10.1038/sj.bjp.0704955; Chen SJ, 1999, J INVEST DERMATOL, V112, P49, DOI 10.1046/j.1523-1747.1999.00477.x; Chen SJ, 2000, J CELL PHYSIOL, V183, P381, DOI 10.1002/(SICI)1097-4652(200006)183:3<381::AID-JCP11>3.0.CO;2-O; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Eickelberg O, 2001, FASEB J, V15, P797, DOI 10.1096/fj.00-0233com; ELDER GA, 1992, NUCLEIC ACIDS RES, V20, P6281, DOI 10.1093/nar/20.23.6281; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Galvin KM, 1997, MOL CELL BIOL, V17, P3723, DOI 10.1128/MCB.17.7.3723; Ghosh AK, 2001, J BIOL CHEM, V276, P11041, DOI 10.1074/jbc.M004709200; Ghosh AK, 2000, ONCOGENE, V19, P3546, DOI 10.1038/sj.onc.1203693; Goodman RH, 2000, GENE DEV, V14, P1553; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Higashi K, 1998, MATRIX BIOL, V16, P447, DOI 10.1016/S0945-053X(98)90016-6; Higashi K, 2003, J BIOL CHEM, V278, P5156, DOI 10.1074/jbc.M208724200; Hu JB, 2001, J BIOL CHEM, V276, P287, DOI 10.1074/jbc.M004885200; Hughes TR, 2002, J BIOL CHEM, V277, P11097, DOI 10.1074/jbc.M106774200; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; Inagaki Y, 2001, J CELL PHYSIOL, V187, P117, DOI 10.1002/1097-4652(2001)9999:9999<00::AID-JCP1059>3.0.CO;2-S; JACOB G, 1999, P NATL ACAD SCI USA, V96, P12719; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Jurchott K, 2003, J BIOL CHEM, V278, P27988, DOI 10.1074/jbc.M212966200; KAHARI VM, 1990, J CLIN INVEST, V86, P1489, DOI 10.1172/JCI114866; KICK D, 1987, NUCLEIC ACIDS RES, V15, P4099, DOI 10.1093/nar/15.10.4099; Koike K, 1997, FEBS LETT, V417, P390, DOI 10.1016/S0014-5793(97)01296-9; KULOZIK M, 1990, J CLIN INVEST, V86, P917, DOI 10.1172/JCI114793; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MAUVIEL A, 1993, WOUNDS, V5, P137; MAUVIEL A, 1993, J CELL BIOCHEM, V53, P288, DOI 10.1002/jcb.240530404; Mead JR, 2003, J BIOL CHEM, V278, P17741, DOI 10.1074/jbc.M301602200; Montani V, 1998, ENDOCRINOLOGY, V139, P280, DOI 10.1210/en.139.1.280; Mori Y, 2000, EXP CELL RES, V258, P374, DOI 10.1006/excr.2000.4930; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nishihara A, 1999, J BIOL CHEM, V274, P28716, DOI 10.1074/jbc.274.40.28716; Norman JT, 2001, J BIOL CHEM, V276, P29880, DOI 10.1074/jbc.M103145200; Ohga T, 1996, CANCER RES, V56, P4224; PELTONEN J, 1990, J INVEST DERMATOL, V94, P365, DOI 10.1111/1523-1747.ep12874491; Raffetseder U, 2003, J BIOL CHEM, V278, P18241, DOI 10.1074/jbc.M212518200; Ramana CV, 2001, P NATL ACAD SCI USA, V98, P6674, DOI 10.1073/pnas.111164198; Sengupta PK, 2002, J BIOL CHEM, V277, P24926, DOI 10.1074/jbc.M111712200; Shi Y, 1997, BBA-REV CANCER, V1332, pF49, DOI 10.1016/S0304-419X(96)00044-3; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; Skabkin MA, 2001, J BIOL CHEM, V276, P44841, DOI 10.1074/jbc.M107581200; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407; Yao YL, 2001, MOL CELL BIOL, V21, P5979, DOI 10.1128/MCB.21.17.5979-5991.2001; Yuan WH, 1999, J CELL PHYSIOL, V179, P97, DOI 10.1002/(SICI)1097-4652(199904)179:1<97::AID-JCP12>3.3.CO;2-5; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang W, 2000, J BIOL CHEM, V275, P39237, DOI 10.1074/jbc.M003339200; Zhu XS, 2001, MOL CELL BIOL, V21, P7078, DOI 10.1128/MCB.21.20.7078-7088.2001	51	135	145	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43470	43479		10.1074/jbc.M302339200	http://dx.doi.org/10.1074/jbc.M302339200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12917425	hybrid			2022-12-25	WOS:000186157000092
J	Mu, XM; Chang, CS				Mu, XM; Chang, CS			TR3 orphan nuclear receptor mediates apoptosis through up-regulating E2F1 in human prostate cancer LNCaP cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; NGFI-B; DNA-BINDING; INDUCTION; SUPERFAMILY; NUR77; MEMBER; PROTEINS; PATHWAY; DEATH	Early studies suggested both TR3 orphan receptor ( TR3) and apoptosis mediator E2F1 might play an important role in mediating prostate cancer cell apoptosis. Their linkage and relationship, however, remain unclear. Here we found that 12-O-tetradecanoylphorbol-13- acetate (TPA) could induce cell apoptosis via induction of TR3 and E2F1 expression in LNCaP prostate cancer cells. Addition of antisense E2F1 could partially rescue the TR3-mediated cell apoptosis, and transfection of the TR3 dominant-negative plasmid could block the TR3-induced E2F1 expression. These data suggest that TPA is able to induce LNCaP cell apoptosis via induction of TR3 resulting in the induction of E2F1. Promoter reporter assays show that TR3 can induce E2F1 expression via binding to the TR3 response element (TR3RE) in the E2F1 promoter - 316 to - 324 bp region. TR3 can bind specifically to this TR3RE with a K-d of 6.29 nM, and mutations of this E2F1-TR3RE can partially block the TR3-mediated E2F1 expression. Taken together, these data suggest that TPA is able to induce cell apoptosis via a TPA 3 TR3 3 E2F1 3 apoptosis pathway in LNCaP cells. Further studies of how to modulate this pathway may allow us to better understand how to control the prostate cancer growth.	Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Pathol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Urol, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Chang, CS (corresponding author), Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Pathol, Rochester, NY 14642 USA.			Chang, Chawnshang/0000-0001-8510-3516	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047258, R01DK056984] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 47258, DK56984] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BUTTYAN R, 1988, MOL ENDOCRINOL, V2, P650, DOI 10.1210/mend-2-7-650; CHANG C, 1989, J STEROID BIOCHEM, V34, P391; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; Cheng LEC, 1997, EMBO J, V16, P1865, DOI 10.1093/emboj/16.8.1865; CUNHA GR, 1987, ENDOCR REV, V8, P338, DOI 10.1210/edrv-8-3-338; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; ISAACS JT, 1992, J ANDROL, V13, P457; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; Katagiri Y, 2000, NAT CELL BIOL, V2, P435, DOI 10.1038/35017072; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Li Y, 1998, MOL CELL BIOL, V18, P4719, DOI 10.1128/MCB.18.8.4719; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; Mu XM, 1998, ENDOCRINE, V9, P27, DOI 10.1385/ENDO:9:1:27; Mu XM, 2000, J BIOL CHEM, V275, P23877, DOI 10.1074/jbc.M910158199; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Phillips A, 1997, MOL CELL BIOL, V17, P5946, DOI 10.1128/MCB.17.10.5946; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Strathdee CA, 1999, GENE, V229, P21, DOI 10.1016/S0378-1119(99)00045-1; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Uemura H, 1998, ENDOCRINOLOGY, V139, P2329, DOI 10.1210/en.139.5.2329; vanGinkel PR, 1997, J BIOL CHEM, V272, P18367, DOI 10.1074/jbc.272.29.18367; Wang WL, 1999, MOL ENDOCRINOL, V13, P1373, DOI 10.1210/me.13.8.1373; WATSON MA, 1989, MOL CELL BIOL, V9, P4213, DOI 10.1128/MCB.9.10.4213; Weih F, 1996, P NATL ACAD SCI USA, V93, P5533, DOI 10.1073/pnas.93.11.5533; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; YOUNG CYF, 1994, ONCOL RES, V6, P203	38	38	41	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42840	42845		10.1074/jbc.M305594200	http://dx.doi.org/10.1074/jbc.M305594200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12947120	hybrid			2022-12-25	WOS:000186157000015
J	Wick, MJ; Ramos, FJ; Chen, H; Quon, MJ; Dong, LQ; Liu, F				Wick, MJ; Ramos, FJ; Chen, H; Quon, MJ; Dong, LQ; Liu, F			Mouse 3-phosphoinositide-dependent protein kinase-1 undergoes dimerization and trans-phosphorylation in the activation loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; DOCKING SITE; PDK1; IDENTIFICATION; MECHANISM; POCKET; PKC	Activation of mouse 3-phosphoinositide-dependent protein kinase-1 (mPDK1) requires phosphorylation at a conserved serine residue, Ser(244), in the activation loop. However, the mechanism by which mPDK1 is phosphorylated at this site remains unclear. We have found that kinase-defective mPDK1 (mPDK1(KD)), but not a kinase-defective mPDK1 in which Ser(244) was replaced with alanine (mPDK1(KD/S244A)), is significantly phosphorylated in intact cells and is a direct substrate of wild-type mPDK1 fused to the yellow fluorescence protein. Phosphoamino acid analysis and phosphopeptide mapping studies revealed that mPDK1 trans-autophosphorylation occurred mainly on Ser(244). On the other hand, Ser(399) and Thr(516), two recently identified autophosphorylation sites of mPDK1, are phosphorylated primarily through a cis mechanism. In vivo labeling studies revealed that insulin stimulated both mPDK1KD and mPDK1(KD/S244A) phosphorylation in Chinese hamster ovary cells overexpressing the insulin receptor. However, Western blot analysis using a phosphospecific antibody revealed no increase in insulin-stimulated phosphorylation of Ser244 in these cells overexpressing mPDK1. mPDK1 undergoes dimerization in cells and this self-association is enhanced by kinase inactivation. Deletion of the extreme C terminus disrupts mPDK1 dimerization and Ser(244) trans-phosphorylation, suggesting that dimerization is important for mPDK1 transphosphorylation. Taken together, our results show that mPDK1 autophosphorylation occurs at multiple sites through both cis and trans mechanisms and suggest that dimerization and trans-phosphorylation may serve as mechanisms to regulate PDK1 activity in cells.	Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; NCCAM, Diabet Unit, Clin Invest Lab, NIH, Bethesda, MD 20892 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; National Institutes of Health (NIH) - USA; NIH National Center for Complementary & Alternative Medicine	Liu, F (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pharmacol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	liuf@uthscsa.edu	Quon, Michael/B-1970-2008	Quon, Michael/0000-0002-9601-9915; QUON, MICHAEL/0000-0002-5289-3707	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [Z01AT000002, ZIAAT000002] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056166] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK56166] Funding Source: Medline	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Balendran A, 2000, J BIOL CHEM, V275, P20806, DOI 10.1074/jbc.M000421200; Biondi RM, 2000, EMBO J, V19, P979, DOI 10.1093/emboj/19.5.979; Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287; Chen H, 2001, BIOCHEMISTRY-US, V40, P11851, DOI 10.1021/bi010743c; Dong LQ, 1999, J BIOL CHEM, V274, P8117, DOI 10.1074/jbc.274.12.8117; Dong LQ, 2002, BIOCHEM BIOPH RES CO, V294, P136, DOI 10.1016/S0006-291X(02)00449-7; Frodin M, 2002, EMBO J, V21, P5396, DOI 10.1093/emboj/cdf551; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; Grillo S, 2000, EUR J BIOCHEM, V267, P6642, DOI 10.1046/j.1432-1327.2000.01759.x; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Park J, 2001, J BIOL CHEM, V276, P37459, DOI 10.1074/jbc.M105916200; Prowse CN, 2001, J BIOL CHEM, V276, P99, DOI 10.1074/jbc.M008137200; Storz P, 2002, FRONT BIOSCI-LANDMRK, V7, pD886, DOI 10.2741/storz; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; Wick K. L. R., 2001, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V1, P209; Wick MJ, 2002, J BIOL CHEM, V277, P16632, DOI 10.1074/jbc.M112402200; Wick MJ, 2001, J BIOL CHEM, V276, P42843, DOI 10.1074/jbc.M102116200; Wick MJ, 2000, J BIOL CHEM, V275, P40400, DOI 10.1074/jbc.M003937200; Ziegler WH, 1999, CURR BIOL, V9, P522, DOI 10.1016/S0960-9822(99)80236-X	23	53	56	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42913	42919		10.1074/jbc.M304172200	http://dx.doi.org/10.1074/jbc.M304172200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12923190	hybrid			2022-12-25	WOS:000186157000024
J	Yellaturu, CR; Rao, GN				Yellaturu, CR; Rao, GN			A requirement for calcium-independent phospholipase A(2) in thrombin-induced arachidonic acid release and growth in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; P388D(1) MACROPHAGES; PHOSPHATIDATE PHOSPHOHYDROLASE; SIGNAL-TRANSDUCTION; BROMOENOL LACTONE; METABOLITES; EXPRESSION; PHOSPHORYLATION; IDENTIFICATION; PROLIFERATION	Thrombin is a potent mitogen for vascular smooth muscle cells (VSMC). To understand its mitogenic signaling events, we have studied the role of calcium-independent phospholipase A(2) (iPLA(2)). Without affecting its levels, thrombin increased iPLA(2) activity in a time-dependent manner in VSMC. Thrombin also induced arachidonic acid release and DNA synthesis by about 2-fold as compared with control. Down-regulation of iPLA(2) activity by its specific inhibitor, bromoenol lactone, or its expression by antisense oligonucleotides, significantly reduced thrombin-induced arachidonic acid release and DNA synthesis in VSMC. To learn the mechanism of thrombin-stimulated iPLA(2) activity, we next tested the role of p38 MAPK. Thrombin stimulated p38 MAPK phosphorylation and activity in a time-dependent manner in VSMC. Inhibition of p38 MAPK activity by SB203580 and SB202190 resulted in decreased iPLA(2) activity, arachidonic acid release, and DNA synthesis induced by thrombin in VSMC. Together, these results for the first time demonstrate that iPLA(2) plays a role in thrombin-induced arachidonic acid release and growth in VSMC and that these responses are mediated by p38 MAPK.	Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Ctr Vasc Biol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Rao, GN (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Physiol, 894 Union Ave, Memphis, TN 38163 USA.	grao@physio1.utmem.edu			NHLBI NIH HHS [R01 HL64165] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064165] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; Anderson KM, 1997, J BIOL CHEM, V272, P30504, DOI 10.1074/jbc.272.48.30504; BACHHUBER BG, 1995, AM J PHYSIOL-CELL PH, V268, pC1141, DOI 10.1152/ajpcell.1995.268.5.C1141; Balsinde J, 1996, J BIOL CHEM, V271, P31937, DOI 10.1074/jbc.271.50.31937; Balsinde J, 1997, J BIOL CHEM, V272, P29317, DOI 10.1074/jbc.272.46.29317; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P4449, DOI 10.1074/jbc.273.8.4449; Chai YC, 1996, J BIOL CHEM, V271, P17791, DOI 10.1074/jbc.271.30.17791; Chen JK, 2001, MOL CELL BIOL, V21, P6322, DOI 10.1128/MCB.21.18.6322-6331.2001; DETHLEFSEN SM, 1994, EXP CELL RES, V212, P262, DOI 10.1006/excr.1994.1142; Ehsan A, 2000, VASC MED, V5, P103, DOI 10.1191/135886300668426194; Ettenson DS, 2000, VASC MED, V5, P97; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; Ghosh SK, 2002, J BIOL CHEM, V277, P21325, DOI 10.1074/jbc.M201608200; Gijon MA, 2000, J BIOL CHEM, V275, P20146, DOI 10.1074/jbc.M908941199; GLASGOW WC, 1992, J BIOL CHEM, V267, P10771; GOETZL EJ, 1995, FASEB J, V9, P1051, DOI 10.1096/fasebj.9.11.7649404; GOLUBIC M, 1991, EMBO J, V10, P2897, DOI 10.1002/j.1460-2075.1991.tb07839.x; GRONICH J, 1994, J CLIN INVEST, V93, P1224, DOI 10.1172/JCI117076; Hansson GK, 2002, CIRC RES, V91, P281, DOI 10.1161/01.RES.0000029784.15893.10; Jenkins CM, 2002, J BIOL CHEM, V277, P32807, DOI 10.1074/jbc.M202568200; Larsson PKA, 1998, J BIOL CHEM, V273, P207, DOI 10.1074/jbc.273.1.207; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LINDNER V, 1991, P NATL ACAD SCI USA, V88, P3739, DOI 10.1073/pnas.88.9.3739; Maggi LB, 2002, J BIOL CHEM, V277, P38449, DOI 10.1074/jbc.M206247200; Muthalif MM, 1996, J BIOL CHEM, V271, P30149, DOI 10.1074/jbc.271.47.30149; Muthalif MM, 2001, J BIOL CHEM, V276, P39653, DOI 10.1074/jbc.M103136200; Panini SR, 2001, J LIPID RES, V42, P1678; PEPPELENBOSCH MP, 1993, CELL, V74, P565, DOI 10.1016/0092-8674(93)80057-L; Pfister SL, 1998, J BIOL CHEM, V273, P30879, DOI 10.1074/jbc.273.47.30879; Ramanadham S, 1999, J BIOL CHEM, V274, P13915, DOI 10.1074/jbc.274.20.13915; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; RAO GN, 1994, BIOCHEM J, V299, P197, DOI 10.1042/bj2990197; RAO GN, 1994, J BIOL CHEM, V269, P32586; RAO GN, 1995, J CLIN INVEST, V96, P842, DOI 10.1172/JCI118130; Roshak AK, 2000, J BIOL CHEM, V275, P35692, DOI 10.1074/jbc.M002273200; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Shinohara H, 1999, J BIOL CHEM, V274, P12263, DOI 10.1074/jbc.274.18.12263; Steer SA, 2002, AM J PHYSIOL-CELL PH, V283, pC1621, DOI 10.1152/ajpcell.00109.2002; TSAI MH, 1991, MOL CELL BIOL, V11, P2785, DOI 10.1128/MCB.11.5.2785; Wissing D, 1997, P NATL ACAD SCI USA, V94, P5073, DOI 10.1073/pnas.94.10.5073; Yellaturu CR, 2003, J BIOL CHEM, V278, P9986, DOI 10.1074/jbc.M211276200	46	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43831	43837		10.1074/jbc.M301472200	http://dx.doi.org/10.1074/jbc.M301472200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12928445	hybrid			2022-12-25	WOS:000186157000133
J	McAlinden, A; Smith, TA; Sandell, LJ; Ficheux, D; Parry, DAD; Hulmes, DJS				McAlinden, A; Smith, TA; Sandell, LJ; Ficheux, D; Parry, DAD; Hulmes, DJS			alpha-helical coiled-coil oligomerization domains are almost ubiquitous in the collagen superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; TRIPLE-HELIX; CRYSTAL-STRUCTURE; METAPHYSEAL CHONDRODYSPLASIA; FIBRILLAR COLLAGEN; NC1 DOMAIN; OSTEOGENESIS IMPERFECTA; MOLECULAR RECOGNITION; PRO-ALPHA-1(I) CHAIN; EXTRACELLULAR-MATRIX	alpha-Helical coiled coils are widely occurring protein oligomerization motifs. Here we show that most members of the collagen superfamily contain short, repeating heptad sequences typical of coiled coils. Such sequences are found at the N-terminal ends of the C-propeptide domains in all fibrillar procollagens. When fused C-terminal to a reporter molecule containing a collagen-like sequence that does not spontaneously trimerize, the C-propeptide heptad repeats induced trimerization. C-terminal heptad repeats were also found in the oligomerization domains of the multiplexins (collagens XV and XVIII). N-terminal heptad repeats are known to drive trimerization in transmembrane collagens, whereas fibril-associated collagens with interrupted triple helices, as well as collagens VII, XIII, XXIII, and XXV, were found to contain heptad repeats between collagen domains. Finally, heptad repeats were found in the von Willebrand factor A domains known to be involved in trimerization of collagen VI, as well as in collagen VII. These observations suggest that coiled-coil oligomerization domains are widely used in the assembly of collagens and collagen-like proteins.	Univ Lyon 1, CNRS, UMR 5086, IBCP, F-69367 Lyon 07, France; Washington Univ, Sch Med, Barnes Jewish Hosp, Dept Orthoped Surg, St Louis, MO 63110 USA; Massey Univ, Inst Fundamental Sci, Palmerston North, New Zealand	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Barnes-Jewish Hospital; Washington University (WUSTL); Massey University	Hulmes, DJS (corresponding author), Univ Lyon 1, CNRS, UMR 5086, IBCP, 7 Passage Vercors, F-69367 Lyon 07, France.	d.hulmes@ibcp.fr		Hulmes, David/0000-0002-0651-1317; McAlinden, Audrey/0000-0001-8433-4224; Lynch, Thomasin/0000-0001-8253-2024	NIAMS NIH HHS [AR 48250-01, AR 36994] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR048250, R01AR036994] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Areida SK, 2001, J BIOL CHEM, V276, P1594, DOI 10.1074/jbc.M008709200; Balding SD, 1997, BIOCHEMISTRY-US, V36, P8821, DOI 10.1021/bi970675n; Ball SG, 2001, J BIOL CHEM, V276, P7422, DOI 10.1074/jbc.M002816200; Banyard J, 2003, J BIOL CHEM, V278, P20989, DOI 10.1074/jbc.M210616200; BATEMAN JF, 1989, J BIOL CHEM, V264, P10960; Beck K, 1998, J STRUCT BIOL, V122, P17, DOI 10.1006/jsbi.1998.3965; Bernocco S, 2001, J BIOL CHEM, V276, P48930, DOI 10.1074/jbc.M108611200; Bogin O, 2002, STRUCTURE, V10, P165, DOI 10.1016/S0969-2126(02)00697-4; Boot-Handford RP, 2003, BIOESSAYS, V25, P142, DOI 10.1002/bies.10230; Boot-Handford RP, 2003, J BIOL CHEM, V278, P31067, DOI 10.1074/jbc.M212889200; Boutaud A, 2000, J BIOL CHEM, V275, P30716, DOI 10.1074/jbc.M004569200; Brown JH, 1996, PROTEINS, V26, P134; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bulleid NJ, 1997, EMBO J, V16, P6694, DOI 10.1093/emboj/16.22.6694; Colombatti A, 2000, MATRIX BIOL, V19, P289, DOI 10.1016/S0945-053X(00)00074-3; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; DION AS, 1987, J MOL BIOL, V193, P127, DOI 10.1016/0022-2836(87)90632-2; Dublet B, 1999, J BIOL CHEM, V274, P18909, DOI 10.1074/jbc.274.27.18909; ENGEL J, 1991, ANNU REV BIOPHYS BIO, V20, P137, DOI 10.1146/annurev.biophys.20.1.137; Engel J, 2000, MATRIX BIOL, V19, P283, DOI 10.1016/S0945-053X(00)00075-5; Exposito JY, 2002, ANAT RECORD, V268, P302, DOI 10.1002/ar.10162; Frank S, 2003, J BIOL CHEM, V278, P7747, DOI 10.1074/jbc.C200698200; Frank S, 2000, J BIOL CHEM, V275, P11672, DOI 10.1074/jbc.275.16.11672; Gordon MK, 2002, FASEB J, V16, pA359; Hakansson K, 1999, STRUCTURE, V7, P255, DOI 10.1016/S0969-2126(99)80036-7; Hakansson K, 2000, PROTEIN SCI, V9, P1607, DOI 10.1110/ps.9.9.1607; HARBURY PB, 1994, NATURE, V371, P80, DOI 10.1038/371080a0; Hashimoto T, 2002, EMBO J, V21, P1524, DOI 10.1093/emboj/21.7.1524; Hohenester E, 2002, MATRIX BIOL, V21, P115, DOI 10.1016/S0945-053X(01)00191-3; HOPPE HJ, 1994, FEBS LETT, V344, P191, DOI 10.1016/0014-5793(94)00383-1; Illidge C, 2001, INT J BIOCHEM CELL B, V33, P521, DOI 10.1016/S1357-2725(01)00013-9; KADLER K, 1995, PROTEIN PROFILE, V2, P491; Kammerer RA, 1997, MATRIX BIOL, V15, P555, DOI 10.1016/S0945-053X(97)90031-7; Kishore U, 2000, IMMUNOPHARMACOLOGY, V49, P159, DOI 10.1016/S0162-3109(00)80301-X; Lamande SR, 2002, J BIOL CHEM, V277, P1949, DOI 10.1074/jbc.M109932200; Latvanlehto A, 2003, J BIOL CHEM, V278, P37590, DOI 10.1074/jbc.M305974200; Lees JF, 1997, EMBO J, V16, P908, DOI 10.1093/emboj/16.5.908; Lesage A, 1996, BIOCHEMISTRY-US, V35, P9647, DOI 10.1021/bi952666p; Lim AL, 1998, J CELL BIOCHEM, V71, P216, DOI 10.1002/(SICI)1097-4644(19981101)71:2<216::AID-JCB7>3.3.CO;2-K; Litowski JR, 2001, J PEPT RES, V58, P477, DOI 10.1034/j.1399-3011.2001.10972.x; Lupas A, 1996, METHOD ENZYMOL, V266, P513; Marks DS, 1999, J BIOL CHEM, V274, P3632, DOI 10.1074/jbc.274.6.3632; Matsushita M, 2001, IMMUNOL REV, V180, P78, DOI 10.1034/j.1600-065X.2001.1800107.x; Mazzorana M, 2001, J BIOL CHEM, V276, P27989, DOI 10.1074/jbc.M101633200; McAlinden A, 2002, J BIOL CHEM, V277, P41274, DOI 10.1074/jbc.M202257200; McLaughlin SH, 1998, MATRIX BIOL, V16, P369, DOI 10.1016/S0945-053X(98)90010-5; Mechling DE, 1996, J BIOL CHEM, V271, P13781, DOI 10.1074/jbc.271.23.13781; Mongiat M, 2000, J BIOL CHEM, V275, P25471, DOI 10.1074/jbc.M001426200; Myllyharju J, 2001, ANN MED, V33, P7, DOI 10.3109/07853890109002055; Nakamura K, 2001, BIOCHEM BIOPH RES CO, V280, P1028, DOI 10.1006/bbrc.2000.4210; Oganesian A, 1997, J HISTOCHEM CYTOCHEM, V45, P1469, DOI 10.1177/002215549704501104; Ohno K, 1998, P NATL ACAD SCI USA, V95, P9654, DOI 10.1073/pnas.95.16.9654; Pace JM, 2001, J MED GENET, V38, P443, DOI 10.1136/jmg.38.7.443; Pace JM, 2003, MATRIX BIOL, V22, P3, DOI 10.1016/S0945-053X(03)00007-6; Pan OH, 1998, J BIOL CHEM, V273, P14205, DOI 10.1074/jbc.273.23.14205; PIHLAJANIEMI T, 1984, J BIOL CHEM, V259, P2941; Ricard-Blum S, 2000, UNCONVENTIONAL COLLA; Sasaki T, 2000, J MOL BIOL, V301, P1179, DOI 10.1006/jmbi.2000.3996; Sasaki T, 1998, EMBO J, V17, P4249, DOI 10.1093/emboj/17.15.4249; Sato K, 2002, J BIOL CHEM, V277, P37678, DOI 10.1074/jbc.M205347200; SHERIFF S, 1994, NAT STRUCT BIOL, V1, P789, DOI 10.1038/nsb1194-789; Snellman A, 2000, EMBO J, V19, P5051, DOI 10.1093/emboj/19.19.5051; Sundaramoorthy M, 2002, J BIOL CHEM, V277, P31142, DOI 10.1074/jbc.M201740200; Than ME, 2002, P NATL ACAD SCI USA, V99, P6607, DOI 10.1073/pnas.062183499; WEIS WI, 1994, STRUCTURE, V2, P1227, DOI 10.1016/S0969-2126(94)00124-3; WILLING MC, 1990, J CLIN INVEST, V85, P282, DOI 10.1172/JCI114424; WOOLFSON DN, 1995, PROTEIN SCI, V4, P1596, DOI 10.1002/pro.5560040818; Zhang PN, 2001, J BIOL CHEM, V276, P19862, DOI 10.1074/jbc.M100597200	68	68	85	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42200	42207		10.1074/jbc.M302429200	http://dx.doi.org/10.1074/jbc.M302429200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12920133	hybrid			2022-12-25	WOS:000185989500078
J	Pyhtila, B; Rexach, M				Pyhtila, B; Rexach, M			A gradient of affinity for the karyopherin Kap95p along the yeast nuclear pore complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; IMPORTIN-BETA; PROTEIN INTERACTIONS; NUCLEOPORIN; NUP2P; TRANSPORT; EXPORT; SRP1P/IMPORTIN-ALPHA; IDENTIFICATION; TRANSLOCATION	Karyopherins (Kaps) transport cargo across the nuclear pore complex (NPC) by interacting with nucleoporins that contain phenylalanine-glycine (FG) peptide repeats (FG Nups). As a test of the "affinity gradient" model for Kap translocation, we measured the apparent affinity of Kap95p to FG Nups representing three distinct regions of the S. cerevisiae NPC. We find that the affinity of Kap95p-Kap60p-cargo complexes to Nup1p (a nuclear basket Nup) is 225-fold higher than to Nup100p (a central scaffold Nup) and 4000-fold higher than to Nup42p (a cytoplasmic filament Nup), revealing a steep gradient of affinity for Kap95p complexes along the yeast NPC. A high affinity binding site for a Kap95p import complex was mapped to the C terminus of Nup1p, and, surprisingly, deletion of all FG repeats in that region did not eliminate binding of the complex. Instead, a 36-amino acid truncation of the C terminus of Nup1p reduced its affinity for the Kap95p import complex by 450-fold. Mutant yeast that express Nup1pDelta36 instead of full-length Nup1p display specific defects in Kap95p localization and Kap95p-mediated nuclear import. We conclude that a high affinity binding site for Kap95p at the nuclear basket increases the translocation efficiency of Kap95p import complexes across the NPC.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA	Stanford University	Rexach, M (corresponding author), Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA.				NIGMS NIH HHS [R01 GM 61900-01A2] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061900] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen NPC, 2002, MOL CELL PROTEOMICS, V1, P930, DOI 10.1074/mcp.T200012-MCP200; Allen NPC, 2001, J BIOL CHEM, V276, P29268, DOI 10.1074/jbc.M102629200; Bayliss R, 2000, CELL, V102, P99, DOI 10.1016/S0092-8674(00)00014-3; Bayliss R, 2002, J BIOL CHEM, V277, P50597, DOI 10.1074/jbc.M209037200; Ben-Efraim I, 2001, J CELL BIOL, V152, P411, DOI 10.1083/jcb.152.2.411; Blobel G, 1995, COLD SPRING HARB SYM, V60, P1; BOGERD AM, 1994, J CELL BIOL, V127, P319, DOI 10.1083/jcb.127.2.319; Booth JW, 1999, J BIOL CHEM, V274, P32360, DOI 10.1074/jbc.274.45.32360; Cingolani G, 1999, NATURE, V399, P221, DOI 10.1038/20367; DAVIS LI, 1990, CELL, V61, P965, DOI 10.1016/0092-8674(90)90062-J; Denning D, 2001, J CELL BIOL, V154, P937, DOI 10.1083/jcb.200101007; Denning DP, 2003, P NATL ACAD SCI USA, V100, P2450, DOI 10.1073/pnas.0437902100; Dilworth DJ, 2001, J CELL BIOL, V153, P1465, DOI 10.1083/jcb.153.7.1465; ENENKEL C, 1995, J BIOL CHEM, V270, P16499, DOI 10.1074/jbc.270.28.16499; Floer M, 1997, J BIOL CHEM, V272, P19538, DOI 10.1074/jbc.272.31.19538; Gilchrist D, 2002, J BIOL CHEM, V277, P18161, DOI 10.1074/jbc.M112306200; Hood JK, 1998, J BIOL CHEM, V273, P35142, DOI 10.1074/jbc.273.52.35142; Hood JK, 2000, J CELL SCI, V113, P1471; Huang L, 2002, MOL CELL PROTEOMICS, V1, P434, DOI 10.1074/mcp.M200027-MCP200; Kaffman A, 1998, GENE DEV, V12, P2673, DOI 10.1101/gad.12.17.2673; LOEB JDJ, 1993, MOL BIOL CELL, V4, P209, DOI 10.1091/mbc.4.2.209; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Ribbeck K, 2001, EMBO J, V20, P1320, DOI 10.1093/emboj/20.6.1320; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Shulga N, 2000, J CELL BIOL, V149, P1027, DOI 10.1083/jcb.149.5.1027; Shulga N, 1996, J CELL BIOL, V135, P329, DOI 10.1083/jcb.135.2.329; Solsbacher J, 2000, MOL CELL BIOL, V20, P8468, DOI 10.1128/MCB.20.22.8468-8479.2000; Strahm Y, 1999, EMBO J, V18, P5761, DOI 10.1093/emboj/18.20.5761; Walther TC, 2001, EMBO J, V20, P5703, DOI 10.1093/emboj/20.20.5703; Wozniak RW, 1998, TRENDS CELL BIOL, V8, P184, DOI 10.1016/S0962-8924(98)01248-3	31	96	100	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42699	42709		10.1074/jbc.M307135200	http://dx.doi.org/10.1074/jbc.M307135200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12917401	hybrid			2022-12-25	WOS:000185989500137
J	Scheinfeld, MH; Ghersi, E; Davies, P; D'Adamio, L				Scheinfeld, MH; Ghersi, E; Davies, P; D'Adamio, L			Amyloid beta protein precursor is phosphorylated by JNK-1 independent of, yet facilitated by, JNK-interacting protein (JIP)-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; ALZHEIMERS-DISEASE; GAMMA-SECRETASE; CYTOPLASMIC DOMAIN; INTRACELLULAR DOMAIN; DEPENDENT REGULATION; A-BETA; ACTIVATION; NOTCH; FE65	Alzheimer's disease (AD) is genetically linked to the processing of amyloid beta protein precursor (AbetaPP). Aside from being the precursor of the amyloid beta (Abeta) found in plaques in the brains of patients with AD, little is known regarding the functional role of AbetaPP. We have recently reported biochemical evidence linking AbetaPP to the JNK signaling cascade by finding that JNK-interacting protein-1 (JIP-1) binds AbetaPP. In order to study the functional implications of this interaction we assayed the carboxyl-terminal of AbetaPP for phosphorylation. We found that the threonine 668 within the AbetaPP intracellular domain (AID or elsewhere AICD) is indeed phosphorylated by JNK1. We surprisingly found that although JIP-1 can facilitate this phosphorylation, it is not required for this process. We also found that JIP-1 only facilitated phosphorylation of AbetaPP but not of the two other family members APLP1 (amyloid precursor-like protein 1) and APLP2. Understanding the connection between AbetaPP phosphorylation and the JNK signaling pathway, which mediates cell response to stress may have important implications in understanding the pathogenesis of Alzheimer's disease.	Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	D'Adamio, L (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	ldadamio@aecom.yu.edu		D'Adamio, Luciano/0000-0002-9820-4882; D'Adamio, Luciano/0000-0002-2204-9441; Scheinfeld, Meir H/0000-0001-8880-4318	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32 GM 07288] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ando K, 2001, J BIOL CHEM, V276, P40353, DOI 10.1074/jbc.M104059200; Aplin AE, 1996, J NEUROCHEM, V67, P699; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Coffey ET, 2000, J NEUROSCI, V20, P7602; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; Goedert M, 1997, FEBS LETT, V409, P57, DOI 10.1016/S0014-5793(97)00483-3; Haass C, 1999, SCIENCE, V286, P916, DOI 10.1126/science.286.5441.916; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Heber S, 2000, J NEUROSCI, V20, P7951; Inomata H, 2003, J BIOL CHEM, V278, P22946, DOI 10.1074/jbc.M212160200; Koo EH, 2002, TRAFFIC, V3, P763, DOI 10.1034/j.1600-0854.2002.31101.x; Lin A, 2003, BIOESSAYS, V25, P17, DOI 10.1002/bies.10204; Matsuda S, 2001, J NEUROSCI, V21, P6597; Niikura T, 2002, J NEUROSCI RES, V70, P380, DOI 10.1002/jnr.10354; Nussbaum RL, 2003, NEW ENGL J MED, V348, P1356, DOI 10.1056/NEJM2003ra020003; Passer Brent, 2000, Journal of Alzheimer's Disease, V2, P289; Ramelot TA, 2001, J MOL BIOL, V307, P871, DOI 10.1006/jmbi.2001.4535; Reynolds CH, 1997, J NEUROCHEM, V68, P1736; Roncarati R, 2002, P NATL ACAD SCI USA, V99, P7102, DOI 10.1073/pnas.102192599; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Sato T, 2003, J BIOL CHEM, V278, P24294, DOI 10.1074/jbc.M211161200; Scheinfeld MH, 2002, J BIOL CHEM, V277, P3767, DOI 10.1074/jbc.M108357200; Scheinfeld MH, 2003, P NATL ACAD SCI USA, V100, P1729, DOI 10.1073/pnas.0437908100; Shoji M, 2000, MOL BRAIN RES, V85, P221, DOI 10.1016/S0169-328X(00)00245-X; Sisodia SS, 2002, NAT REV NEUROSCI, V3, P281, DOI 10.1038/nrn785; Standen CL, 2001, J NEUROCHEM, V76, P316, DOI 10.1046/j.1471-4159.2001.00102.x; SUZUKI T, 1994, EMBO J, V13, P1114, DOI 10.1002/j.1460-2075.1994.tb06360.x; Tarr PE, 2002, J BIOL CHEM, V277, P16798, DOI 10.1074/jbc.M110286200; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Von Koch CS, 1997, NEUROBIOL AGING, V18, P661, DOI 10.1016/S0197-4580(97)00151-6; Weidemann A, 2002, BIOCHEMISTRY-US, V41, P2825, DOI 10.1021/bi015794o; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Yu CJ, 2001, J BIOL CHEM, V276, P43756, DOI 10.1074/jbc.C100410200; Zhu XW, 2001, J NEUROCHEM, V76, P435, DOI 10.1046/j.1471-4159.2001.00046.x; Zhu XW, 2001, MECH AGEING DEV, V123, P39, DOI 10.1016/S0047-6374(01)00342-6	36	41	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42058	42063		10.1074/jbc.M304853200	http://dx.doi.org/10.1074/jbc.M304853200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12917434	hybrid			2022-12-25	WOS:000185989500062
J	Ueda, K; Arakawa, H; Nakamura, Y				Ueda, K; Arakawa, H; Nakamura, Y			Dual-specificity phosphatase 5 (DUSP5) as a direct transcriptional target of tumor suppressor p53	ONCOGENE			English	Article						DUSP5; p53; Erk1/2	ACTIVATED PROTEIN-KINASE; P53-DEPENDENT APOPTOSIS; GENE; IDENTIFICATION; PHOSPHATASE; EXPRESSION; MUTATIONS; PHOSPHORYLATION; STIMULATION; GROWTH	Dual-specificity phosphatase 5 (DUSP5), a VH1-Iike enzyme that hydrolyses nuclear substrates phosphorylated on both tyrosine and serine/threonine residues, has a potential role in deactivation of mitogen- or stress-activated protein kinases. Using cDNA-microarray technology, we found that the expression of DUSP5 mRNA was dramatically increased by exogenous p53 in U373MG, a p53-mutant glioblastoma cell line. Transcription of DUSP5 was also remarkably activated by endogenous p53 in response to DNA damage in colon-cancer cells (p53+/+) that contained wild-type p53, but not in p53-/- cells. Chromatin-immunoprecipitation (ChIP) and reporter assays demonstrated that endogenous p53 protein would bind directly to the promoter region of the DUSP5 gene, implying p53-dependent transcriptional activity. Overexpression of DUSP5 suppressed the growth of several types of human cancer cells, in which Erk1/2 was significantly dephosphorylated. If, as the results suggest, DUSP5 is a direct target of p53, it represents a novel mechanism by which p53 might negatively regulate cell-cycle progression by downregulating mitogen- or stress-activated protein kinases.	Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab,Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Nakamura, Y (corresponding author), Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	yusuke@ims.u-tokyo.ac.jp	Arakawa, Hirofumi/L-3459-2013	Arakawa, Hirofumi/0000-0001-6077-0638				Brondello JM, 1999, SCIENCE, V286, P2514, DOI 10.1126/science.286.5449.2514; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Furuhata T, 1996, ONCOGENE, V13, P1965; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Iiizumi M, 2002, CANCER RES, V62, P1246; ISHIBASHI T, 1994, J BIOL CHEM, V269, P29897; Kim TI, 2002, ANN NY ACAD SCI, V973, P241, DOI 10.1111/j.1749-6632.2002.tb04641.x; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kovanen PE, 2003, J BIOL CHEM, V278, P5205, DOI 10.1074/jbc.M209015200; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MARTELL KJ, 1994, GENOMICS, V22, P462, DOI 10.1006/geno.1994.1411; Marti F, 2001, J IMMUNOL, V166, P197, DOI 10.4049/jimmunol.166.1.197; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MIYASHITA T, 1995, CELL, V80, P293; Mori T, 2002, NEOPLASIA, V4, P268, DOI 10.1038/sj.neo.7900235; Mori T, 2002, ONCOGENE, V21, P2914, DOI 10.1038/sj.onc.1205459; Ng CC, 1999, GENE CHROMOSOME CANC, V26, P329, DOI 10.1002/(SICI)1098-2264(199912)26:4<329::AID-GCC7>3.0.CO;2-C; Nishimori H, 1997, ONCOGENE, V15, P2145, DOI 10.1038/sj.onc.1201542; Ochi K, 2002, NEOPLASIA, V4, P82, DOI 10.1038/sj.neo.7900211; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Okamura S, 2001, MOL CELL, V8, P85, DOI 10.1016/S1097-2765(01)00284-2; Ono K, 2000, CANCER RES, V60, P5007; OREN M, 1994, SEMIN CANCER BIOL, V5, P221; Shiraishi K, 2000, CANCER RES, V60, P3722; Stefanovsky VY, 2001, MOL CELL, V8, P1063, DOI 10.1016/S1097-2765(01)00384-7; Takei Y, 1998, GENE CHROMOSOME CANC, V23, P1; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; Urano T, 1997, CANCER RES, V57, P3281; Yoo J, 2002, ARCH PATHOL LAB MED, V126, P1096	31	94	98	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2003	22	36					5586	5591		10.1038/sj.onc.1206845	http://dx.doi.org/10.1038/sj.onc.1206845			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944906	Bronze			2022-12-25	WOS:000184865900007
J	Gao, HM; Liu, B; Zhang, WQ; Hong, JS				Gao, HM; Liu, B; Zhang, WQ; Hong, JS			Synergistic dopaminergic neurotoxicity of MPTP and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson's disease	FASEB JOURNAL			English	Article						inflammation; microglia; NADPH oxidase; synergistic neurotoxicity	NITRIC-OXIDE SYNTHASE; ENVIRONMENTAL RISK-FACTORS; SUBSTANTIA-NIGRA; NADPH OXIDASE; GLIAL-CELLS; MICROGLIAL ACTIVATION; INTRANIGRAL INJECTION; INFLAMMATORY REACTION; ALZHEIMERS-DISEASE; PESTICIDE EXPOSURE	Parkinson's disease (PD) is a profound movement disorder resulting from progressive degeneration of the nigrostriatal dopaminergic pathway. Although its etiology remains unknown, increasing evidence suggests the involvement of multiple factors such as environmental toxins and genetic susceptibilities in the pathogenesis of PD. In this study using mesencephalic neuronglia cultures as an in vitro PD model, we demonstrated that the neurotoxin 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP, 0.1-0.5 muM) and an inflammogen lipopolysaccharide (LPS, 0.5 ng/ml) synergistically induced a progressive and selective degeneration of dopaminergic neurons. The synergistic neurotoxicity was observed when both agents were applied either simultaneously or in tandem. The synergistic neurotoxicity was more prominent when lower doses of both agents were applied for a longer period of time. Mechanistically, microglial NADPH oxidase-mediated generation of reactive oxygen species played a pivotal role in the synergistic neurotoxicity: MPTP and LPS synergistically stimulated the NADPH oxidase-mediated release of superoxide free radical; pharmacological inhibition and genetic inactivation of NADPH oxidase prevented superoxide production and the synergistic neurotoxicity. Additionally, inhibition of nitric oxide synthase afforded significant neuroprotection, suggesting the involvement of nitric oxide in the synergistic neurotoxicity. This study lends strong support for a multifactorial etiology of PD and provides clues for therapeutic interventions.	NIEHS, Neuropharmacol Sect, Lab Pharmacol & Chem, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Gao, HM (corresponding author), NIEHS, Neuropharmacol Sect, Lab Pharmacol & Chem, NIH, POB 12233,F1-01, Res Triangle Pk, NC 27709 USA.	gao@niehs.nih.gov	liu, Bin/A-7695-2009; gao, huiming/C-8454-2012; Hong, Jau-shyong/F-1920-2019	Hong, Jau-shyong/0000-0002-3056-8401				AKIYAMA H, 1989, BRAIN RES, V489, P247, DOI 10.1016/0006-8993(89)90857-3; Alam M, 2002, BEHAV BRAIN RES, V136, P317, DOI 10.1016/S0166-4328(02)00180-8; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Beal MF, 2001, NAT REV NEUROSCI, V2, P325, DOI 10.1038/35072550; BECKMAN JS, 1993, NATURE, V364, P584, DOI 10.1038/364584a0; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; Casals J, 1998, J NEURAL TRANSM, V105, P645, DOI 10.1007/s007020050086; Cassarino DS, 1997, BBA-MOL BASIS DIS, V1362, P77, DOI 10.1016/S0925-4439(97)00070-7; Castano A, 1998, J NEUROCHEM, V70, P1584; CHAN P, 1991, J NEUROCHEM, V57, P348, DOI 10.1111/j.1471-4159.1991.tb02134.x; CHAO CC, 1992, J IMMUNOL, V149, P2736; Cicchetti F, 2002, EUR J NEUROSCI, V15, P991, DOI 10.1046/j.1460-9568.2002.01938.x; Dehmer T, 2000, J NEUROCHEM, V74, P2213, DOI 10.1046/j.1471-4159.2000.0742213.x; Du YS, 2001, P NATL ACAD SCI USA, V98, P14669, DOI 10.1073/pnas.251341998; Fleckenstein AE, 1997, EUR J PHARMACOL, V334, P111, DOI 10.1016/S0014-2999(97)01175-8; Gao HM, 2003, J NEUROSCI, V23, P1228, DOI 10.1523/JNEUROSCI.23-04-01228.2003; Gao HM, 2002, J NEUROSCI, V22, P782, DOI 10.1523/JNEUROSCI.22-03-00782.2002; Gao HM, 2002, J NEUROCHEM, V81, P1285, DOI 10.1046/j.1471-4159.2002.00928.x; Gorell JM, 1998, NEUROLOGY, V50, P1346, DOI 10.1212/WNL.50.5.1346; Greenamyre JT, 1999, BIOCHEM SOC SYMP, V66, P85, DOI 10.1042/bss0660085; Hanson GR, 1998, ANN NY ACAD SCI, V844, P103, DOI 10.1111/j.1749-6632.1998.tb08225.x; Hantraye P, 1996, NAT MED, V2, P1017, DOI 10.1038/nm0996-1017; HASEGAWA E, 1990, BIOCHEM BIOPH RES CO, V170, P1049, DOI 10.1016/0006-291X(90)90498-C; Herishanu YO, 2001, CAN J NEUROL SCI, V28, P144, DOI 10.1017/S0317167100052835; Hirsch EC, 1998, ANN NEUROL, V44, pS115, DOI 10.1002/ana.410440717; Hunot S, 1999, J NEUROSCI, V19, P3440; Hunot S, 1997, P NATL ACAD SCI USA, V94, P7531, DOI 10.1073/pnas.94.14.7531; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Iravani MM, 2002, NEUROSCIENCE, V110, P49, DOI 10.1016/S0306-4522(01)00562-0; Jenner P, 1998, MOVEMENT DISORD, V13, P24; Kidd P M, 2000, Altern Med Rev, V5, P502; Kim WG, 2000, J NEUROSCI, V20, P6309, DOI 10.1523/JNEUROSCI.20-16-06309.2000; Kurkowska-Jastrzebska I, 1999, EXP NEUROL, V156, P50, DOI 10.1006/exnr.1998.6993; LANGSTON JW, 1985, LIFE SCI, V36, P201; Langston JW, 1999, ANN NEUROL, V46, P598, DOI 10.1002/1531-8249(199910)46:4<598::AID-ANA7>3.0.CO;2-F; Li YB, 1998, BIOCHEM BIOPH RES CO, V253, P295, DOI 10.1006/bbrc.1998.9729; Liberatore GT, 1999, NAT MED, V5, P1403; Ling ZD, 2002, MOVEMENT DISORD, V17, P116, DOI 10.1002/mds.10078; Liou HH, 1997, NEUROLOGY, V48, P1583, DOI 10.1212/WNL.48.6.1583; Liu B, 2000, J PHARMACOL EXP THER, V295, P125; Liu B, 2000, NEUROSCIENCE, V97, P749, DOI 10.1016/S0306-4522(00)00057-9; Liu B, 2003, J PHARMACOL EXP THER, V304, P1, DOI 10.1124/jpet.102.035048; Liu B, 2002, ANN NY ACAD SCI, V962, P318, DOI 10.1111/j.1749-6632.2002.tb04077.x; McCormack AL, 2002, NEUROBIOL DIS, V10, P119, DOI 10.1006/nbdi.2002.0507; MCGEER PL, 1988, NEUROLOGY, V38, P1285, DOI 10.1212/WNL.38.8.1285; Nagatsu T, 2000, J NEURAL TRANSM-SUPP, P143; Nagatsu T, 2000, ADV RES NEURODEGENER, V8, P277; Noh KM, 2000, J NEUROSCI, V20; Olanow CW, 1999, ANNU REV NEUROSCI, V22, P123, DOI 10.1002/mds.23732; Park SU, 2002, J NEUROSCI, V22, P4399, DOI 10.1523/JNEUROSCI.22-11-04399.2002; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Przedborski S, 1996, P NATL ACAD SCI USA, V93, P4565, DOI 10.1073/pnas.93.10.4565; RAJPUT AH, 1987, NEUROLOGY, V37, P1820, DOI 10.1212/WNL.37.11.1820; RAVENHOLT RT, 1982, LANCET, V2, P860; Ritz B, 2000, INT J EPIDEMIOL, V29, P323, DOI 10.1093/ije/29.2.323; SCHULZ JB, 1995, J NEUROCHEM, V64, P936, DOI 10.1046/j.1471-4159.1995.64020936.x; SEMCHUK KM, 1992, NEUROLOGY, V42, P1328, DOI 10.1212/WNL.42.7.1328; SNYDER SH, 1985, NATURE, V317, P198, DOI 10.1038/317198a0; Sriram K, 2002, FASEB J, V16, P1474, DOI 10.1096/fj.02-0216fje; SUZUKI K, 1990, ADV NEUROL, V53, P215; SUZUKI K, 1992, J NEUROL SCI, V109, P219, DOI 10.1016/0022-510X(92)90172-H; Tammariello SP, 2000, J NEUROSCI, V20; Thiruchelvam M, 2000, J NEUROSCI, V20, P9207; Vila M, 2001, CURR OPIN NEUROL, V14, P483, DOI 10.1097/00019052-200108000-00009; WILLIAMS DB, 1991, NEUROLOGY, V41, P1554, DOI 10.1212/WNL.41.10.1554; Wu DC, 2002, J NEUROSCI, V22, P1763, DOI 10.1523/JNEUROSCI.22-05-01763.2002; Xie Z, 2002, J NEUROSCI, V22, P3484	67	131	135	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1957	+		10.1096/fj.03-0203fje	http://dx.doi.org/10.1096/fj.03-0203fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12923073				2022-12-25	WOS:000185345100007
J	Wang, LH; Ho, B; Ding, JL				Wang, LH; Ho, B; Ding, JL			Transcriptional regulation of limulus factor C - Repression of an NF kappa B motif modulates its responsiveness to bacterial lipopolysaccharide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; HORSESHOE-CRAB; SERINE-PROTEASE; DROSOPHILA TOLL; FACTOR-X; INNATE IMMUNITY; MOLECULAR-BASIS; COAGULATION; GENE; SEQUENCE	Serine proteases play fundamental roles in invertebrate development, hemostasis, and innate immunity. This is exemplified by the limulus Factor C, which is a serine protease that binds a pathogen-associated molecule, lipopolysaccharide (LPS) to trigger a blood coagulation cascade. As a central molecule in the limulus innate immunity and hemostasis, Factor C gene expression has been detected in two major immune defense tissues, the amebocytes and hepatopancreas. Infection of the limulus with live Gram-negative bacteria induces a 2-3-fold increase in mRNA transcripts in both tissues. However, in vitro studies in Drosophila cell lines using Factor C promoter-reporter chimera DNA constructs, and site-directed mutagenesis of the promoter demonstrated that a proximal kappaB binding site, aided by an adjacent dorsal-like binding motif responds dramatically to LPS and dorsal transcription factor overexpression. Electrophoretic mobility shift assay further confirmed a strong interaction of the limulus kappaB motif with Rel proteins. However, deletion constructs of the Factor C promoter harboring different numbers of dorsal-like binding sites upstream of the kappaB motif as well as the electrophoretic mobility shift assay of these motifs with Rel proteins strongly suggest that the up-regulation of Factor C gene expression is attenuated during microbial challenge. The repression of the dramatic activation of this pathogen-responsive gene by LPS is probably effected via competition between the dorsal-like motifs over the proximal LPS-responsive kappaB unit, or through inhibition from the upstream repressive element(s), which accounts for the gene expression pattern observed in vivo. Our findings demonstrate that blood coagulation and innate immune response are integrated at the transcriptional level in this ancient organism, and that this LPS-responsive serine protease is controlled by an evolutionarily conserved NFkappaB pathway.	Natl Univ Singapore, Dept Biol Sci, Singapore 117543, Singapore; Natl Univ Singapore, Dept Microbiol, Singapore 117543, Singapore	National University of Singapore; National University of Singapore	Ding, JL (corresponding author), Natl Univ Singapore, Dept Biol Sci, 14 Sci Dr 4, Singapore 117543, Singapore.	dbsdjl@nus.edu.sg	Ding, Jeak/H-8057-2012					Akira S, 1997, ADV IMMUNOL, V65, P1, DOI 10.1016/S0065-2776(08)60740-3; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; Bergner A, 1996, EMBO J, V15, P6789, DOI 10.1002/j.1460-2075.1996.tb01070.x; CHOW BKC, 1991, J BIOL CHEM, V266, P18927; Cicala C, 1998, LIFE SCI, V62, P1817, DOI 10.1016/S0024-3205(97)01167-3; Citarella F, 1997, BLOOD, V90, P1501, DOI 10.1182/blood.V90.4.1501.1501_1501_1507; CITARELLA F, 1993, BIOCHIM BIOPHYS ACTA, V1172, P197, DOI 10.1016/0167-4781(93)90294-N; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Ding Jeak L., 1995, Molecular Marine Biology and Biotechnology, V4, P90; DING JL, 1993, BIOCHIM BIOPHYS ACTA, V1202, P149, DOI 10.1016/0167-4838(93)90076-4; Dushay MS, 1996, P NATL ACAD SCI USA, V93, P10343, DOI 10.1073/pnas.93.19.10343; ERDMANN D, 1995, J BIOL CHEM, V270, P22988, DOI 10.1074/jbc.270.39.22988; Gateff E., 1980, INVERTEBRATE SYSTEMS, P517; GAY NJ, 1992, BIOCHIM BIOPHYS ACTA, V1132, P290, DOI 10.1016/0167-4781(92)90163-T; GEORGEL P, 1995, NUCLEIC ACIDS RES, V23, P1140, DOI 10.1093/nar/23.7.1140; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Hader T, 2000, CURR BIOL, V10, P51, DOI 10.1016/S0960-9822(99)00265-1; HASSAN JH, 1992, THROMB HAEMOSTASIS, V67, P478; Hoffman M, 2001, THROMB HAEMOSTASIS, V85, P958, DOI 10.1055/s-0037-1615947; Hoffman M, 1996, HAEMOSTASIS, V26, P12; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; HUANG MN, 1992, J BIOL CHEM, V267, P15440; Inamori K, 2000, J ENDOTOXIN RES, V6, P397, DOI 10.1179/096805100101532342; IP YT, 1991, CELL, V64, P439; Iwanaga S, 2002, CURR OPIN IMMUNOL, V14, P87, DOI 10.1016/S0952-7915(01)00302-8; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; Khush RS, 2000, TRENDS GENET, V16, P442, DOI 10.1016/S0168-9525(00)02095-3; Krem MM, 2002, TRENDS BIOCHEM SCI, V27, P67, DOI 10.1016/S0968-0004(01)02007-2; KURACHI S, 1994, BIOCHEMISTRY-US, V33, P1580, DOI 10.1021/bi00172a039; Lee SK, 2000, J BIOL CHEM, V275, P12470, DOI 10.1074/jbc.275.17.12470; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Leulier F, 2003, NAT IMMUNOL, V4, P478, DOI 10.1038/ni922; Ligoxygakis P, 2002, SCIENCE, V297, P114, DOI 10.1126/science.1072391; Liu C, 2001, J BIOL CHEM, V276, P34686, DOI 10.1074/jbc.M105566200; Mackay IS, 1996, CLIN EXP ALLERGY, V26, P1; MACKMAN N, 1995, FASEB J, V9, P883, DOI 10.1096/fasebj.9.10.7615158; MASON P, 1993, GENE TRANSCRIPTION P, P47; MIAO CH, 1992, J BIOL CHEM, V267, P7395; Michel T, 2001, NATURE, V414, P756, DOI 10.1038/414756a; Misra S, 1998, DEVELOPMENT, V125, P1261; Mizuguchi K, 1998, TRENDS BIOCHEM SCI, V23, P239, DOI 10.1016/S0968-0004(98)01216-X; MOON DK, 1988, J IMMUNOL, V141, P1536; Morisato D, 1995, ANNU REV GENET, V29, P371, DOI 10.1146/annurev.genet.29.1.371; MUTA T, 1991, J BIOL CHEM, V266, P6554; Muta T, 1996, CURR OPIN IMMUNOL, V8, P41, DOI 10.1016/S0952-7915(96)80103-8; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; Opal SM, 2000, CRIT CARE MED, V28, pS77, DOI 10.1097/00003246-200009001-00017; PETERSEN UM, 1995, EMBO J, V14, P3146, DOI 10.1002/j.1460-2075.1995.tb07317.x; Pollak ES, 1996, J BIOL CHEM, V271, P1738, DOI 10.1074/jbc.271.3.1738; RAWLINGS ND, 1993, BIOCHEM J, V290, P205, DOI 10.1042/bj2900205; Sambrook J, 1988, MOL CLONING LAB MANU; Soderhall K, 1998, CURR OPIN IMMUNOL, V10, P23, DOI 10.1016/S0952-7915(98)80026-5; Tan NS, 2000, FASEB J, V14, P859, DOI 10.1096/fasebj.14.7.859; Tetsuka T, 2000, J BIOL CHEM, V275, P4383, DOI 10.1074/jbc.275.6.4383; THISSE C, 1991, CELL, V65, P1191, DOI 10.1016/0092-8674(91)90014-P; Wang J, 2002, J BIOL CHEM, V277, P36363, DOI 10.1074/jbc.M202837200; WAY M, 1995, J CELL BIOL, V128, P51, DOI 10.1083/jcb.128.1.51; Wilberding JA, 2000, THROMB HAEMOSTASIS, V84, P1031	60	10	11	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49428	49437		10.1074/jbc.M306641200	http://dx.doi.org/10.1074/jbc.M306641200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	12949077	hybrid			2022-12-25	WOS:000186829000111
J	Munshi, A; Cannella, D; Brickner, H; Salles-Passador, I; Podust, V; Fotedar, R; Fotedar, A				Munshi, A; Cannella, D; Brickner, H; Salles-Passador, I; Podust, V; Fotedar, R; Fotedar, A			Cell cycle-dependent phosphorylation of the large subunit of replication factor C (RF-C) leads to its dissociation from the RF-C complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE ALPHA-PRIMASE; DNA-REPLICATION; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; 37-KDA SUBUNIT; S-PHASE; RECONSTITUTION; CLONING; RAD24; GENE	The five subunit replication factor C (RF-C) complex plays a critical role in DNA elongation. We find that the large subunit of RF-C (RF-Cp145) is phosphorylated in vivo whereas the smaller RF- C subunits are not phosphorylated. The phosphorylation of endogenous RF-Cp145 is modulated in a cell cycle-dependent manner. Phosphorylation is maximal in G(2)/M and is inhibited by an inhibitor of cyclin-dependent kinases. Phosphorylation of purified recombinant RF-C complex in vitro reveals that RF-Cp145 is preferentially phosphorylated by cdc2-cyclin B but not by cdk2-cyclin A or cdk2-cyclin E. In vitro phosphorylation of RF-C complex by cdc2-cyclin B kinases leads to dissociation of phosphorylated RF-Cp145 from the RF-C complex. Using different approaches we demonstrate that phosphorylated RF-Cp145 is indeed dissociated from RF-Cp40 and RF-Cp37 in vivo. These results suggest that destabilization of the RF-C complex by CDKs may inactivate the RF-C complex at the end of S phase.	Inst Biol Struct, F-38027 Grenoble 1, France; Sidney Kimmel Canc Ctr, San Diego, CA 92121 USA; Vanderbilt Univ, Dept Mol Biol, Nashville, TN 37235 USA	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); Vanderbilt University	Fotedar, A (corresponding author), Inst Biol Struct, 41 Rue Jules Horowitz, F-38027 Grenoble 1, France.	afotedar@skcc.org	Cannella, Dominique/F-4879-2019	Cannella, Dominique/0000-0002-1665-9833	NCI NIH HHS [CA92321, CA74435] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092321, R01CA074435] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bellaoui M, 2003, EMBO J, V22, P4304, DOI 10.1093/emboj/cdg406; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; BUNZ F, 1993, P NATL ACAD SCI USA, V90, P11014, DOI 10.1073/pnas.90.23.11014; BURBELO PD, 1993, P NATL ACAD SCI USA, V90, P11543, DOI 10.1073/pnas.90.24.11543; Cai JS, 1996, P NATL ACAD SCI USA, V93, P12896, DOI 10.1073/pnas.93.23.12896; CHEN M, 1992, P NATL ACAD SCI USA, V89, P5211, DOI 10.1073/pnas.89.12.5211; CHEN M, 1992, P NATL ACAD SCI USA, V89, P2516, DOI 10.1073/pnas.89.7.2516; CULLMANN G, 1995, MOL CELL BIOL, V15, P4661; Ellison V, 1998, J BIOL CHEM, V273, P5979, DOI 10.1074/jbc.273.10.5979; FOTEDAR R, 1991, COLD SH Q B, V56, P325; Fotedar R, 1996, EMBO J, V15, P4423, DOI 10.1002/j.1460-2075.1996.tb00815.x; Fotedar R, 1996, ONCOGENE, V12, P2155; Frouin I, 2002, EMBO J, V21, P2485, DOI 10.1093/emboj/21.10.2485; Green CM, 2000, CURR BIOL, V10, P39, DOI 10.1016/S0960-9822(99)00263-8; HAYLES J, 1994, CELL, V78, P813, DOI 10.1016/S0092-8674(94)90542-8; HOWELL EA, 1994, MOL CELL BIOL, V14, P255, DOI 10.1128/MCB.14.1.255; HUBSCHER U, 1996, DNA REPLICATION EUKA, P525; Itzhaki JE, 1997, NAT GENET, V15, P258, DOI 10.1038/ng0397-258; Jallepalli PV, 1997, GENE DEV, V11, P2767, DOI 10.1101/gad.11.21.2767; Jeruzalmi D, 2001, CELL, V106, P429, DOI 10.1016/S0092-8674(01)00463-9; Jeruzalmi D, 2001, CELL, V106, P417, DOI 10.1016/S0092-8674(01)00462-7; Jiang W, 1999, P NATL ACAD SCI USA, V96, P6193, DOI 10.1073/pnas.96.11.6193; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; LI XY, 1994, P NATL ACAD SCI USA, V91, P868, DOI 10.1073/pnas.91.3.868; LI XY, 1994, J BIOL CHEM, V269, P21880; Maga G, 1997, BIOCHEMISTRY-US, V36, P5300, DOI 10.1021/bi962809n; Mayer ML, 2001, MOL CELL, V7, P959, DOI 10.1016/S1097-2765(01)00254-4; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Meijer L, 1997, METHOD ENZYMOL, V283, P113; Naiki T, 2000, MOL CELL BIOL, V20, P5888, DOI 10.1128/MCB.20.16.5888-5896.2000; Nishitani H, 2001, J BIOL CHEM, V276, P44905, DOI 10.1074/jbc.M105406200; O'Donnell M, 2001, CURR BIOL, V11, pR935, DOI 10.1016/S0960-9822(01)00559-0; Pennaneach V, 2001, MOL CELL, V7, P715, DOI 10.1016/S1097-2765(01)00217-9; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; Podust VN, 1997, J BIOL CHEM, V272, P6303, DOI 10.1074/jbc.272.10.6303; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; Shimomura T, 1998, MOL CELL BIOL, V18, P5485, DOI 10.1128/MCB.18.9.5485; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; Treuner K, 1999, J BIOL CHEM, V274, P15556, DOI 10.1074/jbc.274.22.15556; Uhlmann F, 1997, J BIOL CHEM, V272, P10058; Uhlmann F, 1996, P NATL ACAD SCI USA, V93, P6521, DOI 10.1073/pnas.93.13.6521; Voitenleitner C, 1997, ONCOGENE, V14, P1611, DOI 10.1038/sj.onc.1200975; Voitenleitner C, 1999, MOL CELL BIOL, V19, P646; Wuarin J, 2002, CELL, V111, P419, DOI 10.1016/S0092-8674(02)01042-5	45	9	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48467	48473		10.1074/jbc.M309349200	http://dx.doi.org/10.1074/jbc.M309349200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12947101	hybrid			2022-12-25	WOS:000186731400132
J	Zhu, Y; Cai, XL; Wang, ZY; Hong, MM				Zhu, Y; Cai, XL; Wang, ZY; Hong, MM			An interaction between a MYC protein and an EREBP protein is involved in transcriptional regulation of the rice Wx gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; FUNCTIONAL-ANALYSIS; ARABIDOPSIS; EXPRESSION; ENDOSPERM; IDENTIFICATION; SEQUENCE; ENCODES; REGION	We previously demonstrated that a 31-bp nucleotide sequence located upstream of the rice Wx gene played an important role in its expression. We further showed that this cis-acting regulator interacts with nuclear proteins extracted from developing rice endosperm. We used the 31-bp sequence as bait in a yeast one-hybrid system to isolate several cDNA clones from a rice cDNA expression library. One of these cDNAs encodes a MYC protein, designated OsBP-5, which is 335 amino acids long and contains a putative basic helix-loop-helix-ZIP DNA-binding domain. This domain exhibits 50% amino acid sequence identity with the R/B proteins that regulate the expression of genes involved in anthocyanin biosynthesis in plants. The results of electrophoretic mobility shift assays (EMSAs) and Southwestern gel blots indicate that this protein binds specifically to the CAACGTG motif within the 31-bp sequence. However, by itself, the OsBP-5 protein is unable to trans-activate a lacZ reporter gene controlled by the 31-bp sequence when tested in a yeast expression system. Interestingly, OsBP-5 can trans-activate this reporter gene when another protein, OsEBP-89, a member of the EREBP family of transcription factors, is present. Furthermore, in vitro pull-down experiments show that a protein isolated from developing rice endosperm interacts with the OsBP-5 protein, and Western blots confirm that the interacting protein is OsEBP-89. The formation of a supershift band in EMSAs also indicates that two proteins interact with each other. Interference of OsBP-5 gene expression by double-stranded RNA reduces the amylose content in mature seed of transgenic rice plants but has no visible effect on their phenotype. These results suggest that the OsBP-5 and OsEBP-89 proteins act synergistically, perhaps as a heterodimer, to regulate the transcription of the rice Wx gene.	Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai Inst Plant Physiol & Ecol, Natl Key Lab Plant Mol Genet, Shanghai 200032, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Hong, MM (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai Inst Plant Physiol & Ecol, Natl Key Lab Plant Mol Genet, 300 Fenglin Rd, Shanghai 200032, Peoples R China.	Hongmm@iris.sipp.ac.cn		cai, xiu ling/0000-0001-8333-4556				Abe H, 1997, PLANT CELL, V9, P1859, DOI 10.1105/tpc.9.10.1859; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; Buttner M, 1997, P NATL ACAD SCI USA, V94, P5961, DOI 10.1073/pnas.94.11.5961; Chen Li, 1999, Acta Phytophysiologica Sinica, V25, P110; Chen Li, 1997, Acta Phytophysiologica Sinica, V23, P313; Chuang CF, 2000, P NATL ACAD SCI USA, V97, P4985, DOI 10.1073/pnas.060034297; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; Diaz I, 2002, PLANT J, V29, P453, DOI 10.1046/j.0960-7412.2001.01230.x; Fink G., 1991, METHOD ENZYMOL, V194, P14; Ge Hong-Fei, 2000, Acta Phytophysiologica Sinica, V26, P159; GOFF SA, 1992, GENE DEV, V6, P864, DOI 10.1101/gad.6.5.864; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HIEI Y, 1994, PLANT J, V6, P271, DOI 10.1046/j.1365-313X.1994.6020271.x; JULIANO BO, 1971, CEREAL SCI TODAY, V16, P334; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LI YZ, 1995, PLANT SCI, V108, P181, DOI 10.1016/0168-9452(95)04143-I; Liu Qiao-Quan, 1998, Acta Phytophysiologica Sinica, V24, P259; LLOYD AM, 1992, SCIENCE, V258, P1773, DOI 10.1126/science.1465611; Miller JH., 1972, EXPT MOL GENETICS; Mol J, 1996, CRIT REV PLANT SCI, V15, P525, DOI 10.1080/07352689609382369; Moon YH, 1999, PLANT MOL BIOL, V40, P167, DOI 10.1023/A:1026429922616; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; Payne CT, 2000, GENETICS, V156, P1349; ROTH BA, 1991, PLANT CELL, V3, P317, DOI 10.1105/tpc.3.3.317; Sambrook J, 1989, MOL CLONING LAB MANU, V2; SCHMITZ ML, 1989, J BIOL CHEM, V264, P1467; Singh KB, 1998, PLANT PHYSIOL, V118, P1111, DOI 10.1104/pp.118.4.1111; TAKAIWA F, 1990, MOL GEN GENET, V224, P289, DOI 10.1007/BF00271563; WANG ZY, 1995, PLANT J, V7, P613, DOI 10.1046/j.1365-313X.1995.7040613.x; WANG ZY, 1990, NUCLEIC ACIDS RES, V18, P5898, DOI 10.1093/nar/18.19.5898; WANG ZY, 1994, SCI CHINA SER B, V37, P437; Yang HJ, 2002, PLANT MOL BIOL, V50, P379, DOI 10.1023/A:1019859612791; Yao CaiPing, 1996, Acta Phytophysiologica Sinica, V22, P431; ZACHGO S, 1995, DEVELOPMENT, V121, P2861; Zheng FQ, 1993, PLANT PHYSL COMMUN, V29, P438	35	99	116	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47803	47811		10.1074/jbc.M302806200	http://dx.doi.org/10.1074/jbc.M302806200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12947109	hybrid			2022-12-25	WOS:000186731400056
J	Wongtrakool, C; Malpel, S; Gorenstein, J; Sedita, J; Ramirez, MI; Underhill, TM; Cardoso, WV				Wongtrakool, C; Malpel, S; Gorenstein, J; Sedita, J; Ramirez, MI; Underhill, TM; Cardoso, WV			Down-regulation of retinoic acid receptor alpha signaling is required for sacculation and type I cell formation in the developing lung	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRANCHING MORPHOGENESIS; TRANSCRIPTION FACTOR; ALVEOLUS FORMATION; DIFFERENTIATION; EXPRESSION; GENE; DEFECTS; PATTERN; GATA-6; BETA	Although retinoic acid (RA) has been shown to be critical for lung development, little is known about when RA is required and the role of individual RA receptors (RAR) in this process. Previously reported data from an RA responsive element RARE-lacZ reporter mouse show that when epithelial tubules are branching and differentiating RA signaling becomes markedly down-regulated in the epithelium. It is unclear why this down-regulation occurs and what role it might play in the developing lung. Here we analyze the effects of preventing potential progenitors of the distal lung from turning off RA signaling by locally expressing constitutively activated RARalpha or RARbeta chimeric receptors (RARVP16) in branching airways of transgenic mice. Continued RA activation resulted in lung immaturity in both cases, but the phenotypes were remarkably different. RARalphaVP16 lungs did not expand to form saccules or morphologically identifiable type I cells. High levels of surfactant protein C (Sp-C), thyroid transcription factor-1 (Ttf1), and Gata6, but not Sp-A or Sp-B in the epithelium at birth suggested that in these lungs differentiation was arrested at an early stage. These alterations were not observed in RARbetaVP16 lungs, which showed relatively less severe changes. Our data suggest a model in which activation of RAR signaling at the onset of lung development establishes an initial program that assigns distal cell fate to the prospective lung epithelium. Downregulation of RA signaling, however, is required to allow completion of later steps of this differentiation program that ultimately form mature type I and II cells.	Boston Univ, Sch Med, Ctr Pulm, Dept Med, Boston, MA 02118 USA; Univ Western Ontario, Sch Dent, London, ON N6A 5B8, Canada	Boston University; Western University (University of Western Ontario)	Cardoso, WV (corresponding author), Boston Univ, Sch Med, Ctr Pulm, Dept Med, 80 E Concord St,R-304, Boston, MA 02118 USA.	wcardoso@lung.bumc.bu.edu		Ramirez, Maria Isabel/0000-0001-6294-4419; Cardoso, Wellington/0000-0002-2550-3697	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067129] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL067129, R01 HL067129-01, R01 HL/HD 67129-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bellusci S, 1997, DEVELOPMENT, V124, P4867; CARDOSO WV, 1995, AM J RESP CELL MOL, V12, P464, DOI 10.1165/ajrcmb.12.5.7742011; Cardoso WV, 1996, DEV DYNAM, V207, P47, DOI 10.1002/(SICI)1097-0177(199609)207:1<47::AID-AJA6>3.0.CO;2-W; Celli G, 1998, EMBO J, V17, P1642, DOI 10.1093/emboj/17.6.1642; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chazaud C, 1999, DEVELOPMENT, V126, P2589; Colbert MC, 1997, J CLIN INVEST, V100, P1958, DOI 10.1172/JCI119727; Dickman ED, 1997, DEVELOPMENT, V124, P3111; DOLLE P, 1990, DEVELOPMENT, V110, P1133; Ghatpande S, 2000, DEV BIOL, V219, P59, DOI 10.1006/dbio.1999.9601; Gove C, 1997, EMBO J, V16, P355, DOI 10.1093/emboj/16.2.355; Hind M, 2002, AM J PHYSIOL-LUNG C, V282, pL468, DOI 10.1152/ajplung.00196.2001; IKEDA K, 1994, AM J PHYSIOL, V267, pL309, DOI 10.1152/ajplung.1994.267.3.L309; Kastner P, 1997, DEVELOPMENT, V124, P4749; Keijzer R, 2001, DEVELOPMENT, V128, P503; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; Koutsourakis M, 2001, MECH DEVELOP, V105, P105, DOI 10.1016/S0925-4773(01)00386-0; Liu C, 2002, AM J PHYSIOL-LUNG C, V283, pL468, DOI 10.1152/ajplung.00044.2002; Malpel S, 2000, DEVELOPMENT, V127, P3057; Massaro D, 2002, AM J PHYSIOL-LUNG C, V282, pL345, DOI 10.1152/ajplung.00374.2001; Massaro GD, 2000, PHYSIOL GENOMICS, V4, P51, DOI 10.1152/physiolgenomics.2000.4.1.51; Massaro GD, 2003, AM J PHYSIOL-LUNG C, V284, pL431, DOI 10.1152/ajplung.00245.2002; MENDELSOHN C, 1994, DEVELOPMENT, V120, P2749; Mendelson CR, 2000, ANNU REV PHYSIOL, V62, P875, DOI 10.1146/annurev.physiol.62.1.875; METZLER MD, 1993, ENDOCRINOLOGY, V133, P1990, DOI 10.1210/en.133.5.1990; Minoo P, 1999, DEV BIOL, V209, P60, DOI 10.1006/dbio.1999.9234; Mollard R, 2000, INT J DEV BIOL, V44, P457; Mollard R, 2000, MECH DEVELOP, V94, P223, DOI 10.1016/S0925-4773(00)00303-8; Morrisey EE, 1996, DEV BIOL, V177, P309, DOI 10.1006/dbio.1996.0165; Niederreither K, 1999, NAT GENET, V21, P444, DOI 10.1038/7788; Park WY, 1998, DEV BIOL, V201, P125, DOI 10.1006/dbio.1998.8994; Perl AKT, 2002, P NATL ACAD SCI USA, V99, P10482, DOI 10.1073/pnas.152238499; Perl AKT, 2003, DEV BIOL, V258, P154, DOI 10.1016/S0012-1606(03)00106-4; PETERS K, 1994, EMBO J, V13, P3296, DOI 10.1002/j.1460-2075.1994.tb06631.x; Ramirez MI, 2003, DEV BIOL, V256, P61, DOI 10.1016/S0012-1606(02)00098-2; ROSSANT J, 1991, GENE DEV, V5, P1333, DOI 10.1101/gad.5.8.1333; SCHUGER L, 1993, DEV BIOL, V159, P462, DOI 10.1006/dbio.1993.1256; Sekine K, 1999, NAT GENET, V21, P138, DOI 10.1038/5096; Taneja R, 1996, P NATL ACAD SCI USA, V93, P6197, DOI 10.1073/pnas.93.12.6197; Tsukui T, 1999, P NATL ACAD SCI USA, V96, P11376, DOI 10.1073/pnas.96.20.11376; UNDERHILL TM, 1994, MOL ENDOCRINOL, V8, P274, DOI 10.1210/me.8.3.274; Weaver M, 2000, DEVELOPMENT, V127, P2695; WERT SE, 1993, DEV BIOL, V156, P426, DOI 10.1006/dbio.1993.1090; Weston AD, 2000, J CELL BIOL, V148, P679, DOI 10.1083/jcb.148.4.679; Williams MC, 2003, ANNU REV PHYSIOL, V65, P669, DOI 10.1146/annurev.physiol.65.092101.142446; WILSON JG, 1953, AM J ANAT, V92, P189, DOI 10.1002/aja.1000920202; Yang HH, 2002, DEVELOPMENT, V129, P2233; YOUNG SL, 1991, AM J PHYSIOL, V260, pL113, DOI 10.1152/ajplung.1991.260.2.L113	48	46	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46911	46918		10.1074/jbc.M307977200	http://dx.doi.org/10.1074/jbc.M307977200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12947094	Green Accepted, hybrid			2022-12-25	WOS:000186569400085
J	Huber, WE; Price, ER; Widlund, HR; Du, JY; Davis, IJ; Wegner, M; Fisher, DE				Huber, WE; Price, ER; Widlund, HR; Du, JY; Davis, IJ; Wegner, M; Fisher, DE			A tissue-restricted cAMP transcriptional response - SOX10 modulates alpha-melanocyte-stimulating hormone-triggered expression of microphthalmia-associated transcription factor in melanocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WAARDENBURG-SYNDROME; FACTOR GENE; MOUSE MODEL; PROMOTER; MITF; ACTIVATION; PAX3; MUTATION; DEAFNESS; PATHWAY	alpha-Melanocyte-stimulating hormone (MSH) utilizes cAMP to trigger pigmentation of melanocytes via activation of melanocyte-restricted microphthalmia-associated transcription factor (M-MITF) expression. M-MITF is a melanocyte-restricted helix-loop-helix transcription factor capable of transactivating promoters for multiple genes whose products modulate pigmentation. Although M-MITF promoter activation by MSH is known to occur through a conserved cAMP-response element (CRE), it remains unclear how this CRE exhibits such exquisitely tissue-restricted responsiveness. Here we show that cAMP-mediated CRE-binding protein activation of the M-MITF promoter requires a second DNA element located similar to100 bp upstream, a site that is bound and activated by SOX10. Mutations in the SOX10 transcription factor, like MITF, results in a disorder known as Waardenburg Syndrome. The cAMP response of the M-MITF promoter was analyzed in melanoma and neuroblastoma cells (which are neural crest-derived but lack both M-MITF and SOX10 expression). M-MITF promoter responsiveness to cAMP was found to depend upon SOX10, and reciprocally, SOX10 transactivation was dependent upon the CRE. Ectopic SOX10 expression, in cooperation with cAMP signaling, activated the M-MITF promoter function and the expression of measurable endogenous M-MITF transcripts in neuroblastoma cells. SOX10(dom), a mutant allele, failed to cooperate with cAMP in neuroblastoma cells and attenuated the cAMP responsiveness of the M-MITF promoter in melanoma cells. These observations demonstrate a means whereby the ubiquitous cAMP signaling machinery is harnessed to produce a highly tissue-restricted transcriptional response by cooperating with architectural factors, in this case SOX10.	Dana Farber Canc Inst, Div Pediat Hematol Oncol, Boston, MA 02115 USA; Harvard Univ, Childrens Hosp, Sch Med, Boston, MA 02115 USA; Univ Erlangen Nurnberg, Inst Biochem, D-91054 Erlangen, Germany	Harvard University; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital; Harvard Medical School; University of Erlangen Nuremberg	Fisher, DE (corresponding author), Dana Farber Canc Inst, Div Pediat Hematol Oncol, 44 Binney St, Boston, MA 02115 USA.			Widlund, Hans/0000-0002-7506-2447; Wegner, Michael/0000-0002-4586-3294; Davis, Ian/0000-0002-1552-0960	NIAMS NIH HHS [AR43369] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043369] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BENTLEY NJ, 1994, MOL CELL BIOL, V14, P7996, DOI 10.1128/MCB.14.12.7996; Bertolotto C, 1998, J CELL BIOL, V142, P827, DOI 10.1083/jcb.142.3.827; Bondurand N, 2000, HUM MOL GENET, V9, P1907, DOI 10.1093/hmg/9.13.1907; Dorsky RI, 1998, NATURE, V396, P370, DOI 10.1038/24620; Dorsky RI, 2000, GENE DEV, V14, P158; Fuse N, 1996, BIOCHEM BIOPH RES CO, V219, P702, DOI 10.1006/bbrc.1996.0298; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; Hemesath TJ, 1998, NATURE, V391, P298, DOI 10.1038/34681; Herbarth B, 1998, P NATL ACAD SCI USA, V95, P5161, DOI 10.1073/pnas.95.9.5161; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; Kuhlbrodt K, 1998, J NEUROSCI, V18, P237, DOI 10.1523/jneurosci.18-01-00237.1998; Lee M, 2000, J BIOL CHEM, V275, P37978, DOI 10.1074/jbc.M003816200; Mayall TP, 1997, GENE DEV, V11, P887, DOI 10.1101/gad.11.7.887; MOORE KJ, 1995, TRENDS GENET, V11, P442, DOI 10.1016/S0168-9525(00)89143-X; Pan L, 2001, J BIOL CHEM, V276, P45530, DOI 10.1074/jbc.M103010200; Potterf SB, 2000, HUM GENET, V107, P1, DOI 10.1007/s004390050001; Price ER, 1998, J BIOL CHEM, V273, P33042, DOI 10.1074/jbc.273.49.33042; Price ER, 2001, NEURON, V30, P15, DOI 10.1016/S0896-6273(01)00259-8; Price ER, 1998, J BIOL CHEM, V273, P17983, DOI 10.1074/jbc.273.29.17983; Saito H, 2002, J BIOL CHEM, V277, P28787, DOI 10.1074/jbc.M203719200; Southard-Smith EM, 1998, NAT GENET, V18, P60, DOI 10.1038/ng0198-60; Tabuchi A, 2002, J BIOL CHEM, V277, P35920, DOI 10.1074/jbc.M204784200; Takeda K, 2000, J BIOL CHEM, V275, P14013, DOI 10.1074/jbc.C000113200; Verastegui C, 2000, J BIOL CHEM, V275, P30757, DOI 10.1074/jbc.C000445200; Watanabe A, 1998, NAT GENET, V18, P283, DOI 10.1038/ng0398-283; YASUMOTO KI, 1994, MOL CELL BIOL, V14, P8058, DOI 10.1128/MCB.14.12.8058	27	72	76	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45224	45230		10.1074/jbc.M309036200	http://dx.doi.org/10.1074/jbc.M309036200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12944398	hybrid			2022-12-25	WOS:000186452300023
J	Le Goff, MM; Hindson, VJ; Jowitt, TA; Scott, PG; Bishop, PN				Le Goff, MM; Hindson, VJ; Jowitt, TA; Scott, PG; Bishop, PN			Characterization of opticin and evidence of stable dimerization in solution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE TAG ANALYSIS; PROTEODERMATAN SULFATE; OSTEOINDUCTIVE FACTOR; ARTICULAR-CARTILAGE; MOLECULAR-CLONING; NEIBANK PROJECT; PROTEIN; PROTEOGLYCAN; SCATTERING; COLLAGEN	Opticin is a class III member of the extracellular matrix small leucine-rich repeat protein (SLRP) family that was initially identified in the eye in association with the collagen fibrils of the vitreous humor. Recombinant and tissue-extracted forms of bovine opticin were subjected to biochemical and biophysical characterization. Following SDS-PAGE the predominant component produced by both forms was a broad band between 45-52 kDa. There was evidence for two-stage processing and, additionally, a proteolytic cleavage product of similar to25 kDa. Deconvolution of circular dichroism spectra revealed beta-sheet (41%), beta-turn (21%), and alpha-helix (10%), and thermal denaturation experiments showed a transition with a midpoint of 47degreesC. Weight-averaged molecular mass measurements using both light scattering and analytical ultracentrifugation demonstrated that opticin exists in solution as a stable dimer of similar to90 kDa, which can be dissociated into a monomer by denaturation with 2.5 M guanidine hydrochloride or during SDS-polyacrylamide electrophoresis. Opticin remains a dimer after removal of the amino-terminal region by O-sialoglycoprotein endopeptidase digestion, suggesting that dimer formation is mediated by the leucine-rich repeats. Dimerization could have a number of functional consequences, including divalent ligand interactions.	Univ Manchester, Wellcome Trust Ctr Cell Matrix Res, Sch Biol Sci, Manchester M13 9PT, Lancs, England; Univ Manchester, Sch Med, Res Grp Eye & Vis Sci, Manchester M13 9PT, Lancs, England; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada	University of Manchester; University of Manchester; University of Alberta	Bishop, PN (corresponding author), Univ Manchester, Wellcome Trust Ctr Cell Matrix Res, Sch Biol Sci, Rm 2-205,Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.			Bishop, Paul/0000-0001-7937-7932; Jowitt, Thomas/0000-0002-4045-0933				Font B, 1998, EUR J BIOCHEM, V254, P580, DOI 10.1046/j.1432-1327.1998.2540580.x; Friedman JS, 2002, HUM MOL GENET, V11, P1333, DOI 10.1093/hmg/11.11.1333; Friedman JS, 2000, INVEST OPHTH VIS SCI, V41, P2059; Funderburgh JL, 1997, J BIOL CHEM, V272, P28089, DOI 10.1074/jbc.272.44.28089; Hansen JE, 1998, GLYCOCONJUGATE J, V15, P115, DOI 10.1023/A:1006960004440; Henry SP, 2001, J BIOL CHEM, V276, P12212, DOI 10.1074/jbc.M011290200; Iozzo RV, 1999, J BIOL CHEM, V274, P18843, DOI 10.1074/jbc.274.27.18843; Jiang P, 1998, ANAL BIOCHEM, V259, P8, DOI 10.1006/abio.1998.2637; Johnson HJ, 1997, J BIOL CHEM, V272, P18709, DOI 10.1074/jbc.272.30.18709; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; LARSSON T, 1991, J BIOL CHEM, V266, P20428; LIU J, 1994, J BIOL CHEM, V269, P28366; MADISEN L, 1990, DNA CELL BIOL, V9, P303, DOI 10.1089/dna.1990.9.303; Mansson B, 2001, J BIOL CHEM, V276, P32883, DOI 10.1074/jbc.M101680200; Monigatti F, 2002, BIOINFORMATICS, V18, P769, DOI 10.1093/bioinformatics/18.5.769; Pellegrini B, 2002, GENE, V282, P121, DOI 10.1016/S0378-1119(01)00842-3; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; Ramamurthy P, 1996, J BIOL CHEM, V271, P19578, DOI 10.1074/jbc.271.32.19578; Reardon AJ, 2000, J BIOL CHEM, V275, P2123, DOI 10.1074/jbc.275.3.2123; Roughley PJ, 1996, BIOCHEM J, V318, P779, DOI 10.1042/bj3180779; SCOTT P G, 1991, Biochemical Society Transactions, V19, p377S; SCOTT PG, 1986, BIOCHEM BIOPH RES CO, V138, P1348, DOI 10.1016/S0006-291X(86)80431-4; Scott PG, 2003, J BIOL CHEM, V278, P18353, DOI 10.1074/jbc.M211936200; SHINOMURA T, 1992, J BIOL CHEM, V267, P1265; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; Takanosu M, 2001, INVEST OPHTH VIS SCI, V42, P2202; Tanford C., 1961, PHYSICAL CHEMISTRY M, P381; Wistow G, 2002, MOL VIS, V8, P205; Wistow G, 2002, MOL VIS, V8, P185; ZANGRANDO D, 1989, BIOPOLYMERS, V28, P1295, DOI 10.1002/bip.360280710	31	37	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45280	45287		10.1074/jbc.M303117200	http://dx.doi.org/10.1074/jbc.M303117200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12951322	hybrid			2022-12-25	WOS:000186452300029
J	Bloom, DA; Jaiswal, AK				Bloom, DA; Jaiswal, AK			Phosphorylation of Nrf2 at Ser(40) by protein kinase C in response to antioxidants leads to the release of Nrf2 from INrf2, but is not required for Nrf2 stabilization/accumulation in the nucleus and transcriptional activation of antioxidant response element-mediated NAD(P)H : quinone oxidoreductase-1 gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCTION; ENZYMES; KEAP1; SUSCEPTIBILITY; DEGRADATION; DISRUPTION; DEFICIENCY; MECHANISM; NAD(P)H; CELLS	The antioxidant response element ( ARE) and transcription factor Nrf2 regulate basal expression and antioxidant induction of NAD(P)H: quinone oxidoreductase-1 (NQO1) and other detoxifying genes. Under normal conditions, Nrf2 is targeted for proteasomal degradation by INrf2. Oxidative stress causes release of Nrf2 from INrf2. Nrf2 translocates to the nucleus, binds to the ARE, and activates gene expression. In this study, we demonstrate that protein kinase C (PKC) plays a significant role in the regulation of ARE-mediated NQO1 gene expression and induction in response to t-butylhydroquinone. Treatment of HepG2 cells with the PKC inhibitors staurosporine and calphostin C repressed ARE-mediated induction of a luciferase reporter as well as that of the endogenous NQO1 gene. Similar experiments with inhibitors of MEK/ERK, p38, phosphatidylinositol 3-kinase, and tyrosine kinases failed to repress ARE-mediated gene expression. The PKC inhibitor staurosporine blocked the nuclear translocation of Nrf2, suggesting that Nrf2 might be the target for PKC regulation. A Prosite search revealed the presence of seven putative PKC sites in mouse Nrf2. The PKC site at Ser(40) is conserved among species and lies in the Neh2 domain, which interacts with INrf2. We demonstrate that phosphorylation of Ser40 is necessary for Nrf2 release from INrf2, but is not required for Nrf2 stabilization/ accumulation in the nucleus and transcriptional activation of ARE-mediated NQO1 gene expression. A peptide that competes with endogenous Nrf2 for INrf2 binding was able to induce ARE activity more effectively than t-butylhydroquinone, and Nrf2 that accumulated in the nucleus as a result was not phosphorylated.	Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA	Baylor College of Medicine	Jaiswal, AK (corresponding author), Baylor Coll Med, Dept Pharmacol, 1 Baylor Plaza, Houston, TX 77030 USA.	ajaiswal@bcm.tmc.edu			NIGMS NIH HHS [GM47466] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047466, R01GM047466] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Dhakshinamoorthy S, 2001, ONCOGENE, V20, P3906, DOI 10.1038/sj.onc.1204506; Dhakshinamoorthy S, 2000, CURR TOP CELL REGUL, V36, P201; Dieter MZ, 2001, BIOCHEM PHARMACOL, V61, P215, DOI 10.1016/S0006-2952(00)00525-6; Dinkova-Kostova AT, 2002, P NATL ACAD SCI USA, V99, P11908, DOI 10.1073/pnas.172398899; Gaikwad A, 2001, J BIOL CHEM, V276, P22559, DOI 10.1074/jbc.M101053200; Gong PF, 2001, J BIOL CHEM, V276, P27018, DOI 10.1074/jbc.M103658200; Huang HC, 2000, P NATL ACAD SCI USA, V97, P12475, DOI 10.1073/pnas.220418997; Huang HC, 2002, J BIOL CHEM, V277, P42769, DOI 10.1074/jbc.M206911200; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 2003, GENES CELLS, V8, P379, DOI 10.1046/j.1365-2443.2003.00640.x; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Jaiswal AK, 2000, FREE RADICAL BIO MED, V29, P254, DOI 10.1016/S0891-5849(00)00306-3; Kang KW, 2000, MOL PHARMACOL, V58, P1017, DOI 10.1124/mol.58.5.1017; Long DJ, 2000, CANCER RES, V60, P5913; Long DJ, 2002, CANCER RES, V62, P3030; Long DJ, 2001, JNCI-J NATL CANCER I, V93, P1166, DOI 10.1093/jnci/93.15.1166; McMahon M, 2003, J BIOL CHEM, V278, P21592, DOI 10.1074/jbc.M300931200; Nguyen T, 2000, J BIOL CHEM, V275, P15466, DOI 10.1074/jbc.M000361200; Nguyen T, 2003, J BIOL CHEM, V278, P4536, DOI 10.1074/jbc.M207293200; Radjendirane V, 1998, J BIOL CHEM, V273, P7382, DOI 10.1074/jbc.273.13.7382; SHAW PM, 1991, EUR J BIOCHEM, V195, P171, DOI 10.1111/j.1432-1033.1991.tb15691.x; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627; Yu R, 1996, CANCER RES, V56, P2954; Yu R, 1999, J BIOL CHEM, V274, P27545, DOI 10.1074/jbc.274.39.27545; Yu R, 2000, J BIOL CHEM, V275, P2322, DOI 10.1074/jbc.275.4.2322; Yu R, 2000, J BIOL CHEM, V275, P39907, DOI 10.1074/jbc.M004037200	28	399	414	2	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44675	44682		10.1074/jbc.M307633200	http://dx.doi.org/10.1074/jbc.M307633200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12947090	hybrid			2022-12-25	WOS:000186306700100
J	Hinoi, T; Loda, M; Fearon, ER				Hinoi, T; Loda, M; Fearon, ER			Silencing of CDX2 expression in colon cancer via a dominant repression pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E-CADHERIN EXPRESSION; HOMEOBOX GENE CDX2; COLORECTAL-CANCER; PROTEIN EXPRESSION; BREAST-CANCER; MUTANT MICE; CARCINOMAS; EPITHELIUM; DROSOPHILA; CELLS	CDX2 is a caudal-related homeobox transcription factor whose expression in the adult is normally restricted to intestinal epithelium. Mice heterozygous for germ line Cdx2 inactivation develop intestinal polyps, and the lesions lack Cdx2 expression. Prior studies indicate some human colon carcinomas also lack CDX2 expression. To address the role of CDX2 defects in colon cancer development, we analyzed CDX2 expression in 45 primary colorectal carcinomas. Four carcinomas lacked CDX2 expression, and three others showed aberrant cytoplasmic localization of CDX2, although no significant CDX2 gene defects were seen in the seven tumors. Marked reductions in CDX2 transcript and protein levels were seen in five of 13 colorectal cell lines, and nuclear run-off data indicated reduced transcription was a major factor in CDX2 silencing. Treatment with the DNA demethylating agent 5-aza- 2'-deoxycytidine and/or the histone deacetylase inhibitor trichostatin A did not restore CDX2 expression in CDX2-negative lines. However, consistent with a role for dominant repression mechanisms in CDX2 silencing, all somatic cell hybrids resulting from pairwise fusions between colon cancer lines with intact CDX2 expression and lines lacking CDX2 had reduced CDX2 transcripts and protein. A roughly 9.5-kb 5'-flanking region from the human CDX2 gene contained key cis elements for regulating transcription in colon cancer cells. Restoration of CDX2 expression suppressed proliferation and soft agar growth in the CDX2-negative HT-29 colon cancer cell line. Our findings suggest CDX2 inactivation in colon cancer results from defects in trans-acting pathways regulating CDX2 transcription, and CDX2 silencing contributes to the altered phenotype of some colorectal cancers.	Univ Michigan, Med Ctr, Div Mol Med & Genet, Dept Internal Med,Sch Med, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Ctr Canc, Ann Arbor, MI 48109 USA; Harvard Univ, Brigham & Womens Hosp, Dept Pathol, Sch Med, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Dana Farber Canc Inst, Sch Med,Dept Adult Oncol, Boston, MA 02115 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard Medical School	Fearon, ER (corresponding author), Univ Michigan, Med Ctr, Div Mol Med & Genet, Dept Internal Med,Sch Med, 1150 W Med Ctr Dr,4301 MSRB 3, Ann Arbor, MI 48109 USA.		Hinoi, Takao/AAI-1443-2020	Hinoi, Takao/0000-0003-0462-6177	NCI NIH HHS [CA82223] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R56CA082223, R01CA082223] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Beck F, 1999, P NATL ACAD SCI USA, V96, P7318, DOI 10.1073/pnas.96.13.7318; BECK F, 1995, DEV DYNAM, V204, P219, DOI 10.1002/aja.1002040302; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; da Costa LT, 1999, ONCOGENE, V18, P5010, DOI 10.1038/sj.onc.1202872; Drummond F, 1997, ANN HUM GENET, V61, P393, DOI 10.1017/S0003480097006465; EE HC, 1995, AM J PATHOL, V147, P586; Freshney RI, 1994, CULTURE ANIMAL CELLS, P166; Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4; GRAFF JR, 1995, CANCER RES, V55, P5195; GREENBERG ME, 1997, CURRENT PROTOCOLS MO; Hajra KM, 2002, CANCER RES, V62, P1613; Hajra KM, 1999, ONCOGENE, V18, P7274, DOI 10.1038/sj.onc.1203336; Hinoi T, 2001, AM J PATHOL, V159, P2239, DOI 10.1016/S0002-9440(10)63074-X; Hinoi T, 2002, GASTROENTEROLOGY, V123, P1565, DOI 10.1053/gast.2002.36598; JAMES R, 1994, J BIOL CHEM, V269, P15229; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kim S, 2002, GASTROENTEROLOGY, V123, P1163, DOI 10.1053/gast.2002.36043; KIMURA K, 1994, J BIOL CHEM, V269, P18961; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; Maehama T, 2001, ANNU REV BIOCHEM, V70, P247, DOI 10.1146/annurev.biochem.70.1.247; Mallo GV, 1998, J BIOL CHEM, V273, P14030, DOI 10.1074/jbc.273.22.14030; Mallo GV, 1997, INT J CANCER, V74, P35, DOI 10.1002/(SICI)1097-0215(19970220)74:1<35::AID-IJC7>3.0.CO;2-1; MLODZIK M, 1987, CELL, V48, P465, DOI 10.1016/0092-8674(87)90197-8; Qualtrough D, 2002, GUT, V51, P184, DOI 10.1136/gut.51.2.184; Silberg DG, 2000, GASTROENTEROLOGY, V119, P961, DOI 10.1053/gast.2000.18142; Silberg DG, 1997, GASTROENTEROLOGY, V113, P478, DOI 10.1053/gast.1997.v113.pm9247467; Sivagnanasundaram S, 2001, BRIT J CANCER, V84, P218, DOI 10.1054/bjoc.2000.1544; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; SUBRAMANIAN V, 1995, CELL, V83, P641, DOI 10.1016/0092-8674(95)90104-3; Suh ER, 2002, J BIOL CHEM, V277, P35795, DOI 10.1074/jbc.M205567200; Tamai Y, 1999, CANCER RES, V59, P2965; Tamura G, 2000, J NATL CANCER I, V92, P569, DOI 10.1093/jnci/92.7.569; Vogelstein B, 2002, GENETIC BASIS HUMAN, P583; Wicking C, 1998, ONCOGENE, V17, P657, DOI 10.1038/sj.onc.1201971; Woodford-Richens KL, 2001, BRIT J CANCER, V84, P1314, DOI 10.1054/bjoc.2001.1800; Yagi OK, 1999, BRIT J CANCER, V79, P440, DOI 10.1038/sj.bjc.6690068	37	83	85	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44608	44616		10.1074/jbc.M307435200	http://dx.doi.org/10.1074/jbc.M307435200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12947088	hybrid			2022-12-25	WOS:000186306700091
J	Liao, YL; Willis, IM; Moir, RD				Liao, YL; Willis, IM; Moir, RD			The Brf1 and Bdp1 subunits of transcription factor TFIIIB bind to overlapping sites in the tetratricopeptide repeats of Tfc4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-III; TPR DOMAIN; DNA; RECRUITMENT; INITIATION; MUTATION; ENCODES; COMPLEX; ROLES; AUTOINHIBITION	The RNA polymerase III initiation factor TFIIIB is assembled onto DNA through interactions involving the Tfc4 subunit of the assembly factor TFIIIC and two subunits of TFIIIB, Brf1 and Bdp1. Tfc4 contains two arrays of tetratricopeptide repeats (TPRs), each of which provides a binding site for Brf1. Dominant mutations in the ligand binding channel of the first TPR array, TPRs1-5, and on the back side of this array, increase Brf1 binding by Tfc4. Here we examine the biological importance of the second TPR array, TPRs6-9. Radical mutations at phylogenetically conserved residues in the ligand binding channel of TPRs6-9 impair pol III reporter gene transcription. Biochemical studies on one such mutation, L469K in TPR7, revealed a defect in the recruitment of Brf1 into TFIIIB-TFIIIC-DNA complexes and diminished the direct interaction between Tfc4 and Brf1. Multicopy suppression analysis implicates TPR9 in Brf1 binding and TPRs7 and 8 in binding to more than one ligand. Indeed, the L469K mutation also decreased the binding affinity for Bdp1 incorporation into TFIIIB-TFIIIC-DNA complexes and inhibited binary interactions between Bdp1 and Tfc4. The Bdp1 binding domain in Tfc4 was mapped to TPRs1-9, a domain that contains both TPR arrays and thus overlaps two of the known binding sites for Brf1. The properties of the L469K mutation identify both Brf1 and Bdp1 as ligands for the second TPR array.	Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Moir, RD (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	moir@aecom.yu.edu		Willis, Ian/0000-0001-6599-2395	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042728] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42728] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; CHAUSSIVERT N, 1995, J BIOL CHEM, V270, P15353, DOI 10.1074/jbc.270.25.15353; Cloutier TE, 2001, P NATL ACAD SCI USA, V98, P9581, DOI 10.1073/pnas.161292298; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; Deprez E, 1999, MOL CELL BIOL, V19, P8042; Dumay-Odelot H, 2002, MOL CELL BIOL, V22, P298, DOI 10.1128/MCB.22.1.298-308.2002; Gatto GJ, 2000, NAT STRUCT BIOL, V7, P1091; Grove A, 1999, J MOL BIOL, V285, P1429, DOI 10.1006/jmbi.1998.2347; Hsieh YJ, 1999, MOL CELL BIOL, V19, P4944; Hsieh YJ, 1999, MOL CELL BIOL, V19, P7697; Ishiguro A, 2002, MOL CELL BIOL, V22, P3264, DOI 10.1128/MCB.22.10.3264-3275.2002; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KHOO B, 1994, GENE DEV, V8, P2879, DOI 10.1101/gad.8.23.2879; Kumar A, 1998, COLD SPRING HARB SYM, V63, P121, DOI 10.1101/sqb.1998.63.121; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; Lapouge K, 2000, MOL CELL, V6, P899, DOI 10.1016/S1097-2765(00)00087-3; Librizzi MD, 1996, J BIOL CHEM, V271, P32695, DOI 10.1074/jbc.271.51.32695; LOPEZDELEON A, 1992, CELL, V71, P211, DOI 10.1016/0092-8674(92)90350-L; Main ERG, 2003, STRUCTURE, V11, P497, DOI 10.1016/S0969-2126(03)00076-5; MARCK C, 1993, P NATL ACAD SCI USA, V90, P4027, DOI 10.1073/pnas.90.9.4027; Moir RD, 1997, MOL CELL BIOL, V17, P7119, DOI 10.1128/MCB.17.12.7119; Moir RD, 2000, J BIOL CHEM, V275, P26591, DOI 10.1074/jbc.M003991200; Moir RD, 2002, MOL CELL BIOL, V22, P6131, DOI 10.1128/MCB.22.17.6131-6141.2002; Moir RD, 2002, J BIOL CHEM, V277, P694, DOI 10.1074/jbc.M108924200; MOIR RD, 2004, ASSEMBLY INITIATION; Moore DD, 1995, GLOB MOB SURV; RAMEAU G, 1994, MOL CELL BIOL, V14, P822, DOI 10.1128/MCB.14.1.822; Rozenfeld S, 2001, MOL GENET GENOMICS, V265, P705, DOI 10.1007/s004380100467; Ruth J, 1996, EMBO J, V15, P1941, DOI 10.1002/j.1460-2075.1996.tb00545.x; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; Schramm L, 2002, GENE DEV, V16, P2593, DOI 10.1101/gad.1018902; SCHULTZ P, 1989, EMBO J, V8, P3815, DOI 10.1002/j.1460-2075.1989.tb08559.x; Scott PH, 2001, J BIOL CHEM, V276, P1005, DOI 10.1074/jbc.M005417200; Sethy-Coraci I, 1998, NUCLEIC ACIDS RES, V26, P2344, DOI 10.1093/nar/26.10.2344; White RJ, 1998, INT J ONCOL, V12, P741; WILLIS I, 1989, EMBO J, V8, P4281, DOI 10.1002/j.1460-2075.1989.tb08614.x	37	14	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44467	44474		10.1074/jbc.M308354200	http://dx.doi.org/10.1074/jbc.M308354200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12930823	hybrid			2022-12-25	WOS:000186306700074
J	Olsson, T; Thelander, M; Ronne, H				Olsson, T; Thelander, M; Ronne, H			A novel type of chloroplast stromal hexokinase is the major glucose-phosphorylating enzyme in the moss Physcomitrella patens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER ENVELOPE MEMBRANE; SUBCELLULAR-LOCALIZATION; PROTEIN IMPORT; SUGAR SENSOR; REPRESSION; STARCH; IDENTIFICATION; MECHANISMS; GENETICS; LEAVES	Hexokinase catalyzes the first step in the metabolism of glucose but has also been proposed to be involved in sugar sensing and signaling both in yeast and in plants. We have cloned a hexokinase gene, PpHXK1, in the moss Physcomitrella patens where gene function can be studied directly by gene targeting. PpHxk1 is a novel type of chloroplast stromal hexokinase that differs from previously studied membrane-bound plant hexokinases. Enzyme assays on a knock-out mutant revealed that PpHxk1 is the major glucose-phosphorylating enzyme in Physcomitrella, accounting for 80% of the total activity in protonemal tissue. The mutant is deficient in the response to glucose, which in wild type moss induces the formation of caulonemal filaments that protrude from the edge of the colony. Growth on glucose in the dark is strongly reduced in the mutant. Sequence data suggest that most plants including Physcomitrella and Arabidopsis have both chloroplast-imported hexokinases similar to PpHxk1 and traditional membrane-bound hexokinases. We propose that the two types of plant hexokinases have distinct physiological roles.	Swedish Univ Agr Sci, Dept Plant Biol & Forest Genet, SE-75007 Uppsala, Sweden	Swedish University of Agricultural Sciences	Ronne, H (corresponding author), Swedish Univ Agr Sci, Dept Plant Biol & Forest Genet, Box 7080, SE-75007 Uppsala, Sweden.	Hans.Ronne@vbsg.slu.se		Ronne, Hans/0000-0002-1645-6091				ASHTON NW, 1979, PLANTA, V144, P427, DOI 10.1007/BF00380118; COSIO E, 1984, J BIOL CHEM, V259, P7688; Cove D J, 1991, Symp Soc Exp Biol, V45, P31; da-Silva WS, 2001, J EXP BOT, V52, P1191, DOI 10.1093/jexbot/52.359.1191; David S., 1996, WEEDS WORLD, V3, P43; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; ENTIAN KD, 1980, MOL GEN GENET, V178, P633, DOI 10.1007/BF00337871; Frommer WB, 2003, SCIENCE, V300, P261, DOI 10.1126/science.1084120; Halford NG, 1999, TRENDS PLANT SCI, V4, P117, DOI 10.1016/S1360-1385(99)01377-1; Halford NG, 1999, TRENDS PLANT SCI, V4, P251, DOI 10.1016/S1360-1385(99)01432-6; Imaizumi T, 2002, PLANT CELL, V14, P373, DOI 10.1105/tpc.010388; JANG JC, 1994, PLANT CELL, V6, P1665, DOI 10.1105/tpc.6.11.1665; Jang JC, 1997, PLANT CELL, V9, P5, DOI 10.1105/tpc.9.1.5; Johnston M, 1999, TRENDS GENET, V15, P29, DOI 10.1016/S0168-9525(98)01637-0; KANG F, 1994, PLANT J, V6, P795, DOI 10.1046/j.1365-313X.1994.6060795.x; Keegstra K, 1999, PLANT CELL, V11, P557, DOI 10.1105/tpc.11.4.557; MIERNYK JA, 1983, ARCH BIOCHEM BIOPHYS, V226, P458, DOI 10.1016/0003-9861(83)90315-6; Moore B, 2003, SCIENCE, V300, P332, DOI 10.1126/science.1080585; Moore BD, 1999, TRENDS PLANT SCI, V4, P250, DOI 10.1016/S1360-1385(99)01433-8; Neuhaus HE, 2000, BBA-BIOMEMBRANES, V1465, P307, DOI 10.1016/S0005-2736(00)00146-2; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; QI QG, 1995, PLANT PHYSIOL, V107, P413, DOI 10.1104/pp.107.2.413; Reski R, 1998, BOT ACTA, V111, P1; Rolland F, 2002, FEMS YEAST RES, V2, P183, DOI 10.1111/j.1567-1364.2002.tb00084.x; Rolland F, 2002, PLANT CELL, V14, pS185, DOI 10.1105/tpc.010455; Rolland F, 2001, TRENDS BIOCHEM SCI, V26, P310, DOI 10.1016/S0968-0004(01)01805-9; RONNE H, 1995, TRENDS GENET, V11, P12, DOI 10.1016/S0168-9525(00)88980-5; Rose TM, 1998, NUCLEIC ACIDS RES, V26, P1628, DOI 10.1093/nar/26.7.1628; SCHAEFER D, 1991, MOL GEN GENET, V226, P418, DOI 10.1007/BF00260654; Schaefer DG, 2002, ANNU REV PLANT BIOL, V53, P477, DOI 10.1146/annurev.arplant.53.100301.135202; Schaefer DG, 2001, PLANT PHYSIOL, V127, P1430, DOI 10.1104/pp.010786; SCHAFER G, 1977, PLANT PHYSIOL, V60, P286, DOI 10.1104/pp.60.2.286; Schleiff E, 2001, BBA-MOL CELL RES, V1541, P22, DOI 10.1016/S0167-4889(01)00152-5; Schumaker KS, 1997, PLANT CELL, V9, P1099, DOI 10.1105/tpc.9.7.1099; SIEBERT PD, 1992, NATURE, V359, P557, DOI 10.1038/359557a0; SINGH KK, 1993, PLANT PHYSIOL, V102, P587, DOI 10.1104/pp.102.2.587; STITT M, 1978, BIOCHIM BIOPHYS ACTA, V544, P200, DOI 10.1016/0304-4165(78)90223-4; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tranel PJ, 1996, PLANT CELL, V8, P2093, DOI 10.1105/tpc.8.11.2093; TRANEL PJ, 1995, EMBO J, V14, P2436, DOI 10.1002/j.1460-2075.1995.tb07241.x; Veramendi J, 1999, PLANT PHYSIOL, V121, P123, DOI 10.1104/pp.121.1.123; Veramendi J, 2002, PLANT MOL BIOL, V49, P491, DOI 10.1023/A:1015528014562; Weber A, 2000, PLANT CELL, V12, P787, DOI 10.1105/tpc.12.5.787; Wiese A, 1999, FEBS LETT, V461, P13, DOI 10.1016/S0014-5793(99)01417-9	44	85	96	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44439	44447		10.1074/jbc.M306265200	http://dx.doi.org/10.1074/jbc.M306265200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12941966	hybrid			2022-12-25	WOS:000186306700071
J	Shan, B; Xu, J; Zhuo, Y; Morris, CA; Morris, GF				Shan, B; Xu, J; Zhuo, Y; Morris, CA; Morris, GF			Induction of p53-dependent activation of the human proliferating cell nuclear antigen gene in chromatin by ionizing radiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING FUNCTION; WILD-TYPE P53; IN-VIVO; TRANSCRIPTIONAL REGULATION; HUMAN-FIBROBLASTS; PROMOTER ACTIVITY; CYCLE CHECKPOINT; TYPE-1 TAX; PCNA; PROTEIN	A human fibroblast cell line with conditional p53 expression displayed a p53-dependent increase in both the protein and mRNA levels of proliferating cell nuclear antigen (PCNA) after exposure to ionizing radiation (IR). The combination of p53 induction and IR cooperated to activate a transiently expressed human PCNA promoter-reporter gene via a p53-responsive element. Chromatin immunoprecipitation assays with antibodies specific for p53 or p300/CREB-binding protein revealed specific p53-dependent enrichment of PCNA promoter sequences in immunoprecipitates of sheared chromatin prepared from irradiated cells. Maximal and specific association of acetylated histone H4 with the PCNA promoter also depended on p53 induction and exposure to IR. These data demonstrate p53 binding to a target site in the PCNA promoter, recruitment of p300/CREB-binding protein, and localized acetylation of histone H4 in an IR-dependent manner. These molecular events are likely to play a role in mediating activation of PCNA gene expression by p53 during the cellular response to DNA damage. The analyses indicate that the combination of p53 induction and IR activate the PCNA gene via mechanisms similar to that of p21/wild-type p53-activated factor but to a lesser extent. This differential regulation of PCNA and p21/wild-type p53-activated factor may establish the proper ratio of the two proteins to coordinate DNA repair with cell cycle arrest.	Tulane Canc Ctr, Dept Pathol, Programs Mol & Cellular Biol & Lung Biol, New Orleans, LA 70112 USA; Tulane Canc Ctr, Dept Med, Programs Mol & Cellular Biol & Lung Biol, New Orleans, LA 70112 USA; Tulane Canc Ctr, Dept Microbiol & Immunol, Programs Mol & Cellular Biol & Lung Biol, New Orleans, LA 70112 USA; Tulane Xavier Ctr Bioenvironm Res, New Orleans, LA 70112 USA	Tulane University; Tulane University; Tulane University; Tulane University; Xavier University of Louisiana	Morris, GF (corresponding author), Tulane Univ, Hlth Sci Ctr, Dept Pathol, SL-79,1430 Tulane Ave, New Orleans, LA 70112 USA.			Shan, Bin/0000-0002-6869-2678; Xu, Jin/0000-0001-6617-5311	NIEHS NIH HHS [ES07856] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R29ES007856] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; ALMENDRAL JM, 1987, P NATL ACAD SCI USA, V84, P1575, DOI 10.1073/pnas.84.6.1575; Amundson SA, 2000, RADIAT RES, V154, P342, DOI 10.1667/0033-7587(2000)154[0342:IOPMBI]2.0.CO;2; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Appella E, 2000, PATHOL BIOL, V48, P227; Ard PG, 2002, MOL CELL BIOL, V22, P5650, DOI 10.1128/MCB.22.16.5650-5661.2002; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Boyd KE, 1999, MOL CELL BIOL, V19, P8393; Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; Chan HM, 2001, J CELL SCI, V114, P2363; CHANG CD, 1990, MOL CELL BIOL, V10, P3289, DOI 10.1128/MCB.10.7.3289; Chang HW, 1999, J CELL BIOCHEM, V73, P423, DOI 10.1002/(SICI)1097-4644(19990601)73:3<423::AID-JCB13>3.0.CO;2-9; Cook JL, 1999, ONCOGENE, V18, P2373, DOI 10.1038/sj.onc.1202566; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Goldring JPD, 1996, ANAL BIOCHEM, V242, P197, DOI 10.1006/abio.1996.0453; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; Goukassian DA, 1999, J INVEST DERMATOL, V112, P25, DOI 10.1046/j.1523-1747.1999.00468.x; Grossman SR, 2001, EUR J BIOCHEM, V268, P2773, DOI 10.1046/j.1432-1327.2001.02226.x; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; HALL PA, 1993, ONCOGENE, V8, P203; Hanawalt PC, 2002, ONCOGENE, V21, P8949, DOI 10.1038/sj.onc.1206096; Hasan S, 2001, NATURE, V410, P387, DOI 10.1038/35066610; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HUANG DY, 1994, MOL CELL BIOL, V14, P4233, DOI 10.1128/MCB.14.6.4233; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JACKSON P, 1994, BIOCHEM BIOPH RES CO, V203, P133, DOI 10.1006/bbrc.1994.2159; JASKULSKI D, 1988, J BIOL CHEM, V263, P10175; JASKULSKI D, 1988, SCIENCE, V240, P1544, DOI 10.1126/science.2897717; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Kannabiran C, 1999, ONCOGENE, V18, P7825, DOI 10.1038/sj.onc.1203294; Kao SY, 2000, J BIOL CHEM, V275, P35926, DOI 10.1074/jbc.M004397200; Karuppayil SM, 1998, J BIOL CHEM, V273, P17303, DOI 10.1074/jbc.273.28.17303; Kawabe T, 2002, ONCOGENE, V21, P1717, DOI 10.1038/sj.onc.1205229; Lemoine FJ, 2000, AIDS RES HUM RETROV, V16, P1623, DOI 10.1089/08892220050193056; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Liu G, 2003, J BIOL CHEM, V278, P17557, DOI 10.1074/jbc.M210696200; MacCallum DE, 1996, ONCOGENE, V13, P2575; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; Mishra A, 2000, AM J RESP CELL MOL, V22, P543, DOI 10.1165/ajrcmb.22.5.3851; Mishra A, 1997, AM J RESP CELL MOL, V16, P479, DOI 10.1165/ajrcmb.16.4.9115760; Momand J, 1997, J CELL BIOCHEM, V64, P343; Morris GF, 1996, P NATL ACAD SCI USA, V93, P895, DOI 10.1073/pnas.93.2.895; MORRIS GF, 1991, J VIROL, V65, P6397, DOI 10.1128/JVI.65.12.6397-6406.1991; MORRIS GF, 1989, J BIOL CHEM, V264, P13856; North S, 2000, PATHOL BIOL, V48, P255; Noya F, 2002, J BIOL CHEM, V277, P17271, DOI 10.1074/jbc.M112441200; Oren M, 2002, BIOCHEM PHARMACOL, V64, P865, DOI 10.1016/S0006-2952(02)01149-8; Paunesku T, 2001, INT J RADIAT BIOL, V77, P1007, DOI 10.1080/09553000110069335; Prives C, 1999, J PATHOL, V187, P112; Saifudeen Z, 2002, AM J PHYSIOL-RENAL, V283, pF727, DOI 10.1152/ajprenal.00114.2002; Scott M, 2001, J CELL SCI, V114, P3455; SHIVAKUMAR CV, 1995, MOL CELL BIOL, V15, P6785; SPAETE RR, 1985, J VIROL, V56, P135, DOI 10.1128/JVI.56.1.135-143.1985; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; Szak ST, 2001, MOL CELL BIOL, V21, P3375, DOI 10.1128/MCB.21.10.3375-3386.2001; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Tommasi S, 1999, J BIOL CHEM, V274, P27829, DOI 10.1074/jbc.274.39.27829; Tournier S, 1996, MOL BIOL CELL, V7, P651, DOI 10.1091/mbc.7.4.651; Tsurimoto T., 1999, FRONT BIOSCI, V4, P849; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R; Wenz F, 1998, RADIAT RES, V149, P32, DOI 10.2307/3579679; Woloschak Gayle E, 2002, Mil Med, V167, P42; Woloschak GE, 1996, CARCINOGENESIS, V17, P2357, DOI 10.1093/carcin/17.11.2357; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; Xu J, 1999, MOL CELL BIOL, V19, P12; YAMAGUCHI M, 1994, EUR J BIOCHEM, V221, P227, DOI 10.1111/j.1432-1033.1994.tb18733.x; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821	77	36	38	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44009	44017		10.1074/jbc.M302671200	http://dx.doi.org/10.1074/jbc.M302671200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12947108	hybrid			2022-12-25	WOS:000186306700016
J	Tabb, MM; Sun, AX; Zhou, CC; Grun, F; Errandi, J; Romero, K; Pham, H; Inoue, S; Mallick, S; Lin, M; Forman, BM; Blumberg, B				Tabb, MM; Sun, AX; Zhou, CC; Grun, F; Errandi, J; Romero, K; Pham, H; Inoue, S; Mallick, S; Lin, M; Forman, BM; Blumberg, B			Vitamin K-2 regulation of bone homeostasis is mediated by the steroid and xenobiotic receptor SXR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREGNANE-X RECEPTOR; ORPHAN NUCLEAR RECEPTORS; MATRIX GLA PROTEIN; ST JOHNS WORT; ALKALINE-PHOSPHATASE; MINERAL DENSITY; OSTEOBLASTIC CELLS; OSTEOSARCOMA CELLS; DRUG-METABOLISM; MESSENGER-RNA	Vitamin K-2 is a critical nutrient required for blood clotting that also plays an important role in bone formation. Vitamin K-2 supplementation up-regulates the expression of bone markers, increases bone density in vivo, and is used clinically in the management of osteoporosis. The mechanism of vitamin K-2 action in bone formation was thought to involve its normal role as an essential cofactor for gamma-carboxylation of bone matrix proteins. However, there is evidence that suggests vitamin K-2 also has a transcriptional regulatory function. Vitamin K-2 bound to and activated the orphan nuclear receptor SXR and induced expression of the SXR target gene, CYP3A4, identifying it as a bona fide SXR ligand. Vitamin K-2 treatment of osteosarcoma cells increased mRNA levels for the osteoblast markers bone alkaline phosphatase, osteoprotegerin, osteopontin, and matrix Gla protein. The known SXR activators rifampicin and hyperforin induced this panel of bone markers to an extent similar to vitamin K-2. Vitamin K-2 was able to induce bone markers in primary osteocytes isolated from wild-type murine calvaria but not in cells isolated from mice deficient in the SXR ortholog PXR. We infer that vitamin K-2 is a transcriptional regulator of bone-specific genes that acts through SXR to favor the expression of osteoblastic markers. Thus, SXR has a novel role as a mediator of bone homeostasis in addition to its role as a xenobiotic sensor. An important implication of this work is that a subset of SXR activators may function as effective therapeutic agents for the management of osteoporosis.	Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92697 USA; Univ Tokyo, Dept Geriatr Med, Bunkyo Ku, Tokyo 1130033, Japan; City Hope Natl Med Ctr, Beckman Res Inst, Div Mol Med, Gonda Diabet Res Ctr, Duarte, CA 91010 USA	University of California System; University of California Irvine; University of Tokyo; City of Hope; Beckman Research Institute of City of Hope	Blumberg, B (corresponding author), Univ Calif Irvine, Dept Dev & Cell Biol, 5205 McGaugh Hall, Irvine, CA 92697 USA.		Grun, Felix/C-8271-2011	Zhou, Changcheng/0000-0001-7649-0710	NATIONAL CANCER INSTITUTE [R21CA087222] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060572] Funding Source: NIH RePORTER; NCI NIH HHS [CA-87222] Funding Source: Medline; NIGMS NIH HHS [GM-60572] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKEDO Y, 1992, BIOCHEM BIOPH RES CO, V187, P814, DOI 10.1016/0006-291X(92)91269-V; AKIYAMA Y, 1994, EUR J PHARMACOL, V263, P181, DOI 10.1016/0014-2999(94)90539-8; Bertilsson G, 1998, P NATL ACAD SCI USA, V95, P12208, DOI 10.1073/pnas.95.21.12208; BINKLEY NC, 1995, J NUTR, V125, P1812, DOI 10.1093/jn/125.7.1812; Blumberg B, 1998, GENE DEV, V12, P3195, DOI 10.1101/gad.12.20.3195; Blumberg B, 1998, GENE DEV, V12, P1269, DOI 10.1101/gad.12.9.1269; Booth SL, 2000, AM J CLIN NUTR, V71, P1201; BOUCKAERT JH, 1960, NATURE, V185, P849, DOI 10.1038/185849a0; BUCK J, 1993, J EXP MED, V178, P675, DOI 10.1084/jem.178.2.675; Dotzlaw H, 1999, CLIN CANCER RES, V5, P2103; Dussault I, 2001, J BIOL CHEM, V276, P33309, DOI 10.1074/jbc.C100375200; FEDDE KN, 1992, BONE MINER, V17, P145, DOI 10.1016/0169-6009(92)90726-T; Feskanich D, 1999, AM J CLIN NUTR, V69, P74; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; FRASER JD, 1990, CALCIFIED TISSUE INT, V46, P270, DOI 10.1007/BF02555007; Grun F, 2002, J BIOL CHEM, V277, P43691, DOI 10.1074/jbc.M206553200; HALL JG, 1980, AM J MED, V68, P122, DOI 10.1016/0002-9343(80)90181-3; HARA K, 1993, J BONE MINER RES, V8, P535; HARA K, 1995, BONE, V16, P179, DOI 10.1016/8756-3282(94)00027-W; HART JP, 1985, J CLIN ENDOCR METAB, V60, P1268, DOI 10.1210/jcem-60-6-1268; Hofbauer LC, 1998, BIOCHEM BIOPH RES CO, V250, P776, DOI 10.1006/bbrc.1998.9394; Iwamoto I, 1999, MATURITAS, V31, P161, DOI 10.1016/S0378-5122(98)00114-5; Jones SA, 2000, MOL ENDOCRINOL, V14, P27, DOI 10.1210/me.14.1.27; Kameda T, 1996, BIOCHEM BIOPH RES CO, V220, P515, DOI 10.1006/bbrc.1996.0436; Kaneki M, 2001, NUTRITION, V17, P315, DOI 10.1016/S0899-9007(00)00554-2; KERNER SA, 1989, P NATL ACAD SCI USA, V86, P4455, DOI 10.1073/pnas.86.12.4455; KLIBANSKI A, 2000, NIH CONSENSUS STATE, V17, P1; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; Koshihara Y, 1996, CALCIFIED TISSUE INT, V59, P466, DOI 10.1007/s002239900159; Koshihara Y, 1997, J BONE MINER RES, V12, P431, DOI 10.1359/jbmr.1997.12.3.431; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luo GB, 1997, NATURE, V386, P78, DOI 10.1038/386078a0; MAJESKA RJ, 1982, J BIOL CHEM, V257, P3362; Makishima M, 2002, SCIENCE, V296, P1313, DOI 10.1126/science.1070477; MANOLAGAS SC, 1981, J BIOL CHEM, V256, P7115; Masuyama H, 2002, ENDOCRINOLOGY, V143, P55, DOI 10.1210/en.143.1.55; Moore LB, 2000, P NATL ACAD SCI USA, V97, P7500, DOI 10.1073/pnas.130155097; Moore LB, 2000, J BIOL CHEM, V275, P15122, DOI 10.1074/jbc.M001215200; MULKINS MA, 1983, J BIOL CHEM, V258, P6219; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; ORIMO H, 1992, J BONE MINER RES, V7, pS122; Orwoll ES, 1996, ANN INTERN MED, V124, P187, DOI 10.7326/0003-4819-124-2-199601150-00001; PARTRIDGE NC, 1981, ENDOCRINOLOGY, V108, P213, DOI 10.1210/endo-108-1-213; Price PA, 1998, ARTERIOSCL THROM VAS, V18, P1400, DOI 10.1161/01.ATV.18.9.1400; PRINCE CW, 1987, COLLAGEN REL RES, V7, P305; REINHOLT FP, 1990, P NATL ACAD SCI USA, V87, P4473, DOI 10.1073/pnas.87.12.4473; Rodan GA, 1998, P NATL ACAD SCI USA, V95, P13361, DOI 10.1073/pnas.95.23.13361; RODAN SB, 1987, CANCER RES, V47, P4961; SANO Y, 1995, J NUTR SCI VITAMINOL, V41, P499, DOI 10.3177/jnsv.41.499; Schmiedlin-Ren P, 2001, DRUG METAB DISPOS, V29, P1446; SEEMAN E, 1994, J BONE MINER RES, V9, P739; SHEARER MJ, 1995, LANCET, V345, P229, DOI 10.1016/S0140-6736(95)90227-9; Shiraki M, 2000, J BONE MINER RES, V15, P515, DOI 10.1359/jbmr.2000.15.3.515; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698; Sugawara Y, 2002, JPN J PHARMACOL, V88, P262, DOI 10.1254/jjp.88.262; Sumida A, 2000, BIOCHEM BIOPH RES CO, V267, P756, DOI 10.1006/bbrc.1999.2029; SUTTIE JW, 1985, ANNU REV BIOCHEM, V54, P459, DOI 10.1146/annurev.bi.54.070185.002331; Synold TW, 2001, NAT MED, V7, P584, DOI 10.1038/87912; Tamada T, 2001, J BONE MINER METAB, V19, P45, DOI 10.1007/s007740170059; Torgerson DJ, 1996, J BONE MINER RES, V11, P293; Tsuda E, 1997, BIOCHEM BIOPH RES CO, V234, P137, DOI 10.1006/bbrc.1997.6603; Uematsu T, 1996, J PHARM SCI, V85, P1012, DOI 10.1021/js9600641; Urayama S, 2000, J LAB CLIN MED, V136, P181, DOI 10.1067/mlc.2000.108754; VERMEER C, 1995, ANNU REV NUTR, V15, P1, DOI 10.1146/annurev.nutr.15.1.1; Weber P, 1997, INT J VITAM NUTR RES, V67, P350; Wentworth JM, 2000, J ENDOCRINOL, V166, pR11, DOI 10.1677/joe.0.166R011; Willson TM, 2002, NAT REV DRUG DISCOV, V1, P259, DOI 10.1038/nrd753; WONG GL, 1975, P NATL ACAD SCI USA, V72, P3167, DOI 10.1073/pnas.72.8.3167; Xie W, 2001, J BIOL CHEM, V276, P37739, DOI 10.1074/jbc.R100033200; Xie W, 2000, NATURE, V406, P435, DOI 10.1038/35019116; Yasuda H, 1998, ENDOCRINOLOGY, V139, P1329, DOI 10.1210/en.139.3.1329; YOUNG MF, 1990, GENOMICS, V7, P491, DOI 10.1016/0888-7543(90)90191-V; ZERNIK J, 1990, DIFFERENTIATION, V44, P207, DOI 10.1111/j.1432-0436.1990.tb00619.x; [No title captured]	75	272	298	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					43919	43927		10.1074/jbc.M303136200	http://dx.doi.org/10.1074/jbc.M303136200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12920130	hybrid			2022-12-25	WOS:000186306700007
J	Wang, L; Han, YQ; Kim, CS; Lee, YK; Moore, DD				Wang, L; Han, YQ; Kim, CS; Lee, YK; Moore, DD			Resistance of SHP-null mice to bile acid-induced liver damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORPHAN NUCLEAR RECEPTOR; NEGATIVE FEEDBACK-REGULATION; PRIMARY RAT HEPATOCYTES; X-RECEPTOR; SALT TRANSPORTERS; IN-VIVO; EXPRESSION; 7-ALPHA-HYDROXYLASE; CHOLESTEROL; PATHWAY	The orphan nuclear hormone receptor SHP ( gene designation NROB2) is an important component of a negative regulatory cascade by which high levels of bile acids repress bile acid biosynthesis. Short term studies in SHP null animals confirm this function and also reveal the existence of additional pathways for bile acid negative feedback regulation. We have used long term dietary treatments to test the role of SHP in response to chronic elevation of bile acids, cholesterol, or both. In contrast to the increased sensitivity predicted from the loss of negative feedback regulation, the SHP null mice were relatively resistant to the hepatotoxicity associated with a diet containing 0.5% cholic acid and the much more severe effects of a diet containing both 0.5% cholic acid and 2% cholesterol. This was associated with decreased hepatic accumulation of cholesterol and triglycerides in the SHP null mice. There were also alterations in the expression of a number of genes involved in cholesterol and bile acid homeostasis, notably cholesterol 12alpha-hydroxylase (CYP8B1), which was strongly re-expressed in the SHP null mice, but not the wild type mice fed either bile acid containing diet. This contrasts with the strong repression of CYP8B1 observed with short term bile acid feeding, as well as the effects of long term feeding on other bile acid biosynthetic enzymes such as cholesterol 7alpha-hydroxylase (CYP7A1). CYP8B1 expression could contribute to the decreased toxicity of the chronic bile acid treatment by increasing the hydrophilicity of the bile acid pool. These results identify an unexpected role for SHP in hepatotoxicity and suggest new approaches to modulating effects of chronically elevated bile acids in cholestasis.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine	Moore, DD (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053366, P01DK057743] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK53366, P01-DK57743] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AXELSON M, 1992, J BIOL CHEM, V267, P1701; Bahar RJ, 1999, GASTROENTEROL CLIN N, V28, P27, DOI 10.1016/S0889-8553(05)70042-X; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; CHIANG JYL, 1998, FRONT BIOSCI, V3, P176; Denson LA, 2001, GASTROENTEROLOGY, V121, P140, DOI 10.1053/gast.2001.25503; Fayard E, 2001, CURR OPIN LIPIDOL, V12, P113, DOI 10.1097/00041433-200104000-00004; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Gupta S, 2001, J BIOL CHEM, V276, P15816, DOI 10.1074/jbc.M010878200; Hartmann G, 2002, J PHARMACOL EXP THER, V303, P273, DOI 10.1124/jpet.102.039404; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Johansson L, 2000, MOL CELL BIOL, V20, P1124, DOI 10.1128/MCB.20.4.1124-1133.2000; Kast HR, 2002, J BIOL CHEM, V277, P2908, DOI 10.1074/jbc.M109326200; Kerr TA, 2002, DEV CELL, V2, P713, DOI 10.1016/S1534-5807(02)00154-5; Lee YK, 2000, MOL CELL BIOL, V20, P187, DOI 10.1128/MCB.20.1.187-195.2000; Lee YK, 2002, J BIOL CHEM, V277, P2463, DOI 10.1074/jbc.M105161200; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Lu TT, 2001, J BIOL CHEM, V276, P37735, DOI 10.1074/jbc.R100035200; Meier PJ, 2002, ANNU REV PHYSIOL, V64, P635, DOI 10.1146/annurev.physiol.64.082201.100300; Pandak WM, 2001, GASTROENTEROLOGY, V120, P1801, DOI 10.1053/gast.2001.24833; PAYNE DW, 1995, J BIOL CHEM, V270, P18888, DOI 10.1074/jbc.270.32.18888; Rust C, 2000, J BIOL CHEM, V275, P20210, DOI 10.1074/jbc.M909992199; SCHMUCKER DL, 1990, HEPATOLOGY, V12, P1216, DOI 10.1002/hep.1840120523; Schwarz M, 1998, CURR OPIN LIPIDOL, V9, P113, DOI 10.1097/00041433-199804000-00006; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; St-Pierre MV, 2001, J EXP BIOL, V204, P1673; Staudinger J, 2001, DRUG METAB DISPOS, V29, P1467; Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698; Torchia EC, 2001, BMC BIOCHEM, V2, DOI 10.1186/1471-2091-2-11; VANDEHEIJNING BJM, 1994, J LIPID RES, V35, P1002; Vlahcevic ZR, 1997, GASTROENTEROLOGY, V113, P1949, DOI 10.1016/S0016-5085(97)70015-5; vonDippe P, 1996, J BIOL CHEM, V271, P18176, DOI 10.1074/jbc.271.30.18176; Wang DQH, 1999, AM J PHYSIOL-GASTR L, V276, pG751, DOI 10.1152/ajpgi.1999.276.3.G751; Wang L, 2001, P NATL ACAD SCI USA, V98, P361, DOI 10.1073/pnas.011508498; Wang L, 2002, DEV CELL, V2, P721, DOI 10.1016/S1534-5807(02)00187-9; Wolters H, 2002, J HEPATOL, V37, P556, DOI 10.1016/S0168-8278(02)00247-7; Xie W, 2001, P NATL ACAD SCI USA, V98, P3375, DOI 10.1073/pnas.051014398; Yu CD, 2000, J BIOL CHEM, V275, P15482, DOI 10.1074/jbc.275.20.15482	38	90	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44475	44481		10.1074/jbc.M305258200	http://dx.doi.org/10.1074/jbc.M305258200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12933814	hybrid			2022-12-25	WOS:000186306700075
J	Barnham, KJ; Ciccotosto, GD; Tickler, AK; Ali, FE; Smith, DG; Williamson, NA; Lam, YH; Carrington, D; Tew, D; Kocak, G; Volitakis, I; Separovic, F; Barrow, CJ; Wade, JD; Masters, CL; Cherny, RA; Curtain, CC; Bush, AI; Cappai, R				Barnham, KJ; Ciccotosto, GD; Tickler, AK; Ali, FE; Smith, DG; Williamson, NA; Lam, YH; Carrington, D; Tew, D; Kocak, G; Volitakis, I; Separovic, F; Barrow, CJ; Wade, JD; Masters, CL; Cherny, RA; Curtain, CC; Bush, AI; Cappai, R			Neurotoxic, redox-competent Alzheimer's beta-amyloid is released from lipid membrane by methionine oxidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-BETA; HYDROGEN-PEROXIDE; PEPTIDE 1-40; IN-VITRO; DISEASE; PROTEIN; COPPER; ZINC; MECHANISMS; NEURODEGENERATION	The amyloid beta peptide is toxic to neurons, and it is believed that this toxicity plays a central role in the progression of Alzheimer's disease. The mechanism of this toxicity is contentious. Here we report that an Abeta peptide with the sulfur atom of Met-35 oxidized to a sulfoxide (Met(O)Abeta) is toxic to neuronal cells, and this toxicity is attenuated by the metal chelator clioquinol and completely rescued by catalase implicating the same toxicity mechanism as reduced Abeta. However, unlike the unoxidized peptide, Met(O)Abeta is unable to penetrate lipid membranes to form ion channel-like structures, and beta-sheet formation is inhibited, phenomena that are central to some theories for Abeta toxicity. Our results show that, like the unoxidized peptide, Met(O)Abeta will coordinate Cu2+ and reduce the oxidation state of the metal and still produce H2O2. We hypothesize that Met(O)Abeta production contributes to the elevation of soluble Abeta seen in the brain in Alzheimer's disease.	Univ Melbourne, Dept Pathol, Melbourne, Vic 3010, Australia; Mental Hlth Res Inst Victoria, Parkville, Vic 3010, Australia; Univ Melbourne, Sch Chem, Melbourne, Vic 3010, Australia; Howard Florey Inst Med Res, Melbourne, Vic 3010, Australia; Monash Univ, Sch Phys & Mat Engn, Clayton, Vic 3168, Australia; Harvard Univ, Sch Med, Massachusetts Gen Hosp E, Lab Oxidat Biol,Genet & Aging Res Unit, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp E, Dept Psychiat, Charlestown, MA 02129 USA	University of Melbourne; University of Melbourne; Florey Institute of Neuroscience & Mental Health; Monash University; Harvard University; Harvard University	Barnham, KJ (corresponding author), Univ Melbourne, Dept Pathol, Melbourne, Vic 3010, Australia.	kbarnham@unimelb.edu.au	Separovic, Frances/D-9698-2011; Bush, Ashley I/A-1186-2007; Bush, Ashley/Y-2457-2019; Williamson, Nicholas A/O-9812-2016	Separovic, Frances/0000-0002-6484-2763; Bush, Ashley I/0000-0001-8259-9069; Bush, Ashley/0000-0001-8259-9069; Williamson, Nicholas A/0000-0002-2173-3452; Volitakis, Irene/0000-0003-0766-817X				ARISPE N, 1993, P NATL ACAD SCI USA, V90, P567, DOI 10.1073/pnas.90.2.567; ATHERTON E, 1983, J CHEM SOC CHEM COMM, P1060, DOI 10.1039/c39830001060; Atwood CS, 1998, J BIOL CHEM, V273, P12817, DOI 10.1074/jbc.273.21.12817; Atwood CS, 2000, J NEUROCHEM, V75, P1219, DOI 10.1046/j.1471-4159.2000.0751219.x; BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BOAS JF, 1978, BIOL MAGNETIC RESONA; Bush AI, 2000, CURR OPIN CHEM BIOL, V4, P184, DOI 10.1016/S1367-5931(99)00073-3; Butterfield DA, 2001, TRENDS MOL MED, V7, P548, DOI 10.1016/S1471-4914(01)02173-6; Cherny RA, 2001, NEURON, V30, P665, DOI 10.1016/S0896-6273(01)00317-8; CORNELL BA, 1988, BIOPHYS J, V53, P67, DOI 10.1016/S0006-3495(88)83066-2; Cuajungco MP, 2000, J BIOL CHEM, V275, P19439, DOI 10.1074/jbc.C000165200; Curtain CC, 2001, J BIOL CHEM, V276, P20466, DOI 10.1074/jbc.M100175200; Curtain CC, 2003, J BIOL CHEM, V278, P2977, DOI 10.1074/jbc.M205455200; DADO GP, 1993, J AM CHEM SOC, V115, P12609, DOI 10.1021/ja00079a060; Dong J, 2003, BIOCHEMISTRY-US, V42, P2768, DOI 10.1021/bi0272151; Gabbita SP, 1999, J NEUROCHEM, V73, P1660, DOI 10.1046/j.1471-4159.1999.0731660.x; GORDON LM, 1988, ADV MEMBRANE FLUIDIT, V1; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Harkany T, 2000, REV NEUROSCIENCE, V11, P329; Harkany T, 1999, PROG NEURO-PSYCHOPH, V23, P963, DOI 10.1016/S0278-5846(99)00058-5; Harper JD, 1999, BIOCHEMISTRY-US, V38, P8972, DOI 10.1021/bi9904149; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; Hou LM, 2002, J BIOL CHEM, V277, P40173, DOI 10.1074/jbc.C200338200; Huang XD, 1999, BIOCHEMISTRY-US, V38, P7609, DOI 10.1021/bi990438f; Huang XD, 1999, J BIOL CHEM, V274, P37111, DOI 10.1074/jbc.274.52.37111; HUBBELL WL, 1971, J AM CHEM SOC, V93, P314; Kourie JI, 2001, CELL MOL NEUROBIOL, V21, P173, DOI 10.1023/A:1010932603406; Kuo YM, 2001, J BIOL CHEM, V276, P12991, DOI 10.1074/jbc.M007859200; Lee JY, 2002, P NATL ACAD SCI USA, V99, P7705, DOI 10.1073/pnas.092034699; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; Lovell MA, 1998, J NEUROL SCI, V158, P47, DOI 10.1016/S0022-510X(98)00092-6; MARTINS RN, 1986, J NEUROCHEM, V46, P1042, DOI 10.1111/j.1471-4159.1986.tb00615.x; MATTSON MP, 1993, BRAIN RES, V621, P35, DOI 10.1016/0006-8993(93)90295-X; McLean CA, 1999, ANN NEUROL, V46, P860, DOI 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M; Multhaup G, 1998, ALZHEIMERS REP, V1, P147; NASLUND J, 1994, P NATL ACAD SCI USA, V91, P8378, DOI 10.1073/pnas.91.18.8378; Nishino S, 2001, INORG CHEM COMMUN, V4, P86, DOI 10.1016/S1387-7003(00)00213-6; Opazo C, 2002, J BIOL CHEM, V277, P40302, DOI 10.1074/jbc.M206428200; Palmblad M, 2002, J BIOL CHEM, V277, P19506, DOI 10.1074/jbc.M112218200; PIKE CJ, 1993, J NEUROSCI, V13, P1676; RITCHIE CW, 2003, IN PRESS ARCH NEUROL; Roher AE, 1996, J BIOL CHEM, V271, P20631, DOI 10.1074/jbc.271.34.20631; SAITO H, 1986, MAGN RESON CHEM, V24, P835, DOI 10.1002/mrc.1260241002; Sayre LM, 2000, J NEUROCHEM, V74, P270, DOI 10.1046/j.1471-4159.2000.0740270.x; Schoneich C, 2002, ARCH BIOCHEM BIOPHYS, V397, P370, DOI 10.1006/abbi.2001.2621; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Smith MA, 1997, P NATL ACAD SCI USA, V94, P9866, DOI 10.1073/pnas.94.18.9866; Tabner BJ, 2002, FREE RADICAL BIO MED, V32, P1076, DOI 10.1016/S0891-5849(02)00801-8; Terry RD, 1996, J NEUROPATH EXP NEUR, V55, P1023, DOI 10.1097/00005072-199655100-00001; Tickler AK, 2001, J PEPT SCI, V7, P488, DOI 10.1002/psc.342; TOMBS MP, 1959, BIOCHEM J, V73, P167, DOI 10.1042/bj0730167; Varadarajan S, 1999, BRAIN RES BULL, V50, P133, DOI 10.1016/S0361-9230(99)00093-3; Varadarajan S, 2001, J AM CHEM SOC, V123, P5625, DOI 10.1021/ja010452r; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Watson AA, 1998, BIOCHEMISTRY-US, V37, P12700, DOI 10.1021/bi9810757; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; Yatin SM, 1999, NEUROBIOL AGING, V20, P325; Yoshiike Y, 2001, J BIOL CHEM, V276, P32293, DOI 10.1074/jbc.M010706200	60	158	168	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42959	42965		10.1074/jbc.M305494200	http://dx.doi.org/10.1074/jbc.M305494200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12925530	Green Published, hybrid			2022-12-25	WOS:000186157000030
J	Gupta, S; Fanzo, JC; Hu, CM; Cox, D; Jang, SY; Lee, AE; Greenberg, S; Pernis, AB				Gupta, S; Fanzo, JC; Hu, CM; Cox, D; Jang, SY; Lee, AE; Greenberg, S; Pernis, AB			T cell receptor engagement leads to the recruitment of IBP, a novel guanine nucleotide exchange factor, to the immunological synapse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE C-THETA; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; VAV PROTEINS; RHO-GTPASES; ACTIVATION; TCR; CYTOSKELETON; MODULATION; SWAP-70	Reorganization of the actin cytoskeleton is crucial to the formation and function of the immunological synapse. Rho GTPases are critical mediators of cytoskeletal reorganization, and their activity at the synapse is likely to be stringently regulated. Guanine nucleotide exchange factors (GEFs) belonging to the Dbl family of proteins represent one major class of proteins that regulate the activity of Rho GTPases. Here we demonstrate that IBP, a homologue of SWAP-70, is a novel GEF for Rac1 and Cdc42 in T lymphocytes, which is recruited to the immunological synapse upon engagement of the antigen receptor. Mutational analysis supports a model whereby IBP is inactive in unstimulated cells. Upon engagement of the T cell receptor, its GEF activity is enhanced by tyrosine phosphorylation, as well as by binding newly generated phosphatidylinositol 3,4,5-trisphosphate. Although it is known that T cell receptor engagement leads to the recruitment of Vav to the immunological synapse, these findings indicate that other GEFs, such as IBP, also relocalize to this intercellular region. The recruitment and activation of distinct classes of GEFs may allow for precise control of Rho GTPase function at the crucial interface between T cells and antigen presenting cells.	Columbia Univ, Dept Med, New York, NY 10032 USA; Columbia Univ, Dept Med & Pharmacol, New York, NY 10032 USA; Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA	Columbia University; Columbia University; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Pernis, AB (corresponding author), Columbia Univ, Dept Med, 630 W 168th St, New York, NY 10032 USA.	abp1@columbia.edu	Fanzo, Jessica/HCH-3533-2022	Cox, Dianne/0000-0002-0591-9767; Fanzo, Jessica/0000-0002-6760-1359	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062215] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI050514] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K01AR002158] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL-62215] Funding Source: Medline; NIAID NIH HHS [P01 AI50514-01] Funding Source: Medline; NIAMS NIH HHS [K01 AR002158] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141; ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; Bauch A, 2000, ADV IMMUNOL, V75, P89, DOI 10.1016/S0065-2776(00)75002-4; Borggrefe T, 1999, EUR J IMMUNOL, V29, P1812, DOI 10.1002/(SICI)1521-4141(199906)29:06<1812::AID-IMMU1812>3.0.CO;2-J; Bromley SK, 2001, ANNU REV IMMUNOL, V19, P375, DOI 10.1146/annurev.immunol.19.1.375; Bustelo XR, 2001, ONCOGENE, V20, P6372, DOI 10.1038/sj.onc.1204780; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Clements JL, 1999, J CLIN INVEST, V103, P925, DOI 10.1172/JCI6562; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3; Delon J, 2000, CURR BIOL, V10, pR923, DOI 10.1016/S0960-9822(00)00870-8; Dustin ML, 2000, NAT IMMUNOL, V1, P23, DOI 10.1038/76877; Fischer KD, 1998, SEMIN IMMUNOL, V10, P317, DOI 10.1006/smim.1998.0124; Gupta S, 1999, J EXP MED, V190, P1837, DOI 10.1084/jem.190.12.1837; Gupta S, 2003, HUM IMMUNOL, V64, P389, DOI 10.1016/S0198-8859(03)00024-7; Gupta S, 1998, J IMMUNOL, V161, P5997; Hakeda-Suzuki S, 2002, NATURE, V416, P438, DOI 10.1038/416438a; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Hoffman GR, 2002, FEBS LETT, V513, P85, DOI 10.1016/S0014-5793(01)03310-5; Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374; Kane LP, 2000, CURR OPIN IMMUNOL, V12, P242, DOI 10.1016/S0952-7915(00)00083-2; Krawczyk C, 2001, J LEUKOCYTE BIOL, V69, P317; Latour S, 2001, CURR OPIN IMMUNOL, V13, P299, DOI 10.1016/S0952-7915(00)00219-3; Liu YH, 2000, J BIOL CHEM, V275, P3603, DOI 10.1074/jbc.275.5.3603; Monks CRF, 1997, NATURE, V385, P83, DOI 10.1038/385083a0; Qian DP, 1997, J EXP MED, V185, P1253, DOI 10.1084/jem.185.7.1253; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Roumier A, 2001, IMMUNITY, V15, P715, DOI 10.1016/S1074-7613(01)00225-4; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Shinohara M, 2002, NATURE, V416, P759, DOI 10.1038/416759a; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Symons M, 2000, TRENDS CELL BIOL, V10, P415, DOI 10.1016/S0962-8924(00)01832-8; Tanaka Y, 2003, IMMUNITY, V18, P403, DOI 10.1016/S1074-7613(03)00054-2; Turner M, 2002, NAT REV IMMUNOL, V2, P476, DOI 10.1038/nri840; van der Merwe PA, 2002, CURR OPIN IMMUNOL, V14, P293, DOI 10.1016/S0952-7915(02)00350-3; van Leeuwen JEM, 1999, CURR OPIN IMMUNOL, V11, P242, DOI 10.1016/S0952-7915(99)80040-5; Ward SG, 2001, CURR OPIN IMMUNOL, V13, P332, DOI 10.1016/S0952-7915(00)00223-5; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9	40	60	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43541	43549		10.1074/jbc.M308960200	http://dx.doi.org/10.1074/jbc.M308960200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12923183	hybrid			2022-12-25	WOS:000186157000100
J	Kawagoe, J; Ohmichi, M; Takahashi, T; Ohshima, C; Mabuchi, S; Takahashi, K; Igarashi, H; Mori-Abe, A; Saitoh, M; Du, BT; Ohta, T; Kimura, A; Kyo, S; Inoue, M; Kurachi, H				Kawagoe, J; Ohmichi, M; Takahashi, T; Ohshima, C; Mabuchi, S; Takahashi, K; Igarashi, H; Mori-Abe, A; Saitoh, M; Du, BT; Ohta, T; Kimura, A; Kyo, S; Inoue, M; Kurachi, H			Raloxifene inhibits estrogen-induced up-regulation of telomerase activity in a human breast cancer cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NITRIC-OXIDE SYNTHASE; PROTEIN-KINASE; OVARIAN-CANCER; AKT; TAMOXIFEN; PREVENTION; PHOSPHORYLATION; THERAPY; ACTIVATION	The mechanism by which raloxifene acts in the chemoprevention of breast cancer remains unclear. Because telomerase activity is involved in estrogen-induced carcinogenesis, we examined the effect of raloxifene on estrogen-induced up-regulation of telomerase activity in MCF-7 human breast cancer cell line. Raloxifene inhibited the induction of cell growth and telomerase activity by 17beta-estradiol (E2). Raloxifene inhibited the E2-induced expression of the human telomerase catalytic subunit ( hTERT), and transient expression assays using luciferase reporter plasmids containing various fragments of the hTERT promoter showed that the estrogen-responsive element appeared to be partially responsible for the action of raloxifene. E2 induced the phosphorylation of Akt, and pretreatment with a phosphatidylinositol 3-kinase (PI3K) inhibitor, LY294002, attenuated the E2-induced increases of the telomerase activity and hTERT promoter activity. Raloxifene inhibited the E2-induced Akt phosphorylation. In addition, raloxifene also inhibited the E2-induced hTERT expression via the PI3K/Akt/NFkappaB cascade. Moreover, raloxifene also inhibited the E2-induced phosphorylation of hTERT, association of NFkappaB with hTERT, and nuclear accumulation of hTERT. These results show that raloxifene inhibited the E2-induced up-regulation of telomerase activity not only by transcriptional regulation of hTERT via an estrogen-responsive element-dependent mechanism and the PI3K/Akt/NFkappaB cascade but also by post-translational regulation via phosphorylation of hTERT and association with NFkappaB.	Yamagata Univ, Sch Med, Dept Obstet & Gynecol, Yamagata 9909585, Japan; Yamagata Univ, Sch Med, Div Nursing, Yamagata 9909585, Japan; Osaka Univ, Sch Med, Dept Obstet & Gynecol, Suita, Osaka 5650871, Japan; Kanazawa Univ, Sch Med, Dept Obstet & Gynecol, Kanazawa, Ishikawa 9208640, Japan	Yamagata University; Yamagata University; Osaka University; Kanazawa University	Ohmichi, M (corresponding author), Yamagata Univ, Sch Med, Dept Obstet & Gynecol, 2-2-2 Iidanishi, Yamagata 9909585, Japan.	masa@med.id.yamagata-u.ac.jp	Mabuchi, Seiji/AAX-1986-2020					ADAMS MR, 1990, ARTERIOSCLEROSIS, V10, P1051, DOI 10.1161/01.ATV.10.6.1051; ADAMS MR, 1987, ARTERIOSCLEROSIS, V7, P378, DOI 10.1161/01.ATV.7.4.378; Akalin A, 2001, CANCER RES, V61, P4791; Akiyama M, 2003, CANCER RES, V63, P18; Akiyama M, 2002, CANCER RES, V62, P3876; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BarrettConnor E, 1997, CIRCULATION, V95, P252, DOI 10.1161/01.CIR.95.1.252; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; Castoria G, 2001, EMBO J, V20, P6050, DOI 10.1093/emboj/20.21.6050; Cauley JA, 2001, BREAST CANCER RES TR, V65, P125, DOI 10.1023/A:1006478317173; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Chen SJ, 1996, CIRCULATION, V93, P577, DOI 10.1161/01.CIR.93.3.577; Choi Y, 2002, ONCOGENE, V21, P5289, DOI 10.1038/sj.onc.1205650; Clark AS, 2002, MOL CANCER THER, V1, P707; Cuzick J, 2002, LANCET, V360, P817; Cuzick J, 2003, LANCET, V361, P296, DOI 10.1016/S0140-6736(03)12342-2; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Fishman J, 1995, ANN NY ACAD SCI, V768, P91, DOI 10.1111/j.1749-6632.1995.tb12113.x; FREISS G, 1994, MOL ENDOCRINOL, V8, P1389, DOI 10.1210/me.8.10.1389; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARLEY CB, 1995, CURR OPIN GENET DEV, V5, P249, DOI 10.1016/0959-437X(95)80016-6; Hisamoto K, 2001, J BIOL CHEM, V276, P47642, DOI 10.1074/jbc.M103853200; Hisamoto K, 2001, J BIOL CHEM, V276, P3459, DOI 10.1074/jbc.M005036200; Holt SE, 1999, GENE DEV, V13, P817, DOI 10.1101/gad.13.7.817; JACOBSSON J, 1992, J HEART LUNG TRANSPL, V11, P1188; Kang SS, 1999, J BIOL CHEM, V274, P13085, DOI 10.1074/jbc.274.19.13085; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kuschel B, 2000, EUR J CANCER PREV, V9, P139, DOI 10.1097/00008469-200006000-00001; Kyo S, 1997, J GEN VIROL, V78, P401, DOI 10.1099/0022-1317-78-2-401; Kyo S, 1999, CANCER RES, V59, P5917; Lacey JV, 2002, JAMA-J AM MED ASSOC, V288, P334, DOI 10.1001/jama.288.3.334; Mabuchi S, 2002, J BIOL CHEM, V277, P33490, DOI 10.1074/jbc.M204042200; Markman M, 1996, GYNECOL ONCOL, V62, P4, DOI 10.1006/gyno.1996.0181; Marth C, 1997, INT J GYNECOL CANCER, V7, P256, DOI 10.1046/j.1525-1438.1997.00463.x; Ozes ON, 1999, NATURE, V401, P82; Paez Juan, 2003, Cancer Treat Res, V115, P145; Perez-Tenorio G, 2002, BRIT J CANCER, V86, P540, DOI 10.1038/sj.bjc.6600126; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Powles T, 1998, LANCET, V352, P98; Riggs BL, 2003, NEW ENGL J MED, V348, P618, DOI 10.1056/NEJMra022219; Seimiya H, 2000, EMBO J, V19, P2652, DOI 10.1093/emboj/19.11.2652; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; Stoica GE, 2003, MOL ENDOCRINOL, V17, P818, DOI 10.1210/me.2002-0330; Veronesi U, 1998, LANCET, V352, P93; Wang ZO, 2002, ONCOGENE, V21, P3517, DOI 10.1038/sj.onc.1205463; Yang J, 1999, EMBO J, V18, P2174, DOI 10.1093/emboj/18.8.2174; Yin L, 2000, J BIOL CHEM, V275, P36671, DOI 10.1074/jbc.M007378200	51	59	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43363	43372		10.1074/jbc.M304363200	http://dx.doi.org/10.1074/jbc.M304363200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12917431	hybrid			2022-12-25	WOS:000186157000080
J	Pirch, T; Landmeier, S; Jung, H				Pirch, T; Landmeier, S; Jung, H			Transmembrane domain II of the Na plus /proline transporter PutP of Escherichia coli forms part of a conformationally flexible, cytoplasmic exposed aqueous cavity within the membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+/PROLINE TRANSPORTER; SECONDARY STRUCTURE; LACTOSE PERMEASE; NA+/GLUCOSE COTRANSPORTER; SUBSTRATE-BINDING; SYMPORTER FAMILY; PROTEIN; TOPOLOGY; RECONSTITUTION; PURIFICATION	The Na+/proline transporter PutP of Escherichia coli is a member of a large family of Na+/substrate symporters. Previous work on PutP suggests an involvement of the region ranging from Asp-55 to Gly-58 in binding of Na+ and/or proline (Pirch, T., Quick, M., Nietschke, M., Langkamp, M., Jung, H. (2002) J. Biol. Chem. 277, 8790-8796). In this study, a complete Cys scanning mutagenesis of transmembrane domain II (TM II) of PutP was performed to further elucidate the role of the TM in the transport process. Strong defects of PutP function were observed upon substitution of Ala-48, Ala-53, Trp-59, and Gly-63 by Cys in addition to the previously characterized residues Asp-55, Ser-57, and Gly-58. However, except for Asp-55 none of these residues proved essential for function. The activity of eight mutants was sensitive to N-ethylmaleimide inhibition with the sensitive positions clustering predominantly on a hydrophilic face in the cytoplasmic half of TM II. The same face was also highly accessible to the bulky sulfhydryl reagent fluorescein 5-maleimide in randomly oriented membrane vesicles, suggesting an unrestricted accessibility of the corresponding amino acid positions via an aqueous pathway. Na+ stimulated the reactivity of Cys toward fluorescein 5-maleimide at two positions while proline inhibited reaction of the sulfhydryl group at nine positions. Taken together, the results demonstrate that TM II of PutP is of particular functional importance. It is proposed that hydrophilic residues in the cytoplasmic half of TM II participate in the formation of an aqueous cavity in the membrane that allows Na+ and/or proline binding to residues located in the middle of the TM (e.g. Asp-55 and Ser-57). In addition, the data indicate that TM II participates in Na+-and proline-induced conformational alterations.	Univ Osnabruck, Fachbereich Biol Chem, Abt Mikrobiol, D-49069 Osnabruck, Germany	University Osnabruck	Jung, H (corresponding author), Univ Osnabruck, Fachbereich Biol Chem, Abt Mikrobiol, D-49069 Osnabruck, Germany.	jung_h@biologie.uni-osnabrueck.de	Jung, Heinrich/K-3790-2014	Jung, Heinrich/0000-0002-5450-3063				Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; AURORA R, 1994, SCIENCE, V264, P1126, DOI 10.1126/science.8178170; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN CC, 1985, J MEMBRANE BIOL, V84, P157, DOI 10.1007/BF01872213; Cordes FS, 2002, J MOL BIOL, V323, P951, DOI 10.1016/S0022-2836(02)01006-9; Dave N, 2000, BIOPHYS J, V79, P747, DOI 10.1016/S0006-3495(00)76332-6; Fann MC, 2003, J BACTERIOL, V185, P3863, DOI 10.1128/JB.185.13.3863-3870.2003; HANADA K, 1988, J BIOL CHEM, V263, P7181; Jung H, 1998, BBA-BIOENERGETICS, V1365, P60, DOI 10.1016/S0005-2728(98)00044-9; Jung H, 1998, J BIOL CHEM, V273, P26400, DOI 10.1074/jbc.273.41.26400; Jung H, 1998, BIOCHEMISTRY-US, V37, P11083, DOI 10.1021/bi980684b; Jung H, 2002, FEBS LETT, V529, P73, DOI 10.1016/S0014-5793(02)03184-8; Jung H, 2001, BBA-BIOENERGETICS, V1505, P131, DOI 10.1016/S0005-2728(00)00283-8; JUNG K, 1995, BIOCHEMISTRY-US, V34, P1030, DOI 10.1021/bi00003a038; le Coutre J, 2002, BIOCHEMISTRY-US, V41, P8082, DOI 10.1021/bi025692d; Levy O, 1998, J BIOL CHEM, V273, P22657, DOI 10.1074/jbc.273.35.22657; Miller J.H., 1992, SHORT COURSE BACTERI, P150; NAKAO T, 1987, MOL GEN GENET, V208, P70, DOI 10.1007/BF00330424; Panayotova-Heiermann M, 1999, FEBS LETT, V459, P386, DOI 10.1016/S0014-5793(99)01292-2; PanayotovaHeiermann M, 1997, J BIOL CHEM, V272, P20324, DOI 10.1074/jbc.272.33.20324; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Pirch T, 2002, J BIOL CHEM, V277, P8790, DOI 10.1074/jbc.M111008200; Poelarends GJ, 2002, J BIOL CHEM, V277, P42891, DOI 10.1074/jbc.M206508200; Quick M, 1998, BIOCHEMISTRY-US, V37, P13800, DOI 10.1021/bi980562j; Quick M, 1999, BIOCHEMISTRY-US, V38, P13523, DOI 10.1021/bi991256o; Quick M, 1996, EUR J BIOCHEM, V239, P732, DOI 10.1111/j.1432-1033.1996.0732u.x; Quick M, 1997, BIOCHEMISTRY-US, V36, P4631, DOI 10.1021/bi963063w; REIZER J, 1994, BBA-REV BIOMEMBRANES, V1197, P133, DOI 10.1016/0304-4157(94)90003-5; Saier MH, 1999, J CELL BIOCHEM, P84; STALMACH ME, 1983, J BACTERIOL, V156, P481, DOI 10.1128/JB.156.2.481-486.1983; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Turk E, 1997, J MEMBRANE BIOL, V159, P1, DOI 10.1007/s002329900264; Wegener C, 2000, BIOCHEMISTRY-US, V39, P4831, DOI 10.1021/bi992442x; Weinglass AB, 1999, P NATL ACAD SCI USA, V96, P11178, DOI 10.1073/pnas.96.20.11178; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZHOU JD, 1995, J MOL BIOL, V251, P237, DOI 10.1006/jmbi.1995.0431	39	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42942	42949		10.1074/jbc.M308253200	http://dx.doi.org/10.1074/jbc.M308253200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12923181	hybrid			2022-12-25	WOS:000186157000028
J	Polit, A; Bonarek, P; Kepys, B; Kedracka-Krok, S; Gorecki, A; Wasylewski, Z				Polit, A; Bonarek, P; Kepys, B; Kedracka-Krok, S; Gorecki, A; Wasylewski, Z			Kinetic studies of cAMP-induced allosteric changes in mutants T127I, S128A, and T127I/S128A of the cAMP receptor protein from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-AMP; ACTIVATOR PROTEIN; BINDING; SITE; DNA; TRANSCRIPTION; MUTAGENESIS; COMPLEX	The cAMP receptor protein (CRP) regulates the expression of several genes in Escherichia coli. The protein is a homodimer, and each monomer is folded into two distinct structural domains. After allosteric transitions resulting from the binding of cAMP, CRP specifically binds to DNA and activates transcription. We have used stopped-flow fluorometry measurements of CRP mutants bearing amino acid substitutions T127I, S128A, and T127I/S128A to study the kinetics of conformational changes in the protein induced by cAMP binding. Amino acid substitutions at positions 127 and 128 were chosen because these residues play a crucial role in interdomain and intersubunit communication during allosteric transition. Using N-iodoacetylaminoethyl-5-naphthylamine-1-sulfonic acid-labeled Cys(178), localized in the protein helix-turn helix motif, we observed conformational changes in the helix-turn helix, localized in the C-terminal domain, upon binding of cAMP to high affinity sites (CRP.cAMP(2)) in the N-terminal domain of CRP. The rate constants for the forward and backward conformational changes depend on the amino acid substitution: k(c)=3.62 s(-1) and k(-c)=3.13 s(-1) for CRP T127I and k(c)=0.42 s(-1) and k(-c)=0.78 s(-1) for CRP S128A. These values can be compared with k(c)=9.7 s(-1) and k(-c)=0.31 s(-1) for wild-type CRP. The observed conformational changes can be described by the sequential model of allostery, with the amino acid substitutions influencing the allosteric changes. In the case of the double mutant, the observed rate constant of cAMP binding supports the suggestion that this unligated mutant possesses the structure that is close to the allosteric conformation necessary for promoter binding. The results of intrinsic fluorescence measurements suggest that the formation of the CRP.cAMP(4) complex results from displacement of equilibrium between the two forms of the CRP.cAMP(2) complex in the mutants studied, similar to wild-type CRP. The observed conformational changes occur according to a concerted model of allostery, and isomerization equilibrium between the two CRP states depends on the amino acid substitution. The data presented in this study indicate that Ser(128) and Thr(127) in CRP play an important role in the kinetics of intramolecular transitions triggered by cAMP.	Jagiellonian Univ, Fac Biotechnol, Dept Phys Biochem, PL-30387 Krakow, Poland	Jagiellonian University	Wasylewski, Z (corresponding author), Jagiellonian Univ, Fac Biotechnol, Dept Phys Biochem, Ul Gronostajowa 7, PL-30387 Krakow, Poland.	wasylewski@mol.uj.edu.pl		Polit, Agnieszka/0000-0001-5811-9838; Bonarek, Piotr/0000-0002-5408-6220; Gorecki, Andrzej/0000-0002-4159-447X				ANDERSON WB, 1971, J BIOL CHEM, V246, P5929; Blaszczyk U, 2001, J PROTEIN CHEM, V20, P601, DOI 10.1023/A:1013708000833; Busby S, 1999, J MOL BIOL, V293, P199, DOI 10.1006/jmbi.1999.3161; CANTOR CR, 1980, BIOPHYSICAL CHEM, P887; CHENG XD, 1995, BIOCHEMISTRY-US, V34, P10816, DOI 10.1021/bi00034a014; Chu SY, 2001, J BIOL CHEM, V276, P11230, DOI 10.1074/jbc.M010428200; EILEN E, 1977, J MOL BIOL, V114, P47, DOI 10.1016/0022-2836(77)90282-0; Fersht A, 1999, STRUCTURE MECH PROTE, P132; HARMAN JG, 2001, BIOCHIM BIOPHYS ACTA, V1574, P1; HUDSON EN, 1973, BIOCHEMISTRY-US, V12, P4154, DOI 10.1021/bi00745a019; LEE FJ, 1994, NUCLEIC ACIDS RES, V22, P2894; Leu SF, 1999, BIOCHEMISTRY-US, V38, P6222, DOI 10.1021/bi982938z; Lin SH, 2002, BIOCHEMISTRY-US, V41, P11857, DOI 10.1021/bi026099z; Malecki J, 2000, J BIOL CHEM, V275, P8480, DOI 10.1074/jbc.275.12.8480; *MERCK CO INC, 1976, MERCK IND; Mukhopadhyay J, 1999, FEBS LETT, V453, P215, DOI 10.1016/S0014-5793(99)00719-X; Passner JM, 1997, P NATL ACAD SCI USA, V94, P2843, DOI 10.1073/pnas.94.7.2843; Passner JM, 2000, J MOL BIOL, V304, P847, DOI 10.1006/jmbi.2000.4231; Polit A, 2003, EUR J BIOCHEM, V270, P1413, DOI 10.1046/j.1432-1033.2003.03497.x; TAKAHASHI M, 1980, BIOCHEMISTRY-US, V19, P5124, DOI 10.1021/bi00563a029; TANIGUCHI T, 1979, P NATL ACAD SCI USA, V76, P5090, DOI 10.1073/pnas.76.10.5090; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; Won HS, 2000, BIOCHEMISTRY-US, V39, P13953, DOI 10.1021/bi000012x; WU CW, 1974, BIOCHEMISTRY-US, V13, P2573, DOI 10.1021/bi00709a016	24	7	7	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43020	43026		10.1074/jbc.M306398200	http://dx.doi.org/10.1074/jbc.M306398200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12939272	hybrid			2022-12-25	WOS:000186157000038
J	Shen, WJ; Patel, S; Natu, V; Hong, R; Wang, J; Azhar, S; Kraemer, FB				Shen, WJ; Patel, S; Natu, V; Hong, R; Wang, J; Azhar, S; Kraemer, FB			Interaction of hormone-sensitive lipase with steroidogeneic acute regulatory protein - Facilitation of cholesterol transfer in adrenal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-BINDING PROTEIN; TARGETED DISRUPTION; MOLECULAR-CLONING; ESTER HYDROLASE; STAR; DOMAIN; TRAFFICKING; MECHANISM; TRANSPORT; IDENTIFICATION	Hormone-sensitive lipase (HSL) is responsible for the neutral cholesteryl ester hydrolase activity in steroidogenic tissues. Through its action, HSL is involved in regulating intracellular cholesterol metabolism and making unesterified cholesterol available for steroid hormone production. Steroidogenic acute regulatory protein ( StAR) facilitates the movement of cholesterol from the outer mitochondrial membrane to the inner mitochondrial membrane and is a critical regulatory step in steroidogenesis. In the current studies we demonstrate a direct interaction of HSL with StAR using in vitro glutathione S-transferase pull-down experiments. The 37-kDa StAR is coimmunoprecipitated with HSL from adrenals of animals treated with ACTH. Deletional mutations show that HSL interacts with the N-terminal as well as a central region of StAR. Coexpression of HSL and StAR in Chinese hamster ovary cells results in higher cholesteryl ester hydrolytic activity of HSL. Transient overexpression of HSL in Y1 adrenocortical cells increases mitochondrial cholesterol content under conditions in which StAR is induced. It is proposed that the interaction of HSL with StAR in cytosol increases the hydrolytic activity of HSL and that together HSL and StAR facilitate cholesterol movement from lipid droplets to mitochondria for steroidogenesis.	Stanford Univ, Div Endocrinol, Dept Med, Stanford, CA 94305 USA; Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Kraemer, FB (corresponding author), Stanford Univ, Div Endocrinol, Dept Med, S-025, Stanford, CA 94305 USA.		Kraemer, Fredric/AAC-3633-2019	Kraemer, Fredric/0000-0003-2468-7807; Shen, Wen-Jun/0000-0001-5150-1698	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046942] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 46942] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Blanchette-Mackie EJ, 2000, BBA-MOL CELL BIOL L, V1486, P171, DOI 10.1016/S1388-1981(00)00055-X; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bose HS, 1996, NEW ENGL J MED, V335, P1870, DOI 10.1056/NEJM199612193352503; Brown RC, 2001, INT REV NEUROBIOL, V46, P117; Caron KM, 1997, P NATL ACAD SCI USA, V94, P11540, DOI 10.1073/pnas.94.21.11540; Christenson LK, 2000, BBA-MOL CELL BIOL L, V1529, P175, DOI 10.1016/S1388-1981(00)00147-5; Contreras JA, 1996, J BIOL CHEM, V271, P31426, DOI 10.1074/jbc.271.49.31426; DIBARTOLOMEIS MJ, 1986, J BIOL CHEM, V261, P4432; Fielding CJ, 1997, J LIPID RES, V38, P1503; Ghosh S, 1995, BBA-LIPID LIPID MET, V1259, P305, DOI 10.1016/0005-2760(95)00184-0; Hoekstra D, 2000, CURR OPIN CELL BIOL, V12, P496, DOI 10.1016/S0955-0674(00)00122-8; Kallen CB, 1998, J BIOL CHEM, V273, P26285, DOI 10.1074/jbc.273.41.26285; Kraemer FB, 2002, ENDOCRINOLOGY, V143, P801, DOI 10.1210/en.143.3.801; Kraemer FB, 2002, J LIPID RES, V43, P1585, DOI 10.1194/jlr.R200009-JLR200; Lehner R, 1999, BIOCHEM J, V343, P1, DOI 10.1042/0264-6021:3430001; Liscum L, 1999, BBA-MOL CELL BIOL L, V1438, P19, DOI 10.1016/S1388-1981(99)00043-8; Miller WL, 1999, J STEROID BIOCHEM, V69, P131, DOI 10.1016/S0960-0760(98)00153-8; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Osterlund T, 1999, J BIOL CHEM, V274, P15382, DOI 10.1074/jbc.274.22.15382; Osterlund T, 1996, BIOCHEM J, V319, P411, DOI 10.1042/bj3190411; Osterlund T, 2001, EUR J BIOCHEM, V268, P1899, DOI 10.1046/j.1432-1327.2001.02097.x; Osuga J, 2000, P NATL ACAD SCI USA, V97, P787, DOI 10.1073/pnas.97.2.787; Petrescu AD, 2001, J BIOL CHEM, V276, P36970, DOI 10.1074/jbc.M101939200; PROBST MR, 1994, J BIOL CHEM, V269, P21650; PROKOCIMER PG, 1988, MOL PHARMACOL, V33, P338; REAVEN E, 1990, J BIOL CHEM, V265, P19100; Romanowski MJ, 2002, P NATL ACAD SCI USA, V99, P6949, DOI 10.1073/pnas.052140699; Shen WJ, 1999, P NATL ACAD SCI USA, V96, P5528, DOI 10.1073/pnas.96.10.5528; Shen WJ, 2001, J BIOL CHEM, V276, P49443, DOI 10.1074/jbc.M104095200; Soccio RE, 2002, P NATL ACAD SCI USA, V99, P6943, DOI 10.1073/pnas.052143799; Stocco DM, 1999, VITAM HORM, V55, P399; Stocco DM, 2001, ANNU REV PHYSIOL, V63, P193, DOI 10.1146/annurev.physiol.63.1.193; Syu LJ, 1999, MOL CELL, V4, P109, DOI 10.1016/S1097-2765(00)80192-6; Tsujishita Y, 2000, NAT STRUCT BIOL, V7, P408; Watari H, 2000, EXP CELL RES, V255, P56, DOI 10.1006/excr.1999.4774; Wei CJ, 1999, BIOCHEM J, V340, P345, DOI 10.1042/0264-6021:3400345; Zhang M, 2002, J BIOL CHEM, V277, P33300, DOI 10.1074/jbc.M200003200	37	52	53	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43870	43876		10.1074/jbc.M303934200	http://dx.doi.org/10.1074/jbc.M303934200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12925534	hybrid, Green Submitted			2022-12-25	WOS:000186157000137
J	Sun, Y; Mochizuki, Y; Majerus, PW				Sun, Y; Mochizuki, Y; Majerus, PW			Inositol 1,3,4-trisphosphate 5/6-kinase inhibits tumor necrosis factor-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; COP9 SIGNALOSOME; CASPASE ACTIVATION; PROTEIN-KINASE; DEATH DOMAIN; PHOSPHORYLATION; EXPRESSION; FAS; INDUCTION; CLEAVAGE	Tumor necrosis factor receptor 1 (TNF-R1) signaling elicits a wide range of biological responses, including inflammation, proliferation, differentiation, and apoptosis. TNF-R1 activates both caspase-mediated apoptosis and NF-kappaB transcription of anti-apoptotic factors. We now report a link between the TNF-R1 and inositol phosphate signaling pathways. We observed that overexpression of inositol 1,3,4-trisphosphate 5/6-kinase (5/6-kinase) inhibited apoptosis induced by TNFalpha. The antiapoptotic effect by 5/6-kinase is not attributable to NF-kappaB activation, as no changes were detected in the levels of NF-kappaB DNA binding, IkappaBalpha degradation, or antiapoptotic factors, such as x-linked inhibitor of apoptosis protein. Decreased expression of 5/6-kinase by RNA interference rendered HeLa cells more susceptible to TNFalpha-induced apoptosis. Overexpression of 5/6-kinase in human embryonic kidney 293 cells inhibited TNFalpha-induced activation of caspases-8, -3, and -9, BID, and poly(ADP-ribose) polymerase. However, 5/6-kinase did not protect against Fas-, etoposide-, or cycloheximide-induced apoptosis. Further, 5/6-kinase protected against apoptosis induced by the overexpression of TNF-R1-associated death domain but not Fas- associated death domain. Therefore, we suggest that 5/6-kinase modifies TNFalpha-induced apoptosis by interfering with the activation of TNF-R1-associated death domain.	Washington Univ, Sch Med, Dept Internal Med, Div Hematol, St Louis, MO 63110 USA	Washington University (WUSTL)	Majerus, PW (corresponding author), Washington Univ, Sch Med, Dept Internal Med, Div Hematol, 660 S Euclid Ave,Campus Box 8125, St Louis, MO 63110 USA.	phil@im.wustl.edu						Chang SC, 2002, J BIOL CHEM, V277, P43836, DOI 10.1074/jbc.M206134200; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Decker P, 2000, J BIOL CHEM, V275, P9043, DOI 10.1074/jbc.275.12.9043; Deshmukh M, 1996, J CELL BIOL, V135, P1341, DOI 10.1083/jcb.135.5.1341; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; HANSEN CA, 1988, FEBS LETT, V236, P53, DOI 10.1016/0014-5793(88)80284-9; Irvine RF, 2001, NAT REV MOL CELL BIO, V2, P327, DOI 10.1038/35073015; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M., 1999, SCI SIGNAL TRANSDUCT, V5, P1; Kemp CJ, 2001, CANCER RES, V61, P327; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lyapina S, 2001, SCIENCE, V292, P1382, DOI 10.1126/science.1059780; Majerus PW, 1996, GENE DEV, V10, P1051, DOI 10.1101/gad.10.9.1051; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Odom AR, 2000, SCIENCE, V287, P2026, DOI 10.1126/science.287.5460.2026; Scaffidi C, 2000, J IMMUNOL, V164, P1236, DOI 10.4049/jimmunol.164.3.1236; Schwechheimer C, 2001, SCIENCE, V292, P1379, DOI 10.1126/science.1059776; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Shimada K, 2002, JPN J CANCER RES, V93, P1164, DOI 10.1111/j.1349-7006.2002.tb01219.x; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; Sun Y, 2002, J BIOL CHEM, V277, P45759, DOI 10.1074/jbc.M208709200; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Tomoda K, 2002, J BIOL CHEM, V277, P2302, DOI 10.1074/jbc.M104431200; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Verbsky JW, 2002, J BIOL CHEM, V277, P31857, DOI 10.1074/jbc.M205682200; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wilson MP, 2001, J BIOL CHEM, V276, P40998, DOI 10.1074/jbc.M106605200; Wilson MP, 1996, J BIOL CHEM, V271, P11904, DOI 10.1074/jbc.271.20.11904; Yang BF, 2003, J BIOL CHEM, V278, P7043, DOI 10.1074/jbc.M211278200; Yang XN, 2000, BIOCHEM J, V351, P551, DOI 10.1042/0264-6021:3510551; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	38	19	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43645	43653		10.1074/jbc.M300674200	http://dx.doi.org/10.1074/jbc.M300674200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12925536	hybrid			2022-12-25	WOS:000186157000113
J	Yoo, JY; Ghiassi, M; Jirmanova, L; Balliet, AG; Hoffman, B; Fornace, AJ; Liebermann, DA; Bottinger, EP; Roberts, AB				Yoo, JY; Ghiassi, M; Jirmanova, L; Balliet, AG; Hoffman, B; Fornace, AJ; Liebermann, DA; Bottinger, EP; Roberts, AB			Transforming growth factor-beta-induced apoptosis is mediated by SMad-dependent expression of GADD45b through p38 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOMA-CELL LINE; A-INDUCED APOPTOSIS; TGF-BETA; PROTEIN-KINASE; SIGNAL-TRANSDUCTION; REGRESSING LIVER; MAP KINASES; CULTURED-HEPATOCYTES; POSSIBLE ASSOCIATION; TRANSGENIC MICE	Transforming growth factor-beta(TGF-beta)-dependent apoptosis is important in the elimination of damaged or abnormal cells from normal tissues in vivo. In this report, we identify GADD45b as an effector of TGF-beta-induced apoptosis. GADD45b has been shown to be a positive mediator of apoptosis induced by certain cytokines and oncogenes. We show that Gadd45b is an immediate-early response gene for TGF-beta and that the proximal Gadd45b promoter is activated by TGF-beta through the action of Smad2, Smad3, and Smad4. We show that ectopic expression of GADD45b in AML12 murine hepatocytes is sufficient to activate p38 and to trigger apoptotic cell death, whereas antisense inhibition of Gadd45b expression blocks TGF-beta-dependent p38 activation and apoptosis. Furthermore, we also show that TGF-beta can activate p38 and induce apoptosis in mouse primary hepatocytes from wild-type mice, but not from Gadd45b(-/-) mice. All of these findings suggest that GADD45b participates in TGF-beta-induced apoptosis by acting upstream of p38 activation.	NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA; NCI, Basic Res Lab, NIH, Bethesda, MD 20892 USA; Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Yeshiva University; Albert Einstein College of Medicine	Roberts, AB (corresponding author), NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bldg 41,Rm C629,41 Lib Dr,MSC 5055, Bethesda, MD 20892 USA.		Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X	DIVISION OF BASIC SCIENCES - NCI [Z01BC007184] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amanullah A, 2003, NATURE, V424, P741, DOI 10.1038/424741b; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Balliet AG, 2001, DNA CELL BIOL, V20, P239, DOI 10.1089/104454901750219125; BEDOSSA P, 1995, HEPATOLOGY, V21, P760, DOI 10.1016/0270-9139(95)90530-8; Buenemann CL, 2001, CARCINOGENESIS, V22, P447, DOI 10.1093/carcin/22.3.447; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Bulavin DV, 2003, MOL CELL BIOL, V23, P3859, DOI 10.1128/MCB.23.11.3859-3871.2003; Chen RH, 1997, CELL GROWTH DIFFER, V8, P821; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; De Zutter GS, 2001, P NATL ACAD SCI USA, V98, P6168, DOI 10.1073/pnas.111027698; Di Mari JF, 1999, AM J PHYSIOL-RENAL, V277, pF195, DOI 10.1152/ajprenal.1999.277.2.F195; Fukuchi Y, 2001, ONCOGENE, V20, P704, DOI 10.1038/sj.onc.1204142; FUKUDA K, 1993, HEPATOLOGY, V18, P945, DOI 10.1002/hep.1840180428; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; Hannigan M, 1998, BIOCHEM BIOPH RES CO, V246, P55, DOI 10.1006/bbrc.1998.8570; Haufel T, 1999, ANTICANCER RES, V19, P105; Hsing AY, 1996, CANCER RES, V56, P5146; Jang CW, 2002, NAT CELL BIOL, V4, P51, DOI 10.1038/ncb731; JIRTLE RL, 1991, DIGEST DIS SCI, V36, P659, DOI 10.1007/BF01297035; Johansson N, 2000, J CELL SCI, V113, P227; Karsdal MA, 2001, J BIOL CHEM, V276, P39350, DOI 10.1074/jbc.M008738200; KOSEKI T, 1995, FEBS LETT, V376, P247, DOI 10.1016/0014-5793(95)01290-7; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Larisch S, 2000, NAT CELL BIOL, V2, P915, DOI 10.1038/35046566; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; LIN JK, 1992, CANCER RES, V52, P385; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Mita H, 2002, MOL CELL BIOL, V22, P4544, DOI 10.1128/MCB.22.13.4544-4555.2002; Moser GJ, 1996, CARCINOGENESIS, V17, P1835, DOI 10.1093/carcin/17.9.1835; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; OBERHAMMER F, 1992, TOXICOL LETT, V64-5, P701, DOI 10.1016/0378-4274(92)90250-N; OBERHAMMER F, 1993, HEPATOLOGY, V18, P1238; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; Park HJ, 2002, HEPATOLOGY, V35, P1360, DOI 10.1053/jhep.2002.33205; Park KM, 2001, J BIOL CHEM, V276, P11870, DOI 10.1074/jbc.M007518200; Perlman R, 2001, NAT CELL BIOL, V3, P708, DOI 10.1038/35087019; Ravanti L, 1999, J BIOL CHEM, V274, P37292, DOI 10.1074/jbc.274.52.37292; RIESENBICHLER H, 1994, CARCINOGENESIS LOND, V15, P2763; ROBERTS RL, 1998, PROG LIVER DIS, V3, P57; Saltzman A, 1998, EXP CELL RES, V242, P244, DOI 10.1006/excr.1998.4096; Sanchez A, 1996, J BIOL CHEM, V271, P7416, DOI 10.1074/jbc.271.13.7416; SANDERSON N, 1995, P NATL ACAD SCI USA, V92, P2572, DOI 10.1073/pnas.92.7.2572; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Schiffer M, 2001, J CLIN INVEST, V108, P807, DOI 10.1172/JCI12367; Schramek H, 2002, NEWS PHYSIOL SCI, V17, P62, DOI 10.1152/nips.01365.2001; Schrantz N, 2001, MOL BIOL CELL, V12, P3139, DOI 10.1091/mbc.12.10.3139; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SUE SR, 1995, ANN SURG, V222, P171, DOI 10.1097/00000658-199508000-00009; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Takekawa M, 2002, EMBO J, V21, P6473, DOI 10.1093/emboj/cdf643; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Valderrama-Carvajal H, 2002, NAT CELL BIOL, V4, P963, DOI 10.1038/ncb885; Wong C, 1999, MOL CELL BIOL, V19, P1821; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yamamoto M, 1998, HEPATOLOGY, V27, P959, DOI 10.1002/hep.510270410; Yang YC, 2003, P NATL ACAD SCI USA, V100, P10269, DOI 10.1073/pnas.1834070100; YHILDESHEIM J, 2002, CANCER RES, V62, P7305; Zhang D, 2000, NAT MED, V6, P556, DOI 10.1038/75037; Zhang W, 1999, ONCOGENE, V18, P4899, DOI 10.1038/sj.onc.1202885; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	65	190	204	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43001	43007		10.1074/jbc.M307869200	http://dx.doi.org/10.1074/jbc.M307869200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12933797	hybrid			2022-12-25	WOS:000186157000035
J	Cadinanos, J; Varela, I; Mandel, DA; Schmidt, WK; Diaz-Perales, A; Lopez-Otin, C; Freije, JMP				Cadinanos, J; Varela, I; Mandel, DA; Schmidt, WK; Diaz-Perales, A; Lopez-Otin, C; Freije, JMP			AtFACE-2, a functional prenylated protein protease from Arabidopsis thaliana related to mammalian Ras-converting enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-ASSOCIATED METALLOPROTEASE; SACCHAROMYCES-CEREVISIAE; CAAX PROTEASES; IDENTIFICATION; STE24P; GENE; FARNESYLTRANSFERASE; ISOPRENYLATION; TRANSFERASE; EXPRESSION	Eukaryotic proteins containing a CAAX (A is aliphatic amino acid) C-terminal tetrapeptide sequence generally undergo a lipid modification, the addition of a prenyl group. Proteins that are modified by prenylation, such as Ras GTPases, can be subsequently modified by a proteolytic event that removes a C-terminal tripeptide (AAX). Two distinct proteases have been identified that are involved in the CAAX proteolytic step, FACE-1/Ste24 and FACE-2/Rce1. These proteases have different enzymatic properties, substrate specificities, and biological functions. However, a proposal has been made that plants lack a FACE-2/Rce1-type protease. Here, we describe the isolation of a cDNA from Arabidopsis thaliana that encodes a 311-aa protein with characteristics that are similar to the FACE-2/Rce1 group of enzymes. Northern blot analysis demonstrates widespread expression of this gene in plant tissues. Heterologous expression of the A. thaliana cDNA in yeast restores CAAX proteolytic activity to yeast lacking native CAAX proteases. The recombinant protein produced in this system displays an in vivo substrate specificity profile distinct from At-Ste24 and cleaves a farnesylated CAAX tetrapeptide in vitro. These results provide evidence for the existence of a previously unsuspected plant FACE-2/Rce1 ortholog and support the evolutionary conservation of dual CAAX proteolytic systems in eukaryotes.	Univ Oviedo, Dept Bioquim & Biol Mol, Inst Univ Oncol, E-33006 Oviedo, Spain; Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA	University of Oviedo; Instituto Universitario de Oncologia de Asturias; University System of Georgia; University of Georgia	Freije, JMP (corresponding author), Univ Oviedo, Dept Bioquim & Biol Mol, Inst Univ Oncol, 4-9,Campus Cristo, E-33006 Oviedo, Spain.	jmpf@correo.uniovi.es	Varela, Ignacio/AAA-7680-2021; Varela, Ignacio/G-1699-2016; López-Otín, Carlos/AAB-2106-2020; Díaz-Perales, Araceli/D-8433-2016; Freije, José M.P./A-6535-2008	Varela, Ignacio/0000-0002-0969-506X; Varela, Ignacio/0000-0002-0969-506X; López-Otín, Carlos/0000-0001-6964-1904; Díaz-Perales, Araceli/0000-0002-1093-3627; Freije, José M.P./0000-0002-4688-8266; Cadinanos, Juan/0000-0001-7561-7759				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bergo MO, 2002, MOL CELL BIOL, V22, P171, DOI 10.1128/MCB.22.1.171-181.2002; Bergo MO, 2002, P NATL ACAD SCI USA, V99, P13049, DOI 10.1073/pnas.192460799; Boyartchuk VL, 1997, SCIENCE, V275, P1796, DOI 10.1126/science.275.5307.1796; Bracha K, 2002, J BIOL CHEM, V277, P29856, DOI 10.1074/jbc.M202916200; Cadinanos J, 2003, BIOCHEM J, V370, P1047, DOI 10.1042/BJ20021514; Chary SN, 2002, PLANT J, V32, P735, DOI 10.1046/j.1365-313X.2002.01463.x; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; Cox AD, 2002, CURR OPIN PHARMACOL, V2, P388, DOI 10.1016/S1471-4892(02)00181-9; Crowell DN, 2000, PROG LIPID RES, V39, P393, DOI 10.1016/S0163-7827(00)00010-2; Cutler S, 1996, SCIENCE, V273, P1239, DOI 10.1126/science.273.5279.1239; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Dolence JM, 2000, BIOCHEMISTRY-US, V39, P4096, DOI 10.1021/bi9923611; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; Freije JMP, 1999, GENOMICS, V58, P270, DOI 10.1006/geno.1999.5834; FujimuraKamada K, 1997, J CELL BIOL, V136, P271, DOI 10.1083/jcb.136.2.271; GEORGOPAPADAKOU NH, 1994, ANAL BIOCHEM, V218, P273, DOI 10.1006/abio.1994.1178; HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; Kim E, 1999, J BIOL CHEM, V274, P8383, DOI 10.1074/jbc.274.13.8383; Kumagai H, 1999, BBA-GEN SUBJECTS, V1426, P468, DOI 10.1016/S0304-4165(98)00170-6; MICHAELIS S, 1988, MOL CELL BIOL, V8, P1309, DOI 10.1128/MCB.8.3.1309; Nijbroek GL, 1998, METHOD ENZYMOL, V292, P193; Oldenburg KR, 1997, NUCLEIC ACIDS RES, V25, P451, DOI 10.1093/nar/25.2.451; Otto JC, 1999, J BIOL CHEM, V274, P8379, DOI 10.1074/jbc.274.13.8379; Pendas AM, 2002, NAT GENET, V31, P94, DOI 10.1038/ng871; POWERS S, 1986, CELL, V47, P413, DOI 10.1016/0092-8674(86)90598-2; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; Schmidt WK, 1998, P NATL ACAD SCI USA, V95, P11175, DOI 10.1073/pnas.95.19.11175; Schmidt WK, 2000, J BIOL CHEM, V275, P6227, DOI 10.1074/jbc.275.9.6227; SIKORSKI RS, 1989, GENETICS, V122, P19; Tam A, 1998, J CELL BIOL, V142, P635, DOI 10.1083/jcb.142.3.635; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Trueblood CE, 2000, MOL CELL BIOL, V20, P4381, DOI 10.1128/MCB.20.12.4381-4392.2000; Vernoud V, 2003, PLANT PHYSIOL, V131, P1191, DOI 10.1104/pp.013052; Vicient CM, 1999, ANAL BIOCHEM, V268, P412, DOI 10.1006/abio.1998.3045; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; Yalovsky S, 2000, PLANT CELL, V12, P1267, DOI 10.1105/tpc.12.8.1267; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zhang YM, 2001, MOL BIOL CELL, V12, P1303, DOI 10.1091/mbc.12.5.1303	40	43	46	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42091	42097		10.1074/jbc.M306700200	http://dx.doi.org/10.1074/jbc.M306700200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12928436	hybrid			2022-12-25	WOS:000185989500066
J	Li, HD; Ayer, LM; Lytton, J; Deans, JP				Li, HD; Ayer, LM; Lytton, J; Deans, JP			Store-operated cation entry mediated by CD20 in membrane rafts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-CELL RECEPTOR; FC-EPSILON-RI; AFFINITY IGE RECEPTOR; LIPID RAFTS; CALCIUM INFLUX; ENDOPLASMIC-RETICULUM; SIGNAL-TRANSDUCTION; CA2+ CHANNELS; FAMILY; IDENTIFICATION	B cell activation requires sustained elevation of cytoplasmic free calcium, achieved by influx through store-operated calcium (SOC) channels. The molecular identity of these channels is not known. Ectopic expression of the raft-associated tetraspan protein CD20 in Chinese hamster ovary cells introduced a novel SOC entry pathway that was permeable to strontium as well as to calcium. The activity of this SOC pathway was abolished by deletion of a cytoplasmic sequence in CD20 essential for its efficient raft localization. Strontium-permeable SOC channels were detected in B cells, and B cell receptor-stimulated influx was significantly reduced by downregulation of CD20 expression using short interfering RNA and also by cholesterol depletion. This is the first evidence that raft-associated CD20 constitutes a component of a SOC entry pathway activated by the B cell receptor.	Univ Calgary, Hlth Sci Ctr, Dept Biochem & Mol Biol, Immunol Res Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Cardiovasc Res Grp, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Calgary	Deans, JP (corresponding author), Univ Calgary, Hlth Sci Ctr, Dept Biochem & Mol Biol, Immunol Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.			Lytton, Jonathan/0000-0003-4770-2512				Awasthi-Kalia M, 2001, BIOCHEM BIOPH RES CO, V287, P77, DOI 10.1006/bbrc.2001.5536; Barabe F, 2002, J BIOL CHEM, V277, P13473, DOI 10.1074/jbc.M112149200; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Bootman MD, 2001, SEMIN CELL DEV BIOL, V12, P3, DOI 10.1006/scdb.2000.0211; BUBIEN JK, 1993, J CELL BIOL, V121, P1121, DOI 10.1083/jcb.121.5.1121; Cheng PC, 1999, J EXP MED, V190, P1549, DOI 10.1084/jem.190.11.1549; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Deans JP, 1998, J BIOL CHEM, V273, P344, DOI 10.1074/jbc.273.1.344; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Donato JL, 2002, J CLIN INVEST, V109, P51, DOI 10.1172/JCI14025; FIELD KA, 1995, P NATL ACAD SCI USA, V92, P9201, DOI 10.1073/pnas.92.20.9201; Guo BC, 2000, IMMUNITY, V13, P243, DOI 10.1016/S1074-7613(00)00024-8; Hostager BS, 2000, J BIOL CHEM, V275, P15392, DOI 10.1074/jbc.M909520199; Ishibashi K, 2001, GENE, V264, P87, DOI 10.1016/S0378-1119(00)00598-9; Isshiki M, 1999, CELL CALCIUM, V26, P201, DOI 10.1054/ceca.1999.0073; Janes PW, 2000, SEMIN IMMUNOL, V12, P23, DOI 10.1006/smim.2000.0204; KANZAKI M, 1995, J BIOL CHEM, V270, P13099, DOI 10.1074/jbc.270.22.13099; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; Kiselyov K, 2001, BIOCHEM J, V360, P17, DOI 10.1042/0264-6021:3600017; Lewis RS, 1999, ADV SEC MESS PHOSPH, V33, P279; Liang YH, 2001, GENOMICS, V72, P119, DOI 10.1006/geno.2000.6472; Lockwich TP, 2000, J BIOL CHEM, V275, P11934, DOI 10.1074/jbc.275.16.11934; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Montell C, 2002, MOL CELL, V9, P229, DOI 10.1016/S1097-2765(02)00448-3; Mori Y, 2002, J EXP MED, V195, P673, DOI 10.1084/jem.20011758; O'Keefe TL, 1998, IMMUNOGENETICS, V48, P125, DOI 10.1007/s002510050412; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Petrie RJ, 2002, J IMMUNOL, V169, P2886, DOI 10.4049/jimmunol.169.6.2886; Petrie RJ, 2000, J IMMUNOL, V165, P1220, DOI 10.4049/jimmunol.165.3.1220; Pizzo P, 2002, EUR J IMMUNOL, V32, P3082, DOI 10.1002/1521-4141(200211)32:11<3082::AID-IMMU3082>3.0.CO;2-2; Polyak MJ, 2002, BLOOD, V99, P3256, DOI 10.1182/blood.V99.9.3256; Polyak MJ, 1998, J IMMUNOL, V161, P3242; Prakriya M, 2001, J PHYSIOL-LONDON, V536, P3, DOI 10.1111/j.1469-7793.2001.t01-1-00003.x; Putney JW, 1999, BIOESSAYS, V21, P38; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; Ralevic V, 1998, PHARMACOL REV, V50, P413; Rodgers W, 1996, J CELL BIOL, V135, P1515, DOI 10.1083/jcb.135.6.1515; SCHILLING WP, 1989, J BIOL CHEM, V264, P12838; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; TEDDER TE, 1994, IMMUNOL TODAY, V15, P450, DOI 10.1016/0167-5699(94)90276-3; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Trepakova ES, 2001, J BIOL CHEM, V276, P7782, DOI 10.1074/jbc.M010104200; Tsoi M, 1998, J BIOL CHEM, V273, P4155, DOI 10.1074/jbc.273.7.4155; VACA L, 1994, AM J PHYSIOL-CELL PH, V267, pC920, DOI 10.1152/ajpcell.1994.267.4.C920	48	128	135	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42427	42434		10.1074/jbc.M308802200	http://dx.doi.org/10.1074/jbc.M308802200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12920111	hybrid			2022-12-25	WOS:000185989500106
J	Poumbourios, P; Maerz, AL; Drummer, HE				Poumbourios, P; Maerz, AL; Drummer, HE			Functional evolution of the HIV-1 envelope glycoprotein 120 association site of glycoprotein 41	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; NEUTRALIZING ANTIBODY-RESPONSE; INTERMOLECULAR DISULFIDE BOND; V3 LOOP; SOLUBLE CD4; RECEPTOR-BINDING; ATOMIC-STRUCTURE; IN-VIVO; TRANSMEMBRANE GLYCOPROTEIN; CONFORMATIONAL-CHANGES	Protein-protein interaction surfaces can exhibit structural plasticity, a mechanism whereby an interface adapts to mutations as binding partners coevolve. The HIV-1 envelope glycoprotein gp120-gp41 complex, which is responsible for receptor attachment and membrane fusion, represents an extreme example of a coevolving complex as up to 35% amino acid sequence divergence has been observed in these proteins among HIV-1 isolates. In this study, the function of conserved gp120 contact residues, Leu(593), Trp(596), Gly(597), Lys(601), and Trp(610) within the disulfide-bonded region of gp41, was examined in envelope glycoproteins derived from diverse HIV-1 isolates. We found that the gp120-gp41 association function of the disulfide-bonded region is conserved. However, the contribution of individual residues to gp41 folding and/or stability, gp120-gp41 association, membrane fusion function, and viral entry varied from isolate to isolate. In gp120-gp41 derived from the dual-tropic isolate, HIV-1(89.6), the importance of Trp596 for fusion function was dependent on the chemokine receptor utilized as a fusion cofactor. Thus, the engagement of alternative chemokine receptors may evoke distinct fusion-activation signals involving the site of gp120-gp41 association. An examination of chimeric glycoproteins revealed that the isolate-specific functional contributions of particular gp120-contact residues are influenced by the sequence of gp120 hypervariable regions 1, 2, and 3. These data indicate that the gp120-gp41 association site is structurally and functionally adaptable, perhaps to maintain a functional glycoprotein complex in a setting of host selective pressures driving the rapid coevolution of gp120 and gp41.	St Vincents Inst Med Res, Virol Unit, Fitzroy, Vic 3065, Australia	St. Vincent's Institute of Medical Research	Poumbourios, P (corresponding author), St Vincents Inst Med Res, Virol Unit, 41 Victoria Parade, Fitzroy, Vic 3065, Australia.			Drummer, Heidi/0000-0002-0042-6277				ABACIOGLU YH, 1994, AIDS RES HUM RETROV, V10, P371, DOI 10.1089/aid.1994.10.371; Abrahamyan LG, 2003, J VIROL, V77, P5829, DOI 10.1128/JVI.77.10.5829-5836.2003; Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Atwell S, 1997, SCIENCE, V278, P1125, DOI 10.1126/science.278.5340.1125; Basmaciogullari S, 2002, J VIROL, V76, P10791, DOI 10.1128/JVI.76.21.10791-10800.2002; Bieniasz PD, 1997, EMBO J, V16, P2599, DOI 10.1093/emboj/16.10.2599; Binley JM, 2003, J VIROL, V77, P5678, DOI 10.1128/JVI.77.10.5678-5684.2003; Binley JM, 2000, J VIROL, V74, P627, DOI 10.1128/JVI.74.2.627-643.2000; Bjorndal A, 1997, J VIROL, V71, P7478; Blaak H, 2000, P NATL ACAD SCI USA, V97, P1269, DOI 10.1073/pnas.97.3.1269; Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; Carrillo A, 1996, J VIROL, V70, P1310, DOI 10.1128/JVI.70.2.1310-1316.1996; Cayabyab M, 1999, J VIROL, V73, P976, DOI 10.1128/JVI.73.2.976-984.1999; Center RJ, 2002, J VIROL, V76, P7863, DOI 10.1128/JVI.76.15.7863-7867.2002; Chakrabarti LA, 2002, J VIROL, V76, P1588, DOI 10.1128/JVI.76.4.1588-1599.2002; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chertova E, 2002, J VIROL, V76, P5315, DOI 10.1128/JVI.76.11.5315-5325.2002; Cho MW, 1998, J VIROL, V72, P2509, DOI 10.1128/JVI.72.3.2509-2515.1998; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; COLLMAN R, 1992, J VIROL, V66, P7517, DOI 10.1128/JVI.66.12.7517-7521.1992; CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016; Cormier EG, 2002, J VIROL, V76, P8953, DOI 10.1128/JVI.76.17.8953-8957.2002; Cormier EG, 2001, J VIROL, V75, P5541, DOI 10.1128/JVI.75.12.5541-5549.2001; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Derdeyn CA, 2001, J VIROL, V75, P8605, DOI 10.1128/JVI.75.18.8605-8614.2001; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; EARL PL, 1991, J VIROL, V65, P2047, DOI 10.1128/JVI.65.4.2047-2055.1991; Etemad-Moghadam B, 1999, J VIROL, V73, P8873, DOI 10.1128/JVI.73.10.8873-8879.1999; Farzan M, 1998, J VIROL, V72, P7620, DOI 10.1128/JVI.72.9.7620-7625.1998; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Fox DG, 1997, J VIROL, V71, P759, DOI 10.1128/JVI.71.1.759-765.1997; FREED EO, 1994, J VIROL, V68, P2503, DOI 10.1128/JVI.68.4.2503-2512.1994; Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276; Gao F, 1996, J VIROL, V70, P1651, DOI 10.1128/JVI.70.3.1651-1667.1996; GROENINK M, 1993, SCIENCE, V260, P1513, DOI 10.1126/science.8502996; Hallenberger S, 1997, J VIROL, V71, P1036, DOI 10.1128/JVI.71.2.1036-1045.1997; HALLENBERGER S, 1992, NATURE, V360, P358, DOI 10.1038/360358a0; HATCH WC, 1992, J IMMUNOL, V148, P3055; HELSETH E, 1991, J VIROL, V65, P2119, DOI 10.1128/JVI.65.4.2119-2123.1991; Hoffman NG, 2002, J VIROL, V76, P3852, DOI 10.1128/JVI.76.8.3852-3864.2002; Hoffman TL, 1998, P NATL ACAD SCI USA, V95, P11360, DOI 10.1073/pnas.95.19.11360; Hu QX, 2000, J VIROL, V74, P11858, DOI 10.1128/JVI.74.24.11858-11872.2000; HWANG SS, 1992, SCIENCE, V257, P535, DOI 10.1126/science.1636088; HWANG SS, 1991, SCIENCE, V253, P71, DOI 10.1126/science.1905842; Imamichi H, 2002, P NATL ACAD SCI USA, V99, P13813, DOI 10.1073/pnas.212511599; Jones PLS, 1998, J BIOL CHEM, V273, P404, DOI 10.1074/jbc.273.1.404; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; Karlsson GB, 1996, J VIROL, V70, P6136, DOI 10.1128/JVI.70.9.6136-6142.1996; Kolchinsky P, 1999, J VIROL, V73, P8120, DOI 10.1128/JVI.73.10.8120-8126.1999; Koshiba T, 2003, J BIOL CHEM, V278, P7573, DOI 10.1074/jbc.M211154200; KUIKEN CL, 2000, HUMAN RETROVIRUSES A; Kwong PD, 2000, STRUCTURE, V8, P1329, DOI 10.1016/S0969-2126(00)00547-5; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; Labrosse B, 2001, J VIROL, V75, P5457, DOI 10.1128/JVI.75.12.5457-5464.2001; LEONARD CK, 1990, J BIOL CHEM, V265, P10373; Lineberger JE, 2002, J VIROL, V76, P3522, DOI 10.1128/JVI.76.7.3522-3533.2002; Lo Conte L, 1999, J MOL BIOL, V285, P2177; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; Ly A, 2000, J VIROL, V74, P6769, DOI 10.1128/JVI.74.15.6769-6776.2000; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; Maerz AL, 2001, J VIROL, V75, P6635, DOI 10.1128/JVI.75.14.6635-6644.2001; Melikyan GB, 2000, J CELL BIOL, V151, P413, DOI 10.1083/jcb.151.2.413; MOORE JP, 1993, J VIROL, V67, P4785, DOI 10.1128/JVI.67.8.4785-4796.1993; MOORE JP, 1992, J VIROL, V66, P235, DOI 10.1128/JVI.66.1.235-243.1992; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; MUSTER T, 1993, J VIROL, V67, P6642, DOI 10.1128/JVI.67.11.6642-6647.1993; Myszka DG, 2000, P NATL ACAD SCI USA, V97, P9026, DOI 10.1073/pnas.97.16.9026; OBRIEN WA, 1994, J VIROL, V68, P5264, DOI 10.1128/JVI.68.8.5264-5269.1994; Palmer C, 1996, VIROLOGY, V220, P436, DOI 10.1006/viro.1996.0331; Poumbourios P, 1997, J VIROL, V71, P2041, DOI 10.1128/JVI.71.3.2041-2049.1997; Reeves JD, 2002, P NATL ACAD SCI USA, V99, P16249, DOI 10.1073/pnas.252469399; Richman DD, 2003, P NATL ACAD SCI USA, V100, P4144, DOI 10.1073/pnas.0630530100; Rizzuto C, 2000, AIDS RES HUM RETROV, V16, P741, DOI 10.1089/088922200308747; Rizzuto CD, 1998, SCIENCE, V280, P1949, DOI 10.1126/science.280.5371.1949; Ross TM, 1998, P NATL ACAD SCI USA, V95, P7682, DOI 10.1073/pnas.95.13.7682; Sanders RW, 2000, J VIROL, V74, P5091, DOI 10.1128/JVI.74.11.5091-5100.2000; SATTENTAU QJ, 1991, J EXP MED, V174, P407, DOI 10.1084/jem.174.2.407; Shioda T, 1997, J VIROL, V71, P4871, DOI 10.1128/JVI.71.7.4871-4881.1997; Singh A, 2000, J VIROL, V74, P10229, DOI 10.1128/JVI.74.21.10229-10235.2000; Smyth RJ, 1998, J VIROL, V72, P4478, DOI 10.1128/JVI.72.5.4478-4484.1998; Stamatatos L, 1998, J VIROL, V72, P7840, DOI 10.1128/JVI.72.10.7840-7845.1998; Sullivan N, 1998, J VIROL, V72, P6332, DOI 10.1128/JVI.72.8.6332-6338.1998; SULLIVAN N, 1995, J VIROL, V69, P4413, DOI 10.1128/JVI.69.7.4413-4422.1995; Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303; Theodore TS, 1996, AIDS RES HUM RETROV, V12, P191, DOI 10.1089/aid.1996.12.191; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; van Rij RP, 2000, J CLIN INVEST, V106, P1039, DOI 10.1172/JCI7953; WEISS CD, 1990, J VIROL, V64, P5674, DOI 10.1128/JVI.64.11.5674-5677.1990; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; Weissenhorn W, 1997, P NATL ACAD SCI USA, V94, P6065, DOI 10.1073/pnas.94.12.6065; Wolinsky SM, 1996, SCIENCE, V272, P537, DOI 10.1126/science.272.5261.537; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; WYATT R, 1993, J VIROL, V67, P4557, DOI 10.1128/JVI.67.8.4557-4565.1993; WYATT R, 1995, J VIROL, V69, P5723, DOI 10.1128/JVI.69.9.5723-5733.1995; Zhang CWH, 2001, J BIOL CHEM, V276, P39577, DOI 10.1074/jbc.M107147200; Zhang LQ, 2002, J VIROL, V76, P9465, DOI 10.1128/JVI.76.18.9465-9473.2002; Zhang PF, 2002, J VIROL, V76, P644, DOI 10.1128/JVI.76.2.644-655.2002	99	33	33	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42149	42160		10.1074/jbc.M305223200	http://dx.doi.org/10.1074/jbc.M305223200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12923196	hybrid			2022-12-25	WOS:000185989500073
J	Juntti-Berggren, L; Webb, DL; Arkhammar, POG; Schultz, V; Schweda, EKH; Tornheim, K; Berggren, PO				Juntti-Berggren, L; Webb, DL; Arkhammar, POG; Schultz, V; Schweda, EKH; Tornheim, K; Berggren, PO			Dihydroxyacetone-induced oscillations in cytoplasmic free Ca2+ and the ATP/ADP ratio in pancreatic beta-cells at substimulatory glucose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED INSULIN-SECRETION; ALPHA-KETOISOCAPROIC ACID; PURINE NUCLEOTIDE CYCLE; SENSITIVE K+ CHANNELS; PULSATILE INSULIN; MUSCLE EXTRACTS; B-CELLS; GLYCOLYTIC OSCILLATIONS; PYRIDINE-NUCLEOTIDES; INTRACELLULAR PH	Glucose stimulation of pancreatic beta-cells causes oscillatory influx of Ca2+, leading to pulsatile insulin secretion. We have proposed that this is due to oscillations of glycolysis and the ATP/ADP ratio, which modulate the activity of ATP-sensitive K+ channels. We show here that dihydroxyacetone, a secretagogue that feeds into glycolysis below the putative oscillator phosphofructokinase, could cause a single initial peak in cytoplasmic free Ca2+ ([Ca2+](i)) but did not by itself cause repeated oscillations in [Ca2+](i) in mouse pancreatic beta-cells. However, in the presence of a substimulatory concentration of glucose (4 mM), dihydroxyacetone induced [Ca2+](i) oscillations. Furthermore, these oscillations correlated with oscillations in the ATP/ADP ratio, as seen previously with glucose stimulation. Insulin secretion in response to dihydroxyacetone was transient in the absence of glucose but was considerably enhanced and somewhat prolonged in the presence of a substimulatory concentration of glucose, in accordance with the enhanced [Ca2+](i) response. These results are consistent with the hypothesized role of phosphofructokinase as the generator of the oscillations. Dihydroxyacetone may affect phosphofructokinase by raising the free concentration of fructose 1,6-bisphosphate to a critical level at which it activates the enzyme autocatalytically, thereby inducing the pulses of phosphofructokinase activity that cause the metabolic oscillations.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Karolinska Inst, Karolinska Hosp, Rolf Luft Ctr Diabet Res, Dept Mol Med, S-17176 Stockholm, Sweden; Karolinska Inst, Clin Res Ctr, S-14186 Huddinge, Sweden; Univ Coll S Stockholm, S-14186 Huddinge, Sweden	Boston University; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Sodertorn University	Tornheim, K (corresponding author), Boston Univ, Sch Med, Dept Biochem, 650 Albany St,Rm 815, Boston, MA 02118 USA.	tornheim@bu.edu		Tornheim, Keith/0000-0002-6235-5128; Berggren, Per-Olof/0000-0001-8991-413X; Webb, Dominic-Luc/0000-0002-6979-9194	NIDDK NIH HHS [DK35914, DK58508, DK53064] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035914, R01DK053064, R56DK035914, R01DK058508, R37DK035914] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIZAWA T, 1994, AM J PHYSIOL, V266, pC622, DOI 10.1152/ajpcell.1994.266.3.C622; ANDRES V, 1990, J BIOL CHEM, V265, P21441; ARKHAMMAR P, 1986, BIOSCIENCE REP, V6, P355, DOI 10.1007/BF01116422; Asanuma N, 1997, ENDOCRINOLOGY, V138, P751, DOI 10.1210/en.138.2.751; AVIDOR Y, 1962, J BIOL CHEM, V237, P2377; BERGSTEN P, 1994, J BIOL CHEM, V269, P8749; BUSA WB, 1986, ANNU REV PHYSIOL, V48, P389; CHOU HF, 1992, AM J PHYSIOL, V262, pE800, DOI 10.1152/ajpendo.1992.262.6.E800; COOK DL, 1984, NATURE, V311, P271, DOI 10.1038/311271a0; DAVIES J, 1994, BIOCHEM J, V304, P295, DOI 10.1042/bj3040295; Deeney JT, 2001, J BIOL CHEM, V276, P36946, DOI 10.1074/jbc.M105056200; DUCHEN MR, 1993, BIOCHEM J, V294, P35, DOI 10.1042/bj2940035; GEMBAL M, 1993, J CLIN INVEST, V91, P871, DOI 10.1172/JCI116308; GILON P, 1993, J BIOL CHEM, V268, P22265; GRANT AM, 1980, DIABETOLOGIA, V19, P114, DOI 10.1007/BF00421856; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HELLMAN B, 1965, ANN NY ACAD SCI, V131, P541, DOI 10.1111/j.1749-6632.1965.tb34819.x; HELLMAN B, 1974, ARCH BIOCHEM BIOPHYS, V162, P448, DOI 10.1016/0003-9861(74)90204-5; JUNTTIBERGGREN L, 1992, BIOCHEM J, V287, P59, DOI 10.1042/bj2870059; JUNTTIBERGGREN L, 1994, J BIOL CHEM, V269, P14391; KANATSUNA T, 1981, DIABETES, V30, P231, DOI 10.2337/diabetes.30.3.231; Kindmark H, 2001, J BIOL CHEM, V276, P34530, DOI 10.1074/jbc.M102492200; LACY PE, 1967, DIABETES, V16, P35, DOI 10.2337/diab.16.1.35; Larsson O, 1996, P NATL ACAD SCI USA, V93, P5161, DOI 10.1073/pnas.93.10.5161; Lenzen S, 2000, BBA-GEN SUBJECTS, V1523, P65, DOI 10.1016/S0304-4165(00)00100-8; LERNMARK A, 1974, DIABETOLOGIA, V10, P431, DOI 10.1007/BF01221634; LONGO EA, 1991, J BIOL CHEM, V266, P9314; LOWRY OH, 1964, J BIOL CHEM, V239, P31; LOWRY OH, 1972, FLEXIBLE SYSTEM ENZY, P168; MACDONALD MJ, 1989, ARCH BIOCHEM BIOPHYS, V270, P15, DOI 10.1016/0003-9861(89)90002-7; MALAISSE WJ, 1976, MOL CELL ENDOCRINOL, V4, P1, DOI 10.1016/0303-7207(76)90002-2; MATTHEWS DR, 1983, DIABETOLOGIA, V24, P231; MATTHEWS DR, 1983, DIABETES, V32, P617, DOI 10.2337/diabetes.32.7.617; MEGLASSON MD, 1987, DIABETES, V36, P477, DOI 10.2337/diabetes.36.4.477; MISLER S, 1989, J MEMBRANE BIOL, V109, P135, DOI 10.1007/BF01870852; NILSSON T, 1987, BIOCHEM J, V248, P329, DOI 10.1042/bj2480329; Nilsson T, 1996, BIOCHEM J, V314, P91, DOI 10.1042/bj3140091; PANTEN U, 1975, DIABETOLOGIA, V11, P569, DOI 10.1007/BF01222108; PAOLISSO G, 1987, DIABETES, V36, P566, DOI 10.2337/diabetes.36.5.566; Porksen N, 1997, AM J PHYSIOL-ENDOC M, V273, pE908; PRALONG WF, 1990, EMBO J, V9, P53, DOI 10.1002/j.1460-2075.1990.tb08079.x; Prentki M, 1997, DIABETOLOGIA, V40, pS32, DOI 10.1007/s001250051395; Salgado AP, 1996, J BIOL CHEM, V271, P8738, DOI 10.1074/jbc.271.15.8738; SCHULTZ V, 1993, ANAL BIOCHEM, V215, P302, DOI 10.1006/abio.1993.1591; SHEPHERD RM, 1995, J BIOL CHEM, V270, P7915, DOI 10.1074/jbc.270.14.7915; TORNHEIM K, 1976, J BIOL CHEM, V251, P7322; TORNHEIM K, 1973, J BIOL CHEM, V248, P2670; TORNHEIM K, 1975, J BIOL CHEM, V250, P6304; Tornheim K, 1997, DIABETES, V46, P1375, DOI 10.2337/diabetes.46.9.1375; TRIVEDI B, 1966, J BIOL CHEM, V241, P4110; TSUURA Y, 1994, DIABETOLOGIA, V37, P1082, DOI 10.1007/s001250050220; Webb DL, 1996, J BIOL CHEM, V271, P19074, DOI 10.1074/jbc.271.32.19074; WEIGLE DS, 1987, DIABETES, V36, P764, DOI 10.2337/diab.36.6.764; YANEY GC, 1995, DIABETES, V44, P1285, DOI 10.2337/diabetes.44.11.1285; ZAWALICH WS, 1978, ENDOCRINOLOGY, V103, P2027, DOI 10.1210/endo-103-6-2027; ZAWALICH WS, 1979, DIABETES, V28, P252, DOI 10.2337/diab.28.3.252	56	19	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40710	40716		10.1074/jbc.M308248200	http://dx.doi.org/10.1074/jbc.M308248200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12917415	hybrid			2022-12-25	WOS:000185847200036
J	Frouin, I; Maga, G; Denegri, M; Riva, F; Savio, M; Spadari, S; Prosperi, E; Scovassi, AI				Frouin, I; Maga, G; Denegri, M; Riva, F; Savio, M; Spadari, S; Prosperi, E; Scovassi, AI			Human proliferating cell nuclear antigen, poly(ADP-ribose) polymerase-1, and p21(waf1/cip1) - A dynamic exchange of partners	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPLICATION; PCNA; REPAIR; COMPLEX; IDENTIFICATION; ASSOCIATION; FIBROBLASTS; RECRUITMENT; IRRADIATION; EXPRESSION	We addressed the analysis of the physical and functional association of proliferating cell nuclear antigen (PCNA), a protein involved in many DNA transactions, with poly(ADP-ribose) polymerase (PARP-1), an enzyme that plays a crucial role in DNA repair and interacts with many DNA replication/repair factors. We demonstrated that PARP-1 and PCNA co-immunoprecipitated both from the soluble and the DNA-bound fraction isolated from S-phase-synchronized HeLa cells. Immunoprecipitation experiments with purified proteins further confirmed a physical association between PARP-1 and PCNA. To investigate the effect of this association on PARP-1 activity, an assay based on the incorporation of radioactive NAD was performed. Conversely, the effect of PARP-1 on PCNA-dependent DNA synthesis was assessed by a DNA polymerase delta assay. A marked inhibition of both reactions was found. Unexpectedly, PARP-1 activity also decreased in the presence of p21(waf1/cip1). By pull-down experiments, we provided the first evidence for an association between PARP- 1 and p21, which involves the C-terminal part of p21 protein. This association was further demonstrated to occur also in vivo in MNNG (N-methyl-N'-nitro-N-nitrosoguanidine)-treated human fibroblasts. These observations suggest that PARP-1 and p21 could cooperate in regulating the functions of PCNA during DNA replication/repair.	CNR, Ist Genet Mol, I-27100 Pavia, Italy; Univ Pavia, Dipartimento Med Sperimentale, Sez Patol Gen, I-27100 Pavia, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR); University of Pavia	Scovassi, AI (corresponding author), CNR, Ist Genet Mol, Via Abbiategrasso 207, I-27100 Pavia, Italy.	scovassi@igm.cnr.it	Scovassi, Anna Ivana/F-2458-2010; Maga, Giovanni/C-5409-2009; denegri, marco/D-9307-2019; Prosperi, Ennio/A-3439-2014	Scovassi, Anna Ivana/0000-0003-3484-9881; Maga, Giovanni/0000-0001-8092-1552; denegri, marco/0000-0003-1665-0625; Prosperi, Ennio/0000-0001-5391-5157				Burkle A, 2001, BIOESSAYS, V23, P795, DOI 10.1002/bies.1115; Cox LS, 1997, TRENDS CELL BIOL, V7, P493, DOI 10.1016/S0962-8924(97)01170-7; Dantzer F, 1998, NUCLEIC ACIDS RES, V26, P1891, DOI 10.1093/nar/26.8.1891; Donzelli M, 1999, ONCOGENE, V18, P439, DOI 10.1038/sj.onc.1202309; DOTTO GP, 2000, BIOCHIM BIOPHYS ACTA, V1471, P43; EKI T, 1991, J BIOL CHEM, V266, P3087; EKI T, 1994, FEBS LETT, V356, P261, DOI 10.1016/0014-5793(94)01280-6; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; Frouin I, 2003, EMBO REP, V4, P666, DOI 10.1038/sj.embor.embor886; Frouin I, 2002, EMBO J, V21, P2485, DOI 10.1093/emboj/21.10.2485; GOUBIN F, 1995, ONCOGENE, V10, P2281; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; Knibiehler M, 1996, FEBS LETT, V391, P66, DOI 10.1016/0014-5793(96)00702-8; KUPPER JH, 1995, MOL CELL BIOL, V15, P3154; Pleschke JM, 2000, J BIOL CHEM, V275, P40974, DOI 10.1074/jbc.M006520200; Prosperi E, 1997, Prog Cell Cycle Res, V3, P193; PROSPERI E, 1993, EXP CELL RES, V205, P320, DOI 10.1006/excr.1993.1092; ROOS G, 1993, LAB INVEST, V68, P204; Savio M, 1998, CARCINOGENESIS, V19, P591, DOI 10.1093/carcin/19.4.591; Savio M, 1996, ONCOGENE, V13, P1591; Simbulan-Rosenthal CM, 1998, BIOCHEMISTRY-US, V37, P9363, DOI 10.1021/bi9731089; SimbulanRosenthal CM, 1996, BIOCHEMISTRY-US, V35, P11622, DOI 10.1021/bi953010z; Stivala LA, 2001, ONCOGENE, V20, P563, DOI 10.1038/sj.onc.1204132; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R	25	74	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39265	39268		10.1074/jbc.C300098200	http://dx.doi.org/10.1074/jbc.C300098200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12930846	hybrid			2022-12-25	WOS:000185713800002
J	Ivanisevic, L; Banerjee, K; Saragovi, HU				Ivanisevic, L; Banerjee, K; Saragovi, HU			Differential cross-regulation of TrkA and TrkC tyrosine kinase receptors with p75	ONCOGENE			English	Article						receptor; neurotrophin; cross-regulation; ligand; Trk; signal transduction	NERVE GROWTH-FACTOR; NF-KAPPA-B; NEUROTROPHIN SIGNAL-TRANSDUCTION; CULTURED HIPPOCAMPAL-NEURONS; HIGH-AFFINITY; FUNCTIONAL INTERACTIONS; HUMAN NEUROBLASTOMAS; FACTOR-BINDING; P75(NTR); CELLS	The neurotrophins neurotrophin-3 (NT-3), brain-derived growth factor (BDNF) and nerve growth factor (NGF) bind to the p75 receptor, but each neurotrophin also binds a more selective Trk receptor (e.g. TrkA-NGF and TrkC-NT-3). The biochemical signals following engagement of either Trk or p75 with ligands are well understood, but long-term biological outcomes (trophic, proapoptotic or differentiative) remain unclear because they are cell/tissue specific. For example, Trk receptors are usually trophic but when overexpressed they can be proapoptotic in neuroblastomas and medulloblastomas. We hypothesized that coexpression of Trk and p75 receptors may lead to cross-regulation of signals and different biological outcomes; and used receptor-selective ligands to study cross-regulation by these receptors. We show that in the absence of Trk activation, expression of TrkC is permissive of p75 trophic and differentiation signals induced by p75 ligands, whereas expression of TrkA abolishes trophic and differentiation signals induced by p75 ligands. In contrast, in the presence of Trk activation, p75 ligands can regulate TrkA-mediated survival and TrkC-mediated differentiation. Therefore, a complex homeostasis of p75-selective and Trk-selective signals may determine the fate of cells expressing both receptors.	McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Oncol Canc Ctr, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University	Saragovi, HU (corresponding author), McGill Univ, Dept Pharmacol & Therapeut, 3655 Drummond St 1320, Montreal, PQ H3G 1Y6, Canada.	Uri@pharma.mcgill.ca						Atwal JK, 2000, NEURON, V27, P265, DOI 10.1016/S0896-6273(00)00035-0; Bamji SX, 1998, J CELL BIOL, V140, P911, DOI 10.1083/jcb.140.4.911; Barker PA, 1998, CELL DEATH DIFFER, V5, P346, DOI 10.1038/sj.cdd.4400375; Baskey JC, 2002, J NEUROCHEM, V80, P501, DOI 10.1046/j.0022-3042.2001.00730.x; Bhakar AL, 1999, J BIOL CHEM, V274, P21443, DOI 10.1074/jbc.274.30.21443; Bibel M, 1999, EMBO J, V18, P616, DOI 10.1093/emboj/18.3.616; Bilderback TR, 2001, J NEUROCHEM, V76, P1540, DOI 10.1046/j.1471-4159.2001.00171.x; Brann AB, 2002, J BIOL CHEM, V277, P9812, DOI 10.1074/jbc.M109862200; Brann AB, 1999, J NEUROSCI, V19, P8199; Bredesen DE, 1997, TRENDS NEUROSCI, V20, P287, DOI 10.1016/S0166-2236(96)01049-1; Brodeur GM, 1997, J NEURO-ONCOL, V31, P49, DOI 10.1023/A:1005729329526; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; Chao M, 1998, BRAIN RES REV, V26, P295, DOI 10.1016/S0165-0173(97)00036-2; Dechant G, 1997, J NEUROSCI, V17, P5281; Esposito D, 2001, J BIOL CHEM, V276, P32687, DOI 10.1074/jbc.M011674200; Frade JM, 1998, BIOESSAYS, V20, P137, DOI 10.1002/(SICI)1521-1878(199802)20:2<137::AID-BIES6>3.0.CO;2-Q; Gentry JJ, 2000, J BIOL CHEM, V275, P7558, DOI 10.1074/jbc.275.11.7558; Hapner SJ, 1998, DEV BIOL, V201, P90, DOI 10.1006/dbio.1998.8970; Hempstead BL, 2002, CURR OPIN NEUROBIOL, V12, P260, DOI 10.1016/S0959-4388(02)00321-5; Hirata H, 2001, GLIA, V36, P245, DOI 10.1002/glia.1113; Ito H, 2003, J NEUROSCI RES, V72, P211, DOI 10.1002/jnr.10564; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; Kramer K, 1997, EUR J CANCER, V33, P2090, DOI 10.1016/S0959-8049(97)00210-4; Kuner P, 1998, J NEUROSCI RES, V54, P465, DOI 10.1002/(SICI)1097-4547(19981115)54:4<465::AID-JNR4>3.0.CO;2-T; Kuner P, 1998, J NEUROSCI RES, V54, P798, DOI 10.1002/(SICI)1097-4547(19981215)54:6<798::AID-JNR7>3.3.CO;2-K; Lachyankar MB, 2003, J NEUROSCI RES, V71, P157, DOI 10.1002/jnr.10480; Lee R, 2001, SCIENCE, V294, P1945, DOI 10.1126/science.1065057; MacDonald JIS, 1996, MOL CELL NEUROSCI, V7, P371, DOI 10.1006/mcne.1996.0027; MacPhee IJ, 1997, J BIOL CHEM, V272, P23547, DOI 10.1074/jbc.272.38.23547; MAHADEO D, 1994, J BIOL CHEM, V269, P6884; Maliartchouk S, 1997, J NEUROSCI, V17, P6031; Meakin SO, 1999, J BIOL CHEM, V274, P9861, DOI 10.1074/jbc.274.14.9861; Postigo A, 2002, GENE DEV, V16, P633, DOI 10.1101/gad.217902; Rabizadeh S, 1999, CELL DEATH DIFFER, V6, P1222, DOI 10.1038/sj.cdd.4400614; Roux PP, 2001, J BIOL CHEM, V276, P23097, DOI 10.1074/jbc.M011520200; Saragovi HU, 1998, J BIOL CHEM, V273, P34933, DOI 10.1074/jbc.273.52.34933; Sarmiere PD, 2001, MOL CELL NEUROSCI, V18, P320, DOI 10.1006/mcne.2001.1021; Schubert KM, 2000, J BIOL CHEM, V275, P13330, DOI 10.1074/jbc.275.18.13330; Urdiales JL, 1998, J NEUROSCI, V18, P6767; Vesa J, 2000, J BIOL CHEM, V275, P24414, DOI 10.1074/jbc.M001641200; Yamashiro DJ, 1996, ONCOGENE, V12, P37; Yamashita T, 2002, J CELL BIOL, V157, P565, DOI 10.1083/jcb.200202010; Yan CH, 2002, MOL PHARMACOL, V61, P710, DOI 10.1124/mol.61.4.710; Zaccaro MC, 2001, J BIOL CHEM, V276, P31023, DOI 10.1074/jbc.M104630200	46	33	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2003	22	36					5677	5685		10.1038/sj.onc.1206864	http://dx.doi.org/10.1038/sj.onc.1206864			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944916				2022-12-25	WOS:000184865900017
J	Amin, HM; Medeiros, LJ; Ma, Y; Feretzaki, M; Das, P; Leventaki, V; Rassidakis, GZ; O'Connor, SL; McDonnell, TJ; Lai, R				Amin, HM; Medeiros, LJ; Ma, Y; Feretzaki, M; Das, P; Leventaki, V; Rassidakis, GZ; O'Connor, SL; McDonnell, TJ; Lai, R			Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma	ONCOGENE			English	Article						anaplastic large cell lymphoma; AG490; STAT; JAK; NPM-ALK	NON-HODGKINS LYMPHOMA; STAT3 ACTIVATION; TYROSINE KINASE; CONSTITUTIVE ACTIVATION; SURVIVIN EXPRESSION; SIGNAL TRANSDUCER; HUMAN OVARIAN; PROTEIN; GROWTH; AG490	Signal transducer and activator of transcription 3 (STAT3), normally activated by Janus kinase (JAK) in response to cytokine stimulation, has been shown to have oncogenic potential. In addition to JAK, recent data suggest that STAT3 can also be activated by other proteins such as the aberrant fusion protein, NPM-ALK, which is expressed in a subset of systemic anaplastic large cell lymphoma (ALCL). In this study, we investigated the possible role of JAK in activating STAT3 in ALCL using two ALK-positive ALCL cell lines, Karpas 299 and SU-DHL-1. At the steady state, JAK3 showed detectable tyrosine phosphorylation by immunoprecipitation. Treatment with AG490, a JAK inhibitor, decreased but did not completely abrogate tyrosine phosphorylation of JAK3 and STAT3 in a concentration-dependent manner. Similar results were obtained using two other inhibitors of JAK3, WHI-P131 and WHI-P154. These biochemical changes were associated with apoptosis in both cell lines that was coupled with activation of caspase 3 and decreased bcl-xL and bcl-2. Cell cycle analysis revealed a decrease in the S phase, which may be attributed to cyclin D3 downregulation and P21(waf1) upregulation. Importantly, the tyrosine kinase activity of NPM-ALK, as assessed by an in vitro assay, decreased with increasing concentrations of AG490. Our findings highlight the importance of JAK3 in activating STAT3 in ALCL, and that NPM-ALK-mediated activation of STAT3 is influenced by the functional status of JAK3.	Univ Texas, MD Anderson Canc Ctr, Dept Histopathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Lai, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Histopathol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	raymondmail_65@yahoo.com	Rassidakis, George/V-9553-2019; Leventaki, Vasiliki/N-8175-2018					Alas S, 2001, CANCER RES, V61, P5137; Altieri DC, 2001, TRENDS MOL MED, V7, P542, DOI 10.1016/S1471-4914(01)02243-2; Aoki Y, 2003, BLOOD, V101, P1535, DOI 10.1182/blood-2002-07-2130; Bai RY, 1998, MOL CELL BIOL, V18, P6951, DOI 10.1128/MCB.18.12.6951; Bai RY, 2000, BLOOD, V96, P4319, DOI 10.1182/blood.V96.13.4319; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Burke WM, 2001, ONCOGENE, V20, P7925, DOI 10.1038/sj.onc.1204990; Coqueret O, 2000, J BIOL CHEM, V275, P18794, DOI 10.1074/jbc.M001601200; Delsol G, 2001, WHO CLASSIFICATION T, P230; Epling-Burnette PK, 2001, J CLIN INVEST, V107, P351, DOI 10.1172/JCI9940; Epling-Burnette PK, 2001, J IMMUNOL, V166, P7486, DOI 10.4049/jimmunol.166.12.7486; EPSTEIN AL, 1974, CANCER-AM CANCER SOC, V34, P1851, DOI 10.1002/1097-0142(197412)34:6<1851::AID-CNCR2820340602>3.0.CO;2-4; Eriksen KW, 2001, LEUKEMIA, V15, P787, DOI 10.1038/sj.leu.2402093; Falini B, 1999, BLOOD, V93, P2697; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; Fukada T, 1998, EMBO J, V17, P6670, DOI 10.1093/emboj/17.22.6670; Gascoyne RD, 1999, BLOOD, V93, P3913, DOI 10.1182/blood.V93.11.3913.411k22_3913_3921; Grad JM, 2000, CURR OPIN ONCOL, V12, P543, DOI 10.1097/00001622-200011000-00006; Huang M, 2000, GYNECOL ONCOL, V79, P67, DOI 10.1006/gyno.2000.5931; Imada K, 2000, MOL IMMUNOL, V37, P1, DOI 10.1016/S0161-5890(00)00018-3; Kijima T, 2002, CELL GROWTH DIFFER, V13, P355; Kirken RA, 2001, TRANSPLANT P, V33, P95, DOI 10.1016/S0041-1345(00)02791-3; Kube D, 2001, BLOOD, V98, P762, DOI 10.1182/blood.V98.3.762; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Liu JB, 2002, AM J RESP CELL MOL, V27, P306, DOI 10.1165/rcmb.4850; Ma ZG, 2000, BLOOD, V95, P2144, DOI 10.1182/blood.V95.6.2144; Mahboubi K, 2001, LAB INVEST, V81, P327, DOI 10.1038/labinvest.3780241; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; MORGAN R, 1989, BLOOD, V73, P2155; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Naka T, 1998, P NATL ACAD SCI USA, V95, P15577, DOI 10.1073/pnas.95.26.15577; Narla RK, 1998, CLIN CANCER RES, V4, P2463; Nielsen M, 1997, P NATL ACAD SCI USA, V94, P6764, DOI 10.1073/pnas.94.13.6764; Ning ZQ, 2001, ONCOGENE, V20, P4528, DOI 10.1038/sj.onc.1204590; Pulford K, 2001, CURR OPIN HEMATOL, V8, P231, DOI 10.1097/00062752-200107000-00009; Rane SG, 2002, ONCOGENE, V21, P3334, DOI 10.1038/sj.onc.1205398; SHIOTA M, 1995, BLOOD, V86, P1954, DOI 10.1182/blood.V86.5.1954.bloodjournal8651954; Slupianek A, 2001, CANCER RES, V61, P2194; STEIN H, 1985, BLOOD, V66, P848; Sudbeck EA, 1999, CLIN CANCER RES, V5, P1569; Sun XM, 2001, BLOOD, V97, P2008, DOI 10.1182/blood.V97.7.2008; Turturro F, 2001, ONCOGENE, V20, P4466, DOI 10.1038/sj.onc.1204582; Uckun FM, 1999, CLIN CANCER RES, V5, P2954; Wang LH, 1999, J IMMUNOL, V162, P3897; Wei LH, 2001, ONCOGENE, V20, P5799, DOI 10.1038/sj.onc.1204733; Zamo A, 2002, ONCOGENE, V21, P1038, DOI 10.1038/sj.onc.1205152; Zhang Q, 2002, J IMMUNOL, V168, P466, DOI 10.4049/jimmunol.168.1.466	51	104	112	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2003	22	35					5399	5407		10.1038/sj.onc.1206849	http://dx.doi.org/10.1038/sj.onc.1206849			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JC	12934099				2022-12-25	WOS:000184735000004
J	Lodygin, D; Yazdi, AS; Sander, CA; Herzinger, T; Hermeking, H				Lodygin, D; Yazdi, AS; Sander, CA; Herzinger, T; Hermeking, H			Analysis of 14-3-3 sigma expression in hyperproliferative skin diseases reveals selective loss associated with CpG-methylation in basal cell carcinoma	ONCOGENE			English	Article						tumour suppressor; basal cell carcinoma; CpG-methylation; keratinocytes; cell cycle	HIGH-FREQUENCY; EARLY EVENT; HYPERMETHYLATION; GENE; INACTIVATION; LEADS	The p53-regulated 14-3-3sigma gene encodes an inhibitor of cell cycle progression essential for senescence and clonal evolution of keratinocytes in vitro. Here we analysed the in vivo expression of 14-3-3sigma protein in several skin diseases, which are characterized by hyperproliferative keratinocytes. Unexpectedly, the 14-3-3sigma protein was expressed at high levels in psoriasis (11 of 11 patients), condylomata acuminata (11/11), actinic keratoses (11/11) and squamous cell carcinomas (SCC) (11/11). However, keratinocytes that had undergone transformation to basal cell carcinoma (BCC) showed partial (10 of 41; 24.4%) or complete (19 of 41; 46.3%) loss of 14-3-3sigma protein expression. BCC (5/5), SCC (6/6) and actinic keratoses (7/7) concomitantly expressed the p53-homolog p63 and 14-3-3sigma at high levels, ruling out potential inhibitory effects of p63 isoforms on 14-3-3sigma transcription as the basis for loss of 14-3-3sigma expression. Of 41 BCC samples isolated by laser-capture microdissection, 28 (68.3%) showed CpG-hypermethylation of the 14-3-3sigma promoter combined with reduced or absent 14-3-3sigma protein levels in 22 cases (78.6%). Since it has been reported that BCC retain wild-type p16(INK4A) and here BCC with CpG-methylation of 14-3-3sigma did not show CpG-methylation of p16(INK4A) (0/17), silencing of 14-3-3sigma may contribute to evasion of senescence in BCC. As experimental removal of 14-3-3sigma sensitizes to DNA damage, silencing of 14-3-3sigma may explain the high efficacy of radiation therapy in the treatment of BCC.	Max Planck Inst Biochem, D-82152 Martinsried, Germany; Univ Munich, Dept Dermatol, D-80539 Munich, Germany	Max Planck Society; University of Munich	Hermeking, H (corresponding author), Max Planck Inst Biochem, Klopferspitz 18A, D-82152 Martinsried, Germany.	herme@biochem.mpg.de						Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Dellambra E, 2000, J CELL BIOL, V149, P1117, DOI 10.1083/jcb.149.5.1117; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Gasco M, 2002, ONCOGENE, V21, P1876, DOI 10.1038/sj.onc.1205256; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Ivanova T, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-4; Iwata N, 2000, ONCOGENE, V19, P5298, DOI 10.1038/sj.onc.1203898; Laronga C, 2000, J BIOL CHEM, V275, P23106, DOI 10.1074/jbc.M905616199; Li Z, 2002, CANCER RES, V62, P1939; MILLER SJ, 1991, J AM ACAD DERMATOL, V24, P1, DOI 10.1016/0190-9622(91)70001-I; Pellegrini G, 2001, P NATL ACAD SCI USA, V98, P3156, DOI 10.1073/pnas.061032098; Samuel T, 2001, J BIOL CHEM, V276, P45201, DOI 10.1074/jbc.M106427200; Saridaki Z, 2000, J INVEST DERMATOL, V115, P719, DOI 10.1046/j.1523-1747.2000.00098.x; Schubert J, 1997, Mund Kiefer Gesichtschir, V1, P44; Tokugawa T, 2002, CANCER RES, V62, P4938; Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438; Urano T, 2002, NATURE, V417, P871, DOI 10.1038/nature00826; Westfall MD, 2003, MOL CELL BIOL, V23, P2264, DOI 10.1128/MCB.23.7.2264-2276.2003; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4	20	72	74	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2003	22	35					5519	5524		10.1038/sj.onc.1206854	http://dx.doi.org/10.1038/sj.onc.1206854			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JC	12934112				2022-12-25	WOS:000184735000017
J	Miro-Mur, F; Meiller, A; Haddada, H; May, E				Miro-Mur, F; Meiller, A; Haddada, H; May, E			p73 alpha expression induces both accumulation and activation of wt-p53 independent of the p73 alpha transcriptional activity	ONCOGENE			English	Article						p53; p73 alpha; p73 alpha R292H; recombinant adenovirus; protein stability; transcriptional activity	DNA-DAMAGE; P53-DEPENDENT MANNER; FEEDBACK LOOP; P53 PROTEIN; MCF7 CELLS; P73; APOPTOSIS; P63; DEGRADATION; DELTA-NP73	The p53 tumor suppressor gene belongs to a multigene family that includes two paralogues, p63 and p73. p73alpha has common activities with p53, such as DNA binding and transactivation, and can thus activate the transcription of p53-responsive genes. Using the adenoviral system, we report that an overexpression of either wt-p73alpha or one of the two transcriptional inactive mutants, DeltaNp73alpha or p73alpha:R292H, induces an accumulation of the endogenous wt-p53 expressed in the three transformed cell lines, SK-N-SH, MCF-7 and U-2OS, without stimulating the p53 gene transcription. p73-mediated accumulation of p53 protein coincides with an increase of p53-target gene expression in cells expressing either wt-p73alpha or the transcriptional inactive mutant p73alphaR292H, but not DeltaNp73alpha: that encodes a dominant-negative mutant of both p73 and p53. The fact that an ectopic expression of p73alpha:R292H leads to both accumulation of p53 and stimulation of p53 target gene expression strongly suggests that p73alpha is able to induce activation of p53. This was confirmed by showing that p73alphaR292H no longer stimulated Waf1/p21 expression in MCF7/R-A1 cells that expressed a transcriptional inactive mutant of p53. We thus conclude that p73alpha: protein was able to both stabilize and activate wt-p53 protein, independent of the p73alpha transcriptional activity.	CEA, Lab Cancerogenese Mol, UMR 217, CEA CNRS,DRR,DSV, F-92265 Fontenay Aux Roses, France; Univ Autonoma Barcelona, Fac Ciencies, Dept Bioquim & Biol Mol, E-08193 Barcelona, Spain; Inst Gustave Roussy, INSERM, U3652, F-94805 Villejuif, France	CEA; Autonomous University of Barcelona; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy	May, E (corresponding author), CEA, Lab Cancerogenese Mol, UMR 217, CEA CNRS,DRR,DSV, Route Panorama,BP 6, F-92265 Fontenay Aux Roses, France.		Miro-Mur, Francesc A./AAT-3013-2020	Miro-Mur, Francesc A./0000-0003-3936-2693; MEILLER, Anne/0000-0001-5546-3035				Balint E, 1999, ONCOGENE, V18, P3923, DOI 10.1038/sj.onc.1202781; Cai ZZ, 1997, J BIOL CHEM, V272, P96; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Drane P, 2002, CELL DEATH DIFFER, V9, P527, DOI 10.1038/sj.cdd.4400983; Drane P, 2001, ONCOGENE, V20, P430, DOI 10.1038/sj.onc.1204101; Fillippovich I, 2001, ONCOGENE, V20, P514, DOI 10.1038/sj.onc.1204118; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kartasheva NN, 2002, ONCOGENE, V21, P4715, DOI 10.1038/sj.onc.1205584; Levrero M, 2000, J CELL SCI, V113, P1661; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Nakagawa T, 2002, MOL CELL BIOL, V22, P2575, DOI 10.1128/MCB.22.8.2575-2585.2002; Stiewe T, 2002, J BIOL CHEM, V277, P14177, DOI 10.1074/jbc.M200480200; Stiewe T, 2002, CANCER RES, V62, P3598; Vossio S, 2002, ONCOGENE, V21, P3796, DOI 10.1038/sj.onc.1205465; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zhu JH, 2001, ONCOGENE, V20, P4050, DOI 10.1038/sj.onc.1204516	24	10	11	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 21	2003	22	35					5451	5456		10.1038/sj.onc.1206538	http://dx.doi.org/10.1038/sj.onc.1206538			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JC	12934105				2022-12-25	WOS:000184735000010
J	Stroh, C; Held, E; Samraj, AK; Schulze-Osthoff, K				Stroh, C; Held, E; Samraj, AK; Schulze-Osthoff, K			Specific inhibition of transcription factor NF-kappa B through intracellular protein delivery of I kappa B alpha by the Herpes virus protein VP22	ONCOGENE			English	Article						NF-kappa B; I kappa B alpha; VP22; protein transduction	BIOLOGICALLY-ACTIVE PROTEINS; GENE-THERAPY; TRANSDUCTION; ACTIVATION; CELLS; EXPRESSION; VIVO; PEPTIDE; TRAFFICKING; DISTINCT	In many cancers, a high constitutive activation of transcription factor NF-kappaB has been implicated in tumor progression and apoptosis resistance, making NF-kappaB an attractive target for cancer therapy. Here, we describe the specific inhibition of NF-kappaB by the intracellular delivery of IkappaBalpha through VP22-mediated protein transduction. The Herpes virus protein VP22 has attracted great attention in gene therapy, because of its ability to migrate from an original expressing cell into surrounding recipient cells, resulting in high levels of protein transduction. To evaluate the use of VP22 as a vehicle for NF-kappaB inhibition, we expressed several versions of VP22-IkappaBalpha fusion proteins in baculovirus, bacteria, and mammalian cells. While we could not detect transcellular migration of different VP22-IkappaBalpha constructs, interestingly, baculovirally expressed VP22-IkappaBalpha was efficiently delivered into cells after exogenous administration. The purified and imported VP22-IkappaBalpha retained its function and efficiently inhibited both constitutive and inducible NF-kappaB activation. We further show that the 34 C-terminal amino acids of VP22 were sufficient for the import property, suggesting also that the ability of intercellular migration and cellular import are not linked to each other. Together, our results demonstrate that recombinant VP22 acts as an efficient vehicle for the exogenous delivery of IkappaBalpha and, moreover, might find applications to block NF-kappaB activation specifically.	Univ Dusseldorf, Inst Mol Med, D-40225 Dusseldorf, Germany; Univ Munster, Dept Immunol & Cell Biol, D-4400 Munster, Germany	Heinrich Heine University Dusseldorf; University of Munster	Schulze-Osthoff, K (corresponding author), Univ Dusseldorf, Inst Mol Med, Univ Str 1, D-40225 Dusseldorf, Germany.		Schulze-Osthoff, Klaus/N-9025-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720; Held, Jurgen/0000-0003-1130-9727				Aradhya S, 2001, CURR OPIN GENET DEV, V11, P300, DOI 10.1016/S0959-437X(00)00194-5; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; Epinat JC, 1999, ONCOGENE, V18, P6896, DOI 10.1038/sj.onc.1203218; Ferrari D, 1999, J BIOL CHEM, V274, P13205, DOI 10.1074/jbc.274.19.13205; Ford KG, 2001, GENE THER, V8, P1, DOI 10.1038/sj.gt.3301383; Fujihara SM, 2000, J IMMUNOL, V165, P1004, DOI 10.4049/jimmunol.165.2.1004; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; GOEBELER M, 1995, J IMMUNOL, V155, P2459; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; Hu YL, 2001, NATURE, V410, P710, DOI 10.1038/35070605; Kabouridis PS, 2002, J IMMUNOL, V169, P2587, DOI 10.4049/jimmunol.169.5.2587; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kueltzo LA, 2000, J BIOL CHEM, V275, P33213, DOI 10.1074/jbc.M002476200; Makarov SS, 2000, MOL MED TODAY, V6, P441, DOI 10.1016/S1357-4310(00)01814-1; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; Normand N, 2001, J BIOL CHEM, V276, P15042, DOI 10.1074/jbc.M010294200; Phelan A, 1998, NAT BIOTECHNOL, V16, P440, DOI 10.1038/nbt0598-440; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Schwarze SR, 2000, TRENDS PHARMACOL SCI, V21, P45, DOI 10.1016/S0165-6147(99)01429-7; Swinney DC, 2002, J BIOL CHEM, V277, P23573, DOI 10.1074/jbc.M200842200; Tomita T, 1999, ARTHRITIS RHEUM, V42, P2532, DOI 10.1002/1529-0131(199912)42:12<2532::AID-ANR5>3.0.CO;2-2; Wesselborg S, 1997, J BIOL CHEM, V272, P12422, DOI 10.1074/jbc.272.19.12422; Wills KN, 2001, J VIROL, V75, P8733, DOI 10.1128/JVI.75.18.8733-8741.2001; Wybranietz WA, 2001, GENE THER, V8, P1654, DOI 10.1038/sj.gt.3301564; Wybranietz WA, 1999, J GENE MED, V1, P265; Zender L, 2002, GASTROENTEROLOGY, V123, P608, DOI 10.1053/gast.2002.34756; Zhou G, 1997, J BIOL CHEM, V272, P15174, DOI 10.1074/jbc.272.24.15174	32	20	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 14	2003	22	34					5367	5373		10.1038/sj.onc.1206544	http://dx.doi.org/10.1038/sj.onc.1206544			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JB	12917639				2022-12-25	WOS:000184734900017
J	Zhong, SP; Goto, H; Inagaki, M; Dong, ZG				Zhong, SP; Goto, H; Inagaki, M; Dong, ZG			Phosphorylation at serine 28 and acetylation at lysine 9 of histone H3 induced by trichostatin A	ONCOGENE			English	Article						histone H3; trichostatin A; phosphorylation; acetylation; ultraviolet; MAP kinase	ACTIVATED PROTEIN-KINASE; MITOTIC CHROMOSOME CONDENSATION; B-INDUCED PHOSPHORYLATION; P38 MAP KINASE; GENE ACTIVATION; CYCLIC TETRAPEPTIDE; CHROMATIN STRUCTURE; IN-VITRO; DEACETYLASE; EXPRESSION	Trichostatin A (TSA), a histone deacetylase inhibitor, strongly increases acetylation of the N-terminal tails of histone H3. Many studies have correlated the function of TSA with the hyperacetylation of histone. Although histone H3 is known to be phosphorylated, the effect of acetylation on phosphorylation is not known. Here, we report that in JB6 cells, TSA induces both acetylation at lysine 9 and phosphorylation at serine 28 of histone H3. UVB irradiation, which is known to induce phosphorylation at serine 28, did not significantly affect phosphorylation of histone H3 in TSA-pretreated JB6 cells. In contrast, TSA markedly increased phosphorylation and acetylation of histone H3 in UVB-pretreated JB6 cells. TSA strongly activated MAP kinases. Moreover, PD98059 and SB202190 inhibited TSA-induced phosphorylation but not acetylation of histone H3. Dominant negative mutant ERK2 and dominant negative mutant p38 kinase blocked TSA-stimulated phosphorylation of histone H3 at serine 28. The results indicate that TSA-induced phosphorylation of histone H3 at serine 28 occurs through activation of the MAP kinase pathway and phosphorylated histone H3 is more sensitive to TSA-induced hyperacetylation. The facilitation of phosphorylation and acetylation of histone H3 induced by TSA may play a critical regulatory role in chromatin remodeling and gene expression.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA; Aichi Canc Ctr, Res Inst, Biochem Lab, Chikusa Ku, Aichi 4648681, Japan	University of Minnesota System; Aichi Cancer Center	Dong, ZG (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.	zgdong@hi.umn.edu	Inagaki, Masaki/B-9920-2016	Goto, Hidemasa/0000-0002-6796-4467	NATIONAL CANCER INSTITUTE [R01CA077646, P01CA027502] Funding Source: NIH RePORTER; NCI NIH HHS [CA77646, CA27502] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BARRATT MJ, 1994, P NATL ACAD SCI USA, V91, P4781, DOI 10.1073/pnas.91.11.4781; BRADBURY EM, 1992, BIOESSAYS, V14, P9; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; Chen WY, 2000, P NATL ACAD SCI USA, V97, P377, DOI 10.1073/pnas.97.1.377; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Clayton AL, 2000, EMBO J, V19, P3714, DOI 10.1093/emboj/19.14.3714; Dangond F, 1998, BIOCHEM BIOPH RES CO, V247, P833, DOI 10.1006/bbrc.1998.8891; Davie JR, 1999, J CELL BIOCHEM, P141; Davie JR, 1998, J CELL BIOCHEM, P203; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; Furumai R, 2001, P NATL ACAD SCI USA, V98, P87, DOI 10.1073/pnas.011405598; Goto H, 1999, J BIOL CHEM, V274, P25543, DOI 10.1074/jbc.274.36.25543; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; HONDA BM, 1975, J BIOL CHEM, V250, P8681; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Huang CS, 1999, ONCOGENE, V18, P2828, DOI 10.1038/sj.onc.1202639; KIJIMA M, 1993, J BIOL CHEM, V268, P22429; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; Lo WS, 2000, MOL CELL, V5, P917, DOI 10.1016/S1097-2765(00)80257-9; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; Medina V, 1997, CANCER RES, V57, P3697; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Oh-hashi K, 1999, BIOCHEM BIOPH RES CO, V263, P504, DOI 10.1006/bbrc.1999.1237; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Rincon M, 1998, EMBO J, V17, P2817, DOI 10.1093/emboj/17.10.2817; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; Salvador LM, 2001, J BIOL CHEM, V276, P40146, DOI 10.1074/jbc.M106710200; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; She QB, 2002, J BIOL CHEM, V277, P24039, DOI 10.1074/jbc.M109907200; Smalley KSM, 1999, BIOCHEM BIOPH RES CO, V263, P239, DOI 10.1006/bbrc.1999.1351; Spencer VA, 1999, GENE, V240, P1, DOI 10.1016/S0378-1119(99)00405-9; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Watts RG, 1998, ONCOGENE, V17, P3493, DOI 10.1038/sj.onc.1202259; Wei Y, 1998, P NATL ACAD SCI USA, V95, P7480, DOI 10.1073/pnas.95.13.7480; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; Zhang YG, 2001, J BIOL CHEM, V276, P20913, DOI 10.1074/jbc.M009047200; Zhang YG, 2001, J BIOL CHEM, V276, P14572, DOI 10.1074/jbc.M004615200; Zhong SP, 2000, J BIOL CHEM, V275, P20980, DOI 10.1074/jbc.M909934199; Zhong SP, 2001, J BIOL CHEM, V276, P33213, DOI 10.1074/jbc.M103973200; Zhong SP, 2001, J BIOL CHEM, V276, P12932, DOI 10.1074/jbc.M010931200	49	45	46	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2003	22	34					5291	5297		10.1038/sj.onc.1206507	http://dx.doi.org/10.1038/sj.onc.1206507			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JB	12917630				2022-12-25	WOS:000184734900008
J	Jiang, XC; Beyer, TP; Li, ZQ; Liu, J; Quan, W; Schmidt, RJ; Zhang, YY; Bensch, WR; Eacho, PI; Cao, GQ				Jiang, XC; Beyer, TP; Li, ZQ; Liu, J; Quan, W; Schmidt, RJ; Zhang, YY; Bensch, WR; Eacho, PI; Cao, GQ			Enlargement of high density lipoprotein in mice via liver X receptor activation requires apolipoprotein E and is abolished by cholesteryl ester transfer protein expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID TRANSFER PROTEIN; TRANSGENIC MICE; TANGIER-DISEASE; A-I; ABCA1 TRANSPORTER; HUMAN CETP; GENE; BINDING; IDENTIFICATION; METABOLISM	The factors involved in the generation of larger high density lipoprotein (HDL) particles, HDL1 and HDLc, are still not well understood. Administration of a specific synthetic liver X receptor (LXR) agonist, T0901317, in mice resulted in an increase of not only HDL cholesterol but also HDL particle size (Cao, G., Beyer, T. P., Yang, X. P., Schmidt, R. J., Zhang, Y., Bensch, W. R., Kauffman, R. F., Gao, H., Ryan, T. P., Liang, Y., Eacho, P. I., and Jiang, X. C. (2002) J. Biol. Chem. 277, 39561 - 39565). We have investigated the roles that apoE and CETP may play in this process. We treated apoE-deficient, cholesterol ester transport protein (CETP) transgenic, and wild type mice with various doses of the LXR agonist and monitored their HDL levels. Fast protein liquid chromatography and apolipoprotein analysis revealed that in apoE knockout mouse plasma, there was neither induction of larger HDL formation nor increase of HDL cholesterol, suggesting that apoE is essential for the LXR agonist effects on HDL metabolism. In CETP transgenic mice, CETP expression completely abolished LXR agonist-mediated HDL enlargement and greatly attenuated HDL cholesterol levels. Analysis of HDL particles by electron microscope and nondenaturing gel electrophoresis revealed similar findings. In apoE-deficient mice, LXR agonist also produced a significant increase in very low density lipoprotein/low density lipoprotein cholesterol and apolipoprotein B content. Our studies provide direct evidence that apoE and CETP are intimately involved in the accumulation of the enlarged HDL ( HDL1 or HDLc) particles in mice.	Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA; SUNY Downstate Med Ctr, Dept Anat & Cell Biol, Brooklyn, NY 11203 USA	Eli Lilly; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Jiang, XC (corresponding author), Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA.	xjiang@downstate.edu; Guoqing_Cao@lilly.com			NHLBI NIH HHS [HL-69817, HL-64735] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064735, R01HL069817] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; AGELLON LB, 1991, J BIOL CHEM, V266, P10796; Attie AD, 2001, J LIPID RES, V42, P1717; Basso F, 2003, J LIPID RES, V44, P296, DOI 10.1194/jlr.M200414-JLR200; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Cao GQ, 2003, J BIOL CHEM, V278, P1131, DOI 10.1074/jbc.M210208200; Cao GQ, 2002, J BIOL CHEM, V277, P39561, DOI 10.1074/jbc.M207187200; Costet P, 2000, J BIOL CHEM, V275, P28240; DESILVA HV, 1994, J LIPID RES, V35, P1297; EISENBERG S, 1984, J LIPID RES, V25, P1017; Fowler AJ, 2003, J INVEST DERMATOL, V120, P246, DOI 10.1046/j.1523-1747.2003.12033.x; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; GORDON V, 1983, J BIOL CHEM, V258, P6202; GRASS DS, 1995, J LIPID RES, V36, P1082; HAYEK T, 1992, J CLIN INVEST, V90, P505, DOI 10.1172/JCI115887; Herrera VLM, 1999, NAT MED, V5, P1383, DOI 10.1038/70956; INNERARITY TL, 1978, BIOCHEMISTRY-US, V17, P1440, DOI 10.1021/bi00601a013; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Jiang XC, 1999, J CLIN INVEST, V103, P907, DOI 10.1172/JCI5578; Joseph SB, 2003, NAT MED, V9, P213, DOI 10.1038/nm820; Kiss RS, 2003, J BIOL CHEM, V278, P10119, DOI 10.1074/jbc.M300137200; KOO C, 1985, J BIOL CHEM, V260, P1934; Laffitte BA, 2001, P NATL ACAD SCI USA, V98, P507, DOI 10.1073/pnas.021488798; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Lu TT, 2001, J BIOL CHEM, V276, P37735, DOI 10.1074/jbc.R100035200; Luo Y, 2000, J CLIN INVEST, V105, P513, DOI 10.1172/JCI8573; MAHLEY RW, 1982, MED CLIN N AM, V66, P375, DOI 10.1016/S0025-7125(16)31426-2; Mak PA, 2002, J LIPID RES, V43, P2037, DOI 10.1194/jlr.C200014-JLR200; McNeish J, 2000, P NATL ACAD SCI USA, V97, P4245, DOI 10.1073/pnas.97.8.4245; Neufeld EB, 2002, BIOCHEM BIOPH RES CO, V297, P974, DOI 10.1016/S0006-291X(02)02274-X; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; PLUMP AS, 1995, ANNU REV NUTR, V15, P495, DOI 10.1146/annurev.nu.15.070195.002431; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; Singaraja RR, 2001, J BIOL CHEM, V276, P33969, DOI 10.1074/jbc.M102503200; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Tall AR, 2000, ARTERIOSCL THROM VAS, V20, P1185, DOI 10.1161/01.ATV.20.5.1185; TALL AR, 1986, J LIPID RES, V27, P361; Vaisman BL, 2001, J CLIN INVEST, V108, P303; Wierzbicki AS, 2002, CURR MED RES OPIN, V18, P36, DOI 10.1185/030079902125000165; WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551; YAMASHITA S, 1990, J CLIN INVEST, V86, P688, DOI 10.1172/JCI114764; Zak Z, 2002, J LIPID RES, V43, P2164, DOI 10.1194/jlr.M200253-JLR200	47	42	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49072	49078		10.1074/jbc.M304274200	http://dx.doi.org/10.1074/jbc.M304274200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	12947111	hybrid			2022-12-25	WOS:000186829000069
J	Szurmant, H; Bunn, MW; Cannistraro, VJ; Ordal, GW				Szurmant, H; Bunn, MW; Cannistraro, VJ; Ordal, GW			Bacillus subtilis hydrolyzes CheY-P at the location of its action, the flagellar switch	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; ESCHERICHIA-COLI; CHEMOTACTIC RESPONSE; TRANSCRIPTION FACTOR; THERMOTOGA-MARITIMA; GENE; PHOSPHORYLATION; EXPRESSION; MECHANISM; PROTEIN	In this report we show that in Bacillus subtilis the flagellar switch, which controls direction of flagellar rotation based on levels of the chemotaxis primary response regulator, CheY-P, also causes hydrolysis of CheY-P to form CheY and P-i. This task is performed in Escherichia coli by CheZ, which interestingly enough is primarily located at the receptors, not at the switch. In particular we have identified the phosphatase as FliY, which resembles E. coli switch protein FliN only in its C-terminal part, while an additional N-terminal domain is homologous to another switch protein FliM and to CheC, a protein found in the archaea and many bacteria but not in E. coli. Previous E. coli studies have localized the CheY-P binding site of the switch to FliM residues 6 - 15. These residues are almost identical to the residues 6 - 15 in both B. subtilis FliM and FliY. We were able to show that both of these proteins are capable of binding CheY-P in vitro. Deletion of this binding region in B. subtilis mutant fliM caused the same phenotype as a cheY mutant ( clockwise flagellar rotation), whereas deletion of it in fliY caused the opposite. We showed that FliY increases the rate of CheY-P hydrolysis in vitro. Consequently, we imagine that the duration of enhanced CheY-P levels caused by activation of the CheA kinase upon attractant binding to receptors, is brief due both to adaptational processes and to phosphatase activity of FliY.	Univ Illinois, Coll Med, Dept Biochem, Urbana, IL 61801 USA; Univ Illinois, Coll Liberal Arts & Sci, Dept Biochem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Ordal, GW (corresponding author), Univ Illinois, Coll Med, Dept Biochem, Urbana, IL 61801 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054365] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM54365] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIZAWA SI, 2002, ACILLUS SUBTILIS ITS, P437; Berg H C, 1974, Antibiot Chemother (1971), V19, P55; Bhandari P, 1997, J BACTERIOL, V179, P4403, DOI 10.1128/jb.179.13.4403-4406.1997; BISCHOFF DS, 1993, BIOCHEMISTRY-US, V32, P9256, DOI 10.1021/bi00086a035; BISCHOFF DS, 1992, MOL MICROBIOL, V6, P2715, DOI 10.1111/j.1365-2958.1992.tb01448.x; BISCHOFF DS, 1991, J BIOL CHEM, V266, P12301; BISCHOFF DS, 1992, MOL MICROBIOL, V6, P23, DOI 10.1111/j.1365-2958.1992.tb00833.x; Bren A, 1998, J MOL BIOL, V278, P507, DOI 10.1006/jmbi.1998.1730; Celandroni F, 2000, FEMS MICROBIOL LETT, V190, P247, DOI 10.1016/S0378-1097(00)00343-8; DAVANLOO P, 1984, P NATL ACAD SCI-BIOL, V81, P2035, DOI 10.1073/pnas.81.7.2035; GLUCH MF, 1995, J BACTERIOL, V177, P5473, DOI 10.1128/jb.177.19.5473-5479.1995; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; IRETON K, 1993, GENE DEV, V7, P283, DOI 10.1101/gad.7.2.283; Karatan E, 2001, J BIOL CHEM, V276, P43618, DOI 10.1074/jbc.M104955200; Kirby JR, 1999, J BIOL CHEM, V274, P11092, DOI 10.1074/jbc.274.16.11092; Kirby JR, 2000, MOL MICROBIOL, V35, P44, DOI 10.1046/j.1365-2958.2000.01676.x; Kirby JR, 2001, MOL MICROBIOL, V42, P573, DOI 10.1046/j.1365-2958.2001.02581.x; Kristich CJ, 2002, J BIOL CHEM, V277, P25356, DOI 10.1074/jbc.M201334200; LARSEN SH, 1974, NATURE, V249, P74, DOI 10.1038/249074a0; LEONHARDT H, 1988, J GEN MICROBIOL, V134, P605; Macnab R., 1996, ESCHERICHIA COLI SAL, V2nd ed, P119; MCCLEARY WR, 1994, J BIOL CHEM, V269, P31567; Nelson KE, 2001, METHOD ENZYMOL, V330, P169; PARKINSON JS, 1982, J BACTERIOL, V151, P106, DOI 10.1128/JB.151.1.106-113.1982; PEREGO M, 1994, CELL, V79, P1047, DOI 10.1016/0092-8674(94)90035-3; Perego M, 2001, MOL MICROBIOL, V42, P133, DOI 10.1046/j.1365-2958.2001.02611.x; Senesi S, 2002, MICROBIOL-SGM, V148, P1785, DOI 10.1099/00221287-148-6-1785; Stock JB, 1996, ESCHERICHIA COLI SAL, P1103; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; ULLAH AHJ, 1981, J BACTERIOL, V145, P958, DOI 10.1128/JB.145.2.958-965.1981; WELCH M, 1993, P NATL ACAD SCI USA, V90, P8787, DOI 10.1073/pnas.90.19.8787; YAMAGUCHI S, 1986, J BACTERIOL, V168, P1172, DOI 10.1128/jb.168.3.1172-1179.1986; Zhao R, 2002, NAT STRUCT BIOL, V9, P570; ZUBERI AR, 1991, J BACTERIOL, V173, P710, DOI 10.1128/jb.173.2.710-719.1991	34	52	55	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48611	48616		10.1074/jbc.M306180200	http://dx.doi.org/10.1074/jbc.M306180200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	12920116	hybrid, Green Submitted			2022-12-25	WOS:000186829000013
J	Belfort, GM; Kandror, KV				Belfort, GM; Kandror, KV			Cellugyrin and synaptogyrin facilitate targeting of synaptophysin to a ubiquitous synaptic vesicle-sized compartment in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO; SUBCELLULAR-LOCALIZATION; MEMBRANE-PROTEINS; BIOGENESIS; TRANSPORT; SYNAPTOTAGMIN; MICROVESICLES; FIBROBLASTS; PC12-CELLS; SIGNALS	Cellugyrin represents a ubiquitously expressed four-transmembrane domain protein that is closely related to synaptic vesicle protein synaptogyrin and, more remotely, to synaptophysin. We report here that, in PC12 cells, cellugyrin is localized in synaptic-like microvesicles (SLMVs), along with synaptogyrin and synaptophysin. Upon overexpression of synaptophysin in PC12 cells, it is localized in rapidly sedimenting membranes and practically is not delivered to the SLMVs. On the contrary, the efficiency of the SLMV targeting of exogenously expressed cellugyrin and synaptogyrin is high. Moreover, expression of cellugyrin ( or synaptogyrin) in PC12 cells dramatically and specifically increases SLMV targeting of endogenous synaptophysin. Finally, we utilized the SLMV purification scheme on a series of non-neuroendocrine cell types including the mouse fibroblast cell line 3T3-L1, the Chinese hamster ovary cell line CHO-K1, and the monkey kidney epithelial cell line COS7 and found that a cellugyrin-positive microvesicular compartment was present in all cell types tested. We suggest that synaptic vesicles have evolved from cellugyrin-positive ubiquitous microvesicles and that neuroendocrine SLMVs represent a step along that pathway of evolution.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Boston University	Kandror, KV (corresponding author), Boston Univ, Sch Med, Dept Biochem, K124D,715 Albany St, Boston, MA 02118 USA.			Kandror, Konstantin/0000-0002-8601-9313				Blagoveshchenskaya AD, 1999, MOL BIOL CELL, V10, P3979, DOI 10.1091/mbc.10.11.3979; Blagoveshchenskaya AD, 2000, MOL BIOL CELL, V11, P1801, DOI 10.1091/mbc.11.5.1801; Blagoveshchenskaya AD, 1999, J CELL BIOL, V145, P1419, DOI 10.1083/jcb.145.7.1419; CAMERON PL, 1991, J CELL BIOL, V115, P151, DOI 10.1083/jcb.115.1.151; CHILCOTE TJ, 1995, J CELL BIOL, V129, P219, DOI 10.1083/jcb.129.1.219; CLIFTOGRADY L, 1990, J CELL BIOL, V110, P1693, DOI 10.1083/jcb.110.5.1693; DESNOS C, 1995, J CELL BIOL, V130, P1041, DOI 10.1083/jcb.130.5.1041; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; Faundez V, 1997, J CELL BIOL, V138, P505, DOI 10.1083/jcb.138.3.505; FEANY MB, 1993, J CELL BIOL, V123, P575, DOI 10.1083/jcb.123.3.575; Fernandez-Chacon R, 1999, ANNU REV PHYSIOL, V61, P753, DOI 10.1146/annurev.physiol.61.1.753; GROTE E, 1995, CELL, V81, P581, DOI 10.1016/0092-8674(95)90079-9; Haass NK, 1996, J CELL BIOL, V134, P731, DOI 10.1083/jcb.134.3.731; Hubner K, 2002, INT REV CYTOL, V214, P103; Janz R, 1999, NEURON, V24, P687, DOI 10.1016/S0896-6273(00)81122-8; Janz R, 1998, J BIOL CHEM, V273, P2851, DOI 10.1074/jbc.273.5.2851; JOHNSTON PA, 1989, EMBO J, V8, P2863, DOI 10.1002/j.1460-2075.1989.tb08434.x; Kedra D, 1998, HUM GENET, V103, P131, DOI 10.1007/s004390050795; Kupriyanova TA, 2000, J BIOL CHEM, V275, P36263, DOI 10.1074/jbc.M002797200; Kupriyanova TA, 2002, J BIOL CHEM, V277, P9133, DOI 10.1074/jbc.M106999200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUBE RE, 1994, J CELL BIOL, V127, P1589, DOI 10.1083/jcb.127.6.1589; LEUBE RE, 1989, CELL, V59, P433, DOI 10.1016/0092-8674(89)90028-7; LINSTEDT AD, 1991, NEURON, V7, P309, DOI 10.1016/0896-6273(91)90269-6; LOWE AW, 1988, J CELL BIOL, V106, P51, DOI 10.1083/jcb.106.1.51; NAVONE F, 1986, J CELL BIOL, V103, P2511, DOI 10.1083/jcb.103.6.2511; Shi GY, 1998, J CELL BIOL, V143, P947, DOI 10.1083/jcb.143.4.947; Sugita S, 1999, J BIOL CHEM, V274, P18893, DOI 10.1074/jbc.274.27.18893; Thoidis G, 2001, TRAFFIC, V2, P577, DOI 10.1034/j.1600-0854.2001.20807.x; Xu Z, 2002, J BIOL CHEM, V277, P47972, DOI 10.1074/jbc.C200486200	30	16	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47971	47978		10.1074/jbc.M304174200	http://dx.doi.org/10.1074/jbc.M304174200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12928441	hybrid			2022-12-25	WOS:000186731400075
J	Clement, MJ; Imberty, A; Phalipon, A; Perez, S; Simenel, C; Mulard, LA; Delepierre, M				Clement, MJ; Imberty, A; Phalipon, A; Perez, S; Simenel, C; Mulard, LA; Delepierre, M			Conformational studies of the O-specific polysaccharide of Shigella flexneri 5a and of four related synthetic pentasaccharide fragments using NMR and molecular modeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYSENTERIAE TYPE-1; CAPSULAR POLYSACCHARIDE; COUPLING-CONSTANTS; CONJUGATE VACCINES; FORCE-FIELD; SEROTYPE 5A; EPITOPE; MECHANICS; SPECTRA; ANTIGEN	As part of a program for the development of synthetic vaccines against the pathogen Shigella flexneri, we used a combination of NMR and molecular modeling methods to study the conformations of the O-specific polysaccharide (O-SP) of S. flexneri 5a and of four related synthetic pentasaccharide fragments. The NMR study, based on the analysis of H-1 and C-13 chemical shifts, the evaluation of inter-residue distances, and the measurement of one- and three-bond heteronuclear coupling constants, showed that the conformation of one of the four pentasaccharides is similar to that of the native O-SP in solution. Interestingly, inhibition enzyme-linked immunosorbent assay demonstrated that a protective monoclonal antibody specific for S. flexneri 5a has a greater affinity for this pentasaccharide than for the others. We carried out a complete conformational search on the pentasaccharides using the CICADA algorithm interfaced with MM3 force field. We calculated Boltzmann-averaged inter-residue distances and (3)J(C,H) coupling constants for the different conformational families and compared the results with NMR data for all pentasaccharides. Our experimental data are consistent with only one conformational family. We also used molecular modeling data to build models of the O-SP with the molecular builder program POLYS. The models that are in agreement with NMR data adopt right-handed 3-fold helical structures in which the branched glucosyl residue points outwards.	Inst Pasteur, CNRS, URA 2185, Unite RMN Biomol, F-75724 Paris 15, France; Univ Grenoble 1, CNRS, CERMAV, F-38041 Grenoble 09, France; Inst Pasteur, CNRS, URA 2128, Unite Chim Organ, F-75724 Paris 15, France; Inst Pasteur, Unite Pathogenie Microbienne Mol, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Delepierre, M (corresponding author), Inst Pasteur, CNRS, URA 2185, Unite RMN Biomol, 28 Rue Dr Roux, F-75724 Paris 15, France.	murield@pasteur.fr	Imberty, Anne/P-6451-2018	Imberty, Anne/0000-0001-6825-9527				ALLINGER NL, 1989, J AM CHEM SOC, V111, P8551, DOI 10.1021/ja00205a001; ALLINGER NL, 1990, J AM CHEM SOC, V112, P8293, DOI 10.1021/ja00179a012; BALEJA JD, 1990, J MAGN RESON, V87, P375, DOI 10.1016/0022-2364(90)90015-2; BOCK K, 1982, J CHEM SOC PERK T 2, P59, DOI 10.1039/p29820000059; BOCK K, 1974, J CHEM SOC        P2, V2, P293; BOYD J, 1992, J MAGN RESON, V98, P660, DOI 10.1016/0022-2364(92)90021-X; Brisson JR, 1997, BIOCHEMISTRY-US, V36, P3278, DOI 10.1021/bi961819l; Bush CA, 1999, ANNU REV BIOPH BIOM, V28, P269, DOI 10.1146/annurev.biophys.28.1.269; Cadoz M, 1998, VACCINE, V16, P1391, DOI 10.1016/S0264-410X(98)00097-8; Chandrasekaran R, 1997, ADV CARBOHYD CHEM BI, V52, P311, DOI 10.1016/S0065-2318(08)60094-3; CLORE GM, 1988, FEBS LETT, V238, P17, DOI 10.1016/0014-5793(88)80216-3; DAVIS AL, 1992, J MAGN RESON, V98, P207, DOI 10.1016/0022-2364(92)90126-R; Delay C, 1997, CARBOHYD RES, V302, P67, DOI 10.1016/S0008-6215(97)00101-8; DESVAUX H, 1994, J MAGN RESON SER A, V108, P219, DOI 10.1006/jmra.1994.1114; EMSLEY L, 1992, J MAGN RESON, V97, P135, DOI 10.1016/0022-2364(92)90242-Y; Engelsen SB, 1996, BIOPOLYMERS, V39, P417, DOI 10.1002/(SICI)1097-0282(199609)39:3<417::AID-BIP13>3.3.CO;2-R; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; Gunawardena S, 1999, BIOCHEMISTRY-US, V38, P12062, DOI 10.1021/bi9910272; IMBERTY A, 1994, GLYCOBIOLOGY, V4, P351, DOI 10.1093/glycob/4.3.351; IMBERTY A, 1995, GLYCOCONJUGATE J, V12, P331, DOI 10.1007/BF00731336; *IUPAC IUB, 1971, ARCH BIOCHEM BIOPHYS, V145, P405; JANSSON PE, 1988, CARBOHYD RES, V179, P359, DOI 10.1016/0008-6215(88)84132-6; JANSSON PE, 1987, CARBOHYD RES, V166, P271, DOI 10.1016/0008-6215(87)80063-0; KAY LE, 1992, J MAGN RESON, V97, P359, DOI 10.1016/0022-2364(92)90320-7; KENNE L, 1977, CARBOHYD RES, V56, P363, DOI 10.1016/S0008-6215(00)83357-1; KOCA J, 1995, J COMPUT CHEM, V16, P296, DOI 10.1002/jcc.540160305; Koca J, 1998, PROG BIOPHYS MOL BIO, V70, P137, DOI 10.1016/S0079-6107(98)00029-7; KOCA J, 1994, J MOL STRUC-THEOCHEM, V114, P13, DOI 10.1016/0166-1280(94)80091-X; KOCA J, 1993, J MOL STRUCT, V291, P255, DOI 10.1016/0022-2860(93)85049-Z; Kotloff KL, 1999, B WORLD HEALTH ORGAN, V77, P651; Krishnamurthy VV, 1996, J MAGN RESON SER A, V121, P33, DOI 10.1006/jmra.1996.0132; Lemieux R. U., 1979, ACS SYM SER, V87, P17, DOI DOI 10.1021/BK-1979-0087.CH002; LEMIEUX RU, 1980, CAN J CHEM, V58, P631, DOI 10.1139/v80-098; MacLennan JM, 2000, JAMA-J AM MED ASSOC, V283, P2795, DOI 10.1001/jama.283.21.2795; MACLEOD CM, 1945, J EXP MED, V82, P445, DOI 10.1084/jem.82.6.445; Mulard LA, 2002, TETRAHEDRON, V58, P2593, DOI 10.1016/S0040-4020(02)00148-5; Mulard LA, 2002, EUR J ORG CHEM, V2002, P2486; Mulard LA, 2000, J CARBOHYD CHEM, V19, P193, DOI 10.1080/07328300008544074; Mulard LA, 2000, J CARBOHYD CHEM, V19, P503, DOI 10.1080/07328300008544096; Mulard LA, 1999, J CARBOHYD CHEM, V18, P721, DOI 10.1080/07328309908544033; Nyholm PG, 2001, GLYCOBIOLOGY, V11, P945, DOI 10.1093/glycob/11.11.945; Passwell JH, 2001, INFECT IMMUN, V69, P1351, DOI 10.1128/IAI.69.3.1351-1357.2001; Perez S, 1998, CARBOHYD RES, V314, P141, DOI 10.1016/S0008-6215(98)00305-X; PEREZ S, 1991, CARBOHYD RES, V212, P253, DOI 10.1016/0008-6215(91)84062-J; PHALIPON A, 1995, J EXP MED, V182, P769, DOI 10.1084/jem.182.3.769; Pitner JB, 2000, CARBOHYD RES, V324, P17, DOI 10.1016/S0008-6215(99)00279-7; Pozsgay V, 1993, Bioorg Med Chem, V1, P237, DOI 10.1016/S0968-0896(00)82129-X; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; ROBBINS JB, 1997, NEW GENERATION VACCI, P803; SANSONETTI PJ, 1991, REV INFECT DIS, V13, pS285; SIMMONS DAR, 1971, BACTERIOL REV, V35, P117, DOI 10.1128/MMBR.35.2.117-148.1971; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; STOTT K, 1995, J AM CHEM SOC, V117, P4199, DOI 10.1021/ja00119a048; TAYLOR DN, 1993, INFECT IMMUN, V61, P3678, DOI 10.1128/IAI.61.9.3678-3687.1993; TVAROSKA I, 1989, CARBOHYD RES, V189, P359, DOI 10.1016/0008-6215(89)84112-6; WENGER JD, 1997, NEW GENERATION VACCI, P489; WILLKER W, 1995, MAGN RESON CHEM, V33, P632, DOI 10.1002/mrc.1260330804; WILLKER W, 1993, MAGN RESON CHEM, V31, P287, DOI 10.1002/mrc.1260310315; Zou W, 1999, J IMMUNOL, V163, P820	59	36	37	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47928	47936		10.1074/jbc.M308259200	http://dx.doi.org/10.1074/jbc.M308259200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12925526	hybrid			2022-12-25	WOS:000186731400071
J	Akhtar, MK; Kaderbhai, NN; Hopper, DJ; Kelly, SL; Kaderbhai, MA				Akhtar, MK; Kaderbhai, NN; Hopper, DJ; Kelly, SL; Kaderbhai, MA			Export of a heterologous cytochrome P450 (CYP105D1) in Escherichia coli is associated with periplasmic accumulation of uroporphyrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORPHYRIA-CUTANEA-TARDA; DELTA-AMINOLEVULINIC-ACID; 5-AMINOLEVULINIC ACID; MOLECULAR-BIOLOGY; PROTEIN EXPORT; HEME-SYNTHESIS; OXIDATION; BINDING; LIVER; MICE	This report suggests an important physiological role of a CYP in the accumulation of uroporphyrin I arising from catalytic oxidative conversion of uroporphyrinogen I to uroporphyrin I in the periplasm of Escherichia coli cultured in the presence of 5-aminolevulinic acid. A structurally competent Streptomyces griseus CYP105D1 was expressed as an engineered, exportable form in aerobically grown E. coli. Its progressive induction in the presence of 5-aminolevulinic acid-supplemented medium was accompanied by an accumulation of a greater than 100-fold higher amount of uroporphyrin I in the periplasm relative to cells lacking CYP105D1. Expression of a cytoplasm-resident engineered CYP105D1 at a comparative level to the secreted form was far less effective in promoting porphyrin accumulation in the periplasm. Expression at a 10-fold molar excess over the exported CYP105D1 of another periplasmically exported hemoprotein, the globular core of cytochrome b(5), did not substitute the role of the periplasmically localized CYP105D1 in promoting porphyrin production. This, therefore, eliminated the possibility that uroporphyrin accumulation is merely a result of increased hemoprotein synthesis. Moreover, in the strain that secreted CYP105D1, uroporphyrin production was considerably reduced by azole-based P450 inhibitors. Production of both holo-CYP105D1 and uroporphyrin was dependent upon 5-aminolevulinic acid, except that at higher concentrations this resulted in a decrease in uroporphyrin. This study suggests that the exported CYP105D1 oxidatively catalyzes periplasmic conversion of uroporphyrinogen I to uroporphyrin I in E. coli. The findings have significant implications in the ontogenesis of human uroporphyria-related diseases.	Univ Wales, Inst Biol Sci, Aberystwyth SY23 3DD, Ceredigion, Wales	Aberystwyth University	Kaderbhai, MA (corresponding author), Univ Wales, Inst Biol Sci, Cledwyn Bldg, Aberystwyth SY23 3DD, Ceredigion, Wales.							BEALE SI, 1994, CIBA F SYMP, V180, P156; Berks BC, 2000, MOL MICROBIOL, V35, P260, DOI 10.1046/j.1365-2958.2000.01719.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bruce JIE, 2000, BRIT J PHARMACOL, V131, P761, DOI 10.1038/sj.bjp.0703631; CHARTRAND P, 1979, J GEN MICROBIOL, V110, P61, DOI 10.1099/00221287-110-1-61; Constantin D, 1996, BIOCHEM PHARMACOL, V52, P1407, DOI 10.1016/S0006-2952(96)00475-3; COX R, 1973, J BACTERIOL, V113, P122, DOI 10.1128/JB.113.1.122-132.1973; CROCKETT N, 1991, TETRAHEDRON, V47, P6003, DOI 10.1016/S0040-4020(01)86492-9; DAWSON RMC, 1987, DATA BIOCH RES, P213; Doss MO, 2000, ALCOHOL ALCOHOLISM, V35, P109, DOI 10.1093/alcalc/35.2.109; Elder GH, 1998, SEMIN LIVER DIS, V18, P67, DOI 10.1055/s-2007-1007142; Estabrook R W, 1978, Methods Enzymol, V52, P212; Franklin MR, 2000, BIOCHEM PHARMACOL, V60, P1325, DOI 10.1016/S0006-2952(00)00449-4; GALLAGHER SR, 1999, CURRENT PROTOCOLS MO, V2, DOI DOI 10.12B.11-10.12B.15; Goldman BS, 1997, J MOL BIOL, V268, P724, DOI 10.1006/jmbi.1997.0992; GOODHEW CF, 1986, BIOCHIM BIOPHYS ACTA, V852, P288, DOI 10.1016/0005-2728(86)90234-3; Gorman N, 2002, HEPATOLOGY, V35, P912, DOI 10.1053/jhep.2002.32487; Gorman N, 1998, COMP BIOCHEM PHYS C, V121, P405, DOI 10.1016/S0742-8413(98)10059-2; HANSPETER K, 1988, FAT SOLUBLE PIGMENTS; HARDING V, 1993, BIOCHEM J, V293, P751, DOI 10.1042/bj2930751; HENDERSON MJ, 1989, CLIN CHEM, V35, P1043; JACOBS JM, 1990, J BIOCHEM TOXICOL, V5, P193, DOI 10.1002/jbt.2570050310; JACOBS JM, 1989, BIOCHEM J, V258, P247, DOI 10.1042/bj2580247; KADERBHAI MA, 1990, DNA CELL BIOL, V9, P11, DOI 10.1089/dna.1990.9.11; Kaderbhai MA, 2001, APPL ENVIRON MICROB, V67, P2136, DOI 10.1128/AEM.67.5.2136-2138.2001; Kaderbhai N, 1997, BIOTECHNOL APPL BIOC, V25, P53, DOI 10.1111/j.1470-8744.1997.tb00414.x; KARIM A, 1993, BIO-TECHNOL, V11, P612, DOI 10.1038/nbt0593-612; KIKUCHI Y, 1981, NUCLEIC ACIDS RES, V9, P5671, DOI 10.1093/nar/9.21.5671; Kim J, 2000, CELL STRESS CHAPERON, V5, P267, DOI 10.1379/1466-1268(2000)005<0267:SDPEAT>2.0.CO;2; Lamb D, 1999, DRUG RESIST UPDATE, V2, P390, DOI 10.1054/drup.1999.0112; LIM CK, 1986, METHOD ENZYMOL, V123, P383; MERCER EI, 1993, PROG LIPID RES, V32, P357, DOI 10.1016/0163-7827(93)90016-P; Moore MR, 1998, CLIN DERMATOL, V16, P203, DOI 10.1016/S0738-081X(97)00201-0; Mylchreest E, 1997, TOXICOL APPL PHARM, V145, P23, DOI 10.1006/taap.1997.8157; OMURA T, 1964, J BIOL CHEM, V239, P2370; PHILIPPDORMSTON WK, 1975, Z NATURFORSCH C, V30, P425; Rendic S, 2002, DRUG METAB REV, V34, P83, DOI 10.1081/DMR-120001392; RIMINGTON C, 1960, BIOCHEM J, V75, P620, DOI 10.1042/bj0750620; Sampietro M, 1999, HAEMATOLOGICA, V84, P248; Sarkany RPE, 1999, ADV EXP MED BIOL, V455, P235; SASARMAN A, 1968, J BACTERIOL, V96, P1882; Sassa S, 2000, J INTERN MED, V247, P169, DOI 10.1046/j.1365-2796.2000.00618.x; SINCLAIR P, 1987, BIOCHEM BIOPH RES CO, V146, P1324, DOI 10.1016/0006-291X(87)90794-7; Sinclair PR, 1997, J LAB CLIN MED, V130, P197, DOI 10.1016/S0022-2143(97)90096-2; Sinclair PR, 1998, DRUG METAB DISPOS, V26, P1019; Sinclair PR, 1997, DRUG METAB DISPOS, V25, P779; Sinclair PR, 1998, BIOCHEM J, V330, P149; SPENCER P, 1995, BIOCHEM J, V305, P151, DOI 10.1042/bj3050151; Tsukazaki N, 1998, BRIT J DERMATOL, V138, P1015; Verderber E, 1997, J BACTERIOL, V179, P4583, DOI 10.1128/jb.179.14.4583-4590.1997	50	5	5	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45555	45562		10.1074/jbc.M212685200	http://dx.doi.org/10.1074/jbc.M212685200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12930844	hybrid			2022-12-25	WOS:000186452300063
J	Crisp, RJ; Pollington, A; Galea, C; Jaron, S; Yamaguchi-Iwai, Y; Kaplan, J				Crisp, RJ; Pollington, A; Galea, C; Jaron, S; Yamaguchi-Iwai, Y; Kaplan, J			Inhibition of heme biosynthesis prevents transcription of iron uptake genes in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED SIDEROBLASTIC ANEMIA; SACCHAROMYCES-CEREVISIAE; MITOCHONDRIAL; FRATAXIN; ATAXIA; TRANSPORTER; MUTATION; OXYGEN; DEFICIENCY; EXPRESSION	Yeast are capable of modifying their metabolism in response to environmental changes. We investigated the activity of the oxygen-dependent high-affinity iron uptake system of Saccharomyces cerevisiae under conditions of heme depletion. We found that the absence of heme, due to a deletion in the gene that encodes delta-aminolevulinic acid synthase (HEM1), resulted in decreased transcription of genes belonging to both the iron and copper regulons, but not the zinc regulon. Decreased transcription of the iron regulon was not due to decreased expression of the iron sensitive transcriptional activator Aft1p. Expression of the constitutively active allele AFT1-1(up) was unable to induce transcription of the high affinity iron uptake system in heme-depleted cells. We demonstrated that under heme-depleted conditions, Aft1p-GFP was able to cycle normally between the nucleus and cytosol in response to cytosolic iron. Despite the inability to induce transcription under low iron conditions, chromatin immunoprecipitation demonstrated that Aft1p binds to the FET3 promoter in the absence of heme. Finally, we provide evidence that under heme-depleted conditions, yeast are able to regulate mitochondrial iron uptake and do not accumulate pathologic iron concentrations, as is seen when iron-sulfur cluster synthesis is disrupted.	Univ Utah, Sch Med, Dept Pathol, Div Cell Biol & Immunol, Salt Lake City, UT 84132 USA; St Jude Childrens Res Hosp, Dept Biol Struct, Memphis, TN 38105 USA; Kyoto Univ, Grad Sch Biostudies, Dept Appl Mol Biol, Sakyo Ku, Kyoto 6068502, Japan	Utah System of Higher Education; University of Utah; St Jude Children's Research Hospital; Kyoto University	Kaplan, J (corresponding author), Univ Utah, Sch Med, Dept Pathol, Div Cell Biol & Immunol, 50 N Med Dr, Salt Lake City, UT 84132 USA.	jerry.kaplan@path.utah.edu	Galea, Charles/C-5074-2013; Galea, Charles/O-8800-2014	Galea, Charles/0000-0003-0485-7709; Galea, Charles/0000-0003-2730-1105; McGehee, Annette/0000-0002-8175-3404	NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052380, R37DK030534, R01DK030534, T32DK007115] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA 42014] Funding Source: Medline; NIDDK NIH HHS [NIDDK 30534, T32 DK07115-29, NIDDK 52380] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allikmets R, 1999, HUM MOL GENET, V8, P743, DOI 10.1093/hmg/8.5.743; APARICIO O, 2003, CURRENT PROTOCOLS MO, V61; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Askwith CC, 1996, MOL MICROBIOL, V20, P27, DOI 10.1111/j.1365-2958.1996.tb02485.x; Becerra M, 2002, MOL MICROBIOL, V43, P545, DOI 10.1046/j.1365-2958.2002.02724.x; Bekri S, 2000, BLOOD, V96, P3256; Bradley JL, 2000, HUM MOL GENET, V9, P275, DOI 10.1093/hmg/9.2.275; Chen OS, 2000, J BIOL CHEM, V275, P7626, DOI 10.1074/jbc.275.11.7626; Chen OS, 2002, P NATL ACAD SCI USA, V99, P12321, DOI 10.1073/pnas.192449599; Duby G, 2002, HUM MOL GENET, V11, P2635, DOI 10.1093/hmg/11.21.2635; Fleming MD, 2002, SEMIN HEMATOL, V39, P270, DOI 10.1053/shem.2002.35637; Foury F, 1999, FEBS LETT, V456, P281, DOI 10.1016/S0014-5793(99)00961-8; Gaisne M, 1999, CURR GENET, V36, P195, DOI 10.1007/s002940050490; GOLLUB EG, 1977, J BIOL CHEM, V252, P2846; GRIMAL D, 1980, MOL GEN GENET, V178, P713, DOI 10.1007/BF00337883; Hassett RF, 1998, J BIOL CHEM, V273, P7628, DOI 10.1074/jbc.273.13.7628; Jensen LT, 2002, J MOL BIOL, V318, P251, DOI 10.1016/S0022-2836(02)00093-1; Kwast KE, 2002, J BACTERIOL, V184, P250, DOI 10.1128/JB.184.1.250-265.2002; Kwast KE, 1998, J EXP BIOL, V201, P1177; Lascaris R, 2003, GENOME BIOL, V4; Li LT, 2001, J BIOL CHEM, V276, P29515, DOI 10.1074/jbc.M103944200; Li LT, 2001, J BIOL CHEM, V276, P5036, DOI 10.1074/jbc.M008969200; Lill R, 1999, BIOL CHEM, V380, P1157, DOI 10.1515/BC.1999.147; Muhlenhoff U, 2002, HUM MOL GENET, V11, P2025, DOI 10.1093/hmg/11.17.2025; Ponka P, 1997, BLOOD, V89, P1; Protchenko O, 2001, J BIOL CHEM, V276, P49244, DOI 10.1074/jbc.M109220200; Puccio H, 2001, NAT GENET, V27, P181, DOI 10.1038/84818; Radisky DC, 1999, J BIOL CHEM, V274, P4497, DOI 10.1074/jbc.274.8.4497; Stearman R, 1998, GENE, V212, P197, DOI 10.1016/S0378-1119(98)00179-6; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; ter Linde JJM, 1999, J BACTERIOL, V181, P7409, DOI 10.1128/JB.181.24.7409-7413.1999; THORSNESS M, 1989, MOL CELL BIOL, V9, P5702, DOI 10.1128/MCB.9.12.5702; Vasconcelles MJ, 2001, J BIOL CHEM, V276, P14374, DOI 10.1074/jbc.M009546200; Waters BM, 2002, J BIOL CHEM, V277, P33749, DOI 10.1074/jbc.M206214200; Yamaguchi-Iwai Y, 2002, J BIOL CHEM, V277, P18914, DOI 10.1074/jbc.M200949200; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x	36	68	70	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45499	45506		10.1074/jbc.M307229200	http://dx.doi.org/10.1074/jbc.M307229200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12928433	hybrid			2022-12-25	WOS:000186452300056
J	Stewart, RS; Harris, DA				Stewart, RS; Harris, DA			Mutational analysis of topological determinants in prion protein (PrP) and measurement of transmembrane and cytosolic PrP during prion infection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; TRANSLOCATION CHANNEL; SIGNAL SEQUENCES; MEMBRANE; DEGRADATION; BIOGENESIS; DISEASES; CONTAINS; PEPTIDE; DOMAIN	The prion protein (PrP) can adopt multiple membrane topologies, including a fully translocated form ((PrP)-Pr-Sec), two transmembrane forms ((PrP)-Pr-Ntm and (PrP)-Pr-Ctm), and a cytosolic form. It is important to understand the factors that influence production of these species, because two of them, (PrP)-Pr-Ctm and cytosolic PrP, have been proposed to be key neurotoxic intermediates in certain prion diseases. In this paper, we perform a mutational analysis of PrP synthesized using an in vitro translation system in order to further define sequence elements that influence the formation of (PrP)-Pr-Ctm. We find that substitution of charged residues in the hydrophobic core of the signal peptide increases synthesis of (PrP)-Pr-Ctm and also reduces the efficiency of translocation into microsomes. Combining these mutations with substitutions in the transmembrane domain causes the protein to be synthesized exclusively with the (PrP)-Pr-Ctm topology. Reducing the spacing between the signal peptide and the transmembrane domain also increases (PrP)-Pr-Ctm. In contrast, topology is not altered by mutations that prevent signal peptide cleavage or by deletion of the C-terminal signal for glycosylphosphatidylinositol anchor addition. Removal of the signal peptide completely blocks translocation. Taken together, our results are consistent with a model in which the signal peptide and transmembrane domain function in distinct ways as determinants of PrP topology. We also present characterization of an antibody that selectively recognizes (PrP)-Pr-Ctm and cytosolic PrP by virtue of their uncleaved signal peptides. By using this antibody, as well as the distinctive gel mobility of (PrP)-Pr-Ctm and cytosolic PrP, we show that the amounts of these two forms in cultured cells and rodent brain are not altered by infection with scrapie prions. We conclude that (PrP)-Pr-Ctm and cytosolic PrP are unlikely to be obligate neurotoxic intermediates in familial or infectiously acquired prion diseases.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Harris, DA (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave, St Louis, MO 63110 USA.			Harris, David/0000-0002-6985-5790	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS041500, R01NS035496] Funding Source: NIH RePORTER; NINDS NIH HHS [NS41500, NS35496] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bosque PJ, 2000, J VIROL, V74, P4377, DOI 10.1128/JVI.74.9.4377-4386.2000; Brown Lesley R., 2002, P103; Chiesa R, 2003, J VIROL, V77, P7611, DOI 10.1128/JVI.77.13.7611-7622.2003; Chiesa R, 2001, NEUROBIOL DIS, V8, P743, DOI 10.1006/nbdi.2001.0433; Chiesa R, 1998, NEURON, V21, P1339, DOI 10.1016/S0896-6273(00)80653-4; Collinge J, 2001, ANNU REV NEUROSCI, V24, P519, DOI 10.1146/annurev.neuro.24.1.519; DEFEA KA, 1994, J BIOL CHEM, V269, P16810; Drisaldi B, 2003, J BIOL CHEM, V278, P21732, DOI 10.1074/jbc.M213247200; Fons RD, 2003, J CELL BIOL, V160, P529, DOI 10.1083/jcb.200210095; Hegde RS, 1999, NATURE, V402, P822, DOI 10.1038/45574; Hegde RS, 1998, MOL CELL, V2, P85, DOI 10.1016/S1097-2765(00)80116-1; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; Holscher C, 2001, J BIOL CHEM, V276, P13388, DOI 10.1074/jbc.M007331200; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; Kim SJ, 2002, MOL BIOL CELL, V13, P3775, DOI 10.1091/mbc.E02-05-0293; Kim SJ, 2002, DEV CELL, V2, P207, DOI 10.1016/S1534-5807(01)00120-4; Kim SJ, 2001, J BIOL CHEM, V276, P26132, DOI 10.1074/jbc.M101638200; LEHMANN S, 1995, J BIOL CHEM, V270, P24589, DOI 10.1074/jbc.270.41.24589; Ma JY, 2002, SCIENCE, V298, P1781, DOI 10.1126/science.1073725; Ma JY, 2002, SCIENCE, V298, P1785, DOI 10.1126/science.1073619; Ma JY, 2001, P NATL ACAD SCI USA, V98, P14955, DOI 10.1073/pnas.011578098; Nishida N, 2000, J VIROL, V74, P320, DOI 10.1128/JVI.74.1.320-325.2000; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Quaglio E, 2001, J BIOL CHEM, V276, P11432, DOI 10.1074/jbc.M009666200; Rutkowski DT, 2001, P NATL ACAD SCI USA, V98, P7823, DOI 10.1073/pnas.141125098; STAHL N, 1990, BIOCHEMISTRY-US, V29, P5405, DOI 10.1021/bi00474a028; Stewart RS, 2001, MOL BIOL CELL, V12, P881, DOI 10.1091/mbc.12.4.881; Stewart RS, 2001, J BIOL CHEM, V276, P2212, DOI 10.1074/jbc.M006763200; VIDUGIRIENE J, 1995, EMBO J, V14, P4686, DOI 10.1002/j.1460-2075.1995.tb00150.x; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; Yedidia Y, 2001, EMBO J, V20, P5383, DOI 10.1093/emboj/20.19.5383; Zanusso G, 1998, P NATL ACAD SCI USA, V95, P8812, DOI 10.1073/pnas.95.15.8812	32	64	65	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45960	45968		10.1074/jbc.M307833200	http://dx.doi.org/10.1074/jbc.M307833200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12933795	hybrid			2022-12-25	WOS:000186452300110
J	Zeng, YC; Tao, NB; Chung, KN; Heuser, JE; Lublin, DM				Zeng, YC; Tao, NB; Chung, KN; Heuser, JE; Lublin, DM			Endocytosis of oxidized low density lipoprotein through scavenger receptor CD36 utilizes a lipid raft pathway that does not require caveolin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE-DERIVED MACROPHAGES; DECAY-ACCELERATING FACTOR; GPI-ANCHORED PROTEINS; MEMBRANE-PROTEIN; GOLGI-COMPLEX; BINDING-SITE; CELL-SURFACE; IN-VIVO; TRANSPORT; DOMAINS	The scavenger receptor CD36 binds a diverse array of ligands, including thrombospondin-1, oxidized low density lipoprotein (OxLDL), fatty acids, anionic phospholipids, and apoptotic cells. CD36 has been reported to be present in lipid rafts/caveolae, but little is known about the membrane trafficking of this protein at baseline or following ligand binding. Here, we determined that expression of CD36 in Chinese hamster ovary (CHO) cells and endogenous expression of CD36 in C32 cells led to a homogeneous distribution of the protein on the plasma membrane, as judged by confocal fluorescence microscopy. This homogeneous pattern was observed both by anti-CD36 antibody staining and by live cell imaging of CHO cells expressing a chimeric CD36-green fluorescent protein construct. In contrast, caveolin-1 displayed its usual punctate surface distribution. Correspondingly, dual labeling of CD36 and caveolin-1 showed essentially no overlap, neither by immunofluorescence light microscopy nor by immunogold electron microscopy. Furthermore, isolation of lipid rafts by sucrose gradient ultracentrifugation of cold Triton X-100 cell lysates yielded both CD36 and caveolin-1, but immunoprecipitates of caveolin-1 did not contain CD36. Binding of OxLDL led to internalization of CD36 and OxLDL into endosomal structures that did not contain caveolin-1 or transferrin but that co-internalized the glycosyl-phosphatidylinositol-anchored protein decay accelerating factor, a lipid raft protein. Furthermore, expression of CD36 in the caveolin-1-negative KB cell line is sufficient for OxLDL-induced internalization of CD36, indicating that caveolin-1 is not required for this endocytic process. Taken together, these data demonstrate that at steady state, CD36 is localized in lipid rafts but not in caveolae, and that binding of OxLDL to CD36 leads to endocytosis through a lipid raft pathway that is distinct from the clathrin-mediated or caveolin internalization pathways.	Washington Univ, Sch Med, Dept Pathol, Div Lab Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Lublin, DM (corresponding author), Washington Univ, Sch Med, Dept Pathol, Div Lab Med, 660 S Euclid Ave,Box 8118, St Louis, MO 63110 USA.		Heuser, John/H-5940-2012; Eckhardt, Erik/G-1567-2010		NHLBI NIH HHS [T32-HL07038] Funding Source: Medline; NIGMS NIH HHS [GM41297] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007038] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM041297, R01GM041297] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; COYNE KE, 1992, J IMMUNOL, V149, P2906; DIETZEN DJ, 1995, J BIOL CHEM, V270, P6838, DOI 10.1074/jbc.270.12.6838; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; Febbraio M, 2000, J CLIN INVEST, V105, P1049, DOI 10.1172/JCI9259; Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI200114006; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; Gargalovic P, 2001, J BIOL CHEM, V276, P26164, DOI 10.1074/jbc.M011291200; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GREENWALT DE, 1990, BIOCHEMISTRY-US, V29, P7054, DOI 10.1021/bi00482a015; GRIFFITHS G, 1984, J ULTRA MOL STRUCT R, V89, P65, DOI 10.1016/S0022-5320(84)80024-6; KNOWLES DM, 1984, J IMMUNOL, V132, P2170; Kunjathoor VV, 2002, J BIOL CHEM, V277, P49982, DOI 10.1074/jbc.M209649200; Lamaze C, 2001, MOL CELL, V7, P661, DOI 10.1016/S1097-2765(01)00212-X; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; London E, 2000, BBA-BIOMEMBRANES, V1508, P182, DOI 10.1016/S0304-4157(00)00007-1; LUBLIN DM, 1991, J EXP MED, V174, P35, DOI 10.1084/jem.174.1.35; MONTESANO R, 1982, NATURE, V296, P651, DOI 10.1038/296651a0; Nabi IR, 2003, J CELL BIOL, V161, P673, DOI 10.1083/jcb.200302028; Nichols BJ, 2002, NAT CELL BIOL, V4, P374, DOI 10.1038/ncb787; Nichols BJ, 2001, J CELL BIOL, V153, P529, DOI 10.1083/jcb.153.3.529; Nichols BJ, 2001, TRENDS CELL BIOL, V11, P406, DOI 10.1016/S0962-8924(01)02107-9; NICHOLSON AC, 1995, ARTERIOSCL THROM VAS, V15, P269, DOI 10.1161/01.ATV.15.2.269; NOZAKI S, 1995, J CLIN INVEST, V96, P1859, DOI 10.1172/JCI118231; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; Pelkmans L, 2002, SCIENCE, V296, P535, DOI 10.1126/science.1069784; Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539; Razani B, 2002, PHARMACOL REV, V54, P431, DOI 10.1124/pr.54.3.431; Razani B, 2001, J BIOL CHEM, V276, P38121; REN Y, 1995, J EXP MED, V181, P1857, DOI 10.1084/jem.181.5.1857; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Sabharanjak S, 2002, DEV CELL, V2, P411, DOI 10.1016/S1534-5807(02)00145-4; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; Schubert W, 2001, J BIOL CHEM, V276, P48619, DOI 10.1074/jbc.C100613200; SILVERSTEIN RL, 1989, J CLIN INVEST, V84, P546, DOI 10.1172/JCI114197; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Souto RP, 2003, J BIOL CHEM, V278, P18321, DOI 10.1074/jbc.M211541200; TANDON NN, 1989, J BIOL CHEM, V264, P7570; Tao NB, 1996, J BIOL CHEM, V271, P22315, DOI 10.1074/jbc.271.37.22315; Thorne RF, 2000, J BIOL CHEM, V275, P35264, DOI 10.1074/jbc.M003969200	52	94	96	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45931	45936		10.1074/jbc.M307722200	http://dx.doi.org/10.1074/jbc.M307722200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12947091	hybrid			2022-12-25	WOS:000186452300106
J	Joaquin, M; Watson, RJ				Joaquin, M; Watson, RJ			The cell cycle-regulated B-Myb transcription factor overcomes cyclin-dependent kinase inhibitory activity of p57(KIP2) by interacting with its cyclin-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MYB; S PHASE; A-MYB; PHOSPHORYLATION; EXPRESSION; PROLIFERATION; PROTEIN; GENE; DIFFERENTIATION; ACTIVATION	The cell cycle-regulated B-Myb transcription factor is required for early embryonic development and is implicated in regulating cell growth and differentiation. In addition to its transcriptional regulatory properties, recent data indicate that B-Myb can release active cyclin/ Cdk2 activity from the retinoblastoma-related p107 protein by directly interacting with the p107 N terminus. As this p107 domain has homology to the cyclin-binding domains of the p21(Waf1/Cip1) family of cyclin-dependent kinase inhibitors (CKIs), we investigated in this study whether B-Myb could also interact with these CKIs. No in vivo interaction was found with either p21(Waf1/Cip1) or p27(KIP1), however, binding to p57(KIP2) was readily detectable in both in vivo and in vitro assays. The B-Myb-interacting region of p57(KIP2) mapped to the cyclin-binding domain. Consistent with this, B-Myb competed with cyclin A2 for binding to p57(KIP2), resulting in release of active cyclin/ Cdk2 kinase. Moreover, B-Myb partially overcame the ability of p57(KIP2) to induce G(1) arrest in Saos-2 cells. Despite similarities with previous p107 studies, the B-Myb domains required for interaction with p57(KIP2) were quite different from those implicated for p107. Thus, it is evident that B-Myb may promote cell proliferation by a non-transcriptional mechanism that involves release of active cyclin/ Cdk2 from p57(KIP2) as well as p107.	Univ London Imperial Coll Sci Technol & Med, Ludwig Inst Canc Res, London W2 1PG, England; Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Virol, London W2 1PG, England	Imperial College London; Ludwig Institute for Cancer Research; Imperial College London	Watson, RJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Ludwig Inst Canc Res, Norfolk Pl, London W2 1PG, England.		Joaquin, Manel/E-2216-2015; Joaquin, Manel/O-6533-2019	Joaquin, Manel/0000-0001-8973-5916; Joaquin, Manel/0000-0001-8973-5916				Ansieau S, 1997, J MOL MED-JMM, V75, P815, DOI 10.1007/s001090050170; ARSURA M, 1992, BLOOD, V79, P2708; Bartsch O, 1999, EUR J BIOCHEM, V260, P384, DOI 10.1046/j.1432-1327.1999.00191.x; Beall EL, 2002, NATURE, V420, P833, DOI 10.1038/nature01228; Bessa M, 2001, BLOOD CELL MOL DIS, V27, P416, DOI 10.1006/bcmd.2001.0399; Bessa M, 2001, ONCOGENE, V20, P3376, DOI 10.1038/sj.onc.1204439; Bies J, 1996, ONCOGENE, V12, P355; Castano E, 1998, MOL CELL BIOL, V18, P5380, DOI 10.1128/MCB.18.9.5380; Engelhard A, 2000, EXP CELL RES, V254, P153, DOI 10.1006/excr.1999.4742; Golay J, 1997, CELL GROWTH DIFFER, V8, P1305; Hashimoto Y, 1998, J BIOL CHEM, V273, P16544, DOI 10.1074/jbc.273.26.16544; Iolascon A, 1998, HAEMATOLOGICA, V83, P771; Iwai N, 2001, ONCOGENE, V20, P1425, DOI 10.1038/sj.onc.1204236; Joaquin M, 2002, ONCOGENE, V21, P7923, DOI 10.1038/sj.onc.1206001; Johnson LR, 2002, J BIOL CHEM, V277, P4088, DOI 10.1074/jbc.M105112200; Johnson TK, 1999, J BIOL CHEM, V274, P36741, DOI 10.1074/jbc.274.51.36741; Kikuchi J, 2003, MOL BIOTECHNOL, V23, P203, DOI 10.1385/MB:23:3:203; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; RASCHELLA G, 1995, J BIOL CHEM, V270, P8540, DOI 10.1074/jbc.270.15.8540; Reynaud EG, 2000, J BIOL CHEM, V275, P18767, DOI 10.1074/jbc.M907412199; Robinson C, 1996, ONCOGENE, V12, P1855; Rushton JJ, 2003, ONCOGENE, V22, P308, DOI 10.1038/sj.onc.1206131; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; Sala A, 1996, J BIOL CHEM, V271, P9363, DOI 10.1074/jbc.271.16.9363; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Santilli G, 2001, ONCOGENE, V20, P8167, DOI 10.1038/sj.onc.1204943; Saville MK, 1998, ONCOGENE, V17, P2679, DOI 10.1038/sj.onc.1202503; Sitzmann J, 1996, ONCOGENE, V12, P1889; Tanaka Y, 1999, J BIOL CHEM, V274, P28067, DOI 10.1074/jbc.274.40.28067; Toscani A, 1997, NATURE, V386, P713, DOI 10.1038/386713a0; Watanabe H, 1998, P NATL ACAD SCI USA, V95, P1392, DOI 10.1073/pnas.95.4.1392; Yan Y, 1997, GENE DEV, V11, P973, DOI 10.1101/gad.11.8.973; Zhang PM, 1997, NATURE, V387, P151, DOI 10.1038/387151a0; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7	39	25	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44255	44264		10.1074/jbc.M308953200	http://dx.doi.org/10.1074/jbc.M308953200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12947099	hybrid			2022-12-25	WOS:000186306700046
J	Mendez, CF; Leibiger, IB; Leibiger, B; Hoy, M; Gromada, J; Berggren, PO; Bertorello, AM				Mendez, CF; Leibiger, IB; Leibiger, B; Hoy, M; Gromada, J; Berggren, PO; Bertorello, AM			Rapid association of protein kinase C-epsilon with insulin granules is essential for insulin exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; SIGNAL-TRANSDUCTION; GLUCOSE; TRANSLOCATION; LOCALIZATION; SECRETION; ISLETS; TRANSCRIPTION; STIMULATION; ACTIVATION	Glucose-dependent exocytosis of insulin requires activation of protein kinase C (PKC). However, because of the great variety of isoforms and their ubiquitous distribution within the beta-cell, it is difficult to predict the importance of a particular isoform and its mode of action. Previous data revealed that two PKC isoforms (alpha and epsilon) translocate to membranes in response to glucose (Zaitzev, S.V., Efendic, S., Arkhammar, P., Bertorello, A.M., and Berggren, P. O. (1995) Proc. Natl. Acad. Sci. U.S.A. 92, 9712-9716). Using confocal microscopy, we have now established that in response to glucose, PKC-epsilon but not PKC-alpha associates with insulin granules and that green fluorescent protein-tagged PKC-epsilon changes its distribution within the cell periphery upon stimulation of beta-cells with glucose. Definite evidence of PKC-epsilon requirement during insulin granule exocytosis was obtained by using a dominant negative mutant of this isoform. The presence of this mutant abolished glucose-induced insulin secretion, whereas transient expression of the wildtype PKC-epsilon led to a significant increase in insulin exocytosis. These results suggest that association of PKC-epsilon with insulin granule membranes represents an important component of the secretory network because it is essential for insulin exocytosis in response to glucose.	Karolinska Hosp, Karolinska Inst, Dept Mol Med, Rolf Luft Ctr Diabet Res, SE-17176 Stockholm, Sweden; Univ Buenos Aires, Fac Med, Dept Bioquim Humana, Buenos Aires, DF, Argentina; Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark	Karolinska Institutet; Karolinska University Hospital; University of Buenos Aires; Novo Nordisk	Berggren, PO (corresponding author), Karolinska Hosp, Karolinska Inst, Dept Mol Med, Rolf Luft Ctr Diabet Res, SE-17176 Stockholm, Sweden.			Mendez, Carlos Fernando/0000-0002-9659-1866; Berggren, Per-Olof/0000-0001-8991-413X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058508] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-58508] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Deeney JT, 2000, J BIOL CHEM, V275, P9363, DOI 10.1074/jbc.275.13.9363; Eliasson L, 1996, SCIENCE, V271, P813, DOI 10.1126/science.271.5250.813; GANESAN S, 1992, J CELL BIOL, V119, P313, DOI 10.1083/jcb.119.2.313; GANESAN S, 1990, P NATL ACAD SCI USA, V87, P9893, DOI 10.1073/pnas.87.24.9893; Jones PM, 1998, ENDOCR REV, V19, P429, DOI 10.1210/er.19.4.429; Keller P, 2001, NAT CELL BIOL, V3, P140, DOI 10.1038/35055042; Leibiger B, 1998, P NATL ACAD SCI USA, V95, P9307, DOI 10.1073/pnas.95.16.9307; LERNMARK A, 1974, DIABETOLOGIA, V10, P431, DOI 10.1007/BF01221634; MARTELL AE, 1971, CRITICAL STABILITY C, V2; MARTELL AE, 1971, CRITICAL STABILITY C, V1; Matschinsky FM, 1996, DIABETES, V45, P223, DOI 10.2337/diabetes.45.2.223; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; Moede T, 1999, FEBS LETT, V461, P229, DOI 10.1016/S0014-5793(99)01446-5; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; NILSSON T, 1987, BIOCHEM J, V248, P329, DOI 10.1042/bj2480329; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Pinton P, 2002, J BIOL CHEM, V277, P37702, DOI 10.1074/jbc.M204478200; Soh JW, 1999, MOL CELL BIOL, V19, P1313; Vaaraniemi J, 1999, J CELL PHYSIOL, V181, P83, DOI 10.1002/(SICI)1097-4652(199910)181:1<83::AID-JCP9>3.0.CO;2-G; Yedovitzky M, 1997, J BIOL CHEM, V272, P1417, DOI 10.1074/jbc.272.3.1417; ZAITSEV SV, 1995, P NATL ACAD SCI USA, V92, P9712, DOI 10.1073/pnas.92.21.9712	21	57	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44753	44757		10.1074/jbc.M308664200	http://dx.doi.org/10.1074/jbc.M308664200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12941947	hybrid			2022-12-25	WOS:000186306700109
J	Strutz-Seebohm, N; Werner, M; Madsen, DM; Seebohm, G; Zheng, Y; Walker, CS; Maricq, AV; Hollmann, M				Strutz-Seebohm, N; Werner, M; Madsen, DM; Seebohm, G; Zheng, Y; Walker, CS; Maricq, AV; Hollmann, M			Functional analysis of Caenorhabditis elegans glutamate receptor subunits by domain transplantation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAINATE-BINDING-PROTEINS; CENTRAL-NERVOUS-SYSTEM; POINT MUTATION; ION CHANNELS; K+ CHANNELS; INWARD RECTIFICATION; CALCIUM PERMEABILITY; CONDUCTION PATHWAYS; N-GLYCOSYLATION; AMPA	Glutamate receptors are not only abundant and important mediators of fast excitatory synaptic transmission in vertebrates, but they also serve a similar function in invertebrates such as Drosophila and the nematode Caenorhabditis elegans. In C. elegans, an animal with only 302 neurons, 10 different glutamate receptor subunits have been identified and cloned. To study the ion channel properties of these receptor subunits, we recorded glutamate-gated currents from Xenopus oocytes that expressed either C. elegans glutamate receptor subunits or chimeric rat/C. elegans glutamate receptor subunits. The chimeras were constructed between the C. elegans glutamate receptor pore domains and either the rat kainate receptor subunit GluR6, the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate ( AMPA) receptor subunit GluR1, or the N-methyl-D-aspartate ( NMDA) receptor subunit NMDAR1-1a. Although native subunits were nonfunctional, 9 of 10 ion pores were found to conduct current upon transplantation into rat receptor subunits. A provisional classification of the C. elegans glutamate receptor subunits was attempted based on functionality of the chimeras. C. elegans glutamate receptor ion pores, at a position homologous to a highly conserved site critical for ion permeation properties in vertebrate glutamate receptor pores, contain amino acids not found in vertebrate glutamate receptors. We show that the pore-constricting Q/R site, which in vertebrate receptors determines calcium permeability and rectification properties of the ion channel, in C. elegans can be occupied by other amino acids, including, surprisingly, lysine and proline, without loss of these properties.	Ruhr Univ Bochum, Dept Biochem 1, D-44780 Bochum, Germany; Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA; Univ Utah, Dept Physiol, Salt Lake City, UT 84112 USA; Univ Utah, Eccles Program Human Mol Biol & Genet, Salt Lake City, UT 84112 USA	Ruhr University Bochum; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Hollmann, M (corresponding author), Ruhr Univ Bochum, Dept Biochem 1, Bldg NC,Level 6,Rm 170, D-44780 Bochum, Germany.			Hollmann, Michael/0000-0001-8000-7787	NINDS NIH HHS [NS 35812] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035812] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Armstrong N, 1998, NATURE, V395, P913, DOI 10.1038/27692; Bahring R, 1997, J PHYSIOL-LONDON, V502, P575, DOI 10.1111/j.1469-7793.1997.575bj.x; BOWIE D, 1995, NEURON, V15, P453, DOI 10.1016/0896-6273(95)90049-7; Brockie PJ, 2001, NEURON, V31, P617, DOI 10.1016/S0896-6273(01)00394-4; Brockie PJ, 2001, J NEUROSCI, V21, P1510, DOI 10.1523/JNEUROSCI.21-05-01510.2001; BURNASHEV N, 1992, NEURON, V8, P189, DOI 10.1016/0896-6273(92)90120-3; Burnashev N, 1996, J PHYSIOL-LONDON, V496, P165, DOI 10.1113/jphysiol.1996.sp021674; Chen GQ, 1999, NATURE, V402, P817, DOI 10.1038/45568; CURUTCHET P, 1992, BIOCHEM BIOPH RES CO, V182, P1089, DOI 10.1016/0006-291X(92)91843-F; DINGLEDINE R, 1992, J NEUROSCI, V12, P4080; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Everts I, 1997, MOL PHARMACOL, V52, P861, DOI 10.1124/mol.52.5.861; Greger IH, 2002, NEURON, V34, P759, DOI 10.1016/S0896-6273(02)00693-1; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HART AC, 1995, NATURE, V378, P82, DOI 10.1038/378082a0; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; Higuchi M, 2000, NATURE, V406, P78, DOI 10.1038/35017558; HOLLMANN M, 1994, NEURON, V13, P1331, DOI 10.1016/0896-6273(94)90419-7; Hollmann M., 1999, V141, P3; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; Kuner T, 2003, TRENDS NEUROSCI, V26, P27, DOI 10.1016/S0166-2236(02)00010-3; KUNER T, 1999, HDB EXPT PHARM IONON, P219; Lerma J, 2001, PHYSIOL REV, V81, P971, DOI 10.1152/physrev.2001.81.3.971; Littleton JT, 2000, NEURON, V26, P35, DOI 10.1016/S0896-6273(00)81135-6; Lu Z, 2001, NATURE, V413, P809, DOI 10.1038/35101535; MACKINNON R, 1995, NEURON, V14, P889, DOI 10.1016/0896-6273(95)90327-5; MARICQ AV, 1995, NATURE, V378, P78, DOI 10.1038/378078a0; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; Mellem JE, 2002, NEURON, V36, P933, DOI 10.1016/S0896-6273(02)01088-7; MILEDI R, 1984, J PHYSIOL-LONDON, V357, P173, DOI 10.1113/jphysiol.1984.sp015495; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; Panchenko VA, 1999, J PHYSIOL-LONDON, V520, P337, DOI 10.1111/j.1469-7793.1999.t01-1-00337.x; Panchenko VA, 2001, J GEN PHYSIOL, V117, P345, DOI 10.1085/jgp.117.4.345; PARTIN KM, 1993, NEURON, V11, P1069, DOI 10.1016/0896-6273(93)90220-L; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; Soto F, 1996, P NATL ACAD SCI USA, V93, P3684, DOI 10.1073/pnas.93.8.3684; Sprengel R, 2001, TRENDS PHARMACOL SCI, V22, P7, DOI 10.1016/S0165-6147(00)01588-1; Stern-Bach Y, 1998, NEURON, V21, P907, DOI 10.1016/S0896-6273(00)80605-4; Strutz N, 2002, J BIOL CHEM, V277, P48035, DOI 10.1074/jbc.M209647200; Tikhonov DB, 2002, BIOPHYS J, V82, P1884, DOI 10.1016/S0006-3495(02)75538-0; ULTSCH A, 1992, P NATL ACAD SCI USA, V89, P10484, DOI 10.1073/pnas.89.21.10484; Villmann C, 1997, J NEUROSCI, V17, P7634, DOI 10.1523/jneurosci.17-20-07634.1997; Villmann C, 1999, EUR J NEUROSCI, V11, P1765, DOI 10.1046/j.1460-9568.1999.00594.x; WO ZG, 1995, TRENDS NEUROSCI, V18, P161; WOOD MW, 1995, P NATL ACAD SCI USA, V92, P4882, DOI 10.1073/pnas.92.11.4882	46	13	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44691	44701		10.1074/jbc.M305497200	http://dx.doi.org/10.1074/jbc.M305497200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12930835	hybrid			2022-12-25	WOS:000186306700102
J	Arnold, SM; Kaufman, RJ				Arnold, SM; Kaufman, RJ			The noncatalytic portion of human UDP-glucose : glycoprotein glucosyltransferase I confers UDP-glucose binding and transferase function to the catalytic domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MISFOLDED GLYCOPROTEINS; ENDOPLASMIC-RETICULUM; MOLECULAR CHAPERONE; CALNEXIN; CALRETICULIN; OLIGOSACCHARIDE; RECOGNITION; ACCEPTOR; ANALOGS; ERP57	The eukaryotic cell monitors the fidelity of protein folding in the endoplasmic reticulum and only permits properly folded and/or assembled proteins to transit to the Golgi compartment in a process termed "quality control." An endoplasmic reticulum (ER) lumenal sensor for quality control is the UDP-glucose: glycoprotein glucosyltransferase that targets unfolded glycoproteins for transient, calcium-dependent glucosylation. This modification mediates glycoprotein interaction with the folding machinery comprised of calnexin or calreticulin in conjunction with ERp57. Two human UGT homologues, HUGT1 and HUGT2, exist that share 55% identity. The highest degree of identity resides in the COOH-terminal 20% of these proteins, the putative catalytic domain of HUGT1. However, only HUGT1 displays the expected functional activity. The contribution of the NH2-terminal remainder of HUGT1 to glucosyltransferase function is presently unknown. In this report we demonstrate that HUGT2 is localized to the ER in a manner that overlaps the distribution of HUGT1. Analysis of a series of HUGT1 and HUGT2 chimeric proteins demonstrated that the carboxyl-terminal region of HUGT2 contains a catalytic domain that is functional in place of the analogous portion of HUGT1. Whereas neither catalytic domain displayed detectable activity when expressed alone, co-expression of either catalytic domain with the noncatalytic amino-terminal portion of HUGT1 conferred UDP-Glc binding and transfer of glucose that was specific for unfolded glycoprotein substrates. The results indicate that the amino-terminal 80% of HUGT1 is required for activation of the catalytic domain, whereas the homologous portion of HUGT2 cannot provide this function.	Univ Michigan, Med Ctr, Sch Med, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Kaufman, RJ (corresponding author), Univ Michigan, Med Ctr, Sch Med, Howard Hughes Med Inst, 4570 MSRB 2,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.				NHLBI NIH HHS [P01 HL57346] Funding Source: Medline; NIGMS NIH HHS [GM07767] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057346] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arnold SM, 2000, BIOCHEMISTRY-US, V39, P2149, DOI 10.1021/bi9916473; Campbell JA, 1997, BIOCHEM J, V326, P929, DOI 10.1042/bj3260929u; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Guerin M, 2003, J BIOL CHEM, V278, P20540, DOI 10.1074/jbc.M300891200; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; Hosokawa N, 2001, EMBO REP, V2, P415, DOI 10.1093/embo-reports/kve084; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Molinari M, 2003, SCIENCE, V299, P1397, DOI 10.1126/science.1079474; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Oda Y, 2003, SCIENCE, V299, P1394, DOI 10.1126/science.1079181; Oliver JD, 1997, SCIENCE, V275, P86, DOI 10.1126/science.275.5296.86; Persson K, 2001, NAT STRUCT BIOL, V8, P166, DOI 10.1038/84168; RADOMINSKA A, 1994, METHOD ENZYMOL, V230, P330; SOUSA M, 1995, EMBO J, V14, P4196, DOI 10.1002/j.1460-2075.1995.tb00093.x; Spiro RG, 1996, J BIOL CHEM, V271, P11588, DOI 10.1074/jbc.271.19.11588; Tessier DC, 2000, GLYCOBIOLOGY, V10, P403, DOI 10.1093/glycob/10.4.403; Trombetta ES, 2000, J CELL BIOL, V148, P1123, DOI 10.1083/jcb.148.6.1123; TROMBETTA SE, 1992, J BIOL CHEM, V267, P9236; WADA I, 1995, J BIOL CHEM, V270, P20298, DOI 10.1074/jbc.270.35.20298; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; Yoshida H, 2003, DEV CELL, V4, P265, DOI 10.1016/S1534-5807(03)00022-4; Zapun A, 1998, J BIOL CHEM, V273, P6009, DOI 10.1074/jbc.273.11.6009	22	48	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43320	43328		10.1074/jbc.M305800200	http://dx.doi.org/10.1074/jbc.M305800200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12913004	hybrid			2022-12-25	WOS:000186157000075
J	Dominguez, JE; Munoz, MC; Zafra, D; Sanchez-Perez, I; Baque, S; Caron, M; Mercurio, C; Barbera, A; Perona, R; Gomis, R; Guinovart, JJ				Dominguez, JE; Munoz, MC; Zafra, D; Sanchez-Perez, I; Baque, S; Caron, M; Mercurio, C; Barbera, A; Perona, R; Gomis, R; Guinovart, JJ			The antidiabetic agent sodium tungstate activates glycogen synthesis through an insulin receptor-independent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED DIABETIC RATS; PROTEIN-KINASE-B; P70 S6 KINASE; SYNTHASE KINASE-3; SKELETAL-MUSCLE; MAP KINASE; GROWTH-FACTOR; PHOSPHATASE; INHIBITION; PHOSPHORYLATION	Sodium tungstate is a powerful antidiabetic agent when administered orally. In primary cultured hepatocytes, tungstate showed insulin-like actions, which led to an increase in glycogen synthesis and accumulation. However, this compound did not significantly alter the insulin receptor activation state or dephosphorylation rate in cultured cells (CHO-R) or in primary hepatocytes, in either short or long term treatments. In contrast, at low concentrations, tungstate induced a transient strong activation of extracellular signal-regulated kinases 1 and 2 (ERK1/2) after 5 - 10 min of treatment, in a similar way to insulin. Moreover, this compound did not significantly delay or inhibit the dephosphorylation of ERK1/2. ERK1/2 activation triggered a cascade of downstream events, which included the phosphorylation of p90rsk and glycogen synthase-kinase 3beta. Experiments with a specific inhibitor of ERK1/2 activation and kinase assays indicate that these proteins were directly involved in the stimulation of glycogen synthase and glycogen synthesis induced by tungstate without a direct involvement of protein kinase B (PKB/Akt). These results show a direct involvement of ERK1/2 in the mechanism of action of tungstate at the hepatic level.	IRBB, E-08028 Barcelona, Spain; Biomed Res Inst Alberto Sols, E-28029 Madrid, Spain; Univ Barcelona, Dept Biochem & Mol Biol, E-08028 Barcelona, Spain; INSERM, U402, Fac Med St Antoine, F-75571 Paris 12, France; European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; Hosp Clin Barcelona, Endocrinol & Diabet Unit, E-08036 Barcelona, Spain; Inst Invest Biomed August Pi & Sunyer, E-08036 Barcelona, Spain	Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); University of Barcelona; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; IRCCS European Institute of Oncology (IEO); University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Guinovart, JJ (corresponding author), IRBB, Barcelona Sci Pk,Josep Samitier 1-5, E-08028 Barcelona, Spain.	guinovart@pcb.ub.es	Sánchez-Pérez, Isabel/R-4107-2016	Sánchez-Pérez, Isabel/0000-0002-4829-201X; Zafra, Delia/0000-0003-4143-0659; Mercurio, Ciro/0000-0001-6240-4607; Barbera, Albert/0000-0003-4080-3572				AMMERMAN C, 1980, MINERAL TOLERANCE DO, P515; BARBERA A, 1994, J BIOL CHEM, V269, P20047; Barbera A, 1997, DIABETOLOGIA, V40, P143, DOI 10.1007/s001250050655; Barbera A, 2001, DIABETOLOGIA, V44, P507, DOI 10.1007/s001250100479; Barthel A, 1998, BIOCHEM BIOPH RES CO, V243, P509, DOI 10.1006/bbrc.1998.8134; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; CHAN TM, 1976, ANAL BIOCHEM, V71, P96, DOI 10.1016/0003-2697(76)90014-2; CHANG PY, 1995, J BIOL CHEM, V270, P29928; Cohen P, 1978, Biochem Soc Symp, P69; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; CRANS DC, 1992, BIOCHEMISTRY-US, V31, P11731, DOI 10.1021/bi00162a009; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Domingo JL, 2002, BIOL TRACE ELEM RES, V88, P97, DOI 10.1385/BTER:88:2:097; Dufresne SD, 2001, MOL CELL BIOL, V21, P81, DOI 10.1128/MCB.21.1.81-87.2001; ELDARFINKELMAN H, 1995, J BIOL CHEM, V270, P987, DOI 10.1074/jbc.270.3.987; Foster JD, 1998, ARCH BIOCHEM BIOPHYS, V354, P125, DOI 10.1006/abbi.1998.0695; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Giron MD, 2003, FEBS LETT, V542, P84, DOI 10.1016/S0014-5793(03)00352-1; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; Le Lamer S, 2002, PHARMACOL TOXICOL, V90, P100, DOI 10.1034/j.1600-0773.2002.900208.x; Lee JY, 2001, NAT STRUCT BIOL, V8, P789, DOI 10.1038/nsb0901-789; LI JP, 1995, BIOCHEMISTRY-US, V34, P6218, DOI 10.1021/bi00018a026; Lin Tai-An, 1994, Journal of Biological Chemistry, V269, P21255; MASSAGUE J, 1977, FEBS LETT, V82, P317, DOI 10.1016/0014-5793(77)80610-8; MOLLER DE, 1994, AM J PHYSIOL, V266, pC351, DOI 10.1152/ajpcell.1994.266.2.C351; Muda M, 1996, J BIOL CHEM, V271, P4319; Munoz MC, 2001, DIABETES, V50, P131, DOI 10.2337/diabetes.50.1.131; Palanivel R, 1998, MED SCI RES, V26, P541; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Reiter NJ, 2002, BIOCHEMISTRY-US, V41, P1051, DOI 10.1021/bi011577b; REYNET C, 1990, MOL ENDOCRINOL, V4, P304, DOI 10.1210/mend-4-2-304; Rodriguez-Gallardo J, 2000, EUR J PHARMACOL, V402, P199, DOI 10.1016/S0014-2999(00)00492-1; Sanchez-Perez I, 2000, ONCOGENE, V19, P5142, DOI 10.1038/sj.onc.1203887; Shaw M, 1999, FEBS LETT, V461, P120, DOI 10.1016/S0014-5793(99)01434-9; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; STANKIEWICZ PJ, 1988, BIOCHEMISTRY-US, V27, P206, DOI 10.1021/bi00401a031; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUTHERLAND C, 1994, FEBS LETT, V338, P37, DOI 10.1016/0014-5793(94)80112-6; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; VANETTEN RL, 1974, J AM CHEM SOC, V96, P6782, DOI 10.1021/ja00828a053; WELSH GI, 1993, BIOCHEM J, V294, P625, DOI 10.1042/bj2940625; Welsh GI, 1998, FEBS LETT, V421, P125, DOI 10.1016/S0014-5793(97)01548-2	44	37	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42785	42794		10.1074/jbc.M308334200	http://dx.doi.org/10.1074/jbc.M308334200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12925525	hybrid			2022-12-25	WOS:000186157000009
J	Khanna, S; Roy, S; Ryu, H; Bahadduri, P; Swaan, PW; Ratan, RR; Sen, CK				Khanna, S; Roy, S; Ryu, H; Bahadduri, P; Swaan, PW; Ratan, RR; Sen, CK			Molecular basis of vitamin E action - Tocotrienol modulates 12-lipoxygenase, a key mediator of glutamate-induced neurodegeneration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; OXIDATIVE STRESS; ALPHA-TOCOPHEROL; ARACHIDONATE 12-LIPOXYGENASE; GLUTATHIONE METABOLISM; SOYBEAN LIPOXYGENASE; NEURONAL CELLS; CYSTINE UPTAKE; CANINE BRAIN; GLIAL-CELLS	Vitamin E is a generic term for tocopherols and tocotrienols. This work is based on our striking evidence that, in neuronal cells, nanomolar concentrations of alpha-tocotrienol, but not alpha-tocopherol, block glutamate-induced death by suppressing early activation of c-Src kinase (Sen, C. K., Khanna, S., Roy, S., and Packer, L. (2000) J. Biol. Chem. 275, 13049 - 13055). This study on HT4 and immature primary cortical neurons suggests a central role of 12-lipoxygenase (12-LOX) in executing glutamate-induced neurodegeneration. BL15, an inhibitor of 12-LOX, prevented glutamate-induced neurotoxicity. Moreover, neurons isolated from 12-LOX-deficient mice were observed to be resistant to glutamate-induced death. In the presence of nanomolar alpha-tocotrienol, neurons were resistant to glutamate-, homocysteine, and L-buthionine sulfoximine-induced toxicity. Long-term time-lapse imaging studies revealed that neurons and their axo-dendritic network are fairly motile under standard culture conditions. Such motility was arrested in response to glutamate challenge. Tocotrienol-treated primary neurons maintained healthy growth and motility even in the presence of excess glutamate. The study of 12-LOX activity and metabolism revealed that this key mediator of glutamate- induced neurodegeneration is subject to control by the nutrient alpha-tocotrienol. In silico docking studies indicated that alpha-tocotrienol may hinder the access of arachidonic acid to the catalytic site of 12-LOX by binding to the opening of a solvent cavity close to the active site. These findings lend further support to alpha-tocotrienol as a potent neuroprotective form of vitamin E.	Ohio State Univ, Med Ctr, Dorothy M Davis Heart & Lung Res Inst 512, Bioinformat & Computat Biol Core Lab, Columbus, OH 43210 USA; Ohio State Univ, Med Ctr, Dept Surg, Mol Med Lab, Columbus, OH 43210 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Sen, CK (corresponding author), Ohio State Univ, Med Ctr, Dorothy M Davis Heart & Lung Res Inst 512, Bioinformat & Computat Biol Core Lab, 473 W 12th Ave, Columbus, OH 43210 USA.	sen-1@medctr.osu.edu	Sen, Chandan K/A-8762-2013; Khanna, Savita/E-3378-2011	Ryu, Hoon/0000-0001-6544-3732; Swaan, Peter/0000-0003-1767-1487	NINDS NIH HHS [R01 NS042617] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042617] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AZZI A, 1995, AM J CLIN NUTR, V62, P1337, DOI 10.1093/ajcn/62.6.1337S; Bains JS, 1997, BRAIN RES REV, V25, P335, DOI 10.1016/S0165-0173(97)00045-3; BASHAN N, 1992, AM J PHYSIOL, V262, pC682, DOI 10.1152/ajpcell.1992.262.3.C682; BERNSTEIN FC, 1977, EUR J BIOCHEM, V80, P319, DOI 10.1111/j.1432-1033.1977.tb11885.x; Borngraber S, 1999, J BIOL CHEM, V274, P37345, DOI 10.1074/jbc.274.52.37345; BOSCOBOINIK DO, 1994, BBA-MOL CELL RES, V1224, P418, DOI 10.1016/0167-4889(94)90277-1; Brigelius-Flohe R, 1999, FASEB J, V13, P1145, DOI 10.1096/fasebj.13.10.1145; BRUGGE JS, 1985, NATURE, V316, P554, DOI 10.1038/316554a0; CHOI DW, 1990, CEREBROVAS BRAIN MET, V2, P105; Dargusch R, 2002, J NEUROCHEM, V81, P1394, DOI 10.1046/j.1471-4159.2002.00950.x; Dringen R, 2000, EUR J BIOCHEM, V267, P4912, DOI 10.1046/j.1432-1327.2000.01597.x; Eberhard J, 2000, ANAL BIOCHEM, V280, P258, DOI 10.1006/abio.2000.4540; Froissard P, 1997, EUR J PHARMACOL, V326, P93, DOI 10.1016/S0014-2999(97)00155-6; Gillmor SA, 1997, NAT STRUCT BIOL, V4, P1003, DOI 10.1038/nsb1297-1003; Goodsell DS, 1996, J MOL RECOGNIT, V9, P1, DOI 10.1002/(SICI)1099-1352(199601)9:1<1::AID-JMR241>3.0.CO;2-6; GROSSMAN S, 1984, INT J BIOCHEM, V16, P281, DOI 10.1016/0020-711X(84)90101-0; HAGMANN W, 1993, PROSTAGLANDINS, V46, P471, DOI 10.1016/0090-6980(93)90066-G; Han D, 1997, BIOFACTORS, V6, P321, DOI 10.1002/biof.5520060303; Han D, 1997, AM J PHYSIOL-REG I, V273, pR1771, DOI 10.1152/ajpregu.1997.273.5.R1771; KATO S, 1992, NEUROSCIENCE, V48, P903, DOI 10.1016/0306-4522(92)90278-A; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lepley RA, 1996, J BIOL CHEM, V271, P6179, DOI 10.1074/jbc.271.11.6179; Li YH, 1997, NEURON, V19, P453, DOI 10.1016/S0896-6273(00)80953-8; Minor W, 1996, BIOCHEMISTRY-US, V35, P10687, DOI 10.1021/bi960576u; MORRIS GM, 2001, AUTODOCK REFERENCE M; MULLER DPR, 1989, ANN NY ACAD SCI, V570, P146; MULLER DPR, 1990, CRIT REV NEUROBIOL, V5, P239; MURPHY TH, 1990, FASEB J, V4, P1624, DOI 10.1096/fasebj.4.6.2180770; NISHIYAMA M, 1993, J HISTOCHEM CYTOCHEM, V41, P111, DOI 10.1177/41.1.8417106; NISHIYAMA M, 1992, J NEUROCHEM, V58, P1395, DOI 10.1111/j.1471-4159.1992.tb11355.x; O'Byrne D, 2000, FREE RADICAL BIO MED, V29, P834, DOI 10.1016/S0891-5849(00)00371-3; OKA A, 1993, J NEUROSCI, V13, P1441; Paul R, 2001, NAT MED, V7, P222, DOI 10.1038/84675; PEARCE BC, 1994, J MED CHEM, V37, P526, DOI 10.1021/jm00030a012; PEARCE BC, 1992, J MED CHEM, V35, P3595, DOI 10.1021/jm00098a002; Pereira CMF, 1997, FREE RADICAL BIO MED, V23, P637, DOI 10.1016/S0891-5849(97)00020-8; REDDANNA P, 1985, FEBS LETT, V193, P39, DOI 10.1016/0014-5793(85)80075-2; Roy S, 2002, METHOD ENZYMOL, V352, P326; Sagara Y, 2002, J BIOL CHEM, V277, P36204, DOI 10.1074/jbc.M203895200; Schubert D, 2001, J NEUROSCI, V21, P7455, DOI 10.1523/JNEUROSCI.21-19-07455.2001; Schulz JB, 2000, EUR J BIOCHEM, V267, P4904, DOI 10.1046/j.1432-1327.2000.01595.x; Sen CK, 2000, J BIOL CHEM, V275, P13049, DOI 10.1074/jbc.275.17.13049; Sen CK, 2002, J BIOL CHEM, V277, P33284, DOI 10.1074/jbc.M203391200; SERBINOVA EA, 1994, METHOD ENZYMOL, V234, P354; SUARNA C, 1993, BIOCHIM BIOPHYS ACTA, V1166, P163, DOI 10.1016/0005-2760(93)90092-N; SUZUKI Y, 1993, BIOCHEMISTRY-US, V32, P10692, DOI 10.1021/bi00091a020; Tan Shirlee, 2001, Current Topics in Medicinal Chemistry, V1, P497, DOI 10.2174/1568026013394741; Tan SL, 1998, J CELL BIOL, V141, P1423, DOI 10.1083/jcb.141.6.1423; Tirosh O, 2000, NEUROSCIENCE, V97, P531, DOI 10.1016/S0306-4522(00)00028-2; TOMEO AC, 1995, LIPIDS, V30, P1179, DOI 10.1007/BF02536621; TRABER MG, 1995, AM J CLIN NUTR, V62, P1501; Traber MG, 1996, ANNU REV NUTR, V16, P321, DOI 10.1146/annurev.nu.16.070196.001541; YAMAMOTO S, 1992, BIOCHIM BIOPHYS ACTA, V1128, P117, DOI 10.1016/0005-2760(92)90297-9	53	221	241	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43508	43515		10.1074/jbc.M307075200	http://dx.doi.org/10.1074/jbc.M307075200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12917400	hybrid, Green Accepted			2022-12-25	WOS:000186157000096
J	Schmidt, A; Jelsch, C; Ostergaard, P; Rypniewski, W; Lamzin, VS				Schmidt, A; Jelsch, C; Ostergaard, P; Rypniewski, W; Lamzin, VS			Trypsin revisited crystallography at (sub) atomic resolution and quantum chemistry revealing details of catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BARRIER HYDROGEN-BONDS; X-RAY-STRUCTURE; DENSITY PARAMETERS; PROTEIN-STRUCTURE; DIFFRACTION DATA; WATER MOLECULE; ACYL-ENZYME; SERINE; BINDING; REFINEMENT	A series of crystal structures of trypsin, containing either an autoproteolytic cleaved peptide fragment or a covalently bound inhibitor, were determined at atomic and ultra-high resolution and subjected to ab initio quantum chemical calculations and multipole refinement. Quantum chemical calculations reproduced the observed active site crystal structure with severe deviations from standard stereochemistry and indicated the protonation state of the catalytic residues. Multipole refinement directly revealed the charge distribution in the active site and proved the validity of the ab initio calculations. The combined results confirmed the catalytic function of the active site residues and the two water molecules acting as the nucleophile and the proton donor. The crystal structures represent snapshots from the reaction pathway, close to a tetrahedral intermediate. The de-acylation of trypsin then occurs in true S(N)2 fashion.	DESY, European Mol Biol Lab, D-22607 Hamburg, Germany; Polish Acad Sci, Inst Bioorgan Chem, PL-61704 Poznan, Poland; DESY, Inst Biochem & Mol Biol, Univ Hosp, D-22603 Hamburg, Germany; UHP, Fac Sci, LCM3B CNRS, Lab Cristallog & Modelisat Mat Mineraux & Biol, F-54506 Vandoeuvre Les Nancy, France; Novozymes Prot Design, DK-2880 Bagsvaerd, Denmark	European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Polish Academy of Sciences; Institute of Bioorganic Chemistry of the Polish Academy of Sciences; Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); University of Hamburg; Universite de Lorraine; Novozymes	Schmidt, A (corresponding author), DESY, European Mol Biol Lab, D-22607 Hamburg, Germany.	andrea@embl-hamburg.de	Rypniewski, Wojciech/W-5330-2018	Rypniewski, Wojciech/0000-0002-6097-5518; jelsch, christian/0000-0002-2655-0313; Lamzin, Victor/0000-0002-6058-7793				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brandsdal BO, 2001, PROTEIN SCI, V10, P1584, DOI 10.1110/ps.940101; CLELAND WW, 1994, SCIENCE, V264, P1887, DOI 10.1126/science.8009219; Cleland WW, 1998, J BIOL CHEM, V273, P25529, DOI 10.1074/jbc.273.40.25529; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Fokine A, 2002, ACTA CRYSTALLOGR D, V58, P1387, DOI 10.1107/S0907444902010284; FREY PA, 1994, SCIENCE, V264, P1927, DOI 10.1126/science.7661899; HANSEN NK, 1978, ACTA CRYSTALLOGR A, V34, P909, DOI 10.1107/S0567739478001886; Jelsch C, 1998, ACTA CRYSTALLOGR D, V54, P1306, DOI 10.1107/S0907444998004466; Katona G, 2002, J BIOL CHEM, V277, P21962, DOI 10.1074/jbc.M200676200; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lamzin VS, 1999, J BIOL CHEM, V274, P20753, DOI 10.1074/jbc.274.30.20753; Lin J, 1998, BIOCHEMISTRY-US, V37, P11940, DOI 10.1021/bi980278s; Lu WY, 1997, J MOL BIOL, V266, P441, DOI 10.1006/jmbi.1996.0781; MARQUART M, 1983, ACTA CRYSTALLOGR B, V39, P480, DOI 10.1107/S010876818300275X; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Meijers R, 2001, J BIOL CHEM, V276, P9316, DOI 10.1074/jbc.M010870200; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otlewski J, 2001, ACTA BIOCHIM POL, V48, P419; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pal D, 2002, ANGEW CHEM INT EDIT, V41, P4663, DOI 10.1002/anie.200290009; PERONA JJ, 1993, SCIENCE, V261, P620, DOI 10.1126/science.8342029; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; PICHONPESME V, 1995, J PHYS CHEM-US, V99, P6242, DOI 10.1021/j100016a071; RYPNIEWSKI WR, 1993, PROTEIN ENG, V6, P341, DOI 10.1093/protein/6.4.341; Rypniewski WR, 2001, ACTA CRYSTALLOGR D, V57, P8, DOI 10.1107/S0907444900014116; Schiott B, 1998, P NATL ACAD SCI USA, V95, P12799, DOI 10.1073/pnas.95.22.12799; Schmidt A, 2002, CURR OPIN STRUC BIOL, V12, P698, DOI 10.1016/S0959-440X(02)00394-9; SCHMIDT MW, 1993, J COMPUT CHEM, V14, P1347, DOI 10.1002/jcc.540141112; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; SINGER PT, 1993, SCIENCE, V259, P669, DOI 10.1126/science.8430314; Talhout R, 2001, EUR J BIOCHEM, V268, P1554, DOI 10.1046/j.1432-1327.2001.01991.x; Topf M, 2002, PROTEINS, V47, P357, DOI 10.1002/prot.10097; Tronrud DE, 1997, METHOD ENZYMOL, V277, P306, DOI 10.1016/S0076-6879(97)77017-4; TSILIKOUNAS E, 1992, BIOCHEMISTRY-US, V31, P12839, DOI 10.1021/bi00166a019; WARSHEL A, 1995, SCIENCE, V269, P102, DOI 10.1126/science.7661987; Wilmouth RC, 2001, NAT STRUCT BIOL, V8, P689, DOI 10.1038/90401	37	59	60	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43357	43362		10.1074/jbc.M306944200	http://dx.doi.org/10.1074/jbc.M306944200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12937176	hybrid			2022-12-25	WOS:000186157000079
J	Shimizu, S; Ugi, S; Maegawa, H; Egawa, K; Nishio, Y; Yoshizaki, T; Shi, K; Nagai, Y; Morino, K; Nemoto, K; Nakamura, T; Bryer-Ash, M; Kashiwagi, A				Shimizu, S; Ugi, S; Maegawa, H; Egawa, K; Nishio, Y; Yoshizaki, T; Shi, K; Nagai, Y; Morino, K; Nemoto, K; Nakamura, T; Bryer-Ash, M; Kashiwagi, A			Protein-tyrosine phosphatase 1B as new activator for hepatic lipogenesis via sterol regulatory element-binding protein-1 gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN SENSITIVITY; RESISTANCE; MICE; PATHWAY; GLUCOSE; LIVERS; SP1; 2A; PHOSPHORYLATION; OVEREXPRESSION	Like hyperglycemia, postprandial (diet-induced) hypertriglyceridemia is thought to play crucial roles in the pathogenesis of insulin resistant/metabolic syndrome. Sterol regulatory element-binding protein-1 (SREBP-1) is a key transcription factor to induce postprandial hypertriglyceridemia. We found that insulin-resistant rats fed a diet high in fructose showed an increased protein-tyrosine phosphatase 1B (PTP1B) content with strong expression of SREBP-1 mRNA in the liver. To clarify the association of PTP1B with SREBP-1 gene expression, we overexpressed PTP1B in rat hepatocytes, which led to increased mRNA content and promoter activity of SREBP-1a and -1c, resulting in the increased mRNA expression of fatty-acid synthase, one of the SREBP-1-responsive lipogenic genes. Because PTP1B overexpression increased phosphatase 2A (PP2A) activity, we inhibited PP2A activity by expression of its selective inhibitor, SV40 small t antigen and found that this normalized the PTP1B-enhanced SREBP-1a and -1c mRNA expressions through activation of the Sp1 site. These results indicate that PTP1B may regulate gene expression of SREBP-1 via enhancement of PP2A activity, thus mediating hepatic lipogenesis and postprandial hypertriglyceridemia. We demonstrate here a unique serial activation of the PTP1B-PP2A axis as a novel mechanism for the regulation of gene expression in the biosynthesis of triglyceride.	Shiga Univ Med Sci, Dept Med, Div Endocrinol & Metab, Shiga 5202192, Japan; Shiga Univ Med Sci, Dept Anat, Shiga 5202192, Japan; Univ Calif Los Angeles, Dept Med, Div Endocrinol Diabet & Hypertens, Gonda Goldschmied Diabet Ctr, Los Angeles, CA 90095 USA; W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90095 USA	Shiga University of Medical Science; Shiga University of Medical Science; University of California System; University of California Los Angeles; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center	Maegawa, H (corresponding author), Shiga Univ Med Sci, Dept Med, Div Endocrinol & Metab, Shiga 5202192, Japan.		MORINO, KATSUTARO/I-3207-2019	MORINO, KATSUTARO/0000-0003-2420-3817; Maegawa, Hiroshi/0000-0002-4611-8149				Amemiya-Kudo M, 2000, J BIOL CHEM, V275, P31078, DOI 10.1074/jbc.M005353200; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; CHEN J, 1994, J BIOL CHEM, V269, P7957; Cheng A, 2002, EUR J BIOCHEM, V269, P1050, DOI 10.1046/j.0014-2956.2002.02756.x; Deng X, 2002, BIOCHEM BIOPH RES CO, V290, P256, DOI 10.1006/bbrc.2001.6148; Di Paola R, 2002, AM J HUM GENET, V70, P806, DOI 10.1086/339270; Du XL, 2000, P NATL ACAD SCI USA, V97, P12222, DOI 10.1073/pnas.97.22.12222; Egawa K, 2001, J BIOL CHEM, V276, P10207, DOI 10.1074/jbc.M009489200; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Johnson TO, 2002, NAT REV DRUG DISCOV, V1, P696, DOI 10.1038/nrd895; Kenner KA, 1996, J BIOL CHEM, V271, P19810, DOI 10.1074/jbc.271.33.19810; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; Lacroix I, 2002, J BIOL CHEM, V277, P9598, DOI 10.1074/jbc.M111444200; MAEGAWA H, 1995, J BIOL CHEM, V270, P7724, DOI 10.1074/jbc.270.13.7724; Miserez AR, 1997, GENOMICS, V40, P31, DOI 10.1006/geno.1996.4525; Nagai Y, 2002, AM J PHYSIOL-ENDOC M, V282, pE1180, DOI 10.1152/ajpendo.00471.2001; Obata T, 1998, J BIOCHEM-TOKYO, V123, P813; Rondinone CM, 2002, DIABETES, V51, P2405, DOI 10.2337/diabetes.51.8.2405; Samson SLA, 2002, J MOL ENDOCRINOL, V29, P265, DOI 10.1677/jme.0.0290265; Sekine O, 2002, J BIOL CHEM, V277, P36631, DOI 10.1074/jbc.M206266200; Shimano H, 2001, PROG LIPID RES, V40, P439, DOI 10.1016/S0163-7827(01)00010-8; Shimizu S, 2002, ENDOCRINOLOGY, V143, P4563, DOI 10.1210/en.2002-220517; Shimomura I, 2000, MOL CELL, V6, P77, DOI 10.1016/S1097-2765(00)00009-5; Shimomura I, 1999, J BIOL CHEM, V274, P30028, DOI 10.1074/jbc.274.42.30028; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; Taghibiglou C, 2002, J BIOL CHEM, V277, P793, DOI 10.1074/jbc.M106737200; Tobe K, 2001, J BIOL CHEM, V276, P38337, DOI 10.1074/jbc.C100160200; Ugi S, 2002, MOL CELL BIOL, V22, P2375, DOI 10.1128/MCB.22.7.2375-2387.2002; Wang J, 2001, DIABETES OBES METAB, V3, P367, DOI 10.1046/j.1463-1326.2001.00173.x; Zinker BA, 2002, P NATL ACAD SCI USA, V99, P11357, DOI 10.1073/pnas.142298199	32	65	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43095	43101		10.1074/jbc.M306880200	http://dx.doi.org/10.1074/jbc.M306880200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12941932	hybrid			2022-12-25	WOS:000186157000048
J	Gu, XR; Meer, SG; Miyagi, M; Rayborn, ME; Hollyfield, JG; Crabb, JW; Salomon, RG				Gu, XR; Meer, SG; Miyagi, M; Rayborn, ME; Hollyfield, JG; Crabb, JW; Salomon, RG			Carboxyethylpyrrole protein adducts and autoantibodies, biomarkers for age-related macular degeneration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDIZED PHOSPHOLIPIDS; PATHOGENESIS; OXIDATION; DRUSEN; PRODUCTS; FAMILY	Age-related macular degeneration (AMD) is a slow, progressive disease with both genetic and environmental risk factors. Free radical-induced oxidation of docosahexaenoate (DHA)-containing lipids generates omega-(2-carboxyethyl)pyrrole (CEP) protein adducts that are more abundant in ocular tissues from AMD than normal human donors. To understand better the role of oxidative damage in AMD, we have synthesized CEP-modified proteins, produced anti-CEP antibodies, and initiated analysis of CEP immunoreactivity and autoantibodies in human plasma. A highly selective rabbit polyclonal anti-CEP antibody was raised that binds CEP 1000 times more strongly than carboxypropylpyrrole, a close structural analogue. The CEP adduct uniquely indicates oxidative modification from DHA derivatives because CEP protein modifications cannot arise from any other common polyunsaturated fatty acid. Immunocytochemistry localized CEP to photoreceptor rod outer segments and retinal pigment epithelium in mouse retina and demonstrated more intense CEP immunoreactivity in photoreceptors from a human AMD donor compared with healthy human retina. The mean level of anti-CEP immunoreactivity in AMD human plasma (n = 19 donors) was 1.5-fold higher (p = 0.004) than in age-matched controls (n = 19 donors). Sera from AMD patients demonstrated mean titers of anti-CEP autoantibody 2.3-fold higher than controls (p = 0.02). Of individuals (n = 13) exhibiting both antigen and autoantibody levels above the mean for non-AMD controls, 92% had AMD. These results suggest that together CEP immunoreactivity and autoantibody titer may have diagnostic utility in predicting AMD susceptibility.	Cleveland Clin Fdn, Cole Eye Inst i31, Cleveland, OH 44195 USA; Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Case Western Reserve University	Crabb, JW (corresponding author), Cleveland Clin Fdn, Cole Eye Inst i31, 9500 Euclid Ave, Cleveland, OH 44195 USA.	crabbj@ccf.org; rgs@po.cwru.edu	Salomon, Robert G/C-3463-2008	Salomon, Robert/0000-0001-9456-3557	NATIONAL EYE INSTITUTE [R01EY014239, R56EY014240, R01EY014240, R01EY002362] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053315] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021249] Funding Source: NIH RePORTER; NEI NIH HHS [EY 6603, EY 2362, EY 14240, EY 14239] Funding Source: Medline; NHLBI NIH HHS [HL 53315] Funding Source: Medline; NIGMS NIH HHS [GM 21249] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7; ALVAREZ RA, 1994, INVEST OPHTH VIS SCI, V35, P402; Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5; Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899; Crabb JW, 1998, J BIOL CHEM, V273, P20712, DOI 10.1074/jbc.273.33.20712; DECAPRIO AP, 1987, MOL PHARMACOL, V32, P542; Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9; FLIESLER SJ, 1983, PROG LIPID RES, V22, P79; Gu XR, 2003, J ORG CHEM, V68, P3749, DOI 10.1021/jo026721t; Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6; Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798; Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417; Kaur K, 1997, CHEM RES TOXICOL, V10, P1387, DOI 10.1021/tx970112c; KLEIN R, 1992, OPHTHALMOLOGY, V99, P933; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; Miyagi M, 2002, MOL CELL PROTEOMICS, V1, P293, DOI 10.1074/mcp.M100034-MCP200; Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2; Podrez EA, 2002, J BIOL CHEM, V277, P38517, DOI 10.1074/jbc.M205924200; Podrez EA, 2002, J BIOL CHEM, V277, P38503, DOI 10.1074/jbc.M203318200; Salomon RG, 2000, BBA-MOL CELL BIOL L, V1485, P225, DOI 10.1016/S1388-1981(00)00038-X; Sayre LM, 1996, CHEM RES TOXICOL, V9, P1194, DOI 10.1021/tx960094j; Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEINBRECHER UP, 1987, J BIOL CHEM, V262, P3603; Stone EM, 2001, HUM MOL GENET, V10, P2285, DOI 10.1093/hmg/10.20.2285; Subbanagounder G, 2002, VASC PHARMACOL, V38, P201, DOI 10.1016/S1537-1891(02)00170-2; Sun MJ, 2002, J ORG CHEM, V67, P3575, DOI 10.1021/jo0105383; WANG N, 1992, CURR EYE RES, V11, P783, DOI 10.3109/02713689209000751; West KA, 2001, EXP EYE RES, V73, P479, DOI 10.1006/exer.2001.1058	29	246	257	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42027	42035		10.1074/jbc.M305460200	http://dx.doi.org/10.1074/jbc.M305460200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12923198	hybrid			2022-12-25	WOS:000185989500058
J	Kubiak, TM; Larsen, MJ; Zantello, MR; Bowman, JW; Nulf, SC; Lowery, DE				Kubiak, TM; Larsen, MJ; Zantello, MR; Bowman, JW; Nulf, SC; Lowery, DE			Functional annotation of the putative orphan Caenorhabditis elegans G-protein-coupled receptor C10C6.2 as a FLP15 peptide receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FMRFAMIDE-RELATED PEPTIDES; DROSOPHILA-MELANOGASTER; NEUROPEPTIDES; IDENTIFICATION; CLONING; ALLATOSTATINS; RFAMIDE; LIGANDS; FAMILY; FARPS	This report describes the cloning and functional annotation of a Caenorhabditis elegans orphan G-protein-coupled receptor (GPCR) (C10C6.2) as a receptor for the FMRFamide-related peptides (FaRPs) encoded on the flp15 precursor gene, leading to the receptor designation FLP15-R. A cDNA encoding C10C6.2 was obtained using PCR techniques, confirmed identical to the Worm-pep-predicted sequence, and cloned into a vector appropriate for eucaryotic expression. A [S-35]guanosine 5'-O-(thiotriphosphate) (GTPgammaS) assay with membranes prepared from Chinese hamster ovary (CHO) cells transiently transfected with FLP15-R was used as a read-out for receptor activation. FLP15-R was activated by putative FLP15 peptides, GGPQGPLRF-NH2 (FLP15-1), RG-PSGPLRF-NH2 (FLP15-2A), its des-Arg(1) counterpart, GPSGPLRF-NH2 (FLP15-2B), and to a lesser extent, by a tobacco hornworm Manduca sexta FaRP, GNSFLRF-NH2 (F7G) (potency ranking FLP15-2A > FLP15-1 > FLP15-2B >> F7G). FLP15-R activation was abolished in the transfected cells pretreated with pertussis toxin, suggesting a preferential receptor coupling to G(i)/G(o) proteins. The functional expression of FLP15-R in mammalian cells was temperature-dependent. Either no stimulation or significantly lower ligand-evoked [S-35]GTPgammaS binding was observed in membranes prepared from transfected FLP15-R/CHO cells cultured at 37 degreesC. However, a 37 to 28 degreesC temperature shift implemented 24 h post-transfection consistently resulted in an improved activation signal and was essential for detectable functional expression of FLP15-R in CHO cells. To our knowledge, the FLP15 receptor is only the second deorphanized C. elegans neuropeptide GPCR reported to date.	Pharmacia Corp, Anim Hlth Discovery Res, Kalamazoo, MI 49001 USA	Pfizer	Kubiak, TM (corresponding author), Pfizer Inc, Vet Med R&D, 7000 Portage Rd, Kalamazoo, MI 49001 USA.	teresa.m.kubiak@pfizer.com		Lowery, David/0000-0001-5111-4719				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ausubel FM, 1991, CURRENT PROTOCOLS MO; Bargmann CI, 1998, SCIENCE, V282, P2028, DOI 10.1126/science.282.5396.2028; Belles X, 1999, PEPTIDES, V20, P11, DOI 10.1016/S0196-9781(98)00155-7; Brownlee DJA, 1996, PARASITOL TODAY, V12, P343, DOI 10.1016/0169-4758(96)10052-1; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Civelli O, 2001, TRENDS NEUROSCI, V24, P230, DOI 10.1016/S0166-2236(00)01763-X; Coward P, 1999, ANAL BIOCHEM, V270, P242, DOI 10.1006/abio.1999.4061; Coward P, 1998, P NATL ACAD SCI USA, V95, P352, DOI 10.1073/pnas.95.1.352; COWDEN C, 1995, PEPTIDES, V16, P491, DOI 10.1016/0196-9781(94)00211-N; de Bono M, 1998, CELL, V94, P679, DOI 10.1016/S0092-8674(00)81609-8; DOCKRAY GJ, 1986, REGUL PEPTIDES, V16, P27, DOI 10.1016/0167-0115(86)90192-8; Espinoza E, 2000, MOL NEUROBIOL, V21, P35; Fujisawa Y, 1999, J NEUROSCI, V19, P9618; Furukawa Y, 2001, J NEUROSCI, V21, P8247, DOI 10.1523/JNEUROSCI.21-20-08247.2001; Geary TG, 1999, ANN NY ACAD SCI, V897, P212, DOI 10.1111/j.1749-6632.1999.tb07893.x; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GREENBERG MJ, 1992, PROG BRAIN RES, V92, P25, DOI 10.1016/S0079-6123(08)61162-0; HALTON DW, 1994, ADV PARASIT, V34, P163, DOI 10.1016/S0065-308X(08)60139-6; Hinuma S, 2000, NAT CELL BIOL, V2, P703, DOI 10.1038/35036326; Kingan TG, 1997, MOL CELL ENDOCRINOL, V133, P19, DOI 10.1016/S0303-7207(97)00140-8; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kubiak TM, 2003, J BIOL CHEM, V278, P33724, DOI 10.1074/jbc.M304861200; Kubiak TM, 2002, BIOCHEM BIOPH RES CO, V291, P313, DOI 10.1006/bbrc.2002.6459; KUBIAK TM, 2002, PEPTIDES 2002, P540; Larsen MJ, 2001, BIOCHEM BIOPH RES CO, V286, P895, DOI 10.1006/bbrc.2001.5476; Lenz C, 2000, BIOCHEM BIOPH RES CO, V273, P1126, DOI 10.1006/bbrc.2000.3062; Lenz C, 2001, BIOCHEM BIOPH RES CO, V286, P1117, DOI 10.1006/bbrc.2001.5475; Li C, 1999, BRAIN RES, V848, P26, DOI 10.1016/S0006-8993(99)01972-1; Maule AG, 1996, PARASITOLOGY, V113, pS119, DOI 10.1017/S0031182000077933; Maule AG, 1996, INT J PARASITOL, V26, P927, DOI 10.1016/S0020-7519(96)80066-X; Nathoo AN, 2001, P NATL ACAD SCI USA, V98, P14000, DOI 10.1073/pnas.241231298; Nelson LS, 1998, MOL BRAIN RES, V58, P103, DOI 10.1016/S0169-328X(98)00106-5; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; PRICE DA, 1989, BIOL BULL, V177, P198, DOI 10.2307/1541933; Shaw C, 1996, INT J PARASITOL, V26, P335, DOI 10.1016/0020-7519(96)00012-4; Siehler S, 1999, N-S ARCH PHARMACOL, V360, P500, DOI 10.1007/s002109900142; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tsutsui K, 2000, BIOCHEM BIOPH RES CO, V275, P661, DOI 10.1006/bbrc.2000.3350; WALKER RJ, 1992, COMP BIOCHEM PHYS C, V102, P213, DOI 10.1016/0742-8413(92)90104-F; YANG HYT, 1985, P NATL ACAD SCI USA, V82, P7757, DOI 10.1073/pnas.82.22.7757	41	41	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42115	42120		10.1074/jbc.M304056200	http://dx.doi.org/10.1074/jbc.M304056200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12937167	hybrid			2022-12-25	WOS:000185989500069
J	Leech, HK; Raux, E; McLean, KJ; Munro, AW; Robinson, NJ; Borrelly, GPM; Malten, M; Jahn, D; Rigby, SEJ; Heathcote, P; Warren, MJ				Leech, HK; Raux, E; McLean, KJ; Munro, AW; Robinson, NJ; Borrelly, GPM; Malten, M; Jahn, D; Rigby, SEJ; Heathcote, P; Warren, MJ			Characterization of the cobaltochelatase CbiX(L) - Evidence for a 4Fe-4S center housed within an MXCXXC motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COBALAMIN VITAMIN-B-12 BIOSYNTHESIS; IDENTIFICATION; PROTEIN; HEME; FERROCHELATASE; INSERTION; PATHWAYS; GENES; HYPB; ZINC	CbiX is a cobaltochelatase required for the biosynthesis of vitamin B-12 and is found in Archaea as a short form (CbiX(S) containing 120 - 145 amino acids) and in some bacteria as a longer version ( CbiX(L) containing 300 - 350 amino acids). Purification of either recombinant Bacillus megaterium or Synechocystis CbiXL in Escherichia coli, which is facilitated by the presence of a naturally occurring histidine-rich region of the protein, results in the isolation of a dark brown protein solution. The UV/ visible spectrum of the protein is consistent with the presence of a redox group, and the lack of definition within the spectrum is suggestive of a 4Fe-4S center. The presence of an iron-sulfur center was confirmed by EPR analysis of the proteins, which produces a pseudoaxial spectrum with g values at 2.04, 1.94, and 1.90. The EPR spectrum was absent at 70 K, an observation that is diagnostic of a 4Fe-4S center. Redox potentiometry coupled with optical spectroscopy allowed the midpoint potential of the redox center to be determined for the CbiXL from both B. megaterium and Synechocystis. Sequence analysis of CbiXL proteins reveals only two conserved cysteine residues within the CbiXL proteins, which are part of an MXCXXC motif. Mutagenesis of the two cysteines leads to loss of both the EPR spectrum and UV/ visible spectral features of the Fe-S center in the protein, clearly indicating that these residues are involved in ligating the cofactor to the apoprotein possibly in a butterfly arrangement. The potential physiological role of the iron-sulfur center is discussed.	Queen Mary Univ London, Sch Biol Sci, London E1 4NS, England; Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Med Sch Newcastle Upon Tyne, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Tech Univ Braunschweig, Inst Microbiol, D-38106 Braunschweig, Germany	University of London; Queen Mary University London; University of Leicester; Newcastle University - UK; Braunschweig University of Technology	Warren, MJ (corresponding author), Queen Mary Univ London, Sch Biol Sci, Mile End Rd, London E1 4NS, England.	m.j.warren@qmul.ac.uk	McLean, Kirsty J/GXI-2853-2022; Heathcote, Peter/B-3749-2011; Munro, Andrew/G-5639-2019; Robinson, Nigel J/J-6363-2012	Munro, Andrew/0000-0002-4642-180X; Robinson, Nigel J/0000-0001-5586-1092; McLean, Kirsty/0000-0002-7193-5044; Warren, Martin/0000-0002-6028-6456; Jahn, Dieter/0000-0002-4064-9205				Al-Karadaghi S, 1997, STRUCTURE, V5, P1501, DOI 10.1016/S0969-2126(97)00299-2; ARCHER VEV, 1994, P NATL ACAD SCI USA, V91, P316, DOI 10.1073/pnas.91.1.316; BATTERSBY AR, 1982, J CHEM SOC CHEM COMM, P1393, DOI 10.1039/c39820001393; Brindley AA, 2003, J BIOL CHEM, V278, P22388, DOI 10.1074/jbc.M302468200; Daff SN, 1997, BIOCHEMISTRY-US, V36, P13816, DOI 10.1021/bi971085s; Dailey HA, 2000, CELL MOL LIFE SCI, V57, P1909, DOI 10.1007/PL00000672; Dailey TA, 2002, J BACTERIOL, V184, P2460, DOI 10.1128/JB.184.9.2460-2464.2002; Dutton P L, 1978, Methods Enzymol, V54, P411; FU CL, 1995, P NATL ACAD SCI USA, V92, P2333, DOI 10.1073/pnas.92.6.2333; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; Kerby RL, 1997, J BACTERIOL, V179, P2259, DOI 10.1128/jb.179.7.2259-2266.1997; LI PM, 1991, P NATL ACAD SCI USA, V88, P9210, DOI 10.1073/pnas.88.20.9210; Munro AW, 2001, BIOCHEMISTRY-US, V40, P1956, DOI 10.1021/bi001718u; Ost TWB, 2001, BIOCHEMISTRY-US, V40, P13421, DOI 10.1021/bi010716m; Raux E, 1997, J BACTERIOL, V179, P3202, DOI 10.1128/jb.179.10.3202-3212.1997; Raux E, 1998, BIOCHEM J, V335, P167, DOI 10.1042/bj3350167; Raux E, 1998, BIOCHEM J, V335, P159, DOI 10.1042/bj3350159; Raux E, 2003, BIOCHEM J, V370, P505, DOI 10.1042/BJ20021443; REY L, 1994, J BACTERIOL, V176, P6066, DOI 10.1128/jb.176.19.6066-6073.1994; Rutherford JC, 1999, J BIOL CHEM, V274, P25827, DOI 10.1074/jbc.274.36.25827; RYGUS T, 1991, APPL MICROBIOL BIOT, V35, P594; Schubert HL, 1999, BIOCHEMISTRY-US, V38, P10660, DOI 10.1021/bi9906773; Schubert HL, 2002, EMBO J, V21, P2068, DOI 10.1093/emboj/21.9.2068; Scott AI, 2003, J ORG CHEM, V68, P2529, DOI 10.1021/jo020728t; Tottey S, 2002, J BIOL CHEM, V277, P5490, DOI 10.1074/jbc.M105857200; Warren MJ, 2002, NAT PROD REP, V19, P390, DOI 10.1039/B108967F; WARREN MJ, 1990, TRENDS BIOCHEM SCI, V15, P486, DOI 10.1016/0968-0004(90)90304-T	27	39	44	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41900	41907		10.1074/jbc.M306112200	http://dx.doi.org/10.1074/jbc.M306112200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12917443	hybrid			2022-12-25	WOS:000185989500043
J	Mizukoshi, T; Tanaka, T; Arai, K; Kohda, D; Masai, H				Mizukoshi, T; Tanaka, T; Arai, K; Kohda, D; Masai, H			A critical role of the 3 ' terminus of nascent DNA chains in recognition of stalled replication forks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI PRIA; PROTEIN; RECG; RECOMBINATION; HELICASE; RESTART; BINDING; MUTANTS; STRAND; REVERSAL	Arrest of replication forks by various internal and external threats evokes a myriad of cellular reactions, collectively known as DNA replication checkpoint responses. In bacteria, PriA is essential for restoration of stalled replication forks and recombinational repair of double-stranded DNA breaks and is a candidate sensor protein that may recognize arrested forks. Here, we report that PriA protein specifically recognizes 3' termini of arrested nascent DNA chains at model stalled replication forks in vitro. Mutations in the putative "3' terminus binding pocket" present in the N-terminal segment of PriA result in reduced binding to stalled replication fork structures and loss of its biological functions. The results suggest a mechanism by which stalled replication forks are recognized by a sensor protein for checkpoint responses.	Tokyo Metropolitan Inst Med Sci, Dept Cell Biol, Bunkyo Ku, Tokyo 1138613, Japan; Biomol Engn Res Inst, Dept Biol Struct, Osaka 5650874, Japan; Univ Tokyo, Inst Med Sci, Dept mol & Dev Biol, Tokyo 1088639, Japan	Tokyo Metropolitan Institute of Medical Science; University of Tokyo	Masai, H (corresponding author), Tokyo Metropolitan Inst Med Sci, Dept Cell Biol, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138613, Japan.		Kohda, Daisuke/I-4990-2019	Kohda, Daisuke/0000-0001-8234-3776				Boddy MN, 2001, CURR BIOL, V11, pR953, DOI 10.1016/S0960-9822(01)00572-3; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; Fukuoh A, 1997, EMBO J, V16, P203, DOI 10.1093/emboj/16.1.203; Gregg AV, 2002, MOL CELL, V9, P241, DOI 10.1016/S1097-2765(02)00455-0; Grompone G, 2003, MOL MICROBIOL, V48, P845, DOI 10.1046/j.1365-2958.2003.03480.x; INOUE H, 1990, GENE, V96, P23, DOI 10.1016/0378-1119(90)90336-P; Jezewska MJ, 2000, J BIOL CHEM, V275, P27865; Jones JM, 2000, MOL MICROBIOL, V36, P519, DOI 10.1046/j.1365-2958.2000.01888.x; Kogoma T, 1996, J BACTERIOL, V178, P1258, DOI 10.1128/jb.178.5.1258-1264.1996; LEE EH, 1990, P NATL ACAD SCI USA, V87, P4620, DOI 10.1073/pnas.87.12.4620; LEE EH, 1991, P NATL ACAD SCI USA, V88, P3029, DOI 10.1073/pnas.88.8.3029; Liu J, 1999, J BIOL CHEM, V274, P25033, DOI 10.1074/jbc.274.35.25033; Liu JI, 1999, P NATL ACAD SCI USA, V96, P3552, DOI 10.1073/pnas.96.7.3552; Marians KJ, 2000, TRENDS BIOCHEM SCI, V25, P185, DOI 10.1016/S0968-0004(00)01565-6; MASAI H, 1994, EMBO J, V13, P5338, DOI 10.1002/j.1460-2075.1994.tb06868.x; Masai H, 1999, BIOCHIMIE, V81, P847, DOI 10.1016/S0300-9084(99)00211-4; McGlynn P, 1997, J MOL BIOL, V270, P212, DOI 10.1006/jmbi.1997.1120; McGlynn P, 2001, P NATL ACAD SCI USA, V98, P8227, DOI 10.1073/pnas.111008698; NURSE P, 1990, P NATL ACAD SCI USA, V87, P4615, DOI 10.1073/pnas.87.12.4615; Nurse P, 1999, J BIOL CHEM, V274, P25026, DOI 10.1074/jbc.274.35.25026; NURSE P, 1991, J BACTERIOL, V173, P6686, DOI 10.1128/jb.173.21.6686-6693.1991; Polard P, 2002, NUCLEIC ACIDS RES, V30, P1593, DOI 10.1093/nar/30.7.1593; Sandler SJ, 2000, J BACTERIOL, V182, P9, DOI 10.1128/JB.182.1.9-13.2000; Sandler SJ, 1996, GENETICS, V143, P5; Sharples GJ, 1999, J BACTERIOL, V181, P5543, DOI 10.1128/JB.181.18.5543-5550.1999; Singleton MR, 2001, CELL, V107, P79, DOI 10.1016/S0092-8674(01)00501-3; STAUDENBAUER WL, 1979, MOL GEN GENET, V177, P113, DOI 10.1007/BF00267260; Tanaka T, 2003, GENES CELLS, V8, P251, DOI 10.1046/j.1365-2443.2003.00630.x; Tanaka T, 2002, J BIOL CHEM, V277, P38062, DOI 10.1074/jbc.M204397200; Whitby MC, 1998, J BIOL CHEM, V273, P19729, DOI 10.1074/jbc.273.31.19729	30	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42234	42239		10.1074/jbc.C300285200	http://dx.doi.org/10.1074/jbc.C300285200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12917421	hybrid			2022-12-25	WOS:000185989500082
J	Figueroa, C; Vojtek, AB				Figueroa, C; Vojtek, AB			Akt negatively regulates translation of the ternary complex factor Elk-1	ONCOGENE			English	Article						Elk-1; Sap1a; Akt/PKB; translational control; Ets; cross-talk	PROTEIN-KINASE-B; C-FOS TRANSCRIPTION; EPITHELIAL-CELLS; RAS; DIFFERENTIATION; EXPRESSION; PATHWAY; BINDING; MOUSE; PHOSPHORYLATION	Cross-talk between signaling pathways plays an important role in regulation of cell growth, differentiation, survival, and death. Here, we show that Akt regulates the Elk-1 transcription factor, independent of its negative regulation of Raf kinases. Using a constitutively active Mek1 to bypass the regulation of Raf by Akt, we find that the Elk-1 and Sap1a proteins are dramatically decreased in the presence of activated Akt. Akt catalytic activity is required. Also, Mek-dependent activation of a TCF (Etk-1/Sap-1a)-dependent c-fos reporter is decreased by activated Akt. Neither the level of Elk-1 mRNA nor the stability of the Elk-1 protein is altered by activated Akt. Instead, the rate of incorporation of labeled methionine into Elk-1 protein is decreased in the presence of Akt. In addition, the level of the Elk-1 protein but not GFP is significantly decreased in the presence of activated Akt, when GFP is expressed from an IRES element in a bicistronic message with Elk-1. We conclude that Akt negatively regulates translation of the Elk-1 mRNA. A coding region determinant that maps within the first 279 nts of the Elk-1 message is necessary and sufficient for Akt-mediated regulation of Elk-1.	Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Vojtek, AB (corresponding author), Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA.			Figueroa-Romero, Claudia/0000-0001-7546-4190				Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Ayllon V, 2000, MOL MEMBR BIOL, V17, P65; Boyer TG, 1999, NATURE, V399, P276, DOI 10.1038/20466; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Choudhury GG, 2001, J BIOL CHEM, V276, P35636, DOI 10.1074/jbc.M100946200; CHOUDHURY GG, 1997, AM J PHYSIOL, V273, P931; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; Galetic I, 2003, J BIOL CHEM, V278, P4416, DOI 10.1074/jbc.M210578200; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Guan KL, 2000, J BIOL CHEM, V275, P27354; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Janknecht R, 1996, BIOCHEM BIOPH RES CO, V228, P831, DOI 10.1006/bbrc.1996.1740; JUN T, 1999, SCI STKE, P10591; Kaneko S, 2002, J BIOL CHEM, V277, P23230, DOI 10.1074/jbc.M201733200; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; Lemm I, 2002, MOL CELL BIOL, V22, P3959, DOI 10.1128/MCB.22.12.3959-3969.2002; Macdonald P, 2001, CURR OPIN CELL BIOL, V13, P326, DOI 10.1016/S0955-0674(00)00215-5; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; MANSOUR SJ, 1994, J BIOCHEM-TOKYO, V116, P304, DOI 10.1093/oxfordjournals.jbchem.a124524; MARTI A, 1994, ONCOGENE, V9, P1213; McManus EJ, 2002, NAT CELL BIOL, V4, pE214, DOI 10.1038/ncb0902-e214; Moelling K, 2002, J BIOL CHEM, V277, P31099, DOI 10.1074/jbc.M111974200; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Nakamura Y, 2000, NUCLEIC ACIDS RES, V28, P292, DOI 10.1093/nar/28.1.292; Nissen LJ, 2001, J BIOL CHEM, V276, P5213, DOI 10.1074/jbc.M007824200; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Preston GA, 2000, CELL DEATH DIFFER, V7, P215, DOI 10.1038/sj.cdd.4400637; Preston GA, 1996, MOL CELL BIOL, V16, P211; Rich KA, 1997, J NEUROBIOL, V32, P593, DOI 10.1002/(SICI)1097-4695(19970605)32:6<593::AID-NEU5>3.0.CO;2-V; Roberts EC, 2001, MOL CELL BIOL, V21, P524, DOI 10.1128/MCB.21.2.524-533.2001; Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101-1009; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Sheng HM, 2001, CANCER RES, V61, P2670; Sheng HM, 2001, J BIOL CHEM, V276, P14498, DOI 10.1074/jbc.M010093200; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; Steinhilb ML, 2001, J BIOL CHEM, V276, P4476, DOI 10.1074/jbc.M008793200; Stevens JL, 2002, SCIENCE, V296, P755, DOI 10.1126/science.1068943; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; Timchenko LT, 2002, MOL CELL BIOL, V22, P7242, DOI 10.1128/MCB.22.20.7242-7257.2002; TROUCHE D, 1993, NATURE, V363, P79, DOI 10.1038/363079a0; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Vanhoutte P, 2001, J BIOL CHEM, V276, P5189, DOI 10.1074/jbc.M006678200; VOJTEK AB, 1993, J CELL SCI, V105, P777; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597; Yang SH, 2001, MOL CELL BIOL, V21, P2802, DOI 10.1128/MCB.21.8.2802-2814.2001; Yates PR, 1999, EMBO J, V18, P968, DOI 10.1093/emboj/18.4.968; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	52	14	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2003	22	36					5554	5561		10.1038/sj.onc.1206496	http://dx.doi.org/10.1038/sj.onc.1206496			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944902				2022-12-25	WOS:000184865900003
J	Calissano, M; Latchman, DS				Calissano, M; Latchman, DS			Functional interaction between the small GTP-binding protein Rin and the N-terminal of Brn-3a transcription factor	ONCOGENE			English	Article						Brn-3a; Pou; Rin; RAS yeast two hybrid	GENE-EXPRESSION; NEURONAL CELLS; DOMAIN; ACTIVATION; FAMILY; SUBFAMILY; OUTGROWTH; GANGLION; DISTINCT	Brn-3a is a transcription factor belonging to the class IV of POU domain transcription factors. It is expressed throughout the peripheral nervous system but especially in postmitotic sensory neurons of dorsal root ganglia. Brn-3a is known to regulate different genes involved in neuronal differentiation and survival. It has been shown that some of these genes require the N-terminal domain of Brn-3a in order to be activated and this effect is observed only in neurons suggesting that it may require a neuronal-specific cofactor. In order to identify this putative factor(s) we screened a cDNA library via a variant of the original yeast two-hybrid system. By using the N-terminal of Brn-3a as the bait, we have repeatedly isolated a protein named Rin, an incompletely characterized small GTP-binding protein expressed only in neurons. In this work, we describe the evidence for a functional interaction between Brn-3a and Rin and demonstrate the role of Rin in modulating the activation of the Brn-3a regulated egr-1 promoter by the N-terminal domain of Brn-3a.	UCL, Inst Child Hlth, Med Mol Biol Unit, London WC1N 1EH, England	University of London; University College London	Calissano, M (corresponding author), UCL, Inst Child Hlth, Med Mol Biol Unit, 30 Guilford St, London WC1N 1EH, England.	m.calissano@ich.ucl.ac.uk			Telethon [487/B] Funding Source: Medline	Telethon(Fondazione Telethon)		Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; Ensor E, 2001, J BIOL CHEM, V276, P5204, DOI 10.1074/jbc.M007068200; FEDTSOVA NG, 1995, MECH DEVELOP, V53, P291, DOI 10.1016/0925-4773(95)00435-1; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GERRERO MR, 1993, P NATL ACAD SCI USA, V90, P10841, DOI 10.1073/pnas.90.22.10841; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; LAKIN ND, 1995, J BIOL CHEM, V270, P15858, DOI 10.1074/jbc.270.26.15858; Lee CHJ, 1996, J NEUROSCI, V16, P6784; LILLYCROP KA, 1992, NUCLEIC ACIDS RES, V20, P5093, DOI 10.1093/nar/20.19.5093; Liu YZ, 1996, J MOL NEUROSCI, V7, P77, DOI 10.1007/BF02736850; Morris PJ, 1996, MOL BRAIN RES, V43, P279, DOI 10.1016/S0169-328X(96)00207-0; NINKINA NN, 1993, NUCLEIC ACIDS RES, V21, P3175, DOI 10.1093/nar/21.14.3175; PATEL G, 1992, ONCOGENE, V7, P283; Rusyn EV, 2000, ONCOGENE, V19, P4685, DOI 10.1038/sj.onc.1203836; Shao HP, 1999, ARCH BIOCHEM BIOPHYS, V371, P207, DOI 10.1006/abbi.1999.1448; Smith MD, 1998, J BIOL CHEM, V273, P16715, DOI 10.1074/jbc.273.27.16715; Smith MD, 2001, MOL CELL NEUROSCI, V17, P460, DOI 10.1006/mcne.2000.0927; Smith MD, 1997, MOL CELL BIOL, V17, P345, DOI 10.1128/MCB.17.1.345; Smith MD, 1999, MOL BRAIN RES, V74, P117, DOI 10.1016/S0169-328X(99)00271-5; Smith MD, 1998, NUCLEIC ACIDS RES, V26, P4100, DOI 10.1093/nar/26.18.4100; Spencer ML, 2002, J BIOL CHEM, V277, P17605, DOI 10.1074/jbc.M111400200; THEIL T, 1993, NUCLEIC ACIDS RES, V21, P5921, DOI 10.1093/nar/21.25.5921; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; Xiang MQ, 1996, P NATL ACAD SCI USA, V93, P11950, DOI 10.1073/pnas.93.21.11950; Xiang MQ, 1998, DEV BIOL, V197, P155, DOI 10.1006/dbio.1998.8868; Xiang MQ, 1997, P NATL ACAD SCI USA, V94, P9445, DOI 10.1073/pnas.94.17.9445	27	8	12	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2003	22	35					5408	5414		10.1038/sj.onc.1206635	http://dx.doi.org/10.1038/sj.onc.1206635			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JC	12934100				2022-12-25	WOS:000184735000005
J	Mulloy, R; Salinas, S; Philips, A; Hipskind, RA				Mulloy, R; Salinas, S; Philips, A; Hipskind, RA			Activation of cyclin D1 expression by the ERK5 cascade	ONCOGENE			English	Article						MEK5; ERK1/2; NF kappa B; CRE; CCL-39 cells; breast cancer	NF-KAPPA-B; HUMAN BREAST-CANCER; CAMP-RESPONSIVE ELEMENT; C-JUN PROMOTER; GROWTH-FACTOR; BINDING PROTEIN; TRANSCRIPTION FACTOR-2; KINASE; GENE; CELLS	Transcriptional activation of the cyclin D1 gene is a key step in cell proliferation. Accordingly, cyclin D1 overexpression is frequently an early step in neoplastic transformation, particularly in mammary epithelium. Numerous studies have linked elevated cyclin D1 promoter activity to a sustained activation of the ERK1/2 cascade. Here we show that the ERK5 cascade, a distinct mitogen-induced MAPK pathway, can also drive cyclin D1 expression. In CCL39 cells, serum induces a strong, prolonged peak of ERK1/2 and ERK5 phosphorylation, and subsequently elevates cyctin D1 mRNA and protein levels. Overexpression of constitutively active MEK5 and wt ERK5 induces a cyclin D1 reporter gene (D1-973-luciferase) at least as well as constitutively active MEK1. Activation is blocked by kinase-dead mutants of ERK5 and ERK2, respectively. Mutation of the CRE at -50 in the cyclin D1 promoter decreases activation by the ERK5 but not the ERK1/2 cascade. Importantly, expression of kinase-dead ERK5 diminishes endogenous cyclin D1 protein induction by serum in CCL39 cells and the breast cancer cell lines MCF-7 and HS579. These data identify the cyclin D1 gene as a novel target of the ERK5 cascade, an observation with important implications in cancers involving cyclin D1 deregulation.	Inst Genet Mol Montpellier, CNRS, UMR 5535, IFR 122, F-34293 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Hipskind, RA (corresponding author), Inst Genet Mol Montpellier, CNRS, UMR 5535, IFR 122, 1919 Route Mende, F-34293 Montpellier 5, France.	hipskind@soleil.igm.cnrs-mop.fr	Salinas, Sara/O-1150-2019; PHILIPS, Alexandre/AAB-6047-2020; Salinas, Sara/O-1856-2013	Salinas, Sara/0000-0003-4492-2093; Salinas, Sara/0000-0003-4492-2093				Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; Albanese C, 1999, J BIOL CHEM, V274, P34186, DOI 10.1074/jbc.274.48.34186; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; Balmanno K, 1999, ONCOGENE, V18, P3085, DOI 10.1038/sj.onc.1202647; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; Beier F, 1999, P NATL ACAD SCI USA, V96, P1433, DOI 10.1073/pnas.96.4.1433; Boulon S, 2002, MOL CELL BIOL, V22, P7769, DOI 10.1128/MCB.22.22.7769-7779.2002; Brown JR, 1998, MOL CELL BIOL, V18, P5609, DOI 10.1128/MCB.18.9.5609; BRUNET A, 1994, ONCOGENE, V9, P3379; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; DICKSON C, 1995, CANCER LETT, V90, P43, DOI 10.1016/0304-3835(94)03676-A; English JM, 1998, J BIOL CHEM, V273, P3854, DOI 10.1074/jbc.273.7.3854; Esparis-Ogando A, 2002, MOL CELL BIOL, V22, P270, DOI 10.1128/MCB.22.1.270-285.2002; Gillett C, 1996, INT J CANCER, V69, P92, DOI 10.1002/(SICI)1097-0215(19960422)69:2<92::AID-IJC4>3.3.CO;2-I; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hamel PA, 1997, CANCER INVEST, V15, P143, DOI 10.3109/07357909709115767; HAN TH, 1995, MOL CELL BIOL, V15, P2907; Hateboer G, 1998, MOL CELL BIOL, V18, P6679, DOI 10.1128/MCB.18.11.6679; Henry DO, 2000, MOL CELL BIOL, V20, P8084, DOI 10.1128/MCB.20.21.8084-8092.2000; HERBER, 1994, ONCOGENE, V9, P2105; Hinz M, 1999, MOL CELL BIOL, V19, P2690; HIPSKIND RA, 1994, MOL CELL BIOL, V14, P6219, DOI 10.1128/MCB.14.9.6219; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; Kato Y, 2000, IMMUNOL RES, V21, P233, DOI 10.1385/IR:21:2-3:233; LAVOIE J, J BIOL CHEM, V271, P20608; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; Marinissen MJ, 1999, MOL CELL BIOL, V19, P4289; MCINTOSH GG, 1995, ONCOGENE, V11, P885; Mody N, 2001, FEBS LETT, V502, P21, DOI 10.1016/S0014-5793(01)02651-5; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; Nagata D, 2001, J BIOL CHEM, V276, P662, DOI 10.1074/jbc.M005522200; Page K, 2002, AM J RESP CELL MOL, V27, P204, DOI 10.1165/ajrcmb.27.2.20010016oc; Pearson G, 2001, J BIOL CHEM, V276, P7927, DOI 10.1074/jbc.M009764200; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Watanabe G, 1998, MOL CELL BIOL, V18, P3212, DOI 10.1128/MCB.18.6.3212; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500	46	75	78	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2003	22	35					5387	5398		10.1038/sj.onc.1206839	http://dx.doi.org/10.1038/sj.onc.1206839			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JC	12934098				2022-12-25	WOS:000184735000003
J	Murad, A; Nath, AK; Cha, ST; Demir, E; Flores-Riveros, J; Sierra-Honigmann, MR				Murad, A; Nath, AK; Cha, ST; Demir, E; Flores-Riveros, J; Sierra-Honigmann, MR			Leptin is an autocrine/paracrine regulator of wound healing	FASEB JOURNAL			English	Article						hypoxia; ischemia; tissue injury	ENDOTHELIAL GROWTH-FACTOR; TRANSCRIPTIONAL ACTIVATION; DIABETIC MICE; EXPRESSION; ANGIOGENESIS; PLACENTA; RECEPTOR; MOUSE; CELLS; GENE	Leptin, a 16 kDa pleiotropic cytokine primarily expressed in adipose tissue, has been shown to cause multiple systemic biological actions. Recently, leptin has also been documented as an important component of the wound healing process and its receptor appears to be expressed in wound tissue. We have previously demonstrated that leptin is a potent angiogenic factor exerting direct effects on endothelial cells and that transcription of its encoding gene is regulated by hypoxia. Here, we hypothesize that leptin expression is acutely up-regulated in the ischemic tissue of experimental wounds. Using a combination of in situ hybridization and quantitative RTPCR experiments, we show that leptin expression is rapidly and steadily up-regulated in skin tissue from incisional and excisional wounds. By immunohistochemistry, we demonstrate increased and sustained leptin protein levels in basal keratinocytes, blood vessel walls, and fibroblasts. To determine whether leptin is required for normal healing, excisional wounds were treated with neutralizing anti-leptin antibodies. This treatment markedly hampered healing progression and prevented wound closure and contraction. Finally, a transient rise in circulating blood leptin levels was detected within the first 24 h after inflicting the injury; we present evidence suggesting that this elevation is due to increased leptin production at the ischemic wound site. We conclude that leptin is acutely up-regulated in the injured skin and propose that this local production of leptin serves a critical functional role as an autocrine/paracrine regulator of normal wound healing.	Univ Calif Los Angeles, Los Angeles, CA 90024 USA; Yale Univ, Sch Med, Dept Biol, New Haven, CT USA; Hollis Eden Pharmaceut, San Diego, CA USA	University of California System; University of California Los Angeles; Yale University	Sierra-Honigmann, MR (corresponding author), Cedars Sinai Res Inst, Dept Surg, Div Plast Surg, 8700 Beverly Blvd, Los Angeles, CA 90048 USA.	honigmannr@cshs.org						Akira S, 1997, INT J BIOCHEM CELL B, V29, P1401, DOI 10.1016/S1357-2725(97)00063-0; ALBERTSON S, 1993, SURGERY, V114, P368; Albertson S, 1993, SURGERY, V114, P72; Ambrosini G, 2002, J BIOL CHEM, V277, P34601, DOI 10.1074/jbc.M205172200; Antczak M, 1997, HUM REPROD, V12, P2226, DOI 10.1093/humrep/12.10.2226; Bado A, 1998, NATURE, V394, P790, DOI 10.1038/29547; Cao RH, 2001, P NATL ACAD SCI USA, V98, P6390, DOI 10.1073/pnas.101564798; ChristofidouSolomidou M, 1997, AM J PATHOL, V151, P975; COLEMAN DL, 1973, DIABETOLOGIA, V9, P287, DOI 10.1007/BF01221856; DVONCH VM, 1992, SURGERY, V112, P18; Frank S, 2000, J CLIN INVEST, V106, P501, DOI 10.1172/JCI9148; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Gainsford T, 1996, P NATL ACAD SCI USA, V93, P14564, DOI 10.1073/pnas.93.25.14564; GOODSON WH, 1986, DIABETES, V35, P491, DOI 10.2337/diab.35.4.491; GREENHALGH DG, 1990, AM J PATHOL, V136, P1235; GROSFELD A, 2002, J BIOL CHEM; Henson MC, 1999, J CLIN ENDOCR METAB, V84, P2543, DOI 10.1210/jc.84.7.2543; Hoggard N, 1997, P NATL ACAD SCI USA, V94, P11073, DOI 10.1073/pnas.94.20.11073; Howdieshell TR, 1998, ANN SURG, V228, P707, DOI 10.1097/00000658-199811000-00011; HUMMEL KP, 1972, BIOCHEM GENET, V7, P1, DOI 10.1007/BF00487005; Lambert PD, 2001, P NATL ACAD SCI USA, V98, P4652, DOI 10.1073/pnas.061034298; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Lord GM, 1998, NATURE, V394, P897, DOI 10.1038/29795; Masuzaki H, 1997, NAT MED, V3, P1029, DOI 10.1038/nm0997-1029; Nakata M, 1999, DIABETES, V48, P426, DOI 10.2337/diabetes.48.2.426; Nissen NN, 1998, AM J PATHOL, V152, P1445; Ring BD, 2000, ENDOCRINOLOGY, V141, P446, DOI 10.1210/en.141.1.446; Santos-Alvarez J, 1999, CELL IMMUNOL, V194, P6, DOI 10.1006/cimm.1999.1490; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Senaris R, 1997, ENDOCRINOLOGY, V138, P4501, DOI 10.1210/en.138.10.4501; Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683; Smith-Kirwin SM, 1998, J CLIN ENDOCR METAB, V83, P1810, DOI 10.1210/jc.83.5.1810; Tonnesen MG, 2000, J INVEST DERM SYMP P, V5, P40, DOI 10.1046/j.1087-0024.2000.00014.x; Touw IP, 2000, MOL CELL ENDOCRINOL, V160, P1, DOI 10.1016/S0303-7207(99)00206-3; TSUBOI R, 1990, J EXP MED, V172, P245, DOI 10.1084/jem.172.1.245; Tsuboi Ryoji, 1992, Journal of Dermatology (Tokyo), V19, P673	36	109	129	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1895	+		10.1096/fj.03-0068fje	http://dx.doi.org/10.1096/fj.03-0068fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12923067				2022-12-25	WOS:000185345100003
J	Wiendl, H; Mitsdoerffer, M; Schneider, D; Chen, LP; Lochmuller, H; Melms, A; Weller, M				Wiendl, H; Mitsdoerffer, M; Schneider, D; Chen, LP; Lochmuller, H; Melms, A; Weller, M			Human muscle cells express a B7-related molecule, B7-H1, with strong negative immune regulatory potential: a novel mechanism of counterbalancing the immune attack in idiopathic inflammatory myopathies	FASEB JOURNAL			English	Article						T cells; MHC class I/II; IFN-gamma; myopathy; immune regulation; costimulation	NATURAL-KILLER-CELLS; CD8(+) T-CELLS; B7 FAMILY; MYOBLAST TRANSPLANTATION; DIFFERENTIAL EXPRESSION; RECEPTOR REPERTOIRE; ENDOTHELIAL-CELLS; CLASS-I; HLA-G; POLYMYOSITIS	B7-H1 is a novel B7 family protein attributed to costimulatory and immune regulatory functions. Here we report that human myoblasts cultured from control subjects and patients with inflammatory myopathies as well as TE671 muscle rhabdomyosarcoma cells express high levels of B7-H1 after stimulation with the inflammatory cytokine IFN-gamma. Coculture experiments of MHC class I/II-positive myoblasts with CD4 and CD8 T cells in the presence of antigen demonstrated the functional consequences of muscle-related B7-H1 expression: production of inflammatory cytokines, IFN-gamma and IL-2, by CD4 as well CD8 T cells was markedly enhanced in the presence of a neutralizing anti-B7-H1 antibody. This observation was paralleled by an augmented expression of the T cell activation markers CD25, ICOS, and CD69, thus showing B7-H1-mediated inhibition of T cell activation. Further, we investigated 23 muscle biopsy specimens from patients with polymyositis ( PM), inclusion body myositis (IBM), dermatomyositis (DM), and nonmyopathic controls for B7-H1 expression by immunohistochemistry: B7-H1 was expressed in PM, IBM, and DM specimens but not in noninflammatory and nonmyopathic controls. Staining was predominantly localized to areas of strong inflammation and to muscle cells as well as mononuclear cells. These data highlight the immune regulatory properties of muscle cells and suggest that B7-H1 expression represents an inhibitory mechanism induced upon inflammatory stimuli and aimed at protecting muscle fibers from immune aggression.	Univ Tubingen, Dept Neurol, Sch Med, D-72076 Tubingen, Germany; Mayo Clin Rochester, Dept Immunol, Rochester, MN 55905 USA; Univ Munich, Dept Neurol, D-8000 Munich, Germany; Univ Munich, Genzentrum, Friedrich Baur Inst, Munich, Germany	Eberhard Karls University of Tubingen; Mayo Clinic; University of Munich; University of Munich	Wiendl, H (corresponding author), Univ Tubingen, Dept Neurol, Sch Med, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.	heinz.wiendl@uni-tuebingen.de	Wiendl, Heinz/AAX-6041-2021	Lochmuller, Hanns/0000-0003-2324-8001; Beier, Dagmar/0000-0002-3336-157X; Weller, Michael/0000-0002-1748-174X; Wiendl, Heinz/0000-0003-4310-3432				Behrens L, 1998, J IMMUNOL, V161, P5943; BENDER A, 1995, J EXP MED, V181, P1863, DOI 10.1084/jem.181.5.1863; Bernasconi P, 1998, J NEUROIMMUNOL, V85, P52, DOI 10.1016/S0165-5728(97)00254-3; Carreno BM, 2002, ANNU REV IMMUNOL, V20, P29, DOI 10.1146/annurev.immunol.20.091101.091806; Carter LL, 2002, EUR J IMMUNOL, V32, P634, DOI 10.1002/1521-4141(200203)32:3<634::AID-IMMU634>3.0.CO;2-9; Coyle AJ, 2001, NAT IMMUNOL, V2, P203, DOI 10.1038/85251; Dalakas Marinos C, 2002, Adv Neurol, V88, P253; DALAKAS MC, 1995, ANN NEUROL, V37, P74; Dong HD, 1999, NAT MED, V5, P1365; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; EMSLIESMITH AM, 1989, HUM PATHOL, V20, P224, DOI 10.1016/0046-8177(89)90128-7; Eppihimer MJ, 2002, MICROCIRCULATION, V9, P133, DOI 10.1038/sj/mn/7800123; Freeman GJ, 2000, J EXP MED, V192, P1027, DOI 10.1084/jem.192.7.1027; GOEBELS N, 1992, J IMMUNOL, V149, P661; Goebels N, 1996, J CLIN INVEST, V97, P2905, DOI 10.1172/JCI118749; HOHLFELD R, 1990, J CLIN INVEST, V86, P370, DOI 10.1172/JCI114711; HOHLFELD R, 1994, IMMUNOL TODAY, V15, P269, DOI 10.1016/0167-5699(94)90006-X; ILLA I, 1992, ANN NEUROL, V31, P46, DOI 10.1002/ana.410310109; Ishida M, 2002, IMMUNOL LETT, V84, P57, DOI 10.1016/S0165-2478(02)00142-6; KARPATI G, 1988, ANN NEUROL, V23, P64, DOI 10.1002/ana.410230111; Kobata T, 2000, Rev Immunogenet, V2, P74; Latchman Y, 2001, NAT IMMUNOL, V2, P261, DOI 10.1038/85330; Liang L, 2002, CURR OPIN IMMUNOL, V14, P384, DOI 10.1016/S0952-7915(02)00342-4; MANTEGAZZA R, 1993, J CLIN INVEST, V91, P2880, DOI 10.1172/JCI116533; Mazanet MM, 2002, J IMMUNOL, V169, P3581, DOI 10.4049/jimmunol.169.7.3581; MICHAELIS D, 1993, AM J PATHOL, V143, P1142; Murata K, 1999, AM J PATHOL, V155, P453, DOI 10.1016/S0002-9440(10)65141-3; Nagaraju K, 2000, P NATL ACAD SCI USA, V97, P9209, DOI 10.1073/pnas.97.16.9209; Nagaraju K, 2001, ACTA PHYSIOL SCAND, V171, P215, DOI 10.1046/j.1365-201x.2001.00823.x; Nagaraju K, 1999, CLIN IMMUNOL, V92, P161, DOI 10.1006/clim.1999.4743; Okazaki T, 2001, P NATL ACAD SCI USA, V98, P13866, DOI 10.1073/pnas.231486598; Petroff MG, 2002, PLACENTA, V23, pS95, DOI 10.1053/plac.2002.0813; Sharpe AH, 2002, NAT REV IMMUNOL, V2, P116, DOI 10.1038/nri727; Tseng SY, 2001, J EXP MED, V193, P839, DOI 10.1084/jem.193.7.839; Wang SD, 2003, J EXP MED, V197, P1083, DOI 10.1084/jem.20021752; Wiendl H, 2000, ANN NEUROL, V48, P679, DOI 10.1002/1531-8249(200010)48:4<679::AID-ANA19>3.3.CO;2-M; Wiendl H, 2003, BRAIN, V126, P176, DOI 10.1093/brain/awg017; Wiendl H, 2002, J IMMUNOL, V169, P515, DOI 10.4049/jimmunol.169.1.515	38	90	100	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1892	+		10.1096/fj.03-0039fje	http://dx.doi.org/10.1096/fj.03-0039fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12923066				2022-12-25	WOS:000185345100002
J	Huang, HC; Shi, GY; Jiang, SJ; Shi, CS; Wu, CM; Yang, HY; Wu, HL				Huang, HC; Shi, GY; Jiang, SJ; Shi, CS; Wu, CM; Yang, HY; Wu, HL			Thrombomodulin-mediated cell adhesion - Involvement of its lectin-like domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPH-NODE METASTASIS; E-CADHERIN; EPIDERMAL DIFFERENTIATION; TUMOR-CELLS; EXPRESSION; CARCINOMA; MICE; THROMBIN; RECEPTOR; PROTEIN	Thrombomodulin (TM) is an integral membrane glycoprotein that is a potent anticoagulant factor. TM may also possess functions distinct from its anticoagulant activity. Here the influence of TM on cell adhesion was studied in TM-negative melanoma A2058 cells transfected with green fluorescent protein-tagged TM (TMG) or lectin domain-deleted TM (TMG(DeltaL)). Confocal microscopy demonstrated that both TMG and TMG(DeltaL) were distributed in the plasma membrane. TMG-expressed cells grew as closely clustered colonies, with TM localized prominently in the intercellular boundaries. TMG(DeltaL)-expressed cells grew singly. Overexpression of TMG, but not TMG(DeltaL), decreased monolayer permeability in vitro and tumor growth in vivo. The cell-to-cell adhesion in TMG-expressed cells was Ca2+-dependent and was inhibited by monoclonal antibody against the lectin-like domain of TM. The effects of TM-mediated cell adhesion were abolished by the addition of mannose, chondroitin sulfate A, or chondroitin sulfate C. In addition, anti-lectin-like domain antibody disrupted the close clustering of the endogenous TM-expressed keratinocyte HaCaT cell line derived from normal human epidermis. Double-labeling immunofluorescence staining revealed similar distributions of TM and actin filament in the cortex region of the TMG-expressed cells. Thus, TM can function as a Ca2+-dependent cell-to-cell adhesion molecule. Binding of specific carbohydrates to the lectin-like domain is essential for this specific function.	Natl Cheng Kung Univ, Coll Med, Dept Biochem, Tainan 701, Taiwan; Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan 701, Taiwan; China Med Coll, Dept Med Technol, Taichung 404, Taiwan; Natl Taiwan Univ, Inst Mol & Cell Biol, Taipei 107, Taiwan	National Cheng Kung University; National Cheng Kung University; China Medical University Taiwan; National Taiwan University	Wu, HL (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Biochem, Tainan 701, Taiwan.	halnwu@mail.ncku.edu.tw	Huang, Huey-Chun/O-3852-2015	Huang, Huey-Chun/0000-0002-3300-5946; Shi, Chung-Sheng/0000-0002-5548-7675				BOFFA MC, 1987, J HISTOCHEM CYTOCHEM, V35, P1267, DOI 10.1177/35.11.2821107; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Chay CH, 2000, J CELL BIOCHEM, P123; Conacci-Sorrell M, 2002, J CLIN INVEST, V109, P987, DOI 10.1172/JCI200215429; Conway EM, 1997, BLOOD, V89, P652, DOI 10.1182/blood.V89.2.652; Conway EM, 1999, BLOOD, V93, P3442, DOI 10.1182/blood.V93.10.3442.410k17_3442_3450; Conway EM, 2002, J EXP MED, V196, P565, DOI 10.1084/jem.20020077; ESMON CT, 1995, FASEB J, V9, P946, DOI 10.1096/fasebj.9.10.7615164; ESMON CT, 1982, J BIOL CHEM, V257, P7944; GABIUS H, 1997, J CANC INVEST, V15, P454; HEALY AM, 1995, P NATL ACAD SCI USA, V92, P850, DOI 10.1073/pnas.92.3.850; Herren B, 2001, EXP CELL RES, V271, P152, DOI 10.1006/excr.2001.5353; HIRANO S, 1987, J CELL BIOL, V105, P2501, DOI 10.1083/jcb.105.6.2501; Hubbard AK, 2000, FREE RADICAL BIO MED, V28, P1379, DOI 10.1016/S0891-5849(00)00223-9; Hynes RO, 1996, J CLIN INVEST, V98, P2193, DOI 10.1172/JCI119027; Jackson DE, 1996, PATHOLOGY, V28, P225, DOI 10.1080/00313029600169024; JACOB GS, 1995, ADV EXP MED BIOL, V376, P283; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; Lane DA, 2000, BLOOD, V95, P1517, DOI 10.1182/blood.V95.5.1517.005k48_1517_1532; LARGER DJ, 1995, AM J PATHOL, V146, P933; LARUE L, 1994, P NATL ACAD SCI USA, V91, P8263, DOI 10.1073/pnas.91.17.8263; Matsushita Y, 1998, CANCER LETT, V127, P195, DOI 10.1016/S0304-3835(98)00038-X; MODY R, 1995, J PHARMACOL TOX MET, V33, P1, DOI 10.1016/1056-8719(94)00052-6; NAWA K, 1990, BIOCHEM BIOPH RES CO, V171, P729, DOI 10.1016/0006-291X(90)91207-9; Ogawa H, 2000, CANCER LETT, V149, P95, DOI 10.1016/S0304-3835(99)00348-1; PETERSEN TE, 1988, FEBS LETT, V231, P51, DOI 10.1016/0014-5793(88)80700-2; PIGNATELLI M, 1992, BRIT J CANCER, V66, P629, DOI 10.1038/bjc.1992.328; Pokutta S, 2002, CURR OPIN STRUC BIOL, V12, P255, DOI 10.1016/S0959-440X(02)00318-4; POLLACK L, 1983, J CELL BIOL, V97, P293, DOI 10.1083/jcb.97.2.293; Raife TJ, 1998, J INVEST MED, V46, P127; RAIFE TJ, 1994, J CLIN INVEST, V93, P1846, DOI 10.1172/JCI117171; RIETHMACHER D, 1995, P NATL ACAD SCI USA, V92, P855, DOI 10.1073/pnas.92.3.855; STAHL PD, 1992, CURR OPIN IMMUNOL, V4, P49, DOI 10.1016/0952-7915(92)90123-V; SUEHIRO T, 1995, HEPATOLOGY, V21, P1285, DOI 10.1002/hep.1840210511; SUZUKI K, 1987, EMBO J, V6, P1891, DOI 10.1002/j.1460-2075.1987.tb02448.x; Tabata M, 1997, J ORAL PATHOL MED, V26, P258, DOI 10.1111/j.1600-0714.1997.tb01234.x; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TEZUKA Y, 1995, CANCER RES, V55, P4196; Togashi H, 2002, NEURON, V35, P77, DOI 10.1016/S0896-6273(02)00748-1; Varki A, 2001, BRAZ J MED BIOL RES, V34, P711, DOI 10.1590/S0100-879X2001000600003; Wilhelm S, 1998, INT J ONCOL, V13, P645; Zhang YM, 1998, J CLIN INVEST, V101, P1301, DOI 10.1172/JCI925	42	132	136	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46750	46759		10.1074/jbc.M305216200	http://dx.doi.org/10.1074/jbc.M305216200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12951323	hybrid			2022-12-25	WOS:000186569400066
J	Bylebyl, GR; Belichenko, I; Johnson, ES				Bylebyl, GR; Belichenko, I; Johnson, ES			The SUMO isopeptidase Ulp2 prevents accumulation of SUMO chains in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONJUGATING ENZYME; PROTEIN SMT3P; IN-VITRO; UBIQUITIN; SUMOYLATION; ENCODES; HOMOLOG; BINDING; LIGASE; UBC9P	The ubiquitin-related protein SUMO functions by becoming covalently attached to lysine residues in other proteins. Unlike ubiquitin, which is often linked to its substrates as a polyubiquitin chain, only one SUMO moiety is attached per modified site in most substrates. However, SUMO has recently been shown to form chains in vitro and in mammalian cells, with a lysine in the non-ubiquitin-like N-terminal extension serving as the major SUMO-SUMO branch site. To investigate the physiological function of SUMO chains, we generated Saccharomyces cerevisiae strains that expressed mutant SUMOs lacking various lysine residues. Otherwise wildtype strains lacking any of the nine lysines in SUMO were viable, had no obvious growth defects or stress sensitivities, and had SUMO conjugate patterns that did not differ dramatically from wild type. However, mutants lacking the SUMO-specific isopeptidase Ulp2 accumulated high molecular weight SUMO-containing species, which formed only when the N-terminal lysines of SUMO were present, suggesting that they contained SUMO chains. Furthermore SUMO branch-site mutants suppressed several of the phenotypes of ulp2Delta, consistent with the possibility that some ulp2Delta phenotypes are caused by accumulation of SUMO chains. We also found that a mutant SUMO whose non-ubiquitin- like N-terminal domain had been entirely deleted still carried out all the essential functions of SUMO. Thus, the ubiquitin-like domain of SUMO is sufficient for conjugation and all downstream functions required for yeast viability. Our data suggest that SUMO can form chains in vivo in yeast but demonstrate conclusively that chain formation is not required for the essential functions of SUMO in S. cerevisiae.	Thomas Jefferson Univ, Dept Mol Pharmacol & Biochem, Philadelphia, PA 19107 USA	Jefferson University	Johnson, ES (corresponding author), Thomas Jefferson Univ, Dept Mol Pharmacol & Biochem, 233 S 10th St,BLSB 231, Philadelphia, PA 19107 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062268] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM62268] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bachant J, 2002, MOL CELL, V9, P1169, DOI 10.1016/S1097-2765(02)00543-9; Bencsath KP, 2002, J BIOL CHEM, V277, P47938, DOI 10.1074/jbc.M207442200; Bernier-Villamor V, 2002, CELL, V108, P345, DOI 10.1016/S0092-8674(02)00630-X; Best JL, 2002, MOL CELL, V10, P843, DOI 10.1016/S1097-2765(02)00699-8; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; DOHMEN RJ, 1995, J BIOL CHEM, V270, P18099, DOI 10.1074/jbc.270.30.18099; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Johnson ES, 1999, J CELL BIOL, V147, P981, DOI 10.1083/jcb.147.5.981; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Johnson ES, 2002, NAT CELL BIOL, V4, pE295, DOI 10.1038/ncb1202-e295; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kim KI, 2002, J CELL PHYSIOL, V191, P257, DOI 10.1002/jcp.10100; Li SJ, 2000, MOL CELL BIOL, V20, P2367, DOI 10.1128/MCB.20.7.2367-2377.2000; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Li YH, 2003, P NATL ACAD SCI USA, V100, P259, DOI 10.1073/pnas.0235361100; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Okuma T, 1999, BIOCHEM BIOPH RES CO, V254, P693, DOI 10.1006/bbrc.1998.9995; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Sampson DA, 2001, J BIOL CHEM, V276, P21664, DOI 10.1074/jbc.M100006200; Schwartz DC, 2003, TRENDS BIOCHEM SCI, V28, P321, DOI 10.1016/S0968-0004(03)00113-0; Schwienhorst I, 2000, MOL GEN GENET, V263, P771, DOI 10.1007/s004380000254; Sherman F., 1986, METHODS YEAST GENETI; Smith J.A., 2000, CURRENT PROTOCOLS MO; Strunnikov AV, 2001, GENETICS, V158, P95; Takahashi Y, 1999, BIOCHEM BIOPH RES CO, V259, P582, DOI 10.1006/bbrc.1999.0821; Takahashi Y, 2003, J BIOCHEM, V133, P415, DOI 10.1093/jb/mvg054; Takahashi Y, 2001, J BIOL CHEM, V276, P48973, DOI 10.1074/jbc.M109295200; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819	32	197	201	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44113	44120		10.1074/jbc.M308357200	http://dx.doi.org/10.1074/jbc.M308357200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12941945	hybrid			2022-12-25	WOS:000186306700029
J	Chen, H; Montagnani, M; Funahashi, T; Shimomura, I; Quon, MJ				Chen, H; Montagnani, M; Funahashi, T; Shimomura, I; Quon, MJ			Adiponectin stimulates production of nitric oxide in vascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; FATTY-ACID OXIDATION; INSULIN-RESISTANCE; MICROVASCULAR RECRUITMENT; HORMONE ADIPONECTIN; GLOBULAR DOMAIN; PLASMA-PROTEIN; GLUCOSE-UPTAKE; MUSCLE; GENE	Adiponectin is secreted by adipose cells and mimics many metabolic actions of insulin. However, mechanisms by which adiponectin acts are poorly understood. The vascular action of insulin to stimulate endothelial production of nitric oxide ( NO), leading to vasodilation and increased blood flow is an important component of insulin-stimulated whole body glucose utilization. Therefore, we hypothesized that adiponectin may also stimulate production of NO in endothelium. Bovine aortic endothelial cells in primary culture loaded with the NO-specific fluorescent dye 4,5-diaminofluorescein diacetate (DAF-2 DA) were treated with lysophosphatidic acid (LPA) (a calcium-releasing agonist) or adiponectin (10 mug/ml bacterially produced full-length adiponectin). LPA treatment increased production of NO by similar to4-fold. Interestingly, adiponectin treatment significantly increased production of NO by similar to3-fold. Preincubation of cells with wortmannin ( phosphatidylinositol 3-kinase inhibitor) blocked only adiponectin- but not LPA-mediated production of NO. Using phospho-specific antibodies, we observed that either adiponectin or insulin treatment ( but not LPA treatment) caused phosphorylation of both Akt at Ser(473) and endothelial nitric-oxide synthase (eNOS) at Ser(1179) that was inhibitable by wortmannin. We next transfected bovine aortic endothelial cells with dominant-inhibitory mutants of Akt (Akt-AAA) or AMP-activated protein kinase (AMPK) (AMPK-K45R). Neither mutant affected production of NO in response to LPA treatment. Importantly, only AMPK-K45R, but not Akt-AAA, caused a significant partial inhibition of NO production in response to adiponectin. Moreover, AMPK-K45R inhibited phosphorylation of eNOS at Ser(1179) in response to adiponectin but not in response to insulin. We conclude that adiponectin has novel vascular actions to directly stimulate production of NO in endothelial cells using phosphatidylinositol 3-kinase-dependent pathways involving phosphorylation of eNOS at Ser(1179) by AMPK. Thus, the effects of adiponectin to augment metabolic actions of insulin in vivo may be due, in part, to vasodilator actions of adiponectin.	NCCAM, Diabet Unit, Clin Invest Lab, NIH, Bethesda, MD 20892 USA; Univ Bari, Sch Med, Dept Pharmacol & Human Physiol, I-70124 Bari, Italy; Osaka Univ, Grad Sch Med, Suita, Osaka 5650871, Japan	National Institutes of Health (NIH) - USA; NIH National Center for Complementary & Alternative Medicine; Universita degli Studi di Bari Aldo Moro; Osaka University	Quon, MJ (corresponding author), NCCAM, Diabet Unit, Clin Invest Lab, NIH, Bldg 10,Rm 6C-205,10 Ctr Dr MSC 1632, Bethesda, MD 20892 USA.	quonm@nih.gov	Montagnani, Monica/AAV-2057-2020; Quon, Michael/B-1970-2008	Montagnani, Monica/0000-0002-5697-8185; Quon, Michael/0000-0002-9601-9915; QUON, MICHAEL/0000-0002-5289-3707	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [Z02AT000001, ZIAAT000001, Z01AT000001] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [ZIFAT000001] Funding Source: NIH RePORTER	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Arita Y, 1999, BIOCHEM BIOPH RES CO, V257, P79, DOI 10.1006/bbrc.1999.0255; Baron AD, 1999, CONT ENDOCRINOL, V12, P247; Beltowski Jerzy, 2003, Med Sci Monit, V9, pRA55; Berg AH, 2002, TRENDS ENDOCRIN MET, V13, P84, DOI 10.1016/S1043-2760(01)00524-0; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014-5793(98)01705-0; Clark MG, 2003, AM J PHYSIOL-ENDOC M, V284, pE241, DOI 10.1152/ajpendo.00408.2002; Diez JJ, 2003, EUR J ENDOCRINOL, V148, P293, DOI 10.1530/eje.0.1480293; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Hara K, 2002, DIABETES, V51, P536, DOI 10.2337/diabetes.51.2.536; Heilbronn LK, 2003, CURR PHARM DESIGN, V9, P1411, DOI 10.2174/1381612033454766; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; Kishida K, 2003, BIOCHEM BIOPH RES CO, V306, P286, DOI 10.1016/S0006-291X(03)00940-9; Kondo H, 2002, DIABETES, V51, P2325, DOI 10.2337/diabetes.51.7.2325; Kubota N, 2002, J BIOL CHEM, V277, P25863, DOI 10.1074/jbc.C200251200; Kumada M, 2003, ARTERIOSCL THROM VAS, V23, P85, DOI 10.1161/01.ATV.0000048856.22331.50; Ma K, 2002, J BIOL CHEM, V277, P34658, DOI 10.1074/jbc.C200362200; Maeda K, 1996, BIOCHEM BIOPH RES CO, V221, P286, DOI 10.1006/bbrc.1996.0587; Maeda N, 2002, NAT MED, V8, P731, DOI 10.1038/nm724; Matsuda M, 2002, J BIOL CHEM, V277, P37487, DOI 10.1074/jbc.M206083200; Montagnani M, 2002, MOL ENDOCRINOL, V16, P1931, DOI 10.1210/me.2002-0074; Montagnani M, 2001, J BIOL CHEM, V276, P30392, DOI 10.1074/jbc.M103702200; Montagnani M, 2000, DIABETES OBES METAB, V2, P285, DOI 10.1046/j.1463-1326.2000.00092.x; Morrow VA, 2003, J BIOL CHEM, V278, P31629, DOI 10.1074/jbc.M212831200; Nakano Y, 1996, J BIOCHEM-TOKYO, V120, P803; Ouchi N, 2001, CIRCULATION, V103, P1057, DOI 10.1161/01.CIR.103.8.1057; Ouchi N, 1999, CIRCULATION, V100, P2473, DOI 10.1161/01.CIR.100.25.2473; Pellme F, 2003, DIABETES, V52, P1182, DOI 10.2337/diabetes.52.5.1182; QUON MJ, 1992, BIOCHEMISTRY-US, V31, P9947, DOI 10.1021/bi00156a013; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Shimabukuro M, 2003, J CLIN ENDOCR METAB, V88, P3236, DOI 10.1210/jc.2002-021883; Tomas E, 2002, P NATL ACAD SCI USA, V99, P16309, DOI 10.1073/pnas.222657499; Vincent MA, 2003, AM J PHYSIOL-ENDOC M, V285, pE123, DOI 10.1152/ajpendo.00021.2003; Vincent MA, 2002, DIABETES, V51, P42, DOI 10.2337/diabetes.51.1.42; Vincent Michelle A, 2003, Curr Diab Rep, V3, P279, DOI 10.1007/s11892-003-0018-9; Waki H, 2003, J BIOL CHEM, V278, P40352, DOI 10.1074/jbc.M300365200; Wu XD, 2003, DIABETES, V52, P1355, DOI 10.2337/diabetes.52.6.1355; Yamauchi T, 2003, NATURE, V423, P762, DOI 10.1038/nature01705; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; Yokota T, 2000, BLOOD, V96, P1723, DOI 10.1182/blood.V96.5.1723; Yu JG, 2002, DIABETES, V51, P2968, DOI 10.2337/diabetes.51.10.2968; Zeng GY, 1996, J CLIN INVEST, V98, P894, DOI 10.1172/JCI118871; Zeng GY, 2000, CIRCULATION, V101, P1539, DOI 10.1161/01.CIR.101.13.1539; Zou MH, 2003, J BIOL CHEM, V278, P34003, DOI 10.1074/jbc.M300215200	47	818	865	2	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					45021	45026		10.1074/jbc.M307878200	http://dx.doi.org/10.1074/jbc.M307878200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12944390	hybrid			2022-12-25	WOS:000186306700139
J	Redko, Y; Tock, MR; Adams, CJ; Kaberdin, VR; Grasby, JA; McDowall, KJ				Redko, Y; Tock, MR; Adams, CJ; Kaberdin, VR; Grasby, JA; McDowall, KJ			Determination of the catalytic parameters of the N-terminal half of Escherichia coli ribonuclease E and the identification of critical functional groups in RNA substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; RIBOSOMAL-RNA; RESTRICTION-ENDONUCLEASE; AFFINITY-CHROMATOGRAPHY; DIRECT EXPRESSION; GENE-PRODUCT; CLONED GENES; CAFA PROTEIN; IN-VIVO; CLEAVAGE	Ribonuclease E is required for the rapid decay and correct processing of RNA in Escherichia coli. A detailed understanding of the hydrolysis of RNA by this and related enzymes will require the integration of structural and molecular data with quantitative measurements of RNA hydrolysis. Therefore, an assay for RNaseE that can be set up to have relatively high throughput while being sensitive and quantitative will be advantageous. Here we describe such an assay, which is based on the automated high pressure liquid chromatography analysis of fluorescently labeled RNA samples. We have used this assay to optimize reaction conditions, to determine for the first time the catalytic parameters for a polypeptide of RNaseE, and to investigate the RNaseE-catalyzed reaction through the modification of functional groups within an RNA substrate. We find that catalysis is dependent on both protonated and unprotonated functional groups and that the recognition of a guanosine sequence determinant that is upstream of the scissile bond appears to consist of interactions with the exocyclic 2-amino group, the 7N of the nucleobase and the imino proton or 6-keto group. Additionally, we find that a ribose-like sugar conformation is preferred in the 5'-nucleotide of the scissile phosphodiester bond and that a 2'-hydroxyl group proton is not essential. Steric bulk at the 2' position in the 5'-nucleotide appears to be inhibitory to the reaction. Combined, these observations establish a foundation for the functional interpretation of a three-dimensional structure of the catalytic domain of RNaseE when solved.	Univ Leeds, Fac Biol Sci, Astbury Ctr Struct Mol Biol, Leeds LS2 9JT, W Yorkshire, England; Univ Sheffield, Dept Chem, Krebs Inst, Ctr Chem Biol, Sheffield S3 7HF, S Yorkshire, England; Vienna Bioctr, Dept Genet & Microbiol, Max F Perutz Labs, A-1030 Vienna, Austria	University of Leeds; University of Sheffield; Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL)	McDowall, KJ (corresponding author), Univ Leeds, Fac Biol Sci, Astbury Ctr Struct Mol Biol, Manton Bldg, Leeds LS2 9JT, W Yorkshire, England.		McDowall, Kenneth/GYA-5735-2022; Kaberdin, Vladimir/C-3870-2017	Kaberdin, Vladimir/0000-0002-7166-5136; McDowall, Kenneth/0000-0003-2528-2190				Baldwin GS, 1999, J MOL BIOL, V288, P87, DOI 10.1006/jmbi.1999.2672; Bessarab DA, 1998, P NATL ACAD SCI USA, V95, P3157, DOI 10.1073/pnas.95.6.3157; Blackburn G.M, 1996, NUCL ACIDS CHEM BIOL; Carpousis AJ, 1999, TRENDS GENET, V15, P24, DOI 10.1016/S0168-9525(98)01627-8; CARPOUSIS AJ, 1994, CELL, V76, P889, DOI 10.1016/0092-8674(94)90363-8; Coburn GA, 1999, PROG NUCLEIC ACID RE, V62, P55; Condon C, 2002, NUCLEIC ACIDS RES, V30, P5339, DOI 10.1093/nar/gkf691; CORMACK RS, 1993, P NATL ACAD SCI USA, V90, P9006, DOI 10.1073/pnas.90.19.9006; Cornish-Bowden A, 2001, FUNDAMENTALS ENZYME; Dickman MJ, 2002, RNA, V8, P247, DOI 10.1017/S1355838202012888; EHRETSMANN CP, 1992, GENE DEV, V6, P149, DOI 10.1101/gad.6.1.149; EHRETSMANN CP, 1992, FASEB J, V6, P3186, DOI 10.1096/fasebj.6.13.1397840; Feng YA, 2002, P NATL ACAD SCI USA, V99, P14746, DOI 10.1073/pnas.202590899; Fersht A., 1999, STRUCTURE MECH PROTE, DOI 10.1142/10574; GHORA BK, 1978, CELL, V15, P1055, DOI 10.1016/0092-8674(78)90289-1; Grunberg-Manago M, 1999, ANNU REV GENET, V33, P193, DOI 10.1146/annurev.genet.33.1.193; GUSCHLBAUER W, 1980, NUCLEIC ACIDS RES, V8, P1421, DOI 10.1093/nar/8.6.1421; Huang HJ, 1998, NATURE, V391, P99, DOI 10.1038/34219; Jain C, 2002, MOL MICROBIOL, V43, P1053, DOI 10.1046/j.1365-2958.2002.02808.x; Jiang XQ, 2000, J BACTERIOL, V182, P2468, DOI 10.1128/JB.182.9.2468-2475.2000; Kaberdin VR, 2003, NUCLEIC ACIDS RES, V31, P4710, DOI 10.1093/nar/gkg690; Kaberdin VR, 1998, P NATL ACAD SCI USA, V95, P11637, DOI 10.1073/pnas.95.20.11637; Kaberdin VR, 2000, J MOL BIOL, V301, P257, DOI 10.1006/jmbi.2000.3962; KANAYA S, 1990, BIOCHEM J, V271, P59, DOI 10.1042/bj2710059; Keck JL, 1998, J BIOL CHEM, V273, P34128, DOI 10.1074/jbc.273.51.34128; Kido M, 1996, J BACTERIOL, V178, P3917, DOI 10.1128/jb.178.13.3917-3925.1996; Lee K, 2002, MOL MICROBIOL, V43, P1445, DOI 10.1046/j.1365-2958.2002.02848.x; Leroy A, 2002, MOL MICROBIOL, V45, P1231, DOI 10.1046/j.1365-2958.2002.03104.x; Li ZW, 1999, EMBO J, V18, P2878, DOI 10.1093/emboj/18.10.2878; LINCHAO S, 1994, J BIOL CHEM, V269, P10797; LODI PJ, 1991, BIOCHEMISTRY-US, V30, P6948, DOI 10.1021/bi00242a020; Lopez PJ, 1999, MOL MICROBIOL, V33, P188, DOI 10.1046/j.1365-2958.1999.01465.x; MACKIE GA, 1992, J BIOL CHEM, V267, P1054; Mackie GA, 1998, NATURE, V395, P720, DOI 10.1038/27246; Mackie GA, 2000, J BIOL CHEM, V275, P25069, DOI 10.1074/jbc.C000363200; MCDOWALL KJ, 1995, NATURE, V374, P287, DOI 10.1038/374287a0; McDowall KJ, 1996, J MOL BIOL, V255, P349, DOI 10.1006/jmbi.1996.0027; Miczak A, 1996, P NATL ACAD SCI USA, V93, P3865, DOI 10.1073/pnas.93.9.3865; MORITA M, 1979, EUR J BIOCHEM, V97, P435, DOI 10.1111/j.1432-1033.1979.tb13131.x; Nilsson RP, 2002, BIOTECHNIQUES, V33, P272, DOI 10.2144/02332bm03; Ow MC, 2000, MOL MICROBIOL, V38, P854, DOI 10.1046/j.1365-2958.2000.02186.x; PORATH J, 1975, NATURE, V258, P598, DOI 10.1038/258598a0; Price N., 1999, FUNDAMENTALS ENZYMOL; Regnier P, 2000, BIOESSAYS, V22, P235; ROSENBERG AH, 1987, GENE, V59, P191, DOI 10.1016/0378-1119(87)90327-1; SMITH MC, 1988, J BIOL CHEM, V263, P7211; Steinhardt J., 1969, MULTIPLE EQUILIBRIA; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Symmons MF, 2002, TRENDS BIOCHEM SCI, V27, P11, DOI 10.1016/S0968-0004(01)01999-5; TAMM J, 1985, P NATL ACAD SCI USA, V82, P2257, DOI 10.1073/pnas.82.8.2257; TARASEVICIENE L, 1995, J BIOL CHEM, V270, P26391, DOI 10.1074/jbc.270.44.26391; Tock MR, 2000, J BIOL CHEM, V275, P8726, DOI 10.1074/jbc.275.12.8726; Vanzo NF, 1998, GENE DEV, V12, P2770, DOI 10.1101/gad.12.17.2770; Walsh AP, 2001, NUCLEIC ACIDS RES, V29, P1864, DOI 10.1093/nar/29.9.1864; WATERS TR, 1994, BIOCHEMISTRY-US, V33, P1812, DOI 10.1021/bi00173a026	56	33	33	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44001	44008		10.1074/jbc.M306760200	http://dx.doi.org/10.1074/jbc.M306760200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12947103	hybrid			2022-12-25	WOS:000186306700015
J	Hall, AM; Smith, AJ; Bernlohr, DA				Hall, AM; Smith, AJ; Bernlohr, DA			Characterization of the acyl-CoA synthetase activity of purified murine fatty acid transport protein 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PLASMA-MEMBRANE; CARDIAC MYOCYTES; BINDING-PROTEIN; MAMMALIAN-CELLS; RAT-LIVER; EXPRESSION; METABOLISM; CLONING; CD36	Fatty acid transport protein 1 (FATP1) is an similar to63-kDa plasma membrane protein that facilitates the influx of fatty acids into adipocytes as well as skeletal and cardiac myocytes. Previous studies with FATP1 expressed in COS1 cell extracts suggested that FATP1 exhibits very long chain acyl-CoA synthetase (ACS) activity and that such activity may be linked to fatty acid transport. To address the enzymatic activity of the isolated protein, murine FATP1 and ACS1 were engineered to contain a C-terminal Myc-His tag expressed in COS1 cells via adenoviral-mediated infection and purified to homogeneity using nickel affinity chromatography. Kinetic analysis of the purified enzymes was carried out for long chain palmitic acid (C16:0) and very long chain lignoceric acid (C24:0) as well as for ATP and CoA. FATP1 exhibited similar substrate specificity for fatty acids 16-24 carbons in length, whereas ACS1 was 10-fold more active on long chain fatty acids relative to very long chain fatty acids. The very long chain acyl-CoA synthetase activity of the two enzymes was comparable as were the K-m values for both ATP and coenzyme A. Interestingly, FATP1 was insensitive to inhibition by triacsin C, whereas ACS1 was inhibited by micromolar concentrations of the compound. These data represent the first characterization of purified FATP1 and indicate that the enzyme is a broad substrate specificity acyl-CoA synthetase. These findings are consistent with the hypothesis that that fatty acid uptake into cells is linked to their esterification with coenzyme A.	Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Bernlohr, DA (corresponding author), Univ Minnesota, Dept Biochem Mol Biol & Biophys, 321 Church St SE,6-155 Jackson Hall, Minneapolis, MN 55455 USA.			Hall, Angela Marie/0000-0003-0006-7910				Abumrad N, 1999, BBA-MOL CELL BIOL L, V1441, P4, DOI 10.1016/S1388-1981(99)00137-7; Abumrad N, 1998, J LIPID RES, V39, P2309; ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; BABBITT PC, 1992, BIOCHEMISTRY-US, V31, P5594, DOI 10.1021/bi00139a024; Coe NR, 1999, J BIOL CHEM, V274, P36300, DOI 10.1074/jbc.274.51.36300; Faergeman NJ, 1997, BIOCHEM J, V323, P1; Faergeman NJ, 1997, J BIOL CHEM, V272, P8531, DOI 10.1074/jbc.272.13.8531; Frohnert BI, 2000, PROG LIPID RES, V39, P83, DOI 10.1016/S0163-7827(99)00018-1; Gargiulo CE, 1999, J LIPID RES, V40, P881; Hamilton JA, 2002, MOL CELL BIOCHEM, V239, P17, DOI 10.1023/A:1020542220599; Hamilton JA, 2001, J MOL NEUROSCI, V16, P99, DOI 10.1385/JMN:16:2-3:99; Hatch GM, 2002, J LIPID RES, V43, P1380, DOI 10.1194/jlr.M200130-JLR200; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Herrmann T, 2001, GENE, V270, P31, DOI 10.1016/S0378-1119(01)00489-9; Hirsch D, 1998, P NATL ACAD SCI USA, V95, P8625, DOI 10.1073/pnas.95.15.8625; Irie H, 2003, P NATL ACAD SCI USA, V100, P6819, DOI 10.1073/pnas.1132094100; Kim JH, 2001, J BIOL CHEM, V276, P24667, DOI 10.1074/jbc.M010793200; Knudsen J, 1999, MOL CELL BIOCHEM, V192, P95, DOI 10.1023/A:1006830606060; Luiken JJFP, 1997, J LIPID RES, V38, P745; Luiken JJFP, 1999, J LIPID RES, V40, P1007; Moulson CL, 2003, P NATL ACAD SCI USA, V100, P5274, DOI 10.1073/pnas.0431186100; NAGAMATSU K, 1986, LIPIDS, V21, P328, DOI 10.1007/BF02535695; NAGAMATSU K, 1985, BIOCHIM BIOPHYS ACTA, V836, P80, DOI 10.1016/0005-2760(85)90223-1; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; SORRENTINO D, 1988, J CLIN INVEST, V82, P928, DOI 10.1172/JCI113700; Stuhlsatz-Krouper SM, 1998, J BIOL CHEM, V273, P28642, DOI 10.1074/jbc.273.44.28642; STUMP DD, 1993, AM J PHYSIOL, V265, pG894, DOI 10.1152/ajpgi.1993.265.5.G894; Uchiyama A, 1996, J BIOL CHEM, V271, P30360, DOI 10.1074/jbc.271.48.30360; Watkins PA, 1998, J BIOL CHEM, V273, P18210, DOI 10.1074/jbc.273.29.18210; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Zou ZY, 2003, J BIOL CHEM, V278, P16414, DOI 10.1074/jbc.M210557200; Zou ZY, 2002, J BIOL CHEM, V277, P31062, DOI 10.1074/jbc.M205034200	32	134	141	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43008	43013		10.1074/jbc.M306575200	http://dx.doi.org/10.1074/jbc.M306575200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12937175	hybrid			2022-12-25	WOS:000186157000036
J	Ivanova, J; Salama, G; Clancy, RM; Schor, NF; Nylander, KD; Stoyanovsky, DA				Ivanova, J; Salama, G; Clancy, RM; Schor, NF; Nylander, KD; Stoyanovsky, DA			Formation of nitroxyl and hydroxyl radical in solutions of sodium trioxodinitrate - Effects of pH and cytotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-SPIN-RESONANCE; NITRIC-OXIDE; ALDEHYDE DEHYDROGENASE; AQUEOUS-SOLUTION; ANGELIS SALT; HYDROGEN-PEROXIDE; HPLC-EC; ANION; PEROXYNITRITE; NO	Despite its negative redox potential, nitroxyl (HNO) can trigger reactions of oxidation. Mechanistically, these reactions were suggested to occur with the intermediate formation of either hydroxyl radical ((OH)-O-.) or peroxynitrite (ONOO-). In this work, we present further experimental evidence that HNO can generate (OH)-O-.. Sodium trioxodinitrate (Na2N2O3), a commonly used donor of HNO, oxidized phenol and Me2SO to benzene diols and .CH3, respectively. The oxidation of Me2SO was O-2-independent, suggesting that this process reflected neither the intermediate formation of ONOO- nor a redox cycling of transition metal ions that could initiate Fentonlike reactions. In solutions of phenol, Na2N2O3 yielded benzene-1,2-diol and benzene-1,4-diol at a ratio of 2: 1, which is consistent with the generation of free (OH)-O-.. Ethanol and Me2SO, which are efficient scavengers of (OH)-O-., impeded the hydroxylation of phenol. A mechanism for the hydrolysis of Na2N2O3 is proposed that includes dimerization of HNO to cis-hyponitrous acid (HO-N = N- OH) with a concomitant azo-type homolytic fission of the latter to N-2 and (OH)-O-.. The HNO-dependent production of (OH)-O-. was with 1 order of magnitude higher at pH 6.0 than at pH 7.4. Hence, we hypothesized that HNO can exert selective toxicity to cells subjected to acidosis. In support of this thesis, Na2N2O3 was markedly more toxic to human fibroblasts and SK-N-SH neuroblastoma cells at pH 6.2 than at pH 7.4. Scavengers of (OH)-O-. impeded the cytotoxicity of Na2N2O3. These results suggest that the formation of HNO may be viewed as a toxicological event in tissues subjected to acidosis.	Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA; NYU, Sch Med, Dept Rheumatol, New York, NY 10016 USA; Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15213 USA; Childrens Hosp Pittsburgh, Pediat Ctr Neurosci, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; New York University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Stoyanovsky, DA (corresponding author), Univ Pittsburgh, Dept Surg, MUH654 NW,3459 5th Ave, Pittsburgh, PA 15213 USA.		Ivanova, Juliana/AAN-3235-2021; Ivanova, Juliana/HGA-1586-2022	Ivanova, Juliana/0000-0002-3213-2046; Ivanova, Juliana/0000-0002-3213-2046; Schor, Nina/0000-0002-3817-7376; Stoyanovsky, Detcho/0000-0001-5591-4780	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009648] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES09648-01A2] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Al-Ajlouni AM, 1999, INORG CHEM, V38, P1592, DOI 10.1021/ic981194a; ANDERSON JH, 1963, ANALYST, V88, P494, DOI 10.1039/an9638800494; Andersson SE, 1999, J RHEUMATOL, V26, P2018; Bai P, 2001, FREE RADICAL BIO MED, V31, P1616, DOI 10.1016/S0891-5849(01)00756-0; Bartberger MD, 2001, P NATL ACAD SCI USA, V98, P2194, DOI 10.1073/pnas.041481598; Bartberger MD, 2002, P NATL ACAD SCI USA, V99, P10958, DOI 10.1073/pnas.162095599; BONNER FT, 1975, INORG CHEM, V14, P558, DOI 10.1021/ic50145a022; BUCHHOLZ JR, 1965, J AM CHEM SOC, V87, P2350, DOI 10.1021/ja01089a008; BUETTNER GR, 1987, FREE RADICAL BIO MED, V3, P259, DOI 10.1016/S0891-5849(87)80033-3; Chazotte-Aubert L, 1999, J BIOL CHEM, V274, P20909, DOI 10.1074/jbc.274.30.20909; Choi YB, 2000, NAT NEUROSCI, V3, P15, DOI 10.1038/71090; Conway TT, 1998, J MED CHEM, V41, P2903, DOI 10.1021/jm980200+; Daiber A, 1998, NITRIC OXIDE-BIOL CH, V2, P259, DOI 10.1006/niox.1998.0186; DeMaster EG, 1997, ALCOHOL, V14, P181, DOI 10.1016/S0741-8329(96)00142-5; DONALD CE, 1986, INORG CHEM, V25, P2676, DOI 10.1021/ic00236a004; DOYLE MP, 1988, J AM CHEM SOC, V110, P593, DOI 10.1021/ja00210a047; Ellis A, 2000, BRIT J PHARMACOL, V129, P315, DOI 10.1038/sj.bjp.0703058; FIELD RJ, 1982, J PHYS CHEM-US, V86, P2443, DOI 10.1021/j100210a040; GASBARRINI A, 1992, J BIOL CHEM, V267, P7545; HAGE JP, 1995, BIOORGAN MED CHEM, V3, P1383, DOI 10.1016/0968-0896(95)00123-X; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Hogg N, 1996, FEBS LETT, V382, P223, DOI 10.1016/0014-5793(96)00086-5; Hughes MN, 1999, BBA-BIOENERGETICS, V1411, P263, DOI 10.1016/S0005-2728(99)00019-5; HUGHES MN, 1976, J CHEM SOC DALTON, P703; ITO S, 1992, J ORG CHEM, V57, P6937, DOI 10.1021/jo00051a048; Jacobi J, 2002, AM J HEALTH-SYST PH, V59, pS3, DOI 10.1093/ajhp/59.suppl_1.S3; JANZEN EG, 1992, FREE RADICAL BIO MED, V12, P169, DOI 10.1016/0891-5849(92)90011-5; Jensen DE, 1998, BIOCHEM J, V331, P659, DOI 10.1042/bj3310659; KIGOSHI M, 1993, B CHEM SOC JPN, V66, P2954, DOI 10.1246/bcsj.66.2954; Kim WK, 1999, NEURON, V24, P461, DOI 10.1016/S0896-6273(00)80859-4; Kirsch M, 2002, J BIOL CHEM, V277, P13379, DOI 10.1074/jbc.M108079200; LEE MJC, 1992, J MED CHEM, V35, P3648, DOI 10.1021/jm00098a008; Lee MJC, 2001, NITRIC OXIDE-BIOL CH, V5, P278, DOI 10.1006/niox.2001.0349; LOECHLER EL, 1987, J AM CHEM SOC, V109, P3076, DOI 10.1021/ja00244a034; Ma XL, 1999, P NATL ACAD SCI USA, V96, P14617, DOI 10.1073/pnas.96.25.14617; Miranda KM, 2001, J BIOL CHEM, V276, P1720, DOI 10.1074/jbc.M006174200; Miranda KM, 2003, J INORG BIOCHEM, V93, P52, DOI 10.1016/S0162-0134(02)00498-1; MOTOHASHI N, 1993, CHEM PHARM BULL, V41, P1842; MURPHY ME, 1991, P NATL ACAD SCI USA, V88, P10860, DOI 10.1073/pnas.88.23.10860; NAGASAWA HT, 1995, J MED CHEM, V38, P1865, DOI 10.1021/jm00011a005; Naughton P, 2002, J BIOL CHEM, V277, P40666, DOI 10.1074/jbc.M203863200; Nelli S, 2000, BRIT J PHARMACOL, V131, P356, DOI 10.1038/sj.bjp.0703550; Novakov CP, 2001, CHEM RES TOXICOL, V14, P1239, DOI 10.1021/tx015507h; Ohshima H, 1999, FREE RADICAL BIO MED, V26, P1305, DOI 10.1016/S0891-5849(98)00327-X; Ohshima H, 1998, FREE RADICAL BIO MED, V25, P1057, DOI 10.1016/S0891-5849(98)00141-5; Owens LM, 1996, CIRCULATION, V94, P10, DOI 10.1161/01.CIR.94.1.10; Paolocci N, 2003, P NATL ACAD SCI USA, V100, P5537, DOI 10.1073/pnas.0937302100; PIERCE GB, 1991, DIFFERENTIATION, V46, P181, DOI 10.1111/j.1432-0436.1991.tb00880.x; RAGHAVAN NV, 1980, J AM CHEM SOC, V102, P3495, DOI 10.1021/ja00530a031; Shafirovich V, 2002, P NATL ACAD SCI USA, V99, P7340, DOI 10.1073/pnas.112202099; Sharpe MA, 1998, BIOCHEM J, V332, P9, DOI 10.1042/bj3320009; SMITH PAS, 1960, J AM CHEM SOC, V82, P5731, DOI 10.1021/ja01506a043; Stoyanovsky DA, 1999, CHEM RES TOXICOL, V12, P730, DOI 10.1021/tx9900371; Stoyanovsky DA, 1999, J AM CHEM SOC, V121, P5093, DOI 10.1021/ja990318v; Stoyanovsky DA, 1999, ANAL CHEM, V71, P715, DOI 10.1021/ac980657r; STOYANOVSKY DA, 1995, ARCH BIOCHEM BIOPHYS, V323, P343, DOI 10.1006/abbi.1995.9955; Stubbs M, 2000, MOL MED TODAY, V6, P15, DOI 10.1016/S1357-4310(99)01615-9; TOWELL J, 1991, ANAL BIOCHEM, V196, P111, DOI 10.1016/0003-2697(91)90126-E; Uppu RM, 1998, ARCH BIOCHEM BIOPHYS, V358, P1, DOI 10.1006/abbi.1998.0825; Vaananen AJ, 2003, FREE RADICAL RES, V37, P381, DOI 10.1080/1071576031000061011; VanUffelen BE, 1998, BIOCHEM J, V330, P719; VAUPEL PW, 1981, CANCER RES, V41, P2008; VELTWISCH D, 1980, J CHEM SOC PERK T 2, P146, DOI 10.1039/p29800000146; Waldmann R, 2001, ADV EXP MED BIOL, V502, P293; Wink DA, 1998, ARCH BIOCHEM BIOPHYS, V351, P66, DOI 10.1006/abbi.1997.0565; Wong PSY, 1998, BIOCHEMISTRY-US, V37, P5362, DOI 10.1021/bi973153g; Xia Y, 2000, FREE RADICAL BIO MED, V29, P793, DOI 10.1016/S0891-5849(00)00427-5	68	23	23	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42761	42768		10.1074/jbc.M305544200	http://dx.doi.org/10.1074/jbc.M305544200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12920123	hybrid			2022-12-25	WOS:000186157000006
J	Lushnikov, AY; Bogdanov, A; Lyubchenko, YL				Lushnikov, AY; Bogdanov, A; Lyubchenko, YL			DNA recombination - Holliday junctions dynamics and branch migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATOMIC-FORCE MICROSCOPY; GENETIC RECOMBINATION; CRYSTAL-STRUCTURES; REPLICATION FORKS; 4-WAY JUNCTIONS; COMPLEX	Holliday junctions are critical intermediates for homologous, site-specific recombination, DNA repair, and replication. A wealth of structural information is available for immobile four-way junctions, but the controversy on the mechanism of branch migration of Holliday junctions remains unsolved. Two models for the mechanism of branch migration were suggested. According to the early model of Alberts-Meselson-Sigal (Sigal, N., and Alberts, B. (1972) J. Mol. Biol. 71, 789-793 and Meselson, M. (1972) J. Mol. Biol. 71, 795-798), exchanging DNA strands around the junction remain parallel during branch migration. Kinetic studies of branch migration (Panyutin, I. G., and Hsieh, P. (1994) Proc. Natl. Acad. Sci. U.S.A. 91, 2021-2025) suggest an alternative model in which the junction adopts an extended conformation. We tested these models using a Holliday junction undergoing branch migration and time-lapse atomic force microscopy, an imaging technique capable of imaging DNA dynamics. The single molecule atomic force microscopy experiments performed in the presence and in the absence of divalent cations show that mobile Holliday junctions adopt an unfolded conformation during branch migration that is retained despite a broad range of motion in the arms of the junction. This conformation of the junction remains unchanged until strand separation. The data obtained support the model for branch migration having the extended conformation of the Holliday junction.	Arizona State Univ, Sch Life Sci, Tempe, AZ 85287 USA; St Petersburg State Univ, Dept Phys, St Petersburg 188512, Russia	Arizona State University; Arizona State University-Tempe; Saint Petersburg State University	Lyubchenko, YL (corresponding author), Arizona State Univ, Sch Life Sci, Tempe, AZ 85287 USA.		Bogdanov, Alexey A./P-1231-2017; Alexey, Bogdanov/AHD-2822-2022	Bogdanov, Alexey A./0000-0002-7887-4635; Alexey, Bogdanov/0000-0002-7887-4635	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062235] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 62235] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Biswas I, 1998, J MOL BIOL, V279, P795, DOI 10.1006/jmbi.1998.1769; CHURCHILL MEA, 1988, P NATL ACAD SCI USA, V85, P4653, DOI 10.1073/pnas.85.13.4653; Constantinou A, 2001, CELL, V104, P259, DOI 10.1016/S0092-8674(01)00210-0; Cromie GA, 2001, MOL CELL, V8, P1163, DOI 10.1016/S1097-2765(01)00419-1; Eichman BF, 2002, J MOL BIOL, V320, P1037, DOI 10.1016/S0022-2836(02)00540-5; Fogg JM, 2000, BIOCHEMISTRY-US, V39, P4082, DOI 10.1021/bi992785v; Grompone G, 2002, MOL MICROBIOL, V44, P1331, DOI 10.1046/j.1365-2958.2002.02962.x; Ho PS, 2001, CURR OPIN STRUC BIOL, V11, P302, DOI 10.1016/S0959-440X(00)00219-0; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; Huffman KE, 1999, J MOL BIOL, V286, P1, DOI 10.1006/jmbi.1998.2468; LEACH DRF, 1996, GENETIC RECOMBINATIO; Lilley DMJ, 1999, NAT STRUCT BIOL, V6, P897, DOI 10.1038/13255; Lilley DMJ, 1997, P NATL ACAD SCI USA, V94, P9513, DOI 10.1073/pnas.94.18.9513; Lyubchenko YL, 1997, P NATL ACAD SCI USA, V94, P496, DOI 10.1073/pnas.94.2.496; Lyubchenko YL, 2002, MICROSC MICROANAL, V8, P170; McGlynn P, 2001, P NATL ACAD SCI USA, V98, P8235, DOI 10.1073/pnas.121007798; McKinney SA, 2003, NAT STRUCT BIOL, V10, P93, DOI 10.1038/nsb883; MESELSON M, 1972, J MOL BIOL, V71, P795, DOI 10.1016/0022-2828(72)90048-X; PANYUTIN IG, 1994, P NATL ACAD SCI USA, V91, P2021, DOI 10.1073/pnas.91.6.2021; PANYUTIN IG, 1995, EMBO J, V14, P1819, DOI 10.1002/j.1460-2075.1995.tb07170.x; Postow L, 2001, J BIOL CHEM, V276, P2790, DOI 10.1074/jbc.M006736200; SEEMAN NC, 1994, ANNU REV BIOPH BIOM, V23, P53, DOI 10.1146/annurev.bb.23.060194.000413; Sha R, 2000, BIOCHEMISTRY-US, V39, P11514, DOI 10.1021/bi0010468; Sha RJ, 2002, BIOCHEMISTRY-US, V41, P5950, DOI 10.1021/bi020001z; Shlyakhtenko LS, 2000, NUCLEIC ACIDS RES, V28, P3472, DOI 10.1093/nar/28.18.3472; Shlyakhtenko LS, 2003, ULTRAMICROSCOPY, V97, P279, DOI 10.1016/S0304-3991(03)00053-6; Shlyakhtenko LS, 1998, J MOL BIOL, V280, P61, DOI 10.1006/jmbi.1998.1855; Shlyakhtenko LS, 2000, J MOL BIOL, V296, P1169, DOI 10.1006/jmbi.2000.3542; SIGAL N, 1972, J MOL BIOL, V71, P789, DOI 10.1016/S0022-2836(72)80039-1; SRINIVASAN AR, 1994, BIOCHEMISTRY-US, V33, P9389, DOI 10.1021/bi00198a004; Van Duyne GD, 2001, ANNU REV BIOPH BIOM, V30, P87, DOI 10.1146/annurev.biophys.30.1.87	31	29	29	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43130	43134		10.1074/jbc.M308228200	http://dx.doi.org/10.1074/jbc.M308228200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12949070	hybrid			2022-12-25	WOS:000186157000053
J	Morais, VA; Crystal, AS; Pijak, DS; Carlin, D; Costa, J; Lee, VMY; Doms, RW				Morais, VA; Crystal, AS; Pijak, DS; Carlin, D; Costa, J; Lee, VMY; Doms, RW			The transmembrane domain region of nicastrin mediates direct interactions with APH-1 and the gamma-secretase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; BETA-APP; INTRACELLULAR DOMAIN; INTRAMEMBRANE PROTEOLYSIS; GLYCOSYLATED NICASTRIN; ALZHEIMERS-DISEASE; A-BETA; PRESENILIN; CLEAVAGE; NOTCH	Nicastrin (NCT) is a type I integral membrane protein that is one of the four essential components of the gamma-secretase complex, a protein assembly that catalyzes the intramembranous cleavage of the amyloid precursor protein and Notch. Other gamma-secretase components include presenilin-1 (PS1), APH-1, and PEN-2, all of which span the membrane multiple times. The mechanism by which NCT associates with the gamma-secretase complex and regulates its activity is unclear. To avoid the misfolding phenotype often associated with introducing deletions or mutations into heavily glycosylated and disulfide-bonded proteins such as NCT, we produced chimeras between human (hNCT) and Caenorhabditis elegans NCT (ceNCT). Although ceNCT did not associate with human gamma-secretase components, all of the ceNCT/hNCT chimeras interacted with gamma-secretase components from human, C. elegans, or both, indicating that they folded correctly. A region at the C-terminal end of hNCT, encompassing the last 50 residues of its ectodomain, the transmembrane domain, and the cytoplasmic domain was important for mediating interactions with human PS1, APH-1, and PEN-2. This finding is consistent with the fact that the bulk of the gamma-secretase complex proteins resides within the membrane, with relatively small extramembranous domains. Finally, hNCT associated with hAPH-1 in the absence of PS, consistent with NCT and APH-1 forming a subcomplex prior to association with PS1 and PEN-2 and indicating that the interactions between NCT with PS1 may be indirect or stabilized by the presence of APH-1.	Univ Penn, Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA; Univ Penn, Dept Pathol & Lab Med, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA; Inst Biol Expt & Tecnol, Inst Tecnol Quim & Biol, P-2781901 Oeiras, Portugal	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	Doms, RW (corresponding author), Univ Penn, Sch Med, Dept Microbiol, 225 Johnson Pavil,3610 Hamilton Walk, Philadelphia, PA 19104 USA.		Costa, Júlia C/B-7131-2008	Costa, Júlia C/0000-0001-7782-6319; Morais, Vanessa/0000-0002-0830-0548; Crystal, Adam/0000-0002-2302-2654	PHS HHS [P01-11542] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Arawaka S, 2002, J NEUROCHEM, V83, P1065, DOI 10.1046/j.1471-4159.2002.01207.x; Chen FS, 2001, NAT CELL BIOL, V3, P751, DOI 10.1038/35087069; Chung HM, 2001, NAT CELL BIOL, V3, P1129, DOI 10.1038/ncb1201-1129; Crystal AS, 2003, J BIOL CHEM, V278, P20117, DOI 10.1074/jbc.M213107200; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Gu YJ, 2003, J BIOL CHEM, V278, P7374, DOI 10.1074/jbc.M209499200; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Herreman A, 2003, J CELL SCI, V116, P1127, DOI 10.1242/jcs.00292; Hu Y, 2003, J CELL BIOL, V161, P685, DOI 10.1083/jcb.200304014; Hu Y, 2002, DEV CELL, V2, P69, DOI 10.1016/S1534-5807(01)00105-8; Kaether C, 2002, J CELL BIOL, V158, P551, DOI 10.1083/jcb.200201123; Kim DY, 2002, J BIOL CHEM, V277, P49976, DOI 10.1074/jbc.M210179200; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Kimberly WT, 2002, J BIOL CHEM, V277, P35113, DOI 10.1074/jbc.M204446200; Kopan R, 2002, NEURON, V33, P321, DOI 10.1016/S0896-6273(02)00585-8; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Lammich S, 2002, J BIOL CHEM, V277, P44754, DOI 10.1074/jbc.M206872200; Lee SF, 2002, J BIOL CHEM, V277, P45013, DOI 10.1074/jbc.M208164200; Leem JY, 2002, J BIOL CHEM, V277, P19236, DOI 10.1074/jbc.C200148200; Levitan D, 2001, DEV BIOL, V240, P654, DOI 10.1006/dbio.2001.0486; Li T, 2003, J NEUROSCI, V23, P3272; Lopez-Schier H, 2002, DEV CELL, V2, P79, DOI 10.1016/S1534-5807(01)00109-5; Luo WJ, 2003, J BIOL CHEM, V278, P7850, DOI 10.1074/jbc.C200648200; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; Murphy MP, 2003, FASEB J, V17, P1138, DOI 10.1096/fj.02-1050fje; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Popot JL, 2000, ANNU REV BIOCHEM, V69, P881, DOI 10.1146/annurev.biochem.69.1.881; Shirotani K, 2003, J BIOL CHEM, V278, P16474, DOI 10.1074/jbc.C300095200; Sisodia SS, 2002, NAT REV NEUROSCI, V3, P281, DOI 10.1038/nrn785; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Wang R, 1996, J BIOL CHEM, V271, P31894, DOI 10.1074/jbc.271.50.31894; Xia WM, 2000, P NATL ACAD SCI USA, V97, P9299, DOI 10.1073/pnas.97.16.9299; Yang DS, 2002, J BIOL CHEM, V277, P28135, DOI 10.1074/jbc.M110871200; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	46	63	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43284	43291		10.1074/jbc.M305685200	http://dx.doi.org/10.1074/jbc.M305685200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12917438	hybrid			2022-12-25	WOS:000186157000071
J	Calipel, A; Lefevre, G; Pouponnot, C; Mouriaux, F; Eychene, A; Mascarelli, F				Calipel, A; Lefevre, G; Pouponnot, C; Mouriaux, F; Eychene, A; Mascarelli, F			Mutation of B-Raf in human choroidal melanoma cells mediates cell proliferation and transformation through the MEK/ERK pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASES; UVEAL MELANOMA; CONSTITUTIVE ACTIVATION; GERMLINE MUTATIONS; SIGNALING PATHWAYS; ONCOGENIC RAS; HUMAN CANCER; CYCLIN D1; BRAF GENE; N-RAS	The BRAF gene, encoding a mitogen-activated protein kinase kinase kinase, is mutated in several human cancers, with the highest incidence occurring in cutaneous melanoma. The activating V599E mutation accounted for 80% of all mutations detected in cutaneous melanoma cell lines. Reconstitution experiments have shown that this mutation increases ectopically expressed B-Raf kinase activity and induces NIH3T3 cell transformation. Here we used tumor-derived cell lines to characterize the activity of endogenous mutated B-Raf protein and assess its specific role in transformation. We show that three cell lines (OCM-1, MKT-BR, and SP-6.5) derived from human choroidal melanoma, the most frequent primary ocular neoplasm in humans, express B-Raf containing the V599E mutation. These melanoma cells showed a 10-fold increase in endogenous B-Raf(V599E) kinase activity and a constitutive activation of the MEK/ERK pathway that is independent of Ras. This, as well as melanoma cell proliferation, was strongly diminished by siRNA-mediated depletion of the mutant B-Raf protein. Moreover, blocking B-Raf(V599E)-induced ERK activation by different experimental approaches significantly reduced cell proliferation and anchorage-independent growth of melanoma cells. Finally, quantitative immunoblot analysis allowed us to identify signaling and cell cycle proteins that are differentially expressed between normal melanocytes and melanoma cells. Although the expression of signaling molecules was not sensitive to U0126 in melanoma cells, the expression of a cluster of cell cycle proteins remained regulated by the B-Raf(V599E)/MEK/ERK pathway. Our results pinpoint this pathway as an important component in choroidal melanoma cell lines.	Inst Biomed Cordeliers, INSERM, U450, F-75006 Paris, France; Inst Curie, CNRS, Unite Mixte Rech 146, F-91406 Orsay, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Mascarelli, F (corresponding author), Inst Biomed Cordeliers, INSERM, U450, 15 Rue Ecole Med, F-75006 Paris, France.	fmascar@infobiogen.fr	Eychene, Alain/M-8838-2017; Mascarelli, Frederic/L-8916-2018; Mouriaux, Frederic/T-1440-2019	EYCHENE, Alain/0000-0002-6818-7225				Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; BOS JL, 1989, CANCER RES, V49, P4682; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; Cacace AM, 1999, MOL CELL BIOL, V19, P229; CATLING AD, 1994, J BIOL CHEM, V269, P30014; Cohen J, 2003, J NATL CANCER I, V95, P625, DOI 10.1093/jnci/95.8.625; Cohen Y, 2003, INVEST OPHTH VIS SCI, V44, P2876, DOI 10.1167/iovs.02-1329; Coupland SE, 2000, J PATHOL, V191, P120; CUTFORTH T, 1994, CELL, V77, P1027, DOI 10.1016/0092-8674(94)90442-1; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Delmas C, 2003, J BIOL CHEM, V278, P12443, DOI 10.1074/jbc.M209523200; Denouel-Galy A, 1998, CURR BIOL, V8, P46, DOI 10.1016/S0960-9822(98)70019-3; Edmunds SC, 2003, BRIT J CANCER, V88, P1403, DOI 10.1038/sj.bjc.6600919; Ewanowich C, 2001, ARCH PATHOL LAB MED, V125, P208; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Goding CR, 1997, CELL GROWTH DIFFER, V8, P935; Grammatikakis N, 1999, MOL CELL BIOL, V19, P1661; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; HU DN, 1993, INVEST OPHTH VIS SCI, V34, P2210; IKAWA S, 1988, MOL CELL BIOL, V8, P2651, DOI 10.1128/MCB.8.6.2651; Ito Y, 2000, ONCOLOGY-BASEL, V59, P68, DOI 10.1159/000012140; Jaiswal RK, 1996, J BIOL CHEM, V271, P23626, DOI 10.1074/jbc.271.39.23626; KANMITCHELL J, 1989, INVEST OPHTH VIS SCI, V30, P829; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; Kimura ET, 2003, CANCER RES, V63, P1454; Kortylewski M, 2001, BIOCHEM J, V357, P297, DOI 10.1042/0264-6021:3570297; Lee JY, 1997, BIOCHEM BIOPH RES CO, V237, P667, DOI 10.1006/bbrc.1997.7212; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; MARX M, 1988, EMBO J, V7, P3369, DOI 10.1002/j.1460-2075.1988.tb03209.x; Merbs SL, 1999, INVEST OPHTH VIS SCI, V40, P779; MOOY CM, 1991, BRIT J CANCER, V64, P411, DOI 10.1038/bjc.1991.319; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MOURIAUX F, 2001, INVESTIG OPHTHALMOL, V41, P2837; O'Connor DS, 2002, CANCER CELL, V2, P43, DOI 10.1016/S1535-6108(02)00084-3; OHTA M, 1994, CANCER RES, V54, P5269; Papin C, 1998, J BIOL CHEM, V273, P24939, DOI 10.1074/jbc.273.38.24939; Papin C, 1996, ONCOGENE, V12, P2213; Papp T, 1999, J MED GENET, V36, P610; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248-4900(01)01125-X; Peyssonnaux C, 2000, MOL CELL BIOL, V20, P7068, DOI 10.1128/MCB.20.19.7068-7079.2000; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P6430; Roy F, 2002, GENE DEV, V16, P427, DOI 10.1101/gad.962902; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Singh AD, 1996, SEMIN ONCOL, V23, P768; SOPARKER CN, 1993, INVEST OPHTH VIS SCI, V34, P2203; Soufir N, 2000, BRIT J CANCER, V82, P818, DOI 10.1054/bjoc.1999.1005; Treinies I, 1999, MOL CELL BIOL, V19, P321; Walker GJ, 2002, J INVEST DERMATOL, V119, P783, DOI 10.1046/j.1523-1747.2002.00217.x; Wang DM, 1998, J BIOL CHEM, V273, P33027, DOI 10.1074/jbc.273.49.33027; Wang X, 1996, MELANOMA RES, V6, P405, DOI 10.1097/00008390-199612000-00001; Wilkinson MG, 2000, FASEB J, V14, P2147, DOI 10.1096/fj.00-0102rev	54	104	109	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42409	42418		10.1074/jbc.M308709200	http://dx.doi.org/10.1074/jbc.M308709200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12917419	hybrid			2022-12-25	WOS:000185989500104
J	Horman, S; Beauloye, C; Vertommen, D; Vanoverschelde, JL; Hue, L; Rider, MH				Horman, S; Beauloye, C; Vertommen, D; Vanoverschelde, JL; Hue, L; Rider, MH			Myocardial ischemia and increased heart work modulate the phosphorylation state of eukaryotic elongation factor-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; MESSENGER-RNA TRANSLATION; CARDIAC MYOCYTES; S6 KINASE; RAT-HEART; FACTOR-II; INSULIN; INHIBITION; CARDIOMYOCYTES; DEPHOSPHORYLATION	Protein synthesis, in particular peptide chain elongation, is an energy-consuming biosynthetic process. AMP-activated protein kinase ( AMPK) is a key regulatory enzyme involved in cellular energy homeostasis. Therefore, we tested the hypothesis that, as in liver, it could mediate the inhibition of protein synthesis by oxygen deprivation in heart by modulating the phosphorylation of eukaryotic elongation factor-2 (eEF2), which becomes inactive in its phosphorylated form. In anoxic cardiomyocytes, AMPK activation was associated with an inhibition of protein synthesis and an increase in phosphorylation of eEF2. Rapamycin, an inhibitor of the mammalian target of rapamycin ( mTOR), did not mimic the effect of oxygen deprivation to inhibit protein synthesis in cardiomyocytes or lead to eEF2 phosphorylation in perfused hearts, suggesting that AMPK activation did not inhibit mTOR/p70 ribosomal protein S6 kinase (p70S6K) signaling. Human recombinant eEF2 kinase (eEF2K) was phosphorylated by AMPK in a time- and AMP-dependent fashion, and phosphorylation led to eEF2K activation, similar to that observed in extracts from ischemic hearts. In contrast, increasing the workload resulted in a dephosphorylation of eEF2, which was rapamycin-insensitive, thus excluding a role for mTOR in this effect. eEF2K activity was unchanged by increasing the workload, suggesting that the decrease in eEF2 phosphorylation could result from the activation of an eEF2 phosphatase.	Univ Louvain, Sch Med, Christian de Duve Inst Cellular Pathol, Hormone & Metab Res Unit, B-1200 Brussels, Belgium; Univ Louvain, Sch Med, Div Cardiol, B-1200 Brussels, Belgium	Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Rider, MH (corresponding author), Univ Louvain, Sch Med, Christian de Duve Inst Cellular Pathol, HORM Unit, Ave Hippocrate 75,ICP UCL 7529, B-1200 Brussels, Belgium.		Vanoverschelde, Jean-Louis/A-6830-2008	Vanoverschelde, Jean-Louis/0000-0002-8133-8913; Vertommen, Didier/0000-0001-7648-8282				Alirezaei M, 2001, J NEUROCHEM, V76, P1080, DOI 10.1046/j.1471-4159.2001.00105.x; Beauloye C, 2001, CIRC RES, V88, P513, DOI 10.1161/01.RES.88.5.513; Beauloye C, 2002, FEBS LETT, V531, P324, DOI 10.1016/S0014-5793(02)03552-4; BERGMEYER HU, 1984, METHOD ENZYMAT AN, V8, P500; Bolster DR, 2002, J BIOL CHEM, V277, P23977, DOI 10.1074/jbc.C200171200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTTGEREIT F, 1995, BIOCHEM J, V312, P163, DOI 10.1042/bj3120163; DAVIES SP, 1989, EUR J BIOCHEM, V186, P123, DOI 10.1111/j.1432-1033.1989.tb15185.x; Diggle TA, 1998, BIOCHEM J, V336, P525, DOI 10.1042/bj3360525; Dorovkov MV, 2002, BIOCHEMISTRY-US, V41, P13444, DOI 10.1021/bi026494p; Dubbelhuis PF, 2002, FEBS LETT, V521, P39, DOI 10.1016/S0014-5793(02)02815-6; Everett AD, 2001, AM J PHYSIOL-HEART C, V281, pH161, DOI 10.1152/ajpheart.2001.281.1.H161; Hait WN, 1996, FEBS LETT, V397, P55, DOI 10.1016/S0014-5793(96)01140-4; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; HONGO K, 1995, AM J PHYSIOL-CELL PH, V269, pC690, DOI 10.1152/ajpcell.1995.269.3.C690; Horman S, 2002, CURR BIOL, V12, P1419, DOI 10.1016/S0960-9822(02)01077-1; Hovland R, 1999, FEBS LETT, V444, P97, DOI 10.1016/S0014-5793(99)00039-3; JEFFERSON LS, 1971, J BIOL CHEM, V246, P2171; Kemp BE, 1999, TRENDS BIOCHEM SCI, V24, P22, DOI 10.1016/S0968-0004(98)01340-1; KIRA Y, 1984, AM J PHYSIOL, V246, pC247, DOI 10.1152/ajpcell.1984.246.3.C247; Krause U, 2002, EUR J BIOCHEM, V269, P3751, DOI 10.1046/j.1432-1033.2002.03074.x; Lawrence JC, 1997, TRENDS BIOCHEM SCI, V22, P345, DOI 10.1016/S0968-0004(97)01101-8; Lefebvre V, 1996, J BIOL CHEM, V271, P22289, DOI 10.1074/jbc.271.37.22289; Marsin AS, 2000, CURR BIOL, V10, P1247, DOI 10.1016/S0960-9822(00)00742-9; McLeod LE, 2002, FEBS LETT, V531, P448, DOI 10.1016/S0014-5793(02)03582-2; McLeod LE, 2001, FEBS LETT, V489, P225, DOI 10.1016/S0014-5793(01)02100-7; PROUD CG, 1992, CURR TOP CELL REGUL, V32, P243; REDPATH NT, 1993, EUR J BIOCHEM, V213, P689, DOI 10.1111/j.1432-1033.1993.tb17809.x; STERN MD, 1988, P NATL ACAD SCI USA, V85, P6954, DOI 10.1073/pnas.85.18.6954; TAEGTMEYER H, 1980, BIOCHEM J, V186, P701, DOI 10.1042/bj1860701; VINCENT MF, 1991, DIABETES, V40, P1259, DOI 10.2337/diabetes.40.10.1259; Wang LJ, 2002, FEBS LETT, V531, P285, DOI 10.1016/S0014-5793(02)03536-6; Wang LJ, 2000, AM J PHYSIOL-HEART C, V278, pH1056, DOI 10.1152/ajpheart.2000.278.4.H1056; Wang XM, 2002, BIOCHEM J, V367, P475, DOI 10.1042/BJ20020677; Wang XM, 2001, EMBO J, V20, P4370, DOI 10.1093/emboj/20.16.4370; Welsh GI, 1998, FEBS LETT, V421, P125, DOI 10.1016/S0014-5793(97)01548-2; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621; WOLLENBERGER A, 1971, CARDIOLOGY, V56, P48, DOI 10.1159/000169341; Woods A, 2003, J BIOL CHEM, V278, P28434, DOI 10.1074/jbc.M303946200	39	99	106	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41970	41976		10.1074/jbc.M302403200	http://dx.doi.org/10.1074/jbc.M302403200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12920134	hybrid			2022-12-25	WOS:000185989500052
J	Sampson, LJ; Leyland, ML; Dart, C				Sampson, LJ; Leyland, ML; Dart, C			Direct interaction between the actin-binding protein filamin-A and the inwardly rectifying potassium channel, Kir2.1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARTERIAL SMOOTH-MUSCLE; CYTOPLASMIC DOMAIN; ANCHORING PROTEIN; FOCAL ADHESION; CELLS; CYTOSKELETON; IDENTIFICATION; PSD-95/SAP90; MUTATIONS; MEMBRANE	The role of filamins in actin cross-linking and membrane stabilization is well established, but recently their ability to interact with a variety of transmembrane receptors and signaling proteins has led to speculation of additional roles in scaffolding and signal transduction. Here we report a direct interaction between filamin-A and Kir2.1, an isoform of inwardly rectifying potassium channel expressed in vascular smooth muscle and an important regulator of vascular tone. Yeast two-hybrid screening of a porcine coronary artery cDNA library using the carboxyl terminus of Kir2.1 as bait yielded cDNA encoding a fragment of filamin-A (residues 2481-2647). Interaction between filamin-A and Kir2.1 was confirmed by in vitro overlay assay of membrane-bound Kir2.1 with glutathione S-transferase fusion protein of the isolated filamin clone. Additionally, antibodies directed against Kir2.1 coimmunoprecipitated filamin-A from arterial smooth muscle cell lysates, and immunocytochemical analysis of individual arterial smooth muscle cells showed that Kir2.1 and filamin co-localize in "hotspots" at the cell membrane. Interaction with filamin-A was found to have no effect on Kir2.1 channel behavior but, rather, increased the number of functional channels resident within the membrane. We conclude that filamin-A is potentially an important regulator of Kir2.1 surface expression and location within vascular smooth muscle.	Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England; Univ Leicester, Dept Biochem, Leicester LE1 9HN, Leics, England	University of Leicester; University of Leicester	Sampson, LJ (corresponding author), Univ Leicester, Dept Cell Physiol & Pharmacol, POB 138, Leicester LE1 9HN, Leics, England.			Dart, Caroline/0000-0002-3509-8349				Bobanovic LK, 2002, J NEUROSCI, V22, P4814, DOI 10.1523/JNEUROSCI.22-12-04814.2002; Bradley KK, 1999, J PHYSIOL-LONDON, V515, P639, DOI 10.1111/j.1469-7793.1999.639ab.x; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; BURRIDGE K, 1996, ANNU REV CELL DEV BI, V12, P487; Cohen NA, 1996, NEURON, V17, P759, DOI 10.1016/S0896-6273(00)80207-X; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; Dart C, 2001, J BIOL CHEM, V276, P20499, DOI 10.1074/jbc.M101425200; DRAEGER A, 1989, J CELL SCI, V94, P703; Fox JW, 1998, NEURON, V21, P1315, DOI 10.1016/S0896-6273(00)80651-0; Gerthoffer WT, 2001, J APPL PHYSIOL, V91, P963, DOI 10.1152/jappl.2001.91.2.963; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; HOCK RS, 1990, BIOCHEMISTRY-US, V29, P9441, DOI 10.1021/bi00492a019; Horio Y, 1997, J BIOL CHEM, V272, P12885, DOI 10.1074/jbc.272.20.12885; Inanobe A, 2002, AM J PHYSIOL-CELL PH, V282, pC1396, DOI 10.1152/ajpcell.00615.2001; Isomoto S, 1997, JPN J PHYSIOL, V47, P11, DOI 10.2170/jjphysiol.47.11; Leonardi A, 2000, J BIOL CHEM, V275, P271, DOI 10.1074/jbc.275.1.271; Leonoudakis D, 2001, J CELL SCI, V114, P987; LEONOUDAKIS D, 2003, BIOPHYS J, V84, P224; Leyland ML, 1999, PFLUG ARCH EUR J PHY, V438, P778, DOI 10.1007/s004240051106; Lin RW, 2001, P NATL ACAD SCI USA, V98, P5258, DOI 10.1073/pnas.011538198; Loo DT, 1998, J BIOL CHEM, V273, P23304, DOI 10.1074/jbc.273.36.23304; Marti A, 1997, J BIOL CHEM, V272, P2620, DOI 10.1074/jbc.272.5.2620; Meyer SC, 1997, J BIOL CHEM, V272, P2914, DOI 10.1074/jbc.272.5.2914; Nehring RB, 2000, J NEUROSCI, V20, P156, DOI 10.1523/JNEUROSCI.20-01-00156.2000; Nichols CG, 1997, ANNU REV PHYSIOL, V59, P171, DOI 10.1146/annurev.physiol.59.1.171; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; Petrecca K, 2000, J NEUROSCI, V20, P8736; Plaster NM, 2001, CELL, V105, P511, DOI 10.1016/S0092-8674(01)00342-7; Quayle JM, 1996, J PHYSIOL-LONDON, V494, P715, DOI 10.1113/jphysiol.1996.sp021527; Seck T, 2003, J BIOL CHEM, V278, P10408, DOI 10.1074/jbc.M209655200; SHARMA CP, 1995, J IMMUNOL, V154, P3461; Small JV, 1998, ACTA PHYSIOL SCAND, V164, P341; STENDAHL OI, 1980, J CELL BIOL, V84, P215, DOI 10.1083/jcb.84.2.215; Stonehouse AH, 1999, HISTOCHEM CELL BIOL, V112, P457, DOI 10.1007/s004180050429; Stossel TP, 2001, NAT REV MOL CELL BIO, V2, P138, DOI 10.1038/35052082; Tigges U, 2003, J BIOL CHEM, V278, P23561, DOI 10.1074/jbc.M302302200; TYLER JM, 1980, J CELL BIOL, V85, P489, DOI 10.1083/jcb.85.2.489; van der Flier A, 2001, BBA-MOL CELL RES, V1538, P99, DOI 10.1016/S0167-4889(01)00072-6; WANG K, 1975, P NATL ACAD SCI USA, V72, P4483, DOI 10.1073/pnas.72.11.4483; Zaritsky JJ, 2000, CIRC RES, V87, P160, DOI 10.1161/01.RES.87.2.160; Zhang WJ, 1998, J NEUROSCI, V18, P914	41	75	75	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41988	41997		10.1074/jbc.M307479200	http://dx.doi.org/10.1074/jbc.M307479200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12923176	hybrid			2022-12-25	WOS:000185989500054
J	Liang, Y; Mirnics, ZK; Yan, CH; Nylander, KD; Schor, NF				Liang, Y; Mirnics, ZK; Yan, CH; Nylander, KD; Schor, NF			Bcl-2 mediates induction of neural differentiation	ONCOGENE			English	Article						neural differentiation; TrkA; nerve growth factor; Bcl-2; DNA microarray	NERVE GROWTH-FACTOR; NEURONATIN MESSENGER-RNA; EXPRESSION; APOPTOSIS; RECEPTOR; DEATH; CELLS; POTENTIATION; PATHWAYS; SIGNALS	Bcl-2 is an antiapoptotic protein expressed in a wide variety of cell types. We have found that overexpression of bcl-2 in PC12 neural crest tumor cells leads to increased expression of neural differentiation-associated genes and decreased expression of proliferation-related genes. Culture growth rate decreases as well. Overexpression of bcl-2 also leads to increased expression of TrkA and increased phosphorylation of signal transductants in, albeit not specific for, the TrkA-MEK-ERK pathway. Blocking of NGF-mediated signaling through TrkA prevents Bcl-2-associated expression changes in differentiation-associated genes, raising the possibility that Bcl-2 mediates induction of neural differentiation through TrkA/NGF signaling.	Univ Pittsburgh, Div Child Neurol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Pediat Ctr Neurosci, Pittsburgh, PA 15213 USA; Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Schor, NF (corresponding author), Univ Pittsburgh, Div Child Neurol, 3705 5th Ave, Pittsburgh, PA 15213 USA.			Schor, Nina/0000-0002-3817-7376; Korade, Zeljka/0000-0002-8690-4507				Boilly B, 2000, CYTOKINE GROWTH F R, V11, P295, DOI 10.1016/S1359-6101(00)00014-9; Bottner M, 2000, J NEUROCHEM, V75, P2227, DOI 10.1046/j.1471-4159.2000.0752227.x; Cortazzo M, 1996, CANCER RES, V56, P1199; Fujita A, 2000, BIOCHEM BIOPH RES CO, V269, P1, DOI 10.1006/bbrc.1999.1893; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; Grellier P, 1998, CANCER RES, V58, P1670; Hamada S, 2001, NEUROSCI RES, V41, P207, DOI 10.1016/S0168-0102(01)00281-4; Huttunen HJ, 2002, J BIOL CHEM, V277, P38635, DOI 10.1074/jbc.M202515200; JOSEPH R, 1995, BRAIN RES, V690, P92, DOI 10.1016/0006-8993(95)00621-V; Joseph R, 1996, BRAIN RES, V738, P32, DOI 10.1016/0006-8993(96)00768-8; Kalaydjieva L, 2000, AM J HUM GENET, V67, P47, DOI 10.1086/302978; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Liang Y, 2002, MOL PHARMACOL, V61, P142, DOI 10.1124/mol.61.1.142; Mani S, 2001, MOL CELL NEUROSCI, V17, P54, DOI 10.1006/mcne.2000.0931; Middleton G, 1998, J NEUROSCI, V18, P3344; Oh YJ, 1996, NEUROSCI LETT, V202, P161, DOI 10.1016/0304-3940(95)12235-4; Rong YP, 2002, ACTA BIOCH BIOPH SIN, V34, P411; Saragovi HU, 1998, J BIOL CHEM, V273, P34933, DOI 10.1074/jbc.273.52.34933; Schor NF, 2000, ONCOGENE, V19, P472, DOI 10.1038/sj.onc.1203324; Schwarz CS, 2002, NEUROREPORT, V13, P2439, DOI 10.1097/00001756-200212200-00013; Suzuki A, 1998, BRAIN RES, V801, P59, DOI 10.1016/S0006-8993(98)00523-X; Vaudry D, 2002, SCIENCE, V296, P1648, DOI 10.1126/science.1071552; Yan CH, 2002, CANCER RES, V62, P4867; Zhang KZ, 1996, P NATL ACAD SCI USA, V93, P4504, DOI 10.1073/pnas.93.9.4504	24	24	24	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 21	2003	22	35					5515	5518		10.1038/sj.onc.1206844	http://dx.doi.org/10.1038/sj.onc.1206844			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JC	12934111				2022-12-25	WOS:000184735000016
J	Mohan, S; Burk, RD				Mohan, S; Burk, RD			von Hippel-Lindau protein complex is regulated by cell density	ONCOGENE			English	Article						VHL; cell density; cell-cell contact	TUMOR-SUPPRESSOR GENE; GROWTH-FACTOR EXPRESSION; DEPENDENT REGULATION; SOMATIC MUTATIONS; RENAL-CARCINOMA; VHL; PRODUCT; BINDING; UBIQUITINATION; HEMANGIOBLASTOMAS	Mutations in the von Hippel-Lindau (VHL) gene are involved in the VHL family cancer syndrome and sporadic renal cell carcinoma. Previous studies indicated that VHL-induced growth arrest required high cell density and growth on extracellular matrix. In the present study, VHL protein (pVHL) levels were observed to be dramatically increased in cells grown to high cell density compared to cells grown at low cell density. Reverse transcription-polymerase chain reaction and Northern blot analysis indicated that VHL mRNA levels were equivalent in sparse and dense cells. The pVHL was rapidly degraded when cell-cell contact was disturbed by trypsinization or EDTA release. Treatment of cells with a proteasome inhibitor blocked the degradation of pVHL. Using a set of VHL deletions fused to GFP, a cell density-dependent region (CDDR) was identified and localized to the c-terminus of pVHL. In addition, other members of the VBC protein complex also showed a cell density-dependent regulation similar to pVHL. Cell density regulation of VHL did not require elongin binding and density-dependent regulation of other VBC components was not dependent on pVHL. In addition, hypoxia inducible factor-2alpha protein levels were elevated in sparse cells with low levels of pVHL and reduced or absent in confluent cells containing abundant VHL. These results indicate that pVHL levels and thus function are tightly regulated by cell-cell signaling. In addition, care must be taken when interpreting studies of VHL function and subcellular localization of cells grown at subconfluent conditions.	Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Marion Bessin Liver Res Ctr, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Albert Einstein Canc Res Ctr, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Pediat, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Burk, RD (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Marion Bessin Liver Res Ctr, Ullmann Bldg,Rm 515,1300 Morris Pk Ave, Bronx, NY 10461 USA.	burk@aecom.yu.edu			NATIONAL CANCER INSTITUTE [R01CA085412] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA85412] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMSLER K, 1994, J CELL PHYSIOL, V159, P331, DOI 10.1002/jcp.1041590216; Baba M, 2001, ONCOGENE, V20, P2727, DOI 10.1038/sj.onc.1204397; CHEN F, 1995, HUM MUTAT, V5, P66, DOI 10.1002/humu.1380050109; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Davidowitz EJ, 2001, MOL CELL BIOL, V21, P865, DOI 10.1128/MCB.21.3.865-874.2001; Feldman DE, 1999, MOL CELL, V4, P1051, DOI 10.1016/S1097-2765(00)80233-6; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; FOSTER K, 1994, HUM MOL GENET, V3, P2169, DOI 10.1093/hmg/3.12.2169; Fuqua C, 1996, ANNU REV MICROBIOL, V50, P727, DOI 10.1146/annurev.micro.50.1.727; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hornyak TJ, 2000, J INVEST DERMATOL, V115, P106, DOI 10.1046/j.1523-1747.2000.00030.x; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Iliopoulos O, 1998, P NATL ACAD SCI USA, V95, P11661, DOI 10.1073/pnas.95.20.11661; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; KANNO H, 1994, CANCER RES, V54, P4845; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Kojima N, 2000, BIOCHEM BIOPH RES CO, V277, P152, DOI 10.1006/bbrc.2000.3635; Krieg M, 2000, ONCOGENE, V19, P5435, DOI 10.1038/sj.onc.1203938; Lallemand D, 1998, EMBO J, V17, P5615, DOI 10.1093/emboj/17.19.5615; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Lee JY, 1998, CANCER RES, V58, P504; Lee S, 1996, P NATL ACAD SCI USA, V93, P1770, DOI 10.1073/pnas.93.5.1770; Lee YS, 1998, J INVEST DERMATOL, V111, P762, DOI 10.1046/j.1523-1747.1998.00365.x; Lindon C, 2001, DEV BIOL, V240, P574, DOI 10.1006/dbio.2001.0435; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Lubensky IA, 1996, AM J PATHOL, V149, P2089; Mukhopadhyay D, 1998, GENE EXPRESSION, V7, P53; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; Pause A, 1998, P NATL ACAD SCI USA, V95, P993, DOI 10.1073/pnas.95.3.993; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; Schoenfeld A, 1998, P NATL ACAD SCI USA, V95, P8817, DOI 10.1073/pnas.95.15.8817; Schoenfeld AR, 2000, P NATL ACAD SCI USA, V97, P8507, DOI 10.1073/pnas.97.15.8507; Schoenfeld AR, 2001, INT J CANCER, V91, P457, DOI 10.1002/1097-0215(20010215)91:4<457::AID-IJC1072>3.0.CO;2-P; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Singh RK, 1996, CELL GROWTH DIFFER, V7, P397; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298	41	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2003	22	34					5270	5280		10.1038/sj.onc.1206592	http://dx.doi.org/10.1038/sj.onc.1206592			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JB	12917628				2022-12-25	WOS:000184734900006
J	Miyakawa-Naito, A; Uhlen, P; Lal, M; Aizman, O; Mikoshiba, K; Brismar, H; Zelenin, S; Aperia, A				Miyakawa-Naito, A; Uhlen, P; Lal, M; Aizman, O; Mikoshiba, K; Brismar, H; Zelenin, S; Aperia, A			Cell signaling Microdomain with Na,K-ATPase and inositol 1,4,5-trisphosphate receptor generates calcium oscillations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; 2-AMINOETHOXYDIPHENYL BORATE 2-APB; NA+/K+-ATPASE; CA2+ RELEASE; OUABAIN; IDENTIFICATION; SPECIFICITY; INVOLVEMENT; INHIBITION; EXPRESSION	Recent studies indicate novel roles for the ubiquitous ion pump, Na,K-ATPase, in addition to its function as a key regulator of intracellular sodium and potassium concentration. We have previously demonstrated that ouabain, the endogenous ligand of Na, K-ATPase, can trigger intracellular Ca2+ oscillations, a versatile intracellular signal controlling a diverse range of cellular processes. Here we report that Na, K-ATPase and inositol 1,4,5-trisphosphate (InsP(3)) receptor (InsP(3)R) form a cell signaling microdomain that, in the presence of ouabain, generates slow Ca2+ oscillations in renal cells. Using fluorescent resonance energy transfer ( FRET) measurements, we detected a close spatial proximity between Na, K-ATPase and InsP(3)R. Ouabain significantly enhanced FRET between Na, K-ATPase and InsP(3)R. The FRET effect and ouabain-induced Ca2+ oscillations were not observed following disruption of the actin cytoskeleton. Partial truncation of the NH2 terminus of Na, K-ATPase catalytic alpha1-subunit abolished Ca2+ oscillations and downstream activation of NF-kappaB. Ouabain-induced Ca2+ oscillations occurred in cells expressing an InsP3 sponge and were hence independent of InsP3 generation. Thus, we present a novel principle for a cell signaling microdomain where an ion pump serves as a receptor.	Astrid Lindgren Childrens Hosp, Karolinska Inst, Dept Woman & Child Hlth, S-17176 Stockholm, Sweden; Univ Tokyo, Inst Med Sci, Dept Basic Med Sci, Minato Ku, Tokyo 1088639, Japan	Karolinska Institutet; University of Tokyo	Aperia, A (corresponding author), Astrid Lindgren Childrens Hosp, Karolinska Inst, Dept Woman & Child Hlth, Q2-09, S-17176 Stockholm, Sweden.	anita.aperia@ks.se	Mikoshiba, Katsuhiko/N-7943-2015; Brismar, Hjalmar/E-8524-2011	Brismar, Hjalmar/0000-0003-0578-4003; Uhlen, Per/0000-0003-1446-1062				Aizman O, 2001, P NATL ACAD SCI USA, V98, P13420, DOI 10.1073/pnas.221315298; Belusa R, 1997, J BIOL CHEM, V272, P20179, DOI 10.1074/jbc.272.32.20179; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; Blaustein MR, 2001, TRENDS NEUROSCI, V24, P602, DOI 10.1016/S0166-2236(00)01891-9; Bootman MD, 2002, FASEB J, V16, DOI 10.1096/fj.02-0037rev; BOURGUIGNON LYW, 1993, J BIOL CHEM, V268, P7290; Boxenbaum N, 1998, J BIOL CHEM, V273, P23086, DOI 10.1074/jbc.273.36.23086; DALY SE, 1994, J BIOL CHEM, V269, P23944; Daly SE, 1996, J BIOL CHEM, V271, P23683, DOI 10.1074/jbc.271.39.23683; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; Delmas P, 2002, NEURON, V34, P209, DOI 10.1016/S0896-6273(02)00641-4; DEVARAJAN P, 1994, P NATL ACAD SCI USA, V91, P2965, DOI 10.1073/pnas.91.8.2965; DIBARTOLO V, 1995, LIFE SCI, V57, P1417, DOI 10.1016/0024-3205(95)02104-Q; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; FELDER CC, 1995, FASEB J, V9, P619, DOI 10.1096/fasebj.9.8.7768353; Haas M, 2000, J BIOL CHEM, V275, P27832; HAMLYN JM, 1991, P NATL ACAD SCI USA, V88, P6259, DOI 10.1073/pnas.88.14.6259; Haux J, 1999, MED HYPOTHESES, V53, P543, DOI 10.1054/mehy.1999.0985; Ichitani Y, 2001, CELL TISSUE RES, V303, P235, DOI 10.1007/s004410000296; Johenning FW, 2002, NEURON, V34, P173, DOI 10.1016/S0896-6273(02)00665-7; JORGENSEN PL, 1982, ANN NY ACAD SCI, V402, P207, DOI 10.1111/j.1749-6632.1982.tb25743.x; Karin M., 1999, SCI SIGNAL TRANSDUCT, V5, P1; Kenworthy AK, 2001, METHODS, V24, P289, DOI 10.1006/meth.2001.1189; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Lichtstein D, 2000, HYPERTENS RES, V23, pS51, DOI 10.1291/hypres.23.Supplement_S51; Lingrel JB, 1997, ANN NY ACAD SCI, V834, P194, DOI 10.1111/j.1749-6632.1997.tb52251.x; MONKAWA T, 1995, J BIOL CHEM, V270, P14700, DOI 10.1074/jbc.270.24.14700; Ng T, 1999, SCIENCE, V283, P2085, DOI 10.1126/science.283.5410.2085; Peng M, 1996, J BIOL CHEM, V271, P10372, DOI 10.1074/jbc.271.17.10372; Peppiatt CM, 2003, CELL CALCIUM, V34, P97, DOI 10.1016/S0143-4160(03)00026-5; REPKE KRH, 1995, ANTI-CANCER DRUG DES, V10, P177; Segall L, 2002, J BIOL CHEM, V277, P35202, DOI 10.1074/jbc.M206115200; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; SKOU JC, 1992, J BIOENERG BIOMEMBR, V24, P249; SUGIYAMA T, 1994, FEBS LETT, V354, P149, DOI 10.1016/0014-5793(94)01099-4; Tang TS, 2003, NEURON, V39, P227, DOI 10.1016/S0896-6273(03)00366-0; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Uchiyama T, 2002, J BIOL CHEM, V277, P8106, DOI 10.1074/jbc.M108337200; Uhlen P, 2000, NATURE, V405, P694, DOI 10.1038/35015091; Vakkuri O, 2000, J ENDOCRINOL, V165, P669, DOI 10.1677/joe.0.1650669; Wouters FS, 2001, TRENDS CELL BIOL, V11, P203, DOI 10.1016/S0962-8924(01)01982-1; Xie ZJ, 2002, EUR J BIOCHEM, V269, P2434, DOI 10.1046/j.1432-1033.2002.02910.x; Yang J, 2002, P NATL ACAD SCI USA, V99, P7711, DOI 10.1073/pnas.102006299; Zelenina M, 2002, AM J PHYSIOL-RENAL, V283, pF309, DOI 10.1152/ajprenal.00260.2001	47	148	152	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50355	50361		10.1074/jbc.M305378200	http://dx.doi.org/10.1074/jbc.M305378200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	12947118	hybrid			2022-12-25	WOS:000187068200085
J	Peterson, JH; Woolhead, CA; Bernstein, HD				Peterson, JH; Woolhead, CA; Bernstein, HD			Basic amino acids in a distinct subset of signal peptides promote interaction with the signal recognition particle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; MALTOSE-BINDING PROTEIN; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; NASCENT PREPROLACTIN; TARGETING PATHWAYS; SECRETORY PROTEIN; ANCHOR SEQUENCES; TRIGGER FACTOR; IN-VITRO	Previous studies have demonstrated that signal peptides bind to the signal recognition particle (SRP) primarily via hydrophobic interactions with the 54-kDa protein subunit. The crystal structure of the conserved SRP ribonucleoprotein core, however, raised the surprising possibility that electrostatic interactions between basic amino acids in signal peptides and the phosphate backbone of SRP RNA may also play a role in signal sequence recognition. To test this possibility we examined the degree to which basic amino acids in a signal peptide influence the targeting of two Escherichia coli proteins, maltose binding protein and OmpA. Whereas both proteins are normally targeted to the inner membrane by SecB, we found that replacement of their native signal peptides with another moderately hydrophobic but unusually basic signal peptide (DeltaEspP) rerouted them into the SRP pathway. Reduction in either the net positive charge or the hydrophobicity of the DeltaEspP signal peptide decreased the effectiveness of SRP recognition. A high degree of hydrophobicity, however, compensated for the loss of basic residues and restored SRP binding. Taken together, the data suggest that the formation of salt bridges between SRP RNA and basic amino acids facilitates the binding of a distinct subset of signal peptides whose hydrophobicity falls slightly below a threshold level.	NIDDK, Genet & Biochem Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Bernstein, HD (corresponding author), NIDDK, Genet & Biochem Branch, NIH, Bldg 5,Rm 201, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK052022, ZIADK052022] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS DW, 1992, J BIOL CHEM, V267, P7761; Batey RT, 2000, SCIENCE, V287, P1232, DOI 10.1126/science.287.5456.1232; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; Clemons WM, 1999, J MOL BIOL, V292, P697, DOI 10.1006/jmbi.1999.3090; COLLIER DN, 1989, J BACTERIOL, V171, P4640, DOI 10.1128/jb.171.9.4640-4647.1989; CONNOLLY T, 1991, SCIENCE, V252, P1171, DOI 10.1126/science.252.5009.1171; de Gier JWL, 1998, P NATL ACAD SCI USA, V95, P14646, DOI 10.1073/pnas.95.25.14646; DEGIER JW, 1996, FEBS LETT, V99, P307; Freymann DM, 1997, NATURE, V385, P361, DOI 10.1038/385361a0; GILMORE R, 1982, J CELL BIOL, V95, P470, DOI 10.1083/jcb.95.2.470; HIGH S, 1991, J CELL BIOL, V113, P35, DOI 10.1083/jcb.113.1.35; Keenan RJ, 2001, ANNU REV BIOCHEM, V70, P755, DOI 10.1146/annurev.biochem.70.1.755; Keenan RJ, 1998, CELL, V94, P181, DOI 10.1016/S0092-8674(00)81418-X; Koch HG, 1999, MOL BIOL CELL, V10, P2163, DOI 10.1091/mbc.10.7.2163; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KUMAMOTO CA, 1985, J BACTERIOL, V163, P267, DOI 10.1128/JB.163.1.267-274.1985; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lee HC, 2002, J BIOL CHEM, V277, P43527, DOI 10.1074/jbc.M205950200; Lee HC, 2001, P NATL ACAD SCI USA, V98, P3471, DOI 10.1073/pnas.051484198; LESLEY SA, 1991, J BIOL CHEM, V266, P2632; Lu Y, 2001, EMBO J, V20, P6724, DOI 10.1093/emboj/20.23.6724; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; MILLER JD, 1993, NATURE, V366, P351, DOI 10.1038/366351a0; Ng DTW, 1996, J CELL BIOL, V134, P269, DOI 10.1083/jcb.134.2.269; NOTHWEHR SF, 1990, J BIOL CHEM, V265, P17202; Park SK, 2002, J BACTERIOL, V184, P2642, DOI 10.1128/JB.184.10.2642-2653.2002; PORITZ MA, 1990, SCIENCE, V250, P1111, DOI 10.1126/science.1701272; RANDALL LL, 1986, CELL, V46, P921, DOI 10.1016/0092-8674(86)90074-7; SAKAGUCHI M, 1992, P NATL ACAD SCI USA, V89, P16, DOI 10.1073/pnas.89.1.16; Sijbrandi R, 2003, J BIOL CHEM, V278, P4654, DOI 10.1074/jbc.M211630200; SZCZESNASKORUPA E, 1987, J BIOL CHEM, V262, P8896; Ulbrandt ND, 1997, CELL, V88, P187, DOI 10.1016/S0092-8674(00)81839-5; Ullers RS, 2003, J CELL BIOL, V161, P679, DOI 10.1083/jcb.200302130; Valent QA, 1998, EMBO J, V17, P2504, DOI 10.1093/emboj/17.9.2504; Voigt S, 1996, J CELL BIOL, V134, P25, DOI 10.1083/jcb.134.1.25; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; VONHEIJNE G, 1989, NATURE, V341, P456, DOI 10.1038/341456a0; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545	39	66	67	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					46155	46162		10.1074/jbc.M309082200	http://dx.doi.org/10.1074/jbc.M309082200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12949068	hybrid			2022-12-25	WOS:000186452300133
J	Sawaya, R; Schwer, B; Shuman, S				Sawaya, R; Schwer, B; Shuman, S			Genetic and biochemical analysis of the functional domains of yeast tRNA ligase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHODIESTER BOND FORMATION; CRYSTAL-STRUCTURE; MUTATIONAL ANALYSIS; DNA-LIGASE; POLYNUCLEOTIDE KINASE; WHEAT-GERM; SPLICING ENDONUCLEASE; ADENYLYLATION SITE; JUNCTION PHOSPHATE; CAPPING ENZYME	Yeast tRNA ligase (Trl1) converts cleaved tRNA half-molecules into spliced tRNAs containing a 2'-PO4, 3'-5' phosphodiester at the splice junction. Trl1 performs three reactions: (i) the 2',3'-cyclic phosphate of the proximal fragment is hydrolyzed to a 3'-OH, 2'-PO4 by a cyclic phosphodiesterase (CPD); (ii) the 5'-OH of the distal fragment is phosphorylated by an NTP-dependent polynucleotide kinase; and (iii) the 3'-OH, 2'-PO4, and 5'-PO4 ends are sealed by an ATP-dependent RNA ligase. Trl1 consists of an N-terminal adenylyltransferase domain that resembles T4 RNA ligase 1, a central domain that resembles T4 polynucleotide kinase, and a C-terminal CPD domain that resembles the 2H phosphotransferase enzyme superfamily. Here we show that all three domains are essential in vivo, although they need not be linked in the same polypeptide. We identify five amino acids in the adenylyltransferase domain ( Lys(114), Glu(266), Gly(267), Lys(284), and Lys(286)) that are essential for Trl1 activity and are located within motifs I ((114)(K) under bar ANG(117)), IV ((266)(EG) under bar FVI270), and V ((FF)-F-282 (K) under barI (K) under bar (286)) that comprise the active sites of DNA ligases, RNA capping enzymes, and T4 RNA ligases 1 and 2. Mutations K404A and T405A in the P-loop ((401)GXGKT(405)) of the central kinase-like domain had no effect on Trl1 function in vivo. The K404A and T405A mutations eliminated ATP-dependent kinase activity but preserved GTP-dependent kinase activity. A double alanine mutant in the P-loop was lethal in vivo and abolished GTP-dependent kinase activity. These results suggest that GTP is the physiological substrate and that the Trl1 kinase has a single NTP binding site of which the P-loop is a component. Two other mutations in the central domain were lethal in vivo and either abolished (D425A) or severely reduced (R511A) GTP-dependent RNA kinase activity in vitro. Mutations of the signature histidines of the CPD domain were either lethal (H777A) or conferred a ts growth phenotype (H673A).	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.	s-shuman@ski.mskcc.org						Abelson J, 1998, J BIOL CHEM, V273, P12685, DOI 10.1074/jbc.273.21.12685; AMITSUR M, 1987, EMBO J, V6, P2499, DOI 10.1002/j.1460-2075.1987.tb02532.x; APOSTOL BL, 1991, J BIOL CHEM, V266, P7445; BAYMILLER J, 1994, GENE, V142, P129, DOI 10.1016/0378-1119(94)90367-0; BELFORD HG, 1993, J BIOL CHEM, V268, P2444; CRANSTON JW, 1974, J BIOL CHEM, V249, P7447; Culver GM, 1997, J BIOL CHEM, V272, P13203, DOI 10.1074/jbc.272.20.13203; CULVER GM, 1993, SCIENCE, V261, P206, DOI 10.1126/science.8392224; Fabbri S, 1998, SCIENCE, V280, P284, DOI 10.1126/science.280.5361.284; Fabrega C, 2003, MOL CELL, V11, P1549, DOI 10.1016/S1097-2765(03)00187-4; FILIPOWICZ W, 1983, CELL, V32, P547, DOI 10.1016/0092-8674(83)90474-9; Fruscoloni P, 2001, EMBO REP, V2, P217, DOI 10.1093/embo-reports/kve040; Galburt EA, 2002, STRUCTURE, V10, P1249, DOI 10.1016/S0969-2126(02)00835-3; GEGENHEIMER P, 1983, J BIOL CHEM, V258, P8365; Gonzalez TN, 1999, EMBO J, V18, P3119, DOI 10.1093/emboj/18.11.3119; GREER CL, 1983, CELL, V32, P537, DOI 10.1016/0092-8674(83)90473-7; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Hakansson K, 1997, CELL, V89, P545, DOI 10.1016/S0092-8674(00)80236-6; HEAPHY S, 1987, BIOCHEMISTRY-US, V26, P1688, DOI 10.1021/bi00380a030; Ho CK, 2002, P NATL ACAD SCI USA, V99, P12709, DOI 10.1073/pnas.192184699; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hofmann A, 2000, EMBO J, V19, P6207, DOI 10.1093/emboj/19.22.6207; Kaufmann G, 2000, TRENDS BIOCHEM SCI, V25, P70, DOI 10.1016/S0968-0004(99)01525-X; KlemanLeyer K, 1997, CELL, V89, P839, DOI 10.1016/S0092-8674(00)80269-X; KONARSKA M, 1982, P NATL ACAD SCI-BIOL, V79, P1474, DOI 10.1073/pnas.79.5.1474; LASKI FA, 1983, J BIOL CHEM, V258, P1974; Lee JY, 2000, EMBO J, V19, P1119, DOI 10.1093/emboj/19.5.1119; Li H, 2000, J MOL BIOL, V302, P639, DOI 10.1006/jmbi.2000.3941; Li H, 1998, SCIENCE, V280, P279, DOI 10.1126/science.280.5361.279; Mazumder R, 2002, NUCLEIC ACIDS RES, V30, P5229, DOI 10.1093/nar/gkf645; Nasr F, 2000, NUCLEIC ACIDS RES, V28, P1676, DOI 10.1093/nar/28.8.1676; Negri ED, 1997, CELL, V89, P859, DOI 10.1016/S0092-8674(00)80271-8; Odell M, 2000, MOL CELL, V6, P1183, DOI 10.1016/S1097-2765(00)00115-5; PEEBLES CL, 1983, CELL, V32, P525, DOI 10.1016/0092-8674(83)90472-5; PHIZICKY EM, 1992, J BIOL CHEM, V267, P4577; PHIZICKY EM, 1986, J BIOL CHEM, V261, P2978; PICK L, 1986, J BIOL CHEM, V261, P6684; PICK L, 1986, J BIOL CHEM, V261, P6694; Sawaya R, 2003, BIOCHEMISTRY-US, V42, P8240, DOI 10.1021/bi034396d; SCHWARTZ RC, 1983, J BIOL CHEM, V258, P8374; Shuman S, 2001, PROG NUCLEIC ACID RE, V66, P1; SHUMAN S, 1979, J BIOL CHEM, V254, P396; Shuman S, 2002, NAT REV MOL CELL BIO, V3, P619, DOI 10.1038/nrm880; SHUMAN S, 1995, MOL MICROBIOL, V17, P405, DOI 10.1111/j.1365-2958.1995.mmi_17030405.x; Sidrauski C, 1996, CELL, V87, P405, DOI 10.1016/S0092-8674(00)81361-6; SILBER R, 1972, P NATL ACAD SCI USA, V69, P3009, DOI 10.1073/pnas.69.10.3009; Spinelli SL, 1997, RNA, V3, P1388; Sriskanda V, 2002, J BIOL CHEM, V277, P9661, DOI 10.1074/jbc.M110613200; Sriskanda V, 2002, NUCLEIC ACIDS RES, V30, P903, DOI 10.1093/nar/30.4.903; Subramanya HS, 1996, CELL, V85, P607, DOI 10.1016/S0092-8674(00)81260-X; SUGINO A, 1977, J BIOL CHEM, V252, P1732; THOGERSEN HC, 1985, EUR J BIOCHEM, V147, P325, DOI 10.1111/j.1432-1033.1985.tb08753.x; Trotta CR, 1997, CELL, V89, P849, DOI 10.1016/S0092-8674(00)80270-6; Uhlenbeck O.C., 1982, ENZYMES, V15, P31, DOI [10.1016/s1874-6047(08)60274-7, DOI 10.1016/S1874-6047(08)60274-7]; Wang LK, 2003, J BIOL CHEM, V278, P29454, DOI 10.1074/jbc.M304320200; Wang LK, 2002, NUCLEIC ACIDS RES, V30, P1073, DOI 10.1093/nar/30.4.1073; Wang LK, 2002, EMBO J, V21, P3873, DOI 10.1093/emboj/cdf397; Wang LK, 2001, J BIOL CHEM, V276, P26868, DOI 10.1074/jbc.M103663200; Wang SP, 1997, P NATL ACAD SCI USA, V94, P9573, DOI 10.1073/pnas.94.18.9573; WESTAWAY SK, 1993, J BIOL CHEM, V268, P2435; WESTAWAY SK, 1988, J BIOL CHEM, V263, P3171; XU Q, 1990, BIOCHEMISTRY-US, V29, P6132, DOI 10.1021/bi00478a004; Yin SM, 2003, J BIOL CHEM, V278, P17601, DOI 10.1074/jbc.M300817200; ZILLMANN M, 1991, MOL CELL BIOL, V11, P5410, DOI 10.1128/MCB.11.11.5410; Zofallova L, 2000, RNA, V6, P1019, DOI 10.1017/S1355838200000613	65	68	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					43928	43938		10.1074/jbc.M307839200	http://dx.doi.org/10.1074/jbc.M307839200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12933796	hybrid			2022-12-25	WOS:000186306700008
J	Tian, YN; Ke, S; Chen, M; Sheng, T				Tian, YN; Ke, S; Chen, M; Sheng, T			Interactions between the aryl hydrocarbon receptor and P-TEFb - Sequential recruitment of transcription factors and differential phosphorylation of C-terminal domain of RNA polymerase II at cyp1a1 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; HEAT-SHOCK PROTEIN; MESSENGER-RNA; AH RECEPTOR; GLUCOCORTICOID-RECEPTOR; CYTOCHROME P4501A1; DIOXIN RECEPTOR; ELONGATION; COMPLEX; BINDING	The expression of the cytochrome P450 1A1 gene (cyp1a1) is regulated by the aryl hydrocarbon receptor (AhR), which is a ligand-activated transcription factor that mediates most toxic responses induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). In the nucleus, ligand-activated AhR binds to the xenobiotic response elements, initiating chromatin remodeling and recruitment of coregulators, leading to the formation of preinitiation complex followed by elongation. Here, we report that ligand-activated AhR recruits the positive transcription elongation factor (P-TEFb) and RNA polymerase II (RNA PII) to the cyp1a1 promoter with concomitant phosphorylation of the RNA PII carboxyl domain (CTD). Interestingly, the serine 2 and serine 5 of the heptapeptide repeats (YSPTSPS) were sequentially phosphorylated upon TCDD treatment. Inhibition of P-TEFb kinase activity by 5,6-dichloro-1-beta-D-ribofuranosyl-benzimidazole (DRB) suppressed CTD phosphorylation (especially serine 2 phosphorylation) and abolished processive elongation without disrupting the assembly of the preinitiation complex at the cyp1a1 promoter. Remarkably, we found that activation of NF-kappaB by TNF-alpha selectively inhibited TCDD-induced serine 2 phosphorylation in mouse liver cells, suggesting that residue-specific phosphorylation of RNA PII CTD at the cyp1a1 promoter is an important regulatory point upon which signal "cross-talk" converges. Finally, we show that ligand-activated AhR associated with P-TEFb through the C terminus of cyclin T1, suggesting that AhR recruit the P-TEFb to the cyp1a1 promoter whereupon its kinase subunit phosphorylates the RNA PII CTD.	Texas A&M Univ, Dept Vet Physiol & Pharmacol, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station	Tian, YN (corresponding author), Texas A&M Univ, Dept Vet Physiol & Pharmacol, MS 4466, College Stn, TX 77843 USA.				NIEHS NIH HHS [ES 09859, ES 09106] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009859, P30ES009106] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Barboric M, 2001, MOL CELL, V8, P327, DOI 10.1016/S1097-2765(01)00314-8; Beischlag TV, 2002, MOL CELL BIOL, V22, P4319, DOI 10.1128/MCB.22.12.4319-4333.2002; Carver LA, 1998, J BIOL CHEM, V273, P33580, DOI 10.1074/jbc.273.50.33580; Chao SH, 2000, J BIOL CHEM, V275, P28345, DOI 10.1074/jbc.C000446200; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; DENIS M, 1988, BIOCHEM BIOPH RES CO, V155, P801, DOI 10.1016/S0006-291X(88)80566-7; Eberhardy SR, 2002, J BIOL CHEM, V277, P40156, DOI 10.1074/jbc.M207441200; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; Ho CK, 1999, MOL CELL, V3, P405, DOI 10.1016/S1097-2765(00)80468-2; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Kanazawa S, 2000, IMMUNITY, V12, P61, DOI 10.1016/S1074-7613(00)80159-4; Ke S, 2001, J BIOL CHEM, V276, P39638, DOI 10.1074/jbc.M106286200; Kino T, 2002, J BIOL CHEM, V277, P2396, DOI 10.1074/jbc.M106312200; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Lee DK, 2001, J BIOL CHEM, V276, P9978, DOI 10.1074/jbc.M002285200; Ma Q, 1997, J BIOL CHEM, V272, P8878; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; Meyer BK, 1998, MOL CELL BIOL, V18, P978, DOI 10.1128/MCB.18.2.978; MORGAN JE, 1992, P NATL ACAD SCI USA, V89, P11622, DOI 10.1073/pnas.89.23.11622; Moteki S, 2002, MOL CELL, V10, P599, DOI 10.1016/S1097-2765(02)00660-3; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; OKINO ST, 1995, MOL CELL BIOL, V15, P3714; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; Rodriguez CR, 2000, MOL CELL BIOL, V20, P104, DOI 10.1128/MCB.20.1.104-112.2000; Schroeder SC, 2000, GENE DEV, V14, P2435, DOI 10.1101/gad.836300; Swanson HI, 1998, MOL PHARMACOL, V54, P671; Taube R, 2002, MOL CELL BIOL, V22, P321, DOI 10.1128/MCB.22.1.321-331.2002; Tian Y, 1999, J BIOL CHEM, V274, P510, DOI 10.1074/jbc.274.1.510; Wang S, 2002, J BIOL CHEM, V277, P11821, DOI 10.1074/jbc.M110122200; Whitlock JP, 1999, ANNU REV PHARMACOL, V39, P103, DOI 10.1146/annurev.pharmtox.39.1.103; Yamaguchi Y, 1999, CELL, V97, P41, DOI 10.1016/S0092-8674(00)80713-8; Yamaguchi Y, 1999, J BIOL CHEM, V274, P8085, DOI 10.1074/jbc.274.12.8085; Zhou MS, 2000, MOL CELL BIOL, V20, P5077, DOI 10.1128/MCB.20.14.5077-5086.2000	37	71	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44041	44048		10.1074/jbc.M306443200	http://dx.doi.org/10.1074/jbc.M306443200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12917420	hybrid			2022-12-25	WOS:000186306700020
J	Bizat, N; Hermel, JM; Humbert, S; Jacquard, C; Creminon, C; Escartin, C; Saudou, F; Krajewski, S; Hantraye, P; Brouillet, E				Bizat, N; Hermel, JM; Humbert, S; Jacquard, C; Creminon, C; Escartin, C; Saudou, F; Krajewski, S; Hantraye, P; Brouillet, E			In vivo calpain/caspase cross-talk during 3-nitropropionic acid-induced striatal degeneration - Implication of a calpain-mediated cleavage of active caspase-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUNTINGTONS-DISEASE; CELL-DEATH; APOPTOSIS; ACTIVATION; MODEL; REPEAT; VULNERABILITY; MITOCHONDRIA; ISCHEMIA; PROTEASE	The role of caspases and calpains in neurodegeneration remains unclear. In this study, we focused on these proteases in a rat model of Huntington's disease using the mitochondrial toxin 3-nitropropionic acid (3NP). Results showed that 3NP-induced death of striatal neurons was preceded by cytochrome c redistribution, transient caspase-9 processing, and activation of calpain, whereas levels of the active/processed form of caspase-3 remained low and were even reduced as compared with control animals. We evidenced here that this decrease in active caspase-3 levels could be attributed to calpain activation. Several observations supported this conclusion. 1) Pharmacological blockade of calpain in 3NP-treated rats increased the levels of endogenous processed caspase-9 and caspase-3. 2) Cell-free extracts prepared from the striatum of 3NP-treated rats degraded in vitro the p34 and p20 subunits of active recombinant caspase-9 and caspase-3, respectively. 3) This degradation of p34 and p20 could be mimicked by purified mu-calpain and was prevented by calpain inhibitors. 4) mu-Calpain produced a loss of the DEVDase (Asp-Glu-Val-Asp) activity of active caspase-3. 5) Western blot analysis and experiments with S-35-radiolabeled caspase-3 showed that mu-calpain cleaved the p20 subunit of active caspase-3 near its catalytic site. 6) mu-Calpain activity was selectively inhibited (IC50 of 100 muM) by a 12 amino acid peptide corresponding to the C terminus of p20. Our results showed that calpain can down-regulate the caspase-9/caspase-3 cell death pathway during neurodegeneration due to chronic mitochondrial defects in vivo and that this effect may involve, at least in part, direct cleavage of the caspase-3 p20 subunit.	CEA, Serv Hosp Frederic Joliot, DSV, DRM,Unite Rech Associee CEA CNRS 2210, F-91401 Orsay, France; Inst Curie, CNRS, UMR 146, F-91405 Orsay, France; CENS, CEA, Serv Pharmacol & Immunol, DRM,DSV, F-91191 Gif Sur Yvette, France; Burnham Inst, Program Cell Death & Apoptosis, Program Apoptosis Cell Death & Aging, La Jolla, CA 92037 USA; CEA, Serv Hosp Frederic Joliot, U2IBP, DRM,DSV, F-91401 Orsay, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; CEA; UDICE-French Research Universities; Universite Paris Saclay; Sanford Burnham Prebys Medical Discovery Institute; CEA; UDICE-French Research Universities; Universite Paris Saclay	Brouillet, E (corresponding author), CEA, Serv Hosp Frederic Joliot, DSV, DRM,Unite Rech Associee CEA CNRS 2210, F-91401 Orsay, France.		Escartin, Carole/A-1952-2010; SAUDOU, Frédéric/L-3454-2014; Brouillet, Emmanuel/B-4784-2014; Humbert, Sandrine/S-2981-2016	Escartin, Carole/0000-0003-3613-4118; SAUDOU, Frédéric/0000-0001-6107-1046; Brouillet, Emmanuel/0000-0001-6322-7403; Hermel, Jean-Michel/0000-0001-7902-8994; Jacquard, Carine/0000-0003-0972-8455; Humbert, Sandrine/0000-0002-9501-2658	NINDS NIH HHS [NS36821] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036821] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBIN RL, 1992, NEUROLOGY, V42, P733, DOI 10.1212/WNL.42.4.733; BEAL MF, 1992, ANN NEUROL, V31, P119, DOI 10.1002/ana.410310202; Beal MF, 2000, TRENDS NEUROSCI, V23, P298, DOI 10.1016/S0166-2236(00)01584-8; BEAL MF, 1986, NATURE, V321, P168, DOI 10.1038/321168a0; BEAL MF, 1993, J NEUROSCI, V13, P4181; Benchoua A, 2001, J NEUROSCI, V21, P7127, DOI 10.1523/JNEUROSCI.21-18-07127.2001; Bizat N, 2003, J NEUROSCI, V23, P5020; Blomgren K, 2001, J BIOL CHEM, V276, P10191, DOI 10.1074/jbc.M007807200; Brouillet E, 1998, J NEUROCHEM, V70, P794; BROUILLET E, 1993, J NEUROCHEM, V60, P356, DOI 10.1111/j.1471-4159.1993.tb05859.x; Brouillet E, 1999, PROG NEUROBIOL, V59, P427, DOI 10.1016/S0301-0082(99)00005-2; BROUILLET E, 1995, P NATL ACAD SCI USA, V92, P7101; Browne SE, 1997, ANN NEUROL, V41, P646, DOI 10.1002/ana.410410514; Chua BT, 2000, J BIOL CHEM, V275, P5131, DOI 10.1074/jbc.275.7.5131; COLES CJ, 1979, J BIOL CHEM, V255, P772; Cryns VL, 1996, J BIOL CHEM, V271, P31277, DOI 10.1074/jbc.271.49.31277; Dash PK, 2000, NEUROREPORT, V11, P2811, DOI 10.1097/00001756-200008210-00040; DIFIGLIA M, 1990, TRENDS NEUROSCI, V13, P286, DOI 10.1016/0166-2236(90)90111-M; FERRANTE RJ, 1993, EXP NEUROL, V119, P46, DOI 10.1006/exnr.1993.1006; Gafni J, 2002, J NEUROSCI, V22, P4842, DOI 10.1523/JNEUROSCI.22-12-04842.2002; Garcia M, 2002, J NEUROSCI, V22, P2174, DOI 10.1523/JNEUROSCI.22-06-02174.2002; Gu M, 1996, ANN NEUROL, V39, P385, DOI 10.1002/ana.410390317; Harper PS, 1991, HUNTINGTONS DIS; Jenkins BG, 1998, NEUROLOGY, V50, P1357, DOI 10.1212/WNL.50.5.1357; Kim YJ, 2001, P NATL ACAD SCI USA, V98, P12784, DOI 10.1073/pnas.221451398; Krajewski S, 1999, P NATL ACAD SCI USA, V96, P5752, DOI 10.1073/pnas.96.10.5752; Laforet GA, 2001, J NEUROSCI, V21, P9112, DOI 10.1523/JNEUROSCI.21-23-09112.2001; Lankiewicz S, 2000, J BIOL CHEM, V275, P17064, DOI 10.1074/jbc.275.22.17064; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; McDonald MC, 2001, FASEB J, V15, P171, DOI 10.1096/fj.99-0645com; Mittoux V, 2002, J NEUROSCI, V22, P4478, DOI 10.1523/JNEUROSCI.22-11-04478.2002; Palfi SP, 1996, J NEUROSCI, V16, P3019; Panov AV, 2002, NAT NEUROSCI, V5, P731, DOI 10.1038/nn884; Qin ZH, 2001, J BIOL CHEM, V276, P8079, DOI 10.1074/jbc.M007028200; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; Sawa A, 1999, NAT MED, V5, P1194, DOI 10.1038/13518; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Wolf BB, 1999, BLOOD, V94, P1683, DOI 10.1182/blood.V94.5.1683.417k37_1683_1692; Zeron MM, 2002, NEURON, V33, P849, DOI 10.1016/S0896-6273(02)00615-3	40	110	112	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43245	43253		10.1074/jbc.M305057200	http://dx.doi.org/10.1074/jbc.M305057200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12917435	hybrid, Green Published			2022-12-25	WOS:000186157000066
J	Much, B; Wahl-Schott, C; Zong, XG; Schneider, A; Baumann, L; Moosmang, S; Ludwig, A; Biel, M				Much, B; Wahl-Schott, C; Zong, XG; Schneider, A; Baumann, L; Moosmang, S; Ludwig, A; Biel, M			Role of subunit heteromerization and N-linked glycosylation in the formation of functional hyperpolarization-activated cyclic nucleotide-gated channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT-NEGATIVE SUPPRESSION; PACEMAKER CHANNELS; HCN CHANNELS; ION CHANNELS; BETA-SUBUNIT; EXPRESSION; DOMAIN; MECHANISMS; CURRENTS; TERMINUS	The coassembly of homologous subunits to heteromeric complexes serves as an important mechanism in generating ion channel diversity. Here, we have studied heteromerization in the hyperpolarization- activated cyclic nucleotide-gated (HCN) channel family. Using a combination of fluorescence confocal microscopy, coimmunoprecipitation, and electrophysiology we found that upon coexpression in HEK293 cells almost all dimeric combinations of HCN channel subunits give rise to the formation of stable channel complexes in the plasma membrane. We also identified HCN1/HCN2 heteromers in mouse brain indicating that heteromeric channels exist in vivo. Surprisingly, HCN2 and HCN3 did not coassemble to heteromeric channels. This finding indicates that heteromerization requires specific structural determinants that are not present in all HCN channel combinations. Using N-glycosidase F we show that native as well as recombinant HCN channels are glycosylated resulting in a 10 - 20-kDa shift in the molecular weight. Tunicamycin, an inhibitor of N-linked glycosylation, blocked surface membrane expression of HCN2. Similarly, a mutant HCN2 channel in which the putative N-glycosylation site in the loop between S5 and the pore helix was replaced by glutamine (HCN2(N380Q)) was not inserted into the plasma membrane and did not yield detectable whole-cell currents. These results indicate that N-linked glycosylation is required for cell surface trafficking of HCN channels. Cotransfection of HCN2(N380Q) with HCN4, but not with HCN3, rescued cell surface expression of HCN2(N380Q). Immunoprecipitation revealed that this rescue was due to the formation of a HCN2(N380Q)/HCN4 heteromeric channel. Taken together our results indicate that subunit heteromerization and glycosylation are important determinants of the formation of native HCN channels.	Univ Munich, Dept Pharm Pharmakol Nat Wissensch, D-81377 Munich, Germany; Tech Univ Munich, Inst Pharmakol & Toxikol, D-80802 Munich, Germany	University of Munich; Technical University of Munich	Biel, M (corresponding author), Univ Munich, Dept Pharm Pharmakol Nat Wissensch, Butenandtstr 7, D-81377 Munich, Germany.	mbiel@cup.uni-muenchen.de	Biel, Martin/G-1175-2014; Wahl-Schott, Christian A/J-2623-2015	Biel, Martin/0000-0002-9974-3052; 				Altomare C, 2003, J PHYSIOL-LONDON, V549, P347, DOI 10.1113/jphysiol.2002.027698; Biel M, 2002, TRENDS CARDIOVAS MED, V12, P206, DOI 10.1016/S1050-1738(02)00162-7; Bonigk W, 1999, J NEUROSCI, V19, P5332; Chen C, 2001, J GEN PHYSIOL, V117, P491, DOI 10.1085/jgp.117.5.491; Choe S, 2002, NAT REV NEUROSCI, V3, P115, DOI 10.1038/nrn727; Demontis GC, 2002, J PHYSIOL-LONDON, V542, P89, DOI 10.1113/jphysiol.2002.017640; DIFRANCESCO D, 1993, ANNU REV PHYSIOL, V55, P455, DOI 10.1146/annurev.physiol.55.1.455; Er F, 2003, CIRCULATION, V107, P485, DOI 10.1161/01.CIR.0000045672.32920.CB; Gerstner A, 2000, J NEUROSCI, V20, P1324; Kaupp UB, 2002, PHYSIOL REV, V82, P769, DOI 10.1152/physrev.00008.2002; Kaupp UB, 2001, ANNU REV PHYSIOL, V63, P235, DOI 10.1146/annurev.physiol.63.1.235; Ludwig A, 2003, EMBO J, V22, P216, DOI 10.1093/emboj/cdg032; Ludwig A, 1999, EMBO J, V18, P2323, DOI 10.1093/emboj/18.9.2323; McCormick DA, 1997, ANNU REV NEUROSCI, V20, P185, DOI 10.1146/annurev.neuro.20.1.185; Mellor J, 2002, SCIENCE, V295, P143, DOI 10.1126/science.1064285; Moosmang S, 2001, EUR J BIOCHEM, V268, P1646, DOI 10.1046/j.1432-1327.2001.02036.x; Muller F, 2003, EUR J NEUROSCI, V17, P2084, DOI 10.1046/j.1460-9568.2003.02634.x; Petrecca K, 1999, J PHYSIOL-LONDON, V515, P41, DOI 10.1111/j.1469-7793.1999.041ad.x; Proenza C, 2002, J BIOL CHEM, V277, P29634, DOI 10.1074/jbc.M200504200; Robinson RB, 2003, ANNU REV PHYSIOL, V65, P453, DOI 10.1146/annurev.physiol.65.092101.142734; Santoro B, 2000, J NEUROSCI, V20, P5264, DOI 10.1523/JNEUROSCI.20-14-05264.2000; Santoro B, 1997, P NATL ACAD SCI USA, V94, P14815, DOI 10.1073/pnas.94.26.14815; Satler CA, 1998, HUM GENET, V102, P265, DOI 10.1007/s004390050690; Sautter A, 1998, P NATL ACAD SCI USA, V95, P4696, DOI 10.1073/pnas.95.8.4696; Schulze-Bahr E, 2003, J CLIN INVEST, V111, P1537, DOI 10.1172/JCI200316387; Stevens DR, 2001, NATURE, V413, P631, DOI 10.1038/35098087; Tran N, 2002, J BIOL CHEM, V277, P43588, DOI 10.1074/jbc.M208477200; Ulens C, 2001, J BIOL CHEM, V276, P6069, DOI 10.1074/jbc.C000738200; Weitz D, 2002, NEURON, V36, P881, DOI 10.1016/S0896-6273(02)01098-X; Xue T, 2002, CIRC RES, V90, P1267, DOI 10.1161/01.RES.0000024390.97889.C6; Yu H, 2001, CIRC RES, V88, pE84, DOI 10.1161/hh1201.093511; Zheng J, 2002, NEURON, V36, P891, DOI 10.1016/S0896-6273(02)01099-1; Zhong HM, 2002, NATURE, V420, P193, DOI 10.1038/nature01201	33	146	148	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43781	43786		10.1074/jbc.M306958200	http://dx.doi.org/10.1074/jbc.M306958200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12928435	hybrid			2022-12-25	WOS:000186157000128
J	Sneddon, WB; Syme, CA; Bisello, A; Magyar, CE; Rochdi, MD; Parent, JL; Weinman, EJ; Abou-Samra, AB; Friedman, PA				Sneddon, WB; Syme, CA; Bisello, A; Magyar, CE; Rochdi, MD; Parent, JL; Weinman, EJ; Abou-Samra, AB; Friedman, PA			Activation-independent parathyroid hormone receptor internalization is regulated by NHERF1 (EBP50)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; CHRONIC-RENAL-FAILURE; PTH-RELATED PROTEIN; PDZ-DOMAIN; KINASE-A; SIGNAL-TRANSDUCTION; BINDING PROTEIN; PLASMA-MEMBRANE; PHOSPHOLIPASE-C; EZRIN	Parathyroid hormone (PTH) regulates extracellular calcium homeostasis through the type 1 PTH receptor (PTH1R) expressed in kidney and bone. The PTH1R undergoes beta-arrestin/dynamin-mediated endocytosis in response to the biologically active forms of PTH, PTH-(1 34), and PTH-( 1 - 84). We now show that amino-truncated forms of PTH that do not activate the PTH1R nonetheless induce PTH1R internalization in a cell-specific pattern. Activation-independent PTH1R endocytosis proceeds through a distinct arrestin-independent mechanism that is operative in cells lacking the adaptor protein Na/H exchange regulatory factor 1 (NHERF1) (ezrin-binding protein 50). Using a combination of radioligand binding experiments and quantitative, live cell confocal microscopy of fluorescently tagged PTH1Rs, we show that in kidney distal tubule cells and rat osteosarcoma cells, which lack NHERF1, the synthetic antagonist PTH-( 7 - 34) and naturally circulating PTH-( 7 - 84) induce internalization of PTH1R in a beta-arrestin-independent but dynamin-dependent manner. Expression of NHERF1 in these cells inhibited antagonist-induced endocytosis. Conversely, expression of dominant-negative forms of NHERF1 conferred internalization sensitivity to PTH-( 7 - 34) in cells expressing NHERF1. Mutation of the PTH1R PDZ-binding motif abrogated interaction of the receptor with NHERF1. These mutated receptors were fully functional but were now internalized in response to PTH-( 7 - 34) even in NHERF1-expressing cells. Removing the NHERF1 ERM domain or inhibiting actin polymerization allowed otherwise inactive ligands to internalize the PTH1R. These results demonstrate that NHERF1 acts as a molecular switch that legislates the conditional efficacy of PTH fragments. Distinct endocytic pathways are determined by NHERF1 that are operative for the PTH1R in kidney and bone cells.	Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Med, Div Endocrinol, Pittsburgh, PA 15261 USA; Univ Sherbrooke, Fac Med, Div Rheumatol, Sherbrooke, PQ J1H 5N4, Canada; Univ Sherbrooke, Clin Res Ctr, Sherbrooke, PQ J1H 5N4, Canada; Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA; Dept Vet Affairs Med Ctr, Baltimore, MD 21201 USA; Massachusetts Gen Hosp, Dept Med, Endocrine Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; Univ Pittsburgh, Sch Med, Dept Med, Div Renal, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Sherbrooke; University of Sherbrooke; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Friedman, PA (corresponding author), Univ Pittsburgh, Sch Med, Dept Pharmacol, E-1347 Biomed Sci Tower, Pittsburgh, PA 15261 USA.		Abou-Samra, Abdul/ABE-8723-2020	Abou-Samra, Abdul/0000-0001-8735-1142	NIDDK NIH HHS [DK-62078, DK-54171] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054171, R01DK062078] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altschuler Y, 1998, J CELL BIOL, V143, P1871, DOI 10.1083/jcb.143.7.1871; BERRYMAN M, 1993, J CELL SCI, V105, P1025; Bhowmick N, 1998, ENDOCRINOLOGY, V139, P3185, DOI 10.1210/en.139.7.3185; Bisello A, 2002, J BIOL CHEM, V277, P38524, DOI 10.1074/jbc.M202544200; Breton S, 2000, J BIOL CHEM, V275, P18219, DOI 10.1074/jbc.M909857199; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Bretscher A, 2000, ANNU REV CELL DEV BI, V16, P113, DOI 10.1146/annurev.cellbio.16.1.113; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Chauvin S, 2002, MOL ENDOCRINOL, V16, P2720, DOI 10.1210/me.2002-0049; CHEUNG AH, 1990, MOL PHARMACOL, V37, P775; Dicker F, 1999, P NATL ACAD SCI USA, V96, P5476, DOI 10.1073/pnas.96.10.5476; DOPPELT SH, 1986, P NATL ACAD SCI USA, V83, P7557, DOI 10.1073/pnas.83.19.7557; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Ferrari SL, 2001, MOL ENDOCRINOL, V15, P149, DOI 10.1210/me.15.1.149; Ferrari SL, 2000, J BONE MINER RES, V15, P198, DOI 10.1359/jbmr.2000.15.2.198; Ferrari SL, 1999, J BIOL CHEM, V274, P29968, DOI 10.1074/jbc.274.42.29968; Flannery PJ, 2001, BIOCHEM PHARMACOL, V62, P1047, DOI 10.1016/S0006-2952(01)00749-3; FLUECK JA, 1977, J CLIN INVEST, V60, P1367, DOI 10.1172/JCI108897; Fouassier L, 2000, J BIOL CHEM, V275, P25039, DOI 10.1074/jbc.C000092200; Friedman PA, 1999, ENDOCRINOLOGY, V140, P301, DOI 10.1210/en.140.1.301; FUJIMORI A, 1992, ENDOCRINOLOGY, V130, P29, DOI 10.1210/en.130.1.29; Gardella TJ, 1996, ENDOCRINOLOGY, V137, P3936, DOI 10.1210/en.137.9.3936; Gentili C, 2001, CELL SIGNAL, V13, P131, DOI 10.1016/S0898-6568(00)00145-5; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; GOLDMAN ME, 1988, ENDOCRINOLOGY, V123, P2597, DOI 10.1210/endo-123-5-2597; HABENER JF, 1977, RECENT PROG HORM RES, V33, P249; HASHIZUME Y, 1993, J HISTOCHEM CYTOCHEM, V41, P273, DOI 10.1177/41.2.8419463; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; HORIUCHI N, 1983, SCIENCE, V220, P1053, DOI 10.1126/science.6302844; Huang ZM, 1999, ENDOCRINOLOGY, V140, P1294, DOI 10.1210/en.140.3.1294; HUNYADY L, 1994, J BIOL CHEM, V269, P24798; Ingraffea J, 2002, EUR J CELL BIOL, V81, P61, DOI 10.1078/0171-9335-00218; John MR, 1999, J CLIN ENDOCR METAB, V84, P4287, DOI 10.1210/jc.84.11.4287; Juppner H, 2001, ENDOCRINOLOGY, P969; Kenakin T, 2002, NAT REV DRUG DISCOV, V1, P103, DOI 10.1038/nrd722; Khanna C, 2001, CANCER RES, V61, P3750; Lau AG, 2001, BIOCHEMISTRY-US, V40, P8572, DOI 10.1021/bi0103516; Li JG, 2002, J BIOL CHEM, V277, P27545, DOI 10.1074/jbc.M200058200; Mahon MJ, 2002, NATURE, V417, P858, DOI 10.1038/nature00816; Malecz N, 1998, MOL ENDOCRINOL, V12, P1846, DOI 10.1210/me.12.12.1846; Nguyen-Yamamoto L, 2002, EUR J ENDOCRINOL, V147, P123, DOI 10.1530/eje.0.1470123; Rapacciuolo A, 2003, J BIOL CHEM, V278, P35403, DOI 10.1074/jbc.M305675200; Reczek D, 1998, J BIOL CHEM, V273, P18452, DOI 10.1074/jbc.273.29.18452; Rochdi MD, 2002, J BIOL CHEM, V277, P40751, DOI 10.1074/jbc.M207910200; Roettger BF, 1997, MOL PHARMACOL, V51, P357; Roth BL, 1999, NEURON, V23, P629, DOI 10.1016/S0896-6273(02)23443-1; Shenolikar S, 2001, AM J PHYSIOL-RENAL, V280, pF389, DOI 10.1152/ajprenal.2001.280.3.F389; Sitaraman SV, 2002, J BIOL CHEM, V277, P33188, DOI 10.1074/jbc.M202522200; Slatopolsky E, 2000, KIDNEY INT, V58, P753, DOI 10.1046/j.1523-1755.2000.00222.x; TAMURA T, 1989, BIOCHEM BIOPH RES CO, V159, P1352, DOI 10.1016/0006-291X(89)92259-6; Tawfeek HA, 1999, J BONE MINER RES, V14, pS542; Tawfeek HAW, 2002, MOL ENDOCRINOL, V16, P1, DOI 10.1210/me.16.1.1; Tawfeek HAW, 2001, AM J PHYSIOL-ENDOC M, V281, pE545, DOI 10.1152/ajpendo.2001.281.3.E545; TIAN J, 1994, AM J NEPHROL, V14, P41, DOI 10.1159/000168684; URENA P, 1994, KIDNEY INT, V45, P605, DOI 10.1038/ki.1994.79; Vilardaga JP, 2002, J BIOL CHEM, V277, P8121, DOI 10.1074/jbc.M110433200; Vilardaga JP, 2001, J BIOL CHEM, V276, P33435, DOI 10.1074/jbc.M011495200; Voltz JW, 2001, ONCOGENE, V20, P6309, DOI 10.1038/sj.onc.1204774; Wade JB, 2001, AM J PHYSIOL-CELL PH, V280, pC192, DOI 10.1152/ajpcell.2001.280.1.C192; Weinman EJ, 2001, J BIOL CHEM, V276, P42339, DOI 10.1074/jbc.M106153200; Willins DL, 1999, NEUROSCIENCE, V91, P599, DOI 10.1016/S0306-4522(98)00653-8; Zhang P, 1998, J CLIN ENDOCR METAB, V83, P3365, DOI 10.1210/jc.83.9.3373	62	135	136	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43787	43796		10.1074/jbc.M306019200	http://dx.doi.org/10.1074/jbc.M306019200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12920119	hybrid			2022-12-25	WOS:000186157000129
J	Mahajan, NP; Earp, HS				Mahajan, NP; Earp, HS			An SH2 domain-dependent, phosphotyrosine-independent interaction between Vav1 and the Mer receptor tyrosine kinase - A mechanism for localizing guanine nucleotide-exchange factor action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIGMENT EPITHELIAL-CELLS; C-MER; RHO-GTPASES; RCS RAT; EXPRESSION ANALYSIS; APOPTOTIC CELLS; TYRO-3 FAMILY; PROTEIN-S; GENE 6; PHAGOCYTOSIS	Mer belongs to the Mer/Axl/Tyro3 receptor tyrosine kinase family, which regulates immune homeostasis in part by triggering monocyte ingestion of apoptotic cells. Mutations in Mer can also cause retinitis pigmentosa, again due to defective phagocytosis of apoptotic material. Although, some functional aspects of Mer have been deciphered, how receptor activation lead to the physiological consequences is not understood. By using yeast two-hybrid assays, we identified the carboxyl-terminal region of the guanine nucleotide-exchange factor (GEF) Vav1 as a Mer-binding partner. Unlike similar (related) receptors, Mer interacted with Vav1 constitutively and independently of phosphotyrosine, yet the site of binding localized to the Vav1 SH2 domain. Mer activation resulted in tyrosine phosphorylation of Vav1 and release from Mer, whereas Vav1 was neither phosphorylated nor released from kinase-dead Mer. Mutation of the Vav1 SH2 domain phosphotyrosine coordinating Arg-696 did not alter Mer/Vav1 constitutive binding or Vav1 tyrosine phosphorylation but did retard Vav1 release from autophosphorylated Mer. Ligand-dependent activation of Mer in human monocytes led to Vav1 release and stimulated GDP replacement by GTP on RhoA family members. This unusual constitutive, SH2 domain-dependent, but phosphotyrosine-independent, interaction and its regulated local release and subsequent activation of Rac1, Cdc42, and RhoA may explain how Mer coordinates precise cytoskeletal changes governing the ingestion of apoptotic material by macrophages and pigmented retinal epithelial cells.	Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Earp, HS (corresponding author), Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA.							Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Camenisch TD, 1999, J IMMUNOL, V162, P3498; Caron E, 1998, SCIENCE, V282, P1717, DOI 10.1126/science.282.5394.1717; Chen J, 1997, ONCOGENE, V14, P2033, DOI 10.1038/sj.onc.1201039; Chimini G, 2000, NAT CELL BIOL, V2, pE191, DOI 10.1038/35036454; Cohen PL, 2002, J EXP MED, V196, P135, DOI 10.1084/jem.20012094; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645; Fadok VA, 2001, J CLIN INVEST, V108, P957, DOI 10.1172/JCI14122; FADOK VA, 1992, J IMMUNOL, V148, P2207; Feng W, 2002, J BIOL CHEM, V277, P17016, DOI 10.1074/jbc.M107876200; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Gal A, 2000, NAT GENET, V26, P270, DOI 10.1038/81555; Georgescu MM, 1999, MOL CELL BIOL, V19, P1171; GODOWSKI PJ, 1995, CELL, V82, P355, DOI 10.1016/0092-8674(95)90424-7; GRAHAM DK, 1994, CELL GROWTH DIFFER, V5, P647; GRAHAM DK, 1995, ONCOGENE, V10, P2349; Guttridge KL, 2002, J BIOL CHEM, V277, P24057, DOI 10.1074/jbc.M112086200; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hall MO, 2001, EXP EYE RES, V73, P509, DOI 10.1006/exer.2001.1062; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; Leverrier Y, 2001, CURR BIOL, V11, P195, DOI 10.1016/S0960-9822(01)00047-1; LING L, 1995, MOL CELL BIOL, V15, P6582; Lu QX, 1999, NATURE, V398, P723, DOI 10.1038/19554; Lu QX, 2001, SCIENCE, V293, P306, DOI 10.1126/science.1061663; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MERENGERE LE, 1992, J BIOL CHEM, V267, P22779; Nagata K, 1996, J BIOL CHEM, V271, P30022, DOI 10.1074/jbc.271.47.30022; Nakano T, 1997, J BIOL CHEM, V272, P29411, DOI 10.1074/jbc.272.47.29411; Reddien PW, 2000, NAT CELL BIOL, V2, P131, DOI 10.1038/35004000; Sakaguchi K, 1998, MOL ENDOCRINOL, V12, P536, DOI 10.1210/me.12.4.536; Sayos J, 1998, NATURE, V395, P462, DOI 10.1038/26683; Scott RS, 2001, NATURE, V411, P207, DOI 10.1038/35075603; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; Vollrath D, 2001, P NATL ACAD SCI USA, V98, P12584, DOI 10.1073/pnas.221364198; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; Woodside DG, 2001, CURR BIOL, V11, P1799, DOI 10.1016/S0960-9822(01)00565-6	37	78	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42596	42603		10.1074/jbc.M305817200	http://dx.doi.org/10.1074/jbc.M305817200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12920122	hybrid			2022-12-25	WOS:000185989500125
J	Motohashi, K; Koyama, F; Nakanishi, Y; Ueoka-Nakanishi, H; Hisabori, T				Motohashi, K; Koyama, F; Nakanishi, Y; Ueoka-Nakanishi, H; Hisabori, T			Chloroplast cyclophilin is a target protein of thioredoxin - Thiol modulation of the peptidyl-prolyl cis-trans isomerase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ARABIDOPSIS-THALIANA; ESCHERICHIA-COLI; PLANT; EXPRESSION; CLONING; IDENTIFICATION; PURIFICATION; PHOSPHATASE; CYSTEINES	Chloroplast cyclophilin has been identified as a potential candidate of enzymes in chloroplasts that are regulated by thioredoxin ( Motohashi, K., Kondoh, A., Stumpp, M. T., and Hisabori, T. ( 2001) Proc. Natl. Acad. Sci. U. S. A. 98, 11224 - 11229). In the present study we found that the peptidyl-prolyl cis-trans isomerase activity of cyclophilin is fully inactivated in the oxidized form. Reduction of cyclophilin by thioredoxin-m recovered the isomerase activity. Two crucial disulfide bonds were determined by disulfide-linked peptide mapping. The relevance of these cysteines for isomerase activity was confirmed by the mutagenesis studies. Because four cysteine residues in Arabidopsis thaliana cyclophilin were conserved in the isoforms from several organisms, it appears that this redox regulation must be one of the common regulation systems of cyclophilin.	Tokyo Inst Technol, Chem Resources Lab, Yokohama, Kanagawa 2268503, Japan; JST, ATP Syst Project, ERATO, Yokohama, Kanagawa 2260026, Japan	Tokyo Institute of Technology; Japan Science & Technology Agency (JST)	Hisabori, T (corresponding author), Tokyo Inst Technol, Chem Resources Lab, Nagatsuta 4259, Yokohama, Kanagawa 2268503, Japan.	thisabor@res.titech.ac.jp	Motohashi, Ken/I-4970-2019; Hisabori, Toru/E-5205-2014	Motohashi, Ken/0000-0002-8414-2836; Hisabori, Toru/0000-0003-2046-0277; zhong xi, hua dai/0000-0001-8619-9513				Balmer Y, 2003, P NATL ACAD SCI USA, V100, P370, DOI 10.1073/pnas.232703799; Baumann U, 2002, CELL MOL LIFE SCI, V59, P1042, DOI 10.1007/s00018-002-8485-8; Berardini TZ, 2001, SCIENCE, V291, P2405, DOI 10.1126/science.1057144; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREIMAN A, 1992, J BIOL CHEM, V267, P21293; BUCHANAN BB, 1980, ANNU REV PLANT PHYS, V31, P341, DOI 10.1146/annurev.pp.31.060180.002013; DOLINSKI K, 1997, GUIDEBOOK MOL CHAPER, P359; Dornan J, 1999, J BIOL CHEM, V274, P34877, DOI 10.1074/jbc.274.49.34877; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FISCHER G, 1984, BIOCHIM BIOPHYS ACTA, V791, P87, DOI 10.1016/0167-4838(84)90285-1; Fulgosi H, 1998, EMBO J, V17, P1577, DOI 10.1093/emboj/17.6.1577; GASSER CS, 1990, P NATL ACAD SCI USA, V87, P9519, DOI 10.1073/pnas.87.24.9519; GLAZER AN, 1975, CHEM MODIFICATION PR, P21; HAYANO T, 1991, BIOCHEMISTRY-US, V30, P3041, DOI 10.1021/bi00226a009; HAYMAN GT, 1994, BBA-GENE STRUCT EXPR, V1219, P536, DOI 10.1016/0167-4781(94)90083-3; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1995, STRUCTURE, V3, P239, DOI 10.1016/S0969-2126(01)00153-8; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Jacquot JP, 1997, NEW PHYTOL, V136, P543, DOI 10.1046/j.1469-8137.1997.00784.x; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; Lee SP, 2001, J BIOL CHEM, V276, P29826, DOI 10.1074/jbc.M101822200; LIPPUNER V, 1994, J BIOL CHEM, V269, P7863; LIU J, 1990, P NATL ACAD SCI USA, V87, P2304, DOI 10.1073/pnas.87.6.2304; LUAN S, 1994, PLANT CELL, V6, P885, DOI 10.1105/tpc.6.6.885; LUAN S, 1994, P NATL ACAD SCI USA, V91, P984, DOI 10.1073/pnas.91.3.984; Motohashi K, 2001, P NATL ACAD SCI USA, V98, P11224, DOI 10.1073/pnas.191282098; Ruelland E, 1999, TRENDS PLANT SCI, V4, P136, DOI 10.1016/S1360-1385(99)01391-6; SAITO T, 1995, PLANT CELL PHYSIOL, V36, P377, DOI 10.1093/oxfordjournals.pcp.a078770; Saito T, 1999, PLANT CELL PHYSIOL, V40, P77, DOI 10.1093/oxfordjournals.pcp.a029477; SCHREIBER SL, 1992, CELL, V70, P365, DOI 10.1016/0092-8674(92)90158-9; SCHURMANN P, 1995, METHOD ENZYMOL, V252, P274; Schurmann P, 2000, ANNU REV PLANT PHYS, V51, P371, DOI 10.1146/annurev.arplant.51.1.371; Sheldon PS, 1996, BIOCHEM J, V315, P965, DOI 10.1042/bj3150965; Stumpp MT, 1999, BIOCHEM J, V341, P157, DOI 10.1042/0264-6021:3410157; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; Vener AV, 1999, BIOCHEMISTRY-US, V38, P14955, DOI 10.1021/bi990971v; WALSH CT, 1992, J BIOL CHEM, V267, P13115; Yano H, 2001, P NATL ACAD SCI USA, V98, P4794, DOI 10.1073/pnas.071041998	40	112	122	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31848	31852		10.1074/jbc.M304258200	http://dx.doi.org/10.1074/jbc.M304258200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12923164	hybrid			2022-12-25	WOS:000184782100049
J	Stampfer, MR; Garbe, J; Nijjar, T; Wigington, D; Swisshelm, K; Yaswen, P				Stampfer, MR; Garbe, J; Nijjar, T; Wigington, D; Swisshelm, K; Yaswen, P			Loss of p53 function accelerates acquisition of telomerase activity in indefinite lifespan human mammary epithelial cell lines	ONCOGENE			English	Article						immortal transformation; telomerase; telomeres; TGF beta; genomic instability; conversion; p53	HUMAN BREAST-CANCER; MUTANT P53-INDUCED IMMORTALIZATION; HUMAN-PAPILLOMAVIRUS TYPE-16; CARCINOMA IN-SITU; HUMAN FIBROBLASTS; TUMOR-CELLS; EXPRESSION; GENE; TRANSFORMATION; PROTEIN	We describe novel effects of p53 loss on immortal transformation, based upon comparison of immortally transformed human mammary epithelial cell (HMEC) lines lacking functional p53 with closely related p53(+) lines. Our previous studies of p53(+) immortal HMEC lines indicated that overcoming the stringent replicative senescence step associated with critically short telomeres (agonescence), produced indefinite lifespan lines that maintained growth without immediately expressing telomerase activity. These telomerase(-) 'conditionally immortal' HMEC underwent an additional step, termed conversion, to become fully immortal telomerase( +) lines with uniform good growth. The very gradual conversion process was associated with slow heterogeneous growth and high expression of the cyclin-dependent kinase inhibitor p57(Kip2). We now show that p53 suppresses telomerase activity and is necessary for the p57 expression in early passage p53(+) conditionally immortal HMEC lines, and that p53(-/-) lines exhibit telomerase reactivation and attain full immortality much more rapidly. A p53-inhibiting genetic suppressor element introduced into early passages of a conditionally immortal telomerase(-) p53(+) HMEC line led to rapid induction of hTERT mRNA, expression of telomerase activity, loss of p57 expression, and quick attainment of uniform good growth. These studies indicate that derangements in p53 function may impact malignant progression through direct effects on the conversion process, a potentially rate-limiting step in HMEC acquisition of uniform unlimited growth potential. These studies also provide evidence that the function of p53 in suppression of telomerase activity is separable from its cell cycle checkpoint function.	Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of Washington; University of Washington Seattle	Stampfer, MR (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Bldg 70A1118, Berkeley, CA 94720 USA.				NCI NIH HHS [CA24844] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA024844, R01CA024844] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; Allred DC, 2000, J MAMMARY GLAND BIOL, V5, P351, DOI 10.1023/A:1009573710675; ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Bacchetti S, 1996, CANCER SURV, V28, P197; BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; Bednarek AK, 1997, CLIN CANCER RES, V3, P11; Bodnar AG, 1996, EXP CELL RES, V228, P58, DOI 10.1006/excr.1996.0299; Brenner AJ, 1998, ONCOGENE, V17, P199, DOI 10.1038/sj.onc.1201919; Brenner AJ, 1996, CLIN CANCER RES, V2, P1993; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Bunz F, 2002, CANCER RES, V62, P1129; Cao YA, 1997, CANCER RES, V57, P5584; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Chan SWL, 2002, ONCOGENE, V21, P553, DOI 10.1038/sj.onc.1205082; Chang S, 2001, SEMIN CANCER BIOL, V11, P227, DOI 10.1006/scbi.2000.0374; CLARK R, 1988, CANCER RES, V48, P4689; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; Done SJ, 1998, CANCER RES, V58, P785; FINER MH, 1994, BLOOD, V83, P43; Gao QS, 1996, CANCER RES, V56, P3129; Garbe J, 1999, ONCOGENE, V18, P2169, DOI 10.1038/sj.onc.1202523; Gollahon LS, 1996, ONCOGENE, V12, P715; HAMMOND SL, 1984, P NATL ACAD SCI-BIOL, V81, P5435, DOI 10.1073/pnas.81.17.5435; HERMAN JG, 1995, CANCER RES, V55, P4525; Iacopetta B, 1998, CLIN CANCER RES, V4, P1597; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Li H, 1999, ONCOGENE, V18, P6785, DOI 10.1038/sj.onc.1203061; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; Nijjar T, 1999, CANCER RES, V59, P5112; Nonet GH, 2001, CANCER RES, V61, P1250; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; Poremba C, 1999, J CLIN ONCOL, V17, P2020, DOI 10.1200/JCO.1999.17.7.2020; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579; Roos G, 1998, INT J CANCER, V79, P343, DOI 10.1002/(SICI)1097-0215(19980821)79:4<343::AID-IJC6>3.0.CO;2-V; Sandhu C, 1997, MOL CELL BIOL, V17, P2458, DOI 10.1128/MCB.17.5.2458; SHAY JW, 1995, MOL CELL BIOL, V15, P425, DOI 10.1128/MCB.15.1.425; SHAY JW, 1993, ONCOGENE, V8, P1407; Shpitz B, 1999, BREAST CANCER RES TR, V58, P65, DOI 10.1023/A:1006394209922; Sjogren S, 1996, J NATL CANCER I, V88, P173, DOI 10.1093/jnci/88.3-4.173; Stampfer M, 1985, J TISSUE CULTURE MET, V9, P107; Stampfer MR, 1997, MOL BIOL CELL, V8, P2391, DOI 10.1091/mbc.8.12.2391; STAMPFER MR, 1993, EXP CELL RES, V208, P175, DOI 10.1006/excr.1993.1236; Stampfer MR, 2000, J MAMMARY GLAND BIOL, V5, P365, DOI 10.1023/A:1009525827514; Stampfer MR, 2001, P NATL ACAD SCI USA, V98, P4498, DOI 10.1073/pnas.071483998; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; STAMPFER MR, 2001, ADV CELL AGING GERON, V8, P103; STAMPFER MR, 1988, BREAST CANCER CELLUL, P1; Sugino T, 1996, INT J CANCER, V69, P301, DOI 10.1002/(SICI)1097-0215(19960822)69:4<301::AID-IJC11>3.0.CO;2-8; Tlsty TD, 2001, J MAMMARY GLAND BIOL, V6, P235, DOI 10.1023/A:1011369026168; WALEN KH, 1989, CANCER GENET CYTOGEN, V37, P249, DOI 10.1016/0165-4608(89)90056-3; WEINSTATSASLOW D, 1995, NAT MED, V1, P1257, DOI 10.1038/nm1295-1257; Xu DW, 2000, ONCOGENE, V19, P5123, DOI 10.1038/sj.onc.1203890	57	55	56	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 14	2003	22	34					5238	5251		10.1038/sj.onc.1206667	http://dx.doi.org/10.1038/sj.onc.1206667			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JB	12917625				2022-12-25	WOS:000184734900003
J	Kim, HS; Kim, EM; Lee, JP; Park, CH; Kim, S; Seo, JH; Chang, KA; Yu, E; Jeong, SJ; Chong, YH; Suh, YH				Kim, HS; Kim, EM; Lee, JP; Park, CH; Kim, S; Seo, JH; Chang, KA; Yu, E; Jeong, SJ; Chong, YH; Suh, YH			C-terminal fragments of amyloid precursor protein exert neurotoxicity by inducing glycogen synthase kinase-3 beta expression	FASEB JOURNAL			English	Article						Alzheimer's disease; Fe65; CP2/LSF/LBP1 transcription factor; AICD	ALZHEIMERS-DISEASE; INTRACELLULAR DOMAIN; BETA-CATENIN; MOLECULAR-CLONING; KINASE 3-BETA; FE65; DEGENERATION; APOPTOSIS; APP; TAU	The AICD ( amyloid precursor protein [APP] intracellular domain) and C31, the caspase-cleaved C-terminal fragment of APP, have been found in the brains of patients with Alzheimer's disease (AD). Here, we demonstrate for the first time that the C-terminal fragments of APP (AICD [C57, C59] and C31) exert neurotoxicity on differentiated PC 12 cells and rat primary cortical neurons by inducing the expression of glycogen synthase kinase 3beta, forming a ternary complex with Fe65 and CP2/LSF/LBP1 in the nucleus, whereas deletion mutants and a point mutant with Y682G of the YENPTY domain, a Fe65 binding domain, do not. Moreover, expression of APP770 and Swedish mutant form of APP increased the levels of C-terminal fragments of APP (APP-CTs) in neuronal cells and also induced the up-regulation of glycogen synthase kinase-3beta at both the mRNA and the protein levels. In addition, we show that CP2/LSF/LBP1 binding site (nt + 0 to similar to+ 10) in human glycogen synthase kinase 3beta promoter region is essential for the induction of the gene transcription by APP-CTs. The neurotoxicities induced by APP-CTs ( AICD and C31) were accompanied by an increase in the active form of glycogen synthase knase-3beta, and by the induction of tau phosphorylation and a reduction in nuclear beta-catenin levels, and led to apoptosis.	Seoul Natl Univ, Coll Med, Dept Pharmacol,MRC, Natl Creat Res Initiat Ctr Alzheimers Dementia, Seoul 110799, South Korea; Ewha Womans Univ, Coll Med, Div Neurosci, Med Res Ctr,Dep Microbiol, Seoul 158056, South Korea; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Seoul National University (SNU); Ewha Womans University; Harvard University; Harvard Medical School	Suh, YH (corresponding author), Seoul Natl Univ, Coll Med, Dept Pharmacol,MRC, Natl Creat Res Initiat Ctr Alzheimers Dementia, Seoul 110799, South Korea.	yhsuh@plaza.snu.ac.kr	Kim, Hye Sun/J-2752-2012; Suh, Yoo-Hun/J-2761-2012					AO Y, 2001, P NATL ACAD SCI USA, V98, P14979; Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Bhat RV, 2000, P NATL ACAD SCI USA, V97, P11074, DOI 10.1073/pnas.190297597; Biederer T, 2002, J NEUROSCI, V22, P7340; Bing ZY, 1999, J BIOL CHEM, V274, P24649, DOI 10.1074/jbc.274.35.24649; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Buxbaum JD, 1998, J NEUROSCI, V18, P9629; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; DeGiorgio LA, 2000, BRAIN RES, V874, P137, DOI 10.1016/S0006-8993(00)02545-2; Faure S, 1997, EMBO J, V16, P5550, DOI 10.1093/emboj/16.18.5550; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; Graef IA, 1999, NATURE, V401, P703, DOI 10.1038/44378; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; Kimberly WT, 2001, J BIOL CHEM, V276, P40288, DOI 10.1074/jbc.C100447200; Lau KF, 1999, GENOMICS, V60, P121, DOI 10.1006/geno.1999.5875; LIM LC, 1992, MOL CELL BIOL, V12, P828, DOI 10.1128/MCB.12.2.828; Lu DC, 2000, NAT MED, V6, P397, DOI 10.1038/74656; Lucas JJ, 2001, EMBO J, V20, P27, DOI 10.1093/emboj/20.1.27; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; PASSER B, 2000, ALZ REPORTS, V2, P289; Pei JJ, 1999, J NEUROPATH EXP NEUR, V58, P1010, DOI 10.1097/00005072-199909000-00011; Roncarati R, 2002, P NATL ACAD SCI USA, V99, P7102, DOI 10.1073/pnas.102192599; Russo T, 1998, FEBS LETT, V434, P1, DOI 10.1016/S0014-5793(98)00941-7; SCHEINFELD MH, 2003, IN PRESS P NATL ACAD; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; SIMEONE A, 1994, DEV NEUROSCI-BASEL, V16, P53, DOI 10.1159/000112088; Suh YH, 2002, PHARMACOL REV, V54, P469, DOI 10.1124/pr.54.3.469; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Taylor AE, 2001, J MED GENET, V38, P232, DOI 10.1136/jmg.38.4.232; TROJANOWSKI JQ, 1993, CLIN NEUROSCI, V1, P184; Weihl CC, 1999, NEUROREPORT, V10, P2527, DOI 10.1097/00001756-199908200-00017; Wolfe MS, 2001, J BIOL CHEM, V276, P5413, DOI 10.1074/jbc.R000026200; YOON JB, 1994, MOL CELL BIOL, V14, P1776, DOI 10.1128/MCB.14.3.1776; Zambrano N, 1998, J BIOL CHEM, V273, P20128, DOI 10.1074/jbc.273.32.20128; Zhang JW, 2000, J NEUROCHEM, V75, P2346, DOI 10.1046/j.1471-4159.2000.0752346.x; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208; Zhu M, 2002, NEUROBIOL AGING, V23, pS205	42	193	204	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1951	+		10.1096/fj.03-0106fje	http://dx.doi.org/10.1096/fj.03-0106fje			28	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12923068				2022-12-25	WOS:000185345100014
J	Canals, M; Marcellino, D; Fanelli, F; Ciruela, F; de Benedetti, P; Goldberg, SR; Neve, K; Fuxe, K; Agnati, LF; Woods, AS; Ferre, S; Lluis, C; Bouvier, M; Franco, R				Canals, M; Marcellino, D; Fanelli, F; Ciruela, F; de Benedetti, P; Goldberg, SR; Neve, K; Fuxe, K; Agnati, LF; Woods, AS; Ferre, S; Lluis, C; Bouvier, M; Franco, R			Adenosine A(2A)-dopamine D2 receptor-receptor heteromerization - Qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; FUNCTIONAL GABA(B) RECEPTOR; ADENOSINE A(2A) RECEPTORS; DOPAMINE D2 RECEPTORS; INTEGRATIVE MECHANISM; LIGAND-BINDING; TRANSFER BRET; LIVE CELLS; HETERODIMERIZATION; OLIGOMERIZATION	There is evidence for strong functional antagonistic interactions between adenosine A(2A) receptors (A(2A)Rs) and dopamine D-2 receptors (D(2)Rs). Although a close physical interaction between both receptors has recently been shown using co-immunoprecipitation and co-localization assays, the existence of a A(2A)R-D2R protein-protein interaction still had to be demonstrated in intact living cells. In the present work, fluorescence resonance energy transfer ( FRET) and bioluminescence resonance energy transfer (BRET) techniques were used to confirm the occurrence of A(2A)R-D2R interactions in cotransfected cells. The degree of A(2A)R-D2R heteromerization, measured by BRET, did not vary after receptor activation with selective agonists, alone or in combination. BRET competition experiments were performed using a chimeric D2R-D1R in which helices 5 and 6, the third intracellular loop (I3), and the third extracellular loop (E3) of the D2R were replaced by those of the dopamine D-1 receptor (D1R). Although the wild type D2R was able to decrease the BRET signal, the chimera failed to achieve any effect. This suggests that the helix 5-I3-helix 6-E3 portion of D2R holds the site(s) for interaction with A(2A)R. Modeling of A(2A)R and D2R using a modified rhodopsin template followed by molecular dynamics and docking simulations gave essentially two different possible modes of interaction between D2R and A(2A)R. In the most probable one, helix 5 and/or helix 6 and the N-terminal portion of I3 from D2R approached helix 4 and the C-terminal portion of the C-tail from the A(2A)R, respectively.	Univ Barcelona, Dept Biochem & Mol Biol, E-08028 Barcelona, Spain; Univ Modena & Reggio Emilia, Dulbecco Telethon Inst, I-41100 Modena, Italy; Univ Modena & Reggio Emilia, Dept Chem, I-41100 Modena, Italy; Univ Modena & Reggio Emilia, Dept Biomed Sci, I-41100 Modena, Italy; NIDA, DHHS, NIH, Intramural Res Program, Baltimore, MD 21224 USA; Karolinska Inst, Dept Neurosci, Div Cellular & Mol Neurochem, S-17177 Stockholm, Sweden; Univ Montreal, Dept Biochem, Montreal, PQ H3C 3J7, Canada; Dept Vet Affairs Med Ctr, Portland, OR 97239 USA	University of Barcelona; Fondazione Telethon; Dulbecco Telethon Institute (DTI); Universita di Modena e Reggio Emilia; Universita di Modena e Reggio Emilia; Universita di Modena e Reggio Emilia; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); NIH National Institute on Drug Abuse (NIDA); Karolinska Institutet; Universite de Montreal; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Portland Health Care System	Franco, R (corresponding author), Univ Barcelona, Dept Biochem & Mol Biol, Marti & Franques 1, E-08028 Barcelona, Spain.		Marcellino, Daniel/HDM-8433-2022; Franco, Rafael/C-3694-2015; Fanelli, Francesca/O-8807-2014; Ciruela, F./A-5096-2013; Ferre, Sergi/K-6115-2014; Bouvier, Michel/H-2758-2014; soler, martha maricel m gomez/L-6025-2014	Marcellino, Daniel/0000-0002-4618-7267; Franco, Rafael/0000-0003-2549-4919; Fanelli, Francesca/0000-0002-7620-6895; Ciruela, F./0000-0003-0832-3739; Ferre, Sergi/0000-0002-1747-1779; Bouvier, Michel/0000-0003-1128-0100; soler, martha maricel m gomez/0000-0002-4412-8108; Fuxe, Kjell/0000-0001-8491-4288; Canals, Meritxell/0000-0002-7942-5006	Telethon [TCP00068] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [Z01DA000003] Funding Source: NIH RePORTER	Telethon(Fondazione Telethon); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Agnati LF, 2003, PHARMACOL REV, V55, P509, DOI 10.1124/pr.55.3.2; AGNATI LF, 1980, MED BIOL, V58, P182; Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; Ausiello G, 1997, PROTEINS, V28, P556, DOI 10.1002/(SICI)1097-0134(199708)28:4<556::AID-PROT9>3.3.CO;2-C; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Chen R, 2003, PROTEINS, V52, P80, DOI 10.1002/prot.10389; Dasgupta S, 1996, EUR J PHARMACOL, V316, P325, DOI 10.1016/S0014-2999(96)00665-6; Diaz-Cabiale Z, 2001, NEUROREPORT, V12, P1831; Dixon AK, 1997, J NEUROCHEM, V69, P315; Ferre S, 1997, TRENDS NEUROSCI, V20, P482, DOI 10.1016/S0166-2236(97)01096-5; FERRE S, 1991, P NATL ACAD SCI USA, V88, P7238, DOI 10.1073/pnas.88.16.7238; Ferre Sergi, 2003, Current Medicinal Chemistry - Central Nervous System Agents, V3, P1, DOI 10.2174/1568015033357779; Franco R, 2003, TRENDS BIOCHEM SCI, V28, P238, DOI 10.1016/S0968-0004(03)00065-3; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; FUXE K, 1985, MED RES REV, V5, P441, DOI 10.1002/med.2610050404; George SR, 2002, NAT REV DRUG DISCOV, V1, P808, DOI 10.1038/nrd913; Gines S, 2000, P NATL ACAD SCI USA, V97, P8606, DOI 10.1073/pnas.150241097; Guo W, 2003, J BIOL CHEM, V278, P4385, DOI 10.1074/jbc.C200679200; Hillion J, 2002, J BIOL CHEM, V277, P18091, DOI 10.1074/jbc.M107731200; Issafras H, 2002, J BIOL CHEM, V277, P34666, DOI 10.1074/jbc.M202386200; Jensen AA, 2002, EUR J BIOCHEM, V269, P5076, DOI 10.1046/j.1432-1033.2002.03218.x; JONES DT, 1992, NATURE, V358, P86, DOI 10.1038/358086a0; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; Kammerer RA, 1999, BIOCHEMISTRY-US, V38, P13263, DOI 10.1021/bi991018t; Kniazeff J, 2002, J NEUROSCI, V22, P7352; Kozell LB, 1997, MOL PHARMACOL, V52, P1137, DOI 10.1124/mol.52.6.1137; Kull B, 1999, BIOCHEM PHARMACOL, V58, P1035, DOI 10.1016/S0006-2952(99)00184-7; Kuner R, 1999, SCIENCE, V283, P74, DOI 10.1126/science.283.5398.74; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; Mercier JF, 2002, J BIOL CHEM, V277, P44925, DOI 10.1074/jbc.M205767200; Milligan G, 2001, TRENDS PHARMACOL SCI, V22, P513, DOI 10.1016/S0165-6147(00)01801-0; Ng GYK, 1996, BIOCHEM BIOPH RES CO, V227, P200, DOI 10.1006/bbrc.1996.1489; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Patel RC, 2002, P NATL ACAD SCI USA, V99, P3294, DOI 10.1073/pnas.042705099; Ramsay D, 2002, BIOCHEM J, V365, P429, DOI 10.1042/BJ20020251; Rios CD, 2001, PHARMACOL THERAPEUT, V92, P71, DOI 10.1016/S0163-7258(01)00160-7; Rocheville M, 2000, SCIENCE, V288, P154, DOI 10.1126/science.288.5463.154; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Salim H, 2000, J NEUROCHEM, V74, P432, DOI 10.1046/j.1471-4159.2000.0740432.x; Terrillon S, 2003, MOL ENDOCRINOL, V17, P677, DOI 10.1210/me.2002-0222; TORVINEN M, 2001, SOC NEUR ABSTR, V27, P379; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539; Zimmermann T, 2002, FEBS LETT, V531, P245, DOI 10.1016/S0014-5793(02)03508-1; ZOLI M, 1993, MOL NEUROBIOL, V7, P293, DOI 10.1007/BF02769180	48	361	366	0	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46741	46749		10.1074/jbc.M306451200	http://dx.doi.org/10.1074/jbc.M306451200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12933819	Green Published, hybrid			2022-12-25	WOS:000186569400065
J	Cavet, JS; Graham, AI; Meng, WM; Robinson, NJ				Cavet, JS; Graham, AI; Meng, WM; Robinson, NJ			A cadmium-lead-sensing ArsR-SmtB repressor with novel sensory sites - Complementary metal discrimination by NMTR and CMTR in a common cytosol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUREUS PI258 CADC; STAPHYLOCOCCUS-AUREUS; METALLOREGULATORY PROTEINS; BINDING-SITES; PLASMID PI258; ZINC SENSOR; RESISTANCE; OPERON; GENE; SELECTIVITY	We report a cadmium- and lead-detecting transcriptional repressor from Mycobacterium tuberculosis designated CmtR. Two genes were co-transcribed with cmtR, one encoding a deduced P-1 type ATPase. Purified CmtR bound to the cmt operator-promoter, and repression of transcription was lost after introduction of a stop codon into cmtR. Assays of metal-dependent expression from cmt and nmt operator-promoters established that the metal specificity of CmtR in vivo was perfectly inverted relative to the nickel-cobalt sensor NmtR from the same organism, with CmtR totally insensitive to Co(II) or Ni(II) and NmtR totally insensitive to Cd(II) or Pb(II). Absorption spectroscopy of Cd(II)-, Co( II)-, and Ni( II)substituted CmtR revealed S- to metal-charge-transfer which was absent in NmtR, providing diagnostic metal-difference spectra that discriminated between metal-binding to these two proteins. Ni( II)- binding isothermal titrations of CmtR are complex, with K-app = 1.8 x 10(4) M-1 for site(1), three orders of magnitude weaker than K-Ni for NmtR. Mixing equimolar apo-NmtR and apo-CmtR with 0.9 equivalents of Cd( II) gave Cd( II)- dependent difference spectra almost identical to Cd( II)(0.9)-CmtR. Thus, Cd( II) bound to CmtR in preference to NmtR, whereas the converse was true for Ni( II); this correlates faithfully with and provides a simplistic basis for metal-sensing preferences. In contrast, CmtR and NmtR had similar affinities for Co( II), and alternative explanations for Co(II) sensitivities are invoked. ArsR-SmtB repressors detect metals through derivatives of one or both of two possible allosteric sites at either carboxyl-terminal alpha5 helices or helix alpha3 proximal to the DNA-binding site. Unexpectedly, neither site was required for inducer recognition by CmtR. The mutants in potential metal ligands in, or near, these regions, Cys(4), Cys(35), Asp(79), His(81), Asp(97), Asp(99), Glu(105), Glu(111), and Glu(114), retained both repression and inducer recognition. Crucially, substitution of Cys(57), Cys(61), and Cys(102) with Ser revealed that each of these three residues is obligatory for Cd( II) detection, and this defines completely new sensory sites.	Univ Newcastle, Sch Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Manchester, Manchester M13 9PT, Lancs, England	Newcastle University - UK; University of Manchester	Robinson, NJ (corresponding author), Univ Newcastle, Sch Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.		Robinson, Nigel J/J-6363-2012	Robinson, Nigel J/0000-0001-5586-1092; Cavet, Jennifer/0000-0001-5913-7157				Busenlehner LS, 2003, FEMS MICROBIOL REV, V27, P131, DOI 10.1016/S0168-6445(03)00054-8; Busenlehner LS, 2002, J MOL BIOL, V319, P685, DOI 10.1016/S0022-2836(02)00299-1; Busenlehner LS, 2001, BIOCHEMISTRY-US, V40, P4426, DOI 10.1021/bi010006g; Cave JS, 2002, J BIOL CHEM, V277, P38441, DOI 10.1074/jbc.M207677200; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Cook WJ, 1998, J MOL BIOL, V275, P337, DOI 10.1006/jmbi.1997.1443; Da Silva J. F., 2001, BIOL CHEM ELEMENTS I; ENDO G, 1995, J BACTERIOL, V177, P4437, DOI 10.1128/jb.177.15.4437-4441.1995; HUCKLE JW, 1993, MOL MICROBIOL, V7, P177, DOI 10.1111/j.1365-2958.1993.tb01109.x; Kuroda M, 1999, MICROBIOL IMMUNOL, V43, P115, DOI 10.1111/j.1348-0421.1999.tb02382.x; MORBY AP, 1993, NUCLEIC ACIDS RES, V21, P921, DOI 10.1093/nar/21.4.921; NUCIFORA G, 1989, P NATL ACAD SCI USA, V86, P3544, DOI 10.1073/pnas.86.10.3544; Outten CE, 2001, SCIENCE, V292, P2488, DOI 10.1126/science.1060331; Pennella MA, 2003, P NATL ACAD SCI USA, V100, P3713, DOI 10.1073/pnas.0636943100; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Rother D, 1999, MOL GEN GENET, V262, P154, DOI 10.1007/s004380051070; Rulisek L, 1998, J INORG BIOCHEM, V71, P115, DOI 10.1016/S0162-0134(98)10042-9; Sambrook J., 2002, MOL CLONING LAB MANU; SAUTON MB, 1912, CR HEBD ACAD SCI, V155, P860; Shi WP, 1996, J BIOL CHEM, V271, P9291, DOI 10.1074/jbc.271.16.9291; SHI WP, 1994, J BIOL CHEM, V269, P19826; Singh VK, 1999, MOL MICROBIOL, V33, P200, DOI 10.1046/j.1365-2958.1999.01466.x; Sun Y, 2001, J BIOL CHEM, V276, P14955, DOI 10.1074/jbc.M010595200; Thelwell C, 1998, P NATL ACAD SCI USA, V95, P10728, DOI 10.1073/pnas.95.18.10728; TIMM JL, 1994, J BACTERIOL, V176, P6749, DOI 10.1128/JB.176.21.6749-6753.1994; Turner JS, 1996, NUCLEIC ACIDS RES, V24, P3714, DOI 10.1093/nar/24.19.3714; VanZile ML, 2000, BIOCHEMISTRY-US, V39, P11818, DOI 10.1021/bi001140o; VanZile ML, 2002, BIOCHEMISTRY-US, V41, P9776, DOI 10.1021/bi020178t; VanZile ML, 2002, BIOCHEMISTRY-US, V41, P9765, DOI 10.1021/bi0201771; Wong MD, 2002, J BIOL CHEM, V277, P40930, DOI 10.1074/jbc.M206536200; Xu C, 1996, J BIOL CHEM, V271, P2427, DOI 10.1074/jbc.271.5.2427	31	63	69	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44560	44566		10.1074/jbc.M307877200	http://dx.doi.org/10.1074/jbc.M307877200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12939264	hybrid			2022-12-25	WOS:000186306700085
J	Dowdy, SC; Mariani, A; Janknecht, R				Dowdy, SC; Mariani, A; Janknecht, R			HER2/Neu- and TAK1-mediated up-regulation of the transforming growth factor beta inhibitor Smad7 via the ETS protein ER81	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR ER81; N-TERMINAL KINASE; SIGNAL-TRANSDUCTION; DNA-BINDING; OVARIAN CARCINOMAS; COLORECTAL-CANCER; BREAST-CANCER; CELL-CYCLE; GENE; RECEPTOR	The cytokine transforming growth factor beta (TGF-beta) plays an important role in preventing tumor formation by blocking cell cycle progression. Accordingly, many cancers demonstrate mutations in TGF-beta signaling components or enhanced expression of inhibitors of the TGF-beta pathway such as Smad7. In this report we show that the oncoprotein HER2/Neu is able to collaborate with the ETS transcription factor ER81 to activate Smad7 transcription in breast, endometrial, and ovarian cancer cell lines. ER81 binds to two ETS sites within the Smad7 promoter, and mutation of one of these ETS sites greatly decreases Smad7 induction by HER2/Neu and ER81. Furthermore, we show that Smad7 activation involves the processing of signals from HER2/Neu to ER81 via the ERK mitogen-activated protein kinase pathway. Thus, we have uncovered a novel mechanism by which oncogenic HER2/Neu, in collaboration with ER81, can induce carcinogenesis through Smad7 upregulation. Moreover, we show that TAK1, a TGF-beta-activated protein kinase, stimulates ER81 via the p38 mitogen-activated protein kinase pathway and thereby induces the Smad7 promoter. This suggests that attenuation of TGF-beta signaling by activating Smad7 transcription may proceed not only through TGF-beta receptor-regulated Smad proteins but also through an independent pathway involving ER81 and TAK1.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic	Janknecht, R (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Guggenheim Bldg 1501A,200 1st St SW, Rochester, MN 55905 USA.			Janknecht, Ralf/0000-0003-1741-1562	NATIONAL CANCER INSTITUTE [R01CA085257] Funding Source: NIH RePORTER; NCI NIH HHS [CA085257, R01 CA085257] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Afrakhte M, 1998, BIOCHEM BIOPH RES CO, V249, P505, DOI 10.1006/bbrc.1998.9170; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Benz CC, 1997, ONCOGENE, V15, P1513, DOI 10.1038/sj.onc.1201331; Block C, 1996, NAT STRUCT BIOL, V3, P244, DOI 10.1038/nsb0396-244; Bojovic BB, 2001, J BIOL CHEM, V276, P4509, DOI 10.1074/jbc.M005509200; Bosc DG, 2002, J CELL BIOCHEM, V86, P174, DOI 10.1002/jcb.10205; Bosc DG, 2001, ONCOGENE, V20, P6215, DOI 10.1038/sj.onc.1204820; Boulay JL, 2001, GENE CHROMOSOME CANC, V31, P240, DOI 10.1002/gcc.1140; BredemeierErnst I, 1997, FEBS LETT, V408, P47, DOI 10.1016/S0014-5793(97)00387-6; Brodin G, 2000, J BIOL CHEM, V275, P29023, DOI 10.1074/jbc.M002815200; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Cahill MA, 1996, CURR BIOL, V6, P16, DOI 10.1016/S0960-9822(02)00410-4; Chen T, 2001, CANCER RES, V61, P4679; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; De Haro L, 2002, NUCLEIC ACIDS RES, V30, P2972; de Launoit Y, 2000, ADV EXP MED BIOL, V480, P107; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Edlund S, 2003, MOL BIOL CELL, V14, P529, DOI 10.1091/mbc.02-03-0037; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Goel A, 2003, MOL CELL BIOL, V23, P6243, DOI 10.1128/MCB.23.17.6243-6254.2003; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Greenall A, 2001, J BIOL CHEM, V276, P16207, DOI 10.1074/jbc.M011582200; Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI12466; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Hellstrom I, 2001, CANCER RES, V61, P2420; HETZEL DJ, 1992, GYNECOL ONCOL, V47, P179, DOI 10.1016/0090-8258(92)90103-P; Holtmann H, 2001, J BIOL CHEM, V276, P3508, DOI 10.1074/jbc.M004376200; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Janknecht R, 1996, MOL CELL BIOL, V16, P1550; Janknecht R, 2003, ONCOGENE, V22, P746, DOI 10.1038/sj.onc.1206185; Janknecht R, 2001, J BIOL CHEM, V276, P41856, DOI 10.1074/jbc.M106630200; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; Kim SJ, 2000, CYTOKINE GROWTH F R, V11, P159, DOI 10.1016/S1359-6101(99)00039-8; Kimura N, 2000, J BIOL CHEM, V275, P17647, DOI 10.1074/jbc.M908622199; Kleeff J, 1999, ONCOGENE, V18, P5363, DOI 10.1038/sj.onc.1202909; Lee J, 2000, J LEUKOCYTE BIOL, V68, P909; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Liu XD, 2001, CYTOKINE GROWTH F R, V12, P1, DOI 10.1016/S1359-6101(00)00031-9; Lynch MA, 1998, CANCER RES, V58, P4227; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; PARSONS R, 1995, CANCER RES, V55, P5548; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; Riggins GJ, 1997, CANCER RES, V57, P2578; Shepherd TG, 2001, CURR BIOL, V11, P1739, DOI 10.1016/S0960-9822(01)00536-X; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Stein B, 1997, J BIOL CHEM, V272, P19509, DOI 10.1074/jbc.272.31.19509; Suzuki C, 2002, J BIOL CHEM, V277, P39919, DOI 10.1074/jbc.M201901200; Terada Y, 1999, KIDNEY INT, V56, P1378, DOI 10.1046/j.1523-1755.1999.00665.x; Tsai CM, 1996, CANCER RES, V56, P1068; Uchida K, 2001, BIOCHEM BIOPH RES CO, V289, P376, DOI 10.1006/bbrc.2001.5984; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; von Gersdorff G, 2000, J BIOL CHEM, V275, P11320, DOI 10.1074/jbc.275.15.11320; Wong C, 1999, MOL CELL BIOL, V19, P1821; Wu JM, 2002, J BIOL CHEM, V277, P42669, DOI 10.1074/jbc.M205501200; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yamaguchi K, 1999, EMBO J, V18, P179, DOI 10.1093/emboj/18.1.179; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zimmerman CM, 2000, GENE, V249, P17, DOI 10.1016/S0378-1119(00)00162-1	75	76	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44377	44384		10.1074/jbc.M307202200	http://dx.doi.org/10.1074/jbc.M307202200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12947087	hybrid			2022-12-25	WOS:000186306700062
J	Smith, SM; Pentlicky, S; Klase, Z; Singh, M; Neuveut, C; Lu, CY; Reitz, MS; Yarchoan, R; Marx, PA; Jeang, KT				Smith, SM; Pentlicky, S; Klase, Z; Singh, M; Neuveut, C; Lu, CY; Reitz, MS; Yarchoan, R; Marx, PA; Jeang, KT			An in vivo replication-important function in the second coding exon of Tat is constrained against mutation despite cytotoxic T lymphocyte selection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CELLULAR IMMUNE-RESPONSES; HIV-1 INFECTION; CYNOMOLGUS MONKEYS; VIRAL REPLICATION; RHESUS MACAQUES; VACCINE; PROTEIN; ESCAPE; DISEASE	Human and simian immunodeficiency virus (HIV/SIV) Tat proteins are specified by two coding exons. Tat functions in the transcription of primate lentiviruses. A plethora of in vitro data currently suggests that the second coding exon of Tat is largely devoid of function. However, whether the second exon of Tat contributes functionally to viral pathogenesis in vivo remains unknown. To address this question directly, we compared infection of rhesus macaques with an SIV, engineered to express only the first coding exon of Tat (SIVtat1ex), to counterpart infection with wild-type SIVmac239 virus, which expresses the full 2-exon Tat. This comparison showed that the second coding exon of Tat contributes to chronic SIV replication in vivo. Interestingly, in macaques, we observed a cytotoxic T lymphocytes (CTL) response to the second coding exon of Tat, which appears to durably control SIV replication. When SIV mutated in an attempt to escape this second Tat-exon-CTL, the resulting virus was less replicatively fit and failed to populate the host in vivo. Our study provides the first evidence that the second coding exon in Tat embodies an important function for in vivo replication. We suggest the second coding exon of Tat as an example of a functionally constrained "epitope" whose elicited CTL response cannot be escaped by virus mutation without producing a virus that replicates poorly in vivo.	St Michaels Hosp, Newark, NJ 07102 USA; Univ Med & Dent New Jersey, Newark, NJ 07102 USA; Inst Pasteur, Unite Recombinaison & Express, F-75015 Paris, France; NIAID, Mol Virol Sect, NIH, Bethesda, MD 20892 USA; Univ Maryland, Inst Biotechnol, Inst Human Virol, Baltimore, MD 21201 USA; NCI, HIV & AIDS Malignancy Branch, Div Clin Sci, NIH, Bethesda, MD 20892 USA; Tulane Univ, Hlth Sci Ctr, Dept Trop Med, Covington, LA 70433 USA; Tulane Natl Primate Res Ctr, Covington, LA 70433 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Tulane University; Tulane University	Smith, SM (corresponding author), St Michaels Hosp, Newark, NJ 07102 USA.		Smith, Stephen/GQQ-5975-2022; Jeang, Kuan-Teh/A-2424-2008	Smith, Stephen/0000-0002-9158-6136; Neuveut, Christine/0000-0001-6520-271X; LU, CHUN-YI/0000-0002-5240-2808	NATIONAL CANCER INSTITUTE [Z01SC006737, ZIASC006737] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000547, Z01AI000547] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Addo MM, 2001, P NATL ACAD SCI USA, V98, P1781, DOI 10.1073/pnas.98.4.1781; Agwale SM, 2002, P NATL ACAD SCI USA, V99, P10037, DOI 10.1073/pnas.152313899; Allen TM, 2002, J VIROL, V76, P4108, DOI 10.1128/JVI.76.8.4108-4112.2002; Allen TM, 2000, NATURE, V407, P386, DOI 10.1038/35030124; Amara RR, 2001, SCIENCE, V292, P69, DOI 10.1126/science.1058915; Barouch DH, 2003, J VIROL, V77, P7367, DOI 10.1128/JVI.77.13.7367-7375.2003; Barouch DH, 2002, NATURE, V415, P335, DOI 10.1038/415335a; BOOTH J, 1998, 16 ANN S NONH PRIM M; BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; Boucher C, 1996, AIDS, V10, pS15; BUONAGURO L, 1992, J VIROL, V66, P7159, DOI 10.1128/JVI.66.12.7159-7167.1992; Cafaro A, 1999, NAT MED, V5, P643, DOI 10.1038/9488; Cafaro A, 2001, VACCINE, V19, P2862, DOI 10.1016/S0264-410X(01)00002-0; Cafaro A, 2000, J MED PRIMATOL, V29, P193, DOI 10.1034/j.1600-0684.2000.290313.x; CARMICHAEL A, 1993, J EXP MED, V177, P249, DOI 10.1084/jem.177.2.249; Dailey P. J., 1995, Journal of Medical Primatology, V24, P209; Evans DT, 1999, NAT MED, V5, P1270, DOI 10.1038/15224; GALLO RC, 1987, NATURE, V326, P435; Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212; Goulder PJR, 2001, NATURE, V412, P334, DOI 10.1038/35085576; Hirsch VM, 1996, J VIROL, V70, P3741, DOI 10.1128/JVI.70.6.3741-3752.1996; HOPE TJ, 1990, J VIROL, V64, P5360, DOI 10.1128/JVI.64.11.5360-5366.1990; Izmailova E, 2003, NAT MED, V9, P191, DOI 10.1038/nm822; Jeang K T, 1994, Curr Top Microbiol Immunol, V188, P123; Jeang KT, 1999, J BIOL CHEM, V274, P28837, DOI 10.1074/jbc.274.41.28837; Katzenstein TL, 1996, AIDS, V10, P167, DOI 10.1097/00002030-199602000-00006; KLEIN MR, 1995, J EXP MED, V181, P1365, DOI 10.1084/jem.181.4.1365; Klenerman P, 2002, CURR OPIN MICROBIOL, V5, P408, DOI 10.1016/S1369-5274(02)00339-9; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; Lafrenie RM, 1997, J IMMUNOL, V159, P4077; Li CJ, 1997, P NATL ACAD SCI USA, V94, P8116, DOI 10.1073/pnas.94.15.8116; Mayers D, 1996, AIDS, V10, pS9; McMichael AJ, 2001, NATURE, V410, P980, DOI 10.1038/35073658; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; MOORE JP, 1994, J VIROL, V68, P6836, DOI 10.1128/JVI.68.11.6836-6847.1994; Mortara L, 1998, J VIROL, V72, P1403, DOI 10.1128/JVI.72.2.1403-1410.1998; Neuveut C, 1996, J VIROL, V70, P5572, DOI 10.1128/JVI.70.8.5572-5581.1996; NEUVEUT C, 2003, IN PRESS J BIOMED SC; Nijhuis M, 1999, AIDS, V13, P2349, DOI 10.1097/00002030-199912030-00006; O'Connor DH, 2002, DNA CELL BIOL, V21, P659, DOI 10.1089/104454902760330192; Ott M, 1997, SCIENCE, V275, P1481, DOI 10.1126/science.275.5305.1481; Pauza CD, 2000, P NATL ACAD SCI USA, V97, P3515, DOI 10.1073/pnas.070049797; PINCUS SH, 1994, J CLIN INVEST, V93, P2505, DOI 10.1172/JCI117260; Reed L.J., 1983, AM J HYG, V27, P493; RINALDO C, 1995, J VIROL, V69, P5838, DOI 10.1128/JVI.69.9.5838-5842.1995; SCALA G, 1994, J EXP MED, V179, P961, DOI 10.1084/jem.179.3.961; Silvera P, 2002, J VIROL, V76, P3800, DOI 10.1128/JVI.76.8.3800-3809.2002; Singh MK, 2001, AIDS RES HUM RETROV, V17, P1265, DOI 10.1089/088922201750461320; Smith SM, 1999, AIDS RES HUM RETROV, V15, P1691, DOI 10.1089/088922299309739; Smith SM, 2002, J BIOMED SCI, V9, P100, DOI 10.1007/BF02256020; STERN TL, 1995, J VIROL, V69, P1860, DOI 10.1128/JVI.69.3.1860-1867.1995; Stittelaar KJ, 2002, VACCINE, V20, P2921, DOI 10.1016/S0264-410X(02)00219-0; Verhoef K, 1998, AIDS RES HUM RETROV, V14, P1553, DOI 10.1089/aid.1998.14.1553; WESTENDORP MO, 1994, J VIROL, V68, P4177, DOI 10.1128/JVI.68.7.4177-4185.1994; Yang OO, 2003, J EXP MED, V197, P1365, DOI 10.1084/jem.20022138	56	45	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44816	44825		10.1074/jbc.M307546200	http://dx.doi.org/10.1074/jbc.M307546200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12947089	hybrid			2022-12-25	WOS:000186306700116
J	Yu, SW; Girotto, S; Zhao, XB; Magliozzo, RS				Yu, SW; Girotto, S; Zhao, XB; Magliozzo, RS			Rapid formation of Compound II and a tyrosyl radical in the Y229F mutant of Mycobacterium tuberculosis catalase-peroxidase disrupts catalase but not peroxidase function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ISONIAZID ACTIVATION; HORSERADISH-PEROXIDASE; KATG; SUSCEPTIBILITY; PURIFICATION; OXIDATION; ENZYME; PLANT	Catalase-peroxidases (KatG), which belong to Class I heme peroxidase enzymes, have high catalase activity and substantial peroxidase activity. The Y229F mutant of Mycobacterium tuberculosis KatG was prepared and characterized to investigate the functional role of this conserved residue unique to KatG enzymes. Purified, overexpressed KatG[ Y229F] exhibited severely reduced steady-state catalase activity while the peroxidase activity was enhanced. Optical stopped-flow experiments showed rapid formation of Compound (Cmpd) II ( oxyferryl heme intermediate) in the reaction of resting KatG[ Y229F] with peroxyacetic acid or chloroperoxybenzoic acid, without detectable accumulation of Cmpd I ( oxyferryl heme pi-cation radical intermediate), the latter being readily observed in the wild-type enzyme under similar conditions. Facile formation of Cmpd III ( oxyferrous enzyme) also occurred in the mutant in the presence of micromolar hydrogen peroxide. Thus, the lost catalase function may be explained in part because of formation of intermediates that do not participate in catalatic turnover. The source of the reducing equivalent required for generation of Cmpd II from Cmpd I was shown by rapid freeze-quench electron paramagnetic resonance spectroscopy to be a tyrosine residue, just as in wild-type KatG. The kinetic coupling of radical generation and Cmpd II formation was shown in KatG[ Y229F]. Residue Y229, which is a component of a newly defined three amino acid adduct in catalase-peroxidases, is critically important for protecting the catalase activity of KatG.	CUNY Brooklyn Coll, Dept Chem, Brooklyn, NY 11210 USA; CUNY Brooklyn Coll, Dept Biochem, Brooklyn, NY 11210 USA; CUNY, Grad Ctr, Brooklyn, NY 11210 USA	City University of New York (CUNY) System; Brooklyn College (CUNY); City University of New York (CUNY) System; Brooklyn College (CUNY); City University of New York (CUNY) System	Magliozzo, RS (corresponding author), CUNY Brooklyn Coll, Dept Chem, 2900 Bedford Ave, Brooklyn, NY 11210 USA.		Girotto, Stefania/F-5997-2012		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043582] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-43582] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Carpena X, 2003, J MOL BIOL, V327, P475, DOI 10.1016/S0022-2836(03)00122-0; Chouchane S, 2000, BIOCHEMISTRY-US, V39, P9975, DOI 10.1021/bi0005815; Chouchane S, 2002, J BIOL CHEM, V277, P42633, DOI 10.1074/jbc.M207916200; DUNFORD H, 1999, HEME PEROXIDASES, P140; Goodwin DC, 1997, BIOCHEMISTRY-US, V36, P139, DOI 10.1021/bi961465y; Heering HA, 2002, BIOCHEMISTRY-US, V41, P9237, DOI 10.1021/bi025740u; HEYM B, 1993, J BACTERIOL, V175, P4255, DOI 10.1128/JB.175.13.4255-4259.1993; Hillar A, 2000, BIOCHEMISTRY-US, V39, P5868, DOI 10.1021/bi0000059; Jakopitsch C, 2003, BIOCHEMISTRY-US, V42, P5292, DOI 10.1021/bi026944d; Jakopitsch C, 2003, EUR J BIOCHEM, V270, P1006, DOI 10.1046/j.1432-1033.2003.03476.x; Jakopitsch C, 2003, J BIOL CHEM, V278, P20185, DOI 10.1074/jbc.M211625200; Johnsson K, 1997, J BIOL CHEM, V272, P2834, DOI 10.1074/jbc.272.5.2834; LOEWEN PC, 1990, MOL GEN GENET, V224, P147, DOI 10.1007/BF00259461; Magliozzo RS, 1996, J AM CHEM SOC, V118, P11303, DOI 10.1021/ja962047j; Magliozzo RS, 1997, J BIOL CHEM, V272, P8867; MARCINKEVICIENE JA, 1995, J BIOL CHEM, V270, P22290, DOI 10.1074/jbc.270.38.22290; MILLER MA, 1994, NAT STRUCT BIOL, V1, P524, DOI 10.1038/nsb0894-524; NAKAJIMA R, 1987, J BIOL CHEM, V262, P2576; Regelsberger G, 2000, J BIOL CHEM, V275, P22854, DOI 10.1074/jbc.M002371200; Regelsberger G, 2001, BIOCHEM SOC T, V29, P99; RodriguezLopez JN, 1997, J BIOL CHEM, V272, P5469, DOI 10.1074/jbc.272.9.5469; Saint-Joanis B, 1999, BIOCHEM J, V338, P753, DOI 10.1042/0264-6021:3380753; SANDERS BC, 1964, PEROXIDASE, P218; WELINDER KG, 1992, BIOCHEM SOC T, V20, P337, DOI 10.1042/bst0200337; WELINDER KG, 1991, BIOCHIM BIOPHYS ACTA, V1080, P215; Wengenack NL, 1999, J AM CHEM SOC, V121, P9748, DOI 10.1021/ja992590a; WITTENBE.BA, 1967, BIOCHEMISTRY-US, V6, P1970, DOI 10.1021/bi00859a013; Yamada Y, 2002, NAT STRUCT BIOL, V9, P691, DOI 10.1038/nsb834; Yu SW, 2003, J BIOL CHEM, V278, P14769, DOI 10.1074/jbc.M300326200; Yu SW, 2002, PROTEIN SCI, V11, P58, DOI 10.1110/ps.ps.09902; Zamocky M, 2001, FEBS LETT, V492, P177, DOI 10.1016/S0014-5793(01)02237-2	31	54	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44121	44127		10.1074/jbc.M304757200	http://dx.doi.org/10.1074/jbc.M304757200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12944408	hybrid			2022-12-25	WOS:000186306700030
J	Heinemann, FS; Korza, G; Ozols, J				Heinemann, FS; Korza, G; Ozols, J			A plasminogen-like protein selectively degrades stearoyl-CoA desaturase in liver microsomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; RAT-LIVER; ELECTROPHORETIC ANALYSIS; POLYACRYLAMIDE GELS; SYSTEM; MICE; DEGRADATION; DEFICIENCY; COMPLEX; CELLS	Stearoyl-CoA desaturase (SCD) is an integral membrane protein of the endoplasmic reticulum that is rapidly and selectively degraded when isolated liver microsomes are incubated at 37degreesC. We previously reported the purification of a 90-kDa microsomal protein with SCD protease activity and characterized the inhibitor sensitivity of the protease. Here we show that the 90-kDa protein is a microsomal form of plasminogen (Pg) and that the purified SCD protease contains a spectrum of plasmin-like derivatives. The 90-kDa protein was identified as Pg by mass spectrometry of its tryptic peptides. The purified SCD protease reacted with Pg antibody, and immunoblotting demonstrated enrichment of Pg by the purification procedure established for the SCD protease. Analysis of microsomes by zymography demonstrated a single band of proteolytic activity at 70-kDa corresponding to the mobility of Pg in nonreduced polyacrylamide gels. When microsomes were incubated at 37degreesC prior to zymography, an intense band of proteolytic activity developed at 30-kDa. The purified SCD protease displayed a spectrum of proteolytic bands ranging from 70 to 30 kDa. Degradation of SCD by the purified protease and by microsomes was inhibited by bdellin, a plasmin inhibitor from the medicinal leech Hirudo medicinalis. To explore the role of Pg in the degradation of SCD in vivo, we examined SCD expression and degradation in microsomes isolated from Pg-deficient (Pg-/-) mice. Compared with microsomes from wild-type littermate control mice, liver microsomes from Pg-/- mice had significantly higher levels of SCD. Degradation of SCD in microsomes from Pg-/- mice was markedly diminished, whereas liver microsomes from control mice showed rapid SCD degradation similar to that observed in rat liver microsomes. These findings indicate that SCD is degraded by a protease related to Pg and suggest that plasmin moonlights as an intracellular protease.	Univ Connecticut, Ctr Hlth, Dept Biochem, Farmington, CT 06030 USA; Hoag Mem Hosp, Dept Pathol, Newport Beach, CA 92663 USA	University of Connecticut	Ozols, J (corresponding author), Univ Connecticut, Ctr Hlth, Dept Biochem, Farmington, CT 06030 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026351] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-26351] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACHMANN F, 2001, HEMOSTASIS THROMBOSI, P275; Bezerra JA, 1999, P NATL ACAD SCI USA, V96, P15143, DOI 10.1073/pnas.96.26.15143; Bisgaard HC, 1998, LAB INVEST, V78, P237; Braun S, 2002, EMBO J, V21, P615, DOI 10.1093/emboj/21.4.615; BUGGE TH, 1995, GENE DEV, V9, P794, DOI 10.1101/gad.9.7.794; Chen ZL, 1999, J NEUROSCI, V19, P9813; Cohen P, 2002, SCIENCE, V297, P240, DOI 10.1126/science.1071527; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; ENOCH HG, 1976, J BIOL CHEM, V251, P5095; Heinemann FS, 1998, MOL BIOL CELL, V9, P3445, DOI 10.1091/mbc.9.12.3445; Heinemann FS, 2003, BIOCHEMISTRY-US, V42, P6929, DOI 10.1021/bi034071x; Heinemann FS, 2003, PROSTAG LEUKOTR ESS, V68, P123, DOI 10.1016/S0952-3278(02)00262-4; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; Irigoyen JP, 1999, CELL MOL LIFE SCI, V56, P104, DOI 10.1007/PL00000615; Kates M., 1984, MEMBRANE FLUIDITY, P379; Kornblatt JA, 2003, BIOCHEM BIOPH RES CO, V305, P518, DOI 10.1016/S0006-291X(03)00804-0; KORZA G, 1988, J BIOL CHEM, V263, P3486; Leber TM, 1997, ANAL BIOCHEM, V249, P24, DOI 10.1006/abio.1997.2170; Leyland H, 1996, HEPATOLOGY, V24, P1172, DOI 10.1002/hep.510240532; Liang GS, 2002, J BIOL CHEM, V277, P9520, DOI 10.1074/jbc.M111421200; MANGEL WF, 1990, SCIENCE, V248, P69, DOI 10.1126/science.2108500; MARCUS G, 1979, J BIOL CHEM, V254, P1211; MARCUS G, 1978, J BIOL CHEM, V253, P733; Miles LA, 2003, TRENDS CARDIOVAS MED, V13, P21, DOI 10.1016/S1050-1738(02)00190-1; Moser M, 1998, EUR J BIOCHEM, V253, P212, DOI 10.1046/j.1432-1327.1998.2530212.x; MYRSET AH, 1991, BIOCHIM BIOPHYS ACTA, V1070, P229, DOI 10.1016/0005-2736(91)90169-9; Mziaut H, 2000, P NATL ACAD SCI USA, V97, P8883, DOI 10.1073/pnas.97.16.8883; Mziaut H, 2002, BBA-MOL CELL BIOL L, V1583, P45, DOI 10.1016/S1388-1981(02)00159-2; Nebl T, 2002, J BIOL CHEM, V277, P43399, DOI 10.1074/jbc.M205386200; Ntambi JM, 1999, J LIPID RES, V40, P1549; Ntambi JM, 2002, P NATL ACAD SCI USA, V99, P11482, DOI 10.1073/pnas.132384699; OSHINO N, 1972, ARCH BIOCHEM BIOPHYS, V149, P369, DOI 10.1016/0003-9861(72)90335-9; Ozols J, 1997, MOL BIOL CELL, V8, P2281, DOI 10.1091/mbc.8.11.2281; PirieShepherd SR, 1997, J BIOL CHEM, V272, P7408, DOI 10.1074/jbc.272.11.7408; PLOPLIS VA, 1995, CIRCULATION, V92, P2585, DOI 10.1161/01.CIR.92.9.2585; Rester U, 1999, J MOL BIOL, V293, P93, DOI 10.1006/jmbi.1999.3162; ROCHE PC, 1983, BIOCHIM BIOPHYS ACTA, V745, P82, DOI 10.1016/0167-4838(83)90172-3; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Yue CC, 1996, J BIOL CHEM, V271, P22245, DOI 10.1074/jbc.271.36.22245; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zhang L, 2002, THROMB HAEMOSTASIS, V87, P493; ZHEN L, 1995, J BIOL CHEM, V270, P11912, DOI 10.1074/jbc.270.20.11912; Zheng Y, 1999, NAT GENET, V23, P268, DOI 10.1038/15446	43	25	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42966	42975		10.1074/jbc.M306240200	http://dx.doi.org/10.1074/jbc.M306240200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12928439	hybrid			2022-12-25	WOS:000186157000031
J	Holt, PJ; Morgan, DJ; Sazanov, LA				Holt, PJ; Morgan, DJ; Sazanov, LA			The location of NuoL and NuoM subunits in the membrane domain of the Escherichia coli complex I - Implications for the mechanism of proton pumping	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADH-UBIQUINONE OXIDOREDUCTASE; DNA-ENCODED SUBUNITS; 3-DIMENSIONAL STRUCTURE; QUINONE OXIDOREDUCTASE; NEUROSPORA-CRASSA; PARACOCCUS-DENITRIFICANS; STRUCTURAL ORGANIZATION; ELECTRON-MICROSCOPY; ND5 SUBUNIT; DEHYDROGENASE	The molecular organization of bacterial NADH: ubiquinone oxidoreductase (complex I or NDH-1) is not established, apart from a rough separation into dehydrogenase, connecting and membrane domains. In this work, complex I was purified from Escherichia coli and fragmented by replacing dodecylmaltoside with other detergents. Exchange into decyl maltoside led to the removal of the hydrophobic subunit NuoL from the otherwise intact complex. Diheptanoyl phosphocholine led to the loss of NuoL and NuoM subunits, whereas other subunits remained in the complex. The presence of N,N-dimethyldodecylamine N-oxide or Triton X-100 led to further disruption of the membrane domain into fragments containing NuoL/M/N, NuoA/K/N, and NuoH/J subunits. Among the hydrophilic subunits, NuoCD was most readily dissociated from the complex, whereas NuoB was partially dissociated from the peripheral arm assembly in N, N-dimethyldodecylamine N-oxide. A model of subunit arrangement in bacterial complex I based on these data is proposed. Subunits NuoL and NuoM, which are homologous to antiporters and are implicated in proton pumping, are located at the distal end of the membrane arm, spatially separated from the redox centers of the peripheral arm. This is consistent with proposals that the mechanism of proton pumping by complex I is likely to involve long range conformational changes.	MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research	Sazanov, LA (corresponding author), MRC, Dunn Human Nutr Unit, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.		Sazanov, Leonid A/ABF-2125-2021	Sazanov, Leonid A/0000-0002-0977-7989				Albracht SPJ, 2000, FEBS LETT, V485, P1, DOI 10.1016/S0014-5793(00)02172-4; Amarneh B, 2003, BIOCHEMISTRY-US, V42, P4800, DOI 10.1021/bi0340346; Bai YD, 1998, EMBO J, V17, P4848, DOI 10.1093/emboj/17.16.4848; Bai YD, 2000, MOL CELL BIOL, V20, P805, DOI 10.1128/MCB.20.3.805-815.2000; BELOGRUDOV G, 1994, BIOCHEMISTRY-US, V33, P4571, DOI 10.1021/bi00181a018; Bottcher B, 2002, J BIOL CHEM, V277, P17970, DOI 10.1074/jbc.M112357200; Brandt U, 1997, BBA-BIOENERGETICS, V1318, P79, DOI 10.1016/S0005-2728(96)00141-7; Brandt U, 2003, FEBS LETT, V545, P9, DOI 10.1016/S0014-5793(03)00387-9; Cardol P, 2002, J MOL BIOL, V319, P1211, DOI 10.1016/S0022-2836(02)00407-2; Carroll J, 2002, J BIOL CHEM, V277, P50311, DOI 10.1074/jbc.M209166200; Di Bernardo S, 2001, FEBS LETT, V508, P385, DOI 10.1016/S0014-5793(01)03111-8; Djafarzadeh R, 2000, BBA-BIOENERGETICS, V1459, P230, DOI 10.1016/S0005-2728(00)00154-7; Dutton PL, 1998, BBA-BIOENERGETICS, V1364, P245, DOI 10.1016/S0005-2728(98)00031-0; EARLEY FGP, 1987, FEBS LETT, V219, P108, DOI 10.1016/0014-5793(87)81200-0; FEARNLEY IM, 1992, BIOCHIM BIOPHYS ACTA, V1140, P105, DOI 10.1016/0005-2728(92)90001-I; FINEL M, 1992, BIOCHEMISTRY-US, V31, P11425, DOI 10.1021/bi00161a022; Fisher N, 2000, J MOL BIOL, V296, P1153, DOI 10.1006/jmbi.2000.3509; Friedrich T, 1998, BBA-BIOENERGETICS, V1364, P134, DOI 10.1016/S0005-2728(98)00024-3; Friedrich T, 2001, J BIOENERG BIOMEMBR, V33, P169, DOI 10.1023/A:1010722717257; Friedrich T, 2000, FEBS LETT, V479, P1, DOI 10.1016/S0014-5793(00)01867-6; GALANTE YM, 1979, ARCH BIOCHEM BIOPHYS, V192, P559, DOI 10.1016/0003-9861(79)90126-7; Gemperli AC, 2003, P NATL ACAD SCI USA, V100, P839, DOI 10.1073/pnas.0237328100; Gemperli AC, 2002, J BIOL CHEM, V277, P33811, DOI 10.1074/jbc.M204860200; Gong X, 2003, J BIOL CHEM, V278, P25731, DOI 10.1074/jbc.M302361200; Grigorieff N, 1998, J MOL BIOL, V277, P1033, DOI 10.1006/jmbi.1998.1668; Guenebaut V, 1997, J MOL BIOL, V265, P409, DOI 10.1006/jmbi.1996.0753; Guenebaut V, 1998, J MOL BIOL, V276, P105, DOI 10.1006/jmbi.1997.1518; Hauser H, 2000, BBA-BIOMEMBRANES, V1508, P164, DOI 10.1016/S0304-4157(00)00008-3; HOFHAUS G, 1991, J MOL BIOL, V221, P1027, DOI 10.1016/0022-2836(91)80190-6; HOFHAUS G, 1995, MOL CELL BIOL, V15, P964; HOFHAUS G, 1993, EMBO J, V12, P3043, DOI 10.1002/j.1460-2075.1993.tb05973.x; KIKUNO R, 1985, FEBS LETT, V189, P85, DOI 10.1016/0014-5793(85)80847-4; LEIF H, 1995, EUR J BIOCHEM, V230, P538, DOI 10.1111/j.1432-1033.1995.tb20594.x; LEONARD K, 1987, J MOL BIOL, V194, P277, DOI 10.1016/0022-2836(87)90375-5; Mathiesen C, 2002, BBA-BIOENERGETICS, V1556, P121, DOI 10.1016/S0005-2728(02)00343-2; Nakamaru-Ogiso E, 2003, BIOCHEMISTRY-US, V42, P746, DOI 10.1021/bi0269660; Peng GH, 2003, BIOCHEMISTRY-US, V42, P3032, DOI 10.1021/bi026876v; Sazanov LA, 2003, J BIOL CHEM, V278, P19483, DOI 10.1074/jbc.M208959200; Sazanov LA, 2000, BIOCHEMISTRY-US, V39, P7229, DOI 10.1021/bi000335t; Sazanov LA, 2000, J MOL BIOL, V302, P455, DOI 10.1006/jmbi.2000.4079; Sousa R, 1999, BBA-BIOENERGETICS, V1411, P142, DOI 10.1016/S0005-2728(99)00014-6; Takano S, 1996, BIOCHEMISTRY-US, V35, P9120, DOI 10.1021/bi9605853; Videira A, 1998, BBA-BIOENERGETICS, V1364, P89, DOI 10.1016/S0005-2728(98)00020-6; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X; Yagi T, 2003, BIOCHEMISTRY-US, V42, P2266, DOI 10.1021/bi027158b; Yagi T, 1998, BBA-BIOENERGETICS, V1364, P125, DOI 10.1016/S0005-2728(98)00023-1; Yano T, 1999, J BIOL CHEM, V274, P28598, DOI 10.1074/jbc.274.40.28598; Zickermann V, 2003, J BIOL CHEM, V278, P29072, DOI 10.1074/jbc.M302713200	48	50	54	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43114	43120		10.1074/jbc.M308247200	http://dx.doi.org/10.1074/jbc.M308247200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12923180	hybrid			2022-12-25	WOS:000186157000051
J	Krug, AW; Grossmann, C; Schuster, C; Freudinger, R; Mildenberger, S; Govindan, MV; Gekle, M				Krug, AW; Grossmann, C; Schuster, C; Freudinger, R; Mildenberger, S; Govindan, MV; Gekle, M			Aldosterone stimulates epidermal growth factor receptor expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC FIBROSIS; RAPID ACTIONS; TRANSCRIPTION; SPIRONOLACTONE; CELL; MINERALOCORTICOIDS; DYSFUNCTION; ACTIVATION; BINDING; DNA	The steroid hormone aldosterone plays an important role during pathological tissue modifications, similar to cardiovascular or renal fibrosis. The underlying mechanisms for the pathological actions are not understood. Interaction of aldosterone with the epidermal growth factor (EGF) receptor is an attractive hypothesis to explain pathological tissue remodeling elicited by aldosterone, because (i) mineralocorticoids can sensitize cells for EGF, (ii) mineralocorticoid receptor (MR)-antagonists reduce EGFR-mRNA expression, (iii) EGFR itself supports the development of cardiovascular or renal fibrosis, and (iv) signaling elements involved in the pathological action of aldosterone (similar to ERK1/2 or NFkappaB) are typical downstream modules during EGF signaling. In addition, an interaction of aldosterone and EGF with respect to ERK1/2 activation has been described. Here we show that aldosterone stimulates EGFR expression in renal tissue of adrenalectomized rats and in human renal primary cell cultures. Furthermore, Chinese hamster ovary (CHO) cells normally devoid of EGFR or MR express EGFR after transfection with human MR (CHO-MR cells) but not after transfection with human glucocorticoid receptor (CHO-GR cells). In CHO-MR cells, EGFR-expression is up-regulated by aldosterone and inhibited by spironolactone. CHO-MR cells but not CHO-GR cells respond with ERK1/2 phosphorylation to EGF exposure. The responsiveness to other peptide hormones was virtually not affected. These data suggest that EGFR is an aldosterone-induced protein and is involved in the manifold (patho) biological actions of aldosterone.	Univ Wurzburg, Inst Physiol, D-97070 Wurzburg, Germany; Univ Laval, Hotel Dieu Quebec, Ctr Rech, Quebec City, PQ G1R 2J6, Canada	University of Wurzburg; Laval University	Gekle, M (corresponding author), Univ Wurzburg, Inst Physiol, Rontgenring 9, D-97070 Wurzburg, Germany.	michael.gekle@mail.uni-wuerzburg.de						ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; Bauersachs J, 2002, J AM COLL CARDIOL, V39, P351, DOI 10.1016/S0735-1097(01)01729-6; Blasi ER, 2003, KIDNEY INT, V63, P1791, DOI 10.1046/j.1523-1755.2003.00929.x; Bonvalet JP, 1998, KIDNEY INT, pS49; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; CHAIDARUN SS, 1994, J ENDOCRINOL, V143, P489, DOI 10.1677/joe.0.1430489; Croxtall JD, 2000, BRIT J PHARMACOL, V130, P289, DOI 10.1038/sj.bjp.0703272; Dorrance AM, 2001, AM J PHYSIOL-REG I, V281, pR944, DOI 10.1152/ajpregu.2001.281.3.R944; Eaton DC, 2001, J MEMBRANE BIOL, V184, P313, DOI 10.1007/s00232-001-0098-x; Epstein M, 2001, AM J KIDNEY DIS, V37, P677, DOI 10.1016/S0272-6386(01)80115-3; Epstein M, 2001, J ROY SOC MED, V94, P378, DOI 10.1177/014107680109400803; Fiebeler A, 2001, HYPERTENSION, V37, P787, DOI 10.1161/01.HYP.37.2.787; Flamant M, 2002, FASEB J, V16, P327, DOI 10.1096/fj.02-0115fje; Florian JA, 2001, AM J PHYSIOL-REG I, V281, pR878, DOI 10.1152/ajpregu.2001.281.3.R878; Funder J, 2001, CLIN EXP PHARMACOL P, V28, P1002, DOI 10.1046/j.1440-1681.2001.03586.x; GEKLE M, 1994, PFLUG ARCH EUR J PHY, V428, P157, DOI 10.1007/BF00374853; Gekle M, 2002, AM J PHYSIOL-RENAL, V282, pF669, DOI 10.1152/ajprenal.00159.2001; Gekle M, 2002, STEROIDS, V67, P499, DOI 10.1016/S0039-128X(01)00183-0; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; Johnson AC, 2000, MOL MED, V6, P17, DOI 10.1007/BF03401931; Johnson AC, 1996, J BIOL CHEM, V271, P3033; KAGEYAMA R, 1989, J BIOL CHEM, V264, P15508; Kagiyama S, 2003, HYPERTENSION, V41, P824, DOI 10.1161/01.HYP.0000047104.42047.9B; Kelly MJ, 2001, TRENDS ENDOCRIN MET, V12, P152, DOI 10.1016/S1043-2760(01)00377-0; Krug AW, 2003, PFLUG ARCH EUR J PHY, V446, P492, DOI 10.1007/s00424-003-1033-z; Krug AW, 2002, J BIOL CHEM, V277, P45892, DOI 10.1074/jbc.M208851200; Lijnen P, 2000, J MOL CELL CARDIOL, V32, P865, DOI 10.1006/jmcc.2000.1129; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nishi H, 2001, J BIOL CHEM, V276, P41717, DOI 10.1074/jbc.M101241200; Pitt B, 2003, NEW ENGL J MED, V348, P1309, DOI 10.1056/NEJMoa030207; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; Rubinstein YR, 1998, FEBS LETT, V431, P268, DOI 10.1016/S0014-5793(98)00774-1; Stockand JD, 2003, AM J PHYSIOL-HEART C, V284, pH176, DOI 10.1152/ajpheart.00421.2002; Stockand JD, 2002, AM J PHYSIOL-RENAL, V282, pF559, DOI 10.1152/ajprenal.00320.2001; Terzi F, 2000, J CLIN INVEST, V106, P225, DOI 10.1172/JCI8315; Verrey F, 2000, KIDNEY INT, V57, P1277, DOI 10.1046/j.1523-1755.2000.00962.x; Verrey F, 1999, AM J PHYSIOL-RENAL, V277, pF319, DOI 10.1152/ajprenal.1999.277.3.F319; Versteeg HH, 2000, BIOCHEM J, V350, P717, DOI 10.1042/0264-6021:3500717; WIEDERHOLT M, 1966, PFLUG ARCH GES PHYS, V292, P316, DOI 10.1007/BF00363200; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; ZENNARO MC, 1995, J BIOL CHEM, V270, P21016, DOI 10.1074/jbc.270.36.21016	45	88	90	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43060	43066		10.1074/jbc.M308134200	http://dx.doi.org/10.1074/jbc.M308134200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12939263	hybrid			2022-12-25	WOS:000186157000043
J	Springhetti, EM; Istomina, NE; Whisstock, JC; Nikitina, T; Woodcock, CL; Grigoryev, SA				Springhetti, EM; Istomina, NE; Whisstock, JC; Nikitina, T; Woodcock, CL; Grigoryev, SA			Role of the M-loop and reactive center loop domains in the folding and bridging of nucleosome arrays by MENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCANNING FORCE MICROSCOPY; GLOBIN CHROMOSOMAL DOMAIN; HIGHER-ORDER STRUCTURE; CHROMATIN STRUCTURE; LINKER HISTONES; GENE ACTIVITY; PROTEIN MENT; HETEROCHROMATIN; DNA; RESOLUTION	MENT is a developmentally regulated heterochromatin-associated protein that condenses chromatin in terminally differentiated avian blood cells. Its homology to the serpin protein family suggests that the conserved serpin reactive center loop (RCL) and the unique M-loop are important for its function. To examine the role of these domains, we studied the interaction of wild-type and mutant MENT with naked DNA and biochemically defined nucleosome arrays reconstituted from 12-mer repeats containing nucleosome positioning sequences. Wild-type MENT folded the naked DNA duplexes into closely juxtaposed parallel structures ("tramlines"). Deletion of the M-loop, but not inactivation of the RCL, prevented tramline formation and the cooperative interaction of MENT with DNA. Reconstitution of wildtype MENT with nucleosome arrays caused their tight folding and self-association. M-loop deletion inhibited nucleosome array folding, whereas the inactive RCL mutant was competent to fold the nucleosome arrays, but had a significantly impaired ability to cause their self-association. Bifunctional chemical cross-linking of MENT revealed oligomerization of wild-type MENT in the presence of chromatin and DNA. This oligomerization was severely reduced in the RCL mutant. We propose that the mechanism of MENT-induced heterochromatin formation involves two independent events: bringing together nucleosome linkers within a chromatin fiber and formation of protein bridges between chromatin fibers. Ordered binding of MENT to linker DNA via its unique M-loop domain promotes the folding of chromatin, whereas bridging of chromatin fibers is facilitated by MENT oligomerization mediated by the RCL.	Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Biochem & Mol Biol, Hershey, PA 17033 USA; Moscow MV Lomonosov State Univ, Dept Mol Biol, Moscow 119899, Russia; Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia; Univ Massachusetts, Dept Biol, Amherst, MA 01003 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Lomonosov Moscow State University; Monash University; University of Massachusetts System; University of Massachusetts Amherst	Grigoryev, SA (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Biochem & Mol Biol, 500 Univ Dr,POB 850, Hershey, PA 17033 USA.			Whisstock, James/0000-0003-4200-5611	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043786, R01GM059118] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-43786, GM-59118] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravind L, 1998, NUCLEIC ACIDS RES, V26, P4413, DOI 10.1093/nar/26.19.4413; BOULIKAS T, 1980, P NATL ACAD SCI-BIOL, V77, P127, DOI 10.1073/pnas.77.1.127; Brown KE, 1999, MOL CELL, V3, P207, DOI 10.1016/S1097-2765(00)80311-1; CREIGHTON TE, 1993, PROTEINS STRUCTURES, P369; Dunstone MA, 2000, PROTEIN SCI, V9, P417; Elliott PR, 1996, NAT STRUCT BIOL, V3, P676, DOI 10.1038/nsb0896-676; Francastel C, 2000, NAT REV MOL CELL BIO, V1, P137, DOI 10.1038/35040083; FRENSTER JH, 1974, CELL NUCLEUS, P565; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GARCIARAMIREZ M, 1995, J BIOL CHEM, V270, P17923, DOI 10.1074/jbc.270.30.17923; Georgel PT, 2003, J BIOL CHEM, V278, P32181, DOI 10.1074/jbc.M305308200; GRIGORYEV SA, 1992, EXP CELL RES, V198, P268, DOI 10.1016/0014-4827(92)90379-M; Grigoryev SA, 1998, J BIOL CHEM, V273, P3082, DOI 10.1074/jbc.273.5.3082; Grigoryev SA, 1999, J BIOL CHEM, V274, P5626, DOI 10.1074/jbc.274.9.5626; Grigoryev SA, 2001, BIOCHEM CELL BIOL, V79, P227, DOI 10.1139/bcb-79-3-227; Hansen JC, 2002, ANNU REV BIOPH BIOM, V31, P361, DOI 10.1146/annurev.biophys.31.101101.140858; Hennig W, 1999, CHROMOSOMA, V108, P1, DOI 10.1007/s004120050346; Horn PJ, 2002, SCIENCE, V297, P1824, DOI 10.1126/science.1074200; Huntington JA, 1999, J MOL BIOL, V293, P449, DOI 10.1006/jmbi.1999.3184; Irving JA, 2002, J BIOL CHEM, V277, P13192, DOI 10.1074/jbc.M108460200; Istomina NE, 2003, MOL CELL BIOL, V23, P6455, DOI 10.1128/MCB.23.18.6455-6468.2003; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leuba SH, 1998, BIOPHYS J, V74, P2830, DOI 10.1016/S0006-3495(98)77990-1; Leuba SH, 1998, BIOPHYS J, V74, P2823, DOI 10.1016/S0006-3495(98)77989-5; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; Lomas DA, 2000, RESP MED, V94, pS3, DOI 10.1053/rmed.2000.0850; MEERSSEMAN G, 1991, J MOL BIOL, V220, P89, DOI 10.1016/0022-2836(91)90383-H; Richards EJ, 2002, CELL, V108, P489, DOI 10.1016/S0092-8674(02)00644-X; RING D, 1979, J BIOL CHEM, V254, P1688; Sharp AM, 1999, STRUCTURE, V7, P111, DOI 10.1016/S0969-2126(99)80018-5; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; SIMPSON RT, 1985, CELL, V42, P799, DOI 10.1016/0092-8674(85)90276-4; Singh PB, 1998, DEV GENET, V22, P85, DOI 10.1002/(SICI)1520-6408(1998)22:1<85::AID-DVG9>3.0.CO;2-3; STEIN PE, 1991, J MOL BIOL, V221, P941, DOI 10.1016/0022-2836(91)80185-W; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; THOMAS JO, 1992, NUCLEIC ACIDS RES, V20, P187, DOI 10.1093/nar/20.2.187; TYLER JM, 1980, J ULTRA MOL STRUCT R, V71, P95, DOI 10.1016/S0022-5320(80)90098-2; VANHOLDE KE, 1998, PRINCIPLES PHYSICAL, P613; VERREAULT A, 1993, COLD SPRING HARB SYM, V58, P15, DOI 10.1101/SQB.1993.058.01.005; Wang GZ, 2000, MOL CELL BIOL, V20, P6970, DOI 10.1128/MCB.20.18.6970-6983.2000; WEINTRAUB H, 1984, CELL, V38, P17, DOI 10.1016/0092-8674(84)90522-1; Whisstock J, 1998, TRENDS BIOCHEM SCI, V23, P63, DOI 10.1016/S0968-0004(97)01172-9; WOOD WI, 1982, J BIOL CHEM, V257, P7730; Woodcock CL, 2001, CURR OPIN GENET DEV, V11, P130, DOI 10.1016/S0959-437X(00)00169-6; Woodcock CL, 1998, METHOD CELL BIOL, V53, P167; Zlatanova J, 2003, J MOL BIOL, V331, P1, DOI 10.1016/S0022-2836(03)00691-0; ZLATANOVA J, 1992, J CELL SCI, V103, P889	49	41	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43384	43393		10.1074/jbc.M307635200	http://dx.doi.org/10.1074/jbc.M307635200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12930828	hybrid			2022-12-25	WOS:000186157000082
J	Casey, DM; Yagi, T; Kamiya, R; Witman, GB				Casey, DM; Yagi, T; Kamiya, R; Witman, GB			DC3, the smallest subunit of the Chlamydomonas flagellar outer dynein arm-docking complex, is a redox-sensitive calcium-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EF-HAND; LIGHT-CHAIN; CONFORMATIONAL CHANGE; TARGET RECOGNITION; MAGNESIUM BINDING; BENDING PATTERNS; TROPONIN-C; CALMODULIN; REINHARDTII; MUTANT	The outer dynein arm-docking complex (ODA-DC) targets the outer dynein arm to its correct binding site on the flagellar axoneme. The Chlamydomonas ODA-DC contains three proteins; loss of any one prevents normal assembly of the outer arm, leading to a slow, jerky swimming phenotype. We showed previously that the smallest ODA-DC subunit, DC3, has four EF-hands (Casey, D. M., Inaba, K., Pazour, G. J., Takada, S., Wakabayashi, K., Wilkerson, C. G., Kamiya, R., and Witman, G. B. (2003) Mol. Biol. Cell 14, <LF>3650-3663). Two of the EF-hands fit the consensus pattern for calcium binding, and one of these contains two cysteine residues within its binding loop. To determine whether the predicted EF-hands are functional, we purified bacterially expressed wild-type DC3 and analyzed its calcium-binding potential in the presence and absence of dithiothreitol and Mg2+. The protein bound one calcium ion with an affinity (K-d) of similar to1 x 10(-5) M. Calcium binding was observed only in the presence of dithiothreitol and thus is redox-sensitive. DC3 also bound Mg2+ at physiological concentrations but with a much lower affinity. Changing the essential glutamate to glutamine in both EF-hands eliminated the calcium binding activity of the bacterially expressed protein. To investigate the role of the EF-hands in vivo, we transformed the modified DC3 gene into a Chlamydomonas insertional mutant lacking DC3. The transformed strain swam normally, assembled a normal number of outer arms, and had a normal photoshock response, indicating that the Glu to Gln mutations did not affect ODA-DC assembly, outer arm assembly, or Ca2+-mediated outer arm activity. Thus, DC3 is a true calcium-binding protein, but the function of this activity remains unknown.	Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Tokyo 113, Japan	University of Massachusetts System; University of Massachusetts Worcester; University of Tokyo	Witman, GB (corresponding author), Univ Massachusetts, Sch Med, Dept Cell Biol, 55 Lake Ave N, Worcester, MA 01655 USA.	george.witman@umassmed.edu		Witman, George/0000-0002-9497-9218	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R35GM130326, R01GM030626] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM030626, GM 30326] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ababou A, 2001, PROTEIN SCI, V10, P301, DOI 10.1110/ps.33601; Bayley PM, 1996, PROTEIN SCI, V5, P1215, DOI 10.1002/pro.5560050701; Berggard T, 2002, J BIOL CHEM, V277, P16662, DOI 10.1074/jbc.M200415200; BROKAW CJ, 1983, CELL MOTIL CYTOSKEL, V3, P131, DOI 10.1002/cm.970030204; Casey DM, 2003, MOL BIOL CELL, V14, P3650, DOI 10.1091/mbc.E03-01-0057; Davis JP, 2002, J BIOL CHEM, V277, P49716, DOI 10.1074/jbc.M208488200; DEBUCHY R, 1989, EMBO J, V8, P2803, DOI 10.1002/j.1460-2075.1989.tb08426.x; DUNAHAY TG, 1993, BIOTECHNIQUES, V15, P452; Evans JH, 1999, CELL CALCIUM, V26, P103, DOI 10.1054/ceca.1999.0060; FINDLAY WA, 1995, BIOCHEMISTRY-US, V34, P2087, DOI 10.1021/bi00007a001; GITELMAN SE, 1980, J CELL BIOL, V87, P764, DOI 10.1083/jcb.87.3.764; GORMAN DS, 1965, P NATL ACAD SCI USA, V54, P1665, DOI 10.1073/pnas.54.6.1665; HAIECH J, 1991, J BIOL CHEM, V266, P3427; Harris E.H., 1989, CHLAMYDOMONAS SOURCE, P1; Harrison A, 2002, CELL MOTIL CYTOSKEL, V52, P131, DOI 10.1002/cm.10044; Hayashi M, 2002, CELL MOTIL CYTOSKEL, V53, P273, DOI 10.1002/cm.10075; JAMIESON GA, 1979, P NATL ACAD SCI USA, V76, P6471, DOI 10.1073/pnas.76.12.6471; KAMIYA R, 1988, J CELL BIOL, V107, P2253, DOI 10.1083/jcb.107.6.2253; KAMIYA R, 1985, J CELL SCI, V74, P181; Kamiya R, 2000, METHODS, V22, P383, DOI 10.1006/meth.2000.1090; KING SM, 1995, J CELL SCI, V108, P3757; Koutoulis A, 1997, J CELL BIOL, V137, P1069, DOI 10.1083/jcb.137.5.1069; LADANT D, 1995, J BIOL CHEM, V270, P3179; Li MX, 1999, BIOCHEMISTRY-US, V38, P8289, DOI 10.1021/bi9901679; LINSE S, 1995, ADV SEC MESS PHOSPH, V30, P89; MITCHELL DR, 1985, J CELL BIOL, V100, P1228, DOI 10.1083/jcb.100.4.1228; Mizoue LS, 2002, CURR OPIN STRUC BIOL, V12, P459, DOI 10.1016/S0959-440X(02)00348-2; MOSS AG, 1995, METHOD CELL BIOL, V47, P281, DOI 10.1016/S0091-679X(08)60821-3; MOSS AG, 1999, MICROSC ANAL, V34, P7; NAITOH Y, 1972, SCIENCE, V176, P523, DOI 10.1126/science.176.4034.523; Nelson MR, 1998, BIOMETALS, V11, P297, DOI 10.1023/A:1009253808876; Ohki SY, 1997, BIOCHEMISTRY-US, V36, P4309, DOI 10.1021/bi962759m; OLWIN BB, 1984, J BIOL CHEM, V259, P949; OMOTO CK, 1985, CELL MOTIL CYTOSKEL, V5, P53, DOI 10.1002/cm.970050105; PatelKing RS, 1996, J BIOL CHEM, V271, P6283, DOI 10.1074/jbc.271.11.6283; PAZOUR GJ, 1995, J CELL BIOL, V131, P427, DOI 10.1083/jcb.131.2.427; PIPERNO G, 1990, J CELL BIOL, V110, P379, DOI 10.1083/jcb.110.2.379; PROCYSHYN RM, 1994, J BIOL CHEM, V269, P1641; REID RE, 1980, J THEOR BIOL, V84, P401, DOI 10.1016/S0022-5193(80)80013-0; REID RE, 1995, ARCH BIOCHEM BIOPHYS, V323, P115, DOI 10.1006/abbi.1995.0016; SAGER R, 1953, ANN NY ACAD SCI, V56, P831, DOI 10.1111/j.1749-6632.1953.tb30261.x; Sia SK, 1997, J BIOL CHEM, V272, P18216, DOI 10.1074/jbc.272.29.18216; Spyracopoulos L, 1997, BIOCHEMISTRY-US, V36, P12138, DOI 10.1021/bi971223d; TAKADA S, 1994, J CELL BIOL, V126, P737, DOI 10.1083/jcb.126.3.737; Takada S, 2002, MOL BIOL CELL, V13, P1015, DOI 10.1091/mbc.01-04-0201; Tikunova SB, 2001, BIOCHEMISTRY-US, V40, P3348, DOI 10.1021/bi0021333; WITMAN GB, 1986, METHOD ENZYMOL, V134, P280; Witman George B., 1993, Trends in Cell Biology, V3, P403, DOI 10.1016/0962-8924(93)90091-E; Yanagimachi R., 1988, PHYSL REPRODUCTION, V1, P135; Yang PF, 2001, J CELL BIOL, V153, P1315, DOI 10.1083/jcb.153.6.1315	50	35	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42652	42659		10.1074/jbc.M303064200	http://dx.doi.org/10.1074/jbc.M303064200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12920131	hybrid			2022-12-25	WOS:000185989500131
J	Kim, SJ; Sung, JY; Um, JW; Hattori, N; Mizuno, Y; Tanaka, K; Paik, SR; Kim, J; Chung, KC				Kim, SJ; Sung, JY; Um, JW; Hattori, N; Mizuno, Y; Tanaka, K; Paik, SR; Kim, J; Chung, KC			Parkin cleaves intracellular alpha-synuclein inclusions via the activation of calpain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEIN LIGASE; A-BETA COMPONENT; O-GLYCOSYLATION; HUMAN BRAIN; CELL-DEATH; DISEASE; GENE; EXPRESSION; MUTATIONS; SUBSTRATE	Mutations in the alpha-synuclein and parkin genes cause heritable forms of Parkinson's disease. In the present study, we examined the possible functional relationship between the parkin and alpha-synuclein genes in a conditionally immortalized embryonic hippocampal cell (H19-7) line. Whereas transient transfection of alpha-synuclein into neuronal H19-7 cells caused the formation of its intracytoplasmic inclusions and a significant cell death, the combined overexpression of parkin restored the alpha-synuclein-induced decrease in cell viability to control levels. In addition, the overexpression of parkin was found to generate selective cleavage of alpha-synuclein. Furthermore, the cytoprotective effect of parkin on alpha-synuclein-induced cell death was not inhibited in the presence of a proteasome inhibitor. Interestingly, the overexpression of parkin induced the activation of an intracellular cysteine protease, calpain, but not caspase, and the cytoprotective effect of parkin on alpha-synuclein cytotoxicity was significantly inhibited by the presence of calpain-specific inhibitors. In conclusion, our results suggest that parkin accelerates the degradation of alpha-synuclein via the activation of the nonproteasomal protease, calpain, leading to the prevention of alpha-synuclein-induced cell death in embryonic hippocampal progenitor cells.	Yonsei Univ, Coll Sci, Dept Biol, Seoul 120749, South Korea; Yonsei Univ, Coll Med, Dept Med Sci, Seoul 120749, South Korea; Yonsei Univ, Coll Med, Dept Microbiol, Seoul 120749, South Korea; Yonsei Univ, Coll Med, Brain Korea Projects Med Sci 21, Seoul 120749, South Korea; Inha Univ, Coll Med, Dept Biochem, Inchon 402751, South Korea; Juntendo Univ, Sch Med, Dept Neurol, Tokyo 1138421, Japan; Tokyo Metropolitan Inst Med Sci, Tokyo 1138613, Japan	Yonsei University; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Inha University; Juntendo University; Tokyo Metropolitan Institute of Medical Science	Chung, KC (corresponding author), Yonsei Univ, Coll Sci, Dept Biol, Shinchon Dong 134, Seoul 120749, South Korea.	kchung@yonsei.ac.kr						Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Braak H, 1999, NEUROSCI LETT, V265, P67, DOI 10.1016/S0304-3940(99)00208-6; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Carragher NO, 2002, MOL CELL BIOL, V22, P257, DOI 10.1128/MCB.22.1.257-269.2002; Choi P, 2001, NEUROREPORT, V12, P2839, DOI 10.1097/00001756-200109170-00017; Chung KC, 1999, J NEUROCHEM, V72, P1482, DOI 10.1046/j.1471-4159.1999.721482.x; Comer FI, 2000, J BIOL CHEM, V275, P29179, DOI 10.1074/jbc.R000010200; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; D'Agata V, 2000, MOL BRAIN RES, V75, P345, DOI 10.1016/S0169-328X(99)00286-7; Dantuma NP, 2000, NAT BIOTECHNOL, V18, P538, DOI 10.1038/75406; EVES EM, 1992, P NATL ACAD SCI USA, V89, P4373, DOI 10.1073/pnas.89.10.4373; Gasser T, 2001, ADV NEUROL, V86, P23; Giasson BI, 2001, NEURON, V31, P885, DOI 10.1016/S0896-6273(01)00439-1; GOLBE LI, 1990, NEUROLOGY, V40, P7; Hattori N, 2000, NEUROPATHOLOGY, V20, pS85; Hirsch EC, 1997, J NEURAL TRANSM-SUPP, P79; Hsu LJ, 1998, J NEUROCHEM, V71, P338; Imai Y, 2000, J BIOL CHEM, V275, P35661, DOI 10.1074/jbc.C000447200; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Lang AE, 1998, NEW ENGL J MED, V339, P1130, DOI 10.1056/NEJM199810153391607; Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652; Mishizen-Eberz AJ, 2003, J NEUROCHEM, V86, P836, DOI 10.1046/j.1471-4159.2003.01878.x; MouattPrigent A, 1996, NEUROSCIENCE, V73, P979, DOI 10.1016/0306-4522(96)00100-5; Muchowski PJ, 2002, P NATL ACAD SCI USA, V99, P727, DOI 10.1073/pnas.022628699; Munoz E, 1997, NEUROSCI LETT, V235, P57, DOI 10.1016/S0304-3940(97)00710-6; Paik SR, 1997, ARCH BIOCHEM BIOPHYS, V344, P325, DOI 10.1006/abbi.1997.0207; Peng XR, 2002, MOL CELL BIOL, V22, P378, DOI 10.1128/MCB.22.1.378-387.2002; Pink JJ, 2000, EXP CELL RES, V255, P144, DOI 10.1006/excr.1999.4790; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Rosser BG, 2000, METH MOL B, V144, P245; Saito M, 2000, BRAIN DEV-JPN, V22, pS115; SAITO Y, 1994, FEBS LETT, V353, P327, DOI 10.1016/0014-5793(94)01075-7; SASAKI T, 1984, J BIOL CHEM, V259, P2489; Schlossmacher MG, 2002, AM J PATHOL, V160, P1655, DOI 10.1016/S0002-9440(10)61113-3; Shaw P, 1996, ONCOGENE, V12, P921; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Shimura H, 1999, ANN NEUROL, V45, P668, DOI 10.1002/1531-8249(199905)45:5<668::AID-ANA19>3.0.CO;2-Z; Solano SM, 2000, ANN NEUROL, V47, P201, DOI 10.1002/1531-8249(200002)47:2<201::AID-ANA10>3.0.CO;2-F; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Sung JY, 2001, J BIOL CHEM, V276, P27441, DOI 10.1074/jbc.M101318200; Tamada Y, 2000, BIOCHEM BIOPH RES CO, V275, P300, DOI 10.1006/bbrc.2000.3298; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714; Xu Y, 2002, J BIOL CHEM, V277, P21474, DOI 10.1074/jbc.M111689200; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797	48	58	59	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41890	41899		10.1074/jbc.M306017200	http://dx.doi.org/10.1074/jbc.M306017200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12917442	hybrid			2022-12-25	WOS:000185989500042
J	Pastore, A; Tozzi, G; Gaeta, LM; Bertini, E; Serafini, V; Di Cesare, S; Bonetto, V; Casoni, F; Carrozzo, R; Federici, G; Piemonte, F				Pastore, A; Tozzi, G; Gaeta, LM; Bertini, E; Serafini, V; Di Cesare, S; Bonetto, V; Casoni, F; Carrozzo, R; Federici, G; Piemonte, F			Actin glutathionylation increases in fibroblasts of patients with Friedreich's ataxia - A potential role in the pathogenesis of the disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUN DNA-BINDING; OXIDATIVE STRESS; S-THIOLATION; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; MOLECULAR PATHOGENESIS; OXIDIZED GLUTATHIONE; RESPIRATORY BURST; MITOCHONDRIAL; IDENTIFICATION; PROTEINS	Increasing evidence suggests that iron-mediated oxidative stress might underlie the development of neurodegeneration in Friedreich's ataxia (FRDA), an autosomal recessive ataxia caused by decreased expression of frataxin, a protein implicated in iron metabolism. In this study, we demonstrate that, in fibroblasts of patients with FRDA, the cellular redox equilibrium is shifted toward more protein-bound glutathione. Furthermore, we found that actin is glutathionylated, probably as a result of the accumulation of reactive oxygen species, generated by iron overload in the disease. Indeed, high-pressure liquid chromatography analysis of control fibroblasts in vivo treated with FeSO4 showed a significant increase in the protein-bound/free GSH ratio, and Western blot analysis indicated a relevant rise in glutathionylation. Actin glutathionylation contributes to impaired microfilament organization in FRDA fibroblasts. Rhodamine phalloidin staining revealed a disarray of actin filaments and a reduced signal of F-actin fluorescence. The same hematoxylin/eosin-stained cells showed abnormalities in size and shape. When we treated FRDA fibroblasts with reduced glutathione, we obtained a complete rescue of cytoskeletal abnormalities and cell viability. Thus, we conclude that oxidative stress may induce actin glutathionylation and impairment of cytoskeletal functions in FRDA fibroblasts.	Childrens Hosp & Res Inst Bambino Gesu, Mol Med Unit, I-00165 Rome, Italy; Childrens Hosp & Res Inst Bambino Gesu, Flow Cytometr Unit, I-00165 Rome, Italy; Childrens Hosp & Res Inst Bambino Gesu, Biochem Lab, I-00165 Rome, Italy; Mario Negri Inst Pharmacol Res, Dulbecco Telethon Inst, I-20157 Milan, Italy	IRCCS Bambino Gesu; IRCCS Bambino Gesu; IRCCS Bambino Gesu; Fondazione Telethon; Dulbecco Telethon Institute (DTI); Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Piemonte, F (corresponding author), Childrens Hosp & Res Inst Bambino Gesu, Mol Med Unit, Piazza S Onofrio 4, I-00165 Rome, Italy.	piemonte@opbg.net	Pastore, Anna/J-8409-2014; Bonetto, Valentina/ABB-6383-2020; Piemonte, Fiorella/A-2809-2014; Bonetto, Valentina/I-4694-2018; Tozzi, Giulia/K-8605-2018; Carrozzo, Rosalba/A-2808-2014; Casoni, Filippo/AAN-8298-2020; DI CESARE, SILVIA/AAB-5754-2020; Casoni, Filippo/E-7531-2010; Bertini, Enrico/ABG-1278-2020; Bertini, Enrico/A-2284-2014; Tozzi, Giulia/ABB-3829-2021	Pastore, Anna/0000-0002-0990-9419; Bonetto, Valentina/0000-0003-0456-2054; Piemonte, Fiorella/0000-0003-1825-9347; Bonetto, Valentina/0000-0003-0456-2054; Carrozzo, Rosalba/0000-0002-3327-4054; Casoni, Filippo/0000-0002-1172-8377; DI CESARE, SILVIA/0000-0002-9912-7997; Bertini, Enrico/0000-0001-9276-4590; Tozzi, Giulia/0000-0002-1745-2797	Telethon [TCP01010] Funding Source: Medline	Telethon(Fondazione Telethon)		Aksenov MY, 2001, NEUROSCIENCE, V103, P373, DOI 10.1016/S0306-4522(00)00580-7; Barrett WC, 1999, J BIOL CHEM, V274, P34543, DOI 10.1074/jbc.274.49.34543; Borges CR, 2002, J BIOL CHEM, V277, P48295, DOI 10.1074/jbc.M209042200; Bradley JL, 2000, HUM MOL GENET, V9, P275, DOI 10.1093/hmg/9.2.275; BRANDWEIN HJ, 1981, J BIOL CHEM, V256, P2958; BRIGELIUS R, 1983, BIOCHEM PHARMACOL, V32, P2529, DOI 10.1016/0006-2952(83)90014-X; CAPPEL RE, 1989, J BIOL CHEM, V264, P9180; CHAI YC, 1994, ARCH BIOCHEM BIOPHYS, V310, P273, DOI 10.1006/abbi.1994.1167; Chen ZF, 1998, J PHARMACOL EXP THER, V285, P608; Cohen G, 1997, P NATL ACAD SCI USA, V94, P4890, DOI 10.1073/pnas.94.10.4890; COLLARD JF, 1995, NATURE, V375, P61, DOI 10.1038/375061a0; Cotgreave IA, 1998, BIOCHEM BIOPH RES CO, V242, P1, DOI 10.1006/bbrc.1997.7812; Dalle-Donne I, 2000, J MUSCLE RES CELL M, V21, P171, DOI 10.1023/A:1005671319604; Dalle-Donne I, 2003, FREE RADICAL BIO MED, V34, P23, DOI 10.1016/S0891-5849(02)01182-6; Delatycki MB, 1999, ANN NEUROL, V45, P673, DOI 10.1002/1531-8249(199905)45:5<673::AID-ANA20>3.3.CO;2-H; Eaton P, 2002, J BIOL CHEM, V277, P9806, DOI 10.1074/jbc.M111454200; Emond M, 2000, NEUROLOGY, V55, P1752, DOI 10.1212/WNL.55.11.1752; ERNEST MJ, 1974, J BIOL CHEM, V249, P5011; FernandezCheca JC, 1997, AM J PHYSIOL-GASTR L, V273, pG7, DOI 10.1152/ajpgi.1997.273.1.G7; Fratelli M, 2002, P NATL ACAD SCI USA, V99, P3505, DOI 10.1073/pnas.052592699; GILBERT HF, 1995, METHOD ENZYMOL, V251, P8, DOI 10.1016/0076-6879(95)51107-5; GILBERT HF, 1982, J BIOL CHEM, V257, P2086; Hayes JD, 1999, FREE RADICAL RES, V31, P273, DOI 10.1080/10715769900300851; HOUSSE AO, 2002, HEART LOND, V87, P346; JahngenHodge J, 1997, J BIOL CHEM, V272, P28218, DOI 10.1074/jbc.272.45.28218; Klatt P, 1999, J BIOL CHEM, V274, P15857, DOI 10.1074/jbc.274.22.15857; Klatt P, 1999, FASEB J, V13, P1481, DOI 10.1096/fasebj.13.12.1481; Klatt P, 2000, EUR J BIOCHEM, V267, P4928, DOI 10.1046/j.1432-1327.2000.01601.x; Knight SAB, 1999, AM J HUM GENET, V64, P365, DOI 10.1086/302270; Lamarche J., 1993, HDB CEREBELLAR DIS, P453; Lerman-Sagie T, 2001, J INHERIT METAB DIS, V24, P28, DOI 10.1023/A:1005642302316; Lodi R, 2001, ANN NEUROL, V49, P590; NAKASHIMA K, 1970, Archives of Biochemistry and Biophysics, V141, P579, DOI 10.1016/0003-9861(70)90177-3; Pandolfo M, 1999, ARCH NEUROL-CHICAGO, V56, P1201, DOI 10.1001/archneur.56.10.1201; Pastore A, 2003, CLIN CHIM ACTA, V333, P19, DOI 10.1016/S0009-8981(03)00200-6; Pastore A, 2001, CLIN CHEM, V47, P1467; Patel PI, 2001, AM J HUM GENET, V69, P15, DOI 10.1086/321283; Piemonte F, 2001, EUR J CLIN INVEST, V31, P1007, DOI 10.1046/j.1365-2362.2001.00922.x; Puccio H, 2000, HUM MOL GENET, V9, P887, DOI 10.1093/hmg/9.6.887; Puccio H, 2001, NAT GENET, V27, P181, DOI 10.1038/84818; Radisky DC, 1999, J BIOL CHEM, V274, P4497, DOI 10.1074/jbc.274.8.4497; RAVICHANDRAN V, 1994, J BIOL CHEM, V269, P25010; Reddy S, 2000, BIOCHEM J, V347, P821, DOI 10.1042/0264-6021:3470821; ROKUTAN K, 1994, AM J PHYSIOL, V266, pG247, DOI 10.1152/ajpgi.1994.266.2.G247; Schulz JB, 2000, NEUROLOGY, V55, P1719, DOI 10.1212/WNL.55.11.1719; Schulz JB, 2000, EUR J BIOCHEM, V267, P4904, DOI 10.1046/j.1432-1327.2000.01595.x; SCHUPPEKOISTINEN I, 1994, EUR J BIOCHEM, V221, P1033, DOI 10.1111/j.1432-1033.1994.tb18821.x; SILVA CM, 1989, J BIOL CHEM, V264, P6638; SOFIC E, 1992, NEUROSCI LETT, V142, P128, DOI 10.1016/0304-3940(92)90355-B; STOURNARAS C, 1990, BIOCHIM BIOPHYS ACTA, V1037, P86, DOI 10.1016/0167-4838(90)90105-O; Tozzi G, 2002, ARCH DIS CHILD, V86, P376, DOI 10.1136/adc.86.5.376; Tsapara A, 1999, FEBS LETT, V455, P117, DOI 10.1016/S0014-5793(99)00848-0; Vorgerd M, 2000, NEUROMUSCULAR DISORD, V10, P430, DOI 10.1016/S0960-8966(00)00108-5; WALVOGEL D, 1999, ANN NEUROL, V46, P123; Wang J, 2001, J BIOL CHEM, V276, P47763, DOI 10.1074/jbc.C100415200; Ward NE, 1998, J BIOL CHEM, V273, P12558, DOI 10.1074/jbc.273.20.12558; Wong A, 1999, HUM MOL GENET, V8, P425, DOI 10.1093/hmg/8.3.425	57	130	130	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42588	42595		10.1074/jbc.M301872200	http://dx.doi.org/10.1074/jbc.M301872200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12915401	hybrid			2022-12-25	WOS:000185989500124
J	Westman, BJ; Perdomo, J; Sunde, M; Crossley, M; Mackay, JP				Westman, BJ; Perdomo, J; Sunde, M; Crossley, M; Mackay, JP			The C-terminal domain of Eos forms a high order complex in solution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; DNA-BINDING PROTEINS; TRANSCRIPTION FACTOR; IKAROS FAMILY; CENTROMERIC HETEROCHROMATIN; LYMPHOCYTE DEVELOPMENT; GENE-EXPRESSION; ZINC FINGERS; DIMERIZATION; HOMEOSTASIS	Ikaros family transcription factors play important roles in the control of hematopoiesis. Family members are predicted to contain up to six classic zinc fingers that are arranged into N- and C-terminal domains. The N- terminal domain is responsible for site-specific DNA binding, whereas the C-terminal domain primarily mediates the homo- and hetero-oligomerization between family members. Although the mechanisms of action of these proteins are not completely understood, the zinc finger domains are known to play a central role. In the current study, we have sought to understand the physical and functional properties of these domains, in particular the C-terminal domain. We show that the N- terminal domain from Eos, and not its C-terminal region, is required to recognize GGGA consensus sequences. Surprisingly, in contrast to the behavior exhibited by Ikaros, the C-terminal domain of Eos inhibits the DNA-binding activity of the full-length protein. In addition, we have used a range of biophysical techniques to demonstrate that the C-terminal domain of Eos mediates the formation of complexes that consist of nine or ten molecules. These results constitute the first direct demonstration that Ikaros family proteins can form higher order complexes in solution, and we discuss this unexpected result in the context of what is currently known about the family members and their possible mechanism of action.	Univ Sydney, Sch Mol & Microbial Biosci, Sydney, NSW 2006, Australia	University of Sydney	Mackay, JP (corresponding author), Univ Sydney, Sch Mol & Microbial Biosci, Sydney, NSW 2006, Australia.		Crossley, Merlin/D-7888-2011; Sunde, Margaret/ABH-2584-2020; Sunde, Margaret/A-5186-2016; Perdomo, Jose/H-8871-2019; Mackay, Joel/D-6834-2011	Crossley, Merlin/0000-0003-2057-3642; Sunde, Margaret/0000-0002-0150-3203; Sunde, Margaret/0000-0002-0150-3203; Perdomo, Jose/0000-0002-1554-708X; Mackay, Joel/0000-0001-7508-8033				Avitahl N, 1999, IMMUNITY, V10, P333, DOI 10.1016/S1074-7613(00)80033-3; Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; Casimiro DR, 1997, STRUCTURE, V5, P1407, DOI 10.1016/S0969-2126(97)00291-8; Cobb BS, 2000, GENE DEV, V14, P2146, DOI 10.1101/gad.816400; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; Dixon MP, 2002, J BIOL CHEM, V277, P23186, DOI 10.1074/jbc.M112184200; Espinas ML, 1999, J BIOL CHEM, V274, P16461, DOI 10.1074/jbc.274.23.16461; Garmendia J, 2000, MICROBIOL-SGM, V146, P2555, DOI 10.1099/00221287-146-10-2555; Georgopoulos K, 1997, ANNU REV IMMUNOL, V15, P155, DOI 10.1146/annurev.immunol.15.1.155; Georgopoulos K, 2002, NAT REV IMMUNOL, V2, P162, DOI 10.1038/nri747; GEORGOPOULOS K, 1992, SCIENCE, V258, P808, DOI 10.1126/science.1439790; Hahm K, 1998, GENE DEV, V12, P782, DOI 10.1101/gad.12.6.782; Hayes D. B., 1995, SEDNTERP; Hernandez JA, 2002, BIOCHEM J, V366, P315, DOI 10.1042/BJ20020135; Honma Y, 1999, FEBS LETT, V447, P76, DOI 10.1016/S0014-5793(99)00265-3; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; Katsani KR, 1999, EMBO J, V18, P698, DOI 10.1093/emboj/18.3.698; Kelley CM, 1998, CURR BIOL, V8, P508, DOI 10.1016/S0960-9822(98)70202-7; Kim J, 1999, IMMUNITY, V10, P345, DOI 10.1016/S1074-7613(00)80034-5; Koipally J, 2002, J BIOL CHEM, V277, P13007, DOI 10.1074/jbc.M111371200; Koipally J, 2002, J BIOL CHEM, V277, P27697, DOI 10.1074/jbc.M201694200; Laity JH, 2000, J MOL BIOL, V295, P719, DOI 10.1006/jmbi.1999.3406; Leonhartsberger S, 2000, EUR J BIOCHEM, V267, P3672, DOI 10.1046/j.1432-1327.2000.01399.x; Mackay JP, 1998, J BIOL CHEM, V273, P30560, DOI 10.1074/jbc.273.46.30560; Matthews JM, 2000, EUR J BIOCHEM, V267, P1030, DOI 10.1046/j.1432-1327.2000.01095.x; McCarty AS, 2003, MOL CELL, V11, P459, DOI 10.1016/S1097-2765(03)00043-1; MOLNAR A, 1994, MOL CELL BIOL, V14, P8292, DOI 10.1128/MCB.14.12.8292; Momeni P, 2000, NAT GENET, V24, P71, DOI 10.1038/71717; Morgan B, 1997, EMBO J, V16, P2004, DOI 10.1093/emboj/16.8.2004; Nakayama H, 1999, CANCER RES, V59, P3931; Nichogiannopoulou A, 1999, J EXP MED, V190, P1201, DOI 10.1084/jem.190.9.1201; Nichogiannopoulou A, 1998, SEMIN IMMUNOL, V10, P119, DOI 10.1006/smim.1998.0113; Perdomo J, 2000, J BIOL CHEM, V275, P38347, DOI 10.1074/jbc.M005457200; Perdomo J, 2002, EUR J BIOCHEM, V269, P5885, DOI 10.1046/j.1432-1033.2002.03313.x; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6197, DOI 10.1093/nar/18.21.6197; Robinson DN, 1997, J CELL BIOL, V138, P799, DOI 10.1083/jcb.138.4.799; Sambrook J., 2002, MOL CLONING LAB MANU; Sun L, 1999, CLIN CANCER RES, V5, P2112; Sun L, 1996, EMBO J, V15, P5358, DOI 10.1002/j.1460-2075.1996.tb00920.x; Sun L, 1999, P NATL ACAD SCI USA, V96, P680, DOI 10.1073/pnas.96.2.680; Trinh LA, 2001, GENE DEV, V15, P1817, DOI 10.1101/gad.905601; Wolfe SA, 2000, ANNU REV BIOPH BIOM, V29, P183, DOI 10.1146/annurev.biophys.29.1.183; Wyman C, 1997, SCIENCE, V275, P1658, DOI 10.1126/science.275.5306.1658	43	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42419	42426		10.1074/jbc.M306817200	http://dx.doi.org/10.1074/jbc.M306817200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12917396	hybrid			2022-12-25	WOS:000185989500105
J	Beniston, RG; Campo, MS				Beniston, RG; Campo, MS			Quercetin elevates p27(Kip1) and arrests both primary and HPV16 E6/E7 transformed human keratinocytes in G1	ONCOGENE			English	Article						HFK; HPV E6/E7; quercetin; cell cycle; p27(Kip1)	HUMAN-PAPILLOMAVIRUS DNA; CELL-CYCLE; GASTRIC-CANCER; BRACKEN FERN; E7; PROTEIN; PTAQUILOSIDE; DEGRADATION; APOPTOSIS; P53	Our previous work with primary bovine fibroblasts demonstrated that quercetin, a potent mutagen found in high levels in bracken fern (Pteridium aquilinum), arrested cells in G1 and G2/M, in correlation with p53 activation. The expression of bovine papillomavirus type 4 (BPV-4) E7 overcame this arrest and lead to the development of tumorigenic cells lines (Beniston et al., 2001). Given the possible link between papillomavirus infection, bracken fern in the diet and cancer of the upper gastrointestinal (GI) tract in humans, we investigated whether a similar situation would occur in human cells transformed by human papillomavirus type 16 (HPV-16) oncoproteins. Quercetin arrested primary human foreskin keratinocytes in G1. Arrest was linked to an elevation of the cyclin-dependent kinase inhibitor (cdki) p27(Kip1). Expression of the HPV16 E6 and E7 oncoproteins in transformed cells failed to abrogate cell cycle arrest. GI arrest in the transformed cells was also linked to an increase of p27(Kip1) with a concomitant reduction of cyctin E-associated kinase activity. This elevation of p27(Kip1) was due not only to increased protein half-life, but also to increased mRNA transcription.	Univ Glasgow, Sch Vet, Inst Comparat Med, Glasgow G61 1QH, Lanark, Scotland	University of Glasgow	Campo, MS (corresponding author), Univ Glasgow, Sch Vet, Inst Comparat Med, Garscube Estate, Glasgow G61 1QH, Lanark, Scotland.	s.campo@vet.gla.ac.uk						Alonso-Amelot ME, 2001, INT J CANCER, V91, P252, DOI 10.1002/1097-0215(200002)9999:9999&lt;::AID-IJC1028&gt;3.0.CO;2-; AlonsoAmelot ME, 1996, NATURE, V382, P587, DOI 10.1038/382587a0; Arber N, 2000, GASTROENTEROLOGY, V118, P1045, DOI 10.1016/S0016-5085(00)70357-X; Ashby ADM, 2001, J GEN VIROL, V82, P2353, DOI 10.1099/0022-1317-82-10-2353; Beniston RG, 2001, CARCINOGENESIS, V22, P1069, DOI 10.1093/carcin/22.7.1069; BJELDANES LF, 1977, SCIENCE, V197, P577, DOI 10.1126/science.327550; Boyer SN, 1996, CANCER RES, V56, P4620; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; CAIRNEY M, 1995, CARCINOGENESIS, V16, P1997, DOI 10.1093/carcin/16.8.1997; CAMPO MS, 1994, CARCINOGENESIS, V15, P1597, DOI 10.1093/carcin/15.8.1597; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Casagrande F, 2001, BIOCHEM PHARMACOL, V61, P1205, DOI 10.1016/S0006-2952(01)00583-4; Casson AG, 1997, INT J CANCER, V72, P739, DOI 10.1002/(SICI)1097-0215(19970904)72:5<739::AID-IJC6>3.0.CO;2-T; CHANG FJ, 1990, INT J CANCER, V45, P21, DOI 10.1002/ijc.2910450106; Choi JA, 2001, INT J ONCOL, V19, P837; CONRAD M, 1993, J VIROL, V67, P6170, DOI 10.1128/JVI.67.10.6170-6178.1993; COOPER K, 1995, J PATHOL, V175, P273, DOI 10.1002/path.1711750304; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; de Villiers EM, 1999, INT J CANCER, V81, P225, DOI 10.1002/(SICI)1097-0215(19990412)81:2&lt;225::AID-IJC10&gt;3.0.CO;2-0; Dell C, 2001, CELL MOL LIFE SCI, V58, P1923, DOI 10.1007/PL00000827; FAZAL F, 1990, CARCINOGENESIS, V11, P2005, DOI 10.1093/carcin/11.11.2005; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; Galiana C, 1995, MOL CARCINOGEN, V14, P286, DOI 10.1002/mc.2940140409; GALPIN OP, 1990, BRIT J CANCER, V61, P737, DOI 10.1038/bjc.1990.165; Gillison ML, 2000, JNCI-J NATL CANCER I, V92, P709, DOI 10.1093/jnci/92.9.709; Hara T, 2001, J BIOL CHEM, V276, P48937, DOI 10.1074/jbc.M107274200; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; Hirayama T., 1979, NUTR CANCER, V1, P67; HIRONO I, 1987, J NATL CANCER I, V79, P1143; ISHIDATE M, 1988, MUTAT RES, V195, P151, DOI 10.1016/0165-1110(88)90023-1; Iwashita K, 2000, BIOSCI BIOTECH BIOCH, V64, P1813, DOI 10.1271/bbb.64.1813; JACKSON ME, 1991, MOL CARCINOGEN, V4, P382, DOI 10.1002/mc.2940040510; JACKSON ME, 1995, DNA TUMOUR VIRUSES O; Jones DL, 1997, VIROLOGY, V239, P97, DOI 10.1006/viro.1997.8851; JONES DL, 1921, GENE DEV, P11; LIANG Y, 2002, NAT MED, V10, P1163; Lloyd RV, 1999, AM J PATHOL, V154, P313, DOI 10.1016/S0002-9440(10)65277-7; Malek NP, 2001, NATURE, V413, P323, DOI 10.1038/35095083; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Marliere CA, 2000, BRACKEN FERN TOXICIT, V4, P144; Martin LG, 1998, J VIROL, V72, P975, DOI 10.1128/JVI.72.2.975-985.1998; MATOBA M, 1987, MUTAGENESIS, V2, P419, DOI 10.1093/mutage/2.6.419; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Nakayama K, 2001, BIOCHEM BIOPH RES CO, V282, P853, DOI 10.1006/bbrc.2001.4627; NAKAYASU M, 1986, MUTAT RES, V174, P79, DOI 10.1016/0165-7992(86)90081-3; OELZE I, 1995, J VIROL, V69, P4489, DOI 10.1128/JVI.69.7.4489-4494.1995; PENNIE WD, 1992, VIROLOGY, V190, P861, DOI 10.1016/0042-6822(92)90926-G; Plaumann B, 1996, ONCOGENE, V13, P1605; Potter DM, 2000, BRIT J CANCER, V83, P914, DOI 10.1054/bjoc.2000.1368; Reinstein E, 2000, ONCOGENE, V19, P5944, DOI 10.1038/sj.onc.1203989; Rong Y, 2000, ANTICANCER RES, V20, P4339; Sano T, 2002, PATHOL INT, V52, P375, DOI 10.1046/j.1440-1827.2002.01359.x; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SORSDAHL K, 1994, CANCER DETECT PREV, V18, P179; STRAIGHT SW, 1995, J VIROL, V69, P3185, DOI 10.1128/JVI.69.5.3185-3192.1995; Suzuk L, 1996, CANCER-AM CANCER SOC, V78, P704; SUZUKI S, 1991, JPN J CANCER RES, V82, P1061, DOI 10.1111/j.1349-7006.1991.tb01757.x; Syrjanen KJ, 2002, J CLIN PATHOL, V55, P721, DOI 10.1136/jcp.55.10.721; TOGAWA K, 1994, GASTROENTEROLOGY, V107, P128, DOI 10.1016/0016-5085(94)90070-1; Vance KW, 1999, J BIOL CHEM, V274, P27839, DOI 10.1074/jbc.274.39.27839; VILLALOBOSSALAZ.J, 1995, BRACKEN ENV ISSUE, P102; Yamashita N, 2000, FREE RADICAL RES, V33, P623, DOI 10.1080/10715760000301141; Zehbe I, 1999, ONCOGENE, V18, P2201, DOI 10.1038/sj.onc.1202549; ZerfassThome K, 1996, ONCOGENE, V13, P2323; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	66	25	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2003	22	35					5504	5514		10.1038/sj.onc.1206848	http://dx.doi.org/10.1038/sj.onc.1206848			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JC	12934110	Green Accepted			2022-12-25	WOS:000184735000015
J	Nuhse, TS; Boller, T; Peck, SC				Nuhse, TS; Boller, T; Peck, SC			A plasma membrane syntaxin is phosphorylated in response to the bacterial elicitor flagellin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASES; DISEASE RESISTANCE; MASS-SPECTROMETRY; CALCIUM CHANNELS; PLANT-CELLS; ARABIDOPSIS; GENE; DEFENSE; EXOCYTOSIS; LOCALIZATION	In vivo pulse labeling of suspension-cultured Arabidopsis cells with [P-32] orthophosphate allows a systematic analysis of dynamic changes in protein phosphorylation. Here, we use this technique to investigate signal transduction events at the plant plasma membrane triggered upon perception of microbial elicitors of defense responses, using as a model elicitor flg22, a peptide corresponding to the most conserved domain of bacterial flagellin. We demonstrate that two-dimensional gel electrophoresis in conjunction with mass spectrometry is a suitable tool for the identification of intrinsic membrane proteins, and we show that among them a syntaxin, AtSyp122, is phosphorylated rapidly in response to flg22. Although incorporation of radioactive phosphate into the protein only occurs significantly after elicitation, immunoblot analysis after two-dimensional gel separation indicates that the protein is also phosphorylated prior to elicitation. These results indicate that flg22 elicits either an increase in the rate of turnover of phosphate or an additional de novo phosphorylation event. In vitro, phosphorylation of AtSyp122 is calcium-dependent. In vitro phosphorylated peptides separated by two-dimensional thin layer chromatography comigrate with two of the three in vivo phosphopeptides, indicating that this calcium-dependent phosphorylation is biologically relevant. These results indicate a regulatory link between elicitor-induced calcium fluxes and the rapid phosphorylation of a syntaxin. Because syntaxins are known to be important in membrane fusion and exocytosis, we hypothesize that one of the functions of the calcium signal is to stimulate exocytosis of defense-related proteins and compounds.	Friedrich Miescher Inst Biomed Res, CH-4002 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Peck, SC (corresponding author), Friedrich Miescher Inst Biomed Res, CH-4002 Basel, Switzerland.	scott.peck@bbsrc.ac.uk	Boller, Thomas/G-3500-2012	Boller, Thomas/0000-0001-6768-7503				Asai T, 2002, NATURE, V415, P977, DOI 10.1038/415977a; Atlas D, 2001, J NEUROCHEM, V77, P972, DOI 10.1046/j.1471-4159.2001.00347.x; Blume B, 2000, PLANT CELL, V12, P1425, DOI 10.1105/tpc.12.8.1425; BOLLER T, 1995, ANNU REV PLANT PHYS, V46, P189, DOI 10.1146/annurev.arplant.46.1.189; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Chang SY, 2002, J CELL SCI, V115, P783; Cheng SH, 2002, PLANT PHYSIOL, V129, P469, DOI 10.1104/pp.005645; Chung SH, 2000, J BIOL CHEM, V275, P25286, DOI 10.1074/jbc.M004204200; Dubois T, 2002, EUR J BIOCHEM, V269, P909, DOI 10.1046/j.0014-2956.2001.02725.x; Durrant WE, 2000, PLANT CELL, V12, P963, DOI 10.1105/tpc.12.6.963; Felix G, 1999, PLANT J, V18, P265, DOI 10.1046/j.1365-313X.1999.00265.x; FELIX G, 1991, P NATL ACAD SCI USA, V88, P8831, DOI 10.1073/pnas.88.19.8831; Foletti DL, 2000, J NEUROSCI, V20, P4535, DOI 10.1523/JNEUROSCI.20-12-04535.2000; Foster LJ, 1998, BIOCHEMISTRY-US, V37, P11089, DOI 10.1021/bi980253t; Geelen D, 2002, PLANT CELL, V14, P387, DOI 10.1105/tpc.010328; Gobom J, 1999, J MASS SPECTROM, V34, P105, DOI 10.1002/(SICI)1096-9888(199902)34:2<105::AID-JMS768>3.0.CO;2-4; Gomez-Gomez L, 2000, MOL CELL, V5, P1003, DOI 10.1016/S1097-2765(00)80265-8; Gomez-Gomez L, 1999, PLANT J, V18, P277, DOI 10.1046/j.1365-313X.1999.00451.x; HARLOW DL, 1999, USING ANTIBODIES LAB; Hepler PK, 2001, ANNU REV CELL DEV BI, V17, P159, DOI 10.1146/annurev.cellbio.17.1.159; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Jarvis SE, 2002, J BIOL CHEM, V277, P44399, DOI 10.1074/jbc.M206902200; Klenchin VA, 2000, BIOCHIMIE, V82, P399, DOI 10.1016/S0300-9084(00)00208-X; LARSSON C, 1994, METHOD ENZYMOL, V228, P451; Lauber MH, 1997, J CELL BIOL, V139, P1485, DOI 10.1083/jcb.139.6.1485; Leyman B, 2000, PLANT J, V24, P369, DOI 10.1046/j.1365-313x.2000.00886.x; Leyman B, 1999, SCIENCE, V283, P537, DOI 10.1126/science.283.5401.537; LINTHORST HJM, 1991, CRIT REV PLANT SCI, V10, P123, DOI 10.1080/07352689109382309; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; Marash M, 2001, EMBO J, V20, P411, DOI 10.1093/emboj/20.3.411; MARTIN GB, 1993, SCIENCE, V262, P1432, DOI 10.1126/science.7902614; Martin ML, 2000, PLANT J, V24, P429, DOI 10.1046/j.1365-313x.2000.00889.x; Masaki R, 1998, J BIOCHEM-TOKYO, V124, P311, DOI 10.1093/oxfordjournals.jbchem.a022113; Nuhse TS, 2000, J BIOL CHEM, V275, P7521, DOI 10.1074/jbc.275.11.7521; Peck SC, 2001, PLANT CELL, V13, P1467, DOI 10.1105/tpc.13.6.1467; Peters C, 1999, SCIENCE, V285, P1084, DOI 10.1126/science.285.5430.1084; Rabilloud T, 1998, ELECTROPHORESIS, V19, P758, DOI 10.1002/elps.1150190526; Romeis T, 2001, CURR OPIN PLANT BIOL, V4, P407, DOI 10.1016/S1369-5266(00)00193-X; Romeis T, 1999, PLANT CELL, V11, P273, DOI 10.1105/tpc.11.2.273; Romeis T, 2001, EMBO J, V20, P5556, DOI 10.1093/emboj/20.20.5556; Sanderfoot AA, 2000, PLANT PHYSIOL, V124, P1558, DOI 10.1104/pp.124.4.1558; Sanderfoot AA, 2001, PLANT CELL, V13, P659, DOI 10.1105/tpc.13.3.659; Santoni V, 1999, BIOCHIMIE, V81, P655, DOI 10.1016/S0300-9084(99)80122-9; Santoni V, 2000, ELECTROPHORESIS, V21, P3329, DOI 10.1002/1522-2683(20001001)21:16<3329::AID-ELPS3329>3.0.CO;2-F; Schaller GE, 1995, METHOD CELL BIOL, V50, P129, DOI 10.1016/S0091-679X(08)61027-4; Schmelzer E, 2002, TRENDS PLANT SCI, V7, P411, DOI 10.1016/S1360-1385(02)02307-5; SONG WY, 1995, SCIENCE, V270, P1804, DOI 10.1126/science.270.5243.1804; Stensballe A, 2001, PROTEOMICS, V1, P207, DOI 10.1002/1615-9861(200102)1:2<207::AID-PROT207>3.3.CO;2-V; Sutter JU, 2000, PLANT CELL, V12, P1127, DOI 10.1105/tpc.12.7.1127; Turner KM, 1999, TRENDS NEUROSCI, V22, P459, DOI 10.1016/S0166-2236(99)01436-8; WALCHSOLIMENA C, 1995, J CELL BIOL, V128, P637, DOI 10.1083/jcb.128.4.637; WIDELL S, 1990, PLANT PLASMA MEMBRAN, P17; Wu CC, 2003, NAT BIOTECHNOL, V21, P532, DOI 10.1038/nbt819; Wu MN, 1999, NEURON, V23, P593, DOI 10.1016/S0896-6273(00)80811-9; Zhang SQ, 2001, TRENDS PLANT SCI, V6, P520, DOI 10.1016/S1360-1385(01)02103-3	55	86	92	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45248	45254		10.1074/jbc.M307443200	http://dx.doi.org/10.1074/jbc.M307443200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12949074	hybrid			2022-12-25	WOS:000186452300026
J	Liu, J; Batkai, S; Pacher, P; Harvey-White, J; Wagner, JA; Cravatt, BF; Gao, B; Kunos, G				Liu, J; Batkai, S; Pacher, P; Harvey-White, J; Wagner, JA; Cravatt, BF; Gao, B; Kunos, G			Lipopolysaccharide induces anandamide synthesis in macrophages via CD14/MAPK/phosphoinositide 3-kinase/NF-kappa B independently of platelet-activating factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-KAPPA-B; CB1 CANNABINOID RECEPTORS; NECROSIS-FACTOR-ALPHA; ACID AMIDE HYDROLASE; ENDOGENOUS CANNABINOIDS; BACTERIAL LIPOPOLYSACCHARIDE; N-ARACHIDONOYLETHANOLAMINE; HEMORRHAGIC-SHOCK; HUMAN MONOCYTES; TNF-ALPHA	Macrophage-derived endocannabinoids have been implicated in endotoxin (lipopolysaccharide (LPS))-induced hypotension, but the endocannabinoid involved and the mechanism of its regulation by LPS are unknown. In RAW264.7 mouse macrophages, LPS (10 ng/ ml) increases anandamide (AEA) levels > 10-fold via CD14-, NF-kappaB-, and p44/42-dependent, platelet-activating factor-independent activation of the AEA biosynthetic enzymes, N-acyltransferase and phospholipase D. LPS also induces the AEA-degrading enzyme fatty acid amidohydrolase ( FAAH), and inhibition of FAAH activity potentiates, whereas actinomycin D or cycloheximide blocks the LPS-induced increase in AEA levels and N-acyltransferase and phospholipase D activities. In contrast, cellular levels of the endocannabinoid 2-arachidonoylglycerol (2-AG) are unaffected by LPS but increased by platelet-activating factor. LPS similarly induces AEA, but not 2-AG, in mouse peritoneal macrophages where basal AEA levels are higher, and the LPS-stimulated increase in AEA is potentiated in cells from FAAH(-/-) as compared with FAAH(+/+) mice. Intravenous administration of 10(7) LPS-treated mouse macrophages to anesthetized rats elicits hypotension, which is much greater in response to FAAH(-/-) than FAAH(+/+) cells and is susceptible to inhibition by SR141716, a cannabinoid CB1 receptor antagonist. We conclude that AEA and 2-AG synthesis are differentially regulated in macrophages, and AEA rather than 2-AG is a major contributor to LPS-induced hypotension.	NIAAA, Lab Physiol Sci, Bethesda, MD 20892 USA; Univ Wurzburg, Dept Med, D-97080 Wurzburg, Germany; Scripps Inst, La Jolla, CA 92037 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); University of Wurzburg; Scripps Research Institute	Kunos, G (corresponding author), NIAAA, Lab Physiol Sci, 12420 Parklawn Dr,MSC-8115, Bethesda, MD 20892 USA.		Pacher, Pal/B-6378-2008; Batkai, Sandor/G-3889-2010; Batkai, Sandor/H-7983-2014	Pacher, Pal/0000-0001-7036-8108; 	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [Z01AA000351, Z01AA000368, ZIAAA000351, ZIAAA000368] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Altavilla D, 2001, FREE RADICAL BIO MED, V30, P1055, DOI 10.1016/S0891-5849(01)00492-0; Batkai S, 2001, NAT MED, V7, P827, DOI 10.1038/89953; Berdyshev EV, 2001, FASEB J, V15, P2171, DOI 10.1096/fj.01-0181com; BRAQUET P, 1987, IMMUNOL TODAY, V8, P345, DOI 10.1016/0167-5699(87)90010-7; Bulger EM, 2002, SHOCK, V17, P173, DOI 10.1097/00024382-200203000-00003; Cadas H, 1997, J NEUROSCI, V17, P1226; Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0; Cravatt BF, 2001, P NATL ACAD SCI USA, V98, P9371, DOI 10.1073/pnas.161191698; DENTENER MA, 1993, J IMMUNOL, V150, P2885; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Di Marzo V, 1999, EUR J BIOCHEM, V264, P258, DOI 10.1046/j.1432-1327.1999.00631.x; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; diMarzo V, 1996, BIOCHEM J, V316, P977, DOI 10.1042/bj3160977; Dinh TP, 2002, CHEM PHYS LIPIDS, V121, P149, DOI 10.1016/S0009-3084(02)00150-0; DOHERTY DE, 1989, J IMMUNOL, V143, P3673; Facchinetti F, 2003, GLIA, V41, P161, DOI 10.1002/glia.10177; Fowler CJ, 2000, BRIT J PHARMACOL, V131, P498, DOI 10.1038/sj.bjp.0703569; Gardiner SM, 1998, BRIT J PHARMACOL, V125, P1543, DOI 10.1038/sj.bjp.0702250; GIUFFRIDA A, 1998, LIPID 2 MESSENGERS, P113; Guha M, 2001, CELL SIGNAL, V13, P85, DOI 10.1016/S0898-6568(00)00149-2; HERBERT JM, 1991, J PHARMACOL EXP THER, V259, P44; Hillard CJ, 1997, J NEUROCHEM, V69, P631, DOI 10.1046/j.1471-4159.1997.69020631.x; Ibuki Y, 2003, BBA-MOL CELL RES, V1593, P159, DOI 10.1016/S0167-4889(02)00385-3; Jarai Z, 1999, P NATL ACAD SCI USA, V96, P14136, DOI 10.1073/pnas.96.24.14136; LINDELL TJ, 1970, SCIENCE, V170, P447, DOI 10.1126/science.170.3956.447; Liu J, 2000, BIOCHEM J, V346, P835, DOI 10.1042/0264-6021:3460835; LUMSDEN AB, 1988, HEPATOLOGY, V8, P232, DOI 10.1002/hep.1840080207; Maccarrone M, 2001, ARCH BIOCHEM BIOPHYS, V393, P321, DOI 10.1006/abbi.2001.2500; MINGHETTI L, 1995, J NEUROCHEM, V65, P2690; Moesgaard B, 2002, COMP BIOCHEM PHYS B, V131, P475, DOI 10.1016/S1096-4959(02)00003-9; Mukhopadhyay S, 2002, AM J PHYSIOL-HEART C, V282, pH2046, DOI 10.1152/ajpheart.00497.2001; MULLER JM, 1993, IMMUNOBIOLOGY, V187, P233; Offertaler L, 2003, MOL PHARMACOL, V63, P699, DOI 10.1124/mol.63.3.699; Pestonjamasp VK, 1998, BBA-LIPID LIPID MET, V1394, P249, DOI 10.1016/S0005-2760(98)00110-6; RANKIN JA, 1990, J CLIN INVEST, V86, P1556, DOI 10.1172/JCI114875; Ros J, 2002, GASTROENTEROLOGY, V122, P85, DOI 10.1053/gast.2002.30305; Sancho R, 2003, MOL PHARMACOL, V63, P429, DOI 10.1124/mol.63.2.429; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Sugiura T, 1996, EUR J BIOCHEM, V240, P53, DOI 10.1111/j.1432-1033.1996.0053h.x; Sugiura T, 1998, BIOCHEM BIOPH RES CO, V243, P838, DOI 10.1006/bbrc.1998.8187; Swantek JL, 1999, J BIOL CHEM, V274, P11667, DOI 10.1074/jbc.274.17.11667; SZABO C, 1993, CIRC RES, V73, P991, DOI 10.1161/01.RES.73.6.991; VALONE FH, 1988, J IMMUNOL, V140, P2389; Varga K, 1998, FASEB J, V12, P1035, DOI 10.1096/fasebj.12.11.1035; VARGA K, 1995, EUR J PHARMACOL, V278, P279, DOI 10.1016/0014-2999(95)00181-J; Wagner JA, 2001, J AM COLL CARDIOL, V38, P2048, DOI 10.1016/S0735-1097(01)01671-0; Wagner JA, 1997, NATURE, V390, P518, DOI 10.1038/37371; Wang L, 2003, P NATL ACAD SCI USA, V100, P1393, DOI 10.1073/pnas.0336351100; WEBER C, 1993, EUR J IMMUNOL, V23, P852, DOI 10.1002/eji.1830230413; WRIGHT SD, 1991, SCIENCE, V252, P1321, DOI 10.1126/science.252.5010.1321-a	50	179	187	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					45034	45039		10.1074/jbc.M306062200	http://dx.doi.org/10.1074/jbc.M306062200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12949078	hybrid			2022-12-25	WOS:000186306700141
J	Polgar, J; Lane, WS; Chung, SH; Houng, AK; Reed, GL				Polgar, J; Lane, WS; Chung, SH; Houng, AK; Reed, GL			Phosphorylation of SNAP-23 in activated human platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SYNAPTOSOME-ASSOCIATED PROTEIN; SYNAPTIC SNARE COMPLEX; MOLECULAR-MECHANISMS; GRANULE SECRETION; ALPHA-GRANULE; SYNTAXIN 4; ISOCITRATE DEHYDROGENASE; NEUROTRANSMITTER RELEASE; CRYSTAL-STRUCTURE	Phosphorylation of SNARE proteins may provide a critical link between cell activation and secretory processes. Platelets contain all three members of the SNAP23/25/29 gene family, but by comparison to brain tissue, SNAP-23 is the most highly enriched of these proteins in platelets. SNAP-23 function is required for exocytosis from platelet alpha, dense, and lysosomal granules. SNAP-23 was phosphorylated largely on serine residues in platelets activated with thrombin. Phosphorylation kinetics paralleled or preceded granule secretion. Inhibition studies suggested that SNAP-23 phosphorylation proceeds largely through a protein kinase C (PKC) mechanism and purified PKC directly phosphorylated recombinant (r-) SNAP-23 (up to 0.3 mol of phosphate/mol of protein). Five major tryptic phosphopeptides were identified in cellular SNAP-23 isolated from activated platelets; three phosphopeptides co-migrated with those identified in PKC-phosphorylated r-SNAP-23. In contrast, only one major phosphopeptide was identified when SNAP-23, engaged in a ternary SNARE complex, was phosphorylated by PKC. Ion trap mass spectrometry revealed that platelet SNAP-23 was phosphorylated at Ser(23)/Thr(24) and Ser(161), after cell activation by thrombin; these sites were also identified in PKC-phosphorylated r-SNAP-23. SNAP-23 mutants that mimic phosphorylation at Ser(23)/Thr(24) inhibited syntaxin 4 interactions, whereas a phosphorylation mutant of Ser(161) had only minor effects. Taken together these studies show that SNAP-23 is phosphorylated in platelets during cell activation through a PKC-related mechanism at two or more sites with kinetics that parallel or precede granule secretion. Because mutants that mimic SNAP-23 phosphorylation affect syntaxin 4 interactions, we hypothesize that SNAP-23 phosphorylation may be important for modulating SNARE-complex interactions during membrane trafficking and fusion.	Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, Boston, MA 02115 USA; Harvard Univ, Microchem & Proteom Anal Facil, Cambridge, MA 02138 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University	Reed, GL (corresponding author), Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, 665 Huntington Ave, Boston, MA 02115 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064057] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-64057] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Antonin W, 2002, NAT STRUCT BIOL, V9, P107, DOI 10.1038/nsb746; Bernstein AM, 1999, BLOOD, V93, P571, DOI 10.1182/blood.V93.2.571.402k05_571_579; BROEKMAN MJ, 1992, METHOD ENZYMOL, V215, P21; Cabaniols JP, 1999, MOL BIOL CELL, V10, P4033, DOI 10.1091/mbc.10.12.4033; Chen D, 2000, BLOOD, V96, P1782, DOI 10.1182/blood.V96.5.1782.h8001782_1782_1788; Chen D, 2000, BLOOD, V95, P921, DOI 10.1182/blood.V95.3.921.003k17_921_929; Chittum HS, 1998, BIOCHEMISTRY-US, V37, P10866, DOI 10.1021/bi981042r; Chung SH, 2000, J BIOL CHEM, V275, P25286, DOI 10.1074/jbc.M004204200; DEAN AM, 1990, SCIENCE, V249, P1044, DOI 10.1126/science.2204110; DEAN AM, 1989, J BIOL CHEM, V264, P20482; Elzagallaai A, 2000, BLOOD, V95, P894, DOI 10.1182/blood.V95.3.894.003k15_894_902; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Fasshauer D, 1998, P NATL ACAD SCI USA, V95, P15781, DOI 10.1073/pnas.95.26.15781; Fasshauer D, 1998, BIOCHEMISTRY-US, V37, P10354, DOI 10.1021/bi980542h; Fasshauer D, 1997, J BIOL CHEM, V272, P28036, DOI 10.1074/jbc.272.44.28036; Feng D, 2002, BLOOD, V99, P4006, DOI 10.1182/blood.V99.11.4006; Flaumenhaft R, 1999, J BIOL CHEM, V274, P2492, DOI 10.1074/jbc.274.4.2492; Foletti DL, 2000, J NEUROSCI, V20, P4535, DOI 10.1523/JNEUROSCI.20-12-04535.2000; Foster LJ, 1998, BIOCHEMISTRY-US, V37, P11089, DOI 10.1021/bi980253t; Genoud S, 1999, J NEUROCHEM, V72, P1699, DOI 10.1046/j.1471-4159.1999.721699.x; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; Hanson PI, 1997, CURR OPIN NEUROBIOL, V7, P310, DOI 10.1016/S0959-4388(97)80057-8; Hirling H, 1996, P NATL ACAD SCI USA, V93, P11945, DOI 10.1073/pnas.93.21.11945; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; KNIGHT DE, 1993, METHOD ENZYMOL, V221, P123, DOI 10.1016/0076-6879(93)21012-W; Lemons PP, 1997, BLOOD, V90, P1490, DOI 10.1182/blood.V90.4.1490.1490_1490_1500; Lemons PP, 2000, BIOCHEM BIOPH RES CO, V267, P875, DOI 10.1006/bbrc.1999.2039; Marash M, 2001, EMBO J, V20, P411, DOI 10.1093/emboj/20.3.411; MEISENHELDER J, 1999, CURRENT PROTOCOLS PR; MICHELSON AD, 1996, PRACT APPROACH SER, P111; NIELANDER HB, 1995, J NEUROCHEM, V65, P1712; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; Polgar J, 2002, BLOOD, V100, P1081, DOI 10.1182/blood.V100.3.1081; Polgar J, 1999, BLOOD, V94, P1313, DOI 10.1182/blood.V94.4.1313.416k27_1313_1318; Ravichandran V, 1996, J BIOL CHEM, V271, P13300, DOI 10.1074/jbc.271.23.13300; Reed GL, 2000, BLOOD, V96, P3334; Reed GL, 1999, BLOOD, V93, P2617, DOI 10.1182/blood.V93.8.2617.408k19_2617_2626; Risinger C, 1999, J NEUROCHEM, V72, P614, DOI 10.1046/j.1471-4159.1999.0720614.x; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sambrook J., 2002, MOL CLONING LAB MANU; SEFTON BM, 1995, CURRENT PROTOCOLS MO; Shimazaki Y, 1996, J BIOL CHEM, V271, P14548, DOI 10.1074/jbc.271.24.14548; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; Steegmaier M, 1998, J BIOL CHEM, V273, P34171, DOI 10.1074/jbc.273.51.34171; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; Vaughan PFT, 1998, MOL NEUROBIOL, V18, P125, DOI 10.1007/BF02914269; Vogel K, 1999, BIOCHEM BIOPH RES CO, V258, P407, DOI 10.1006/bbrc.1999.0652; Yoshioka A, 2001, J BIOL CHEM, V276, P39379, DOI 10.1074/jbc.M102933200	49	71	72	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44369	44376		10.1074/jbc.M307864200	http://dx.doi.org/10.1074/jbc.M307864200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12930825	hybrid			2022-12-25	WOS:000186306700061
J	Putney, LK; Barber, DL				Putney, LK; Barber, DL			Na-H exchange-dependent increase in intracellular pH times G(2)/M entry and transition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+/H+ EXCHANGER; CELL-CYCLE; PHOSPHORYLATION; PROLIFERATION; NHE1; TRANSLOCATION; CYTOSKELETON; MIGRATION; AMILORIDE; ISOFORMS	It is well established that activation of the Na-H exchanger NHE1 and increases in intracellular pH (pH(i)) are early and universal responses to mitogens and have permissive effects in promoting cell proliferation. Despite this evidence, a specific role for NHE1 or pH(i) in cell cycle progression remains undetermined. We now show that NHE1 activity and pH(i) regulate the timing of G(2)/M entry and transition. Prior to G(2)/M entry there is a rapid and transient increase in NHE1 activity and pH(i), but in fibroblasts expressing a mutant NHE1 that lacks ion translocation activity, this increase in pH(i) is attenuated, S phase is delayed, and G(2)/M transition is impaired. In the absence of ion translocation by NHE1, expression of cyclin B1 and the kinase activity of Cdc2 are decreased and Wee1 kinase expression increases. Increasing pH(i) in the absence of NHE1 activity, however, is sufficient to restore Cdc2 activity and cyclin B1 expression and to promote G(2)/M entry and transition. These data indicate that a transient increase in pH(i) induced by NHE1 promotes the timing of G(2)/M, and they suggest that increases in pH(i) at the completion of S phase may constitute a previously unrecognized checkpoint for progression to G(2) and mitosis.	Univ Calif San Francisco, Dept Stomatol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Barber, DL (corresponding author), Univ Calif San Francisco, Dept Stomatol, HSW604, San Francisco, CA 94143 USA.	barber@itsa.ucsf.edu			NIGMS NIH HHS [GM63465, GM47413] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047413, F32GM063465] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATHERTONFESSLER S, 1993, MOL CELL BIOL, V13, P1675, DOI 10.1128/MCB.13.3.1675; BUSSOLINO F, 1989, J BIOL CHEM, V264, P18284; COUNILLON L, 1993, MOL PHARMACOL, V44, P1041; COUNILLON L, 1994, BIOCHEMISTRY-US, V33, P10463, DOI 10.1021/bi00200a030; DELVAUX M, 1990, AM J PHYSIOL, V259, pG842, DOI 10.1152/ajpgi.1990.259.5.G842; Denker SP, 2002, J CELL BIOL, V159, P1087, DOI 10.1083/jcb.200208050; Denker SP, 2002, CURR OPIN CELL BIOL, V14, P214, DOI 10.1016/S0955-0674(02)00304-6; Denker SP, 2000, MOL CELL, V6, P1425, DOI 10.1016/S1097-2765(00)00139-8; FRANCHI A, 1986, P NATL ACAD SCI USA, V83, P9388, DOI 10.1073/pnas.83.24.9388; Furnari B, 1999, MOL BIOL CELL, V10, P833, DOI 10.1091/mbc.10.4.833; Ginzinger DG, 2002, EXP HEMATOL, V30, P503, DOI 10.1016/S0301-472X(02)00806-8; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HORVAT B, 1993, EUR J CANCER, V29A, P132, DOI 10.1016/0959-8049(93)90591-3; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; KAPUS A, 1994, J BIOL CHEM, V269, P23544; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; Putney LK, 2002, ANNU REV PHARMACOL, V42, P527, DOI 10.1146/annurev.pharmtox.42.092001.143801; Reshkin SJ, 2000, FASEB J, V14, P2185, DOI 10.1096/fj.00-0029com; Tominaga T, 1998, EMBO J, V17, P4712, DOI 10.1093/emboj/17.16.4712; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721	25	201	207	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44645	44649		10.1074/jbc.M308099200	http://dx.doi.org/10.1074/jbc.M308099200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12947095	hybrid			2022-12-25	WOS:000186306700096
J	Baxa, U; Taylor, KL; Wall, JS; Simon, MN; Cheng, NQ; Wickner, RB; Steven, AC				Baxa, U; Taylor, KL; Wall, JS; Simon, MN; Cheng, NQ; Wickner, RB; Steven, AC			Architecture of Ure2p prion filaments - The N-terminal domains form a central core fiber	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMISSION ELECTRON-MICROSCOPY; YEAST SACCHAROMYCES-CEREVISIAE; NUCLEAR-LOCALIZATION; PROTEIN DETERMINANT; PODOSPORA-ANSERINA; MASS ANALYSIS; IN-VITRO; SCRAPIE; GENE; ORGANIZATION	The [URE3] prion is an inactive, self-propagating, filamentous form of the Ure2 protein, a regulator of nitrogen catabolism in yeast. The N-terminal "prion" domain of Ure2p determines its in vivo prion properties and in vitro amyloid-forming ability. Here we determined the overall structures of Ure2p filaments and related polymers of the prion domain fused to other globular proteins. Protease digestion of 25-nm diameter Ure2p filaments trimmed them to 4-nm filaments, which mass spectrometry showed to be composed of prion domain fragments, primarily residues similar to1-70. Fusion protein filaments with diameters of 14-25 nm were also reduced to 4-nm filaments by proteolysis. The prion domain transforms from the most to the least protease-sensitive part upon filament formation in each case, implying that it undergoes a conformational change. Intact filaments imaged by cryo-electron microscopy or after vanadate staining by scanning transmission electron microscopy (STEM) revealed a central 4-nm core with attached globular appendages. STEM mass per unit length measurements of unstained filaments yielded 1 monomer per 0.45 nm in each case. These observations strongly support a unifying model whereby subunits in Ure2p filaments, as well as in fusion protein filaments, are connected by interactions between their prion domains, which form a 4-nm amyloid filament backbone, surrounded by the corresponding C-terminal moieties.	NIAMSD, Struct Biol Lab, NIH, Bethesda, MD 20892 USA; NIDDK, Lab Biochem & Genet, NIH, Bethesda, MD 20892 USA; Brookhaven Natl Labs, Dept Biol, Upton, NY 11973 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); United States Department of Energy (DOE); Brookhaven National Laboratory	Steven, AC (corresponding author), Bldg 50,Rm 1517,50 South Dr,MSC 8025, Bethesda, MD 20892 USA.	Alasdair_Steven@nih.gov		Baxa, Ulrich/0000-0002-7263-5078	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK024943] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Balguerie A, 2003, EMBO J, V22, P2071, DOI 10.1093/emboj/cdg213; Baxa U, 2002, P NATL ACAD SCI USA, V99, P5253, DOI 10.1073/pnas.082097899; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Blinder D, 1996, J BACTERIOL, V178, P4734, DOI 10.1128/jb.178.15.4734-4736.1996; Bousset L, 2001, BIOCHEMISTRY-US, V40, P13564, DOI 10.1021/bi011007b; Bousset L, 2003, J STRUCT BIOL, V141, P132, DOI 10.1016/S1047-8477(02)00606-8; Bousset L, 2002, EMBO J, V21, P2903, DOI 10.1093/emboj/cdf303; Bousset L, 2001, STRUCTURE, V9, P39, DOI 10.1016/S0969-2126(00)00553-0; Caffrey M, 2000, J BIOL CHEM, V275, P19877, DOI 10.1074/jbc.M001036200; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; Cerritelli ME, 1996, J MOL BIOL, V260, P767, DOI 10.1006/jmbi.1996.0436; Cheng N, 1999, J STRUCT BIOL, V127, P169, DOI 10.1006/jsbi.1999.4120; COSCHIGANO PW, 1991, MOL CELL BIOL, V11, P822, DOI 10.1128/MCB.11.2.822; DRILLIEN R, 1973, BIOCHEM BIOPH RES CO, V53, P367, DOI 10.1016/0006-291X(73)90671-2; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; Edskes HK, 2002, P NATL ACAD SCI USA, V99, P16384, DOI 10.1073/pnas.162349599; Edskes HK, 1999, P NATL ACAD SCI USA, V96, P1498, DOI 10.1073/pnas.96.4.1498; Glover JR, 1997, CELL, V89, P811, DOI 10.1016/S0092-8674(00)80264-0; KIRKLAND EJ, 1998, ADV COMPUTING ELECT, P33; Komar AA, 1998, BIOL CHEM, V379, P1295; Kulkarni AA, 2001, J BIOL CHEM, V276, P32136, DOI 10.1074/jbc.M104580200; LACROUTE F, 1971, J BACTERIOL, V106, P519, DOI 10.1128/JB.106.2.519-522.1971; Liebman SW, 1999, J BIOL CHEM, V274, P1181, DOI 10.1074/jbc.274.3.1181; Maddelein ML, 1999, MOL CELL BIOL, V19, P4516; MASISON DC, 1995, SCIENCE, V270, P93, DOI 10.1126/science.270.5233.93; Masison DC, 1997, P NATL ACAD SCI USA, V94, P12503, DOI 10.1073/pnas.94.23.12503; Muller SA, 2001, MICRON, V32, P21, DOI 10.1016/S0968-4328(00)00022-6; Nazabal A, 2003, BIOCHEMISTRY-US, V42, P8852, DOI 10.1021/bi0344275; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Perrett S, 1999, J MOL BIOL, V290, P331, DOI 10.1006/jmbi.1999.2872; Priola SA, 2001, ADV PROTEIN CHEM, V57, P1; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Schlumpberger M, 2000, PROTEIN SCI, V9, P440; Speransky VV, 2001, J CELL BIOL, V153, P1327, DOI 10.1083/jcb.153.6.1327; Steinmetz MO, 1998, J MOL BIOL, V276, P1, DOI 10.1006/jmbi.1997.1529; Taylor KL, 1999, SCIENCE, V283, P1339, DOI 10.1126/science.283.5406.1339; TERAVANESYAN MD, 1994, GENETICS, V137, P671; THOMAS D, 1994, BIOL CELL, V80, P181, DOI 10.1016/0248-4900(94)90041-8; Thual C, 1999, J BIOL CHEM, V274, P13666, DOI 10.1074/jbc.274.19.13666; Thual C, 2001, BIOCHEMISTRY-US, V40, P1764, DOI 10.1021/bi001916l; Trus BL, 1996, J STRUCT BIOL, V116, P61, DOI 10.1006/jsbi.1996.0011; Umland TC, 2001, P NATL ACAD SCI USA, V98, P1459, DOI 10.1073/pnas.041607898; Wall JS, 1998, METHOD CELL BIOL, V53, P139; WALL JS, 1986, ANNU REV BIOPHYS BIO, V15, P355; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; Wickner RB, 1996, ANNU REV GENET, V30, P109, DOI 10.1146/annurev.genet.30.1.109	46	136	137	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43717	43727		10.1074/jbc.M306004200	http://dx.doi.org/10.1074/jbc.M306004200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12917441	hybrid			2022-12-25	WOS:000186157000121
J	Shi, XL; Chabarek, K; Budai, A; Zhu, ZW				Shi, XL; Chabarek, K; Budai, A; Zhu, ZW			Iron requirement for GAL gene induction in the yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COPPER TRANSPORT; FET3 PROTEIN; DEGRADATION; DEFICIENCY; METABOLISM; EXPRESSION; HOMOLOG; DISEASE; CLUSTER; SYSTEM	Iron is an essential nutrient. Its deficiency hinders the synthesis of ATP and DNA. We report that galactose metabolism is defective when iron availability is restricted. Our data support this connection because 1) galactose-mediated induction of GAL promoter-dependent gene expression was diminished by iron limitation, and 2) iron-deficient mutants grew slowly on galactose-containing medium. These two defects were immediately corrected by iron replacement. Inherited defects in human galactose metabolism are characteristic of the disease called galactosemia. Our findings suggest that iron-deficient galactosemic individuals might be more severely compromised than iron-replete individuals. This work shows that iron homeostasis and galactose metabolism are linked with one another.	Univ Calif Santa Cruz, Dept Environm Toxicol, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz	Zhu, ZW (corresponding author), Univ Calif Santa Cruz, Dept Environm Toxicol, Santa Cruz, CA 95064 USA.	zhu@biology.ucsc.edu		Budai, Alice/0000-0002-6675-4548				ALGERI AA, 1981, GENETICS, V97, P27; Andrews NC, 1999, NEW ENGL J MED, V341, P1986, DOI 10.1056/NEJM199912233412607; Askwith C, 1997, J BIOL CHEM, V272, P401; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Askwith CC, 1998, J BIOL CHEM, V273, P22415, DOI 10.1074/jbc.273.35.22415; Blaiseau PL, 2001, J BIOL CHEM, V276, P34221, DOI 10.1074/jbc.M104987200; BOMFORD A, 1976, Q J MED, V45, P611; BROACH JR, 1979, J MOL BIOL, V131, P41, DOI 10.1016/0022-2836(79)90300-0; Cammack R, 1990, IRON TRANSPORT STORA, P17; Casas C, 1997, YEAST, V13, P621, DOI 10.1002/(SICI)1097-0061(19970615)13:7<621::AID-YEA121>3.0.CO;2-U; DALLMAN PR, 1986, ANNU REV NUTR, V6, P13, DOI 10.1146/annurev.nu.06.070186.000305; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; deSilva D, 1997, J BIOL CHEM, V272, P14208, DOI 10.1074/jbc.272.22.14208; Halliwell B., 1991, FREE RADICALS BIOL M; Hassett RF, 1998, J BIOL CHEM, V273, P23274, DOI 10.1074/jbc.273.36.23274; Hellman NE, 2002, ANNU REV NUTR, V22, P439, DOI 10.1146/annurev.nutr.22.012502.114457; Ideker T, 2001, SCIENCE, V292, P929, DOI 10.1126/science.292.5518.929; JESEN L, 2000, MOL CELL BIOL, V20, P3918; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; KARLIN KD, 1993, SCIENCE, V261, P701, DOI 10.1126/science.7688141; Labbe S, 1997, J BIOL CHEM, V272, P15951, DOI 10.1074/jbc.272.25.15951; LaVaute T, 2001, NAT GENET, V27, P209, DOI 10.1038/84859; LEE RL, 1966, J CLIN INVEST, V47, P2058; LELOIR LF, 1951, ARCH BIOCHEM BIOPHYS, V33, P186, DOI 10.1016/0003-9861(51)90096-3; LOHR D, 1995, FASEB J, V9, P777, DOI 10.1096/fasebj.9.9.7601342; Looker AC, 1997, JAMA-J AM MED ASSOC, V277, P973, DOI 10.1001/jama.277.12.973; MAGUIRE PH, 2000, HUM MOL GENET, V9, P2789; NUNNARI J, 1993, SCIENCE, V262, P1997, DOI 10.1126/science.8266095; Ooi CE, 1996, EMBO J, V15, P3515, DOI 10.1002/j.1460-2075.1996.tb00720.x; OSAKI S, 1971, J BIOL CHEM, V246, P3018; Palmer AE, 2002, BIOCHEMISTRY-US, V41, P6438, DOI 10.1021/bi011979j; Petry KG, 1998, TRENDS GENET, V14, P98, DOI 10.1016/S0168-9525(97)01379-6; POLLITT E, 1993, ANNU REV NUTR, V13, P521, DOI 10.1146/annurev.nu.13.070193.002513; Rutherford JC, 2001, P NATL ACAD SCI USA, V98, P14322, DOI 10.1073/pnas.261381198; RUZICKA FJ, 1995, BIOCHEMISTRY-US, V34, P5610, DOI 10.1021/bi00016a036; Segal S, 1995, METABOLIC MOL BASIS, P967; Sia RAL, 1996, MOL BIOL CELL, V7, P1657, DOI 10.1091/mbc.7.11.1657; Spizzo T, 1997, MOL GEN GENET, V256, P547; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; Yamaguchi-Iwai Y, 2002, J BIOL CHEM, V277, P18914, DOI 10.1074/jbc.M200949200; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x; Yonkovich J, 2002, J BIOL CHEM, V277, P23981, DOI 10.1074/jbc.C200203200; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632; Zhou B, 2001, NAT GENET, V28, P345, DOI 10.1038/ng572	44	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43110	43113		10.1074/jbc.M307011200	http://dx.doi.org/10.1074/jbc.M307011200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12944385	hybrid			2022-12-25	WOS:000186157000050
J	Vaz, FM; Houtkooper, RH; Valianpour, F; Barth, PG; Wanders, RJA				Vaz, FM; Houtkooper, RH; Valianpour, F; Barth, PG; Wanders, RJA			Only one splice variant of the human TAZ gene encodes a functional protein with a role in cardiolipin metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED CARDIOSKELETAL MYOPATHY; LEFT-VENTRICULAR NONCOMPACTION; N-TRIMETHYLLYSINE HYDROXYLASE; BARTH-SYNDROME; G4.5 GENE; SACCHAROMYCES-CEREVISIAE; CARNITINE BIOSYNTHESIS; ESSENTIAL REQUIREMENT; MUTATION; IDENTIFICATION	Barth syndrome (BTHS) is an X-linked recessive disorder caused by mutations in the TAZ gene and is characterized by cardiomyopathy, short stature, neutropenia, and 3-methylglutaconic aciduria. Recently it was found that BTHS patients exhibit a profound cardiolipin deficiency although the biosynthetic capacity to synthesize this lipid from its precursor phosphatidylglycerol is entirely normal. Like BTHS patients, a Saccharomyces cerevisiae strain, in which the yeast orthologue of the human TAZ gene has been disrupted, exhibits an abnormal cardiolipin profile as determined by tandem mass spectrometry. Additionally, this yeast strain grows poorly on non-fermentable carbon sources. We have used both properties of this yeast disruptant as a readout system to test the physiological functionality of each of 12 different splice variants that have been reported for the human TAZ gene. Our results demonstrate that only the splice variant lacking exon 5 was able to complement the retarded growth of the yeast disruptant on selective plates and restore the cardiolipin profile to the wild type pattern. We conclude that this splice variant most likely represents the only physiologically important mRNA, at least with regard to cardiolipin metabolism.	Univ Amsterdam, Acad Med Ctr, Dept Clin Chem, Lab Genet Metab Dis F0 224, NL-1100 DE Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Pediat, Lab Genet Metab Dis F0 224, NL-1100 DE Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Emma Childrens Hosp, NL-1100 DE Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam	Vaz, FM (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Clin Chem, Lab Genet Metab Dis F0 224, POB 22700, NL-1100 DE Amsterdam, Netherlands.		Houtkooper, Riekelt/P-5001-2019; Houtkooper, Riekelt H/E-1602-2011	Houtkooper, Riekelt H/0000-0001-9961-0842; Vaz, Frederic/0000-0002-9048-1041				Barth PG, 1999, J INHERIT METAB DIS, V22, P555, DOI 10.1023/A:1005568609936; BECKER D M, 1991, P182; Bione S, 1996, NAT GENET, V12, P385, DOI 10.1038/ng0496-385; BOLHUIS PA, 1991, AM J HUM GENET, V48, P481; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cantlay AM, 1999, J PEDIATR-US, V135, P311, DOI 10.1016/S0022-3476(99)70126-5; Chen R, 2002, MOL GENET METAB, V77, P319, DOI 10.1016/S1096-7192(02)00195-6; DAdamo P, 1997, AM J HUM GENET, V61, P862, DOI 10.1086/514886; FOLCH J, 1957, J BIOL CHEM, V226, P497; FRANZUSOFF A, 1991, P662; Hatch GM, 1998, INT J MOL MED, V1, P33; Hogenboom S, 2002, J LIPID RES, V43, P90; Ichida F, 2001, CIRCULATION, V103, P1256; Johnston J, 1997, AM J HUM GENET, V61, P1053, DOI 10.1086/301604; KADENBACH B, 1982, FEBS LETT, V139, P109, DOI 10.1016/0014-5793(82)80498-5; Koshkin V, 2000, BIOCHEM J, V347, P687, DOI 10.1042/0264-6021:3470687; Mashkevich G, 1997, J BIOL CHEM, V272, P14356, DOI 10.1074/jbc.272.22.14356; Neuwald AF, 1997, CURR BIOL, V7, pR465; NOEL H, 1986, EUR J BIOCHEM, V155, P99, DOI 10.1111/j.1432-1033.1986.tb09463.x; Orstavik KH, 1998, AM J HUM GENET, V63, P1457, DOI 10.1086/302095; ROBINSON NC, 1993, J BIOENERG BIOMEMBR, V25, P153, DOI 10.1007/BF00762857; Sakamoto O, 2001, HUM GENET, V109, P559, DOI 10.1007/s00439-001-0612-3; Swiegers JH, 2002, FEMS MICROBIOL LETT, V210, P19, DOI 10.1016/S0378-1097(02)00520-7; Valianpour F, 2002, CLIN CHEM, V48, P1390; Vaz FM, 2001, J BIOL CHEM, V276, P33512, DOI 10.1074/jbc.M105929200; Vesel S, 2003, EUR J HUM GENET, V11, P97, DOI 10.1038/sj.ejhg.5200926; Vreken P, 2000, BIOCHEM BIOPH RES CO, V279, P378, DOI 10.1006/bbrc.2000.3952; Wach A, 1996, YEAST, V12, P259, DOI 10.1002/(SICI)1097-0061(19960315)12:3<259::AID-YEA901>3.0.CO;2-C	28	113	115	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43089	43094		10.1074/jbc.M305956200	http://dx.doi.org/10.1074/jbc.M305956200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12930833	hybrid			2022-12-25	WOS:000186157000047
J	Wakabayashi, S; Hisamitsu, T; Pang, TX; Shigekawa, M				Wakabayashi, S; Hisamitsu, T; Pang, TX; Shigekawa, M			Kinetic dissection of two distinct proton binding sites in Na+/H+ exchangers by measurement of reverse mode reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-RESIDUES; CYTOPLASMIC DOMAIN; THYMIC LYMPHOCYTES; GROWTH-FACTORS; PH REGULATION; ANTIPORTER; H+; AMILORIDE; DEPENDENCE; HISTIDINE-226	We examined the effect of intracellular acidification on the reverse mode of Na+/ H+ exchange by measuring Na-22(+) efflux from Na-22(+)-loaded PS120 cells expressing the Na+/ H+ exchanger (NHE) isoforms NHE1, NHE2, and NHE3. The 5-(N- ethyl-N-isopropyl) amiloride (EIPA)- or amiloride- sensitive fraction of Na-22(+) efflux was dramatically accelerated by cytosolic acidification as opposed to thermodynamic prediction, supporting the concept that these NHE isoforms are activated by protonation of an internal binding site(s) distinct from the H+ transport site. Intracellular pH (pH(i)) dependence of Na-22(+) efflux roughly exhibited a bell-shaped profile; mild acidification from pH(i) 7.5 to 7 dramatically accelerated Na-22(+) efflux, whereas acidification from pH(i) 6.6 gradually decreased it. Alkalinization above pHi 7.5 completely suppressed EIPA-sensitive Na-22(+) efflux. Cell ATP depletion and mutation of NHE1 at Arg(440) (R440D) caused a large acidic shift of the pH(i) profile for Na-22(+) efflux, whereas mutation at Gly(455) (G455Q) caused a significant alkaline shift. Because these mutations and ATP depletion cause correspondingly similar effects on the forward mode of Na+/H+ exchange, it is most likely that they alter exchange activity by modulating affinity of the internal modifier site for protons. The data provide substantial evidence that a proton modifier site( s) distinct from the transport site controls activities of at least three NHE isoforms through cooperative interaction with multiple protons.	Natl Cardiovasc Ctr, Res Inst, Dept Mol Physiol, Osaka 5658565, Japan	National Cerebral & Cardiovascular Center - Japan	Wakabayashi, S (corresponding author), Natl Cardiovasc Ctr, Res Inst, Dept Mol Physiol, Fujishirodai 5-7-1, Osaka 5658565, Japan.	wak@ri.ncvc.go.jp						ARONSON PS, 1982, NATURE, V299, P161, DOI 10.1038/299161a0; ARONSON PS, 1985, ANNU REV PHYSIOL, V47, P545, DOI 10.1146/annurev.ph.47.030185.002553; CASSEL D, 1986, J BIOL CHEM, V261, P5460; Cha B, 2003, J MEMBRANE BIOL, V191, P49, DOI 10.1007/s00232-002-1044-2; Counillon L, 2000, J BIOL CHEM, V275, P1, DOI 10.1074/jbc.275.1.1; Dibrov P, 1998, BIOCHEMISTRY-US, V37, P8282, DOI 10.1021/bi9801457; GERCHMAN Y, 1993, P NATL ACAD SCI USA, V90, P1212, DOI 10.1073/pnas.90.4.1212; GOSS GG, 1994, J BIOL CHEM, V269, P8741; GREEN J, 1988, J GEN PHYSIOL, V92, P239, DOI 10.1085/jgp.92.2.239; GREEN J, 1988, J BIOL CHEM, V263, P5012; GRINSTEIN S, 1984, J GEN PHYSIOL, V83, P341, DOI 10.1085/jgp.83.3.341; GRINSTEIN S, 1985, J GEN PHYSIOL, V85, P765, DOI 10.1085/jgp.85.5.765; GRINSTEIN S, 1984, J GEN PHYSIOL, V84, P585, DOI 10.1085/jgp.84.4.585; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; Haworth RS, 2003, J BIOL CHEM, V278, P31676, DOI 10.1074/jbc.M304400200; Hayashi H, 2002, J BIOL CHEM, V277, P11090, DOI 10.1074/jbc.M111868200; Ikeda T, 1997, J BIOCHEM-TOKYO, V121, P295; Kinsella JL, 1998, BIOCHEM CELL BIOL, V76, P743, DOI 10.1139/bcb-76-5-743; MOOLENAAR WH, 1983, NATURE, V304, P645, DOI 10.1038/304645a0; ORLOWSKI J, 1993, J BIOL CHEM, V268, P16369; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; OTSU K, 1993, J BIOL CHEM, V268, P3184; Pang TX, 2001, J BIOL CHEM, V276, P17367, DOI 10.1074/jbc.M100296200; PARIS S, 1984, J BIOL CHEM, V259, P989; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; RIMON A, 1995, J BIOL CHEM, V270, P26813, DOI 10.1074/jbc.270.45.26813; Segel IH, 1975, ENZYME KINETICS, P346; TSE CM, 1993, P NATL ACAD SCI USA, V90, P9110, DOI 10.1073/pnas.90.19.9110; VAUGHANJONES RD, 1990, J PHYSIOL-LONDON, V428, P441, DOI 10.1113/jphysiol.1990.sp018221; VIGNE P, 1984, EMBO J, V3, P1865, DOI 10.1002/j.1460-2075.1984.tb02060.x; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; Wakabayashi S, 1997, PHYSIOL REV, V77, P51, DOI 10.1152/physrev.1997.77.1.51; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P13710; Wakabayashi S, 2003, J BIOL CHEM, V278, P11828, DOI 10.1074/jbc.M213243200; WANG DH, 1995, AM J PHYSIOL-CELL PH, V269, pC392, DOI 10.1152/ajpcell.1995.269.2.C392; Wiebe CA, 2001, BIOCHEM J, V357, P1, DOI 10.1042/0264-6021:3570001	36	73	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43580	43585		10.1074/jbc.M306690200	http://dx.doi.org/10.1074/jbc.M306690200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12928437	hybrid			2022-12-25	WOS:000186157000105
J	Bartosch, B; Vitelli, A; Granier, C; Goujon, C; Dubuisson, J; Pascale, S; Scarselli, E; Cortese, R; Nicosia, A; Cosset, FL				Bartosch, B; Vitelli, A; Granier, C; Goujon, C; Dubuisson, J; Pascale, S; Scarselli, E; Cortese, R; Nicosia, A; Cosset, FL			Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B TYPE-I; DC-SIGN; HYPERVARIABLE REGION-1; LOW-DENSITY; FUNCTIONAL-ANALYSIS; CANDIDATE RECEPTOR; ENVELOPE PROTEIN; E2 GLYCOPROTEIN; DENDRITIC CELLS; INFECTION	Several cell surface molecules have been proposed as receptor candidates, mediating cell entry of hepatitis C virus (HCV) on the basis of their physical association with virions or with soluble HCV E2 glycoproteins. However, due to the lack of infectious HCV particles, evidence that these receptor candidates support infection was missing. Using our recently described infectious HCV pseudotype particles (HCVpp) that display functional E1E2 glycoprotein complexes, here we show that HCV is a pH-dependent virus, implying that its receptor component(s) mediate virion internalization by endocytosis. Expression of the CD81 tetraspanin in non-permissive CD81-negative hepato-carcinoma cells was sufficient to restore susceptibility to HCVpp infection, confirming its critical role as a cell attachment factor. As a cell surface molecule likely to mediate endosomal trafficking, we demonstrate that the human scavenger receptor class B type 1 (SR-B1), a high-density lipoprotein-internalization molecule that we previously proposed as a novel HCV receptor candidate due to its affinity with E2 glycoproteins, is required for infection of CD81-expressing hepatic cells. By receptor competition assays, we found that SR-B1 antibodies that blocked binding of soluble E2 could prevent HCVpp infectivity. Furthermore, we establish that the hyper-variable region 1 of the HCV E2 glycoprotein is a critical determinant mediating entry in SR-B1-positive cells. Finally, by correlating expression of HCV receptors and infectivity, we suggest that, besides CD81 and SR-B1, additional hepatocyte-specific co-factor(s) are necessary for HCV entry.	Ecole Normale Super Lyon, Inst Federat Rech 128, INSERM, U412,Lab Vectorol Retrovirale & Therapie Genique, F-69364 Lyon 07, France; Inst Recerche Biol Mol P Angeletti, I-00040 Rome, Italy; Inst Pasteur, Inst Biol Lille, CNRS, UPR2511, F-59021 Lille, France	Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	Cosset, FL (corresponding author), Ecole Normale Super Lyon, Inst Federat Rech 128, INSERM, U412,Lab Vectorol Retrovirale & Therapie Genique, 46 Allee Italie, F-69364 Lyon 07, France.	flcosset@ens-lyon.fr	Bartosch, Birke/I-7255-2018; Goujon, Caroline/B-3914-2014; Cosset, François-Loïc/M-5862-2019; Dubuisson, Jean/E-6813-2016	Bartosch, Birke/0000-0001-6354-4660; Goujon, Caroline/0000-0001-8571-1108; Cosset, François-Loïc/0000-0001-8842-3726; Christelle, GRANIER/0000-0001-8987-0632; Scarselli, Elisa/0000-0002-5393-6713; Dubuisson, Jean/0000-0003-1626-7693				Agnello V, 1999, P NATL ACAD SCI USA, V96, P12766, DOI 10.1073/pnas.96.22.12766; Akbar SMF, 2001, INTERVIROLOGY, V44, P199, DOI 10.1159/000050047; Alvarez CP, 2002, J VIROL, V76, P6841, DOI 10.1128/JVI.76.13.6841-6844.2002; Andre P, 2002, J VIROL, V76, P6919, DOI 10.1128/JVI.76.14.6919-6928.2002; Auffermann-Gratzinger S, 2001, BLOOD, V97, P3171, DOI 10.1182/blood.V97.10.3171; Bain C, 2001, GASTROENTEROLOGY, V120, P512, DOI 10.1053/gast.2001.21212; Bartosch B, 2003, J EXP MED, V197, P633, DOI 10.1084/jem.20021756; Baumert TF, 1998, J VIROL, V72, P3827, DOI 10.1128/JVI.72.5.3827-3836.1998; Breiner KM, 2001, HEPATOLOGY, V34, P803, DOI 10.1053/jhep.2001.27810; Buonocore L, 2002, J VIROL, V76, P6865, DOI 10.1128/JVI.76.14.6865-6872.2002; CALVO D, 1993, J BIOL CHEM, V268, P18929; Drummer HE, 2003, FEBS LETT, V546, P385, DOI 10.1016/S0014-5793(03)00635-5; DUBUISSON J, 1994, J VIROL, V68, P6147, DOI 10.1128/JVI.68.10.6147-6160.1994; Flint M, 1999, J VIROL, V73, P6782, DOI 10.1128/JVI.73.8.6782-6790.1999; Flint M, 2000, J VIROL, V74, P702, DOI 10.1128/JVI.74.2.702-709.2000; Flint M, 1999, J VIROL, V73, P6235, DOI 10.1128/JVI.73.8.6235-6244.1999; Forns X, 2000, P NATL ACAD SCI USA, V97, P13318, DOI 10.1073/pnas.230453597; Gardner JP, 2003, P NATL ACAD SCI USA, V100, P4498, DOI 10.1073/pnas.0831128100; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Halary F, 2002, IMMUNITY, V17, P653, DOI 10.1016/S1074-7613(02)00447-8; Heinz FX, 2001, CURR OPIN MICROBIOL, V4, P450, DOI 10.1016/S1369-5274(00)00234-4; Hsu M, 2003, P NATL ACAD SCI USA, V100, P7271, DOI 10.1073/pnas.0832180100; Krieger M, 2001, J CLIN INVEST, V108, P793, DOI 10.1172/JCI200114011; Lagging LM, 1998, J VIROL, V72, P3539, DOI 10.1128/JVI.72.5.3539-3546.1998; Lavillette D, 2002, J VIROL, V76, P9673, DOI 10.1128/JVI.76.19.9673-9685.2002; Lerat H, 1998, BLOOD, V91, P3841, DOI 10.1182/blood.V91.10.3841.3841_3841_3849; LINDENBACH BD, 2001, FIELDS VIROLOGY, P991; LOZACH PY, 2003, J BIOL CHEM; MAJOR ME, 2001, FIELDS VIROLOGY, V1, P1127; Matsuura Y, 2001, VIROLOGY, V286, P263, DOI 10.1006/viro.2001.0971; MCCLURE MO, 1990, J GEN VIROL, V71, P767, DOI 10.1099/0022-1317-71-4-767; Monazahian M, 1999, J MED VIROL, V57, P223, DOI 10.1002/(SICI)1096-9071(199903)57:3<223::AID-JMV2>3.0.CO;2-4; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; Navarro-Sanchez E, 2003, EMBO REP, V4, P723, DOI 10.1038/sj.embor.embor866; Navas MC, 2002, J MED VIROL, V67, P152, DOI 10.1002/jmv.2204; Negre D, 2000, GENE THER, V7, P1613, DOI 10.1038/sj.gt.3301292; Owsianka A, 2001, J GEN VIROL, V82, P1877, DOI 10.1099/0022-1317-82-8-1877; Penin F, 2001, J VIROL, V75, P5703, DOI 10.1128/JVI.75.12.5703-5710.2001; Petracca R, 2000, J VIROL, V74, P4824, DOI 10.1128/JVI.74.10.4824-4830.2000; Pileri P, 1998, SCIENCE, V282, P938, DOI 10.1126/science.282.5390.938; Pohlmann S, 2003, J VIROL, V77, P4070, DOI 10.1128/JVI.77.7.4070-4080.2003; Robertson B, 1998, ARCH VIROL, V143, P2493, DOI 10.1007/s007050050479; Roccasecca R, 2003, J VIROL, V77, P1856, DOI 10.1128/JVI.77.3.1856-1867.2003; Sandrin V, 2002, BLOOD, V100, P823, DOI 10.1182/blood-2001-11-0042; Scarselli E, 2002, EMBO J, V21, P5017, DOI 10.1093/emboj/cdf529; Shaw ML, 2003, J MED VIROL, V70, P361, DOI 10.1002/jmv.10404; Sieczkarski SB, 2002, J GEN VIROL, V83, P1535, DOI 10.1099/0022-1317-83-7-1535; Takikawa S, 2000, J VIROL, V74, P5066, DOI 10.1128/JVI.74.11.5066-5074.2000; Tassaneetrithep B, 2003, J EXP MED, V197, P823, DOI 10.1084/jem.20021840; Triyatni M, 2002, J VIROL, V76, P9335, DOI 10.1128/JVI.76.18.9335-9344.2002; VISHNYAKOVA TG, 2003, J BIOL CHEM; Wellnitz S, 2002, J VIROL, V76, P1181, DOI 10.1128/JVI.76.3.1181-1193.2002; Wensel DL, 2003, J VIROL, V77, P3460, DOI 10.1128/JVI.77.6.3460-3469.2003; Yagnik AT, 2000, PROTEINS, V40, P355, DOI 10.1002/1097-0134(20000815)40:3<355::AID-PROT20>3.0.CO;2-K; Zucchelli S, 2001, HEPATOLOGY, V33, P692, DOI 10.1053/jhep.2001.22175	55	469	518	0	43	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41624	41630		10.1074/jbc.M305289200	http://dx.doi.org/10.1074/jbc.M305289200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12913001	hybrid			2022-12-25	WOS:000185989500010
J	Haga, N; Fujita, N; Tsuruo, T				Haga, N; Fujita, N; Tsuruo, T			Mitochondrial aggregation precedes cytochrome c 1release from mitochondria during apoptosis	ONCOGENE			English	Article						apoptosis; mitochondria; aggregation; cytochrome c; laser scanning cytometer	CELL-DEATH; ROCK-I; RELEASE; ACTIVATION; CASPASE-2; CLEAVAGE; PROTEIN; BCL-2; BAX; REQUIREMENT	Mitochondria play a central role in apoptotic signaling pathways. Upon exposure to apoptotic stimuli, mitochondria release cytochrome c to the cytoplasm and activate caspase cascade leading to cell death. However, the events upstream of cytochrome c release are not fully understood. Here, we quantitate mitochondrial aggregation in situ using a novel laser scanning cytometry technique and reveal that mitochondria aggregate during apoptosis in a budding-like shape. The quantitative analysis reveals that mitochondrial aggregation is not inhibited by caspase-3 inhibitor ZEVD. Furthermore, bcl-x(L) transfection cannot suppress mitochondrial aggregation. However, overexpression of bcl-x(L) inhibits cytochrome c release from mitochondria. Therefore, mitochondrial aggregation is an event upstream of cytochrome c release during apoptosis. This mitochondrial aggregation was not observed in human leukemia H9 cells where apoptosis occurs in a mitochondria-independent fashion. Our studies imply that changes in the localization of mitochondria participate in the regulation of apoptosis through cytochrome c release.	Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo 1130032, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Tokyo 1708455, Japan	University of Tokyo; Japanese Foundation for Cancer Research	Tsuruo, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo 1130032, Japan.		Fujita, Naoya/A-7349-2010	Fujita, Naoya/0000-0002-9631-9264				Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; De Vos K, 1998, J BIOL CHEM, V273, P9673, DOI 10.1074/jbc.273.16.9673; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; Ferreira CG, 2000, CANCER RES, V60, P7133; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Haga N, 1998, INT J CANCER, V76, P86, DOI 10.1002/(SICI)1097-0215(19980330)76:1<86::AID-IJC14>3.0.CO;2-E; Hirotani M, 1999, J BIOL CHEM, V274, P20415, DOI 10.1074/jbc.274.29.20415; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Mashima T, 1997, ONCOGENE, V14, P1007, DOI 10.1038/sj.onc.1200919; Meier P, 2000, NATURE, V407, P796, DOI 10.1038/35037734; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Paroni G, 2002, J BIOL CHEM, V277, P15147, DOI 10.1074/jbc.M112338200; Reed JC, 2002, MOL CELL, V9, P1, DOI 10.1016/S1097-2765(02)00437-9; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Sahara S, 1999, NATURE, V401, P168, DOI 10.1038/43678; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Sakamoto H, 2000, BLOOD, V95, P3214, DOI 10.1182/blood.V95.10.3214; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Sebbagh M, 2001, NAT CELL BIOL, V3, P346, DOI 10.1038/35070019; Takada S, 1999, ONCOGENE, V18, P6965, DOI 10.1038/sj.onc.1203188; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhivotovsky B, 1998, NATURE, V391, P449, DOI 10.1038/35060	36	73	76	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2003	22	36					5579	5585		10.1038/sj.onc.1206576	http://dx.doi.org/10.1038/sj.onc.1206576			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944905				2022-12-25	WOS:000184865900006
J	Beebe, K; Merriman, E; Schimmel, P				Beebe, K; Merriman, E; Schimmel, P			Structure-specific tRNA determinants for editing a mischarged amino acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER RIBONUCLEIC-ACID; I TRANSFER-RNA; PHENYLALANINE TRANSFER-RNA; TO-SITE TRANSLOCATION; ESCHERICHIA-COLI; PROTEIN-SYNTHESIS; GENETIC-CODE; SYNTHETASE STRUCTURE; TERTIARY STRUCTURE; CELL VIABILITY	Alanyl-tRNA synthetase efficiently aminoacylates tRNA(Ala) and an RNA minihelix that comprises just one domain of the two-domain L-shaped tRNA structure. It also clears mischarged tRNA(Ala) using a specialized domain in its C-terminal half. In contrast to full-length tRNA(Ala), minihelix(Ala) was robustly mischarged and could not be edited. Addition in trans of the missing anticodon-containing domain did not activate editing of mischarged minihelix(Ala). To understand these differences between minihelix(Ala) and tRNA(Ala), several chimeric full tRNAs were constructed. These had the acceptor stem of a non-cognate tRNA replaced with the stem of tRNA(Ala). The chimeric tRNAs collectively introduced multiple sequence changes in all parts but the acceptor stem. However, although the acceptor stem in isolation (as the minihelix) lacked determinants for editing, alanyl-tRNA synthetase effectively cleared a mischarged amino acid from each chimeric tRNA. Thus, a covalently continuous two-domain structure per se, not sequence, is a major determinant for clearance of errors of aminoacylation by alanyl-tRNA synthetase. Because errors of aminoacylation are known to be deleterious to cell growth, structure-specific determinants constitute a powerful selective pressure to retain the format of the two-domain L-shaped tRNA.	Scripps Res Inst, Dept Mol Biol & Chem, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Schimmel, P (corresponding author), 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	schimmel@scripps.edu			NIGMS NIH HHS [GM15539] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM015539, R01GM015539] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON JJ, 1972, J BACTERIOL, V109, P315, DOI 10.1128/JB.109.1.315-325.1972; BALDWIN AN, 1966, J BIOL CHEM, V241, P839; Beebe K, 2003, EMBO J, V22, P668, DOI 10.1093/emboj/cdg065; Bishop AC, 2003, P NATL ACAD SCI USA, V100, P490, DOI 10.1073/pnas.0237335100; Bishop AC, 2002, P NATL ACAD SCI USA, V99, P585, DOI 10.1073/pnas.012611299; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUECHTER DD, 1993, BIOCHEMISTRY-US, V32, P5267, DOI 10.1021/bi00070a039; CARTER CW, 1993, ANNU REV BIOCHEM, V62, P715, DOI 10.1146/annurev.bi.62.070193.003435; CAVARELLI J, 1993, FASEB J, V7, P79, DOI 10.1096/fasebj.7.1.8422978; Chen JF, 2000, BIOCHEMISTRY-US, V39, P6726, DOI 10.1021/bi000108r; CUSACK S, 1995, NAT STRUCT BIOL, V2, P824, DOI 10.1038/nsb1095-824; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; de Pouplana LR, 2001, CELL, V104, P191, DOI 10.1016/S0092-8674(01)00204-5; DEBRUIJN MHL, 1983, EMBO J, V2, P1309, DOI 10.1002/j.1460-2075.1983.tb01586.x; dePouplana LR, 1997, BIOCHEMISTRY-US, V36, P15041, DOI 10.1021/bi971788+; DIGIULIO M, 1992, J THEOR BIOL, V159, P199; Dock-Bregeon AC, 2000, CELL, V103, P877, DOI 10.1016/S0092-8674(00)00191-4; Doring V, 2001, SCIENCE, V292, P501, DOI 10.1126/science.1057718; ELDRED EW, 1972, J BIOL CHEM, V247, P2961; ENGLISCH S, 1986, NUCLEIC ACIDS RES, V14, P7529, DOI 10.1093/nar/14.19.7529; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; Farrow MA, 1999, BIOCHEMISTRY-US, V38, P16898, DOI 10.1021/bi9920782; Fersht A., 1985, ENZYME STRUCTURE MEC; FERSHT AR, 1977, BIOCHEMISTRY-US, V16, P1025, DOI 10.1021/bi00624a034; FERSHT AR, 1976, BIOCHEMISTRY-US, V15, P3342, DOI 10.1021/bi00660a026; FRANCKLYN C, 1989, NATURE, V337, P478, DOI 10.1038/337478a0; Hale SP, 1997, SCIENCE, V276, P1250, DOI 10.1126/science.276.5316.1250; Hale SP, 1997, TETRAHEDRON, V53, P11985, DOI 10.1016/S0040-4020(97)00711-4; Hendrickson TL, 2002, MOL CELL, V9, P353, DOI 10.1016/S1097-2765(02)00449-5; HOU YM, 1988, NATURE, V333, P140, DOI 10.1038/333140a0; Ibba M, 2000, ANNU REV BIOCHEM, V69, P617, DOI 10.1146/annurev.biochem.69.1.617; JAKUBOWSKI H, 1992, MICROBIOL REV, V56, P412, DOI 10.1128/MMBR.56.3.412-429.1992; KIM SH, 1974, SCIENCE, V185, P435, DOI 10.1126/science.185.4149.435; LAPOINTE J, 1991, TRANSLATION EUKARYOT, P35; Lin L, 1996, NATURE, V384, P33, DOI 10.1038/384033b0; Lovato MA, 2001, EMBO J, V20, P4846, DOI 10.1093/emboj/20.17.4846; LUDMERER SW, 1987, J BIOL CHEM, V262, P10801; MAIZELS N, 1994, P NATL ACAD SCI USA, V91, P6729, DOI 10.1073/pnas.91.15.6729; Martinis S A, 1997, Nucleic Acids Symp Ser, V36, P125; Martinis Susan A., 1995, P349; MCCLAIN WH, 1988, SCIENCE, V240, P793, DOI 10.1126/science.2452483; MORAS D, 1992, TRENDS BIOCHEM SCI, V17, P159, DOI 10.1016/0968-0004(92)90326-5; MURAMATSU T, 1988, NATURE, V336, P179, DOI 10.1038/336179a0; Musier-Forsyth K, 1999, ACCOUNTS CHEM RES, V32, P368, DOI 10.1021/ar970148w; Nangle LA, 2002, J BIOL CHEM, V277, P45729, DOI 10.1074/jbc.M208093200; Noller H.F., 1993, RNA WORLD, P137; Nomanbhoy TK, 1999, MOL CELL, V4, P519, DOI 10.1016/S1097-2765(00)80203-8; Nordin BE, 1999, J BIOL CHEM, V274, P6835, DOI 10.1074/jbc.274.11.6835; NUREKI O, 1994, J MOL BIOL, V236, P710, DOI 10.1006/jmbi.1994.1184; Nureki O, 1998, SCIENCE, V280, P578, DOI 10.1126/science.280.5363.578; PARK SJ, 1988, J BIOL CHEM, V263, P16527; RAO ST, 1973, J MOL BIOL, V76, P241, DOI 10.1016/0022-2836(73)90388-4; RIBAS DP, 1993, PROTEIN SCI, V2, P2259; RICH A, 1976, ANNU REV BIOCHEM, V45, P805, DOI 10.1146/annurev.bi.45.070176.004105; ROBERTUS JD, 1974, NATURE, V250, P546, DOI 10.1038/250546a0; SCHIMMEL P, 1993, P NATL ACAD SCI USA, V90, P8763, DOI 10.1073/pnas.90.19.8763; SCHIMMEL P, 1995, CELL, V81, P983, DOI 10.1016/S0092-8674(05)80002-9; SCHIMMEL PR, 1979, ANNU REV BIOCHEM, V48, P601, DOI 10.1146/annurev.bi.48.070179.003125; SCHMIDT E, 1995, BIOCHEMISTRY-US, V34, P11204, DOI 10.1021/bi00035a028; SCHMIDT E, 1994, SCIENCE, V264, P265, DOI 10.1126/science.8146659; SCHREIER AA, 1972, BIOCHEMISTRY-US, V11, P1582, DOI 10.1021/bi00759a006; SHI JP, 1992, BIOCHEMISTRY-US, V31, P4931, DOI 10.1021/bi00136a002; Shi PY, 1998, RNA, V4, P276; Silvian LF, 1999, SCIENCE, V285, P1074, DOI 10.1126/science.285.5430.1074; STARZYK RM, 1987, SCIENCE, V237, P1614, DOI 10.1126/science.3306924; Steer BA, 1999, BIOCHEMISTRY-US, V38, P4965, DOI 10.1021/bi990038s; Steinberg S, 1997, J MOL BIOL, V266, P269, DOI 10.1006/jmbi.1996.0803; Steitz TA, 1991, CURR OPIN STRUC BIOL, V1, P139, DOI 10.1016/0959-440X(91)90022-L; TSUI WC, 1981, NUCLEIC ACIDS RES, V9, P4627, DOI 10.1093/nar/9.18.4627; WALTER AE, 1994, P NATL ACAD SCI USA, V91, P9218, DOI 10.1073/pnas.91.20.9218; WEBSTER T, 1984, SCIENCE, V226, P1315, DOI 10.1126/science.6390679; WEINER AM, 1987, P NATL ACAD SCI USA, V84, P7383, DOI 10.1073/pnas.84.21.7383; Wolfson AD, 2002, P NATL ACAD SCI USA, V99, P5965, DOI 10.1073/pnas.092152799; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	74	17	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45056	45061		10.1074/jbc.M307080200	http://dx.doi.org/10.1074/jbc.M307080200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12949076	hybrid			2022-12-25	WOS:000186452300004
J	Ibdah, M; Zhang, XH; Schmidt, J; Vogt, T				Ibdah, M; Zhang, XH; Schmidt, J; Vogt, T			A novel Mg2+-dependent O-methyltransferase in the phenylpropanoid metabolism of Mesembryanthemum crystallinum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAFFEOYL-COENZYME-A; ADENOSYL-L-METHIONINE; LIGNIN BIOSYNTHESIS; MOLECULAR-CLONING; ACID 3-O-METHYLTRANSFERASE; SUBSTRATE-SPECIFICITY; METHYLATION PATHWAY; COA 3-O-METHYLTRANSFERASE; HETEROLOGOUS EXPRESSION; MONOLIGNOL BIOSYNTHESIS	Upon irradiation with elevated light intensities, the ice plant (Mesembryanthemum crystallinum) accumulates a complex pattern of methylated and glycosylated flavonol conjugates in the upper epidermal layer. Identification of a flavonol methylating activity, partial purification of the enzyme, and sequencing of the corresponding peptide fragments revealed a novel S-adenosyl-L-methionine-dependent O-methyltransferase that was specific for flavonoids and caffeoyl-CoA. Cloning and functional expression of the corresponding cDNA verified that the new methyltransferase is a multifunctional 26.6-kDa Mg2+-dependent enzyme, which shows a significant sequence similarity to the cluster of caffeoyl coenzyme A-methylating enzymes. Functional analysis of highly homologous members from chickweed (Stellaria longipes), Arabidopsis thaliana, and tobacco (Nicotiana tabacum) demonstrated that the enzymes from the ice plant, chickweed, and A. thaliana possess a broader substrate specificity toward o-hydroquinone-like structures than previously anticipated for Mg2+-dependent O-methyltransferases, and are distinctly different from the tobacco enzyme. Besides caffeoyl-CoA and flavonols, a high specificity was also observed for caffeoylglucose, a compound never before reported to be methylated by any plant O-methyltransferase. Based on phylogenetic analysis of the amino acid sequence and differences in acceptor specificities among both animal and plant O-methyltransferases, we propose that the enzymes from the Centrospermae, along with the predicted gene product from A. thaliana, form a novel subclass within the caffeoyl coenzyme A-dependent O-methyltransferases, with potential divergent functions not restricted to lignin monomer biosynthesis.	Leibniz Inst Plant Biochem, Dept Secondary Metab, D-06120 Halle An Der Saale, Germany; Leibniz Inst Plant Biochem, Dept Bioorgan Chem, D-06120 Halle An Der Saale, Germany; Univ Illinois, Dept Crop Sci, Urbana, IL 61801 USA	Leibniz Institut fur Pflanzenbiochemie; Leibniz Institut fur Pflanzenbiochemie; University of Illinois System; University of Illinois Urbana-Champaign	Vogt, T (corresponding author), Inst Plant Biochem, Dept Secondary Metab, Weinberg 3, D-06120 Halle An Der Saale, Germany.	tvogt@ipb-halle.de	Zhang, Xing-Hai/AAR-6703-2021	Zhang, Xing-Hai/0000-0001-9261-4242				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Anterola AM, 2002, J BIOL CHEM, V277, P18272, DOI 10.1074/jbc.M112051200; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; BOKERN M, 1992, BOT ACTA, V105, P146, DOI 10.1111/j.1438-8677.1992.tb00280.x; BUSAM G, 2000, PLANT PHYSIOL, V115, P1039; Cacace S, 2003, PHYTOCHEMISTRY, V62, P127, DOI 10.1016/S0031-9422(02)00483-1; Chen CY, 2000, PLANT PHYSIOL, V123, P853, DOI 10.1104/pp.123.3.853; Cushman JC, 2000, CURR OPIN PLANT BIOL, V3, P117, DOI 10.1016/S1369-5266(99)00052-7; DAVIN LB, 1992, RECENT ADV PHYTOCHEM, V26, P325; Day A, 2001, PHYSIOL PLANTARUM, V113, P275, DOI 10.1034/j.1399-3054.2001.1130216.x; EDWARDS R, 1991, ARCH BIOCHEM BIOPHYS, V287, P372, DOI 10.1016/0003-9861(91)90492-2; Frick S, 1999, PLANT J, V17, P329, DOI 10.1046/j.1365-313X.1999.00379.x; Fujiwara H, 1998, PLANT J, V16, P421, DOI 10.1046/j.1365-313x.1998.00312.x; Gang DR, 2002, PLANT CELL, V14, P505, DOI 10.1105/tpc.010327; Guo DJ, 2001, PLANT CELL, V13, P73, DOI 10.1105/tpc.13.1.73; Hoffmann L, 2003, J BIOL CHEM, V278, P95, DOI 10.1074/jbc.M209362200; Hoffmann L, 2001, J BIOL CHEM, V276, P36831, DOI 10.1074/jbc.M104977200; Ibdah M, 2002, PLANT CELL ENVIRON, V25, P1145, DOI 10.1046/j.1365-3040.2002.00895.x; Ibrahim RK, 2000, RECENT ADV PHYTOCHEM, V34, P349, DOI 10.1016/S0079-9920(00)80012-X; Inoue K, 1998, PLANT PHYSIOL, V117, P761, DOI 10.1104/pp.117.3.761; Joshi CP, 1998, PLANT MOL BIOL, V37, P663, DOI 10.1023/A:1006035210889; Kawamoto H, 1997, PHYTOCHEMISTRY, V46, P473, DOI 10.1016/S0031-9422(97)00330-0; Li LG, 1997, P NATL ACAD SCI USA, V94, P5461, DOI 10.1073/pnas.94.10.5461; Li LG, 2000, J BIOL CHEM, V275, P6537, DOI 10.1074/jbc.275.9.6537; Li LG, 1999, PLANT MOL BIOL, V40, P555, DOI 10.1023/A:1006244325250; Mabry T. J., 1980, Encyclopedia of Plant Physiology. New Series. Volume 8. Secondary plant products [Bell, A.E.; Charlwood, B.V. (Editors)]., P513; Mannisto PT, 1999, PHARMACOL REV, V51, P593; Markham KR, FLAVONOIDS, DOI 10.1016/0022-2860(71)87109-0; Maury S, 1999, PLANT PHYSIOL, V121, P215, DOI 10.1104/pp.121.1.215; Meng H, 1998, PLANT MOL BIOL, V38, P513, DOI 10.1023/A:1006071708728; Milkowski C, 2000, PLANTA, V211, P883, DOI 10.1007/s004250000411; Muzac I, 2000, ARCH BIOCHEM BIOPHYS, V375, P385, DOI 10.1006/abbi.1999.1681; NDong C, 2003, J BIOL CHEM, V278, P6854, DOI 10.1074/jbc.M209439200; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; O'Leary KA, 2003, BIOCHEM PHARMACOL, V65, P479, DOI 10.1016/S0006-2952(02)01510-1; Osakabe K, 1999, P NATL ACAD SCI USA, V96, P8955, DOI 10.1073/pnas.96.16.8955; PAKUSCH AE, 1989, ARCH BIOCHEM BIOPHYS, V271, P488, DOI 10.1016/0003-9861(89)90299-3; Paquette S, 2003, PHYTOCHEMISTRY, V62, P399, DOI 10.1016/S0031-9422(02)00558-7; SALMINEN M, 1990, GENE, V93, P241, DOI 10.1016/0378-1119(90)90231-F; SCHMITT D, 1991, J BIOL CHEM, V266, P17416; Schroder G, 2002, PHYTOCHEMISTRY, V59, P1, DOI 10.1016/S0031-9422(01)00421-6; STOCKIGT J, 1975, Z NATURFORSCH C, V30, P352; STRACK D, 1987, J PLANT PHYSIOL, V131, P61, DOI 10.1016/S0176-1617(87)80268-7; Taguchi G, 2001, EUR J BIOCHEM, V268, P4086, DOI 10.1046/j.1432-1327.2001.02325.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; ULMANEN I, 1991, EUR J BIOCHEM, V202, P1013, DOI 10.1111/j.1432-1033.1991.tb16464.x; VIDGREN J, 1994, NATURE, V368, P354, DOI 10.1038/368354a0; Vogt T, 1999, PHYTOCHEMISTRY, V52, P583, DOI 10.1016/S0031-9422(99)00151-X; Vogt T, 2000, TRENDS PLANT SCI, V5, P380, DOI 10.1016/S1360-1385(00)01720-9; Wein M, 2002, PLANT J, V31, P755, DOI 10.1046/j.1365-313X.2002.01396.x; Yamazaki M, 1999, J BIOL CHEM, V274, P7405, DOI 10.1074/jbc.274.11.7405; YE ZH, 1995, PLANT PHYSIOL, V108, P459, DOI 10.1104/pp.108.2.459; YE ZH, 1994, PLANT CELL, V6, P1427, DOI 10.1105/tpc.6.10.1427; ZHANG XH, 1995, PLANT PHYSIOL, V108, P429, DOI 10.1104/pp.108.1.429; Zhang XH, 1997, J BIOSCIENCE, V22, P161, DOI 10.1007/BF02704730; ZHU BT, 1994, J BIOL CHEM, V269, P292; Ziegler J, 1997, ANAL BIOCHEM, V250, P257, DOI 10.1006/abio.1997.2248; Zubieta C, 2002, PLANT CELL, V14, P1265, DOI 10.1105/tpc.001412; Zubieta C, 2001, NAT STRUCT BIOL, V8, P271, DOI 10.1038/85029	59	102	109	5	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					43961	43972		10.1074/jbc.M304932200	http://dx.doi.org/10.1074/jbc.M304932200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12941960	hybrid			2022-12-25	WOS:000186306700011
J	Pakula, TM; Laxell, M; Huuskonen, A; Uusitalo, J; Saloheimo, M; Penttila, M				Pakula, TM; Laxell, M; Huuskonen, A; Uusitalo, J; Saloheimo, M; Penttila, M			The effects of drugs inhibiting protein secretion in the filamentous fungus Trichoderma reesei - Evidence for down-regulation of genes that encode secreted proteins in the stressed cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM STRESS; TRANSCRIPTION FACTOR; BREFELDIN-A; MESSENGER-RNA; DISULFIDE-ISOMERASE; TRANSMEMBRANE PROTEIN; ASPERGILLUS-NIGER; CALCIUM; PATHWAY; ER	To study the mechanisms of protein secretion as well as the cellular responses to impaired protein folding and transport in filamentous fungi, we have analyzed Trichoderma reesei cultures treated with chemical agents that interfere with these processes, dithiothreitol, brefeldin A, and the Ca2+-ionophore A23187. The effects of the drugs on the kinetics of protein synthesis and transport were characterized using metabolic labeling of synthesized proteins. Cellobiohydrolase I (CBHI, Cel7A), the major secreted cellulase, was analyzed as a model protein. Northern analysis showed that under conditions where protein transport was inhibited ( treatments with dithiothreitol or brefeldin A) the unfolded protein response pathway was activated. The active form of the hac1 mRNA that mediates unfolded protein response signaling was induced, followed by induction of the foldase and chaperone genes pdi1 and bip1. Concomitant with the activation of the unfolded protein response pathway, the transcript levels of genes encoding secreted proteins, like cellulases and xylanases, were drastically decreased, suggesting a novel type of feedback mechanism activated in response to impairment in protein folding or transport ( repression under secretion stress (RESS)). By studying expression of the reporter gene lacZ under cbh1 promoters of different length, it was shown that the feedback response was mediated through the cellulase promoter.	VTT Biotechnol, Espoo 02044, Finland	VTT Technical Research Center Finland	Pakula, TM (corresponding author), VTT Biotechnol, POB 1500, Espoo 02044, Finland.	tiina.pakula@vtt.fi	Penttilä, Merja E/A-4710-2013	Penttila, Merja/0000-0002-6929-1032				ALBERINI CM, 1990, NATURE, V347, P485, DOI 10.1038/347485a0; [Anonymous], [No title captured]; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; BROSTROM CO, 1989, J BIOL CHEM, V264, P1644; BROSTROM CO, 1990, ANNU REV PHYSIOL, V52, P577; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Casagrande R, 2000, MOL CELL, V5, P729, DOI 10.1016/S1097-2765(00)80251-8; Chardin P, 1999, CELL, V97, P153, DOI 10.1016/S0092-8674(00)80724-2; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; Cox JS, 1996, CELL, V87, P391, DOI 10.1016/S0092-8674(00)81360-4; Derkx PMF, 2001, MOL GENET GENOMICS, V266, P537, DOI 10.1007/s004380100587; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; HERRUER MH, 1988, NUCLEIC ACIDS RES, V16, P7917, DOI 10.1093/nar/16.16.7917; HORWITZ MS, 1969, VIROLOGY, V39, P682, DOI 10.1016/0042-6822(69)90006-3; Ilmen M, 1997, APPL ENVIRON MICROB, V63, P1298; Ilmen M, 1996, MOL GEN GENET, V253, P303, DOI 10.1007/s004380050326; JAMSA E, 1994, YEAST, V10, P355, DOI 10.1002/yea.320100308; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; KERANEN S, 1995, CURR OPIN BIOTECH, V6, P534, DOI 10.1016/0958-1669(95)80088-3; Khalaj V, 2001, FUNGAL GENET BIOL, V32, P55, DOI 10.1006/fgbi.2000.1245; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Kubicek CP, 1998, TRICHODERMA GLIOCLAD, V1, P49; Li Y, 2000, MOL CELL BIOL, V20, P3843, DOI 10.1128/MCB.20.11.3843-3851.2000; LODISH HF, 1990, J BIOL CHEM, V265, P10893; LODISH HF, 1992, J BIOL CHEM, V267, P12753; LOFTFIELD RB, 1958, J BIOL CHEM, V231, P925; Ma YJ, 2001, CELL, V107, P827, DOI 10.1016/S0092-8674(01)00623-7; MANDELS M, 1971, APPL MICROBIOL, V21, P152, DOI 10.1128/AEM.21.1.152-154.1971; Martinez IM, 2003, PLANT CELL, V15, P561, DOI 10.1105/tpc.007609; Montenecourt B. S. ., 1979, ACS SYM SER, V181, P289, DOI DOI 10.1021/BA-1979-0181.CH014; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Mori K, 2000, P NATL ACAD SCI USA, V97, P4660, DOI 10.1073/pnas.050010197; MORI K, 1993, CELL, V74, P743; Mori K, 1996, GENES CELLS, V1, P803, DOI 10.1046/j.1365-2443.1996.d01-274.x; Morinaga N, 1999, J BIOL CHEM, V274, P17417, DOI 10.1074/jbc.274.25.17417; NEVALAINEN H, 1995, MYCOTA, V2, P303; Ngiam C, 2000, APPL ENVIRON MICROB, V66, P775, DOI 10.1128/AEM.66.2.775-782.2000; Ngiam C, 1997, CURR GENET, V31, P133, DOI 10.1007/s002940050187; Nikawa J, 1996, NUCLEIC ACIDS RES, V24, P4222, DOI 10.1093/nar/24.21.4222; NIKAWA JI, 1992, MOL MICROBIOL, V6, P1441, DOI 10.1111/j.1365-2958.1992.tb00864.x; PAHL HL, 1995, EMBO J, V14, P2580, DOI 10.1002/j.1460-2075.1995.tb07256.x; Pakula TM, 2000, MICROBIOL-SGM, V146, P223, DOI 10.1099/00221287-146-1-223; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; Peyroche A, 1999, MOL CELL, V3, P275, DOI 10.1016/S1097-2765(00)80455-4; Prieto S, 2000, J BIOL CHEM, V275, P14155, DOI 10.1074/jbc.275.19.14155; PROSTKO CR, 1992, J BIOL CHEM, V267, P16751; Punt PJ, 1998, APPL MICROBIOL BIOT, V50, P447, DOI 10.1007/s002530051319; Saloheimo A, 2000, J BIOL CHEM, V275, P5817, DOI 10.1074/jbc.275.8.5817; Saloheimo M, 2003, MOL MICROBIOL, V47, P1149, DOI 10.1046/j.1365-2958.2003.03363.x; Saloheimo M, 2002, APPL ENVIRON MICROB, V68, P4546, DOI 10.1128/AEM.68.9.4546-4553.2002; Saloheimo M, 1999, MOL GEN GENET, V262, P35, DOI 10.1007/s004380051057; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shen XH, 2001, CELL, V107, P893, DOI 10.1016/S0092-8674(01)00612-2; Sidrauski C, 1997, CELL, V90, P1031, DOI 10.1016/S0092-8674(00)80369-4; Spanfo S, 1999, J BIOL CHEM, V274, P17705, DOI 10.1074/jbc.274.25.17705; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; vanGemeren IA, 1997, GENE, V198, P43, DOI 10.1016/S0378-1119(97)00290-4; WILEMAN T, 1991, J BIOL CHEM, V266, P4500; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741	62	112	115	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					45011	45020		10.1074/jbc.M302372200	http://dx.doi.org/10.1074/jbc.M302372200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12941955	hybrid			2022-12-25	WOS:000186306700138
J	Pfeifer, G; Schirmer, J; Leemhuis, J; Busch, C; Meyer, DK; Aktories, K; Barth, H				Pfeifer, G; Schirmer, J; Leemhuis, J; Busch, C; Meyer, DK; Aktories, K; Barth, H			Cellular uptake of Clostridium difficile toxin B - Translocation of the N-terminal catalytic domain into the cytosol of eukaryotic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MORPHOLOGICAL-CHANGES; RHO-PROTEINS; LOCALIZATION; INFECTION; GENE	Clostridium difficile toxin B (269 kDa) is one of the causative agents of antibiotic-associated diarrhea and pseudomembranous colitis. Toxin B acts in the cytosol of eukaryotic target cells where it inactivates Rho GTPases by monoglucosylation. The catalytic domain of toxin B is located at the N terminus ( amino acid residues 1 - 546). The C-terminal and the middle region of the toxin seem to be involved in receptor binding and translocation. Here we studied whether the full-length toxin or only a part of the holotoxin is translocated into the cytosol. Vero cells were treated with recombinant glutathione S-transferase-toxin B, and thereafter, toxin B fragments were isolated by affinity precipitation of the glutathione S-transferase-tagged protein from the cytosolic fraction of intoxicated cells. The toxin fragment (similar to65 kDa) was recognized by an antibody against the N terminus of toxin B and was identified by matrix-assisted laser desorption ionization time-of-flight mass spectrometry analysis as the catalytic domain of toxin B. The toxin fragment located in the cytosol possessed glucosyltransferase activity that could modify RhoA in vitro, but it was not able to intoxicate intact cells. After treatment of Vero cells with a radiolabeled fragment of toxin B ( amino acid residues 547 - 2366), radioactivity was identified in the membrane fraction of Vero cells but not in the cytosolic fraction of Vero cells. Furthermore, analysis of cells by fluorescence microscopy revealed that the C terminus of toxin B was located in endosomes, whereas the N terminus was detected in the cytosol. Protease inhibitors, which were added to the cell medium, delayed intoxication of cells by toxin B and pH-dependent translocation of the toxin from the cell surface across the cell membrane. The data indicate that toxin B is proteolytically processed during its cellular uptake process.	Univ Freiburg, Inst Expt & Klin Pharmakol & Toxikol, D-79104 Freiburg, Germany	University of Freiburg	Aktories, K (corresponding author), Univ Freiburg, Inst Expt & Klin Pharmakol & Toxikol, Otto Krayer Haus,Albertstr 25, D-79104 Freiburg, Germany.		Barth, Holger/E-7920-2013; Aktories, Klaus/CAJ-5682-2022	Aktories, Klaus/0000-0002-5397-0436				BARROSO LA, 1994, MICROB PATHOGENESIS, V16, P297, DOI 10.1006/mpat.1994.1030; Barth H, 2001, J BIOL CHEM, V276, P10670, DOI 10.1074/jbc.M009445200; Borriello SP, 1998, J ANTIMICROB CHEMOTH, V41, P13, DOI 10.1093/jac/41.suppl_3.13; FREY SM, 1992, INFECT IMMUN, V60, P2488, DOI 10.1128/IAI.60.6.2488-2492.1992; Hildebrand B, 1997, BRAIN RES, V759, P285, DOI 10.1016/S0006-8993(97)00268-0; Hofmann F, 1997, J BIOL CHEM, V272, P11074; JUST I, 1995, J BIOL CHEM, V270, P13932, DOI 10.1074/jbc.270.23.13932; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; Kelly CP, 1998, ANNU REV MED, V49, P375; KELLY CP, 1994, NEW ENGL J MED, V330, P257, DOI 10.1056/NEJM199401273300406; Lyerly David M., 1995, P867; MULLER H, 1992, INFECT IMMUN, V60, P3007; Qa'Dan M, 2000, INFECT IMMUN, V68, P2470, DOI 10.1128/IAI.68.5.2470-2474.2000; Spyres LM, 2003, INFECT IMMUN, V71, P3294, DOI 10.1128/IAI.71.6.3294-3301.2003; Spyres LM, 2001, INFECT IMMUN, V69, P599, DOI 10.1128/IAI.69.1.599-601.2001; Thelestam M, 2000, CURR TOP MICROBIOL, V250, P85; VONEICHELSTREIBER C, 1991, BIOCHEM SOC T, V19, P1154, DOI 10.1042/bst0191154; VONEICHELSTREIBER C, 1992, J BACTERIOL, V174, P6707, DOI 10.1128/JB.174.20.6707-6710.1992	18	105	111	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44535	44541		10.1074/jbc.M307540200	http://dx.doi.org/10.1074/jbc.M307540200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12941936	hybrid			2022-12-25	WOS:000186306700082
J	Hsieh, T; Gordon, RE; Clemmons, DR; Busby, WH; Duan, CM				Hsieh, T; Gordon, RE; Clemmons, DR; Busby, WH; Duan, CM			Regulation of vascular smooth muscle cell responses to insulin-like growth factor (IGF)-I by local IGF-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; FACTOR (IGF)-BINDING PROTEINS; FACTOR-I; EXTRACELLULAR-MATRIX; PHOSPHATIDYLINOSITOL 3-KINASE; GENE-EXPRESSION; FACTOR ISOFORMS; AMINO-ACIDS; IGFBP-5; MIGRATION	Insulin-like growth factor (IGF)-I is a pleiotropic hormone that regulates vascular smooth muscle cell (VSMC) migration, proliferation, apoptosis, and differentiation. These actions are mediated by the IGF-I receptor. How activation of the same receptor by the same ligand leads to these diverse cellular responses is not well understood. Here we describe a novel mechanism specifying VSMC responses to IGF-I stimulation, distinctive for the pivotal roles of local IGF-binding proteins (IGFBPs). The role of local IGFBPs was indicated by comparing the activities of IGF-I and des-1-3-IGF-I, an IGF-I analog with reduced binding affinity to IGF-BPs. Compared with IGF-I, des-1-3-IGF-I was more potent in stimulating DNA synthesis but much less potent in inducing directed migration of VSMCs. When the effects of individual IGFBPs were tested, IGFBP-2 and IGFBP-4 were found to inhibit IGF-I-stimulated DNA synthesis and migration. IGFBP-5 had an inhibitory effect on IGF-I-stimulated DNA synthesis, but it strongly potentiated IGF-I-induced VSMC migration. By using a non-IGF-binding IGFBP- 5 mutant and an IGF-I-neutralizing antibody, it was demonstrated that IGFBP- 5 also stimulates VSMC migration in an IGF-independent manner. This effect of IGFBP- 5 was inhibited by soluble heparin and by treating cells with heparinase. Mutation of the heparin-binding motif of IGFBP-5 reduced its migration promoting activity. These findings suggest that local IGFBPs are important determinants of cellular responses to IGF-I stimulation, and a key player in this paradigm is IGFBP-5. IGFBP-5 not only modulates IGF-I actions, but it also stimulates cell migration by interacting with cell-surface heparan sulfate proteoglycans.	Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA; Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA	University of Michigan System; University of Michigan; University of North Carolina; University of North Carolina Chapel Hill	Duan, CM (corresponding author), Univ Michigan, Dept Mol Cellular & Dev Biol, Nat Sci Bldg,Rm 3065B, Ann Arbor, MI 48109 USA.				NHLBI NIH HHS [R01HL60679] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060679] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abrass CK, 1997, AM J PHYSIOL-RENAL, V273, pF899, DOI 10.1152/ajprenal.1997.273.6.F899; ALBERCHTBUEHLER G, 1977, CELL, V11, P395; Amaar YG, 2002, J BIOL CHEM, V277, P12053, DOI 10.1074/jbc.M110872200; ANDRESS DL, 1995, J BIOL CHEM, V270, P28289; Andress DL, 1998, AM J PHYSIOL-ENDOC M, V274, pE744, DOI 10.1152/ajpendo.1998.274.4.E744; Anwar A, 2002, CIRCULATION, V105, P1220, DOI 10.1161/hc1002.105187; ARAI T, 1994, J BIOL CHEM, V269, P20388; Arai T, 1996, J BIOL CHEM, V271, P6099, DOI 10.1074/jbc.271.11.6099; Bai HZ, 1999, CIRC RES, V85, P229, DOI 10.1161/01.RES.85.3.229; Baxter RC, 2000, AM J PHYSIOL-ENDOC M, V278, pE967, DOI 10.1152/ajpendo.2000.278.6.E967; Bayes-Genis A, 2000, CIRC RES, V86, P125, DOI 10.1161/01.RES.86.2.125; BOOTH BA, 1995, GROWTH REGULAT, V5, P1; BORNFELDT KE, 1994, J CLIN INVEST, V93, P1266, DOI 10.1172/JCI117081; Busby WH, 2000, J BIOL CHEM, V275, P37638, DOI 10.1074/jbc.M006107200; Cheng HL, 2000, J BIOL CHEM, V275, P27197; Clemmons DR, 2001, ENDOCR REV, V22, P800, DOI 10.1210/er.22.6.800; Clemmons DR, 1997, DIABETES REV, V5, P353; COHICK WS, 1993, J CELL PHYSIOL, V157, P52, DOI 10.1002/jcp.1041570107; COHICK WS, 1995, J CELL PHYSIOL, V164, P187, DOI 10.1002/jcp.1041640123; Duan C, 2002, J ENDOCRINOL, V175, P41, DOI 10.1677/joe.0.1750041; Duan C, 2000, CIRC RES, V86, P15, DOI 10.1161/01.RES.86.1.15; DUAN C, 1996, J BIOL CHEM, V272, P4280; Duan CM, 1999, P NATL ACAD SCI USA, V96, P15274, DOI 10.1073/pnas.96.26.15274; Duan CM, 2003, MOL CELL ENDOCRINOL, V206, P75, DOI 10.1016/S0303-7207(03)00212-0; Duan CM, 1998, J BIOL CHEM, V273, P16836, DOI 10.1074/jbc.273.27.16836; Ewton DZ, 1998, J CELL PHYSIOL, V177, P47, DOI 10.1002/(SICI)1097-4652(199810)177:1<47::AID-JCP5>3.0.CO;2-E; FRANCIS GL, 1992, J MOL ENDOCRINOL, V8, P213, DOI 10.1677/jme.0.0080213; GIANNELLANETO D, 1992, CIRC RES, V71, P646, DOI 10.1161/01.RES.71.3.646; GOCKERMAN A, 1995, ENDOCRINOLOGY, V136, P4168, DOI 10.1210/en.136.10.4168; Imai Y, 1999, ENDOCRINOLOGY, V140, P4228, DOI 10.1210/en.140.9.4228; Imai Y, 2000, J BIOL CHEM, V275, P18188, DOI 10.1074/jbc.M000070200; JONES JI, 1993, J CELL BIOL, V121, P679, DOI 10.1083/jcb.121.3.679; KAMYAR A, 1994, CIRC RES, V74, P576, DOI 10.1161/01.RES.74.4.576; LINHARDT RJ, 1994, CURRENT PROTOCOLS MO, V3; Maures TJ, 2002, ENDOCRINOLOGY, V143, P2722, DOI 10.1210/en.143.7.2722; Miyakoshi N, 2001, J CLIN INVEST, V107, P73, DOI 10.1172/JCI10459; MOHAN S, 1995, J BIOL CHEM, V270, P20424, DOI 10.1074/jbc.270.35.20424; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; Parker A, 1998, MOL BIOL CELL, V9, P2383, DOI 10.1091/mbc.9.9.2383; Patel VA, 2001, CIRC RES, V88, P895, DOI 10.1161/hh0901.090305; Perks CM, 2002, BIOCHEM BIOPH RES CO, V294, P995, DOI 10.1016/S0006-291X(02)00570-3; Rees C, 1998, J CELL BIOCHEM, V71, P375, DOI 10.1002/(SICI)1097-4644(19981201)71:3<375::AID-JCB6>3.0.CO;2-M; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; Rusnati M, 1996, INT J CLIN LAB RES, V26, P15, DOI 10.1007/BF02644769; Sakata H, 1997, J BIOL CHEM, V272, P9457; Schedlich LJ, 1998, J BIOL CHEM, V273, P18347, DOI 10.1074/jbc.273.29.18347; Schedlich LJ, 2000, J BIOL CHEM, V275, P23462, DOI 10.1074/jbc.M002208200; Schneider MR, 2001, BIOCHEM BIOPH RES CO, V288, P435, DOI 10.1006/bbrc.2001.5785; Sowers JR, 1997, HYPERTENSION, V29, P691, DOI 10.1161/01.HYP.29.3.691; Stringer SE, 1997, J BIOL CHEM, V272, P20508, DOI 10.1074/jbc.272.33.20508; Summerford C, 1998, J VIROL, V72, P1438, DOI 10.1128/JVI.72.2.1438-1445.1998; Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200; Wang JW, 1997, J CLIN INVEST, V100, P1425, DOI 10.1172/JCI119663; Yano KJ, 1999, ENDOCRINOLOGY, V140, P4622, DOI 10.1210/en.140.10.4622; Zaina S, 2002, J BIOL CHEM, V277, P4505, DOI 10.1074/jbc.M108061200; Zheng B, 1998, J BIOL CHEM, V273, P8994, DOI 10.1074/jbc.273.15.8994	56	58	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42886	42892		10.1074/jbc.M303835200	http://dx.doi.org/10.1074/jbc.M303835200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12917428	hybrid			2022-12-25	WOS:000186157000020
J	Ilangumaran, S; Finan, D; Raine, J; Rottapel, R				Ilangumaran, S; Finan, D; Raine, J; Rottapel, R			Suppressor of cytokine signaling 1 regulates an endogenous inhibitor of a mast cell protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMATOPOIETIC-CELLS; NEGATIVE REGULATION; JAK/STAT PATHWAY; KINASE-ACTIVITY; SOCS BOX; MOUSE; DEGRADATION; TRYPTASE; EXPRESSION; ACTIVATION	Suppressor of cytokine signaling 1 (SOCS1) is a negative regulator of c-Kit and interleukin-3 (IL-3) receptor signaling. We examined the role of SOCS1 in regulating IL-3-induced cell growth of primary bone marrow-derived mast cells (BMMCs) from SOCS1(-/-) mice. Instead of showing increased proliferation, SOCS1-deficient BMMCs responded poorly to IL-3 and stem cell factor. SOCS1(-/-) BMMCs showed increased apoptosis and defective cell cycle entry. We show that the growth retardation of SOCS1(-/-) BMMCs was due to a cell intrinsic defect. Protein tyrosine phosphorylation following IL-3 stimulation was markedly diminished in SOCS1(-/-) BMMCs. Intriguingly, JAK2 and STAT5 proteins were selectively diminished in SOCS1(-/-) BMMCs, which also showed lower molecular mass products of p85 and Vav suggesting proteolytic degradation. Incubation of the SOCS1(-/-) BMMC lysate with STAT5, p85, and Vav immunoprecipitated from SOCS1(+/+) cells directly demonstrated the dysregulated proteolytic activity in SOCS1(-/-) BMMCs. The proteolytic activity in SOCS1(-/-) BMMCs was selectively inhibited by phenylmethylsulfonyl fluoride and soybean trypsin inhibitor, suggesting that the protease regulated by SOCS1 is a tryptase. The dysregulated tryptase in SOCS1(-/-) BMMCs is unlikely to be mMCP6 or mMCP7, because the enzyme activity was not inhibited by Polybrene but was inhibited by normal mouse plasma. SOCS1(+/+) BMMC lysate inhibited the proteolytic activity present in SOCS1(-/-) BMMC lysate, indicating that SOCS1(-/-) BMMCs lack an endogenous protease inhibitor. These results show that SOCS1 is required for the expression and/or stability of an endogenous protease inhibitor, which protects mast cells from their own proteolytic enzymes.	Univ Hlth Network, Princess Margaret Hosp, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; St Michaels Hosp, Toronto, ON M5B 1W8, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University of Toronto; University of Toronto	Rottapel, R (corresponding author), Univ Hlth Network, Princess Margaret Hosp, Ontario Canc Inst, Rm 10-108,610 Univ Ave, Toronto, ON M5G 2M9, Canada.	rottapel@uhnres.utoronto.ca		Rottapel, Robert/0000-0002-6024-5558; Ilangumaran, Subburaj/0000-0002-7563-576X				Alexander WS, 2002, NAT REV IMMUNOL, V2, P410, DOI 10.1038/nri818; Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; ATKINS FM, 1985, LAB INVEST, V52, P278; Cairns JA, 1996, J IMMUNOL, V156, P275; Danial NN, 1998, MOL CELL BIOL, V18, P6795, DOI 10.1128/MCB.18.11.6795; De Sepulveda P, 2000, J BIOL CHEM, V275, P14005, DOI 10.1074/jbc.C000106200; De Sepulveda P, 1999, EMBO J, V18, P904; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Frantsve J, 2001, MOL CELL BIOL, V21, P3547, DOI 10.1128/MCB.21.10.3547-3557.2001; Galli S J, 1994, Curr Opin Hematol, V1, P33; Ghildyal N, 1996, J EXP MED, V184, P1061, DOI 10.1084/jem.184.3.1061; GORDON JR, 1990, IMMUNOL TODAY, V11, P458, DOI 10.1016/0167-5699(90)90176-A; Gurish MF, 2001, J EXP MED, V194, pF1, DOI 10.1084/jem.194.1.F1; Hallgren J, 2000, BIOCHEMISTRY-US, V39, P13068, DOI 10.1021/bi000973b; Huang CF, 1997, J BIOL CHEM, V272, P31885, DOI 10.1074/jbc.272.50.31885; Huang CF, 1998, J CLIN IMMUNOL, V18, P169, DOI 10.1023/A:1020574820797; Hunt JE, 1996, J BIOL CHEM, V271, P2851, DOI 10.1074/jbc.271.5.2851; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; Ilangumaran S, 2002, J IMMUNOL, V169, P5010, DOI 10.4049/jimmunol.169.9.5010; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; Kile BT, 2002, TRENDS BIOCHEM SCI, V27, P235, DOI 10.1016/S0968-0004(02)02085-6; Knight PA, 2000, J EXP MED, V192, P1849, DOI 10.1084/jem.192.12.1849; Leonard WJ, 2000, J ALLERGY CLIN IMMUN, V105, P877, DOI 10.1067/mai.2000.106899; Malaviya R, 2001, IMMUNITY, V15, P313, DOI 10.1016/S1074-7613(01)00184-4; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; MATSUMOTO R, 1995, J BIOL CHEM, V270, P19524, DOI 10.1074/jbc.270.33.19524; MCNEIL HP, 1992, P NATL ACAD SCI USA, V89, P11174, DOI 10.1073/pnas.89.23.11174; Metcalfe DD, 1997, PHYSIOL REV, V77, P1033, DOI 10.1152/physrev.1997.77.4.1033; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Narazaki M, 1998, P NATL ACAD SCI USA, V95, P13130, DOI 10.1073/pnas.95.22.13130; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; Reddy EP, 2000, ONCOGENE, V19, P2532, DOI 10.1038/sj.onc.1203594; REYNOLDS DS, 1991, J BIOL CHEM, V266, P3847; Rottapel R, 2002, ONCOGENE, V21, P4351, DOI 10.1038/sj.onc.1205537; Shuai K, 2000, ONCOGENE, V19, P2638, DOI 10.1038/sj.onc.1203522; Sommerhoff CP, 2001, AM J RESP CRIT CARE, V164, pS52, DOI 10.1164/ajrccm.164.supplement_2.2106058; Starr R, 1999, BIOESSAYS, V21, P47, DOI 10.1002/(SICI)1521-1878(199901)21:1<47::AID-BIES6>3.0.CO;2-N; STEVENS RL, 1989, IMMUNOL TODAY, V10, P381, DOI 10.1016/0167-5699(89)90272-7; Tyers M, 1999, P NATL ACAD SCI USA, V96, P12230, DOI 10.1073/pnas.96.22.12230; Ungureanu D, 2002, MOL CELL BIOL, V22, P3316, DOI 10.1128/MCB.22.10.3316-3326.2002; Ward AC, 2000, BLOOD, V95, P19; Watowich SS, 1996, ANNU REV CELL DEV BI, V12, P91, DOI 10.1146/annurev.cellbio.12.1.91; Wedemeyer J, 2000, CURR OPIN IMMUNOL, V12, P624, DOI 10.1016/S0952-7915(00)00154-0; Wong GW, 2001, J BIOL CHEM, V276, P20648, DOI 10.1074/jbc.M010422200; Wong UW, 1999, J BIOL CHEM, V274, P30784, DOI 10.1074/jbc.274.43.30784; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143	50	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41871	41880		10.1074/jbc.M308382200	http://dx.doi.org/10.1074/jbc.M308382200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12917417	hybrid			2022-12-25	WOS:000185989500040
J	Schweizer, A; Briand, C; Grutter, MG				Schweizer, A; Briand, C; Grutter, MG			Crystal structure of caspase-2, apical initiator of the intrinsic apoptotic pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; PROGRAMMED CELL-DEATH; 3-DIMENSIONAL STRUCTURE; ACTIVATION; FAMILY; INHIBITOR; PROTEASE; MECHANISM; COMPLEX; SPECIFICITIES	The cell death protease caspase-2 has recently been recognized as the most apical caspase in the apoptotic cascade ignited during cell stress signaling. Cytotoxic stress, such as that caused by cancer therapies, leads to activation of caspase-2, which acts as a direct effector of the mitochondrion-dependent apoptotic pathway resulting in programmed cell death. Here we report the x-ray structure of caspase-2 in complex with the inhibitor acetyl-Leu-Asp-Glu-Ser-Asp-aldehyde at 1.65-Angstrom resolution. Compared with other caspases, significant structural differences prevail in the active site region and the dimer interface. The structure reveals the hydrophobic properties of the S5 specificity pocket, which is unique to caspase-2, and provides the details of the inhibitorprotein interactions in subsites S1-S4. These features form the basis of caspase-2 specificity and allow the design of caspase-2-directed ligands for medical and analytical use. Another unique feature of caspase-2 is a disulfide bridge at the dimer interface, which covalently links the two monomers. Consistent with this finding, caspase-2 exists as a (p19/p12)(2) dimer in solution, even in the absence of substrates or inhibitors. The intersubunit disulfide bridge stabilizes the dimeric form of caspase-2, whereas all other long prodomain caspases exist as monomers in solution, and dimer formation is driven by ligand binding. Therefore, the central disulfide bridge appears to represent a novel way of dimer stabilization in caspases.	Univ Zurich, Dept Biochem, CH-8057 Zurich, Switzerland	University of Zurich	Grutter, MG (corresponding author), Univ Zurich, Dept Biochem, CH-8057 Zurich, Switzerland.	gruetter@bioc.unizh.ch						Baliga B, 2003, CELL DEATH DIFFER, V10, P16, DOI 10.1038/sj.cdd.4401166; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Blanchard H, 2000, J MOL BIOL, V302, P9, DOI 10.1006/jmbi.2000.4041; Blanchard H, 1999, STRUCTURE, V7, P1125, DOI 10.1016/S0969-2126(99)80179-8; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Braun JS, 1999, NAT MED, V5, P298, DOI 10.1038/6514; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Chang DW, 2003, J BIOL CHEM, V278, P16466, DOI 10.1074/jbc.C300089200; Cursio R, 1999, FASEB J, V13, P253, DOI 10.1096/fasebj.13.2.253; Donepudi M, 2003, MOL CELL, V11, P543, DOI 10.1016/S1097-2765(03)00059-5; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Ellerby LM, 1999, J NEUROCHEM, V72, P185, DOI 10.1046/j.1471-4159.1999.0720185.x; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; EVANS SV, 1993, J MOL GRAPHICS, V11, P127; Faderl S, 1999, CLIN CANCER RES, V5, P4041; Garcia-Calvo M, 1999, CELL DEATH DIFFER, V6, P362, DOI 10.1038/sj.cdd.4400497; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Himi T, 1998, EUR J NEUROSCI, V10, P777, DOI 10.1046/j.1460-9568.1998.00073.x; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; Kumar S, 2002, SCIENCE, V297, P1290, DOI 10.1126/science.1076118; Lamkanfi M, 2002, CELL DEATH DIFFER, V9, P358, DOI 10.1038/sj.cdd.4400989; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; MILLIGAN CE, 1995, NEURON, V15, P385, DOI 10.1016/0896-6273(95)90042-X; Mittl PRE, 1997, J BIOL CHEM, V272, P6539, DOI 10.1074/jbc.272.10.6539; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rathmell JC, 1999, ANNU REV IMMUNOL, V17, P781, DOI 10.1146/annurev.immunol.17.1.781; Read SH, 2002, J CELL BIOL, V159, P739, DOI 10.1083/jcb.200209004; Renatus M, 2001, P NATL ACAD SCI USA, V98, P14250, DOI 10.1073/pnas.231465798; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; Sevignani C, 2003, CANCER RES, V63, P1183; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Stennicke HR, 1999, METHODS, V17, P313, DOI 10.1006/meth.1999.0745; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Talanian RV, 1996, J BIOL CHEM, V271, P21853, DOI 10.1074/jbc.271.36.21853; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Troy CM, 2003, CELL DEATH DIFFER, V10, P101, DOI 10.1038/sj.cdd.4401175; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Watt W, 1999, STRUCTURE, V7, P1135, DOI 10.1016/S0969-2126(99)80180-4; Wei YY, 2000, CHEM BIOL, V7, P423, DOI 10.1016/S1074-5521(00)00123-X; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0	48	85	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42441	42447		10.1074/jbc.M304895200	http://dx.doi.org/10.1074/jbc.M304895200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12920126	hybrid, Green Published			2022-12-25	WOS:000185989500108
J	Tanner, JA; Watt, RM; Chai, YB; Lu, LY; Lin, MC; Peiris, JSM; Poon, LLM; Kung, HF; Huang, JD				Tanner, JA; Watt, RM; Chai, YB; Lu, LY; Lin, MC; Peiris, JSM; Poon, LLM; Kung, HF; Huang, JD			The severe acute respiratory syndrome (SARS) coronavirus NTPase/helicase belongs to a distinct class of 5 ' to 3 ' viral helicases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATITIS-C VIRUS; MESSENGER-RNA SYNTHESIS; PRIMASE INHIBITORS; DOMAIN; ARTERIVIRUS; SEQUENCE; PROTEINS; INSIGHTS; THERAPY; DISEASE	The putative NTPase/helicase protein from severe acute respiratory syndrome coronavirus (SARS-CoV) is postulated to play a number of crucial roles in the viral life cycle, making it an attractive target for anti-SARS therapy. We have cloned, expressed, and purified this protein as an N-terminal hexahistidine fusion in Escherichia coli and have characterized its helicase and NTPase activities. The enzyme unwinds doublestranded DNA, dependent on the presence of a 5' single-stranded overhang, indicating a 5' to 3' polarity of activity, a distinct characteristic of coronaviridae helicases. We provide the first quantitative analysis of the polynucleic acid binding and NTPase activities of a Nidovirus helicase, using a high throughput phosphate release assay that will be readily adaptable to the future testing of helicase inhibitors. All eight common NTPs and dNTPs were hydrolyzed by the SARS helicase in a magnesium-dependent reaction, stimulated by the presence of either single-stranded DNA or RNA. The enzyme exhibited a preference for ATP, dATP, and dCTP over the other NTP/dNTP substrates. Homopolynucleotides significantly stimulated the ATPase activity ( 15 - 25-fold) with the notable exception of poly(G) and poly(dG), which were non-stimulatory. We found a large variation in the apparent strength of binding of different homopolynucleotides, with dT(24) binding over 10 times more strongly than dA(24) as observed by the apparent K-m.	Univ Hong Kong, Fac Med, Dept Biochem, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Queen Mary Hosp, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Inst Mol Biol, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong; University of Hong Kong	Huang, JD (corresponding author), Univ Hong Kong, Fac Med, Dept Biochem, Hong Kong, Hong Kong, Peoples R China.		Peiris, Joseph/C-4380-2009; Poon, Leo/AAP-6887-2020; Chai, Yubo/I-1896-2013; Chai, Yubo/AAP-5928-2020; Watt, Rory M./B-2177-2009; Poon, Leo Lit Man/C-4382-2009; Tanner, Julian A./C-4412-2009; /C-4277-2009	Chai, Yubo/0000-0002-2316-8071; Chai, Yubo/0000-0002-2316-8071; Watt, Rory M./0000-0002-8718-1988; Poon, Leo Lit Man/0000-0002-9101-7953; Tanner, Julian A./0000-0002-5459-1526; /0000-0001-7531-2816				Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658; Bautista EM, 2002, VIROLOGY, V298, P258, DOI 10.1006/viro.2002.1495; BAYKOV AA, 1988, ANAL BIOCHEM, V171, P266, DOI 10.1016/0003-2697(88)90484-8; Borowski P, 2002, ANTIVIR RES, V55, P397, DOI 10.1016/S0166-3542(02)00096-7; Borowski P, 2001, J VIROL, V75, P3220, DOI 10.1128/JVI.75.7.3220-3229.2001; Caruthers JM, 2002, CURR OPIN STRUC BIOL, V12, P123, DOI 10.1016/S0959-440X(02)00298-1; Crute JJ, 2002, NAT MED, V8, P386, DOI 10.1038/nm0402-386; Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747; Holmes KV, 2003, J CLIN INVEST, V111, P1605, DOI [10.1172/JCI18819, 10.1172/JCI200318819]; Kadare G, 1997, J VIROL, V71, P2583; Kalinina NO, 2002, VIROLOGY, V296, P321, DOI 10.1006/viro.2001.1328; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; Kleymann G, 2002, NAT MED, V8, P392, DOI 10.1038/nm0402-392; Kleymann G, 2003, EXPERT OPIN INV DRUG, V12, P165, DOI 10.1517/13543784.12.2.165; Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781; Lai MMC, 1997, ADV VIRUS RES, V48, P1, DOI 10.1016/S0065-3527(08)60286-9; Laity JH, 2001, CURR OPIN STRUC BIOL, V11, P39, DOI 10.1016/S0959-440X(00)00167-6; Li YI, 2001, J VIROL, V75, P12114, DOI 10.1128/JVI.75.24.12114-12120.2001; Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953; Pasternak AO, 2001, EMBO J, V20, P7220, DOI 10.1093/emboj/20.24.7220; Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2; Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952; Seybert A, 2000, J VIROL, V74, P9586, DOI 10.1128/JVI.74.20.9586-9593.2000; Seybert A, 2000, RNA, V6, P1056, DOI 10.1017/S1355838200000728; Thiel V, 2003, J GEN VIROL, V84, P2305, DOI 10.1099/vir.0.19424-0; van Dinten LC, 2000, J VIROL, V74, P5213, DOI 10.1128/JVI.74.11.5213-5223.2000; van Marle G, 1999, J VIROL, V73, P5274, DOI 10.1128/JVI.73.7.5274-5281.1999; Wardell AD, 1999, J GEN VIROL, V80, P701, DOI 10.1099/0022-1317-80-3-701; Yao NH, 1997, NAT STRUCT BIOL, V4, P463, DOI 10.1038/nsb0697-463; Ziebuhr J, 2000, J GEN VIROL, V81, P853, DOI 10.1099/0022-1317-81-4-853	30	133	148	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39578	39582		10.1074/jbc.C300328200	http://dx.doi.org/10.1074/jbc.C300328200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12917423	hybrid, Green Published			2022-12-25	WOS:000185713800040
J	Hirano, S; Tominaga, Y; Ichinoe, A; Ushijima, Y; Tsuchimoto, D; Honda-Ohnishi, Y; Ohtsubo, T; Sakumi, K; Nakabeppu, Y				Hirano, S; Tominaga, Y; Ichinoe, A; Ushijima, Y; Tsuchimoto, D; Honda-Ohnishi, Y; Ohtsubo, T; Sakumi, K; Nakabeppu, Y			Mutator phenotype of MUTYH-null mouse embryonic stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; SCHIZOSACCHAROMYCES-POMBE; NUCLEAR ANTIGEN; FISSION YEAST; DNA; PROTEINS; HOMOLOG; MYH; MUTATIONS; MITOCHONDRIA	To evaluate the antimutagenic role of a mammalian mutY homolog, namely the Mutyh gene, which encodes adenine DNA glycosylase excising adenine misincorporated opposite 8-oxoguanine in the template DNA, we generated MUTYH-null mouse embryonic stem (ES) cells. In the MUTYH-null cells carrying no adenine DNA glycosylase activity, the spontaneous mutation rate increased 2-fold in comparison with wild type cells. The expression of wild type mMUTYH or mutant mMUTYH protein with amino acid substitutions at the proliferating cell nuclear antigen binding motif restored the increased spontaneous mutation rates of the MUTYH-null ES cells to the wild type level. The expression of a mutant mMUTYH protein with an amino acid substitution (G365D) that corresponds to a germ-line mutation (G382D) found in patients with multiple colorectal adenomas could not suppress the elevated spontaneous mutation rate of the MUTYH-null ES cells. Although the recombinant mMUTYH(G365D) purified from Escherichia coli cells had a substantial level of adenine DNA glycosylase activity as did wild type MUTYH, no adenine DNA glycosylase activity was detected in the MUTYH-null ES cells expressing the mMUTYH(G365D) mutant protein. The germ-line mutation (G382D) of the human MUTYH gene is therefore likely to be responsible for the occurrence of a mutator phenotype in these patients.	Kyushu Univ, Med Inst Bioregulat, Div Neurofunct Genom, Fukuoka 8128582, Japan; Japan Sci & Technol Corp, CREST, Fukuoka 8128582, Japan	Kyushu University; Japan Science & Technology Agency (JST)	Nakabeppu, Y (corresponding author), Kyushu Univ, Med Inst Bioregulat, Div Neurofunct Genom, Fukuoka 8128582, Japan.		Nakabeppu, Yusaku/A-8902-2011; Sakumi, Kunihiko/G-4808-2011	Nakabeppu, Yusaku/0000-0002-6739-242X; 				Al-Tassan N, 2002, NAT GENET, V30, P227, DOI 10.1038/ng828; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; CAPIZZI RL, 1973, MUTAT RES, V17, P147, DOI 10.1016/0027-5107(73)90265-0; Chang DY, 2002, J BIOL CHEM, V277, P11853, DOI 10.1074/jbc.M111739200; Chang DY, 2001, MOL GENET GENOMICS, V266, P336, DOI 10.1007/s004380100567; Gu YS, 2002, J BIOL CHEM, V277, P11135, DOI 10.1074/jbc.M108618200; Hayashi H, 2002, CURR BIOL, V12, P335, DOI 10.1016/S0960-9822(02)00686-3; Ide Y, 2003, GENOMICS, V81, P47, DOI 10.1016/S0888-7543(02)00009-5; Kreegipuu A, 1999, NUCLEIC ACIDS RES, V27, P237, DOI 10.1093/nar/27.1.237; Luria SE, 1943, GENETICS, V28, P491; Nakabeppu Y, 2001, PROG NUCLEIC ACID RE, V68, P75; Ohtsubo T, 2000, NUCLEIC ACIDS RES, V28, P1355, DOI 10.1093/nar/28.6.1355; Parker A, 2001, J BIOL CHEM, V276, P5547, DOI 10.1074/jbc.M008463200; ROSSMAN TG, 1995, MUTAT RES-FUND MOL M, V328, P21, DOI 10.1016/0027-5107(94)00190-G; Rossman TG, 1997, MUTAT RES-FUND MOL M, V373, P75, DOI 10.1016/S0027-5107(96)00192-3; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; Sieber OM, 2003, NEW ENGL J MED, V348, P791, DOI 10.1056/NEJMoa025283; TAJIRI T, 1995, MUTAT RES-DNA REPAIR, V336, P257, DOI 10.1016/0921-8777(94)00062-B; Tsuchimoto D, 2001, NUCLEIC ACIDS RES, V29, P2349, DOI 10.1093/nar/29.11.2349; Tsuzuki T, 2001, P NATL ACAD SCI USA, V98, P11456, DOI 10.1073/pnas.191086798	20	76	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38121	38124		10.1074/jbc.C300316200	http://dx.doi.org/10.1074/jbc.C300316200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12917422	hybrid			2022-12-25	WOS:000185575100005
J	Elsasser, A; Franzen, M; Kohlmann, A; Weisser, M; Schnittger, S; Schoch, C; Reddy, VA; Burel, S; Zhang, DE; Ueffing, M; Tenen, DG; Hiddemann, W; Behre, G				Elsasser, A; Franzen, M; Kohlmann, A; Weisser, M; Schnittger, S; Schoch, C; Reddy, VA; Burel, S; Zhang, DE; Ueffing, M; Tenen, DG; Hiddemann, W; Behre, G			The fusion protein AML1-ETO in acute myeloid leukemia with translocation t(8;21) induces c-jun protein expression via the proximal AP-1 site of the c-jun promoter in an indirect, JNK-dependent manner	ONCOGENE			English	Article						AML1-ETO; c-jun; JNK1; AML; myeloid	COLONY-STIMULATING FACTOR; N-TERMINAL KINASE; HA-RAS GENE; TRANSCRIPTION FACTOR; C/EBP-ALPHA; GRANULOCYTIC DIFFERENTIATION; LINEAGE COMMITMENT; DOWN-REGULATION; DNA-BINDING; CELLS	Overexpression of proto-oncogene c-jun and constitutive activation of the Jun N-terminal kinase (JNK) signaling pathway have been implicated in the leukemic transformation process. However, c-jun expression and the role of the JNK signaling pathway have not been investigated in primary acute myeloid leukemia (AML) cells with frequently observed balanced rearrangements such as t(8;21). In the present study, we report elevated c-jun mRNA expression in AML patient bone marrow cells with t(8;21), t(15;17) or inv(16), and a high correlation in mRNA expression levels of AML1-ETO and c-jun within t(8;21)-positive AML patient cells. In myeloid U937 cells, c-jun mRNA and protein expression increase upon inducible expression of AML1-ETO. AML1-ETO transactivates the human c-jun promoter through the proximal activator protein (AP-1) site by activating the JNK pathway. Overexpression of JNK-inhibitor JIP-1 and chemical JNK inhibitors reduce the transactivation capacity of AML1-ETO on the c-jun promoter and the proapoptotic function of AML1-ETO in U937 cells. An autocrine mechanism involving granulocyte-colony stimulating factor (G-CSF) and G-CSF receptor (G-CSF-R) might participate in AML1-ETO mediated JNK-signaling, because AML1-ETO induces G-CSF and G-CSF-R expression, and G-CSF-R-neutralizing antibodies reduce AML1-ETO-induced JNK phosphorylation. These data suggest a model in which AML1-ETO induces protooncogene c-jun expression via the proximal AP-1 site of the c-jun promoter in a JNK-dependent manner.	Univ Munich, Univ Hosp Grosshadern, Dept Internal Med 3, Munich, Germany; GSF, Natl Res Ctr Environm & Hlth, D-81377 Munich, Germany; Scripps Res Inst, La Jolla, CA USA; Tech Univ, Inst Human Genet, D-81377 Munich, Germany; Harvard Univ, Sch Med, Harvard Inst Med, Boston, MA 02115 USA	University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; Scripps Research Institute; Technical University of Munich; Harvard University; Harvard Medical School	Behre, G (corresponding author), Univ Munich, Dept Internal Med 3, Marchioninistr 15, D-81377 Munich, Germany.			Tenen, Daniel/0000-0002-6423-3888	NATIONAL CANCER INSTITUTE [R01CA041456] Funding Source: NIH RePORTER; NCI NIH HHS [CA41456] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alcalay M, 2001, ONCOGENE, V20, P5680, DOI 10.1038/sj.onc.1204642; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; Baumann MA, 2001, AM J HEMATOL, V68, P99, DOI 10.1002/ajh.1160; Behre G, 1999, METHODS, V17, P231, DOI 10.1006/meth.1998.0733; Behre G, 1999, J BIOL CHEM, V274, P4939, DOI 10.1074/jbc.274.8.4939; Behre G, 1999, BIOTECHNIQUES, V26, P24, DOI 10.2144/99261bm03; Behre G, 2002, J BIOL CHEM, V277, P26293, DOI 10.1074/jbc.M202301200; Bloomfield CD, 2002, GENE CHROMOSOME CANC, V33, P362, DOI 10.1002/gcc.10046; Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77; BRADBURY D, 1992, LEUKEMIA, V6, P562; Braess J, 2001, BRIT J HAEMATOL, V113, P975, DOI 10.1046/j.1365-2141.2001.02866.x; Brandstetter T, 1998, INT J CANCER, V75, P847, DOI 10.1002/(SICI)1097-0215(19980316)75:6<847::AID-IJC6>3.0.CO;2-V; Burel SA, 2001, MOL CELL BIOL, V21, P5577, DOI 10.1128/MCB.21.16.5577-5590.2001; Burgess GS, 1998, BLOOD, V92, P2450, DOI 10.1182/blood.V92.7.2450.2450_2450_2460; Chiariello M, 2000, MOL CELL BIOL, V20, P1747, DOI 10.1128/MCB.20.5.1747-1758.2000; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Emig M, 1999, LEUKEMIA, V13, P1825, DOI 10.1038/sj.leu.2401566; Frank RC, 1999, ONCOGENE, V18, P1701, DOI 10.1038/sj.onc.1202459; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; Han ZN, 1999, J PHARMACOL EXP THER, V291, P124; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Katayama N, 1998, AM J HEMATOL, V58, P31, DOI 10.1002/(SICI)1096-8652(199805)58:1<31::AID-AJH6>3.0.CO;2-1; Kiaris H, 1999, ONCOGENE, V18, P7168, DOI 10.1038/sj.onc.1203213; Kohzaki H, 1999, ONCOGENE, V18, P4055, DOI 10.1038/sj.onc.1202735; KUROKAWA M, 1995, ONCOGENE, V11, P833; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Lou JR, 2000, ONCOGENE, V19, P2695, DOI 10.1038/sj.onc.1203588; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; Mulloy JC, 2002, BLOOD, V99, P15, DOI 10.1182/blood.V99.1.15; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Rangatia J, 2002, MOL CELL BIOL, V22, P8681, DOI 10.1128/MCB.22.24.8681-8694.2002; Rausch O, 1999, J BIOL CHEM, V274, P4096, DOI 10.1074/jbc.274.7.4096; Rausch O, 1997, MOL CELL BIOL, V17, P1170, DOI 10.1128/MCB.17.3.1170; Reddy VA, 2002, BLOOD, V100, P483, DOI 10.1182/blood.V100.2.483; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; Schoch C, 2002, P NATL ACAD SCI USA, V99, P10008, DOI 10.1073/pnas.142103599; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; Shimizu K, 2000, BLOOD, V96, P288, DOI 10.1182/blood.V96.1.288.013k05_288_296; SPINNER DM, 1995, INT J CANCER, V63, P423, DOI 10.1002/ijc.2910630321; STEIN B, 1992, PHOTOCHEM PHOTOBIOL, V55, P409, DOI 10.1111/j.1751-1097.1992.tb04255.x; Sueoka E, 1998, BRIT J HAEMATOL, V101, P737, DOI 10.1046/j.1365-2141.1998.00757.x; TANAKA T, 1995, MOL CELL BIOL, V15, P2383; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; Vangala RK, 2003, BLOOD, V101, P270, DOI 10.1182/blood-2002-04-1288; Wei P, 1998, MOL ENDOCRINOL, V12, P1322, DOI 10.1210/me.12.9.1322; Wong C, 1999, MOL CELL BIOL, V19, P1821; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Zada AAP, 2003, ONCOGENE, V22, P2296, DOI 10.1038/sj.onc.1206330	50	33	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2003	22	36					5646	5657		10.1038/sj.onc.1206673	http://dx.doi.org/10.1038/sj.onc.1206673			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944913				2022-12-25	WOS:000184865900014
J	Leaner, VD; Kinoshita, I; Birrer, MJ				Leaner, VD; Kinoshita, I; Birrer, MJ			AP-1 complexes containing cJun and JunB cause cellular transformation of Rat1a fibroblasts and share transcriptional targets	ONCOGENE			English	Article						cJun; JunB; JunD; transcriptional targets	ANCHORAGE-INDEPENDENT GROWTH; BREAST-CANCER CELLS; C-JUN; PROTEIN-KINASE; V-JUN; RAT-1A CELLS; EXPRESSION; CAVEOLIN-1; FOS; GENE	To investigate the role of individual Jun proteins in cell growth and transformation, we have used a doxycycline-inducible retroviral vector to regulate their expression in rat fibroblasts. AP-1 complexes enriched with cJun and JunB result in morphological alterations and anchorage-independent cell growth consistent with a transformation-like phenotype, whereas complexes enriched with JunD had an antiproliferative effect. These results suggest that genes regulated by both cJun and JunB are potentially involved in transformation and that they can be distinguished from those regulated by AP-1 complexes containing JunD. To identify genes regulated by cJun and JunB that may have a role in anchorage-independent growth, we investigated differential gene expression by each of the Jun family members using the Affymetrix Rat oligonucleotide microarray, RG_U34A containing approximately 8000 genes. Differentially regulated genes were identified and grouped for correlation with regulation by the different Jun proteins. A total of 33 candidate genes were found to be differentially regulated by both cJun and JunB and not by JunD. These genes have roles in cell metabolism, growth, signal transduction, migration and adhesion. We validated the differential regulation by cJun and JunB of 10 candidate genes by Northern blot analysis. Of these, eight were further characterized as potential direct targets of AP-1 regulation based on Northern blot results showing differential regulation that correlate with cJun expression. Our results show that inducible cJun and JunB expression result in anchorage-independent growth of Rat1a cells, distinct from JunD-expressing cells. This model system and a functional genomic approach enabled us to differentiate AP-1-regulated genes involved in transformation from AP-1-regulated genes known as bystander genes. This approach significantly reduces the number of bystanders and allows for the targeting of genes specifically involved in transformation.	NCI, Cell & Canc Biol Dept, NIH, Rockville, MD 20850 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Birrer, MJ (corresponding author), NCI, Cell & Canc Biol Dept, NIH, 9610 Med Ctr Dr,Room 300, Rockville, MD 20850 USA.							ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Briggs J, 2002, ONCOGENE, V21, P7077, DOI 10.1038/sj.onc.1205857; Buse P, 1999, J BIOL CHEM, V274, P7253, DOI 10.1074/jbc.274.11.7253; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; Cohen SB, 2001, ONCOGENE, V20, P141, DOI 10.1038/sj.onc.1204077; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; Fiucci G, 2002, ONCOGENE, V21, P2365, DOI 10.1038/sj.onc.1205300; Fu SL, 1999, P NATL ACAD SCI USA, V96, P5716, DOI 10.1073/pnas.96.10.5716; Hartl M, 2001, P NATL ACAD SCI USA, V98, P13601, DOI 10.1073/pnas.241451198; Henriet P, 2000, P NATL ACAD SCI USA, V97, P10026, DOI 10.1073/pnas.170290997; HIRAI SI, 1990, ONCOGENE, V5, P39; Ho CC, 2002, AM J PATHOL, V161, P1647, DOI 10.1016/S0002-9440(10)64442-2; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; Kato K, 2002, CANCER, V94, P929, DOI 10.1002/cncr.10329.abs; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; Kinoshita I, 2003, ONCOGENE, V22, P2710, DOI 10.1038/sj.onc.1206371; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; Li LK, 2001, CANCER RES, V61, P4386; LIM AL, 1994, MATRIX BIOL, V14, P21, DOI 10.1016/0945-053X(94)90026-4; Macian F, 2001, ONCOGENE, V20, P2476, DOI 10.1038/sj.onc.1204386; Maeshima Y, 2000, J BIOL CHEM, V275, P21340, DOI 10.1074/jbc.M001956200; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; Mechta-Grigoriou F, 2001, ONCOGENE, V20, P2378, DOI 10.1038/sj.onc.1204381; MELLSTROM B, 1991, ONCOGENE, V6, P1959; Mikosz CA, 2001, J BIOL CHEM, V276, P16649, DOI 10.1074/jbc.M010842200; NARANJO JR, 1991, ONCOGENE, V6, P223; Nishitani Junko, 2002, Cellular and Molecular Biology Online Papers, V48, pOL331; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; Passegue E, 2002, NAT GENET, V30, P158, DOI 10.1038/ng790; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; RYSECK RP, 1991, ONCOGENE, V6, P533; Sambrook J., 2002, MOL CLONING LAB MANU; Schorpp-Kistner M, 1999, EMBO J, V18, P934, DOI 10.1093/emboj/18.4.934; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; Semb H, 1998, AM J HUM GENET, V63, P1588, DOI 10.1086/302173; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Thepot D, 2000, DEVELOPMENT, V127, P143; Timme TL, 2000, ONCOGENE, V19, P3256, DOI 10.1038/sj.onc.1203654; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; Vial E, 2000, ONCOGENE, V19, P5020, DOI 10.1038/sj.onc.1203867; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Watsuji T, 1997, BIOCHEM BIOPH RES CO, V234, P769, DOI 10.1006/bbrc.1997.6705; WEBSTER MK, 1993, J BIOL CHEM, V268, P11482; Weinstein J, 1997, J BIOL CHEM, V272, P28501, DOI 10.1074/jbc.272.45.28501; WEINSTEIN J, 1994, MOL CELL BIOL, V14, P3350, DOI 10.1128/MCB.14.5.3350; Wilson E, 2002, ATHEROSCLEROSIS, V162, P289, DOI 10.1016/S0021-9150(01)00718-3; Zarka TA, 2003, INT J GYNECOL CANCER, V13, P240, DOI 10.1136/ijgc-00009577-200303000-00024; Zhong Y, 2001, CLIN CANCER RES, V7, P1683	55	44	48	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2003	22	36					5619	5629		10.1038/sj.onc.1206644	http://dx.doi.org/10.1038/sj.onc.1206644			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944910				2022-12-25	WOS:000184865900011
J	Mulholland, DJ; Read, JT; Rennie, PS; Cox, ME; Nelson, CC				Mulholland, DJ; Read, JT; Rennie, PS; Cox, ME; Nelson, CC			Functional localization and competition between the androgen receptor and T-cell factor for nuclear beta-catenin: a means for inhibition of the Tcf signaling axis	ONCOGENE			English	Article						androgen receptor; prostate cancer; coactivator; Tcf signaling; beta-catenin	TRANSCRIPTIONAL ACTIVITY; PROSTATE-CANCER; HORMONE-RECEPTORS; ACTIVATION; PROTEIN; PATHWAY; COMPLEX; GROWTH; TRANSLOCATION; COACTIVATORS	Recent reports suggest that the beta-catenin-T-cell factor (Tcf) (BCT) signaling pathway is important in the progression of prostate cancer. Evidence suggests that the androgen receptor (AR) can repress BCT-mediated transcription both in prostate cancer and colon cancer cells (Chesire and Isaacs, 2002). In this study, we validate such findings and show that repression of BCT signaling is facilitated by competition between the AR and Tcf. Measurements of the Tcf transcriptional reporter (TOPFLASH) indicated that AR+DHT-mediated repression can inhibit BCT transcription in the presence of WT and exogenous activating beta-catenin (Delta1-130bp). Transient transfections in SW480 cells (APC(mut/mut)) showed that this mode of repression is functionally independent of APC-mediated beta-catenin ubiquitination. Using a recently developed red flourescent protein (HcRed), we demonstrate novel observations about the nuclear distribution of Tcf. Furthermore, with the use of red (HeRed-AR and HcRed-Tcf) and green fusion proteins (beta-catenin-EGFP), we provide morphological evidence of a reciprocal balance of nuclear beta-catenin-EGFP (BC-EGFP). By cotransfecting in LNCaP prostate tumor cells and using quantitative imaging software, we demonstrated a 62.0% colocalization of HcRed-AR and BC-EGFP in the presence of DHT and 63.3% colocalization of HcRed-Tcf/BC-EGFP in the absence of DHT. Costaining for activated RNA Pol II (phosphoserine 2) and HcRed-Tcf suggested that Tcf foci contain transcriptional 'hotspots' validating that these sites have the capacity for transcriptional activity. Given this apparent androgen-dependent competition for nuclear BC-EGFP, we chose to assess our hypothesis by in vivo and in vitro binding assays. SW480 cells transiently transfected with an AR expression construct, treated with DHT and immunoprecipitated for Tcf showed less associated beta-catenin when compared to Tcf precipitates from untreated cells. Furthermore, by treating cells with DHT+Casodex, we were able to abrogate the androgen-sensitive AR/beta-catenin interaction, in addition to relieving transcriptional repression of the TOPFLASH reporter. In vitro binding assays, with increasing amounts of AR(S35), resulted in decreased Tcf(S35) association with immunoprecipitated recombinant beta-catenin-HIS. These data suggest that in steady-state conditions, AR has the ability to compete out Tcf binding for beta-catenin. Finally, using SW480 cells, we show that AR-mediated repression of the BCT pathway has implications for cell cycle progression and in vitro growth. Using FACs analysis, we observed a 26.1% increase in accumulation of cells in the G1 phase of the cell cycle, while in vitro growth assays showed a 35% reduction in viable cells transfected with AR+DHT treatment. Together, our data strongly suggest that a reciprocal balance of nuclear beta-catenin facilitates AR-mediated repression of BCT-driven transcription and cell growth.	Jack Bell Res, Prostate Ctr, Vancouver, BC V6H 3Z6, Canada	University of British Columbia	Mulholland, DJ (corresponding author), Jack Bell Res, Prostate Ctr, Vancouver, BC V6H 3Z6, Canada.							Barker N, 2000, ADV CANCER RES, V77, P1; Barnes DM, 1998, BREAST CANCER RES TR, V52, P1, DOI 10.1023/A:1006103831990; Cairns P, 1997, CANCER RES, V57, P4997; CARLSSON P, 1993, GENE DEV, V7, P2418, DOI 10.1101/gad.7.12a.2418; Catalano MG, 2000, INT J CANCER, V86, P325, DOI 10.1002/(SICI)1097-0215(20000501)86:3<325::AID-IJC4>3.0.CO;2-G; Chen RH, 2001, CANCER RES, V61, P4445; Chesire DR, 2002, ONCOGENE, V21, P8453, DOI 10.1038/sj.onc.1206049; Chesire DR, 2002, ONCOGENE, V21, P2679, DOI 10.1038/sj.onc.1205352; Chesire DR, 2000, PROSTATE, V45, P323, DOI 10.1002/1097-0045(20001201)45:4<323::AID-PROS7>3.0.CO;2-W; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; Davies MA, 1999, CANCER RES, V59, P2551; Easwaran V, 1999, CURR BIOL, V9, P1415, DOI 10.1016/S0960-9822(00)80088-3; Giannini AL, 2000, EXP CELL RES, V255, P207, DOI 10.1006/excr.1999.4785; GLEAVE M, 1991, CANCER RES, V51, P3753; Helmbrecht K, 2001, ENDOCRINOLOGY, V142, P5261, DOI 10.1210/en.142.12.5261; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; Janne OA, 2000, BIOCHEM SOC T, V28, P401, DOI 10.1042/0300-5127:0280401; Knop M, 2002, BIOTECHNIQUES, V33, P592, DOI 10.2144/02333rr02_11819a; Knudsen KE, 1999, CANCER RES, V59, P2297; Miller LD, 2001, MOL CELL BIOL, V21, P6626, DOI 10.1128/MCB.21.19.6626-6639.2001; Mulholland DJ, 2002, J BIOL CHEM, V277, P17933, DOI 10.1074/jbc.M200135200; Pawlowski JE, 2002, J BIOL CHEM, V277, P20702, DOI 10.1074/jbc.M200545200; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Polakis P, 2001, CELL, V105, P563, DOI 10.1016/S0092-8674(01)00379-8; QUIGLEY CA, 1995, ENDOCR REV, V16, P271, DOI 10.1210/er.16.3.271; Rivera OJ, 2003, MOL ENDOCRINOL, V17, P128, DOI 10.1210/me.2002-0165; Saitoh M, 2002, MOL ENDOCRINOL, V16, P694, DOI 10.1210/me.16.4.694; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; Schulman IG, 1996, MOL CELL BIOL, V16, P3807; Shtutman Michael, 2002, Cancer Research, V62, P5947; Simcha I, 1998, J CELL BIOL, V141, P1433, DOI 10.1083/jcb.141.6.1433; Snoek R, 1996, J STEROID BIOCHEM, V59, P243, DOI 10.1016/S0960-0760(96)00116-1; Song LN, 2003, MOL CELL BIOL, V23, P1674, DOI 10.1128/MCB.23.5.1674-1687.2003; Tomura A, 2001, J BIOL CHEM, V276, P28395, DOI 10.1074/jbc.M101755200; Truica CI, 2000, CANCER RES, V60, P4709; Yang FJ, 2002, J BIOL CHEM, V277, P11336, DOI 10.1074/jbc.M111962200; Yeh Shuyuan, 1999, Keio Journal of Medicine, V48, P87	37	97	98	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2003	22	36					5602	5613		10.1038/sj.onc.1206802	http://dx.doi.org/10.1038/sj.onc.1206802			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944908				2022-12-25	WOS:000184865900009
J	Larijani, B; Hume, AN; Tarafder, AK; Seabra, MC				Larijani, B; Hume, AN; Tarafder, AK; Seabra, MC			Multiple factors contribute to inefficient prenylation of Rab27a in Rab prenylation diseases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GERANYLGERANYL TRANSFERASE; ESCORT PROTEIN; GUNMETAL MOUSE; SMALL GTPASES; BINDING; CHOROIDEREMIA; DISSOCIATION; MECHANISM; ASSOCIATION; RESOLUTION	Post-translational geranylgeranylation of Rab GTPases is essential for their membrane association and function as regulators of intracellular vesicular transport. The reaction is catalyzed by Rab geranylgeranyltransferase (RGGT) and is assisted by the Rab escort proteins ( REP), which form stable complexes with newly synthesized GDP-bound Rabs. Two genetic diseases involve the Rab geranylgeranylation machinery: choroideremia, an X-linked retinal degeneration resulting from loss-of-function mutations in REP1, and gunmetal, a mouse model of Hermansky-Pudlak syndrome resulting from mutations in the alpha-subunit of RGGT. A small subset of Rab proteins is selectively under-prenylated in both diseases, most notably Rab27a. Here we analyze why Rab27a is selectively affected in diseases of Rab geranylgeranylation. Semi-quantitative immunoblotting suggests that mass action, i.e. the amount of Rab27a relative to other Rabs, is unlikely to be a factor as the expression level of Rab27a is similar to other Rabs not affected in these diseases. In vitro binding assays and fluorescence resonance energy transfer detected by fluorescence lifetime imaging microscopy in intact cells demonstrate that Rab27a binds equally well to both REP1 and REP2, suggesting differential affinity of Rab27a for REP isoforms is not an important factor. However, steady-state kinetic analysis of the geranylgeranylation reaction indicates that REP2-Rab27a has lower affinity for RGGT compared with REP1-Rab27a. Furthermore, we show that Rab27a has relatively low GTPase activity, presumably decreasing the affinity of the REP interaction in vivo. We suggest that the restricted phenotypes observed in these diseases result from multiple contributing factors.	Univ London Imperial Coll Sci Technol & Med, Fac Med, Div Biomed Sci, London SW7 2AZ, England; Canc Res UK, London Res Inst, Cell Biophys Lab, London WC2A 3PX, England	Imperial College London; Cancer Research UK	Seabra, MC (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Div Biomed Sci, Sir Alexander Fleming Bldg, London SW7 2AZ, England.	m.seabra@imperial.ac.uk	Larijani, Banafshe/H-3909-2015; Seabra, Miguel/AAC-3099-2019; Seabra, Miguel C/M-3280-2013	Larijani, Banafshe/0000-0003-4735-1169; Seabra, Miguel C/0000-0002-6404-4892; Tarafder, Abul/0000-0002-0368-6111; Hume, Alistair/0000-0001-9443-1087				ALEXANDROV K, 1994, EMBO J, V13, P5262, DOI 10.1002/j.1460-2075.1994.tb06860.x; Alexandrov K, 1998, FEBS LETT, V425, P460, DOI 10.1016/S0014-5793(98)00290-7; Anant JS, 1998, BIOCHEMISTRY-US, V37, P12559, DOI 10.1021/bi980881a; ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; Arland V, 2003, VISION RES, V43, P919, DOI 10.1016/S0042-6989(02)00389-9; ARMSTRONG SA, 1995, METHOD ENZYMOL, V257, P30; CREMERS FPM, 1994, J BIOL CHEM, V269, P2111; Desnoyers L, 1998, P NATL ACAD SCI USA, V95, P12266, DOI 10.1073/pnas.95.21.12266; Detter JC, 2000, P NATL ACAD SCI USA, V97, P4144, DOI 10.1073/pnas.080517697; FARNSWORTH CC, 1994, P NATL ACAD SCI USA, V91, P11963, DOI 10.1073/pnas.91.25.11963; Gomes AQ, 2003, MOL BIOL CELL, V14, P1882, DOI 10.1091/mbc.E02-10-0639; Hughes WE, 2002, J BIOL CHEM, V277, P22974, DOI 10.1074/jbc.M201391200; Larijani B, 2003, CURR BIOL, V13, P78, DOI 10.1016/S0960-9822(02)01395-7; Liang ZM, 2000, BIOCHEM J, V346, P501, DOI 10.1042/0264-6021:3460501; Long SB, 2002, NATURE, V419, P645, DOI 10.1038/nature00986; Pereira-Leal JB, 2003, BIOCHEM BIOPH RES CO, V301, P92, DOI 10.1016/S0006-291X(02)02963-7; Pereira-Leal JB, 2001, FEBS LETT, V498, P197, DOI 10.1016/S0014-5793(01)02483-8; Pereira-Leal Jose B, 2002, Methods Mol Biol, V189, P157; Pfeffer SR, 2001, TRENDS CELL BIOL, V11, P487, DOI 10.1016/S0962-8924(01)02147-X; Seabra MC, 2002, TRENDS MOL MED, V8, P23, DOI 10.1016/S1471-4914(01)02227-4; SEABRA MC, 1993, SCIENCE, V259, P377, DOI 10.1126/science.8380507; SEABRA MC, 1995, J BIOL CHEM, V270, P24420, DOI 10.1074/jbc.270.41.24420; Seabra MC, 1996, OPHTHALMIC GENET, V17, P43, DOI 10.3109/13816819609057869; Seabra MC, 1996, J BIOL CHEM, V271, P14398, DOI 10.1074/jbc.271.24.14398; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; Seabra MC, 1998, METH MOL B, V84, P251; SEABRA MC, 2000, ENZYMES, V21, P131; Segev N, 2001, CURR OPIN CELL BIOL, V13, P500, DOI 10.1016/S0955-0674(00)00242-8; SHAPIRO AD, 1993, J BIOL CHEM, V268, P6925; Shen F, 1996, J BIOL CHEM, V271, P3692; Simon I, 1996, J BIOL CHEM, V271, P20470, DOI 10.1074/jbc.271.34.20470; Thoma NH, 2001, J BIOL CHEM, V276, P48631, DOI 10.1074/jbc.M106470200; Thoma NH, 2001, BIOCHEMISTRY-US, V40, P268, DOI 10.1021/bi002034p; Thoma NH, 2001, J BIOL CHEM, V276, P48637, DOI 10.1074/jbc.M108241200; Wilson AL, 1996, J BIOL CHEM, V271, P10932, DOI 10.1074/jbc.271.18.10932; YOKOYAMA K, 2000, LIPID MODIFICATIONS, V21, P106; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055; Zhang H, 2000, STRUCTURE, V8, P241, DOI 10.1016/S0969-2126(00)00102-7; Zhang Q, 2002, BRIT J HAEMATOL, V117, P414, DOI 10.1046/j.1365-2141.2002.03444.x	39	60	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46798	46804		10.1074/jbc.M307799200	http://dx.doi.org/10.1074/jbc.M307799200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12941939	hybrid			2022-12-25	WOS:000186569400071
J	George, KM; Schule, T; Sandoval, LE; Jennings, LL; Taylor, P; Thompson, CM				George, KM; Schule, T; Sandoval, LE; Jennings, LL; Taylor, P; Thompson, CM			Differentiation between acetylcholinesterase and the organophosphate-inhibited form using antibodies and the correlation of antibody recognition with reactivation mechanism and rate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BUTYRYLCHOLINESTERASE; CHOLINESTERASES; ISOMALATHION; EXPRESSION; PRODUCTS; KINETICS; SITE	Two types of polyclonal antibodies were generated from (a) a decapeptide sequence that includes the active site serine of acetylcholinesterase (anti-AChE(10S)) and (b) the identical decapeptide sequence phosphorylated at the active site serine of acetylcholinesterase (anti-AChE(10SP)). The anti-AChE(10S) antiserum was found to specifically recognize native, control, and vehicle-treated recombinant mouse AChE (rMoAChE) but did not recognize rMoAChE that was phosphorylated by the four organophosphate (OP) compounds tested. Conversely the anti-AChE(10SP) antiserum recognized phosphoserine rMoAChE that resulted from reaction with phosphorous oxychloride (POCl3) but did not recognize native or vehicle-treated rMoAChE. Anti-AChE(10SP) also did not recognize OP-AChE conjugates that resulted from the reaction of rMoAChE with other OP compounds that afford neutral or monoanionic phosphoserine groups thereby indicating a high specificity for a precise OP conjugate. Antisera recognition correlated well with the rates of enzyme inhibition, aging, and oxime-induced reactivation indicating these antisera can both quantify the extent and type of inhibition and also differentiate between select mechanisms of inhibition. The ability to discern mechanistic differences between native AChE and OP-AChE conjugates suggests that these antisera can be used to identify biomarkers of OP exposure in a mechanism-based approach.	Univ Montana, Ctr Environm Hlth Sci, Missoula, MT 59812 USA; Univ Montana, Ctr Struct & Funct Neurosci, Missoula, MT 59812 USA; Univ Montana, Dept Biomed & Pharmaceut Sci, Missoula, MT 59812 USA; Univ Calif San Diego, Sch Med, Dept Pharmacol, La Jolla, CA 92093 USA	University of Montana System; University of Montana; University of Montana System; University of Montana; University of Montana System; University of Montana; University of California System; University of California San Diego	Thompson, CM (corresponding author), Univ Montana, Ctr Environm Hlth Sci, Missoula, MT 59812 USA.	cmthomp@selway.umt.edu	Jennings, Lori/R-7152-2019					ASHANI Y, 1990, BIOCHEMISTRY-US, V29, P2456, DOI 10.1021/bi00462a004; Barak R, 1997, FEBS LETT, V407, P347, DOI 10.1016/S0014-5793(97)00375-X; Barnes JM, 1999, INT ARCH OCC ENV HEA, V72, pM68, DOI 10.1007/PL00014219; BERKMAN CE, 1993, CHEM RES TOXICOL, V6, P28, DOI 10.1021/tx00031a004; BERKMAN CE, 1993, CHEM RES TOXICOL, V6, P724, DOI 10.1021/tx00035a019; Carr RL, 1996, TOXICOL APPL PHARM, V139, P365, DOI 10.1006/taap.1996.0177; CHATEL JM, 1993, P NATL ACAD SCI USA, V90, P2476, DOI 10.1073/pnas.90.6.2476; Doorn JA, 2001, TOXICOL APPL PHARM, V176, P73, DOI 10.1006/taap.2001.9279; Elhanany E, 2001, CHEM RES TOXICOL, V14, P912, DOI 10.1021/tx0100542; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; FRANK AW, 1984, CRC CR REV BIOCH MOL, V16, P51, DOI 10.3109/10409238409102806; FUKUTO TR, 1990, ENVIRON HEALTH PERSP, V87, P245, DOI 10.2307/3431032; GENTRY MK, 1993, CHEM-BIOL INTERACT, V87, P227, DOI 10.1016/0009-2797(93)90046-2; GENTRY MK, 1995, J NEUROCHEM, V64, P842; George KM, 2002, TOXICOL LETT, V126, P99, DOI 10.1016/S0378-4274(01)00449-0; HARLOW E, 1998, ANTIBODIES LAB MANUA, P471; JARV J, 1984, BIOORG CHEM, V12, P259, DOI 10.1016/0045-2068(84)90010-5; Jianmongkol S, 1999, TOXICOL APPL PHARM, V155, P43, DOI 10.1006/taap.1998.8608; Lessenger J E, 1999, J Am Board Fam Pract, V12, P307; Marchot P, 1996, PROTEIN SCI, V5, P672; Millard CB, 1999, BIOCHEMISTRY-US, V38, P7032, DOI 10.1021/bi982678l; OGERT RA, 1990, J NEUROCHEM, V55, P756, DOI 10.1111/j.1471-4159.1990.tb04556.x; Ordentlich A, 1996, J BIOL CHEM, V271, P11953, DOI 10.1074/jbc.271.20.11953; QUINN DM, 1987, CHEM REV, V87, P955, DOI 10.1021/cr00081a005; Quistad GB, 2000, CHEM RES TOXICOL, V13, P652, DOI 10.1021/tx000028o; REIGART JR, 1999, PUBLICATION USEPA; SEGALL Y, 1993, BIOCHEMISTRY-US, V32, P13441, DOI 10.1021/bi00212a009; Simon S, 1997, J BIOL CHEM, V272, P33045, DOI 10.1074/jbc.272.52.33045; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; THOMPSON CM, 1992, J AM CHEM SOC, V114, P10710, DOI 10.1021/ja00053a005; WASSERMAN L, 1993, J NEUROCHEM, V61, P2124, DOI 10.1111/j.1471-4159.1993.tb07450.x; Wierdl M, 2000, BIOCHEM PHARMACOL, V59, P773, DOI 10.1016/S0006-2952(99)00389-5; Wilson BH, 1992, ORGANOPHOSPHATES CHE, P107; WILSON BW, 1992, REV ENVIRON CONTAM T, V128, P55; Worek F, 1999, ARCH TOXICOL, V73, P7, DOI 10.1007/s002040050580	35	26	29	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45512	45518		10.1074/jbc.M304781200	http://dx.doi.org/10.1074/jbc.M304781200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12933813	hybrid			2022-12-25	WOS:000186452300058
J	Searfoss, GH; Jordan, WH; Calligaro, DO; Galbreath, EJ; Schirtzinger, LM; Berridge, BR; Gao, H; Higgins, MA; May, PC; Ryan, TP				Searfoss, GH; Jordan, WH; Calligaro, DO; Galbreath, EJ; Schirtzinger, LM; Berridge, BR; Gao, H; Higgins, MA; May, PC; Ryan, TP			Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional gamma-secretase inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; AMYLOID PRECURSOR PROTEIN; CELL-DIFFERENTIATION; ADIPOSE-TISSUE; NOTCH; GENE; INTESTINE; DOMAIN; ADIPOGENESIS; PRESENILINS	Functional gamma-secretase inhibitors (FGSIs) can block the cleavage of several transmembrane proteins including amyloid precursor protein (APP), and the cell fate regulator Notch-1. FGSIs, by inhibiting APP processing, block the generation of amyloid beta (Abeta) peptides and may slow the development of Alzheimer's disease. FGSIs used to inhibit APP processing may disrupt Notch processing, thus interfering with cell fate determination. Described herein is a FGSI-mediated gastrointestinal toxicity characterized by cell population changes in the ileum of rats, which are indicative of Notch signaling disruption. Microarray analysis of ileum from FGSI-treated rats revealed differential expression responses in a number of genes indicative of Notch signaling perturbation, including the serine protease adipsin. We were able to show that FGSI-treated rats had elevated levels of adipsin protein in gastrointestinal contents and feces, and by immunohistochemistry demonstrated that adipsin containing ileum crypt cells were increased in FGSI-treated rats. The mouse Adipsin proximal promoter contains a putative binding site for the Notch-induced transcriptional regulator Hes-1, which we demonstrate is able to bind Hes-1. Additional studies in 3T3-L1 preadipocytes demonstrate that this FGSI inhibits Hes-1 expression while up-regulating adipsin expression. Overexpression of Hes-1 was able to down-regulate adipsin expression and block pre-adipocyte differentiation. We propose that adipsin is a Hes-1-regulated gene that is de-repressed during FGSI-mediated disruption of Notch/Hes-1 signaling. Additionally, the aberrant expression of adipsin, and its presence in feces may serve as a noninvasive biomarker of gastrointestinal toxicity associated with perturbed Notch signaling.	Lilly Res Labs, Dept Lead Optimizat Toxicol, Greenfield, IN 46140 USA; Lilly Res Labs, Dept Pathol, Greenfield, IN 46140 USA; Lilly Res Labs, Dept Invest Toxicol, Greenfield, IN 46140 USA; Lilly Res Labs, Dept BioRTP, Greenfield, IN 46140 USA; Lilly Res Labs, Dept Neurosci, Greenfield, IN 46140 USA	Eli Lilly; Eli Lilly; Eli Lilly; Eli Lilly; Eli Lilly	Ryan, TP (corresponding author), Lilly Res Labs, Dept Lead Optimizat Toxicol, Greenfield, IN 46140 USA.	timryan@lilly.com		Galbreath, Elizabeth/0000-0003-0162-8329				Apelqvist A, 1999, NATURE, V400, P877, DOI 10.1038/23716; BAKER BC, 1991, BIOCHEM J, V279, P775, DOI 10.1042/bj2790775; BALKE N, 1995, FEBS LETT, V371, P300, DOI 10.1016/0014-5793(95)00926-Z; Beher D, 2001, J BIOL CHEM, V276, P45394, DOI 10.1074/jbc.M103075200; BJARNASON I, 1994, PHARMACOL THERAPEUT, V62, P145, DOI 10.1016/0163-7258(94)90008-6; Bray S, 1998, CELL, V93, P499, DOI 10.1016/S0092-8674(00)81180-0; Chan YM, 1999, NEURON, V23, P201, DOI 10.1016/S0896-6273(00)80771-0; Chen FS, 2002, J BIOL CHEM, V277, P36521, DOI 10.1074/jbc.M205093200; CHENG H, 1974, AM J ANAT, V141, P537, DOI 10.1002/aja.1001410407; COOK KS, 1987, SCIENCE, V237, P402, DOI 10.1126/science.3299705; DAVIES NM, 1995, DIS COLON RECTUM, V38, P1311, DOI 10.1007/BF02049158; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; Deftos ML, 2000, IMMUNITY, V13, P73, DOI 10.1016/S1074-7613(00)00009-1; Doerfler P, 2001, P NATL ACAD SCI USA, V98, P9312, DOI 10.1073/pnas.161102498; Dovey HF, 2001, J NEUROCHEM, V76, P173, DOI 10.1046/j.1471-4159.2001.00012.x; Fisher AL, 1996, MOL CELL BIOL, V16, P2670; Fortini ME, 2002, NAT REV MOL CELL BIO, V3, P673, DOI 10.1038/nrm910; Garces C, 1997, J BIOL CHEM, V272, P29729, DOI 10.1074/jbc.272.47.29729; Hoyne GF, 2000, IMMUNOLOGY, V100, P281, DOI 10.1046/j.1365-2567.2000.00073.x; Iso T, 2002, J BIOL CHEM, V277, P6598, DOI 10.1074/jbc.M110495200; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jarriault S, 1998, MOL CELL BIOL, V18, P7423, DOI 10.1128/MCB.18.12.7423; Jensen J, 2000, NAT GENET, V24, P36, DOI 10.1038/71657; Kageyama R, 2000, MOL CELLS, V10, P1, DOI 10.1007/s10059-000-0001-0; Kao LC, 2002, ENDOCRINOLOGY, V143, P2119, DOI 10.1210/en.143.6.2119; Lee CS, 2002, GENE DEV, V16, P1488, DOI 10.1101/gad.985002; Mills JC, 2001, P NATL ACAD SCI USA, V98, P12334, DOI 10.1073/pnas.231487198; Miner JL, 2001, PROTEIN EXPRES PURIF, V23, P14, DOI 10.1006/prep.2001.1482; Moldes M, 1997, MOL CELL BIOL, V17, P1796, DOI 10.1128/MCB.17.4.1796; NEWBERNE PM, 1988, TOXICOL PATHOL, V16, P184, DOI 10.1177/019262338801600211; Palaparti A, 1997, J BIOL CHEM, V272, P26604, DOI 10.1074/jbc.272.42.26604; Seiffert D, 2000, J BIOL CHEM, V275, P34086, DOI 10.1074/jbc.M005430200; Skipper M, 2000, NAT GENET, V24, P3, DOI 10.1038/71653; Soukas A, 2001, J BIOL CHEM, V276, P34167, DOI 10.1074/jbc.M104421200; Suh E, 1996, MOL CELL BIOL, V16, P619; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; WHITE RT, 1992, J BIOL CHEM, V267, P9210; WILKISON WO, 1990, J BIOL CHEM, V265, P477; Wolfe MS, 2001, J BIOL CHEM, V276, P5413, DOI 10.1074/jbc.R000026200; WU J, 1998, Patent No. [09828268, 9828268]; Yang Q, 2001, SCIENCE, V294, P2155, DOI 10.1126/science.1065718; Zheng JL, 2000, DEVELOPMENT, V127, P4551	42	277	292	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					46107	46116		10.1074/jbc.M307757200	http://dx.doi.org/10.1074/jbc.M307757200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12949072	hybrid			2022-12-25	WOS:000186452300128
J	Tetaud, C; Falguieres, T; Carlier, K; Lecluse, Y; Garibal, J; Coulaud, D; Busson, P; Steffensen, R; Clausen, H; Johannes, L; Wiels, J				Tetaud, C; Falguieres, T; Carlier, K; Lecluse, Y; Garibal, J; Coulaud, D; Busson, P; Steffensen, R; Clausen, H; Johannes, L; Wiels, J			Two distinct Gb3/CD77 signaling pathways leading to apoptosis are triggered by anti-Gb3/CD77 mAb and verotoxin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BURKITTS-LYMPHOMA CELLS; CYTOCHROME-C RELEASE; SHIGA TOXIN; RETROGRADE TRANSPORT; INDUCE APOPTOSIS; ENDOTHELIAL-CELLS; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; B-SUBUNIT; ACTIVATION	Globotriasosylceramide (Gb3), a neutral glycosphingolipid, is the B-cell differentiation antigen CD77 and acts as the receptor for most Shiga toxins, including verotoxin-1 (VT-1). We have shown that both anti-Gb3/CD77 mAb and VT-1 induce apoptosis in Burkitt's lymphoma cells. We compared the apoptotic pathways induced by these two molecules by selecting cell lines sensitive to only one of these inducers or to both. In all these cell lines (including the apoptosis-resistant line), VT-1 was transported to the endoplasmic reticulum and inhibited protein synthesis similarly, suggesting that VT-1-induced apoptosis is dissociated from these processes. VT-1 triggered a caspase- and mitochondria-dependent pathway (rapid activation of caspases 8 and 3 associated with a loss of mitochondrial membrane potential (Deltapsi(m)) and the release of cytochrome c from mitochondria). In contrast, the anti-Gb3/CD77 mAb-induced pathway was caspase- independent and only involved partial depolarization of mitochondria. Antioxidant compounds had only marginal effects on VT-1-induced apoptosis but strongly protected cells from anti-Gb3/CD77 mAb-induced apoptosis. VT-1- and anti-Gb3/CD77 mAb-treated cells displayed very different features on electron microscopy. These results clearly indicate that the binding of different ligands to Gb3/CD77 triggers completely different apoptotic pathways.	Inst Gustave Roussy, CNRS, UMR 8126, Lab Interact Mol & Canc, F-94805 Villejuif, France; Inst Curie, Unite Mixte Rech 144, F-75248 Paris 05, France; Inst Gustave Roussy, Serv Commun Cytometrie, Inst Federat Rech 54, F-94805 Villejuif, France; Univ Copenhagen, Sch Dent, DK-2200 Copenhagen N, Denmark	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); Sorbonne Universite; UNICANCER; Gustave Roussy; University of Copenhagen	Wiels, J (corresponding author), Inst Gustave Roussy, CNRS, UMR 8126, Lab Interact Mol & Canc, Rue Camille Desmoulins, F-94805 Villejuif, France.		Johannes, Ludger/W-8593-2019; Wiels, Joëlle/AGL-2319-2022; Johannes, Ludger/M-9778-2017; clausen, henrik/AAD-8016-2021	Johannes, Ludger/0000-0002-2168-0004; Wiels, Joëlle/0000-0002-3313-2937; Johannes, Ludger/0000-0002-2168-0004; Falguieres, Thomas/0000-0003-2867-0500; Busson, Pierre/0000-0003-1027-3400; Clausen, Henrik/0000-0002-0915-5055; Garibal, Julie/0000-0002-6583-0561				ABE A, 1992, J BIOCHEM-TOKYO, V111, P191, DOI 10.1093/oxfordjournals.jbchem.a123736; Andrieu-Abadie N, 2001, FREE RADICAL BIO MED, V31, P717, DOI 10.1016/S0891-5849(01)00655-4; Arab S, 1998, J NEURO-ONCOL, V40, P137, DOI 10.1023/A:1006010019064; Arab S, 1998, J CELL PHYSIOL, V177, P646, DOI 10.1002/(SICI)1097-4652(199812)177:4<646::AID-JCP15>3.0.CO;2-B; Brigotti M, 2002, FASEB J, V16, DOI 10.1096/fj.01-0521com; Chandra J, 2000, FREE RADICAL BIO MED, V29, P323, DOI 10.1016/S0891-5849(00)00302-6; Ching JCY, 2002, INFECT IMMUN, V70, P4669, DOI 10.1128/IAI.70.8.4669-4677.2002; Deas O, 1997, INT IMMUNOL, V9, P117, DOI 10.1093/intimm/9.1.117; ENDO Y, 1988, EUR J BIOCHEM, V171, P45, DOI 10.1111/j.1432-1033.1988.tb13756.x; Falguieres T, 2001, MOL BIOL CELL, V12, P2453, DOI 10.1091/mbc.12.8.2453; Garcia-Ruiz C, 2000, FASEB J, V14, P847, DOI 10.1096/fasebj.14.7.847; Ghafourifar P, 1999, J BIOL CHEM, V274, P6080, DOI 10.1074/jbc.274.10.6080; Gorman A, 1997, FEBS LETT, V404, P27, DOI 10.1016/S0014-5793(97)00069-0; HAKOMORI S, 1995, J BIOCHEM, V118, P1091, DOI 10.1093/oxfordjournals.jbchem.a124992; Hampton MB, 1997, FEBS LETT, V414, P552, DOI 10.1016/S0014-5793(97)01068-5; HARDIE DL, 1993, EUR J IMMUNOL, V23, P997, DOI 10.1002/eji.1830230502; Johannes L, 2000, TRAFFIC, V1, P119, DOI 10.1034/j.1600-0854.2000.010204.x; Johannes L, 1997, J BIOL CHEM, V272, P19554, DOI 10.1074/jbc.272.31.19554; Kiyokawa N, 2001, J CELL BIOCHEM, V81, P128, DOI 10.1002/1097-4644(20010401)81:1<128::AID-JCB1029>3.0.CO;2-G; KOJIMA H, 1987, BIOCHEM BIOPH RES CO, V143, P716, DOI 10.1016/0006-291X(87)91413-6; Kojio S, 2000, FEMS IMMUNOL MED MIC, V29, P275, DOI 10.1111/j.1574-695X.2000.tb01534.x; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Lingwood CA, 1996, TRENDS MICROBIOL, V4, P147, DOI 10.1016/0966-842X(96)10017-2; Liu B, 1998, J BIOL CHEM, V273, P11313, DOI 10.1074/jbc.273.18.11313; MANGENEY M, 1993, CANCER RES, V53, P5314; MANGENEY M, 1991, EUR J IMMUNOL, V21, P1131, DOI 10.1002/eji.1830210507; Marcato P, 2002, INFECT IMMUN, V70, P1279, DOI 10.1128/IAI.70.3.1279-1286.2002; MARCUS DM, 1981, SEMIN HEMATOL, V18, P63; Muramatsu T, 2000, J BIOCHEM, V127, P171, DOI 10.1093/oxfordjournals.jbchem.a022590; Nakagawa I, 1999, MOL MICROBIOL, V33, P1190, DOI 10.1046/j.1365-2958.1999.01564.x; OBRIEN AD, 1992, CURR TOP MICROBIOL, V180, P65; Paton JC, 1998, CLIN MICROBIOL REV, V11, P450, DOI 10.1128/CMR.11.3.450; Pijpers AHJM, 2001, J AM SOC NEPHROL, V12, P767, DOI 10.1681/ASN.V124767; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; Sandvig K, 2000, EMBO J, V19, P5943, DOI 10.1093/emboj/19.22.5943; SANDVIG K, 1992, EXP CELL RES, V200, P253, DOI 10.1016/0014-4827(92)90171-4; Sandvig K, 2001, TOXICON, V39, P1629, DOI 10.1016/S0041-0101(01)00150-7; Steffensen R, 2000, J BIOL CHEM, V275, P16723, DOI 10.1074/jbc.M000728200; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; Taga S, 1997, BLOOD, V90, P2757, DOI 10.1182/blood.V90.7.2757.2757_2757_2767; Taguchi T, 1998, KIDNEY INT, V53, P1681, DOI 10.1046/j.1523-1755.1998.00939.x; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Waterhouse NJ, 2001, J CELL BIOL, V153, P319, DOI 10.1083/jcb.153.2.319; Williams JM, 1997, TOXICOL LETT, V91, P121, DOI 10.1016/S0378-4274(97)03879-4; Yamashita T, 1999, P NATL ACAD SCI USA, V96, P9142, DOI 10.1073/pnas.96.16.9142	46	62	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45200	45208		10.1074/jbc.M303868200	http://dx.doi.org/10.1074/jbc.M303868200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12944404	hybrid			2022-12-25	WOS:000186452300020
J	Cho, IJ; Kim, SG				Cho, IJ; Kim, SG			Oltipraz inhibits 3-methylcholanthrene induction of CYP1A1 by CCAAT/enhancer-binding protein activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARYL-HYDROCARBON RECEPTOR; GLUTATHIONE-S-TRANSFERASE; NUCLEAR TRANSLOCATOR ARNT; AH RECEPTOR; SIGNAL-TRANSDUCTION; ENZYME-INDUCTION; GENE-EXPRESSION; H4IIE CELLS; RAT-LIVER; HEPATOCYTES	Oltipraz, a cancer chemopreventive agent, induces CYP1A1 to a certain extent by transactivation of the gene via the Ah receptor (AhR)-xenobiotic response element (XRE) pathway. Previously, we showed that oltipraz promoted CCAAT/enhancer binding protein beta (C/EBPbeta) activation, which leads to the induction of glutathione S-transferase. Given that oltipraz activates C/EBPbeta for gene transactivation and that the putative C/EBP binding site is located in the CYP1A1 promoter region, this study investigated the effect of oltipraz on CYP1A1 induction by 3-methylcholanthrene (3-MC). 3-MC induced CYP1A1 in H4IIE cells in a time- and concentration-dependent manner. Gel shift analysis showed that 3-MC increased the band intensity of protein binding to the XRE. Immunocompetition analysis verified the specificity of AhR-XRE binding. Oltipraz (30 muM) induced CYP1A1 and the CYP1A1 promoter-luciferase gene and increased AhR DNA binding activity, which was 10 - 20% of those in 3-MC (100 nM)-treated cells. However, AhR-XRE binding was not increased after 10 muM oltipraz treatment. Oltipraz (10 muM) significantly inhibited CYP1A1 and CYP1A1-luciferase gene induction by 3-MC with no increase in AhR DNA binding. Oltipraz enhanced protein binding to the C/EBP binding site in the gene promoter and the binding complex comprised of C/EBPbeta and partly C/EBPdelta. Overexpression of dominant-negative mutant C/EBP significantly abolished the ability of oltipraz to suppress 3-MC-inducible CYP1A1 and the CYP1A1 reporter gene expression. Consistently, C/EBPbeta overexpression blocked CYP1A1 reporter gene induction by 3-MC. These results provide evidence that oltipraz suppresses 3-MC induction of CYP1A1 gene expression and that activation of C/EBPbeta by oltipraz contributes to suppression of 3-MC-inducible AhR-mediated CYP1A1 expression.	Seoul Natl Univ, Coll Pharm, Natl Res Lab, Seoul 151742, South Korea; Seoul Natl Univ, Pharmaceut Sci Res Inst, Seoul 151742, South Korea	Seoul National University (SNU); Seoul National University (SNU)	Kim, SG (corresponding author), Seoul Natl Univ, Coll Pharm, Natl Res Lab, Seoul 151742, South Korea.							Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; Alexandrov K, 2002, CARCINOGENESIS, V23, P1969, DOI 10.1093/carcin/23.12.1969; Baba T, 2001, J BIOL CHEM, V276, P33101, DOI 10.1074/jbc.M011497200; Backlund M, 1997, J BIOL CHEM, V272, P31755, DOI 10.1074/jbc.272.50.31755; Beischlag TV, 2002, MOL CELL BIOL, V22, P4319, DOI 10.1128/MCB.22.12.4319-4333.2002; BERGELSON S, 1994, ONCOGENE, V9, P565; BOLTON MG, 1993, CANCER RES, V53, P3499; CARRIER F, 1994, BIOCHEM PHARMACOL, V48, P1767, DOI 10.1016/0006-2952(94)90463-4; Cho MK, 2003, HEPATOLOGY, V37, P686, DOI 10.1053/jhep.2003.50078; CONNEY AH, 1986, LIFE SCI, V39, P2493, DOI 10.1016/0024-3205(86)90103-7; deSousa G, 1996, CELL BIOL TOXICOL, V12, P351, DOI 10.1007/BF00438170; Diehl AM, 1998, J BIOL CHEM, V273, P30843, DOI 10.1074/jbc.273.47.30843; EGNER PA, 1994, CARCINOGENESIS, V15, P177, DOI 10.1093/carcin/15.2.177; FERREC EL, 2001, CARCINOGENESIS, V21, P49; Ferrec Eric Le, 2002, Journal of Biological Chemistry, V277, P24780; GUENGERICH FP, 1990, CRIT REV BIOCHEM MOL, V25, P97; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; Iwanari M, 2002, ARCH TOXICOL, V76, P287, DOI 10.1007/s00204-002-0340-z; Jover R, 2002, FASEB J, V16, P1799, DOI 10.1096/fj.02-0195fje; Kang KW, 2001, MOL PHARMACOL, V59, P1147, DOI 10.1124/mol.59.5.1147; Kang KW, 2003, CARCINOGENESIS, V24, P475, DOI 10.1093/carcin/24.3.475; Kang KW, 2003, J NATL CANCER I, V95, P53, DOI 10.1093/jnci/95.1.53; Kang KW, 2002, FREE RADICAL BIO MED, V32, P1017, DOI 10.1016/S0891-5849(02)00788-8; Kobayashi A, 1997, J BIOCHEM, V122, P703; Kwak MK, 2001, MUTAT RES-FUND MOL M, V480, P305, DOI 10.1016/S0027-5107(01)00190-7; LANGOUET S, 1995, CANCER RES, V55, P5574; Langouet S, 1997, CARCINOGENESIS, V18, P1343, DOI 10.1093/carcin/18.7.1343; Lewis DFV., 1996, CYTOCHROMES P450 STR, P115; Mimura J, 1999, GENE DEV, V13, P20, DOI 10.1101/gad.13.1.20; Moinova HR, 1999, BIOCHEM BIOPH RES CO, V261, P661, DOI 10.1006/bbrc.1999.1109; Morel Y, 1998, J BIOL CHEM, V273, P26969, DOI 10.1074/jbc.273.41.26969; Nguyen TA, 1999, ARCH BIOCHEM BIOPHYS, V367, P250, DOI 10.1006/abbi.1999.1282; Reiners JJ, 1998, MOL PHARMACOL, V53, P438, DOI 10.1124/mol.53.3.438; Rowlands JC, 1997, CRIT REV TOXICOL, V27, P109, DOI 10.3109/10408449709021615; SCHREIBER E, 1990, NUCLEIC ACIDS RES, V18, P5495, DOI 10.1093/nar/18.18.5495; Sofowora GG, 2001, CANCER CHEMOTH PHARM, V47, P505, DOI 10.1007/s002800000245; SOGAWA K, 1986, P NATL ACAD SCI USA, V83, P8044, DOI 10.1073/pnas.83.21.8044; THOMAS PE, 1983, J BIOL CHEM, V258, P4590; Vasiliou V, 1995, BIOCHEM PHARMACOL, V50, P1885, DOI 10.1016/0006-2952(95)02083-7; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; Wasserman WW, 1997, P NATL ACAD SCI USA, V94, P5361, DOI 10.1073/pnas.94.10.5361; WHITLOCK JP, 1987, PHARMACOL REV, V39, P147	42	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44103	44112		10.1074/jbc.M307597200	http://dx.doi.org/10.1074/jbc.M307597200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12941938	hybrid			2022-12-25	WOS:000186306700028
J	Clark, RJ; McDonough, PM; Swanson, E; Trost, SU; Suzuki, M; Fukuda, M; Dillmann, WH				Clark, RJ; McDonough, PM; Swanson, E; Trost, SU; Suzuki, M; Fukuda, M; Dillmann, WH			Diabetes and the accompanying hyperglycemia impairs cardiomyocyte calcium cycling through increased nuclear O-GlcNAcylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED N-ACETYLGLUCOSAMINE; INSULIN-RESISTANCE; CARDIAC MYOCYTES; GENE-EXPRESSION; MUSCLE-CELLS; PROTEINS; GLYCOSYLATION; CA2+; HEART; CONTRACTILITY	Diabetic cardiomyopathy is characterized by impaired cardiac contractility leading to poor myocardial performance. We investigated the role that the hexosamine pathway, and especially altered nuclear O-Glc-NAcylation, plays in the development of diabetic cardiomyopathy. Incubating neonatal rat cardiomyocytes in high glucose ( 25 mM) resulted in prolonged calcium transients when compared with myocytes incubated in normal glucose (5.5 mM), which is consistent with delayed myocardial relaxation. High glucose-treated myocytes also exhibited reduced sarcoendoplasmic reticulum Ca2+-ATPase 2a (SERCA2a) mRNA and protein expression, decreased SERCA2a promoter activity, and increased O-GlcNAcylation of nuclear proteins compared with myocytes treated with normal glucose. Exposure of myocytes to 8 mM glucosamine or an adenovirus expressing O-GlcNAc-transferase (OGT) resulted in prolonged calcium transient decays and significantly reduced SERCA2a protein levels, whereas treatment with an adenovirus encoding O-GlcNAcase (GCA) resulted in improved calcium transients and SERCA2a protein levels in myocytes exposed to high glucose. Effects of elevated glucose or altered O-GlcNAcylation were also observed on essential transcription factors involved in cardiomyocyte function. High glucose-treated myocytes ( with or without OGT adenovirus) exhibited increased levels of O-GlcNAcylated specificity protein 1 compared with control myocytes, whereas infecting high glucose-treated myocytes with GCA adenovirus reduced the degree of specificity protein 1 Glc-NAcylation. Treatment of myocytes with 25 mM glucose, 8 mM glucosamine, or OGT adenovirus also significantly reduced levels of myocytes enhancer factor-2A protein compared with control myocytes, whereas infection with GCA adenovirus resulted in improved myocytes enhancer factor-2 expression. Our results suggest that the hexosamine pathway, and O-GlcNAcylation in particular, is important in impaired cardiac myocyte function and the development of diabetic cardiomyopathy.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Burnham Inst, Glycobiol Program, La Jolla, CA 92037 USA	University of California System; University of California San Diego; Sanford Burnham Prebys Medical Discovery Institute	Dillmann, WH (corresponding author), Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.				NCI NIH HHS [R37CA33000] Funding Source: Medline; NHLBI NIH HHS [HL66917] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA033000] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066917] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMED SS, 1975, AM HEART J, V89, P153, DOI 10.1016/0002-8703(75)90039-3; Baker DL, 1996, J BIOL CHEM, V271, P5921, DOI 10.1074/jbc.271.10.5921; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; BOUCHARD RA, 1991, AM J PHYSIOL, V260, pH341, DOI 10.1152/ajpheart.1991.260.2.H341; CAGLIERO E, 1988, J MOL CELL CARDIOL, V20, P427, DOI 10.1016/S0022-2828(88)80134-2; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Comer FI, 2001, ANAL BIOCHEM, V293, P169, DOI 10.1006/abio.2001.5132; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DILLMANN WH, 1988, DIABETES METAB REV, V4, P789, DOI 10.1002/dmr.5610040807; DUKSIN D, 1982, J BIOL CHEM, V257, P3105; FEIN FS, 1980, CIRC RES, V47, P922, DOI 10.1161/01.RES.47.6.922; GALDERISI M, 1991, AM J CARDIOL, V68, P85, DOI 10.1016/0002-9149(91)90716-X; GANGULY PK, 1983, AM J PHYSIOL, V244, pE528, DOI 10.1152/ajpendo.1983.244.6.E528; Gao Y, 2001, J BIOL CHEM, V276, P9838, DOI 10.1074/jbc.M010420200; GUPTA RK, 1993, BIOPHYS J, V65, P2547, DOI 10.1016/S0006-3495(93)81320-1; HALTIWANGER RS, 1992, J BIOL CHEM, V267, P9005; Hanover JA, 1999, ARCH BIOCHEM BIOPHYS, V362, P38, DOI 10.1006/abbi.1998.1016; Hart GW, 1997, ANNU REV BIOCHEM, V66, P315, DOI 10.1146/annurev.biochem.66.1.315; Hartong R, 1996, J MOL CELL CARDIOL, V28, P2467, DOI 10.1006/jmcc.1996.0239; Hawkins M, 1997, J CLIN INVEST, V99, P2173, DOI 10.1172/JCI119390; He HP, 1999, CIRCULATION, V100, P974, DOI 10.1161/01.CIR.100.9.974; He HP, 1997, J CLIN INVEST, V100, P380, DOI 10.1172/JCI119544; LagadicGossmann D, 1996, AM J PHYSIOL-HEART C, V270, pH1529, DOI 10.1152/ajpheart.1996.270.5.H1529; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; MCCLAIN DA, 1992, P NATL ACAD SCI USA, V89, P8150, DOI 10.1073/pnas.89.17.8150; McClain DA, 1996, DIABETES, V45, P1003, DOI 10.2337/diabetes.45.8.1003; MCDONOUGH PM, 1994, J BIOL CHEM, V269, P9466; Moriscot AS, 1997, ENDOCRINOLOGY, V138, P26, DOI 10.1210/en.138.1.26; Parker GJ, 2003, J BIOL CHEM, V278, P10022, DOI 10.1074/jbc.M207787200; PENPARGKUL S, 1981, J MOL CELL CARDIOL, V13, P303, DOI 10.1016/0022-2828(81)90318-7; PENPARGKUL S, 1980, CIRC RES, V47, P911, DOI 10.1161/01.RES.47.6.911; Periasamy M, 2001, J MOL CELL CARDIOL, V33, P1053, DOI 10.1006/jmcc.2001.1366; Pierce GN, 1997, CARDIOVASC RES, V34, P41, DOI 10.1016/S0008-6363(97)00010-2; Ren J, 1997, AM J PHYSIOL-HEART C, V273, pH2876, DOI 10.1152/ajpheart.1997.273.6.H2876; ROBINSON KA, 1995, DIABETES, V44, P1438, DOI 10.2337/diabetes.44.12.1438; ROHRER DK, 1991, J BIOL CHEM, V266, P8638; Schannwell CM, 2002, CARDIOLOGY, V98, P33, DOI 10.1159/000064682; Trost SU, 2002, DIABETES, V51, P1166, DOI 10.2337/diabetes.51.4.1166; Vosseller K, 2002, P NATL ACAD SCI USA, V99, P5313, DOI 10.1073/pnas.072072399; WECKBECKER G, 1983, ANAL BIOCHEM, V132, P405, DOI 10.1016/0003-2697(83)90027-1; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714; Yang XY, 2002, CELL, V110, P69, DOI 10.1016/S0092-8674(02)00810-3; Yang XY, 2001, P NATL ACAD SCI USA, V98, P6611, DOI 10.1073/pnas.111099998; ZARICH SW, 1988, J AM COLL CARDIOL, V12, P114, DOI 10.1016/0735-1097(88)90364-6; ZORZANO A, 1997, AM J CARDIOL, V80, P65	47	281	288	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44230	44237		10.1074/jbc.M303810200	http://dx.doi.org/10.1074/jbc.M303810200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12941958	hybrid			2022-12-25	WOS:000186306700043
J	Kataoka, Y; Matsumura, I; Ezoe, S; Nakata, S; Takigawa, E; Sato, Y; Kawasaki, A; Yokota, T; Nakajima, K; Felsani, A; Kanakura, Y				Kataoka, Y; Matsumura, I; Ezoe, S; Nakata, S; Takigawa, E; Sato, Y; Kawasaki, A; Yokota, T; Nakajima, K; Felsani, A; Kanakura, Y			Reciprocal inhibition between MyoD and STAT3 in the regulation of growth and differentiation of myoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; CELL-CYCLE; C-MYC; MYOGENIC DIFFERENTIATION; SIGNALING PATHWAYS; SKELETAL-MUSCLE; KINASE PATHWAY; MET RECEPTOR; PROLIFERATION	The development of myoblasts is regulated by various growth factors as well as by intrinsic muscle-specific transcriptional factors. In this study, we analyzed the roles for STAT3 in the growth and differentiation of myoblasts in terms of cell cycle regulation and interaction with MyoD using C2C12 cells. Here we found that STAT3 inhibited myogenic differentiation induced by low serum or MyoD as efficiently as the Ras/mitogen-activated protein kinase cascade. As for this mechanism, we found that STAT3 not only promoted cell cycle progression through the induction of c-myc but also inhibited MyoD activities through direct interaction. STAT3 inhibited not only DNA binding activities of MyoD but also its transcriptional activities. However, the inhibited transcriptional activities were restored by the supplement of p300/CBP and PCAF, suggesting that STAT3 might deprive MyoD of these transcriptional cofactors. In addition, we found that MyoD inhibited DNA binding activities of STAT3, thereby inhibiting STAT3-dependent cell growth and survival of Ba/F3 cells. These results suggest that the development of muscle cells is regulated by the coordination of cytokine signals and intrinsic transcription factors.	Osaka Univ, Grad Sch Med, Dept Hematol & Oncol, Suita, Osaka 5650871, Japan; Kanazawa Univ, Grad Sch Med Sci, Dept Canc Med, Div Stem Cell Biol, Kanazawa, Ishikawa 9208640, Japan; Osaka City Univ, Sch Med, Dept Immunol, Abeno Ku, Osaka 5450051, Japan; Inst Technol Biomed, I-00137 Rome, Italy	Osaka University; Kanazawa University; Osaka Metropolitan University	Matsumura, I (corresponding author), Osaka Univ, Grad Sch Med, Dept Hematol & Oncol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Felsani, Armando/D-1784-2010; Yokota, Takashi/F-6021-2011; Yokota, Takashi/J-8483-2015	Felsani, Armando/0000-0001-8851-6295; 				Bellido T, 1998, J BIOL CHEM, V273, P21137, DOI 10.1074/jbc.273.33.21137; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Bonni A, 1997, SCIENCE, V278, P477, DOI 10.1126/science.278.5337.477; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Cenciarelli C, 1999, MOL CELL BIOL, V19, P5203; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; CRESCENZI M, 1990, P NATL ACAD SCI USA, V87, P8442, DOI 10.1073/pnas.87.21.8442; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Giraud S, 2002, J BIOL CHEM, V277, P8004, DOI 10.1074/jbc.M111486200; Gires O, 1999, EMBO J, V18, P3064, DOI 10.1093/emboj/18.11.3064; Gredinger E, 1998, J BIOL CHEM, V273, P10436, DOI 10.1074/jbc.273.17.10436; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Hansen SH, 2000, MOL CELL BIOL, V20, P9364, DOI 10.1128/MCB.20.24.9364-9375.2000; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; HOLLENBERG SM, 1993, P NATL ACAD SCI USA, V90, P8028, DOI 10.1073/pnas.90.17.8028; Husmann Irene, 1996, Cytokine and Growth Factor Reviews, V7, P249, DOI 10.1016/S1359-6101(96)00029-9; Ihara S, 1997, EMBO J, V16, P5345, DOI 10.1093/emboj/16.17.5345; Jones NC, 2001, J CELL PHYSIOL, V186, P104, DOI 10.1002/1097-4652(200101)186:1<104::AID-JCP1015>3.0.CO;2-0; Kerkhoff E, 1998, ONCOGENE, V16, P211, DOI 10.1038/sj.onc.1201520; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; Lawlor MA, 2000, J CELL BIOL, V151, P1131, DOI 10.1083/jcb.151.6.1131; Leshem Y, 2002, EXP CELL RES, V274, P288, DOI 10.1006/excr.2002.5473; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; MARTELLI F, 1994, ONCOGENE, V9, P3579; Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261; Matsumura I, 1998, MOL CELL BIOL, V18, P4282, DOI 10.1128/MCB.18.7.4282; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; Megeney LA, 1996, DEV GENET, V19, P139, DOI 10.1002/(SICI)1520-6408(1996)19:2<139::AID-DVG5>3.0.CO;2-A; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; Perry RLS, 2001, MOL CELL, V8, P291, DOI 10.1016/S1097-2765(01)00302-1; Polesskaya A, 2000, J BIOL CHEM, V275, P34359, DOI 10.1074/jbc.M003815200; Polesskaya A, 2001, MOL CELL BIOL, V21, P5312, DOI 10.1128/MCB.21.16.5312-5320.2001; Rawls A, 1997, CELL, V89, P5, DOI 10.1016/S0092-8674(00)80175-0; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Sabourin LA, 2000, CLIN GENET, V57, P16, DOI 10.1034/j.1399-0004.2000.570103.x; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Schuringa JJ, 2001, FEBS LETT, V495, P71, DOI 10.1016/S0014-5793(01)02354-7; Shirogane T, 1999, IMMUNITY, V11, P709, DOI 10.1016/S1074-7613(00)80145-4; Simon AR, 2002, AM J PHYSIOL-LUNG C, V282, pL1296, DOI 10.1152/ajplung.00315.2001; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; Tanaka H, 2002, MOL CELL, V9, P1017, DOI 10.1016/S1097-2765(02)00522-1; Tureckova J, 2001, J BIOL CHEM, V276, P39264, DOI 10.1074/jbc.M104991200; Wei Q, 2001, FEBS LETT, V490, P171, DOI 10.1016/S0014-5793(01)02120-2; Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951-3964.2000; Yanagisawa M, 1999, NEUROSCI LETT, V269, P169, DOI 10.1016/S0304-3940(99)00447-4; Zauberman A, 2001, J BIOL CHEM, V276, P24719, DOI 10.1074/jbc.M005813200; Zhang JM, 1999, EMBO J, V18, P926, DOI 10.1093/emboj/18.4.926; Zhang XK, 1999, MOL CELL BIOL, V19, P7138; Zong CS, 2000, J BIOL CHEM, V275, P15099, DOI 10.1074/jbc.M000089200	57	46	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44178	44187		10.1074/jbc.M304884200	http://dx.doi.org/10.1074/jbc.M304884200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12947115	hybrid			2022-12-25	WOS:000186306700037
J	Rehli, M; Niller, HH; Ammon, C; Langmann, S; Schwarzfischer, L; Andreesen, R; Krause, SW				Rehli, M; Niller, HH; Ammon, C; Langmann, S; Schwarzfischer, L; Andreesen, R; Krause, SW			Transcriptional regulation of CHI3L1, a gene for late stages of macrophage differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CARTILAGE GP-39; CHITINASE PROTEIN FAMILY; LIGATION-MEDIATED PCR; PU.1 TRANSCRIPTION; MONOCYTIC DIFFERENTIATION; MYELOID DEVELOPMENT; MAMMALIAN MEMBER; POTENTIAL MARKER; SERUM YKL-40; FACTORS SP1	The protein product of the CHI3L1 gene, human cartilage 39-kDa glycoprotein (HC-gp39), is a tissue-restricted, chitin-binding lectin and member of glycosyl hydrolase family 18. In contrast to many other monocyte/macrophage markers, its expression is absent in monocytes and strongly induced during late stages of human macrophage differentiation. To gain insights into the molecular mechanisms underlying its cell type-restricted and maturation-associated expression in macrophages, we initiated a detailed study of the proximal HC-gp39 promoter. Deletion analysis of reporter constructs in macrophage-like THP-1 cells localized a region directing high levels of macrophage-specific reporter gene expression to similar to300 bp adjacent to the major transcriptional start site. The promoter sequence contained consensus binding sites for several known factors, and specific binding of nuclear PU.1, Sp1, Sp3, USF, AML-1, and C/EBP proteins was detectable in gel shift assays. In vivo footprinting assays with dimethyl sulfate demonstrate that the protection of corresponding sequences was enhanced in macrophages compared with monocytes. Mutational analysis of transcription factor binding sites indicated a predominant role for a single Sp1 binding site in regulating HC-gp39 promoter activity. In addition, gel shift assays using nuclear extracts of monocytes and macrophages demonstrated that the binding of nuclear Sp1, but not Sp3, markedly increases during macrophage differentiation. Our results further highlight the important role of Sp1 in macrophage gene regulation.	Univ Regensburg, Dept Hematol & Oncol, D-93042 Regensburg, Germany; Univ Regensburg, Inst Med Microbiol & Hyg, D-93042 Regensburg, Germany	University of Regensburg; University of Regensburg	Rehli, M (corresponding author), Univ Regensburg, Dept Hematol & Oncol, D-93042 Regensburg, Germany.		Rehli, Michael/E-9093-2011	Rehli, Michael/0000-0003-3992-932X; Krause, Stefan/0000-0002-5259-4651				Anderson KL, 1998, BLOOD, V91, P3702, DOI 10.1182/blood.V91.10.3702; Behre G, 1999, J BIOL CHEM, V274, P4939, DOI 10.1074/jbc.274.8.4939; BOOT RG, 1995, J BIOL CHEM, V270, P26252, DOI 10.1074/jbc.270.44.26252; Boot RG, 1999, ARTERIOSCL THROM VAS, V19, P687, DOI 10.1161/01.ATV.19.3.687; CHEN HM, 1995, ONCOGENE, V11, P1549; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cintin C, 1999, BRIT J CANCER, V79, P1494, DOI 10.1038/sj.bjc.6690238; Eichbaum Q, 1997, BLOOD, V90, P4135, DOI 10.1182/blood.V90.10.4135; EICHBAUM QG, 1994, J EXP MED, V179, P1985, DOI 10.1084/jem.179.6.1985; FEINMAN R, 1994, EMBO J, V13, P3852, DOI 10.1002/j.1460-2075.1994.tb06696.x; Friedman AD, 2002, ONCOGENE, V21, P3377, DOI 10.1038/sj.onc.1205324; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; HAKALA BE, 1993, J BIOL CHEM, V268, P25803; Heydemann A, 1996, MOL CELL BIOL, V16, P1676; Hume DA, 2002, J LEUKOCYTE BIOL, V72, P621; JOHANSEN JS, 1995, EUR J CANCER, V31A, P1437, DOI 10.1016/0959-8049(95)00196-P; Johansen JS, 1997, SCAND J GASTROENTERO, V32, P582, DOI 10.3109/00365529709025104; JOHANSEN JS, 1993, BRIT J RHEUMATOL, V32, P949; Krause SW, 1996, J LEUKOCYTE BIOL, V60, P540, DOI 10.1002/jlb.60.4.540; Langmann T, 1999, J LIPID RES, V40, P870; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; Maxam A M, 1980, Methods Enzymol, V65, P499; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; Nerlov C, 2000, BLOOD, V95, P2543, DOI 10.1182/blood.V95.8.2543.008k19_2543_2551; NILLER HH, 1995, J BIOL CHEM, V270, P12864, DOI 10.1074/jbc.270.21.12864; PAHL HL, 1993, J BIOL CHEM, V268, P5014; Querfurth E, 2000, GENE DEV, V14, P2515, DOI 10.1101/gad.177200; Recklies AD, 2002, BIOCHEM J, V365, P119, DOI 10.1042/BJ20020075; Rehli M, 1999, J IMMUNOL, V162, P1559; Rehli M, 2000, J BIOL CHEM, V275, P9773, DOI 10.1074/jbc.275.13.9773; Rehli M, 1997, GENOMICS, V43, P221, DOI 10.1006/geno.1997.4778; Renkema GH, 1998, EUR J BIOCHEM, V251, P504, DOI 10.1046/j.1432-1327.1998.2510504.x; Ries S, 1998, J LIPID RES, V39, P2125; ROSMARIN AG, 1995, P NATL ACAD SCI USA, V92, P801, DOI 10.1073/pnas.92.3.801; SAKAMOTO S, 2001, J BIOL CHEM; SANFANG C, 2003, EUR J BIOCHEM, V270, P1855; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Tondravi MM, 1997, NATURE, V386, P81, DOI 10.1038/386081a0; Vangala RK, 2003, BLOOD, V101, P270, DOI 10.1182/blood-2002-04-1288; Volck B, 1998, P ASSOC AM PHYSICIAN, V110, P351; Vos K, 2000, ANN RHEUM DIS, V59, P544, DOI 10.1136/ard.59.7.544; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; ZHANG DE, 1994, J IMMUNOL, V153, P3276; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705	47	175	185	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44058	44067		10.1074/jbc.M306792200	http://dx.doi.org/10.1074/jbc.M306792200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12933821	hybrid			2022-12-25	WOS:000186306700022
J	Shelness, GS; Hou, L; Ledford, AS; Parks, JS; Weinberg, RB				Shelness, GS; Hou, L; Ledford, AS; Parks, JS; Weinberg, RB			Identification of the lipoprotein initiating domain of apolipoprotein B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; LOW-DENSITY-LIPOPROTEIN; CARBOXYL-TERMINAL TRUNCATION; APO-B; ENDOPLASMIC-RETICULUM; LIPID TRANSFER; RAT-LIVER; SECRETION; EXPRESSION; VITELLOGENIN	We have explored the minimum sequence requirement for the initiation of apolipoprotein B ( apoB)-mediated triglyceride-rich lipoprotein assembly. A series of apoB COOH-terminal truncation mutants, spanning a range from apoB34 (amino acid residues 1-1544 of apoB100) to apoB19 (residues 1-862) were transfected into COS cells with and without coexpression of the microsomal triglyceride transfer protein (MTP). ApoB34, - 25, - 23, - 21, - 20.5, and - 20.1 underwent efficient conversion to buoyant lipoproteins when coexpressed with MTP. ApoB19.5 (amino acids 1 - 884) also directed MTP-dependent particle assembly, although at reduced efficiency. When apoB19.5 was truncated by another 22 amino acids to form apoB19, MTP-dependent lipoprotein assembly was abolished. Analysis of the lipid stoichiometry of secreted lipoproteins revealed that all apoB truncation mutants formed spherical particles containing a hydrophobic core. Even highly truncated assembly-competent forms of apoB, such as apoB19.5 and 20.1, formed lipoproteins with surface: core lipid ratios of < 1. We conclude that the translation of the first &SIM; 884 amino acids of apoB completes a domain capable of initiating nascent lipoprotein assembly. The composition of lipids recruited into lipoproteins by this initiating domain is consistent with formation of small emulsion particles, perhaps by simultaneous desorption of both polar and neutral lipids from a saturated bilayer.	Wake Forest Univ, Sch Med, Dept Pathol, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Internal Med, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Physiol & Pharmacol, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest University; Wake Forest University	Shelness, GS (corresponding author), Wake Forest Univ, Sch Med, Dept Pathol, Winston Salem, NC 27157 USA.				NHLBI NIH HHS [R01 HL030897-23, R01 HL030897, HL49373, HL54176, HL30897] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030897, R01HL054176, R23HL030897, P01HL049373] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEXANDER CA, 1976, J CELL BIOL, V69, P241, DOI 10.1083/jcb.69.2.241; Anderson TA, 1998, STRUCT FOLD DES, V6, P895, DOI 10.1016/S0969-2126(98)00091-4; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Babin PJ, 1999, J MOL EVOL, V49, P150, DOI 10.1007/PL00006528; BAKER ME, 1988, BIOCHEM J, V255, P1057, DOI 10.1042/bj2551057; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Carraway M, 2000, BIOCHEMISTRY-US, V39, P9737, DOI 10.1021/bi000791h; CHAN L, 1992, J BIOL CHEM, V267, P25621; Chevet E, 2001, CURR OPIN STRUC BIOL, V11, P120, DOI 10.1016/S0959-440X(00)00168-8; Dashti N, 2002, BIOCHEMISTRY-US, V41, P6978, DOI 10.1021/bi011757l; Davis RA, 1999, BBA-MOL CELL BIOL L, V1440, P1, DOI 10.1016/S1388-1981(99)00083-9; DeLozier JA, 2001, J LIPID RES, V42, P399; Farese RV, 1996, J LIPID RES, V37, P347; Fisher EA, 2002, J BIOL CHEM, V277, P17377, DOI 10.1074/jbc.R100068200; Fisher EA, 2001, J BIOL CHEM, V276, P27855, DOI 10.1074/jbc.M008885200; Gordon DA, 2000, BBA-MOL CELL BIOL L, V1486, P72, DOI 10.1016/S1388-1981(00)00049-4; GRAHAM DL, 1991, BIOCHEMISTRY-US, V30, P5616, DOI 10.1021/bi00236a040; HERSCOVITZ H, 1991, P NATL ACAD SCI USA, V88, P7313, DOI 10.1073/pnas.88.16.7313; HERSCOVITZ H, 1995, P NATL ACAD SCI USA, V92, P659, DOI 10.1073/pnas.92.3.659; Herscovitz H, 2001, J LIPID RES, V42, P51; Hussain MM, 2003, J LIPID RES, V44, P22, DOI 10.1194/jlr.R200014-JLR200; Ingram MF, 1997, J BIOL CHEM, V272, P10279; Mann CJ, 1999, J MOL BIOL, V285, P391, DOI 10.1006/jmbi.1998.2298; MCLEOD RS, 1994, J BIOL CHEM, V269, P2852; OHLENDORF DH, 1977, J BIOL CHEM, V252, P7992; OLOFSSON SO, 1987, ATHEROSCLEROSIS, V68, P1, DOI 10.1016/0021-9150(87)90088-8; PEASE RJ, 1991, NATURE, V353, P448, DOI 10.1038/353448a0; SCHUMAKER VN, 1994, ADV PROTEIN CHEM, V45, P205; Segrest JP, 1999, J LIPID RES, V40, P1401; Segrest JP, 2001, J LIPID RES, V42, P1346; SEGREST JP, 1994, ARTERIOSCLER THROMB, V14, P1674, DOI 10.1161/01.ATV.14.10.1674; Sellers JA, 2001, J LIPID RES, V42, P1897; Shelness GS, 2001, CURR OPIN LIPIDOL, V12, P151, DOI 10.1097/00041433-200104000-00008; Shelness GS, 1996, J LIPID RES, V37, P408; SHELNESS GS, 1994, J BIOL CHEM, V269, P9310; SPRING DJ, 1992, J BIOL CHEM, V267, P14839; Weinberg RB, 2000, J LIPID RES, V41, P1419; YANG CY, 1990, P NATL ACAD SCI USA, V87, P5523, DOI 10.1073/pnas.87.14.5523; YAO ZM, 1991, J BIOL CHEM, V266, P3300	39	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44702	44707		10.1074/jbc.M307562200	http://dx.doi.org/10.1074/jbc.M307562200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12941937	hybrid			2022-12-25	WOS:000186306700103
J	Brooks, DR; Hooper, NM; Isaac, RE				Brooks, DR; Hooper, NM; Isaac, RE			The Caenorhabditis elegans orthologue of mammalian puromycin-sensitive aminopeptidase has roles in embryogenesis and reproduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENKEPHALIN-DEGRADING AMINOPEPTIDASES; NEURON-SPECIFIC AMINOPEPTIDASE; CYSTEINE PROTEASE GENE; C-ELEGANS; RAT-BRAIN; FUNCTIONAL EXPRESSION; NEUROPEPTIDE GENE; IDENTIFICATION; PURIFICATION; NEMATODE	Mammals possess membrane-associated and cytosolic forms of the puromycin-sensitive aminopeptidase (PSA; EC 3.4.11.14). Increasing evidence suggests the membrane PSA is involved in neuromodulation within the central nervous system and in reproductive biology. The functional roles of the cytosolic PSA are less clear. The genome of the nematode Caenorhabditis elegans encodes an aminopeptidase, F49E8.3 (PAM-1), that is orthologous to PSA, and sequence analysis predicts it to be cytosolic. We have determined the spatio/temporal gene expression pattern of pam-1 by using the promoter region of F49E8.3 to control expression in the nematode of a second exon translational fusion of the aminopeptidase to green fluorescent protein. Cytosolic fluorescence was observed throughout development in the intestine and nerve cells of the head. Neuronal expression was also observed in the tail of adult males. Recombinant PAM-1, expressed and purified from Escherichia coli, hydrolyzed the N-terminal amino acid from peptide substrates. Favored substrates had positively charged or small neutral amino acids in the N-terminal position. Peptide hydrolysis was inhibited by the metal-chelating agent 1,10-phenanthroline and by the aminopeptidase inhibitors actinonin, amastatin, and leuhistin. However, the enzyme was similar to 100-fold less sensitive toward puromycin (IC50, 135 muM) than other PSA homologues. Following inactivation of the enzyme, aminopeptidase activity was recovered with Zn2+, Co2+, and Ni2+. Silencing expression of pam-1 by RNA interference resulted in 30% embryonic lethality. Surviving adult hermaphrodites deposited large numbers of oocytes throughout the self-fertile period. The overall brood size was, however, unaffected. We conclude that pam-1 encodes an aminopeptidase that clusters phylogenetically with the PSAs, despite attenuated sensitivity toward puromycin, and that it functions in embryo development and reproduction of the nematode.	Univ Leeds, Fac Biol Sci, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Brooks, DR (corresponding author), Univ Leeds, Fac Biol Sci, Miall Bldg, Leeds LS2 9JT, W Yorkshire, England.	bgydrb@leeds.ac.uk		Hooper, Nigel/0000-0002-5811-3484				Baset HA, 1998, J BIOL CHEM, V273, P27978, DOI 10.1074/jbc.273.43.27978; Blelloch R, 1999, DEV BIOL, V216, P382, DOI 10.1006/dbio.1999.9491; Britton C, 1998, J MOL BIOL, V283, P15, DOI 10.1006/jmbi.1998.2093; Bui YK, 2002, MOL BIOL CELL, V13, P1641, DOI 10.1091/mbc.02-01-0008; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CONSTAM DB, 1995, J BIOL CHEM, V270, P26931, DOI 10.1074/jbc.270.45.26931; de Gandarias JM, 1999, BRAIN RES BULL, V50, P283, DOI 10.1016/S0361-9230(99)00189-6; DYER SH, 1990, J NEUROCHEM, V54, P547, DOI 10.1111/j.1471-4159.1990.tb01906.x; Ferro ES, 1999, DNA CELL BIOL, V18, P781, DOI 10.1089/104454999314926; GROS C, 1985, NEUROPEPTIDES, V5, P485, DOI 10.1016/0143-4179(85)90060-5; Hashmi S, 2002, J BIOL CHEM, V277, P3477, DOI 10.1074/jbc.M106117200; Hishida R, 1996, EMBO J, V15, P4111, DOI 10.1002/j.1460-2075.1996.tb00786.x; Hui KS, 1998, J BIOL CHEM, V273, P31053, DOI 10.1074/jbc.273.47.31053; Hui M, 2003, NEUROCHEM RES, V28, P855, DOI 10.1023/A:1023263123911; Jacob TC, 2003, J NEUROSCI, V23, P2122; Joshua GWP, 2001, MOL BIOCHEM PARASIT, V113, P223, DOI 10.1016/S0166-6851(01)00221-3; Kagechika H, 1999, BIOL PHARM BULL, V22, P1010; Kakuta H, 2003, BIOORG MED CHEM LETT, V13, P83, DOI 10.1016/S0960-894X(02)00845-4; Kamath RS, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2000-2-1-research0002; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kelly WG, 1997, GENETICS, V146, P227; Komoda M, 2001, BIOORGAN MED CHEM, V9, P121, DOI 10.1016/S0968-0896(00)00231-5; Laurent V, 2001, EUR J BIOCHEM, V268, P5430, DOI 10.1046/j.0014-2956.2001.02483.x; Laustsen PG, 2001, EUR J BIOCHEM, V268, P98, DOI 10.1046/j.1432-1327.2001.01848.x; Lee MC, 2002, SYNAPSE, V43, P102, DOI 10.1002/syn.10014; Maeda I, 2001, CURR BIOL, V11, P171, DOI 10.1016/S0960-9822(01)00052-5; MCLELLAN S, 1988, J NEUROCHEM, V51, P1552, DOI 10.1111/j.1471-4159.1988.tb01124.x; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Nelson LS, 1998, SCIENCE, V281, P1686, DOI 10.1126/science.281.5383.1686; Nelson LS, 1998, MOL BRAIN RES, V58, P103, DOI 10.1016/S0169-328X(98)00106-5; Nguyen HMK, 2002, NEUROPHARMACOLOGY, V42, P1089, DOI 10.1016/S0028-3908(02)00054-0; Nishiwaki K, 2000, SCIENCE, V288, P2205, DOI 10.1126/science.288.5474.2205; Osada T, 1999, J NEUROSCI, V19, P6068, DOI 10.1523/JNEUROSCI.19-14-06068.1999; Osada T, 2001, MOL ENDOCRINOL, V15, P960, DOI 10.1210/me.15.6.960; Osada T, 2001, MOL ENDOCRINOL, V15, P882, DOI 10.1210/me.15.6.882; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Podbilewicz B, 1996, MOL BIOL CELL, V7, P1877, DOI 10.1091/mbc.7.12.1877; Rawlings ND, 2002, NUCLEIC ACIDS RES, V30, P343, DOI 10.1093/nar/30.1.343; RAY C, 1992, MOL BIOCHEM PARASIT, V51, P239, DOI 10.1016/0166-6851(92)90074-T; Reinke V, 2000, MOL CELL, V6, P605, DOI 10.1016/S1097-2765(00)00059-9; Santos AN, 2000, CELL IMMUNOL, V201, P22, DOI 10.1006/cimm.2000.1629; Saric T, 2001, J BIOL CHEM, V276, P36474, DOI 10.1074/jbc.M105517200; SCHINKMANN K, 1992, J COMP NEUROL, V316, P251, DOI 10.1002/cne.903160209; SCHNEBLI HP, 1979, BIOCHIM BIOPHYS ACTA, V569, P89, DOI 10.1016/0005-2744(79)90084-6; Schulz C, 2001, DEV GENES EVOL, V211, P581, DOI 10.1007/s00427-001-0194-z; Scott AL, 1996, PARASITOL TODAY, V12, P425, DOI 10.1016/0169-4758(96)10063-6; SHARROCK WJ, 1983, DEV BIOL, V96, P182, DOI 10.1016/0012-1606(83)90321-4; Shrimpton CN, 2002, ENDOCR REV, V23, P647, DOI 10.1210/er.2001-0032; Simmer F, 2002, CURR BIOL, V12, P1317, DOI 10.1016/S0960-9822(02)01041-2; Singson A, 2001, DEV BIOL, V230, P101, DOI 10.1006/dbio.2000.0118; Stoltze L, 2000, NAT IMMUNOL, V1, P413, DOI 10.1038/80852; TAYLOR A, 1993, FASEB J, V7, P290, DOI 10.1096/fasebj.7.2.8440407; Tcherepanova I, 2000, J BIOL CHEM, V275, P26359, DOI 10.1074/jbc.M000956200; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Thompson MW, 1999, BIOCHEM BIOPH RES CO, V258, P234, DOI 10.1006/bbrc.1999.0604; Timmons L, 2001, GENE, V263, P103, DOI 10.1016/S0378-1119(00)00579-5; Tobler AR, 1997, J NEUROCHEM, V68, P889; Vincent B, 1996, J NEUROSCI, V16, P5049; Waggoner LF, 2000, GENETICS, V154, P1181; Wen CH, 1997, DEVELOPMENT, V124, P4759; Yamamoto Y, 2000, FORENSIC SCI INT, V113, P143, DOI 10.1016/S0379-0738(00)00280-2; Zhang Y, 2002, NATURE, V418, P331, DOI 10.1038/nature00891	62	27	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42795	42801		10.1074/jbc.M306216200	http://dx.doi.org/10.1074/jbc.M306216200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12930831	hybrid			2022-12-25	WOS:000186157000010
J	Senawong, T; Peterson, VJ; Avram, D; Shepherd, DM; Frye, RA; Minucci, S; Leid, M				Senawong, T; Peterson, VJ; Avram, D; Shepherd, DM; Frye, RA; Minucci, S; Leid, M			Involvement of the histone deacetylase SIRT1 in chicken ovalbumin upstream promoter transcription factor (COUP-TF)-interacting protein 2-mediated transcriptional repression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEINS; YEAST SIR2; N-COR; GENE; COREPRESSOR; FAMILY; NAD; INTERACTS; COMPLEX; HP1	Chicken ovalbumin upstream promoter transcription factor (COUP-TF)-interacting proteins 1 and 2 (CTIP1 and CTIP2) enhance transcriptional repression mediated by COUP-TF II and have been implicated in hematopoietic cell development and malignancies. CTIP1 and CTIP2 are also sequence-specific DNA-binding proteins that repress transcription through direct, COUP-TF-independent binding to a GC-rich response element. CTIP1- and CTIP2-mediated transcriptional repression is insensitive to trichostatin A, an inhibitor of known class I and II histone deacetylases. However, chromatin immunoprecipitation assays revealed that expression of CTIP2 in mammalian cells resulted in deacetylation of histones H3 and/or H4 that were associated with the promoter region of a reporter gene. CTIP2-mediated transcriptional repression, as well as deacetylation of promoter-associated histones H3/H4 in CTIP2-transfected cells, was reversed by nicotinamide, an inhibitor of class III histone deacetylases such as the mammalian homologs of yeast Silent Information Regulator 2 (Sir2). The human homolog of yeast Sir2, SIRT1, was found to interact directly with CTIP2 and was recruited to the promoter template in a CTIP2-dependent manner. Moreover, SIRT1 enhanced the deacetylation of template-associated histones H3/H4 in CTIP2-transfected cells, and stimulated CTIP2-dependent transcriptional repression. Finally, endogenous SIRT1 and CTIP2 co-purified from Jurkat cell nuclear extracts in the context of a large (1-2 mDa) complex. These findings implicate SIRT1 as a histone H3/H4 deacetylase in mammalian cells and in transcriptional repression mediated by CTIP2.	Oregon State Univ, Coll Pharm, Dept Pharmaceut Sci, Mol Pharmacol Lab, Corvallis, OR 97331 USA; Oregon State Univ, Coll Pharm, Mol & Cellular Biol Program, Corvallis, OR 97331 USA; Oregon State Univ, Environm Hlth Sci Ctr, Corvallis, OR 97331 USA; Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA; Univ Montana, Coll Pharm, Dept Pharmaceut Sci, Ctr Environm Hlth Sci, Missoula, MT 59812 USA; Univ Pittsburgh, Dept Pathol, Pittsburgh Vet Affairs Med Ctr 132L, Pittsburgh, PA 15240 USA; Univ Milan, Dept Physiol & Biochem, European Inst Oncol, Dept Expt Oncol, I-20126 Milan, Italy	Oregon State University; Oregon State University; Oregon State University; Albany Medical College; University of Montana System; University of Montana; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; IRCCS European Institute of Oncology (IEO); University of Milan	Leid, M (corresponding author), Oregon State Univ, Coll Pharm, Dept Pharmaceut Sci, Mol Pharmacol Lab, Corvallis, OR 97331 USA.	Mark.Leid@oregonstate.edu	Senawong, Thanaset/GSE-3777-2022; Minucci, Saverio/J-9669-2012		NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060852] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES00210, P30 ES000210, P30 ES000210-35] Funding Source: Medline; NIGMS NIH HHS [R01 GM060852, R01 GM060852-02] Funding Source: Medline; PHS HHS [EM60852] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Avram D, 2000, J BIOL CHEM, V275, P10315, DOI 10.1074/jbc.275.14.10315; Avram D, 2002, BIOCHEM J, V368, P555, DOI 10.1042/BJ20020496; Bernard OA, 2001, LEUKEMIA, V15, P1495, DOI 10.1038/sj.leu.2402249; Bitterman KJ, 2002, J BIOL CHEM, V277, P45099, DOI 10.1074/jbc.M205670200; CEREGHINI S, 1984, EMBO J, V3, P1243, DOI 10.1002/j.1460-2075.1984.tb01959.x; de Haan G, 2000, J BIOL CHEM, V275, P13493, DOI 10.1074/jbc.275.18.13493; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dowell P, 1997, J BIOL CHEM, V272, P2013, DOI 10.1074/jbc.272.3.2013; Dowell P, 1997, J BIOL CHEM, V272, P33435, DOI 10.1074/jbc.272.52.33435; Finnin MS, 2001, NAT STRUCT BIOL, V8, P621, DOI 10.1038/89668; Fischer DD, 2002, J BIOL CHEM, V277, P6656, DOI 10.1074/jbc.M108055200; Fischle W, 2001, J BIOL CHEM, V276, P35826, DOI 10.1074/jbc.M104935200; Frye RA, 2000, BIOCHEM BIOPH RES CO, V273, P793, DOI 10.1006/bbrc.2000.3000; Frye RA, 1999, BIOCHEM BIOPH RES CO, V260, P273, DOI 10.1006/bbrc.1999.0897; Gao L, 2002, J BIOL CHEM, V277, P25748, DOI 10.1074/jbc.M111871200; Gray SG, 2001, EXP CELL RES, V262, P75, DOI 10.1006/excr.2000.5080; Grozinger CM, 2001, J BIOL CHEM, V276, P38837, DOI 10.1074/jbc.M106779200; Guarente L, 2000, GENE DEV, V14, P1021; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hermanson O, 2002, TRENDS ENDOCRIN MET, V13, P55, DOI 10.1016/S1043-2760(01)00527-6; Huang EY, 2000, GENE DEV, V14, P45; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kaczynski J, 2001, J BIOL CHEM, V276, P36749, DOI 10.1074/jbc.M105831200; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Lechner MS, 2000, MOL CELL BIOL, V20, P6449, DOI 10.1128/MCB.20.17.6449-6465.2000; Liu PT, 2003, NAT IMMUNOL, V4, P525, DOI 10.1038/ni925; Lorenz P, 2001, BIOL CHEM, V382, P637, DOI 10.1515/BC.2001.075; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nakamura T, 2000, MOL CELL BIOL, V20, P3178, DOI 10.1128/MCB.20.9.3178-3186.2000; Nevrivy DJ, 2000, J BIOL CHEM, V275, P16827, DOI 10.1074/jbc.275.22.16827; REEVES R, 1985, NUCLEIC ACIDS RES, V13, P3599, DOI 10.1093/nar/13.10.3599; Rohr O, 2003, J VIROL, V77, P5415, DOI 10.1128/JVI.77.9.5415-5427.2003; Roopra A, 2000, MOL CELL BIOL, V20, P2147, DOI 10.1128/MCB.20.6.2147-2157.2000; Ryan RF, 1999, MOL CELL BIOL, V19, P4366; Saiki Y, 2000, GENOMICS, V70, P387, DOI 10.1006/geno.2000.6385; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Satterwhite E, 2001, BLOOD, V98, P3413, DOI 10.1182/blood.V98.12.3413; Smith CL, 1997, J BIOL CHEM, V272, P27493, DOI 10.1074/jbc.272.44.27493; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Wakabayashi Y, 2003, NAT IMMUNOL, V4, P533, DOI 10.1038/ni927; Wakabayashi Y, 2003, BIOCHEM BIOPH RES CO, V301, P598, DOI 10.1016/S0006-291X(02)03069-3; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301; Zhou XB, 2001, P NATL ACAD SCI USA, V98, P10572, DOI 10.1073/pnas.191375098	55	105	114	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43041	43050		10.1074/jbc.M307477200	http://dx.doi.org/10.1074/jbc.M307477200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12930829	Green Accepted, hybrid			2022-12-25	WOS:000186157000041
J	Ukomadu, C; Dutta, A				Ukomadu, C; Dutta, A			p21-dependent inhibition of colon cancer cell growth by mevastatin is independent of inhibition of G(1) cyclin-dependent kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COA REDUCTASE; S-PHASE; A GENE; P21; LOVASTATIN; ARREST; PHOSPHORYLATION; P21(WAF1/CIP1); TRANSCRIPTION; PATHWAY	Mevastatin arrested HCT116 colon cancer cells at the G(1)/S transition and increased cellular levels of p21(CIP1/WAF1). p21-deficient colon cancer cells continued to proliferate in the presence of mevastatin. Although p21 was necessary for the G(1)/S block, the G(1) cyclin-dependent kinases (Cdks) cyclin E-Cdk2 and cyclin D-Cdk4 remained active. Despite the activity of the G(1) Cdks the retinoblastoma protein was hypophosphorylated due to unknown mechanisms that were dependent on the p21 protein. The resulting decrease in cyclin A mRNA and protein led to a decrease in the activity of cyclin A-Cdk2. Therefore, although p21 was required for the G(1)/S arrest of HCT116 colon cancer cells by mevastatin, its mode of action was more complicated than the simple formation of a physical complex with cyclin-Cdk2. This mechanism of inhibition is different from that seen in prostate cancer cells (Ukomadu, C., and Dutta, A. (2003) J. Biol. Chem. 278, 4840-4846) where the activating phosphorylation of cyclin E-Cdk2 is suppressed and p21 is not required, suggesting the existence of cell line-specific differences in the mechanism by which statins arrest the cell cycle.	Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Gastroenterol, Boston, MA 02115 USA	University of Virginia; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Dutta, A (corresponding author), Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA.		Dutta, Anindya/P-3203-2016	Dutta, Anindya/0000-0002-4319-0073	NCI NIH HHS [R01 CA 89406] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089406] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Angus SP, 2002, EXP CELL RES, V276, P201, DOI 10.1006/excr.2002.5510; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Coqueret O, 2000, J BIOL CHEM, V275, P18794, DOI 10.1074/jbc.M001601200; DECLUE JE, 1991, CANCER RES, V51, P712; Delavaine L, 1999, ONCOGENE, V18, P5381, DOI 10.1038/sj.onc.1202923; Fouty BW, 2003, CIRC RES, V92, P501, DOI 10.1161/01.RES.0000061180.03813.0F; Greenwood J, 2003, FASEB J, V17, P905, DOI 10.1096/fj.02-1014fje; Harris TE, 2001, J BIOL CHEM, V276, P29200, DOI 10.1074/jbc.M011587200; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Izumi M, 2001, J BIOL CHEM, V276, P48526, DOI 10.1074/jbc.M107190200; KEYOMARSI K, 1991, CANCER RES, V51, P3602; Kim WS, 2001, INVEST NEW DRUG, V19, P81, DOI 10.1023/A:1006481423298; Kitaura H, 2000, J BIOL CHEM, V275, P10477, DOI 10.1074/jbc.275.14.10477; Lee SJ, 1998, J BIOL CHEM, V273, P10618, DOI 10.1074/jbc.273.17.10618; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Rao S, 1998, ONCOGENE, V17, P2393, DOI 10.1038/sj.onc.1202322; Rao S, 1999, P NATL ACAD SCI USA, V96, P7797, DOI 10.1073/pnas.96.14.7797; Rao S, 1999, EXP CELL RES, V252, P211, DOI 10.1006/excr.1999.4620; Retterstol K, 1996, AM J CARDIOL, V78, P1369, DOI 10.1016/S0002-9149(96)00649-2; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Snowden AW, 2000, MOL CELL BIOL, V20, P2676, DOI 10.1128/MCB.20.8.2676-2686.2000; Ukomadu C, 2003, J BIOL CHEM, V278, P4840, DOI 10.1074/jbc.M208658200; Vega GL, 2003, ARCH NEUROL-CHICAGO, V60, P510, DOI 10.1001/archneur.60.4.510; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Yamaguchi R, 2000, EXP CELL RES, V261, P271, DOI 10.1006/excr.2000.5053; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158	29	72	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43586	43594		10.1074/jbc.M307194200	http://dx.doi.org/10.1074/jbc.M307194200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12930830	hybrid			2022-12-25	WOS:000186157000106
J	Weljie, AM; Robertson, KM; Vogel, HJ				Weljie, AM; Robertson, KM; Vogel, HJ			Conformational changes in the Ca2+-regulatory region from soybean calcium-dependent protein kinase-alpha - Fluorescence resonance energy transfer studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-LIKE DOMAIN; TRANSFER DISTANCE MEASUREMENTS; TROPONIN-C; INTRAMOLECULAR BINDING; INHIBITORY REGION; NMR-SPECTROSCOPY; COLICIN-A; COMPLEX; SIGNAL; CDPK	Calcium-dependent protein kinases are key proteins involved in plant and protozoal Ca2+ signaling. These unique molecules include a calcium regulatory calmodulin-like domain (CLD), which binds to another small regulatory domain named the junction domain (JD). Both CLD and JD are part of the same polypeptide as the protein kinase domain. The CLD consists of N- and C-terminal lobes, each having two helix-loop-helix Ca2+-binding motifs. In this study, fluorescence resonance energy transfer using a series of Trp and Cys site-directed mutants was undertaken to probe the relative motions of the two lobes of CLD between the apo- and Ca2+-saturated forms, as well as bound to a peptide encoding the JD sequence. Using an IAEDANS-modified Cys, a total of 15 Trp-->Cys distances were measured in these three states from the five donor-acceptor combinations F334W-Cys(436), L371W-Cys(436), L403W-Cys(436), F334W-L403C, and L371W-L403C. Consistent with recently reported NMR diffusion measurements and with H-1, N-15 heteronuclear correlation NMR spectra, the distances derived from fluorescence resonance energy transfer measurements in apoCLD indicate partial unfolding and a subsequent contraction on binding Ca2+, which is maintained on addition of the JD peptide. Interpretation of the distances suggests that the Ca2+-saturated form is open with the two lobes sitting side-by-side although highly flexible. The transition to the JD-CLD state appears to be accompanied by a rotation of the N- and C-terminal domains with respect to each other inducing a slightly more closed overall complex. The observed differences between the behavior of CLD and the well studied related protein calmodulin are likely because of different physiological requirements for activation in vivo.	Univ Calgary, Dept Biol Sci, Struct Biol Res Lab, Calgary, AB T2N 1N4, Canada	University of Calgary	Vogel, HJ (corresponding author), Univ Calgary, Dept Biol Sci, Struct Biol Res Lab, 2500 Univ Dr 1 NW, Calgary, AB T2N 1N4, Canada.		Weljie, Aalim M/B-6203-2012; Weljie, Aalim/V-6952-2019	Weljie, Aalim/0000-0002-7145-4494				BARBATO G, 1992, BIOCHEMISTRY-US, V31, P5269, DOI 10.1021/bi00138a005; CHATTOPADHYAYA R, 1992, J MOL BIOL, V228, P1177, DOI 10.1016/0022-2836(92)90324-D; Chou JJ, 2001, NAT STRUCT BIOL, V8, P990, DOI 10.1038/nsb1101-990; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dong WJ, 2000, PROTEIN SCI, V9, P280; Dong WJ, 2003, J BIOL CHEM, V278, P8686, DOI 10.1074/jbc.M212886200; Dong WJ, 2001, J MOL BIOL, V314, P51, DOI 10.1006/jmbi.2001.5118; DOSREMEDIOS CG, 1995, J STRUCT BIOL, V115, P175, DOI 10.1006/jsbi.1995.1042; HARMON AC, 1994, BIOCHEMISTRY-US, V33, P7278, DOI 10.1021/bi00189a032; Harmon AC, 2000, TRENDS PLANT SCI, V5, P154, DOI 10.1016/S1360-1385(00)01577-6; HARPER JF, 1994, BIOCHEMISTRY-US, V33, P7267, DOI 10.1021/bi00189a031; Huang JF, 1996, BIOCHEMISTRY-US, V35, P13222, DOI 10.1021/bi960498a; Kohno T, 1998, J BIOMOL NMR, V12, P109, DOI 10.1023/A:1008254603368; LAKEY JH, 1993, J MOL BIOL, V230, P1055, DOI 10.1006/jmbi.1993.1218; LAKEY JH, 1991, J MOL BIOL, V218, P639, DOI 10.1016/0022-2836(91)90707-D; Lakowicz J R, 1999, PRINCIPLES FLUORESCE, P367, DOI 10.1007/978-1-4757-3061-6; LAKOWICZ JR, 1988, BIOCHEMISTRY-US, V27, P9149, DOI 10.1021/bi00426a012; Lee SY, 2000, BIOCHEMISTRY-US, V39, P4225, DOI 10.1021/bi992697a; Luan S, 2002, PLANT CELL, V14, pS389, DOI 10.1105/tpc.001115; Neuhaus D., 1989, NUCL OVERHAUSER EFFE, P451; Sanders D, 2002, PLANT CELL, V14, pS401, DOI 10.1105/tpc.002899; SELVIN PR, 1995, METHOD ENZYMOL, V246, P300; Sheen J, 1996, SCIENCE, V274, P1900, DOI 10.1126/science.274.5294.1900; Sheldahl C, 2003, BIOPHYS J, V84, P1057, DOI 10.1016/S0006-3495(03)74922-4; VOGEL HJ, 1983, FEBS LETT, V157, P241, DOI 10.1016/0014-5793(83)80554-7; WANG CK, 1986, J MOL BIOL, V191, P509, DOI 10.1016/0022-2836(86)90145-2; Weljie AM, 2003, PROTEIN SCI, V12, P228, DOI 10.1110/ps.0226203; Weljie AM, 2000, PROTEINS, V39, P343, DOI 10.1002/(SICI)1097-0134(20000601)39:4<343::AID-PROT70>3.0.CO;2-2; WU PG, 1994, ANAL BIOCHEM, V218, P1, DOI 10.1006/abio.1994.1134; Yoo BC, 1996, BIOCHEMISTRY-US, V35, P12029, DOI 10.1021/bi9606612; Yoshino H, 1996, BIOCHEMISTRY-US, V35, P2388, DOI 10.1021/bi952121v; ZHANG M, 1995, NAT STRUCT BIOL, V2, P758, DOI 10.1038/nsb0995-758; Zhao XM, 2000, BBA-PROTEIN STRUCT M, V1479, P247, DOI 10.1016/S0167-4838(00)00026-1	34	8	8	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43764	43769		10.1074/jbc.M306799200	http://dx.doi.org/10.1074/jbc.M306799200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12941950	hybrid			2022-12-25	WOS:000186157000126
J	Beck, GR; Knecht, N				Beck, GR; Knecht, N			Osteopontin regulation by inorganic phosphate is ERK1/2-, protein kinase C-, and proteasome-dependent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOBLAST-LIKE CELLS; SMOOTH-MUSCLE-CELLS; FIBROBLAST-GROWTH-FACTOR; P-I TRANSPORT; MC3T3-E1 CELLS; EXTRACELLULAR SIGNAL; PARATHYROID-HORMONE; GENE-EXPRESSION; DOWN-REGULATION; STIMULATION	The generation of inorganic phosphate by alkaline phosphatase during osteoblast differentiation represents an important signaling event, although the molecular and cellular consequences are currently undefined. We have previously described osteopontin as a gene regulated by an increase in inorganic phosphate not only in osteoblasts but also in other cell types. We describe here the identification of specific signaling pathways required for the stimulation of osteopontin expression by inorganic phosphate. We have determined that phosphate selectively activates the extracellular signal-regulated kinase (ERK1/2) signaling pathway but does not activate the other mitogen-activated protein kinase signaling proteins, p38, or the c-Jun N-terminal kinase. In addition, our results suggest that cellular exposure to 10 mM inorganic phosphate causes a biphasic ERK1/2 activation. The second ERK1/2 activation is required for osteopontin regulation, whereas the first is not sufficient. Analysis of common protein kinase families has revealed that phosphate-induced osteopontin expression specifically uses a protein kinase C-dependent signaling pathway. In addition, our results suggest that protein kinase C and ERK1/2 are not part of the same pathway but constitute two distinct pathways. Finally, we have determined that the proteasomal activity is required not only for phosphate-induced expression of osteopontin but also for the induction of osteopontin in response to 12-O-tetradecanoylphorbol 13-acetate and okadaic acid. The data presented here define for the first time the ability of increased inorganic phosphate to stimulate specific signaling pathways resulting in functionally significant changes in gene expression and identify three important signaling pathways in the regulation of osteopontin.	NCI, Ctr Canc Res, Basic Res Lab, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Beck, GR (corresponding author), NCI, Ctr Canc Res, Basic Res Lab, Bldg 576,Rm 110, Frederick, MD 21702 USA.	gbeck@ncifcrf.gov	Beck, George/AAO-2117-2020		DIVISION OF BASIC SCIENCES - NCI [Z01BC010434] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [K22CA084573] Funding Source: NIH RePORTER; NCI NIH HHS [CA 84573] Funding Source: Medline	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams CS, 2001, J BIOL CHEM, V276, P20316, DOI 10.1074/jbc.M006492200; Adams J, 2002, TRENDS MOL MED, V8, pS49, DOI 10.1016/S1471-4914(02)02315-8; AHMADO A, 1990, BIOCHEM SOC T, V18, P624, DOI 10.1042/bst0180624; Almond JB, 2002, LEUKEMIA, V16, P433, DOI 10.1038/sj.leu.2402417; Atkins KB, 1997, ARCH BIOCHEM BIOPHYS, V343, P157, DOI 10.1006/abbi.1997.0151; Barletta F, 2002, MOL ENDOCRINOL, V16, P301, DOI 10.1210/me.16.2.301; BAYLINK D, 1971, J CLIN INVEST, V50, P2519, DOI 10.1172/JCI106752; Beck GR, 2000, P NATL ACAD SCI USA, V97, P8352, DOI 10.1073/pnas.140021997; Beck GR, 1998, J CELL BIOCHEM, V68, P269, DOI 10.1002/(SICI)1097-4644(19980201)68:2<269::AID-JCB13>3.0.CO;2-A; Beck GR, 2003, EXP CELL RES, V288, P288, DOI 10.1016/S0014-4827(03)00213-1; BELLOWS CG, 1992, BONE MINER, V17, P15, DOI 10.1016/0169-6009(92)90707-K; Bidder M, 2002, J BIOL CHEM, V277, P44485, DOI 10.1074/jbc.M206235200; BINGHAM PJ, 1974, CALC TISS RES, V14, P31, DOI 10.1007/BF02060281; Caverzasio J, 1996, KIDNEY INT, V49, P975, DOI 10.1038/ki.1996.138; Chang PL, 2002, INT J BIOCHEM CELL B, V34, P1142, DOI 10.1016/S1357-2725(02)00035-3; CRAIG AM, 1989, J BIOL CHEM, V264, P9682; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Denhardt DT, 2001, ANNU REV PHARMACOL, V41, P723, DOI 10.1146/annurev.pharmtox.41.1.723; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fenteany G, 1998, J BIOL CHEM, V273, P8545, DOI 10.1074/jbc.273.15.8545; Fisher LW, 1995, ACTA ORTHOP SCAND, V66, P61, DOI 10.3109/17453679509157649; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; Fujita T, 2001, BIOCHEM BIOPH RES CO, V280, P348, DOI 10.1006/bbrc.2000.4108; Furger Kara A., 2001, Current Molecular Medicine (Hilversum), V1, P621, DOI 10.2174/1566524013363339; Goekjian PG, 1999, CURR MED CHEM, V6, P877; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hipskind Robert A., 1998, Frontiers in Bioscience, V3, pD804; Hullinger TG, 2000, J CELL BIOCHEM, V78, P607, DOI 10.1002/1097-4644(20000915)78:4<607::AID-JCB10>3.0.CO;2-F; Imai T, 1996, AM J PHYSIOL-ENDOC M, V271, pE694, DOI 10.1152/ajpendo.1996.271.4.E694; Kanatani M, 2002, J CELL PHYSIOL, V190, P306, DOI 10.1002/jcp.10067; Kavanaugh MP, 1996, KIDNEY INT, V49, P959, DOI 10.1038/ki.1996.135; Kim HJ, 2002, J CELL BIOCHEM, V87, P93, DOI 10.1002/jcb.10280; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KUNKLER KJ, 1991, AM J PHYSIOL, V260, pE751, DOI 10.1152/ajpendo.1991.260.5.E751; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Masukawa H, 2001, J CELL BIOCHEM, V83, P47, DOI 10.1002/jcb.1206; Moses S, 2001, ARCH BIOCHEM BIOPHYS, V396, P133, DOI 10.1006/abbi.2001.2578; Murray EJB, 1998, EXP CELL RES, V242, P460, DOI 10.1006/excr.1998.4090; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; Oates AJ, 1997, INVAS METAST, V17, P1; PIZURKI L, 1991, J BONE MINER RES, V6, P1235; Sanders JL, 1996, J BONE MINER RES, V11, P1862; SELZ T, 1991, AM J PHYSIOL, V260, pE833, DOI 10.1152/ajpendo.1991.260.6.E833; SELZ T, 1989, AM J PHYSIOL, V256, pE93, DOI 10.1152/ajpendo.1989.256.1.E93; ShiokawaSawada M, 1997, J BONE MINER RES, V12, P1165, DOI 10.1359/jbmr.1997.12.8.1165; SMITH JH, 1989, J CELL PHYSIOL, V139, P189, DOI 10.1002/jcp.1041390126; Suzuki A, 2001, BONE, V28, P589, DOI 10.1016/S8756-3282(01)00459-8; Suzuki A, 2000, J BONE MINER RES, V15, P95, DOI 10.1359/jbmr.2000.15.1.95; Takemoto M, 1999, BIOCHEM BIOPH RES CO, V258, P722, DOI 10.1006/bbrc.1999.0701; TAMAOKI T, 1991, METHOD ENZYMOL, V201, P340; Tokuda H, 2002, J ENDOCRINOL, V172, P271, DOI 10.1677/joe.0.1720271; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Veldman CM, 1997, BONE, V21, P41, DOI 10.1016/S8756-3282(97)00077-X; Veldman CR, 1998, ENDOCRINOLOGY, V139, P89, DOI 10.1210/en.139.1.89; Wang XD, 2002, J CELL BIOCHEM, V87, P417, DOI 10.1002/jcb.10323; Wilkinson KD, 1999, J NUTR, V129, P1933, DOI 10.1093/jn/129.11.1933; Xie YS, 2001, KIDNEY INT, V60, P1645, DOI 10.1046/j.1523-1755.2001.00032.x; Xie ZL, 2001, J CELL PHYSIOL, V188, P132, DOI 10.1002/jcp.1104; You J, 2001, J BIOL CHEM, V276, P13365, DOI 10.1074/jbc.M009846200; Zhen XC, 1997, J BONE MINER RES, V12, P36, DOI 10.1359/jbmr.1997.12.1.36	61	127	130	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41921	41929		10.1074/jbc.M304470200	http://dx.doi.org/10.1074/jbc.M304470200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12920127	hybrid			2022-12-25	WOS:000185989500046
J	Chaturvedi, S; Bhakuni, V				Chaturvedi, S; Bhakuni, V			Unusual structural, functional, and stability properties of serine hydroxymethyltransferase from Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRIDOXAL 5'-PHOSPHATE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; SHEEP LIVER; D-ALANINE; PURIFICATION; TRANSHYDROXYMETHYLASE; COMPARTMENTATION; TRANSAMINATION; MITOCHONDRIAL	From the genome analysis of the Mycobacterium tuberculosis two putative genes namely GlyA and GlyA2 have been proposed to encode for the enzyme serine hydroxymethyltransferase. We have cloned, overexpressed, and purified to homogeneity their respective protein products, serine hydroxymethyltransferase, SHM1 and SHM2. The recombinant SHM1 and SHM2 exist as homodimers of molecular mass about 90 kDa under physiological conditions, however, SHM2 has more compact conformation and higher thermal stability than SHM1. The most interesting structural observation was that the SHM1 contains 1 mol of pyridoxal 5'-phosphate (PLP)/mol of enzyme dimer. This is the first report of such a unique stoichiometry of PLP and enzyme dimer for SHMT. The SHM2 contains 2 mol of PLP/mol of enzyme dimer, which is the usual stoichiometry reported for SHMT. Functionally both the recombinant enzymes showed catalysis of reversible interconversion of serine and glycine and aldol cleavage of a 3-hydroxyamino acid. However, unlike SHMT from other sources both SHM1 and SHM2 do not undergo half-transamination reaction with D-alanine resulting in formation of apoenzyme but L-cysteine removed the prosthetic group, PLP, from both the recombinant enzymes leaving the respective inactive apoenzymes. Comparative structural studies on the two enzymes showed that the SHM1 is resistant to alkaline denaturation up to pH 10.5, whereas the native SHM2 dimer dissociates into monomer at pH 9. Urea- and guanidinium chloride-induced two-step unfolding of SHM1 and SHM2 with the first step being dissociation of dimer into apomonomer at low denaturant concentrations followed by unfolding of the stabilized monomer at higher denaturant concentrations.	Cent Drug Res Inst, Div Mol & Struct Biol, Lucknow 226001, Uttar Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Central Drug Research Institute (CDRI)	Bhakuni, V (corresponding author), Cent Drug Res Inst, Div Mol & Struct Biol, Lucknow 226001, Uttar Pradesh, India.	bhakuniv@rediffmail.com						ANDREWS P, 1965, BIOCHEM J, V96, P569; ANGELACCIO S, 1992, BIOCHEMISTRY-US, V31, P155, DOI 10.1021/bi00116a023; APPLING DR, 1991, FASEB J, V5, P2645, DOI 10.1096/fasebj.5.12.1916088; BESSON V, 1995, PLANT PHYSIOL BIOCH, V33, P665; Bhatt AN, 2002, BIOCHEMISTRY-US, V41, P12115, DOI 10.1021/bi020356i; Cai K, 1996, J BIOL CHEM, V271, P2987, DOI 10.1074/jbc.271.6.2987; CAI K, 1995, J BIOL CHEM, V270, P19294, DOI 10.1074/jbc.270.33.19294; Cai K, 1996, J BIOL CHEM, V271, P27311, DOI 10.1074/jbc.271.44.27311; Capelluto DGS, 1999, MOL BIOCHEM PARASIT, V98, P187, DOI 10.1016/S0166-6851(98)00166-2; Capelluto DGS, 2000, EUR J BIOCHEM, V267, P712, DOI 10.1046/j.1432-1327.2000.01047.x; Contestabile R, 2001, EUR J BIOCHEM, V268, P6508, DOI 10.1046/j.0014-2956.2001.02606.x; GARROW TA, 1993, J BIOL CHEM, V268, P11910; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; MALKIN LI, 1964, BIOCHIM BIOPHYS ACTA, V85, P117, DOI 10.1016/0926-6569(64)90172-5; MANOHAR R, 1982, J BIOSCIENCES, V4, P31, DOI 10.1007/BF02702579; McNeil JB, 1996, GENETICS, V142, P371; Prakash K, 2002, PROTEIN SCI, V11, P46, DOI 10.1110/ps.ps.20102; Renwick SB, 1998, STRUCTURE, V6, P1105, DOI 10.1016/S0969-2126(98)00112-9; SAKAMOTO M, 1996, Z BIOSCI BIOTECH BIO, V60, P1914; Scarsdale JN, 1999, BIOCHEMISTRY-US, V38, P8347, DOI 10.1021/bi9904151; SCHIRCH L, 1964, J BIOL CHEM, V239, P3797; SCHIRCH L, 1982, ADV ENZYMOL RAMB, V53, P83; SCHIRCH L, 1962, J BIOL CHEM, V237, P2578; SCHIRCH V, 1985, J BACTERIOL, V163, P1; SHANE B, 1989, VITAM HORM, V45, P263; SHOSTAK K, 1988, BIOCHEMISTRY-US, V27, P8007, DOI 10.1021/bi00421a006; TAYLOR RT, 1965, ANAL BIOCHEM, V13, P80, DOI 10.1016/0003-2697(65)90120-X; ULEVITCH RJ, 1977, BIOCHEMISTRY-US, V16, P5342, DOI 10.1021/bi00643a027; Venkatesha B, 1998, BBA-PROTEIN STRUCT M, V1384, P141, DOI 10.1016/S0167-4838(98)00013-2	30	30	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40793	40805		10.1074/jbc.M306192200	http://dx.doi.org/10.1074/jbc.M306192200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12913008	hybrid			2022-12-25	WOS:000185847200048
J	Trempat, P; Villalva, C; Laurent, G; Armstrong, F; Delsol, G; Dastugue, N; Brousset, P				Trempat, P; Villalva, C; Laurent, G; Armstrong, F; Delsol, G; Dastugue, N; Brousset, P			Chronic myeloproliferative disorders with rearrangement of the platelet-derived growth factor alpha receptor: a new clinical target for STI571/Glivec	ONCOGENE			English	Article						chronic myeloid leukaemia; STI-571/Glivec; PDGFRA	GASTROINTESTINAL STROMAL TUMORS; CHRONIC MYELOID-LEUKEMIA; ABL TYROSINE KINASE; IMATINIB MESYLATE; DERMATOFIBROSARCOMA PROTUBERANS; BCR; STI571; INHIBITOR; EFFICACY; PDGFRA	Two cases of atypical chronic myeloid leukaemia (CML) carrying the t(4;22)(q12;q11) translocation involving the breakpoint cluster region (BCR) and platelet-derived growth factor a receptor (PDGFRA) genes have been recently characterized. We report a third case of atypical CML with the same translocation but with a distinct breakpoint fusing BCR exon 1 with PDGFRA exon 13. The patient had a clinical presentation of CML with progressive transformation in B-cell acute lymphoblastic leukaemia. The involvement of PDGFRA led us to treat the patient with the small organic compound imatinib mesylate/STI571 (Glivec) that blocks the ATP binding site of tyrosine kinases such as Abelson, KIT and platelet-derived growth factor receptors. The patient subsequently achieved a rapid clinical and molecular response clearly demonstrating, for the first time, that Glivec is active against PDGFRA in vivo. Therefore, our study expands the list of Glivec targets and has direct biological and also clinical implications.	Purpan Hosp, Ctr Physiopathol Toulouse Purpan, INSERM, U563, Toulouse, France; Purpan Hosp, Dept Pathol, Toulouse, France; Purpan Hosp, Dept Haematol, Toulouse, France; Purpan Hosp, Dept Cytogenet, Toulouse, France	CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; CHU de Toulouse; CHU de Toulouse	Brousset, P (corresponding author), CHU Purpan, INSERM, Anat Pathol Lab, U563, F-31059 Toulouse, France.							Apperley JF, 2002, NEW ENGL J MED, V347, P481, DOI 10.1056/NEJMoa020150; Baxter EJ, 2002, HUM MOL GENET, V11, P1391, DOI 10.1093/hmg/11.12.1391; Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139; Cools J, 1999, BLOOD, V94, P1820, DOI 10.1182/blood.V94.5.1820.417k09_1820_1824; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2002, ONCOGENE, V21, P8541, DOI 10.1038/sj.onc.1206081; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; Magnusson MK, 2002, BLOOD, V100, P1088, DOI 10.1182/blood-2002-01-0165; Maki RG, 2002, INT J CANCER, V100, P623, DOI 10.1002/ijc.10535; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; Petzer AL, 2002, BRIT J HAEMATOL, V117, P623, DOI 10.1046/j.1365-2141.2002.03523.x; Rubin BP, 2002, J CLIN ONCOL, V20, P3586, DOI 10.1200/JCO.2002.01.027; Thijsen SFT, 1999, LEUKEMIA, V13, P1646, DOI 10.1038/sj.leu.2401565; van Oosterom AT, 2001, LANCET, V358, P1421, DOI 10.1016/S0140-6736(01)06535-7	15	50	52	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2003	22	36					5702	5706		10.1038/sj.onc.1206543	http://dx.doi.org/10.1038/sj.onc.1206543			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944919				2022-12-25	WOS:000184865900020
J	Zehntner, SP; Brisebois, M; Tran, E; Owens, T; Fournier, S				Zehntner, SP; Brisebois, M; Tran, E; Owens, T; Fournier, S			Constitutive expression of a costimulatory ligand on antigen-presenting cells in the nervous system drives demyelinating disease	FASEB JOURNAL			English	Article						autoimmunity; CD28-B7; microglia; CD8+T cells	CD8(+) T-CELLS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; B7 COSTIMULATION; MICE; BLOCKADE; TH1; MOLECULES; CTLA4IG; BRAIN; BLOOD	It has been proposed that the activation status of antigen-presenting cells (APCs) plays a significant role in the development of autoimmune disease. Whether expression of costimulatory ligands on tissue-resident APCs controls organ-specific autoimmune responses has not been tested. We here report that transgenic mice constitutively expressing the costimulatory ligand B7.2/CD86 on microglia in the central nervous system (CNS) and on related cells in the proximal peripheral nervous tissue spontaneously develop autoimmune demyelinating disease. Disease-affected nervous tissue in transgenic mice showed infiltration characterized by a predominance of CD8+ memory-effector T cells, as well as CD4+ T cells. Transgenic animals lacking alphabeta TCR+ T cells were completely resistant to disease development. Transgenic T cells induced disease when adoptively transferred into T cell-deficient B7.2 transgenic recipients but not into non-transgenic recipients. These data provide evidence that B7/CD28 interactions within the nervous tissue are critical determinants of disease development. Our findings have important implications for understanding the etiology of nervous system autoimmune diseases such as multiple sclerosis (MS) and Guillain-Barre syndrome (GBS).	McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2B4, Canada; McGill Univ, Montreal Neurol Inst, Neuroimmunol Unit, Montreal, PQ H3A 2B4, Canada	McGill University; McGill University	Fournier, S (corresponding author), McGill Univ, Dept Microbiol & Immunol, 3775 Univ St, Montreal, PQ H3A 2B4, Canada.	sylvie.fournier@mcgill.ca		Owens, Trevor/0000-0001-9315-6036				Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Arima T, 1996, J IMMUNOL, V156, P4916; Babbe H, 2000, J EXP MED, V192, P393, DOI 10.1084/jem.192.3.393; Brabb T, 1997, J IMMUNOL, V159, P497; Brabb T, 2000, J EXP MED, V192, P871, DOI 10.1084/jem.192.6.871; Chambers CA, 2001, TRENDS IMMUNOL, V22, P217, DOI 10.1016/S1471-4906(01)01868-3; Chang TT, 1999, J EXP MED, V190, P733, DOI 10.1084/jem.190.5.733; Christensen JE, 2001, INT IMMUNOL, V13, P593, DOI 10.1093/intimm/13.4.593; Croxford JL, 1998, EUR J IMMUNOL, V28, P3904, DOI 10.1002/(SICI)1521-4141(199812)28:12<3904::AID-IMMU3904>3.0.CO;2-5; FINCK BK, 1994, SCIENCE, V265, P1225, DOI 10.1126/science.7520604; Fournier S, 1997, IMMUNITY, V6, P327, DOI 10.1016/S1074-7613(00)80335-0; Hickey WF, 2001, GLIA, V36, P118, DOI 10.1002/glia.1101; Huseby ES, 2001, J EXP MED, V194, P669, DOI 10.1084/jem.194.5.669; Issazadeh S, 1998, J IMMUNOL, V161, P1104; Katz-Levy Y, 1999, J CLIN INVEST, V104, P599, DOI 10.1172/JCI7292; KHOURY SJ, 1995, J IMMUNOL, V155, P4521; Kiefer R, 2000, J NEUROL NEUROSUR PS, V69, P362, DOI 10.1136/jnnp.69.3.362; Laflamme N, 2003, EUR J IMMUNOL, V33, P1127, DOI 10.1002/eji.200323821; Laflamme N, 2001, J NEUROCHEM, V79, P648, DOI 10.1046/j.1471-4159.2001.00603.x; LENSCHOW DJ, 1995, J EXP MED, V181, P1145, DOI 10.1084/jem.181.3.1145; Lyons JA, 1999, J NEUROIMMUNOL, V93, P26, DOI 10.1016/S0165-5728(98)00185-4; Miller SD, 1995, IMMUNITY, V3, P739, DOI 10.1016/1074-7613(95)90063-2; Oliveira-dos-Santos AJ, 1999, J IMMUNOL, V162, P4490; Perrin PJ, 1999, J IMMUNOL, V163, P1704; RENNO T, 1995, J IMMUNOL, V154, P944; Rivest S, 2000, P SOC EXP BIOL MED, V223, P22, DOI 10.1046/j.1525-1373.2000.22304.x; Sindern E, 1997, J NEUROL SCI, V151, P29, DOI 10.1016/S0022-510X(97)00082-8; Sun DM, 2001, J IMMUNOL, V166, P7579, DOI 10.4049/jimmunol.166.12.7579; Tada Y, 1999, J IMMUNOL, V162, P203; Tran EH, 2000, J IMMUNOL, V164, P2759, DOI 10.4049/jimmunol.164.5.2759; VANDENBERG LH, 1995, J NEUROIMMUNOL, V58, P37, DOI 10.1016/0165-5728(94)00185-Q; WINDHAGEN A, 1995, J EXP MED, V182, P1985, DOI 10.1084/jem.182.6.1985; Yu X, 2000, J IMMUNOL, V164, P3543, DOI 10.4049/jimmunol.164.7.3543; Zhu Y, 2001, J NEUROIMMUNOL, V114, P114, DOI 10.1016/S0165-5728(01)00241-7	34	41	43	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1910	+		10.1096/fj.03-0199fje	http://dx.doi.org/10.1096/fj.03-0199fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12923072				2022-12-25	WOS:000185345100009
J	Fulco, M; Costanzo, A; Merlo, P; Mangiacasale, R; Strano, S; Blandino, G; Balsano, C; Lavia, P; Levrero, M				Fulco, M; Costanzo, A; Merlo, P; Mangiacasale, R; Strano, S; Blandino, G; Balsano, C; Lavia, P; Levrero, M			p73 is regulated by phosphorylation at the G2/M transition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; DNA-DAMAGE; P53 HOMOLOG; C-ABL; TRANSCRIPTIONAL ACTIVITY; APOPTOTIC RESPONSE; P53-HOMOLOG P73; TARGET GENES; P63; CELLS	p73 is a p53 paralog that encodes proapoptotic (transactivation-competent (TA)) and antiapoptotic ( dominant negative) isoforms. TAp73 transcription factors mediate cell cycle arrest and/or apoptosis in response to DNA damage and are involved in developmental processes in the central nervous system and the immune system. p73 proteins may also play a role in the regulation of cell growth. Indeed, p73 expression is itself modulated during the cell cycle and TAp73 proteins accumulate in S phase cells. In addition, the function of p73 proteins is also regulated by post-translational modifications and protein-protein interactions in different cellular and pathophysiological contexts. Here we show that p73 is a physiological target of the p34(cdc2)-cyclin B mitotic kinase complex in vivo. Both p73beta and p73alpha isoforms are hyperphosphorylated in normal mitotic cells and during mitotic arrest induced by microtubule-targeting drugs. p34(cdc2)-cyclin B phosphorylates and associates with p73 in vivo, which results in a decreased ability of p73 to both bind DNA and activate transcription in mitotic cells. Indeed, p73 is excluded from condensed chromosomes in meta- and anaphase, redistributes throughout the mitotic cytoplasm, and unlike p53, shows no association with centrosomes. Together these results indicate that M phase-specific phosphorylation of p73 by p34(cdc2)- cyclin B is associated with negative regulation of its transcriptional activating function.	Univ Roma La Sapienza, Policlin Umberto I, Fdn Andrea Cesalpino, Gene Express Lab, I-00161 Rome, Italy; Univ Roma Tor Vergata, Dept Dermatol, I-00133 Rome, Italy; CNR, Ctr Evolutionary Genet, I-00185 Rome, Italy; Regina Elena Inst Canc Res, Mol Oncogenesis Lab, I-00158 Rome, Italy; Univ Aquila, Dept Internal Med, I-67100 Laquila, Italy; Univ Cagliari, Dept Internal Med, I-09124 Cagliari, Italy	Sapienza University Rome; University Hospital Sapienza Rome; University of Rome Tor Vergata; Consiglio Nazionale delle Ricerche (CNR); IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of L'Aquila; University of Cagliari	Levrero, M (corresponding author), Univ Roma La Sapienza, Policlin Umberto I, Fdn Andrea Cesalpino, Gene Express Lab, Viale Policlin 155, I-00161 Rome, Italy.		Costanzo, Antonio/GZG-2433-2022; Lavia, Patrizia/J-5793-2019; Balsano, Clara/AAK-9870-2020; Strano, Sabrina/K-9654-2016; Costanzo, Antonio/D-3896-2012; Blandino, Giovanni/B-1137-2013; Merlo, Paola/K-5330-2014; Lavia, Patrizia/AAL-3982-2021; strano, sabrina/B-6743-2013; Levrero, Massimo/G-5680-2016	Costanzo, Antonio/0000-0001-9697-2557; Lavia, Patrizia/0000-0003-3310-6701; Balsano, Clara/0000-0002-9615-7031; Blandino, Giovanni/0000-0002-6970-2241; Merlo, Paola/0000-0003-0105-7044; strano, sabrina/0000-0002-6341-4230; Levrero, Massimo/0000-0002-4978-0875	Telethon [E.1325] Funding Source: Medline	Telethon(Fondazione Telethon)		Agami R, 1999, NATURE, V399, P809; Balint E, 1999, ONCOGENE, V18, P3923, DOI 10.1038/sj.onc.1202781; Bastians H, 1999, MOL BIOL CELL, V10, P3927, DOI 10.1091/mbc.10.11.3927; Bergamaschi D, 2003, CANCER CELL, V3, P387, DOI 10.1016/S1535-6108(03)00079-5; BOYER JC, 1995, CANCER RES, V55, P6063; Chen DY, 2002, MOL BIOL CELL, V13, P276, DOI 10.1091/mbc.01-10-0523; Ciciarello M, 2001, J BIOL CHEM, V276, P19205, DOI 10.1074/jbc.M009528200; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; De Laurenzi V, 1999, CELL DEATH DIFFER, V6, P389, DOI 10.1038/sj.cdd.4400521; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Dobbelstein M, 1999, ONCOGENE, V18, P2101, DOI 10.1038/sj.onc.1202512; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Fontemaggi G, 2002, J BIOL CHEM, V277, P43359, DOI 10.1074/jbc.M205573200; Gaiddon C, 2003, J BIOL CHEM, V278, P27421, DOI 10.1074/jbc.M300251200; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; GAUTHIERROUVIERE C, 1991, CELL REGUL, V2, P575, DOI 10.1091/mbc.2.7.575; Gong JG, 1999, NATURE, V399, P806; Gottesfeld JM, 1997, TRENDS BIOCHEM SCI, V22, P197, DOI 10.1016/S0968-0004(97)01045-1; Holmes JK, 1996, J BIOL CHEM, V271, P25240, DOI 10.1074/jbc.271.41.25240; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Levrero M, 2000, J CELL SCI, V113, P1661; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; MARTINEZBALBAS MA, 1995, CELL, V83, P29, DOI 10.1016/0092-8674(95)90231-7; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Ongkeko WM, 1999, CURR BIOL, V9, P829, DOI 10.1016/S0960-9822(99)80367-4; PEDICONI N, 2003, IN PRESS NAT CELL BI; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Sciortino S, 2001, EMBO REP, V2, P1018, DOI 10.1093/embo-reports/kve223; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Strano S, 2001, J BIOL CHEM, V276, P15164, DOI 10.1074/jbc.M010484200; Strano S, 2001, FEBS LETT, V490, P163, DOI 10.1016/S0014-5793(01)02119-6; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Vossio S, 2002, ONCOGENE, V21, P3796, DOI 10.1038/sj.onc.1205465; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zeng XY, 1999, MOL CELL BIOL, V19, P3257	43	34	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49196	49202		10.1074/jbc.M304921200	http://dx.doi.org/10.1074/jbc.M304921200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	12920125	hybrid			2022-12-25	WOS:000186829000084
J	Wojtyra, UA; Thibault, G; Tuite, A; Houry, WA				Wojtyra, UA; Thibault, G; Tuite, A; Houry, WA			The N-terminal zinc binding domain of ClpX is a dimerization domain that modulates the chaperone function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-DEPENDENT PROTEASES; MU-TRANSPOSASE TETRAMER; HEAT-SHOCK-PROTEIN; ESCHERICHIA-COLI; DEGRADATION MACHINE; CRYSTAL-STRUCTURE; MOLECULAR CHAPERONE; HSP100 CHAPERONE; TAGGING SYSTEM; COMPLEX	Clp ATPases are unique chaperones that promote protein unfolding and subsequent degradation by proteases. The mechanism by which this occurs is poorly understood. Here we demonstrate that the N-terminal domain of ClpX is a C4-type zinc binding domain (ZBD) involved in substrate recognition. ZBD forms a very stable dimer that is essential for promoting the degradation of some typical ClpXP substrates such as lambdaO and MuA but not GFP-SsrA. Furthermore, experiments indicate that ZBD contains a primary binding site for the lambdaO substrate and for the cofactor SspB. Removal of ZBD from the ClpX sequence renders the ATPase activity of ClpX largely insensitive to the presence of ClpP, substrates, or the SspB cofactor. All these results indicate that ZBD plays an important role in the ClpX mechanism of function and that ATP binding and/or hydrolysis drives a conformational change in ClpX involving ZBD.	Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto	Houry, WA (corresponding author), Univ Toronto, Dept Biochem, Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	walid.houry@utoronto.ca	Thibault, Guillaume/J-9730-2013	Thibault, Guillaume/0000-0002-7926-4812				BAKER TA, 1993, CELL, V74, P723, DOI 10.1016/0092-8674(93)90519-V; Banecki B, 2001, J BIOL CHEM, V276, P18843, DOI 10.1074/jbc.M007507200; Barnett ME, 2000, J BIOL CHEM, V275, P37565, DOI 10.1074/jbc.M005211200; Beinker P, 2002, J BIOL CHEM, V277, P47160, DOI 10.1074/jbc.M207853200; Bochtler M, 2000, NATURE, V403, P800, DOI 10.1038/35001629; Bohn C, 2002, MOL GENET GENOMICS, V266, P827, DOI 10.1007/s00438-001-0601-1; BOWIE JU, 1989, BIOCHEMISTRY-US, V28, P7139, DOI 10.1021/bi00444a001; Burton RE, 2001, EMBO J, V20, P3092, DOI 10.1093/emboj/20.12.3092; Clarke AK, 2000, J BACTERIOL, V182, P7092, DOI 10.1128/JB.182.24.7092-7096.2000; Dougan DA, 2002, MOL CELL, V9, P673, DOI 10.1016/S1097-2765(02)00485-9; FLANAGAN JM, 1995, BIOCHEMISTRY-US, V34, P10910, DOI 10.1021/bi00034a025; Flynn JM, 2003, MOL CELL, V11, P671, DOI 10.1016/S1097-2765(03)00060-1; Flynn JM, 2001, P NATL ACAD SCI USA, V98, P10584, DOI 10.1073/pnas.191375298; Gottesman S, 1998, GENE DEV, V12, P1338, DOI 10.1101/gad.12.9.1338; Grimaud R, 1998, J BIOL CHEM, V273, P12476, DOI 10.1074/jbc.273.20.12476; Guo FS, 2002, J BIOL CHEM, V277, P46743, DOI 10.1074/jbc.M207796200; Guo FS, 2002, J BIOL CHEM, V277, P46753, DOI 10.1074/jbc.M208104200; Hoskins JR, 2000, P NATL ACAD SCI USA, V97, P8892, DOI 10.1073/pnas.97.16.8892; Hoskins JR, 2002, ADV PROTEIN CHEM, V59, P413; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; Kim YI, 2000, MOL CELL, V5, P639, DOI 10.1016/S1097-2765(00)80243-9; Kim YI, 2001, NAT STRUCT BIOL, V8, P230, DOI 10.1038/84967; Lee C, 2001, MOL CELL, V7, P627, DOI 10.1016/S1097-2765(01)00209-X; Levchenko I, 2000, SCIENCE, V289, P2354, DOI 10.1126/science.289.5488.2354; LEVCHENKO I, 1995, GENE DEV, V9, P2399, DOI 10.1101/gad.9.19.2399; Li JZ, 2003, STRUCTURE, V11, P323, DOI 10.1016/S0969-2126(03)00030-3; Lo JH, 2001, PROTEIN SCI, V10, P551, DOI 10.1110/ps.41401; MHAMMEDIALAOUI A, 1994, MOL MICROBIOL, V11, P1109, DOI 10.1111/j.1365-2958.1994.tb00387.x; Mogk A, 2003, J BIOL CHEM, V278, P17615, DOI 10.1074/jbc.M209686200; Morgan GJ, 2002, J MOL BIOL, V317, P337, DOI 10.1006/jmbi.2002.5437; NORBY JG, 1988, METHOD ENZYMOL, V156, P116; Pace CN, 2000, PROTEINS, P1; Reid BG, 2001, P NATL ACAD SCI USA, V98, P3768, DOI 10.1073/pnas.071043698; ROBERTS JD, 1983, NUCLEIC ACIDS RES, V11, P7435, DOI 10.1093/nar/11.21.7435; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Singh SK, 2000, P NATL ACAD SCI USA, V97, P8898, DOI 10.1073/pnas.97.16.8898; Singh SK, 2001, J BIOL CHEM, V276, P29420, DOI 10.1074/jbc.M103489200; Wah DA, 2002, CHEM BIOL, V9, P1237, DOI 10.1016/S1074-5521(02)00268-5; WAWRZYNOW A, 1995, EMBO J, V14, P1867, DOI 10.1002/j.1460-2075.1995.tb07179.x; Weber-Ban EU, 1999, NATURE, V401, P90, DOI 10.1038/43481; Zeth K, 2002, NAT STRUCT BIOL, V9, P906, DOI 10.1038/nsb869; Zhou YN, 2001, GENE DEV, V15, P627, DOI 10.1101/gad.864401	43	84	86	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					48981	48990		10.1074/jbc.M307825200	http://dx.doi.org/10.1074/jbc.M307825200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	12937164	hybrid, Green Published			2022-12-25	WOS:000186829000059
J	Jendreyko, N; Popkov, M; Beerli, RR; Chung, JH; McGavern, DB; Rader, C; Barbas, CF				Jendreyko, N; Popkov, M; Beerli, RR; Chung, JH; McGavern, DB; Rader, C; Barbas, CF			Intradiabodies, bispecific, tetravalent antibodies for the simultaneous functional knockout of two cell surface receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-CHAIN ANTIBODY; GROWTH-FACTOR; GENE-THERAPY; IN-VIVO; INTRACELLULAR IMMUNIZATION; TUMOR ANGIOGENESIS; HIV-1 INFECTION; TUBE FORMATION; INTRABODIES; INHIBITION	The specific and high affinity binding properties of intracellular antibodies (intrabodies), combined with their ability to be stably expressed in defined organelles, provides powerful tools with a wide range of applications in the field of functional genomics and gene therapy. Intrabodies have been used to specifically target intracellular proteins, manipulate biological processes, and contribute to the understanding of their functions as well as for the generation of phenotypic knockouts in vivo by surface depletion of extracellular or transmembrane proteins. In order to study the biological consequences of knocking down two receptor-tyrosine kinases, we developed a novel intrabody-based strategy. Here we describe the design, engineering, and characterization of a bispecific, tetravalent endoplasmic reticulum (ER)-targeted intradiabody for simultaneous surface depletion of two endothelial transmembrane receptors, Tie-2 and vascular endothelial growth factor receptor 2 (VEGF-R2). Comparison of the ER-targeted intradiabody with the corresponding conventional ER-targeted single-chain antibody fragment ( scFv) intrabodies demonstrated that the intradiabody is significantly more efficient with respect to efficiency and duration of surface depletion of Tie-2 and VEGF-R2. In vitro endothelial cell tube formation assays suggest that the bispecific intradiabody exhibits strong antiangiogenic activity, whereas the effect of the monospecific scFv intrabodies was weaker. These findings suggest that simultaneous interference with the VEGF and the Tie-2 receptor pathways results in at least additive antiangiogenic effects, which may have implications for future drug developments. In conclusion, we have identified a highly effective ER-targeted intrabody format for the simultaneous functional knockout of two cell surface receptors.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Neuropharmacol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute	Rader, C (corresponding author), Scripps Res Inst, Dept Mol Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		McGavern, Dorian/HCH-3601-2022; Chung, Junho/J-2792-2012	McGavern, Dorian/0000-0001-9568-545X; Rader, Christoph/0000-0001-9955-3454	NCI NIH HHS [CA 94966, CA 86258] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA094966, R01CA086258] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bai JR, 2003, J BIOL CHEM, V278, P1433, DOI 10.1074/jbc.M208297200; Barbas C. F., 2001, PHAGE DISPLAY LAB MA; BEERLI RR, 1994, J BIOL CHEM, V269, P23931; Beerli RR, 2002, NAT BIOTECHNOL, V20, P135, DOI 10.1038/nbt0202-135; Coloma MJ, 1997, NAT BIOTECHNOL, V15, P159, DOI 10.1038/nbt0297-159; Dallabrida SM, 2000, J BIOL CHEM, V275, P32281, DOI 10.1074/jbc.M001446200; Deshane J, 1995, J CLIN INVEST, V96, P2980, DOI 10.1172/JCI118370; Deshane J, 1997, GYNECOL ONCOL, V64, P378, DOI 10.1006/gyno.1996.4566; FitzGerald K, 1997, PROTEIN ENG, V10, P1221, DOI 10.1093/protein/10.10.1221; Goldman CK, 1998, P NATL ACAD SCI USA, V95, P8795, DOI 10.1073/pnas.95.15.8795; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Henderson AM, 2001, J BIOL CHEM, V276, P6169, DOI 10.1074/jbc.M008506200; Hitt DC, 2000, MOL BIOTECHNOL, V14, P197, DOI 10.1385/MB:14:3:197; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; Hudson PJ, 2003, NAT MED, V9, P129, DOI 10.1038/nm0103-129; Lener M, 2000, EUR J BIOCHEM, V267, P1196, DOI 10.1046/j.1432-1327.2000.01125.x; Lin PN, 1997, J CLIN INVEST, V100, P2072, DOI 10.1172/JCI119740; Lin PN, 1998, P NATL ACAD SCI USA, V95, P8829, DOI 10.1073/pnas.95.15.8829; Marasco WA, 1997, GENE THER, V4, P11, DOI 10.1038/sj.gt.3300346; MARASCO WA, 1993, P NATL ACAD SCI USA, V90, P7889, DOI 10.1073/pnas.90.16.7889; Marasco WA, 1998, HUM GENE THER, V9, P1627, DOI 10.1089/hum.1998.9.11-1627; Maur AAD, 2002, J BIOL CHEM, V277, P45075, DOI 10.1074/jbc.M205264200; MHASHILKAR AM, 1995, EMBO J, V14, P1542, DOI 10.1002/j.1460-2075.1995.tb07140.x; Millauer B, 1996, CANCER RES, V56, P1615; Muller KM, 1998, FEBS LETT, V432, P45, DOI 10.1016/S0014-5793(98)00829-1; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; Popkov M, 2003, J MOL BIOL, V325, P325, DOI 10.1016/S0022-2836(02)01232-9; Rader C, 2000, J BIOL CHEM, V275, P13668, DOI 10.1074/jbc.275.18.13668; Rader C, 2002, FASEB J, V16, P2000, DOI 10.1096/fj.02-0281fje; Rajpal A, 2001, J BIOL CHEM, V276, P33139, DOI 10.1074/jbc.M101332200; Ruberti F, 2000, J NEUROSCI, V20, P2589; Siemeister G, 1999, CANCER RES, V59, P3185; Steinberger P, 2000, P NATL ACAD SCI USA, V97, P805, DOI 10.1073/pnas.97.2.805; Strube RW, 2002, J IMMUNOL METHODS, V263, P149, DOI 10.1016/S0022-1759(02)00035-2; Todorovska A, 2001, J IMMUNOL METHODS, V248, P47, DOI 10.1016/S0022-1759(00)00342-2; Visintin M, 1999, P NATL ACAD SCI USA, V96, P11723, DOI 10.1073/pnas.96.21.11723; Wagner RW, 1997, MOL MED TODAY, V3, P31, DOI 10.1016/S1357-4310(96)10053-8; Zhu QA, 1999, J IMMUNOL METHODS, V231, P207, DOI 10.1016/S0022-1759(99)00158-1	39	45	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47812	47819		10.1074/jbc.M307002200	http://dx.doi.org/10.1074/jbc.M307002200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12947084	hybrid			2022-12-25	WOS:000186731400057
J	Vicente, R; Escalada, A; Coma, M; Fuster, G; Sanchez-Tillo, E; Lopez-Iglesias, C; Soler, C; Solsona, C; Celada, A; Felipe, A				Vicente, R; Escalada, A; Coma, M; Fuster, G; Sanchez-Tillo, E; Lopez-Iglesias, C; Soler, C; Solsona, C; Celada, A; Felipe, A			Differential voltage-dependent K+ channel responses during proliferation and activation in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; CELL-LINE J774.1; POTASSIUM CHANNELS; MURINE MACROPHAGES; BETA-SUBUNITS; ION CHANNELS; WHOLE-CELL; TYROSINE PHOSPHORYLATION; BRAIN MACROPHAGES; MOUSE MACROPHAGES	Voltage-dependent K+ channels (VDPC) are expressed in most mammalian cells and involved in the proliferation and activation of lymphocytes. However, the role of VDPC in macrophage responses is not well established. This study was undertaken to characterize VDPC in macrophages and determine their physiological role during proliferation and activation. Macrophages proliferate until an endotoxic shock halts cell growth and they become activated. By inducing a schedule that is similar to the physiological pattern, we have identified the VDPC in non-transformed bone marrow-derived macrophages and studied their regulation. Patch clamp studies demonstrated that cells expressed outward delayed and inwardly rectifying K+ currents. Pharmacological data, mRNA, and protein analysis suggest that these currents were mainly mediated by Kv1.3 and Kir2.1 channels. Macrophage colony-stimulating factor-dependent proliferation induced both channels. Lipopolysaccharide (LPS)-induced activation differentially regulated VDPC expression. While Kv1.3 was further induced, Kir2.1 was down-regulated. TNF-alpha mimicked LPS effects, and studies with TNF-alpha receptor I/II double knockout mice demonstrated that LPS regulation mediates such expression by TNF-alpha-dependent and -independent mechanisms. This modulation was dependent on mRNA and protein synthesis. In addition, bone marrow-derived macrophages expressed Kv1.5 mRNA with no apparent regulation. VDPC activities seem to play a critical role during proliferation and activation because not only cell growth, but also inducible nitric-oxide synthase expression were inhibited by blocking their activities. Taken together, our results demonstrate that the differential regulation of VDPC is crucial in intracellular signals determining the specific macrophage response.	Univ Barcelona, Biomed Res Inst Barcelona, Macrophage Biol Grp, E-08028 Barcelona, Spain; Univ Barcelona, Dept Bioquim & Biol Mol, Mol Physiol Lab, E-08028 Barcelona, Spain; Univ Barcelona, Serv Cientificotecn, Unitat Reconeixement Mol In Situ, E-08028 Barcelona, Spain; Univ Barcelona, Dept Fisiol, E-08028 Barcelona, Spain; Univ Barcelona, Dept Biol Cellular & Anat Patol, Cellular & Mol Neurobiol Lab, E-08907 Lhospitalet De Llobregat, Spain	Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; University of Barcelona; University of Barcelona; University of Barcelona; University of Barcelona; University of Barcelona	Celada, A (corresponding author), Univ Barcelona, Biomed Res Inst Barcelona, Macrophage Biol Grp, Barcelona Sci Pk,Josep Samitier 1-5, E-08028 Barcelona, Spain.		García, Rubén Vicente/L-1097-2014; Fuster, Gemma/B-5468-2019; Fuster, Gemma/ACH-5814-2022; Celada, Antonio/I-1714-2016; Soler, Concepció/L-1185-2014; Felipe, Antonio/M-8297-2015	García, Rubén Vicente/0000-0003-0401-4808; Fuster, Gemma/0000-0002-4501-2422; Soler, Concepció/0000-0001-6502-5012; Felipe, Antonio/0000-0002-7294-6431; Celada, Antonio/0000-0003-3883-2171				ATTALI B, 1992, J BIOL CHEM, V267, P8650; Autieri MV, 1997, J NEUROIMMUNOL, V77, P8, DOI 10.1016/S0165-5728(97)00050-7; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Blunck R, 2001, J IMMUNOL, V166, P1009, DOI 10.4049/jimmunol.166.2.1009; Bock J, 2002, BIOCHEM BIOPH RES CO, V295, P526, DOI 10.1016/S0006-291X(02)00695-2; Bortner CD, 1999, J BIOL CHEM, V274, P21953, DOI 10.1074/jbc.274.31.21953; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Cahalan MD, 2001, J CLIN IMMUNOL, V21, P235, DOI 10.1023/A:1010958907271; Cain K, 2001, J BIOL CHEM, V276, P41985, DOI 10.1074/jbc.M107419200; CELADA A, 1989, EUR J IMMUNOL, V19, P1103, DOI 10.1002/eji.1830190621; CELADA A, 1994, IMMUNOL TODAY, V15, P100, DOI 10.1016/0167-5699(94)90150-3; Chittajallu R, 2002, P NATL ACAD SCI USA, V99, P2350, DOI 10.1073/pnas.042698399; Colden-Stanfield M, 1998, AM J PHYSIOL-CELL PH, V275, pC267, DOI 10.1152/ajpcell.1998.275.1.C267; Coma M, 2003, FEBS LETT, V536, P45, DOI 10.1016/S0014-5793(03)00009-7; Cullell-Young M, 2001, IMMUNOGENETICS, V53, P136, DOI 10.1007/s002510100312; Dallaporta B, 1999, J IMMUNOL, V162, P6534; DeCoursey TE, 1996, J MEMBRANE BIOL, V152, P141, DOI 10.1007/s002329900093; DECOURSEY TE, 1999, INFLAMMATION BASIC P, P141; Eder C, 1997, N-S ARCH PHARMACOL, V355, P198, DOI 10.1007/PL00004932; Eder C, 1997, N-S ARCH PHARMACOL, V356, P233, DOI 10.1007/PL00005046; Eder C, 1998, AM J PHYSIOL-CELL PH, V275, pC327, DOI 10.1152/ajpcell.1998.275.2.C327; Fischer-Lougheed J, 2001, J CELL BIOL, V153, P677, DOI 10.1083/jcb.153.4.677; FREEDMAN BD, 1992, J IMMUNOL, V149, P3784; FREEDMAN BD, 1995, J BIOL CHEM, V270, P22406, DOI 10.1074/jbc.270.38.22406; Fuster G, 2002, METHOD FIND EXP CLIN, V24, P253, DOI 10.1358/mf.2002.24.5.802301; GALLIN EK, 1989, AM J PHYSIOL, V257, pC77, DOI 10.1152/ajpcell.1989.257.1.C77; GALLIN EK, 1988, J MEMBRANE BIOL, V103, P55, DOI 10.1007/BF01871932; GALLIN EK, 1984, BIOPHYS J, V46, P821, DOI 10.1016/S0006-3495(84)84080-1; GALLIN EK, 1985, J PHYSIOL-LONDON, V369, P475, DOI 10.1113/jphysiol.1985.sp015911; GALLIN EK, 1991, PHYSIOL REV, V71, P775, DOI 10.1152/physrev.1991.71.3.775; GALLIN EK, 1981, AM J PHYSIOL, V241, pC9, DOI 10.1152/ajpcell.1981.241.1.C9; GARCIACALVO M, 1993, J BIOL CHEM, V268, P18866; Ghiani CA, 1999, J NEUROSCI, V19, P5380; Grande M, 2003, J CELL PHYSIOL, V195, P187, DOI 10.1002/jcp.10203; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; Holmes TC, 1996, J NEUROSCI, V16, P1581; Holmes TC, 1997, J NEUROSCI, V17, P8964; JUDGE SIV, 1994, AM J PHYSIOL-CELL PH, V267, pC1691, DOI 10.1152/ajpcell.1994.267.6.C1691; Kalman K, 1998, J BIOL CHEM, V273, P32697, DOI 10.1074/jbc.273.49.32697; Kotecha SA, 1999, J NEUROSCI, V19, P10680, DOI 10.1523/JNEUROSCI.19-24-10680.1999; LeppleWienhues A, 1996, J MEMBRANE BIOL, V151, P149, DOI 10.1007/s002329900066; Levite M, 2000, J EXP MED, V191, P1167, DOI 10.1084/jem.191.7.1167; Lowry MAR, 1998, CLIN EXP IMMUNOL, V111, P597; LU L, 1993, J MEMBRANE BIOL, V132, P267; MARUYAMA N, 1994, AM J RESP CELL MOL, V10, P514, DOI 10.1165/ajrcmb.10.5.8179913; McCormack T, 1999, J BIOL CHEM, V274, P20123, DOI 10.1074/jbc.274.29.20123; MCKINNEY LC, 1988, J MEMBRANE BIOL, V103, P41, DOI 10.1007/BF01871931; MCKINNEY LC, 1992, J MEMBRANE BIOL, V130, P265; NELSON DJ, 1992, J MEMBRANE BIOL, V125, P201; OGAWA M, 1993, BLOOD, V81, P2844; Qiu MR, 2002, CLIN EXP IMMUNOL, V130, P67, DOI 10.1046/j.1365-2249.2002.01965.x; Schilling T, 2000, AM J PHYSIOL-CELL PH, V279, pC1123, DOI 10.1152/ajpcell.2000.279.4.C1123; Schmid-Antomarchi H, 1997, J IMMUNOL, V159, P6209; Sobko A, 1998, J NEUROSCI, V18, P10398; Soler C, 2001, FASEB J, V15, P1979, DOI 10.1096/fj.01-0022com; Soler C, 2001, J BIOL CHEM, V276, P30043, DOI 10.1074/jbc.M101807200; Stanley ER, 1997, MOL REPROD DEV, V46, P4, DOI 10.1002/(SICI)1098-2795(199701)46:1<4::AID-MRD2>3.0.CO;2-V; Sweet MJ, 1996, J LEUKOCYTE BIOL, V60, P8, DOI 10.1002/jlb.60.1.8; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; Valledor AF, 2000, J IMMUNOL, V164, P29, DOI 10.4049/jimmunol.164.1.29; VICENTE R, 2003, J PHYSL P, V548, DOI UNSP 020; WIELAND SJ, 1990, J CELL PHYSIOL, V142, P643, DOI 10.1002/jcp.1041420326; Xaus J, 1999, IMMUNITY, V11, P103, DOI 10.1016/S1074-7613(00)80085-0; Xaus J, 2000, BLOOD, V95, P3823; YPEY DL, 1984, P NATL ACAD SCI-BIOL, V81, P3083, DOI 10.1073/pnas.81.10.3083; Yu SP, 1999, J NEUROCHEM, V73, P933, DOI 10.1046/j.1471-4159.1999.0730933.x	66	138	148	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46307	46320		10.1074/jbc.M304388200	http://dx.doi.org/10.1074/jbc.M304388200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12923194	hybrid, Green Published			2022-12-25	WOS:000186569400014
J	Witt, H; Bordignon, E; Carbonera, D; Dekker, JP; Karapetyan, N; Teutloff, C; Webber, A; Lubitz, W; Schlodder, E				Witt, H; Bordignon, E; Carbonera, D; Dekker, JP; Karapetyan, N; Teutloff, C; Webber, A; Lubitz, W; Schlodder, E			Species-specific differences of the spectroscopic properties of P700 - Analysis of the influence of non-conserved amino acid residues by site-directed mutagenesis of photosystem I from Chlamydomonas reinhardtii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMARY ELECTRON-DONOR; REACTION CENTERS; CHLOROPHYLL-A; EXTINCTION COEFFICIENTS; CONSERVED HISTIDINES; PROTEIN COMPLEX; AXIAL LIGANDS; ABSORPTION; STATE; ARRANGEMENT	We applied optical spectroscopy, magnetic resonance techniques, and redox titrations to investigate the properties of the primary electron donor P700 in photosystem I (PS I) core complexes from cyanobacteria (Thermosynechococcus elongatus, Spirulina platensis, and Synechocystis sp. PCC 6803), algae (Chlamydomonas reinhardtii CC2696), and higher plants (Spinacia oleracea). Remarkable species-specific differences of the optical properties of P700 were revealed monitoring the ((3)P700-P700) and (P700(+.)-P700) absorbance and CD difference spectra. The main bleaching band in the Q(y) region differs in peak position and line width for the various species. In cyanobacteria the absorbance of P700 extends more to the red compared with algae and higher plants which is favorable for energy transfer from red core antenna chlorophylls to P700 in cyanobacteria. The amino acids in the environment of P700 are highly conserved with two distinct deviations. In C. reinhardtii a Tyr is found at position PsaB659 instead of a Trp present in all other organisms, whereas in Synechocystis a Phe is found instead of a Trp at the homologous position PsaA679. We constructed several mutants in C. reinhardtii CC2696. Strikingly, no PS I could be detected in the mutant YW B659 indicating steric constraints unique to this organism. In the mutants WA A679 and YA B659 significant changes of the spectral features in the ((3)P700 - P700), the (P700(+.)-P700) absorbance difference and in the (P700(+.)-P700) CD difference spectra are induced. The results indicate structural differences among PS I from higher plants, algae, and cyanobacteria and give further insight into specific protein-cofactor interactions contributing to the optical spectra.	Tech Univ Berlin, Max Volmer Lab Biophys Chem, D-10623 Berlin, Germany; Univ Padua, Dipartimento Chim Fis, I-35131 Padua, Italy; Russian Acad Sci, AN Bakh Biochem Inst, Moscow 119071, Russia; Vrije Univ Amsterdam, Dept Phys & Astron, NL-1081 HV Amsterdam, Netherlands; Arizona State Univ, Dept Plant Biol, Ctr Study Early Events Photosynth, Tempe, AZ 85287 USA; MPI Bioanorgan Chem, D-45470 Mulheim, Germany	Technical University of Berlin; University of Padua; Research Center of Biotechnology RAS; Russian Academy of Sciences; Vrije Universiteit Amsterdam; Arizona State University; Arizona State University-Tempe	Witt, H (corresponding author), Tech Univ Berlin, Max Volmer Lab Biophys Chem, Str 17 Juni 135, D-10623 Berlin, Germany.	h.witt.berlin@web.de; eber0535@mailbox.tu-berlin.de	Carbonera, Donatella/B-4219-2018; Schlodder, Eberhard/AAP-6766-2021	Carbonera, Donatella/0000-0002-5499-1140; Bordignon, Enrica/0000-0003-2450-5161				ANGERHOFER A, 1991, CHLOROPHYLLS, P945; Baymann D, 2001, BBA-BIOENERGETICS, V1507, P291, DOI 10.1016/S0005-2728(01)00209-2; Breton J, 2001, BBA-BIOENERGETICS, V1507, P180, DOI 10.1016/S0005-2728(01)00206-7; Brettel K, 1997, BBA-BIOENERGETICS, V1318, P322, DOI 10.1016/S0005-2728(96)00112-0; Byrdin M, 2002, BIOPHYS J, V83, P433, DOI 10.1016/S0006-3495(02)75181-3; Carbonera D, 1997, BBA-BIOENERGETICS, V1322, P115, DOI 10.1016/S0005-2728(97)00068-6; Cometta A, 2000, BIOPHYS J, V79, P3235, DOI 10.1016/S0006-3495(00)76556-8; CUI LY, 1995, BIOCHEMISTRY-US, V34, P1549, DOI 10.1021/bi00005a011; FLEMMING C, 1995, THESIS TU BERLIN; Fromme P, 1998, BBA-BIOENERGETICS, V1365, P175, DOI 10.1016/S0005-2728(98)00059-0; FROMME P, 2003, LIGHT HARVESTING ANT, P253; GILLIE JK, 1989, PHOTOSYNTH RES, V22, P233, DOI 10.1007/BF00048302; Gobets B, 2001, BIOPHYS J, V81, P407, DOI 10.1016/S0006-3495(01)75709-8; Guergova-Kuras M, 2001, P NATL ACAD SCI USA, V98, P4437, DOI 10.1073/pnas.081078898; Harris EH, 1989, CHLAMYDOMONAS SOURCE, P25, DOI [DOI 10.1016/B978-0-12-326880-8.50007-9, DOI 10.1126/SCIENCE.246.4936.1503-A]; HEATHCOTE P, 2001, BIOCH BIOPHYS ACTA, V1507; Hippler M, 1998, BBA-BIOENERGETICS, V1367, P1, DOI 10.1016/S0005-2728(98)00136-4; HIYAMA T, 1972, BIOCHIM BIOPHYS ACTA, V267, P160, DOI 10.1016/0005-2728(72)90147-8; HUBER M, 1986, CHEM PHYS LETT, V132, P467, DOI 10.1016/0009-2614(86)80648-0; Jordan P, 2001, NATURE, V411, P909, DOI 10.1038/35082000; Kass H, 2001, J PHYS CHEM B, V105, P1225, DOI 10.1021/jp0032311; KASS H, 1995, THESIS TU BERLIN; Krabben L, 2000, BIOCHEMISTRY-US, V39, P13012, DOI 10.1021/bi001200q; KRABBEN L, 1999, THESIS TU BERLIN; Kruip J, 1999, J BIOL CHEM, V274, P18181, DOI 10.1074/jbc.274.26.18181; KRUIP J, 1993, J BIOL CHEM, V268, P23353; KWA SLS, 1994, PHOTOCHEM PHOTOBIOL, V59, P219, DOI 10.1111/j.1751-1097.1994.tb05026.x; Leibl W, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P595; Lubitz W., 1991, CHLOROPHYLLS, P903; MANNA P, 1999, FUNCTION MOL GENETIC, V1; Palsson LO, 1998, BIOPHYS J, V74, P2611, DOI 10.1016/S0006-3495(98)77967-6; PHILIPSON KD, 1972, BIOCHEMISTRY-US, V11, P4591, DOI 10.1021/bi00774a027; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; RAUTTER J, 1995, BIOCHEMISTRY-US, V34, P8130, DOI 10.1021/bi00025a020; RAUTTER J, 1994, BIOCHEMISTRY-US, V33, P12077, DOI 10.1021/bi00206a010; Redding K, 1998, EMBO J, V17, P50, DOI 10.1093/emboj/17.1.50; Rochaix JD, 2001, PLANT PHYSIOL, V127, P1394, DOI 10.1104/pp.010628; RUTHERFORD AW, 1981, BIOCHIM BIOPHYS ACTA, V635, P225, DOI 10.1016/0005-2728(81)90022-0; Scheller HV, 2001, BBA-BIOENERGETICS, V1507, P41, DOI 10.1016/S0005-2728(01)00196-7; Schlodder E, 1998, BIOCHEMISTRY-US, V37, P9466, DOI 10.1021/bi973182r; SCHLODDER E, 2001, PS2001 P 12 INT C PH; Schwabe TME, 2000, INDIAN J BIOCHEM BIO, V37, P351; SETIF P, 1984, BIOCHIM BIOPHYS ACTA, V767, P404, DOI 10.1016/0005-2728(84)90038-0; SHUBIN VV, 1986, PHOTOSYNTH RES, V9, P3, DOI 10.1007/BF00029726; SONOIKE K, 1989, BIOCHIM BIOPHYS ACTA, V976, P210, DOI 10.1016/S0005-2728(89)80232-4; VANDERLEE J, 1993, PHOTOSYNTH RES, V35, P311, DOI 10.1007/BF00016562; Webber AN, 2001, BBA-BIOENERGETICS, V1507, P61, DOI 10.1016/S0005-2728(01)00198-0; WILLIAMS JC, 1992, BIOCHEMISTRY-US, V31, P11029, DOI 10.1021/bi00160a012; Witt H, 2002, BIOCHEMISTRY-US, V41, P8557, DOI 10.1021/bi025822i; Xu W, 2003, J BIOL CHEM, V278, P27876, DOI 10.1074/jbc.M302965200	50	56	59	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46760	46771		10.1074/jbc.M304776200	http://dx.doi.org/10.1074/jbc.M304776200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12933812	hybrid, Green Published			2022-12-25	WOS:000186569400067
J	Zhang, Z; Palzkill, T				Zhang, Z; Palzkill, T			Determinants of binding affinity and specificity for the interaction of TEM-1 and SME-1 beta-lactamase with beta-lactamase inhibitory protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOT-SPOTS; RESIDUES; SCHEME; POTENT; ENERGY	The hydrolysis of beta-lactam antibiotics by class A beta-lactamases is a common cause of bacterial resistance to these agents. The beta-lactamase inhibitory protein (BLIP) is able to bind and inhibit several class A beta-lactamases, including TEM-1 beta-lactamase and SME-1 beta-lactamase. Although the TEM-1 and SME-1 enzymes share 33% amino acid sequence identity and a similar fold, they differ substantially in surface electrostatic properties and the conformation of a loop-helix region that BLIP binds. Alanine-scanning mutagenesis was performed to identify the residues on BLIP that contribute to its binding affinity for each of these enzymes. The results indicate that the sequence requirements for binding are similar for both enzymes with most of the binding free energy provided by two patches of aromatic residues on the surface of BLIP. Polar residues such as several serines in the interface do not make significant contributions to affinity for either enzyme. In addition, the specificity of binding is significantly altered by mutation of two charged residues, Glu(73) and Lys(74), that are buried in the structure of the TEM-1.BLIP complex as well as by residues located on two loops that insert into the active site pocket. Based on the results, a E73A/Y50A double mutant was constructed that exhibited a 220,000-fold change in binding specificity for the TEM-1 versus SME-1 enzymes.	Baylor Coll Med, Struct & Computat Biol & Mol Biophys Program, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; Baylor Coll Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Palzkill, T (corresponding author), Baylor Coll Med, Struct & Computat Biol & Mol Biophys Program, Houston, TX 77030 USA.	timothyp@bcm.tmc.edu						Albeck S, 1999, BIOCHEMISTRY-US, V38, P11, DOI 10.1021/bi981772z; AMANN E, 1983, GENE, V25, P167, DOI 10.1016/0378-1119(83)90222-6; AMBLER RP, 1991, BIOCHEM J, V276, P269, DOI 10.1042/bj2760269; Atwell S, 1997, SCIENCE, V278, P1125, DOI 10.1126/science.278.5340.1125; Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSH K, 1995, ANTIMICROB AGENTS CH, V39, P1211, DOI 10.1128/AAC.39.6.1211; Cantu C, 1997, J BIOL CHEM, V272, P29144, DOI 10.1074/jbc.272.46.29144; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; del Alamo M, 2003, J BIOL CHEM, V278, P27923, DOI 10.1074/jbc.M304466200; DeLano WL, 2002, CURR OPIN STRUC BIOL, V12, P14, DOI 10.1016/S0959-440X(02)00283-X; DENNIS MS, 1994, J BIOL CHEM, V269, P22129; DORAN JL, 1990, J BACTERIOL, V172, P4909, DOI 10.1128/jb.172.9.4909-4918.1990; GRIBSKOV M, 1984, NUCLEIC ACIDS RES, V12, P539, DOI 10.1093/nar/12.1Part2.539; HENDSCH ZS, 1994, PROTEIN SCI, V3, P211; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUANG W, 2000, J BIOL CHEM, V275, P14984; Huang WZ, 1998, ANTIMICROB AGENTS CH, V42, P2893, DOI 10.1128/AAC.42.11.2893; JELSCH C, 1993, PROTEINS, V16, P364, DOI 10.1002/prot.340160406; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; Lo Conte L, 1999, J MOL BIOL, V285, P2177; Ma BY, 2003, P NATL ACAD SCI USA, V100, P5772, DOI 10.1073/pnas.1030237100; Majiduddin FK, 2003, ANTIMICROB AGENTS CH, V47, P1062, DOI 10.1128/AAC.47.3.1062-1067.2003; Myers DP, 2001, BIOCHEMISTRY-US, V40, P13230, DOI 10.1021/bi0155908; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Petrosino J, 1999, J BIOL CHEM, V274, P2394, DOI 10.1074/jbc.274.4.2394; Queenan AM, 2000, ANTIMICROB AGENTS CH, V44, P3035, DOI 10.1128/AAC.44.11.3035-3039.2000; Rudgers GW, 1999, J BIOL CHEM, V274, P6963, DOI 10.1074/jbc.274.11.6963; Selzer T, 2000, NAT STRUCT BIOL, V7, P537; Sheinerman FB, 2000, CURR OPIN STRUC BIOL, V10, P153, DOI 10.1016/S0959-440X(00)00065-8; Sougakoff W, 2002, ACTA CRYSTALLOGR D, V58, P267, DOI 10.1107/S0907444901019606; STRYNADKA NCJ, 1994, NATURE, V368, P657, DOI 10.1038/368657a0; Strynadka NCJ, 1996, NAT STRUCT BIOL, V3, P290, DOI 10.1038/nsb0396-290; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; Thorn KS, 2001, BIOINFORMATICS, V17, P284, DOI 10.1093/bioinformatics/17.3.284; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001	39	48	52	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45706	45712		10.1074/jbc.M308572200	http://dx.doi.org/10.1074/jbc.M308572200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12933802	hybrid			2022-12-25	WOS:000186452300080
J	Agarwal, R; Tang, ZY; Yu, HT; Cohen-Fix, O				Agarwal, R; Tang, ZY; Yu, HT; Cohen-Fix, O			Two distinct pathways for inhibiting Pds1 ubiquitination in response to DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAK; SACCHAROMYCES-CEREVISIAE; ANAPHASE INHIBITOR; BUDDING YEAST; CHECKPOINT PATHWAYS; MITOSIS; CDC20; PHOSPHORYLATION; PROTEOLYSIS; APC	The presence of DNA damage activates a conserved cellular response known as the DNA damage checkpoint pathway. This pathway induces a cell cycle arrest that persists until the damage is repaired. Consequently, the failure to arrest in response to DNA damage is associated with genomic instability. In budding yeast, activation of the DNA damage checkpoint pathway leads to a mitotic cell cycle arrest. Following the detection of DNA damage, the checkpoint signal is transduced via the Mec1 kinase, which in turn activates two kinases, Rad53 and Chk1 that act in parallel pathways to bring about the cell cycle arrest. The downstream target of Rad53 is unknown. The target of Chk1 is Pds1, an inhibitor of anaphase initiation whose degradation is a prerequisite for mitotic progression. Pds1 degradation is dependent on its ubiquitination by the anaphase-promoting complex/ cyclosome ubiquitin ligase, acting in conjunction with the Cdc20 protein (APC/C-Cdc20). Previous studies showed that the Rad53 and Chk1 pathways independently lead to Pds1 stabilization but the mechanism for this was unknown. In the present study we show that both the Chk1 and the Rad53 pathways inhibit the APC/ C-Cdc20-dependent ubiquitination of Pds1 but they affect different steps of the process: the Rad53 pathway inhibits the Pds1-Cdc20 interaction whereas Chk1-dependent phosphorylation of Pds1 inhibits the ubiquitination reaction itself. Finally, we show that once the DNA damage is repaired, Pds1 dephosphorylation is involved in the recovery from the checkpoint induced cell cycle arrest.	NIDDK, Mol & Cellular Biol Lab, NIH, Bethesda, MD 20892 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Cohen-Fix, O (corresponding author), NIDDK, Mol & Cellular Biol Lab, NIH, Bethesda, MD 20892 USA.			Yu, Hongtao/0000-0002-8861-049X	NIGMS NIH HHS [GM61542] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK057803] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061542] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agarwal R, 2002, GENE DEV, V16, P1371, DOI 10.1101/gad.971402; AMON A, 1992, NATURE, V355, P368, DOI 10.1038/355368a0; Ciosk R, 1998, CELL, V93, P1067, DOI 10.1016/S0092-8674(00)81211-8; Cohen-Fix O, 1997, P NATL ACAD SCI USA, V94, P14361, DOI 10.1073/pnas.94.26.14361; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; Gardner R, 1999, EMBO J, V18, P3173, DOI 10.1093/emboj/18.11.3173; Haber JE, 2000, CURR OPIN CELL BIOL, V12, P286, DOI 10.1016/S0955-0674(00)00090-9; Hilioti Z, 2001, CURR BIOL, V11, P1347, DOI 10.1016/S0960-9822(01)00399-2; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; Leroy C, 2003, MOL CELL, V11, P827, DOI 10.1016/S1097-2765(03)00058-3; Lim HH, 1996, MOL GEN GENET, V253, P138, DOI 10.1007/s004380050306; Lim HH, 1998, CURR BIOL, V8, P231, DOI 10.1016/S0960-9822(98)70088-0; Marsolier MC, 2000, GENETICS, V154, P1523; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Morgan DO, 2002, NATURE, V418, P495, DOI 10.1038/418495a; Nasmyth K, 2000, SCIENCE, V288, P1379, DOI 10.1126/science.288.5470.1379; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Prinz S, 1998, CURR BIOL, V8, P750, DOI 10.1016/S0960-9822(98)70298-2; Resnick M A, 1975, Basic Life Sci, V5B, P549; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; Schwab M, 2001, EMBO J, V20, P5165, DOI 10.1093/emboj/20.18.5165; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; Shirayama M, 1999, NATURE, V402, P203, DOI 10.1038/46080; Uhlmann F, 2000, CELL, V103, P375, DOI 10.1016/S0092-8674(00)00130-6; Vaze MB, 2002, MOL CELL, V10, P373, DOI 10.1016/S1097-2765(02)00593-2; Visintin R, 1998, MOL CELL, V2, P709, DOI 10.1016/S1097-2765(00)80286-5; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Walworth NC, 2001, CURR OPIN GENET DEV, V11, P78, DOI 10.1016/S0959-437X(00)00160-X; Wang H, 2001, GENE DEV, V15, P1361, DOI 10.1101/gad.893201; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141; Yamamoto A, 1996, J CELL BIOL, V133, P99, DOI 10.1083/jcb.133.1.99; Zachariae W, 1998, SCIENCE, V282, P1721, DOI 10.1126/science.282.5394.1721	33	80	82	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					45027	45033		10.1074/jbc.M306783200	http://dx.doi.org/10.1074/jbc.M306783200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12947083	hybrid			2022-12-25	WOS:000186306700140
J	Chan, PC; Chen, YL; Cheng, CH; Yu, KC; Cary, LA; Shu, KH; Ho, WL; Chen, HC				Chan, PC; Chen, YL; Cheng, CH; Yu, KC; Cary, LA; Shu, KH; Ho, WL; Chen, HC			Src phosphorylates Grb2-associated binder 1 upon hepatocyte growth factor stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; FOCAL ADHESION KINASE; EPITHELIAL MORPHOGENESIS DOWNSTREAM; SIGNAL-REGULATED KINASE; DOCKING PROTEIN GAB1; GRB2 BINDING-SITE; C-MET; ADAPTER PROTEIN; FACTOR HGF; PHOSPHATIDYLINOSITOL 3-KINASE	Grb2-associated binder 1 (Gab1) is known to play an important role in hepatocyte growth factor (HGF) signaling, which rapidly becomes tyrosine-phosphorylated upon HGF stimulation. In this study, we found that the tyrosine phosphorylation of Gab1 in the cells derived from Src/Yes/Fyn null mouse embryos was similar to40% lower than that in their wild type counterparts upon HGF stimulation. Increased expression of wild-type Src enhanced HGF-induced phosphorylation of Gab1, and, in contrast, expression of the Src kinase-deficient mutant or treatment of the specific Src inhibitor PP1 suppressed it. Expression of a constitutively active Src mutant (Y527F) or oncogenic v-Src led to a prominent increase in Gab1 phosphorylation independent of HGF stimulation. Moreover, Src interacted with Gab1 via both its Src homology 2 and 3 domains and was capable of phosphorylating purified Gab1 in vitro. Finally, the increased phosphorylation of Gab1 by Src selectively potentiated HGF-induced activation of ERK and AKT. Taken together, our results establish a new role for Src in HGF-induced Gab1 phosphorylation.	Natl Chung Hsing Univ, Dept Life Sci, Taichung 40227, Taiwan; Natl Chung Hsing Univ, Grad Inst Biomed Sci, Taichung 40227, Taiwan; Taichung Vet Gen Hosp, Dept Pathol, Taichung 40705, Taiwan; Taichung Vet Gen Hosp, Nephrol Sect, Taichung 40705, Taiwan; Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA	National Chung Hsing University; National Chung Hsing University; Taichung Veterans General Hospital; Taichung Veterans General Hospital; Fred Hutchinson Cancer Center	Chen, HC (corresponding author), Natl Chung Hsing Univ, Dept Life Sci, Taichung 40227, Taiwan.							Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; Cary LA, 2002, MOL CELL BIOL, V22, P2427, DOI 10.1128/MCB.22.8.2427-2440.2002; Chan PC, 2002, J BIOL CHEM, V277, P50373, DOI 10.1074/jbc.M204691200; Chen HC, 1998, J BIOL CHEM, V273, P25777, DOI 10.1074/jbc.273.40.25777; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Cunnick JM, 2001, J BIOL CHEM, V276, P24380, DOI 10.1074/jbc.M010275200; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; Garcia-Guzman M, 1999, ONCOGENE, V18, P7775, DOI 10.1038/sj.onc.1203198; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; Gu HH, 2003, TRENDS CELL BIOL, V13, P122, DOI 10.1016/S0962-8924(03)00002-3; Gual P, 2000, ONCOGENE, V19, P1509, DOI 10.1038/sj.onc.1203514; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; Itoh M, 2000, MOL CELL BIOL, V20, P3695, DOI 10.1128/MCB.20.10.3695-3704.2000; Kong M, 2003, J BIOL CHEM, V278, P5837, DOI 10.1074/jbc.M208286200; Lehr S, 1999, BIOCHEMISTRY-US, V38, P151, DOI 10.1021/bi9818265; Lehr S, 2000, BIOCHEMISTRY-US, V39, P10898, DOI 10.1021/bi000982k; Lock LS, 2002, MOL BIOL CELL, V13, P2132, DOI 10.1091/mbc.02-02-0031; Lock LS, 2000, J BIOL CHEM, V275, P31536, DOI 10.1074/jbc.M003597200; Maroun CR, 2000, MOL CELL BIOL, V20, P8513, DOI 10.1128/MCB.20.22.8513-8525.2000; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, ONCOGENE, V6, P501; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; Ong SH, 1997, BIOCHEM BIOPH RES CO, V238, P261, DOI 10.1006/bbrc.1997.7272; PELICCI G, 1995, ONCOGENE, V10, P1631; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Rahimi N, 1998, J BIOL CHEM, V273, P33714, DOI 10.1074/jbc.273.50.33714; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; Sachs M, 2000, J CELL BIOL, V150, P1375, DOI 10.1083/jcb.150.6.1375; Sakkab D, 2000, J BIOL CHEM, V275, P10772, DOI 10.1074/jbc.275.15.10772; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177; ZHU H, 1994, J BIOL CHEM, V269, P29943	47	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44075	44082		10.1074/jbc.M305745200	http://dx.doi.org/10.1074/jbc.M305745200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12941962	hybrid			2022-12-25	WOS:000186306700024
J	Feranchak, AP; Kilic, G; Wojtaszek, PA; Qadri, I; Fitz, JG				Feranchak, AP; Kilic, G; Wojtaszek, PA; Qadri, I; Fitz, JG			Volume-sensitive tyrosine kinases regulate liver cell volume through effects on vesicular trafficking and membrane Na+ permeability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATION-SELECTIVE CHANNELS; RAT HEPATOCYTES; PROTEIN-KINASE; CALCIUM INFLUX; ATP RELEASE; MAP KINASE; C-SRC; CONDUCTANCE; PHOSPHORYLATION; ACTIVATION	In liver cells, the influx of Na+ mediated by nonselective cation (NSC) channels in the plasma membrane contributes importantly to regulation of cell volume. Under basal conditions, channels are closed; but both physiologic (e.g. insulin) and pathologic (e.g. oxidative stress) stimuli that are known to stimulate tyrosine kinases are associated with large increases in membrane Na+ permeability to similar to 80 pA/pF or more. Consequently, the purpose of these studies was to evaluate whether volume-sensitive tyrosine kinases mediate cell volume increases through effects on the activity or distribution of NSC channel proteins. In HTC hepatoma cells, decreases in cell volume evoked by hypertonic exposure increased total cellular tyrosine kinase activity similar to20-fold. Moreover, hypertonic exposure (320 - 400 mosM) was followed after a delay by NSC channel activation and partial recovery of cell volume toward basal values ( regulatory volume increase (RVI)). The tyrosine kinase inhibitors genistein and erbstatin prevented both NSC channel activation and RVI. Similarly, hypertonic exposure resulted in an increase in p60(c-src) activity, and intracellular dialysis with recombinant p60(c-src) led to activation of NSC currents in the absence of an osmolar gradient. Utilizing FM1-43 fluorescence, exposure to hypertonic media caused a rapid increase in the rate of exocytosis of similar to 40% (p < 0.01), and genistein inhibited both exocytosis and channel activation. These findings indicate that volume-sensitive increases in p60(c-src) and/or related tyrosine kinases play a key role in the regulation of membrane Na+ permeability, suggesting that increases in the NSC conductance may be mediated in part through rapid recruitment of a distinct pool of channel-containing vesicles.	Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Fitz, JG (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pediat, Rm 6412,Campus Box B158, Denver, CO 80262 USA.		Qadri, Ishtiaq/I-6889-2013	Qadri, Ishtiaq/0000-0003-4334-0585	NIDDK NIH HHS [DK 43278, DK 46082, R01 DK078587, DK 61480, K08 DK061480] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK046082, K08DK061480, R01DK046082, R01DK043278] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALHABORI M, 1992, BIOCHEM J, V282, P789, DOI 10.1042/bj2820789; BERGER HA, 1993, J BIOL CHEM, V268, P2037; BETZ WJ, 1992, J NEUROSCI, V12, P363, DOI 10.1523/jneurosci.12-02-00363.1992; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Bohmer C, 2001, FEBS LETT, V494, P125, DOI 10.1016/S0014-5793(01)02303-1; Broome MA, 1996, J BIOL CHEM, V271, P16798, DOI 10.1074/jbc.271.28.16798; BRUCK R, 1992, AM J PHYSIOL, V262, pG806, DOI 10.1152/ajpgi.1992.262.5.G806; CARINI R, 1994, BIOCHEM BIOPH RES CO, V202, P360, DOI 10.1006/bbrc.1994.1936; Daulhac L, 1999, J BIOL CHEM, V274, P20657, DOI 10.1074/jbc.274.29.20657; Dunkelberg JC, 2001, HEPATOLOGY, V33, P1349, DOI 10.1053/jhep.2001.24750; Feranchak AP, 2001, J CLIN INVEST, V108, P1495, DOI 10.1172/JCI200112190; Feranchak AP, 1998, J BIOL CHEM, V273, P14906, DOI 10.1074/jbc.273.24.14906; FITZ JG, 1994, AM J PHYSIOL, V266, pG677, DOI 10.1152/ajpgi.1994.266.4.G677; FITZ JG, 1994, AM J PHYSIOL, V266, pG544, DOI 10.1152/ajpgi.1994.266.4.G544; FITZ JG, 1991, J MEMBRANE BIOL, V122, P1, DOI 10.1007/BF01872734; Gentili C, 2002, J CELL BIOCHEM, V86, P773, DOI 10.1002/jcb.10264; Gilmore ES, 2001, J BIOL CHEM, V276, P42610, DOI 10.1074/jbc.M106919200; GOMAN RM, 1999, AM J PHYSIOL, V277, pG1222; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HEASLEY LE, 1994, AM J PHYSIOL, V267, pF366, DOI 10.1152/ajprenal.1994.267.3.F366; Hunter T, 1998, PHILOS T R SOC B, V353, P583, DOI 10.1098/rstb.1998.0228; Jones RJ, 2000, EUR J CANCER, V36, P1595, DOI 10.1016/S0959-8049(00)00153-2; Kapus A, 1999, J BIOL CHEM, V274, P8093, DOI 10.1074/jbc.274.12.8093; Kilic G, 2001, J BIOL CHEM, V276, P26762, DOI 10.1074/jbc.M100992200; Krump E, 1997, J BIOL CHEM, V272, P17303, DOI 10.1074/jbc.272.28.17303; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; LIDOFSKY SD, 1993, J BIOL CHEM, V268, P14632; Lidofsky SD, 1997, J MEMBRANE BIOL, V157, P231, DOI 10.1007/s002329900231; Misra S, 2003, AM J PHYSIOL-GASTR L, V285, pG316, DOI 10.1152/ajpgi.00048.2003; Ouwens DM, 2001, BBA-MOL CELL RES, V1540, P97, DOI 10.1016/S0167-4889(01)00126-4; PRINCE LS, 1994, P NATL ACAD SCI USA, V91, P5192, DOI 10.1073/pnas.91.11.5192; Qin SF, 2003, BIOCHEMISTRY-US, V42, P2995, DOI 10.1021/bi0205911; Reinehr R, 2003, FASEB J, V17, P731, DOI 10.1096/fj.02-0915fje; Rizoli SB, 1999, J BIOL CHEM, V274, P22072, DOI 10.1074/jbc.274.31.22072; Roman RM, 1997, J BIOL CHEM, V272, P21970, DOI 10.1074/jbc.272.35.21970; Schlenker T, 2000, GASTROENTEROLOGY, V118, P395, DOI 10.1016/S0016-5085(00)70222-8; Schliess F, 2000, CELL PHYSIOL BIOCHEM, V10, P403, DOI 10.1159/000016378; Szaszi K, 1997, J BIOL CHEM, V272, P16670, DOI 10.1074/jbc.272.26.16670; Tsunoda Y, 1996, BIOCHEM BIOPH RES CO, V227, P876, DOI 10.1006/bbrc.1996.1599; Wehner F, 1998, J PHYSIOL-LONDON, V506, P127, DOI 10.1111/j.1469-7793.1998.127bx.x; WONDERGEM R, 1994, ALCOHOL CLIN EXP RES, V18, P1230, DOI 10.1111/j.1530-0277.1994.tb00110.x	42	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44632	44638		10.1074/jbc.M301958200	http://dx.doi.org/10.1074/jbc.M301958200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12939281	hybrid			2022-12-25	WOS:000186306700094
J	Wang, L; Yang, L; Luo, YN; Zheng, Y				Wang, L; Yang, L; Luo, YN; Zheng, Y			A novel strategy for specifically down-regulating individual Rho GTPase activity in tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING PROTEINS P190; BINDING-PROTEIN; BREAST-CANCER; RAS; CDC42; TRANSFORMATION; CLONING; RAC1; DBL; OVEREXPRESSION	The Rho family GTPases RhoA, RhoB, and RhoC regulate the actin cytoskeleton, cell movement, and cell growth. Unlike Ras, up-regulation or overexpression of these GDP/GTP binding molecular switches, but not activating point mutations, has been associated with human cancer. Although they share over 85% sequence identity, RhoA, RhoB, and RhoC appear to play distinct roles in cell transformation and metastasis. In NIH 3T3 cells, RhoA or RhoB overexpression causes transformation whereas RhoC increases the cell migration rate. To specifically target RhoA, RhoB, or RhoC function, we have generated a set of chimeric molecules by fusing the RhoGAP domain of p190, a GTPase-activating protein that accelerates the intrinsic GTPase activity of all three Rho GTPases, with the C-terminal hypervariable sequences of RhoA, RhoB, or RhoC. The p190-Rho chimeras were active as GTPase-activating proteins toward RhoA in vitro, co-localized with the respective active Rho proteins, and specifically down-regulated Rho protein activities in cells depending on which Rho GTPase sequences were included in the chimeras. In particular, the p190-RhoA-C chimera specifically inhibited RhoA-induced transformation whereas p190-RhoC-C specifically reversed the migration phenotype induced by the active RhoC. In human mammary epithelial-RhoC breast cancer cells, p190-RhoC-C, but not p190-RhoA-C or p190-RhoB-C, reversed the anchorage-independent growth and invasion phenotypes caused by RhoC overexpression. In the highly metastatic A375-M human melanoma cells, p190-RhoC-C specifically reversed migration, and invasion phenotypes attributed to RhoC up-regulation. Thus, we have developed a novel strategy utilizing RhoGAP-Rho chimeras to specifically down-regulate individual Rho activity and demonstrate that this approach may be applied to multiple human tumor cells to reverse the growth and/or invasion phenotypes associated with disregulation of a distinct subtype of Rho GTPase.	Univ Cincinnati, Div Expt Hematol, Childrens Hosp Res Fdn, Cincinnati, OH 45229 USA; Univ Cincinnati, Mol Dev Biol Program, Childrens Hosp Res Fdn, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati	Zheng, Y (corresponding author), Univ Cincinnati, Div Expt Hematol, Childrens Hosp Res Fdn, Cincinnati, OH 45229 USA.	yi.zheng@chmcc.org	Zheng, Yi/J-7235-2015	Zheng, Yi/0000-0001-7089-6074	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060523] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 60523, GM 53948] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; BARFOD ET, 1993, J BIOL CHEM, V268, P26059; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Boettner B, 2002, GENE, V286, P155, DOI 10.1016/S0378-1119(02)00426-2; BOS JL, 1989, CANCER RES, V49, P4682; Brouns MR, 2000, DEVELOPMENT, V127, P4891; Brouns MR, 2001, NAT CELL BIOL, V3, P361, DOI 10.1038/35070042; CICCHETTI P, 1995, EMBO J, V14, P3127, DOI 10.1002/j.1460-2075.1995.tb07315.x; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Crooke ST, 1996, ANTISENSE NUCLEIC A, V6, P145, DOI 10.1089/oli.1.1996.6.145; del Peso L, 1997, ONCOGENE, V15, P3047; DEVROE E, 2002, BMC BIOTECHNOLOGY; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B; GJERTSEN MK, 1995, LANCET, V346, P1399, DOI 10.1016/S0140-6736(95)92408-6; Gu Y, 2001, J BIOL CHEM, V276, P15929, DOI 10.1074/jbc.M010445200; Guo FK, 2003, J BIOL CHEM, V278, P14414, DOI 10.1074/jbc.M300341200; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Jaffe AB, 2002, ADV CANCER RES, V84, P57, DOI 10.1016/S0065-230X(02)84003-9; Jordan P, 1999, ONCOGENE, V18, P6835, DOI 10.1038/sj.onc.1203233; Kamai T, 2001, BJU INT, V87, P227, DOI 10.1046/j.1464-410x.2001.02030.x; Keely PJ, 2001, LANCET, V358, P1744, DOI 10.1016/S0140-6736(01)06840-4; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Lamarche-Vane N, 1998, J BIOL CHEM, V273, P29172, DOI 10.1074/jbc.273.44.29172; Lerm M, 2000, FEMS MICROBIOL LETT, V188, P1; Li R, 1997, J BIOL CHEM, V272, P32830, DOI 10.1074/jbc.272.52.32830; Lin R, 1999, J BIOL CHEM, V274, P23633, DOI 10.1074/jbc.274.33.23633; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; Midgley RS, 2002, CRIT REV ONCOL HEMAT, V44, P109, DOI 10.1016/S1040-8428(01)00189-5; Moon SY, 2003, TRENDS CELL BIOL, V13, P13, DOI 10.1016/S0962-8924(02)00004-1; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Nur-E-Kamal MSA, 1999, ONCOGENE, V18, P7787; Olofsson B, 1999, CELL SIGNAL, V11, P545, DOI 10.1016/S0898-6568(98)00063-1; Prendergast GC, 2001, NAT REV CANCER, V1, P162, DOI 10.1038/35101096; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Schambach A, 2000, MOL THER, V2, P435, DOI 10.1006/mthe.2000.0191; Schnelzer A, 2000, ONCOGENE, V19, P3013, DOI 10.1038/sj.onc.1203621; Schwieger M, 2002, J EXP MED, V196, P1227, DOI 10.1084/jem.20020824; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; Suwa H, 1998, BRIT J CANCER, V77, P147, DOI 10.1038/bjc.1998.23; Tanaka T, 2003, EMBO J, V22, P1025, DOI 10.1093/emboj/cdg106; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; VAN AL, 1997, GENE DEV, V11, P2295; van Golen KL, 2000, CANCER RES, V60, P5832; Vanni C, 2002, J BIOL CHEM, V277, P19745, DOI 10.1074/jbc.M111025200; Wang DZM, 1997, CANCER RES, V57, P2478; Yang FC, 2001, P NATL ACAD SCI USA, V98, P5614, DOI 10.1073/pnas.101546898; Yoshioka K, 1998, J BIOL CHEM, V273, P5146, DOI 10.1074/jbc.273.9.5146; Yuan BZ, 1998, CANCER RES, V58, P2196; Zhang BL, 1998, BIOCHEMISTRY-US, V37, P5249, DOI 10.1021/bi9718447; Zhang BL, 1998, J BIOL CHEM, V273, P8776, DOI 10.1074/jbc.273.15.8776; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9; Zhu KJ, 2000, J BIOL CHEM, V275, P25993, DOI 10.1074/jbc.M003780200; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	60	60	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44617	44625		10.1074/jbc.M308929200	http://dx.doi.org/10.1074/jbc.M308929200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12939257	hybrid			2022-12-25	WOS:000186306700092
J	Carr, MD; Bloemink, MJ; Dentten, E; Whelan, AO; Gordon, SV; Kelly, G; Frenkiel, TA; Hewinson, RG; Williamson, RA				Carr, MD; Bloemink, MJ; Dentten, E; Whelan, AO; Gordon, SV; Kelly, G; Frenkiel, TA; Hewinson, RG; Williamson, RA			Solution structure of the Mycobacterium tuberculosis complex protein MPB70 - From tuberculosis pathogenesis to inherited human corneal disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TORSION ANGLE DYNAMICS; T-CELL; ANTIGENIC PROTEIN; NMR; ASSIGNMENT; MPB83; GENE; IDENTIFICATION; VACCINATION; RESOLUTION	The closely related mycobacteria responsible for tuberculosis produce an unusually high number of secreted proteins, many of which are clearly implicated in pathogenesis and protective immunity. Falling within this category are the closely related proteins MPB70 and MPB83. The structure of MPB70 reveals a complex and novel bacterial fold, which has clear structural homology to the two C-terminal FAS1 domains of the cell adhesion protein fasciclin I, whose structures were reported very recently. Assessment of the surface features of MPB70, the sequence divergence between MPB70 and MPB83, the conservation of residues across a group of FAS1 domains, and the locations of disease-inducing mutations in betaig-h3 strongly suggests that MPB70 and MPB83 contain two functional surfaces on opposite faces, which are probably involved in binding to host cell proteins. This analysis also suggests that these functional surfaces are retained in the FAS1 proteins associated with mediating interactions between cells and the extracellular matrix (fasciclin I, periostin, and betaig-h3) and furthermore that some of the human corneal disease-inducing substitutions identified in betaig-h3 will perturb interactions at these sites.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Univ Kent, Dept Biosci, Canterbury CT2 7NJ, Kent, England; Vet Labs Agcy, Dept Bacterial Dis, TB Res Grp, Addlestone KT15 3NB, Surrey, England; Natl Inst Med Res, MRC, Biomed NMR Ctr, London NW7 1AA, England	University of Leicester; University of Kent; Veterinary Laboratories Agency; MRC National Institute for Medical Research	Carr, MD (corresponding author), Univ Leicester, Dept Biochem, Adrian Bldg,Univ Rd, Leicester LE1 7RH, Leics, England.	mdc12@le.ac.uk	Hewinson, Glyn/AAA-2364-2019; Hewinson, Glyn/J-1902-2014; Hewinson, Glyn/F-7077-2010; Whelan, Adam O/C-9497-2011	Bloemink, Marieke Johanna/0000-0001-9441-2783; Hewinson, Glyn/0000-0002-5517-4281; Carr, Mark/0000-0002-3939-0996; Gordon, Stephen/0000-0002-4833-5542				ARCHER SJ, 1991, J MAGN RESON, V95, P636, DOI 10.1016/0022-2364(91)90182-S; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; Berthet FX, 1998, MICROBIOL-UK, V144, P3195, DOI 10.1099/00221287-144-11-3195; Billings PC, 2002, J BIOL CHEM, V277, P28003, DOI 10.1074/jbc.M106837200; BILLMANJACOBE H, 1990, IMMUNOL CELL BIOL, V68, P359, DOI 10.1038/icb.1990.49; Bloemink MJ, 2001, J BIOMOL NMR, V20, P185, DOI 10.1023/A:1011239727839; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; Chambers MA, 2002, INFECT IMMUN, V70, P2159, DOI 10.1128/IAI.70.4.2159-2165.2002; Clout NJ, 2003, STRUCTURE, V11, P197, DOI 10.1016/S0969-2126(03)00002-9; Cole ST, 2001, NATURE, V409, P1007, DOI 10.1038/35059006; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DOLORES M, 2001, FEMS MICROBIOL LETT, V203, P95; FIFIS T, 1994, SCAND J IMMUNOL, V39, P267, DOI 10.1111/j.1365-3083.1994.tb03370.x; FIFIS T, 1991, INFECT IMMUN, V59, P800, DOI 10.1128/IAI.59.3.800-807.1991; Fratti RA, 2003, P NATL ACAD SCI USA, V100, P5437, DOI 10.1073/pnas.0737613100; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; GUNTERT P, 1991, Journal of Biomolecular NMR, V1, P447, DOI 10.1007/BF02192866; Harboe M, 1998, INFECT IMMUN, V66, P289, DOI 10.1128/IAI.66.1.289-296.1998; HARBOE M, 1984, AM REV RESPIR DIS, V129, P444; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; HEWINSON RG, 1993, J GEN MICROBIOL, V139, P1253, DOI 10.1099/00221287-139-6-1253; Hewinson RG, 1996, SCAND J IMMUNOL, V43, P490, DOI 10.1046/j.1365-3083.1996.d01-78.x; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; Kim JE, 2000, J BIOL CHEM, V275, P30907, DOI 10.1074/jbc.M002752200; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kupce E, 1996, J MAGN RESON SER A, V118, P299, DOI 10.1006/jmra.1996.0042; Lemercinier X, 2001, BIOCHEMISTRY-US, V40, P9552, DOI 10.1021/bi010184+; Lowrie DB, 1999, NATURE, V400, P269, DOI 10.1038/22326; MARION D, 1989, J AM CHEM SOC, V111, P1515, DOI 10.1021/ja00186a066; McIntosh PB, 1998, BIOCHEMISTRY-US, V37, P9619, DOI 10.1021/bi972861z; Michell SL, 2003, J BIOL CHEM, V278, P16423, DOI 10.1074/jbc.M207959200; MIURA K, 1983, INFECT IMMUN, V39, P540, DOI 10.1128/IAI.39.2.540-545.1983; Morris S, 2000, VACCINE, V18, P2155, DOI 10.1016/S0264-410X(99)00540-X; Munier FL, 2002, INVEST OPHTH VIS SCI, V43, P949; Murray CJL, 1998, P NATL ACAD SCI USA, V95, P13881, DOI 10.1073/pnas.95.23.13881; ORME IM, 1988, INFECT IMMUN, V56, P3310, DOI 10.1128/IAI.56.12.3310-3312.1988; POLLOCK JM, 1994, IMMUNOLOGY, V82, P9; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; Renshaw PS, 2002, J BIOL CHEM, V277, P21598, DOI 10.1074/jbc.M201625200; ROCHE PW, 1994, J INFECT DIS, V170, P1326, DOI 10.1093/infdis/170.5.1326; Shindyalov IN, 1998, PROTEIN ENG, V11, P739, DOI 10.1093/protein/11.9.739; SKLENAR V, 1993, J MAGN RESON SER A, V102, P241, DOI 10.1006/jmra.1993.1098; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; Williamson RA, 1999, J BIOL CHEM, V274, P37226, DOI 10.1074/jbc.274.52.37226; Young DB, 1999, SCIENCE, V284, P1479, DOI 10.1126/science.284.5419.1479; ZUIDERWEG ERP, 1990, J MAGN RESON, V86, P210, DOI 10.1016/0022-2364(90)90228-2	48	45	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43736	43743		10.1074/jbc.M307235200	http://dx.doi.org/10.1074/jbc.M307235200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12917404	hybrid			2022-12-25	WOS:000186157000123
J	Chang, CSS; Olcese, R; Olsen, RW				Chang, CSS; Olcese, R; Olsen, RW			A single M1 residue in the beta 2 subunit alters channel gating of GABA(A) receptor in anesthetic modulation and direct activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-AMINOBUTYRIC-ACID; A RECEPTOR; GLYCINE RECEPTORS; ACETYLCHOLINE-RECEPTOR; GENERAL-ANESTHETICS; ANTAGONIST AFFINITY; BINDING-SITES; VOLATILE; IDENTIFICATION; ETOMIDATE	General anesthetics allosterically modulate the activity of neuronal gamma-aminobutyric acid, type A (GABA(A)), receptors. Previous mutational studies from our laboratory and others have shown that the regions in transmembrane domain 1 (M1) and pre- M1 of alpha and beta subunits in GABA receptors are essential for positive modulation of GABA binding and function by the intravenous (IV) general anesthetics. Mutation of beta2Gly-219 to Phe corresponded in rho nearly eliminated the modulatory effect of IV anesthetics in alpha1/beta2/gamma2S combination. However, the general anesthetics retained the ability to directly open the channel of mutant G219F, and the apparent affinity for GABA was increased, and desensitization rate was reduced. In this study, we made additional single mutations such as 219 Ser, Cys, Ile, Asp, Arg, Tyr, and Trp. The larger side chains of the replacement residues produced the greatest reduction in enhancement of GABA currents by IV anesthetics at clinical concentrations ( Trp > Tyr = Phe > Arg > Asp > Ile > Cys > Ser = wild type). Compared with a 2-3-fold response in wild type, pentobarbital and propofol enhanced less than 0.5-fold; etomidate and alphaxalone modulation was reduced from more than 4- to 1-fold in G219F, G219Y, and G219W. A linear correlation was observed between the volume of the residue at position 219 and the loss of modulation. An identical correlation was found for the effect of modulation on left-shift in the GABA EC50 value; furthermore, the same rank order of residues, related to size, was found for reduction in the maximal direct channel-gating by pentobarbital ( 1 mM) and etomidate ( 100 muM) and for increased apparent affinity for direct gating by the IV anesthetics.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Anesthesiol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Olsen, RW (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, 650 Young Dr S,CHS 23-338, Los Angeles, CA 90095 USA.	Rolsen@mednet.ucla.edu			NIGMS NIH HHS [GM08652] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMIN J, 1993, NATURE, V366, P565, DOI 10.1038/366565a0; BARKER JL, 1978, J PHYSIOL-LONDON, V280, P355, DOI 10.1113/jphysiol.1978.sp012388; Belelli D, 1997, P NATL ACAD SCI USA, V94, P11031, DOI 10.1073/pnas.94.20.11031; Bera AK, 2002, J BIOL CHEM, V277, P43002, DOI 10.1074/jbc.M206321200; Birnir B, 1997, SYNAPSE, V26, P324, DOI 10.1002/(SICI)1098-2396(199707)26:3<324::AID-SYN13>3.0.CO;2-V; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Bywater RP, 2001, J COMPUT AID MOL DES, V15, P533, DOI 10.1023/A:1011197908960; CARLSON BX, 1992, J PHARMACOL EXP THER, V263, P1401; Carlson BX, 2000, MOL PHARMACOL, V57, P474, DOI 10.1124/mol.57.3.474; Chang CSS, 2003, J NEUROCHEM, V85, P47; CHANGEUX JP, 1992, Q REV BIOPHYS, V25, P395, DOI 10.1017/S0033583500004352; Chiara DC, 1999, BIOCHEMISTRY-US, V38, P6689, DOI 10.1021/bi9901735; Chiara DC, 1997, J BIOL CHEM, V272, P32940, DOI 10.1074/jbc.272.52.32940; Corringer PJ, 2000, ANNU REV PHARMACOL, V40, P431, DOI 10.1146/annurev.pharmtox.40.1.431; Dalziel JE, 1999, EUR J PHARMACOL, V385, P283, DOI 10.1016/S0014-2999(99)00710-4; DAUBAS P, 1990, NEURON, V5, P49, DOI 10.1016/0896-6273(90)90032-B; Duncalfe LL, 1996, J BIOL CHEM, V271, P9209, DOI 10.1074/jbc.271.16.9209; Engblom AC, 2002, J BIOL CHEM, V277, P17438, DOI 10.1074/jbc.M111215200; Gordijn B, 2000, PATIENT EDUC COUNS, V41, P1, DOI 10.1016/S0738-3991(00)00123-3; HALES TG, 1991, BRIT J PHARMACOL, V104, P619, DOI 10.1111/j.1476-5381.1991.tb12479.x; HARPAZ Y, 1994, STRUCTURE, V2, P641, DOI 10.1016/S0969-2126(00)00065-4; HARRIS BD, 1995, MOL PHARMACOL, V47, P363; HARRISON NL, 1993, MOL PHARMACOL, V44, P628; HARRISON NL, 1984, BRAIN RES, V323, P287, DOI 10.1016/0006-8993(84)90299-3; Horenstein J, 2001, NAT NEUROSCI, V4, P477, DOI 10.1038/87425; Jenkins A, 2002, NEUROPHARMACOLOGY, V43, P669, DOI 10.1016/S0028-3908(02)00175-2; Jenkins A, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-06-j0002.2001; JONES MV, 1995, J PHARMACOL EXP THER, V274, P962; Krasowski MD, 2000, BRIT J PHARMACOL, V129, P731, DOI 10.1038/sj.bjp.0703087; Krasowski MD, 1998, MOL PHARMACOL, V53, P530, DOI 10.1124/mol.53.3.530; LONGONI B, 1992, ADV BIOCHEM PSYCHOPH, V47, P365; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; Mascia MP, 2000, P NATL ACAD SCI USA, V97, P9305, DOI 10.1073/pnas.160128797; Mihic SJ, 1996, J PHARMACOL EXP THER, V277, P411; Mihic SJ, 1997, NATURE, V389, P385, DOI 10.1038/38738; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; Moody EJ, 1997, J NEUROCHEM, V69, P1310; Nishikawa K, 2002, NEUROPHARMACOLOGY, V42, P337, DOI 10.1016/S0028-3908(01)00189-7; Olsen RW, 1998, TOXICOL LETT, V101, P193, DOI 10.1016/S0378-4274(98)00185-4; Olsen RW, 2004, METH NE FRO NEUROSCI, P47; OLSEN RW, 1995, ADV BIOCHEM PSYCHOPH, V48, P57; OLSEN RW, 2003, ENCY BIOL CHEM; ORTELLS MO, 1995, TRENDS NEUROSCI, V18, P121, DOI 10.1016/0166-2236(95)93887-4; ROBERTSON B, 1989, BRIT J PHARMACOL, V98, P167, DOI 10.1111/j.1476-5381.1989.tb16878.x; Sawyer GW, 2002, J BIOL CHEM, V277, P50036, DOI 10.1074/jbc.M209281200; Sieghart W., 2002, Current Topics in Medicinal Chemistry, V2, P795, DOI 10.2174/1568026023393507; SIGEL E, 1992, EMBO J, V11, P2017, DOI 10.1002/j.1460-2075.1992.tb05258.x; SMITH GB, 1994, J BIOL CHEM, V269, P20380; Srinivasan S, 1999, J BIOL CHEM, V274, P26633, DOI 10.1074/jbc.274.38.26633; Steinbach JH, 2001, J PHYSIOL-LONDON, V537, P715; Thompson SA, 1996, BRIT J PHARMACOL, V117, P521, DOI 10.1111/j.1476-5381.1996.tb15221.x; UCHIDA I, 1995, NEUROSCI LETT, V185, P203, DOI 10.1016/0304-3940(95)11263-V; WAFFORD KA, 1994, NEURON, V12, P775, DOI 10.1016/0896-6273(94)90330-1; Wagner DA, 2001, J NEUROSCI, V21, P67, DOI 10.1523/JNEUROSCI.21-01-00067.2001; Whiting PJ, 1995, INT REV NEUROBIOL, V38, P95, DOI 10.1016/S0074-7742(08)60525-5; Wick MJ, 1998, P NATL ACAD SCI USA, V95, P6504, DOI 10.1073/pnas.95.11.6504; YANG J, 1992, FASEB J, V6, P914, DOI 10.1096/fasebj.6.3.1740240; ZAMAN SH, 1992, EUR J PHARM-MOLEC PH, V225, P321, DOI 10.1016/0922-4106(92)90106-6	58	48	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42821	42828		10.1074/jbc.M306978200	http://dx.doi.org/10.1074/jbc.M306978200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12939268	hybrid			2022-12-25	WOS:000186157000013
J	Hundahl, C; Fago, A; Malte, H; Weber, RE				Hundahl, C; Fago, A; Malte, H; Weber, RE			Allosteric effect of water in fish and human hemoglobins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN EQUILIBRIA; ANGUILLA-ANGUILLA; EEL HEMOGLOBIN; OSMOTIC-STRESS; HYDRATION; TROUT; BINDING; TRANSITIONS; ACCLIMATION; MODEL	Prompted by the reported lack of solvation effects on the oxygen affinity of fish ( trout I) hemoglobin that questioned allosteric water binding in human hemoglobin A (Bellelli, A., Brancaccio, A., and Brunori, M. ( 1993) J. Biol. Chem. 268, 4742 - 4744), we have investigated solvation effects in fish and human hemoglobins by means of the osmotic stress method and allosteric analysis. In contrast to the earlier report, we demonstrate that water potential does affect oxygen affinity of trout hemoglobin I in the presence of inert solutes like betaine. Moreover, we show that upon oxygenation electrophoretically anodic hemoglobin from trout and eel bind a similar number of water molecules as does human hemoglobin A, whereas the cathodic hemoglobins of trout and eel bind smaller, but mutually similar, numbers of water molecules. Addition of cofactors strongly increases the number of water molecules bound to eel hemoglobin A ( as in human hemoglobin) but only weakly affects water binding to eel hemoglobin C.	Univ Aarhus, Dept Zoophysiol, Inst Biol Sci, DK-8000 Aarhus C, Denmark	Aarhus University	Weber, RE (corresponding author), Univ Aarhus, Dept Zoophysiol, Inst Biol Sci, CF Mollers Alle 131, DK-8000 Aarhus C, Denmark.		Malte, Hans/J-6018-2013; Fago, Angela/J-5946-2013; Hundahl, Christian Ansgar/H-3938-2015	Fago, Angela/0000-0001-7315-2628; 				Arosio D, 2002, BIOPOLYMERS, V63, P1, DOI 10.1002/bip.1057; BELLELLI A, 1993, J BIOL CHEM, V268, P4742; BINOTTI I, 1971, ARCH BIOCHEM BIOPHYS, V142, P274, DOI 10.1016/0003-9861(71)90284-0; BRITTAIN T, 1987, COMP BIOCHEM PHYS B, V86, P473, DOI 10.1016/0305-0491(87)90434-2; Brunori M, 1975, Curr Top Cell Regul, V9, P1; BRUNORI M, 1978, P NATL ACAD SCI USA, V75, P4310, DOI 10.1073/pnas.75.9.4310; CHOTHIA C, 1976, P NATL ACAD SCI USA, V73, P3793, DOI 10.1073/pnas.73.11.3793; COLOMBO MF, 1992, SCIENCE, V256, P655, DOI 10.1126/science.1585178; Colombo MF, 1999, BIOCHEMISTRY-US, V38, P11741, DOI 10.1021/bi9905361; COLOMBO MF, 1994, P NATL ACAD SCI USA, V91, P10517, DOI 10.1073/pnas.91.22.10517; Colombo MF, 1996, J BIOL CHEM, V271, P4895; Courtenay ES, 2000, BIOCHEMISTRY-US, V39, P4455, DOI 10.1021/bi992887l; DIPRISCO G, 1992, COMP BIOCHEM PHYS B, V102, P661, DOI 10.1016/0305-0491(92)90062-V; Fago A, 1997, J BIOL CHEM, V272, P15628, DOI 10.1074/jbc.272.25.15628; FAGO A, 1995, J BIOL CHEM, V270, P18897, DOI 10.1074/jbc.270.32.18897; Feuerlein RJ, 1996, J COMP PHYSIOL B, V165, P597, DOI 10.1007/BF00301127; GIARDINA B, 1978, BIOCHEM J, V175, P407, DOI 10.1042/bj1750407; LESK AM, 1985, J MOL BIOL, V183, P267, DOI 10.1016/0022-2836(85)90219-0; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; Parsegian VA, 2000, P NATL ACAD SCI USA, V97, P3987, DOI 10.1073/pnas.97.8.3987; Rand RP, 2000, CELL MOL LIFE SCI, V57, P1018, DOI 10.1007/PL00000742; Royer WE, 1996, P NATL ACAD SCI USA, V93, P14526, DOI 10.1073/pnas.93.25.14526; Tame JRH, 1996, J MOL BIOL, V259, P749, DOI 10.1006/jmbi.1996.0355; WEBER RE, 1976, J EXP BIOL, V65, P333; WEBER RE, 1976, J EXP BIOL, V64, P75; WEBER RE, 1992, J APPL PHYSIOL, V72, P1611, DOI 10.1152/jappl.1992.72.4.1611; WYMAN J, 1964, ADV PROTEIN CHEM, V19, P223, DOI 10.1016/S0065-3233(08)60190-4; Wyman J., 1990, BINDING LINKAGE FUNC, P123	28	15	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42769	42773		10.1074/jbc.M307515200	http://dx.doi.org/10.1074/jbc.M307515200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12925528	hybrid			2022-12-25	WOS:000186157000007
J	Ren, XM; Shand, SH; Takimoto, K				Ren, XM; Shand, SH; Takimoto, K			Effective association of Kv channel-interacting proteins with Kv4 channel is mediated with their unique core peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL CALCIUM SENSOR-1; TRANSIENT OUTWARD CURRENT; 3-DIMENSIONAL STRUCTURE; CA2+-BINDING PROTEIN; POTASSIUM CHANNELS; CRYSTAL-STRUCTURE; K+-CURRENTS; EXPRESSION; MODULATION; VENTRICLE	Kv channel-interacting proteins (KChIPs) and neuronal calcium sensor-1 (NCS-1) have been shown to interact with Kv4 channel alpha-subunits to regulate the expression and/or gating of these channels. Here we examine the specificity and sites of these proteins for interaction with Kv channel proteins. Immunoprecipitation and green fluorescent protein imaging show that KChIPs ( but not NCS-1) effectively bind to Kv4.3 protein and localize at the plasma membrane when channel proteins are coexpressed. Analysis with chimeric proteins between KChIP2 and NCS-1 reveals that the three regions of KChIP2 ( the linker between the first and second EF hands, the one between the third and fourth EF hands, and the C-terminal peptide after the fourth EF hand) are necessary and sufficient for its effective binding to Kv4.3 protein. The chimera with these three KChIP2 portions slowed inactivation and facilitated recovery from inactivation of Kv4.3 current. These results indicate that the sequence difference in these three regions between KChIPs and NCS-1 determines the specificity and affinity for interaction with Kv4 protein. Because the three identified regions surround the large hydrophobic crevice based on the NCS-1 crystal structure, this crevice may be the association site of KChIPs for the channel protein.	Univ Pittsburgh, Grad Sch Publ Hlth, Dept Environm & Occupat Hlth, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Ctr Biol Imaging, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Takimoto, K (corresponding author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Environm & Occupat Hlth, 3343 Forbes Ave, Pittsburgh, PA 15260 USA.							Ames JB, 2000, BIOCHEMISTRY-US, V39, P12149, DOI 10.1021/bi0012890; Ames JB, 1999, J BIOL CHEM, V274, P19329, DOI 10.1074/jbc.274.27.19329; Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; Bahring R, 2001, J BIOL CHEM, V276, P23888, DOI 10.1074/jbc.M101320200; Bourne Y, 2001, J BIOL CHEM, V276, P11949, DOI 10.1074/jbc.M009373200; Decher N, 2001, CARDIOVASC RES, V52, P255, DOI 10.1016/S0008-6363(01)00374-1; Deschenes I, 2002, FEBS LETT, V528, P183, DOI 10.1016/S0014-5793(02)03296-9; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; Guo WN, 2002, J BIOL CHEM, V277, P26436, DOI 10.1074/jbc.M201431200; Holmqvist MH, 2001, J NEUROSCI, V21, P4154, DOI 10.1523/JNEUROSCI.21-12-04154.2001; Kuo HC, 2001, CELL, V107, P801, DOI 10.1016/S0092-8674(01)00588-8; Nakamura TY, 2001, P NATL ACAD SCI USA, V98, P12808, DOI 10.1073/pnas.221168498; Nakamura TY, 2001, FEBS LETT, V499, P205, DOI 10.1016/S0014-5793(01)02560-1; Olshevskaya EV, 1999, J BIOL CHEM, V274, P10823, DOI 10.1074/jbc.274.16.10823; Patel SP, 2002, J PHYSIOL-LONDON, V539, P649, DOI 10.1113/jphysiol.2001.015156; Rosati B, 2003, J PHYSIOL-LONDON, V548, P815, DOI 10.1113/jphysiol.2002.033704; Rosati B, 2001, J PHYSIOL-LONDON, V533, P119, DOI 10.1111/j.1469-7793.2001.0119b.x; Takimoto K, 2002, J BIOL CHEM, V277, P26904, DOI 10.1074/jbc.M203651200; TANAKA T, 1995, NATURE, V376, P444, DOI 10.1038/376444a0; Vijay-Kumar S, 1999, NAT STRUCT BIOL, V6, P80; Yang EK, 2001, J BIOL CHEM, V276, P4839, DOI 10.1074/jbc.M004768200	22	19	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43564	43570		10.1074/jbc.M302337200	http://dx.doi.org/10.1074/jbc.M302337200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12928444	hybrid			2022-12-25	WOS:000186157000103
J	Suen, DF; Wu, SSH; Chang, HC; Dhugga, KS; Huang, AHC				Suen, DF; Wu, SSH; Chang, HC; Dhugga, KS; Huang, AHC			Cell wall reactive proteins in the coat and wall of maize pollen - Potential role in pollen tube growth on the stigma and through the style	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARABIDOPSIS-THALIANA; BRASSICA-NAPUS; GRASS-POLLEN; GENE FAMILIES; EXPRESSION; INHIBITOR; TAPETUM; GLYCOPROTEINS; PURIFICATION; ALLERGENS	The surface of a pollen grain consists of an outermost coat and an underlying wall. In maize (Zea mays L.), the pollen coat contains two major proteins derived from the adjacent tapetum cells in the anthers. One of the proteins is a 35-kDa endoxylanase (Wu, S.S.H., Suen, D.F., Chang, H.C., and Huang, A.H.C. (2002) J. Biol. Chem. 277, 49055-49064). The other protein of 70 kDa was purified to homogeneity and shown to be a beta-glucanase. Its gene sequence and the developmental pattern of its mRNA differ from those of the known beta-glucanases that hydrolyze the callose wall of the microspore tetrad. Mature pollen placed in a liquid medium released about nine major proteins. These proteins were partially sequenced and identified via GenBank(TM) data bases, and some had not been previously reported to be in pollen. They appear to have wall-loosening, structural, and enzymatic functions. A novel pollen wall-bound protein of 17 kDa has a unique pattern of cysteine distribution in its sequence (six tandem repeats of CX3CX10-15) that could chelate cations and form signal-receiving finger motifs. These pollen-released proteins were synthesized in the pollen interior, and their mRNA increased during pollen maturation and germination. They were localized mainly in the pollen tube wall. The pollen shell was isolated and found to contain no detectable proteins. We suggest that the pollen-coat beta-glucanase and xylanase hydrolyze the stigma wall for pollen tube entry and that the pollen secrete proteins to loosen or become new wall constituents of the tube and to break the wall of the transmitting track for tube advance.	Univ Calif Riverside, Dept Bot & Plant Sci, Ctr Plant Cell Biol, Riverside, CA 92521 USA; DuPont Co Inc, Pioneer Hi Bred Int Inc, Agron Traits Dept, Johnston, IA 50131 USA	University of California System; University of California Riverside; DuPont; Pioneer Hi-Bred International, Inc.	Huang, AHC (corresponding author), Univ Calif Riverside, Dept Bot & Plant Sci, Ctr Plant Cell Biol, Riverside, CA 92521 USA.		Suen, Der-Fen/ACF-7547-2022	Dhugga, Kanwarpal/0000-0003-2477-3422				ALLEN RL, 1993, PLANT J, V3, P261, DOI 10.1046/j.1365-313X.1993.t01-14-00999.x; Andersson K, 2003, INT ARCH ALLERGY IMM, V130, P87, DOI 10.1159/000069013; Baumberger N, 2001, GENE DEV, V15, P1128, DOI 10.1101/gad.200201; Bewley JD, 2000, BIOCH MOL BIOL PLANT, P988; BIELY P, 1980, EUR J BIOCHEM, V108, P313, DOI 10.1111/j.1432-1033.1980.tb04725.x; Bih FY, 1999, J BIOL CHEM, V274, P22884, DOI 10.1074/jbc.274.32.22884; BROADWATER AH, 1993, GENE, V131, P227, DOI 10.1016/0378-1119(93)90297-G; BURGESS WH, 1980, BIOCHIM BIOPHYS ACTA, V623, P257, DOI 10.1016/0005-2795(80)90254-8; Camardella L, 2000, EUR J BIOCHEM, V267, P4561, DOI 10.1046/j.1432-1327.2000.01510.x; Cosgrove DJ, 1997, P NATL ACAD SCI USA, V94, P6559, DOI 10.1073/pnas.94.12.6559; Cosgrove DJ, 2000, NATURE, V407, P321, DOI 10.1038/35030000; Ferris PJ, 2001, BIOCHEMISTRY-US, V40, P2978, DOI 10.1021/bi0023605; Greiner S, 1998, PLANT PHYSIOL, V116, P733, DOI 10.1104/pp.116.2.733; Harvey AJ, 2001, PHYSIOL PLANTARUM, V113, P108, DOI 10.1034/j.1399-3054.2001.1130115.x; HIRD DL, 1993, PLANT J, V4, P1023, DOI 10.1046/j.1365-313X.1993.04061023.x; Hrmova M, 1996, J BIOL CHEM, V271, P5277, DOI 10.1074/jbc.271.9.5277; Kim HU, 2002, J BIOL CHEM, V277, P22677, DOI 10.1074/jbc.M109298200; Kim JB, 2000, PLANT PHYSIOL, V123, P471, DOI 10.1104/pp.123.2.471; Ladomery M, 2002, ANN HUM GENET, V66, P331, DOI 10.1017/S0003480002001215; LEVER M, 1977, ANAL BIOCHEM, V81, P21, DOI 10.1016/0003-2697(77)90594-2; Levy I, 2002, BIOMOL ENG, V19, P17, DOI 10.1016/S1389-0344(02)00007-2; MASCARENHAS JP, 1993, PLANT CELL, V5, P1303, DOI 10.1105/tpc.5.10.1303; Mayfield JA, 2001, SCIENCE, V292, P2482, DOI 10.1126/science.1060972; McCormick S, 1998, CURR OPIN PLANT BIOL, V1, P18, DOI 10.1016/S1369-5266(98)80122-2; Piffanelli P, 1997, PLANT J, V11, P549, DOI 10.1046/j.1365-313X.1997.11030549.x; RUBINSTEIN AL, 1995, P NATL ACAD SCI USA, V92, P3086, DOI 10.1073/pnas.92.8.3086; SAINI JP, 1986, MAYDICA, V31, P227; Sambrook J., 2002, MOL CLONING LAB MANU; SHOWALTER AM, 1993, PLANT CELL, V5, P9, DOI 10.1105/tpc.5.1.9; Soloaga A, 1996, EUR J BIOCHEM, V238, P418, DOI 10.1111/j.1432-1033.1996.0418z.x; Sommer-Knudsen J, 1998, PHYTOCHEMISTRY, V47, P483, DOI 10.1016/S0031-9422(97)00724-3; STAIGER CJ, 1993, PLANT J, V4, P631, DOI 10.1046/j.1365-313X.1993.04040631.x; STIEGLITZ H, 1977, DEV BIOL, V57, P87, DOI 10.1016/0012-1606(77)90356-6; Stratford S, 2001, PLANT MOL BIOL, V46, P43, DOI 10.1023/A:1010659425399; Taylor LP, 1997, ANNU REV PLANT PHYS, V48, P461, DOI 10.1146/annurev.arplant.48.1.461; VANREE R, 1995, J ALLERGY CLIN IMMUN, V95, P970, DOI 10.1016/S0091-6749(95)70097-8; Wu SSH, 2002, J BIOL CHEM, V277, P49055, DOI 10.1074/jbc.M208804200; Wu SSH, 1997, P NATL ACAD SCI USA, V94, P12711, DOI 10.1073/pnas.94.23.12711; Wu YJ, 2001, PLANT PHYSIOL, V126, P222, DOI 10.1104/pp.126.1.222	39	57	65	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43672	43681		10.1074/jbc.M307843200	http://dx.doi.org/10.1074/jbc.M307843200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12930826	hybrid			2022-12-25	WOS:000186157000116
J	Takeda, M; Terasawa, H; Sakakura, M; Yamaguchi, Y; Kajiwara, M; Kawashima, H; Miyasaka, M; Shimada, I				Takeda, M; Terasawa, H; Sakakura, M; Yamaguchi, Y; Kajiwara, M; Kawashima, H; Miyasaka, M; Shimada, I			Hyaluronan recognition mode of CD44 revealed by cross-saturation and chemical shift perturbation experiments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-CARBOHYDRATE INTERACTIONS; 3-DIMENSIONAL SOLUTION STRUCTURE; NMR INVESTIGATIONS; BINDING-SITES; LINK MODULE; SULFATE PROTEOGLYCAN; EXTRACELLULAR-MATRIX; ESCHERICHIA-COLI; HEVEIN DOMAINS; CELL-MIGRATION	CD44 is the main cell surface receptor for hyaluronic acid (HA) and contains a functional HA-binding domain (HABD) composed of a Link module with N- and C-terminal extensions. The contact residues of human CD44 HABD for HA have been determined by cross-saturation experiments and mapped on the topology of CD44 HABD, which we elucidated by NMR. The contact residues are distributed in both the consensus fold for the Link module superfamily and the additional structural elements consisting of the flanking regions. Interestingly, the contact residues exhibit small changes in chemical shift upon HA binding. In contrast, the residues with large chemical shift changes are localized in the C-terminal extension and the first alpha-helix and are generally inconsistent with the contact residues. These results suggest that, upon ligand binding, the C-terminal extension and the first alpha-helix undergo significant conformational changes, which may account for the broad ligand specificity of CD44 HABD.	Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; Japan Biol Informat Consortium, Japan Biol Informat Res Ctr, Chuo Ku, Tokyo 1040032, Japan; Meiji Pharmaceut Univ, Dept Med Chem, Kiyose, Tokyo 2048588, Japan; Osaka Univ, Grad Sch Med, Lab Mol & Cellular Recognit, Suita, Osaka 5650871, Japan; Natl Inst Adv Ind Sci & Technol, Biol Informat Res Ctr, Koto Ku, Tokyo 1350064, Japan	University of Tokyo; Meiji Pharmaceutical University; Osaka University; National Institute of Advanced Industrial Science & Technology (AIST)	Shimada, I (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan.	shimada@iw-nmr.f.u-tokyo.ac.jp	Miyasaka, Masayuki/AAM-6343-2020; Yamaguchi, Yoshiki/N-5246-2015	Yamaguchi, Yoshiki/0000-0003-0100-5439				ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; Asensio JL, 2000, CHEM BIOL, V7, P529, DOI 10.1016/S1074-5521(00)00136-8; Asensio JL, 1998, GLYCOBIOLOGY, V8, P569, DOI 10.1093/glycob/8.6.569; Asensio JL, 2000, PROTEINS, V40, P218, DOI 10.1002/(SICI)1097-0134(20000801)40:2<218::AID-PROT50>3.3.CO;2-G; Bajorath J, 1998, J BIOL CHEM, V273, P338, DOI 10.1074/jbc.273.1.338; Banerji S, 1998, PROTEIN EXPRES PURIF, V14, P371, DOI 10.1006/prep.1998.0971; Chen J, 1999, J BIOL CHEM, V274, P19601, DOI 10.1074/jbc.274.28.19601; CLORE GM, 1994, METHOD ENZYMOL, V239, P349; Day AJ, 2002, J BIOL CHEM, V277, P4585, DOI 10.1074/jbc.R100036200; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Espinosa JF, 2000, EUR J BIOCHEM, V267, P3965, DOI 10.1046/j.1432-1327.2000.01415.x; Fujii K, 2001, J IMMUNOL, V167, P1198, DOI 10.4049/jimmunol.167.3.1198; Fujimoto T, 2001, INT IMMUNOL, V13, P359, DOI 10.1093/intimm/13.3.359; Fujisaki T, 1999, CANCER RES, V59, P4427; GIBBS SJ, 1991, J MAGN RESON, V93, P395, DOI 10.1016/0022-2364(91)90014-K; Goddard T. D., 2001, SPARKY 3; GOLDSTEIN LA, 1989, CELL, V56, P1063, DOI 10.1016/0092-8674(89)90639-9; Jimenez-Barbero J, 1999, CURR OPIN STRUC BIOL, V9, P549, DOI 10.1016/S0959-440X(99)00004-4; Kahmann JD, 2000, STRUCTURE, V8, P763, DOI 10.1016/S0969-2126(00)00163-5; Kawashima H, 2002, J BIOL CHEM, V277, P12921, DOI 10.1074/jbc.M200396200; Kawashima H, 2000, J BIOL CHEM, V275, P35448, DOI 10.1074/jbc.M003387200; Kohda D, 1996, CELL, V86, P767, DOI 10.1016/S0092-8674(00)80151-8; KRAULIS PJ, 1989, BIOCHEMISTRY-US, V28, P7241, DOI 10.1021/bi00444a016; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; LESLEY J, 1998, FRONT BIOSCI, V3, P616; MORI S, 1995, J MAGN RESON SER B, V108, P94, DOI 10.1006/jmrb.1995.1109; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; Naor D, 1997, ADV CANCER RES, V71, P241, DOI 10.1016/S0065-230X(08)60101-3; Noble PW, 2002, MATRIX BIOL, V21, P25, DOI 10.1016/S0945-053X(01)00184-6; Parkar AA, 1997, FEBS LETT, V410, P413, DOI 10.1016/S0014-5793(97)00621-2; PEACH RJ, 1993, J CELL BIOL, V122, P257, DOI 10.1083/jcb.122.1.257; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; ROSENBERG L, 1988, J BIOL CHEM, V263, P18071; Skelton TP, 1998, J CELL BIOL, V140, P431, DOI 10.1083/jcb.140.2.431; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; Sugahara KN, 2003, J BIOL CHEM, V278, P32259, DOI 10.1074/jbc.M300347200; Takahashi H, 2000, NAT STRUCT BIOL, V7, P220; Tawada A, 2002, GLYCOBIOLOGY, V12, P421, DOI 10.1093/glycob/cwf048; ToyamaSorimachi N, 1997, J BIOL CHEM, V272, P26714, DOI 10.1074/jbc.272.42.26714; TOYAMASORIMACHI N, 1995, J BIOL CHEM, V270, P7437, DOI 10.1074/jbc.270.13.7437; Uchida K, 1995, J BIOL CHEM, V270, P30862, DOI 10.1074/jbc.270.52.30862; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Wuthrich K, 2000, NAT STRUCT BIOL, V7, P188, DOI 10.1038/73278; YU Q, 1995, BIOTECHNIQUES, V19, P122	45	48	48	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43550	43555		10.1074/jbc.M308199200	http://dx.doi.org/10.1074/jbc.M308199200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12928429	hybrid			2022-12-25	WOS:000186157000101
J	Kawasaki-Nishi, S; Nishi, T; Forgac, M				Kawasaki-Nishi, S; Nishi, T; Forgac, M			Interacting helical surfaces of the transmembrane segments of subunits a and c ' of the yeast V-ATPase defined by disulfide-mediated cross-linking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COOH-TERMINAL DOMAIN; H+-ATPASE; PROTON TRANSLOCATION; MUTATIONAL ANALYSIS; VACUOLAR ATPASE; MOLECULAR ARCHITECTURE; LUMINAL ACIDIFICATION; MUTAGENIC ANALYSIS; GENE DUPLICATION; PERIPHERAL STALK	Proton translocation by the vacuolar (H+)-ATPase (or V-ATPase) has been shown by mutagenesis to be dependent upon charged residues present within transmembrane segments of subunit a as well as the three proteolipid subunits (c, c', and c"). Interaction between R735 in TM7 of subunit a and the glutamic acid residue in the middle of TM4 of subunits c and c' or TM2 of subunit c" has been proposed to be essential for proton release to the luminal compartment. In order to determine whether the helical face of TM7 of subunit a containing R735 is capable of interacting with the helical face of TM4 of subunit c' containing the essential glutamic acid residue (Glu-145), cysteine-mediated crosslinking between these subunits in yeast has been performed. Cys-less forms of subunits a and c' as well as forms containing unique cysteine residues were constructed, introduced together into a strain disrupted in both endogenous subunits, and tested for growth at neutral pH, for assembly competence and for cross-linking in the presence of cupric-phenanthroline by SDS-PAGE and Western blot analysis. Four different cysteine mutants of subunit a were each tested pairwise with ten different unique cysteine mutants of subunit c'. Strong cross-linking was observed for the pairs aS728C/c'I142C, aA731C/c'E145C, aA738C/c'F143C, aA738C/c'L147C, and aL739C/c'L147C. Partial cross-linking was observed for an additional 13 of 40 pairs analyzed. When arrayed on a helical wheel diagram, the results suggest that the helical face of TM7 of subunit a containing Arg-735 interacts with the helical face of TM4 of subunit c' centered on Val-146 and bounded by Glu-145 and Leu-147. The results are consistent with a possible rotational flexibility of one or both of these transmembrane segments as well as some flexibility of movement perpendicular to the membrane.	Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA	Tufts University	Forgac, M (corresponding author), Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA.	michael.forgac@tufts.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034928] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034478, R01GM034478] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 34928] Funding Source: Medline; NIGMS NIH HHS [R37 GM034478, R01 GM034478, GM 34478] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGGELER R, 1995, J BIOL CHEM, V270, P9185, DOI 10.1074/jbc.270.16.9185; ARAI H, 1988, J BIOL CHEM, V263, P8796; Arata Y, 2002, BIOCHEMISTRY-US, V41, P11301, DOI 10.1021/bi0262449; Arata Y, 2002, J BIOL CHEM, V277, P3357, DOI 10.1074/jbc.M109967200; Boekema EJ, 1997, P NATL ACAD SCI USA, V94, P14291, DOI 10.1073/pnas.94.26.14291; Bowman BJ, 2002, J BIOL CHEM, V277, P3965, DOI 10.1074/jbc.M109756200; Bowman EJ, 2000, J EXP BIOL, V203, P97; Brown D, 2000, J EXP BIOL, V203, P137; CAIN BD, 1989, J BIOL CHEM, V264, P3292; Cain BD, 2000, J BIOENERG BIOMEMBR, V32, P365, DOI 10.1023/A:1005575919638; Capaldi RA, 2000, J EXP BIOL, V203, P29; Cross RL, 2000, BBA-BIOENERGETICS, V1458, P270, DOI 10.1016/S0005-2728(00)00079-7; CROSS RL, 1990, FEBS LETT, V259, P227, DOI 10.1016/0014-5793(90)80014-A; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; Fillingame RH, 2002, BBA-BIOENERGETICS, V1555, P29, DOI 10.1016/S0005-2728(02)00250-5; Fillingame RH, 2000, J EXP BIOL, V203, P9; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; Futai M, 2000, J EXP BIOL, V203, P107; Futai M, 2000, BBA-BIOENERGETICS, V1458, P276, DOI 10.1016/S0005-2728(00)00080-3; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Girvin ME, 1998, BIOCHEMISTRY-US, V37, P8817, DOI 10.1021/bi980511m; Graham LA, 1998, J CELL BIOL, V142, P39, DOI 10.1083/jcb.142.1.39; Graham LA, 2000, J EXP BIOL, V203, P61; Harrison MA, 1999, J BIOL CHEM, V274, P25461, DOI 10.1074/jbc.274.36.25461; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; Hirata T, 2003, J BIOL CHEM, V278, P23714, DOI 10.1074/jbc.M302756200; HORAZDOVSKY BF, 1993, J BIOL CHEM, V268, P4953; Hutcheon ML, 2001, P NATL ACAD SCI USA, V98, P8519, DOI 10.1073/pnas.151236798; Imamizu H, 2003, P NATL ACAD SCI USA, V100, P5461, DOI 10.1073/pnas.0835746100; Jiang WP, 1998, P NATL ACAD SCI USA, V95, P6607, DOI 10.1073/pnas.95.12.6607; Jiang WP, 2001, P NATL ACAD SCI USA, V98, P4966, DOI 10.1073/pnas.081424898; Junge W, 1996, BER BUNSEN PHYS CHEM, V100, P2014, DOI 10.1002/bbpc.19961001215; KANE PM, 1989, J BIOL CHEM, V264, P19236; Kane PM, 2000, J EXP BIOL, V203, P81; KANE PM, 1992, J BIOL CHEM, V267, P447; Kawasaki-Nishi S, 2001, P NATL ACAD SCI USA, V98, P12397, DOI 10.1073/pnas.221291798; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landolt-Marticorena C, 2000, J BIOL CHEM, V275, P15449, DOI 10.1074/jbc.M000207200; Leng XH, 1996, J BIOL CHEM, V271, P22487, DOI 10.1074/jbc.271.37.22487; Leng XH, 1998, J BIOL CHEM, V273, P6717, DOI 10.1074/jbc.273.12.6717; Leng XH, 1999, J BIOL CHEM, V274, P14655, DOI 10.1074/jbc.274.21.14655; Li YP, 1999, NAT GENET, V23, P447, DOI 10.1038/70563; Liu JZ, 1996, BIOCHEMISTRY-US, V35, P10938, DOI 10.1021/bi9608065; MacLeod KJ, 1999, J BIOL CHEM, V274, P32869, DOI 10.1074/jbc.274.46.32869; MacLeod KJ, 1998, J BIOL CHEM, V273, P150, DOI 10.1074/jbc.273.1.150; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; MARTINEZZAGUILAN R, 1993, AM J PHYSIOL, V265, pC1015, DOI 10.1152/ajpcell.1993.265.4.C1015; McLachlin DT, 1998, J BIOL CHEM, V273, P15162, DOI 10.1074/jbc.273.24.15162; Nanda A, 1996, J BIOL CHEM, V271, P15963, DOI 10.1074/jbc.271.27.15963; Nelson N, 2000, J EXP BIOL, V203, P89; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; Nishi T, 2003, J BIOL CHEM, V278, P5821, DOI 10.1074/jbc.M209875200; Nishi T, 2001, J BIOL CHEM, V276, P34122, DOI 10.1074/jbc.M104682200; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; Ogilvie I, 1997, J BIOL CHEM, V272, P16652, DOI 10.1074/jbc.272.26.16652; Powell B, 2000, J BIOL CHEM, V275, P23654, DOI 10.1074/jbc.M004440200; Rastogi VK, 1999, NATURE, V402, P263, DOI 10.1038/46224; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; Seelert H, 2000, NATURE, V405, P418, DOI 10.1038/35013148; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Sze H, 1999, PLANT CELL, V11, P677, DOI 10.1105/tpc.11.4.677; Tsunoda SP, 2001, P NATL ACAD SCI USA, V98, P898, DOI 10.1073/pnas.031564198; Vasilyeva E, 2000, J BIOL CHEM, V275, P255, DOI 10.1074/jbc.275.1.255; Vik SB, 2000, BBA-BIOENERGETICS, V1458, P457, DOI 10.1016/S0005-2728(00)00094-3; VIK SB, 1994, J BIOL CHEM, V269, P30364; Vonck J, 2002, J MOL BIOL, V321, P307, DOI 10.1016/S0022-2836(02)00597-1; Weber J, 2000, BBA-BIOENERGETICS, V1458, P300, DOI 10.1016/S0005-2728(00)00082-7; Wieczorek H, 2000, J EXP BIOL, V203, P127; Wilkens S, 1999, J BIOL CHEM, V274, P31804, DOI 10.1074/jbc.274.45.31804; Wilkens S, 2001, J BIOL CHEM, V276, P44064, DOI 10.1074/jbc.M106579200; Xu T, 1999, J BIOL CHEM, V274, P28909, DOI 10.1074/jbc.274.41.28909; Yokoyama K, 2003, J BIOL CHEM, V278, P24255, DOI 10.1074/jbc.M303104200; Yoshida M, 2001, NAT REV MOL CELL BIO, V2, P669, DOI 10.1038/35089509	77	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41908	41913		10.1074/jbc.M308026200	http://dx.doi.org/10.1074/jbc.M308026200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12917411	hybrid			2022-12-25	WOS:000185989500044
J	Zou, WQ; Capellari, S; Parchi, P; Sy, MS; Gambetti, P; Chen, SG				Zou, WQ; Capellari, S; Parchi, P; Sy, MS; Gambetti, P; Chen, SG			Identification of novel proteinase K-resistant C-terminal fragments of PrP in Creutzfeldt-Jakob disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PRION PROTEIN; STRAUSSLER-SCHEINKER-DISEASE; SCRAPIE PRION; TRANSGENIC MICE; MOLECULAR-CLONING; TRUNCATED FORMS; AMYLOID PROTEIN; NORMAL BRAIN; PHENOTYPE; ISOFORMS	The central event in the pathogenesis of prion diseases, a group of fatal, transmissible neurodegenerative disorders including Creutzfeldt-Jakob disease (CJD) in humans, is the conversion of the normal or cellular prion protein ( PrPC) into the abnormal or scrapie isoform ( PrPSc). The basis of the PrPC to PrPSc conversion is thought to involve the diminution of alpha-helical domains accompanied by the increase of beta structures within the PrP molecule. Consequently, treatment of PrPSc with proteinase K (PK) generates a large PK-resistant C-terminal core fragment termed PrP27-30 that in human prion diseases has a gel mobility of similar to19-21 kDa for the unglycosylated form, and a ragged N terminus between residues 78 and 103. PrP27-30 is considered the pathogenic and infectious core of PrPSc. Here we report the identification of two novel PK-resistant, but much smaller C-terminal fragments of PrP (PrP-CTF 12/13) in brains of subjects with sporadic CJD. PrP-CTF 12/13, like PrP27-30, derive from both glycosylated as well as unglycosylated forms. The unglycosylated PrP-CTF 12/13 migrate at 12 and 13 kDa and have the N terminus at residues 162/167 and 154/156, respectively. Therefore, PrP-CTF12/13 are 64-76 amino acids N-terminally shorter than PrP27-30 and are about half of the size of PrP27-30. PrP-CTF12/13 are likely to originate from a subpopulation of PrPSc distinct from that which generates PrP27-30. The finding of PrP-CTF12/13 in CJD brains widens the heterogeneity of the PK-resistant PrP fragments associated with prion diseases and may provide useful insights toward the understanding of the PrPSc structure and its formation.	Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA; Natl Prion Dis Pathol Surveillance Ctr, Cleveland, OH 44106 USA	Case Western Reserve University	Chen, SG (corresponding author), Case Western Reserve Univ, Inst Pathol, 2085 Adelbert Rd, Cleveland, OH 44106 USA.	sxc59@cwru.edu	Zou, Wenquan/GWQ-3489-2022; capellari, sabina/F-5545-2012; Chen, Shu G./O-4750-2014; Parchi, Piero/L-9833-2015; Chen, Shu/Z-2943-2019; Zou, Wenquan/ABF-2875-2020; Chen, Shu G./AAK-7301-2021	capellari, sabina/0000-0003-1631-1439; Chen, Shu G./0000-0001-7180-3001; Parchi, Piero/0000-0002-9444-9524; Chen, Shu G./0000-0001-7180-3001	NIA NIH HHS [AG14359, P01 AG014359-040003, P01 AG014359-030003, P01 AG014359-010003, P01 AG014359-050003, AG15162, P01 AG014359-020003, P01 AG014359, P01 AG014359-060003] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG014359, R03AG015162] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BASLER K, 1986, CELL, V46, P417, DOI 10.1016/0092-8674(86)90662-8; BENDHEIM PE, 1992, NEUROLOGY, V42, P149, DOI 10.1212/WNL.42.1.149; BOLTON DC, 1987, ARCH BIOCHEM BIOPHYS, V258, P579, DOI 10.1016/0003-9861(87)90380-8; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; Caughey B, 1998, J BIOL CHEM, V273, P32230, DOI 10.1074/jbc.273.48.32230; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; Chen SG, 1997, NAT MED, V3, P1009, DOI 10.1038/nm0997-1009; CHEN SG, 1995, J BIOL CHEM, V270, P19173, DOI 10.1074/jbc.270.32.19173; Cohen FE, 1998, ANNU REV BIOCHEM, V67, P793, DOI 10.1146/annurev.biochem.67.1.793; DeArmond SJ, 1999, COLD SPRING HARBOR M, V38, P585; Eberl H, 2002, BIOPHYS CHEM, V96, P293, DOI 10.1016/S0301-4622(02)00015-7; Ghetti B, 1996, P NATL ACAD SCI USA, V93, P744, DOI 10.1073/pnas.93.2.744; GOLDFARB LG, 1992, SCIENCE, V258, P806, DOI 10.1126/science.1439789; Harris DA, 1999, CLIN MICROBIOL REV, V12, P429, DOI 10.1128/CMR.12.3.429; HOPE J, 1986, EMBO J, V5, P2591, DOI 10.1002/j.1460-2075.1986.tb04539.x; Jimenez-Huete A, 1998, AM J PATHOL, V153, P1561, DOI 10.1016/S0002-9440(10)65744-6; Kaneko K, 2000, J MOL BIOL, V295, P997, DOI 10.1006/jmbi.1999.3386; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; Kocisko DA, 1996, BIOCHEMISTRY-US, V35, P13434, DOI 10.1021/bi9610562; KRETZSCHMAR HA, 1986, DNA-J MOLEC CELL BIO, V5, P315, DOI 10.1089/dna.1986.5.315; LEHMANN S, 1995, J BIOL CHEM, V270, P24589, DOI 10.1074/jbc.270.41.24589; Li RL, 2000, J MOL BIOL, V301, P567, DOI 10.1006/jmbi.2000.3986; LIAO YCJ, 1986, SCIENCE, V233, P364, DOI 10.1126/science.3014653; MA J, 2002, SCIENCE, V298, P1758; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; Nelson KL, 1997, J BIOL CHEM, V272, P12170, DOI 10.1074/jbc.272.18.12170; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Pan T, 2001, J BIOL CHEM, V276, P37284, DOI 10.1074/jbc.M107358200; Parchi P, 2000, P NATL ACAD SCI USA, V97, P10168, DOI 10.1073/pnas.97.18.10168; Parchi P, 1998, P NATL ACAD SCI USA, V95, P8322, DOI 10.1073/pnas.95.14.8322; Parchi P, 1999, ANN NEUROL, V46, P224, DOI 10.1002/1531-8249(199908)46:2<224::AID-ANA12>3.0.CO;2-W; Parchi P, 1996, ANN NEUROL, V39, P767, DOI 10.1002/ana.410390613; PARCHI P, 1995, CURR OPIN NEUROL, V8, P286, DOI 10.1097/00019052-199508000-00007; PRUSINER SB, 1984, CELL, V38, P127, DOI 10.1016/0092-8674(84)90533-6; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; SAFAR J, 1994, BIOCHEMISTRY-US, V33, P8375, DOI 10.1021/bi00193a027; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; STAHL N, 1990, BIOCHEMISTRY-US, V29, P8879, DOI 10.1021/bi00490a001; Supattapone S, 1999, CELL, V96, P869, DOI 10.1016/S0092-8674(00)80596-6; Supattapone S, 2001, MOL CELL BIOL, V21, P2608, DOI 10.1128/MCB.21.7.2608-2616.2001; TAGLIAVINI F, 1991, EMBO J, V10, P513, DOI 10.1002/j.1460-2075.1991.tb07977.x; Tagliavini F, 2001, J BIOL CHEM, V276, P6009, DOI 10.1074/jbc.M007062200; Telling GC, 1996, SCIENCE, V274, P2079, DOI 10.1126/science.274.5295.2079; TURK E, 1988, EUR J BIOCHEM, V176, P21, DOI 10.1111/j.1432-1033.1988.tb14246.x; Wille H, 2002, P NATL ACAD SCI USA, V99, P3563, DOI 10.1073/pnas.052703499; Zahn R, 2000, P NATL ACAD SCI USA, V97, P145, DOI 10.1073/pnas.97.1.145; Zanusso G, 2002, ELECTROPHORESIS, V23, P347, DOI 10.1002/1522-2683(200202)23:2<347::AID-ELPS347>3.0.CO;2-1; Zou WQ, 2002, J BIOL CHEM, V277, P43942, DOI 10.1074/jbc.M203611200; ZOU WQ, 2002, CHARACTERIZATION PRI, P305	53	117	120	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40429	40436		10.1074/jbc.M308550200	http://dx.doi.org/10.1074/jbc.M308550200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12917418	hybrid			2022-12-25	WOS:000185847200003
J	Kanazawa, S; Soucek, L; Evan, G; Okamoto, T; Peterlin, BM				Kanazawa, S; Soucek, L; Evan, G; Okamoto, T; Peterlin, BM			c-Myc recruits P-TEFb for transcription, cellular proliferation and apoptosis	ONCOGENE			English	Article						c-Myc; P-TEFb; CycT1; apoptosis; proliferation; transcription	RNA-POLYMERASE-II; CARBOXYL-TERMINAL DOMAIN; ELONGATION; TAT; TRANSFORMATION; PROGRESSION; ACTIVATION; MUTATIONS; INTERACTS; NETWORK	c-Myc promotes cellular proliferation, sensitizes cells to apoptosis and prevents differentiation. It binds cyclin T1 structurally and functionally from the positive transcription elongation factor b (P-TEFb). The cyclin-dependent kinase 9 (Cdk9) in P-TEFb then phosporylates the C-terminal domain of RNA polymerase II, which is required for the transition from initiation to elongation of eukaryotic transcription. Inhibiting P-TEFb blocks the transcription of its target genes as well as cellular proliferation and apoptosis induced by c-Myc.	Univ Calif San Francisco, Rosalind Russell Med Res Ctr, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Rosalind Russell Med Res Ctr, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94143 USA; Nagoya City Univ, Sch Med, Dept Mol Genet, Nagoya, Aichi 467, Japan	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Nagoya City University	Peterlin, BM (corresponding author), Univ Calif San Francisco, Rosalind Russell Med Res Ctr, Dept Med, Box 0703,3rd & Parnassus Ave, San Francisco, CA 94143 USA.		Soucek, Laura/AAG-7393-2019; Soucek, Laura/AAG-8377-2019	Soucek, Laura/0000-0002-4750-7971; 				AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; Barboric M, 2001, MOL CELL, V8, P327, DOI 10.1016/S1097-2765(01)00314-8; Baudino TA, 2002, GENE DEV, V16, P2530, DOI 10.1101/gad.1024602; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; Chao SH, 2001, J BIOL CHEM, V276, P31793, DOI 10.1074/jbc.M102306200; Claassen GF, 1999, ONCOGENE, V18, P2925, DOI 10.1038/sj.onc.1202747; CLARK HM, 1994, CANCER RES, V54, P3383; Eberhardy SR, 2001, J BIOL CHEM, V276, P48562, DOI 10.1074/jbc.M109014200; EBERHARDY SR, 2002, J BIOL CHEM; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Greenberg RA, 1999, ONCOGENE, V18, P1219, DOI 10.1038/sj.onc.1202669; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Kanazawa S, 2000, IMMUNITY, V12, P61, DOI 10.1016/S1074-7613(00)80159-4; Kim YK, 2002, MOL CELL BIOL, V22, P4622, DOI 10.1128/MCB.22.13.4622-4637.2002; Lee DK, 2001, J BIOL CHEM, V276, P9978, DOI 10.1074/jbc.M002285200; Lis JT, 2000, GENE DEV, V14, P792; Nasi S, 2001, FEBS LETT, V490, P153, DOI 10.1016/S0014-5793(01)02118-4; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Ramanathan Y, 2001, J BIOL CHEM, V276, P10913, DOI 10.1074/jbc.M010975200; Sakamuro D, 1999, ONCOGENE, V18, P2942, DOI 10.1038/sj.onc.1202725; Simone C, 2002, ONCOGENE, V21, P4137, DOI 10.1038/sj.onc.1205493; Soucek L, 1998, ONCOGENE, V17, P2463, DOI 10.1038/sj.onc.1202199; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Zhou MS, 2000, MOL CELL BIOL, V20, P5077, DOI 10.1128/MCB.20.14.5077-5086.2000	26	132	138	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2003	22	36					5707	5711		10.1038/sj.onc.1206800	http://dx.doi.org/10.1038/sj.onc.1206800			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944920				2022-12-25	WOS:000184865900021
J	Sirri, V; Leibovitch, MP; Leibovitch, SA				Sirri, V; Leibovitch, MP; Leibovitch, SA			Muscle regulatory factor MRF4 activates differentiation in rhabdomyosarcoma RD cells through a positive-acting C-terminal protein domain	ONCOGENE			English	Article						MRF4; rhabdomyosarcoma; transactivation domain; differentiation	KINASE-ACTIVITY; GENE; EXPRESSION; TRANSCRIPTION; INHIBITION; P38	Rhabdomyosarcoma (RMS) has deregulated proliferation and is blocked in the differentiation program despite Myf-5, MyoD and myogenin expression. Here we show that ectopic expression of MRF4, which is not subject to an autoregulatory pathway but regulated by the other MRFs protein family, induces growth arrest and terminal differentiation in RD cells. Deletion mapping identified a positive-acting C-terminal domain in MRF4 as the mediator of transcriptional activity, revealing a conserved motif with helix III in MyoD previously found to initiate expression of endogenous skeletal muscle genes. By using chimeric MyoD/MRF4 proteins, we observe that the G terminal motif of MRF4 rescues MyoD activity in RD cells. Moreover, comparative induction of muscle-specific genes following activation of MyoD, through the expression of a constitutively activated MKK6 either in the absence or presence of MRF4, shows that MyoD and MRF4 can differently regulate muscle genes expression. Together, these results demonstrate that the MRF4 G terminus functions as specification as well as activation domain in tumor cells. They provide a basis to identify gene products necessary for b-HLH-mediated differentiation versus tumor progression.	Inst Gustave Roussy, CNRS, UMR 8125, Lab Genet Oncol, F-94800 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Leibovitch, SA (corresponding author), Inst Gustave Roussy, CNRS, UMR 8125, Lab Genet Oncol, 39 Rue Camille Desmoulins, F-94800 Villejuif, France.	leibovit@igr.fr						Bergstrom DA, 2001, MOL CELL BIOL, V21, P2404, DOI 10.1128/MCB.21.7.2404-2412.2001; BLACK BL, 1995, J BIOL CHEM, V270, P2889, DOI 10.1074/jbc.270.7.2889; BOBER E, 1991, J CELL BIOL, V113, P1255, DOI 10.1083/jcb.113.6.1255; BUCKINGHAM M, 1994, CURR BIOL, V4, P61, DOI 10.1016/S0960-9822(00)00014-2; DIAZ P, 1992, CANCER RES, V52, P6431; EDMONDSON DG, 1993, J BIOL CHEM, V268, P755; FUJISAWASEHARA A, 1990, J BIOL CHEM, V265, P15219; HINTERBERGER TJ, 1991, DEV BIOL, V147, P144, DOI 10.1016/S0012-1606(05)80014-4; Knudsen ES, 1998, CANCER RES, V58, P2042; MAK KL, 1992, MOL CELL BIOL, V12, P4334, DOI 10.1128/MCB.12.10.4334; Meedel TH, 1997, DEVELOPMENT, V124, P1711; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Otten AD, 1997, CELL GROWTH DIFFER, V8, P1151; Puri PL, 2000, GENE DEV, V14, P574; RAO SS, 1994, MOL CELL BIOL, V14, P5259, DOI 10.1128/MCB.14.8.5259; Rawls A, 1998, DEVELOPMENT, V125, P2349; Reynaud EG, 1999, MOL CELL BIOL, V19, P7621; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; Tajbakhsh S, 1997, CELL, V89, P127, DOI 10.1016/S0092-8674(00)80189-0; TAPSCOTT SJ, 1993, SCIENCE, V259, P1450, DOI 10.1126/science.8383879; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951-3964.2000; Zhang JM, 1999, EMBO J, V18, P6983, DOI 10.1093/emboj/18.24.6983	25	16	17	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2003	22	36					5658	5666		10.1038/sj.onc.1206690	http://dx.doi.org/10.1038/sj.onc.1206690			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944914				2022-12-25	WOS:000184865900015
J	Martin, J; Hunt, SL; Dubus, P; Sotillo, R; Nehme-Pelluard, F; Magnuson, MA; Parlow, AF; Malumbres, M; Ortega, S; Barbacid, M				Martin, J; Hunt, SL; Dubus, P; Sotillo, R; Nehme-Pelluard, F; Magnuson, MA; Parlow, AF; Malumbres, M; Ortega, S; Barbacid, M			Genetic rescue of Cdk4 null mice restores pancreatic beta-cell proliferation but not homeostatic cell number	ONCOGENE			English	Article						adenohypophysis; cell cycle regulation; cell proliferation; gene-targeted mice; pancreatic beta cells	RETINOBLASTOMA PROTEIN; CYCLIN D1; INHIBITORS; DEFICIENT; GROWTH; EXPRESSION; ROLES; LIFE; MASS; E2F	Lack of Cdk4 expression in mice leads to insulin-deficient diabetes and female infertility owing to a reduced number of pancreatic beta cells and prolactin-producing pituitary lactotrophs, respectively. Cdk4 null mice display also reduced body and organ size. Here, we show that Cdk4 is essential for the postnatal proliferation of pancreatic beta cells but not for embryonic neogenesis from ductal epithelial cells. Re-expression of endogenous Cdk4 in beta cells and in the pituitary gland of Cdk4 null mice restores cell proliferation and results in fertile and normoglycemic animals, thus, demonstrating that the proliferation defects in these cellular populations are cell autonomous because of the lack of Cdk4 expression. However, these mice remain small in size, indicating that this phenotype is not because of pancreatic- or pituitary-mediated endocrine defects. This phenotype is a consequence of reduced cell numbers rather than reduced cell size. Thus, mammalian Cdk4 is not only involved in controlling proliferation of specific cell types but may play a wider role in establishing homeostatic cell numbers.	Ctr Nacl Invest Oncol, Mol Oncol Program, Madrid 28029, Spain; CSIC, Ctr Nacl Biotecnol, E-28049 Madrid, Spain; Univ Bordeaux 2, F-33076 Bordeaux, France; Vanderbilt Univ, Med Ctr N CCC 3322, Nashville, TN 37232 USA; Harbor UCLA Med Ctr, Res & Educ Inst, Natl Hormone & Peptide Program, Torrance, CA 90509 USA	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); UDICE-French Research Universities; Universite de Bordeaux; Vanderbilt University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	Ortega, S (corresponding author), Ctr Nacl Invest Oncol, Mol Oncol Program, Melchor Fernandez Almagro 3, Madrid 28029, Spain.	s.ortega@cnio.es	Magnuson, Mark/AAY-7172-2021; Malumbres, Marcos/E-8834-2011; Holt, Janet E/B-2415-2013; Magnuson, Mark A/B-1335-2009	Magnuson, Mark/0000-0002-8824-6499; Malumbres, Marcos/0000-0002-0829-6315; Magnuson, Mark A/0000-0002-8824-6499; Sotillo, Rocio/0000-0002-0855-7917; Dubus, Pierre/0000-0003-1803-4711				Bonner-Weir S, 2000, TRENDS ENDOCRIN MET, V11, P375, DOI 10.1016/S1043-2760(00)00305-2; Bonner-Weir S, 2000, J MOL ENDOCRINOL, V24, P297, DOI 10.1677/jme.0.0240297; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; FINEGOOD DT, 1995, DIABETES, V44, P249, DOI 10.2337/diabetes.44.3.249; Franklin DS, 2000, MOL CELL BIOL, V20, P6147, DOI 10.1128/MCB.20.16.6147-6158.2000; Gannon M, 2000, GENESIS, V26, P139, DOI 10.1002/(SICI)1526-968X(200002)26:2<139::AID-GENE12>3.0.CO;2-7; HERRERA PL, 1991, DEVELOPMENT, V113, P1257; Kim SK, 2001, GENE DEV, V15, P111, DOI 10.1101/gad.859401; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Latres E, 2000, EMBO J, V19, P3496, DOI 10.1093/emboj/19.13.3496; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Meyer CA, 2000, EMBO J, V19, P4533, DOI 10.1093/emboj/19.17.4533; Montanya E, 2000, DIABETES, V49, P1341, DOI 10.2337/diabetes.49.8.1341; Moons DS, 2002, ENDOCRINOLOGY, V143, P3001, DOI 10.1210/en.143.8.3001; Moons DS, 2002, ENDOCRINOLOGY, V143, P647, DOI 10.1210/en.143.2.647; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Pavletich NP, 1999, J MOL BIOL, V287, P821, DOI 10.1006/jmbi.1999.2640; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; Reed SI, 1997, CANCER SURV, V29, P7; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Sherr CJ, 2000, CANCER RES, V60, P3689; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Sotillo R, 2001, P NATL ACAD SCI USA, V98, P13312, DOI 10.1073/pnas.241338598; Sotillo R, 2001, EMBO J, V20, P6637, DOI 10.1093/emboj/20.23.6637; Tsutsui T, 1999, MOL CELL BIOL, V19, P7011; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	34	103	109	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2003	22	34					5261	5269		10.1038/sj.onc.1206506	http://dx.doi.org/10.1038/sj.onc.1206506			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JB	12917627				2022-12-25	WOS:000184734900005
J	Hong, GZ; Lockhart, A; Davis, B; Rahmoune, H; Baker, S; Ye, L; Thompson, P; Shou, YP; O'Shaughnessy, K; Ronco, P; Brown, J				Hong, GZ; Lockhart, A; Davis, B; Rahmoune, H; Baker, S; Ye, L; Thompson, P; Shou, YP; O'Shaughnessy, K; Ronco, P; Brown, J			PPAR gamma activation enhances cell surface ENaC alpha via up-regulation of SGK1 in human collecting duct cells	FASEB JOURNAL			English	Article						nuclear receptor; PPAR gamma agonists; sodium retention	EPITHELIAL SODIUM-CHANNEL; RECEPTORS PPARS; ALDOSTERONE; KINASE; EXPRESSION; AGONISTS; CONSEQUENCES; CONVERGENCE; TRANSPORT; DISCOVERY	Peroxisome proliferator-activated receptor gamma (PPARgamma) is a ligand-dependent transcription factor that belongs to the nuclear receptor family that plays a critical role in adipocyte differentiation and lipid metabolism. Here we report for the first time that PPAR. is expressed in human renal cortical collecting ducts (CCD), segments of the nephor involved in regulation of sodium and water homeostasis via action of the epithelial sodium channel (ENaC). ENaC activity is regulated by the hormones aldosterone and insulin, primarily through co-ordinate actions on serum and glucocorticoid regulated kinase 1 (SGK1). We show that SGK1 activity is stimulated by treatment of a human CCD cell line with PPARgamma agonists, paralleled by an increase in SGK1 mRNA that is abolished by pretreatment with a specific PPARgamma antagonist, and that this leads to increased levels of cell surface ENaCalpha. Electrophoretic mobility shift assays suggest that these effects are caused by binding of PPARgamma to a specific response element in the SGK1 promoter. Our results identify SGK1 as a target for PPARgamma and suggest a novel role for PPARgamma in regulation of sodium re-absorption in the CCD via stimulation of ENaC activity. This pathway may play a role in sodium retention caused by activation of PPARgamma in man.	Addenbrookes Hosp, ACCI, Translat Med & Technol, GlaxoSmithKline, Cambridge, England; GlaxoSmithKline, Translat Med & Technol, Res Triangle Pk, NC USA; Addenbrookes Hosp, Clin Pharmacol Unit, Cambridge CB2 2QQ, England; Univ Paris 06, Hop Tenon, Paris, France; INSERM, U489, Paris, France	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; GlaxoSmithKline; University of Cambridge; GlaxoSmithKline; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm)	Hong, GZ (corresponding author), Addenbrookes Hosp, ACCI, Translat Med & Technol, GlaxoSmithKline, Hills Rd, Cambridge, England.	Guizhu_2_Hong@gsk.com	Ronco, Pierre/AAC-8390-2022					Blazer-Yost BL, 1999, AM J PHYSIOL-CELL PH, V277, pC531, DOI 10.1152/ajpcell.1999.277.3.C531; Chen SY, 1999, P NATL ACAD SCI USA, V96, P2514, DOI 10.1073/pnas.96.5.2514; de la Rosa DA, 1999, J BIOL CHEM, V274, P37834, DOI 10.1074/jbc.274.53.37834; Debonneville C, 2001, EMBO J, V20, P7052, DOI 10.1093/emboj/20.24.7052; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Faletti CJ, 2002, AM J PHYSIOL-CELL PH, V282, pC494, DOI 10.1152/ajpcell.00408.2001; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Gorson DM, 1999, ARCH INTERN MED, V159, P99, DOI 10.1001/archinte.159.1.99; Guan YF, 2001, KIDNEY INT, V60, P14, DOI 10.1046/j.1523-1755.2001.00766.x; Guan YF, 1997, AM J PHYSIOL-RENAL, V273, pF1013, DOI 10.1152/ajprenal.1997.273.6.F1013; Hanwell D, 2002, J BIOL CHEM, V277, P9772, DOI 10.1074/jbc.M110904200; Henke BR, 1998, J MED CHEM, V41, P5020, DOI 10.1021/jm9804127; JACKSON KE, 1996, PHARMACOL BASIS THER, P685; JugeAubry C, 1997, J BIOL CHEM, V272, P25252, DOI 10.1074/jbc.272.40.25252; Kassam A, 1998, MOL CELL ENDOCRINOL, V141, P153, DOI 10.1016/S0303-7207(98)00085-9; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Kosari F, 1998, J BIOL CHEM, V273, P13469, DOI 10.1074/jbc.273.22.13469; Leesnitzer LM, 2002, BIOCHEMISTRY-US, V41, P6640, DOI 10.1021/bi0159581; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Loffing J, 2001, AM J PHYSIOL-RENAL, V280, pF675, DOI 10.1152/ajprenal.2001.280.4.F675; Masilamani S, 1999, J CLIN INVEST, V104, pR19, DOI 10.1172/JCI7840; May A, 1997, J AM SOC NEPHROL, V8, P1813; Mukherjee R, 1997, J BIOL CHEM, V272, P8071, DOI 10.1074/jbc.272.12.8071; Murphy GJ, 2000, TRENDS PHARMACOL SCI, V21, P469, DOI 10.1016/S0165-6147(00)01559-5; Naray-Fejes-Toth A, 1999, J BIOL CHEM, V274, P16973, DOI 10.1074/jbc.274.24.16973; PALMER CNA, 1995, J BIOL CHEM, V270, P16114, DOI 10.1074/jbc.270.27.16114; Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024; Pearce D, 2001, TRENDS ENDOCRIN MET, V12, P341, DOI 10.1016/S1043-2760(01)00439-8; PRIE D, 1995, KIDNEY INT, V47, P1310, DOI 10.1038/ki.1995.186; Rieusset J, 2001, FEBS LETT, V502, P98, DOI 10.1016/S0014-5793(01)02674-6; Takeda K, 2001, J BIOL CHEM, V276, P48950, DOI 10.1074/jbc.M108722200; Verrey F, 1999, AM J PHYSIOL-RENAL, V277, pF319, DOI 10.1152/ajprenal.1999.277.3.F319; Wang J, 2001, AM J PHYSIOL-RENAL, V280, pF303, DOI 10.1152/ajprenal.2001.280.2.F303; Wang T, 1999, ANAL BIOCHEM, V269, P198, DOI 10.1006/abio.1999.4022; WEBSTER MK, 1993, MOL CELL BIOL, V13, P2031, DOI 10.1128/MCB.13.4.2031; Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g; Yang TX, 1999, AM J PHYSIOL-RENAL, V277, pF966, DOI 10.1152/ajprenal.1999.277.6.F966; Yoshimoto T, 1997, AM J PHYSIOL-ENDOC M, V272, pE989, DOI 10.1152/ajpendo.1997.272.6.E989	39	93	95	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1966	+		10.1096/fj.03-0181fje	http://dx.doi.org/10.1096/fj.03-0181fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12923071				2022-12-25	WOS:000185345100011
J	Coric, T; Zhang, P; Todorovic, N; Canessa, CM				Coric, T; Zhang, P; Todorovic, N; Canessa, CM			The extracellular domain determines the kinetics of desensitization in acid-sensitive ion channel 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN DEGENERIN MDEG; SENSING ION CHANNELS; NA+ CHANNEL; H+; CONTRIBUTES; CURRENTS; ASIC1	The acid-sensitive ion channel 1 (ASIC1alpha or BNaC2a) is the most abundant of all mammalian proton-gated ion channels and the one that has the broadest distribution in the nervous system. Hallmarks of ASIC1alpha are gating by external protons and rapid desensitization. In sensory neurons ASIC1 may constitute a nociceptor for pain induced by local acidification, whereas in central neurons it may modulate synaptic activity. To gain insight into the functional roles of ASIC1, we cloned and examined the properties of the evolutionarily distant species toadfish (Opsanus tau), similar to420-million year divergent from mammals. Analysis of the protein sequence from fish ASIC1 revealed 76% amino acid identity with the rat orthologue. The regions of highest conservation are the second transmembrane domain and the ectodomain, whereas the amino and carboxyl termini and first transmembrane domain are poorly conserved. At the functional level, fish ASIC1 is gated by external protons with a half-maximal activation at pH(o) 5.6 and a half-maximal inactivation at pH(o) 7.30. The fish differs from the rat channel on having a 25-fold faster rate of desensitization. Functional studies of chimeras made from rat and fish ASIC1 indicate that the extracellular domain specifically, a cluster of three residues, confers the faster desensitization rate to the fish ASIC1.	Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA	Yale University	Canessa, CM (corresponding author), 333 Cedar St, New Haven, CT 06520 USA.	cecilia.canessa@yale.edu	Todorovic, Natasa/AAB-7822-2022; Todorovic, Natasa/B-8760-2009	Todorovic, Natasa/0000-0003-2626-0794				Askwith CC, 2000, NEURON, V26, P133, DOI 10.1016/S0896-6273(00)81144-7; Askwith CC, 2001, P NATL ACAD SCI USA, V98, P6459, DOI 10.1073/pnas.111155398; Baron A, 2001, J BIOL CHEM, V276, P35361, DOI 10.1074/jbc.M105208200; Bassilana F, 1997, J BIOL CHEM, V272, P28819, DOI 10.1074/jbc.272.46.28819; Benson CJ, 2001, ANN NY ACAD SCI, V940, P96; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; Chen CC, 1998, P NATL ACAD SCI USA, V95, P10240, DOI 10.1073/pnas.95.17.10240; Coscoy S, 1999, J BIOL CHEM, V274, P10129, DOI 10.1074/jbc.274.15.10129; de la Rosa DA, 2003, J PHYSIOL-LONDON, V546, P77, DOI 10.1113/jphysiol.2002.030692; de la Rosa DA, 2002, P NATL ACAD SCI USA, V99, P2326, DOI 10.1073/pnas.042688199; Deval E, 2003, NEUROPHARMACOLOGY, V44, P662, DOI 10.1016/S0028-3908(03)00047-9; Fyfe GK, 1999, J BIOL CHEM, V274, P36415, DOI 10.1074/jbc.274.51.36415; Immke DC, 2003, NEURON, V37, P75, DOI 10.1016/S0896-6273(02)01130-3; Immke DC, 2001, NAT NEUROSCI, V4, P869, DOI 10.1038/nn0901-869; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; Kellenberger S, 2001, J GEN PHYSIOL, V118, P679, DOI 10.1085/jgp.118.6.679; Kellenberger S, 1999, J GEN PHYSIOL, V114, P13, DOI 10.1085/jgp.114.1.13; Mamet J, 2002, J NEUROSCI, V22, P10662; Price MP, 2001, NEURON, V32, P1071, DOI 10.1016/S0896-6273(01)00547-5; PUOTI A, 1995, AM J PHYSIOL-CELL PH, V269, pC188, DOI 10.1152/ajpcell.1995.269.1.C188; Sutherland SP, 2001, P NATL ACAD SCI USA, V98, P711, DOI 10.1073/pnas.011404498; Waldmann R, 1996, J BIOL CHEM, V271, P10433, DOI 10.1074/jbc.271.18.10433; Waldmann R, 1999, ANN NY ACAD SCI, V868, P67, DOI 10.1111/j.1749-6632.1999.tb11274.x; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; Wemmie JA, 2002, NEURON, V34, P463, DOI 10.1016/S0896-6273(02)00661-X; Xie JH, 2003, J NEUROPHYSIOL, V89, P2459, DOI 10.1152/jn.00707.2002; Zhang P, 2002, J GEN PHYSIOL, V120, P553, DOI 10.1085/jgp.20028574	28	59	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45240	45247		10.1074/jbc.M304441200	http://dx.doi.org/10.1074/jbc.M304441200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12947112	hybrid			2022-12-25	WOS:000186452300025
J	Ghosh, S; Moore, S; Bell, RM; Dush, M				Ghosh, S; Moore, S; Bell, RM; Dush, M			Functional analysis of a phosphatidic acid binding domain in human Raf-1 kinase - Mutations in the phosphatidate binding domain lead to tail and trunk abnormalities in developing zebrafish embryos	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; PHOSPHOLIPASE-D; CRYSTAL-STRUCTURE; EXPRESSION; C-RAF-1; TRANSLOCATION; MECHANISMS; LIPOSOMES; PATHWAY; RAS	Previously, we and others identified a 35-amino acid segment within human Raf-1 kinase that preferentially binds phosphatidic acid. The presence of phosphatidic acid was found to be necessary for the translocation of Raf-1 to the plasma membrane. We have now employed a combination of alanine-scanning and deletion mutagenesis to identify the critical amino acid residues in Raf-1 necessary for interaction with phosphatidic acid. Progressive mutations within a tetrapeptide motif (residues 398-401 of human Raf-1) reduced and finally eliminated binding of Raf-1 to phosphatidic acid. We then injected zebrafish embryos with RNA encoding wild-type Raf-1 kinase or a mutant version with triple alanine mutations in the tetrapeptide motif and followed the morphological fate of embryonic development. Embryos with mutant but not wild-type Raf-1 exhibited defects in posterior axis formation exemplified by bent trunk and tail structures. Molecular evidence for lack of signaling through mutated Raf-1 was obtained by aberrant in situ hybridization of the ntl ((n) under baro (t) under bar ail) gene, which functions downstream of Raf-1. Our results demonstrate that a functional phosphatidate binding site is necessary for Raf-1 function in embryonic development.	GlaxoSmithKline, Genet Res, Res Triangle Pk, NC 27709 USA	GlaxoSmithKline	Ghosh, S (corresponding author), GlaxoSmithKline, Genet Res, Res Triangle Pk, NC 27709 USA.	sg45653@gsk.com	Ghosh, Sujoy/I-3729-2017	Ghosh, Sujoy/0000-0002-7601-165X				Andresen BT, 2002, FEBS LETT, V531, P65, DOI 10.1016/S0014-5793(02)03483-X; Basu S, 1998, J BIOL CHEM, V273, P30419, DOI 10.1074/jbc.273.46.30419; BAZZI MD, 1991, BIOCHEMISTRY-US, V30, P7961, DOI 10.1021/bi00246a013; Bechoua S, 2001, J BIOL CHEM, V276, P31752, DOI 10.1074/jbc.M101265200; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Colley WC, 1997, BIOCHEM J, V326, P745, DOI 10.1042/bj3260745; Daniel LW, 1999, BBA-MOL CELL BIOL L, V1439, P265, DOI 10.1016/S1388-1981(99)00099-2; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; Exton JH, 2002, FEBS LETT, V531, P58, DOI 10.1016/S0014-5793(02)03405-1; GHOSH S, 1994, J BIOL CHEM, V269, P30785; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; Ghosh Sujoy, 2002, Methods Mol Biol, V199, P49; GRIFFIN K, 1995, DEVELOPMENT, V121, P2983; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; HAUPTMANN G, 1994, TRENDS GENET, V10, P266, DOI 10.1016/0168-9525(90)90008-T; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; Hekman M, 2002, J BIOL CHEM, V277, P24090, DOI 10.1074/jbc.M200576200; Hoshino M, 1998, J BIOL CHEM, V273, P4878, DOI 10.1074/jbc.273.9.4878; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; Improta-Brears T, 1999, MOL CELL BIOCHEM, V198, P171, DOI 10.1023/A:1006981411691; KNIGHTON DR, 1993, ACTA CRYSTALLOGR D, V49, P357, DOI 10.1107/S0907444993000502; Lu KK, 1998, CELL GROWTH DIFFER, V9, P367; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Medhurst AD, 2000, J NEUROSCI METH, V98, P9, DOI 10.1016/S0165-0270(00)00178-3; MORRISON DK, 1990, CANCER CELL-MON REV, V2, P377; QUEST AFG, 1994, PROTEIN KINASE C, P64; Renault Andrew D., 2002, Gene Expression Patterns, V2, P337, DOI 10.1016/S0925-4773(02)00389-1; Rizzo MA, 2000, J BIOL CHEM, V275, P23911, DOI 10.1074/jbc.M001553200; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sciorra VA, 1996, J BIOL CHEM, V271, P14226, DOI 10.1074/jbc.271.24.14226; Shinya M, 2001, DEVELOPMENT, V128, P4153; Xie Z, 2002, J BIOL CHEM, V277, P11979, DOI 10.1074/jbc.M109751200; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	40	73	75	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45690	45696		10.1074/jbc.M302933200	http://dx.doi.org/10.1074/jbc.M302933200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12925535	hybrid			2022-12-25	WOS:000186452300078
J	Han, SY; Xie, WS; Hammes, SR; DeJong, J				Han, SY; Xie, WS; Hammes, SR; DeJong, J			Expression of the germ cell-specific transcription factor ALF in Xenopus oocytes compensates for translational inactivation of the somatic factor TFIIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; TBP-LIKE FACTOR; POLYMERASE-II TRANSCRIPTION; GENE-EXPRESSION; CYTOPLASMIC POLYADENYLATION; SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; MICE LACKING; DNA-BINDING; C-ELEGANS	The discovery of germ cell-specific general transcription factor and coactivator variants has suggested that reproductive tissues control gene expression somewhat differently than somatic tissues. One of these factors, ALF (TFIIAtau), was first described as a testis-specific counterpart of the large (alpha/beta) subunit of TFIIA. Here we characterize endogenous ALF and TFIIA activities in the African clawed frog Xenopus laevis. ALF is present in both testis and ovary in this organism, and it completely replaces TFIIA in immature oocytes. When oocytes undergo progesterone-induced maturation, ALF activity disappears, and TFIIA activity is restored. Reactivation occurs through the translational up-regulation of two maternal TFIIAalpha/beta mRNAs and involves polyadenylation of a conserved 3'-untranslated region module. The effects of ALF overexpression and ALF immunodepletion on a thymidine kinase promoter construct demonstrate that this factor serves as an active replacement for TFIIA. In contrast, overexpression of TFIIA inhibits transcription, indicating that the somatic factor fails to function properly in the context of the oocyte transcription machinery. Overall, the results show that the translationally regulated reciprocal expression of ALF and TFIIA allows for the production of an active TFIIA-like general transcription factor throughout oogenesis.	Univ Texas, Dept Mol & Cell Biol, Richardson, TX 75080 USA; Univ Texas, SW Med Sch, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Sch, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	DeJong, J (corresponding author), Univ Texas, Dept Mol & Cell Biol, Richardson, TX 75080 USA.							Aoyagi N, 2000, J CELL BIOL, V150, pF45, DOI 10.1083/jcb.150.2.F45; Bell P, 1999, EXP CELL RES, V248, P122, DOI 10.1006/excr.1999.4411; Dantonel JC, 2000, MOL CELL, V6, P715, DOI 10.1016/S1097-2765(00)00069-1; de Moor CH, 1999, EMBO J, V18, P2294, DOI 10.1093/emboj/18.8.2294; DEJONG J, 1993, GENE DEV, V7, P2220, DOI 10.1101/gad.7.11.2220; Eddy EM, 2002, RECENT PROG HORM RES, V57, P103, DOI 10.1210/rp.57.1.103; Faber J., 1994, NORMAL TABLE XENOPUS, P2; FOX CA, 1989, GENE DEV, V3, P2151, DOI 10.1101/gad.3.12b.2151; Freiman RN, 2001, SCIENCE, V293, P2084, DOI 10.1126/science.1061935; Han SY, 2001, BIOL REPROD, V64, P507, DOI 10.1095/biolreprod64.2.507; Hiller MA, 2001, GENE DEV, V15, P1021, DOI 10.1101/gad.869101; Hochheimer A, 2002, NATURE, V420, P439, DOI 10.1038/nature01167; HOYLE HD, 1990, J CELL BIOL, V111, P1009, DOI 10.1083/jcb.111.3.1009; Kaltenbach L, 2000, MOL CELL, V6, P705, DOI 10.1016/S1097-2765(00)00068-X; Kashiwabara S, 2002, SCIENCE, V298, P1999, DOI 10.1126/science.1074632; Kay B. K., 1991, XENOPUS LAEVIS PRACT; Kessler SP, 2000, J BIOL CHEM, V275, P26259, DOI 10.1074/jbc.M004006200; Kleene KC, 2001, MECH DEVELOP, V106, P3, DOI 10.1016/S0925-4773(01)00413-0; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Martianov I, 2001, MOL CELL, V7, P509, DOI 10.1016/S1097-2765(01)00198-8; Martianov I, 2002, DEVELOPMENT, V129, P945; Moore PA, 1999, MOL CELL BIOL, V19, P7610; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; Ozer J, 2000, J BIOL CHEM, V275, P122, DOI 10.1074/jbc.275.1.122; Ozer J, 1998, MOL CELL BIOL, V18, P2559, DOI 10.1128/MCB.18.5.2559; Richter JD, 1999, MICROBIOL MOL BIOL R, V63, P446, DOI 10.1128/MMBR.63.2.446-456.1999; Salles FJ, 1999, METHODS, V17, P38, DOI 10.1006/meth.1998.0705; Sassone-Corsi P, 2002, SCIENCE, V296, P2176, DOI 10.1126/science.1070963; TAFURI SR, 1993, J BIOL CHEM, V268, P24255; Teichmann M, 1999, P NATL ACAD SCI USA, V96, P13720, DOI 10.1073/pnas.96.24.13720; Upadhyaya AB, 1999, J BIOL CHEM, V274, P18040, DOI 10.1074/jbc.274.25.18040; Upadhyaya AB, 2003, BBA-GENE STRUCT EXPR, V1625, P88, DOI 10.1016/S0167-4781(02)00541-9; Upadhyaya AB, 2002, J BIOL CHEM, V277, P34208, DOI 10.1074/jbc.M204808200; Veenstra GJC, 2000, SCIENCE, V290, P2312, DOI 10.1126/science.290.5500.2312; Veenstra GJC, 2001, TRENDS BIOCHEM SCI, V26, P665, DOI 10.1016/S0968-0004(01)01970-3; Wang PJ, 2002, HUM MOL GENET, V11, P2341, DOI 10.1093/hmg/11.19.2341; Wang PJ, 2001, NAT GENET, V27, P422, DOI 10.1038/86927; Xie WS, 2002, J BIOL CHEM, V277, P17765, DOI 10.1074/jbc.M200954200; Zhang D, 2001, SCIENCE, V292, P1153, DOI 10.1126/science.1059188	40	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45586	45593		10.1074/jbc.M302884200	http://dx.doi.org/10.1074/jbc.M302884200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12923189	hybrid			2022-12-25	WOS:000186452300067
J	Okamoto, O; Bachy, S; Odenthal, U; Bernaud, J; Rigal, D; Lortat-Jacob, H; Smyth, N; Rousselle, P				Okamoto, O; Bachy, S; Odenthal, U; Bernaud, J; Rigal, D; Lortat-Jacob, H; Smyth, N; Rousselle, P			Normal human keratinocytes bind to the alpha 3LG4/5 domain of unprocessed laminin-5 through the receptor syndecan-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; CELL-SURFACE PROTEOGLYCAN; EPITHELIAL-CELLS; GAMMA-2 CHAIN; INTEGRIN ALPHA-3-BETA-1; WOUND REPAIR; LAMA3 GENE; ADHESION; EXPRESSION; MEMBRANE	Basal keratinocytes of the epidermis adhere to their underlying basement membrane through a specific interaction with laminin-5, which is composed by the association of alpha3, beta3, and gamma2 chains. Laminin-5 has the ability to induce either stable cell adhesion or migration depending on specific processing of different parts of the molecule. One event results in the cleavage of the carboxyl-terminal globular domains 4 and 5 (LG4/5) of the alpha3 chain. In this study, we recombinantly expressed the human alpha3LG4/5 fragment in mammalian cells, and we show that this fragment induces adhesion of normal human keratinocytes and fibrosarcoma-derived HT1080 cells in a heparan- and chondroitin sulfate-dependent manner. Immunoprecipitation experiments with (Na2SO4)-S-35-labeled keratinocyte and HT1080 cell lysates as well as immunoblotting experiments revealed that the major proteoglycan receptor for the alpha3LG4/5 fragment is syndecan-1. Syndecan-4 from keratinocytes also bound to alpha3LG4/5. Furthermore we could show for the first time that unprocessed laminin-5 specifically binds syndecan-1, while processed laminin-5 does not. These results demonstrate that the LG4/5 modules within unprocessed laminin-5 permit its cell binding activity through heparan and chondroitin sulfate chains of syndecan-1 and reinforce previous data suggesting specific properties for the precursor molecule.	Inst Federat Rech 128 Biosci Lyon Gerland, UMR 5086, IBCP, F-69367 Lyon 07, France; Fac Med, Ctr Biochem, D-50931 Cologne, Germany; Etab Francais Sang, F-69007 Lyon, France; Univ Grenoble 1, Inst Biol Struct, Commissariat Energie Atom, CNRS,UMR 5075, F-38027 Grenoble, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); University of Cologne; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA	Rousselle, P (corresponding author), Inst Federat Rech 128 Biosci Lyon Gerland, UMR 5086, IBCP, 7 Passage Vercors, F-69367 Lyon 07, France.		Rousselle, Patricia/J-5290-2019; Rousselle, Patricia/CAF-3915-2022	Rousselle, Patricia/0000-0003-0275-4562; Rousselle, Patricia/0000-0003-0275-4562; Smyth, Neil/0000-0002-3734-2149				Amano S, 2000, J BIOL CHEM, V275, P22728, DOI 10.1074/jbc.M002345200; Baker SE, 1996, J CELL SCI, V109, P2509; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; CAREY DJ, 1994, J CELL BIOL, V124, P161, DOI 10.1083/jcb.124.1.161; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; Champliaud MF, 1996, J CELL BIOL, V132, P1189, DOI 10.1083/jcb.132.6.1189; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Colognato H, 2000, DEV DYNAM, V218, P213, DOI 10.1002/(SICI)1097-0177(200006)218:2<213::AID-DVDY1>3.0.CO;2-R; DAVID G, 1992, J CELL BIOL, V118, P961, DOI 10.1083/jcb.118.4.961; Decline F, 2003, CELL MOTIL CYTOSKEL, V54, P64, DOI 10.1002/cm.10086; Decline F, 2001, J CELL SCI, V114, P811; ELENIUS K, 1991, J CELL BIOL, V114, P585, DOI 10.1083/jcb.114.3.585; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; Gallo R, 1996, J INVEST DERMATOL, V107, P676, DOI 10.1111/1523-1747.ep12365571; Goldfinger LE, 1999, J CELL SCI, V112, P2615; Goldfinger LE, 1998, J CELL BIOL, V141, P255, DOI 10.1083/jcb.141.1.255; Grootjans JJ, 1997, P NATL ACAD SCI USA, V94, P13683, DOI 10.1073/pnas.94.25.13683; Hoffman MP, 1998, J BIOL CHEM, V273, P28633, DOI 10.1074/jbc.273.44.28633; Hoffman MP, 2001, J BIOL CHEM, V276, P22077, DOI 10.1074/jbc.M100774200; Inki P, 1997, MOL HUM REPROD, V3, P299, DOI 10.1093/molehr/3.4.299; Jaakkola P, 1998, FASEB J, V12, P959, DOI 10.1096/fasebj.12.11.959; Kainulainen T, 1998, J HISTOCHEM CYTOCHEM, V46, P353, DOI 10.1177/002215549804600309; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; Lampe PD, 1998, J CELL BIOL, V143, P1735, DOI 10.1083/jcb.143.6.1735; LANGHOFER M, 1993, J CELL SCI, V105, P753; Libby RT, 2000, J NEUROSCI, V20, P6517, DOI 10.1523/JNEUROSCI.20-17-06517.2000; MARINKOVICH MP, 1992, J BIOL CHEM, V267, P17900; MATSUI C, 1995, J BIOL CHEM, V270, P23496, DOI 10.1074/jbc.270.40.23496; Mizushima H, 1997, CELL GROWTH DIFFER, V8, P979; Nguyen BP, 2000, J BIOL CHEM, V275, P31896, DOI 10.1074/jbc.M006379200; Nguyen BP, 2000, CURR OPIN CELL BIOL, V12, P554, DOI 10.1016/S0955-0674(00)00131-9; NISHIYAMA T, 2000, J DERMATOL SCI, V1, P51; OKSALA O, 1995, J HISTOCHEM CYTOCHEM, V43, P125, DOI 10.1177/43.2.7529785; OToole EA, 1997, EXP CELL RES, V233, P330, DOI 10.1006/excr.1997.3586; Perrimon N, 2001, SEMIN CELL DEV BIOL, V12, P65, DOI 10.1006/scdb.2000.0237; RAPRAEGER A, 1985, J BIOL CHEM, V260, P4103; ROUSSELLE P, 1994, J CELL BIOL, V125, P205, DOI 10.1083/jcb.125.1.205; ROUSSELLE P, 1991, J CELL BIOL, V114, P567, DOI 10.1083/jcb.114.3.567; RYAN MC, 1994, J BIOL CHEM, V269, P22779; Ryan MC, 1999, J CELL BIOL, V145, P1309, DOI 10.1083/jcb.145.6.1309; Sadir R, 2001, J BIOL CHEM, V276, P8288, DOI 10.1074/jbc.M008110200; SALMIVIRTA M, 1994, EXP CELL RES, V215, P180, DOI 10.1006/excr.1994.1330; SALMIVIRTA M, 1991, J BIOL CHEM, V266, P7733; Sasaki T, 2001, J MOL BIOL, V314, P751, DOI 10.1006/jmbi.2001.5176; SONNENBERG A, 1993, J CELL SCI, V106, P1083; Tsubota Y, 2000, BIOCHEM BIOPH RES CO, V278, P614, DOI 10.1006/bbrc.2000.3851; Tumova S, 2000, INT J BIOCHEM CELL B, V32, P269, DOI 10.1016/S1357-2725(99)00116-8; Utani A, 2003, J BIOL CHEM, V278, P34483, DOI 10.1074/jbc.M304827200; Utani A, 2001, J BIOL CHEM, V276, P28779, DOI 10.1074/jbc.M101420200; VAILLY J, 1994, EUR J BIOCHEM, V219, P209, DOI 10.1111/j.1432-1033.1994.tb19932.x; Woods A, 2000, J BIOL CHEM, V275, P24233, DOI 10.1074/jbc.R000001200	51	81	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44168	44177		10.1074/jbc.M300726200	http://dx.doi.org/10.1074/jbc.M300726200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12947106	hybrid			2022-12-25	WOS:000186306700036
J	Antonicka, H; Ogilvie, I; Taivassalo, T; Anitori, RP; Haller, RG; Vissing, J; Kennaway, NG; Shoubridge, EA				Antonicka, H; Ogilvie, I; Taivassalo, T; Anitori, RP; Haller, RG; Vissing, J; Kennaway, NG; Shoubridge, EA			Identification and characterization of a common set of complex I assembly intermediates in mitochondria from patients with complex I deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADH-UBIQUINONE OXIDOREDUCTASE; BLUE-NATIVE-ELECTROPHORESIS; CYTOCHROME-C-OXIDASE; HEREDITARY OPTIC NEUROPATHY; BOVINE HEART-MITOCHONDRIA; DNA-ENCODED SUBUNITS; NEUROSPORA MITOCHONDRIA; STRUCTURAL ORGANIZATION; 3-DIMENSIONAL STRUCTURE; GEL-ELECTROPHORESIS	Deficiencies in the activity of complex I (NADH: ubiquinone oxidoreductase) are an important cause of human mitochondrial disease. Complex I is composed of at least 46 structural subunits that are encoded in both nuclear and mitochondrial DNA. Enzyme deficiency can result from either impaired catalytic efficiency or an inability to assemble the holoenzyme complex; however, the assembly process remains poorly understood. We have used two-dimensional Blue-Native/SDS gel electrophoresis and a panel of 11 antibodies directed against structural subunits of the enzyme to investigate complex I assembly in the muscle mitochondria from four patients with complex I deficiency caused by either mitochondrial or nuclear gene defects. Immunoblot analyses of second dimension denaturing gels identified seven distinct complex I subcomplexes in the patients studied, five of which could also be detected in non-denaturing gels in the first dimension. Although the abundance of these intermediates varied among the different patients, a common constellation of subcomplexes was observed in all cases. A similar profile of subcomplexes was present in a human/mouse hybrid fibroblast cell line with a severe complex I deficiency due to an almost complete lack of assembly of the holoenzyme complex. The finding that diverse causes of complex I deficiency produce a similar pattern of complex I subcomplexes suggests that these are intermediates in the assembly of the holoenzyme complex. We propose a possible assembly pathway for the complex, which differs significantly from that proposed for Neurospora, the current model for complex I assembly.	McGill Univ, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada; McGill Univ, Dept Human Genet, Montreal, PQ H3A 2B4, Canada; Presbyterian Med Ctr, Inst Exercise & Environm Med, Neuromuscular Ctr, Dallas, TX 75231 USA; Univ Texas, SW Med Ctr, Dallas, TX 75231 USA; Vet Affairs Med Ctr, Dallas, TX 75231 USA; Univ Copenhagen, Rigshosp, Copenhagen Muscle Res Ctr, DK-2100 Copenhagen, Denmark; Univ Copenhagen, Rigshosp, Dept Neurol, DK-2100 Copenhagen, Denmark; Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA	McGill University; McGill University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; US Department of Veterans Affairs; Veterans Health Administration (VHA); Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen; Oregon Health & Science University	Shoubridge, EA (corresponding author), McGill Univ, Montreal Neurol Inst, 3801 Univ St, Montreal, PQ H3A 2B4, Canada.			Antonicka, Hana/0000-0002-2525-2867				Alves PC, 1998, BIOCHEM CELL BIOL, V76, P139, DOI 10.1139/bcb-76-1-139; Bai YD, 1998, EMBO J, V17, P4848, DOI 10.1093/emboj/17.16.4848; Benit P, 2003, HUM MUTAT, V21, P582, DOI 10.1002/humu.10225; Benit P, 2001, AM J HUM GENET, V68, P1344, DOI 10.1086/320603; Bottcher B, 2002, J BIOL CHEM, V277, P17970, DOI 10.1074/jbc.M112357200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Budde SMS, 2000, BIOCHEM BIOPH RES CO, V275, P63, DOI 10.1006/bbrc.2000.3257; BUSCHGES R, 1994, YEAST, V10, P475, DOI 10.1002/yea.320100406; Cardol P, 2002, J MOL BIOL, V319, P1211, DOI 10.1016/S0022-2836(02)00407-2; Carroll J, 2003, MOL CELL PROTEOMICS, V2, P117, DOI 10.1074/mcp.M300014-MCP200; Carroll J, 2002, J BIOL CHEM, V277, P50311, DOI 10.1074/jbc.M209166200; Coenen MJH, 1999, BIOCHEM BIOPH RES CO, V265, P339, DOI 10.1006/bbrc.1999.1662; DUARTE M, 1995, GENETICS, V139, P1211; Ferreirinha F, 1999, BIOCHEM J, V342, P551, DOI 10.1042/0264-6021:3420551; Grigorieff N, 1998, J MOL BIOL, V277, P1033, DOI 10.1006/jmbi.1998.1668; Guenebaut V, 1997, J MOL BIOL, V265, P409, DOI 10.1006/jmbi.1996.0753; Guenebaut V, 1998, J MOL BIOL, V276, P105, DOI 10.1006/jmbi.1997.1518; HOFHAUS G, 1995, MOL CELL BIOL, V15, P964; HOFHAUS G, 1993, EMBO J, V12, P3043, DOI 10.1002/j.1460-2075.1993.tb05973.x; Janssen R, 2002, HUM GENET, V110, P264, DOI 10.1007/s00439-001-0673-3; Johnston AJ, 2002, J BIOL CHEM, V277, P42197, DOI 10.1074/jbc.M205613200; Karpova OV, 1999, PLANT J, V17, P511, DOI 10.1046/j.1365-313X.1999.00401.x; KLEMENT P, 1995, ANAL BIOCHEM, V231, P218, DOI 10.1006/abio.1995.1523; Kuffner R, 1998, J MOL BIOL, V283, P409, DOI 10.1006/jmbi.1998.2114; Loeffen J, 2001, ANN NEUROL, V49, P195, DOI 10.1002/1531-8249(20010201)49:2<195::AID-ANA39>3.0.CO;2-M; Loeffen J, 1998, AM J HUM GENET, V63, P1598, DOI 10.1086/302154; Man PYW, 2002, J MED GENET, V39, P162, DOI 10.1136/jmg.39.3.162; MILLER AD, 1993, METHOD ENZYMOL, V217, P581; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; NEHLS U, 1992, J MOL BIOL, V227, P1032, DOI 10.1016/0022-2836(92)90519-P; Nijtmans LGJ, 2002, METHODS, V26, P327, DOI 10.1016/S1046-2023(02)00038-5; Nijtmans LGJ, 1998, EUR J BIOCHEM, V254, P389, DOI 10.1046/j.1432-1327.1998.2540389.x; NOSEK J, 1994, J BACTERIOL, V176, P5622, DOI 10.1128/JB.176.18.5622-5630.1994; Petruzzella V, 2001, HUM MOL GENET, V10, P529, DOI 10.1093/hmg/10.5.529; Sazanov LA, 2003, J BIOL CHEM, V278, P19483, DOI 10.1074/jbc.M208959200; Sazanov LA, 2000, BIOCHEMISTRY-US, V39, P7229, DOI 10.1021/bi000335t; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Schuelke M, 1999, NAT GENET, V21, P260, DOI 10.1038/6772; Schulte U, 2001, J BIOENERG BIOMEMBR, V33, P205, DOI 10.1023/A:1010730919074; Schwartz M, 2002, NEW ENGL J MED, V347, P576, DOI 10.1056/NEJMoa020350; Skehel JM, 1998, FEBS LETT, V438, P301, DOI 10.1016/S0014-5793(98)01317-9; Tiranti V, 1999, ANN NEUROL, V46, P161, DOI 10.1002/1531-8249(199908)46:2<161::AID-ANA4>3.0.CO;2-O; Triepels R, 2000, HUM GENET, V106, P385, DOI 10.1007/s004390000278; Triepels RH, 2001, J BIOL CHEM, V276, P8892, DOI 10.1074/jbc.M009903200; TUSCHEN G, 1990, J MOL BIOL, V213, P845, DOI 10.1016/S0022-2836(05)80268-2; van den Heuvel L, 1998, AM J HUM GENET, V62, P262, DOI 10.1086/301716; Videira A, 2002, BBA-BIOENERGETICS, V1555, P187, DOI 10.1016/S0005-2728(02)00276-1; Videira A, 2001, J BIOENERG BIOMEMBR, V33, P197, DOI 10.1023/A:1010778802236; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X; WALLACE DC, 1994, P NATL ACAD SCI USA, V91, P8739, DOI 10.1073/pnas.91.19.8739; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231; Zerbetto E, 1997, ELECTROPHORESIS, V18, P2059, DOI 10.1002/elps.1150181131	54	147	158	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43081	43088		10.1074/jbc.M304998200	http://dx.doi.org/10.1074/jbc.M304998200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12941961	hybrid			2022-12-25	WOS:000186157000046
J	Chan, SY; Appling, DR				Chan, SY; Appling, DR			Regulation of S-adenosylmethionine levels in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTATHIONINE BETA-SYNTHASE; FOLIC-ACID DERIVATIVES; ADENOSYL-L-METHIONINE; ONE-CARBON METABOLISM; RED-BLOOD-CELLS; METHYLENETETRAHYDROFOLATE REDUCTASE; CYSTEINE BIOSYNTHESIS; IN-VIVO; YEAST; HOMOCYSTEINE	Methylenetetrahydrofolate reductase (MTHFR) catalyzes the reduction of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, used to methylate homocysteine in methionine biosynthesis. Methionine can be activated by ATP to give rise to the universal methyl donor, S-adenosylmethionine (AdoMet). Previously, a chimeric MTHFR (Chimera-1) comprised of the yeast Met13p N-terminal catalytic domain and the Arabidopsis thaliana MTHFR (AtMTHFR-1) C-terminal regulatory domain was constructed (Roje, S., Chan, S. Y., Kaplan, F., Raymond, R. K., Horne, D. W., Appling, D. R., and Hanson, A. D. (2002) J. Biol. Chem. 277, 4056-4061). Engineered yeast (SCY4) expressing Chimera-1 accumulated more than 100-fold more AdoMet and 7-fold more methionine than the wild type. Surprisingly, SCY4 showed no appreciable growth defect. The ability of yeast to hyperaccumulate AdoMet was investigated by studying the intracellular compartmentation of AdoMet as well as the mode of hyperaccumulation. Previous studies have established that AdoMet is distributed between the cytosol and the vacuole. A strain expressing Chimera-1 and lacking either vacuoles (vps33 mutant) or vacuolar polyphosphate (vtc1 mutant) was not viable when grown under conditions that favored AdoMet hyperaccumulation. The hyperaccumulation of AdoMet was a robust phenomenon when these cells were grown in medium containing glycine and formate but did not occur when these supplements were replaced by serine. The basis of the nutrient-dependent AdoMet hyperaccumulation effect is discussed in relation to homocysteine biosynthesis and sulfur metabolism.	Univ Texas, Dept Chem & Biochem, Austin, TX 78712 USA; Univ Texas, Inst Mol & Cellular Biol, Austin, TX 78712 USA; Univ Texas, Inst Biochem, Austin, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Appling, DR (corresponding author), Univ Texas, Dept Chem & Biochem, 1 Univ Stn A5300, Austin, TX 78712 USA.				NIDDK NIH HHS [DK61428] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061428] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APPLING DR, 1991, FASEB J, V5, P2645, DOI 10.1096/fasebj.5.12.1916088; Bagley PJ, 1998, P NATL ACAD SCI USA, V95, P13217, DOI 10.1073/pnas.95.22.13217; Blakley R.L., 1969, N HOLLAND RES MONOGR, P1; CHEREST H, 1993, J BACTERIOL, V175, P5366, DOI 10.1128/JB.175.17.5366-5374.1993; Christopher SA, 2002, MOL GENET METAB, V75, P335, DOI 10.1016/S1096-7192(02)00003-3; Clarke S, 2001, HOMOCYSTEINE IN HEALTH AND DISEASE, P63; FAROOQUI JZ, 1983, BIOCHIM BIOPHYS ACTA, V757, P342; FINKELSTEIN JD, 1990, J NUTR BIOCHEM, V1, P228, DOI 10.1016/0955-2863(90)90070-2; FINKELSTEIN JD, 1984, J BIOL CHEM, V259, P9508; Finkelstein JD, 2000, INT J BIOCHEM CELL B, V32, P385, DOI 10.1016/S1357-2725(99)00138-7; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; GREEN JM, 1988, FASEB J, V2, P42, DOI 10.1096/fasebj.2.1.3335280; Hansen J, 2000, MOL GEN GENET, V263, P535, DOI 10.1007/s004380051199; HERBERT V, 1962, J CLIN INVEST, V41, P1263, DOI 10.1172/JCI104589; HOFFMAN CS, 1997, CURRENT PROTOCOLS MO, V2; HORNE DW, 1988, CLIN CHEM, V34, P2357; JACQUEMINFAURE I, 1994, MOL GEN GENET, V244, P519, DOI 10.1007/BF00583903; Jakubowski H, 1997, J BIOL CHEM, V272, P1935; JENCKS DA, 1987, J BIOL CHEM, V262, P2485; Jhee KH, 2000, BIOCHEMISTRY-US, V39, P10548, DOI 10.1021/bi001020g; Kornberg A, 1999, ANNU REV BIOCHEM, V68, P89, DOI 10.1146/annurev.biochem.68.1.89; KUTZBACH C, 1971, BIOCHIM BIOPHYS ACTA, V250, P459, DOI 10.1016/0005-2744(71)90247-6; Maclean KN, 2000, J INORG BIOCHEM, V81, P161, DOI 10.1016/S0162-0134(00)00100-8; MATTHEWS RG, 1984, FOLATES PTERINS, V1, P497; Naoi M, 1999, MECH AGEING DEV, V111, P175, DOI 10.1016/S0047-6374(99)00064-0; Ogawa N, 2000, MOL BIOL CELL, V11, P4309, DOI 10.1091/mbc.11.12.4309; OGUR M, 1977, J BACTERIOL, V129, P926, DOI 10.1128/JB.129.2.926-933.1977; Ono B, 1996, YEAST, V12, P1153, DOI 10.1002/(SICI)1097-0061(19960915)12:11<1153::AID-YEA16>3.0.CO;2-2; PASTERNACK LB, 1992, BIOCHEMISTRY-US, V31, P8713, DOI 10.1021/bi00152a005; Piper MD, 2000, J BIOL CHEM, V275, P30987, DOI 10.1074/jbc.M004248200; Raymond RK, 1999, ARCH BIOCHEM BIOPHYS, V372, P300, DOI 10.1006/abbi.1999.1498; ROCA J, 1992, NUCLEIC ACIDS RES, V20, P4671, DOI 10.1093/nar/20.17.4671; Roe AJ, 2002, MICROBIOL-SGM, V148, P2215, DOI 10.1099/00221287-148-7-2215; Roje S, 2002, J BIOL CHEM, V277, P4056, DOI 10.1074/jbc.M110651200; Rouillon A, 1999, J BIOL CHEM, V274, P28096, DOI 10.1074/jbc.274.40.28096; Russnak R, 2001, J BIOL CHEM, V276, P23849, DOI 10.1074/jbc.M008028200; SCHLENK F, 1970, ARCH BIOCHEM BIOPHYS, V140, P228, DOI 10.1016/0003-9861(70)90027-5; SCHLENK F, 1965, TRANSMETHYLATION MET, P48; SCHWENCKE J, 1976, EUR J BIOCHEM, V65, P49, DOI 10.1111/j.1432-1033.1976.tb10388.x; SELHUB J, 1992, AM J CLIN NUTR, V55, P131, DOI 10.1093/ajcn/55.1.131; SPENCE KD, 1971, J BACTERIOL, V106, P325, DOI 10.1128/JB.106.2.325-330.1971; STOVER P, 1992, BIOCHEMISTRY-US, V31, P2155, DOI 10.1021/bi00122a037; SVIHLA G, 1960, J BACTERIOL, V79, P841, DOI 10.1128/JB.79.6.841-848.1960; Takabatake R, 2001, J BIOCHEM, V129, P827, DOI 10.1093/oxfordjournals.jbchem.a002926; Takagi H, 2003, FEMS MICROBIOL LETT, V218, P291, DOI 10.1111/j.1574-6968.2003.tb11531.x; THOMAS D, 1989, MOL CELL BIOL, V9, P3292, DOI 10.1128/MCB.9.8.3292; THOMAS D, 1991, MOL GEN GENET, V226, P224, DOI 10.1007/BF00273607; URECH K, 1978, ARCH MICROBIOL, V116, P275, DOI 10.1007/BF00417851; VANAERTS LAGJM, 1994, TERATOLOGY, V50, P348, DOI 10.1002/tera.1420500506; VANONI MA, 1984, BIOCHEMISTRY-US, V23, P5272, DOI 10.1021/bi00317a027; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WILSON SD, 1984, ANAL BIOCHEM, V142, P529, DOI 10.1016/0003-2697(84)90502-5; Wise CK, 1997, J CHROMATOGR B, V696, P145, DOI 10.1016/S0378-4347(97)00213-2; WOHLFARTH G, 1991, ARCH MICROBIOL, V155, P378; Zhao WQ, 2002, J NEUROSCI RES, V69, P519, DOI 10.1002/jnr.10314	55	45	49	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43051	43059		10.1074/jbc.M308696200	http://dx.doi.org/10.1074/jbc.M308696200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12937179	hybrid			2022-12-25	WOS:000186157000042
J	Lundasen, T; Liao, W; Angelin, B; Rudling, M				Lundasen, T; Liao, W; Angelin, B; Rudling, M			Leptin induces the hepatic high density lipoprotein receptor scavenger receptor B type I (SR-BI) but not cholesterol 7 alpha-hydroxylase (Cyp7a1) in leptin-deficient (ob/ob) mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIETARY-CHOLESTEROL; ACID SYNTHESIS; OBESE GENE; GROWTH-HORMONE; ZUCKER RAT; WEIGHT; FATTY; STIMULATION; EXPRESSION; METABOLISM	Cholesterol elimination from the body involves reverse cholesterol transport from peripheral tissues in which the elimination of high density lipoprotein (HDL) and low density lipoprotein (LDL) cholesterol by the liver and subsequent biliary excretion as free cholesterol and bile acids are important. In situations of peripheral fat and cholesterol accumulation, such as obesity, these pathways may be overloaded, contributing to increased cholesterol deposition. Leptin has an important role in obesity, suppressing food intake and increasing energy expenditure. This hormone, which is absent in genetically obese ob/ob mice, is also thought to be involved in the coordination of lipid excretion pathways, although available data are somewhat inconsistent. We therefore studied the expression of the hepatic HDL receptor, scavenger receptor class B type I (SR-BI), and the LDL receptor as well as the rate-limiting enzyme in bile acid synthesis, cholesterol 7alpha-hydroxylase (Cyp7a1), in leptin-deficient ob/ob mice and their wildtype controls. In ob/ob mice, protein levels of both LDL receptor and SR-BI were reduced, whereas LDL receptor mRNA levels were increased and those of SR-BI were reduced, regardless of challenge with a 2% cholesterol diet. In ob/ob mice, the enzymatic activity and mRNA for Cyp7a1 were reduced, and the increase in response to dietary cholesterol was blunted. Upon short-term (2 days) treatment with leptin, a dose-dependent increase was seen in the SR-BI protein and mRNA, whereas the Cyp7a1 protein and mRNA were reduced. Our findings indicate that leptin is an important regulator of hepatic SR-BI expression and, thus, HDL cholesterol levels, whereas it does not stimulate Cyp7a1 and bile acid synthesis.	Huddinge Univ Hosp, Karolinska Inst, Novum, Dept Med,Ctr Metab & Endocrinol,Metab Unit, S-14186 Stockholm, Sweden; Huddinge Univ Hosp, Karolinska Inst, Novum, Ctr Nutr & Toxicol,Mol Nutr Unit, S-14186 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet	Rudling, M (corresponding author), Huddinge Univ Hosp, Karolinska Inst, Novum, Dept Med,Ctr Metab & Endocrinol,Metab Unit, S-14186 Stockholm, Sweden.							Ahima RS, 2000, ANNU REV PHYSIOL, V62, P413, DOI 10.1146/annurev.physiol.62.1.413; BRASSIL PJ, 1995, BIOCHEM PHARMACOL, V50, P311, DOI 10.1016/0006-2952(95)00144-O; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; EINARSSON K, 1986, J LIPID RES, V27, P82; Friedman JM, 2002, NUTR REV, V60, pS1, DOI 10.1301/002966402320634878; Galman C, 2003, J LIPID RES, V44, P859, DOI 10.1194/jlr.D200043-JLR200; Galman C, 2002, ENDOCRINOLOGY, V143, P1809, DOI 10.1210/en.143.5.1809; Gullberg H, 2000, MOL ENDOCRINOL, V14, P1739, DOI 10.1210/me.14.11.1739; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Hyogo H, 2002, J BIOL CHEM, V277, P34117, DOI 10.1074/jbc.M203912200; Iida M, 1996, BIOCHEM BIOPH RES CO, V224, P597, DOI 10.1006/bbrc.1996.1070; Krieger M, 1999, ANNU REV BIOCHEM, V68, P523, DOI 10.1146/annurev.biochem.68.1.523; Liang CP, 2001, J BIOL CHEM, V276, P49066, DOI 10.1074/jbc.M107250200; Liao W, 1997, ENDOCRINOLOGY, V138, P3276, DOI 10.1210/en.138.8.3276; NISHINA PM, 1994, METABOLISM, V43, P549, DOI 10.1016/0026-0495(94)90194-5; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Phillips MS, 1996, NAT GENET, V13, P18, DOI 10.1038/ng0596-18; ROACH PD, 1993, BIOCHIM BIOPHYS ACTA, V1170, P165, DOI 10.1016/0005-2760(93)90067-J; RUDLING M, 1993, P NATL ACAD SCI USA, V90, P8851, DOI 10.1073/pnas.90.19.8851; RUDLING M, 1992, P NATL ACAD SCI USA, V89, P6983, DOI 10.1073/pnas.89.15.6983; RUDLING M, 1993, J CLIN INVEST, V91, P2796, DOI 10.1172/JCI116522; SHARKEY MF, 1990, J LIPID RES, V31, P2167; Shimomura I, 1999, J BIOL CHEM, V274, P30028, DOI 10.1074/jbc.274.42.30028; Silver DL, 2000, J CLIN INVEST, V105, P151, DOI 10.1172/JCI8087; Silver DL, 1999, J BIOL CHEM, V274, P4140, DOI 10.1074/jbc.274.7.4140; Trigatti B, 2000, CURR OPIN LIPIDOL, V11, P123, DOI 10.1097/00041433-200004000-00004; TWISK J, 1995, HEPATOLOGY, V21, P501, DOI 10.1016/0270-9139(95)90113-2; Wang DP, 1996, J LIPID RES, V37, P1831; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	31	64	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43224	43228		10.1074/jbc.M302645200	http://dx.doi.org/10.1074/jbc.M302645200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12917427	hybrid			2022-12-25	WOS:000186157000063
J	Bannert, N; Vollhardt, K; Asomuddinov, B; Haag, M; Konig, H; Norley, S; Kurth, R				Bannert, N; Vollhardt, K; Asomuddinov, B; Haag, M; Konig, H; Norley, S; Kurth, R			PDZ domain-mediated interaction of interleukin-16 precursor proteins with myosin phosphatase targeting subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN PHOSPHATASE; BINDING SUBUNIT; SMOOTH-MUSCLE; RHO-KINASE; FUNCTIONAL-ANALYSIS; ACTIN CYTOSKELETON; MOLECULAR-CLONING; NMDA RECEPTOR; EXPRESSION; PHOSPHORYLATION	The cytokine interleukin-16 is generated by posttranscriptional cleavage by caspase-3 of two large precursor isoforms. The smaller protein of 67 kDa (pro-IL-16) is expressed in cells of the immune system and contains three PDZ (postsynaptic density/disc large/zona occludens-1) domains, whereas the larger 141-kDa neuronal variant (npro-IL-16) has two additional PDZ domains in its N-terminal extension that interact with neuronal ion channels. Using the yeast two-hybrid approach we have identified three closely related myosin phosphatase targeting subunits, MYPT1, MYPT2, and MBS85, as binding partners of the IL-16 precursor proteins. These interactions were verified using pull-down assays, coimmunoprecipitations, and plasmon resonance experiments. Binding requires the intact PDZ2 domain of pro-IL-16 and highly related C-terminal regions in the ligands consisting of a short leucine zipper and an indispensable serine at the -1 position, suggesting a novel unconventional PDZ binding mode. Pro-IL-16 and the myosin phosphatase targeting subunits colocalize along actomyosin filaments and stress fibers in transfected COS-7 cells. By modulating and targeting the catalytic phosphatase subunit to its substrates, MYPT1, MYPT2, and MBS85 regulate various contractile processes in muscle and non-muscle cells. Our findings indicate an involvement of the IL-16 precursor molecules in myosin-based contractile processes, most likely in cell motility, providing a functional link to the chemotactic activity of the mature cytokine. Alternatively, an intracellular complex of npro-IL-16, ion channels, and components of myosin motors in neurons suggests a role in protein targeting.	Robert Koch Inst, D-13353 Berlin, Germany; Paul Ehrlich Inst, D-63225 Langen, Germany	Robert Koch Institute; Paul Ehrlich Institute	Bannert, N (corresponding author), Robert Koch Inst, Nordufer 20, D-13353 Berlin, Germany.			Haag, Marion/0000-0002-9162-5131				Arimura T, 2001, J BIOL CHEM, V276, P6073, DOI 10.1074/jbc.M008566200; BAIER M, 1995, NATURE, V378, P563, DOI 10.1038/378563a0; Baier M, 1997, P NATL ACAD SCI USA, V94, P5273, DOI 10.1073/pnas.94.10.5273; Bannert N, 1996, NATURE, V381, P30, DOI 10.1038/381030a0; Bannert N, 1998, IMMUNOGENETICS, V47, P390, DOI 10.1007/s002510050374; Biddison WE, 1998, J IMMUNOL, V160, P444; Broustas CG, 2002, J BIOL CHEM, V277, P3053, DOI 10.1074/jbc.M106343200; Brozovich FV, 2002, CIRC RES, V90, P500, DOI 10.1161/01.RES.0000014224.43774.03; Center DM, 2000, IMMUNOL TODAY, V21, P273, DOI 10.1016/S0167-5699(00)01629-7; CRUIKSHANK WW, 1994, P NATL ACAD SCI USA, V91, P5109, DOI 10.1073/pnas.91.11.5109; Cuppen E, 1998, MOL BIOL CELL, V9, P671, DOI 10.1091/mbc.9.3.671; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Feng W, 2002, J BIOL CHEM, V277, P41140, DOI 10.1074/jbc.M207206200; Fujioka M, 1998, GENOMICS, V49, P59, DOI 10.1006/geno.1998.5222; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hartshorne DJ, 1998, J MUSCLE RES CELL M, V19, P325, DOI 10.1023/A:1005385302064; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; Hirbec H, 2002, J BIOL CHEM, V277, P15221, DOI 10.1074/jbc.C200112200; Hofmann F, 2000, J CELL SCI, V113, P1671; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; Ito M, 1997, BIOCHEMISTRY-US, V36, P7607, DOI 10.1021/bi9702647; Kawano Y, 1999, J CELL BIOL, V147, P1023, DOI 10.1083/jcb.147.5.1023; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Klimiuk PA, 1999, J IMMUNOL, V162, P4293; Kurschner C, 1999, J NEUROSCI, V19, P7770; Lei SB, 2001, J NEUROSCI, V21, P8464, DOI 10.1523/JNEUROSCI.21-21-08464.2001; Maekawa K, 1999, BIOCHEM J, V337, P179, DOI 10.1042/0264-6021:3370179; Mathy NL, 2000, IMMUNOLOGY, V100, P63, DOI 10.1046/j.1365-2567.2000.00997.x; Muhlhahn P, 1998, NAT STRUCT BIOL, V5, P682, DOI 10.1038/1376; Muranyi A, 2002, BIOCHEM J, V366, P211, DOI 10.1042/BJ20020401; Naisbitt S, 2000, J NEUROSCI, V20, P4524, DOI 10.1523/JNEUROSCI.20-12-04524.2000; OKUBO S, 1994, BIOCHEM BIOPH RES CO, V200, P429, DOI 10.1006/bbrc.1994.1467; Qi JC, 2002, J IMMUNOL, V168, P4127, DOI 10.4049/jimmunol.168.8.4127; Seegert Dirk, 2002, Curr Opin Investig Drugs, V3, P562; Setou M, 2000, SCIENCE, V288, P1796, DOI 10.1126/science.288.5472.1796; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Solaro RJ, 2000, CIRC RES, V87, P173, DOI 10.1161/01.RES.87.3.173; Somlyo AP, 2000, J PHYSIOL-LONDON, V522, P177, DOI 10.1111/j.1469-7793.2000.t01-2-00177.x; Surks HK, 2003, CELL SIGNAL, V15, P937, DOI 10.1016/S0898-6568(03)00057-3; Surks HK, 1999, SCIENCE, V286, P1583, DOI 10.1126/science.286.5444.1583; Tan I, 2001, J BIOL CHEM, V276, P21209, DOI 10.1074/jbc.M102615200; Vaccaro P, 2002, FEBS LETT, V512, P345, DOI 10.1016/S0014-5793(02)02220-2; Weick JP, 2003, J NEUROSCI, V23, P3446; Wenthold RJ, 2003, ANNU REV PHARMACOL, V43, P335, DOI 10.1146/annurev.pharmtox.43.100901.135803; Wilson KC, 2003, VIROLOGY, V306, P60, DOI 10.1016/S0042-6822(02)00056-9; Wu HJ, 2002, J BIOL CHEM, V277, P30928, DOI 10.1074/jbc.M203735200; Xia HH, 1997, J CELL BIOL, V139, P507, DOI 10.1083/jcb.139.2.507; Zhang YJ, 1998, J BIOL CHEM, V273, P1144, DOI 10.1074/jbc.273.2.1144	48	27	33	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42190	42199		10.1074/jbc.M306669200	http://dx.doi.org/10.1074/jbc.M306669200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12923170	hybrid			2022-12-25	WOS:000185989500077
J	Seki, K; Fujimori, T; Savagner, P; Hata, A; Aikawa, T; Ogata, N; Nabeshima, Y; Kaechoong, L				Seki, K; Fujimori, T; Savagner, P; Hata, A; Aikawa, T; Ogata, N; Nabeshima, Y; Kaechoong, L			Mouse Snail family transcription repressors regulate chondrocyte, extracellular matrix, type II collagen, and aggrecan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; NEURAL CREST; GENE-EXPRESSION; ALGINATE BEADS; PROTEIN; CARTILAGE; SLUG; DIFFERENTIATION; IDENTIFICATION; ENHANCER	Snail family genes are conserved among species during evolution and encode transcription factors expressed at different stages of development in different tissues. These genes are involved in a broad spectrum of biological functions: cell differentiation, cell motility, cell cycle regulation, and apoptosis. However, little is known about the target genes involved in these functions. Here we show that mouse Snail family members, Snail (Sna) and Slug (Slugh), are involved in chondrocyte differentiation by controlling the expression of type II collagen (Col2a1) and aggrecan. In situ hybridization analysis of developing mouse limb demonstrated that Snail and Slug mRNAs were highly expressed in hypertrophic chondrocytes. Inversely, the expression of collagen type II mRNA disappeared during hypertrophic differentiation. Snail and Slug mRNA expression was down-regulated during differentiation of the mouse chondrogenic cell line ATDC5 and overexpression of exogenous Snail or Slug in ATDC5 cells inhibited expression of collagen type II and aggrecan mRNA. Reporter analysis revealed Snail and Slug suppressed the promoter activity of Col2a1, and the E-boxes in the promoter region were the responsible element. Gel shift assay demonstrated the binding of Snail to the E-box. Because type II collagen and aggrecan are major functional components of extracellular matrix in cartilage, these results suggest an important role for Snail-related transcription repressors during chondrocyte differentiation.	Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA; Kyoto Univ, Grad Sch Med, Dept Pathol & Tumor Biol, Kyoto 6068501, Japan; INSERM 0229, F-34000 Montpellier, France; Tufts Univ, Sch Med, Dept Biochem, MCRI,Tufts New England Med Ctr, Boston, MA 02111 USA	Harvard University; Massachusetts General Hospital; Kyoto University; Institut National de la Sante et de la Recherche Medicale (Inserm); Tufts Medical Center; Tufts University	Seki, K (corresponding author), Kyoto Univ, Grad Sch Med, Sakyo Ku, Yoshida Konoe Cho, Kyoto 8501, Japan.	kseki@anat1.med.kyoto-u.ac.jp	Aikawa, Tomonao/AAV-2302-2021; Fujimori, Toshihiko/L-7711-2016; Savagner, Pierre/AAD-9357-2020	Fujimori, Toshihiko/0000-0001-5200-4634; Aikawa, Tomonao/0000-0001-6906-6874				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Arias AM, 2001, CELL, V105, P425, DOI 10.1016/S0092-8674(01)00365-8; Ashraf SI, 1999, EMBO J, V18, P6426, DOI 10.1093/emboj/18.22.6426; ATSUMI T, 1990, CELL DIFFER DEV, V30, P109, DOI 10.1016/0922-3371(90)90079-C; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792; BONAVENTURE J, 1994, EXP CELL RES, V212, P97, DOI 10.1006/excr.1994.1123; BOULAY JL, 1987, NATURE, V330, P395, DOI 10.1038/330395a0; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Carl TF, 1999, DEV BIOL, V213, P101, DOI 10.1006/dbio.1999.9320; CHEN Q, 1995, DEV BIOL, V172, P293, DOI 10.1006/dbio.1995.0024; FUSE N, 1994, GENE DEV, V8, P2270, DOI 10.1101/gad.8.19.2270; Fuse N, 1996, DEVELOPMENT, V122, P1059; GAROFALO S, 1991, P NATL ACAD SCI USA, V88, P9648, DOI 10.1073/pnas.88.21.9648; Hemavathy K, 2000, GENE, V257, P1, DOI 10.1016/S0378-1119(00)00371-1; HORTON W, 1987, P NATL ACAD SCI USA, V84, P8864, DOI 10.1073/pnas.84.24.8864; Inukai T, 1999, MOL CELL, V4, P343, DOI 10.1016/S1097-2765(00)80336-6; JACENKO O, 1993, NATURE, V365, P56, DOI 10.1038/365056a0; Kataoka H, 2000, NUCLEIC ACIDS RES, V28, P626, DOI 10.1093/nar/28.2.626; Krebsbach PH, 1996, J BIOL CHEM, V271, P4298, DOI 10.1074/jbc.271.8.4298; LaBonne C, 2000, DEV BIOL, V221, P195, DOI 10.1006/dbio.2000.9609; LEE B, 1989, SCIENCE, V244, P978, DOI 10.1126/science.2543071; Lee K, 1996, ENDOCRINOLOGY, V137, P5109, DOI 10.1210/en.137.11.5109; Lefebvre V, 1996, MOL CELL BIOL, V16, P4512; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; Lemare F, 1998, J CELL PHYSIOL, V176, P303, DOI 10.1002/(SICI)1097-4652(199808)176:2<303::AID-JCP8>3.0.CO;2-S; Leung KKH, 1998, J CELL BIOL, V141, P1291, DOI 10.1083/jcb.141.6.1291; Mayor R, 2000, MECH DEVELOP, V97, P47, DOI 10.1016/S0925-4773(00)00412-3; Murray D, 2000, J BIOL CHEM, V275, P3610, DOI 10.1074/jbc.275.5.3610; Nakayama H, 1998, DEV BIOL, V199, P150, DOI 10.1006/dbio.1998.8914; Newman B, 2001, J CELL BIOL, V154, P659, DOI 10.1083/jcb.200106040; NIETO MA, 1992, DEVELOPMENT, V116, P227; NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443; Perissinotto D, 2000, DEVELOPMENT, V127, P2823; Petit B, 1996, EXP CELL RES, V225, P151, DOI 10.1006/excr.1996.0166; Savagner P, 1998, DEV DYNAM, V213, P182, DOI 10.1002/(SICI)1097-0177(199810)213:2<182::AID-AJA3>3.0.CO;2-C; SAVAGNER P, 1990, J BIOL CHEM, V265, P6669; Savagner P, 1997, J CELL BIOL, V137, P1403, DOI 10.1083/jcb.137.6.1403; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; Shukunami C, 1997, J BONE MINER RES, V12, P1174, DOI 10.1359/jbmr.1997.12.8.1174; Shukunami C, 1996, J CELL BIOL, V133, P457, DOI 10.1083/jcb.133.2.457; SMITH DE, 1992, DEVELOPMENT, V116, P1033; Tanaka K, 2000, MOL CELL BIOL, V20, P4428, DOI 10.1128/MCB.20.12.4428-4435.2000; THOROGOOD P, 1986, DEV BIOL, V116, P497, DOI 10.1016/0012-1606(86)90150-8; Watanabe H, 1997, P NATL ACAD SCI USA, V94, P6943, DOI 10.1073/pnas.94.13.6943; Watanabe H, 1999, NAT GENET, V21, P225, DOI 10.1038/6016	47	69	76	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41862	41870		10.1074/jbc.M308336200	http://dx.doi.org/10.1074/jbc.M308336200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12917416	hybrid, Green Accepted, Green Submitted			2022-12-25	WOS:000185989500039
J	Waizenegger, T; Stan, T; Neupert, W; Rapaport, D				Waizenegger, T; Stan, T; Neupert, W; Rapaport, D			Signal-anchor domains of proteins of the outer membrane of mitochondria - Structural and functional characteristics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMPORT RECEPTOR; PREPROTEIN TRANSLOCASE; SACCHAROMYCES-CEREVISIAE; YEAST MITOCHONDRIA; RAT-LIVER; INSERTION; TOM70; TOM20; BIOGENESIS; COMPLEXES	We have studied the topogenesis of a class of mitochondrial outer membrane proteins that expose a hydrophilic domain to the cytosol and are anchored to the membrane by a single transmembrane domain in the N-terminal region. To determine the role of these latter sequences in the targeting and insertion of such proteins we took two approaches. First, a functional complementation assay was used to define the structural elements that together with the anchor domain make up the topogenic signal. Moderate hydrophobicity of the transmembrane domain was found to be the most important requirement. Variants with a scrambled sequence of the membrane-spanning segment were only partially functional suggesting that specificity in the amino acid sequence is also of considerable importance. A net positive charge at both flanking regions of the transmembrane domain contributes to the efficiency of targeting and membrane integration but is not an essential structural feature of this signal. Second, chimeras of Tom20, Tom70, and OM45 were generated that contained the cytosolic domain of Tom20 or Tom70 and the anchor domain of one of the other members of the class. These hybrid proteins were able to rescue the growth of cells lacking Tom20 or Tom70. Thus, anchor domains of outer membrane proteins are functionally interchangeable. They play only a minor role in the specific function of these proteins, but have a decisive role in topogenic signaling.	Univ Munich, Inst Physiol Chem, D-81377 Munich, Germany	University of Munich	Rapaport, D (corresponding author), Univ Munich, Inst Physiol Chem, Butenandtstr 5,Haus B, D-81377 Munich, Germany.							Ahting U, 1999, J CELL BIOL, V147, P959, DOI 10.1083/jcb.147.5.959; Biederer T, 1997, SCIENCE, V278, P1806, DOI 10.1126/science.278.5344.1806; Brix J, 1999, J BIOL CHEM, V274, P16522, DOI 10.1074/jbc.274.23.16522; Cerveny KL, 2001, MOL BIOL CELL, V12, P309, DOI 10.1091/mbc.12.2.309; DAUM G, 1982, J BIOL CHEM, V257, P3028; de Kroon AIPM, 1999, MOL MEMBR BIOL, V16, P205; Dekker PJT, 1998, MOL CELL BIOL, V18, P6515, DOI 10.1128/MCB.18.11.6515; deKroon AIPM, 1997, BBA-BIOMEMBRANES, V1325, P108, DOI 10.1016/S0005-2736(96)00240-4; HARKNESS TAA, 1994, J CELL BIOL, V124, P637, DOI 10.1083/jcb.124.5.637; Iwahashi J, 1997, J BIOL CHEM, V272, P18467, DOI 10.1074/jbc.272.29.18467; Kanaji S, 2000, J CELL BIOL, V151, P277, DOI 10.1083/jcb.151.2.277; LITHGOW T, 1994, J BIOL CHEM, V269, P15325; LITHGOW T, 1995, TRENDS BIOCHEM SCI, V20, P98, DOI 10.1016/S0968-0004(00)88972-0; MCBRIDE HM, 1992, J CELL BIOL, V119, P1451, DOI 10.1083/jcb.119.6.1451; Meisinger C, 2000, ANAL BIOCHEM, V287, P339, DOI 10.1006/abio.2000.4868; MILLAR DG, 1994, J BIOL CHEM, V269, P12229; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; RAMAGE L, 1993, EMBO J, V12, P4115, DOI 10.1002/j.1460-2075.1993.tb06095.x; Rapaport D, 2001, MOL BIOL CELL, V12, P1189, DOI 10.1091/mbc.12.5.1189; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHLOSSMANN J, 1994, J BIOL CHEM, V269, P11893; SCHNEIDER H, 1991, SCIENCE, V254, P1659, DOI 10.1126/science.1661031; Sherman F., 1986, METHODS YEAST GENETI; SHORE GC, 1995, EUR J BIOCHEM, V227, P9, DOI 10.1111/j.1432-1033.1995.tb20354.x; Suzuki H, 2002, J CELL SCI, V115, P1895; van den Brink-van der Laan E, 2001, BIOCHEMISTRY-US, V40, P9677, DOI 10.1021/bi002903a; van Wilpe S, 1999, NATURE, V401, P485, DOI 10.1038/46802; Westermann B, 2000, YEAST, V16, P1421, DOI 10.1002/1097-0061(200011)16:15<1421::AID-YEA624>3.3.CO;2-L; Wiedemann N, 2001, EMBO J, V20, P951, DOI 10.1093/emboj/20.5.951; YAFFE MP, 1989, J BIOL CHEM, V264, P21091; Young JC, 2003, CELL, V112, P41, DOI 10.1016/S0092-8674(02)01250-3	32	60	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42064	42071		10.1074/jbc.M305736200	http://dx.doi.org/10.1074/jbc.M305736200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12917440	hybrid			2022-12-25	WOS:000185989500063
J	Kim, JR; Gibson, TJ; Murphy, RM				Kim, JR; Gibson, TJ; Murphy, RM			Targeted control of kinetics of beta-amyloid self-association by surface tension-modifying peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-METHYLATED DERIVATIVES; FIBRIL FORMATION; ALZHEIMERS-DISEASE; COMMON MECHANISM; SHEET BREAKER; IN-VITRO; TOXICITY; INHIBITION; PROTEIN; LIGANDS	Brain tissue from Alzheimer's patients contains extracellular senile plaques composed primarily of deposits of fibrillar aggregates of beta-amyloid peptide. beta-Amyloid aggregation is postulated to be a major factor in the onset of this neurodegenerative disease. Recently proposed is the hypothesis that oligomeric intermediates, rather than fully formed insoluble fibrils, are cytotoxic. Previously, we reported the discovery of peptides that accelerate beta-amyloid aggregation yet inhibit toxicity in vitro, in support of this hypothesis. These peptides contain two domains: a recognition element designed to bind to beta-amyloid and a disrupting element that alters beta-amyloid aggregation kinetics. Here we show that the aggregation rate-enhancing activity of the disrupting element correlates strongly with its ability to increase surface tension of aqueous solutions. Using the Hofmeister series as a guide, we designed a novel peptide with terminal side-chain trimethylammonium groups in the disrupting domain. The derivatized peptide greatly increased solvent surface tension and accelerated beta-amyloid aggregation kinetics by severalfold. Equivalent increases in surface tension in the absence of a recognition domain had no effect on beta-amyloid aggregation. These results suggest a novel strategy for targeting localized changes in interfacial energy to specific proteins, as a way to selectively alter protein folding, stability, and aggregation.	Univ Wisconsin, Dept Chem Engn, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Murphy, RM (corresponding author), Univ Wisconsin, Dept Chem Engn, 1415 Engn Dr, Madison, WI 53706 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037728] Funding Source: NIH RePORTER; NINDS NIH HHS [NS37728] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahmad A, 2001, BIOCHEMISTRY-US, V40, P1945, DOI 10.1021/bi001933a; Bourot S, 2000, J BIOL CHEM, V275, P1050, DOI 10.1074/jbc.275.2.1050; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Cacace MG, 1997, Q REV BIOPHYS, V30, P241, DOI 10.1017/S0033583597003363; Cairo CW, 2002, BIOCHEMISTRY-US, V41, P8620, DOI 10.1021/bi0156254; Chow MKM, 2001, BIOL CHEM, V382, P1593, DOI 10.1515/BC.2001.194; Doig AJ, 2002, BIOCHEM SOC T, V30, P537, DOI 10.1042/bst0300537; Findeis MA, 1999, BIOCHEMISTRY-US, V38, P6791, DOI 10.1021/bi982824n; Ghanta J, 1996, J BIOL CHEM, V271, P29525, DOI 10.1074/jbc.271.47.29525; Gordon DJ, 2001, BIOCHEMISTRY-US, V40, P8237, DOI 10.1021/bi002416v; Gordon DJ, 2003, BIOCHEMISTRY-US, V42, P475, DOI 10.1021/bi0259857; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; Howlett DR, 1999, BIOCHEM J, V340, P283, DOI 10.1042/0264-6021:3400283; Hughes E, 2000, J BIOL CHEM, V275, P25109, DOI 10.1074/jbc.M003554200; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kim YS, 2001, J BIOL CHEM, V276, P1626, DOI 10.1074/jbc.M007766200; Klunk WE, 1998, LIFE SCI, V63, P1807, DOI 10.1016/S0024-3205(98)00454-8; Kuner P, 2000, J BIOL CHEM, V275, P1673, DOI 10.1074/jbc.275.3.1673; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lin TY, 1996, PROTEIN SCI, V5, P372; Lowe TL, 2001, BIOCHEMISTRY-US, V40, P7882, DOI 10.1021/bi002734u; Nakagami Y, 2002, BRIT J PHARMACOL, V137, P676, DOI 10.1038/sj.bjp.0704911; Pallitto MM, 2001, BIOPHYS J, V81, P1805, DOI 10.1016/S0006-3495(01)75831-6; Pallitto MM, 1999, BIOCHEMISTRY-US, V38, P3570, DOI 10.1021/bi982119e; PIKE CJ, 1993, J NEUROSCI, V13, P1676; Ratnaparkhi GS, 2001, J BIOL CHEM, V276, P28789, DOI 10.1074/jbc.M101906200; Roher AE, 1996, J BIOL CHEM, V271, P20631, DOI 10.1074/jbc.271.34.20631; Seilheimer B, 1997, J STRUCT BIOL, V119, P59, DOI 10.1006/jsbi.1997.3859; SIMMONS LK, 1994, MOL PHARMACOL, V45, P373; Soto C, 1998, NAT MED, V4, P822, DOI 10.1038/nm0798-822; Tjernberg LO, 1996, J BIOL CHEM, V271, P8545, DOI 10.1074/jbc.271.15.8545; Tjernberg LO, 1997, J BIOL CHEM, V272, P12601, DOI 10.1074/jbc.272.19.12601; Wang AJ, 1997, BIOCHEMISTRY-US, V36, P9101, DOI 10.1021/bi970247h; Ward RV, 2000, BIOCHEM J, V348, P137, DOI 10.1042/0264-6021:3480137; Yang DS, 1999, J BIOL CHEM, V274, P32970, DOI 10.1074/jbc.274.46.32970	36	25	27	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40730	40735		10.1074/jbc.M305466200	http://dx.doi.org/10.1074/jbc.M305466200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12917437	hybrid			2022-12-25	WOS:000185847200039
J	Tomar, RS; Matta, H; Chaudhary, PM				Tomar, RS; Matta, H; Chaudhary, PM			Use of adeno-associated viral vector for delivery of small interfering RNA	ONCOGENE			English	Article						AAV; siRNA; RNAi; RNA interference	GENE-EXPRESSION; STABLE SUPPRESSION	Post-transcriptional gene silencing by small interfering RNAs (siRNAs) is rapidly becoming a powerful tool for genetic analysis of mammalian cells. Delivery of siRNA into mammalian cells is usually achieved via the transfection of double-stranded oligonucleotides or plasmids encoding RNA polymerase III promoter-driven small hairpin RNA. Recently, retroviral vectors have been used for siRNA delivery, which overcome the problem of poor transfection efficiency seen with the plasmid-based systems. However, retroviral vectors have several limitations, such as the need for active cell division for gene transduction, oncogenic potential, low titers and gene silencing. In this report, we have adapted a commercially available adenoassociated virus (AAV) vector for siRNA delivery into mammalian cells. We demonstrate the ability of this modified vector to deliver efficiently siRNA into HeLa S3 cells and downregulate p53 and caspase 8 expression. Our results suggest that AAV-based vectors are efficient vectors for the delivery of siRNA into mammalian cells. Based on the known ability of these vectors to infect both dividing and nondividing cells, their use as a therapeutic tool for the delivery of siRNA deserves further study.	Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Div Hematol Oncol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Chaudhary, PM (corresponding author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	preet.chaudhary@utsouthwestern.edu	Chaudhary, Preet/E-1970-2018		NATIONAL CANCER INSTITUTE [P50CA070907] Funding Source: NIH RePORTER; NCI NIH HHS [P50-CA70907] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barton GM, 2002, P NATL ACAD SCI USA, V99, P14943, DOI 10.1073/pnas.242594499; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Devroe Eric, 2002, BMC Biotechnol, V2, P15, DOI 10.1186/1472-6750-2-15; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Lee NS, 2002, NAT BIOTECHNOL, V20, P500, DOI 10.1038/nbt0502-500; MANCHE L, 1992, MOL CELL BIOL, V12, P5238, DOI 10.1128/MCB.12.11.5238; Miyagishi M, 2002, NAT BIOTECHNOL, V20, P497, DOI 10.1038/nbt0502-497; Paddison PJ, 2002, P NATL ACAD SCI USA, V99, P1443, DOI 10.1073/pnas.032652399; Paul CP, 2002, NAT BIOTECHNOL, V20, P505, DOI 10.1038/nbt0502-505; Sharp PA, 1999, GENE DEV, V13, P139, DOI 10.1101/gad.13.2.139; Sharp PA, 2001, GENE DEV, V15, P485, DOI 10.1101/gad.880001; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Stilwell JL, 2003, BIOTECHNIQUES, V34, P148, DOI 10.2144/03341dd01; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599	17	144	192	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2003	22	36					5712	5715		10.1038/sj.onc.1206733	http://dx.doi.org/10.1038/sj.onc.1206733			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944921				2022-12-25	WOS:000184865900022
J	Pignatelli, M; Cocca, C; Santos, A; Perez-Castillo, A				Pignatelli, M; Cocca, C; Santos, A; Perez-Castillo, A			Enhancement of BRCA1 gene expression by the peroxisome proliferator-activated receptor gamma in the MCF-7 breast cancer cell line	ONCOGENE			English	Article						BRCA1; PPAR gamma; regulation	PPAR-GAMMA; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); SUBCELLULAR-LOCALIZATION; PROMOTER REGION; SPORADIC BREAST; OVARIAN-CANCER; INHIBITION; COMPLEX; DIFFERENTIATION; TRANSCRIPTION	BRCA1 has been linked to the genetic susceptibility of a majority of familial breast and ovarian cancers. Several lines of evidence indicate that BRCA1 is a tumor suppressor and its expression is downregulated in sporadic breast and ovarian cancer cases. Therefore, the identification of genes involved in the regulation of BRCA1 gene expression might lead to new insights into the pathogenesis and treatment of these tumors. Peroxisome proliferator-activated receptor gamma (PPARgamma) is a member of the nuclear receptor superfamily that has well-established roles in the regulation of adipocyte development and glucose homeostasis. More recently, it has been shown that ligands of PPARgamma have a potent antitumorigenic activity in breast cancer cells. In the present study we have found that two distinct ligands of PPARgamma; 15-deoxy-Delta-(12,14)-prostaglandin J(2). (15dPG-J(2)) and rosiglitazone, increase the levels of BRCA1 protein in human MCF-7 breast cancer cells. Immunofluorescence microscopy analysis showed that, after treatment with 15dPG-J(2), the BRCA1 protein is mainly localized in the nucleus. Functional analysis by transient transfection of different 5'-flanking region fragments, as well as gel mobility shift assays and mutagenic analysis, suggests that the effects of 15dPG-J(2) and rosiglitazone are mediated through a functional DR1 located between the nucleotides -241 and -229, which is a canonical PPARgamma type response element. Our data suggest that PPARgamma is a crucial gene regulating BRCA1 gene expression and might therefore be important for the BRCA1 regulatory pathway involved in the pathogenesis of sporadic breast and ovarian cancer.	Univ Autonoma Madrid, Inst Invest Biomed, CSIC, E-28049 Madrid, Spain; Univ Complutense Madrid, Dept Bioquim & Biol Mol, Fac Med, E-28040 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Complutense University of Madrid	Perez-Castillo, A (corresponding author), Univ Buenos Aires, Dept Radioisotopos, Fac Farm & Bioquim, RA-1053 Buenos Aires, DF, Argentina.		Santos, Angel/K-3744-2014; Perez-Castillo, Ana/A-9505-2015; izadi, emad/M-1118-2019	Santos, Angel/0000-0002-7551-8483; Perez-Castillo, Ana/0000-0002-2632-5853				Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Baer R, 2002, CURR OPIN GENET DEV, V12, P86, DOI 10.1016/S0959-437X(01)00269-6; Budhram-Mahadeo V, 1999, ONCOGENE, V18, P6684, DOI 10.1038/sj.onc.1203072; Castrillo A, 2000, MOL CELL BIOL, V20, P1692, DOI 10.1128/MCB.20.5.1692-1698.2000; Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fan SJ, 2001, ONCOGENE, V20, P77, DOI 10.1038/sj.onc.1204073; Forman BM, 1996, ANN NY ACAD SCI, V804, P266, DOI 10.1111/j.1749-6632.1996.tb18621.x; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Lebovitz HE, 2001, RECENT PROG HORM RES, V56, P265, DOI 10.1210/rp.56.1.265; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630; Menendez-Hurtado A, 2000, ENDOCRINOLOGY, V141, P4164, DOI 10.1210/en.141.11.4164; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; Nathanson KN, 2001, NAT MED, V7, P552, DOI 10.1038/87876; Picard F, 2002, ANNU REV NUTR, V22, P167, DOI 10.1146/annurev.nutr.22.010402.102808; Pignatelli M, 2001, J CELL SCI, V114, P4117; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Suen TC, 1999, J BIOL CHEM, V274, P31297, DOI 10.1074/jbc.274.44.31297; Thakur S, 1999, J BIOL CHEM, V274, P8837, DOI 10.1074/jbc.274.13.8837; Thomas JE, 1996, J BIOL CHEM, V271, P28630, DOI 10.1074/jbc.271.45.28630; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Wang A, 2000, J BIOL CHEM, V275, P4532, DOI 10.1074/jbc.275.6.4532; Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029; Xu CF, 1997, J BIOL CHEM, V272, P20994, DOI 10.1074/jbc.272.34.20994	30	47	49	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 21	2003	22	35					5446	5450		10.1038/sj.onc.1206824	http://dx.doi.org/10.1038/sj.onc.1206824			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JC	12934104	Bronze			2022-12-25	WOS:000184735000009
J	Chakraborty, S; Sinha, KK; Senyuk, V; Nucifora, G				Chakraborty, S; Sinha, KK; Senyuk, V; Nucifora, G			SUV39H1 interacts with AML1 and abrogates AML1 transactivity. AML1 is methylated in vivo	ONCOGENE			English	Article						AML1; SUV39H1; methylation; repression; Runt domain; EMSA	TRANSCRIPTION FACTOR GATA-1; ACUTE MYELOGENOUS LEUKEMIA; ACUTE MYELOID-LEUKEMIA; CBF-BETA-SMMHC; BINDING; ACETYLATION; GENE; HETEROCHROMATIN; PROTEIN; DOMAIN	Acute myeloid leukemia 1 (AML1) belongs to a family of DNA-binding proteins highly conserved through evolution. AML1 regulates the expression of several hematopoietic genes and is essential for murine fetal liver hematopoiesis. We report here that the histone methyltransferase SUV39H1, a mammalian ortholog of the Drosophila melanogaster SU(VAR) 3-9, forms complex with AML1. SUV39H1 methylates lysine 9 of the histone protein H3 leading to the formation of the high-affinity binding site on chromatin for proteins of the heterochromatin protein 1 family (HP1). The interaction of AML1 with SUV39H1 requires the N-terminus of AML1 where the Runt domain is located. Binding of AML1 to SUV39H1 abrogates the transactivating and DNA-binding properties of AML1 and dissociates the net-like nuclear structure of AML1. It has been reported that AML1 is capable of interaction with histone acetyl transferases (CBP, p300, and MOZ) and with component of the histone deacetylase complex (Sin3), and that the interaction with these coregulators affects the strength of AML1 in promoter regulation. Our data suggest that other enzymes are also involved in gene regulation by AML1 activity by modulating the affinity of AML1 for DNA.	Univ Illinois, Dept Pathol, Chicago, IL 60607 USA; Univ Illinois, Ctr Canc, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Nucifora, G (corresponding author), Univ Illinois, Dept Pathol, Mol Biol Res Bldg,M-C 737,900 S Ashland Ave, Chicago, IL 60607 USA.	nucifora@uic.edu		Sinha, Kislay/0000-0002-6978-4611	NATIONAL CANCER INSTITUTE [R01CA096448, R01CA072675] Funding Source: NIH RePORTER; NCI NIH HHS [CA72675, CA96448] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barton K, 2000, BIOESSAYS, V22, P214, DOI 10.1002/(SICI)1521-1878(200003)22:3<214::AID-BIES2>3.0.CO;2-I; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Britos-Bray M, 1998, BLOOD, V92, P4344, DOI 10.1182/blood.V92.11.4344.423a01_4344_4352; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Cao WS, 1998, J BIOL CHEM, V273, P31534, DOI 10.1074/jbc.273.47.31534; Chakrabarti SR, 2000, P NATL ACAD SCI USA, V97, P13281, DOI 10.1073/pnas.240315897; Chakraborty S, 2001, J BIOL CHEM, V276, P44936, DOI 10.1074/jbc.M106733200; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; El-Osta A, 2001, BIOCHEM BIOPH RES CO, V289, P733, DOI 10.1006/bbrc.2001.6023; Fears S, 1997, P NATL ACAD SCI USA, V94, P1949, DOI 10.1073/pnas.94.5.1949; Ferreira R, 2001, EMBO REP, V2, P794, DOI 10.1093/embo-reports/kve173; Firestein R, 2000, MOL CELL BIOL, V20, P4900, DOI 10.1128/MCB.20.13.4900-4909.2000; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; Hung HL, 1999, MOL CELL BIOL, V19, P3496; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Kitabayashi I, 2001, EMBO J, V20, P7184, DOI 10.1093/emboj/20.24.7184; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Maison C, 2002, NAT GENET, V30, P329, DOI 10.1038/ng843; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Marzio G, 2000, J BIOL CHEM, V275, P10887, DOI 10.1074/jbc.275.15.10887; McNeil S, 1999, P NATL ACAD SCI USA, V96, P14882, DOI 10.1073/pnas.96.26.14882; Michaud J, 2002, BLOOD, V99, P1364, DOI 10.1182/blood.V99.4.1364; Mikhail FM, 2002, LEUKEMIA, V16, P658, DOI 10.1038/sj.leu.2402399; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Osato M, 2001, INT J HEMATOL, V74, P245, DOI 10.1007/BF02982056; Peters AHFM, 2002, NAT GENET, V30, P77, DOI 10.1038/ng789; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Polanowska J, 2001, ONCOGENE, V20, P4115, DOI 10.1038/sj.onc.1204514; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Rhoades KL, 1996, P NATL ACAD SCI USA, V93, P11895, DOI 10.1073/pnas.93.21.11895; Sewalt RGAB, 2002, MOL CELL BIOL, V22, P5539, DOI 10.1128/MCB.22.15.5539-5553.2002; Speck NA, 2002, NAT REV CANCER, V2, P502, DOI 10.1038/nrc840; Vandel L, 2001, MOL CELL BIOL, V21, P6484, DOI 10.1128/MCB.21.19.6484-6494.2001; Vaute O, 2002, NUCLEIC ACIDS RES, V30, P475, DOI 10.1093/nar/30.2.475; Wang CG, 2001, FRONT BIOSCI-LANDMRK, V6, pD610, DOI 10.2741/1wang1; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Yamamoto K, 2003, BIOCHEM BIOPH RES CO, V301, P287, DOI 10.1016/S0006-291X(02)03021-8; Zhang QH, 2000, P NATL ACAD SCI USA, V97, P14323, DOI 10.1073/pnas.011283598; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855	44	57	63	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2003	22	34					5229	5237		10.1038/sj.onc.1206600	http://dx.doi.org/10.1038/sj.onc.1206600			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JB	12917624				2022-12-25	WOS:000184734900002
J	Greenbaum, L; Katcoff, DJ; Dou, HY; Gozlan, Y; Malik, Z				Greenbaum, L; Katcoff, DJ; Dou, HY; Gozlan, Y; Malik, Z			A porphobilinogen deaminase (PBGD) Ran-binding protein interaction is implicated in nuclear trafficking of PBGD in differentiating glioma cells	ONCOGENE			English	Article						PBGD; nuclear-localization; RanBPM; porphyrin	PROTOPORPHYRIN-IX ACCUMULATION; INDUCED PORPHYRIN FLUORESCENCE; PHOTODYNAMIC THERAPY; CLINICAL-EXPERIENCE; TRANSFORMED-CELLS; BASIC PRINCIPLES; REGULATORY ROLE; IN-VITRO; CANCER; TRANSPORT	Porphobilinogen deaminase (PBGD) is a rate-limiting enzyme of the heme biosynthesis pathway, whose level is elevated in various human tumors. PBGD was observed in both nuclear and cytoplasmic fractions of C6 glioma cells by immunostaining. During mitosis, chromatids were intensely stained for PBGD in comparison to the interphase chromatin. Using the yeast two-hybrid system, we identified RanBPM, the nuclear Ran-binding protein, as an interacting partner of PBGD. During butyrate-induced differentiation of C6, both nuclear and cytoplasmic PBGD levels declined as did Ran protein and its nucleotide exchange factor RCC1. N,N'-hexamethylene bis-acetamide-dependent differentiation resulted in an increase of the cytoplasmic PBGD, whereas nuclear PBGD, Ran protein and RCC1 remained unchanged. mRNA levels of PBGD remained unchanged during stimulation with both butyrate and N,N'-hexamethylene bis-acetamide. The enzymatic activity of PBGD and protoporphyrin IX synthesis in C6 cells were dependent on the differentiation induction agent. We conclude that PBGD possibly has a nuclear role in addition to its cytosolic enzymatic activity required for heme synthesis, which is related to cell transformation and differentiation.	Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel	Bar Ilan University	Malik, Z (corresponding author), Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel.							ANNUNZIATO AT, 1988, CHROMOSOMA, V96, P132, DOI 10.1007/BF00331045; ARCANGELI A, 1987, J CELL PHYSIOL, V132, P387, DOI 10.1002/jcp.1041320302; ARCANGELI A, 1993, P NATL ACAD SCI USA, V90, P5858, DOI 10.1073/pnas.90.12.5858; Archer SY, 1999, CURR OPIN GENET DEV, V9, P171, DOI 10.1016/S0959-437X(99)80026-4; BRESLOW R, 1991, P NATL ACAD SCI USA, V88, P5542, DOI 10.1073/pnas.88.13.5542; Cheung WL, 2000, CURR OPIN CELL BIOL, V12, P326, DOI 10.1016/S0955-0674(00)00096-X; CHUANMAO Z, 1999, J CELL SCI, V112, P2453; Dot J, 2002, NEUROREPORT, V13, P1083, DOI 10.1097/00001756-200206120-00022; Gibson SL, 1998, BRIT J CANCER, V77, P235, DOI 10.1038/bjc.1998.39; Goya L, 1996, INT J DEV NEUROSCI, V14, P409, DOI 10.1016/S0736-5748(96)00026-3; Greenbaum L, 2002, BRIT J CANCER, V86, P1006, DOI 10.1038/sj.bjc.6600173; Hinnen P, 1998, BRIT J CANCER, V78, P679, DOI 10.1038/bjc.1998.559; Ideguchi H, 2002, BIOCHEM J, V367, P87, DOI 10.1042/BJ20011851; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; KENNEDY JC, 1990, J PHOTOCH PHOTOBIO B, V6, P143, DOI 10.1016/1011-1344(90)85083-9; Kriegmair M, 1996, J UROLOGY, V155, P105, DOI 10.1016/S0022-5347(01)66559-5; Kuersten S, 2001, TRENDS CELL BIOL, V11, P497, DOI 10.1016/S0962-8924(01)02144-4; LOUIE GV, 1992, NATURE, V359, P33, DOI 10.1038/359033a0; MALIK Z, 1987, BRIT J CANCER, V56, P589, DOI 10.1038/bjc.1987.246; MARKS PA, 1987, CANCER RES, V47, P659; MARKS PA, 1994, P NATL ACAD SCI USA, V91, P10251, DOI 10.1073/pnas.91.22.10251; McLintock Lorna A, 2002, Hematology, V7, P189, DOI 10.1080/1024533021000013906; Nemergut ME, 2001, SCIENCE, V292, P1540, DOI 10.1126/science.292.5521.1540; Nishitani H, 2001, GENE, V272, P25, DOI 10.1016/S0378-1119(01)00553-4; Orenstein A, 2000, DERMATOL SURG, V26, P765, DOI 10.1046/j.1524-4725.2000.00056.x; ORENSTEIN A, 1995, CANCER LETT, V93, P227, DOI 10.1016/0304-3835(95)03814-D; Orenstein A, 1998, LASER MED SCI, V13, P112, DOI 10.1007/s101030050063; ORENSTEIN A, 1996, LASERS LIFE SCI, V7, P1; Ortel B, 1998, BRIT J CANCER, V77, P1744, DOI 10.1038/bjc.1998.292; PARKER KK, 1980, SCIENCE, V208, P179, DOI 10.1126/science.6102413; Peng Q, 1997, CANCER-AM CANCER SOC, V79, P2282; Peng Q, 1997, PHOTOCHEM PHOTOBIOL, V65, P235, DOI 10.1111/j.1751-1097.1997.tb08549.x; Ponka P, 1997, BLOOD, V89, P1; Quimby BB, 2001, CELL MOL LIFE SCI, V58, P1766, DOI 10.1007/PL00000816; Rifkind RA, 1996, PHARMACOL THERAPEUT, V69, P97, DOI 10.1016/0163-7258(95)02044-6; Sazer S, 2000, J CELL SCI, V113, P1111; SCHOENFELD N, 1988, BIOCHEM MED METAB B, V40, P213, DOI 10.1016/0885-4505(88)90121-1; SEGOVIA J, 1994, J NEUROCHEM, V63, P1218; Stepp H, 1998, ENDOSCOPY, V30, P379, DOI 10.1055/s-2007-1001287; Stummer W, 1998, NEUROSURGERY, V42, P518, DOI 10.1097/00006123-199803000-00017; Tunstall RG, 2002, BRIT J CANCER, V87, P246, DOI 10.1038/sj.bjc.6600460; Wang DK, 2002, J BIOL CHEM, V277, P36216, DOI 10.1074/jbc.M205111200; Yoneda Y, 2000, GENES CELLS, V5, P777, DOI 10.1046/j.1365-2443.2000.00366.x	43	27	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 14	2003	22	34					5221	5228		10.1038/sj.onc.1206723	http://dx.doi.org/10.1038/sj.onc.1206723			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JB	12917623				2022-12-25	WOS:000184734900001
J	Richie-Jannetta, R; Francis, SH; Corbin, JD				Richie-Jannetta, R; Francis, SH; Corbin, JD			Dimerization of cGMP-dependent protein kinase I beta is mediated by an extensive amino-terminal leucine zipper motif, and dimerization modulates enzyme function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOS-JUN INTERACTION; X-RAY-SCATTERING; COILED-COIL; DNA-BINDING; CYCLIC-GMP; TRANSCRIPTION FACTOR; MOLECULAR-CLONING; BOVINE AORTA; DOMAIN; ACTIVATION	All mammalian cGMP-dependent protein kinases (PKGs) are dimeric. Dimerization of PKGs involves sequences located near the amino termini, which contain a conserved, extended leucine zipper motif. In PKG Ibeta this includes eight Leu/Ile heptad repeats, and in the present study, deletion and site-directed mutagenesis have been used to systematically delete these repeats or substitute individual Leu/Ile. The enzymatic properties and quaternary structures of these purified PKG mutants have been determined. All had specific enzyme activities comparable to wild type PKG. Simultaneous substitution of alanine at four or more of the Leu/Ile heptad repeats ((L3A/L10A/L17A/I24A), (L31A/I38A/L45A/I52A), (L17A/I24A/L31A/I38A/L45A/I52A), and (L3A/L10A/L45A/I52A)) of the motif produces a monomeric PKG Ibeta. Mutation of two Leu/Ile heptad repeats can produce either a dimeric (L3A/L10A) or monomeric (L17A/I24A and L31A/I38A) PKG. Point mutation of Leu-17 or Ile-24 (L17A or I24A) does not disrupt dimerization. These results suggest that all eight Leu/Ile heptad repeats are involved in dimerization of PKG Ibeta. Six of the eight repeats are sufficient to mediate dimerization, but substitutions at some positions (Leu-17, Ile-24, Leu-31, and Ile-38) appear to have greater impact than others on dimerization. The K-alpha of cGMP for activation of monomeric mutants (PKG Ibeta (Delta1-52) and PKG Ibeta L17A/I24A/L31A/I38A/L45A/I52A) is 2- to 3-fold greater than that for wild type dimeric PKG Ibeta, and there is a corresponding 2- to 3-fold increase in cGMP-dissociation rate of the high affinity cGMP-binding site (site A) of these monomers. These results indicate that dimerization increases sensitivity for cGMP activation of the enzyme.	Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Vanderbilt University	Corbin, JD (corresponding author), Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, 702 Light Hall, Nashville, TN 37232 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007752] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040029] Funding Source: NIH RePORTER; NHLBI NIH HHS [5T32HL 07752] Funding Source: Medline; NIDDK NIH HHS [DK40029] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AITKEN A, 1984, BIOCHIM BIOPHYS ACTA, V790, P219, DOI 10.1016/0167-4838(84)90025-6; Ammendola A, 2001, J BIOL CHEM, V276, P24153, DOI 10.1074/jbc.M101530200; ATKINSON RA, 1991, BIOCHEMISTRY-US, V30, P9387, DOI 10.1021/bi00103a001; Ben-Shahar Y, 2002, SCIENCE, V296, P741, DOI 10.1126/science.1069911; BIKLE DD, 1993, J BIOL CHEM, V268, P620; BURBELO PD, 1994, GENE, V139, P241, DOI 10.1016/0378-1119(94)90763-3; Busch JL, 2002, J BIOL CHEM, V277, P34048, DOI 10.1074/jbc.M202761200; Chu DM, 1997, J BIOL CHEM, V272, P31922, DOI 10.1074/jbc.272.50.31922; CORBIN JD, 1983, J BIOL CHEM, V258, P1391; CORBIN JD, 1986, J BIOL CHEM, V261, P1208; Fautsch MP, 2001, INVEST OPHTH VIS SCI, V42, P2324; FOSTER JL, 1981, J BIOL CHEM, V256, P5029; Francis S H, 1988, Second Messengers Phosphoproteins, V12, P301; Francis SH, 1999, CRIT REV CL LAB SCI, V36, P275, DOI 10.1080/10408369991239213; Francis SH, 1996, J BIOL CHEM, V271, P20748, DOI 10.1074/jbc.271.34.20748; FRANCIS SH, 1993, CYCLIC GMP SYNTHESIS, P115; GAMM DM, 1995, J BIOL CHEM, V270, P27380, DOI 10.1074/jbc.270.45.27380; Gassama-Diagne A, 2001, J BIOL CHEM, V276, P18352, DOI 10.1074/jbc.M009784200; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; JUNIUS FK, 1995, BIOCHEMISTRY-US, V34, P6164, DOI 10.1021/bi00018a020; KALDERON D, 1989, J BIOL CHEM, V264, P10738; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KOUZARIDES T, 1989, NATURE, V340, P568, DOI 10.1038/340568a0; Kubota R, 1997, GENOMICS, V41, P360, DOI 10.1006/geno.1997.4682; KUNKEL TA, 1994, CURRENT PROTOCOLS MO; LANDGRAF W, 1989, EUR J BIOCHEM, V181, P643, DOI 10.1111/j.1432-1033.1989.tb14771.x; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Leon DA, 1997, J BIOL CHEM, V272, P28431, DOI 10.1074/jbc.272.45.28431; LI Y, 1995, J BIOL CHEM, V270, P1935, DOI 10.1074/jbc.270.4.1935; LINCOLN TM, 1978, J BIOL CHEM, V253, P6002; Lu R, 1997, MOL CELL BIOL, V17, P5117, DOI 10.1128/MCB.17.9.5117; Marini MG, 1997, J BIOL CHEM, V272, P16490, DOI 10.1074/jbc.272.26.16490; MIGLIETTA LAP, 1988, J BIOL CHEM, V263, P16096; Moitra J, 1997, BIOCHEMISTRY-US, V36, P12567, DOI 10.1021/bi971424h; MONKEN CE, 1980, J BIOL CHEM, V255, P7067; Orstavik S, 1996, BIOCHEM BIOPH RES CO, V220, P759, DOI 10.1006/bbrc.1996.0477; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; RANNELS SR, 1983, METHOD ENZYMOL, V99, P168; RANSONE LJ, 1989, GENE DEV, V3, P770, DOI 10.1101/gad.3.6.770; RASMUSSEN R, 1991, P NATL ACAD SCI USA, V88, P561, DOI 10.1073/pnas.88.2.561; Reed RB, 1996, J BIOL CHEM, V271, P17570, DOI 10.1074/jbc.271.29.17570; Rook F, 1998, PLANT MOL BIOL, V37, P171, DOI 10.1023/A:1005964327725; SANDBERG M, 1989, FEBS LETT, V255, P321, DOI 10.1016/0014-5793(89)81114-7; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; Smith JA, 1996, J BIOL CHEM, V271, P20756, DOI 10.1074/jbc.271.34.20756; Stansberry J, 2001, J NEUROCHEM, V76, P1177, DOI 10.1046/j.1471-4159.2001.00131.x; Surks HK, 1999, SCIENCE, V286, P1583, DOI 10.1126/science.286.5444.1583; TAKIO K, 1984, BIOCHEMISTRY-US, V23, P4207, DOI 10.1021/bi00313a030; Tamura N, 1996, HYPERTENSION, V27, P552, DOI 10.1161/01.HYP.27.3.552; Tripet B, 2000, J MOL BIOL, V300, P377, DOI 10.1006/jmbi.2000.3866; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; UHLER MD, 1993, J BIOL CHEM, V268, P13586; VANHEECKEREN WJ, 1992, NUCLEIC ACIDS RES, V20, P3721, DOI 10.1093/nar/20.14.3721; Vinson C, 2002, MOL CELL BIOL, V22, P6321, DOI 10.1128/MCB.22.18.6321-6335.2002; Wall ME, 2003, P NATL ACAD SCI USA, V100, P2380, DOI 10.1073/pnas.0534892100; WERNET W, 1989, FEBS LETT, V251, P191, DOI 10.1016/0014-5793(89)81453-X; WOLFE L, 1989, J BIOL CHEM, V264, P7734; WOLFE L, 1989, J BIOL CHEM, V264, P4157; Yuasa K, 1999, J BIOL CHEM, V274, P37429, DOI 10.1074/jbc.274.52.37429; Yuasa K, 2000, J BIOL CHEM, V275, P4897, DOI 10.1074/jbc.275.7.4897; Zeng X, 1997, P NATL ACAD SCI USA, V94, P3673, DOI 10.1073/pnas.94.8.3673; Zhao JK, 1997, J BIOL CHEM, V272, P31929, DOI 10.1074/jbc.272.50.31929	67	38	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50070	50079		10.1074/jbc.M306796200	http://dx.doi.org/10.1074/jbc.M306796200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	12933804	hybrid			2022-12-25	WOS:000187068200051
J	van Pesch, V; Michiels, T				van Pesch, V; Michiels, T			Characterization of interferon-alpha 13, a novel constitutive murine interferon-alpha subtype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUG INITIATOR CODON; THEILERS-VIRUS; MESSENGER-RNA; REGULATORY FACTOR-7; MOUSE MACROPHAGES; GENE-EXPRESSION; DISEASE VIRUS; I INTERFERONS; CROSS-TALK; A GENES	Type-I interferons (IFNs), also called IFNs-alpha/beta, are a family of cytokines induced by viral infection and are primarily involved in antiviral defense of the cells. IFNs-alpha/beta were also reported to be produced constitutively at low levels in mouse and human cells. These so-called endogenous or constitutive IFNs are thought to exert important homeostatic functions in the uninfected host. By searching IFN genes that were not repressed by the leader protein of Theiler's virus, we identified three uncharacterized IFN-alpha genes that are constitutively expressed in uninfected mouse cells, in vitro and in vivo. Two of these genes corresponded to pseudogenes and were tentatively called IFN-alpha(psi2) and IFN-alpha(psi3). IFN-alpha(psi2) transcripts are the most abundant IFN-alpha transcripts detected in several mouse organs in the absence of viral infection. The third gene codes for a new IFN-alpha subtype called IFN-alpha13, which exhibits acid-stable antiviral activity against Theiler's virus, Mengo virus, and vesicular stomatitis virus. IFN-alpha13 displays unusual characteristics, suggesting that it might have a particular function. Firstly, it is transcribed constitutively, independent of viral infection and of interferon regulatory factor-7 induction. Secondly, it contains two N-glycosylation sites, in contrast to other murine IFN-alpha subtypes that contain either one or no N-glycosylation site. In addition to the genes described here above, several other IFN-alpha subtype genes, including a new gene (IFN-alpha14), were expressed in tissues of uninfected mice. In contrast to IFN-alpha13, IFN-alpha14 was found to lack N-glycosylation and have its expression induced in response to viral infection.	Univ Louvain, Christian de Duve Inst Cellular Pathol, Microbial Pathogenesis Unit, MIPA VIRO 74 49, B-1200 Brussels, Belgium	Universite Catholique Louvain	Michiels, T (corresponding author), Univ Louvain, Christian de Duve Inst Cellular Pathol, Microbial Pathogenesis Unit, MIPA VIRO 74 49, 74 Ave Hippocrate, B-1200 Brussels, Belgium.		Michiels, Thomas/ABE-3203-2021; van Pesch, Vincent/AAK-9506-2020	Michiels, Thomas/0000-0001-9615-8053; van Pesch, Vincent/0000-0003-2885-9004				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Au WC, 1998, J BIOL CHEM, V273, P29210, DOI 10.1074/jbc.273.44.29210; Bakheet T, 2001, NUCLEIC ACIDS RES, V29, P246, DOI 10.1093/nar/29.1.246; Barnes BJ, 2001, J BIOL CHEM, V276, P23382, DOI 10.1074/jbc.M101216200; Biron CA, 2001, IMMUNITY, V14, P661, DOI 10.1016/S1074-7613(01)00154-6; Braganca J, 1998, BIOCHIMIE, V80, P673, DOI 10.1016/S0300-9084(99)80021-2; Chinsangaram J, 1999, J VIROL, V73, P9891, DOI 10.1128/JVI.73.12.9891-9898.1999; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; COULOMBEL C, 1991, GENE, V104, P187, DOI 10.1016/0378-1119(91)90249-B; DAUGHERTY B, 1984, J INTERFERON RES, V4, P635, DOI 10.1089/jir.1984.4.635; Deonarain R, 2000, J VIROL, V74, P3404, DOI 10.1128/JVI.74.7.3404-3409.2000; DION M, 1986, BIOCHEM BIOPH RES CO, V138, P826, DOI 10.1016/S0006-291X(86)80571-X; DUCGOIRAN P, 1994, EXP CELL RES, V214, P570, DOI 10.1006/excr.1994.1295; DUKE GM, 1989, J VIROL, V63, P1822, DOI 10.1128/JVI.63.4.1822-1826.1989; Fujii GH, 1999, ONCOGENE, V18, P1765, DOI 10.1038/sj.onc.1202492; GESSANI S, 1991, J VIROL, V65, P989, DOI 10.1128/JVI.65.2.989-991.1991; GOEDDEL DV, 1981, NATURE, V290, P20, DOI 10.1038/290020a0; Gresser I, 2002, CYTOKINE GROWTH F R, V13, P111, DOI 10.1016/S1359-6101(01)00035-1; HALLER O, 1979, J EXP MED, V149, P601, DOI 10.1084/jem.149.3.601; Hata N, 2001, BIOCHEM BIOPH RES CO, V285, P518, DOI 10.1006/bbrc.2001.5159; Hida S, 2000, IMMUNITY, V13, P643, DOI 10.1016/S1074-7613(00)00064-9; Jnaoui K, 1998, VIROLOGY, V244, P397, DOI 10.1006/viro.1998.9134; KELLEY KA, 1985, NUCLEIC ACIDS RES, V13, P805, DOI 10.1093/nar/13.3.805; KHAN NUD, 1990, IMMUNOLOGY, V71, P230; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUGA T, 1989, NUCLEIC ACIDS RES, V17, P3291, DOI 10.1093/nar/17.8.3291; Lee CK, 1999, J EXP MED, V190, P1451, DOI 10.1084/jem.190.10.1451; LEROSCOUET D, 1985, MOL CELL BIOL, V5, P1343, DOI 10.1128/MCB.5.6.1343; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; Meager A, 2002, J IMMUNOL METHODS, V261, P21, DOI 10.1016/S0022-1759(01)00570-1; Michiels T, 1997, J VIROL, V71, P9549, DOI 10.1128/JVI.71.12.9549-9556.1997; Mighell AJ, 2000, FEBS LETT, V468, P109, DOI 10.1016/S0014-5793(00)01199-6; Mitani Y, 2001, GENES CELLS, V6, P631, DOI 10.1046/j.1365-2443.2001.00448.x; Montoya M, 2002, BLOOD, V99, P3263, DOI 10.1182/blood.V99.9.3263; Morin P, 2002, J MOL BIOL, V316, P1009, DOI 10.1006/jmbi.2001.5401; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; NAVARRO S, 1989, J GEN VIROL, V70, P1381, DOI 10.1099/0022-1317-70-6-1381; NICKOLAUS P, 1994, J VIROL, V68, P6763, DOI 10.1128/JVI.68.10.6763-6766.1994; Radhakrishnan R, 1996, STRUCTURE, V4, P1453, DOI 10.1016/S0969-2126(96)00152-9; RESNITZKY D, 1986, CELL, V46, P31, DOI 10.1016/0092-8674(86)90857-3; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; SEIF I, 1986, GENE, V43, P111, DOI 10.1016/0378-1119(86)90014-4; Servant MJ, 2002, J INTERF CYTOK RES, V22, P49, DOI 10.1089/107999002753452656; SHAW GD, 1983, NUCLEIC ACIDS RES, V11, P555, DOI 10.1093/nar/11.3.555; Shaw-Jackson C, 1999, J VIROL, V73, P2729, DOI 10.1128/JVI.73.4.2729-2738.1999; Takaoka A, 2000, SCIENCE, V288, P2357, DOI 10.1126/science.288.5475.2357; Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a; Taniguchi T, 2001, NAT REV MOL CELL BIO, V2, P378, DOI 10.1038/35073080; TOVEY MG, 1987, P NATL ACAD SCI USA, V84, P5038, DOI 10.1073/pnas.84.14.5038; TRAPMAN J, 1988, J GEN VIROL, V69, P67, DOI 10.1099/0022-1317-69-1-67; van Pesch V, 2001, J VIROL, V75, P7811, DOI 10.1128/JVI.75.17.7811-7817.2001; VANHEUVEL M, 1986, J GEN VIROL, V67, P2215, DOI 10.1099/0022-1317-67-10-2215; ZAWATZKY R, 1991, J VIROL, V65, P4839, DOI 10.1128/JVI.65.9.4839-4846.1991; ZWARTHOFF EC, 1985, NUCLEIC ACIDS RES, V13, P791, DOI 10.1093/nar/13.3.791	56	37	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46321	46328		10.1074/jbc.M302554200	http://dx.doi.org/10.1074/jbc.M302554200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12930842	hybrid			2022-12-25	WOS:000186569400015
J	Evans, HR; Sutton, JM; Holloway, DE; Ayriss, J; Shone, CC; Acharya, KR				Evans, HR; Sutton, JM; Holloway, DE; Ayriss, J; Shone, CC; Acharya, KR			The crystal structure of C3stau2 from Staphylococcus aureus and its complex with NAD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATING EXOENZYME; RHO GENE-PRODUCT; CLOSTRIDIUM-BOTULINUM; EXFOLIATIVE TOXIN; C3 EXOENZYME; RIBOSYLTRANSFERASE; PROTEIN; IDENTIFICATION; PURIFICATION; EXPRESSION	The C3stau2 exoenzyme from Staphylococcus aureus is a C3-like ADP-ribosyltransferase that ADP-ribosylates not only RhoA-C but also RhoE/Rnd3. In this study we have crystallized and determined the structure of C3stau2 in both its native form and in complex with NAD at 1.68- and 2.02-Angstrom resolutions, respectively. The topology of C3stau2 is similar to that of C3bot1 from Clostridium botulinum (with which it shares 35% amino acid sequence identity) with the addition of two extra helices after strand beta1. The native structure also features a novel orientation of the catalytic ARTT loop, which approximates the conformation seen for the "NAD bound" form of C3bot1. C3stau2 orients NAD similarly to C3bot1, and on binding NAD, C3stau2 undergoes a clasping motion and a rearrangement of the phosphate-nicotinamide binding loop, enclosing the NAD in the binding site. Comparison of these structures with those of C3bot1 and related toxins reveals a degree of divergence in the interactions with the adenine moiety among the ADP-ribosylating toxins that contrasts with the more conserved interactions with the nicotinamide. Comparison with C3bot1 gives some insight into the different protein substrate specificities of these enzymes.	Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England; Hlth Protect Agcy, Ctr Appl Microbiol & Res, Salisbury SP4 0JG, Wilts, England	University of Bath; Health Protection Agency	Acharya, KR (corresponding author), Univ Bath, Dept Biol & Biochem, Claverton Down, Bath BA2 7AY, Avon, England.	K.R.Acharya@bath.ac.uk	Holloway, Daniel E/S-4944-2016	Holloway, Daniel E/0000-0003-0155-6978; Sutton, J. Mark/0000-0002-2288-0446; Acharya, K. Ravi/0000-0002-3009-4058				Aepfelbacher M, 1997, ARTERIOSCL THROM VAS, V17, P1623, DOI 10.1161/01.ATV.17.9.1623; AKTORIES K, 1988, EUR J BIOCHEM, V172, P445, DOI 10.1111/j.1432-1033.1988.tb13908.x; AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; Czech A, 2001, J INFECT DIS, V184, P785, DOI 10.1086/322983; Dolan KM, 2000, BIOCHEMISTRY-US, V39, P8266, DOI 10.1021/bi992856q; Foster R, 1996, MOL CELL BIOL, V16, P2689; Guasch RM, 1998, MOL CELL BIOL, V18, P4761, DOI 10.1128/MCB.18.8.4761; Han S, 1999, NAT STRUCT BIOL, V6, P932, DOI 10.1038/13300; Han SI, 2001, J MOL BIOL, V305, P95, DOI 10.1006/jmbi.2000.4292; INOUE S, 1991, BIOCHEM BIOPH RES CO, V174, P459, DOI 10.1016/0006-291X(91)91438-I; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JUST I, 1995, BIOCHEMISTRY-US, V34, P334, DOI 10.1021/bi00001a041; JUST I, 1992, J BIOL CHEM, V267, P10274; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; Menetrey J, 2002, J BIOL CHEM, V277, P30950, DOI 10.1074/jbc.M201844200; Nagahama M, 2000, J BACTERIOL, V182, P2096, DOI 10.1128/JB.182.8.2096-2103.2000; NEMOTO Y, 1991, J BIOL CHEM, V266, P19312; Nobes CD, 1998, J CELL BIOL, V141, P187, DOI 10.1083/jcb.141.1.187; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; POPOFF MR, 1991, INFECT IMMUN, V59, P3673, DOI 10.1128/IAI.59.10.3673-3679.1991; RIDLEY AJ, 2001, GTPASES, P89; Sakurai J, 2003, ADV ENZYME REGUL, V43, P361, DOI 10.1016/S0065-2571(02)00044-4; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SHELDRICK GM, 1995, ACTA CRYSTALLOGR B, V51, P423, DOI 10.1107/S0108768195003661; Tsuge H, 2003, J MOL BIOL, V325, P471, DOI 10.1016/S0022-2836(02)01247-0; Wilde C, 2003, BIOCHEMISTRY-US, V42, P9694, DOI 10.1021/bi034583b; Wilde C, 2002, J BIOL CHEM, V277, P14771, DOI 10.1074/jbc.M201072200; Wilde C, 2002, BIOCHEMISTRY-US, V41, P1539, DOI 10.1021/bi015809i; Wilde C, 2001, J BIOL CHEM, V276, P9537, DOI 10.1074/jbc.M011035200; Yamada Y, 2001, ARCH DIS CHILD-FETAL, V84, pF38, DOI 10.1136/fn.84.1.F38; Yamaguchi T, 2002, INFECT IMMUN, V70, P5835, DOI 10.1128/IAI.70.10.5835-5845.2002; Yamaguchi T, 2001, INFECT IMMUN, V69, P7760, DOI 10.1128/IAI.69.12.7760-7771.2001	40	34	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45924	45930		10.1074/jbc.M307719200	http://dx.doi.org/10.1074/jbc.M307719200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12933793	hybrid			2022-12-25	WOS:000186452300105
J	Anderson, PJ; Nesset, A; Bock, PE				Anderson, PJ; Nesset, A; Bock, PE			Effects of activation peptide bond cleavage and fragment 2 interactions on the pathway of exosite I expression during activation of human prethrombin 1 to thrombin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAY CRYSTAL-STRUCTURE; HUMAN-FACTOR-V; BLOOD-COAGULATION PROTEINASES; ANION-BINDING EXOSITE; BOVINE ALPHA-THROMBIN; PROTHROMBIN ACTIVATION; CHLOROMETHYL KETONES; PROEXOSITE-I; FACTOR-XA; FLUORESCENCE PROBES	Activation of prothrombin (Pro) by factor Xa to form thrombin occurs by proteolysis of Arg(271)-Thr(272) and Arg(320)-Ile(321), resulting in expression of regulatory exosites I and II. Cleavage of Pro by thrombin liberates fragment 1 and generates the zymogen analog, prethrombin 1 (Pre 1). The properties of exosite I on Pre 1 and its factor Xa activation intermediates were characterized in spectroscopic and equilibrium binding studies using the fluorescein-labeled probe, hirudin(54-65) ([5F]Hir(54-65)-(SO3-)). Prethrombin 2 (Pre 2), formed by factor Xa cleavage of Pre 1 at Arg(271)-Thr(272), had the same affinity for hirudin(54-65) peptides as Pre 1 in the absence or presence of near-saturating fragment 2 (F2). Pre 2 and thrombin also had indistinguishable affinities for F2. By contrast, cleavage of Pre 1 at Arg(320)-Ile(321), to form active meizothrombin des-fragment 1 MzT(-F1), showed a 11- to 20-fold increase in affinity for hirudin(54-65), indistinguishable from the 13- to 20-fold increase seen for conversion of Pre 2 to thrombin. Thus, factor Xa cleavage of Pre 1 at Arg(271)-Thr(272) does not effect exosite I expression, whereas cleavage at Arg(320)-Ile(321) results in concomitant activation of the catalytic site and exosite I. Furthermore, expression of exosite I on the Pre 1 activation intermediates is not modulated by F2, and exosite II is not activated conformationally. The differential expression of exosite I affinity on the Pre 1 activation intermediates and the previously demonstrated role of (pro) exosite I in factor Va-dependent substrate recognition suggest that changes in exosite I expression may regulate the rate and direction of the Pre 1 activation pathway.	Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37235 USA	Vanderbilt University	Bock, PE (corresponding author), Vanderbilt Univ, Sch Med, Dept Pathol, C3321A Med Ctr N, Nashville, TN 37235 USA.	paul.bock@vanderbilt.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL038779, R01HL038779] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007186] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL38779] Funding Source: Medline; NIDDK NIH HHS [DK-07186] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson PJ, 2000, J BIOL CHEM, V275, P16428, DOI 10.1074/jbc.M001254200; Anderson PJ, 2003, J BIOL CHEM, V278, P44489, DOI 10.1074/jbc.M306916200; Anderson PJ, 2000, J BIOL CHEM, V275, P16435, DOI 10.1074/jbc.M001255200; ARNI RK, 1993, BIOCHEMISTRY-US, V32, P4727, DOI 10.1021/bi00069a006; Ayala YM, 2001, PROTEINS, V45, P107, DOI 10.1002/prot.1130; BERGMAN DA, 1988, ANAL BIOCHEM, V153, P380; Bjork I, 1997, ADV EXP MED BIOL, V425, P17; Bock PE, 1997, J BIOL CHEM, V272, P19837, DOI 10.1074/jbc.272.32.19837; BOCK PE, 1992, J BIOL CHEM, V267, P14963; BOCK PE, 1988, BIOCHEMISTRY-US, V27, P6633, DOI 10.1021/bi00417a063; BOCK PE, 1992, J BIOL CHEM, V267, P14974; BOCK PE, 1989, ARCH BIOCHEM BIOPHYS, V273, P375, DOI 10.1016/0003-9861(89)90496-7; BODE W, 1992, PROTEIN SCI, V1, P426; Boxrud PD, 1996, J PROTEIN CHEM, V15, P231, DOI 10.1007/BF01887403; Butenas S, 2002, BIOCHEMISTRY-MOSCOW+, V67, P3; CARLISLE TL, 1990, J BIOL CHEM, V265, P22044; Chen L, 2003, J BIOL CHEM, V278, P27564, DOI 10.1074/jbc.M302707200; COLMAN RW, 2001, HEMOSTASIS THROMBOSI, P17; Cote HCF, 1997, J BIOL CHEM, V272, P6194, DOI 10.1074/jbc.272.10.6194; DEGEN SJF, 1987, BIOCHEMISTRY-US, V26, P6165, DOI 10.1021/bi00393a033; Dharmawardana KR, 1999, J BIOL CHEM, V274, P18635, DOI 10.1074/jbc.274.26.18635; Dharmawardana KR, 1998, BIOCHEMISTRY-US, V37, P13143, DOI 10.1021/bi9812165; DiCera E, 1997, CELL MOL LIFE SCI, V53, P701, DOI 10.1007/s000180050091; DOYLE MF, 1990, J BIOL CHEM, V265, P10693; Esmon CT, 1996, J BIOL CHEM, V271, P13882, DOI 10.1074/jbc.271.23.13882; FENTON JW, 1977, J BIOL CHEM, V252, P3587; Fuentes-Prior P, 2000, NATURE, V404, P518, DOI 10.1038/35006683; Han JH, 1997, J BIOL CHEM, V272, P28660, DOI 10.1074/jbc.272.45.28660; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; JENNY NS, 2001, HEMOSTASIS THROMBOSI, P171; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; LINDAHL P, 1991, BIOCHEM J, V276, P387, DOI 10.1042/bj2760387; LIU LW, 1994, J BIOL CHEM, V269, P11807; LIU LW, 1991, J BIOL CHEM, V266, P23632; Malkowski MG, 1997, PROTEIN SCI, V6, P1438, DOI 10.1002/pro.5560060708; MANN KG, 1981, METHOD ENZYMOL, V80, P286; MANN KG, 1990, BLOOD, V76, P1; Martin PD, 1997, STRUCTURE, V5, P1681, DOI 10.1016/S0969-2126(97)00314-6; MATHEWS II, 1994, BIOCHEMISTRY-US, V33, P3266, DOI 10.1021/bi00177a018; Monteiro RQ, 2001, PROTEIN SCI, V10, P1897, DOI 10.1110/ps.09001; Monteiro RQ, 2002, THROMB HAEMOSTASIS, V87, P288; Myles T, 2001, J BIOL CHEM, V276, P25143, DOI 10.1074/jbc.M011324200; NASKI MC, 1990, J BIOL CHEM, V265, P13484; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; OLSON ST, 1991, ARCH BIOCHEM BIOPHYS, V286, P533, DOI 10.1016/0003-9861(91)90076-U; Rose T, 2002, J BIOL CHEM, V277, P18875, DOI 10.1074/jbc.M110977200; ROSING J, 1986, J BIOL CHEM, V261, P4224; ROSING J, 1980, J BIOL CHEM, V255, P274; SHEEHAN JP, 1994, P NATL ACAD SCI USA, V91, P5518, DOI 10.1073/pnas.91.12.5518; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; TANS G, 1994, J BIOL CHEM, V269, P15969; TANS G, 1991, J BIOL CHEM, V266, P21864; TSIANG M, 1995, J BIOL CHEM, V270, P16854, DOI 10.1074/jbc.270.28.16854; Verhamme IM, 2002, J BIOL CHEM, V277, P6788, DOI 10.1074/jbc.M110257200; VIJAYALAKSHMI J, 1994, PROTEIN SCI, V3, P2254, DOI 10.1002/pro.5560031211; WANG DC, 1985, J MOL BIOL, V185, P595, DOI 10.1016/0022-2836(85)90074-9; WINZOR DJ, 1995, QUANTITATIVE CHARACT, P62; WU QY, 1994, J BIOL CHEM, V269, P3725; YE J, 1992, J BIOL CHEM, V267, P11023	59	20	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44482	44488		10.1074/jbc.M306917200	http://dx.doi.org/10.1074/jbc.M306917200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12939269	hybrid			2022-12-25	WOS:000186306700076
J	Lee, KA; Fuda, H; Lee, YC; Negishi, M; Strott, CA; Pedersen, LC				Lee, KA; Fuda, H; Lee, YC; Negishi, M; Strott, CA; Pedersen, LC			Crystal structure of human cholesterol sulfotransferase (SULT2B1b) in the presence of pregnenolone and 3 '-phosphoadenosine 5 '-phosphate - Rationale for specificity differences between prototypical SULT2A1 and the SULT2B1 isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN HYDROXYSTEROID SULFOTRANSFERASE; ESTROGEN SULFOTRANSFERASE; MUTATIONAL ANALYSIS; NEUROSTEROIDS; SULFATE; COMPLEX; GENE; KERATINOCYTES; DIFFERENTIATION; TRANSCRIPTION	The gene for human hydroxysteroid sulfotransferase (SULT2B1) encodes two peptides, SULT2B1a and SULT2B1b, that differ only at their amino termini. SULT2B1b has a predilection for cholesterol but is also capable of sulfonating pregnenolone, whereas SULT2B1a preferentially sulfonates pregnenolone and only minimally sulfonates cholesterol. We have determined the crystal structure of SULT2B1a and SULT2B1b bound to the substrate donor product 3'-phosphoadenosine 5'-phosphate at 2.9 and 2.4 Angstrom, respectively, as well as SULT2B1b in the presence of the acceptor substrate pregnenolone at 2.3 Angstrom. These structures reveal a different catalytic binding orientation for the substrate from a previously determined structure of hydroxysteroid sulfotransferase (SULT2A1) binding dehydroepiandrosterone. In addition, the amino-terminal helix comprising residues Asp(19) to Lys(26), which determines the specificity difference between the SULT2B1 isoforms, becomes ordered upon pregnenolone binding, covering the substrate binding pocket.	NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Pharmacogenet Sect, Reprod & Dev Toxicol Lab, NIH, Res Triangle Pk, NC 27709 USA; NICHD, Sect Steroid Regulat, Endocrinol & Reprod Res Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Pedersen, LC (corresponding author), NIEHS, Struct Biol Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.		Negishi, Masahiko/F-7805-2019; Pedersen, Lars/C-6173-2019	Negishi, Masahiko/0000-0002-2076-8928; Pedersen, Lars/0000-0002-4488-4077	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000194] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES080040, Z01ES071005, ZIAES080040] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alomary AA, 2001, INT REV NEUROBIOL, V46, P97; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baulieu EE, 2001, INT REV NEUROBIOL, V46, P1; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; Coughtrie MWH, 1998, CHEM-BIOL INTERACT, V109, P3, DOI 10.1016/S0009-2797(97)00117-8; Engel SR, 2001, INT REV NEUROBIOL, V46, P321; Falany CN, 1997, FASEB J, V11, P206, DOI 10.1096/fasebj.11.4.9068609; Fuda H, 2002, J BIOL CHEM, V277, P36161, DOI 10.1074/jbc.M207165200; Geese WJ, 2001, BIOCHEM BIOPH RES CO, V288, P280, DOI 10.1006/bbrc.2001.5746; Hanley K, 2001, J LIPID RES, V42, P390; Her C, 1998, GENOMICS, V53, P284, DOI 10.1006/geno.1998.5518; JETTEN AM, 1989, J INVEST DERMATOL, V92, P203, DOI 10.1111/1523-1747.ep12276731; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kakuta Y, 1998, TRENDS BIOCHEM SCI, V23, P129, DOI 10.1016/S0968-0004(98)01182-7; Kakuta Y, 1997, NAT STRUCT BIOL, V4, P904, DOI 10.1038/nsb1197-904; Kakuta Y, 1998, J BIOL CHEM, V273, P27325, DOI 10.1074/jbc.273.42.27325; Kallen JA, 2002, STRUCTURE, V10, P1697, DOI 10.1016/S0969-2126(02)00912-7; Kawabe S, 1998, J INVEST DERMATOL, V111, P1098, DOI 10.1046/j.1523-1747.1998.00441.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuroki T, 2000, MUTAT RES-REV MUTAT, V462, P189, DOI 10.1016/S1383-5742(00)00036-3; Lascombe MB, 2002, ACTA CRYSTALLOGR D, V58, P1442, DOI 10.1107/S0907444902011745; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Mellon SH, 2001, INT REV NEUROBIOL, V46, P33; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pedersen LC, 2000, FEBS LETT, V475, P61, DOI 10.1016/S0014-5793(00)01479-4; Pedersen LC, 2002, J BIOL CHEM, V277, P17928, DOI 10.1074/jbc.M111651200; Plassart-Schiess E, 2001, BRAIN RES REV, V37, P133, DOI 10.1016/S0165-0173(01)00113-8; Rehse PH, 2002, BIOCHEM J, V364, P165, DOI 10.1042/bj3640165; Shimizu C, 2003, ENDOCRINOLOGY, V144, P1186, DOI 10.1210/en.2002-221011; Strott CA, 2002, ENDOCR REV, V23, P703, DOI 10.1210/er.2001-0040	32	52	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44593	44599		10.1074/jbc.M308312200	http://dx.doi.org/10.1074/jbc.M308312200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12923182	hybrid			2022-12-25	WOS:000186306700089
J	Linke, K; Wolfram, T; Bussemer, J; Jakob, U				Linke, K; Wolfram, T; Bussemer, J; Jakob, U			The roles of the two zinc binding sites in DnaJ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HSP70 MOLECULAR CHAPERONE; FINGER-LIKE DOMAIN; ATP HYDROLYSIS; CO-CHAPERONE; IN-VIVO; HSP40; MECHANISM; PROTEINS; GRPE; CONSERVATION	All type I DnaJ (Hsp40) homologues share the presence of two highly conserved zinc centers. To elucidate their function, we constructed DnaJ mutants that separately replaced cysteines of either zinc center I or zinc center II with serine residues. We found that in the absence of zinc center I, the autonomous, DnaK-independent chaperone activity of DnaJ is dramatically reduced. Surprisingly, this only slightly impaired the in vivo function of DnaJ, and its ability to function as a co-chaperone in the DnaK/DnaJ/GrpE foldase machine. The DnaJ zinc center II, on the other hand, was found to be absolutely essential for the in vivo and in vitro function of DnaJ. This did not seem to be caused by a lack of substrate binding affinity or an inability to work as an ATPase-stimulating factor. Rather it appears that zinc center II mutant proteins lack a necessary additional interaction site with DnaK, which seems to be crucial for locking-in substrate proteins onto DnaK. These findings led us to a model in which ATP hydrolysis in DnaK is only the first step in converting DnaK into its high affinity binding state. Additional interactions between DnaK and DnaJ are required to make the DnaK/DnaJ/GrpE foldase machinery catalytically active.	Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Jakob, U (corresponding author), Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA.	ujakob@umich.edu			NIGMS NIH HHS [GM065318] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065318] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Banecki B, 1996, J BIOL CHEM, V271, P14840, DOI 10.1074/jbc.271.25.14840; BARDWELL JCA, 1986, J BIOL CHEM, V261, P1782; BUCHBERGER A, 1994, NAT STRUCT BIOL, V1, P95, DOI 10.1038/nsb0294-95; Cheetham ME, 1998, CELL STRESS CHAPERON, V3, P28, DOI 10.1379/1466-1268(1998)003<0028:SFAEOD>2.3.CO;2; Fenn TD, 2003, J APPL CRYSTALLOGR, V36, P944, DOI 10.1107/S0021889803006721; Frydman J, 2001, ANNU REV BIOCHEM, V70, P603, DOI 10.1146/annurev.biochem.70.1.603; Genevaux P, 2002, GENETICS, V162, P1045; Goffin L, 1998, MOL MICROBIOL, V30, P329, DOI 10.1046/j.1365-2958.1998.01067.x; Greene MK, 1998, P NATL ACAD SCI USA, V95, P6108, DOI 10.1073/pnas.95.11.6108; Han WJ, 2003, J BIOL CHEM, V278, P19038, DOI 10.1074/jbc.M300756200; Hennessy F, 2000, CELL STRESS CHAPERON, V5, P347, DOI 10.1379/1466-1268(2000)005<0347:AOTLOC>2.0.CO;2; Herbst R, 1997, J BIOL CHEM, V272, P7099, DOI 10.1074/jbc.272.11.7099; HUNT JB, 1985, ANAL BIOCHEM, V146, P150, DOI 10.1016/0003-2697(85)90409-9; Jakob U, 2000, J BIOL CHEM, V275, P38302, DOI 10.1074/jbc.M005957200; Johnson JL, 2001, J CELL BIOL, V152, P851, DOI 10.1083/jcb.152.4.851; Karzai AW, 1996, J BIOL CHEM, V271, P11236, DOI 10.1074/jbc.271.19.11236; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; Lu Z, 1998, J BIOL CHEM, V273, P5970, DOI 10.1074/jbc.273.10.5970; Lu Z, 1998, J BIOL CHEM, V273, P27824, DOI 10.1074/jbc.273.43.27824; Martinez-Yamout M, 2000, J MOL BIOL, V300, P805, DOI 10.1006/jmbi.2000.3923; Mayer MP, 2000, NAT STRUCT BIOL, V7, P586; Mayer MP, 2002, ADV PROTEIN CHEM, V59, P1; Mayer MP, 1999, J MOL BIOL, V289, P1131, DOI 10.1006/jmbi.1999.2844; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Qian YQ, 1996, J MOL BIOL, V260, P224, DOI 10.1006/jmbi.1996.0394; Rudiger S, 2001, EMBO J, V20, P1042, DOI 10.1093/emboj/20.5.1042; Russell R, 1999, BIOCHEMISTRY-US, V38, P4165, DOI 10.1021/bi9824036; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SELL SM, 1990, J BACTERIOL, V172, P4827, DOI 10.1128/jb.172.9.4827-4835.1990; Sha BD, 2000, STRUCTURE, V8, P799, DOI 10.1016/S0969-2126(00)00170-2; SHI WY, 1992, J BACTERIOL, V174, P6256, DOI 10.1128/JB.174.19.6256-6263.1992; Suh WC, 1999, J BIOL CHEM, V274, P30534, DOI 10.1074/jbc.274.43.30534; Suh WC, 1998, P NATL ACAD SCI USA, V95, P15223, DOI 10.1073/pnas.95.26.15223; Szabo A, 1996, EMBO J, V15, P408, DOI 10.1002/j.1460-2075.1996.tb00371.x; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; Tang W, 2001, BIOCHEMISTRY-US, V40, P14985, DOI 10.1021/bi0107593; WALL D, 1994, J BIOL CHEM, V269, P5446; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x	40	85	89	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44457	44466		10.1074/jbc.M307491200	http://dx.doi.org/10.1074/jbc.M307491200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12941935	hybrid			2022-12-25	WOS:000186306700073
J	Luppen, CA; Leclerc, N; Noh, T; Barski, A; Khokhar, A; Boskey, AL; Smith, E; Frenkel, B				Luppen, CA; Leclerc, N; Noh, T; Barski, A; Khokhar, A; Boskey, AL; Smith, E; Frenkel, B			Brief bone morphogenetic protein 2 treatment of glucocorticoid-inhibited MC3T3-E1 osteoblasts rescues commitment-associated cell cycle and mineralization without alteration of Runx2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; DIFFERENTIATION; EXPRESSION; DEXAMETHASONE; GROWTH; CORTISOL; INDUCTION; RAT; CORTICOSTEROIDS; PROLIFERATION	Glucocorticoids (GCs) inhibit bone formation in vivo. In MC3T3-E1 osteoblasts, chronic administration of 1 muM dexamethasone (DEX) starting at confluency results in > 98% inhibition of bone morphogenetic protein 2 (BMP-2) expression and apatite mineral deposition. Here, it is shown that brief exposure to recombinant human BMP-2 (rhBMP-2), as short as 6 h, is sufficient to induce irreversible commitment to mineralization in DEX-treated cultures. RhBMP-2 dose dependently rescued mineralization but not collagen accumulation in DEX-inhibited cultures. The selective restoration of mineralization was evident in the higher mineral to matrix ratios of DEX/rhBMP-2 co-treated cultures compared with control. We tested the involvement of the runt-related transcription factor 2 (Runx2) in the DEX inhibition and rhBMP-2 rescue of mineralization. Surprisingly, DEX did not decrease Runx2 DNA binding activity, transactivation, or association with the endogenous osteocalcin gene promoter. Furthermore, the rhBMP-2 rescue did not involve Runx2 stimulation, suggesting an important role for factors other than Runx2 in BMP-2 action. Finally, we studied the differentiation-related cell cycle, which persists during commitment to mineralization in untreated cultures, but is inhibited along with mineralization in DEX-treated cultures. Although both rhBMP-2 alone and DEX alone were antimitogenic, rhBMP-2 stimulated this cell cycle in DEX-inhibited cultures. In conclusion, brief rhBMP-2 treatment restores mineralization in DEX-inhibited MC3T3-E1 osteoblasts via a mechanism different from Runx2 stimulation. This restoration may be functionally related to the accompanying rescue of the differentiation-related cell cycle. The efficacy of short term BMP-2 treatment supports the potential of short-lived BMP vectors for skeletal therapy in both traditional and gene therapeutic approaches.	Univ So Calif, Keck Sch Med, Inst Med Genet, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Inst Med Genet, Dept Orthopaed Surg, Los Angeles, CA 90033 USA; Hosp Special Surg, Mineralized Tissues Res Lab, New York, NY 10021 USA	University of Southern California; University of Southern California	Frenkel, B (corresponding author), Univ So Calif, Keck Sch Med, Inst Med Genet, Dept Biochem & Mol Biol, 2250 Alcazar St,CSC-IGM240, Los Angeles, CA 90033 USA.	frenkel@usc.edu		Barski, Artem/0000-0002-1861-5316; Boskey, Adele/0000-0002-6181-2219	NIAMS NIH HHS [AR037661, AR47052] Funding Source: Medline; NIDCR NIH HHS [DE04141, DE07211] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047052, R01AR037661] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE004141, R01DE004141] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Boskey AL, 2002, CALCIFIED TISSUE INT, V71, P145, DOI 10.1007/s00223-001-1121-z; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Canalis E, 2002, ANN NY ACAD SCI, V966, P73, DOI 10.1111/j.1749-6632.2002.tb04204.x; Chang DJ, 1998, J BIOL CHEM, V273, P4892, DOI 10.1074/jbc.273.9.4892; CHEN TL, 1983, ENDOCRINOLOGY, V112, P1739, DOI 10.1210/endo-112-5-1739; Chevalley T, 1996, EUR J ENDOCRINOL, V134, P591, DOI 10.1530/eje.0.1340591; Cooper MS, 1999, J ENDOCRINOL, V163, P159, DOI 10.1677/joe.0.1630159; DELANY AM, 1995, J CELL BIOCHEM, V57, P488, DOI 10.1002/jcb.240570314; DELANY AM, 1995, J BIOL CHEM, V270, P26607, DOI 10.1074/jbc.270.44.26607; DUCY P, 1995, MOL CELL BIOL, V15, P1858; GITELMAN SE, 1994, J CELL BIOL, V126, P1595, DOI 10.1083/jcb.126.6.1595; Gori F, 1999, J BONE MINER RES, V14, P1522, DOI 10.1359/jbmr.1999.14.9.1522; Ishida Y, 1998, J BONE MINER RES, V13, P1822, DOI 10.1359/jbmr.1998.13.12.1822; KAMALIA N, 1992, BLOOD, V79, P320; Kato Y, 2001, J BONE MINER RES, V16, P1622, DOI 10.1359/jbmr.2001.16.9.1622; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; KOSTENSZKY KS, 1974, ACTA BIOL ACAD SCI H, V25, P49; LEBOY PS, 1991, J CELL PHYSIOL, V146, P370, DOI 10.1002/jcp.1041460306; Lecanda F, 1997, J CELL BIOCHEM, V67, P386, DOI 10.1002/(SICI)1097-4644(19971201)67:3<386::AID-JCB10>3.3.CO;2-5; Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783-8792.2000; Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200; Lian JB, 1997, ENDOCRINOLOGY, V138, P2117, DOI 10.1210/en.138.5.2117; Linkhart TA, 1996, BONE, V19, pS1, DOI 10.1016/S8756-3282(96)00138-X; LUKERT B, 1997, OSTEOPOROSIS, P801; Luppen CA, 2003, J BONE MINER RES, V18, P1186, DOI 10.1359/jbmr.2003.18.7.1186; Luppen CA, 2002, J BONE MINER RES, V17, P301, DOI 10.1359/jbmr.2002.17.2.301; Pereira RC, 2002, BONE, V30, P685, DOI 10.1016/S8756-3282(02)00687-7; Pereira RMR, 2001, BONE, V28, P484, DOI 10.1016/S8756-3282(01)00422-7; Prince M, 2001, J CELL BIOCHEM, V80, P424, DOI 10.1002/1097-4644(20010301)80:3<424::AID-JCB160>3.0.CO;2-6; RICKARD DJ, 1994, DEV BIOL, V161, P218, DOI 10.1006/dbio.1994.1022; SAMPATH TK, 1992, J BIOL CHEM, V267, P20352; Shah OJ, 2000, AM J PHYSIOL-ENDOC M, V279, pE74, DOI 10.1152/ajpendo.2000.279.1.E74; SHALHOUB V, 1992, J CELL BIOCHEM, V50, P425, DOI 10.1002/jcb.240500411; Smith E, 2000, J BIOL CHEM, V275, P19992, DOI 10.1074/jbc.M001758200; Smith E, 2002, J BIOL CHEM, V277, P18191, DOI 10.1074/jbc.M109708200; TENENBAUM HC, 1985, ENDOCRINOLOGY, V117, P2211, DOI 10.1210/endo-117-5-2211; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; Van Staa TP, 2000, J BONE MINER RES, V15, P993, DOI 10.1359/jbmr.2000.15.6.993; WANG EA, 1988, P NATL ACAD SCI USA, V85, P9484, DOI 10.1073/pnas.85.24.9484; Waters RV, 2000, ACTA ORTHOP SCAND, V71, P316, DOI 10.1080/000164700317411951; Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241	42	50	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44995	45003		10.1074/jbc.M306730200	http://dx.doi.org/10.1074/jbc.M306730200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12933820	hybrid			2022-12-25	WOS:000186306700136
J	Ma, CL; Wang, J; Luo, J				Ma, CL; Wang, J; Luo, J			Exposure to asphalt fumes activates activator protein-1 through the phosphatidylinositol 3-kinase/Akt signaling pathway in mouse epidermal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3-BETA; NF-KAPPA-B; JB6 CELLS; NEOPLASTIC TRANSFORMATION; AP-1 TRANSACTIVATION; SKIN TUMORIGENESIS; TUMOR PROMOTION; BITUMEN FUMES; IN-VITRO; KINASE-B	Occupational exposure to asphalt fumes may pose a health risk. Experimental studies using animal and in vitro models indicate that condensates from asphalt fumes are genotoxic and can promote skin tumorigenesis. Enhanced activity of activator protein-1 (AP-1) is frequently associated with the promotion of skin tumorigenesis. The current study investigated the effect of exposure to asphalt fumes on AP-1 activation in mouse JB6 P+ epidermal cells and the skin of transgenic mice expressing the AP-1 luciferase reporter gene. Asphalt fumes were generated from a dynamic generation system that simulated road-paving conditions. Exposure to asphalt fumes significantly increased AP-1 activity in JB6 P+ cells as well as in cultured keratinocytes isolated from transgenic mice expressing AP-1 reporter. In addition, topical application of asphalt fumes by painting the tail skin of mice increased AP-1 activity by 14-fold. Exposure to asphalt fumes promoted basal as well as epidermal growth factor-stimulated anchorage-independent growth of JB6 P+ cells in soft agar. It activated phosphatidylinositol 3-kinase and induced phosphorylation of Akt at Ser-473/Thr-308, and concurrently activated downstream p70 S6 kinase as well as glycogen synthase kinase-3beta. Asphalt fumes transiently activated c-Jun NH2-terminal kinases without affecting extracellular signal-regulated kinases and p38 mitogen-activated protein kinases. Further study indicated that blockage of phosphatidylinositol 3-kinase activation eliminated asphalt fume-stimulated AP-1 activation and formation of anchorage-independent colonies in soft agar. This is the first report showing that exposure to asphalt fumes can activate AP-1 and intracellular signaling that may promote skin tumorigenesis, thus providing important evidence on the potential involvement of exposure to asphalt fumes in skin carcinogenesis.	W Virginia Univ, Sch Med, Robert C Byrd Hlth Sci Ctr, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA; Xijing Hosp, Dept Dermatol, Xian 710032, Peoples R China; NIOSH, Ctr Dis Control & Prevent, US Dept Hlth & Human Serv, Morgantown, WV 26505 USA	West Virginia University; Air Force Military Medical University; Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH)	Luo, J (corresponding author), W Virginia Univ, Sch Med, Robert C Byrd Hlth Sci Ctr, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA.		Luo, Jia/E-4674-2012	Luo, Jia/0000-0002-6968-3618	NATIONAL CANCER INSTITUTE [R01CA090385] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R03AA012968] Funding Source: NIH RePORTER; NCI NIH HHS [CA90385] Funding Source: Medline; NIAAA NIH HHS [AA12968] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; *ASPH I, 1989, US ASPH US REP; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; Binet S, 2002, SCI TOTAL ENVIRON, V300, P37, DOI 10.1016/S0048-9697(02)00279-6; Brandt H, 2000, ANN OCCUP HYG, V44, P31, DOI 10.1093/annhyg/44.1.31; Burstyn I, 2000, ANN OCCUP HYG, V44, P43, DOI 10.1093/annhyg/44.1.43; Cohen C, 2002, CLIN CANCER RES, V8, P3728; COLBURN NH, 1979, NATURE, V281, P589, DOI 10.1038/281589a0; COOKE M, 1991, POLYNUCLEAR AROMATIC; Dhar A, 2002, MOL CELL BIOCHEM, V234, P185, DOI 10.1023/A:1015948505117; Dickson LM, 2001, J BIOL CHEM, V276, P21110, DOI 10.1074/jbc.M101257200; DONG ZG, 1995, CARCINOGENESIS, V16, P749, DOI 10.1093/carcin/16.4.749; Dong ZG, 1997, J BIOL CHEM, V272, P9962; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Hakkinen Lari, 2001, Methods in Cell Science, V23, P189, DOI 10.1023/A:1016385109922; HARBERS M, 1992, CARCINOGENESIS, V13, P2403, DOI 10.1093/carcin/13.12.2403; Harvey R. G., 1991, POLYCYCLIC AROMATIC; Hodivala-Dilke Kairbaan, 2002, Methods Mol Biol, V188, P139; Hsu TC, 2000, FREE RADICAL BIO MED, V28, P1338, DOI 10.1016/S0891-5849(00)00220-3; Huang CS, 1997, P NATL ACAD SCI USA, V94, P5826, DOI 10.1073/pnas.94.11.5826; Huang CS, 1996, MOL CELL BIOL, V16, P6427; Huang CS, 1998, P NATL ACAD SCI USA, V95, P156, DOI 10.1073/pnas.95.1.156; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Leis H, 2002, MOL CARCINOGEN, V35, P180, DOI 10.1002/mc.10087; Li JJ, 1997, CANCER RES, V57, P3569; Lin SG, 2003, INT J ONCOL, V22, P829; Liu GM, 2001, P NATL ACAD SCI USA, V98, P7510, DOI 10.1073/pnas.131195198; Luo J, 1999, J NEUROSCI, V19, P10014, DOI 10.1523/jneurosci.19-22-10014.1999; LUTES CC, 1994, EVALUATION EMISSION; Ma CL, 2003, ONCOGENE, V22, P5281, DOI 10.1038/sj.onc.1206675; MACHADO ML, 1993, FUND APPL TOXICOL, V21, P492, DOI 10.1006/faat.1993.1125; Martinez A, 2002, J MED CHEM, V45, P1292, DOI 10.1021/jm011020u; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; RINCON M, 1994, EMBO J, V13, P4370, DOI 10.1002/j.1460-2075.1994.tb06757.x; Segrelles C, 2002, ONCOGENE, V21, P53, DOI 10.1038/sj.onc.1205032; Sivak A, 1997, CANCER LETT, V117, P113, DOI 10.1016/S0304-3835(97)00214-0; Sun YB, 2002, J CELL PHYSIOL, V192, P225, DOI 10.1002/jcp.10132; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Wang J, 2001, ANAL CHEM, V73, P3691, DOI 10.1021/ac010334m; WILDER PJ, 1991, CANCER RES, V51, P5898; Yamada KM, 2001, J CELL SCI, V114, P2375; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; Young MR, 2003, TRENDS MOL MED, V9, P36, DOI 10.1016/S1471-4914(02)00009-6	47	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44265	44272		10.1074/jbc.M309023200	http://dx.doi.org/10.1074/jbc.M309023200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12947100	Green Submitted, hybrid			2022-12-25	WOS:000186306700047
J	McCracken, S; Longman, D; Johnstone, IL; Caceres, JF; Blencowe, BJ				McCracken, S; Longman, D; Johnstone, IL; Caceres, JF; Blencowe, BJ			An evolutionarily conserved role for SRm160 in 3 '-end processing that functions independently of exon junction complex formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPORT; VERTEBRATE POLY(A) POLYMERASE; CAP-BINDING COMPLEX; CAENORHABDITIS-ELEGANS; SPLICING COACTIVATOR; C-ELEGANS; IN-VITRO; CARBOXYL-TERMINUS; INTRONS INFLUENCE; GENE-EXPRESSION	SRm160 (the SR-related nuclear matrix protein of 160 kDa) functions as a splicing coactivator and 3'-end cleavage-stimulatory factor. It is also a component of the splicing-dependent exon-junction complex (EJC), which has been implicated in coupling of pre-mRNA splicing with mRNA turnover and mRNA export. We have investigated whether the association of SRm160 with the EJC is important for efficient 3'-end cleavage. The EJC components RNPS1, REF, UAP56, and Y14 interact with SRm160. However, when these factors were tethered to transcripts, only SRm160 and RNPS1 stimulated 3'-end cleavage. Whereas SRm160 stimulated cleavage to a similar extent in the presence or absence of an active intron, stimulation of 3'-end cleavage by tethered RNPS1 is dependent on an active intron. Assembly of an EJC adjacent to the cleavage and polyadenylation signal in vitro did not significantly affect cleavage efficiency. These results suggest that SRm160 stimulates cleavage independently of its association with EJC components and that the cleavage-stimulatory activity of RNPS1 may be an indirect consequence of its ability to stimulate splicing. Using RNA interference (RNAi) in Caenorhabditis elegans, we determined whether interactions between SRm160 and the cleavage machinery are important in a whole organism context. Simultaneous RNAi of SRm160 and the cleavage factor CstF-50 ( Cleavage stimulation factor 50-kDa subunit) resulted in late embryonic developmental arrest. In contrast, RNAi of CstF-50 in combination with RNPS1 or REFs did not result in an apparent phenotype. Our combined results provide evidence for an evolutionarily conserved interaction between SRm160 and the 3'-end cleavage machinery that functions independently of EJC formation.	Univ Toronto, Charles H Best Inst, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Western Gen Hosp, MRC, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland; Univ Glasgow, Anderson Coll, Wellcome Ctr Mol Parasitol, Glasgow GI1 6NU, Lanark, Scotland	University of Toronto; University of Edinburgh; University of Glasgow	Blencowe, BJ (corresponding author), Univ Toronto, Charles H Best Inst, Banting & Best Dept Med Res, 112 Coll St, Toronto, ON M5G 1L6, Canada.		Caceres, Javier F/D-5260-2013	Caceres, Javier F/0000-0001-8025-6169	Medical Research Council [MC_U127584479] Funding Source: Medline; MRC [MC_U127584479] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Bentley D, 1999, CURR OPIN CELL BIOL, V11, P347, DOI 10.1016/S0955-0674(99)80048-9; Blencowe BJ, 2000, RNA, V6, P111, DOI 10.1017/S1355838200991982; Blencowe BJ, 1998, GENE DEV, V12, P996, DOI 10.1101/gad.12.7.996; Boucher L, 2001, RNA, V7, P1693; De Guzman RN, 1998, BIOPOLYMERS, V48, P181, DOI 10.1002/(SICI)1097-0282(1998)48:2<181::AID-BIP7>3.0.CO;2-L; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; Eldridge AG, 1999, P NATL ACAD SCI USA, V96, P6125, DOI 10.1073/pnas.96.11.6125; Flaherty SM, 1997, P NATL ACAD SCI USA, V94, P11893, DOI 10.1073/pnas.94.22.11893; Fleckner J, 1997, GENE DEV, V11, P1864, DOI 10.1101/gad.11.14.1864; Fong YW, 2001, NATURE, V414, P929, DOI 10.1038/414929a; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; Fribourg S, 2003, NAT STRUCT BIOL, V10, P433, DOI 10.1038/nsb926; Fu GK, 1997, P NATL ACAD SCI USA, V94, P1811, DOI 10.1073/pnas.94.5.1811; Furger A, 2002, GENE DEV, V16, P2792, DOI 10.1101/gad.983602; Gatfield D, 2001, CURR BIOL, V11, P1716, DOI 10.1016/S0960-9822(01)00532-2; Gunderson SI, 1997, GENE DEV, V11, P761, DOI 10.1101/gad.11.6.761; Hirose Y, 2000, GENE DEV, V14, P1415; Hollenbach AD, 2002, J CELL SCI, V115, P3319; IZAURRALDE E, 1994, CELL, V78, P657, DOI 10.1016/0092-8674(94)90530-4; Jensen TH, 2001, CURR BIOL, V11, P1711, DOI 10.1016/S0960-9822(01)00529-2; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kataoka N, 2001, EMBO J, V20, P6424, DOI 10.1093/emboj/20.22.6424; Kim VN, 2001, SCIENCE, V293, P1832, DOI 10.1126/science.1062829; Kim VN, 2001, EMBO J, V20, P2062, DOI 10.1093/emboj/20.8.2062; Kwek KY, 2002, NAT STRUCT BIOL, V9, P800, DOI 10.1038/nsb862; Le Hir H, 2003, TRENDS BIOCHEM SCI, V28, P215, DOI 10.1016/S0968-0004(03)00052-5; Le Hir H, 2000, EMBO J, V19, P6860, DOI 10.1093/emboj/19.24.6860; Le Hir H, 2001, EMBO REP, V2, P1119, DOI 10.1093/embo-reports/kve245; Le Hir H, 2001, EMBO J, V20, P4987, DOI 10.1093/emboj/20.17.4987; Lejeune F, 2002, EMBO J, V21, P3536, DOI 10.1093/emboj/cdf345; Lewis JD, 1996, GENE DEV, V10, P1683, DOI 10.1101/gad.10.13.1683; Longman D, 2000, EMBO J, V19, P1625, DOI 10.1093/emboj/19.7.1625; Longman D, 2003, RNA, V9, P881, DOI 10.1261/rna.5420503; Longman D, 2001, CURR BIOL, V11, P1923, DOI 10.1016/S0960-9822(01)00589-9; Lou H, 1999, MOL CELL BIOL, V19, P78; Lou H, 1998, MOL CELL BIOL, V18, P4977, DOI 10.1128/MCB.18.9.4977; Luo MJ, 2001, NATURE, V413, P644, DOI 10.1038/35098106; Lutz CS, 1996, GENE DEV, V10, P325, DOI 10.1101/gad.10.3.325; Lykke-Andersen J, 2001, SCIENCE, V293, P1836, DOI 10.1126/science.1062786; MacMorris M, 2003, RNA, V9, P847, DOI 10.1261/rna.5480803; Maeda I, 2001, CURR BIOL, V11, P171, DOI 10.1016/S0960-9822(01)00052-5; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; Mayeda A, 1999, EMBO J, V18, P4560, DOI 10.1093/emboj/18.16.4560; McCracken S, 2002, MOL CELL BIOL, V22, P148, DOI 10.1128/MCB.22.1.148-160.2002; McGarvey T, 2000, J CELL BIOL, V150, P309, DOI 10.1083/jcb.150.2.309; NESIC D, 1994, GENE DEV, V8, P363, DOI 10.1101/gad.8.3.363; NIWA M, 1990, GENE DEV, V4, P1552, DOI 10.1101/gad.4.9.1552; NIWA M, 1991, GENE DEV, V5, P2086, DOI 10.1101/gad.5.11.2086; Piano F, 2002, CURR BIOL, V12, P1959, DOI 10.1016/S0960-9822(02)01301-5; Proudfoot N, 2000, TRENDS BIOCHEM SCI, V25, P290, DOI 10.1016/S0968-0004(00)01591-7; Reichert VL, 2002, GENE DEV, V16, P2778, DOI 10.1101/gad.1030602; Rodrigues JP, 2001, P NATL ACAD SCI USA, V98, P1030, DOI 10.1073/pnas.98.3.1030; Ruegsegger U, 1998, MOL CELL, V1, P243, DOI 10.1016/S1097-2765(00)80025-8; Strasser K, 2001, NATURE, V413, P648, DOI 10.1038/35098113; Strasser K, 2000, EMBO J, V19, P410, DOI 10.1093/emboj/19.3.410; Szymczyna BR, 2003, GENE DEV, V17, P461, DOI 10.1101/gad.1060403; Vagner S, 2000, GENE DEV, V14, P403; Virbasius CMA, 1999, MOL CELL, V4, P219, DOI 10.1016/S1097-2765(00)80369-X; Waldmann T, 2002, J BIOL CHEM, V277, P24988, DOI 10.1074/jbc.M204045200; WAN KM, 1994, P NATL ACAD SCI USA, V91, P594, DOI 10.1073/pnas.91.2.594; WASSARMAN KM, 1993, GENE DEV, V7, P647, DOI 10.1101/gad.7.4.647; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2; Zhou ZL, 2000, NATURE, V407, P401, DOI 10.1038/35030160	63	33	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44153	44160		10.1074/jbc.M306856200	http://dx.doi.org/10.1074/jbc.M306856200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12944400	hybrid			2022-12-25	WOS:000186306700034
J	Parra-Palau, JL; Scheper, GC; Wilson, ML; Proud, CG				Parra-Palau, JL; Scheper, GC; Wilson, ML; Proud, CG			Features in the N and C termini of the MAPK-interacting kinase Mnk1 mediate its nucleocytoplasmic shuttling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR 4E; ACTIVATED PROTEIN-KINASE; TRANSLATION INITIATION; MESSENGER-RNA; FACTOR EIF4E; FACTOR 4G; PHOSPHORYLATION; TRANSPORT; TRANSFORMATION; REGULATORS	Eukaryotic initiation factor eIF4E binds to the 5'-cap structure of the mRNA and also to the molecular scaffold protein eIF4G. eIF4E is a phosphoprotein, and the kinases that act on it have been identified as the MAPK-interacting kinases Mnk1 and Mnk2. Mnk1/2 also bind to the scaffold protein eIF4G. The N-terminal region of Mnk1 has previously been shown to bind to importin alpha, a component of the nuclear transport machinery, although Mnk1 itself is cytoplasmic. Here we identify a CRM1-type nuclear export motif in the C-terminal part of Mnk1. Substitution of hydrophobic residues in this motif results in Mnk1 becoming nuclear. This has allowed us to study the features of Mnk1 that are involved in its transport to the nucleus. This process requires part, but not all, of a polybasic region near the N terminus of Mnk1. Residues required for nuclear transport are also required for its interaction with importin alpha. This polybasic region also serves a second function in that it is required for the binding of Mnk1 to eIF4G, although the residues involved in this interaction are not identical to those involved in the binding of Mnk1 to importin alpha. Interaction of Mnk1 with eIF4G promotes the phosphorylation of eIF4E. Mutations that reduce the binding of Mnk1 to eIF4G in vivo and in vitro also decrease the ability of Mnk1 to enhance eIF4E phosphorylation in vivo, underlining the importance of the eIF4G-Mnk1 interaction in this process.	Univ Dundee, Fac Life Sci, Div Mol Physiol, Dundee DD1 5EH, Scotland	University of Dundee	Proud, CG (corresponding author), Univ Dundee, Fac Life Sci, Div Mol Physiol, Dow St, Dundee DD1 5EH, Scotland.	c.g.proud@dundee.ac.uk	Scheper, Gert C/D-7001-2014	Proud, Christopher/0000-0003-0704-6442				Alefantis T, 2003, J BIOL CHEM, V278, P21814, DOI 10.1074/jbc.M211576200; Bohnsack MT, 2002, EMBO J, V21, P6205, DOI 10.1093/emboj/cdf613; Cohen N, 2001, EMBO J, V20, P4547, DOI 10.1093/emboj/20.16.4547; De Benedetti A, 1999, INT J BIOCHEM CELL B, V31, P59, DOI 10.1016/S1357-2725(98)00132-0; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; Kleijn M, 2002, FEBS LETT, V532, P319, DOI 10.1016/S0014-5793(02)03694-3; Kleijn M, 1995, J CELL BIOCHEM, V59, P443, DOI 10.1002/jcb.240590405; Lachance PED, 2002, MOL CELL BIOL, V22, P1656, DOI 10.1128/MCB.22.6.1656-1663.2002; Lawrence JC, 1997, TRENDS BIOCHEM SCI, V22, P345, DOI 10.1016/S0968-0004(97)01101-8; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Li W, 2001, J BIOL CHEM, V276, P29111, DOI 10.1074/jbc.C100284200; Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001; Mahalingam M, 2001, PROG MOLEC, V27, P131; McKendrick L, 2001, MOL CELL BIOL, V21, P3632, DOI 10.1128/MCB.21.11.3632-3641.2001; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; Raught B, 2000, COLD SPRING HARBOR M, V39, P245; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Scheper GC, 2002, EUR J BIOCHEM, V269, P5350, DOI 10.1046/j.1432-1033.2002.03291.x; Scheper GC, 2002, J BIOL CHEM, V277, P3303, DOI 10.1074/jbc.M103607200; Scheper GC, 2001, MOL CELL BIOL, V21, P743, DOI 10.1128/MCB.21.3.743-754.2001; Strudwick S, 2002, DIFFERENTIATION, V70, P10, DOI 10.1046/j.1432-0436.2002.700102.x; Wang XM, 1998, J BIOL CHEM, V273, P9373, DOI 10.1074/jbc.273.16.9373; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Zuberek J, 2003, RNA, V9, P52, DOI 10.1261/rna.2133403	29	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44197	44204		10.1074/jbc.M302398200	http://dx.doi.org/10.1074/jbc.M302398200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12949082	hybrid			2022-12-25	WOS:000186306700039
J	Romero, N; Radi, R; Linares, E; Augusto, O; Detweiler, CD; Mason, RP; Denicola, A				Romero, N; Radi, R; Linares, E; Augusto, O; Detweiler, CD; Mason, RP; Denicola, A			Reaction of human hemoglobin with peroxynitrite Isomerization to nitrate and secondary formation of protein radicals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; NITRIC-OXIDE; CYTOCHROME-C; HORSERADISH-PEROXIDASE; MEDIATED OXIDATION; HUMAN MYOGLOBIN; KINETICS; HEME; IDENTIFICATION; OXYHEMOGLOBIN	Peroxynitrite, a strong oxidant formed intravascularly in vivo, can diffuse onto erythrocytes and be largely consumed via a fast reaction (2x10(4) M-1 s(-1)) with oxyhemoglobin. The reaction mechanism of peroxynitrite with oxyhemoglobin that results in the formation of methemoglobin remains to be elucidated. In this work, we studied the reaction under biologically relevant conditions using millimolar oxyhemoglobin concentrations and a stoichiometric excess of oxyhemoglobin over peroxynitrite. The results support a reaction mechanism that involves the net one-electron oxidation of the ferrous heme, isomerization of peroxynitrite to nitrate, and production of superoxide radical and hydrogen peroxide. Homolytic cleavage of peroxynitrite within the heme iron allows the formation of ferrylhemoglobin in similar to10% yields, which can decay to methemoglobin at the expense of reducing equivalents of the globin moiety. Indeed, spin-trapping studies using 2-methyl-2-nitroso propane and 5,5 dimethyl-1-pyrroline-N-oxide ( DMPO) demonstrated the formation of tyrosyl- and cysteinyl-derived radicals. DMPO also inhibited covalently linked dimerization products and led to the formation of DMPO-hemoglobin adducts. Hemoglobin nitration was not observed unless an excess of peroxynitrite over oxyhemoglobin was used, in agreement with a marginal formation of nitrogen dioxide. The results obtained support a role of oxyhemoglobin as a relevant intravascular sink of peroxynitrite.	Fac Med, Dept Bioquim, Montevideo 11800, Uruguay; Fac Med, Ctr Free Rad & Biomed Res, Montevideo 11800, Uruguay; Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-0513970 Sao Paulo, Brazil; NIEHS, Lab Pharmacol & Chem, NIH, Res Triangle Pk, NC 27709 USA; Univ Republica, Fac Ciencias, Inst Quim Biol, Montevideo 11400, Uruguay	Universidad de la Republica, Uruguay; Universidad de la Republica, Uruguay; Universidade de Sao Paulo; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Universidad de la Republica, Uruguay	Denicola, A (corresponding author), Fac Med, Dept Bioquim, Avda Gral Flores 2125, Montevideo 11800, Uruguay.	denicola@fcien.edu.uy	Mason, Ronald P/G-5967-2019; Linares, Edlaine/AAR-8753-2020; Augusto, Ohara/D-3839-2012	Mason, Ronald P/0000-0002-1859-9109; Linares, Edlaine/0000-0001-8164-3013; Augusto, Ohara/0000-0002-7220-4286; Denicola, Ana/0000-0002-5181-9708	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES050139, ZIAES050139] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AEBI H, 1984, METHOD ENZYMOL, V105, P121; Alayash AI, 1998, ARCH BIOCHEM BIOPHYS, V349, P65, DOI 10.1006/abbi.1997.0449; Alvarez B, 1999, J BIOL CHEM, V274, P842, DOI 10.1074/jbc.274.2.842; Augusto O, 2002, BIOCHEMISTRY-US, V41, P14323, DOI 10.1021/bi0262202; Barr DP, 1996, J BIOL CHEM, V271, P15498, DOI 10.1074/jbc.271.26.15498; BARR DP, 1995, J BIOL CHEM, V270, P12709, DOI 10.1074/jbc.270.21.12709; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Bose-Basu B, 2001, FREE RADICAL BIO MED, V31, P383, DOI 10.1016/S0891-5849(01)00599-8; Bourassa JL, 2001, J AM CHEM SOC, V123, P5142, DOI 10.1021/ja015621m; Brito C, 1999, J IMMUNOL, V162, P3356; Burner U, 2000, J BIOL CHEM, V275, P20597, DOI 10.1074/jbc.M000181200; BYTHEWAY I, 1994, CHEM REV, V94, P639, DOI 10.1021/cr00027a005; Castro L, 1996, ARCH BIOCHEM BIOPHYS, V333, P179, DOI 10.1006/abbi.1996.0379; COTTON ML, 1973, CAN J CHEM, V51, P582, DOI 10.1139/v73-088; D'Agnillo F, 2000, AM J PHYSIOL-HEART C, V279, pH1880, DOI 10.1152/ajpheart.2000.279.4.H1880; Daiber A, 2002, METHOD ENZYMOL, V359, P379; Denicola A, 1998, P NATL ACAD SCI USA, V95, P3566, DOI 10.1073/pnas.95.7.3566; Denicola A, 1996, ARCH BIOCHEM BIOPHYS, V333, P49, DOI 10.1006/abbi.1996.0363; Detweiler CD, 2002, FREE RADICAL BIO MED, V33, P364, DOI 10.1016/S0891-5849(02)00895-X; Exner M, 2000, CHEM RES TOXICOL, V13, P287, DOI 10.1021/tx990201k; Ferrer-Sueta G, 1999, CHEM RES TOXICOL, V12, P442, DOI 10.1021/tx980245d; FLOHE L, 1984, METHOD ENZYMOL, V105, P93; Gatti RM, 1998, ARCH BIOCHEM BIOPHYS, V349, P36, DOI 10.1006/abbi.1997.0451; GATTI RM, 1994, FEBS LETT, V348, P287, DOI 10.1016/0014-5793(94)00625-3; GIULIVI C, 1990, J BIOL CHEM, V265, P19453; GUNTHER MR, 1995, J BIOL CHEM, V270, P16075, DOI 10.1074/jbc.270.27.16075; Gunther MR, 1998, BIOCHEM J, V330, P1293; HARMAN LS, 1984, J BIOL CHEM, V259, P5606; Herold S, 1999, FEBS LETT, V443, P80, DOI 10.1016/S0014-5793(98)01591-9; Herold S, 2003, FREE RADICAL BIO MED, V34, P531, DOI 10.1016/S0891-5849(02)01355-2; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; Jensen MP, 2002, INORG CHEM, V41, P4788, DOI 10.1021/ic011089s; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; KOSAKA H, 1982, BIOCHIM BIOPHYS ACTA, V702, P237; MAO GD, 1994, FREE RADICAL BIO MED, V16, P493, DOI 10.1016/0891-5849(94)90127-9; MCARTHUR KM, 1993, BIOCHIM BIOPHYS ACTA, V1202, P173, DOI 10.1016/0167-4838(93)90002-9; Minetti M, 1999, BIOCHEMISTRY-US, V38, P2078, DOI 10.1021/bi982311g; Minetti M, 2000, BIOCHEMISTRY-US, V39, P6689, DOI 10.1021/bi9927991; Miranda KM, 2001, NITRIC OXIDE-BIOL CH, V5, P62, DOI 10.1006/niox.2000.0319; MOMENTEAU M, 1994, CHEM REV, V94, P659, DOI 10.1021/cr00027a006; MONCADA S, 1986, P NATL ACAD SCI USA, V83, P9164, DOI 10.1073/pnas.83.23.9164; NOHL H, 1993, FREE RADICAL BIO MED, V15, P257, DOI 10.1016/0891-5849(93)90072-3; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Patel RP, 1996, FREE RADICAL RES, V25, P117, DOI 10.3109/10715769609149916; Qian SY, 2002, BIOCHEM J, V363, P281, DOI 10.1042/0264-6021:3630281; Quijano C, 1997, BIOCHEM J, V322, P167, DOI 10.1042/bj3220167; RADI R, 1991, J BIOL CHEM, V266, P4244; Radi R, 2001, FREE RADICAL BIO MED, V30, P463, DOI 10.1016/S0891-5849(00)00373-7; Radi R, 1998, CHEM RES TOXICOL, V11, P720, DOI 10.1021/tx980096z; Radi R., 2000, BIOL CHEM PEROXYNITR, P57; Ramirez DC, 2003, FREE RADICAL BIO MED, V34, P830, DOI 10.1016/S0891-5849(02)01437-5; Romero N, 1999, ARCH BIOCHEM BIOPHYS, V368, P23, DOI 10.1006/abbi.1999.1272; Sampson JB, 1998, ARCH BIOCHEM BIOPHYS, V356, P207, DOI 10.1006/abbi.1998.0772; Schmidt H. H. W., 1996, METHODS NITRIC OXIDE, P491; Torchinsky Y, 1981, SULFUR PROTEINS; Wade RS, 1996, CHEM RES TOXICOL, V9, P1382, DOI 10.1021/tx9600457; WARDMAN P, 1995, METHOD ENZYMOL, V251, P31, DOI 10.1016/0076-6879(95)51108-3; WINTERBOURN CC, 1990, METHOD ENZYMOL, V186, P265; Witting PK, 2000, J BIOL CHEM, V275, P20391, DOI 10.1074/jbc.M000373200; Witting PK, 2001, J BIOL CHEM, V276, P16540, DOI 10.1074/jbc.M011707200; Wolin MS, 2000, ARTERIOSCL THROM VAS, V20, P1430, DOI 10.1161/01.ATV.20.6.1430	61	106	108	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44049	44057		10.1074/jbc.M305895200	http://dx.doi.org/10.1074/jbc.M305895200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12920120	hybrid			2022-12-25	WOS:000186306700021
J	Sakamoto, M; Hirata, H; Ohtsuka, T; Bessho, Y; Kageyama, R				Sakamoto, M; Hirata, H; Ohtsuka, T; Bessho, Y; Kageyama, R			The basic helix-loop-helix genes Hesr1/Hey1 and Hesr2/Hey2 regulate maintenance of neural precursor cells in the brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN ACHAETE-SCUTE; CENTRAL-NERVOUS-SYSTEM; STEM-CELLS; NEURONAL DIFFERENTIATION; GLIAL DIFFERENTIATION; TRANSCRIPTION FACTOR; CORTICAL DEVELOPMENT; FATE SPECIFICATION; PROGENITOR CELLS; DROSOPHILA HAIRY	Neural precursor cells proliferate in the ventricular zone while giving rise to neurons of deep layers first, then those of the superficial layers, and lastly, glial cells in the brain. Thus, it is essential to maintain neural precursor cells until late stages of neural development for generation of a wide variety of cell types. Here, we found that the Hes-related basic helix-loop-helix (bHLH) genes Hesr1/Hey1 and Hesr2/Hey2 are expressed in the ventricular zone, which contains neural precursor cells. Misexpression of Hesr1 and Hesr2 by electroporation in mouse brain at embryonic day 13.5 transiently maintains neural precursor cells and thereby increases late-born neurons, which are located in the superficial layers. In contrast, misexpression of the genes at later stages inhibits neurogenesis and promotes generation of astroglial cells. In transient transfection assay with cultured cells, both Hesr1 and Hesr2 inhibit transcription induced by the neuronal bHLH genes Mash1 and Math3. These results indicate that Hesr1 and Hesr2 negatively regulate neuronal bHLH genes, promote maintenance of neural precursor cells, and increase late-born cell types in the developing brain.	Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Kageyama, R (corresponding author), Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan.			Hirata, Hiromi/0000-0002-3769-7441				AKAZAWA C, 1992, J BIOL CHEM, V267, P21879; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Bae SK, 2000, DEVELOPMENT, V127, P2933; Bertrand N, 2002, NAT REV NEUROSCI, V3, P517, DOI 10.1038/nrn874; Cai L, 2000, DEVELOPMENT, V127, P3021; Castella P, 1999, J NEUROSCI RES, V56, P229, DOI 10.1002/(SICI)1097-4547(19990501)56:3<229::AID-JNR2>3.0.CO;2-Z; Chin MT, 2000, J BIOL CHEM, V275, P6381, DOI 10.1074/jbc.275.9.6381; Desai AR, 2000, DEVELOPMENT, V127, P2863; Donovan J, 2002, CURR BIOL, V12, P1605, DOI 10.1016/S0960-9822(02)01149-1; Furukawa T, 2000, NEURON, V26, P383, DOI 10.1016/S0896-6273(00)81171-X; Gaiano N, 2000, NEURON, V26, P395, DOI 10.1016/S0896-6273(00)81172-1; Gessler M, 2002, CURR BIOL, V12, P1601, DOI 10.1016/S0960-9822(02)01150-8; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; Hatakeyama J, 2001, DEVELOPMENT, V128, P1313; Hitoshi S, 2002, GENE DEV, V16, P846, DOI 10.1101/gad.975202; Hojo M, 2000, DEVELOPMENT, V127, P2515; Honjo T, 1996, GENES CELLS, V1, P1, DOI 10.1046/j.1365-2443.1996.10010.x; ISHIBASHI M, 1994, EMBO J, V13, P1799, DOI 10.1002/j.1460-2075.1994.tb06448.x; Ishibashi M, 1995, GENE DEV, V9, P3136, DOI 10.1101/gad.9.24.3136; Iso T, 2001, MOL CELL BIOL, V21, P6080, DOI 10.1128/MCB.21.17.6080-6089.2001; Iso T, 2001, MOL CELL BIOL, V21, P6071, DOI 10.1128/MCB.21.17.6071-6079.2001; JOHNSON JE, 1992, P NATL ACAD SCI USA, V89, P3596, DOI 10.1073/pnas.89.8.3596; Kageyama R, 1997, CURR OPIN GENET DEV, V7, P659, DOI 10.1016/S0959-437X(97)80014-7; Kokubo H, 1999, BIOCHEM BIOPH RES CO, V260, P459, DOI 10.1006/bbrc.1999.0880; Lee JE, 1997, CURR OPIN NEUROBIOL, V7, P13, DOI 10.1016/S0959-4388(97)80115-8; Leimeister C, 1999, MECH DEVELOP, V85, P173, DOI 10.1016/S0925-4773(99)00080-5; Lutolf S, 2002, DEVELOPMENT, V129, P373; Ma QF, 1996, CELL, V87, P43, DOI 10.1016/S0092-8674(00)81321-5; Maier MM, 2000, BIOCHEM BIOPH RES CO, V275, P652, DOI 10.1006/bbrc.2000.3354; Mizuguchi R, 2001, NEURON, V31, P757, DOI 10.1016/S0896-6273(01)00413-5; Nakagawa O, 1999, DEV BIOL, V216, P72, DOI 10.1006/dbio.1999.9454; Nakagawa O, 2000, P NATL ACAD SCI USA, V97, P13655, DOI 10.1073/pnas.250485597; Nakamura Y, 2000, J NEUROSCI, V20, P283, DOI 10.1523/JNEUROSCI.20-01-00283.2000; Nieto M, 2001, NEURON, V29, P401, DOI 10.1016/S0896-6273(01)00214-8; Novitch BG, 2001, NEURON, V31, P773, DOI 10.1016/S0896-6273(01)00407-X; Ohtsuka T, 2001, J BIOL CHEM, V276, P30467, DOI 10.1074/jbc.M102420200; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; Panchision DM, 2002, CURR OPIN GENET DEV, V12, P478, DOI 10.1016/S0959-437X(02)00329-5; Qian XM, 2000, NEURON, V28, P69, DOI 10.1016/S0896-6273(00)00086-6; Ross SE, 2003, NEURON, V39, P13, DOI 10.1016/S0896-6273(03)00365-9; Sakata Y, 2002, P NATL ACAD SCI USA, V99, P16197, DOI 10.1073/pnas.252648999; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; Satow T, 2001, J NEUROSCI, V21, P1265; Schuurmans C, 2002, CURR OPIN NEUROBIOL, V12, P26, DOI 10.1016/S0959-4388(02)00286-6; Sun Y, 2001, CELL, V104, P365, DOI 10.1016/S0092-8674(01)00224-0; Takebayashi K, 1997, EMBO J, V16, P384, DOI 10.1093/emboj/16.2.384; Takizawa T, 2001, DEV CELL, V1, P749, DOI 10.1016/S1534-5807(01)00101-0; Tanigaki K, 2001, NEURON, V29, P45, DOI 10.1016/S0896-6273(01)00179-9; Tomita K, 2000, EMBO J, V19, P5460, DOI 10.1093/emboj/19.20.5460; Tomita K, 1996, NEURON, V16, P723, DOI 10.1016/S0896-6273(00)80093-8; Zhong TP, 2000, SCIENCE, V287, P1820, DOI 10.1126/science.287.5459.1820; Zhou Q, 2002, CELL, V109, P61, DOI 10.1016/S0092-8674(02)00677-3	52	130	135	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44808	44815		10.1074/jbc.M300448200	http://dx.doi.org/10.1074/jbc.M300448200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12947105	hybrid, Green Submitted			2022-12-25	WOS:000186306700115
J	Sugimoto, I; Takahashi, Y				Sugimoto, I; Takahashi, Y			Evidence that the PsbK polypeptide is associated with the photosystem II core antenna complex CP43	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNECHOCYSTIS SP PCC-6803; PHOTOSYNTHETIC ELECTRON-TRANSPORT; MOLECULAR-MASS PROTEINS; CHLAMYDOMONAS-REINHARDTII; CRYSTAL-STRUCTURE; GENE; NUCLEAR; SUBUNIT; IDENTIFICATION; DESTABILIZES	PsbK is encoded by the chloroplast psbK gene and is one of the small polypeptides of photosystem II ( PSII). This polypeptide is required for accumulation of the PSII complex. In the present study, we generated an antibody against recombinant mature PsbK of Chlamydomonas and used it in Western blots to localize PsbK in the PSII core complex. PsbK was found in the thylakoid membranes, and purification of the PSII core complex from detergent-solubilized thylakoid membranes showed that PsbK is tightly associated with the PSII core complex. We used potassium thiocyanate to separate PSII into subcore complexes, including the D1/D2/ cytochrome b(559) reaction center complex, CP47, and CP43, and we found that PsbK co-purifies with one of the core antenna complexes, CP43, during ion exchange chromatography. Subsequent gel filtration chromatography of the purified CP43 confirmed that PsbK is tightly associated with CP43. Steady-state levels of PsbK were also determined in Chlamydomonas mutants expressing various levels of PSII. Quantitative Western blotting revealed that the levels of PsbK in these mutants are approximately equal to those of CP43, suggesting that PsbK is stable only when associated with CP43 in the chloroplast. Together, our results indicate that PsbK is an integral part of the PSII complex and may participate in the assembly and stability of the PSII complex.	Okayama Univ, Fac Sci, Dept Biol, Okayama 7008530, Japan	Okayama University	Takahashi, Y (corresponding author), Okayama Univ, Fac Sci, Dept Biol, Okayama 7008530, Japan.		Takahashi, Yuichiro/B-2062-2011	Takahashi, Yuichiro/0000-0001-6410-0447				ANBUDURAI PR, 1993, Z NATURFORSCH C, V48, P267; ATTEIA A, 1992, J BIOL CHEM, V267, P226; BENNOUN P, 1986, PLANT MOL BIOL, V6, P151, DOI 10.1007/BF00021484; BLANKENSHIP RE, 2002, MOL MECH PHOTOSYNTHE, P95; Buchel C, 2000, J STRUCT BIOL, V131, P181, DOI 10.1006/jsbi.2000.4294; CHUA NH, 1975, P NATL ACAD SCI USA, V72, P2175, DOI 10.1073/pnas.72.6.2175; DEVITRY C, 1991, J BIOL CHEM, V266, P16614; DEVITRY C, 1989, J CELL BIOL, V109, P991, DOI 10.1083/jcb.109.3.991; GORMAN DS, 1965, P NATL ACAD SCI USA, V54, P1665, DOI 10.1073/pnas.54.6.1665; Hippler M, 2002, PROTIST, V153, P197, DOI 10.1078/1434-4610-00098; IKEUCHI M, 1989, FEBS LETT, V242, P263, DOI 10.1016/0014-5793(89)80482-X; IKEUCHI M, 1988, PLANT CELL PHYSIOL, V29, P1233; IKEUCHI M, 1992, BOT MAG TOKYO, V105, P327, DOI 10.1007/BF02489425; IKEUCHI M, 1991, J BIOL CHEM, V266, P11111; Ikeuchi M, 1995, MOL GEN GENET, V249, P622, DOI 10.1007/BF00418031; Kamiya N, 2003, P NATL ACAD SCI USA, V100, P98, DOI 10.1073/pnas.0135651100; Kim SJ, 1996, FEBS LETT, V390, P175, DOI 10.1016/0014-5793(96)00658-8; KOIKE H, 1989, FEBS LETT, V244, P391, DOI 10.1016/0014-5793(89)80570-8; KUCHKA MR, 1989, CELL, V58, P869, DOI 10.1016/0092-8674(89)90939-2; KUNSTNER P, 1995, J BIOL CHEM, V270, P9651; LORKOVIC ZJ, 1995, P NATL ACAD SCI USA, V92, P8930, DOI 10.1073/pnas.92.19.8930; MAYES SR, 1993, BIOCHEMISTRY-US, V32, P1454, DOI 10.1021/bi00057a008; MAYFIELD SP, 1987, EMBO J, V6, P313, DOI 10.1002/j.1460-2075.1987.tb04756.x; MONOD C, 1992, MOL GEN GENET, V231, P449, DOI 10.1007/BF00292715; MURATA N, 1988, FEBS LETT, V235, P283, DOI 10.1016/0014-5793(88)81280-8; NANBA O, 1987, P NATL ACAD SCI USA, V84, P109, DOI 10.1073/pnas.84.1.109; Ohnishi N, 2001, J BIOL CHEM, V276, P33798, DOI 10.1074/jbc.M104454200; PAKRASI HB, 1990, Z NATURFORSCH C, V45, P423; ROCHAIX JD, 1989, EMBO J, V8, P1013, DOI 10.1002/j.1460-2075.1989.tb03468.x; ROGNER M, 1991, BIOCHEMISTRY-US, V30, P5387; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SILK GW, 1990, NUCLEIC ACIDS RES, V18, P4930, DOI 10.1093/nar/18.16.4930; TAKAHASHI Y, 1994, PLANT MOL BIOL, V24, P779, DOI 10.1007/BF00029859; TAKAHASHI Y, 1991, EMBO J, V10, P2033, DOI 10.1002/j.1460-2075.1991.tb07733.x; Takahashi Y, 1998, J PLANT RES, V111, P101, DOI 10.1007/BF02507156; Takahashi Y, 1996, PLANT CELL PHYSIOL, V37, P161, DOI 10.1093/oxfordjournals.pcp.a028927; YAMAGUCHI N, 1988, PLANT CELL PHYSIOL, V29, P123; Zheleva D, 1998, J BIOL CHEM, V273, P16122, DOI 10.1074/jbc.273.26.16122; Zouni A, 2001, NATURE, V409, P739, DOI 10.1038/35055589	39	41	44	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					45004	45010		10.1074/jbc.M307537200	http://dx.doi.org/10.1074/jbc.M307537200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12939265	hybrid			2022-12-25	WOS:000186306700137
J	Ishima, R; Torchia, DA; Lynch, SM; Gronenborn, AM; Louis, JM				Ishima, R; Torchia, DA; Lynch, SM; Gronenborn, AM; Louis, JM			Solution structure of the mature HIV-1 protease monomer - Insight into the tertiary fold and stability of a precursor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS TYPE-1 PROTEASE; GAG-POL POLYPROTEIN; HUMAN-IMMUNODEFICIENCY; RETROVIRAL PROTEASES; TRANSFRAME PROTEIN; CRYSTAL-STRUCTURES; SUBSTRATE COMPLEX; VIRAL INFECTIVITY; ACTIVE-SITE; NMR	We present the first solution structure of the HIV-1 protease monomer spanning the region Phe(1)-Ala(95) (PR1-95). Except for the terminal regions (residues 1-10 and 91-95) that are disordered, the tertiary fold of the remainder of the protease is essentially identical to that of the individual subunit of the dimer. In the monomer, the side chains of buried residues stabilizing the active site interface in the dimer, such as Asp(25), Asp(29), and Arg(87), are now exposed to solvent. The flap dynamics in the monomer are similar to that of the free protease dimer. We also show that the protease domain of an optimized precursor flanked by 56 amino acids of the N-terminal transframe region is predominantly monomeric, exhibiting a tertiary fold that is quite similar to that of PR1-95 structure. This explains the very low catalytic activity observed for the protease prior to its maturation at its N terminus as compared with the mature protease, which is an active stable dimer under identical conditions. Adding as few as 2 amino acids to the N terminus of the mature protease significantly increases its dissociation into monomers. Knowledge of the protease monomer structure and critical features of its dimerization may aid in the screening and design of compounds that target the protease prior to its maturation from the Gag-Pol precursor.	NIDDK, Chem Phys Lab, NIH, Bethesda, MD 20892 USA; NIDCR, Struct Mol Biol Unit, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Louis, JM (corresponding author), NIDDK, Chem Phys Lab, NIH, Bldg 5,Room 411, Bethesda, MD 20892 USA.	jmlouis@helix.nih.gov		Louis, John M/0000-0002-0052-1899; Gronenborn, Angela M/0000-0001-9072-3525	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000507] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK029025, Z01DK029022] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Beissinger M, 1996, EUR J BIOCHEM, V237, P383, DOI 10.1111/j.1432-1033.1996.0383k.x; CANDOTTI D, 1994, CR ACAD SCI III-VIE, V317, P183; Chou JJ, 2001, J BIOMOL NMR, V21, P377, DOI 10.1023/A:1013336502594; Clore GM, 1998, CURR OPIN CHEM BIOL, V2, P564, DOI 10.1016/S1367-5931(98)80084-7; Condra JH, 1998, HAEMOPHILIA, V4, P610, DOI 10.1046/j.1365-2516.1998.440610.x; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Erickson JW, 1996, ANNU REV PHARMACOL, V36, P545, DOI 10.1146/annurev.pa.36.040196.002553; Ferentz AE, 2000, Q REV BIOPHYS, V33, P29, DOI 10.1017/S0033583500003589; Freedberg DI, 2002, PROTEIN SCI, V11, P221, DOI 10.1110/ps.33202; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; Hubbard S. J., 1993, COMPUTER PROGRAM; Ishima R, 1999, STRUCTURE, V7, P1047, DOI 10.1016/S0969-2126(99)80172-5; Ishima R, 2001, J BIOL CHEM, V276, P49110, DOI 10.1074/jbc.M108136200; KAPLAN AH, 1993, J VIROL, V67, P4050, DOI 10.1128/JVI.67.7.4050-4055.1993; KARACOSTAS V, 1993, VIROLOGY, V193, P661, DOI 10.1006/viro.1993.1174; Katoh E, 2003, PROTEIN SCI, V12, P1376, DOI 10.1110/ps.0300703; KRAUSSLICH HG, 1991, P NATL ACAD SCI USA, V88, P3213, DOI 10.1073/pnas.88.8.3213; Lam PYS, 1996, J MED CHEM, V39, P3514, DOI 10.1021/jm9602571; LAPATTO R, 1989, NATURE, V342, P299, DOI 10.1038/342299a0; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LEIS J, 1988, J VIROL, V62, P1808, DOI 10.1128/JVI.62.5.1808-1809.1988; Louis JM, 1998, BIOCHEMISTRY-US, V37, P2105, DOI 10.1021/bi972059x; LOUIS JM, 1994, P NATL ACAD SCI USA, V91, P7970, DOI 10.1073/pnas.91.17.7970; Louis JM, 2003, J BIOL CHEM, V278, P6085, DOI 10.1074/jbc.M209726200; Louis JM, 1999, NAT STRUCT BIOL, V6, P868; Louis JM, 1999, J BIOL CHEM, V274, P23437, DOI 10.1074/jbc.274.33.23437; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NICHOLSON LK, 1995, NAT STRUCT BIOL, V2, P274, DOI 10.1038/nsb0495-274; OROSZLAN S, 1990, CURR TOP MICROBIOL, V157, P153; Paulus C, 1999, J BIOL CHEM, V274, P21539, DOI 10.1074/jbc.274.31.21539; PEARL L, 1984, FEBS LETT, V174, P96, DOI 10.1016/0014-5793(84)81085-6; PEARL LH, 1987, NATURE, V329, P351, DOI 10.1038/329351a0; Prabu-Jeyabalan M, 2000, J MOL BIOL, V301, P1207, DOI 10.1006/jmbi.2000.4018; RICHARDS AD, 1990, J BIOL CHEM, V265, P7733; Rick SW, 1998, PROTEINS, V32, P7, DOI 10.1002/(SICI)1097-0134(19980701)32:1&lt;7::AID-PROT3&gt;3.0.CO;2-K; ROSE JR, 1993, J BIOL CHEM, V268, P11939; ROSE JR, 1995, J VIROL, V69, P2751; SCHRAMM HJ, 1993, BIOCHEM BIOPH RES CO, V194, P595, DOI 10.1006/bbrc.1993.1863; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; SPINELLI S, 1991, BIOCHIMIE, V73, P1391, DOI 10.1016/0300-9084(91)90169-2; Strisovsky K, 2000, PROTEIN SCI, V9, P1631, DOI 10.1110/ps.9.9.1631; Tessmer U, 1998, J VIROL, V72, P3459, DOI 10.1128/JVI.72.4.3459-3463.1998; Todd MJ, 1998, J MOL BIOL, V283, P475, DOI 10.1006/jmbi.1998.2090; Tycko R, 2000, J AM CHEM SOC, V122, P9340, DOI 10.1021/ja002133q; Vondrasek J, 1997, NAT STRUCT BIOL, V4, P8, DOI 10.1038/nsb0197-8; WEBER IT, 1990, J BIOL CHEM, V265, P10492; WLODAWER A, 1993, ANNU REV BIOCHEM, V62, P543, DOI 10.1146/annurev.bi.62.070193.002551; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279; Wondrak EM, 1996, BIOCHEMISTRY-US, V35, P12957, DOI 10.1021/bi960984y; Wondrak EM, 1996, J BIOL CHEM, V271, P4477, DOI 10.1074/jbc.271.8.4477; Zutshi R, 1997, J AM CHEM SOC, V119, P4841, DOI 10.1021/ja962496j	51	69	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43311	43319		10.1074/jbc.M307549200	http://dx.doi.org/10.1074/jbc.M307549200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12933791	hybrid			2022-12-25	WOS:000186157000074
J	Prasannan, P; Pike, S; Peng, K; Shane, B; Appling, DR				Prasannan, P; Pike, S; Peng, K; Shane, B; Appling, DR			Human mitochondrial C-1-tetrahydrofolate synthase - Gene structure, tissue distribution of the mRNA, and immunolocalization in Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT METHYLENETETRAHYDROFOLATE DEHYDROGENASE; ONE-CARBON METABOLISM; METHENYLTETRAHYDROFOLATE CYCLOHYDROLASE; SACCHAROMYCES-CEREVISIAE; C1-TETRAHYDROFOLATE SYNTHASE; 5,10-METHYLENETETRAHYDROFOLATE DEHYDROGENASE; FORMYLTETRAHYDROFOLATE SYNTHETASE; NONKETOTIC HYPERGLYCINEMIA; TRIFUNCTIONAL ENZYME; TRANSFORMED-CELLS	C-1-tetrahydrofolate (THF) synthase is a trifunctional enzyme found in eukaryotes that contains the activities 10-formyl-THF synthetase, 5,10-methenyl-THF cyclohydrolase, and 5,10-methylene-THF dehydrogenase. The cytoplasmic isozyme of C-1-THF synthase is well characterized in a number of mammals, including humans; but a mitochondrial isozyme has been previously identified only in the yeast Saccharomyces. Here, we report the identification and characterization of the human gene encoding a functional mitochondrial C-1-THF synthase. The gene spans 236 kilobase pairs on chromosome 6 and consists of 28 exons plus one alternative exon. The gene encodes a protein of 978 amino acids, including an N-terminal mitochondrial targeting sequence. The mitochondrial isozyme is 61% identical to the human cytoplasmic isozyme. Expression of the gene was detected in most human tissues, but transcripts were highest in placenta, thymus, and brain. Two mRNAs were detected, a 3.6-kb transcript and a 1.1-kb transcript, and both transcripts were observed in varying ratios in each tissue. The shorter transcript results from an alternative splicing event, where exon 7 is spliced to exon 8a instead of exon 8. Exon 8a is derived from an exonized Alu sequence, sharing no homology with exon 8 of the long transcript, and encodes just 15 amino acids followed by a stop codon and a polyadenylation signal. This short transcript potentially encodes a bifunctional enzyme lacking 10-formyl-THF synthetase activity. Both transcripts initiate at the same 5'-site, 107 nucleotides upstream of the ATG start codon. The full-length ( 2934 bp) cDNA fused to a C-terminal V5 epitope tag was expressed in Chinese hamster ovary cells. Immunoblots of subfractionated cells revealed a 107-kDa protein only in the mitochondrial fractions of these cells, confirming the mitochondrial localization of the protein. Yeast cells expressing the full-length human cDNA exhibited elevated 10-formyl-THF synthetase activity, confirming its identification as the human mitochondrial C-1-THF synthase.	Univ Texas, Inst Mol & Cellular Biol, Dept Chem & Biochem, Austin, TX 78712 USA; Univ Calif Berkeley, Dept Nutr Sci, Berkeley, CA 94720 USA	University of Texas System; University of Texas Austin; University of California System; University of California Berkeley	Appling, DR (corresponding author), Univ Texas, Inst Mol & Cellular Biol, Dept Chem & Biochem, 1 Univ Stn A5300, Austin, TX 78712 USA.			Pike, Schuyler/0000-0003-1366-9486	NIDDK NIH HHS [DK42033, R01 DK042033, R01 DK061428-04, R01 DK061428, DK 61428] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061428, R01DK042033] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agrotis A, 2000, FEBS LETT, V467, P128, DOI 10.1016/S0014-5793(00)01132-7; APPLING DR, 1991, FASEB J, V5, P2645, DOI 10.1096/fasebj.5.12.1916088; BARLOWE C K, 1988, Biofactors, V1, P171; BARLOWE CK, 1990, MOL CELL BIOL, V10, P5679, DOI 10.1128/MCB.10.11.5679; BELANGER C, 1989, J BIOL CHEM, V264, P4837; BIANCHETTI R, 1977, J BIOL CHEM, V252, P2519; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Chang DJ, 1998, FEBS LETT, V422, P279, DOI 10.1016/S0014-5793(98)00024-6; CHEEK WD, 1989, ARCH BIOCHEM BIOPHYS, V270, P504, DOI 10.1016/0003-9861(89)90532-8; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Di Pietro E, 2002, MOL CELL BIOL, V22, P4158, DOI 10.1128/MCB.22.12.4158-4166.2002; GALPER JB, 1969, BIOCHEM BIOPH RES CO, V34, P205, DOI 10.1016/0006-291X(69)90633-0; GARCIAMARTINEZ LF, 1993, BIOCHEMISTRY-US, V32, P4671, DOI 10.1021/bi00068a027; Gregory JF, 2000, AM J CLIN NUTR, V72, P1535; Hamosh A, 1995, METABOLIC MOL BASIS, V1, P1337; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; House JD, 1999, ADV ENZYME REGUL, V39, P69, DOI 10.1016/S0065-2571(98)00008-9; HOWARD KM, 2003, IN PRESS GENE AMST; HUM DW, 1988, J BIOL CHEM, V263, P15946; HUM DW, 1991, PROTEIN ENG, V4, P493, DOI 10.1093/protein/4.4.493; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOIS M, 1989, J BIOL CHEM, V264, P3347; Kawai J, 2001, NATURE, V409, P685, DOI 10.1038/35055500; Kirksey TJ, 1996, ARCH BIOCHEM BIOPHYS, V333, P251, DOI 10.1006/abbi.1996.0388; KORNBERG A, 1955, METHOD ENZYMOL, V1, P441, DOI 10.1016/0076-6879(55)01072-0; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; Lev-Maor G, 2003, SCIENCE, V300, P1288, DOI 10.1126/science.1082588; LEWIS KF, 1978, ARCH BIOCHEM BIOPHYS, V185, P443, DOI 10.1016/0003-9861(78)90187-X; LIN BF, 1993, J BIOL CHEM, V268, P21674; MANROW RE, 1993, J MOL BIOL, V234, P281, DOI 10.1006/jmbi.1993.1583; MEJIA NR, 1988, BIOCHEM BIOPH RES CO, V155, P1, DOI 10.1016/S0006-291X(88)81040-4; MEJIA NR, 1986, J BIOL CHEM, V261, P9509; MEJIA NR, 1985, J BIOL CHEM, V260, P4616; PASTERNACK LB, 1994, BIOCHEMISTRY-US, V33, P74, DOI 10.1021/bi00167a010; Patel H, 2002, ARCH BIOCHEM BIOPHYS, V403, P145, DOI 10.1016/S0003-9861(02)00203-5; PAUKERT JL, 1976, J BIOL CHEM, V251, P5104; PAUKERT JL, 1977, BIOCHEM BIOPH RES CO, V77, P147, DOI 10.1016/S0006-291X(77)80176-9; PERI KG, 1993, BIOCHIM BIOPHYS ACTA, V1171, P281, DOI 10.1016/0167-4781(93)90066-M; Randak C, 2000, J INHERIT METAB DIS, V23, P520, DOI 10.1023/A:1005667707355; Schmidt A, 2000, BIOCHEMISTRY-US, V39, P6325, DOI 10.1021/bi992734y; SCHMIDT E, 1974, METHOD ENZYMAT AN, V2, P650; SHANNON KW, 1986, J BIOL CHEM, V261, P2266; SHANNON KW, 1988, J BIOL CHEM, V263, P7717; SMITH GK, 1980, BIOCHEMISTRY-US, V19, P4313, DOI 10.1021/bi00559a026; SMITH GK, 1990, ARCH BIOCHEM BIOPHYS, V283, P367, DOI 10.1016/0003-9861(90)90656-J; Sorek R, 2002, GENOME RES, V12, P1060, DOI 10.1101/gr.229302; TAN LUL, 1979, CAN J BIOCHEM CELL B, V57, P806, DOI 10.1139/o79-100; Van Hove JLK, 1998, J INHERIT METAB DIS, V21, P799, DOI 10.1023/A:1005462400552; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; VILLAR E, 1985, J BIOL CHEM, V260, P2245; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; WEST MG, 1993, J BIOL CHEM, V268, P153; West MG, 1996, BIOCHEMISTRY-US, V35, P3122, DOI 10.1021/bi952713d; Wiemann S, 2001, GENOME RES, V11, P422, DOI 10.1101/gr.GR1547R; YANG XM, 1993, BIOCHEMISTRY-US, V32, P1118, DOI 10.1021/bi00092a022	56	53	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43178	43187		10.1074/jbc.M304319200	http://dx.doi.org/10.1074/jbc.M304319200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12937168	Green Accepted, hybrid			2022-12-25	WOS:000186157000059
J	Weigel, JA; Weigel, PH				Weigel, JA; Weigel, PH			Characterization of the recombinant rat 175-kDa hyaluronan receptor for endocytosis (HARE)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER ENDOTHELIAL-CELLS; CHONDROITIN SULFATE PROTEOGLYCAN; MEDIATED ENDOCYTOSIS; ASIALOGLYCOPROTEIN RECEPTORS; CARTILAGE PROTEOGLYCANS; EXTRACELLULAR-MATRIX; LYMPHATIC TISSUE; BINDING PROTEINS; ACID; DEGRADATION	Hyaluronan ( HA) and chondroitin sulfate ( CS) clearance from lymph and blood in mammals is mediated by the HA receptor for endocytosis ( HARE), which is present as two isoforms in rat and human (175/300 kDa and 190/315 kDa, respectively) in the sinusoidal endothelial cells of liver, spleen, and lymph nodes (Zhou, B., McGary, C. T., Weigel, J. A., Saxena, A., and Weigel, P. H. (2003) Glycobiology 13, 339 - 349). The small rat and human HARE proteins are not encoded directly by mRNA but are derived from larger precursors. Here we characterize the specificity and function of the 175-kDa HARE, expressed in the absence of the 300-kDa species, in stably transfected SK-Hep-1 cells. The HARE cDNA was fused with a leader sequence to allow correct orientation of the membrane protein. The recombinant rHARE contained similar to 25 kDa of N-linked oligosaccharides and, like the native protein, was able to bind HA in a ligand blot assay, even after de-N-glycosylation. SK-HARE cell lines demonstrated specific I-125-HA endocytosis, receptor recycling, and delivery of HA to lysosomes for degradation. The K-d for the binding of HA (number-average molecular mass similar to 133 kDa) to the 175-kDa HARE at 4 degreesC was 4.1 nM with 160,000 to 220,000 HA-binding sites per cell. The 175-kDa rHARE binds HA, dermatan sulfate, and chondroitin sulfates A, C, D, and E, but not chondroitin, heparin, heparan sulfate, or keratan sulfate. Surprisingly, recognition of glycosaminoglycans (GAGs) other than HA by native or recombinant HARE was temperature-dependent. Although competition was observed at 37 degreesC, none of the other GAGs competed for I-125-HA binding to SK- HARE cells at 4 degreesC. Anti-HARE monoclonal antibody-174 showed a similar temperature-dependence in its ability to block HA endocytosis. These data suggest that temperature-induced conformational changes may alter the GAG specificity of HARE. The results confirm that the 175-kDa rHARE does not require the larger HARE isoform to mediate endocytosis of multiple GAGs.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	Weigel, PH (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA.				NIGMS NIH HHS [GM35978] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035978] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABATANGELO G, 2000, NEW FRONTIERS MED SC; Banerji S, 1999, J CELL BIOL, V144, P789, DOI 10.1083/jcb.144.4.789; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAMLEY PN, 1991, J HEPATOL, V13, P8, DOI 10.1016/0168-8278(91)90856-7; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; ERIKSSON S, 1983, EXP CELL RES, V144, P223, DOI 10.1016/0014-4827(83)90458-5; EVERED D, 1989, CIBA F SYMP, V143, P1; FRASER JRE, 1988, BIOCHEM J, V256, P153, DOI 10.1042/bj2560153; FRASER JRE, 1983, CELL TISSUE RES, V233, P285; Freitas JP, 1996, DERMATOLOGY, V192, P46, DOI 10.1159/000246314; Handler M, 1997, DEV DYNAM, V210, P130, DOI 10.1002/(SICI)1097-0177(199710)210:2<130::AID-AJA6>3.0.CO;2-H; HASCALL VC, 1977, J SUPRAMOL STR CELL, V7, P101, DOI 10.1002/jss.400070110; Hayflick JS, 1998, IMMUNOL RES, V17, P313, DOI 10.1007/BF02786454; HEFFELFINGER SC, 1992, IN VITRO CELL DEV-AN, V28A, P136; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; Jiang H, 2002, J BIOL CHEM, V277, P10531, DOI 10.1074/jbc.M108654200; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; Knudson CB, 2001, SEMIN CELL DEV BIOL, V12, P69, DOI 10.1006/scdb.2000.0243; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai KN, 1998, J LAB CLIN MED, V131, P354, DOI 10.1016/S0022-2143(98)90186-X; Laurent T.C., 1991, DEGRADATION BIOACTIV, P249; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LAURENT TC, 1986, BIOCHEM J, V234, P653, DOI 10.1042/bj2340653; LAURENT UBG, 1991, EXP PHYSIOL, V76, P695, DOI 10.1113/expphysiol.1991.sp003536; LEBEL L, 1988, J APPL PHYSIOL, V64, P1327, DOI 10.1152/jappl.1988.64.4.1327; LEBOEUF RD, 1987, BIOCHEMISTRY-US, V26, P6052, DOI 10.1021/bi00393a016; LEBOEUF RD, 1986, J BIOL CHEM, V261, P2586; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; LUNDIN A, 1985, BRIT J DERMATOL, V112, P663, DOI 10.1111/j.1365-2133.1985.tb02334.x; Luo W, 2000, J BONE MINER METAB, V18, P51, DOI 10.1007/s007740050011; Manicourt DH, 1999, ARTHRITIS RHEUM, V42, P1861, DOI 10.1002/1529-0131(199909)42:9<1861::AID-ANR10>3.0.CO;2-I; MCGARY CT, 1989, BIOCHEM J, V257, P875, DOI 10.1042/bj2570875; MCGARY CT, 1993, HEPATOLOGY, V18, P1465, DOI 10.1002/hep.1840180628; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Michel CC, 1999, PHYSIOL REV, V79, P703, DOI 10.1152/physrev.1999.79.3.703; OKA JA, 1989, J BIOL CHEM, V264, P12016; Politz O, 2002, BIOCHEM J, V362, P155, DOI 10.1042/0264-6021:3620155; RAJA RH, 1984, ANAL BIOCHEM, V139, P168, DOI 10.1016/0003-2697(84)90402-0; RAJA RH, 1988, J BIOL CHEM, V263, P16661; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Schwartz NB, 1999, PROG NUCLEIC ACID RE, V62, P177; SCOTT JE, 1995, J ANAT, V187, P259; STROBEL JL, 1985, ARCH BIOCHEM BIOPHYS, V240, P635, DOI 10.1016/0003-9861(85)90071-2; TAMMI R, 1991, J INVEST DERMATOL, V97, P126, DOI 10.1111/1523-1747.ep12478553; Tammi R, 2001, J BIOL CHEM, V276, P35111, DOI 10.1074/jbc.M103481200; Thylen A, 1999, CANCER-AM CANCER SOC, V86, P2000, DOI 10.1002/(SICI)1097-0142(19991115)86:10<2000::AID-CNCR17>3.3.CO;2-E; Toole BP, 1990, CURR OPIN CELL BIOL, V2, P839, DOI 10.1016/0955-0674(90)90081-O; Toole BP, 1997, J INTERN MED, V242, P35, DOI 10.1046/j.1365-2796.1997.00171.x; TURLEY EA, 1993, BLOOD, V81, P446; TZAICOS C, 1989, BIOCHEM J, V264, P823, DOI 10.1042/bj2640823; Watanabe H, 1998, J BIOCHEM, V124, P687, DOI 10.1093/oxfordjournals.jbchem.a022166; Weigel JA, 2003, J BIOL CHEM, V278, P9808, DOI 10.1074/jbc.M211462200; Weigel P H, 1993, Subcell Biochem, V19, P125; WEIGEL PH, 1983, ANAL BIOCHEM, V133, P437, DOI 10.1016/0003-2697(83)90106-9; Yamada M, 1998, ACTA HAEMATOL-BASEL, V99, P212, DOI 10.1159/000040841; YannarielloBrown J, 1996, BIOCHEM BIOPH RES CO, V218, P314, DOI 10.1006/bbrc.1996.0055; Yik JHN, 2002, J BIOL CHEM, V277, P40844, DOI 10.1074/jbc.M204780200; Yik JHN, 2002, BIOCHEM BIOPH RES CO, V297, P980, DOI 10.1016/S0006-291X(02)02298-2; Yik JHN, 2002, J BIOL CHEM, V277, P23076, DOI 10.1074/jbc.M202748200; Zhou B, 1999, J BIOL CHEM, V274, P33831, DOI 10.1074/jbc.274.48.33831; Zhou B, 2003, GLYCOBIOLOGY, V13, P339, DOI 10.1093/glycob/cwg029; Zhou B, 2002, MOL BIOL CELL, V13, P2853, DOI 10.1091/mbc.02-03-0048; Zhou B, 2000, J BIOL CHEM, V275, P37733, DOI 10.1074/jbc.M003030200	63	45	45	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42802	42811		10.1074/jbc.M307201200	http://dx.doi.org/10.1074/jbc.M307201200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12933790	hybrid			2022-12-25	WOS:000186157000011
J	Wen, RR; Chen, YH; Xue, LQ; Schuman, J; Yang, S; Morris, SW; Wang, DM				Wen, RR; Chen, YH; Xue, LQ; Schuman, J; Yang, S; Morris, SW; Wang, DM			Phospholipase C gamma 2 provides survival signals via Bcl2 and A1 in different subpopulations of B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; RECEPTOR-INDUCED ACTIVATION; LYN-DEFICIENT MICE; TARGETED DISRUPTION; IMMUNE-RESPONSES; PHOSPHOINOSITIDE 3-KINASE; SURFACE-IMMUNOGLOBULIN; LYMPHOID DEVELOPMENT; INDUCED APOPTOSIS; MEMBRANE EXON	PLCgamma2 plays a critical role in B cell receptor (BCR) signaling and its targeted deletion results in defective B cell development and function. Here, we show that PLCgamma2 deficiency specifically blocks B cell maturation at the transitional type 2 (T2) to follicular (FO) B cell transition and the PLCgamma2 pathway regulates survival of B cells. BCR-induced apoptosis is dramatically enhanced in all subsets of splenic PLCgamma2-deficient B cells, especially in T2 and FO B cell subpopulations. We also find that all splenic PLCgamma2-deficient B cell subpopulations express abnormally low levels of Bcl-2 protein. In addition, PLCgamma2 deficiency disrupts BCR-mediated induction of A1 expression. Enforced expression of Bcl-2 prevents BCR-induced apoptosis in all splenic PLCgamma2-deficient B cell subpopulations and partially restores the numbers of PLCgamma2-deficient FO B cells. In contrast to Bcl-2, enforced expression of A1 preferentially prevents BCR-induced apoptosis in PLCgamma2-deficient FO B cells and partially restores the numbers of these B cells. Therefore, the PLCgamma2 pathway provides a survival signal via regulation of Bcl-2 in all splenic B cell subpopulations and via additional induction of A1 in mature FO B cells.	Blood Ctr SE Wisconsin Inc, Blood Res Inst, Milwaukee, WI 53226 USA; St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA; Nanjing Univ, Inst Mol Med, Model Anim Res Ctr, Nanjing 210008, Peoples R China; Med Coll Wisconsin, Dept Microbiol & Mol Genet, Milwaukee, WI 53226 USA	Versiti Blood Center of Wisconsin; St Jude Children's Research Hospital; Nanjing University; Medical College of Wisconsin	Wang, DM (corresponding author), Blood Ctr SE Wisconsin Inc, Blood Res Inst, Milwaukee, WI 53226 USA.	dwang@bcsew.edu			NATIONAL CANCER INSTITUTE [R01CA087064] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073284] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052327] Funding Source: NIH RePORTER; NCI NIH HHS [CA 87064] Funding Source: Medline; NHLBI NIH HHS [HL073284] Funding Source: Medline; NIAID NIH HHS [AI52327] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BENHAMOU LE, 1990, EUR J IMMUNOL, V20, P1405, DOI 10.1002/eji.1830200630; Bunting KD, 1998, NAT MED, V4, P58, DOI 10.1038/nm0198-058; Chan VWF, 1997, IMMUNITY, V7, P69, DOI 10.1016/S1074-7613(00)80511-7; CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0; COGGESHALL KM, 1992, P NATL ACAD SCI USA, V89, P5660, DOI 10.1073/pnas.89.12.5660; Doi TS, 1997, J EXP MED, V185, P953, DOI 10.1084/jem.185.5.953; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Goodnow CC, 1996, P NATL ACAD SCI USA, V93, P2264, DOI 10.1073/pnas.93.6.2264; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Hardy RR, 2001, ANNU REV IMMUNOL, V19, P595, DOI 10.1146/annurev.immunol.19.1.595; HARTLEY SB, 1991, NATURE, V353, P765, DOI 10.1038/353765a0; HASBOLD J, 1990, EUR J IMMUNOL, V20, P1685, DOI 10.1002/eji.1830200810; Healy JI, 1998, ANNU REV IMMUNOL, V16, P645, DOI 10.1146/annurev.immunol.16.1.645; Henderson A, 1998, ANNU REV IMMUNOL, V16, P163, DOI 10.1146/annurev.immunol.16.1.163; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Jumaa H, 1999, IMMUNITY, V11, P547, DOI 10.1016/S1074-7613(00)80130-2; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KERNER JD, 1995, IMMUNITY, V3, P301, DOI 10.1016/1074-7613(95)90115-9; KHAN WN, 1995, IMMUNITY, V3, P283, DOI 10.1016/1074-7613(95)90114-0; KITAMURA D, 1992, NATURE, V356, P154, DOI 10.1038/356154a0; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; Kurosaki T, 1999, ANNU REV IMMUNOL, V17, P555, DOI 10.1146/annurev.immunol.17.1.555; Lam KP, 1997, CELL, V90, P1073, DOI 10.1016/S0092-8674(00)80373-6; LI YS, 1993, J EXP MED, V178, P951, DOI 10.1084/jem.178.3.951; LIN EY, 1993, J IMMUNOL, V151, P1979; Loder F, 1999, J EXP MED, V190, P75, DOI 10.1084/jem.190.1.75; Martin F, 2000, IMMUNITY, V12, P39, DOI 10.1016/S1074-7613(00)80157-0; Martin F, 2001, CURR OPIN IMMUNOL, V13, P195, DOI 10.1016/S0952-7915(00)00204-1; MASON DY, 1992, INT IMMUNOL, V4, P163, DOI 10.1093/intimm/4.2.163; MERINO R, 1994, EMBO J, V13, P683, DOI 10.1002/j.1460-2075.1994.tb06307.x; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; NAKAYAMA K, 1994, P NATL ACAD SCI USA, V91, P3700, DOI 10.1073/pnas.91.9.3700; NISHIZUMI H, 1995, IMMUNITY, V3, P549, DOI 10.1016/1074-7613(95)90126-4; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; Oliver AM, 1997, EUR J IMMUNOL, V27, P2366, DOI 10.1002/eji.1830270935; Pappu R, 1999, SCIENCE, V286, P1949, DOI 10.1126/science.286.5446.1949; PENNYCOOK JL, 1993, J EXP MED, V178, P1007, DOI 10.1084/jem.178.3.1007; Pogue SL, 2000, J IMMUNOL, V165, P1300, DOI 10.4049/jimmunol.165.3.1300; PULENDRAN B, 1995, NATURE, V375, P331, DOI 10.1038/375331a0; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Rothstein TL, 1996, CURR OPIN IMMUNOL, V8, P362, DOI 10.1016/S0952-7915(96)80126-9; SCHULER W, 1986, CELL, V46, P963, DOI 10.1016/0092-8674(86)90695-1; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SHOKAT KM, 1995, NATURE, V375, P334, DOI 10.1038/375334a0; STRASSER A, 1994, NATURE, V368, P457, DOI 10.1038/368457a0; Su TT, 2002, J IMMUNOL, V168, P2101, DOI 10.4049/jimmunol.168.5.2101; Suzuki H, 1999, SCIENCE, V283, P390, DOI 10.1126/science.283.5400.390; TAKATA M, 1995, J EXP MED, V182, P907, DOI 10.1084/jem.182.4.907; Tan JEL, 2001, J BIOL CHEM, V276, P20055, DOI 10.1074/jbc.M010800200; Tarlinton DM, 1997, INT IMMUNOL, V9, P1481, DOI 10.1093/intimm/9.10.1481; THOMIS DC, 1995, SCIENCE, V270, P794, DOI 10.1126/science.270.5237.794; Tomayko MM, 1998, J IMMUNOL, V160, P107; Torres RM, 1996, SCIENCE, V272, P1804, DOI 10.1126/science.272.5269.1804; TSUBATA T, 1993, NATURE, V364, P645, DOI 10.1038/364645a0; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Wang DM, 2000, IMMUNITY, V13, P25, DOI 10.1016/S1074-7613(00)00005-4; Wen RR, 2001, MOL CELL BIOL, V21, P678, DOI 10.1128/MCB.21.2.678-689.2001; Young F, 1997, IMMUNITY, V6, P23, DOI 10.1016/S1074-7613(00)80239-3	62	35	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43654	43662		10.1074/jbc.M307318200	http://dx.doi.org/10.1074/jbc.M307318200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12928432	hybrid			2022-12-25	WOS:000186157000114
J	Zomot, E; Kanner, BI				Zomot, E; Kanner, BI			The interaction of the gamma-aminobutyric acid transporter GAT-1 with the neurotransmitter is selectively impaired by sulfhydryl modification of a conformationally sensitive cysteine residue engineered into extracellular loop IV	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; SEROTONIN TRANSPORTER; DOPAMINE TRANSPORTER; GABA TRANSPORTER; SUBSTRATE-BINDING; XENOPUS OOCYTES; SUBTYPE-A; SITE; IDENTIFICATION; EXPRESSION	The (Na++Cl-)-coupled gamma-aminobutyric acid (GABA) transporter GAT-1 keeps synaptic levels of this neurotransmitter low and thereby enables efficient GABAergic transmission. Extracellular loops (III, IV, and V) have been shown to contain determinants for GABA selectivity and affinity. Here we analyze the role of extracellular loop IV in transport by cysteine scanning mutagenesis. Fourteen residues of this loop have been replaced by cysteine. GABA transport by eight of the fourteen mutants is markedly more sensitive to inhibition by membrane-impermeant methane thiosulfate reagents than wild-type. Mutant A364C has high activity and is potently inhibited by the sulfhydryl reagent. GABA transport by the A364C/C74A double mutant, where the only externally accessible cysteine residue of the wild-type has been replaced by alanine, is also highly sensitive to the sulfhydryl reagents. Maximal sensitivity is observed in the presence of the cosubstrates sodium and chloride. A marked protection is afforded by GABA, provided sodium is present. This protection is also observed at 4degreesC. The non-transportable analogue SKF100330A also protects the double mutant against sulfhydryl modification in the presence of sodium but has the opposite effect in its absence. Electrophysiological analysis shows that upon sulfhydryl modification of this mutant, GABA can no longer induce transport currents. The voltage dependence of the transient currents indicates an increased apparent affinity for sodium. Moreover, GABA is unable to suppress the transient currents. Our results indicate that part of extracellular loop IV is conformationally sensitive, and its modification selectively abolishes the interaction of the transporter with GABA.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Kanner, BI (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91120 Jerusalem, Israel.							ALI FE, 1985, J MED CHEM, V28, P653, DOI 10.1021/jm50001a020; Androutsellis-Theotokis A, 2001, J BIOL CHEM, V276, P45933, DOI 10.1074/jbc.M107462200; Barker EL, 1999, J NEUROSCI, V19, P4705; Bennett ER, 2000, J BIOL CHEM, V275, P34106, DOI 10.1074/jbc.M004229200; Bennett ER, 1997, J BIOL CHEM, V272, P1203, DOI 10.1074/jbc.272.2.1203; Bismuth Y, 1997, J BIOL CHEM, V272, P16096, DOI 10.1074/jbc.272.26.16096; Chen JG, 1997, BIOCHEMISTRY-US, V36, P1479, DOI 10.1021/bi962256g; Chen JG, 1998, J BIOL CHEM, V273, P12675, DOI 10.1074/jbc.273.20.12675; CHIN JG, 1997, J BIOL CHEM, V272, P28321; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; Golovanevsky V, 1999, J BIOL CHEM, V274, P23020, DOI 10.1074/jbc.274.33.23020; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; Hirayama BA, 2001, BRIT J PHARMACOL, V134, P484, DOI 10.1038/sj.bjp.0704274; Kamdar G, 2001, J BIOL CHEM, V276, P4038, DOI 10.1074/jbc.M008483200; KANNER BI, 1994, FEBS LETT, V356, P191, DOI 10.1016/0014-5793(94)01255-5; KANNER BI, 1994, J EXP BIOL, V196, P237; KAVANAUGH MP, 1992, J BIOL CHEM, V267, P22007; KEYNAN S, 1988, BIOCHEMISTRY-US, V27, P12, DOI 10.1021/bi00401a003; KEYNAN S, 1992, BIOCHEMISTRY-US, V31, P1974, DOI 10.1021/bi00122a011; KLEINBERGERDORON N, 1994, J BIOL CHEM, V269, P3063; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Loland CJ, 1999, J BIOL CHEM, V274, P36928, DOI 10.1074/jbc.274.52.36928; Loo DDF, 2000, J BIOL CHEM, V275, P37414, DOI 10.1074/jbc.M007241200; Lu CC, 1999, J GEN PHYSIOL, V114, P429, DOI 10.1085/jgp.114.3.429; MacAulay N, 2003, J BIOL CHEM, V278, P28771, DOI 10.1074/jbc.M213023200; MacAulay N, 2001, J BIOL CHEM, V276, P40476, DOI 10.1074/jbc.M105578200; MAGER S, 1993, NEURON, V10, P177, DOI 10.1016/0896-6273(93)90309-F; MAGER S, 1996, J NEUROSCI, V16, P5404; Nelson N, 1998, J NEUROCHEM, V71, P1785; Norregaard L, 1998, EMBO J, V17, P4266, DOI 10.1093/emboj/17.15.4266; PANTANOWITZ S, 1993, J BIOL CHEM, V268, P3222; RADIAN R, 1986, J BIOL CHEM, V261, P5437; Seal RP, 1998, NEURON, V21, P1487, DOI 10.1016/S0896-6273(00)80666-2; TAMURA S, 1995, J BIOL CHEM, V270, P28712, DOI 10.1074/jbc.270.48.28712; WANG JB, 1995, J NEUROCHEM, V64, P1416	36	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42950	42958		10.1074/jbc.M209307200	http://dx.doi.org/10.1074/jbc.M209307200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12925537	hybrid			2022-12-25	WOS:000186157000029
J	Wilson, EM; Hsieh, MM; Rotwein, P				Wilson, EM; Hsieh, MM; Rotwein, P			Autocrine growth factor signaling by insulin-like growth factor-II mediates MyoD-stimulated myocyte maturation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; SKELETAL-MUSCLE; H19/IGF2 LOCUS; MYOGENIN GENE; IGF-I; DIFFERENTIATION; HYPERTROPHY; EXPRESSION; MICE; METHYLATION	Skeletal muscle differentiation, maturation, and regeneration are regulated by interactions between intrinsic genetic programs controlled by myogenic transcription factors, including members of the MyoD and MEF2 families, and environmental cues mediated by hormones and growth factors. Insulin-like growth factors (IGFs) also play key roles in muscle development, and in the maintenance and repair of mature muscle, but their mechanisms of interaction with other muscle regulatory networks remain undefined. To evaluate the potential interplay between MyoD and IGF signaling pathways, we have studied muscle differentiation in C3H 10T1/2 fibroblasts acutely converted to myoblasts by quantitative infection with a recombinant adenovirus encoding mouse MyoD. In these cells, IGF-II gene and protein expression are induced as early events in differentiation, and the IGF-I receptor and downstream signaling molecules, including Akt, are rapidly activated. Interference with IGF-II production by a tetracycline-inhibited adenovirus expressing an IGF-II cDNA in the antisense orientation reversibly inhibited both production of muscle-specific structural proteins and myocyte fusion to form multinucleated myotubes. Similar results were achieved with a tetracycline-inhibited adenovirus expressing dominant-negative Akt. Our observations identify a robust autocrine amplification network in which MyoD enhances the later steps in muscle differentiation by induction of a locally acting growth factor.	Oregon Hlth & Sci Univ, Div Mol Med, Portland, OR 97239 USA	Oregon Health & Science University	Rotwein, P (corresponding author), Oregon Hlth & Sci Univ, Div Mol Med, 3181 SW Sam Jackson Pk Rd,Mail Code HRC3, Portland, OR 97239 USA.		Rotwein, Peter/R-5783-2019	Rotwein, Peter/0000-0002-9505-1817	NIDDK NIH HHS [5R01-DK42748, R01 DK042748] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042748] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ainscough JFX, 2000, DEVELOPMENT, V127, P3923; Barton ER, 2002, J CELL BIOL, V157, P137, DOI 10.1083/jcb.200108071; Barton-Davis ER, 1998, P NATL ACAD SCI USA, V95, P15603, DOI 10.1073/pnas.95.26.15603; Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; Buckingham M, 2001, CURR OPIN GENET DEV, V11, P440, DOI 10.1016/S0959-437X(00)00215-X; CARONI P, 1994, J CELL BIOL, V125, P893, DOI 10.1083/jcb.125.4.893; Clemmons David R., 1997, Cytokine and Growth Factor Reviews, V8, P45, DOI 10.1016/S1359-6101(96)00053-6; FLORINI JR, 1991, J BIOL CHEM, V266, P15917; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; Ishihara K, 2000, GENOME RES, V10, P664, DOI 10.1101/gr.10.5.664; Issa JPJ, 1996, NAT MED, V2, P281, DOI 10.1038/nm0396-281; Jiang BH, 1999, P NATL ACAD SCI USA, V96, P2077, DOI 10.1073/pnas.96.5.2077; Kaffer CR, 2000, GENE DEV, V14, P1908; KOU K, 1993, MOL ENDOCRINOL, V7, P291, DOI 10.1210/me.7.2.291; LASSAR A, 1994, CURR OPIN CELL BIOL, V6, P432, DOI 10.1016/0955-0674(94)90037-X; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; Musaro A, 2001, NAT GENET, V27, P195, DOI 10.1038/84839; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; Nakae J, 2001, ENDOCR REV, V22, P818, DOI 10.1210/edrv.22.6.0452; Naya FJ, 1999, CURR OPIN CELL BIOL, V11, P683, DOI 10.1016/S0955-0674(99)00036-8; Olson EN, 1996, CELL, V85, P1, DOI 10.1016/S0092-8674(00)81073-9; Paul AC, 2002, J CELL BIOL, V156, P751, DOI 10.1083/jcb.200105147; Polesskaya A, 2001, EMBO J, V20, P6816, DOI 10.1093/emboj/20.23.6816; POWELLBRAXTON L, 1993, GENE DEV, V7, P2609, DOI 10.1101/gad.7.12b.2609; Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101-1009; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; ROTWEIN P, 1990, DNA CELL BIOL, V9, P725, DOI 10.1089/dna.1990.9.725; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; Sabourin LA, 1999, J CELL BIOL, V144, P631, DOI 10.1083/jcb.144.4.631; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Stewart CEH, 1996, J BIOL CHEM, V271, P11330, DOI 10.1074/jbc.271.19.11330; Tureckova J, 2001, J BIOL CHEM, V276, P39264, DOI 10.1074/jbc.M104991200; Vandromme M, 2001, J BIOL CHEM, V276, P8173, DOI 10.1074/jbc.M005587200; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3	36	74	82	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41109	41113		10.1074/jbc.C300299200	http://dx.doi.org/10.1074/jbc.C300299200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12941952	hybrid			2022-12-25	WOS:000185847200086
J	Moghal, N; Sternberg, PW				Moghal, N; Sternberg, PW			Extracellular domain determinants of LET-23 (EGF) receptor tyrosine kinase activity in Caenorhabditis elegans	ONCOGENE			English	Article						LET-23; EGF; ErbB; activation; inhibition; structure	EPIDERMAL-GROWTH-FACTOR; C-ELEGANS; VULVAR DEVELOPMENT; CRYSTAL-STRUCTURE; MAP KINASE; SWISS-MODEL; CELL FATES; GENE; PROTEIN; ENCODES	Negative regulation of ErbB/EGFR signalling pathways is important for normal development and the prevention of cancer. In a genetic screen to uncover mechanisms that negatively regulate ErbB signalling in Caenorhabditis elegans, we isolated a second-site mutation (sy621) that promotes the activity of a gain-of-function allele (sa62gf) of the let-23 (EGF) receptor tyrosine kinase. We show that activation by the sa62 mutation (C359Y) likely results from a break in the conserved disulphide-bonded eighth module at the junction of CR1 and L2. The sy621 mutation causes a G270E change in the third disulphide-bonded module of CR1, and causes no phenotype on its own, but cooperates with the sa62 mutation to. promote receptor activity. Although both sa62 single- and double-mutant receptors can function in the absence of ligand, they can be further activated by ligand. Our results support the current model for ligand-induced dimerization based on the recent crystal structures of HER3 and the EGFR, and provide more evidence for the generation of distinctly activated ErbB family members through mutation.	CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology; Howard Hughes Medical Institute; California Institute of Technology	Moghal, N (corresponding author), CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA.	nmoghal@caltech.edu						Abe Y, 1998, J BIOL CHEM, V273, P11150, DOI 10.1074/jbc.273.18.11150; AROIAN RV, 1991, GENETICS, V128, P251; AROIAN RV, 1994, EMBO J, V13, P360, DOI 10.1002/j.1460-2075.1994.tb06269.x; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; Bargmann CI, 1995, METHOD CELL BIOL, V48, P225; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; Berset T, 2001, SCIENCE, V291, P1055, DOI 10.1126/science.1055642; BRENNER S, 1974, GENETICS, V77, P71; Chang C, 2000, EMBO J, V19, P3283, DOI 10.1093/emboj/19.13.3283; Cho HS, 2002, SCIENCE, V297, P1330, DOI 10.1126/science.1074611; Cho HS, 2003, NATURE, V421, P756, DOI 10.1038/nature01392; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Domagala T, 2000, GROWTH FACTORS, V18, P11, DOI 10.3109/08977190009003231; FERGUSON EL, 1985, GENETICS, V110, P17; Ferguson KM, 2003, MOL CELL, V11, P507, DOI 10.1016/S1097-2765(03)00047-9; Garrett TPJ, 2002, CELL, V110, P763, DOI 10.1016/S0092-8674(02)00940-6; Garrett TPJ, 1998, NATURE, V394, P395, DOI 10.1038/28668; GOTOH N, 1992, BIOCHEM BIOPH RES CO, V186, P768, DOI 10.1016/0006-291X(92)90812-Y; GRANATO M, 1994, NUCLEIC ACIDS RES, V22, P1762, DOI 10.1093/nar/22.9.1762; Greenwald Iva, 1997, Cold Spring Harbor Monograph Series, V33, P519; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hajnal A, 1997, GENE DEV, V11, P2715, DOI 10.1101/gad.11.20.2715; HAN M, 1990, GENETICS, V126, P899; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Hopper NA, 2000, MOL CELL, V6, P65, DOI 10.1016/S1097-2765(00)00008-3; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; Katz WS, 1996, MOL CELL BIOL, V16, P529; KATZ WS, 1995, CELL, V82, P297, DOI 10.1016/0092-8674(95)90317-8; LACKNER MR, 1994, GENE DEV, V8, P160, DOI 10.1101/gad.8.2.160; LEE JH, 1994, GENE DEV, V8, P60, DOI 10.1101/gad.8.1.60; Lesa GM, 1997, MOL BIOL CELL, V8, P779, DOI 10.1091/mbc.8.5.779; Mendrola JM, 2002, J BIOL CHEM, V277, P4704, DOI 10.1074/jbc.M108681200; Moriki T, 2001, J MOL BIOL, V311, P1011, DOI 10.1006/jmbi.2001.4923; Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; Sako Y, 2000, NAT CELL BIOL, V2, P168, DOI 10.1038/35004044; Schlessinger J, 2002, CELL, V110, P669, DOI 10.1016/S0092-8674(02)00966-2; STERNBERG PW, 1986, CELL, V44, P761, DOI 10.1016/0092-8674(86)90842-1; Sternberg PW, 1998, TRENDS GENET, V14, P466, DOI 10.1016/S0168-9525(98)01592-3; Tanner KG, 1999, J BIOL CHEM, V274, P35985, DOI 10.1074/jbc.274.50.35985; Tsuda T, 2000, J BIOL CHEM, V275, P21988, DOI 10.1074/jbc.M003400200; Verveer PJ, 2000, SCIENCE, V290, P1567, DOI 10.1126/science.290.5496.1567; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; WU Y, 1994, GENE DEV, V8, P147, DOI 10.1101/gad.8.2.147; Yarden Y, 2001, EUR J CANCER, V37, pS3; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; Yu XC, 2002, MOL BIOL CELL, V13, P2547, DOI 10.1091/mbc.01-08-0411	54	7	11	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2003	22	35					5471	5480		10.1038/sj.onc.1206648	http://dx.doi.org/10.1038/sj.onc.1206648			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JC	12934107				2022-12-25	WOS:000184735000012
J	Han, BG; Dong, ZZ; Liu, Y; Chen, Q; Hashimoto, K; Zhang, JT				Han, BG; Dong, ZZ; Liu, Y; Chen, Q; Hashimoto, K; Zhang, JT			Regulation of constitutive expression of mouse PTEN by the 5 '-untranslated region	ONCOGENE			English	Article						PTEN; IRES; promoter; 5 '-UTR	INTERNAL RIBOSOME ENTRY; LHERMITTE-DUCLOS-DISEASE; TUMOR-SUPPRESSOR GENE; LONG TERMINAL REPEAT; MESSENGER-RNA; GROWTH-FACTOR; TRANSLATION INITIATION; TRANSCRIPTIONAL ACTIVATION; PROMOTER METHYLATION; NEGATIVE REGULATION	PTEN tumor suppressor serves as a major negative regulator of survival signaling mediated by PI3 kinase/ AKT/protein kinase B pathway, and is inactivated in various human tumors. Elucidation of mechanisms responsible for PTEN expression is important for providing insight into strategies to control the loss of PTEN expression in human cancers. Although recent studies suggested that p53 and Egr-1 can modulate induced PTEN expression, the mechanism responsible for ubiquitous constitutive expression of PTEN remains elusive. PTEN mRNA contains a highly conserved and GC-rich 5-untranslated region (5'-UTR). Recently, it has been shown that the long 5'-UTR sequences of several growth-regulated mRNAs contain promoters that can generate mRNAs with shorter 5'-UTRs. In this paper, we tested whether the 5'-UTR sequence of mouse PTEN contains a promoter that is responsible for constitutive expression of PTEN. We found that the long 5'-UTR sequence of mouse PTEN severely inhibits translation of PTEN and a heterologous gene firefly luciferase. Deletion of the most 5'-UTR sequence would enhance translation efficiency 100-fold. We also showed that the 5'-UTR sequence of mouse PTEN does not have an internal ribosome entry site (IRES) that can mediate cap-independent initiation of translation. Instead, we found that the 5'-UTR sequence of mouse PTEN contains a strong promoter that drives the production of a transcript with shorter 5'-UTRs, which can be translated with higher efficiency. This promoter was mapped to the region between -551 and -220 bases upstream of the translation start codon. Cotransfection analysis using Drosophila SL2 cells showed that Sp1 is one of the major transcription factors that can constitutively activate this promoter. Two endogenous PTEN transcripts with 5'-UTRs of 193 and 109 bases were found in DU145 and H226 cell lines. Based on these observations, we conclude that the PTEN expression may be regulated at both transcriptional and translational levels, and that the 5'-UTR sequence of PTEN contains a promoter that is responsible for constitutive PTEN expression.	Indiana Univ, Sch Med, IUCC, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Walther Canc Inst, Indianapolis, IN 46202 USA; Natl Inst Infect Dis, Tokyo, Japan	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; National Institute of Infectious Diseases (NIID)	Zhang, JT (corresponding author), Indiana Univ, Sch Med, IUCC, Dept Pharmacol & Toxicol, 1044 W Walnut St,R4-166, Indianapolis, IN 46202 USA.	jianzhan@iupui.edu	Zhang, Jian-Ting/L-8334-2015		NCI NIH HHS [CA64539] Funding Source: Medline; NIGMS NIH HHS [GM59475] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064539, R29CA064539] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059475] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ali IU, 1999, JNCI-J NATL CANCER I, V91, P1922, DOI 10.1093/jnci/91.22.1922; Backman SA, 2001, NAT GENET, V29, P396, DOI 10.1038/ng782; Bernstein J, 1997, J BIOL CHEM, V272, P9356; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Coldwell MJ, 2000, ONCOGENE, V19, P899, DOI 10.1038/sj.onc.1203407; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Dahia PLM, 2000, ENDOCR-RELAT CANCER, V7, P115, DOI 10.1677/erc.0.0070115; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Gan WN, 1998, J BIOL CHEM, V273, P5006, DOI 10.1074/jbc.273.9.5006; Gan WN, 1996, J BIOL CHEM, V271, P623, DOI 10.1074/jbc.271.2.623; Groszer M, 2001, SCIENCE, V294, P2186, DOI 10.1126/science.1065518; GUALBERTO A, 1995, J BIOL CHEM, V270, P19680, DOI 10.1074/jbc.270.34.19680; Han BG, 2002, MOL CELL BIOL, V22, P7372, DOI 10.1128/MCB.22.21.7372-7384.2002; Hen BG, 2001, J BIOL CHEM, V276, P7937, DOI 10.1074/jbc.M007470200; Hisatake J, 2001, BLOOD, V97, P2427, DOI 10.1182/blood.V97.8.2427; Huez I, 1998, MOL CELL BIOL, V18, P6178, DOI 10.1128/MCB.18.11.6178; Kang YH, 2002, LAB INVEST, V82, P285, DOI 10.1038/labinvest.3780422; Koutsodontis G, 2001, J BIOL CHEM, V276, P29116, DOI 10.1074/jbc.M104130200; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kozak M, 2001, MOL CELL BIOL, V21, P1899, DOI 10.1128/MCB.21.6.1899-1907.2001; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Kwon CH, 2001, NAT GENET, V29, P404, DOI 10.1038/ng781; Leslie NR, 2002, CELL SIGNAL, V14, P285, DOI 10.1016/S0898-6568(01)00234-0; Li DM, 1997, CANCER RES, V57, P2124; Li G, 2002, DEVELOPMENT, V129, P4159; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Mutter GL, 2001, AM J PATHOL, V158, P1895, DOI 10.1016/S0002-9440(10)64656-1; Ohlsson C, 1998, ENDOCRINOLOGY, V139, P1101, DOI 10.1210/en.139.3.1101; Pestova TV, 2001, P NATL ACAD SCI USA, V98, P7029, DOI 10.1073/pnas.111145798; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RAO CD, 1988, MOL CELL BIOL, V8, P284, DOI 10.1128/MCB.8.1.284; Ross AH, 2001, NEUROSCIENTIST, V7, P278, DOI 10.1177/107385840100700404; Sachs AB, 2000, CELL, V101, P243, DOI 10.1016/S0092-8674(00)80834-X; Salvesen HB, 2001, INT J CANCER, V91, P22, DOI 10.1002/1097-0215(20010101)91:1<22::AID-IJC1002>3.0.CO;2-S; Schneider R, 2001, MOL CELL BIOL, V21, P8238, DOI 10.1128/MCB.21.23.8238-8246.2001; Soria JC, 2002, CLIN CANCER RES, V8, P1178; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Stoneley M, 2000, NUCLEIC ACIDS RES, V28, P687, DOI 10.1093/nar/28.3.687; Suzuki Y, 2000, GENOMICS, V64, P286, DOI 10.1006/geno.2000.6076; Torgeman A, 2001, VIROLOGY, V281, P10, DOI 10.1006/viro.2000.0779; Virolle T, 2001, NAT CELL BIOL, V3, P1124, DOI 10.1038/ncb1201-1124; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Willis AE, 1999, INT J BIOCHEM CELL B, V31, P73, DOI 10.1016/S1357-2725(98)00133-2; ZHANG JT, 1991, J BIOL CHEM, V266, P18224	49	57	61	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2003	22	34					5325	5337		10.1038/sj.onc.1206783	http://dx.doi.org/10.1038/sj.onc.1206783			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JB	12917634				2022-12-25	WOS:000184734900012
J	Bennett, EM; Li, CL; Allan, PW; Parker, WB; Ealick, SE				Bennett, EM; Li, CL; Allan, PW; Parker, WB; Ealick, SE			Structural basis for substrate specificity of Escherichia coli purine nucleoside phosphorylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSITION-STATE ANALYSIS; VIVO GENE-THERAPY; CRYSTAL-STRUCTURE; 5'-DEOXY-5'-METHYLTHIOADENOSINE PHOSPHORYLASE; 3-DIMENSIONAL STRUCTURE; DIFFRACTION DATA; CELLULOMONAS SP; FORMYCIN-B; ENZYME; BINDING	Purine nucleoside phosphorylase catalyzes reversible phosphorolysis of purine nucleosides and 2'- deoxypurine nucleosides to the free base and ribose ( or 2'- deoxyribose) 1- phosphate. Whereas the human enzyme is specific for 6- oxopurine ribonucleosides, the Escherichia coli enzyme accepts additional substrates including 6- oxopurine ribonucleosides, 6- aminopurine ribonucleosides, and to a lesser extent purine arabinosides. These differences have been exploited in a potential suicide gene therapy treatment for solid tumors. In an effort to optimize this suicide gene therapy approach, we have determined the three- dimensional structure of the E. coli enzyme in complex with 10 nucleoside analogs and correlated the structures with kinetic measurements and computer modeling. These studies explain the preference of the enzyme for ribose sugars, show increased flexibility for active site residues Asp(204) and Arg(24), and suggest that interactions involving the 1- and 6- positions of the purine and the 4 '- and 5 '- positions of the ribose provide the best opportunities to increase prodrug specificity and enzyme efficiency.	Cornell Univ, Baker Lab, Dept Chem & Biol Chem, Ithaca, NY 14853 USA; So Res Inst, Birmingham, AL 35205 USA	Cornell University	Ealick, SE (corresponding author), Cornell Univ, Baker Lab, Dept Chem & Biol Chem, Ithaca, NY 14853 USA.	see3@cornell.edu	Li, Chenglong/E-7182-2010	Li, Chenglong/0000-0003-3174-8719	NCI NIH HHS [CA 67763] Funding Source: Medline; NCRR NIH HHS [RR 01646] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U19CA067763] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001646] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AGARWAL KC, 1975, BIOCHEMISTRY-US, V14, P79, DOI 10.1021/bi00672a013; Appleby TC, 2001, J BIOL CHEM, V276, P39232, DOI 10.1074/jbc.M105694200; Appleby TC, 1999, STRUCTURE, V7, P629, DOI 10.1016/S0969-2126(99)80084-7; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Beck C, 1995, HUM GENE THER, V6, P1525, DOI 10.1089/hum.1995.6.12-1525; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRUNGER AT, 1992, X PLOR SYSTEM XRAY C; Bzowska A, 2002, BBA-PROTEIN STRUCT M, V1596, P293, DOI 10.1016/S0167-4838(02)00218-2; BZOWSKA A, 1992, BIOCHIM BIOPHYS ACTA, V1120, P239, DOI 10.1016/0167-4838(92)90243-7; BZOWSKA A, 1990, Z NATURFORSCH C, V45, P59; COOK WJ, 1985, J BIOL CHEM, V260, P2968; CULVER KW, 1992, SCIENCE, V256, P1550, DOI 10.1126/science.1317968; DENNIG CN, 1997, KEYSTONE S; DOSKOCIL J, 1977, COLLECT CZECH CHEM C, V42, P370, DOI 10.1135/cccc19770370; Dranoff G, 1998, J CLIN ONCOL, V16, P2548, DOI 10.1200/JCO.1998.16.7.2548; EALICK SE, 1990, J BIOL CHEM, V265, P1812; Erion MD, 1997, BIOCHEMISTRY-US, V36, P11735, DOI 10.1021/bi961970v; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Fedorov A, 2001, BIOCHEMISTRY-US, V40, P853, DOI 10.1021/bi002499f; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; HART TN, 1992, PROTEINS, V13, P206, DOI 10.1002/prot.340130304; HUGHES BW, 1995, CANCER RES, V55, P3339; Hughes BW, 1998, J BIOL CHEM, V273, P2322, DOI 10.1074/jbc.273.4.2322; JENSEN KF, 1975, EUR J BIOCHEM, V51, P253, DOI 10.1111/j.1432-1033.1975.tb03925.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kierdaszuk B, 1997, BIOPHYS CHEM, V63, P107, DOI 10.1016/S0301-4622(96)02239-9; Kierdaszuk B, 2000, BBA-PROTEIN STRUCT M, V1476, P109, DOI 10.1016/S0167-4838(99)00225-3; Kleywegt GJ, 1999, ACTA CRYSTALLOGR D, V55, P941, DOI 10.1107/S0907444999001031; KLINE PC, 1995, BIOCHEMISTRY-US, V34, P1153, DOI 10.1021/bi00004a008; KLINE PC, 1993, BIOCHEMISTRY-US, V32, P13212, DOI 10.1021/bi00211a033; Koellner G, 2002, J MOL BIOL, V315, P351, DOI 10.1006/jmbi.2001.5211; Koellner G, 1998, J MOL BIOL, V280, P153, DOI 10.1006/jmbi.1998.1799; Koellner G, 1997, J MOL BIOL, V265, P202, DOI 10.1006/jmbi.1996.0730; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEHIKOINEN PK, 1989, BIOCHEM J, V257, P355, DOI 10.1042/bj2570355; Mao C, 1997, STRUCTURE, V5, P1373, DOI 10.1016/S0969-2126(97)00287-6; Mao C, 1998, BIOCHEMISTRY-US, V37, P7135, DOI 10.1021/bi9723919; MAO C, 1995, THESIS CORNELL U ITH; Martiniello-Wilks R, 1998, HUM GENE THER, V9, P1617, DOI 10.1089/hum.1998.9.11-1617; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MESNIL M, 1997, KEYSTONE S, P67; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; Parker WB, 1998, BIOCHEM PHARMACOL, V55, P1673, DOI 10.1016/S0006-2952(98)00034-3; Parker WB, 1997, HUM GENE THER, V8, P1637, DOI 10.1089/hum.1997.8.14-1637; PARKS RE, 1972, ENZYMES, V7, P483; Puhlmann M, 1999, HUM GENE THER, V10, P649, DOI 10.1089/10430349950018724; Qiu D, 1997, J PHYS CHEM A, V101, P3005, DOI 10.1021/jp961992r; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Rosenberg S A, 1999, Hum Gene Ther, V10, P3067; Sacco MG, 1996, GENE THER, V3, P1151; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; Shi WX, 2001, BIOCHEMISTRY-US, V40, P8204, DOI 10.1021/bi010585p; SORSCHER EJ, 1994, GENE THER, V1, P233; STEIN RL, 1981, J BIOL CHEM, V256, P767; Tebbe J, 1999, J MOL BIOL, V294, P1239, DOI 10.1006/jmbi.1999.3327; Waud W. R., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P512; Wielgus-Kutrowska B, 2002, BBA-PROTEIN STRUCT M, V1597, P320, DOI 10.1016/S0167-4838(02)00313-8; Wygoda MR, 1997, CANCER RES, V57, P1699; ZIMMERMAN TP, 1971, CAN J BIOCHEM CELL B, V49, P1050, DOI 10.1139/o71-153	61	77	81	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					47110	47118		10.1074/jbc.M304622200	http://dx.doi.org/10.1074/jbc.M304622200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12937174	hybrid			2022-12-25	WOS:000186569400109
J	Murakami, K; Irie, K; Morimoto, A; Ohigashi, H; Shindo, M; Nagao, M; Shimizu, T; Shirasawa, T				Murakami, K; Irie, K; Morimoto, A; Ohigashi, H; Shindo, M; Nagao, M; Shimizu, T; Shirasawa, T			Neurotoxicity and physicochemical properties of A beta mutant peptides from cerebral amyloid angiopathy - Implication for the pathogenesis of cerebral amyloid angiopathy and Alzheimer's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER-BINDING; PRECURSOR PROTEIN; SENILE PLAQUES; DUTCH-TYPE; AGGREGATION; MUTATION; FIBRILS; STATE; GENE; APP	Cerebral amyloid angiopathy (CAA) due to beta-amyloid (Abeta) is one of the specific pathological features of familial Alzheimer's disease. Abeta mainly consisting of 40- and 42-mer peptides (Abeta40 and Abeta42) exhibits neurotoxicity and aggregative abilities. All of the variants of Abeta40 and Abeta42 found in CAA were synthesized in a highly pure form and examined for neurotoxicity in PC12 cells and aggregative ability. All of the Abeta40 mutants at positions 22 and 23 showed stronger neurotoxicity than wild-type Abeta40. Similar tendency was observed for Abeta42 mutants at positions 22 and 23 whose neurotoxicity was 50-200 times stronger than that of the corresponding Abeta40 mutants, suggesting that these Abeta42 mutants are mainly involved in the pathogenesis of CAA. Although the aggregation of E22G-Abeta42 and D23N-Abeta42 was similar to that of wild-type Abeta42, E22Q-Abeta42 and E22K-Abeta42 aggregated extensively, supporting the clinical evidence that Dutch and Italian patients are diagnosed as hereditary cerebral hemorrhage with amyloidosis. In contrast, A21G mutation needs alternative explanation with the exception of physicochemical properties of Abeta mutants. Attenuated total reflection-Fourier transform infrared spectroscopy spectra suggested that beta-sheet content of the Abeta mutants correlates with their aggregation. However, beta-turn is also a critical secondary structure because residues at positions 22 and 23 that preferably form two-residue beta-turn significantly enhanced the aggregative ability.	Kyoto Univ, Grad Sch Agr, Div Food Sci & Biotechnol, Sakyo Ku, Kyoto 6068502, Japan; Appl Biosyst Japan Ltd, Tokyo 1040032, Japan; Kyoto Univ, Grad Sch Biostudies, Div Integrated Life Sci, Kyoto 6068502, Japan; Tokyo Metropolitan Inst Gerontol, Dept Mol Gerontol, Tokyo 1730015, Japan	Kyoto University; Thermo Fisher Scientific; Applied Biosystems; Kyoto University; Tokyo Metropolitan Institute of Gerontology	Irie, K (corresponding author), Kyoto Univ, Grad Sch Agr, Div Food Sci & Biotechnol, Sakyo Ku, Kitashirakawa Oiwake Cho, Kyoto 6068502, Japan.		Murakami, Kazuma/GQA-7062-2022; Irie, Kazuhiro/A-6121-2014	Murakami, Kazuma/0000-0003-3152-1784; Irie, Kazuhiro/0000-0001-7109-8568				Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; BURDICK D, 1992, J BIOL CHEM, V267, P546; CARPINO LA, 1993, J AM CHEM SOC, V115, P4397, DOI 10.1021/ja00063a082; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P211, DOI 10.1021/bi00699a001; CHOU PY, 1977, J MOL BIOL, V115, P135, DOI 10.1016/0022-2836(77)90094-8; Davis J, 1996, P NATL ACAD SCI USA, V93, P2996, DOI 10.1073/pnas.93.7.2996; Fukuda H, 1999, BIOORG MED CHEM LETT, V9, P953, DOI 10.1016/S0960-894X(99)00121-3; Fukuda H, 1999, BIOORGAN MED CHEM, V7, P1213, DOI 10.1016/S0968-0896(99)00037-1; Goormaghtigh E, 1994, Subcell Biochem, V23, P405; Grabowski TJ, 2001, ANN NEUROL, V49, P697, DOI 10.1002/ana.1009; HENDRIKS L, 1992, NAT GENET, V1, P218, DOI 10.1038/ng0692-218; Irie K, 1998, J AM CHEM SOC, V120, P9159, DOI 10.1021/ja981087f; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; IWATSUBO T, 1995, ANN NEUROL, V37, P294, DOI 10.1002/ana.410370305; JAMES HG, 1979, SAS USERS GUIDE, P357; KAMINO K, 1992, AM J HUM GENET, V51, P998; Kirkitadze MD, 2001, J MOL BIOL, V312, P1103, DOI 10.1006/jmbi.2001.4970; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; Melchor JP, 2000, J NEUROCHEM, V74, P2209, DOI 10.1046/j.1471-4159.2000.0742209.x; Miravalle L, 2000, J BIOL CHEM, V275, P27110; Monji A, 2001, J NEUROCHEM, V77, P1425, DOI 10.1046/j.1471-4159.2001.00392.x; Morimoto A, 2002, BIOCHEM BIOPH RES CO, V295, P306, DOI 10.1016/S0006-291X(02)00670-8; Murakami K, 2002, BIOCHEM BIOPH RES CO, V294, P5, DOI 10.1016/S0006-291X(02)00430-8; Naiki H, 1999, METHOD ENZYMOL, V309, P305; NAIKI H, 1989, ANAL BIOCHEM, V177, P244, DOI 10.1016/0003-2697(89)90046-8; Nilsberth C, 2001, NAT NEUROSCI, V4, P887, DOI 10.1038/nn0901-887; Petkova AT, 2002, P NATL ACAD SCI USA, V99, P16742, DOI 10.1073/pnas.262663499; PIKE CJ, 1993, J NEUROSCI, V13, P1676; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; SHEARMAN MS, 1994, P NATL ACAD SCI USA, V91, P1470, DOI 10.1073/pnas.91.4.1470; Shimizu T, 2002, J NEUROSCI RES, V70, P451, DOI 10.1002/jnr.10350; Shin RW, 1997, J NEUROSCI, V17, P8187; Shindo M, 2001, BIOORGAN MED CHEM, V9, P2073, DOI 10.1016/S0968-0896(01)00100-6; Tagliavini F., 1999, ALZHEIMERS REP, V2, pS28; Teplow DB, 1998, AMYLOID, V5, P121, DOI 10.3109/13506129808995290; Tsubuki S, 2003, LANCET, V361, P1957, DOI 10.1016/S0140-6736(03)13555-6; Van Nostrand WE, 2001, J BIOL CHEM, V276, P32860, DOI 10.1074/jbc.M104135200; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Wang ZZ, 2000, STROKE, V31, P534, DOI 10.1161/01.STR.31.2.534	39	200	207	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					46179	46187		10.1074/jbc.M301874200	http://dx.doi.org/10.1074/jbc.M301874200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12944403	hybrid			2022-12-25	WOS:000186452300136
J	Suzuki, N; Nakatsuka, H; Mochizuki, M; Nishi, N; Kadoya, Y; Utani, A; Oishi, S; Fujii, N; Kleinman, HK; Nomizu, M				Suzuki, N; Nakatsuka, H; Mochizuki, M; Nishi, N; Kadoya, Y; Utani, A; Oishi, S; Fujii, N; Kleinman, HK; Nomizu, M			Biological activities of homologous loop regions in the laminin alpha chain G domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL GLOBULAR DOMAIN; CELL-BINDING SEQUENCES; HEPARIN-BINDING; SYNTHETIC PEPTIDES; NEURITE OUTGROWTH; DEVELOPMENTAL EXPRESSION; BRANCHING MORPHOGENESIS; INTEGRIN-RECOGNITION; SUBMANDIBULAR-GLAND; MOLECULAR-CLONING	Laminin alpha chains (alpha(1)-alpha(5) chains) have diverse chain-specific biological functions. The LG4 modules of laminin alpha chains consist of a 14-stranded beta-sheet (A-N) sandwich structure. Several biologically active sequences have been identified in the connecting loop regions. Here, we evaluated the biological activities of the loop regions of the E and F strands in the LG4 modules using five homologous peptides from each of the mouse alpha chains (EF-1: DYATLQLQEGRLHFMFDLG, alpha(1) chain 2747-2765; EF-2: DFGTVQLRNGFPFFSYDLG, alpha(2) chain 2808-2826; EF-3: RDSFVALYLSEGHVIFALG, alpha(3) chain 2266-2284; EF-4: DFMTLFLAHGRLVFMFNVG, alpha(4) chain 1511-1529; EF-5: SPSLVLFLNHGHFVAQTEGP, alpha(5) chain 3304-3323). These homologous peptides showed chain-specific cell attachment and neurite outgrowth activities. Well organized actin stress fibers and focal contacts with vinculin accumulation were observed in fibroblasts attached on EF-1, whereas fibroblasts on EF-2 and EF-4 showed filopodia with ruffling. Fibroblast attachment to EF-2 and EF-4 was mediated by syndecan-2. In contrast, EF-1 promoted alpha(2)beta(1) integrin-mediated fibroblast attachment and inhibited fibroblast attachment to a recombinant laminin alpha(1) chain LG4-5. The receptors for EF-3 and EF-5 are unknown. Further, when the active core sequence of EF-1 was cyclized, utilizing two additional cysteine residues at both the N and C termini through a disulfide bridge, the cyclic peptide significantly enhanced integrin-mediated cell attachment. These results indicate that integrin-mediated cell attachment to the EF-1 sequence is conformation-dependent and that the loop structure is important for the activity. The homologous peptides, which promote either integrin- or syndecan-mediated cell attachment, may be useful for understanding the cell type- and chain-specific biological activities of the laminins.	Hokkaido Univ, Grad Sch Environm Earth Sci, Kita Ku, Sapporo, Hokkaido 0600810, Japan; Kitasato Univ, Sch Med, Dept Anat, Sagamihara, Kanagawa 2288555, Japan; Chiba Univ, Sch Med, Dept Dermatol, Chiba 2608670, Japan; Kyoto Univ, Grad Sch Pharmaceut Sci, Kyoto 6068501, Japan; NIDCR, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA	Hokkaido University; Kitasato University; Chiba University; Kyoto University; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Nomizu, M (corresponding author), Hokkaido Univ, Grad Sch Environm Earth Sci, Kita Ku, Kita 10 Nishi 5, Sapporo, Hokkaido 0600810, Japan.		Oishi, Shinya/C-1350-2011	Oishi, Shinya/0000-0002-2833-2539	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000230] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ABERDAM D, 1994, CELL ADHES COMMUN, V2, P115, DOI 10.3109/15419069409004431; AUMAILLEY M, 1991, FEBS LETT, V291, P50, DOI 10.1016/0014-5793(91)81101-D; BERNIER SM, 1995, MATRIX BIOL, V14, P447, DOI 10.1016/0945-053X(95)90002-0; Bloom L, 1999, MOL BIOL CELL, V10, P1521, DOI 10.1091/mbc.10.5.1521; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; Colognato H, 2000, DEV DYNAM, V218, P213, DOI 10.1002/(SICI)1097-0177(200006)218:2<213::AID-DVDY1>3.0.CO;2-R; Colognato H, 1997, J BIOL CHEM, V272, P29330, DOI 10.1074/jbc.272.46.29330; COLOGNATOPYKE H, 1995, J BIOL CHEM, V270, P9398, DOI 10.1074/jbc.270.16.9398; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; GALLIANO MF, 1995, J BIOL CHEM, V270, P21820, DOI 10.1074/jbc.270.37.21820; GEHLSEN KR, 1992, J CELL BIOL, V117, P449, DOI 10.1083/jcb.117.2.449; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Hoffman MP, 1998, J BIOL CHEM, V273, P28633, DOI 10.1074/jbc.273.44.28633; Hoffman MP, 2001, J BIOL CHEM, V276, P22077, DOI 10.1074/jbc.M100774200; Hohenester E, 1999, MOL CELL, V4, P783, DOI 10.1016/S1097-2765(00)80388-3; Hosokawa Y, 1999, DEV GROWTH DIFFER, V41, P207; Iivanainen A, 1999, J BIOL CHEM, V274, P14107, DOI 10.1074/jbc.274.20.14107; Iivanainen A, 1997, J BIOL CHEM, V272, P27862, DOI 10.1074/jbc.272.44.27862; Kadoya Y, 1998, DEV DYNAM, V212, P394; KADOYA Y, 2003, IN PRESS DEV BIOL; Kato K, 2002, BIOCHEMISTRY-US, V41, P10747, DOI 10.1021/bi020180k; Kim WH, 1998, INT J CANCER, V77, P632, DOI 10.1002/(SICI)1097-0215(19980812)77:4<632::AID-IJC25>3.0.CO;2-6; KLEINMAN HK, 1989, ARCH BIOCHEM BIOPHYS, V272, P39, DOI 10.1016/0003-9861(89)90192-6; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; Libby RT, 2000, J NEUROSCI, V20, P6517, DOI 10.1523/JNEUROSCI.20-17-06517.2000; Makino M, 2002, EXP CELL RES, V277, P95, DOI 10.1006/excr.2002.5540; MAKINO M, 1999, CONNECT TISSUE, V31, P227; Malinda KM, 1999, FASEB J, V13, P53, DOI 10.1096/fasebj.13.1.53; MATTER ML, 1994, J CELL BIOL, V124, P1083, DOI 10.1083/jcb.124.6.1083; MINER JH, 1995, J BIOL CHEM, V270, P28523, DOI 10.1074/jbc.270.48.28523; Miner JH, 1997, J CELL BIOL, V137, P685, DOI 10.1083/jcb.137.3.685; Mochizuki M, 2003, FASEB J, V17, P875, DOI 10.1096/fj.02-0564fje; Nielsen PK, 2000, J BIOL CHEM, V275, P14517, DOI 10.1074/jbc.275.19.14517; Nomizu M, 1997, J BIOL CHEM, V272, P32198, DOI 10.1074/jbc.272.51.32198; Nomizu M, 1998, J BIOL CHEM, V273, P32491, DOI 10.1074/jbc.273.49.32491; NOMIZU M, 1995, J BIOL CHEM, V270, P20583, DOI 10.1074/jbc.270.35.20583; Nomizu M, 2000, ARCH BIOCHEM BIOPHYS, V378, P311, DOI 10.1006/abbi.2000.1828; NUMA F, 1995, CANCER RES, V55, P4676; Okazaki I, 2002, J BIOL CHEM, V277, P37070, DOI 10.1074/jbc.M201672200; PFAFF M, 1994, J BIOL CHEM, V269, P20233; RASHEED S, 1974, CANCER, V33, P1027, DOI 10.1002/1097-0142(197404)33:4<1027::AID-CNCR2820330419>3.0.CO;2-Z; Richard BL, 1996, EXP CELL RES, V228, P98, DOI 10.1006/excr.1996.0304; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SHIRASUNA K, 1981, CANCER, V48, P745, DOI 10.1002/1097-0142(19810801)48:3<745::AID-CNCR2820480314>3.0.CO;2-7; Simons M, 2001, CELL SIGNAL, V13, P855, DOI 10.1016/S0898-6568(01)00190-5; SKUBITZ APN, 1991, J CELL BIOL, V115, P1137, DOI 10.1083/jcb.115.4.1137; SMITH JW, 1988, J BIOL CHEM, V263, P18726; Song SY, 1997, INT J CANCER, V71, P436, DOI 10.1002/(SICI)1097-0215(19970502)71:3<436::AID-IJC22>3.0.CO;2-C; SONNENBERG A, 1990, J CELL BIOL, V110, P2145, DOI 10.1083/jcb.110.6.2145; SOROKIN L, 1990, J CELL BIOL, V111, P1265, DOI 10.1083/jcb.111.3.1265; SUNG U, 1993, J CELL BIOL, V123, P1255, DOI 10.1083/jcb.123.5.1255; Timpl R, 2000, MATRIX BIOL, V19, P309, DOI 10.1016/S0945-053X(00)00072-X; Utani A, 2001, J BIOL CHEM, V276, P28779, DOI 10.1074/jbc.M101420200; Woods A, 2001, CURR OPIN CELL BIOL, V13, P578, DOI 10.1016/S0955-0674(00)00254-4; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; Yamada Yoshihiko, 1992, Current Opinion in Cell Biology, V4, P819, DOI 10.1016/0955-0674(92)90105-L; Yamaguchi H, 2000, J BIOL CHEM, V275, P29458, DOI 10.1074/jbc.M003103200; YURCHENCO PD, 1993, J BIOL CHEM, V268, P17286	58	71	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45697	45705		10.1074/jbc.M304667200	http://dx.doi.org/10.1074/jbc.M304667200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12933811	hybrid			2022-12-25	WOS:000186452300079
J	Takahata, S; Ryu, H; Ohtsuki, K; Kasahara, K; Kawaichi, M; Kokubo, T				Takahata, S; Ryu, H; Ohtsuki, K; Kasahara, K; Kawaichi, M; Kokubo, T			Identification of a novel TATA element-binding protein binding region at the N terminus of the Saccharomyces cerevisiae TAF1 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TRANSCRIPTION IN-VIVO; YEAST TFIIA/TBP/DNA COMPLEX; SHOW SYNTHETIC LETHALITY; BOX-BINDING; ACTIVATED TRANSCRIPTION; CRYSTAL-STRUCTURE; DNA-BINDING; REPRESSES TRANSCRIPTION; INHIBITORY DOMAIN	TFIID, a multiprotein complex composed of TATA element-binding protein (TBP) and 14 TBP-associated factors (TAFs), can directly recognize core promoter elements and mediate transcriptional activation. The TAF N-terminal domain (TAND) of TAF1 may play a significant role in these two principal TFIID functions by regulating the access of TBP to the TATA element. In yeast, TAND consists of two subdomains, TAND1 (10-37 amino acids (aa)) and TAND2 (46-71 aa), which interact with the concave and convex surfaces of TBP, respectively. Here we demonstrate that another region located on the C-terminal side of TAND2 (82-139 aa) can also bind to TBP and induce transcriptional activation when tethered to DNA as a GAL4 fusion protein. As these properties are the same as those of TAND1, we denoted this sequence as TAND3. Detailed mutational analyses revealed that three blocks of hydrophobic amino acid residues located within TAND3 are required not only for TBP binding and transcriptional activation but also for supporting cell growth and the efficient transcription of a subset of genes. We also show that the surface of TBP recognized by TAND3 is broader than that recognized by TAND1, although these regions overlap partially. Supporting these observations is that TAND1 can be at least partly functionally substituted by TAND3.	Yokohama City Univ, Grad Sch Integrated Sci, Div Mol & Cellular Biol, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan; Nara Inst Sci & Technol, Div Gene Funct Anim, Ikoma 6300192, Japan	Yokohama City University; Nara Institute of Science & Technology	Kokubo, T (corresponding author), Yokohama City Univ, Grad Sch Integrated Sci, Div Mol & Cellular Biol, Tsurumi Ku, 1-7-29 Suehiro Cho, Yokohama, Kanagawa 2300045, Japan.							Adams Alison, 1997, P99; ARNDT KM, 1995, EMBO J, V14, P1490, DOI 10.1002/j.1460-2075.1995.tb07135.x; AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; Baek HJ, 2002, MOL CELL BIOL, V22, P2842, DOI 10.1128/MCB.22.8.2842-2852.2002; Bagby S, 2000, FEBS LETT, V468, P149, DOI 10.1016/S0014-5793(00)01213-8; Bai Y, 1997, MOL CELL BIOL, V17, P3081, DOI 10.1128/MCB.17.6.3081; Banik U, 2001, J BIOL CHEM, V276, P49100, DOI 10.1074/jbc.M109246200; Bhaumik SR, 2002, MOL CELL BIOL, V22, P7365, DOI 10.1128/MCB.22.21.7365-7371.2002; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; Bryant GO, 1996, GENE DEV, V10, P2491, DOI 10.1101/gad.10.19.2491; Butler JEF, 2002, GENE DEV, V16, P2583, DOI 10.1101/gad.1026202; Cang Y, 1999, EMBO J, V18, P6662, DOI 10.1093/emboj/18.23.6662; Cang Y, 2002, P NATL ACAD SCI USA, V99, P12727, DOI 10.1073/pnas.202236699; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; Cheng JX, 2002, CURR BIOL, V12, P934, DOI 10.1016/S0960-9822(02)00866-7; Cheng JX, 2002, CURR BIOL, V12, P1828, DOI 10.1016/S0960-9822(02)01257-5; Chitikila C, 2002, MOL CELL, V10, P871, DOI 10.1016/S1097-2765(02)00683-4; Creton S, 2002, GENE DEV, V16, P3265, DOI 10.1101/gad.234002; Darst RP, 2003, J BIOL CHEM, V278, P13216, DOI 10.1074/jbc.M211445200; Dasgupta A, 2002, P NATL ACAD SCI USA, V99, P2666, DOI 10.1073/pnas.052397899; Deluen C, 2002, MOL CELL BIOL, V22, P6735, DOI 10.1128/MCB.22.19.6735-6749.2002; Furukawa T, 2000, J BIOL CHEM, V275, P29847, DOI 10.1074/jbc.M002989200; Gadbois EL, 1997, P NATL ACAD SCI USA, V94, P3145, DOI 10.1073/pnas.94.7.3145; Galasinski SK, 2000, MOL CELL BIOL, V20, P1923, DOI 10.1128/MCB.20.6.1923-1930.2000; Geiger JH, 1996, SCIENCE, V272, P830, DOI 10.1126/science.272.5263.830; Geisberg JV, 2002, MOL CELL BIOL, V22, P8122, DOI 10.1128/MCB.22.23.8122-8134.2002; Geisberg JV, 2001, MOL CELL BIOL, V21, P2736, DOI 10.1128/MCB.21.8.2736-2742.2001; Goppelt A, 1996, EMBO J, V15, P3105, DOI 10.1002/j.1460-2075.1996.tb00673.x; Goppelt A, 1996, NUCLEIC ACIDS RES, V24, P4450, DOI 10.1093/nar/24.22.4450; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Gregory PD, 1999, EMBO J, V18, P6407, DOI 10.1093/emboj/18.22.6407; Guermah M, 1998, MOL CELL BIOL, V18, P3234, DOI 10.1128/MCB.18.6.3234; Guermah M, 2001, MOL CELL BIOL, V21, P6882, DOI 10.1128/MCB.21.20.6882-6894.2001; Iratni R, 2002, SCIENCE, V298, P1996, DOI 10.1126/science.1073405; Johnson KM, 2003, CURR BIOL, V13, P772, DOI 10.1016/S0960-9822(03)00283-5; Kamada K, 2001, CELL, V106, P71, DOI 10.1016/S0092-8674(01)00417-2; Kim S, 1997, P NATL ACAD SCI USA, V94, P820, DOI 10.1073/pnas.94.3.820; KIM TK, 1994, NATURE, V369, P252, DOI 10.1038/369252a0; Kobayashi A, 2003, NUCLEIC ACIDS RES, V31, P1261, DOI 10.1093/nar/gkg180; Kobayashi A, 2001, J BIOL CHEM, V276, P395, DOI 10.1074/jbc.M008208200; KOKUBO T, 1994, P NATL ACAD SCI USA, V91, P3520, DOI 10.1073/pnas.91.9.3520; Kokubo T, 1998, MOL CELL BIOL, V18, P1003, DOI 10.1128/MCB.18.2.1003; Kotani T, 2000, P NATL ACAD SCI USA, V97, P7178, DOI 10.1073/pnas.120074297; Kotani T, 1998, J BIOL CHEM, V273, P32254, DOI 10.1074/jbc.273.48.32254; Kou HP, 2003, MOL CELL BIOL, V23, P3186, DOI 10.1128/MCB.23.9.3186-3201.2003; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Kuras L, 2000, SCIENCE, V288, P1244, DOI 10.1126/science.288.5469.1244; Lee TI, 2000, ANNU REV GENET, V34, P77, DOI 10.1146/annurev.genet.34.1.77; Li XY, 2000, SCIENCE, V288, P1242, DOI 10.1126/science.288.5469.1242; Li XY, 2002, CURR BIOL, V12, P1240, DOI 10.1016/S0960-9822(02)00932-6; Liu DJ, 1998, CELL, V94, P573, DOI 10.1016/S0092-8674(00)81599-8; Lively TN, 2001, J BIOL CHEM, V276, P25582, DOI 10.1074/jbc.M100278200; LUNDBLACK V, 1998, CURRENT PROTOCOLS MO, V2; Martel LS, 2002, MOL CELL BIOL, V22, P2788, DOI 10.1128/MCB.22.8.2788-2798.2002; Mencia M, 2002, MOL CELL, V9, P823, DOI 10.1016/S1097-2765(02)00490-2; Naar AM, 2001, ANNU REV BIOCHEM, V70, P475, DOI 10.1146/annurev.biochem.70.1.475; Nishikawa J, 1997, P NATL ACAD SCI USA, V94, P85, DOI 10.1073/pnas.94.1.85; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Ozer J, 1998, J BIOL CHEM, V273, P14293, DOI 10.1074/jbc.273.23.14293; Patikoglou GA, 1999, GENE DEV, V13, P3217, DOI 10.1101/gad.13.24.3217; Pereira LA, 2001, MOL CELL BIOL, V21, P7523, DOI 10.1128/MCB.21.21.7523-7534.2001; Prelich G, 1997, MOL CELL BIOL, V17, P2057, DOI 10.1128/MCB.17.4.2057; Pugh BF, 2000, GENE, V255, P1, DOI 10.1016/S0378-1119(00)00288-2; Roeder RG, 1998, COLD SPRING HARB SYM, V63, P201, DOI 10.1101/sqb.1998.63.201; Sanders SL, 2002, MOL CELL BIOL, V22, P6000, DOI 10.1128/MCB.22.16.6000-6013.2002; SIKORSKI RS, 1989, GENETICS, V122, P19; Stargell LA, 1996, MOL CELL BIOL, V16, P4456; STARGELL LA, 1995, SCIENCE, V269, P75, DOI 10.1126/science.7604282; Sullivan SM, 1998, NUCLEIC ACIDS RES, V26, P4487, DOI 10.1093/nar/26.19.4487; Tan S, 1996, NATURE, V381, P127, DOI 10.1038/381127a0; Tora L, 2002, GENE DEV, V16, P673, DOI 10.1101/gad.976402; Tsukihashi Y, 2000, MOL CELL BIOL, V20, P2385, DOI 10.1128/MCB.20.7.2385-2399.2000; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310; Willy PJ, 2000, SCIENCE, V290, P982, DOI 10.1126/science.290.5493.982; Xie YQ, 2000, J BIOL CHEM, V275, P31914, DOI 10.1074/jbc.M003760200	75	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45888	45902		10.1074/jbc.M306886200	http://dx.doi.org/10.1074/jbc.M306886200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12939271	hybrid			2022-12-25	WOS:000186452300102
J	Frank, J; Roux, J; Kawakatsu, H; Su, G; Dagenais, A; Berthiaume, Y; Howard, M; Canessa, CM; Fang, XH; Sheppard, D; Matthay, MA; Pittet, JF				Frank, J; Roux, J; Kawakatsu, H; Su, G; Dagenais, A; Berthiaume, Y; Howard, M; Canessa, CM; Fang, XH; Sheppard, D; Matthay, MA; Pittet, JF			Transforming growth factor-beta 1 decreases expression of the epithelial sodium channel alpha ENaC and alveolar epithelial vectorial sodium and fluid transport via an ERK1/2-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY-DISTRESS-SYNDROME; GROWTH-FACTOR-BETA; ACUTE LUNG INJURY; ACTIVATED PROTEIN-KINASE; III PROCOLLAGEN PEPTIDE; LIQUID CLEARANCE; PULMONARY-FIBROSIS; GENE-EXPRESSION; CELLS; MICE	Acute lung injury (ALI) is characterized by the flooding of the alveolar airspaces with protein-rich edema fluid and diffuse alveolar damage. We have previously reported that transforming growth factor-beta1 (TGF-beta1) is a critical mediator of ALI after intratracheal administration of bleomycin or Escherichia coli endotoxin, at least in part due to effects on lung endothelial and alveolar epithelial permeability. In the present study, we hypothesized that TGF-beta1 would also decrease vectorial ion and water transport across the distal lung epithelium. Therefore, we studied the effect of active TGF-beta1 on Na-22(+) uptake across monolayers of primary rat and human alveolar type II (ATII) cells. TGF-beta1 significantly reduced the amiloride-sensitive fraction of Na-22(+) uptake and fluid transport across monolayers of both rat and human ATII cells. TGF-beta1 also significantly decreased alphaENaC mRNA and protein expression and inhibited expression of a luciferase reporter downstream of the alphaENaC promoter in lung epithelial cells. The inhibitory effect of TGF-beta1 on sodium uptake and alphaENaC expression in ATII cells was mediated by activation of the MAPK, ERK1/2. Consistent with the in vitro results, TGF-beta1 inhibited the amiloride-sensitive fraction of the distal airway epithelial fluid transport in an in vivo rat model at a dose that was not associated with any change in epithelial protein permeability. These data indicate that increased TGF-beta1 activity in the distal airspaces during ALI promotes alveolar edema by reducing distal airway epithelial sodium and fluid clearance. This reduction in sodium and fluid transport is attributable in large part to a reduction in apical membrane alphaENaC expression mediated through an ERK1/2-dependent inhibition of the alphaENaC promoter activity.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94110 USA; Univ Calif San Francisco, Dept Surg, San Francisco, CA 94110 USA; Univ Calif San Francisco, Dept Anesthesia, Surg Res Lab, Cardiovasc Res Inst,Lung Biol Ctr, San Francisco, CA 94110 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA; Univ Montreal, Dept Med, Montreal, PQ H2W 1T7, Canada; Univ Montreal, CHU Montreal, Ctr Rech, Montreal, PQ H2W 1T7, Canada	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Yale University; Universite de Montreal; Universite de Montreal	Pittet, JF (corresponding author), San Francisco Gen Hosp, Dept Anesthesia, Rm 3C-38,1001 Potrero Ave, San Francisco, CA 94110 USA.	pittetj@anesthesia.ucsf.edu	Berthiaume, Yves/K-7588-2012; Roux, Jeremie/A-9746-2013	Roux, Jeremie/0000-0001-5712-8660	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL069900, R56HL088440, R01HL051854] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062188] Funding Source: NIH RePORTER; NHLBI NIH HHS [K08 HL069900-04, K08 HL069900, HL-69900, R56 HL088440, HL-51854] Funding Source: Medline; NIGMS NIH HHS [GM-62188] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barker PM, 1998, J CLIN INVEST, V102, P1634, DOI 10.1172/JCI3971; BROEKELMANN TJ, 1991, P NATL ACAD SCI USA, V88, P6642, DOI 10.1073/pnas.88.15.6642; CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, pC1682, DOI 10.1152/ajpcell.1994.267.6.C1682; CHEN XJ, 2002, AM J RESP CRIT CARE, V165, P751; Chesnutt AN, 1997, AM J RESP CRIT CARE, V156, P840, DOI 10.1164/ajrccm.156.3.9701124; CLARK JG, 1995, ANN INTERN MED, V122, P17, DOI 10.7326/0003-4819-122-1-199501010-00003; Dagenais A, 2001, AM J PHYSIOL-LUNG C, V281, pL217, DOI 10.1152/ajplung.2001.281.1.L217; de la Rosa DA, 2002, J GEN PHYSIOL, V119, P427, DOI 10.1085/jgp.20028559; Fahy RJ, 2003, AM J RESP CELL MOL, V28, P499, DOI 10.1165/rcmb.2002-0092OC; FANG X, 2003, AM J RESP CRIT CARE, V167, P564; Fang XH, 2003, FASEB J, V17, pA87; Folkesson HG, 2000, J APPL PHYSIOL, V88, P416, DOI 10.1152/jappl.2000.88.2.416; Frank JA, 2002, AM J RESP CRIT CARE, V165, P242, DOI 10.1164/ajrccm.165.2.2108087; Furuichi S, 2002, RESPIROLOGY, V7, P193, DOI 10.1046/j.1440-1843.2002.00401.x; GIRI SN, 1993, THORAX, V48, P959, DOI 10.1136/thx.48.10.959; Hashimoto S, 1999, AM J RESP CRIT CARE, V159, P634, DOI 10.1164/ajrccm.159.2.9712090; Hummler E, 1996, NAT GENET, V12, P325, DOI 10.1038/ng0396-325; Hurst V, 1999, AM J PHYSIOL-LUNG C, V276, pL582, DOI 10.1152/ajplung.1999.276.4.L582; Itani OA, 2003, AM J PHYSIOL-RENAL, V284, pF778, DOI 10.1152/ajprenal.00088.2002; Jain L, 2001, AM J PHYSIOL-LUNG C, V280, pL646, DOI 10.1152/ajplung.2001.280.4.L646; Kaminski N, 2000, P NATL ACAD SCI USA, V97, P1778, DOI 10.1073/pnas.97.4.1778; Mairbaurl H, 2002, AM J PHYSIOL-LUNG C, V282, pL659, DOI 10.1152/ajplung.00355; Matthay MA, 2002, PHYSIOL REV, V82, P569, DOI 10.1152/physrev.00003.2002; MATTHAY MA, 1990, AM REV RESPIR DIS, V142, P1250, DOI 10.1164/ajrccm/142.6_Pt_1.1250; McDonald FJ, 1999, P NATL ACAD SCI USA, V96, P1727, DOI 10.1073/pnas.96.4.1727; McNicholas CM, 1997, J GEN PHYSIOL, V109, P681, DOI 10.1085/jgp.109.6.681; Morris RG, 2002, J GEN PHYSIOL, V120, P71, DOI 10.1085/jgp.20018547; Pittet JF, 2001, J CLIN INVEST, V107, P1537, DOI 10.1172/JCI11963; Pittet JF, 2001, J IMMUNOL, V166, P6301, DOI 10.4049/jimmunol.166.10.6301; PITTET JF, 1994, J CLIN INVEST, V94, P663, DOI 10.1172/JCI117383; Planes C, 2002, J BIOL CHEM, V277, P47318, DOI 10.1074/jbc.M209158200; Sartori C, 2002, J APPL PHYSIOL, V93, P1875, DOI 10.1152/japplphysiol.00275.2002; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; SUZUKI S, 1995, AM J PHYSIOL-LUNG C, V268, pL983, DOI 10.1152/ajplung.1995.268.6.L983; WANG A, 1991, J BIOL CHEM, V266, P15598; Wang HC, 2000, J BIOL CHEM, V275, P8600, DOI 10.1074/jbc.275.12.8600; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; Ware LB, 2002, LANCET, V360, P619, DOI 10.1016/S0140-6736(02)09774-X; Ware LB, 2001, AM J RESP CRIT CARE, V163, P1376, DOI 10.1164/ajrccm.163.6.2004035; Yue JB, 2001, PHARMACOL THERAPEUT, V91, P1, DOI 10.1016/S0163-7258(01)00143-7	40	126	134	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					43939	43950		10.1074/jbc.M304882200	http://dx.doi.org/10.1074/jbc.M304882200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12930837	hybrid			2022-12-25	WOS:000186306700009
J	Pantano, C; Shrivastava, P; McElhinney, B; Janssen-Heininger, Y				Pantano, C; Shrivastava, P; McElhinney, B; Janssen-Heininger, Y			Hydrogen peroxide signaling through tumor necrosis factor receptor 1 leads to selective activation of c-Jun N-terminal kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-KAPPA-B; NH2-TERMINAL KINASE; INDUCED APOPTOSIS; OXIDATIVE STRESS; EPITHELIAL-CELLS; IKK ACTIVATION; DEATH; JNK; PROTEIN; DOMAIN	Binding of tumor necrosis factor-alpha (TNFalpha) to its receptor, TNF-R1, results in the activation of inhibitor of kappaB kinase (IKK) and c-Jun N-terminal kinase (JNK) pathways that are coordinately regulated and important in survival and death. We demonstrated previously that in response to hydrogen peroxide (H2O2), the ability of TNFalpha to activate IKK in mouse lung epithelial cells (C10) was inhibited and that H2O2 alone was sufficient to activate JNK and induce cell death. In the current study, we investigated the involvement of TNF-R1 in H2O2-induced JNK activation. In lung fibroblasts from TNF-R1-deficient mice the ability of H2O2 to activate JNK was inhibited compared with fibroblasts from control mice. Additionally, in C10 cells expressing a mutant form of TNF-R1, H2O2-induced JNK activation was also inhibited. Immunoprecipitation of TNF-R1 revealed that in response to H2O2, the adapter proteins, TRADD and TRAF2, and JNK were recruited to the receptor. However, expression of the adaptor protein RIP, which is essential for IKK activation by TNFalpha, was decreased in cells exposed to H2O2, and its chaperone Hsp90 was cleaved. Furthermore, data demonstrating that expression of TRAF2 was not affected by H2O2 and that overexpression of TRAF2 was sufficient to activate JNK provide an explanation for the inability of H2O2 to activate IKK and for the selective activation of JNK by H2O2. Our data demonstrate that oxidative stress interferes with IKK activation while promoting JNK signaling, creating a signaling imbalance that may favor apoptosis.	Univ Vermont, Dept Pathol, Hlth Sci Res Facil, Burlington, VT 05405 USA	University of Vermont	Janssen-Heininger, Y (corresponding author), Univ Vermont, Dept Pathol, Hlth Sci Res Facil, Rm 216A, Burlington, VT 05405 USA.				NHLBI NIH HHS [R01 HL60014, P01 HL67004] Funding Source: Medline; PHS HHS [P20 RL15557] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL067004, R01HL060014] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amdjadi K, 2000, J BIOL CHEM, V275, P22520, DOI 10.1074/jbc.M002573200; Aoki H, 2002, J BIOL CHEM, V277, P10244, DOI 10.1074/jbc.M112355200; Arbiser JL, 2002, P NATL ACAD SCI USA, V99, P715, DOI 10.1073/pnas.022630199; Arnold RS, 2001, P NATL ACAD SCI USA, V98, P5550, DOI 10.1073/pnas.101505898; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; Barinaga M, 1996, SCIENCE, V274, P724, DOI 10.1126/science.274.5288.724; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Chen GQ, 2002, MOL CELL, V9, P401, DOI 10.1016/S1097-2765(02)00450-1; Chen K, 2001, J BIOL CHEM, V276, P16045, DOI 10.1074/jbc.M011766200; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; Finkel T, 2003, CURR OPIN CELL BIOL, V15, P247, DOI 10.1016/S0955-0674(03)00002-4; Garg AK, 2002, MOL IMMUNOL, V39, P509, DOI 10.1016/S0161-5890(02)00207-9; Harper N, 2003, J BIOL CHEM, V278, P25534, DOI 10.1074/jbc.M303399200; Hayakawa M, 2003, EMBO J, V22, P3356, DOI 10.1093/emboj/cdg332; Hess P, 2002, NAT GENET, V32, P201, DOI 10.1038/ng946; Hino T, 1999, AM J RESP CELL MOL, V20, P122, DOI 10.1165/ajrcmb.20.1.3217; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Janssen YMW, 1997, AM J PHYSIOL-LUNG C, V273, pL789, DOI 10.1152/ajplung.1997.273.4.L789; Janssen-Heininger YMW, 1999, AM J RESP CELL MOL, V20, P942, DOI 10.1165/ajrcmb.20.5.3452; Janssen-Heininger YMW, 2000, FREE RADICAL BIO MED, V28, P1317, DOI 10.1016/S0891-5849(00)00218-5; Korn SH, 2001, J BIOL CHEM, V276, P35693, DOI 10.1074/jbc.M104321200; Lamb JA, 2003, MOL CELL, V11, P1479, DOI 10.1016/S1097-2765(03)00203-X; Lei K, 2002, MOL CELL BIOL, V22, P4929, DOI 10.1128/MCB.22.13.4929-4942.2002; Lewis J, 2000, J BIOL CHEM, V275, P10519, DOI 10.1074/jbc.275.14.10519; Li NX, 1999, FASEB J, V13, P1137, DOI 10.1096/fasebj.13.10.1137; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Moore KA, 1997, BIOCHEM J, V326, P17, DOI 10.1042/bj3260017; Nimnual AS, 2003, NAT CELL BIOL, V5, P236, DOI 10.1038/ncb938; Pritchard KA, 2001, J BIOL CHEM, V276, P17621, DOI 10.1074/jbc.C100084200; Reeves EP, 2002, NATURE, V416, P291, DOI 10.1038/416291a; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Sabapathy K, 1999, MECH DEVELOP, V89, P115, DOI 10.1016/S0925-4773(99)00213-0; SCHRAUFSTATTER I, 1988, J CLIN INVEST, V82, P1040, DOI 10.1172/JCI113660; SLUNGAARD A, 1990, J EXP MED, V171, P2025, DOI 10.1084/jem.171.6.2025; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; Tang FM, 2002, MOL CELL BIOL, V22, P8571, DOI 10.1128/MCB.22.24.8571-8579.2002; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680	44	69	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44091	44096		10.1074/jbc.M308487200	http://dx.doi.org/10.1074/jbc.M308487200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12939259	hybrid			2022-12-25	WOS:000186306700026
J	Ryder, JW; Bassel-Duby, R; Olson, EN; Zierath, JR				Ryder, JW; Bassel-Duby, R; Olson, EN; Zierath, JR			Skeletal muscle reprogramming by activation of calcineurin improves insulin action on metabolic pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPE-2 DIABETIC-PATIENTS; GLUT4 GENE-EXPRESSION; PROTEIN-KINASE B; GLUCOSE-TRANSPORT; FIBER-TYPE; TRANSGENIC MICE; IN-VITRO; PHOSPHOINOSITIDE 3-KINASE; SIGNAL-TRANSDUCTION; STIMULATION	The protein phosphatase calcineurin is a signaling intermediate that induces the transformation of fast-twitch skeletal muscle fibers to a slow-twitch phenotype. This reprogramming of the skeletal muscle gene expression profile may have therapeutic applications for metabolic disease. Insulin-stimulated glucose uptake in skeletal muscle is both impaired in individuals with type II diabetes mellitus and positively correlated with the percentage of slow- versus fast-twitch muscle fibers. Using transgenic mice expressing activated calcineurin in skeletal muscle, we report that skeletal muscle reprogramming by calcineurin activation leads to improved insulin-stimulated 2-deoxyglucose uptake in extensor digitorum longus (EDL) muscles compared with wild-type mice, concomitant with increased protein expression of the insulin receptor, Akt, glucose transporter 4, and peroxisome proliferator-activated receptor-gamma co-activator 1. Transgenic mice exhibited elevated glycogen deposition, enhanced amino acid uptake, and increased fatty acid oxidation in EDL muscle. When fed a high-fat diet, transgenic mice maintained superior rates of insulin-stimulated glucose uptake in EDL muscle and were protected against diet-induced glucose intolerance. These results validate calcineurin as a target for enhancing insulin action in skeletal muscle.	Karolinska Inst, Dept Physiol & Pharmacol, Sect Integrat Physiol, S-17177 Stockholm, Sweden; Karolinska Inst, Dept Surg Sci, Sect Integrat Physiol, S-17177 Stockholm, Sweden; Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA	Karolinska Institutet; Karolinska Institutet; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Ryder, JW (corresponding author), Karolinska Inst, Dept Physiol & Pharmacol, Sect Integrat Physiol, S-17177 Stockholm, Sweden.			Zierath, Juleen/0000-0001-6891-7497				Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; Daugaard JR, 2000, DIABETES, V49, P1092, DOI 10.2337/diabetes.49.7.1092; De Windt LJ, 2000, CIRC RES, V86, P255, DOI 10.1161/01.RES.86.3.255; DEFRONZO RA, 1985, J CLIN INVEST, V76, P149, DOI 10.1172/JCI111938; HENRIKSEN EJ, 1990, AM J PHYSIOL, V259, pE593, DOI 10.1152/ajpendo.1990.259.4.E593; HICKEY MS, 1995, AM J PHYSIOL-ENDOC M, V268, pE453, DOI 10.1152/ajpendo.1995.268.3.E453; HINTZ CS, 1982, AM J PHYSIOL, V242, pC218, DOI 10.1152/ajpcell.1982.242.3.C218; Kim YB, 1999, J CLIN INVEST, V104, P733, DOI 10.1172/JCI6928; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Krook A, 2000, DIABETES, V49, P284, DOI 10.2337/diabetes.49.2.284; Krook A, 1997, J BIOL CHEM, V272, P30208, DOI 10.1074/jbc.272.48.30208; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; LOWERY OH, 1972, FLEXIBLE SYSTEM ENZY, P189; Manchester J, 1996, P NATL ACAD SCI USA, V93, P10707, DOI 10.1073/pnas.93.20.10707; Michael LF, 2001, P NATL ACAD SCI USA, V98, P3820, DOI 10.1073/pnas.061035098; Naya FJ, 2000, J BIOL CHEM, V275, P4545, DOI 10.1074/jbc.275.7.4545; OKADA T, 1994, J BIOL CHEM, V269, P3568; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; REN JM, 1993, J BIOL CHEM, V268, P16113; Ryder JW, 1999, BIOCHEM J, V342, P321, DOI 10.1042/0264-6021:3420321; Ryder JW, 2000, DIABETES, V49, P647, DOI 10.2337/diabetes.49.4.647; Saltin B, 2010, COMPR PHYSIOL, P555; Song XM, 1999, AM J PHYSIOL-REG I, V277, pR1690, DOI 10.1152/ajpregu.1999.277.6.R1690; Thai MV, 1998, J BIOL CHEM, V273, P14285, DOI 10.1074/jbc.273.23.14285; Tsao TS, 2001, FASEB J, V15, P958, DOI 10.1096/fj.00-0381; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Wu H, 2001, EMBO J, V20, P6414, DOI 10.1093/emboj/20.22.6414; Wu H, 2000, EMBO J, V19, P1963, DOI 10.1093/emboj/19.9.1963; Wu H, 2002, SCIENCE, V296, P349, DOI 10.1126/science.1071163; Zierath JB, 1997, DIABETES, V46, P215, DOI 10.2337/diabetes.46.2.215	32	104	110	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44298	44304		10.1074/jbc.M304510200	http://dx.doi.org/10.1074/jbc.M304510200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12941959	hybrid			2022-12-25	WOS:000186306700051
J	Takuma, A; Kaneda, T; Sato, T; Ninomiya, S; Kumegawa, M; Hakeda, Y				Takuma, A; Kaneda, T; Sato, T; Ninomiya, S; Kumegawa, M; Hakeda, Y			Dexamethasone enhances osteoclast formation synergistically with transforming growth factor-beta by stimulating the priming of osteoclast progenitors for differentiation into osteoclasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; GLUCOCORTICOID-INDUCED OSTEOPOROSIS; NECROSIS-FACTOR RECEPTOR; OSTEOBLAST-LIKE CELLS; CREB-BINDING-PROTEIN; BONE-RESORPTION; OSTEOPROTEGERIN LIGAND; TRANSCRIPTION FACTORS; SIGNAL-TRANSDUCTION; PARATHYROID-HORMONE	Long-term administration of glucocorticoids (GCs) causes osteoporosis with a rapid and severe bone loss and with a slow and prolonged bone disruption. Although the involvement of GCs in osteoblastic proliferation and differentiation has been studied extensively, their direct action on osteoclasts is still controversial and not conclusive. In this study, we investigated the direct participation of GCs in osteoclastogenesis. Dexamethasone (Dex) at < 10(-8) M stimulated, but at > 10(-7) M depressed, receptor activator of NF-kappaB ligand (RANKL)induced osteoclast formation synergistically with transforming growth factor-beta. The stimulatory action of Dex was restricted to the early phase of osteoclast differentiation and enhanced the priming of osteoclast progenitors ( bone marrow-derived monocytes/ macrophages) toward differentiation into cells of the osteoclast lineage. The osteoclast differentiation depending on RANKL requires the activation of NF-kappaB and AP-1, and the DNA binding of these transcription factors to their respective consensus cis-elements was enhanced by Dex, consistent with the stimulation of osteoclastogenesis. However, Dex did not affect the RANKL-induced signaling pathways such as the activation of IkappaB kinase followed by NF-kappaB nuclear translocation or the activation of JNK. On the other hand, Dex significantly decreased the endogenous production of interferon-beta, and this cytokine depressed the RANKL-elicited DNA binding of NF-kappaB and AP-1, as well as osteoclast formation. Thus, the down-regulation of inhibitory cytokines such as interferon-beta by Dex may allow the osteoclast progenitors to be freed from the suppression of osteoclastogenesis, resulting in an increased number of osteoclasts, as is observed in the early phase of GC-induced osteoporosis.	Meikai Univ, Sch Dent, Dept Oral Anat, Sakado, Saitama 3500283, Japan; Saitama Med Sch, Dept Orthopaed Surg, Moroyama, Saitama 3500495, Japan; Hoshi Univ, Fac Pharmaceut Sci, Dept Pathophysiol, Shinagawa Ku, Tokyo 1428501, Japan	Meikai University; Saitama Medical University; Hoshi University	Hakeda, Y (corresponding author), Meikai Univ, Sch Dent, Dept Oral Anat, Sakado, Saitama 3500283, Japan.							Adcock IM, 2001, IMMUNOL CELL BIOL, V79, P376, DOI 10.1046/j.1440-1711.2001.01025.x; Almawi WY, 2002, J MOL ENDOCRINOL, V28, P69, DOI 10.1677/jme.0.0280069; Armstrong AP, 2002, J BIOL CHEM, V277, P44347, DOI 10.1074/jbc.M202009200; BIKLE DD, 1993, J CLIN ENDOCR METAB, V76, P456, DOI 10.1210/jc.76.2.456; Canalis E, 2002, ANN NY ACAD SCI, V966, P73, DOI 10.1111/j.1749-6632.2002.tb04204.x; CHAMBERS TJ, 1985, J CLIN PATHOL, V38, P241, DOI 10.1136/jcp.38.3.241; CHYUN YS, 1984, ENDOCRINOLOGY, V114, P477, DOI 10.1210/endo-114-2-477; Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551; De Bosscher K, 2000, P NATL ACAD SCI USA, V97, P3919, DOI 10.1073/pnas.97.8.3919; De Bosscher K, 2000, J NEUROIMMUNOL, V109, P16, DOI 10.1016/S0165-5728(00)00297-6; DeBosscher K, 1997, P NATL ACAD SCI USA, V94, P13504, DOI 10.1073/pnas.94.25.13504; Dempster DW, 1997, J ENDOCRINOL, V154, P397, DOI 10.1677/joe.0.1540397; Eberhardt AW, 2001, ENDOCRINOLOGY, V142, P1333, DOI 10.1210/en.142.3.1333; FELIX R, 1990, J BONE MINER RES, V5, P781; GALLWITZ WE, 1993, J BIOL CHEM, V268, P10087; GESSANI S, 1988, J BIOL CHEM, V263, P7454; Hayashi T, 2002, J BIOL CHEM, V277, P27880, DOI 10.1074/jbc.M203836200; Hirayama T, 2002, J ENDOCRINOL, V175, P155, DOI 10.1677/joe.0.1750155; Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4382, DOI 10.1210/en.140.10.4382; Horowitz MC, 2001, CYTOKINE GROWTH F R, V12, P9, DOI 10.1016/S1359-6101(00)00030-7; Hu XY, 2003, J IMMUNOL, V170, P4833, DOI 10.4049/jimmunol.170.9.4833; Jenkins BD, 2001, TRENDS ENDOCRIN MET, V12, P122, DOI 10.1016/S1043-2760(00)00357-X; JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100; Kaji H, 1997, J BONE MINER RES, V12, P734, DOI 10.1359/jbmr.1997.12.5.734; Kaneda T, 2000, J IMMUNOL, V165, P4254, DOI 10.4049/jimmunol.165.8.4254; Kitazawa R, 1999, BBA-GENE STRUCT EXPR, V1445, P134, DOI 10.1016/S0167-4781(99)00032-9; KITAZAWA R, 1994, J CLIN INVEST, V94, P2397, DOI 10.1172/JCI117606; KLEIN RG, 1977, J CLIN INVEST, V60, P253, DOI 10.1172/JCI108762; KODAMA H, 1991, J EXP MED, V173, P269, DOI 10.1084/jem.173.1.269; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; LANGENEGGER T, 1999, CLIN ORTHO, V366, P22; Manolagas SC, 1999, J BONE MINER RES, V14, P1061, DOI 10.1359/jbmr.1999.14.7.1061; Martin TJ, 1998, CRIT REV EUKAR GENE, V8, P107, DOI 10.1615/CritRevEukarGeneExpr.v8.i2.10; McKay LI, 1999, ENDOCR REV, V20, P435, DOI 10.1210/er.20.4.435; McKay LI, 2000, MOL ENDOCRINOL, V14, P1222, DOI 10.1210/me.14.8.1222; MICHAEL AE, 1994, MOL CELL ENDOCRINOL, V100, P55, DOI 10.1016/0303-7207(94)90279-8; Nguyen VT, 2002, J BIOL CHEM, V277, P13796, DOI 10.1074/jbc.M111906200; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; Ohmori Y, 1997, J BIOL CHEM, V272, P14899, DOI 10.1074/jbc.272.23.14899; Palmqvist P, 2002, J IMMUNOL, V169, P3353, DOI 10.4049/jimmunol.169.6.3353; Patschan D, 2001, BONE, V29, P498, DOI 10.1016/S8756-3282(01)00610-X; PAZPACHECO E, 1995, J BONE MINER RES, V10, P1713; Petricoin E, 1996, MOL CELL BIOL, V16, P1419; Pine R, 1997, NUCLEIC ACIDS RES, V25, P4346, DOI 10.1093/nar/25.21.4346; Pitzalis C, 2002, ANN NY ACAD SCI, V966, P108, DOI 10.1111/j.1749-6632.2002.tb04208.x; Reissland P, 1999, IMMUNOBIOLOGY, V200, P227, DOI 10.1016/S0171-2985(99)80072-2; Riccardi C, 2000, THERAPIE, V55, P165; Rubin J, 1998, ENDOCRINOLOGY, V139, P1006, DOI 10.1210/en.139.3.1006; Sheppard KA, 1998, J BIOL CHEM, V273, P29291, DOI 10.1074/jbc.273.45.29291; SHUTO T, 1994, ENDOCRINOLOGY, V134, P1121, DOI 10.1210/en.134.3.1121; Smith E, 2002, J BIOL CHEM, V277, P18191, DOI 10.1074/jbc.M109708200; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; SUDA T, 1995, BONE S2, V17, P87; Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a; TOBIAS J, 1989, ENDOCRINOLOGY, V125, P1290, DOI 10.1210/endo-125-3-1290; UDAGAWA N, 1989, ENDOCRINOLOGY, V125, P1805, DOI 10.1210/endo-125-4-1805; Vidal NOA, 1998, J ENDOCRINOL, V159, P191, DOI 10.1677/joe.0.1590191; Weinstein R S, 2001, Rev Endocr Metab Disord, V2, P65, DOI 10.1023/A:1010007108155; Weinstein RS, 2002, J CLIN INVEST, V109, P1041, DOI 10.1172/JCI200214538; Weinstein RS, 2000, J CLIN ENDOCR METAB, V85, P2907, DOI 10.1210/jc.85.8.2907; Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799; Wissink S, 1998, MOL ENDOCRINOL, V12, P355, DOI 10.1210/me.12.3.355; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888	65	74	81	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44667	44674		10.1074/jbc.M300213200	http://dx.doi.org/10.1074/jbc.M300213200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12944401	hybrid			2022-12-25	WOS:000186306700099
J	Dabney-Smith, C; Mori, H; Cline, K				Dabney-Smith, C; Mori, H; Cline, K			Requirement of a Tha4-conserved transmembrane glutamate in thylakoid Tat translocase assembly revealed by biochemical complementation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-TRANSPORT; ESCHERICHIA-COLI; MEMBRANES; PATHWAYS; SEC; SYSTEM; FORM; BIND	The thylakoid Tat system employs three membrane components and the pH gradient to transport folded proteins. The translocase is signal-assembled, i.e. a receptor complex containing cpTatC and Hcf106 binds the precursor protein, and upon membrane energization, Tha4 is recruited to the precursor-receptor complex to effect translocation. We developed a two-step complementation assay to examine the implied central role of Tha4 in translocation. The first step results in the inactivation of endogenous Tha4 with specific antibodies. The second step involves integrating exogenous Tha4 and presenting the system with precursor protein. We verified this approach by confirming the results obtained recently with the Escherichia coli Tha4 ortholog TatA, i.e. that the carboxyl terminus is dispensable and the amphipathic helix essential for transport. We then investigated a conserved Tha4 transmembrane glutamate in detail. Substitution of glutamate 10 with alanine, glutamine, and even aspartate largely eliminated the ability of Tha4 to complement transport, whereas a conservative substitution elsewhere in the transmembrane domain was without effect. Chemical cross-linking assays showed that the mutated Tha4s failed to be recruited to the receptor complex under transport conditions, indicating a role for the transmembrane glutamate in translocase assembly. This assay promises an avenue into understanding the role of Tha4 in both the assembly and translocation steps of the Tat translocase.	Univ Florida, Dept Hort Sci, Gainesville, FL 32611 USA	State University System of Florida; University of Florida	Cline, K (corresponding author), Univ Florida, Dept Hort Sci, Box 110690, Gainesville, FL 32611 USA.		Dabney-Smith, Carole/C-2432-2008; Cline, Kenneth/J-6238-2013	Dabney-Smith, Carole/0000-0003-1347-3870; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046951] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM46951] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; Berks BC, 2000, MOL MICROBIOL, V35, P260, DOI 10.1046/j.1365-2958.2000.01719.x; Bolhuis A, 2001, J BIOL CHEM, V276, P20213, DOI 10.1074/jbc.M100682200; CLINE K, 1988, PLANT PHYSIOL, V86, P1120, DOI 10.1104/pp.86.4.1120; CLINE K, 1993, EMBO J, V12, P4105, DOI 10.1002/j.1460-2075.1993.tb06094.x; Cline K, 2001, J CELL BIOL, V154, P719, DOI 10.1083/jcb.200105149; FINCHER V, 2001, THESIS U FLORIDA GAI; Henry R, 1997, J CELL BIOL, V136, P823, DOI 10.1083/jcb.136.4.823; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Lee PA, 2002, J BACTERIOL, V184, P5871, DOI 10.1128/JB.184.21.5871-5879.2002; Ma XY, 2000, J BIOL CHEM, V275, P10016, DOI 10.1074/jbc.275.14.10016; Manting EH, 2000, MOL MICROBIOL, V37, P226, DOI 10.1046/j.1365-2958.2000.01980.x; Mori H, 2002, J CELL BIOL, V157, P205, DOI 10.1083/jcb.200202048; Mori H, 2001, BBA-MOL CELL RES, V1541, P80, DOI 10.1016/S0167-4889(01)00150-1; Mori H, 1999, J CELL BIOL, V146, P45, DOI 10.1083/jcb.146.1.45; Mori H, 2001, FEBS LETT, V501, P65, DOI 10.1016/S0014-5793(01)02626-6; Sargent F, 2001, EUR J BIOCHEM, V268, P3361, DOI 10.1046/j.1432-1327.2001.02263.x; Schnell DJ, 2003, CELL, V112, P491, DOI 10.1016/S0092-8674(03)00110-7	18	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43027	43033		10.1074/jbc.M307923200	http://dx.doi.org/10.1074/jbc.M307923200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12941940	hybrid			2022-12-25	WOS:000186157000039
J	Liu, LJ; Bortnick, AE; Nickel, M; Dhanasekaran, P; Subbaiah, PV; Lund-Katz, S; Rothblat, GH; Phillips, MC				Liu, LJ; Bortnick, AE; Nickel, M; Dhanasekaran, P; Subbaiah, PV; Lund-Katz, S; Rothblat, GH; Phillips, MC			Effects of apolipoprotein A-I on ATP-binding cassette transporter A1-mediated efflux of macrophage phospholipid and cholesterol - Formation of nascent high density lipoprotein particles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AIR-WATER-INTERFACE; C-TERMINAL DOMAIN; CELLULAR CHOLESTEROL; LIPID EFFLUX; ABCA1; HDL; CELLS; MEMBRANE; PROTEIN; MECHANISMS	The mechanism of formation of high density lipoprotein (HDL) particles by the action of ATP-binding cassette transporter A1 (ABCA1) is not defined completely. To address this issue, we monitored efflux to apoA-I of phosphatidylcholine (PC), sphingomyelin (SM), and unesterified (free) cholesterol (FC) from J774 macrophages, in which ABCA1 is up-regulated, and investigated the nature of the particles formed. The various apoA-I/lipid particles appearing in the extracellular medium were separated by gel filtration chromatography. The presence of apoA-I in the extracellular medium led to the simultaneous formation of more than one type of poorly lipidated apoA-I-containing particle: there were 9- and 12-nm diameter particles containing similar to3:1 and 1:1 phospholipid/FC (mol/mol), respectively, which were present together with 6-nm monomeric apoA-I. Removal of the C-terminal alpha-helix (residues 223-243) of apoA-I reduced phospholipid and FC efflux and prevented formation of the 9- and 12-nm HDL particles; the apoA-I variant formed larger particles that eluted in the void volume. FC loading of the J774 cells also led to the formation of larger apoA-I-containing particles that were highly enriched in FC. Besides creating HDL particles, ABCA1 mediated release of larger (20-450-nm diameter) FC-rich particles that were not involved in HDL formation and that are probably membrane vesicles. These particles contained 1:1 PC/SM in contrast to the HDL particles, which contained 2:1 PC/SM. This is consistent with lipid raft and non-raft plasma membrane domains being involved primarily in ABCA1-mediated vesicle release and nascent HDL formation, respectively.	Univ Penn, Sch Med, Childrens Hosp Philadelphia, Joseph Stokes Jr Res Inst,Gastrointestinal Nutr D, Philadelphia, PA 19104 USA; Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Rush University	Phillips, MC (corresponding author), Univ Penn, Sch Med, Childrens Hosp Philadelphia, Joseph Stokes Jr Res Inst,Gastrointestinal Nutr D, Abramson Res Bldg,Suite 302,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.		Subbaiah, Papasani/U-1104-2019; Bortnick, Anna/V-5983-2019	Phillips, Michael/0000-0002-7147-8007	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052597, R01HL068585, R56HL068585, P01HL022633, T32HL007443, R01HL063768] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 07443, HL22633, HL68585, HL63768, HL52597] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arakawa R, 2002, J BIOL CHEM, V277, P22426, DOI 10.1074/jbc.M202996200; Attie AD, 2001, J LIPID RES, V42, P1717; Barter PJ, 1996, CURR OPIN LIPIDOL, V7, P82, DOI 10.1097/00041433-199604000-00006; Bielicki JK, 1999, J LIPID RES, V40, P85; BIELICKI JK, 1991, BIOCHIM BIOPHYS ACTA, V1084, P7; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bortnick AE, 2000, J BIOL CHEM, V275, P28634, DOI 10.1074/jbc.M003407200; Burgess JW, 1999, BIOCHEMISTRY-US, V38, P14524, DOI 10.1021/bi990930z; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; Chen W, 2001, J BIOL CHEM, V276, P43564, DOI 10.1074/jbc.M107938200; Cockerill GW, 1999, INT REV CYTOL, V188, P257; Dolo V, 2000, BBA-MOL CELL BIOL L, V1486, P265, DOI 10.1016/S1388-1981(00)00063-9; Drobnik W, 2002, TRAFFIC, V3, P268, DOI 10.1034/j.1600-0854.2002.030404.x; Favari E, 2002, BIOCHEM BIOPH RES CO, V299, P801, DOI 10.1016/S0006-291X(02)02745-6; FIELDING CJ, 1995, J LIPID RES, V36, P211; Fielding CJ, 2001, BBA-MOL CELL BIOL L, V1533, P175, DOI 10.1016/S1388-1981(01)00162-7; FORTE TM, 1993, J LIPID RES, V34, P317; FORTE TM, 1995, J LIPID RES, V36, P148; FORTE TM, 1990, BIOCHIM BIOPHYS ACTA, V1047, P11, DOI 10.1016/0005-2760(90)90254-U; Gargalovic P, 2003, J LIPID RES, V44, P11, DOI 10.1194/jlr.R200005-JLR200; Gillotte KL, 1999, J BIOL CHEM, V274, P2021, DOI 10.1074/jbc.274.4.2021; Gillotte-Taylor K, 2002, J BIOL CHEM, V277, P11811, DOI 10.1074/jbc.M108268200; HARA H, 1992, LIPIDS, V27, P302, DOI 10.1007/BF02536480; HARA H, 1991, J BIOL CHEM, V266, P3080; HOLVOET P, 1995, BIOCHEMISTRY-US, V34, P13334, DOI 10.1021/bi00041a009; JOHNSON WJ, 1986, J BIOL CHEM, V261, P5766; Khovidhunkit W, 2003, J LIPID RES, V44, P1728, DOI 10.1194/jlr.M300100-JLR200; KLANSEK JJ, 1995, J LIPID RES, V36, P2261; KRAMER MF, 1999, CURRENT PROTOCOLS MO; KREBS KE, 1988, BIOCHIM BIOPHYS ACTA, V959, P229, DOI 10.1016/0005-2760(88)90195-6; Lund-Katz S, 2003, FRONT BIOSCI-LANDMRK, V8, pD1044, DOI 10.2741/1077; LUNDKATZ S, 1986, BIOCHEMISTRY-US, V25, P1562, DOI 10.1021/bi00355a016; MACKNESS MI, 1995, ATHEROSCLEROSIS, V115, P243, DOI 10.1016/0021-9150(94)05524-M; Marcel YL, 2003, CURR OPIN LIPIDOL, V14, P151, DOI 10.1097/00041433-200304000-00006; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; Mendez AJ, 2001, J BIOL CHEM, V276, P3158, DOI 10.1074/jbc.M007717200; Morrow JA, 1999, PROTEIN EXPRES PURIF, V16, P224, DOI 10.1006/prep.1999.1069; Neufeld EB, 2001, J BIOL CHEM, V276, P27584, DOI 10.1074/jbc.M103264200; Oram JF, 2003, ARTERIOSCL THROM VAS, V23, P720, DOI 10.1161/01.ATV.0000054662.44688.9A; Oram JF, 2000, BBA-MOL CELL BIOL L, V1529, P321, DOI 10.1016/S1388-1981(00)00157-8; Panagotopulos SE, 2002, J BIOL CHEM, V277, P39477, DOI 10.1074/jbc.M207005200; PHILLIPS MC, 1986, METHOD ENZYMOL, V128, P387; Pike LJ, 2003, J LIPID RES, V44, P655, DOI 10.1194/jlr.R200021-JLR200; Pruzanski W, 2000, J LIPID RES, V41, P1035; Remaley AT, 2003, J LIPID RES, V44, P828, DOI 10.1194/jlr.M200475-JLR200; Rogers DP, 1998, BIOCHEMISTRY-US, V37, P11714, DOI 10.1021/bi973112k; Saito H, 1997, J LIPID RES, V38, P287; Saito H, 2003, J BIOL CHEM, V278, P23227, DOI 10.1074/jbc.M303365200; Sakr SW, 1999, BBA-MOL CELL BIOL L, V1438, P85, DOI 10.1016/S1388-1981(99)00041-4; SCANU AM, 1971, ANAL BIOCHEM, V44, P576, DOI 10.1016/0003-2697(71)90247-8; Schultz Joshua R., 1994, Current Opinion in Lipidology, V5, P126, DOI 10.1097/00041433-199404000-00009; Singaraja RR, 2002, J CLIN INVEST, V110, P35, DOI 10.1172/JCI200215748; SOKOLOFF L, 1974, P SOC EXP BIOL MED, V146, P1166; Sparks DL, 1999, BIOCHEMISTRY-US, V38, P1727, DOI 10.1021/bi981945k; SPARKS DL, 1993, J BIOL CHEM, V268, P23250; SPARKS DL, 1992, J BIOL CHEM, V267, P25839; SUBBAIAH PV, 2000, HDB LIPOPROTEIN TEST; Sviridov D, 1996, J BIOL CHEM, V271, P33277, DOI 10.1074/jbc.271.52.33277; Tall AR, 2002, J CLIN INVEST, V110, P899, DOI 10.1172/JCI200216391; Vaughan AM, 2003, J LIPID RES, V44, P1373, DOI 10.1194/jlr.M300078-JLR200; Wang N, 2003, ARTERIOSCL THROM VAS, V23, P1178, DOI 10.1161/01.ATV.0000075912.83860.26; WEISWEILER P, 1987, CLIN CHIM ACTA, V169, P249, DOI 10.1016/0009-8981(87)90325-1; YANCEY PG, 1995, BIOCHEMISTRY-US, V34, P7955, DOI 10.1021/bi00024a021; Yancey PG, 2003, ARTERIOSCL THROM VAS, V23, P712, DOI 10.1161/01.ATV.0000057572.97137.DD; Yokoyama S, 2000, BBA-MOL CELL BIOL L, V1529, P231, DOI 10.1016/S1388-1981(00)00152-9; Zha XH, 2003, J BIOL CHEM, V278, P10002, DOI 10.1074/jbc.C300024200; Zhang WW, 1998, J LIPID RES, V39, P1601	67	113	114	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42976	42984		10.1074/jbc.M308420200	http://dx.doi.org/10.1074/jbc.M308420200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12928428	hybrid			2022-12-25	WOS:000186157000032
J	Tschan, MP; Fischer, KM; Fung, VS; Pirnia, F; Borner, MM; Fey, MF; Tobler, A; Torbett, BE				Tschan, MP; Fischer, KM; Fung, VS; Pirnia, F; Borner, MM; Fey, MF; Tobler, A; Torbett, BE			Alternative splicing of the human cyclin D-binding Myb-like protein (hDMP1) yields a truncated protein isoform that alters macrophage differentiation patterns	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT-NEGATIVE ISOFORM; ACUTE MYELOID-LEUKEMIA; TRANSCRIPTION FACTOR; FUNCTIONAL-CHARACTERIZATION; AMINOPEPTIDASE N/CD13; GENE-EXPRESSION; MESSENGER-RNA; CELLS; INDUCTION; ARREST	We have cloned two novel, alternatively spliced messages of human cyclin D-binding Myb-like protein (hDMP1). The known, full-length protein has been named hDMP1alpha and the new isoforms, hDMP1beta and hDMP1gamma. The hDMP1alpha, -beta, and -gamma splice variants have unique expression patterns in normal hematopoietic cells; hDMP1beta mRNA transcripts are strongly expressed in quiescent CD34(+) cells and freshly isolated peripheral blood leukocytes, as compared with hDMP1alpha. In contrast, activated T-cells and developing myeloid cells, macrophages, and granulocytes express low levels of hDMP1beta transcripts, and hDMP1gamma is ubiquitously and weakly expressed. Mouse Dmp1 has been shown to activate CD13/aminopeptidase N (APN) and p19(ARF) gene expression via binding to canonical DNA recognition sites in the respective promoters. Assessment of CD13/APN promoter responsiveness demonstrated that hDMP1alpha but not hDMP1beta and -gamma, is a transcriptional activator. Furthermore, hDMP1beta was found to inhibit the CD13/ APN promoter transactivation ability of hDMP1alpha. Stable, ectopic expression of hDMP1beta and, to a lesser extent hDMP1gamma, reduced endogenous cell surface levels of CD13/ APN in U937 cells. Moreover, stable, ectopic expression of hDMP1beta altered phorbol 12-myristate 13-acetate- induced terminal differentiation of U937 cells to macrophages and resulted in maintenance of proliferation. These results demonstrate that hDMP1beta antagonizes hDMP1alpha activity and suggest that cellular functions of hDMP1 may be regulated by cellular hDMP1 isoform levels.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Univ Bern, Dept Clin Res, CH-3010 Bern, Switzerland; Univ Bern, Inst Med Oncol, CH-3010 Bern, Switzerland; Univ Bern, Cent Hematol Lab, CH-3010 Bern, Switzerland; Inselspital Bern, CH-3010 Bern, Switzerland	Scripps Research Institute; University of Bern; University of Bern; University of Bern	Torbett, BE (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10666 N Torrey Pines Rd, La Jolla, CA 92037 USA.	betorbet@scripps.edu	Borner, Markus/B-7583-2011	Tschan, Mario P./0000-0001-5897-3647	NCRR NIH HHS [M01RR00833] Funding Source: Medline; NIDDK NIH HHS [DK49886] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049886] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agarwal M, 1998, J VIROL, V72, P3720, DOI 10.1128/JVI.72.5.3720-3728.1998; Anderson KL, 1998, BLOOD, V91, P3702, DOI 10.1182/blood.V91.10.3702; Bentley D, 2002, CURR OPIN CELL BIOL, V14, P336, DOI 10.1016/S0955-0674(02)00333-2; BERLINER N, 1995, BLOOD, V85, P799, DOI 10.1182/blood.V85.3.799.bloodjournal853799; Bhagwat SV, 2003, BLOOD, V101, P1818, DOI 10.1182/blood-2002-05-1422; Bodner SM, 1999, GENE, V229, P223, DOI 10.1016/S0378-1119(98)00591-5; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chun YS, 2002, BIOCHEM J, V362, P71, DOI 10.1042/0264-6021:3620071; Chun YS, 2001, J CELL SCI, V114, P4051; DREXLER HG, 1987, LEUKEMIA, V1, P697; Ebihara K, 1996, MOL CELL BIOL, V16, P3393; Eymin B, 2003, ONCOGENE, V22, P1822, DOI 10.1038/sj.onc.1206303; Follenzi A, 2000, NAT GENET, V25, P217, DOI 10.1038/76095; Galimi F, 2002, BLOOD, V100, P2732, DOI 10.1182/blood-2002-04-1245; Gan WN, 1998, J BIOL CHEM, V273, P5006, DOI 10.1074/jbc.273.9.5006; HASS R, 1989, EUR J CELL BIOL, V48, P282; Hirai H, 1996, MOL CELL BIOL, V16, P6457; Hur E, 2002, MOL PHARMACOL, V62, P975, DOI 10.1124/mol.62.5.975; Inoue K, 1999, P NATL ACAD SCI USA, V96, P3993, DOI 10.1073/pnas.96.7.3993; Inoue K, 2000, GENE DEV, V14, P1797; Inoue K, 1998, J BIOL CHEM, V273, P29188, DOI 10.1074/jbc.273.44.29188; Inoue K, 1998, MOL CELL BIOL, V18, P1590, DOI 10.1128/MCB.18.3.1590; Kehlen A, 2000, ADV EXP MED BIOL, V477, P49; Kuo ML, 2003, CANCER RES, V63, P1046; Lendeckel U, 1996, BIOCHEM J, V319, P817, DOI 10.1042/bj3190817; Levanon D, 1996, DNA CELL BIOL, V15, P175, DOI 10.1089/dna.1996.15.175; Makino Y, 2001, NATURE, V414, P550, DOI 10.1038/35107085; MENRAD A, 1993, CANCER RES, V53, P1450; Miyoshi H, 1998, J VIROL, V72, P8150, DOI 10.1128/JVI.72.10.8150-8157.1998; Miyoshi H, 1999, SCIENCE, V283, P682, DOI 10.1126/science.283.5402.682; Nakase K, 2000, CANCER RES, V60, P4062; Nakayama H, 2000, EXP HEMATOL, V28, P1232, DOI 10.1016/S0301-472X(00)00530-0; Nogues G, 2002, J BIOL CHEM, V277, P43110, DOI 10.1074/jbc.M208418200; PUI CH, 1993, BLOOD, V82, P889; Riemann D, 1999, IMMUNOL TODAY, V20, P83, DOI 10.1016/S0167-5699(98)01398-X; Riemann D, 1997, J IMMUNOL, V158, P3425; Rosenzwajg M, 2000, BLOOD, V95, P453, DOI 10.1182/blood.V95.2.453; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Shin SW, 2002, P NATL ACAD SCI USA, V99, P9978, DOI 10.1073/pnas.162345999; SHIPP MA, 1993, BLOOD, V82, P1052, DOI 10.1182/blood.V82.4.1052.bloodjournal8241052; SUGIMOTO K, 1992, BLOOD, V79, P2378, DOI 10.1182/blood.V79.9.2378.2378; Sun GQ, 2002, MOL CELL ENDOCRINOL, V190, P147, DOI 10.1016/S0303-7207(01)00726-2; Sun L, 1996, EMBO J, V15, P5358, DOI 10.1002/j.1460-2075.1996.tb00920.x; Tschan MP, 2001, LEUKEMIA LYMPHOMA, V42, P1077, DOI 10.3109/10428190109097728; Yamanaka R, 1997, P NATL ACAD SCI USA, V94, P6462, DOI 10.1073/pnas.94.12.6462; Zwahlen D, 2000, INT J CANCER, V88, P66	47	70	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42750	42760		10.1074/jbc.M307067200	http://dx.doi.org/10.1074/jbc.M307067200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12917399	hybrid			2022-12-25	WOS:000186157000005
J	Zalcenstein, A; Stambolsky, P; Weisz, L; Muller, M; Wallach, D; Goncharov, TM; Krammer, PH; Rotter, V; Oren, M				Zalcenstein, A; Stambolsky, P; Weisz, L; Muller, M; Wallach, D; Goncharov, TM; Krammer, PH; Rotter, V; Oren, M			Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants	ONCOGENE			English	Article						p53; apoptosis; CD 95; Fas/APO-1; repression	APO-1/FAS RECEPTOR/LIGAND SYSTEM; DRUG-INDUCED APOPTOSIS; WILD-TYPE; CD95 APO-1/FAS; IONIZING-RADIATION; OF-FUNCTION; HUMAN MDR1; ACTIVATION; SUPPRESSOR; FAS	Tumor-associated mutant forms of p53 can exert an antiapoptotic gain of function activity, which probably confers a selective advantage upon tumor cells harboring such mutations. We report that mutant p53 suppresses the expression of the CD95 (Fas/APO-1) gene, encoding a death receptor implicated in a variety of apoptotic responses. Moderate (40-50%) downregulation of CD95 mRNA and surface protein expression by mutant p53 correlates with partial protection against CD95-dependent cell death. Excess mutant p53 represses the transcriptional activity of the CD95 promoter, with the extent of repression varying among different tumor-associated p53 mutants. Furthermore, mutant p53 protein binds the CD95 promoter in vitro, in a region distinct from the one implicated in tight interactions of the CD95 gene with witd-type p53. Hence, the CD95 promoter is likely to be a direct target for downregulation by mutant p53. This activity of mutant p53 may contribute to its gain of function effects in oncogenesis.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Univ Hosp, Dept Internal Med 4, D-69115 Heidelberg, Germany; Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; German Canc Res Ctr, Tumor Immunol Program, D-69120 Heidelberg, Germany	Weizmann Institute of Science; Ruprecht Karls University Heidelberg; Weizmann Institute of Science; Helmholtz Association; German Cancer Research Center (DKFZ)	Oren, M (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, POB 26, IL-76100 Rehovot, Israel.	moshe.oren@weizmann.ac.il	Martina, Mueller-Schilling/R-4162-2016	Oren, Moshe/0000-0003-4311-7172				Albor A, 1998, CANCER RES, V58, P2091; Bargonetti J, 2002, CURR OPIN ONCOL, V14, P86, DOI 10.1097/00001622-200201000-00015; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; Boldrini L, 2001, ONCOGENE, V20, P6632, DOI 10.1038/sj.onc.1204727; Cadwell C, 2001, GENE, V277, P15, DOI 10.1016/S0378-1119(01)00696-5; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Embree-Ku M, 2002, BIOL REPROD, V66, P1456, DOI 10.1095/biolreprod66.5.1456; Fanslow W C, 1994, Semin Immunol, V6, P267, DOI 10.1006/smim.1994.1035; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Kremenetskaya OS, 1997, ONCOL RES, V9, P155; Li RZ, 1998, ONCOGENE, V16, P3269, DOI 10.1038/sj.onc.1201867; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Liu G, 2000, P NATL ACAD SCI USA, V97, P4174, DOI 10.1073/pnas.97.8.4174; LOTEM J, 1995, P NATL ACAD SCI USA, V92, P9672, DOI 10.1073/pnas.92.21.9672; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Matas D, 2001, EMBO J, V20, P4163, DOI 10.1093/emboj/20.15.4163; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; MICHALOVITZ D, 1991, J CELL BIOCHEM, V45, P22, DOI 10.1002/jcb.240450108; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Munsch D, 2000, J BIOL CHEM, V275, P3867, DOI 10.1074/jbc.275.6.3867; Murphy KL, 2000, FASEB J, V14, P2291, DOI 10.1096/fj.00-0128com; Newton K, 2000, J EXP MED, V191, P195, DOI 10.1084/jem.191.1.195; O'Connor L, 2000, CANCER RES, V60, P1217; Offer H, 1999, FEBS LETT, V450, P197, DOI 10.1016/S0014-5793(99)00505-0; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Peled A, 1996, CANCER RES, V56, P2148; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Sampath J, 2001, J BIOL CHEM, V276, P39359, DOI 10.1074/jbc.M103429200; Serrano M, 2000, CARCINOGENESIS, V21, P865, DOI 10.1093/carcin/21.5.865; Shao RG, 2001, ONCOGENE, V20, P1852, DOI 10.1038/sj.onc.1204264; Sigal A, 2000, CANCER RES, V60, P6788; Soussi T, 2000, ANN NY ACAD SCI, V910, P121; Spence CL, 2000, METHODS MOL BIOL, V147, P25; Strano S, 2002, J BIOL CHEM, V277, P18817, DOI 10.1074/jbc.M201405200; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; STRAUSS BE, 1995, BIOCHEM BIOPH RES CO, V217, P333, DOI 10.1006/bbrc.1995.2781; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Volkmann M, 2001, J MOL MED-JMM, V79, P594, DOI 10.1007/s001090100244; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Wang XJ, 1998, MOL CARCINOGEN, V23, P185, DOI 10.1002/(SICI)1098-2744(199811)23:3<185::AID-MC7>3.0.CO;2-5; Weinmann AS, 2002, METHODS, V26, P37, DOI 10.1016/S1046-2023(02)00006-3; Yang XL, 1999, ONCOGENE, V18, P4546, DOI 10.1038/sj.onc.1202843; ZASTAWNY RL, 1993, ONCOGENE, V8, P1529	55	97	101	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2003	22	36					5667	5676		10.1038/sj.onc.1206724	http://dx.doi.org/10.1038/sj.onc.1206724			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944915				2022-12-25	WOS:000184865900016
J	Di Bacco, A; Gill, G				Di Bacco, A; Gill, G			The secreted glycoprotein CREG inhibits cell growth dependent on the mannose-6-phosphate/insulin-like growth factor II receptor	ONCOGENE			English	Article						cell proliferation; mannose-6-phosphate receptor; NTERA-2; tumor suppressor	EMBRYONAL CARCINOMA-CELLS; MANNOSE 6-PHOSPHATE; RETINOIC ACID; NEURONAL DIFFERENTIATION; PERINATAL LETHALITY; UROKINASE RECEPTOR; GENE-EXPRESSION; TGF-ALPHA; IGF-II; ACTIVATION	Secreted proteins and their cognate receptors are implicated in a myriad of activities that regulate cell proliferation, differentiation, and development. CREG, a cellular repressor of E1A-stimulated genes, is a secreted glycoprotein that antagonizes cellular transformation by E1A and ras. We have previously shown that CREG expression is induced very early during differentiation of pluripotent cells and, even in the absence of other inducers, CREG promotes neuronal differentiation of human teratocarcinoma NTERA-2 cells. Here we show that ectopic expression of CREG in NTERA-2 cells results in a delay of the G1/S phase transition of the cell cycle and growth inhibition. We show that CREG binds directly to the mannose-6-phosphate/insulin-like growth factor II receptor (M6P/IGF2R) dependent on CREG glycosylation. The M6P/IGF2R is a tumor suppressor that functions to control cell growth through interactions with multiple ligands. By analysing CREG activity in cells lacking M6P/IGF2R expression, we show that this receptor is required for CREG-induced growth inhibition. These studies reveal that CREG inhibits cell growth dependent on the M6P/IGF2R and suggest that interactions between CREG and a well-characterized tumor suppressor may contribute to regulation of proliferation and differentiation in multiple lineages.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Gill, G (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 200 Longwood Ave, Boston, MA 02115 USA.							ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; Baldassarre G, 2000, CELL GROWTH DIFFER, V11, P517; Baldassarre G, 1999, ONCOGENE, V18, P6241, DOI 10.1038/sj.onc.1203031; Blanchard F, 1999, J BIOL CHEM, V274, P24685, DOI 10.1074/jbc.274.35.24685; Boudreau N, 1996, P NATL ACAD SCI USA, V93, P3509, DOI 10.1073/pnas.93.8.3509; CasacciaBonnefil P, 1997, GENE DEV, V11, P2335, DOI 10.1101/gad.11.18.2335; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; DESOUZA AT, 1995, NAT GENET, V11, P447, DOI 10.1038/ng1295-447; deSouza AT, 1997, FASEB J, V11, P60, DOI 10.1096/fasebj.11.1.9034167; DMITROVSKY E, 1990, ONCOGENE RES, V5, P233; FENDERSON BA, 1987, DEV BIOL, V122, P21, DOI 10.1016/0012-1606(87)90328-9; Godar S, 1999, EUR J IMMUNOL, V29, P1004, DOI 10.1002/(SICI)1521-4141(199903)29:03<1004::AID-IMMU1004>3.0.CO;2-Q; Hankins GR, 1996, ONCOGENE, V12, P2003; Ikushima H, 2000, P NATL ACAD SCI USA, V97, P8439, DOI 10.1073/pnas.97.15.8439; Jadot M, 1999, J BIOL CHEM, V274, P21104, DOI 10.1074/jbc.274.30.21104; Jamieson TA, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-4; Journet A, 2000, ELECTROPHORESIS, V21, P3411, DOI 10.1002/1522-2683(20001001)21:16<3411::AID-ELPS3411>3.0.CO;2-M; Kang JX, 1997, P NATL ACAD SCI USA, V94, P13671, DOI 10.1073/pnas.94.25.13671; Kang JX, 1999, CELL GROWTH DIFFER, V10, P591; Kang JX, 1998, P NATL ACAD SCI USA, V95, P13687, DOI 10.1073/pnas.95.23.13687; KIESS W, 1990, EUR J BIOCHEM, V190, P71, DOI 10.1111/j.1432-1033.1990.tb15547.x; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Kong FM, 2000, ONCOGENE, V19, P1572, DOI 10.1038/sj.onc.1203437; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; Kunita R, 2002, GENOMICS, V80, P456, DOI 10.1006/geno.2002.6857; LAU MMH, 1994, GENE DEV, V8, P2953, DOI 10.1101/gad.8.24.2953; LEE SJ, 1988, J BIOL CHEM, V263, P3521; Lorenzo K, 2000, CANCER RES, V60, P4070; Ludwig T, 1996, DEV BIOL, V177, P517, DOI 10.1006/dbio.1996.0182; Ma XY, 2002, BLOOD, V100, P833, DOI 10.1182/blood.V100.3.833; MACDONALD RG, 1991, ENDOCRINOLOGY, V128, P413, DOI 10.1210/endo-128-1-413; MACDONALD RG, 1988, SCIENCE, V239, P1134, DOI 10.1126/science.2964083; Miki R, 2001, P NATL ACAD SCI USA, V98, P2199, DOI 10.1073/pnas.041605498; MILLER WH, 1994, DIFFERENTIATION, V55, P145, DOI 10.1046/j.1432-0436.1994.5520145.x; Mitsuhashi T, 2001, P NATL ACAD SCI USA, V98, P6435, DOI 10.1073/pnas.111051398; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Motyka B, 2000, CELL, V103, P491, DOI 10.1016/S0092-8674(00)00140-9; NOLAN CM, 1990, CELL REGUL, V1, P197, DOI 10.1091/mbc.1.2.197; Nykjaer A, 1998, J CELL BIOL, V141, P815, DOI 10.1083/jcb.141.3.815; Piquemal D, 2002, GENOMICS, V80, P361, DOI 10.1006/geno.2002.6836; PURCHIO AF, 1988, J BIOL CHEM, V263, P14211; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; TODDERUD G, 1988, J BIOL CHEM, V263, P17893; Veal E, 1998, MOL CELL BIOL, V18, P5032, DOI 10.1128/MCB.18.9.5032; Veal E, 2000, ONCOGENE, V19, P2120, DOI 10.1038/sj.onc.1203529; WAHEED A, 1988, BIOCHEM BIOPH RES CO, V152, P1248, DOI 10.1016/S0006-291X(88)80419-4; Wakeman JA, 1998, ONCOGENE, V17, P179, DOI 10.1038/sj.onc.1201942; Wang SN, 1997, CANCER RES, V57, P2543; WANG ZQ, 1994, NATURE, V372, P464, DOI 10.1038/372464a0; Xie S., 2002, MED SCI MONIT INT ME, V8, P293, DOI [10.3390/ijms21186968, DOI 10.3390/IJMS21186968]	53	72	76	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 21	2003	22	35					5436	5445		10.1038/sj.onc.1206670	http://dx.doi.org/10.1038/sj.onc.1206670			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JC	12934103				2022-12-25	WOS:000184735000008
J	Bernardo, PH; Brasch, N; Chai, CLL; Waring, P				Bernardo, PH; Brasch, N; Chai, CLL; Waring, P			A novel redox mechanism for the glutathione-dependent reversible uptake of a fungal toxin in cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY METABOLITES; ASPERGILLUS-FUMIGATUS; SCABROSIN ESTERS; GLIOTOXIN; SPORIDESMIN; APOPTOSIS; EPIPOLYTHIODIOXOPIPERAZINES; TRANSPORTER; TOXICITY; RELEASE	The fungal metabolite gliotoxin is characterized by an internal disulfide bridge and can exist in either disulfide or dithiol forms. Gliotoxin and other members of the epipolythiodioxopiperazine class of toxins have immunosuppressive properties and have been implicated in human and animal mycotoxicoses. The bridged disulfide moiety is thought to be generally essential for biological activity. Here we show that only the natural ( oxidized) form of gliotoxin is actively concentrated in a cell line in a glutathione- dependent manner. Intracellular levels of the toxin can be up to 1500- fold greater than the applied concentration, and toxin in the cells exists almost exclusively in the reduced form. A simple model of toxin entry followed by reduction to the cell- impermeant dithiol explains active uptake, cell density dependence of EC50 values and predicts a value for the maximum concentration of toxin at limiting cell density in agreement with the experiment. Oxidation of the intracellular toxin results in rapid efflux from the cell that also occurs when glutathione levels fall following induction of apoptotic cell death by the toxin. This mechanism allows for minimal production of the toxin while enabling maximal intracellular concentration and thus maximal efficacy of killing in a competitor organism initially present at low cell density. The toxin effluxes from the apoptotic cell exclusively in the oxidized form and can further enter and kill neighboring cells, thus acting in a pseudocatalytic way.	Australian Natl Univ, The Faculties, Ctr Study Bioact Mol, Canberra, ACT 0200, Australia; Australian Natl Univ, Res Sch Chem, Canberra, ACT 0200, Australia	Australian National University; Australian National University	Waring, P (corresponding author), Australian Natl Univ, The Faculties, Ctr Study Bioact Mol, Canberra, ACT 0200, Australia.		Chai, Christina L/A-3133-2014	Chai, Christina/0000-0002-9199-851X				BEAVER JP, 1995, EUR J CELL BIOL, V68, P47; Bernardo PH, 2001, BIOORG MED CHEM LETT, V11, P483, DOI 10.1016/S0960-894X(00)00696-X; Borges-Walmsley MI, 2001, TRENDS MICROBIOL, V9, P71, DOI 10.1016/S0966-842X(00)01920-X; Brodin B, 2002, PHARMACOL TOXICOL, V90, P285, DOI 10.1034/j.1600-0773.2002.900601.x; Chai CLL, 2000, REDOX REP, V5, P257, DOI 10.1179/135100000101535799; Demain AL, 2000, ADV BIOCHEM ENG BIOT, V69, P1; Demain AL, 1999, APPL MICROBIOL BIOT, V52, P455, DOI 10.1007/s002530051546; EICHNER RD, 1988, J BIOL CHEM, V263, P3772; EICHNER RD, 1986, INT J IMMUNOPHARMACO, V8, P789, DOI 10.1016/0192-0561(86)90016-0; EICHNER RD, 1984, AUST J EXP BIOL MED, V82, P479; Ernst-Russell MA, 1999, AUST J CHEM, V52, P279, DOI 10.1071/C99019; FAHEY RC, 1978, J BACTERIOL, V133, P1126, DOI 10.1128/JB.133.3.1126-1129.1978; GOULD GW, 1993, BIOCHEM J, V295, P329, DOI 10.1042/bj2950329; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Hurne AM, 2000, J BIOL CHEM, V275, P25202, DOI 10.1074/jbc.M002278200; JORDAN TW, 1986, J CELL SCI, V85, P33; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Moerman KL, 2003, TOXICOL APPL PHARM, V190, P232, DOI 10.1016/S0041-008X(03)00189-3; MULLBACHER A, 1986, MOL IMMUNOL, V23, P231, DOI 10.1016/0161-5890(86)90047-7; MULLBACHER A, 1988, TRANSPLANTATION, V46, P120; MUNDAY R, 1982, CHEM-BIOL INTERACT, V41, P361, DOI 10.1016/0009-2797(82)90112-0; Nagase T, 1997, BRIT J CANCER, V76, P1001, DOI 10.1038/bjc.1997.499; NEILANDS JB, 1995, J BIOL CHEM, V270, P26723, DOI 10.1074/jbc.270.45.26723; OHLER E, 1972, CHEM BER-RECL, V105, P635, DOI 10.1002/cber.19721050229; Pahl HL, 1996, J EXP MED, V183, P1829, DOI 10.1084/jem.183.4.1829; Paz MM, 2001, J MED CHEM, V44, P2834, DOI 10.1021/jm010072g; Perek N, 2002, CURR DRUG METAB, V3, P97, DOI 10.2174/1389200023338107; Rabenstein DL, 1996, J ORG CHEM, V61, P7391, DOI 10.1021/jo960917+; RICE GC, 1986, CANCER RES, V46, P6105; Richard JL, 1996, MYCOPATHOLOGIA, V134, P167, DOI 10.1007/BF00436725; SCHWEIZER M, 1994, BIOCHEMISTRY-US, V33, P13401, DOI 10.1021/bi00249a028; Tomee JFC, 2000, CLIN EXP ALLERGY, V30, P476, DOI 10.1046/j.1365-2222.2000.00796.x; vandenDobbelsteen DJ, 1996, J BIOL CHEM, V271, P15420, DOI 10.1074/jbc.271.26.15420; WARING P, 1994, TOXICON, V32, P491, DOI 10.1016/0041-0101(94)90301-8; Waring P, 1997, J BIOL CHEM, V272, P17929, DOI 10.1074/jbc.272.29.17929; WARING P, 1995, BIOCHEM PHARMACOL, V49, P1195, DOI 10.1016/0006-2952(95)00039-3; WARING P, 1988, MED RES REV, V8, P499, DOI 10.1002/med.2610080404	37	76	84	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46549	46555		10.1074/jbc.M304825200	http://dx.doi.org/10.1074/jbc.M304825200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12947114	hybrid			2022-12-25	WOS:000186569400040
J	Fux, L; Nussbaum-Shochat, A; Amster-Choder, O				Fux, L; Nussbaum-Shochat, A; Amster-Choder, O			Interactions between the PTS regulation domains of the BglG transcriptional antiterminator from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING DOMAIN; BACILLUS-SUBTILIS; CATALYZED PHOSPHORYLATION; PHOSPHOTRANSFERASE SYSTEM; NEGATIVE REGULATION; CRYSTAL-STRUCTURE; LEUCINE-ZIPPER; PROTEIN; OPERON; LICT	The E. coli BglG protein inhibits transcription termination within the bgl operon in the presence of beta-glucosides. BglG represents a family of transcriptional antiterminators that bind to RNA sequences, which partially overlap rho-independent terminators, and prevent termination by stabilizing an alternative structure of the transcript. The activity of BglG is determined by its dimeric state, which is modulated by reversible phosphorylation catalyzed by BglF, a PTS permease. Only the non-phosphorylated BglG dimer binds to RNA and allows read-through of transcription. BglG is composed of three domains: an RNA-binding domain followed by two domains, PRD1 and PRD2 (PTS regulation domains), which are similar in their sequence and folding. Based on the three-dimensional structure of dimeric LicT, a BglG homologue from Bacillus subtilis, the interactions within the dimer are PRD1-PRD1 and PRD2-PRD2. We have shown before that PRD2 mediates homodimerization very efficiently. Using genetic systems and in vitro techniques that assay and characterize protein-protein interactions, we show here that the PRD1 dimerizes very slowly, but once it does, the homodimers are stable. These results support our model that formation of BglG dimers initiates with PRD2 dimerization followed by zipping up of two BglG monomers to create the active RNA-binding domain. Moreover, our results demonstrate that PRD1 and PRD2 heterodimerize efficiently in vitro and in vivo. The affinity among the PRDs is in the following order: PRD2-PRD2>PRD1-PRD2>PRD1-PRD1. The interaction between PRD1 and PRD2 offers an explanation for the requirement of conserved residues in PRD1 for the phosphorylation of PRD2 by BglF.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Mol Biol, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Amster-Choder, O (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Mol Biol, POB 12272, IL-91120 Jerusalem, Israel.							AMSTERCHODER O, 1990, SCIENCE, V249, P540, DOI 10.1126/science.2200123; AMSTERCHODER O, 1992, SCIENCE, V257, P1395, DOI 10.1126/science.1382312; AMSTERCHODER O, 1989, CELL, V58, P847, DOI 10.1016/0092-8674(89)90937-9; ARNAUD M, 1992, J BACTERIOL, V174, P3161, DOI 10.1128/jb.174.10.3161-3170.1992; Boss A, 1999, J BACTERIOL, V181, P1755, DOI 10.1128/JB.181.6.1755-1766.1999; Center RJ, 1998, PROTEIN SCI, V7, P1612, DOI 10.1002/pro.5560070715; Chen Q, 1999, J BACTERIOL, V181, P462, DOI 10.1128/JB.181.2.462-468.1999; Chen Q, 1997, J BIOL CHEM, V272, P17263, DOI 10.1074/jbc.272.28.17263; Chen Q, 1997, EMBO J, V16, P4617, DOI 10.1093/emboj/16.15.4617; Declerck N, 1999, J MOL BIOL, V294, P389, DOI 10.1006/jmbi.1999.3256; Dmitrova M, 1998, MOL GEN GENET, V257, P205; Ducat T, 2002, J BIOMOL NMR, V23, P325, DOI 10.1023/A:1020264611438; HOUMAN F, 1990, CELL, V62, P1153, DOI 10.1016/0092-8674(90)90392-R; HU JC, 1993, PROTEIN SCI, V2, P1072, DOI 10.1002/pro.5560020701; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; Kruger S, 1996, J BACTERIOL, V178, P2637; Lindner C, 1999, MOL MICROBIOL, V31, P995, DOI 10.1046/j.1365-2958.1999.01262.x; Lopian L, 2003, P NATL ACAD SCI USA, V100, P7099, DOI 10.1073/pnas.1037608100; MAHADEVAN S, 1987, J BACTERIOL, V169, P2570, DOI 10.1128/jb.169.6.2570-2578.1987; MAHADEVAN S, 1987, CELL, V50, P485, DOI 10.1016/0092-8674(87)90502-2; Manival X, 1997, EMBO J, V16, P5019, DOI 10.1093/emboj/16.16.5019; Martin-Verstraete I, 1998, MOL MICROBIOL, V28, P293, DOI 10.1046/j.1365-2958.1998.00781.x; Miller J.H., 1972, EXPT MOL GENETICS; Nussbaum-Shochat A, 1999, P NATL ACAD SCI USA, V96, P4336, DOI 10.1073/pnas.96.8.4336; Reizer J, 1997, CURR OPIN STRUC BIOL, V7, P407, DOI 10.1016/S0959-440X(97)80059-0; Stulke J, 2002, ARCH MICROBIOL, V177, P433, DOI 10.1007/s00203-002-0407-5; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tortosa P, 2001, MOL MICROBIOL, V41, P1381, DOI 10.1046/j.1365-2958.2001.02608.x; Tortosa P, 1997, J BIOL CHEM, V272, P17230, DOI 10.1074/jbc.272.27.17230; van Tilbeurgh H, 2001, CURR OPIN STRUC BIOL, V11, P685, DOI 10.1016/S0959-440X(01)00267-6; van Tilbeurgh H, 2001, EMBO J, V20, P3789, DOI 10.1093/emboj/20.14.3789; vanTilbeurgh H, 1997, EMBO J, V16, P5030, DOI 10.1093/emboj/16.16.5030; Yang YS, 2002, EMBO J, V21, P1987, DOI 10.1093/emboj/21.8.1987	34	14	15	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46203	46209		10.1074/jbc.M306506200	http://dx.doi.org/10.1074/jbc.M306506200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12923168	hybrid			2022-12-25	WOS:000186569400003
J	Scheidt, HA; Muller, P; Herrmann, A; Huster, D				Scheidt, HA; Muller, P; Herrmann, A; Huster, D			The potential of fluorescent and spin-labeled steroid analogs to mimic natural cholesterol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAPID TRANSBILAYER MOVEMENT; ACYL-CHAIN; LIPID DOMAINS; TRANSMEMBRANE MOVEMENT; ERYTHROCYTE-MEMBRANE; UNILAMELLAR VESICLES; BIOLOGICAL-MEMBRANES; MOLECULAR-DYNAMICS; BILAYER-MEMBRANES; MODEL MEMBRANES	Cholesterol analogs are often used to investigate lipid trafficking and membrane organization of native cholesterol. Here, the potential of various spin (doxyl moiety) and fluorescent (7-nitrobenz-2-oxa-1, 3-diazol-4-yl (NBD) group) labeled cholesterol analogs as well as of fluorescent cholestatrienol and the naturally occurring dehydroergosterol to mimic the unique properties of native cholesterol in lipid membranes was studied in 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) membranes by electron paramagnetic resonance, nuclear magnetic resonance, and fluorescence spectroscopy. As cholesterol, all analogs undergo fluctuating motions of large amplitude parallel to the bilayer normal. Native cholesterol keeps a strict orientation in the membrane with the long axis parallel to the bilayer normal. Depending on the chemical modification or the position of the label, cholesterol analogs may adopt an "up-side-down" orientation in the membrane or may even fluctuate between "upright" and up-side-down orientation by rotational motions about the short axis not typical for native cholesterol. Those analogs are not able to induce a comparable condensation of phospholipid membranes as known for native cholesterol revealed by H-2 nuclear magnetic resonance. However, cholesterol-induced lipid condensation is one of the key properties of native cholesterol, and, therefore, a well suited parameter to assess the potential of steroid analogs to mimic cholesterol. The study points to extreme caution when studying cholesterol behavior by the respective analogs. Among seven analogs investigated, only a spin-labeled cholesterol with the doxyl group at the end of the acyl chain and the fluorophore cholestatrienol mimic cholesterol satisfactorily. Dehydroergosterol has a similar upright orientation as cholesterol and could be used at low concentration (about 1 mol %), at which its lower potential to enhance lipid packing density does not perturb membrane organization.	Univ Leipzig, Inst Med Phys & Biophys, Biotechnol Biomed Ctr, Jr Res Grp, D-04103 Leipzig, Germany; Humboldt Univ, Inst Biol Biophys, D-10115 Berlin, Germany	Leipzig University; Humboldt University of Berlin	Huster, D (corresponding author), Univ Leipzig, Inst Med Phys & Biophys, Biotechnol Biomed Ctr, Jr Res Grp, Liebigstr 27, D-04103 Leipzig, Germany.		Scheidt, Holger A./C-1416-2014					Anderson RGW, 2002, SCIENCE, V296, P1821, DOI 10.1126/science.1068886; BoeszeBattaglia K, 1996, BIOCHEMISTRY-US, V35, P6664, DOI 10.1021/bi951846w; BONMATIN JM, 1990, J AM CHEM SOC, V112, P1697, DOI 10.1021/ja00161a007; Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397; Brown RE, 1998, J CELL SCI, V111, P1; BUTKO P, 1992, J BIOCHEM BIOPH METH, V24, P15, DOI 10.1016/0165-022X(92)90043-A; BUTLER KW, 1977, CAN J BIOCHEM, V56, P117; Buton X, 2002, BIOCHEMISTRY-US, V41, P13106, DOI 10.1021/bi020385t; CHATTOPADHYAY A, 1987, BIOCHEMISTRY-US, V26, P39, DOI 10.1021/bi00375a006; Cheng KH, 1999, BIOPHYS J, V77, P3108, DOI 10.1016/S0006-3495(99)77141-9; CHILD P, 1983, J LIPID RES, V24, P1196; DAVIES MA, 1990, BIOCHEMISTRY-US, V29, P4368, DOI 10.1021/bi00470a016; DEMEL RA, 1972, BIOCHIM BIOPHYS ACTA, V255, P321, DOI 10.1016/0005-2736(72)90031-4; Dietrich C, 2001, BIOPHYS J, V80, P1417, DOI 10.1016/S0006-3495(01)76114-0; Endress E, 2002, BIOCHEMISTRY-US, V41, P13078, DOI 10.1021/bi0201670; Fellmann P, 1994, Methods Mol Biol, V27, P161; FISCHER RT, 1984, CHEM PHYS LIPIDS, V36, P1, DOI 10.1016/0009-3084(84)90086-0; FORSLIND E, 1975, J THEOR BIOL, V51, P97, DOI 10.1016/0022-5193(75)90141-1; HAPALA I, 1994, BIOCHEMISTRY-US, V33, P7682, DOI 10.1021/bi00190a023; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; Huster D, 1999, J PHYS CHEM B, V103, P243, DOI 10.1021/jp983428h; Huster D, 1999, J AM CHEM SOC, V121, P1992, DOI 10.1021/ja9838413; Huster D, 1998, BIOCHEMISTRY-US, V37, P17299, DOI 10.1021/bi980078g; Huster D, 2001, BIOPHYS J, V80, P822, DOI 10.1016/S0006-3495(01)76061-4; HYSLOP PA, 1990, BIOCHEMISTRY-US, V29, P1025, DOI 10.1021/bi00456a027; IPSEN JH, 1990, BIOPHYS J, V57, P405, DOI 10.1016/S0006-3495(90)82557-1; John K, 2002, BIOPHYS J, V83, P1525, DOI 10.1016/S0006-3495(02)73922-2; KAVECANSKY J, 1994, BIOCHEMISTRY-US, V33, P2880, DOI 10.1021/bi00176a018; KRAJEWSKIBERTRAND MA, 1992, CHEM PHYS LIPIDS, V63, P235, DOI 10.1016/0009-3084(92)90039-R; LANGE Y, 1981, J BIOL CHEM, V256, P5321; Leventis R, 2001, BIOPHYS J, V81, P2257, DOI 10.1016/S0006-3495(01)75873-0; London E, 2000, BBA-BIOMEMBRANES, V1508, P182, DOI 10.1016/S0304-4157(00)00007-1; MACURA S, 1980, MOL PHYS, V41, P95, DOI 10.1080/00268978000102601; Marsan MP, 1999, BIOPHYS J, V76, P351, DOI 10.1016/S0006-3495(99)77202-4; Maxfield FR, 2002, J CLIN INVEST, V110, P891, DOI 10.1172/JCI200216500; MORROT G, 1987, BIOCHIM BIOPHYS ACTA, V897, P341, DOI 10.1016/0005-2736(87)90431-7; Mukherjee S, 1998, BIOPHYS J, V75, P1915, DOI 10.1016/S0006-3495(98)77632-5; Mukherjee S, 1996, BIOCHEMISTRY-US, V35, P1311, DOI 10.1021/bi951953q; Muller P, 2002, BIOPHYS J, V82, P1418, DOI 10.1016/S0006-3495(02)75496-9; NEMECZ G, 1988, BIOCHIM BIOPHYS ACTA, V943, P511, DOI 10.1016/0005-2736(88)90384-7; Ohvo-Rekila H, 2000, CHEM PHYS LIPIDS, V105, P167, DOI 10.1016/S0009-3084(00)00122-5; OLDFIELD E, 1978, BIOCHEMISTRY-US, V17, P2727, DOI 10.1021/bi00607a006; ROGERS J, 1979, BIOCHIM BIOPHYS ACTA, V552, P23, DOI 10.1016/0005-2736(79)90243-8; Schiller J, 1999, ANAL BIOCHEM, V267, P46, DOI 10.1006/abio.1998.3001; SCHROEDER F, 1991, BIOCHIM BIOPHYS ACTA, V1066, P181; SEIGNEURET M, 1984, BIOCHEMISTRY-US, V23, P4271, DOI 10.1021/bi00314a002; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SMUTZER G, 1986, BIOCHIM BIOPHYS ACTA, V862, P361, DOI 10.1016/0005-2736(86)90239-7; URBINA JA, 1995, BBA-BIOMEMBRANES, V1238, P163, DOI 10.1016/0005-2736(95)00117-L; Vogel A, 2003, BIOPHYS J, V85, P1691, DOI 10.1016/S0006-3495(03)74599-8; WHARTON SA, 1982, BIOCHIM BIOPHYS ACTA, V711, P398, DOI 10.1016/0005-2760(82)90053-4; White Stephen H., 1996, P127; Wustner D, 2002, J BIOL CHEM, V277, P30325, DOI 10.1074/jbc.M202626200; Xu XL, 2001, J BIOL CHEM, V276, P33540, DOI 10.1074/jbc.M104776200; Xu XL, 2000, BIOCHEMISTRY-US, V39, P843, DOI 10.1021/bi992543v; YEAGLE PL, 1990, BIOPHYS J, V57, P413, DOI 10.1016/S0006-3495(90)82558-3; YEAGLE PL, 1985, BIOCHIM BIOPHYS ACTA, V815, P33, DOI 10.1016/0005-2736(85)90470-5	57	155	156	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45563	45569		10.1074/jbc.M303567200	http://dx.doi.org/10.1074/jbc.M303567200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12947110	hybrid			2022-12-25	WOS:000186452300064
J	Strugatsky, D; Gottschalk, KE; Goldshleger, R; Bibi, E; Karlish, SJD				Strugatsky, D; Gottschalk, KE; Goldshleger, R; Bibi, E; Karlish, SJD			Expression of Na+,K+-ATPpase in Pichia pastoris analysis of wild type and D369N mutant proteins by Fe2+-catalyzed oxidative cleavage and molecular modeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; CONSERVED PHOSPHORYLATION LOOP; ENERGY TRANSDUCTION MECHANISM; PARTICLE MESH EWALD; ALPHA-SUBUNIT; CALCIUM-PUMP; NA,K-ATPASE; BINDING; ATPASE; TRANSPORT	Na+,K+-ATPase (pig alpha1,beta1) has been expressed in the methylotrophic yeast Pichia pastoris. A protease-deficient strain was used, recombinant clones were screened for multicopy genomic integrants, and protein expression, and time and temperature of methanol induction were optimized. A 3-liter culture provides 300-500 mg of membrane protein with ouabain binding capacity of 30-50 pmol mg(-1). Turnover numbers of recombinant and renal Na+,K+-ATPase are similar, as are specific chymotryptic cleavages. Wild type (WT) and a D369N mutant have been analyzed by Fe2+- and ATP-Fe2+-catalyzed oxidative cleavage, described for renal Na+,K+-ATPase. Cleavage of the D369N mutant provides strong evidence for two Fe2+ sites: site 1 composed of residues in P and A cytoplasmic domains, and site 2 near trans-membrane segments M3/M1. The D369N mutation suppresses cleavages at site 1, which appears to be a normal Mg2+ site in E-2 conformations. The results suggest a possible role of the charge of Asp(369) on the E-1 <----> E-2 conformational equilibrium. 5'-Adenylyl-beta,gamma-imidodiphosphate(AMP-PNP)-Fe2+-catalyzed cleavage of the D369N mutant produces fragments in P ((VNDS)-V-712) and N (near (440)VAGDA) domains, described for WT, but only at high AMP-PNP-Fe2+ concentrations, and a new fragment in the P domain (near (367)CSDKTGT) resulting from cleavage. Thus, the mutation distorts the active site. A molecular dynamic simulation of ATP-Mg2+ binding to WT and D351N structures of Ca2+-ATPase (analogous to Asp(369) of Na+,K+-ATPase) supplies possible explanations for the new cleavage and for a high ATP affinity, which was observed previously for the mutant. The Asn(351) structure with bound ATP-Mg2+ may resemble the transition state of the WT poised for phosphorylation.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Karlish, SJD (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	steven.karlish@weizmann.ac.il	Gottschalk, Kay/D-6503-2012	Gottschalk, Kay/0000-0002-7951-0972; Bibi, Eitan/0000-0003-3700-2707				Bar Shimon M, 1998, J BIOL CHEM, V273, P34190, DOI 10.1074/jbc.273.51.34190; Beaudet L, 1998, METHOD ENZYMOL, V292, P397; BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E; Berendsen HJC, 1981, INTERMOLECULAR FORCE, P331, DOI [DOI 10.1007/978-94-015-7658-1_21, 10.1007/978-94-015-7658-1_21]; Cereghino JL, 2000, FEMS MICROBIOL REV, V24, P45, DOI 10.1111/j.1574-6976.2000.tb00532.x; Clausen JD, 2001, J BIOL CHEM, V276, P35741, DOI 10.1074/jbc.M105434200; Cremata JA, 1998, METH MOL B, V103, P95; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117; FUKUSHIMA Y, 1978, J BIOL CHEM, V253, P6853; Geering K, 2001, J BIOENERG BIOMEMBR, V33, P425, DOI 10.1023/A:1010623724749; GLYNN IM, 1993, J PHYSIOL-LONDON, V462, P1; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; Goldshleger R, 1997, P NATL ACAD SCI USA, V94, P9596, DOI 10.1073/pnas.94.18.9596; Goldshleger R, 1999, J BIOL CHEM, V274, P16213, DOI 10.1074/jbc.274.23.16213; GOLDSHLEGER R, 2002, P 50 ANN M AM SOC MA; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hua SM, 2002, BIOCHEMISTRY-US, V41, P11405, DOI 10.1021/bi026181u; Jacobsen MD, 2002, BIOCHEMISTRY-US, V41, P1451, DOI 10.1021/bi015891h; JENCKS WP, 1989, METHOD ENZYMOL, V171, P145; Jorgensen PL, 2003, ANNU REV PHYSIOL, V65, P817, DOI 10.1146/annurev.physiol.65.092101.142558; JORGENSEN PL, 1988, METHOD ENZYMOL, V156, P29; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; Karlish SJD, 2003, ANN NY ACAD SCI, V986, P39, DOI 10.1111/j.1749-6632.2003.tb07137.x; Lerner-Marmarosh N, 1999, J BIOL CHEM, V274, P34711, DOI 10.1074/jbc.274.49.34711; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; McIntosh DB, 1999, J BIOL CHEM, V274, P25227, DOI 10.1074/jbc.274.36.25227; Nielsen JM, 1998, BIOCHEMISTRY-US, V37, P1961, DOI 10.1021/bi972524q; Patchornik G, 2000, P NATL ACAD SCI USA, V97, P11954, DOI 10.1073/pnas.220332897; Patchornik G, 2002, BIOCHEMISTRY-US, V41, P11740, DOI 10.1021/bi026334d; Pedersen PA, 1996, J BIOL CHEM, V271, P2514, DOI 10.1074/jbc.271.5.2514; Pedersen PA, 1996, BIOCHEMISTRY-US, V35, P16085, DOI 10.1021/bi961614c; Pedersen PA, 2000, J BIOL CHEM, V275, P37588, DOI 10.1074/jbc.M005610200; PEDERSEN PA, 2001, BIOCHIM BIOPHYS ACTA, V1505, P57; RENDI R, 1964, BIOCHIM BIOPHYS ACTA, V89, P520, DOI 10.1016/0926-6569(64)90078-1; Romanos M, 1998, METH MOL B, V103, P55; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Shin JM, 2001, J BIOL CHEM, V276, P48440, DOI 10.1074/jbc.M106864200; STOKES DL, 2003, IN PRESS ANN REV BIO; Stratton J, 1998, METH MOL B, V103, P107; Sweadner KJ, 2000, GENOMICS, V68, P41, DOI 10.1006/geno.2000.6274; Tal DM, 2001, BIOCHEMISTRY-US, V40, P12505, DOI 10.1021/bi011167n; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Valiakhmetov A, 2003, J BIOL CHEM, V278, P6330, DOI 10.1074/jbc.M208927200; van Gunsteren W, 1996, BIOMOLECULAR SIMULAT; XU C, 2002, J MOL BIOL, V61, P884	48	34	37	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					46064	46073		10.1074/jbc.M308303200	http://dx.doi.org/10.1074/jbc.M308303200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12949069	hybrid			2022-12-25	WOS:000186452300123
J	Crider, BP; Xie, XS				Crider, BP; Xie, XS			Characterization of the functional coupling of bovine brain vacuolar-type H+-translocating ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICLE PROTON PUMP; CLATHRIN-COATED VESICLES; YEAST V-ATPASE; PLASMA-MEMBRANE; BINDING-SITES; MUTATIONAL ANALYSIS; ENTEROCOCCUS-HIRAE; 40-KDA SUBUNIT; B2 SUBUNIT; RECONSTITUTION	Vacuolar-type H+-translocating ATPases (V-ATPases or V-pumps) are complex proteins containing multiple subunits and are organized into two functional domains: a peripheral catalytic sector V-1 and a membranous proton channel V-0. The functional coupling of ATP hydrolysis activity to proton transport in V-pumps requires a regulatory component known as subunit H (SFD) as has been shown both in vivo and in vitro ( Ho, M. N., Hirata, R., Umemoto, N., Ohya, Y., Takatsuki, A., Stevens, T. H., and Anraku, Y. ( 1993) J. Biol. Chem. 268, 18286 - 18292; Xie, X. S., Crider, B. P., Ma, Y. M., and Stone, D. K. ( 1994) J. Biol. Chem. 269, 25809 - 25815). Ca2+ is thought to uncouple V-pumps because it is found to support ATP hydrolysis but not proton transport, while Mg2+ supports both activities. The direct effect of phospholipids on the coupling of V-ATPases has not been reported, likely due to the fact that phospholipids are constituents of biological membranes. We now report that Ca2+-induced uncoupling of the bovine brain V-ATPase can be reversed by imposition of a favorable membrane potential. Furthermore we report a simple "membrane-free" assay system using the V0 proton channel-specific inhibitor bafilomycin as a probe to detect the coupling of V-ATPase under certain conditions. With this system, we have characterized the functional effect of subunit H, divalent cations, and phospholipids on bovine brain V-ATPase and have found that each of these three factors plays a critical role in the functional coupling of the V-pump.	Univ Texas, SW Med Ctr, Eugene McDermott Ctr Human Growth & Dev, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Xie, XS (corresponding author), Univ Texas, SW Med Ctr, Eugene McDermott Ctr Human Growth & Dev, Dallas, TX 75390 USA.				PHS HHS [33627] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALAWQATI Q, 1986, ANNU REV CELL BIOL, V2, P179, DOI 10.1146/annurev.cellbio.2.1.179; ANRAKU Y, 1992, J BIOENERG BIOMEMBR, V24, P395, DOI 10.1007/BF00762532; ARAI K, 1993, J BIOL CHEM, V268, P5649; Arakaki N, 2001, BBA-BIOENERGETICS, V1504, P220, DOI 10.1016/S0005-2728(00)00248-6; Arata Y, 2002, BBA-BIOENERGETICS, V1555, P71, DOI 10.1016/S0005-2728(02)00257-8; Berman MC, 2001, BBA-BIOMEMBRANES, V1513, P95, DOI 10.1016/S0005-2736(01)00356-X; Boekema EJ, 1999, NATURE, V401, P37, DOI 10.1038/43369; BOWMAN BJ, 1992, J BIOENERG BIOMEMBR, V24, P361, DOI 10.1007/BF00762529; CRIDER BP, 1994, J BIOL CHEM, V269, P17379; Curtis KK, 2002, J BIOL CHEM, V277, P8979, DOI 10.1074/jbc.M111708200; DAGGETT SG, 1985, J BIOL CHEM, V260, P6213; Digel JG, 1996, J BIOL CHEM, V271, P19976, DOI 10.1074/jbc.271.33.19976; FENG Y, 1992, J BIOL CHEM, V267, P19769; FLATMARK T, 1985, FEBS LETT, V182, P25, DOI 10.1016/0014-5793(85)81146-7; GLUCK S, 1982, J BIOL CHEM, V257, P9230; GLUCK S, 1992, J EXP BIOL, V172, P29; GLUCK S, 1987, J BIOL CHEM, V262, P15780; Graf R, 1996, J BIOL CHEM, V271, P20908, DOI 10.1074/jbc.271.34.20908; Harvey WR, 1997, J EXP BIOL, V200, P203; HO MN, 1993, J BIOL CHEM, V268, P18286; INESI G, 1989, J BIOL CHEM, V264, P5929; KANE PM, 1989, J BIOL CHEM, V264, P19236; KANE PM, 1995, J BIOL CHEM, V270, P17025; LEE BS, 1995, J BIOL CHEM, V270, P7320, DOI 10.1074/jbc.270.13.7320; Lee BS, 1997, J BIOL CHEM, V272, P174; Lee BS, 1999, J BONE MINER RES, V14, P2127, DOI 10.1359/jbmr.1999.14.12.2127; LOH YP, 1984, J BIOL CHEM, V259, P8238; Lu M, 2001, J BIOL CHEM, V276, P30407, DOI 10.1074/jbc.M008768200; MORIYAMA Y, 1987, J BIOL CHEM, V262, P14723; MULBERG AE, 1991, J BIOL CHEM, V266, P20590; Muller ML, 2002, J MEMBRANE BIOL, V185, P209, DOI 10.1007/s00232-001-0124-z; NELSON N, 1989, J BIOENERG BIOMEMBR, V21, P553, DOI 10.1007/BF00808113; Nelson N, 1996, EXPERIENTIA, V52, P1101, DOI 10.1007/BF01952108; Niessen H, 1997, BLOOD, V90, P4598; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; Papageorgiou S, 1998, J BIOENERG BIOMEMBR, V30, P533, DOI 10.1023/A:1020528432609; Parra KJ, 2000, J BIOL CHEM, V275, P21761, DOI 10.1074/jbc.M002305200; PENG SB, 1993, J BIOL CHEM, V268, P23519; PUOPOLO K, 1992, J BIOL CHEM, V267, P5171; SCHAFER G, 1992, BIOCHIM BIOPHYS ACTA, V1101, P232, DOI 10.1016/0005-2728(92)90233-R; SENIOR AE, 1980, J BIOL CHEM, V255, P7211; Seol JH, 2001, NAT CELL BIOL, V3, P384, DOI 10.1038/35070067; Shao E, 2003, J BIOL CHEM, V278, P12985, DOI 10.1074/jbc.M212096200; SOLIOZ M, 1994, J BIOL CHEM, V269, P9453; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; STONE DK, 1988, KIDNEY INT, V33, P767, DOI 10.1038/ki.1988.65; STONE DK, 1984, J BIOL CHEM, V259, P2701; SUDHOF TC, 1989, P NATL ACAD SCI USA, V86, P6067, DOI 10.1073/pnas.86.16.6067; SZE H, 1992, J EXP BIOL, V172, P123; TAKASE K, 1994, J BIOL CHEM, V269, P11037; Van Walraven HS, 2002, J BIOENERG BIOMEMBR, V34, P455; Wieczorek H, 1999, J BIOENERG BIOMEMBR, V31, P67, DOI 10.1023/A:1005448614450; Wieczorek H, 2000, J EXP BIOL, V203, P127; Williams N, 1988, Prog Clin Biol Res, V273, P87; XIE XS, 1986, J BIOL CHEM, V261, P2492; XIE XS, 1989, J BIOL CHEM, V264, P18870; XIE XS, 1994, J BIOL CHEM, V269, P25809; XIE XS, 1983, J BIOL CHEM, V258, P4834; XIE XS, 1986, P NATL ACAD SCI USA, V83, P8913, DOI 10.1073/pnas.83.23.8913; Xie XS, 1996, J BIOL CHEM, V271, P30980; XIE XS, 1988, J BIOL CHEM, V263, P9859; XIE XS, 1993, J BIOL CHEM, V268, P25063; ZHANG K, 1992, J BIOL CHEM, V267, P9701; Zhou ZM, 1999, J BIOL CHEM, V274, P15913, DOI 10.1074/jbc.274.22.15913	64	38	41	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44281	44288		10.1074/jbc.M307372200	http://dx.doi.org/10.1074/jbc.M307372200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12949075	hybrid			2022-12-25	WOS:000186306700049
J	Fass, DM; Butler, JEF; Goodman, RH				Fass, DM; Butler, JEF; Goodman, RH			Deacetylase activity is required for cAMP activation of a subset of CREB target genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN; C-FOS; TRANSCRIPTION FACTOR; HISTONE-DEACETYLASE; CYCLIC-AMP; CHROMOSOMAL LOCALIZATION; MEMBRANE DEPOLARIZATION; DEPENDENT TRANSCRIPTION; RESPONSIVE ELEMENT; SOMATOSTATIN GENE	Many hormones activate transcription by raising the level of cAMP within cells. In one well studied pathway, cAMP induces protein kinase A to phosphorylate the transcription factor CREB, which binds to a consensus sequence, the cAMP-regulated enhancer, found in many target genes. A generally accepted model suggests that phosphorylated CREB recruits the histone acetyltransferase CBP to activate transcription. In contrast, histone deacetylases have been linked to the cessation of CREB-dependent transcription. Here we tested this model in the regulation of endogenous CREB target genes. We used a constitutively active CREB mutant and microarray analysis to identify target genes in PC12 cells. We then tested the role of histone deacetylase activity in cAMP activation of four of these genes (c-FOS, ICER, NOR-1, and NUR77) by treating cells with the histone deacetylase inhibitor trichostatin A. Consistent with the generally accepted model, trichostatin A enhanced activation of c-FOS and NUR77 by cAMP. Surprisingly, trichostatin A blocked activation of ICER and NOR-1. The block of ICER and NOR-1 activation persisted in the presence of cycloheximide, indicating that the trichostatin A effect did not depend on new protein synthesis. This unexpected role of histone deacetylases in transcriptional activation of certain endogenous CREB target genes was not apparent in transfected reporter genes. Chromatin immunoprecipitation analysis indicated that the differential roles of histone deacetylases in activating or repressing CREB target genes was manifested at the level of preinitiation complex recruitment. These data indicate that histone deacetylases differentially regulate CREB target genes by contributing to either activation or cessation of transcription.	Oregon Hlth & Sci Univ, Vollum Inst L474, Portland, OR 97239 USA	Oregon Health & Science University	Goodman, RH (corresponding author), Oregon Hlth & Sci Univ, Vollum Inst L474, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	goodmanr@ohsu.edu			NIDDK NIH HHS [DK 45423] Funding Source: Medline; NIGMS NIH HHS [GM 66563] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK045423] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM066563] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Bernstein BE, 2000, P NATL ACAD SCI USA, V97, P13708, DOI 10.1073/pnas.250477697; Brivanlou AH, 2002, SCIENCE, V295, P813, DOI 10.1126/science.1066355; Cammas F, 2000, GENE, V253, P231, DOI 10.1016/S0378-1119(00)00263-8; Canettieri G, 2003, NAT STRUCT BIOL, V10, P175, DOI 10.1038/nsb895; Castillo SO, 1997, GENOMICS, V41, P250, DOI 10.1006/geno.1997.4677; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Cosma MP, 2002, MOL CELL, V10, P227, DOI 10.1016/S1097-2765(02)00604-4; CROSBY SD, 1992, P NATL ACAD SCI USA, V89, P4739, DOI 10.1073/pnas.89.10.4739; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; FLETCHER BS, 1991, J BIOL CHEM, V266, P14511; Gardier AM, 2000, J NEUROCHEM, V74, P1363, DOI 10.1046/j.1471-4159.2000.0741363.x; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; Im H, 2003, J BIOL CHEM, V278, P18346, DOI 10.1074/jbc.M300890200; Jang TH, 2000, CHINESE J PHYSIOL, V43, P149; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Kandel ER, 2001, SCIENCE, V294, P1030, DOI 10.1126/science.1067020; Kimura N, 2001, ENDOCRINOLOGY, V142, P1427, DOI 10.1210/en.142.4.1427; Kurdistani SK, 2003, NAT REV MOL CELL BIO, V4, P276, DOI 10.1038/nrm1075; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; Lu Q, 2003, J BIOL CHEM, V278, P15727, DOI 10.1074/jbc.M300546200; MARUYAMA K, 1995, CANCER LETT, V96, P117, DOI 10.1016/0304-3835(95)03921-I; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; MEINKOTH J, 1990, CIBA F SYMP, V150, P47; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; Munshi N, 1998, MOL CELL, V2, P457, DOI 10.1016/S1097-2765(00)80145-8; Naar AM, 2001, ANNU REV BIOCHEM, V70, P475, DOI 10.1146/annurev.biochem.70.1.475; NARANJO JR, 1990, NUCLEIC ACIDS RES, V18, P3605, DOI 10.1093/nar/18.12.3605; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Ohkura N, 1998, GENE, V211, P79, DOI 10.1016/S0378-1119(98)00095-X; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Pijnappel WWMP, 2001, GENE DEV, V15, P2991, DOI 10.1101/gad.207401; Pinaud S, 1998, J MOL BIOL, V280, P785, DOI 10.1006/jmbi.1998.1905; Plevin R, 1997, CELL SIGNAL, V9, P323, DOI 10.1016/S0898-6568(96)00193-3; Rachez C, 2001, CURR OPIN CELL BIOL, V13, P274, DOI 10.1016/S0955-0674(00)00209-X; Rascle A, 2003, MOL CELL BIOL, V23, P4162, DOI 10.1128/MCB.23.12.4162-4173.2003; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; Richards JS, 2001, MOL ENDOCRINOL, V15, P209, DOI 10.1210/me.15.2.209; Robyr D, 2002, CELL, V109, P437, DOI 10.1016/S0092-8674(02)00746-8; Rudolph D, 1998, P NATL ACAD SCI USA, V95, P4481, DOI 10.1073/pnas.95.8.4481; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Schultz DC, 2001, GENE DEV, V15, P428, DOI 10.1101/gad.869501; Schumacher MA, 2000, J BIOL CHEM, V275, P35242, DOI 10.1074/jbc.M007293200; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; Sommer A, 2000, FEBS LETT, V474, P146, DOI 10.1016/S0014-5793(00)01566-0; Tetradis S, 2001, ENDOCRINOLOGY, V142, P663, DOI 10.1210/en.142.2.663; Tinti C, 1996, J BIOL CHEM, V271, P25375, DOI 10.1074/jbc.271.41.25375; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; Wang A, 2002, SCIENCE, V298, P1412, DOI 10.1126/science.1077790; WATSON MA, 1989, MOL CELL BIOL, V9, P4213, DOI 10.1128/MCB.9.10.4213; Xu M, 2003, EMBO J, V22, P893, DOI 10.1093/emboj/cdg094; YOON JK, 1994, MOL CELL BIOL, V14, P7731, DOI 10.1128/MCB.14.12.7731; Zegerman P, 2002, J BIOL CHEM, V277, P11621, DOI 10.1074/jbc.C200045200; Zeng L, 2002, FEBS LETT, V513, P124, DOI 10.1016/S0014-5793(01)03309-9; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	60	113	116	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43014	43019		10.1074/jbc.M305905200	http://dx.doi.org/10.1074/jbc.M305905200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12939274	hybrid			2022-12-25	WOS:000186157000037
J	Lu, D; Shen, JQ; Vil, MD; Zhang, HF; Jimenez, X; Bohlen, P; Witte, L; Zhu, ZP				Lu, D; Shen, JQ; Vil, MD; Zhang, HF; Jimenez, X; Bohlen, P; Witte, L; Zhu, ZP			Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-CHAIN FV; MIMICKING SOMATIC HYPERMUTATION; PHAGE DISPLAY LIBRARY; GROWTH-FACTOR; SURFACE DISPLAY; TUMOR-GROWTH; MONOCLONAL-ANTIBODIES; PROTEIN AFFINITY; RIBOSOME DISPLAY; BINDING-SITE	Vascular endothelial growth factor ( VEGF) and its receptors have been implicated in promoting solid tumor growth and metastasis via stimulating tumor-associated angiogenesis. We previously identified several fully human neutralizing anti-VEGF receptor 2 (or kinase inserting domain-containing receptor (KDR)) antibodies from a large antibody phage display library. These antibodies bind specifically to KDR, block VEGF/KDR interaction, and inhibit VEGF-induced proliferation of human endothelial cells and migration of KDR+ leukemia cells. Three of these antibodies, interestingly, share an identical heavy chain variable (VH) sequence. In this report, we constructed a new library comprising the single VH paired with the variable light chain (VL) repertoire obtained from the original naive human library. Initial in vitro selection revealed that the single VH could pair with a number of different VL while retaining its specificity for KDR. However, a consensus VH/VL pair, clone 1121, was identified after three or four rounds of selection by tailoring the stringency of the panning conditions. Clone 1121 showed a > 30-fold higher binding affinity to KDR (K-d, 100 pM) because of improvement on both association and dissociation constants and blocked VEGF/KDR interaction with an IC50 of similar to 1 nM, compared with that of 3-4 nM for the parent Fab fragments. Further, clone 1121 was more potent in inhibiting VEGF-stimulated KDR phosphorylation in endothelial cells. A binding epitope mapping study on clone 1121 and one of the parent clones, 2C6, demonstrated that both antibodies interacted with the third immunoglobulin domain within the extracellular region of KDR. Several peptide phage display libraries were utilized to further examine the fine binding specificities of the two antibodies. All of the 2C6-binding peptides are cysteine-constrained, whereas clone 1121 binds to both cysteine-constrained and linear peptides. It is noteworthy that most of the 2C6-binding peptides also cross-react with clone 1121, but none of the clone 1121-specific peptides binds to 2C6, indicating that clone 1121 retained part of the original binding epitope(s) of 2C6 while gaining new binding specificity. Taken together, our observation suggests that clone 1121 may have great clinical potential in anti-angiogenesis therapy. It further underscores the efforts to identify antibodies of high affinity for enhanced biological activities.	ImClone Syst Inc, Dept Antibody Technol, New York, NY 10014 USA; ImClone Syst Inc, Dept Mol & Cell Biol, New York, NY 10014 USA; ImClone Syst Inc, Dept Res, New York, NY 10014 USA	Eli Lilly; Eli Lilly; Eli Lilly	Zhu, ZP (corresponding author), ImClone Syst Inc, Dept Antibody Technol, 180 Varick St, New York, NY 10014 USA.							Adams GP, 2001, CANCER RES, V61, P4750; Adams GP, 1998, CANCER RES, V58, P485; Amstutz P, 2001, CURR OPIN BIOTECH, V12, P400, DOI 10.1016/S0958-1669(00)00234-2; Cannon J B, 1990, Targeted Diagn Ther, V3, P121; Chen G, 2001, NAT BIOTECHNOL, V19, P537, DOI 10.1038/89281; Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; CHOTHIA C, 1992, J MOL BIOL, V227, P799, DOI 10.1016/0022-2836(92)90224-8; Chowdhury PS, 1999, NAT BIOTECHNOL, V17, P568, DOI 10.1038/9872; Coia G, 2001, J IMMUNOL METHODS, V251, P187, DOI 10.1016/S0022-1759(01)00300-3; Daugherty PS, 1999, PROTEIN ENG, V12, P613, DOI 10.1093/protein/12.7.613; Daugherty PS, 1998, PROTEIN ENG, V11, P825, DOI 10.1093/protein/11.9.825; de Haard HJ, 1999, J BIOL CHEM, V274, P18218, DOI 10.1074/jbc.274.26.18218; Dias S, 2001, P NATL ACAD SCI USA, V98, P10857, DOI 10.1073/pnas.191117498; Dias S, 2000, J CLIN INVEST, V106, P511, DOI 10.1172/JCI8978; Feldhaus MJ, 2003, NAT BIOTECHNOL, V21, P163, DOI 10.1038/nbt785; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; Fong TAT, 1999, CANCER RES, V59, P99; Glennie MJ, 2000, IMMUNOL TODAY, V21, P403, DOI 10.1016/S0167-5699(00)01669-8; Hanes J, 2000, NAT BIOTECHNOL, V18, P1287, DOI 10.1038/82407; HAWKINS RE, 1992, J MOL BIOL, V226, P889, DOI 10.1016/0022-2836(92)90639-2; Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299; Hoogenboom HR, 2000, IMMUNOL TODAY, V21, P371, DOI 10.1016/S0167-5699(00)01667-4; Irving RA, 2001, J IMMUNOL METHODS, V248, P31, DOI 10.1016/S0022-1759(00)00341-0; Jermutus L, 2001, P NATL ACAD SCI USA, V98, P75, DOI 10.1073/pnas.011311398; JUWEID M, 1992, CANCER RES, V52, P5144; Kabat EA, 1991, SEQUENCES PROTEINS I; Kanai T, 1998, INT J CANCER, V77, P933, DOI 10.1002/(SICI)1097-0215(19980911)77:6<933::AID-IJC23>3.0.CO;2-0; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Klagsbrun Michael, 1996, Cytokine and Growth Factor Reviews, V7, P259, DOI 10.1016/S1359-6101(96)00027-5; Little M, 2000, IMMUNOL TODAY, V21, P364, DOI 10.1016/S0167-5699(00)01668-6; Low NM, 1996, J MOL BIOL, V260, P359, DOI 10.1006/jmbi.1996.0406; Lu D, 2000, J BIOL CHEM, V275, P14321, DOI 10.1074/jbc.275.19.14321; Lu D, 2002, INT J CANCER, V97, P393, DOI 10.1002/ijc.1634; Margerum DW, 2002, J ENVIRON MONITOR, V4, P20, DOI 10.1039/b105541k; Margolin K, 2001, J CLIN ONCOL, V19, P851, DOI 10.1200/JCO.2001.19.3.851; Merchant AM, 1998, NAT BIOTECHNOL, V16, P677, DOI 10.1038/nbt0798-677; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Olson TA, 1997, INT J CANCER, V73, P865; Pavco PA, 2000, CLIN CANCER RES, V6, P2094; Prewett M, 1999, CANCER RES, V59, P5209; RIECHMANN L, 1993, BIOCHEMISTRY-US, V32, P8848, DOI 10.1021/bi00085a016; Schier R, 1996, J MOL BIOL, V263, P551, DOI 10.1006/jmbi.1996.0598; SCHLOM J, 1992, CANCER RES, V52, P1067; VanAntwerp JJ, 2000, BIOTECHNOL PROGR, V16, P31, DOI 10.1021/bp990133s; Witte L, 1998, CANCER METAST REV, V17, P155, DOI 10.1023/A:1006094117427; Wood JM, 2000, CANCER RES, V60, P2178; Wu HR, 1998, P NATL ACAD SCI USA, V95, P6037, DOI 10.1073/pnas.95.11.6037; YANG WP, 1995, J MOL BIOL, V254, P392, DOI 10.1006/jmbi.1995.0626; Zhu Z, 2003, LEUKEMIA, V17, P604, DOI 10.1038/sj.leu.2402831; Zhu ZP, 2002, CURR CANCER DRUG TAR, V2, P135, DOI 10.2174/1568009023333881; Zhu ZP, 1999, CANCER LETT, V136, P203, DOI 10.1016/S0304-3835(98)00324-3; Zhu ZP, 1998, CANCER RES, V58, P3209; ZHU ZP, 2001, RRD CANCER 2, V3, P369, DOI DOI 10.1016/j.compbiolchem.2004.11.003; Zogakis TG, 2001, EXPERT OPIN BIOL TH, V1, P253, DOI 10.1517/14712598.1.2.253	55	162	221	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43496	43507		10.1074/jbc.M307742200	http://dx.doi.org/10.1074/jbc.M307742200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12917408	hybrid			2022-12-25	WOS:000186157000095
J	Marinelli, RA; Tietz, PS; Caride, AJ; Huang, BQ; LaRusso, NF				Marinelli, RA; Tietz, PS; Caride, AJ; Huang, BQ; LaRusso, NF			Water transporting properties of hepatocyte basolateral and canalicular plasma membrane domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT HEPATOCYTES; GASTROINTESTINAL-TRACT; BRUSH-BORDER; CHANNEL; IMMUNOLOCALIZATION; AQUAPORIN-8; VESICLES; KIDNEY; LIVER; LOCALIZATION	Previous work from our laboratory supports an important role for aquaporins (AQPs), a family of water channel proteins, in bile secretion by hepatocytes. To further define the pathways and molecular mechanisms for water movement across hepatocytes, we directly assessed osmotic water permeability (P-f) and activation energy (E-a) in highly purified, rat hepatocytes basolateral membrane vesicles (BLMV) and canalicular membrane (CMV) vesicles by measuring scattered light intensity using stopped-flow spectrophotometry. The time course of scattered light for BLMV and CMV fit well to a single-exponential function. In BLMV, P-f was 108 +/- 4 mum.s(-1) (25degreesC) with an E-a of 7.7 kcal/mol; in CMV, P-f was 86 +/- 5 mum.s(-1) (25degreesC) with an E-a of 8.0 kcal/mol. The AQP blocker, dimethyl sulfoxide, significantly inhibited the P-f of both basolateral (81 +/- 4 mum.s(-1); -25%) and canalicular (59 +/- 4 mum.s(-1); -30%) membrane vesicles. When CMV were isolated from hepatocytes treated with dibutyryl cAMP, a double-exponential fit was needed, implying two functionally different vesicle populations; one population had P-f and E-a values similar to those of CMV from untreated hepatocytes, but the other population had a very high P-f (655 +/- 135 mum.s(-1), 25degreesC) and very low E-a (2.8 kcal/mol). Dimethyl sulfoxide completely inhibited the high P-f value in this second vesicle population. In contrast, P-f and E-a of BLMV were unaltered by cAMP treatment of hepatocytes. Our results are consistent with the presence of both lipid- and AQP-mediated pathways for basolateral and canalicular water movement across the hepatocyte plasma membrane barrier. Our data also suggest that the hepatocyte canalicular membrane domain is rate-limiting for transcellular water transport and that this domain becomes more permeable to water when hepatocytes are exposed to a choleretic agonist, presumably by insertion of AQP molecules. These data suggest a molecular mechanism for the efficient coupling of osmotically active solutes and water transport during canalicular bile formation.	Mayo Clin & Mayo Fdn, Mayo Med Sch, Dept Internal Med, Ctr Basic Res Digest Dis, Rochester, MN 55905 USA; Univ Nacl Rosario, Fac Ciencias Bioquim & Farmaceut, CONICET, Inst Fisiol Expt, RA-2000 Rosario, Santa Fe, Argentina; Mayo Clin & Mayo Fdn, Mayo Med Sch, Dept Biochem & Mol Biol, Ctr Basic Res Digest Dis, Rochester, MN 55905 USA	Mayo Clinic; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of Rosario; Mayo Clinic	LaRusso, NF (corresponding author), Mayo Clin & Mayo Fdn, Mayo Med Sch, Dept Internal Med, Ctr Basic Res Digest Dis, 200 1st St SW, Rochester, MN 55905 USA.							BENGA G, 1989, INT REV CYTOL, V114, P273; Calamita G, 2001, EUR J CELL BIOL, V80, P711, DOI 10.1078/0171-9335-00210; Carbrey JM, 2003, P NATL ACAD SCI USA, V100, P2945, DOI 10.1073/pnas.0437994100; DEGIER J, 1989, WATER TRANSPORT BIOL, V1, P77; Elkjaer ML, 2000, BIOCHEM BIOPH RES CO, V276, P1118, DOI 10.1006/bbrc.2000.3505; Elkjaer ML, 2001, AM J PHYSIOL-RENAL, V281, pF1047, DOI 10.1152/ajprenal.0158.2001; Garcia F, 2001, J BIOL CHEM, V276, P12147, DOI 10.1074/jbc.M009403200; Gradilone SA, 2003, HEPATOLOGY, V37, P1435, DOI 10.1053/jhep.2003.50241; Gradilone SA, 2002, ANAL BIOCHEM, V302, P104, DOI 10.1006/abio.2001.5533; Huebert RC, 2002, J BIOL CHEM, V277, P22710, DOI 10.1074/jbc.M202394200; MA TH, 1993, J BIOL CHEM, V268, P22756; Marinelli RA, 1999, AM J PHYSIOL-GASTR L, V276, pG280, DOI 10.1152/ajpgi.1999.276.1.G280; Masyuk AI, 2002, GASTROENTEROLOGY, V122, P545, DOI 10.1053/gast.2002.31035; MEIER PJ, 1984, J CELL BIOL, V98, P991, DOI 10.1083/jcb.98.3.991; Nicchia GP, 2001, J HISTOCHEM CYTOCHEM, V49, P1547, DOI 10.1177/002215540104901208; Nielsen S, 2002, PHYSIOL REV, V82, P205, DOI 10.1152/physrev.00024.2001; Schnermann J, 1998, P NATL ACAD SCI USA, V95, P9660, DOI 10.1073/pnas.95.16.9660; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Tani T, 2001, ARCH HISTOL CYTOL, V64, P159, DOI 10.1679/aohc.64.159; TIETZ PS, 1995, BIOCHEMISTRY-US, V34, P15436, DOI 10.1021/bi00047a007; Tsukaguchi H, 1998, J BIOL CHEM, V273, P24737, DOI 10.1074/jbc.273.38.24737; UDENFRIEND S, 1972, SCIENCE, V178, P871, DOI 10.1126/science.178.4063.871; VANHEESWIJK MPE, 1986, J MEMBRANE BIOL, V92, P183, DOI 10.1007/BF01870707; VANHOEK AN, 1990, BIOCHIM BIOPHYS ACTA, V1030, P203, DOI 10.1016/0005-2736(90)90296-Z; Verkman AS, 2000, CURR OPIN NEPHROL HY, V9, P517, DOI 10.1097/00041552-200009000-00010; VERKMAN AS, 1986, AM J PHYSIOL, V250, pF633, DOI 10.1152/ajprenal.1986.250.4.F633; VERKMAN AS, 1989, J BIOL CHEM, V264, P20608; Yano M, 1996, J BIOL CHEM, V271, P6702, DOI 10.1074/jbc.271.12.6702	28	50	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43157	43162		10.1074/jbc.M305899200	http://dx.doi.org/10.1074/jbc.M305899200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12939275				2022-12-25	WOS:000186157000056
J	Wang, DY; Visser, NV; Veenhuis, M; van der Klei, IJ				Wang, DY; Visser, NV; Veenhuis, M; van der Klei, IJ			Physical interactions of the peroxisomal targeting signal 1 receptor Pex5p, studied by fluorescence correlation spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HANSENULA-POLYMORPHA; IMPORT MACHINERY; MATRIX PROTEIN; BIOGENESIS; COMPLEX; PEX8P; CELLS; GENE	We have studied Hansenula polymorpha Pex5p and Pex8p using fluorescence correlation spectroscopy (FCS). Pex5p is the Peroxisomal Targeting Signal 1 (PTS1) receptor and Pex8p is an intraperoxisomal protein. Both proteins are essential for PTS1 protein import and have been shown to physically interact. We used FCS to analyze the molecular role of this interaction. FCS is a very sensitive technique that allows analysis of dynamic processes of fluorescently marked molecules at equilibrium in a very tiny volume. We used this technique to determine the oligomeric state of both peroxins and to analyze binding of Pex5p to PTS1 peptides and Pex8p. HpPex5p and HpPex8p were overproduced in Escherichia coli, purified by affinity chromatography, and, when required, labeled with the fluorescent dye Alexa Fluor 488. FCS measurements revealed that the oligomeric state of HpPex5p varied, ranging from monomers at slightly acidic pH to tetramers at neutral pH. HpPex8p formed monomers at all pH values tested. Using fluorescein-labeled PTS1 peptide and unlabeled HpPex5p, we established that PTS1 peptide only bound to tetrameric HpPex5p. Upon addition of HpPex8p, a heterodimeric complex was formed consisting of one HpPex8p and one HpPex5p molecule. This process was paralleled by dissociation of PTS1 peptide from HpPex5p, indicating that Pex8p may play an important role in cargo release from the PTS1 receptor. Our data show that FCS is a powerful technique to explore dynamic physical interactions that occur between peroxins during peroxisomal matrix protein import.	Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, NL-9750 AA Haren, Netherlands	University of Groningen	van der Klei, IJ (corresponding author), Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, POB 14, NL-9750 AA Haren, Netherlands.		van der Klei, Ida J/D-1919-2012	Van der Klei, Ida J./0000-0001-7165-9679				Agne B, 2003, MOL CELL, V11, P635, DOI 10.1016/S1097-2765(03)00062-5; Beechem JM., 2002, TOPICS FLUORESCENCE, P241, DOI DOI 10.1007/0-306-47058-6_5; Dammai V, 2001, CELL, V105, P187, DOI 10.1016/S0092-8674(01)00310-5; Gatto GJ, 2003, BIOCHEMISTRY-US, V42, P1660, DOI 10.1021/bi027034z; Gatto GJ, 2000, NAT STRUCT BIOL, V7, P1091; Gould SJ, 2002, NAT REV MOL CELL BIO, V3, P382, DOI 10.1038/nrm807; Gouveia AMM, 2000, J BIOL CHEM, V275, P32444, DOI 10.1074/jbc.M004366200; Hess ST, 2002, BIOCHEMISTRY-US, V41, P697, DOI 10.1021/bi0118512; Hink MA, 2002, PLANT MOL BIOL, V50, P871, DOI 10.1023/A:1021282619035; Hink MA, 2003, METHOD ENZYMOL, V361, P93; Hink MA, 2000, J BIOL CHEM, V275, P17556, DOI 10.1074/jbc.M001348200; MAGDE D, 1974, BIOPOLYMERS, V13, P29, DOI 10.1002/bip.1974.360130103; Medina MA, 2002, BIOESSAYS, V24, P758, DOI 10.1002/bies.10118; NICOLAY K, 1987, ARCH MICROBIOL, V147, P37, DOI 10.1007/BF00492902; Otera H, 2002, MOL CELL BIOL, V22, P1639, DOI 10.1128/MCB.22.6.1639-1655.2002; Purdue PE, 2001, ANNU REV CELL DEV BI, V17, P701, DOI 10.1146/annurev.cellbio.17.1.701; Rehling P, 2000, J BIOL CHEM, V275, P3593, DOI 10.1074/jbc.275.5.3593; Schliebs W, 1999, J BIOL CHEM, V274, P5666, DOI 10.1074/jbc.274.9.5666; vanderKlei IJ, 1996, ANN NY ACAD SCI, V804, P47; VANDERKLEI IJ, 1995, J BIOL CHEM, V270, P17229, DOI 10.1074/jbc.270.29.17229; WATERHAM HR, 1994, J CELL BIOL, V127, P737, DOI 10.1083/jcb.127.3.737; WIDENGREN J, 1995, J PHYS CHEM-US, V99, P13368, DOI 10.1021/j100036a009	22	73	75	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43340	43345		10.1074/jbc.M307789200	http://dx.doi.org/10.1074/jbc.M307789200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12930827	Green Published, hybrid			2022-12-25	WOS:000186157000077
J	Venkatraman, G; Harada, K; Gomes, AV; Kerrick, WGL; Potter, JD				Venkatraman, G; Harada, K; Gomes, AV; Kerrick, WGL; Potter, JD			Different functional properties of troponin T mutants that cause dilated cardiomyopathy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; CARDIAC-MUSCLE CONTRACTION; THIN FILAMENT REGULATION; ALTERED REGULATION; TERNARY COMPLEX; HEART-FAILURE; MUTATIONS; IDENTIFICATION; PROGRESSION; EXPRESSION	The effects of Troponin T (TnT) mutants R141W and DeltaK210, the only two currently known mutations in TnT that cause dilated cardiomyopathy(DCM) independent of familial hypertrophic cardiomyopathy (FHC), and TnT-K273E, a mutation that leads to a progression from FHC to DCM, were investigated. Studies on the Ca2+ sensitivity of force development in porcine cardiac fibers demonstrated that TnT-DeltaK210 caused a significant decrease in Ca2+ sensitivity, whereas the TnT-R141W did not result in any change in Ca2+ sensitivity when compared with human cardiac wild-type TnT (HC-WTnT). TnT-DeltaK210 also caused a decrease in maximal force when compared with HCWTnT and TnT-R141W. In addition, the TnT-DeltaK210 mutant decreased maximal ATPase activity in the presence of Ca2+. However, the TnT-K273E mutation caused a significant increase in Ca2+ sensitivity but behaved similarly to HCWTnT in actomyosin activation assays. Inhibition of ATPase activity in reconstituted actin-activated myosin ATPase assays was similar for all three TnT mutants and HCWTnT. Additionally, circular dichroism studies suggest that the secondary structure of all three TnT mutants was similar to that of the HCWTnT. These results suggest that a rightward shift in Ca2+ sensitivity is not the only determinant for the phenotype of DCM.	Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA; Univ Miami, Sch Med, Dept Physiol & Biophys, Miami, FL 33136 USA	University of Miami; University of Miami	Potter, JD (corresponding author), Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, 1600 NW 10th Ave, Miami, FL 33136 USA.		Gomes, Aldrin V/I-6529-2018	Gomes, Aldrin V/0000-0002-9819-3036	NHLBI NIH HHS [HL 42325, HL 67415] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL042325, R01HL067415, R01HL042325] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Chandra M, 2001, AM J PHYSIOL-HEART C, V280, pH705, DOI 10.1152/ajpheart.2001.280.2.H705; CHEN YH, 1971, BIOCHEM BIOPH RES CO, V44, P1285, DOI 10.1016/S0006-291X(71)80225-5; Cohn JN, 1997, CIRCULATION, V95, P766; Fatkin D, 2002, PHYSIOL REV, V82, P945, DOI 10.1152/physrev.00012.2002; Fiske CH, 1925, J BIOL CHEM, V66, P375; Freeman K, 2001, AM J PHYSIOL-HEART C, V280, pH151, DOI 10.1152/ajpheart.2001.280.1.H151; Fujino N, 2001, CLIN CARDIOL, V24, P397, DOI 10.1002/clc.4960240510; Fujino N, 2002, AM J CARDIOL, V89, P29, DOI 10.1016/S0002-9149(01)02158-0; Gergely J, 1998, ADV EXP MED BIOL, V453, P169; Gomes AV, 2002, J BIOL CHEM, V277, P35341, DOI 10.1074/jbc.M204118200; Hernandez OM, 2001, J APPL PHYSIOL, V90, P1125, DOI 10.1152/jappl.2001.90.3.1125; Hinkle A, 2003, J BIOL CHEM, V278, P506, DOI 10.1074/jbc.M209194200; Kamisago M, 2000, NEW ENGL J MED, V343, P1688, DOI 10.1056/NEJM200012073432304; Knollmann BC, 2001, TRENDS CARDIOVAS MED, V11, P206, DOI 10.1016/S1050-1738(01)00115-3; Lang R, 2002, J BIOL CHEM, V277, P11670, DOI 10.1074/jbc.M108912200; LESZYK J, 1988, BIOCHEMISTRY-US, V27, P6983, DOI 10.1021/bi00418a047; Li DX, 2001, CIRCULATION, V104, P2188, DOI 10.1161/hc4301.098285; Miller T, 2001, J BIOL CHEM, V276, P3743, DOI 10.1074/jbc.M006746200; Mogensen J, 2003, J CLIN INVEST, V111, P209, DOI 10.1172/JCI200316336; Moore DD, 1995, GLOB MOB SURV; Morimoto S, 2002, P NATL ACAD SCI USA, V99, P913, DOI 10.1073/pnas.022628899; MURAKAMI U, 1976, J BIOCHEM, V80, P611, DOI 10.1093/oxfordjournals.jbchem.a131316; Olson TM, 1998, SCIENCE, V280, P750, DOI 10.1126/science.280.5364.750; Palm T, 2001, BIOPHYS J, V81, P2827, DOI 10.1016/S0006-3495(01)75924-3; PAN BS, 1992, J BIOL CHEM, V267, P23052; POTTER JD, 1995, J BIOL CHEM, V270, P2557, DOI 10.1074/jbc.270.6.2557; POTTER JD, 1982, METHOD ENZYMOL, V85, P241; Redwood C, 2000, CIRC RES, V86, P1146; Robinson P, 2002, J BIOL CHEM, V277, P40710, DOI 10.1074/jbc.M203446200; Schonberger J, 2001, AM J HUM GENET, V69, P249, DOI 10.1086/321978; Seidman JG, 2001, CELL, V104, P557, DOI 10.1016/S0092-8674(01)00242-2; SHENG ZL, 1992, J BIOL CHEM, V267, P25407; STRZELECKAGOLASZEWSKA H, 1975, EUR J BIOCHEM, V55, P221, DOI 10.1111/j.1432-1033.1975.tb02154.x; Szczesna D, 1996, J BIOL CHEM, V271, P8381, DOI 10.1074/jbc.271.14.8381; Szczesna D, 2000, J BIOL CHEM, V275, P624, DOI 10.1074/jbc.275.1.624; Takahashi-Yanaga F, 2001, J BIOCHEM-TOKYO, V130, P127, DOI 10.1093/oxfordjournals.jbchem.a002950; Takeda S, 2002, BIOPHYS J, V82, p170A; Tobacman LS, 1999, J BIOL CHEM, V274, P28363, DOI 10.1074/jbc.274.40.28363; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	40	56	58	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41670	41676		10.1074/jbc.M302148200	http://dx.doi.org/10.1074/jbc.M302148200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12923187	hybrid			2022-12-25	WOS:000185989500016
J	Zhang, R; Cho, HY; Kim, HS; Ma, YG; Osaki, T; Kawabata, S; Soderhall, K; Lee, BL				Zhang, R; Cho, HY; Kim, HS; Ma, YG; Osaki, T; Kawabata, S; Soderhall, K; Lee, BL			Characterization and properties of a 1,3-beta-D-glucan pattern recognition protein of Tenebrio molitor larvae that is specifically degraded by serine protease during prophenoloxidase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; HOLOTRICHIA-DIOMPHALIA LARVAE; FRESH-WATER CRAYFISH; BOMBYX-MORI; MOLECULAR-CLONING; BINDING PROTEIN; INNATE IMMUNITY; MANDUCA-SEXTA; CDNA CLONING; PACIFASTACUS-LENIUSCULUS	Although many different pattern recognition receptors recognizing peptidoglycan and 1,3-beta-D-glucan have been identified in vertebrates and insects, the molecular mechanism of these molecules in the pattern recognition and subsequent signaling is largely unknown. To gain insights into the action mechanism of 1,3-beta-D-glucan pattern recognition protein in the insect prophenoloxidase ( proPO) activation system, we purified a 53-kDa 1,3-beta-D-glucan recognition protein (Tm-GRP) to homogeneity from the hemolymph of the mealworm, Tenebrio molitor, by using a 1,3-beta-D-glucan affinity column. The purified protein specifically bound to 1,3-beta-D-glucan but not to peptidoglycan. Subsequent molecular cloning revealed that Tm-GRP contains a region with close sequence similarity to bacterial glucanases. Strikingly, two catalytically important residues in glucanases are replaced with other nonhomologous amino acids in Tm-GRP. The finding suggests that Tm-GRP has evolved from an ancestral gene of glucanases but retained only the ability to recognize 1,3-beta-D-glucan. A Western blot analysis of the protein level of endogenous Tm-GRP showed that the protein was specifically degraded following the activation of proPO with 1,3-beta-D-glucan and calcium ion. The degradation was significantly retarded by the addition of serine protease inhibitors but not by cysteine or acidic protease inhibitor. These results suggest that 1,3-beta-D-glucan pattern recognition protein is specifically degraded by serine protease(s) during proPO activation, and we propose that this degradation is an important regulatory mechanism of the activation of the proPO system.	Pusan Natl Univ, Coll Pharm, Kumjeong Ku 609735, Busan, South Korea; Kyushu Univ, Fac Sci, Dept Biol, Fukuoka 8128581, Japan; Uppsala Univ, Evolutionary Biol Ctr, Dept Comparat Physiol, SE-75236 Uppsala, Sweden	Pusan National University; Kyushu University; Uppsala University	Lee, BL (corresponding author), Pusan Natl Univ, Coll Pharm, Kumjeong Ku 609735, Busan, South Korea.		Jie, Ying/AAJ-4697-2021	Jie, Ying/0000-0003-4003-2579; Osaki, Tsukasa/0000-0002-9487-3253				Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Ashida Masaaki, 1998, P135; Bachman ES, 1996, P NATL ACAD SCI USA, V93, P6808, DOI 10.1073/pnas.93.13.6808; Beschin A, 1998, J BIOL CHEM, V273, P24948, DOI 10.1074/jbc.273.38.24948; CERENIUS L, 1994, J BIOL CHEM, V269, P29462; Cho MY, 1999, EUR J BIOCHEM, V262, P737, DOI 10.1046/j.1432-1327.1999.00416.x; Choe KM, 2002, SCIENCE, V296, P359, DOI 10.1126/science.1070216; De Gregorio E, 2002, DEV CELL, V3, P581, DOI 10.1016/S1534-5807(02)00267-8; DIMOPOULOS G, P NATL ACAD SCI US, V94, P11506; Gillespie JP, 1997, ANNU REV ENTOMOL, V42, P611, DOI 10.1146/annurev.ento.42.1.611; Gottar M, 2002, NATURE, V416, P640, DOI 10.1038/nature734; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Hultmark D, 2003, CURR OPIN IMMUNOL, V15, P12, DOI 10.1016/S0952-7915(02)00005-5; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Jiang HB, 2003, J BIOL CHEM, V278, P3552, DOI 10.1074/jbc.M205743200; Jiang HB, 1998, P NATL ACAD SCI USA, V95, P12220, DOI 10.1073/pnas.95.21.12220; Kang DW, 1998, P NATL ACAD SCI USA, V95, P10078, DOI 10.1073/pnas.95.17.10078; Kim MS, 2002, J BIOL CHEM, V277, P39999, DOI 10.1074/jbc.M205508200; Kim YS, 2000, J BIOL CHEM, V275, P32721, DOI 10.1074/jbc.M003934200; Lee KY, 2002, EUR J BIOCHEM, V269, P4375, DOI 10.1046/j.1432-1033.2002.03155.x; Lee SY, 2000, J BIOL CHEM, V275, P1337, DOI 10.1074/jbc.275.2.1337; Lee SY, 1998, EUR J BIOCHEM, V257, P615, DOI 10.1046/j.1432-1327.1998.2570615.x; Lee WJ, 1996, P NATL ACAD SCI USA, V93, P7888, DOI 10.1073/pnas.93.15.7888; LEGENDRE N, 1988, BIOTECHNIQUES, V6, P154; Ligoxygakis P, 2002, EMBO J, V21, P6330, DOI 10.1093/emboj/cdf661; Ma CC, 2000, J BIOL CHEM, V275, P7505, DOI 10.1074/jbc.275.11.7505; MCCAULEY R, 1973, MOL CELL BIOCHEM, V1, P73, DOI 10.1007/BF01659940; Medzhitov R, 2002, SCIENCE, V296, P298, DOI 10.1126/science.1068883; Mellroth P, 2003, J BIOL CHEM, V278, P7059, DOI 10.1074/jbc.M208900200; Michel T, 2001, NATURE, V414, P756, DOI 10.1038/414756a; MUTA T, 1995, J BIOL CHEM, V270, P892, DOI 10.1074/jbc.270.2.892; Ochiai M, 1999, J BIOL CHEM, V274, P11854, DOI 10.1074/jbc.274.17.11854; Ochiai M, 2000, J BIOL CHEM, V275, P4995, DOI 10.1074/jbc.275.7.4995; Poget SF, 1999, J MOL BIOL, V290, P867, DOI 10.1006/jmbi.1999.2910; Ramet M, 2002, NATURE, V416, P644, DOI 10.1038/nature735; RAO P, 1989, ANAL BIOCHEM, V181, P18, DOI 10.1016/0003-2697(89)90387-4; Satoh D, 1999, J BIOL CHEM, V274, P7441, DOI 10.1074/jbc.274.11.7441; SGARAMELLA V, 1972, J MOL BIOL, V72, P427, DOI 10.1016/0022-2836(72)90155-6; Shin SW, 1998, INSECT BIOCHEM MOLEC, V28, P827, DOI 10.1016/S0965-1748(98)00077-0; Simmen MW, 1998, P NATL ACAD SCI USA, V95, P4437, DOI 10.1073/pnas.95.8.4437; Soderhall K, 1998, CURR OPIN IMMUNOL, V10, P23, DOI 10.1016/S0952-7915(98)80026-5; Sugumaran M, 2001, ADV EXP MED BIOL, V484, P289; Takaki Y, 2002, J BIOL CHEM, V277, P14281, DOI 10.1074/jbc.M200177200; Takeda K, 2003, CELL MICROBIOL, V5, P143, DOI 10.1046/j.1462-5822.2003.00264.x; Takehana A, 2002, P NATL ACAD SCI USA, V99, P13705, DOI 10.1073/pnas.212301199; Wang RG, 2001, EUR J BIOCHEM, V268, P895, DOI 10.1046/j.1432-1327.2001.01945.x; Werner T, 2000, P NATL ACAD SCI USA, V97, P13772, DOI 10.1073/pnas.97.25.13772; YAHATA N, 1990, GENE, V86, P113, DOI 10.1016/0378-1119(90)90122-8; Yoshida H, 1996, J BIOL CHEM, V271, P13854, DOI 10.1074/jbc.271.23.13854; Young SH, 2000, J BIOL CHEM, V275, P11874, DOI 10.1074/jbc.275.16.11874	50	76	88	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42072	42079		10.1074/jbc.M307475200	http://dx.doi.org/10.1074/jbc.M307475200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12923175	hybrid			2022-12-25	WOS:000185989500064
J	Dolle, L; El Yazidi-Belkoura, I; Adriaenssens, E; Nurcombe, V; Hondermarck, H				Dolle, L; El Yazidi-Belkoura, I; Adriaenssens, E; Nurcombe, V; Hondermarck, H			Nerve growth factor overexpression and autocrine loop in breast cancer cells	ONCOGENE			English	Article						breast cancer; nerve growth factor; autocrine stimulation; cellular growth	STROMAL CELLS; RECEPTORS; EXPRESSION; PROLIFERATION; NEUROTROPHINS; SURVIVAL; RELEASE	We show here that nerve growth factor (NGF), the canonical neurotrophic factor, is synthesized and released by breast cancer cells. High levels of NGF transcript and protein were detected in breast cancer cells by reverse transcription-PCR, Western blotting, ELISA assay and immunohistochemistry. Conversely, NGF production could not be detected in normal breast epithelial cells at either the transcriptional or protein level. Confocal analysis indicated the presence of NGF within classical secretion vesicles. Breast cancer cell-produced NGF was biologically active, as demonstrated by its ability to induce the neuronal differentiation of embryonic neural precursor cells. Importantly, the constitutive growth of breast cancer cells was strongly inhibited by either NGF-neutralizing antibodies or K-252a, a pharmacological inhibitor of NGF receptor TrkA, indicating the existence of an NGF autocrine loop. Together, our data demonstrate the physiological relevance of NGF in breast cancer and its potential interest as a marker and therapeutic target.	Univ Sci & Technol Lille, UPRES EA 1033, F-59655 Villeneuve Dascq, France; Univ Queensland, Sch Biomed Sci, St Lucia, Qld 4072, Australia	Universite de Lille - ISITE; Universite de Lille; University of Queensland	Hondermarck, H (corresponding author), Univ Sci & Technol Lille, UPRES EA 1033, IFR 118,Batiment SN3, F-59655 Villeneuve Dascq, France.	hubert.hondermarck@univ-lille1.fr	El Yazidi-Belkoura, Ikram/AAE-8805-2022; Dollé, Laurent/H-4612-2014; Malwad, Govind V/F-4682-2010	EL YAZIDI-BELKOURA, IKRAM/0000-0002-5323-7509				Adriaenssens E, 1998, AM J PATHOL, V153, P1597, DOI 10.1016/S0002-9440(10)65748-3; ANTON ES, 1994, P NATL ACAD SCI USA, V91, P2795, DOI 10.1073/pnas.91.7.2795; Bange J, 2001, NAT MED, V7, P548, DOI 10.1038/87872; BARBACID M, 1995, CURR OPIN CELL BIOL, V7, P148, DOI 10.1016/0955-0674(95)80022-0; Bonini S, 1996, P NATL ACAD SCI USA, V93, P10955, DOI 10.1073/pnas.93.20.10955; Bourhis XFDL, 1997, INT J CANCER, V71, P42, DOI 10.1002/(SICI)1097-0215(19970328)71:1<42::AID-IJC9>3.0.CO;2-3; Brickman YG, 1998, J BIOL CHEM, V273, P4350, DOI 10.1074/jbc.273.8.4350; Chiarenza A, 2001, CANCER RES, V61, P3002; Clemow DB, 1998, AM J PHYSIOL-REG I, V275, pR1279, DOI 10.1152/ajpregu.1998.275.4.R1279; Colomer R, 2001, CANCER INVEST, V19, P49, DOI 10.1081/CNV-100000074; Dalal R, 1997, MOL CELL ENDOCRINOL, V134, P15, DOI 10.1016/S0303-7207(97)00165-2; Descamps S, 1998, J BIOL CHEM, V273, P16659, DOI 10.1074/jbc.273.27.16659; Descamps S, 2001, CANCER RES, V61, P4337; Descamps S, 2001, J BIOL CHEM, V276, P17864, DOI 10.1074/jbc.M010499200; Dickson C, 2000, BREAST CANCER RES, V2, P191, DOI 10.1186/bcr53; DIMARCO E, 1993, J BIOL CHEM, V268, P22838; El Yazidi-Belkoura I, 2003, J BIOL CHEM, V278, P16952, DOI 10.1074/jbc.M300631200; ETHIER SP, 1995, J NATL CANCER I, V87, P964, DOI 10.1093/jnci/87.13.964; Fawcett JP, 1997, J BIOL CHEM, V272, P8837; GRUETERS A, 1985, PEDIATR RES, V19, P934, DOI 10.1203/00006450-198509000-00014; HATTORI A, 1993, J BIOL CHEM, V268, P2577; KAUFFMAN RF, 1980, J BIOL CHEM, V255, P2735; KELLY R B, 1991, Current Opinion in Cell Biology, V3, P654, DOI 10.1016/0955-0674(91)90037-Y; Le Bourhis X., 2000, BREAST CANC RES TREA, V1722, P1; LEON A, 1994, P NATL ACAD SCI USA, V91, P3739, DOI 10.1073/pnas.91.9.3739; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LILLIEN LE, 1985, NATURE, V317, P632, DOI 10.1038/317632a0; LOSSING C, 1993, PLAST RECONSTR SURG, V91, P1277, DOI 10.1097/00006534-199306000-00014; McAllister AK, 1999, ANNU REV NEUROSCI, V22, P295, DOI 10.1146/annurev.neuro.22.1.295; Moller JC, 1998, J NEUROSCI RES, V51, P463, DOI 10.1002/(SICI)1097-4547(19980215)51:4<463::AID-JNR6>3.0.CO;2-A; Nurcombe V, 2000, J BIOL CHEM, V275, P30009, DOI 10.1074/jbc.M003038200; SMALL DH, 1995, J NEUROSCI, V15, P144; Sofroniew MV, 2001, ANNU REV NEUROSCI, V24, P1217, DOI 10.1146/annurev.neuro.24.1.1217; Tagliabue E, 2000, J BIOL CHEM, V275, P5388, DOI 10.1074/jbc.275.8.5388; Torcia M, 1996, CELL, V85, P345, DOI 10.1016/S0092-8674(00)81113-7; Wang XH, 1997, NEURON, V19, P825, DOI 10.1016/S0896-6273(00)80964-2; YAAR M, 1991, J CELL BIOL, V115, P821, DOI 10.1083/jcb.115.3.821	37	98	121	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2003	22	36					5592	5601		10.1038/sj.onc.1206805	http://dx.doi.org/10.1038/sj.onc.1206805			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944907				2022-12-25	WOS:000184865900008
J	Ortiz-Salmeron, E; Nuccetelli, M; Oakley, AJ; Parker, MW; Lo Bello, M; Garcia-Fuentes, L				Ortiz-Salmeron, E; Nuccetelli, M; Oakley, AJ; Parker, MW; Lo Bello, M; Garcia-Fuentes, L			Thermodynamic description of the effect of the mutation Y49F on human glutathione transferase P1-1 in binding with glutathione and the inhibitor S-hexylglutathione	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROCESSES INVOLVING PROTEINS; HEAT-CAPACITY CHANGES; CATALYTIC MECHANISM; SITE; ANTIBODY; ENTHALPY; WATER; RAT; DNA; MICROCALORIMETRY	The thermodynamics of binding of both the substrate glutathione (GSH) and the competitive inhibitor S-hexylglutathione to the mutant Y49F of human glutathione S-transferase (hGST P1-1), a key residue at the dimer interface, has been investigated by isothermal titration calorimetry and fluorescence spectroscopy. Calorimetric measurements indicated that the binding of these ligands to both the Y49F mutant and wild-type enzyme is enthalpically favorable and entropically unfavorable over the temperature range studied. The affinity of these ligands for the Y49F mutant is lower than those for the wild-type enzyme due mainly to an entropy change. Therefore, the thermodynamic effect of this mutation is to decrease the entropy loss due to binding. Calorimetric titrations in several buffers with different ionization heat amounts indicate a release of protons when the mutant binds GSH, whereas protons are taken up in binding S-hexylglutathione at pH 6.5. This suggests that the thiol group of GSH releases protons to buffer media during binding and a group with low pK(a) (such as Asp(98)) is responsible for the uptake of protons. The temperature dependence of the free energy of binding, DeltaG(0), is weak because of the enthalpy-entropy compensation caused by a large heat capacity change. The heat capacity change is -199.5+/-26.9 cal K-1 mol(-1) for GSH binding and -333.6+/-28.8 cal K-1 mol(-1) for S-hexylglutathione binding. The thermodynamic parameters are consistent with the mutation Tyr(49)-->Phe, producing a slight conformational change in the active site.	Univ Almeria, Fac Expt Sci, Almeria 04120, Spain; Childrens Hosp IRCCS Bambino Gesu, I-00165 Rome, Italy; St Vincents Inst Med Res, Biota Struct Biol Lab, Fitzroy, Vic 3065, Australia; Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy	Universidad de Almeria; IRCCS Bambino Gesu; St. Vincent's Institute of Medical Research; University of Rome Tor Vergata	Garcia-Fuentes, L (corresponding author), Univ Almeria, Fac Expt Sci, Almeria 04120, Spain.	lgarcia@ual.es	Garcia-Fuentes, Luis/D-1125-2016; Ortiz-Salmerón, Emilia/H-1381-2015; Parker, Michael W/F-9069-2013; Oakley, Aaron/A-9464-2013	Garcia-Fuentes, Luis/0000-0003-2471-8052; Ortiz-Salmerón, Emilia/0000-0002-7125-218X; Parker, Michael W/0000-0002-3101-1138; Oakley, Aaron/0000-0002-4764-014X				ARMSTRONG RN, 1991, CHEM RES TOXICOL, V4, P131, DOI 10.1021/tx00020a001; Armstrong RN, 1997, CHEM RES TOXICOL, V10, P2, DOI 10.1021/tx960072x; BALDWIN RL, 1986, P NATL ACAD SCI USA, V83, P8069, DOI 10.1073/pnas.83.21.8069; Board PG, 1997, BIOCHEM J, V328, P929; Brunger A. T., 1993, XPLOR SYSTEM XRAY CR; Caccuri AM, 1999, J BIOL CHEM, V274, P19276, DOI 10.1074/jbc.274.27.19276; Caccuri AM, 1998, BIOCHEMISTRY-US, V37, P3028, DOI 10.1021/bi971903g; Caccuri AM, 1999, BIOCHEM J, V344, P419, DOI 10.1042/0264-6021:3440419; Caccuri AM, 1996, J BIOL CHEM, V271, P16193, DOI 10.1074/jbc.271.27.16193; *CCP4, 1994, ACTA CRYSTALLOGR D, V50, P750; CONNELLY PR, 1994, P NATL ACAD SCI USA, V91, P1964, DOI 10.1073/pnas.91.5.1964; Cooper A, 1994, Methods Mol Biol, V22, P109; Dam TK, 1998, J BIOL CHEM, V273, P32812, DOI 10.1074/jbc.273.49.32812; Fukada H, 1998, PROTEINS, V33, P159, DOI 10.1002/(SICI)1097-0134(19981101)33:2<159::AID-PROT2>3.3.CO;2-F; GarciaFuentes L, 1996, J BIOL CHEM, V271, P27569, DOI 10.1074/jbc.271.44.27569; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HA JH, 1989, J MOL BIOL, V209, P801, DOI 10.1016/0022-2836(89)90608-6; HIBBITS KA, 1994, BIOCHEMISTRY-US, V33, P3584, DOI 10.1021/bi00178a015; Hilser VJ, 1996, PROTEINS, V26, P123, DOI 10.1002/(SICI)1097-0134(199610)26:2<123::AID-PROT2>3.0.CO;2-H; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE B, 1994, BIOPHYS CHEM, V51, P271, DOI 10.1016/0301-4622(94)00048-4; LoBello M, 1997, BIOCHEMISTRY-US, V36, P6207, DOI 10.1021/bi962813z; LOBELLO M, 1995, J BIOL CHEM, V270, P1249; MANNERVIK B, 1985, P NATL ACAD SCI USA, V82, P7202, DOI 10.1073/pnas.82.21.7202; MEYER DJ, 1995, BIOCHEM J, V311, P739, DOI 10.1042/bj3110739; MEYER DJ, 1991, BIOCHEM J, V274, P409, DOI 10.1042/bj2740409; MURPHY KP, 1990, SCIENCE, V247, P559, DOI 10.1126/science.2300815; MURPHY KP, 1995, PROTEINS, V21, P83, DOI 10.1002/prot.340210202; MURPHY KP, 1992, ADV PROTEIN CHEM, V43, P313, DOI 10.1016/S0065-3233(08)60556-2; Oakley AJ, 1998, BIOCHEMISTRY-US, V37, P9912, DOI 10.1021/bi980323w; Oakley AJ, 1997, J MOL BIOL, V274, P84, DOI 10.1006/jmbi.1997.1364; Ortiz-Salmeron E, 2001, BBA-PROTEIN STRUCT M, V1548, P106, DOI 10.1016/S0167-4838(01)00224-2; Ortiz-Salmeron E, 2001, EUR J BIOCHEM, V268, P4307, DOI 10.1046/j.1432-1327.2001.02349.x; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; Pemble SE, 1996, BIOCHEM J, V319, P749, DOI 10.1042/bj3190749; PICARD V, 1994, NUCLEIC ACIDS RES, V22, P2587, DOI 10.1093/nar/22.13.2587; REINEMER P, 1992, J MOL BIOL, V227, P214, DOI 10.1016/0022-2836(92)90692-D; Ricci G, 1996, J BIOL CHEM, V271, P16187, DOI 10.1074/jbc.271.27.16187; Sharp KA, 1997, J PHYS CHEM B, V101, P4343, DOI 10.1021/jp9702457; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; SPOLAR RS, 1992, BIOCHEMISTRY-US, V31, P3947, DOI 10.1021/bi00131a009; SPOLAR RS, 1989, P NATL ACAD SCI USA, V86, P8382, DOI 10.1073/pnas.86.21.8382; Stevens JM, 2000, BIOCHEM J, V347, P193, DOI 10.1042/0264-6021:3470193; Stites WE, 1997, CHEM REV, V97, P1233, DOI 10.1021/cr960387h; STURTEVANT JM, 1977, P NATL ACAD SCI USA, V74, P2236, DOI 10.1073/pnas.74.6.2236; Swaminathan CP, 1999, J BIOL CHEM, V274, P31272, DOI 10.1074/jbc.274.44.31272; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Yassin Z, 2003, INT J BIOL MACROMOL, V31, P155, DOI 10.1016/S0141-8130(02)00077-6	50	19	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46938	46948		10.1074/jbc.M305043200	http://dx.doi.org/10.1074/jbc.M305043200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12937169	hybrid			2022-12-25	WOS:000186569400088
J	Schmidt, H; Krauth-Siegel, RL				Schmidt, H; Krauth-Siegel, RL			Functional and physicochemical characterization of the thioredoxin system in Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI THIOREDOXIN; SITE CYSTEINE RESIDUES; ACTIVE-SITE; DIHYDROLIPOAMIDE DEHYDROGENASE; TRYPANOTHIONE METABOLISM; CRITHIDIA-FASCICULATA; DEPENDENT SYNTHESIS; LIPOIC ACID; TRYPAREDOXIN; REDUCTASE	Trypanosoma brucei, the causative agent of African sleeping sickness, possesses a single thioredoxin that has an unusually high pI value of 8.5 and lacks a conserved aspartyl residue claimed to be involved in catalysis in other thioredoxins. Despite these peculiarities, T. brucei thioredoxin behaves like classical thioredoxins. It is reduced by thioredoxin reductases from different species, serves as donor of reducing equivalents for the ribonucleotide reductase of the parasite, and catalyzes the reduction of protein disulfides. The redox potential of -267 mV was obtained from protein-protein redox equilibration with Escherichia coli thioredoxin. The pK value of T. brucei thioredoxin was determined by two different methods. Carboxamidomethylation of the reduced protein yielded a pK value of 7.4 and generated mono-alkylated protein. The thiolate absorption at 240 nm resulted in a pK of 7.6 and, based on the extinction coefficient of 11.6 mM(-1) cm(-1), there are two (or three) cysteines titrating with very similar pK values. A thioredoxin reductase has not yet been detected in any organism of the order Kinetoplastida. T. brucei thioredoxin is spontaneously reduced by trypanothione (bis(glutathionyl) spermidine). Obviously, a specific thioredoxin reductase is not required as thioredoxin reduction can be conducted by the parasite-specific trypanothione/trypanothione reductase system.	Heidelberg Univ, Biochem Zentrum Heidelberg, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Krauth-Siegel, RL (corresponding author), Heidelberg Univ, Biochem Zentrum Heidelberg, Neuenheimer Feld 504, D-69120 Heidelberg, Germany.	krauth-siegel@urz.uni-heidelberg.de						Alphey MS, 1999, J STRUCT BIOL, V126, P76, DOI 10.1006/jsbi.1999.4091; Arner ESJ, 1996, BIOCHEM BIOPH RES CO, V225, P268, DOI 10.1006/bbrc.1996.1165; Aslund F, 1997, J BIOL CHEM, V272, P30780, DOI 10.1074/jbc.272.49.30780; BENESCH RE, 1955, J AM CHEM SOC, V77, P5877, DOI 10.1021/ja01627a030; Bryk R, 2002, SCIENCE, V295, P1073, DOI 10.1126/science.1067798; Bulaj G, 1998, BIOCHEMISTRY-US, V37, P8965, DOI 10.1021/bi973101r; BUNIK V, 1993, FEBS LETT, V336, P197, DOI 10.1016/0014-5793(93)80801-Z; Debarbieux L, 1998, P NATL ACAD SCI USA, V95, P10751, DOI 10.1073/pnas.95.18.10751; Dormeyer M, 2001, J BIOL CHEM, V276, P10602, DOI 10.1074/jbc.M010352200; Dyson HJ, 1997, BIOCHEMISTRY-US, V36, P2622, DOI 10.1021/bi961801a; FAIRLAMB AH, 1992, ANNU REV MICROBIOL, V46, P695, DOI 10.1146/annurev.micro.46.1.695; Flohe L, 2002, METHOD ENZYMOL, V347, P244; FraserLhostis C, 1997, BIOL CHEM, V378, P1039, DOI 10.1515/bchm.1997.378.9.1039; FRIEMANN R, 2003, IN PRESS FEBS LETT; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; GLEASON FK, 1992, PROTEIN SCI, V1, P609, DOI 10.1002/pro.5560010507; Gommel DU, 1997, EUR J BIOCHEM, V248, P913, DOI 10.1111/j.1432-1033.1997.t01-1-00913.x; GRAUSCHOPF U, 1995, CELL, V83, P947, DOI 10.1016/0092-8674(95)90210-4; Haendeler J, 2002, NAT CELL BIOL, V4, P743, DOI 10.1038/ncb851; Hillebrand H, 2003, J BIOL CHEM, V278, P6809, DOI 10.1074/jbc.M210392200; Hofmann B, 2002, BIOL CHEM, V383, P347, DOI 10.1515/BC.2002.040; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1979, J BIOL CHEM, V254, P3672; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; JACKMAN SA, 1990, BIOCHEM SOC T, V18, P863, DOI 10.1042/bst0180863; KALLIS GB, 1980, J BIOL CHEM, V255, P261; Kanzok SM, 2000, J BIOL CHEM, V275, P40180, DOI 10.1074/jbc.M007633200; Kern R, 2003, BIOCHEM J, V371, P965, DOI 10.1042/BJ20030093; KORTEMME T, 1995, J MOL BIOL, V253, P799, DOI 10.1006/jmbi.1995.0592; KRAUSE G, 1991, J BIOL CHEM, V266, P9494; Krauth-Siegel RL, 2003, BIOL CHEM, V384, P539, DOI 10.1515/BC.2003.062; Krauth-Siegel RL, 2002, METHOD ENZYMOL, V347, P259; Krieger S, 2000, MOL MICROBIOL, V35, P542, DOI 10.1046/j.1365-2958.2000.01721.x; Ludemann H, 1998, FEBS LETT, V431, P381, DOI 10.1016/S0014-5793(98)00793-5; Miranda-Vizuete A, 1997, J BIOL CHEM, V272, P30841, DOI 10.1074/jbc.272.49.30841; Mossner E, 1998, PROTEIN SCI, V7, P1233; MOUTIEZ M, 1994, CHEM PHARM BULL, V42, P2641; NELSON JW, 1994, BIOCHEMISTRY-US, V33, P5974, DOI 10.1021/bi00185a039; Nikitovic D, 1996, J BIOL CHEM, V271, P19180, DOI 10.1074/jbc.271.32.19180; Nogoceke E, 1997, BIOL CHEM, V378, P827, DOI 10.1515/bchm.1997.378.8.827; OPPERDOES FR, 1984, J CELL BIOL, V98, P1178, DOI 10.1083/jcb.98.4.1178; Powis G, 2001, ANNU REV BIOPH BIOM, V30, P421, DOI 10.1146/annurev.biophys.30.1.421; Reckenfelderbaumer N, 2000, J BIOL CHEM, V275, P7547, DOI 10.1074/jbc.275.11.7547; Reckenfelderbaumer N, 2002, J BIOL CHEM, V277, P17548, DOI 10.1074/jbc.M112115200; SAARINEN M, 1995, STRUCTURE, V3, P1097, DOI 10.1016/S0969-2126(01)00245-3; SCHEMPP H, 1994, Z NATURFORSCH C, V49, P691; Schmidt A, 2002, MOL BIOCHEM PARASIT, V125, P207, DOI 10.1016/S0166-6851(02)00215-3; Schoneck R, 1997, EUR J BIOCHEM, V243, P739, DOI 10.1111/j.1432-1033.1997.00739.x; Steinert P, 2000, BIOL CHEM, V381, P211, DOI 10.1515/BC.2000.028; SULLIVAN FX, 1991, MOL BIOCHEM PARASIT, V44, P145, DOI 10.1016/0166-6851(91)90231-T; Takahashi N, 1996, BIOCHEMISTRY-US, V35, P8342, DOI 10.1021/bi960465v; Vlamis-Gardikas A, 2002, METHOD ENZYMOL, V347, P286; Weichsel A, 1996, STRUCTURE, V4, P735, DOI 10.1016/S0969-2126(96)00079-2; Wilkinson SM, 2002, J BIOL CHEM, V277, P17062, DOI 10.1074/jbc.M111126200; Williams CH, 2000, EUR J BIOCHEM, V267, P6110, DOI 10.1046/j.1432-1327.2000.01702.x	56	40	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46329	46336		10.1074/jbc.M305338200	http://dx.doi.org/10.1074/jbc.M305338200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12949079	hybrid			2022-12-25	WOS:000186569400016
J	Arribas, M; Valverde, AM; Benito, M				Arribas, M; Valverde, AM; Benito, M			Role of IRS-3 in the insulin signaling of IRS-1-deficient brown adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNCOUPLING PROTEIN GENE; GROWTH-FACTOR-I; RECEPTOR SUBSTRATE-3 IRS-3; FATTY-ACID SYNTHASE; TRANSCRIPTIONAL ACTIVATOR; PRIMARY CULTURES; IGF-I; EXPRESSION; DIFFERENTIATION; THERMOGENESIS	Insulin receptor substrate-1 (IRS-1) plays an essential role in mediating the insulin signals that trigger mitogenesis, lipid synthesis, and uncoupling protein-1 gene expression in mouse brown adipocytes. Expression of IRS-3 is restricted mainly to white adipose tissue; expression of this IRS protein is virtually absent in brown adipocytes. We have tested the capacity of IRS-3 to mediate insulin actions in IRS-1-deficient brown adipocytes. Thus, we expressed exogenous IRS-3 in immortalized IRS-1(-/-) brown adipocytes at a level comparable with that of endogenous IRS-3 in white adipose tissue. Under these conditions, IRS-3 signaling in response to insulin was observed, as revealed by tyrosine phosphorylation of IRS-3, and the activation of phosphatidylinositol (PI)3-kinase associated with this recombinant protein. However, although insulin promoted the association of Grb-2 with recombinant IRS-3 in IRS-1(-/-) cells, the exogenous expression of this IRS family member failed to activate p42/44 MAPK and mitogenesis in brown adipocytes lacking IRS-1. Downstream of PI 3-kinase, IRS-3 expression restored insulin-induced Akt phosphorylation, which is impaired by the lack of IRS-1 signaling. Whereas the generation of IRS-3 signals enhanced adipocyte determination and differentiation-dependent factor 1/sterol regulatory element-binding protein (ADD-1/SREBP-1c) and fatty acid synthase mRNA and protein expression, activation of this pathway was unable to reconstitute CCAAT/enhancer-binding protein alpha and uncoupling protein-1 transactivation and gene expression in response to insulin. Similar results were obtained following insulin-like growth factor-I stimulation. In brown adipocytes expressing the IRS-3F4 mutant, the association of the p85alpha regulatory subunit via Src homology 2 binding was lost, but insulin nevertheless induced PI 3-kinase activity and Akt phosphorylation in a wortmannin-dependent manner. In contrast, activation of IRS-3F4 signaling failed to restore the induction of ADD-1/SREBP-1c and fatty acid synthase gene expression in IRS-1-deficient brown adipocytes. These studies demonstrate that recombinant IRS-3 may reconstitute some, but not all, of the signals required for insulin action in brown adipocytes. Thus, our data further implicate a unique role for IRS-1 in triggering insulin action in brown adipocytes.	Univ Complutense Madrid, Fac Farm, CSIC, Dept Bioquim & Biol Mol,Inst Bioquim,Ctr Mixto, E-28040 Madrid, Spain	Complutense University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)	Benito, M (corresponding author), Univ Complutense Madrid, Fac Farm, CSIC, Dept Bioquim & Biol Mol,Inst Bioquim,Ctr Mixto, Ciudad Univ, E-28040 Madrid, Spain.		Benito, Manuel/J-5637-2014	Benito, Manuel/0000-0002-7218-406X				AILHAUD G, 1992, ANNU REV NUTR, V12, P207, DOI 10.1146/annurev.nu.12.070192.001231; ALVAREZ R, 1995, J BIOL CHEM, V270, P5666, DOI 10.1074/jbc.270.10.5666; AMY CM, 1989, P NATL ACAD SCI USA, V86, P3114, DOI 10.1073/pnas.86.9.3114; CASSARDDOULCIER AM, 1993, MOL ENDOCRINOL, V7, P497, DOI 10.1210/me.7.4.497; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dalgaard LT, 2001, DIABETOLOGIA, V44, P946, DOI 10.1007/s001250100596; Guerra C, 2001, J CLIN INVEST, V108, P1205, DOI 10.1172/JCI200113103; Guerra C, 1996, J BIOL CHEM, V271, P2076, DOI 10.1074/jbc.271.4.2076; Kaburagi Y, 1997, J BIOL CHEM, V272, P25839, DOI 10.1074/jbc.272.41.25839; Kaburagi Y, 2001, DIABETOLOGIA, V44, P992, DOI 10.1007/s001250100587; Kabuta T, 2002, J BIOL CHEM, V277, P6846, DOI 10.1074/jbc.M107058200; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; KLAUS S, 1994, J CELL SCI, V107, P313; KOZAK UC, 1994, MOL CELL BIOL, V14, P59, DOI 10.1128/MCB.14.1.59; Laustsen PG, 2002, GENE DEV, V16, P3213, DOI 10.1101/gad.1034802; Lavan BE, 1997, J BIOL CHEM, V272, P11439; LORENZO M, 1993, J CELL BIOL, V123, P1567, DOI 10.1083/jcb.123.6.1567; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; Palmer DG, 2002, BIOCHEM BIOPH RES CO, V291, P439, DOI 10.1006/bbrc.2002.6467; Porras A, 1998, MOL ENDOCRINOL, V12, P825, DOI 10.1210/me.12.6.825; Ricquier D, 2000, BIOCHEM J, V345, P161, DOI 10.1042/0264-6021:3450161; Ross SA, 1998, BIOCHEM BIOPH RES CO, V247, P487, DOI 10.1006/bbrc.1998.8821; ROSS SR, 1992, P NATL ACAD SCI USA, V89, P7561, DOI 10.1073/pnas.89.16.7561; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; Teruel T, 1998, J CELL PHYSIOL, V176, P99, DOI 10.1002/(SICI)1097-4652(199807)176:1<99::AID-JCP12>3.3.CO;2-6; TERUEL T, 1995, BIOCHEM J, V310, P771, DOI 10.1042/bj3100771; Teruel T, 1996, BIOCHEM J, V319, P627, DOI 10.1042/bj3190627; TERUEL T, 1995, FEBS LETT, V364, P193, DOI 10.1016/0014-5793(95)00385-M; TRAYHURN P, 1989, CAN J PHYSIOL PHARM, V67, P811, DOI 10.1139/y89-128; Tsuruzoe K, 2001, MOL CELL BIOL, V21, P26, DOI 10.1128/MCB.21.1.26-38.2001; Valverde AM, 1998, ENDOCRINOLOGY, V139, P1229, DOI 10.1210/en.139.3.1229; Valverde AM, 1997, MOL ENDOCRINOL, V11, P595, DOI 10.1210/me.11.5.595; Valverde AM, 1999, DIABETES, V48, P2122, DOI 10.2337/diabetes.48.11.2122; Valverde AM, 2003, J BIOL CHEM, V278, P10221, DOI 10.1074/jbc.M209363200; Xu P, 1999, J BIOL CHEM, V274, P15262, DOI 10.1074/jbc.274.21.15262; YUBERO P, 1994, BIOCHEM BIOPH RES CO, V198, P653, DOI 10.1006/bbrc.1994.1095; Zhou LX, 1999, MOL ENDOCRINOL, V13, P505, DOI 10.1210/me.13.3.505	37	11	14	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45189	45199		10.1074/jbc.M301185200	http://dx.doi.org/10.1074/jbc.M301185200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12944402	hybrid, Green Published			2022-12-25	WOS:000186452300019
J	Outten, FW; Wood, MJ; Munoz, FM; Storz, G				Outten, FW; Wood, MJ; Munoz, FM; Storz, G			The SufE protein and the SufBCD complex enhance SufS cysteine desulfurase activity as part of a sulfur transfer pathway for fe-s cluster assembly in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN SELENOCYSTEINE LYASE; NIFS-LIKE PROTEIN; AZOTOBACTER-VINELANDII; ERWINIA-CHRYSANTHEMI; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; GENE CLONING; ISCU; BIOSYNTHESIS; SCAFFOLD	The sufABCDSE operon of the Gram-negative bacterium Escherichia coli is induced by oxidative stress and iron deprivation. To examine the biochemical roles of the Suf proteins, we purified all of the proteins and assayed their effect on SufS cysteine desulfurase activity. Here we report that the SufE protein can stimulate the cysteine desulfurase activity of the SufS enzyme up to 8-fold and accepts sulfane sulfur from SufS. This sulfur transfer process from SufS to SufE is sheltered from the environment based on its resistance to added reductants and on the analysis of available crystal structures of the proteins. We also found that the SufB, SufC, and SufD proteins associate in a stable complex and that, in the presence of SufE, the SufBCD complex further stimulates SufS activity up to 32-fold. Thus, the SufE protein and the SufBCD complex act synergistically to modulate the cysteine desulfurase activity of SufS. We propose that this sulfur transfer mechanism may be important for limiting sulfide release during oxidative stress conditions in vivo.	NICHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Storz, G (corresponding author), NICHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA.			Storz, Gisela/0000-0001-6698-1241; Outten, Franklin/0000-0002-9095-0194	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001608] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001608] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Agar JN, 2000, BIOCHEMISTRY-US, V39, P7856, DOI 10.1021/bi000931n; BERGLIN EH, 1985, INFECT IMMUN, V49, P538, DOI 10.1128/IAI.49.3.538-543.1985; Cupp-Vickery JR, 2003, J MOL BIOL, V330, P1049, DOI 10.1016/S0022-2836(03)00690-9; Ellis KES, 2001, MOL MICROBIOL, V41, P973, DOI 10.1046/j.1365-2958.2001.02588.x; Flint DH, 1996, J BIOL CHEM, V271, P16068; Fujii T, 2000, BIOCHEMISTRY-US, V39, P1263, DOI 10.1021/bi991732a; Hoff KG, 2002, J BIOL CHEM, V277, P27353, DOI 10.1074/jbc.M202814200; Hoff KG, 2000, P NATL ACAD SCI USA, V97, P7790, DOI 10.1073/pnas.130201997; Kambampati R, 1999, BIOCHEMISTRY-US, V38, P16561, DOI 10.1021/bi991119r; KAMBAMPATI R, 2000, J BIOL CHEM, V278, P38352; Kato S, 2002, P NATL ACAD SCI USA, V99, P5948, DOI 10.1073/pnas.082123599; Krebs C, 2001, BIOCHEMISTRY-US, V40, P14069, DOI 10.1021/bi015656z; Lee JH, 2003, J MICROBIOL, V41, P109; Leimkuhler S, 2001, J BIOL CHEM, V276, P22024, DOI 10.1074/jbc.M102072200; Lima CD, 2002, J MOL BIOL, V315, P1199, DOI 10.1006/jmbi.2001.5308; Loiseau L, 2003, J BIOL CHEM, V278, P38352, DOI 10.1074/jbc.M305953200; Mihara H, 2000, J BIOCHEM-TOKYO, V127, P559, DOI 10.1093/oxfordjournals.jbchem.a022641; Mihara H, 2002, APPL MICROBIOL BIOT, V60, P12, DOI 10.1007/s00253-002-1107-4; Mihara H, 2002, P NATL ACAD SCI USA, V99, P6679, DOI 10.1073/pnas.102176099; Mihara H, 1997, J BIOL CHEM, V272, P22417, DOI 10.1074/jbc.272.36.22417; Mihara H, 1999, J BIOL CHEM, V274, P14768, DOI 10.1074/jbc.274.21.14768; Moller SG, 2001, GENE DEV, V15, P90, DOI 10.1101/gad.850101; Nachin L, 2003, EMBO J, V22, P427, DOI 10.1093/emboj/cdg061; Nachin L, 2001, MOL MICROBIOL, V39, P960, DOI 10.1046/j.1365-2958.2001.02288.x; Ollagnier-de Choudens S, 2003, J BIOL CHEM, V278, P17993, DOI 10.1074/jbc.M300285200; Ollagnier-de-Choudens S, 2001, J BIOL CHEM, V276, P22604, DOI 10.1074/jbc.M102902200; Patzer SI, 1999, J BACTERIOL, V181, P3307, DOI 10.1128/JB.181.10.3307-3309.1999; Rangachari K, 2002, FEBS LETT, V514, P225, DOI 10.1016/S0014-5793(02)02369-4; Schwartz CJ, 2000, P NATL ACAD SCI USA, V97, P9009, DOI 10.1073/pnas.160261497; Schwartz CJ, 2001, P NATL ACAD SCI USA, V98, P14895, DOI 10.1073/pnas.251550898; SEATON BL, 1994, P NATL ACAD SCI USA, V91, P2066, DOI 10.1073/pnas.91.6.2066; Silberg JJ, 2001, J BIOL CHEM, V276, P1696, DOI 10.1074/jbc.M009542200; Smith AD, 2001, J AM CHEM SOC, V123, P11103, DOI 10.1021/ja016757n; Takahashi Y, 1999, J BIOCHEM, V126, P917, DOI 10.1093/oxfordjournals.jbchem.a022535; Takahashi Y, 2002, J BIOL CHEM, V277, P28380, DOI 10.1074/jbc.C200365200; Urbina HD, 2001, J BIOL CHEM, V276, P44521, DOI 10.1074/jbc.M106907200; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264; Zheng M, 2001, J BACTERIOL, V183, P4562, DOI 10.1128/JB.183.15.4562-4570.2001	39	216	231	0	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45713	45719		10.1074/jbc.M308004200	http://dx.doi.org/10.1074/jbc.M308004200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12941942	hybrid			2022-12-25	WOS:000186452300081
J	Pravenec, M; Kazdova, L; Landa, V; Zidek, V; Mlejnek, P; Jansa, P; Wang, JM; Qi, NN; Kurtz, TW				Pravenec, M; Kazdova, L; Landa, V; Zidek, V; Mlejnek, P; Jansa, P; Wang, JM; Qi, NN; Kurtz, TW			Transgenic and recombinant resistin impair skeletal muscle glucose metabolism in the spontaneously hypertensive rat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE FATTY-ACIDS; INSULIN-RESISTANCE; ADIPOSE-TISSUE; GENE-EXPRESSION; OBESITY; CD36; HYPERTRIGLYCERIDEMIA; PATHOGENESIS; TRIGLYCERIDE; DISEASE	Increased serum levels of resistin, a molecule secreted by fat cells, have been proposed as a possible mechanistic link between obesity and insulin resistance. To further investigate the effects of resistin on glucose metabolism, we derived a novel transgenic strain of spontaneously hypertensive rats expressing the mouse resistin gene under the control of the fat-specific aP2 promoter and also performed in vitro studies of the effects of recombinant resistin on glucose metabolism in isolated skeletal muscle. Expression of the resistin transgene was detected by Northern blot analysis in adipose tissue and by real-time PCR in skeletal muscle and was associated with increased serum fatty acids and muscle triglycerides, impaired skeletal muscle glucose metabolism, and glucose intolerance in the absence of any changes in serum resistin concentrations. In skeletal muscle isolated from non-transgenic spontaneously hypertensive rats, in vitro incubation with recombinant resistin significantly inhibited insulin-stimulated glycogenesis and reduced glucose oxidation. These findings raise the possibility that autocrine effects of resistin in adipocytes, leading to release of other prodiabetic effector molecules from fat and/or paracrine actions of resistin secreted by adipocytes embedded within skeletal muscle, may contribute to the pathogenesis of disordered skeletal muscle glucose metabolism and impaired glucose tolerance.	Acad Sci Czech Republ, Inst Physiol, CR-14220 Prague, Czech Republic; Ctr Integrated Genom, Prague 14220, Czech Republic; Charles Univ Prague, Inst Biol & Med Genet, Prague 12800, Czech Republic; Inst Clin & Expt Med, Prague 14021, Czech Republic; Acad Sci Czech Republ, Inst Mol Genet, CR-14220 Prague, Czech Republic; Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA	Czech Academy of Sciences; Institute of Physiology of the Czech Academy of Sciences; Charles University Prague; Institute for Clinical & Experimental Medicine (IKEM); Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; University of California System; University of California San Francisco	Pravenec, M (corresponding author), Acad Sci Czech Republ, Inst Physiol, Videnska 1083, CR-14220 Prague, Czech Republic.	pravenec@biomed.cas.cz	Zidek, Vaclav/C-6685-2012; Mlejnek, Petr/C-2305-2012; Jansa, Petr/B-8153-2019; Jansa, Petr/G-6360-2014; Landa, Vladimir/B-8908-2012; Pravenec, Michal/B-1666-2012	Mlejnek, Petr/0000-0002-4218-8983; Jansa, Petr/0000-0002-1406-1707; Pravenec, Michal/0000-0001-9197-5871	FOGARTY INTERNATIONAL CENTER [R03TW001236] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063709] Funding Source: NIH RePORTER; FIC NIH HHS [TWO1236] Funding Source: Medline; NHLBI NIH HHS [HL63709] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aitman TJ, 1999, NAT GENET, V21, P76, DOI 10.1038/5013; Banerjee RR, 2003, J MOL MED, V81, P218, DOI 10.1007/s00109-003-0428-9; Boden G, 2002, CURR OPIN CLIN NUTR, V5, P545, DOI 10.1097/00075197-200209000-00014; CHARREAU B, 1997, RAT GENOME, V3, P125; DEFRONZO RA, 1991, DIABETES CARE, V14, P173, DOI 10.2337/diacare.14.3.173; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; Fujita H, 2002, BIOCHEM BIOPH RES CO, V298, P345, DOI 10.1016/S0006-291X(02)02464-6; Fukui Y, 2002, DIABETES OBES METAB, V4, P342, DOI 10.1046/j.1463-1326.2002.00215.x; Grundy SM, 1999, AM J CARDIOL, V83, p25F; Holcomb IN, 2000, EMBO J, V19, P4046, DOI 10.1093/emboj/19.15.4046; Hotamisligil GS, 2003, J CLIN INVEST, V111, P173, DOI 10.1172/JCI200317605; Jonke J, 2002, OBES RES, V10, P1; Juan CC, 2001, BIOCHEM BIOPH RES CO, V289, P1328, DOI 10.1006/bbrc.2001.6132; Kelley DE, 2001, DIABETES CARE, V24, P933, DOI 10.2337/diacare.24.5.933; Kim KM, 2001, J BIOL CHEM, V276, P37409, DOI 10.1074/jbc.M106728200; Kraegen EW, 2001, EXP CLIN ENDOCR DIAB, V109, pS189, DOI 10.1055/s-2001-18581; McTernan CL, 2002, LANCET, V359, P46, DOI 10.1016/S0140-6736(02)07281-1; Moon B, 2003, AM J PHYSIOL-ENDOC M, V285, pE106, DOI 10.1152/ajpendo.00457.2002; Moore GBT, 2001, BIOCHEM BIOPH RES CO, V286, P735, DOI 10.1006/bbrc.2001.5460; Muller PY, 2002, BIOTECHNIQUES, V32, P1372; Muller PY, 2002, BIOTECHNIQUES, V33, P514; Nagaev I, 2001, BIOCHEM BIOPH RES CO, V285, P561, DOI 10.1006/bbrc.2001.5173; Pravenec M, 1999, J CLIN INVEST, V103, P1651, DOI 10.1172/JCI6691; Pravenec M, 2001, NAT GENET, V27, P156, DOI 10.1038/84777; Qi NN, 2002, J BIOL CHEM, V277, P48501, DOI 10.1074/jbc.M206655200; Rajala MW, 2003, J CLIN INVEST, V111, P225, DOI 10.1172/JCI200316521; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; REAVEN GM, 1990, HORM METAB RES, V22, P363, DOI 10.1055/s-2007-1004922; REAVEN GM, 1991, AM J MED, V90, pS7, DOI 10.1016/0002-9343(91)90028-V; Savage DB, 2001, DIABETES, V50, P2199, DOI 10.2337/diabetes.50.10.2199; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; VRANA A, 1978, METABOLISM, V27, P885, DOI 10.1016/0026-0495(78)90131-2; Way JM, 2001, J BIOL CHEM, V276, P25651, DOI 10.1074/jbc.C100189200	33	106	113	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45209	45215		10.1074/jbc.M304869200	http://dx.doi.org/10.1074/jbc.M304869200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12944409	hybrid			2022-12-25	WOS:000186452300021
J	Narayanan, B; Islam, MN; Bartelt, D; Ochs, RS				Narayanan, B; Islam, MN; Bartelt, D; Ochs, RS			A direct mass-action mechanism explains capacitative calcium entry in Jurkat and skeletal L6 muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE CA2+ CONCENTRATION; ENDOPLASMIC-RETICULUM; SARCOPLASMIC-RETICULUM; TUMOR PROMOTER; NEURONAL CELLS; ACINAR-CELLS; RECEPTOR; RELEASE; STORES; CHANNELS	We examined capacitative calcium entry (CCE) in Jurkat and in L6 skeletal muscle cells. We found that extracellular Ca2+ can enter the endoplasmic reticulum (ER) of both cell types even in the presence of thapsigargin, which blocks entry into the ER from the cytosol through the CaATPase. Moreover, extracellular Ca2+ entry into the ER was evident even when intracellular flow of Ca2+ was in the direction of ER to cytosol due to the presence of caffeine. ER Ca2+ content was assessed by two separate means. First, we used the Mag-Fura fluorescent dye, which is sensitive only to the relatively high concentrations of Ca2+ found in the ER. Second, we transiently expressed an ER-targeted derivative of aequorin, which reports Ca2+ by luminescence. In both cases, the Ca2+ concentration in the ER increased in response to extracellular Ca2+ after the ER had been previously depleted despite blockade by thapsigargin. We found two differences between the Jurkat and L6 cells. L6, but not Jurkat cells, inhibited Ca2+ uptake at very high Ca2+ concentrations. Second, ryanodine receptor blockers inhibited the appearance of cytosolic Ca2+ during CCE if added before Ca2+ in both cases, but the L6 cells were much more sensitive to ryanodine. Both of these can be explained by the known difference in ryanodine receptors between these cell types. These findings imply that the origin of cytosolic Ca2+ during CCE is the ER. Furthermore, kinetic data demonstrated that Ca2+ filled the ER before the cytosol during CCE. Our results suggest a plasma membrane Ca2+ channel and an ER Ca2+ channel joined in tandem, allowing Ca2+ to flow directly from the extracellular space to the ER. This explains CCE; any decrease in ER [Ca2+] relative to extracellular [Ca2+] would provide the gradient for refilling the ER through a mass-action mechanism.	St Johns Univ, Sch Pharm, Dept Pharmaceut Sci, Jamaica, NY 11439 USA; St Johns Univ, Dept Biol Sci, Jamaica, NY 11439 USA	Saint John's University; Saint John's University	Ochs, RS (corresponding author), St Johns Univ, Sch Pharm, Dept Pharmaceut Sci, 8000 Utopia Pkwy, Jamaica, NY 11439 USA.		Nili, Mona/P-5570-2016	Islam, Mohammad Naimul/0000-0001-7929-9444				Barrero MJ, 1997, J BIOL CHEM, V272, P27694, DOI 10.1074/jbc.272.44.27694; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Bode HP, 1996, BIOCHEM PHARMACOL, V51, P993, DOI 10.1016/0006-2952(96)00048-2; BRINI M, 1995, J BIOL CHEM, V270, P9896, DOI 10.1074/jbc.270.17.9896; Brini M, 1997, MOL BIOL CELL, V8, P129, DOI 10.1091/mbc.8.1.129; CASTEELS R, 1981, J PHYSIOL-LONDON, V317, P263, DOI 10.1113/jphysiol.1981.sp013824; ENDO M, 1985, CURR TOP MEMBR TRANS, V25, P181; FRANZINIARMSTRO.C, 1996, RYANODINE RECEPTORS, P1; Golovina VA, 1997, SCIENCE, V275, P1643, DOI 10.1126/science.275.5306.1643; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hofer AM, 1998, J CELL BIOL, V140, P325, DOI 10.1083/jcb.140.2.325; HOFER AM, 1999, CALCIUM SIGNALING PR; Hopf FW, 1996, J BIOL CHEM, V271, P22358, DOI 10.1074/jbc.271.37.22358; Islam MN, 2002, EXP BIOL MED, V227, P425, DOI 10.1177/153537020222700608; JACKSON TR, 1988, BIOCHEM J, V253, P81, DOI 10.1042/bj2530081; Jeyakumar LH, 1998, J BIOL CHEM, V273, P16011, DOI 10.1074/jbc.273.26.16011; KANG JJ, 1994, BRIT J PHARMACOL, V112, P1216, DOI 10.1111/j.1476-5381.1994.tb13213.x; Kiselyov KI, 2000, MOL CELL, V6, P421, DOI 10.1016/S1097-2765(00)00041-1; Kurebayashi N, 2001, J PHYSIOL-LONDON, V533, P185, DOI 10.1111/j.1469-7793.2001.0185b.x; LENNARD R, 1992, GEN PHARMACOL, V23, P903, DOI 10.1016/0306-3623(92)90244-E; Liu WR, 2002, LIFE SCI, V71, P1279, DOI 10.1016/S0024-3205(02)01826-X; Meldolesi J, 1998, TRENDS BIOCHEM SCI, V23, P10, DOI 10.1016/S0968-0004(97)01143-2; MONTERO M, 1995, EMBO J, V14, P5467, DOI 10.1002/j.1460-2075.1995.tb00233.x; Nakai J, 1998, J BIOL CHEM, V273, P13403, DOI 10.1074/jbc.273.22.13403; Nguyen HN, 2002, BRAIN RES, V924, P159, DOI 10.1016/S0006-8993(01)03229-2; Niemeyer BA, 1996, CELL, V85, P651, DOI 10.1016/S0092-8674(00)81232-5; NORI A, 1996, RYANODINE RECEPTORS, P101; Ogawa Y, 2000, TRENDS CARDIOVAS MED, V10, P65, DOI 10.1016/S1050-1738(00)00050-5; OGDEN D, 1995, PFLUG ARCH EUR J PHY, V429, P587, DOI 10.1007/BF00704165; Philipp S, 2000, CRC METH SIG TRANS, P321; Putney Jr JW, 1997, CAPACITATIVE CALCIUM; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Putney JW, 2001, J CELL SCI, V114, P2223; Robert V, 1998, J BIOL CHEM, V273, P30372, DOI 10.1074/jbc.273.46.30372; Sonnleitner A, 1998, EMBO J, V17, P2790, DOI 10.1093/emboj/17.10.2790; SUGIYAMA T, 1995, AM J PHYSIOL-CELL PH, V269, pC698, DOI 10.1152/ajpcell.1995.269.3.C698; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Wang MC, 2002, J MOL BIOL, V323, P85, DOI 10.1016/S0022-2836(02)00890-2; Wingertzahn MA, 1999, P SOC EXP BIOL MED, V221, P234, DOI 10.1046/j.1525-1373.1999.d01-81.x; Wingertzahn MA, 2001, EXP BIOL MED, V226, P119, DOI 10.1177/153537020122600209; Zucchi R, 1997, PHARMACOL REV, V49, P1	43	18	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44188	44196		10.1074/jbc.M306538200	http://dx.doi.org/10.1074/jbc.M306538200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12947122	hybrid			2022-12-25	WOS:000186306700038
J	Zhang, F; Lin, MH; Abidi, P; Thiel, G; Liu, JW				Zhang, F; Lin, MH; Abidi, P; Thiel, G; Liu, JW			Specific interaction of Egr1 and c/EBP beta leads to the transcriptional activation of the human low density lipoprotein receptor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE; ONCOSTATIN M; EXPRESSION; CELLS; GROWTH; INDUCTION; ELEMENT; IDENTIFICATION; PATHWAY; ZINC	The sterol-independent regulatory element ( SIRE) of the LDL receptor ( LDLR) promoter mediates oncostatin M ( OM)-induced transcription of the LDLR gene through a cholesterol-independent pathway. Our prior studies have detected specific associations of the zinc finger transcription factor Egr1 with the SIRE sequence in OM-stimulated HepG2 cells. Because the SIRE motif is composed of a c/EBP binding site and a cAMP response element, both of which are quite divergent from the classical GC-rich Egr1 recognition sequences, we hypothesized that Egr1 may regulate LDLR transcription through interacting with members of the c/EBP and CREB families. Here, we show that treating HepG2 cells with OM specifically leads to prominent increases of the levels of c/EBPbeta and Egr1 bound to the LDLR promoter in vivo. In vitro, the binding of Egr1 to the SIRE sequence is weak, but is strikingly enhanced in the presence of HepG2 nuclear extract. Mammalian two-hybrid assays demonstrate that the N-terminal transactivation domain of Egr1 specifically interacts with c/EBPbeta but not with c/EBPalpha or CREB. The OM treatment further enhances this interaction, resulting in a large increase in the Egr1 transactivating activity. The direct protein to protein contact between Egr1 and c/EBPbeta is also demonstrated by co-immunoprecipitation experiments. Furthermore, we show that a mutation of the phosphorylation motif of c/EBPbeta diminished the OM-stimulated interaction of Egr1 and c/EBPbeta. Taken together, we provide strong evidence that Egr1 regulates LDLR transcription via a novel mechanism of protein-protein interaction with c/EBPbeta.	Dept Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA; Univ Saarland, Med Ctr, D-66421 Homburg, Germany	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Saarland University	Liu, JW (corresponding author), Dept Vet Affairs Palo Alto Hlth Care Syst, 3801 Miranda Ave, Palo Alto, CA 94304 USA.	Jingwen.Liu@med.va.gov			NATIONAL CANCER INSTITUTE [R01CA083648] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA83648-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adamson ED, 2002, TUMOR BIOL, V23, P93, DOI 10.1159/000059711; Akira S, 1997, INT J BIOCHEM CELL B, V29, P1401, DOI 10.1016/S1357-2725(97)00063-0; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY B, 1988, P NATL ACAD SCI USA, V85, P797; Cohen DM, 1996, P NATL ACAD SCI USA, V93, P11242, DOI 10.1073/pnas.93.20.11242; Day FL, 1999, J BIOL CHEM, V274, P23726, DOI 10.1074/jbc.274.34.23726; DIEKGRAFFE B, 1999, AM J PHYSIOL, V276, pG322; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; Hu JB, 2001, J BIOL CHEM, V276, P287, DOI 10.1074/jbc.M004885200; Kaufmann K, 2001, BIOL CHEM, V382, P1077, DOI 10.1515/BC.2001.135; Levkovitz Y, 2002, J NEUROSCI, V22, P3845, DOI 10.1523/JNEUROSCI.22-10-03845.2002; Li C, 1999, J BIOL CHEM, V274, P6747, DOI 10.1074/jbc.274.10.6747; LIM RW, 1987, ONCOGENE, V1, P263; Liu JW, 2000, J BIOL CHEM, V275, P5214, DOI 10.1074/jbc.275.7.5214; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; Papanikolaou NA, 2000, J BIOL CHEM, V275, P26683; Park JA, 1999, J NEUROCHEM, V73, P450, DOI 10.1046/j.1471-4159.1999.0730450.x; Sato K, 1999, MOL BRAIN RES, V74, P182, DOI 10.1016/S0169-328X(99)00279-X; Svaren J, 2000, J BIOL CHEM, V275, P38524, DOI 10.1074/jbc.M005220200; THIEL G, 1994, J BIOL CHEM, V269, P15294; Thiel G, 2002, J CELL PHYSIOL, V193, P287, DOI 10.1002/jcp.10178; Thiel G, 2000, BBA-GENE STRUCT EXPR, V1493, P289, DOI 10.1016/S0167-4781(00)00207-4; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; Zhang F, 2002, J LIPID RES, V43, P1477, DOI 10.1194/jlr.M200126-JLR200	27	55	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44246	44254		10.1074/jbc.M305564200	http://dx.doi.org/10.1074/jbc.M305564200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12947119	hybrid			2022-12-25	WOS:000186306700045
J	Gozdz, A; Habas, A; Jaworski, J; Zielinska, M; Albrecht, J; Chlystun, M; Jalili, A; Hetman, M				Gozdz, A; Habas, A; Jaworski, J; Zielinska, M; Albrecht, J; Chlystun, M; Jalili, A; Hetman, M			Role of N-methyl-D-aspartate receptors in the neuroprotective activation of extracellular signal-regulated kinase 1/2 by cisplatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED APOPTOSIS; NEURONAL APOPTOSIS; DNA-DAMAGE; POLY(ADP-RIBOSE) POLYMERASE; GANGLION NEURONS; TOPOISOMERASE-I; NMDA RECEPTORS; NERVOUS-SYSTEM; AMINO-ACIDS; CELL-CYCLE	Neurons are exposed to damaging stimuli that can trigger cell death and subsequently cause serious neurological disorders. Therefore, it is important to define defense mechanisms that can be activated in response to damage to reduce neuronal loss. Here we report that cisplatin (CPDD), a neurotoxic anticancer drug that damages DNA, triggered apoptosis and activated the extracellular signal-regulated kinase 1/2 (ERK1/2) pathway in cultured rat cortical neurons. Inhibition of ERK1/2 activation using either pharmacological inhibitors or a dominant-negative mutant of the ERK1/2 activator, mitogen-activated protein kinase kinase 1, increased the toxicity of CPDD. Interestingly, N-methyl-D-aspartate (NMDA) receptor (NMDAR) antagonists reduced the ERK1/2 activation and exacerbated apoptosis in CPDD-treated neurons. Pre-treatment with CPDD increased ERK1/2 activation triggered by exogenous NMDA, suggesting that CPDD augmented NMDAR responsiveness. CPDD-enhanced response of NMDAR and CPDD-mediated ERK1/2 activation were both decreased by inhibition of poly(ADP-ribose) polymerase (PARP). Interestingly, PARP activation did not produce ATP depletion, suggesting involvement of a non-energetic mechanism in NMDAR regulation by PARP. Finally, CPDD toxicity was reduced by brain-derived neurotrophic factor, and this protection required ERK1/2. In summary, our data identify a novel compensatory circuit in central nervous system neurons that couples the DNA injury, through PARP and NMDAR, to the defensive ERK1/2 activation.	Univ Louisville, Kentucky Spinal Cord Injury Res Ctr, Louisville, KY 40292 USA; Univ Louisville, Dept Neurol Surg, Louisville, KY 40292 USA; Univ Louisville, Grad Program Pharmacol & Toxicol, Louisville, KY 40292 USA; Grad Program Mol Med, PL-02109 Warsaw, Poland; Int Inst Mol & Cell Biol, PL-02109 Warsaw, Poland; M Nencki Inst Expt Biol, PL-02093 Warsaw, Poland; Polish Acad Sci, Med Res Ctr, PL-02106 Warsaw, Poland	University of Louisville; University of Louisville; University of Louisville; Miedzynarodowy Instytut Biologii Molekularnej i Komorkowej; Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences; Polish Academy of Sciences	Hetman, M (corresponding author), Univ Louisville, Kentucky Spinal Cord Injury Res Ctr, 511 S Floyd St,MDR626, Louisville, KY 40292 USA.		Gozdz, Agata/AAD-2974-2022; Albrecht, Jan/AAQ-1158-2021; Zielińska, Magdalena/S-6624-2019	Gozdz, Agata/0000-0001-8421-0598; Albrecht, Jan/0000-0001-6063-6228; Zielińska, Magdalena/0000-0001-7388-3092; Jaworski, Jacek/0000-0001-8760-7865	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015576] Funding Source: NIH RePORTER; NCRR NIH HHS [P20-RR15576] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Alam ZI, 1997, J NEUROCHEM, V69, P1196, DOI 10.1046/j.1471-4159.1997.69031196.x; Anderson CNG, 1999, J NEUROSCI, V19, P664; BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; Bowman KJ, 2001, BRIT J CANCER, V84, P106, DOI 10.1054/bjoc.2000.1555; CHERRINGTON JM, 1989, J VIROL, V63, P1435, DOI 10.1128/JVI.63.3.1435-1440.1989; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Gill JS, 1998, J CLIN INVEST, V101, P2842, DOI 10.1172/JCI1130; Gonzalez-Zulueta M, 2000, P NATL ACAD SCI USA, V97, P436, DOI 10.1073/pnas.97.1.436; Ha HC, 2000, NEUROBIOL DIS, V7, P225, DOI 10.1006/nbdi.2000.0324; Hetman M, 1999, J BIOL CHEM, V274, P22569, DOI 10.1074/jbc.274.32.22569; Hetman M, 2000, J NEUROSCI, V20, P2567; Hilgier W, 1999, J NEUROSCI RES, V56, P76, DOI 10.1002/(SICI)1097-4547(19990401)56:1<76::AID-JNR10>3.0.CO;2-Y; Ikonomidou C, 1999, SCIENCE, V283, P70, DOI 10.1126/science.283.5398.70; Keime-Guibert F, 1998, J NEUROL, V245, P695, DOI 10.1007/s004150050271; Komatsu N, 2000, J BIOCHEM-TOKYO, V128, P463, DOI 10.1093/oxfordjournals.jbchem.a022775; Lafon-Cazal M, 2002, EUR J NEUROSCI, V16, P575, DOI 10.1046/j.1460-9568.2002.02124.x; Le DA, 2001, DRUG AGING, V18, P717, DOI 10.2165/00002512-200118100-00001; Liu W, 1998, NEUROREPORT, V9, P2609, DOI 10.1097/00001756-199808030-00034; Llado J, 1999, J NEUROSCI, V19, P10803, DOI 10.1523/JNEUROSCI.19-24-10803.1999; LUKASIUK K, 1995, NEUROCHEM INT, V26, P173, DOI 10.1016/0197-0186(94)00121-A; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Mattson MP, 1997, J NEUROSCI RES, V49, P681, DOI 10.1002/(SICI)1097-4547(19970915)49:6<681::AID-JNR3>3.0.CO;2-3; Miller FD, 2001, CELL MOL LIFE SCI, V58, P1045, DOI 10.1007/PL00000919; Morris EJ, 1996, J CELL BIOL, V134, P757, DOI 10.1083/jcb.134.3.757; Nagayama T, 2000, J NEUROCHEM, V74, P1636, DOI 10.1046/j.1471-4159.2000.0741636.x; OLNEY JW, 1994, NEUROBIOL AGING, V15, P259, DOI 10.1016/0197-4580(94)90127-9; Park DS, 1998, J CELL BIOL, V143, P457, DOI 10.1083/jcb.143.2.457; Rzeski W, 2001, P NATL ACAD SCI USA, V98, P6372, DOI 10.1073/pnas.091113598; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; Stewart DJ, 1991, NEUROLOGICAL COMPLIC, P143; Terro F, 2000, NEUROSCI LETT, V278, P149, DOI 10.1016/S0304-3940(99)00911-8; Trimmer EE, 1999, ESSAYS BIOCHEM, V34, P191, DOI 10.1042/bse0340191; Westbrook Gary L., 1994, Current Opinion in Neurobiology, V4, P337, DOI 10.1016/0959-4388(94)90094-9; WILLIAMSON JR, 1964, METHOD ENZYMOL, V13, P488; WILLIAMSON JR, 1964, METHOD ENZYMOL, V13, P481; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; ZHENG JL, 1995, J NEUROSCI, V15, P5079; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	42	40	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43663	43671		10.1074/jbc.M301554200	http://dx.doi.org/10.1074/jbc.M301554200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12930843	hybrid			2022-12-25	WOS:000186157000115
J	Venkateswarlu, K				Venkateswarlu, K			Interaction protein for cytohesin exchange factors 1 (IPCEF1) binds cytohesin 2 and modifies its activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; PLASMA-MEMBRANE; STIMULATED TRANSLOCATION; ARF; ACTIVATION; PLECKSTRIN; FAMILY; DOMAIN; ARNO; RECRUITMENT	The ADP-ribosylation factor 6 (ARF6) small GTPase functions as a GDP/GTP-regulated switch in the pathways that stimulate actin reorganization and membrane ruffling. The formation of active ARF6(GTP) is stimulated by guanine nucleotide exchange factors (GEFs) such as cytohesins, which translocate to the plasma membrane in agonist-stimulated cells by binding the lipid second messenger phosphatidylinositol 3,4,5-trisphosphate through the pleckstrin homology domain with subsequent ARF6 activation. Using cytohesin 2 as bait in yeast two-hybrid screening, we have isolated a cDNA encoding a protein termed interaction protein for cytohesin exchange factors 1 (IPCEF1). Using yeast two-hybrid and glutathione S-transferase pull-down assays coupled with deletion mutational analysis, the specific domains required for the cytohesin 2-IPCEF1 interaction were mapped to the coiled-coil domain of cytohesin 2 and the C-terminal 121 amino acids of IPCEF1. IPCEF1 also interacts with the other members of the cytohesin family of ARF GEFs, suggesting that the interaction with IPCEF1 is highly conserved among the cytohesin family of ARF GEFs. The interaction of cytohesin 2 and IPCEF1 in mammalian cells was demonstrated by immunoprecipitation. Immunofluorescence analysis revealed that IPCEF1 co-localizes with cytohesin 2 to the cytosol in unstimulated cells and translocates to the plasma membrane via binding to cytohesin 2 in epidermal growth factor-stimulated cells. However, a deletion mutant of IPCEF1 that lacks the cytohesin 2 binding site failed to co-migrate with cytohesin 2 to the membrane in stimulated cells. The functional significance of the IPCEF1-cytohesin 2 interaction is demonstrated by showing that IPCEF1 increases the in vitro and in vivo stimulation of ARF(GTP) formation by cytohesin 2.	Univ Bristol, Sch Med Sci, Dept Pharmacol, Bristol BS8 1TD, Avon, England	University of Bristol	Venkateswarlu, K (corresponding author), Univ Bristol, Sch Med Sci, Dept Pharmacol, Univ Walk, Bristol BS8 1TD, Avon, England.	k.venkateswarlu@bristol.ac.uk	Kanamarlapudi, Venkateswarlu/A-9864-2011	Kanamarlapudi, Venkateswarlu/0000-0002-8739-1483				Bourgoin SG, 2002, J LEUKOCYTE BIOL, V71, P718; Cullen PJ, 2000, CURR BIOL, V10, pR876, DOI 10.1016/S0960-9822(00)00818-6; Cullen PJ, 1999, BIOCHEM SOC T, V27, P683, DOI 10.1042/bst0270683; DIAMOND MS, 1994, CURR BIOL, V4, P506, DOI 10.1016/S0960-9822(00)00111-1; Donaldson JG, 2000, P NATL ACAD SCI USA, V97, P3792, DOI 10.1073/pnas.97.8.3792; Donaldson JG, 2000, CURR OPIN CELL BIOL, V12, P475, DOI 10.1016/S0955-0674(00)00119-8; Dowler S, 1999, BIOCHEM J, V342, P7, DOI 10.1042/0264-6021:3420007; Franco M, 1998, P NATL ACAD SCI USA, V95, P9926, DOI 10.1073/pnas.95.17.9926; Frank S, 1998, J BIOL CHEM, V273, P23, DOI 10.1074/jbc.273.1.23; Geiger C, 2000, EMBO J, V19, P2525, DOI 10.1093/emboj/19.11.2525; Glenn DE, 1998, J NEUROCHEM, V71, P2023; Hmama Z, 1999, J BIOL CHEM, V274, P1050, DOI 10.1074/jbc.274.2.1050; Jackson CL, 2000, TRENDS CELL BIOL, V10, P60, DOI 10.1016/S0962-8924(99)01699-2; Jackson TR, 2000, TRENDS BIOCHEM SCI, V25, P489, DOI 10.1016/S0968-0004(00)01644-3; Klarlund JK, 2000, J BIOL CHEM, V275, P32816, DOI 10.1074/jbc.M002435200; Klarlund JK, 2001, J BIOL CHEM, V276, P40065, DOI 10.1074/jbc.M105260200; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Kliche S, 2001, MOL CELL, V7, P833, DOI 10.1016/S1097-2765(01)00227-1; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; Korthauer U, 2000, J IMMUNOL, V164, P308, DOI 10.4049/jimmunol.164.1.308; Langille SE, 1999, J BIOL CHEM, V274, P27099, DOI 10.1074/jbc.274.38.27099; Lee SY, 2000, J CELL SCI, V113, P1883; Lippincott-Schwartz J, 1998, HISTOCHEM CELL BIOL, V109, P449, DOI 10.1007/s004180050247; Mansour M, 2002, J BIOL CHEM, V277, P32302, DOI 10.1074/jbc.M202898200; Monier S, 1998, J CELL SCI, V111, P3427; Moss J, 1998, J BIOL CHEM, V273, P21431, DOI 10.1074/jbc.273.34.21431; Nagel W, 1998, J BIOL CHEM, V273, P14853, DOI 10.1074/jbc.273.24.14853; Nagel WG, 1998, MOL BIOL CELL, V9, P1981, DOI 10.1091/mbc.9.8.1981; Nevrivy DJ, 2000, J BIOL CHEM, V275, P16827, DOI 10.1074/jbc.275.22.16827; RANDAZZO P, 2000, SCI STKE; Schweitzer JK, 2002, J BIOL CHEM, V277, P27210, DOI 10.1074/jbc.M201569200; Someya A, 2001, P NATL ACAD SCI USA, V98, P2413, DOI 10.1073/pnas.051634798; Stephens DJ, 1999, J BIOL CHEM, V274, P30080, DOI 10.1074/jbc.274.42.30080; Tang PT, 2002, P NATL ACAD SCI USA, V99, P2625, DOI 10.1073/pnas.052712999; Telemenakis I, 1997, EUR J CELL BIOL, V74, P143; Venkateswarlu K, 1999, BIOCHEM BIOPH RES CO, V262, P237, DOI 10.1006/bbrc.1999.1065; Venkateswarlu K, 2000, BIOCHEM J, V345, P719, DOI 10.1042/0264-6021:3450719; Venkateswarlu K, 1999, J CELL SCI, V112, P1957; Venkateswarlu K, 1998, BIOCHEM J, V335, P139, DOI 10.1042/bj3350139; Venkateswarlu K, 1998, CURR BIOL, V8, P463, DOI 10.1016/S0960-9822(98)70181-2; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C	42	50	51	4	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43460	43469		10.1074/jbc.M304078200	http://dx.doi.org/10.1074/jbc.M304078200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12920129	hybrid			2022-12-25	WOS:000186157000091
J	Zakharova, N; Lymar, ES; Yang, E; Malik, S; Zhang, JJL; Roeder, RG; Darnell, JE				Zakharova, N; Lymar, ES; Yang, E; Malik, S; Zhang, JJL; Roeder, RG; Darnell, JE			Distinct transcriptional activation functions of STAT1 alpha and STAT1 beta on DNA and chromatin templates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; INTERFERON-GAMMA; GENE-TRANSCRIPTION; STAT PROTEINS; COFACTORS; MEDIATOR; TYROSINE; BINDING; 91-KDA; DOMAIN	Interferon-induced transcription depends upon tyrosine phosphorylation, subsequent dimerization, and binding to DNA of STAT1. Other factors, including but not necessarily limited to CBP/p300, then bind within the C-terminal 38 amino acid transactivation domain (TAD) to activate transcription. We show that both tyrosine-phosphorylated STAT1alpha (full-length wild-type protein) and STAT1beta (lacking the TAD) stimulate in vitro transcription on a naked DNA template. Furthermore, in a system with purified proteins and naked DNA, STAT1alpha- and STAT1beta-dependent transcription is stimulated by the TRAP/Mediator co-activator complex. Thus STAT1, through some site other than the C-terminal TAD, can interact with TRAP/Mediator or some intermediate protein. Although both STAT1alpha and STAT1beta bind to known STAT sites within in vitro assembled chromatin templates, only STAT1alpha, and not STAT1beta, in cooperation with p300 and acetyl-CoA, stimulated in vitro transcription from chromatin. After interferon-gamma treatment, cells recruit STAT1alpha or -beta to the chromosomal interferon-1 gene, but only STAT1alpha-containing cells recruit p300 and stimulate transcription. We conclude that chromatin remodeling by p300 in vivo makes TRAP/Mediator effective in stimulating transcription.	Rockefeller Univ, Mol Cell Biol Lab, New York, NY 10021 USA; Rockefeller Univ, Biochem & Mol Biol Lab, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Pathol, New York, NY 10021 USA	Rockefeller University; Rockefeller University; Cornell University	Darnell, JE (corresponding author), Rockefeller Univ, Mol Cell Biol Lab, New York, NY 10021 USA.				NCI NIH HHS [CA42567] Funding Source: Medline; NIAID NIH HHS [AI34420, AI32489] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042567] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032489, R37AI034420, R01AI034420] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		An WJ, 2002, MOL CELL, V9, P811, DOI 10.1016/S1097-2765(02)00497-5; Bulger M., 1994, METH MOL G, V5, P241; Carey M, 1998, CELL, V92, P5, DOI 10.1016/S0092-8674(00)80893-4; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; Fyodorov DV, 2002, NATURE, V418, P897, DOI 10.1038/nature00929; Ge H, 1996, METHOD ENZYMOL, V274, P57; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Horvath CM, 2000, TRENDS BIOCHEM SCI, V25, P496, DOI 10.1016/S0968-0004(00)01624-8; Horvath CM, 1996, MOL CELL BIOL, V16, P6957; Ito T, 2000, GENE DEV, V14, P1899; Ito T, 1999, GENE DEV, V13, P1529, DOI 10.1101/gad.13.12.1529; Kaiser K, 1996, TRENDS BIOCHEM SCI, V21, P342, DOI 10.1016/S0968-0004(96)10043-8; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; Lau JF, 2003, MOL CELL BIOL, V23, P620, DOI 10.1128/MCB.23.2.620-628.2003; Lee TI, 2000, ANNU REV GENET, V34, P77, DOI 10.1146/annurev.genet.34.1.77; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Look DC, 1995, J BIOL CHEM, V270, P30264, DOI 10.1074/jbc.270.51.30264; Malik S, 2000, MOL CELL, V5, P753, DOI 10.1016/S1097-2765(00)80254-3; Malik S, 2000, TRENDS BIOCHEM SCI, V25, P277, DOI 10.1016/S0968-0004(00)01596-6; Malik S, 1998, P NATL ACAD SCI USA, V95, P2192, DOI 10.1073/pnas.95.5.2192; Malik S, 1996, MOL CELL BIOL, V16, P1824; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; Myers LC, 2000, ANNU REV BIOCHEM, V69, P729, DOI 10.1146/annurev.biochem.69.1.729; Paulson M, 2002, NAT CELL BIOL, V4, P140, DOI 10.1038/ncb747; POGNONEC P, 1991, MOL CELL BIOL, V11, P5125, DOI 10.1128/MCB.11.10.5125; Roeder RG, 1998, COLD SPRING HARB SYM, V63, P201, DOI 10.1101/sqb.1998.63.201; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; Shen Y, 2001, J VIROL, V75, P2627, DOI 10.1128/JVI.75.6.2627-2633.2001; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; Stoecklin E, 1997, MOL CELL BIOL, V17, P6708, DOI 10.1128/MCB.17.11.6708; Stoecklin Elisabeth, 1996, Nature (London), V383, P726; Vinkemeier U, 1998, SCIENCE, V279, P1048, DOI 10.1126/science.279.5353.1048; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; Yang E, 2002, J BIOL CHEM, V277, P13455, DOI 10.1074/jbc.M112038200; Yang E, 1999, MOL CELL BIOL, V19, P5106; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; Zhang JJ, 1998, EMBO J, V17, P6963, DOI 10.1093/emboj/17.23.6963; Zhang XK, 1999, MOL CELL BIOL, V19, P7138	45	53	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43067	43073		10.1074/jbc.M308166200	http://dx.doi.org/10.1074/jbc.M308166200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12939262	hybrid			2022-12-25	WOS:000186157000044
J	Froeschke, M; Basler, M; Groettrup, M; Dobberstein, B				Froeschke, M; Basler, M; Groettrup, M; Dobberstein, B			Long-lived signal peptide of lymphocytic choriomeningitis virus glycoprotein pGP-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEMLIKI-FOREST-VIRUS; T-CELL EPITOPE; PROTEASOME INHIBITOR LACTACYSTIN; I MEMBRANE-PROTEIN; HLA-E BINDS; SEQUENCE; CLEAVAGE; IDENTIFICATION; CONTAINS; ALPHAVIRUSES	Signal peptides (SPs) direct nascent secretory and membrane proteins to the membrane of the endoplasmic reticulum. They are usually cleaved from the nascent polypeptide by signal peptidase and then further proteolytically processed. The SP of the pre-glycoprotein (pGP-C) of the lymphocytic choriomeningitis virus SPGP-C (signal peptide of pGP-C) shows different properties: 1) The SPGP-C is unusually long ( 58 amino acid residues) and contains two hydrophobic segments interrupted by a lysine residue. 2) The SPGP-C is cleaved only from a subset of pGP-C proteins. A substantial portion of pGP-C accumulates that still contains the SPGP-C. 3) The cleaved SPGP-C is rather long-lived (t(1/2) of more than 6 h). 4) The cleaved SPGP-C resides in the membrane and is resistant to digestion with proteinase K even in the presence of detergents, suggesting a very compact structure. 5) SPGP-C accumulates in virus particles. These unusual features of the cleaved SPGP-C suggest that SPGP-C not only targets the nascent pGP-C to the endoplasmic reticulum membrane but also has additional functions in lymphocytic choriomeningitis virus life cycle.	Univ Heidelberg, Zentrum Mol Biol, D-69120 Heidelberg, Germany; Univ Constance, Dept Immunol, D-78457 Constance, Germany	Ruprecht Karls University Heidelberg; University of Konstanz	Dobberstein, B (corresponding author), Univ Heidelberg, Zentrum Mol Biol, Neuenheimer Feld 282, D-69120 Heidelberg, Germany.			Basler, Michael/0000-0002-9428-2349				ADEN DP, 1976, IMMUNOGENETICS, V3, P209, DOI 10.1007/BF01576954; ANDREWS DW, 1988, J BIOL CHEM, V263, P15791; Bai AL, 1997, J IMMUNOL, V159, P2139; Beyer WR, 2001, J VIROL, V75, P1061, DOI 10.1128/JVI.75.2.1061-1064.2001; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; Braud V, 1997, EUR J IMMUNOL, V27, P1164, DOI 10.1002/eji.1830270517; Braud VM, 1998, NATURE, V391, P795, DOI 10.1038/35869; BRUNS M, 1983, VIROLOGY, V130, P247, DOI 10.1016/0042-6822(83)90135-6; BUCHMEIER MJ, 1992, SCIENCE, V257, P1142, DOI 10.1126/science.257.5073.1142; BUCHMEIER MJ, 1978, VIROLOGY, V89, P133, DOI 10.1016/0042-6822(78)90047-8; BURNS JW, 1993, ARENAVIRIDAE, P17; Eichler R, 2003, FEBS LETT, V538, P203, DOI 10.1016/S0014-5793(03)00160-1; GAEDIGKNITSCHKO K, 1990, VIROLOGY, V175, P282, DOI 10.1016/0042-6822(90)90210-I; Gallimore A, 1998, MOL IMMUNOL, V35, P581, DOI 10.1016/S0161-5890(98)00053-4; GAROFF H, 1982, CURR TOP MICROBIOL, V99, P1; Gewurz BE, 2002, J BIOL CHEM, V277, P11306, DOI 10.1074/jbc.M107904200; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HOMBACH J, 1995, J EXP MED, V182, P1615, DOI 10.1084/jem.182.5.1615; HUYLEBROECK D, 1988, GENE, V66, P163, DOI 10.1016/0378-1119(88)90354-X; Klappa P, 1996, EUR J BIOCHEM, V239, P509, DOI 10.1111/j.1432-1033.1996.0509u.x; KLAVINSKIS LS, 1990, VIROLOGY, V178, P393, DOI 10.1016/0042-6822(90)90336-P; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHMANNGRUBE F, 1971, VIROL MONOGR, V10, P1; Lemberg MK, 2002, MOL CELL, V10, P735, DOI 10.1016/S1097-2765(02)00655-X; Li Y, 2000, VIROLOGY, V272, P417, DOI 10.1006/viro.2000.0357; Li Y, 1996, P NATL ACAD SCI USA, V93, P9606, DOI 10.1073/pnas.93.18.9606; LILJESTROM P, 1991, J VIROL, V65, P4107; Lindemann D, 2001, J VIROL, V75, P5762, DOI 10.1128/JVI.75.13.5762-5771.2001; LIPP J, 1986, CELL, V46, P1103, DOI 10.1016/0092-8674(86)90710-5; LOEWY A, 1995, J VIROL, V69, P469, DOI 10.1128/JVI.69.1.469-475.1995; LUSA S, 1991, VIROLOGY, V185, P843, DOI 10.1016/0042-6822(91)90556-Q; LYKO F, 1995, J BIOL CHEM, V270, P19873, DOI 10.1074/jbc.270.34.19873; Maniatis T., 1982, MOL CLONING LAB MANU; Martoglio B, 1997, EMBO J, V16, P6636, DOI 10.1093/emboj/16.22.6636; Martoglio B, 1998, TRENDS CELL BIOL, V8, P410, DOI 10.1016/S0962-8924(98)01360-9; Rehm A, 2001, EMBO J, V20, P1573, DOI 10.1093/emboj/20.7.1573; ROMANOWSKI V, 1985, VIRUS RES, V3, P101, DOI 10.1016/0168-1702(85)90001-2; RUSSEL M, 1981, P NATL ACAD SCI-BIOL, V78, P1717, DOI 10.1073/pnas.78.3.1717; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P196; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; Weihofen A, 2002, SCIENCE, V296, P2215, DOI 10.1126/science.1070925; Yao JS, 1996, J VIROL, V70, P7910, DOI 10.1128/JVI.70.11.7910-7920.1996	47	66	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41914	41920		10.1074/jbc.M302343200	http://dx.doi.org/10.1074/jbc.M302343200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12917426	hybrid, Green Published			2022-12-25	WOS:000185989500045
J	Jung, KM; Tan, S; Landman, N; Petrova, K; Murray, S; Lewis, R; Kim, PK; Kim, DS; Ryu, SH; Chao, MV; Kim, TW				Jung, KM; Tan, S; Landman, N; Petrova, K; Murray, S; Lewis, R; Kim, PK; Kim, DS; Ryu, SH; Chao, MV; Kim, TW			Regulated intramembrane proteolysis of the p75 neurotrophin receptor modulates its association with the TrkA receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; GROWTH-FACTOR RECEPTOR; GAMMA-SECRETASE ACTIVITY; NOTCH INTRACELLULAR DOMAIN; ALZHEIMERS-DISEASE; TRUNCATED FORM; CLEAVAGE; PRESENILIN; COMPLEX; P75(NTR)	The generation of biologically active proteins by regulated intramembrane proteolysis is a highly conserved mechanism in cell signaling. Presenilin-dependent gamma-secretase activity is responsible for the intramembrane proteolysis of selected type I membrane proteins, including beta-amyloid precursor protein (APP) and Notch. A small fraction of intracellular domains derived from both APP and Notch translocates to and appears to function in the nucleus, suggesting a generic role for gamma-secretase cleavage in nuclear signaling. Here we show that the p75 neurotrophin receptor (p75(NTR)) undergoes presenilin-dependent intramembrane proteolysis to yield the soluble p75-intracellular domain. The p75(NTR) is a multifunctional type I membrane protein that promotes neurotrophin-induced neuronal survival and differentiation by forming a heteromeric co-receptor complex with the Trk receptors. Mass spectrometric analysis revealed that gamma-secretase-mediated cleavage of p75(NTR) occurs at a position located in the middle of the transmembrane (TM) domain, which is reminiscent of the amyloid beta-peptide 40 (Abeta40) cleavage of APP and is topologically distinct from the major TM cleavage site of Notch 1. Size exclusion chromatography and co-immunoprecipitation analyses revealed that TrkA forms a molecular complex together with either full-length p75 or membrane-tethered C-terminal fragments. The p75-ICD was not recruited into the TrkA-containing high molecular weight complex, indicating that gamma-secretase-mediated removal of the p75 TM domain may perturb the interaction with TrkA. Independent of the possible nuclear function, our studies suggest that gamma-secretase-mediated p75(NTR) proteolysis plays a role in the formation/disassembly of the p75-TrkA receptor complex by regulating the availability of the p75 TM domain that is required for this interaction.	Columbia Univ, Coll Phys & Surg, Dept Pathol,Ctr Neurobiol & Behav, Taub Inst Res Alzheimers Dis & Aging Brain, New York, NY 10032 USA; NYU, Med Ctr, Skirball Inst, Mol Neurobiol Program, New York, NY 10016 USA; Pohang Univ Sci & Technol, Div Mol & Life Sci, Pohang 790784, South Korea	Columbia University; New York University; Pohang University of Science & Technology (POSTECH)	Kim, TW (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Pathol,Ctr Neurobiol & Behav, Taub Inst Res Alzheimers Dis & Aging Brain, P&S 14-442, New York, NY 10032 USA.		Jung, Kwang-Mook/F-1035-2018; Tan, Serena/R-6997-2019; Tan, Serena C/G-5423-2012; Petrová, Klaudia/ABB-2954-2021	Jung, Kwang-Mook/0000-0003-4096-6953; Murray, Simon/0000-0001-6671-192X; Tan, Serena/0000-0002-6356-6541; Ryu, Sung Ho/0000-0003-0913-3048; Chao, Moses/0000-0002-6969-3744	NATIONAL CANCER INSTITUTE [R01CA056490] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043467] Funding Source: NIH RePORTER; NCI NIH HHS [CA 056490] Funding Source: Medline; NINDS NIH HHS [NS 43467] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Auld DS, 2002, PROG NEUROBIOL, V68, P209, DOI 10.1016/S0301-0082(02)00079-5; Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; BARKER PA, 1991, J BIOL CHEM, V266, P19113; Bibel M, 1999, EMBO J, V18, P616, DOI 10.1093/emboj/18.3.616; BLUSZTAJN JK, 1992, J NEUROSCI, V12, P793; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Chao MV, 2003, NAT REV NEUROSCI, V4, P299, DOI 10.1038/nrn1078; COYLE JT, 1983, SCIENCE, V219, P1184, DOI 10.1126/science.6338589; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Dechant G, 2002, NAT NEUROSCI, V5, P1131, DOI 10.1038/nn1102-1131; DISTEFANO PS, 1988, P NATL ACAD SCI USA, V85, P270, DOI 10.1073/pnas.85.1.270; DISTEFANO PS, 1993, J NEUROSCI, V13, P2405, DOI 10.1523/JNEUROSCI.13-06-02405.1993; Ebinu JO, 2002, NEURON, V34, P499, DOI 10.1016/S0896-6273(02)00704-3; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Esposito D, 2001, J BIOL CHEM, V276, P32687, DOI 10.1074/jbc.M011674200; Fortini ME, 2002, NAT REV MOL CELL BIO, V3, P673, DOI 10.1038/nrm910; Gu YJ, 2001, J BIOL CHEM, V276, P35235, DOI 10.1074/jbc.C100357200; Haass C, 2002, TRENDS CELL BIOL, V12, P556, DOI 10.1016/S0962-8924(02)02394-2; Hempstead BL, 2002, CURR OPIN NEUROBIOL, V12, P260, DOI 10.1016/S0959-4388(02)00321-5; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Kim DY, 2002, J BIOL CHEM, V277, P49976, DOI 10.1074/jbc.M210179200; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Oberg C, 2001, J BIOL CHEM, V276, P35847, DOI 10.1074/jbc.M103992200; Park JB, 2000, J BIOL CHEM, V275, P21295, DOI 10.1074/jbc.M002463200; PEREZ P, 1995, MOL CELL NEUROSCI, V6, P97, DOI 10.1006/mcne.1995.1010; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Scheinfeld MH, 2002, J BIOL CHEM, V277, P44195, DOI 10.1074/jbc.M208110200; Schlondorff J, 1999, J CELL SCI, V112, P3603; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Seiffert D, 2000, J BIOL CHEM, V275, P34086, DOI 10.1074/jbc.M005430200; Selkoe D, 2003, ANNU REV NEUROSCI, V26, P565, DOI 10.1146/annurev.neuro.26.041002.131334; Shearman MS, 2000, BIOCHEMISTRY-US, V39, P8698, DOI 10.1021/bi0005456; Sofroniew MV, 2001, ANNU REV NEUROSCI, V24, P1217, DOI 10.1146/annurev.neuro.24.1.1217; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Struhl G, 2000, MOL CELL, V6, P625, DOI 10.1016/S1097-2765(00)00061-7; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Weidemann A, 2002, BIOCHEMISTRY-US, V41, P2825, DOI 10.1021/bi015794o; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; ZUPAN AA, 1989, J BIOL CHEM, V264, P11714; ZUPAN AA, 1991, J BIOL CHEM, V266, P15384	44	175	179	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42161	42169		10.1074/jbc.M306028200	http://dx.doi.org/10.1074/jbc.M306028200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12913006	hybrid			2022-12-25	WOS:000185989500074
J	Li, XW; Yang, YJ; Hu, YM; Dang, DM; Regezi, J; Schmidt, BL; Atakilit, A; Chen, B; Ellis, D; Ramos, DM				Li, XW; Yang, YJ; Hu, YM; Dang, DM; Regezi, J; Schmidt, BL; Atakilit, A; Chen, B; Ellis, D; Ramos, DM			alpha(nu)beta(6)-Fyn signaling promotes oral cancer progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; PROTEIN-TYROSINE KINASES; SRC FAMILY KINASES; SQUAMOUS-CELL CARCINOMAS; IN-VIVO; INTEGRIN ALPHA-V-BETA-6; 3-DIMENSIONAL COLLAGEN; BETA-6 INTEGRIN; EXPRESSION; GROWTH	We have previously shown that the integrin beta(6) is neo-expressed in invasive oral squamous cell carcinoma (SCC) and is correlated with oral tumor progression. However, the mechanism by which the integrin beta(6) promotes oral tumor progression is not well understood. The purpose of the present study was to determine whether integrin beta(6) signaling activates Fyn and thus promotes oral squamous cell carcinoma progression. We analyzed the integrin beta(6) signaling complex and investigated the function of these signaling molecules in oral SCC cells. We found that, upon ligation of the integrin beta(6) with fibronectin, beta(6) complexed with Fyn and activated it. The activation of Fyn recruited and activated focal adhesion kinase to this complex. This complex was necessary to activate Shc and to couple beta6 signaling to the Raf-ERK/MAPK pathway. This pathway transcriptionally activated the matrix metalloproteinase-3 gene and promoted oral SCC cell proliferation and experimental metastasis in vivo. These findings indicate that integrin beta(6) signaling activates Fyn and thus promotes oral cancer progression.	Univ Calif San Francisco, Dept Stomatol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Oral & Maxillofacial Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Lung Biol Ctr, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Ramos, DM (corresponding author), Univ Calif San Francisco, Dept Stomatol, San Francisco, CA 94143 USA.			Schmidt, Brian/0000-0002-2409-8984	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012856, R29DE011930, P01DE013904] Funding Source: NIH RePORTER; NIDCR NIH HHS [P01 DE 13904, R01 DE 12856, R29/R01 DE 11930] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Agrez MV, 1997, VIROLOGY, V239, P71, DOI 10.1006/viro.1997.8831; Ahmed N, 2002, ONCOGENE, V21, P1370, DOI 10.1038/sj.onc.1205286; AKIYAMA SK, 1995, CANCER METAST REV, V14, P173, DOI 10.1007/BF00690290; Arihiro K, 2000, Breast Cancer, V7, P19, DOI 10.1007/BF02967183; Barberis L, 2000, J BIOL CHEM, V275, P36532, DOI 10.1074/jbc.M002487200; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; BREUSS JM, 1995, J CELL SCI, V108, P2241; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; BUSK M, 1992, J BIOL CHEM, V267, P5790; Cary LA, 2002, MOL CELL BIOL, V22, P2427, DOI 10.1128/MCB.22.8.2427-2440.2002; CHAN BMC, 1991, SCIENCE, V251, P1600, DOI 10.1126/science.2011740; CHEN WT, 1985, NATURE, V316, P156, DOI 10.1038/316156a0; Ellerbroek SM, 1999, CANCER RES, V59, P1635; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Felsenfeld DP, 1999, NAT CELL BIOL, V1, P200, DOI 10.1038/12021; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; Gelderloos JA, 1998, J BIOL CHEM, V273, P5908, DOI 10.1074/jbc.273.10.5908; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; Hamidi S, 2000, BRIT J CANCER, V82, P1433, DOI 10.1054/bjoc.1999.1130; HRUSKA KA, 1995, ENDOCRINOLOGY, V136, P2984, DOI 10.1210/en.136.7.2984; Huang XZ, 1996, J CELL BIOL, V133, P921, DOI 10.1083/jcb.133.4.921; Kanazawa S, 1996, BLOOD, V87, P865, DOI 10.1182/blood.V87.3.865.bloodjournal873865; Kawakatsu H, 1996, J BIOL CHEM, V271, P5680, DOI 10.1074/jbc.271.10.5680; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Langholz O, 1995, J CELL BIOL, V131, P1903, DOI 10.1083/jcb.131.6.1903; Li XW, 2001, J CELL SCI, V114, P2665; Li XW, 1998, INVAS METAST, V18, P1, DOI 10.1159/000024494; Lochter A, 1999, MOL BIOL CELL, V10, P271, DOI 10.1091/mbc.10.2.271; MAINIERO F, 1995, EMBO J, V14, P4470, DOI 10.1002/j.1460-2075.1995.tb00126.x; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Mariotti A, 2001, J CELL BIOL, V155, P447, DOI 10.1083/jcb.200105017; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; Polte TR, 1997, J BIOL CHEM, V272, P5501, DOI 10.1074/jbc.272.9.5501; PRIETO AL, 1993, P NATL ACAD SCI USA, V90, P10154, DOI 10.1073/pnas.90.21.10154; Ramos DM, 2002, MATRIX BIOL, V21, P297, DOI 10.1016/S0945-053X(02)00002-1; Ravanti L, 1999, J BIOL CHEM, V274, P2446, DOI 10.1074/jbc.274.4.2446; Regezi JA, 2002, ORAL ONCOL, V38, P332, DOI 10.1016/S1368-8375(01)00062-8; RHEINWALD JG, 1981, CANCER RES, V41, P1657; Salazar EP, 2001, J BIOL CHEM, V276, P17788, DOI 10.1074/jbc.M100984200; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SMYTHE WR, 1995, CANCER METAST REV, V14, P229, DOI 10.1007/BF00690294; Stokoe D, 1997, EMBO J, V16, P2384, DOI 10.1093/emboj/16.9.2384; TAKEUCHI M, 1993, J BIOL CHEM, V268, P27413; Volberg T, 2001, J CELL SCI, V114, P2279; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; WEINACKER A, 1994, J BIOL CHEM, V269, P6940; WERB Z, 1989, J BIOL CHEM, V264, P9111; Xue H, 2001, BIOCHEM BIOPH RES CO, V288, P610, DOI 10.1006/bbrc.2001.5813	59	81	98	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41646	41653		10.1074/jbc.M306274200	http://dx.doi.org/10.1074/jbc.M306274200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12917446	hybrid			2022-12-25	WOS:000185989500013
J	Udayakumar, D; Bladen, CL; Hudson, FZ; Dynan, WS				Udayakumar, D; Bladen, CL; Hudson, FZ; Dynan, WS			Distinct pathways of nonhomologous end joining that are differentially regulated by DNA-dependent protein kinase-mediated phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAK; TARGETED DISRUPTION; DAMAGE CHECKPOINT; CATALYTIC SUBUNIT; EARLY PARTICIPANT; VERTEBRATE CELLS; REPAIR; KU; COMPLEX; GENE	Nonhomologous end joining is the most common mechanism of DNA double-strand break repair in human cells. Here we show that nonhomologous end joining can occur by two biochemically distinct pathways. One requires a fraction containing the Mre11-Rad50-NBS1 complex. The other requires a fraction containing a novel, similar to200-kDa factor that does not correspond to any of the previously described double-strand break repair proteins. The two pathways converge, sharing a common requirement for the DNA ligase IV-XRCC4 complex to catalyze the final step of phosphodiester bond formation. Whereas the Mre11-Rad50-NBS1-dependent pathway does not require, and may be inhibited by, DNA-dependent protein kinase-mediated phosphorylation, the new pathway depends on this phosphorylation for release from a DNA-dependent protein kinase-mediated reaction checkpoint. The existence of two distinct pathways, which are differentially regulated by the DNA-dependent protein kinase, provides a possible explanation for the selective repair defects seen in DNA-dependent protein kinase-deficient mutants.	Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA	University System of Georgia; Augusta University	Dynan, WS (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA.			Dynan, William/0000-0002-4045-5662	NIGMS NIH HHS [GM 35866] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035866] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson L, 2001, MOL CELL BIOL, V21, P1719, DOI 10.1128/MCB.21.5.1719-1729.2001; Barnes DE, 1998, CURR BIOL, V8, P1395, DOI 10.1016/S0960-9822(98)00021-9; Bloomfield V.A., 2000, NUCL ACIDS STRUCTURE, V1st ed.; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Chan DW, 2002, GENE DEV, V16, P2333, DOI 10.1101/gad.1015202; Cooper MP, 2000, GENE DEV, V14, P907; de Jager M, 2001, MOL CELL, V8, P1129, DOI 10.1016/S1097-2765(01)00381-1; DeFazio LG, 2002, EMBO J, V21, P3192, DOI 10.1093/emboj/cdf299; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; Featherstone C, 1999, CURR BIOL, V9, pR759, DOI 10.1016/S0960-9822(00)80005-6; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; Haber JE, 2000, TRENDS GENET, V16, P259, DOI 10.1016/S0168-9525(00)02022-9; Hopfner KP, 2002, CURR OPIN STRUC BIOL, V12, P115, DOI 10.1016/S0959-440X(02)00297-X; Huang JR, 2002, NUCLEIC ACIDS RES, V30, P667, DOI 10.1093/nar/30.3.667; Jin SF, 1998, CARCINOGENESIS, V19, P965, DOI 10.1093/carcin/19.6.965; Kim JS, 2002, J BIOL CHEM, V277, P45149, DOI 10.1074/jbc.M209123200; Li BM, 2000, J BIOL CHEM, V275, P28349, DOI 10.1074/jbc.C000289200; Lou ZK, 2003, J BIOL CHEM, V278, P13599, DOI 10.1074/jbc.C300060200; Luo GB, 1999, P NATL ACAD SCI USA, V96, P7376, DOI 10.1073/pnas.96.13.7376; Manolis KG, 2001, EMBO J, V20, P210, DOI 10.1093/emboj/20.1.210; Matsumoto Y, 2000, FEBS LETT, V478, P67, DOI 10.1016/S0014-5793(00)01800-7; MAY Y, 2002, CELL, V108, P892; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Shang YL, 2003, J BIOL CHEM, V278, P6323, DOI 10.1074/jbc.M210749200; Sonoda E, 2001, P NATL ACAD SCI USA, V98, P8388, DOI 10.1073/pnas.111006398; Soubeyrand S, 2001, P NATL ACAD SCI USA, V98, P9605, DOI 10.1073/pnas.171211398; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Stewart GS, 2003, NATURE, V421, P961, DOI 10.1038/nature01446; Symington LS, 2002, MICROBIOL MOL BIOL R, V66, P630, DOI 10.1128/MMBR.66.4.630-670.2002; Taccioli GE, 1998, IMMUNITY, V9, P355, DOI 10.1016/S1074-7613(00)80618-4; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Vogel H, 1999, P NATL ACAD SCI USA, V96, P10770, DOI 10.1073/pnas.96.19.10770; Wang Y, 2000, GENE DEV, V14, P927; Xiao YH, 1997, NUCLEIC ACIDS RES, V25, P2985, DOI 10.1093/nar/25.15.2985; Xu XZ, 2003, J BIOL CHEM, V278, P8795, DOI 10.1074/jbc.M211392200; Yamaguchi-Iwai Y, 1999, EMBO J, V18, P6619, DOI 10.1093/emboj/18.23.6619	37	44	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41631	41635		10.1074/jbc.M306470200	http://dx.doi.org/10.1074/jbc.M306470200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12917393	hybrid			2022-12-25	WOS:000185989500011
J	Watanabe, K; Wang, CCC; Boddy, CN; Cane, DE; Khosla, C				Watanabe, K; Wang, CCC; Boddy, CN; Cane, DE; Khosla, C			Understanding substrate specificity of polyketide synthase modules by generating hybrid multimodular synthases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; BIOSYNTHETIC GENE-CLUSTER; INTERMODULAR COMMUNICATION; DIRECTED MUTAGENESIS; KINETIC-ANALYSIS; ERYTHROMYCIN; EXPRESSION; DOMAIN; ARCHITECTURE; RIFAMYCIN	Modular polyketide biosynthesis can be harnessed to generate rationally designed complex natural products through bioengineering. A detailed understanding of the features that govern transfer and processing of polyketide biosynthetic intermediates is crucial to successfully engineer new polyketide pathways. Previous studies have shown that substrate stereochemistry and protein-protein interactions between polyketide synthase modules are both important factors in this process. Here we investigated the substrate tolerance of different polyketide modules and assessed the relative importance of inter-module chain transfer versus chain elongation activity of some of these modules. By constructing a variety of hybrid modular polyketide synthase systems and assaying their ability to generate polyketide products, it was determined that the substrate tolerance of each individual ketosynthase domain is an important parameter for the successful recombination of polyketide synthase modules. Surprisingly, however, failure by a module to process a candidate substrate was not due to its inability to bind to it. Rather, it appeared to result from a blockage in carbon-carbon bond formation, suggesting that proper orientation of the initially formed acyl thioester in the ketosynthase active site was important for the enzyme-catalyzed decarboxylative condensation reaction.	Stanford Univ, Dept Chem Engn, Stanford, CA 94305 USA; Stanford Univ, Dept Chem, Stanford, CA 94305 USA; Stanford Univ, Dept Biochem, Stanford, CA 94305 USA; Brown Univ, Dept Chem, Providence, RI 02912 USA	Stanford University; Stanford University; Stanford University; Brown University	Khosla, C (corresponding author), Stanford Univ, Dept Chem Engn, Stanford, CA 94305 USA.	ck@chemeng.stanford.edu	Boddy, Christopher N./H-8084-2019; Watanabe, Kenji/N-2012-2015	Watanabe, Kenji/0000-0002-0463-4831; Boddy, Christopher/0000-0002-3259-3184; Khosla, Chaitan/0000-0001-6529-495X; Wang, Clay/0000-0003-2955-7569	NCI NIH HHS [CA 091636] Funding Source: Medline; NIAID NIH HHS [AI 77248] Funding Source: Medline; NIGMS NIH HHS [GM 22172, GM 65035] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA091636] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R43AI077248] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022172, F32GM065035] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		August PR, 1998, CHEM BIOL, V5, P69, DOI 10.1016/S1074-5521(98)90141-7; Cane DE, 2002, CHEM BIOL, V9, P131, DOI 10.1016/S1074-5521(02)00089-3; CORTES J, 1990, NATURE, V348, P176, DOI 10.1038/348176a0; DONADIO S, 1991, SCIENCE, V252, P675, DOI 10.1126/science.2024119; Gokhale RS, 1999, SCIENCE, V284, P482, DOI 10.1126/science.284.5413.482; Hans M, 2003, J AM CHEM SOC, V125, P5366, DOI 10.1021/ja029539i; Hartwell LH, 1999, NATURE, V402, pC47, DOI 10.1038/35011540; Heath RJ, 2002, NAT PROD REP, V19, P581, DOI 10.1039/b110221b; KAO CM, 1995, J AM CHEM SOC, V117, P9105, DOI 10.1021/ja00140a043; Kao CM, 1996, J AM CHEM SOC, V118, P9184, DOI 10.1021/ja9617552; Khosla C, 1999, ANNU REV BIOCHEM, V68, P219, DOI 10.1146/annurev.biochem.68.1.219; Kim BS, 2002, BIOCHEMISTRY-US, V41, P10827, DOI 10.1021/bi0256779; Kumar P, 2003, J AM CHEM SOC, V125, P4097, DOI 10.1021/ja0297537; Lu HX, 2002, BIOCHEMISTRY-US, V41, P12590, DOI 10.1021/bi026006d; Molnar I, 2000, CHEM BIOL, V7, P97, DOI 10.1016/S1074-5521(00)00075-2; Pfeifer BA, 2001, SCIENCE, V291, P1790, DOI 10.1126/science.1058092; Price AC, 2001, J BIOL CHEM, V276, P6551, DOI 10.1074/jbc.M007101200; Ranganathan A, 1999, CHEM BIOL, V6, P731, DOI 10.1016/S1074-5521(00)80020-4; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schupp T, 1998, FEMS MICROBIOL LETT, V159, P201, DOI 10.1111/j.1574-6968.1998.tb12861.x; Staunton J, 2001, NAT PROD REP, V18, P380, DOI 10.1039/a909079g; Tang L, 1999, CHEM BIOL, V6, P553, DOI 10.1016/S1074-5521(99)80087-8; Tang L, 2000, CHEM BIOL, V7, P77, DOI 10.1016/S1074-5521(00)00073-9; Tang L, 2000, SCIENCE, V287, P640, DOI 10.1126/science.287.5453.640; Tsai SC, 2002, BIOCHEMISTRY-US, V41, P12598, DOI 10.1021/bi0260177; Tsuji SY, 2001, BIOCHEMISTRY-US, V40, P2326, DOI 10.1021/bi002463n; Wu N, 2000, J AM CHEM SOC, V122, P4847, DOI 10.1021/ja000023d; Wu N, 2002, BIOCHEMISTRY-US, V41, P5056, DOI 10.1021/bi012086u; Wu N, 2001, J AM CHEM SOC, V123, P6465, DOI 10.1021/ja010219t; Xue YQ, 1998, P NATL ACAD SCI USA, V95, P12111, DOI 10.1073/pnas.95.21.12111; Yin YF, 2003, J AM CHEM SOC, V125, P5671, DOI 10.1021/ja034574q; Yoon YJ, 2002, CHEM BIOL, V9, P203, DOI 10.1016/S1074-5521(02)00095-9	32	56	57	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42020	42026		10.1074/jbc.M305339200	http://dx.doi.org/10.1074/jbc.M305339200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12923197	hybrid			2022-12-25	WOS:000185989500057
J	Massillon, D; Arinze, IJ; Xu, C; Bone, F				Massillon, D; Arinze, IJ; Xu, C; Bone, F			Regulation of glucose-6-phosphatase gene expression in cultured hepatocytes and H4IIE cells by short-chain fatty acids - Role of hepatic nuclear factor-4 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYKINASE GTP GENE; TISSUE-SPECIFIC EXPRESSION; SODIUM-BUTYRATE; HISTONE DEACETYLASE; ORPHAN RECEPTOR; TRANSCRIPTIONAL REPRESSION; METABOLIC-REGULATION; TRICHOSTATIN-A; SP1 SITES; IN-VIVO	Mechanisms underlying dietary nutrient regulation of glucose-6-phosphatase (Glc-6-Pase) gene expression are not well understood. Here we investigated the effects of short-chain fatty acids on the expression of this gene in primary cultures of rat hepatocytes and H4IIE hepatoma cells. Propionate, butyrate, valerate, and caproate induced severalfold increases in the expression of Glc-6-Pase mRNA. In reporter gene assays, propionate, valerate, caproate, and also octanoate increased Glc-6-Pase promoter activity by 6 - 16-fold. Butyrate, by itself, had little or no effect on promoter activity, but it induced a robust increase (45-fold) in promoter activity in cells co-transfected with a plasmid expressing the transcription factor HNF-4alpha(alpha isoforms of hepatic nuclear factor 4). HNF-4alpha also enhanced promoter activity induced by other short-chain fatty acids. A dominant negative form of HNF-4alpha abrogated the fatty acid-induced promoter activity, a finding that accentuates a role for HNF-4alpha in the transcription process studied here. In cells transfected with HNF-4alpha, short-chain fatty acids and trichostatin A, an inhibitor of histone deacetylase, synergistically enhanced promoter activity, suggesting that hyperacetylation of histones is an important component of the transactivation of the Glc-6-Pase gene promoter by HNF-4alpha. Region - 751/ - 466 of this promoter contains seven putative HNF-4alpha-binding motifs. Binding of HNF-4alpha to this region was confirmed by electrophoretic mobility shift and chromatin immunoprecipitation assays, indicating that HNF-4alpha is recruited to the Glc-6-Pase gene promoter during short-chain fatty acid-induced transcription from this promoter.	Case Western Reserve Univ, Sch Med, Dept Nutr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Physiol, Cleveland, OH 44106 USA; Meharry Med Coll, Dept Biochem, Nashville, TN 37208 USA	Case Western Reserve University; Case Western Reserve University; Meharry Medical College	Massillon, D (corresponding author), Case Western Reserve Univ, Sch Med, Dept Nutr, 10900 Euclid Ave, Cleveland, OH 44106 USA.	dxm71@po.cwru.edu						Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; ARION WJ, 1980, J BIOL CHEM, V255, P396; BIRREN BW, 1986, NUCLEIC ACIDS RES, V14, P853, DOI 10.1093/nar/14.2.853; BOFFA LC, 1978, J BIOL CHEM, V253, P3364; BURCHELL A, 1990, FASEB J, V4, P2978, DOI 10.1096/fasebj.4.12.2168325; BURCHELL A, 1985, BIOCHEM J, V230, P489, DOI 10.1042/bj2300489; CAREY M, 2000, TRANSCRIPTIONAL REGU, P266; Chatelain F, 1998, DIABETES, V47, P882, DOI 10.2337/diabetes.47.6.882; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; Davie JR, 1999, J CELL BIOCHEM, P141; Duplus E, 2000, J BIOL CHEM, V275, P30749, DOI 10.1074/jbc.R000015200; Duplus E, 2002, BIOCHEM PHARMACOL, V64, P893, DOI 10.1016/S0006-2952(02)01157-7; Espinos E, 1999, MOL CELL BIOL, V19, P3474; Foster JD, 1997, P SOC EXP BIOL MED, V215, P314; Hanson R W, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P203; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; Heinemeyer T, 1999, NUCLEIC ACIDS RES, V27, P318, DOI 10.1093/nar/27.1.318; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hodny Z, 2000, BIOCHEM J, V346, P93, DOI 10.1042/0264-6021:3460093; Hung WC, 1999, BRIT J CANCER, V80, P705, DOI 10.1038/sj.bjc.6690413; JIANG GQ, 1995, MOL CELL BIOL, V15, P5131; LIU J, 1991, MOL CELL BIOCHEM, V104, P89; LIU JS, 1991, J BIOL CHEM, V266, P19095; LIU ZR, 1995, BIOCHEM J, V308, P105, DOI 10.1042/bj3080105; Massillon D, 1997, DIABETES, V46, P153, DOI 10.2337/diabetes.46.1.153; Massillon D, 1996, J BIOL CHEM, V271, P9871, DOI 10.1074/jbc.271.17.9871; Massillon D, 2001, J BIOL CHEM, V276, P4055, DOI 10.1074/jbc.M007939200; MORROW CS, 1994, J BIOL CHEM, V269, P10739; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; NORDLIE RC, 1993, P SOC EXP BIOL MED, V203, P274; PATEL YM, 1994, J BIOL CHEM, V269, P5619; Rajas F, 2002, J BIOL CHEM, V277, P15736, DOI 10.1074/jbc.M200971200; ROESLER WJ, 1989, J BIOL CHEM, V264, P9657; Ruse MD, 2002, MOL CELL BIOL, V22, P1626, DOI 10.1128/MCB.22.6.1626-1638.2002; SEALY L, 1978, CELL, V14, P115, DOI 10.1016/0092-8674(78)90306-9; Soutoglou E, 2000, MOL CELL, V5, P745, DOI 10.1016/S1097-2765(00)80253-1; Spath GF, 1997, MOL CELL BIOL, V17, P1913; Streeper RS, 1997, J BIOL CHEM, V272, P11698, DOI 10.1074/jbc.272.18.11698; Taylor DG, 1996, NUCLEIC ACIDS RES, V24, P2930, DOI 10.1093/nar/24.15.2930; TIAN JM, 1991, GENE DEV, V5, P2225, DOI 10.1101/gad.5.12a.2225; TOWLE HC, 1995, J BIOL CHEM, V270, P23235, DOI 10.1074/jbc.270.40.23235; Towle HC, 1996, BIOCHEM SOC T, V24, P364, DOI 10.1042/bst0240364; Vaulont S, 2000, J BIOL CHEM, V275, P31555, DOI 10.1074/jbc.R000016200; Wasner C, 2001, BBA-GENE STRUCT EXPR, V1521, P126, DOI 10.1016/S0167-4781(01)00303-7; XANTHOPOULOS KG, 1991, P NATL ACAD SCI USA, V88, P3807, DOI 10.1073/pnas.88.9.3807; Yang JQ, 2001, J BIOL CHEM, V276, P25742, DOI 10.1074/jbc.M102821200; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; ZHONG WM, 1994, MOL CELL BIOL, V14, P7276, DOI 10.1128/MCB.14.11.7276	51	35	37	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40694	40701		10.1074/jbc.M303182200	http://dx.doi.org/10.1074/jbc.M303182200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12915406	hybrid			2022-12-25	WOS:000185847200034
J	Hosoda, N; Kobayashi, T; Uchida, N; Funakoshi, Y; Kikuchi, Y; Hoshino, S; Katada, T				Hosoda, N; Kobayashi, T; Uchida, N; Funakoshi, Y; Kikuchi, Y; Hoshino, S; Katada, T			Translation termination factor eRF3 mediates mRNA decay through the regulation of deadenylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN; ENCODES; NUCLEASE; SUBUNIT; TAIL	Messenger RNA decay, which is a regulated process intimately linked to translation, begins with the dead-enylation of the poly(A) tail at the 3' end. However, the precise mechanism triggering the first step of mRNA decay and its relationship to translation have not been elucidated. Here, we show that the translation termination factor eRF3 mediates mRNA deadenylation and decay in the yeast Saccharomyces cerevisiae. The N-domain of eRF3, which is not necessarily required for translation termination, interacts with the poly(A)-binding protein PABP. When this interaction is blocked by means of deletion or overexpression of the N-domain of eRF3, half-lives of all mRNAs are prolonged. The eRF3 mutant lacking the N-domain is deficient in the poly(A) shortening. Furthermore, the eRF3-mediated mRNA decay requires translation to proceed, especially ribosomal transition through the termination codon. These results indicate that the N-domain of eRF3 mediates mRNA decay by regulating deadenylation in a manner coupled to translation.	Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Physiol Chem, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo; University of Tokyo	Hoshino, S (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Physiol Chem, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	hoshino@mol.f.u-tokyo.ac.jp		Uchida, Naoyuki/0000-0002-4123-6154; Hoshino, Shinichi/0000-0001-6135-7896				BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; BERNSTEIN P, 1989, MOL CELL BIOL, V9, P659, DOI 10.1128/MCB.9.2.659; Boeck R, 1996, J BIOL CHEM, V271, P432, DOI 10.1074/jbc.271.1.432; Brown CE, 1996, MOL CELL BIOL, V16, P5744; Brown CE, 1998, MOL CELL BIOL, V18, P6548, DOI 10.1128/MCB.18.11.6548; Cosson B, 2002, MOL CELL BIOL, V22, P3301, DOI 10.1128/MCB.22.10.3301-3315.2002; Daugeron MC, 2001, NUCLEIC ACIDS RES, V29, P2448, DOI 10.1093/nar/29.12.2448; Frolova L, 1996, RNA, V2, P334; FROLOVA L, 1994, NATURE, V372, P701, DOI 10.1038/372701a0; Hoshino S, 1998, J BIOL CHEM, V273, P22254, DOI 10.1074/jbc.273.35.22254; HOSHINO S, 1989, EMBO J, V8, P3807, DOI 10.1002/j.1460-2075.1989.tb08558.x; Hoshino S, 1999, J BIOL CHEM, V274, P16677, DOI 10.1074/jbc.274.24.16677; IIZUKA N, 1994, MOL CELL BIOL, V14, P7322, DOI 10.1128/MCB.14.11.7322; Jacobson A, 2000, COLD SPRING HARBOR M, V39, P827; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; KIKUCHI Y, 1988, EMBO J, V7, P1175, DOI 10.1002/j.1460-2075.1988.tb02928.x; Kisselev LL, 2000, TRENDS BIOCHEM SCI, V25, P561, DOI 10.1016/S0968-0004(00)01669-8; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; Maquat LE, 2000, COLD SPRING HARBOR M, V39, P849; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; STANSFIELD I, 1995, EMBO J, V14, P4365, DOI 10.1002/j.1460-2075.1995.tb00111.x; Tucker M, 2001, CELL, V104, P377, DOI 10.1016/S0092-8674(01)00225-2; ZHOURAVLEVA G, 1995, EMBO J, V14, P4065, DOI 10.1002/j.1460-2075.1995.tb00078.x	24	122	128	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38287	38291		10.1074/jbc.C300300200	http://dx.doi.org/10.1074/jbc.C300300200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12923185	hybrid			2022-12-25	WOS:000185575100026
J	Logarajah, S; Hunter, P; Kraman, M; Steele, D; Lakhani, S; Bobrow, L; Venkitaraman, A; Wagner, S				Logarajah, S; Hunter, P; Kraman, M; Steele, D; Lakhani, S; Bobrow, L; Venkitaraman, A; Wagner, S			BCL-6 is expressed in breast cancer and prevents mammary epithelial differentiation	ONCOGENE			English	Article						mammary epithelium; differentiation; breast cancer; BCL-6; STAT	GERMINAL-CENTER FORMATION; TRANSCRIPTIONAL REPRESSOR; TERMINAL DIFFERENTIATION; ALPHA-6-BETA-4 INTEGRIN; GENE; PROTEIN; INFLAMMATION; PHOSPHORYLATION; MORPHOGENESIS; SUPPRESSION	Appropriately timed proliferation, differentiation and apoptosis are essential to the normal functions of the mammary epithelium. Here, we report that the transcription factor BCL-6 is expressed in mammary epithelium in nonpregnant animals as well as during early pregnancy. When overexpressed in the nontransformed EpH4 mammary epithelial cell line, BCL-6 prevents the STAT-driven expression of the milk protein beta-casein and duct formation, and prevents apoptosis. Consistent with an antiapoptotic function, we demonstrate that BCL-6 is expressed in 68% of histologically high-grade ductal breast carcinomas, which are clinically the most aggressive. BCL-6 has previously been characterized as a regulator of B lymphocyte growth and development, but our work identifies a novel role for it in mammary epithelial differentiation, which may also implicate it in carcinogenesis.	Univ Cambridge, Dept Med, Wellcome Trust Immunol Unit, Cambridge CB2 2SP, England; Inst Canc Res, Chester Beatty Labs, Breakthrough Toby Robbins Breast Canc Res Ctr, London SW3 6JB, England; Univ Cambridge, Dept Pathol, Cambridge CB2 2XZ, England; Univ Cambridge, Dept Oncol, Cambridge CB2 2XZ, England; Univ Cambridge, MRC, Canc Cell Unit, Cambridge CB2 2XZ, England; Univ Cambridge, Dept Haematol, Cambridge CB2 2XZ, England	University of Cambridge; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge	Wagner, S (corresponding author), Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Haematol, Hammersmith Campus,Du Cane Rd, London W12 ONN, England.		Lakhani, Sunil R/I-1970-2018	Lakhani, Sunil R/0000-0003-4067-2760; Wagner, Simon/0000-0002-8914-0370; Kraman, Matthew/0000-0002-5040-0067; Hunter, Patricia/0000-0002-6224-0654				Allman D, 1996, BLOOD, V87, P5257, DOI 10.1182/blood.V87.12.5257.bloodjournal87125257; Bajalica-Lagercrantz S, 1998, BIOCHEM BIOPH RES CO, V247, P357, DOI 10.1006/bbrc.1998.8551; Baron BW, 2002, P NATL ACAD SCI USA, V99, P2860, DOI 10.1073/pnas.042702599; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; DESPREZ PY, 1995, MOL CELL BIOL, V15, P3398; Fukuda T, 1997, J EXP MED, V186, P439, DOI 10.1084/jem.186.3.439; Harris MB, 1999, MOL CELL BIOL, V19, P7264; Kanazawa N, 1997, PATHOL INT, V47, P600, DOI 10.1111/j.1440-1827.1997.tb04548.x; Liu XW, 1996, MOL ENDOCRINOL, V10, P1496, DOI 10.1210/me.10.12.1496; Mori S, 2000, EMBO J, V19, P5772, DOI 10.1093/emboj/19.21.5772; Muschler J, 1999, MOL BIOL CELL, V10, P2817, DOI 10.1091/mbc.10.9.2817; Niemann C, 1998, J CELL BIOL, V143, P533, DOI 10.1083/jcb.143.2.533; Niu HF, 1998, GENE DEV, V12, P1953, DOI 10.1101/gad.12.13.1953; Reljic R, 2000, J EXP MED, V192, P1841, DOI 10.1084/jem.192.12.1841; Shaffer AL, 2000, IMMUNITY, V13, P199, DOI 10.1016/S1074-7613(00)00020-0; Shvarts A, 2002, GENE DEV, V16, P681, DOI 10.1101/gad.929302; Tang TTL, 2002, J BIOL CHEM, V277, P14255, DOI 10.1074/jbc.M110901200; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Winklehner-Jennewein P, 1998, GENE, V217, P127, DOI 10.1016/S0378-1119(98)00380-1; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; YE BHH, 1993, CANCER RES, V53, P2732; Yoshida T, 1996, BIOCHEM BIOPH RES CO, V228, P216, DOI 10.1006/bbrc.1996.1642	27	64	67	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2003	22	36					5572	5578		10.1038/sj.onc.1206689	http://dx.doi.org/10.1038/sj.onc.1206689			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944904				2022-12-25	WOS:000184865900005
J	Armstrong, JS; Whiteman, M; Rose, P; Jones, DP				Armstrong, JS; Whiteman, M; Rose, P; Jones, DP			The coenzyme Q10 analog decylubiquinone inhibits the redox-activated mitochondrial permeability transition - Role of mitochondrial respiratory complex III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME BC(1) COMPLEX; IRON-SULFUR PROTEIN; OXIDATIVE STRESS; HYDROGEN-PEROXIDE; ELECTRON-TRANSFER; CELL-DEATH; C RELEASE; Q(O) SITE; PORE; GENERATION	The mitochondrial permeability transition (MPT) is a key event in apoptotic and necrotic cell death and is controlled by the cellular redox state. To further investigate the mechanism(s) involved in regulation of the MPT, we used diethylmaleate to deplete GSH in HL60 cells and increase mitochondrial reactive oxygen species (ROS) production. The site of mitochondrial ROS production was determined to be mitochondrial respiratory complex III ( cytochrome bc(1)), because 1) stigmatellin, a Q(o) site inhibitor, blocked ROS production and prevented the MPT and cell death and 2) cytochrome bc1 activity was abolished in cells protected from the redox-dependent MPT by stigmatellin. We next investigated the effect of pretreating cells with coenzyme Q(10) analogs decylubiquinone (dUb) and ubiquinone 0 (Ub0) on the redox-dependent MPT. Pretreatment of HL60 cells with dUb blocked ROS production induced by GSH depletion and prevented activation of the MPT and cell death, whereas Ub0 did not. Since we also found that dUb did not inhibit cytochrome bc1 activity, the mechanism of protection against redox-dependent MPT by dUb may depend on its ability to scavenge ROS generated by cytochrome bc1. These results indicate that dUb, like the clinically used ubiquinone analog idebenone, may serve as a candidate antioxidant compound for the development of pharmacological agents to treat diseases where there is an oxidative stress component.	Natl Univ Singapore, Dept Biochem, Singapore 117597, Singapore; Natl Univ Singapore, Dept Community Occupat & Family Med, Singapore 117597, Singapore; Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA	National University of Singapore; National University of Singapore; Emory University	Armstrong, JS (corresponding author), Natl Univ Singapore, Dept Biochem, Kent Rd, Singapore 117597, Singapore.	bchjsa@nus.edu.sg	Whiteman, Matthew/C-6079-2009	Whiteman, Matthew/0000-0002-6583-6779; Rose, Pete/0000-0001-8494-0902	NEI NIH HHS [EY07892, P30 EY06360] Funding Source: Medline; NIEHS NIH HHS [ES09047] Funding Source: Medline; NATIONAL EYE INSTITUTE [P30EY006360, R01EY007892, R29EY007892] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009047] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Armstrong JS, 2002, FASEB J, V16, P1263, DOI 10.1096/fj.02-0097fje; Armstrong JS, 2002, CELL DEATH DIFFER, V9, P252, DOI 10.1038/sj.cdd.4400959; Barrientos A, 1999, J BIOL CHEM, V274, P16188, DOI 10.1074/jbc.274.23.16188; BASS DA, 1983, J IMMUNOL, V130, P1910; Beyer RE, 1996, P NATL ACAD SCI USA, V93, P2528, DOI 10.1073/pnas.93.6.2528; BOVERIS A, 1976, BIOCHEM J, V156, P435, DOI 10.1042/bj1560435; Boveris A, 2000, IUBMB LIFE, V50, P245, DOI 10.1080/15216540051080912; Bradham CA, 1998, MOL CELL BIOL, V18, P6353, DOI 10.1128/MCB.18.11.6353; Chen Q, 2003, J BIOL CHEM, V278, P36027, DOI 10.1074/jbc.M304854200; Chinopoulos C, 2003, J BIOL CHEM, V278, P27382, DOI 10.1074/jbc.M303808200; Costantini P, 2000, ONCOGENE, V19, P307, DOI 10.1038/sj.onc.1203299; Costantini P, 1996, J BIOL CHEM, V271, P6746, DOI 10.1074/jbc.271.12.6746; Crofts AR, 1999, BIOCHEMISTRY-US, V38, P15791, DOI 10.1021/bi990961u; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Fernandez-Checa JC, 1998, BIOFACTORS, V8, P7, DOI 10.1002/biof.5520080102; FREI B, 1990, P NATL ACAD SCI USA, V87, P4879, DOI 10.1073/pnas.87.12.4879; Genova MW, 2003, EXP BIOL MED, V228, P506, DOI 10.1177/15353702-0322805-14; Geromel V, 2002, MOL GENET METAB, V77, P21, DOI 10.1016/S1096-7192(02)00145-2; GILLIS JC, 1994, DRUG AGING, V5, P133, DOI 10.2165/00002512-199405020-00007; Graeber MB, 1998, J NEUROSCI RES, V52, P1; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Jiang DM, 2001, J BIOL CHEM, V276, P47524, DOI 10.1074/jbc.M108834200; Kelso GF, 2001, J BIOL CHEM, V276, P4588, DOI 10.1074/jbc.M009093200; Kowaltowski AJ, 2001, FEBS LETT, V495, P12, DOI 10.1016/S0014-5793(01)02316-X; Kwong LK, 2002, FREE RADICAL BIO MED, V33, P627, DOI 10.1016/S0891-5849(02)00916-4; Lenaz G, 1998, BBA-BIOENERGETICS, V1366, P53, DOI 10.1016/S0005-2728(98)00120-0; Lenaz G, 2000, BBA-BIOENERGETICS, V1459, P397, DOI 10.1016/S0005-2728(00)00177-8; Lenaz G, 2002, ANN NY ACAD SCI, V959, P199, DOI 10.1111/j.1749-6632.2002.tb02094.x; Liu YB, 2002, J NEUROCHEM, V80, P780, DOI 10.1046/j.0022-3042.2002.00744.x; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; Moghaddas S, 2003, ARCH BIOCHEM BIOPHYS, V414, P59, DOI 10.1016/S0003-9861(03)00166-8; Muller FL, 2003, BIOCHEMISTRY-US, V42, P6493, DOI 10.1021/bi0342160; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; Qian T, 1999, TOXICOL APPL PHARM, V154, P117, DOI 10.1006/taap.1998.8580; Rothman SM, 1999, BIOCHEM SOC SYMP, V66, P111, DOI 10.1042/bss0660111; SANTHAMMA KR, 1993, BIOCHEM BIOPH RES CO, V190, P201, DOI 10.1006/bbrc.1993.1031; Starkov AA, 2001, BIOCHEM BIOPH RES CO, V281, P645, DOI 10.1006/bbrc.2001.4409; Tan SL, 1998, J CELL BIOL, V141, P1423, DOI 10.1083/jcb.141.6.1423; Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016/S0076-6879(96)64044-0; VALLS V, 1994, BIOCHEM MOL BIOL INT, V33, P633; von Ahsen O, 2000, J CELL BIOL, V150, P1027, DOI 10.1083/jcb.150.5.1027; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Walter L, 2000, J BIOL CHEM, V275, P29521, DOI 10.1074/jbc.M004128200; Yang JC, 1998, FREE RADICAL BIO MED, V24, P624, DOI 10.1016/S0891-5849(97)00367-5; Yu CA, 1998, BBA-BIOENERGETICS, V1365, P151, DOI 10.1016/S0005-2728(98)00055-3; Zamzami N, 1996, FEBS LETT, V384, P53, DOI 10.1016/0014-5793(96)00280-3; Zhang L, 2000, J BIOL CHEM, V275, P7656, DOI 10.1074/jbc.275.11.7656; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	49	66	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49079	49084		10.1074/jbc.M307841200	http://dx.doi.org/10.1074/jbc.M307841200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	12949071	hybrid			2022-12-25	WOS:000186829000070
J	Funderburgh, JL; Mann, MM; Funderburgh, ML				Funderburgh, JL; Mann, MM; Funderburgh, ML			Keratocyte phenotype mediates proteoglycan structure - A role for fibroblasts in corneal fibrosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KERATAN SULFATE PROTEOGLYCAN; BETA-GALACTOSIDASE DIGESTION; IN-SITU KERATOMILEUSIS; CHONDROITIN/DERMATAN SULFATE; BOVINE KERATOCYTES; RABBIT CORNEAS; STROMAL CELLS; EXPRESSION; POLYSACCHARIDES; MYOFIBROBLAST	In pathological corneas, accumulation of fibrotic extracellular matrix is characterized by proteoglycans with altered glycosaminoglycans that contribute to the reduced transparency of scarred tissue. During wound healing, keratocytes in the corneal stroma transdifferentiate into fibroblasts and myofibroblasts. In this study, molecular markers were developed to identify keratocyte, fibroblast, and myofibroblast phenotypes in primary cultures of corneal stromal cells and the structure of glycosaminoglycans secreted by these cells was characterized. Quiescent primary keratocytes expressed abundant protein and mRNA for keratocan and aldehyde dehydrogenase class 3 and secreted proteoglycans containing macromolecular keratan sulfate. Expression of these marker compounds was reduced in fibroblasts and also in transforming growth factor-beta-induced myofibroblasts, which expressed high levels of alpha-smooth muscle actin, biglycan, and the extra domain A (EDA or EIIIA) form of cellular fibronectin. Collagen types I and III mRNAs were elevated in both fibroblasts and in myofibroblasts. Expression of these molecular markers clearly distinguishes the phenotypic states of stromal cells in vitro. Glycosaminoglycans secreted by fibroblasts and myofibroblasts were qualitatively similar to and differed from those of keratocytes. Chondroitin/dermatan sulfate abundance, chain length, and sulfation were increased as keratocytes became fibroblasts and myofibroblasts. Fluorophore-assisted carbohydrate electrophoresis analysis demonstrated increased N-acetylgalactosamine sulfation at both 4- and 6-carbons. Hyaluronan, absent in keratocytes, was secreted by fibroblasts and myofibroblasts. Keratan sulfate biosynthesis, chain length, and sulfation were significantly reduced in both fibroblasts and myofibroblasts. The qualitatively similar expression of glycosaminoglycans shared by fibroblasts and myofibroblasts suggests a role for fibroblasts in deposition of non-transparent fibrotic tissue in pathological corneas.	Univ Pittsburgh, Eye & Ear Inst 1011, Dept Ophthalmol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Funderburgh, JL (corresponding author), Univ Pittsburgh, Eye & Ear Inst 1011, Dept Ophthalmol, 203 Lothrop St, Pittsburgh, PA 15213 USA.	jlfunder@pitt.edu			NATIONAL EYE INSTITUTE [R01EY003263, R01EY009368, P30EY008098] Funding Source: NIH RePORTER; NEI NIH HHS [P30 EY008098, 30-EY08098, R01 EY003263, EY09368, EY003263, R01 EY009368-11, R01 EY009368] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Akama TO, 2000, NAT GENET, V26, P237, DOI 10.1038/79987; ANSETH A, 1969, EXP EYE RES, V8, P438, DOI 10.1016/S0014-4835(69)80010-2; ANSETH A, 1969, EXP EYE RES, V8, P310, DOI 10.1016/S0014-4835(69)80044-8; ANSETH A, 1972, ISRAEL J MED SCI, V8, P1543; ANSETH A, 1969, EXP EYE RES, V8, P302, DOI 10.1016/S0014-4835(69)80043-6; Badid C, 2000, HISTOL HISTOPATHOL, V15, P269, DOI 10.14670/HH-15.269; Beales MP, 1999, INVEST OPHTH VIS SCI, V40, P1658; Boesch JS, 1996, J BIOL CHEM, V271, P5150; Chakravarti S, 2000, INVEST OPHTH VIS SCI, V41, P3365; Chen C, 2000, INVEST OPHTH VIS SCI, V41, P4108; CHENG F, 1994, GLYCOBIOLOGY, V4, P685, DOI 10.1093/glycob/4.5.685; CINTRON C, 1990, INVEST OPHTH VIS SCI, V31, P1975; Cook JR, 1999, INVEST OPHTH VIS SCI, V40, P3122; Dugina V, 2001, J CELL SCI, V114, P3285; Fini ME, 1999, PROG RETIN EYE RES, V18, P529, DOI 10.1016/S1350-9462(98)00033-0; FITZSIMMONS TD, 1994, INVEST OPHTH VIS SCI, V35, P2774; FUNDERBURGH JL, 1988, INVEST OPHTH VIS SCI, V29, P1116; FUNDERBURGH JL, 1989, INVEST OPHTH VIS SCI, V30, P435; Funderburgh JL, 1996, J BIOL CHEM, V271, P31431, DOI 10.1074/jbc.271.49.31431; FUNDERBURGH JL, 1990, INVEST OPHTH VIS SCI, V31, P419; FUNDERBURGH JL, 1987, J BIOL CHEM, V262, P11634; FUNDERBURGH JL, 1991, J BIOL CHEM, V266, P14226; FUNDERBURGH JL, 1990, J BIOL CHEM, V265, P8297; Funderburgh JL, 1998, INVEST OPHTH VIS SCI, V39, P1957; Funderburgh JL, 2001, J BIOL CHEM, V276, P44173, DOI 10.1074/jbc.M107596200; GARANA RMR, 1992, INVEST OPHTH VIS SCI, V33, P3271; GIRARD MT, 1993, J CELL SCI, V104, P1001; Harvey DJ, 2000, J AM SOC MASS SPECTR, V11, P900, DOI 10.1016/S1044-0305(00)00156-2; HASSELL JR, 1980, P NATL ACAD SCI-BIOL, V77, P3705, DOI 10.1073/pnas.77.6.3705; HASSELL JR, 1983, ARCH BIOCHEM BIOPHYS, V222, P362, DOI 10.1016/0003-9861(83)90532-5; Huang Y, 1996, EXP EYE RES, V62, P377, DOI 10.1006/exer.1996.0043; Huckerby TN, 1998, EUR J BIOCHEM, V253, P499, DOI 10.1046/j.1432-1327.1998.2530499.x; ISHIZAKI M, 1993, INVEST OPHTH VIS SCI, V34, P3320; JESTER JV, 1987, AM J PATHOL, V127, P140; Jester JV, 1996, CORNEA, V15, P505; Jester JV, 1997, CORNEA, V16, P177; Jester JV, 1999, J CELL SCI, V112, P613; JESTER JV, 1994, INVEST OPHTH VIS SCI, V35, P730; JESTER JV, 1995, INVEST OPHTH VIS SCI, V36, P809; KOUKOULIS GK, 1995, ULTRASTRUCT PATHOL, V19, P37, DOI 10.3109/01913129509014601; Latvala T, 1996, J REFRACT SURG, V12, P677; Long CJ, 2000, J BIOL CHEM, V275, P13918, DOI 10.1074/jbc.275.18.13918; Masur SK, 1996, P NATL ACAD SCI USA, V93, P4219, DOI 10.1073/pnas.93.9.4219; MEHMET H, 1986, EUR J BIOCHEM, V157, P385, DOI 10.1111/j.1432-1033.1986.tb09680.x; Nakazawa K, 1998, ARCH BIOCHEM BIOPHYS, V359, P269, DOI 10.1006/abbi.1998.0897; NAKAZAWA K, 1984, J BIOL CHEM, V259, P3751; Perez-Santonja JJ, 1998, J REFRACT SURG, V14, P602; Piatigorsky J, 2000, J OCUL PHARMACOL TH, V16, P173, DOI 10.1089/jop.2000.16.173; Plaas AH, 2001, J BIOL CHEM, V276, P39788, DOI 10.1074/jbc.M103227200; Plaas AHK, 2001, GLYCOBIOLOGY, V11, P779, DOI 10.1093/glycob/11.10.779; Powell DW, 1999, AM J PHYSIOL-CELL PH, V277, pC1, DOI 10.1152/ajpcell.1999.277.1.C1; QUANTOCK AJ, 1993, CAN J OPHTHALMOL, V28, P266; RODRIGUES M, 1992, AM J OPHTHALMOL, V114, P161, DOI 10.1016/S0002-9394(14)73980-7; ROUGHLEY PJ, 1993, BIOCHEM J, V295, P421, DOI 10.1042/bj2950421; SAWAGUCHI S, 1991, INVEST OPHTH VIS SCI, V32, P1846; Stramer BM, 2001, INVEST OPHTH VIS SCI, V42, P1698; SUNDARRAJ N, 1986, J HISTOCHEM CYTOCHEM, V34, P971, DOI 10.1177/34.8.2426337; Tai GH, 1997, J BIOL CHEM, V272, P28227, DOI 10.1074/jbc.272.45.28227; Tai GH, 1996, J BIOL CHEM, V271, P23535, DOI 10.1074/jbc.271.38.23535; Tuori A, 1997, GRAEF ARCH CLIN EXP, V235, P222, DOI 10.1007/BF00941763; Vaughan MB, 2000, EXP CELL RES, V257, P180, DOI 10.1006/excr.2000.4869; Venkatesan N, 2000, AM J RESP CRIT CARE, V161, P2066, DOI 10.1164/ajrccm.161.6.9909098; Venkatesan N, 2002, AM J PHYSIOL-LUNG C, V283, pL806, DOI 10.1152/ajplung.00061.2002; WATSKY MA, 1995, INVEST OPHTH VIS SCI, V36, P2568; WOLLENSAK J, 1990, GRAEF ARCH CLIN EXP, V228, P517, DOI 10.1007/BF00918483; YUE BYJT, 1988, CURR EYE RES, V7, P81, DOI 10.3109/02713688809047024	66	188	195	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45629	45637		10.1074/jbc.M303292200	http://dx.doi.org/10.1074/jbc.M303292200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12933807	Green Accepted, hybrid			2022-12-25	WOS:000186452300072
J	Mayo, KH; Dings, RPM; Flader, C; Nesmelova, I; Hargittai, B; van der Schaft, DWJ; van Eijk, LI; Walek, D; Haseman, J; Hoye, TR; Griffioen, AW				Mayo, KH; Dings, RPM; Flader, C; Nesmelova, I; Hargittai, B; van der Schaft, DWJ; van Eijk, LI; Walek, D; Haseman, J; Hoye, TR; Griffioen, AW			Design of a partial peptide mimetic of anginex with antiangiogenic and anticancer activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INCREASING PROTEIN BPI; ENDOTHELIAL-CELLS; CRYSTAL-STRUCTURE; ANGIOGENESIS INHIBITOR; ANGSTROM RESOLUTION; ANTITUMOR-ACTIVITY; TUMOR-GROWTH; AMINO-ACID; ENDOSTATIN; ANGIOSTATIN	Based on structure-activity relationships of the angiostatic beta-sheet-forming peptide anginex, we have designed a mimetic, 6DBF7, which inhibits angiogenesis and tumor growth in mice. 6DBF7 is composed of a beta-sheet-inducing dibenzofuran (DBF)-turn mimetic and two short key amino acid sequences from anginex. This novel antiangiogenic molecule is more effective in vivo than parent anginex. In a mouse xenograft model for ovarian carcinoma, 6DBF7 is observed to reduce tumor growth by up to 80%. It is suggested that the activity is based on antiangiogenesis, because in vitro tube formation is inhibited, and because treatment of tumor-bearing mice led to a significant reduction in microvessel density within the tumor. This partial peptide mimetic is the first endothelial cell-specific molecule designed as a substitute for an angiostatic inhibitory peptide.	Univ Minnesota, Hlth Sci Ctr, Dept Biochem, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Mol Biol & Biophys, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Chem, Minneapolis, MN 55455 USA; Univ Hosp Maastricht, Dept Pathol, Res Inst Growth & Dev, Angiogenesis Lab, NL-6202 AZ Maastricht, Netherlands; Univ Hosp Maastricht, Dept Internal Med, Res Inst Growth & Dev, Angiogenesis Lab, NL-6202 AZ Maastricht, Netherlands	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Maastricht University Medical Centre (MUMC)	Mayo, KH (corresponding author), Univ Minnesota, Hlth Sci Ctr, Dept Biochem, 6-155 Jackson Hall,321 Church St, Minneapolis, MN 55455 USA.		Dings, Ruud/R-3772-2019; Dings, Ruud/C-6188-2008; Nesmelova, Irina/D-6033-2015	Dings, Ruud/0000-0001-7686-1331; Nesmelova, Irina/0000-0002-1835-1533	NCI NIH HHS [CA-76497, R01 CA-96090] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA096090, R01CA076497] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beamer LJ, 1997, SCIENCE, V276, P1861, DOI 10.1126/science.276.5320.1861; Bekele H, 1997, J ORG CHEM, V62, P2259, DOI 10.1021/jo961063w; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; BRUNGER AT, 1992, XPLOR MANUAL; CARPINO LA, 1993, J AM CHEM SOC, V115, P4397, DOI 10.1021/ja00063a082; Chen H, 2000, MATRIX BIOL, V19, P597, DOI 10.1016/S0945-053X(00)00107-4; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DIAZ H, 1993, J AM CHEM SOC, V115, P3790, DOI 10.1021/ja00062a061; Dings R. P. M., 2003, BIOCHEM J, V23, P281; Dings RPM, 2003, CANCER RES, V63, P382; Dings RPM, 2003, CANCER LETT, V194, P55, DOI 10.1016/S0304-3835(03)00015-6; DINGS RPM, 2003, IN PRESS ANGIOGENESI; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Griffioen AW, 2001, BIOCHEM J, V354, P233, DOI 10.1042/0264-6021:3540233; GUPTA SK, 1994, J CELL BIOL, V127, P1121, DOI 10.1083/jcb.127.4.1121; Hohenester E, 1998, EMBO J, V17, P1656, DOI 10.1093/emboj/17.6.1656; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0; Karumanchi SA, 2001, MOL CELL, V7, P811, DOI 10.1016/S1097-2765(01)00225-8; KING DS, 1990, INT J PEPT PROT RES, V36, P255; Kranenburg O, 2002, CURR BIOL, V12, P1833, DOI 10.1016/S0960-9822(02)01224-1; LUSTER AD, 1995, J EXP MED, V182, P219, DOI 10.1084/jem.182.1.219; MacDonald NJ, 2001, J BIOL CHEM, V276, P25190, DOI 10.1074/jbc.M100743200; Mayo Kevin H., 2001, Angiogenesis, V4, P45, DOI 10.1023/A:1016672117477; MAYO KH, 1995, BIOCHEMISTRY-US, V34, P11399, DOI 10.1021/bi00036a012; Molema G, 1998, IMMUNOL TODAY, V19, P392, DOI 10.1016/S0167-5699(98)01314-0; Moser TL, 1999, P NATL ACAD SCI USA, V96, P2811, DOI 10.1073/pnas.96.6.2811; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Ramchandran R, 1999, BIOCHEM BIOPH RES CO, V255, P735, DOI 10.1006/bbrc.1999.0248; RUCKER SP, 1989, MOL PHYS, V68, P509, DOI 10.1080/00268978900102331; SHAKA AJ, 1988, J MAGN RESON, V77, P274, DOI 10.1016/0022-2364(88)90178-3; Tan DCW, 2001, FEBS LETT, V494, P150, DOI 10.1016/S0014-5793(01)02314-6; Tan KM, 2002, J CELL BIOL, V159, P373, DOI 10.1083/jcb.200206062; Tarui T, 2001, J BIOL CHEM, V276, P39562, DOI 10.1074/jbc.M101815200; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; TSANG KY, 1994, J AM CHEM SOC, V116, P3988, DOI 10.1021/ja00088a039; van der Schaft DWJ, 2000, BLOOD, V96, P176, DOI 10.1182/blood.V96.1.176.013k32_176_181; van der Schaft DWJ, 2002, FASEB J, V16, P1991, DOI 10.1096/fj.02-0509fje; van der Schaft DWJ, 2002, ANN MED, V34, P19; WIDER G, 1984, J MAGN RESON, V56, P207, DOI 10.1016/0022-2364(84)90099-4; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0; Wild R, 2000, MICROVASC RES, V59, P368, DOI 10.1006/mvre.1999.2233	45	53	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45746	45752		10.1074/jbc.M308608200	http://dx.doi.org/10.1074/jbc.M308608200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12947097	hybrid			2022-12-25	WOS:000186452300085
J	Arima, H; Yamamoto, N; Sobue, K; Umenishi, F; Tada, T; Katsuya, H; Asai, K				Arima, H; Yamamoto, N; Sobue, K; Umenishi, F; Tada, T; Katsuya, H; Asai, K			Hyperosmolar mannitol stimulates expression of aquaporins 4 and 9 through a p38 mitogen-activated protein kinase-dependent pathway in rat astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPERTONICITY-RESPONSIVE ELEMENT; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN INJURY; WATER CHANNEL; MAP KINASE; GENE-EXPRESSION; DIFFERENTIAL REGULATION; MAMMALIAN-CELLS; MESSENGER-RNA; IN-VITRO	The membrane pore proteins, aquaporins (AQPs), facilitate the osmotically driven passage of water and, in some instances, small solutes. Under hyperosmotic conditions, the expression of some AQPs changes, and some studies have shown that the expression of AQP1 and AQP5 is regulated by MAPKs. However, the mechanisms regulating the expression of AQP4 and AQP9 induced by hyperosmotic stress are poorly understood. In this study, we observed that hyperosmotic stress induced by mannitol increased the expression of AQP4 and AQP9 in cultured rat astrocytes, and intraperitoneal infusion of mannitol increased AQP4 and AQP9 in the rat brain cortex. In addition, a p38 MAPK inhibitor, but not ERK and JNK inhibitors, suppressed their expression in cultured astrocytes. AQPs play important roles in maintaining brain homeostasis. The expression of AQP4 and AQP9 in astrocytes changes after brain ischemia or traumatic injury, and some studies have shown that p38 MAPK in astrocytes is activated under similar conditions. Since mannitol is commonly used to reduce brain edema, understanding the regulation of AQPs and p38 MAPK in astrocytes under hyperosmotic conditions induced with mannitol may lead to a control of water movements and a new treatment for brain edema.	Okazaki City Hosp, Dept Anesthesia & Crit Care, Okazaki, Aichi 4448553, Japan; Nagoya City Univ, Grad Sch Med Sci, Dept Anesthesiol & Med Crisis Management, Mizuho Ku, Nagoya, Aichi 4678601, Japan; Nagoya City Univ, Grad Sch Med Sci, Dept Mol Neurobiol, Nagoya, Aichi 4678601, Japan; Univ Colorado, Hlth Sci Ctr, Dept Med, Div Renal Dis & Hypertens, Denver, CO 80262 USA; Nagoya City Univ, Sch Nursing, Dept Pathol, Mizuho Ku, Nagoya, Aichi 4678601, Japan	Nagoya City University; Nagoya City University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Nagoya City University	Arima, H (corresponding author), Okazaki City Hosp, Dept Anesthesia & Crit Care, 3-1 goshoai,Koryuji Cho, Okazaki, Aichi 4448553, Japan.	arima@sb.starcat.ne.jp	Asai, Kiyofumi/H-2356-2014	Asai, Kiyofumi/0000-0001-7015-2251				Agre P, 1998, J BIOL CHEM, V273, P14659, DOI 10.1074/jbc.273.24.14659; Badaut J, 2001, J CEREBR BLOOD F MET, V21, P477, DOI 10.1097/00004647-200105000-00001; Badaut T, 2002, J CEREBR BLOOD F MET, V22, P367, DOI 10.1097/00004647-200204000-00001; BEDFORD JJ, 1993, AM J PHYSIOL, V264, pR1164, DOI 10.1152/ajpregu.1993.264.6.R1164; Borok Z, 1998, AM J RESP CELL MOL, V18, P554, DOI 10.1165/ajrcmb.18.4.2838; Burg MB, 1996, FASEB J, V10, P1598, DOI 10.1096/fasebj.10.14.9002551; Connolly DL, 1998, INT J BIOCHEM CELL B, V30, P169, DOI 10.1016/S1357-2725(97)00124-6; DaSilva J, 1997, J BIOL CHEM, V272, P28373, DOI 10.1074/jbc.272.45.28373; Endo M, 1999, MICROVASC RES, V58, P89, DOI 10.1006/mvre.1999.2158; Fu DX, 2000, SCIENCE, V290, P481, DOI 10.1126/science.290.5491.481; Furuno M, 1996, AM J PHYSIOL-RENAL, V271, pF854, DOI 10.1152/ajprenal.1996.271.4.F854; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hasler U, 2002, J BIOL CHEM, V277, P10379, DOI 10.1074/jbc.M111880200; Hoffert JD, 2000, J BIOL CHEM, V275, P9070, DOI 10.1074/jbc.275.12.9070; Hozawa S, 1996, AM J PHYSIOL-CELL PH, V270, pC1695, DOI 10.1152/ajpcell.1996.270.6.C1695; Ishibashi K, 2000, REV PHYSIOL BIOCH P, V141, P1, DOI 10.1007/BFb0119576; Jenq W, 1998, BIOCHEM BIOPH RES CO, V245, P804, DOI 10.1006/bbrc.1998.8518; JUNG JS, 1994, P NATL ACAD SCI USA, V91, P13052, DOI 10.1073/pnas.91.26.13052; KATO T, 1979, BIOCHIM BIOPHYS ACTA, V579, P216, DOI 10.1016/0005-2795(79)90100-4; KAUFMANN AM, 1992, J NEUROSURG, V77, P584, DOI 10.3171/jns.1992.77.4.0584; Ke CS, 2001, NEUROSCI LETT, V301, P21, DOI 10.1016/S0304-3940(01)01589-0; Kiening KL, 2002, NEUROSCI LETT, V324, P105, DOI 10.1016/S0304-3940(02)00180-5; Ko SBH, 1999, BIOCHEM MOL BIOL INT, V47, P309; Kozono D, 2002, J CLIN INVEST, V109, P1395, DOI 10.1172/JCI200215851; Kultz D, 1998, J EXP BIOL, V201, P3015; Leitch V, 2001, P NATL ACAD SCI USA, V98, P2894, DOI 10.1073/pnas.041616498; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Markert JM, 2001, PHYSIOL GENOMICS, V5, P21, DOI 10.1152/physiolgenomics.2001.5.1.21; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; MATSUDA S, 1995, J BIOL CHEM, V270, P12781, DOI 10.1074/jbc.270.21.12781; Matsuzaki T, 2001, AM J PHYSIOL-CELL PH, V281, pC55, DOI 10.1152/ajpcell.2001.281.1.C55; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Nakahama K, 1999, GLIA, V25, P240, DOI 10.1002/(SICI)1098-1136(19990201)25:3<240::AID-GLIA4>3.3.CO;2-3; Nico B, 2001, J CELL SCI, V114, P1297; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; Papadopoulos MC, 2002, MT SINAI J MED, V69, P242; Park JH, 1996, J MEMBRANE BIOL, V153, P171, DOI 10.1007/s002329900120; SATO Y, 1986, AM J PATHOL, V125, P431; SCHWARTZ LM, 1993, IMMUNOL TODAY, V14, P582, DOI 10.1016/0167-5699(93)90197-S; Sugiyama Y, 2001, BBA-GENE STRUCT EXPR, V1522, P82, DOI 10.1016/S0167-4781(01)00320-7; TAKENAKA M, 1994, J BIOL CHEM, V269, P29379; Taniguchi M, 2000, MOL BRAIN RES, V78, P131, DOI 10.1016/S0169-328X(00)00084-X; Uehara T, 1999, BRAIN RES, V823, P226, DOI 10.1016/S0006-8993(99)01178-6; Umenishi F, 2003, J BIOL CHEM, V278, P15765, DOI 10.1074/jbc.M209980200; Umenishi F, 2002, BIOCHEM BIOPH RES CO, V292, P771, DOI 10.1006/bbrc.2002.6709; Umenishi F, 1998, GENOMICS, V50, P373, DOI 10.1006/geno.1998.5337; Venero JL, 2001, PROG NEUROBIOL, V63, P321, DOI 10.1016/S0301-0082(00)00035-6; Walz T, 1997, NATURE, V387, P624, DOI 10.1038/42512; Wang XY, 2002, J NEUROTRAUM, V19, P615, DOI 10.1089/089771502753754082; Yamamoto N, 2002, MOL BRAIN RES, V104, P96, DOI 10.1016/S0169-328X(02)00322-4; Yamamoto N, 2001, MOL BRAIN RES, V95, P110, DOI 10.1016/S0169-328X(01)00254-6; Yamamoto N, 2001, MOL BRAIN RES, V90, P26, DOI 10.1016/S0169-328X(01)00064-X; Yoneda K, 2001, MOL BRAIN RES, V89, P94, DOI 10.1016/S0169-328X(01)00067-5; Zornow MH, 1996, J NEUROSURG ANESTH, V8, P175, DOI 10.1097/00008506-199604000-00021	55	144	168	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44525	44534		10.1074/jbc.M304368200	http://dx.doi.org/10.1074/jbc.M304368200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12944406	hybrid			2022-12-25	WOS:000186306700081
J	Nehrke, K				Nehrke, K			A reduction in intestinal cell pH(i) due to loss of the Caenorhabditis elegans Na+/H+ exchanger NHX-2 increases life span	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLED OLIGOPEPTIDE TRANSPORTER; PARIETAL-CELLS; C-ELEGANS; CALORIC RESTRICTION; EXPRESSION CLONING; PHARYNGEAL MUSCLE; RABBIT PARIETAL; GENE-TRANSFER; ISOFORMS; LINE	Na+/H+ exchangers are involved in cell volume regulation, fluid secretion and absorption, and pH homeostasis. NHX-2 is a Caenorhabditis elegans Na+/H+ exchanger expressed exclusively at the apical membrane of intestinal epithelial cells. The inactivation of various intestinal nutrient transport proteins has been shown previously to influence aging via metabolic potential and a mechanism resembling caloric restriction. We report here a functional coupling of NHX-2 activity with nutrient uptake that results in long lived worms. Gene inactivation of nhx-2 by RNAi led to a loss of fat stores in the intestine and a 40% increase in longevity. The NHX-2 protein was coincidentally expressed with OPT-2, an oligopeptide transporter that is driven by a transmembrane proton gradient and that is also known to be involved in fat accumulation. Gene inactivation of opt-2 led to a phenotype resembling that of nhx-2, although not as severe. In order to explore this potential functional interaction, we combined RNA interference with a genetically encoded, fluorescence-based reagent to measure intestinal intracellular pH (pH(i)) in live worms under physiological conditions. Our results suggest first that OPT-2 is the main dipeptide uptake pathway in the nematode intestine, and second that dipeptide uptake results in intestinal cell acidification, and finally that recovery following dipeptide-induced acidification is normally a function of NHX-2. The loss of NHX-2 protein results in decreased steady-state intestinal cell pHi, and we hypothesize that this change perturbs proton-coupled nutrient uptake processes such as performed by OPT-2. Our data demonstrate a functional role for a Na+/H+ exchanger in nutrient absorption in vivo and lays the groundwork for examining integrated acid-base physiology in a non-mammalian model organism.	Univ Rochester, Med Ctr, Dept Med, Gastroenterol Unit, Rochester, NY 14642 USA	University of Rochester	Nehrke, K (corresponding author), Univ Rochester, Med Ctr, Dept Med, Gastroenterol Unit, 601 Elmwood Ave,Box 646, Rochester, NY 14642 USA.	keith_nehrke@urmc.rochester.edu		Nehrke, Keith/0000-0001-9697-726X	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE008921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE008921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK062763] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE08921] Funding Source: Medline; NIDDK NIH HHS [DK062763, R21 DK062763, R21 DK062763-01] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson CMH, 2003, BRIT J PHARMACOL, V138, P564, DOI 10.1038/sj.bjp.0705049; Ashrafi K, 2003, NATURE, V421, P268, DOI 10.1038/nature01279; Attaphitaya S, 2001, AM J PHYSIOL-CELL PH, V281, pC1146, DOI 10.1152/ajpcell.2001.281.4.C1146; AVERY L, 1993, GENETICS, V133, P897; Bachmann O, 1998, AM J PHYSIOL-GASTR L, V275, pG1085, DOI 10.1152/ajpgi.1998.275.5.G1085; Bell SM, 1999, AM J PHYSIOL-CELL PH, V276, pC788, DOI 10.1152/ajpcell.1999.276.4.C788; BOLL M, 1994, PFLUG ARCH EUR J PHY, V429, P146, DOI 10.1007/BF02584043; Daniel H, 2003, AM J PHYSIOL-RENAL, V284, pF885, DOI 10.1152/ajprenal.00123.2002; Fei YJ, 1998, BIOCHEM J, V332, P565, DOI 10.1042/bj3320565; Fei YJ, 2000, J BIOL CHEM, V275, P9563, DOI 10.1074/jbc.275.13.9563; Fei YJ, 2003, J BIOL CHEM, V278, P6136, DOI 10.1074/jbc.M208763200; FEI YJ, 1994, NATURE, V368, P563, DOI 10.1038/368563a0; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Franks CJ, 2002, J NEUROPHYSIOL, V87, P954, DOI 10.1152/jn.00233.2001; GRANATO M, 1994, NUCLEIC ACIDS RES, V22, P1762, DOI 10.1093/nar/22.9.1762; Hayashi H, 2002, ANN NY ACAD SCI, V976, P248; HIMUKAI M, 1978, JPN J PHYSIOL, V28, P499; Houthoofd K, 2002, EXP GERONTOL, V37, P1371, DOI 10.1016/S0531-5565(02)00173-0; Jankowski A, 2001, J BIOL CHEM, V276, P48748, DOI 10.1074/jbc.M109003200; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kennedy DJ, 2002, PFLUG ARCH EUR J PHY, V445, P139, DOI 10.1007/s00424-002-0910-1; Kerr R, 2000, NEURON, V26, P583, DOI 10.1016/S0896-6273(00)81196-4; KLASS MR, 1977, MECH AGEING DEV, V6, P413, DOI 10.1016/0047-6374(77)90043-4; Knauf F, 2002, P NATL ACAD SCI USA, V99, P14315, DOI 10.1073/pnas.222531899; Lakowski B, 1998, P NATL ACAD SCI USA, V95, P13091, DOI 10.1073/pnas.95.22.13091; Larsen PL, 2002, SCIENCE, V295, P120, DOI 10.1126/science.1064653; LEVINE SA, 1993, J BIOL CHEM, V268, P25527; MACHEN TE, 2003, AM J PHYSIOL, V26, pC205; MATTHEWS DM, 1974, CLIN SCI MOL MED, V46, P693, DOI 10.1042/cs0460693; Matyash V, 2001, MOL BIOL CELL, V12, P1725, DOI 10.1091/mbc.12.6.1725; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Merris M, 2003, J LIPID RES, V44, P172, DOI 10.1194/jlr.M200323-JLR200; Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190; MUALLEM S, 1985, J BIOL CHEM, V260, P6641; Nehrke K, 2002, J BIOL CHEM, V277, P29036, DOI 10.1074/jbc.M203200200; ORLOWSKI J, 1993, J BIOL CHEM, V268, P16369; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; Repishti M, 2001, AM J PHYSIOL-GASTR L, V281, pG159, DOI 10.1152/ajpgi.2001.281.1.G159; Rogina B, 2000, SCIENCE, V290, P2137, DOI 10.1126/science.290.5499.2137; RONG LA, 1995, J BIOL CHEM, V270, P6456, DOI 10.1074/jbc.270.12.6456; Rossmann H, 2001, AM J PHYSIOL-GASTR L, V281, pG447, DOI 10.1152/ajpgi.2001.281.2.G447; Samuel A D, 2001, BMC Dev Biol, V1, P8, DOI 10.1186/1471-213X-1-8; Sankaranarayanan S, 2001, NAT NEUROSCI, V4, P129, DOI 10.1038/83949; Schultheis PJ, 1998, NAT GENET, V19, P282, DOI 10.1038/969; Schultheis PJ, 1998, J CLIN INVEST, V101, P1243, DOI 10.1172/JCI1249; Shim YH, 2002, MOL REPROD DEV, V61, P358, DOI 10.1002/mrd.10099; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Tatar M, 2003, SCIENCE, V299, P1346, DOI 10.1126/science.1081447; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; Thwaites DT, 1999, J CLIN INVEST, V104, P629, DOI 10.1172/JCI7192; Thwaites DT, 2002, GASTROENTEROLOGY, V122, P1322, DOI 10.1053/gast.2002.32992; Wakabayashi S, 1997, PHYSIOL REV, V77, P51, DOI 10.1152/physrev.1997.77.1.51	52	89	99	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44657	44666		10.1074/jbc.M307351200	http://dx.doi.org/10.1074/jbc.M307351200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12939266	hybrid			2022-12-25	WOS:000186306700098
J	Casamassima, M; D'Adamo, MC; Pessia, M; Tucker, SJ				Casamassima, M; D'Adamo, MC; Pessia, M; Tucker, SJ			Identification of a heteromeric interaction that influences the rectification, gating, and pH sensitivity of Kir4.1/Kir5.1 potassium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROMK K(IR)1.1 CHANNELS; RECTIFIER K+ CHANNEL; ATP; SUBUNIT; RESIDUE; KIR4.1; KIR5.1; CONDUCTANCE; MODULATION; DOMAINS	Heteromultimerization between different potassium channel subunits can generate channels with novel functional properties and thus contributes to the rich functional diversity of this gene family. The inwardly rectifying potassium channel subunit Kir5.1 exhibits highly selective heteromultimerization with Kir4.1 to generate heteromeric Kir4.1/Kir5.1 channels with unique rectification and kinetic properties. These novel channels are also inhibited by intracellular pH within the physiological range and are thought to play a key role in linking K+ and H+ homeostasis by the kidney. However, the mechanisms that control heteromeric K+ channel assembly and the structural elements that generate their unique functional properties are poorly understood. In this study we identify residues at an intersubunit interface between the cytoplasmic domains of Kir5.1 and Kir4.1 that influence the novel rectification and gating properties of heteromeric Kir4.1/Kir5.1 channels and that also contribute to their pH sensitivity. Furthermore, this interaction presents a structural mechanism for the functional coupling of these properties and explains how specific heteromeric interactions can contribute to the novel functional properties observed in heteromeric Kir channels. The highly conserved nature of this structural association between Kir subunits also has implications for understanding the general mechanisms of Kir channel gating and their regulation by intracellular pH.	Univ Oxford, Physiol Lab, Oxford OX1 3PT, England; Univ Perugia, Sch Med, Sect Human Physiol, I-06126 Perugia, Italy; Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, I-66030 Santa Maria Imbaro, Italy	University of Oxford; University of Perugia; Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Tucker, SJ (corresponding author), Univ Oxford, Physiol Lab, Parks Rd, Oxford OX1 3PT, England.	stephen.tucker@physiol.ox.ac.uk	Tucker, Stephen J./ABE-7468-2020; D'Adamo, Maria Cristina/AAD-3701-2022; Tucker, Stephen J./ABE-6741-2020	Tucker, Stephen J./0000-0001-8996-2000; D'Adamo, Maria Cristina/0000-0002-6758-6064; Tucker, Stephen J./0000-0001-8996-2000; Pessia, Mauro/0000-0002-2857-6795				Babenko AP, 2000, J BIOL CHEM, V275, P31563, DOI 10.1074/jbc.C000553200; Choe H, 1997, AM J PHYSIOL-RENAL, V273, pF516, DOI 10.1152/ajprenal.1997.273.4.F516; Cui N, 2003, J MEMBRANE BIOL, V192, P111, DOI 10.1007/s00232-002-1069-6; Doi T, 1996, J BIOL CHEM, V271, P17261, DOI 10.1074/jbc.271.29.17261; Fakler B, 1996, EMBO J, V15, P4093, DOI 10.1002/j.1460-2075.1996.tb00784.x; Giebisch G, 2001, KIDNEY INT, V60, P436, DOI 10.1046/j.1523-1755.2001.060002436.x; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; HEGINBOTHAM L, 1992, SCIENCE, V258, P1152, DOI 10.1126/science.1279807; Hommers LG, 2003, J BIOL CHEM, V278, P1037, DOI 10.1074/jbc.M205325200; Kofuji P, 1996, J PHYSIOL-LONDON, V490, P633, DOI 10.1113/jphysiol.1996.sp021173; Konstas AA, 2003, AM J PHYSIOL-CELL PH, V284, pC910, DOI 10.1152/ajpcell.00479.2002; Kuo AL, 2003, SCIENCE, V300, P1922, DOI 10.1126/science.1085028; Lancaster MK, 2000, J BIOL CHEM, V275, P35831, DOI 10.1074/jbc.M006565200; Lin YW, 2003, J GEN PHYSIOL, V122, P225, DOI 10.1085/jgp.200308822; Lippiat JD, 2002, DIABETES, V51, pS377, DOI 10.2337/diabetes.51.2007.S377; Lourdel S, 2002, J PHYSIOL-LONDON, V538, P391, DOI 10.1113/jphysiol.2001.012961; Nichols CG, 1999, CURR TOP MEMBR, V46, P159; Nichols CG, 1997, ANNU REV PHYSIOL, V59, P171, DOI 10.1146/annurev.physiol.59.1.171; Nishida M, 2002, CELL, V111, P957, DOI 10.1016/S0092-8674(02)01227-8; Pessia M, 2001, J PHYSIOL-LONDON, V532, P359, DOI 10.1111/j.1469-7793.2001.0359f.x; Pessia M, 1996, EMBO J, V15, P2980, DOI 10.1002/j.1460-2075.1996.tb00661.x; Qu ZQ, 2000, J BIOL CHEM, V275, P31573, DOI 10.1074/jbc.M003473200; Reimann F, 1999, CURR OPIN CELL BIOL, V11, P503, DOI 10.1016/S0955-0674(99)80073-8; Riven I, 2003, NEURON, V38, P225, DOI 10.1016/S0896-6273(03)00193-4; Schram G, 2002, J PHYSIOL-LONDON, V544, P337, DOI 10.1113/jphysiol.2002.026047; Schulte U, 1999, P NATL ACAD SCI USA, V96, P15298, DOI 10.1073/pnas.96.26.15298; Schulte U, 1998, J BIOL CHEM, V273, P34575, DOI 10.1074/jbc.273.51.34575; Tanemoto M, 2000, J PHYSIOL-LONDON, V525, P587, DOI 10.1111/j.1469-7793.2000.00587.x; Trapp S, 1998, J GEN PHYSIOL, V112, P333, DOI 10.1085/jgp.112.3.333; TSAI TD, 1995, AM J PHYSIOL-CELL PH, V268, pC1173, DOI 10.1152/ajpcell.1995.268.5.C1173; Tucker SJ, 2000, J BIOL CHEM, V275, P16404, DOI 10.1074/jbc.C000127200; Xu HX, 2000, J PHYSIOL-LONDON, V524, P725, DOI 10.1111/j.1469-7793.2000.00725.x; Yang ZJ, 1999, J PHYSIOL-LONDON, V520, P921, DOI 10.1111/j.1469-7793.1999.00921.x; Yi BA, 2001, NEURON, V29, P657, DOI 10.1016/S0896-6273(01)00241-0	34	41	41	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43533	43540		10.1074/jbc.M306596200	http://dx.doi.org/10.1074/jbc.M306596200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12923169	Green Published, hybrid			2022-12-25	WOS:000186157000099
J	Inamori, K; Endo, T; Ide, Y; Fujii, S; Gu, JG; Honke, K; Taniguchi, N				Inamori, K; Endo, T; Ide, Y; Fujii, S; Gu, JG; Honke, K; Taniguchi, N			Molecular cloning and characterization of human GnT-IX, a novel beta 1,6-N-acetylglucosaminyltransferase that is specifically expressed in the brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGLUCOSAMINYLTRANSFERASE-V; CELL-LINES; OLIGOSACCHARIDES; BINDING; GLYCOPROTEINS; SEQUENCES; MUTATION; GLYCANS; GROWTH; GENE	A novel beta1,6-N-acetylglucosaminyltransferase (beta1, 6GnT) cDNA was identified by a BLAST search using the amino acid sequence of human GnT-V as a query. The full-length sequence was determined by a combination of 5'-rapid amplification of cDNA end analysis and a further data base search. The open reading frame encodes a 792 amino acid protein with a type II membrane protein structure typical of glycosyltransferases. The entire sequence identity to human GnT-V is 42%. When pyridylaminated (PA) agalacto biantennary N-linked oligosaccharide was used as an acceptor substrate, the recombinant enzyme generated a novel product other than the expected GnT-V product, (GlcNAc beta1,2-Manalpha1,3-)[GlcNAcbeta1,2-(GlcNAcbeta1,6-)Manalpha1,6-] Manbeta1,4-GlcNAcbeta1,4-GlcNAc-PA. This new product was identified as [GlcNAcbeta1,2-(GlcNAcbeta1,6-)Manalpha1,3-][GlcNAcbeta1,2-(GlcNAcbeta1,6-)Manalpha1,6-]Manbeta1,4-GlcNAcbeta1,4-GlcNAc-PA by mass spectrometry and H-1 NMR. Namely, the new GnT (designated as GnT-IX) has beta1,6GnT activity not only to the alpha1,6-linked mannose arm but also to the alpha1,3-linked mannose arm of N-glycan, forming a unique structure that has not been reported to date. Northern blot analysis showed that the GnT-IX gene is exclusively expressed in the brain, whereas the GnT-V gene is expressed ubiquitously. These results suggest that GnT-IX is responsible for the synthesis of a unique oligosaccharide structure in the brain.	Osaka Univ, Sch Med, Dept Biochem, Suita, Osaka 5650871, Japan; Kansai Med Univ, Chem Lab, Osaka 5731136, Japan; Kochi Med Sch, Dept Mol Genet, Nanko Ku, Kochi 7838505, Japan	Osaka University; Kansai Medical University; Kochi University	Honke, K (corresponding author), Osaka Univ, Sch Med, Dept Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	khonke@med.kochi-ms.ac.jp	Gu, Jianguo/ABC-9257-2020; Taniguchi, Naoyuki/A-7086-2016; Inamori, Kei-ichiro/ABA-2926-2020; Taniguchi, Naoyuki/I-4182-2014	Inamori, Kei-ichiro/0000-0002-5947-3633; Taniguchi, Naoyuki/0000-0001-5889-5968				CUMMINGS RD, 1984, J BIOL CHEM, V259, P6253; Fukuzumi M, 2001, GLYCOBIOLOGY, V11, P481, DOI 10.1093/glycob/11.6.481; Granovsky M, 2000, NAT MED, V6, P306; HASE S, 1984, J BIOCHEM-TOKYO, V95, P197, DOI 10.1093/oxfordjournals.jbchem.a134585; KNIBBS RN, 1993, J BIOL CHEM, V268, P14940; MARGOLIS RK, 1986, BIOCHEMISTRY-US, V25, P3463, DOI 10.1021/bi00359a055; NISHIKAWA A, 1990, BIOCHIM BIOPHYS ACTA, V1035, P313, DOI 10.1016/0304-4165(90)90094-D; Puche AC, 1996, J COMP NEUROL, V364, P267, DOI 10.1002/(SICI)1096-9861(19960108)364:2<267::AID-CNE6>3.0.CO;2-3; Raju TS, 1998, J BIOL CHEM, V273, P14090, DOI 10.1074/jbc.273.23.14090; SAITO H, 1994, BIOCHEM BIOPH RES CO, V198, P318, DOI 10.1006/bbrc.1994.1045; Sasai K, 2001, J BIOL CHEM, V276, P759, DOI 10.1074/jbc.M004972200; SATO S, 1992, J BIOL CHEM, V267, P6983; SCHACHTER H, 1991, Glycobiology, V1, P453, DOI 10.1093/glycob/1.5.453; SEKO A, 1997, BIOCHIM BIOPHYS ACTA, V17, P1; SHARON N, 1989, SCIENCE, V246, P227, DOI 10.1126/science.2552581; SHOREIBAH M, 1993, J BIOL CHEM, V268, P15381; TANIGUCHI N, 1989, METHOD ENZYMOL, V179, P397; Tatusova TA, 1999, FEMS MICROBIOL LETT, V174, P247, DOI 10.1016/S0378-1097(99)00149-4; Ujita M, 2000, J BIOL CHEM, V275, P15868, DOI 10.1074/jbc.M001034200; VANDENEIJNDEN DH, 1988, J BIOL CHEM, V263, P12461; Warren CE, 2002, J BIOL CHEM, V277, P22829, DOI 10.1074/jbc.M201390200; Weinstein J, 1996, J BIOL CHEM, V271, P27462, DOI 10.1074/jbc.271.44.27462; YOUSEFI S, 1991, J BIOL CHEM, V266, P1772	23	71	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43102	43109		10.1074/jbc.M308255200	http://dx.doi.org/10.1074/jbc.M308255200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12941944	hybrid			2022-12-25	WOS:000186157000049
J	Yoshida, Y; Tokunaga, F; Chiba, T; Iwai, K; Tanaka, K; Tai, T				Yoshida, Y; Tokunaga, F; Chiba, T; Iwai, K; Tanaka, K; Tai, T			Fbs2 is a new member of the E3 ubiquitin ligase family that recognizes sugar chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSIDASE-LIKE PROTEIN; ER-ASSOCIATED DEGRADATION; F-BOX PROTEINS; MISFOLDED GLYCOPROTEINS; ENDOPLASMIC-RETICULUM; SECRETORY PATHWAY; QUALITY-CONTROL; HIF-ALPHA; HYDROXYLATION; TRANSLOCATION	F-box proteins are substrate recognition components of Skp1-Cullin1-F-box protein-Roc1 (SCF) E3 ubiquitin-protein ligases. We reported previously that Fbs1 (F-box protein that recognizes sugar chains; equivalent to Fbx2 or NFB42) binds specifically to proteins attached with high mannose oligosaccharides and subsequently contributes to elimination of N-glycoproteins in cytosol (Yoshida, Y., Chiba, T., Tokunaga, F., Kawasaki, H., Iwai, K., Suzuki, T., Ito, Y., Matsuoka, K., Yoshida, M., Tanaka, K., and Tai, T. (2002) Nature 418, 438 - 442). Here we report the identification of another F-box protein that recognizes N-glycan, Fbs2 (called Fbx6b or FBG2 previously). Although the expression of Fbs1 was restricted to the adult brain and testis, the Fbs2 transcript was widely expressed. The Fbs2 protein forms an SCFFbs2 ubiquitin-ligase complex that targets sugar chains in N-glycoproteins for ubiquitylation. Only glycoproteins bound to concanavalin A lectin and not to wheat germ agglutinin or Ricinus communis agglutinin interacted with Fbs2 in various tissues and cell lines. Pull-down analysis using various oligosaccharides revealed that Man(3-9)GlcNAc(2) glycans were required for efficient Fbs2 binding, whereas modifications of mannose residues by other sugars or deletion of inner GlcNAc reduced Fbs2 binding. Fbs2 interacted with N-glycans of T-cell receptor alpha-subunit (TCRalpha), a typical substrate of the endoplasmic reticulum-associated degradation (ERAD) pathway, and the forced expression of mutant Fbs2DeltaF, which lacks the F-box domain essential for forming the SCF complex, and decrease of endogenous Fbs2 by small interfering RNA led to inhibition of TCRalpha degradation in cells. Thus, Fbs2 is a novel member of F-box protein family that recognizes N-glycans and plays a role in ERAD.	Tokyo Metropolitan Inst Med Sci, Lab Frontier Sci, Bunkyo Ku, Tokyo 1138613, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi, Saitama 3320012, Japan; Osaka City Univ, Grad Sch Med, Dept Mol Cell Biol, Osaka 5458585, Japan	Tokyo Metropolitan Institute of Medical Science; Japan Science & Technology Agency (JST); Osaka Metropolitan University	Yoshida, Y (corresponding author), Tokyo Metropolitan Inst Med Sci, Lab Frontier Sci, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138613, Japan.		IWAI, KAZUHIRO/GSN-7385-2022; Yoshida, Yukiko/ABB-7218-2020	Yoshida, Yukiko/0000-0002-0629-0219; Tokunaga, Fuminori/0000-0003-3626-9119; Iwai, Kazuhiro/0000-0001-5620-5951				Bays NW, 2001, NAT CELL BIOL, V3, P24, DOI 10.1038/35050524; Brodsky JL, 1999, SEMIN CELL DEV BIOL, V10, P507, DOI 10.1006/scdb.1999.0321; Castellino F, 2000, J EXP MED, V191, P1957, DOI 10.1084/jem.191.11.1957; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Erhardt JA, 1998, J BIOL CHEM, V273, P35222, DOI 10.1074/jbc.273.52.35222; Fang D, 1999, BIOCHEM BIOPH RES CO, V261, P357, DOI 10.1006/bbrc.1999.1028; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; HASE S, 1987, ANAL BIOCHEM, V167, P321, DOI 10.1016/0003-2697(87)90171-0; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hosokawa N, 2001, EMBO REP, V2, P415, DOI 10.1093/embo-reports/kve084; Ilyin GP, 2002, GENE, V296, P11, DOI 10.1016/S0378-1119(02)00867-3; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jakob CA, 2001, EMBO REP, V2, P423; Kawakami T, 2001, EMBO J, V20, P4003, DOI 10.1093/emboj/20.15.4003; Kipreos ET, 2000, GENOME BIOL, V1; KOVACSOVICSBANKOWSKI M, 1995, SCIENCE, V267, P243, DOI 10.1126/science.7809629; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Molinari M, 2003, SCIENCE, V299, P1397, DOI 10.1126/science.1079474; Nakatsukasa K, 2001, J BIOL CHEM, V276, P8635, DOI 10.1074/jbc.C100023200; Oda Y, 2003, SCIENCE, V299, P1394, DOI 10.1126/science.1079181; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; Plemper RK, 1999, TRENDS BIOCHEM SCI, V24, P266, DOI 10.1016/S0968-0004(99)01420-6; SOUSA M, 1995, EMBO J, V14, P4196, DOI 10.1002/j.1460-2075.1995.tb00093.x; Swanson R, 2001, GENE DEV, V15, P2660, DOI 10.1101/gad.933301; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; Winston JT, 1999, CURR BIOL, V9, P1180, DOI 10.1016/S0960-9822(00)80021-4; Yoshida Y, 2002, NATURE, V418, P438, DOI 10.1038/nature00890; Yu H, 1997, J BIOL CHEM, V272, P20800, DOI 10.1074/jbc.272.33.20800	32	128	135	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43877	43884		10.1074/jbc.M304157200	http://dx.doi.org/10.1074/jbc.M304157200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12939278	hybrid			2022-12-25	WOS:000186157000138
J	Julien, C; Coulombe, P; Meloche, S				Julien, C; Coulombe, P; Meloche, S			Nuclear export of ERK3 by a CRM1-dependent mechanism regulates its inhibitory action on cell cycle progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; MAP KINASE; NUCLEOCYTOPLASMIC TRANSPORT; SUBCELLULAR-LOCALIZATION; GENE-EXPRESSION; FISSION YEAST; HUMAN HOMOLOG; SIGNAL; TRANSLOCATION; CRM1	Extracellular signal-regulated kinase 3 (ERK3) is an atypical member of the mitogen-activated protein kinase family of serine/threonine kinases. Little is known on the regulation of ERK3 function. Here, we report that ERK3 is constitutively localized in the cytoplasmic and nuclear compartments. In contrast to other mitogen-activated protein kinases, the cellular distribution of ERK3 remains unchanged in response to common mitogenic or stress stimuli and is independent of the enzymatic activity or phosphorylation of the kinase. The cytoplasmic localization of ERK3 is directed by a CRM1-dependent nuclear export mechanism. Treatment of cells with leptomycin B causes the nuclear accumulation of ERK3 in a high percentage of cells. Moreover, ectopic expression of CRM1 promotes the cytoplasmic relocalization of ERK3, whereas overexpression of snurportin 1, which binds CRM1 with high affinity, inhibits the nuclear export of ERK3. We also show that CRM1 binds to ERK3 in vitro. Importantly, we show that enforced localization of ERK3 in the nucleus or cytoplasm markedly attenuates the ability of the kinase to induce cell cycle arrest in fibroblasts. Our results suggest that nucleocytoplasmic shuttling of ERK3 is required for its negative regulatory effect on cell cycle progression.	Inst Rech Clin Montreal, Montreal, PQ H2W 1R7, Canada; Univ Montreal, Dept Pharmacol, Montreal, PQ H2W 1R7, Canada; Univ Montreal, Dept Mol Biol, Montreal, PQ H2W 1R7, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; Universite de Montreal	Meloche, S (corresponding author), Inst Rech Clin Montreal, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.			COULOMBE, Philippe/0000-0002-4638-9694				Adachi M, 1999, EMBO J, V18, P5347, DOI 10.1093/emboj/18.19.5347; Adachi M, 2000, J CELL BIOL, V148, P849, DOI 10.1083/jcb.148.5.849; Aplin AE, 2001, J CELL BIOL, V153, P273, DOI 10.1083/jcb.153.2.273; Ben-Levy R, 1998, CURR BIOL, V8, P1049, DOI 10.1016/S0960-9822(98)70442-7; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; Carmo-Fonseca M, 2002, CELL, V108, P513, DOI 10.1016/S0092-8674(02)00650-5; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Cheng M, 1996, J BIOL CHEM, V271, P8951, DOI 10.1074/jbc.271.15.8951; Cheng M, 1996, J BIOL CHEM, V271, P12057, DOI 10.1074/jbc.271.20.12057; Coulombe P, 2003, MOL CELL BIOL, V23, P4542, DOI 10.1128/MCB.23.13.4542-4558.2003; Coulombe P, 2002, ANAL BIOCHEM, V310, P219, DOI 10.1016/S0003-2697(02)00319-6; Cyert MS, 2001, J BIOL CHEM, V276, P20805, DOI 10.1074/jbc.R100012200; Ferrigno P, 1998, EMBO J, V17, P5606, DOI 10.1093/emboj/17.19.5606; Formstecher E, 2001, DEV CELL, V1, P239, DOI 10.1016/S1534-5807(01)00035-1; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Fukuda M, 1997, J BIOL CHEM, V272, P32642, DOI 10.1074/jbc.272.51.32642; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; Gaits F, 1999, MOL BIOL CELL, V10, P1395, DOI 10.1091/mbc.10.5.1395; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Huber J, 1998, EMBO J, V17, P4114, DOI 10.1093/emboj/17.14.4114; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Kumagai A, 1999, GENE DEV, V13, P1067, DOI 10.1101/gad.13.9.1067; Kutay U, 1997, EMBO J, V16, P1153, DOI 10.1093/emboj/16.6.1153; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; la Cour T, 2003, NUCLEIC ACIDS RES, V31, P393, DOI 10.1093/nar/gkg101; Lee KK, 2002, J BIOL CHEM, V277, P12351, DOI 10.1074/jbc.M108138200; Lenormand P, 1998, J CELL BIOL, V142, P625, DOI 10.1083/jcb.142.3.625; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; McBride KM, 2000, EMBO J, V19, P6196, DOI 10.1093/emboj/19.22.6196; MELOCHE S, 1995, J CELL PHYSIOL, V163, P577, DOI 10.1002/jcp.1041630319; Meloche S, 1996, ONCOGENE, V13, P1575; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Neufeld KL, 2000, P NATL ACAD SCI USA, V97, P12085, DOI 10.1073/pnas.220401797; NISHI K, 1994, J BIOL CHEM, V269, P6320; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Paraskeva E, 1999, J CELL BIOL, V145, P255, DOI 10.1083/jcb.145.2.255; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; Turgeon B, 2002, GENOMICS, V80, P673, DOI 10.1006/geno.2002.7013; Volmat V, 2001, BIOL CELL, V93, P71, DOI 10.1016/S0248-4900(01)01129-7; Wada A, 1998, EMBO J, V17, P1635, DOI 10.1093/emboj/17.6.1635; Whitehurst AW, 2002, P NATL ACAD SCI USA, V99, P7496, DOI 10.1073/pnas.112495999; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; ZHU AX, 1994, MOL CELL BIOL, V14, P8202, DOI 10.1128/MCB.14.12.8202; Zuniga A, 1999, J BIOL CHEM, V274, P21900, DOI 10.1074/jbc.274.31.21900	53	57	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42615	42624		10.1074/jbc.M302724200	http://dx.doi.org/10.1074/jbc.M302724200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12915405	Green Published, hybrid			2022-12-25	WOS:000185989500127
J	Tokoro, M; Asai, T; Kobayashi, S; Takeuchi, T; Nozaki, T				Tokoro, M; Asai, T; Kobayashi, S; Takeuchi, T; Nozaki, T			Identification and characterization of two isoenzymes of methionine gamma-lyase from Entamoeba histolytica - A key enzyme of sulfur-amino acid degradation in an anaerobic parasitic protist that lacks forward and reverse trans-sulfuration pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNECHOCYSTIS PCC 6803; PSEUDOMONAS-PUTIDA; TRICHOMONAS-VAGINALIS; MERCAPTOMETHANE-LYASE; METABOLISM; PURIFICATION; CYSTEINE; GENES; SYNTHASE; CLONING	To better understand the metabolism of sulfur-containing amino acids, which likely plays a key role in a variety of cell functions, in Entamoeba histolytica, we searched the genome data base for genes encoding putative orthologs of enzymes known to be involved in the metabolism. The search revealed that E. histolytica possesses only incomplete cysteine-methionine conversion pathways in both directions. Instead, this parasite possesses genes encoding two isoenzymes of methionine gamma-lyase (EC 4.4.1.11, EhMGL1/2), which has been implicated in the degradation of sulfur-containing amino acids. The two amebic MGL isoenzymes, showing 69% identity to each other, encode 389- and 392-amino acid polypeptides with predicted molecular masses of 42.3 and 42.7 kDa and pIs of 6.01 and 6.63, respectively. Amino acid comparison and phylogenetic analysis suggested that these amebic MGLs are likely to have been horizontally transferred from the Archaea, whereas an MGL from another anaerobic protist Trichomonas vaginalis has MGL isotypes that share a common ancestor with bacteria. Enzymological and immunoblot analyses of the partially purified native amebic MGL confirmed that both of the MGL isotypes are expressed in a comparable amount predominantly in the cytosol and form a homotetramer. Recombinant EhMGL1 and 2 proteins catalyzed degradation of L-methionine, DL-homocysteine, L-cysteine, and O-acetyl-L-serine to form alpha-keto acid, ammonia, and hydrogen sulfide or methanethiol, whereas activity toward cystathionine was negligible. These two isoenzymes showed notable differences in substrate specificity and pH optimum. In addition, we showed that EhMGL is an ideal target for the development of new chemotherapeutic agents against amebiasis by demonstrating an amebicidal effect of the methionine analog trifluoromethionine on trophozoites in culture (IC50 18 muM) and that this effect of trifluoromethionine was completely abolished by the addition of the MGL-specific inhibitor DL-propargylglycine.	Keio Univ, Sch Med, Dept Trop Med & Parasitol, Tokyo 1608582, Japan; Natl Inst Infect Dis, Dept Parasitol, Tokyo 1628640, Japan; Japan Sci & Technol Corp, Precursory Res Embryon Sci & Technol, Tokyo 1900012, Japan	Keio University; National Institute of Infectious Diseases (NIID); Japan Science & Technology Agency (JST)	Nozaki, T (corresponding author), 1-23-1 Toyama,Shinjuku Ku, Tokyo 1628640, Japan.		Kobayashi, seiki/L-4026-2013					Adachi J., 1996, COMPUT SCI MONOGR, V28, P1; ALSTON TA, 1983, BIOCHEM PHARMACOL, V32, P947, DOI 10.1016/0006-2952(83)90608-1; Behbehani K, 1998, Bull World Health Organ, V76 Suppl 2, P64; CLARK CG, 1995, P NATL ACAD SCI USA, V92, P6518, DOI 10.1073/pnas.92.14.6518; Coombs GH, 2001, ANTIMICROB AGENTS CH, V45, P1743, DOI 10.1128/AAC.45.6.1743-1745.2001; CUHEL RL, 1981, J BACTERIOL, V147, P340, DOI 10.1128/JB.147.2.340-349.1981; DIAMOND LS, 1978, T ROY SOC TROP MED H, V72, P431, DOI 10.1016/0035-9203(78)90144-X; DIAMOND LS, 1972, J VIROL, V9, P326, DOI 10.1128/JVI.9.2.326-341.1972; Dias B, 1998, APPL ENVIRON MICROB, V64, P3327; ESAKI N, 1987, METHOD ENZYMOL, V143, P459; FAHEY RC, 1984, SCIENCE, V224, P70, DOI 10.1126/science.6322306; Faleev NG, 1996, ENZYME MICROB TECH, V19, P590, DOI 10.1016/S0141-0229(96)00071-3; Field J, 2000, MOL MICROBIOL, V38, P446, DOI 10.1046/j.1365-2958.2000.02143.x; GILLIN FD, 1980, J PROTOZOOL, V27, P474, DOI 10.1111/j.1550-7408.1980.tb05402.x; Hori H, 1996, CANCER RES, V56, P2116; ITO S, 1976, J BIOCHEM-TOKYO, V80, P1327, DOI 10.1093/oxfordjournals.jbchem.a131405; Jaschkowitz K, 2000, BIOCHEMISTRY-US, V39, P3416, DOI 10.1021/bi992147c; JOHNSTON M, 1979, BIOCHEMISTRY-US, V18, P4690, DOI 10.1021/bi00588a033; Kapatral V, 2002, J BACTERIOL, V184, P2005, DOI 10.1128/JB.184.7.2005-2018.2002; KASHIWAMATA S, 1970, BIOCHIM BIOPHYS ACTA, V212, P488, DOI 10.1016/0005-2744(70)90255-X; KREIS W, 1973, CANCER RES, V33, P1862; KUHNER MK, 1994, MOL BIOL EVOL, V11, P459; LAAKSO S, 1976, ANAL BIOCHEM, V72, P600, DOI 10.1016/0003-2697(76)90572-8; Lancero H, 1996, J DENT RES, V75, P1994, DOI 10.1177/00220345960750121201; LOCKWOOD BC, 1991, BIOCHEM J, V279, P675, DOI 10.1042/bj2790675; Mai ZM, 1999, MOL CELL BIOL, V19, P2198; Mazzuco A, 1997, MICRON, V28, P241, DOI 10.1016/S0968-4328(97)00024-3; McKie AE, 1998, J BIOL CHEM, V273, P5549, DOI 10.1074/jbc.273.10.5549; Mehta PK, 2000, ADV ENZYMOL RAMB, V74, P129; Motoshima H, 2000, J BIOCHEM, V128, P349, DOI 10.1093/oxfordjournals.jbchem.a022760; MULLER M, 1992, BIOSYSTEMS, V28, P33, DOI 10.1016/0303-2647(92)90005-J; NAKAYAMA T, 1988, BIOCHEMISTRY-US, V27, P1587, DOI 10.1021/bi00405a029; NAKAYAMA T, 1984, ANAL BIOCHEM, V138, P421, DOI 10.1016/0003-2697(84)90832-7; Nozaki T, 1999, J BIOL CHEM, V274, P32445, DOI 10.1074/jbc.274.45.32445; Nozaki T, 1998, MOL BIOCHEM PARASIT, V97, P33, DOI 10.1016/S0166-6851(98)00129-7; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; RAVDIN JI, 2000, AMEBIASIS SERIES TRO, V2, P1; REEVES RE, 1984, ADV PARASIT, V23, P105, DOI 10.1016/S0065-308X(08)60286-9; Rosenthal B, 1997, J BACTERIOL, V179, P3736, DOI 10.1128/jb.179.11.3736-3745.1997; Sambrook J, 2001, MOL CLONING LAB MANU, V3rd; Schneider D, 2000, INDIAN J BIOCHEM BIO, V37, P441; Shimizu H, 2001, BBA-PROTEIN STRUCT M, V1549, P61, DOI 10.1016/S0167-4838(01)00245-X; SIEGEL LM, 1965, ANAL BIOCHEM, V11, P126, DOI 10.1016/0003-2697(65)90051-5; SODA K, 1967, AGR BIOL CHEM TOKYO, V31, P1054, DOI 10.1080/00021369.1967.10858916; STARKEBAUM G, 1986, J CLIN INVEST, V77, P1370, DOI 10.1172/JCI112442; Steegborn C, 1999, J BIOL CHEM, V274, P12675, DOI 10.1074/jbc.274.18.12675; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; THOMPSON JF, 1951, ANAL CHEM, V23, P1153, DOI 10.1021/ac60056a029; THONG KW, 1987, MOL BIOCHEM PARASIT, V23, P223, DOI 10.1016/0166-6851(87)90029-6; Tovar J, 1999, MOL MICROBIOL, V32, P1013, DOI 10.1046/j.1365-2958.1999.01414.x; Upcroft JA, 1999, J EUKARYOT MICROBIOL, V46, P447, DOI 10.1111/j.1550-7408.1999.tb04628.x; Walker J, 1997, INT J PARASITOL, V27, P883, DOI 10.1016/S0020-7519(97)00039-8; Wassmann C, 1999, J BIOL CHEM, V274, P26051, DOI 10.1074/jbc.274.37.26051; ZANIN VA, 1989, VOP MED KHIM, V35, P84	54	92	101	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42717	42727		10.1074/jbc.M212414200	http://dx.doi.org/10.1074/jbc.M212414200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12920135	hybrid			2022-12-25	WOS:000185989500139
J	Tauchi, T; Shin-ya, K; Sashida, G; Sumi, M; Nakajima, A; Shimamoto, T; Ohyashiki, JH; Ohyashiki, K				Tauchi, T; Shin-ya, K; Sashida, G; Sumi, M; Nakajima, A; Shimamoto, T; Ohyashiki, JH; Ohyashiki, K			Activity of a novel G-quadruplex-interactive telomerase inhibitor, telomestatin (SOT-095), against human leukemia cells: involvement of ATM-dependent DNA damage response pathways	ONCOGENE			English	Article						telomerase inhibition; ATM; telomere dysfunction	ABL TYROSINE KINASE; ACUTE LYMPHOBLASTIC-LEUKEMIA; HUMAN TUMOR-CELLS; ATAXIA-TELANGIECTASIA; CATIONIC PORPHYRINS; CATALYTIC SUBUNIT; CANCER-CELLS; IN-VITRO; CHECKPOINT; GROWTH	The telomerase complex is responsible for telomere maintenance and represents a promising neoplasia therapeutic target. In order to determine whether G-quadruplex-interactive telomerase inhibitor, telomestatin (SOT-095), might have effects on telomere dynamics and to evaluate the clinical utility, we assessed the effects of telomestatin on BCR-ABL-positive human leukemia cells. We found that treatment with telomestatin reproducibly inhibited telomerase activity in the BCR-ABL-positive leukemic cell lines OM9;22 and K562, resulting in telomere shortening. Inhibition of telomerase activity by telomestatin disrupts' telomere maintenance and ultimately results in telomere dysfunction. Telomestatin completely suppressed the plating efficiency of K562 cells at 1 muM; however, telomestatin had less effects on BFU-Es and CFU-GMs colony formation from normal bone marrow CD34-positive cells. Enhanced chemosensitivity toward imatinib and chemotherapeutic agents was also observed in telomestatin-treated K562 cells. Further, the combination of telomestatin plus imatinib more: effectively inhibited hematopoietic colony formation by primary human chronic myelogenous leukemia. cells. Last, telomestatin induced the activation of ATM and Chk2, and subsequently increased the expression of, p21(CIP1) and p27(KIP1). These results demonstrate that telomere dysfunction induced by telomestatin activates the ATM-dependent DNA damage response. We conclude that telomerase inhibitors combined with the use, of imatinib and other chemotherapeutic agents may be very useful for the treatment of human leukemia.	Tokyo Med Univ, Dept Internal Med 1, Shinjuku Ku, Tokyo 1600023, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Tokyo Med Univ, Intractable Dis Res Ctr, Shinjuku Ku, Tokyo 1600023, Japan	Tokyo Medical University; University of Tokyo; Tokyo Medical University	Tauchi, T (corresponding author), Tokyo Med Univ, Dept Internal Med 1, Shinjuku Ku, 6-7-1 Nishishinjuku, Tokyo 1600023, Japan.		Sashida, Goro/N-5259-2014	Sashida, Goro/0000-0003-2318-5987				Bearss DJ, 2000, ONCOGENE, V19, P6632, DOI 10.1038/sj.onc.1204092; Blackburn EH, 1995, TELOMERES; Blasco Maria A., 1999, Genes and Development, V13, P2353, DOI 10.1101/gad.13.18.2353; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chaves-Dias C, 2001, J IMMUNOL, V166, P6647, DOI 10.4049/jimmunol.166.11.6647; Chehab NH, 2000, GENE DEV, V14, P278; Damm K, 2001, EMBO J, V20, P6958, DOI 10.1093/emboj/20.24.6958; Delhommeau FO, 2002, ONCOGENE, V21, P8262, DOI 10.1038/sj.onc.1206054; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Glukhov AI, 1998, BIOCHEM BIOPH RES CO, V248, P368, DOI 10.1006/bbrc.1998.8801; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Guiducci C, 2001, ONCOGENE, V20, P714, DOI 10.1038/sj.onc.1204145; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hisatomi H, 1999, INT J ONCOL, V14, P727; Izbicka E, 1999, CANCER RES, V59, P639; Kharbanda S, 2000, CURR BIOL, V10, P568, DOI 10.1016/S0960-9822(00)00483-8; Kim MM, 2001, P NATL ACAD SCI USA, V98, P7982, DOI 10.1073/pnas.131211098; KIM MY, 2002, J AM CHEM SOC, V123, P1262; Kondo S, 1998, ONCOGENE, V16, P3323, DOI 10.1038/sj.onc.1201885; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; Lee KH, 2001, P NATL ACAD SCI USA, V98, P3381, DOI 10.1073/pnas.051629198; Liu JP, 1999, FASEB J, V13, P2091, DOI 10.1096/fasebj.13.15.2091; Meyerson M, 2000, J CLIN ONCOL, V18, P2626, DOI 10.1200/JCO.2000.18.13.2626; Nakajima A, 2003, LEUKEMIA, V17, P560, DOI 10.1038/sj.leu.2402825; Nakajima A, 2001, LEUKEMIA, V15, P989, DOI 10.1038/sj.leu.2402137; Ohyashiki JH, 2002, ONCOGENE, V21, P680, DOI 10.1038/sj.onc.1205075; OHYASHIKI K, 1993, LEUKEMIA, V7, P1034; Perry, 1999, Expert Opin Investig Drugs, V8, P1981, DOI 10.1517/13543784.8.12.1981; Sachsinger J, 2001, CANCER RES, V61, P5580; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; Shi DF, 2001, J MED CHEM, V44, P4509, DOI 10.1021/jm010246u; Shieh SY, 2000, GENE DEV, V14, P289; Shin-ya K, 2001, J AM CHEM SOC, V123, P1262, DOI 10.1021/ja005780q; Sun DY, 1997, J MED CHEM, V40, P2113, DOI 10.1021/jm970199z; TAUCHI T, 1994, J BIOL CHEM, V269, P15381; Tauchi T, 2002, CLIN CANCER RES, V8, P3341; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Wheelhouse RT, 1998, J AM CHEM SOC, V120, P3261, DOI 10.1021/ja973792e; ZAHLER AM, 1991, NATURE, V350, P718, DOI 10.1038/350718a0; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388	47	179	189	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 14	2003	22	34					5338	5347		10.1038/sj.onc.1206833	http://dx.doi.org/10.1038/sj.onc.1206833			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JB	12917635				2022-12-25	WOS:000184734900013
J	Fraysse, B; Desaphy, JF; Pierno, S; De Luca, A; Liantonio, A; Mitolo, CI; Camerino, DC				Fraysse, B; Desaphy, JF; Pierno, S; De Luca, A; Liantonio, A; Mitolo, CI; Camerino, DC			Decrease in resting calcium and calcium entry associated with slow-to-fast transition in unloaded rat soleus muscle	FASEB JOURNAL			English	Article						resting cytosolic calcium; sarcolemmal permeability to cations; slow-twitch and fast-twitch skeletal muscles hindlimb unloading-induced slow-to-fast transition; fura-2	MYOSIN HEAVY-CHAIN; SKELETAL-MUSCLE; SARCOPLASMIC-RETICULUM; GENE-EXPRESSION; RYANODINE RECEPTOR; METABOLIC ENZYMES; SARCOMERE-LENGTH; CA2+ TRANSIENTS; MESSENGER-RNA; SINGLE FIBERS	Using fura-2 and the manganese quenching technique, we show here that sarcolemmal permeability to cations (SP-Ca) of slow-twitch muscles is greater than that of fast-twitch ones. This appears to be related to a higher expression and/or activity of stretch-activated channels, whereas leak channel activities are similar. During hindlimb suspension (HU), we found highly correlated decreases in SPCa and resting calcium of soleus muscle toward values of extensor digitorum longus (EDL) muscle. This was significant as soon as 3 days of suspension, contrary to soleus muscle caffeine sensitivity and responsiveness that were not modified after this HU period. After 14 days of HU, SP-Ca, resting calcium, and caffeine response of soleus muscle became similar to that normally observed in EDL muscle. These results demonstrate that the correlated decreases in SP-Ca and resting calcium precede most functional changes due to HU. Given the known shortening of HU soleus muscle, we proposed that this could induce a decrease of SP-Ca and a consequent reduction of resting calcium. According to the crucial role of resting cytosolic free calcium in the maintenance and the adaptation of muscle phenotype, our results suggest that slow-to-fast transition of HU soleus muscle is calcium dependent.	Univ Bari, Dipartimento Farmacobiol, Sez Farmacol, I-70125 Bari, Italy	Universita degli Studi di Bari Aldo Moro	Camerino, DC (corresponding author), Univ Bari, Dipartimento Farmacobiol, Sez Farmacol, Via Orabona 4 Campus, I-70125 Bari, Italy.	conte@farmbiol.uniba.it	Desaphy, Jean-Francois/T-6191-2019; Fraysse, Bodvaël/ABH-3589-2020	Desaphy, Jean-Francois/0000-0001-8816-9369; De Luca, Annamaria/0000-0002-5652-7341; Liantonio, Antonella/0000-0002-4103-7577; FRAYSSE, Bodvael/0000-0002-3782-931X; Pierno, Sabata/0000-0003-3121-2666; Conte, Diana/0000-0003-0162-9698				Allen DL, 2002, J BIOL CHEM, V277, P45323, DOI 10.1074/jbc.M208302200; Bastide B, 2000, BIOCHEM BIOPH RES CO, V270, P442, DOI 10.1006/bbrc.2000.2446; Berchtold MW, 2000, PHYSIOL REV, V80, P1215, DOI 10.1152/physrev.2000.80.3.1215; Booth FW, 1997, INT J SPORTS MED, V18, pS265, DOI 10.1055/s-2007-972723; BRYANT SH, 1991, PFLUG ARCH EUR J PHY, V417, P605, DOI 10.1007/BF00372958; Burkholder TJ, 2001, J EXP BIOL, V204, P1529; Carroll S, 1999, AM J PHYSIOL-CELL PH, V277, pC1122, DOI 10.1152/ajpcell.1999.277.6.C1122; Carroll SL, 1997, J PHYSIOL-LONDON, V501, P573, DOI 10.1111/j.1469-7793.1997.573bm.x; CHAPMAN RA, 1976, J PHYSIOL-LONDON, V258, pP1; Cros N, 2001, J CELL BIOCHEM, V83, P508, DOI 10.1002/jcb.1248; Desaphy JF, 2001, BRAIN, V124, P1100, DOI 10.1093/brain/124.6.1100; DULHUNTY AF, 1983, J PHYSIOL-LONDON, V341, P213, DOI 10.1113/jphysiol.1983.sp014802; Endo M, 2000, HANDB EXP PHARM, V147, P583; Fitts RH, 2000, J APPL PHYSIOL, V89, P823, DOI 10.1152/jappl.2000.89.2.823; Franco-Obregon A, 2002, J PHYSIOL-LONDON, V539, P391, DOI 10.1113/jphysiol.2001.013043; Freyssenet D, 1999, J BIOL CHEM, V274, P9305, DOI 10.1074/jbc.274.14.9305; Frigeri A, 2001, FASEB J, V15, P1282, DOI 10.1096/fj.00-0525fje; GAILLY P, 1993, CELL CALCIUM, V14, P473, DOI 10.1016/0143-4160(93)90006-R; Gajdosik RL, 2001, CLIN BIOMECH, V16, P87, DOI 10.1016/S0268-0033(00)00061-9; Gillis JM, 1996, ACTA PHYSIOL SCAND, V156, P397, DOI 10.1046/j.1365-201X.1996.201000.x; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAWS CM, 1991, P ROY SOC B-BIOL SCI, V245, P173, DOI 10.1098/rspb.1991.0105; Hopf FW, 1996, AM J PHYSIOL-CELL PH, V271, pC1325, DOI 10.1152/ajpcell.1996.271.4.C1325; Hu H, 1997, J MOL CELL CARDIOL, V29, P1511, DOI 10.1006/jmcc.1997.0392; HuchetCadiou C, 1996, J APPL PHYSIOL, V80, P1100, DOI 10.1152/jappl.1996.80.4.1100; Ikemoto M, 2001, FASEB J, V15, P1279, DOI 10.1096/fj.00-0629fje; Ingalls CP, 2001, AVIAT SPACE ENVIR MD, V72, P471; Ingalls CP, 1999, J APPL PHYSIOL, V87, P386, DOI 10.1152/jappl.1999.87.1.386; ISAACSON A, 1970, AM J PHYSIOL, V218, P33, DOI 10.1152/ajplegacy.1970.218.1.33; KANDARIAN S, 1992, J APPL PHYSIOL, V72, P2510, DOI 10.1152/jappl.1992.72.6.2510; Kandarian SC, 1996, AM J PHYSIOL-CELL PH, V270, pC1588, DOI 10.1152/ajpcell.1996.270.6.C1588; Kubis HP, 1997, P NATL ACAD SCI USA, V94, P4205, DOI 10.1073/pnas.94.8.4205; LEDVINA MA, 1995, J APPL PHYSIOL, V78, P2047, DOI 10.1152/jappl.1995.78.6.2047; Makabe M, 1996, PFLUG ARCH EUR J PHY, V432, P717, DOI 10.1007/s004240050190; MANCHESTER JK, 1990, FASEB J, V4, P55, DOI 10.1096/fasebj.4.1.1967237; Meissner JD, 2001, J PHYSIOL-LONDON, V533, P215, DOI 10.1111/j.1469-7793.2001.0215b.x; Meissner JD, 2000, J PHYSIOL-LONDON, V523, P19, DOI 10.1111/j.1469-7793.2000.t01-1-00019.x; Morey-Holton ER, 2002, J APPL PHYSIOL, V92, P1367, DOI 10.1152/japplphysiol.00969.2001; Morgan AJ, 1999, METH MOL B, V114, P93; Olson EN, 2000, BIOESSAYS, V22, P510, DOI 10.1002/(SICI)1521-1878(200006)22:6<510::AID-BIES4>3.3.CO;2-T; PAGALA MK, 1998, AM J PHYSIOL, V274, pC923; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Peters DG, 1999, AM J PHYSIOL-CELL PH, V276, pC1218, DOI 10.1152/ajpcell.1999.276.5.C1218; Pierno S, 2002, BRAIN, V125, P1510, DOI 10.1093/brain/awf162; Pierno S, 1999, FEBS LETT, V449, P12, DOI 10.1016/S0014-5793(99)00202-1; RILEY DA, 1990, J APPL PHYSIOL, V69, P58, DOI 10.1152/jappl.1990.69.1.58; Rossi R, 2001, AM J PHYSIOL-CELL PH, V281, pC585, DOI 10.1152/ajpcell.2001.281.2.C585; SCHULTE LM, 1993, AM J PHYSIOL, V264, pC1308, DOI 10.1152/ajpcell.1993.264.5.C1308; Stevens L, 1999, FEBS LETT, V463, P15, DOI 10.1016/S0014-5793(99)01596-3; STEVENS L, 1992, J APPL PHYSIOL, V72, P1735, DOI 10.1152/jappl.1992.72.5.1735; Suzuki M, 1999, J BIOL CHEM, V274, P6330, DOI 10.1074/jbc.274.10.6330; Taillandier D, 1996, BIOCHEM J, V316, P65, DOI 10.1042/bj3160065; Talmadge RJ, 2000, MUSCLE NERVE, V23, P661, DOI 10.1002/(SICI)1097-4598(200005)23:5<661::AID-MUS3>3.0.CO;2-J; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; TURNER PR, 1991, J CELL BIOL, V115, P1701, DOI 10.1083/jcb.115.6.1701; Tutdibi O, 1999, J PHYSIOL-LONDON, V515, P859, DOI 10.1111/j.1469-7793.1999.859ab.x; Vandebrouck C, 2002, J CELL BIOL, V158, P1089, DOI 10.1083/jcb.200203091; WU KD, 1993, AM J PHYSIOL, V264, pC333, DOI 10.1152/ajpcell.1993.264.2.C333; ZARAINHERZBERG A, 1990, J BIOL CHEM, V265, P4670	59	60	63	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1916	+		10.1096/fj.02-1012fje	http://dx.doi.org/10.1096/fj.02-1012fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12923063				2022-12-25	WOS:000185345100010
J	Bhat, R; Xue, YF; Berg, S; Hellberg, S; Ormo, M; Nilsson, Y; Radesater, AC; Jerning, E; Markgren, PO; Borgegard, T; Nylof, M; Gimenez-Cassina, A; Hernandez, F; Lucas, JJ; Diaz-Nido, J; Avila, J				Bhat, R; Xue, YF; Berg, S; Hellberg, S; Ormo, M; Nilsson, Y; Radesater, AC; Jerning, E; Markgren, PO; Borgegard, T; Nylof, M; Gimenez-Cassina, A; Hernandez, F; Lucas, JJ; Diaz-Nido, J; Avila, J			Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISEASE-LIKE PHOSPHORYLATION; PAIRED HELICAL FILAMENTS; ALZHEIMERS-DISEASE; BETA-CATENIN; TAU-PHOSPHORYLATION; NEURONAL DEGENERATION; INDUCED NEUROTOXICITY; HIPPOCAMPAL-NEURONS; TRANSGENIC MICE; PROTEIN-TAU	Glycogen synthase kinase 3 (GSK3) is a serine/threonine kinase that has been implicated in pathological conditions such as diabetes and Alzheimer's disease. We report the characterization of a GSK3 inhibitor, AR-A014418, which inhibits GSK3 (IC50 = 104 +/- 27 nM), in an ATP-competitive manner (K-i = 38 nM). AR-A014418 does not significantly inhibit cdk2 or cdk5 (IC50 > 100 muM) or 26 other kinases demonstrating high specificity for GSK3. We report the co-crystallization of AR-A014418 with the GSK3beta protein and provide a description of the interactions within the ATP pocket, as well as an understanding of the structural basis for the selectivity of AR-A014418. AR-A014418 inhibits tau phosphorylation at a GSK3-specific site (Ser-396) in cells stably expressing human four-repeat tau protein. AR-A014418 protects N2A neuroblastoma cells against cell death mediated by inhibition of the phosphatidylinositol 3-kinase/protein kinase B survival pathway. Furthermore, AR-A014418 inhibits neurodegeneration mediated by beta-amyloid peptide in hippocampal slices. AR-A014418 may thus have important applications as a tool to elucidate the role of GSK3 in cellular signaling and possibly in Alzheimer's disease. AR-A014418 is the first compound of a family of specific inhibitors of GSK3 that does not significantly inhibit closely related kinases such as cdk2 or cdk5.	AstraZeneca R&D Sodertalje, Res DMPK, S-15185 Sodertalje, Sweden; AstraZeneca R&D, S-43183 Molndal, Sweden; Univ Autonoma Madrid, Consejo Super Invest Cient, E-28049 Madrid, Spain	AstraZeneca; AstraZeneca; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)	Bhat, R (corresponding author), AstraZeneca R&D Sodertalje, Res DMPK, Bldg 231-213B, S-15185 Sodertalje, Sweden.	ratan.bhat@astrazeneca.com	Hernandez, Felix/L-2114-2015; Diaz-Nido, Javier/L-2371-2013; Avila, Jesus/I-2610-2015; Gimenez-Cassina, Alfredo/AAA-6550-2019; Lucas, Jose J./U-6543-2019	Hernandez, Felix/0000-0001-8753-8249; Diaz-Nido, Javier/0000-0002-0927-7925; Avila, Jesus/0000-0002-6288-0571; Gimenez-Cassina, Alfredo/0000-0002-2768-2350; Lucas, Jose J./0000-0003-1597-3916; Xue, Yafeng/0000-0002-7526-8672				Alvarez G, 1999, FEBS LETT, V453, P260, DOI 10.1016/S0014-5793(99)00685-7; Alzheimer A, 1911, Z GESAMTE NEUROL PSY, V4, P356, DOI 10.1007/BF02866241; Avila J, 2000, FEBS LETT, V476, P89, DOI 10.1016/S0014-5793(00)01676-8; Bhat RV, 2000, P NATL ACAD SCI USA, V97, P11074, DOI 10.1073/pnas.190297597; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; BUSCIGLIO J, 1995, NEURON, V14, P879, DOI 10.1016/0896-6273(95)90232-5; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Ferreira A, 1997, MOL CELL NEUROSCI, V9, P220, DOI 10.1006/mcne.1997.0615; Goedert M, 2001, BIOCHEM SOC SYMP, V67, P59, DOI 10.1042/bss0670059; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; HANGER DP, 1992, NEUROSCI LETT, V147, P58, DOI 10.1016/0304-3940(92)90774-2; Hernandez F, 2002, J NEUROCHEM, V83, P1529, DOI 10.1046/j.1471-4159.2002.01269.x; Hers I, 1999, FEBS LETT, V460, P433, DOI 10.1016/S0014-5793(99)01389-7; Hetman M, 2000, J NEUROSCI, V20, P2567; Hong M, 1997, J BIOL CHEM, V272, P25326, DOI 10.1074/jbc.272.40.25326; Hoshi M, 1996, P NATL ACAD SCI USA, V93, P2719, DOI 10.1073/pnas.93.7.2719; ISHIGURO K, 1993, FEBS LETT, V325, P167, DOI 10.1016/0014-5793(93)81066-9; Jackson GR, 2002, NEURON, V34, P509, DOI 10.1016/S0896-6273(02)00706-7; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leclerc S, 2001, J BIOL CHEM, V276, P251, DOI 10.1074/jbc.M002466200; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Leroy K, 2002, ACTA NEUROPATHOL, V103, P91; LOVESTONE S, 1994, CURR BIOL, V4, P1077, DOI 10.1016/S0960-9822(00)00246-3; Lucas JJ, 2001, EMBO J, V20, P27, DOI 10.1093/emboj/20.1.27; Luthman J, 1998, AMINO ACIDS, V14, P263, DOI 10.1007/BF01345273; Martinez A, 2002, J MED CHEM, V45, P1292, DOI 10.1021/jm011020u; MATTSON MP, 1995, METHOD CELL BIOL, V46, P187; Meijer L, 2000, CHEM BIOL, V7, P51, DOI 10.1016/S1074-5521(00)00063-6; MunozMontano JR, 1997, FEBS LETT, V411, P183, DOI 10.1016/S0014-5793(97)00688-1; Murayama M, 1998, FEBS LETT, V433, P73, DOI 10.1016/S0014-5793(98)00886-2; OTVOS L, 1994, J NEUROSCI RES, V39, P669, DOI 10.1002/jnr.490390607; Pei JJ, 1999, J NEUROPATH EXP NEUR, V58, P1010, DOI 10.1097/00005072-199909000-00011; Phiel CJ, 2003, NATURE, V423, P435, DOI 10.1038/nature01640; Rapoport M, 2002, P NATL ACAD SCI USA, V99, P6364, DOI 10.1073/pnas.092136199; Salinas P C, 1999, Bipolar Disord, V1, P87, DOI 10.1034/j.1399-5618.1999.010205.x; Shiurba RA, 1996, BRAIN RES, V737, P119, DOI 10.1016/0006-8993(96)00717-2; Smith DG, 2001, BIOORG MED CHEM LETT, V11, P635, DOI 10.1016/S0960-894X(00)00721-6; STUDER L, 1994, J COMP NEUROL, V340, P281, DOI 10.1002/cne.903400212; TAKAHASHI M, 1994, J NEUROCHEM, V63, P245; Takashima A, 1996, NEUROSCI LETT, V203, P33, DOI 10.1016/0304-3940(95)12257-5; TAKASHIMA A, 1993, P NATL ACAD SCI USA, V90, P7789, DOI 10.1073/pnas.90.16.7789; Takashima A, 1998, P NATL ACAD SCI USA, V95, P9637, DOI 10.1073/pnas.95.16.9637; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208	52	427	450	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45937	45945		10.1074/jbc.M306268200	http://dx.doi.org/10.1074/jbc.M306268200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12928438	hybrid, Green Published			2022-12-25	WOS:000186452300107
J	Masumoto, K; Sakata, Y; Arima, K; Nakao, I; Izuhara, K				Masumoto, K; Sakata, Y; Arima, K; Nakao, I; Izuhara, K			Inhibitory mechanism of a cross-class serpin, the squamous cell carcinoma antigen 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATHEPSIN-K; PROTEINASE-INHIBITOR; MEDIATED APOPTOSIS; PROTEINASE-INHIBITOR-9; PYCNODYSOSTOSIS; CHYMOTRYPSIN; DEGRADATION; DEFICIENCY; TARGET; ENZYME	The squamous cell carcinoma antigen (SCCA) 1 and its homologous molecule, SCCA2, belong to the ovalbumin-serpin family. Although SCCA2 inhibits serine proteinases such as cathepsin G and mast cell chymase, SCCA1 targets cysteine proteinases such as cathepsin S, K, L, and papain. SCCA1 is therefore called a cross-class serpin. The inhibitory mechanism of the standard serpins is well characterized; those use a suicide substrate-like inhibitory mechanism during which an acyl-enzyme intermediate by a covalent bond is formed, and this complex is stable against hydrolysis. However, the inhibitory mechanism of cross-class serpins remains unresolved. In this article, we analyzed the inhibitory mechanism of SCCA1 on a cysteine proteinase, papain. SCCA1 interacted with papain at its reactive site loop, which was then cleaved, as the standard serpins. However, gel-filtration analyses showed that SCCA1 did not form a covalent complex with papain, in contrast to other serpins. Interaction with SCCA1 severely impaired the proteinase activity of papain, probably by inducing conformational change. The decreased, but still existing, proteinase activity of papain was completely inhibited by SCCA1 according to the suicide substrate-like inhibitory mechanism; however, papain recovered its proteinase activity with the compromised level, when all of intact SCCA1 was cleaved. These results suggest that the inhibitory mechanism of SCCA1 is unique among the serpin superfamily in that SCCA1 performs its inhibitory activity in two ways, contributing the suicide substrate-like mechanism without formation of a covalent complex and causing irreversible impairment of the catalytic activity of a proteinase.	Saga Med Sch, Dept Biomol Sci, Div Med Biochem, Saga 8498501, Japan; Saga Med Sch, Ctr Comprehens Community Med, Div Med Res, Saga 8498501, Japan	Saga University; Saga University	Izuhara, K (corresponding author), Saga Med Sch, Dept Biomol Sci, Div Med Biochem, 5-1-1 Nabeshima, Saga 8498501, Japan.		Arima, Kazuhiko/I-8962-2014	Arima, Kazuhiko/0000-0002-0607-8787				Annand RR, 1999, BIOCHEM J, V342, P655, DOI 10.1042/0264-6021:3420655; Bird CH, 1998, MOL CELL BIOL, V18, P6387, DOI 10.1128/MCB.18.11.6387; Bode W, 2000, BBA-PROTEIN STRUCT M, V1477, P241, DOI 10.1016/S0167-4838(99)00276-9; Cataltepe S, 2000, J HISTOCHEM CYTOCHEM, V48, P113, DOI 10.1177/002215540004800112; ENGHILD JJ, 1993, BIOCHEM J, V291, P933, DOI 10.1042/bj2910933; Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236; Hou WS, 1999, J CLIN INVEST, V103, P731, DOI 10.1172/JCI653; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; KATO H, 1977, CANCER, V40, P1621, DOI 10.1002/1097-0142(197710)40:4<1621::AID-CNCR2820400435>3.0.CO;2-I; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; Leung-Toung R, 2002, CURR MED CHEM, V9, P979, DOI 10.2174/0929867024606704; Luke C, 2000, BIOCHEMISTRY-US, V39, P7081, DOI 10.1021/bi000050g; McGettrick AF, 2001, EUR J BIOCHEM, V268, P5868, DOI 10.1046/j.0014-2956.2001.02535.x; Melo RL, 2001, BBA-PROTEIN STRUCT M, V1547, P82, DOI 10.1016/S0167-4838(01)00171-6; Murakami A, 2001, BRIT J CANCER, V84, P851, DOI 10.1054/bjoc.2000.1683; Nakagawa T, 1998, SCIENCE, V280, P450, DOI 10.1126/science.280.5362.450; Nakagawa TY, 1999, IMMUNITY, V10, P207, DOI 10.1016/S1074-7613(00)80021-7; QUAN LT, 1995, J BIOL CHEM, V270, P10377, DOI 10.1074/jbc.270.18.10377; Roth W, 2000, FASEB J, V14, P2075, DOI 10.1096/fj.99-0970com; Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453; Schick C, 1998, BIOCHEMISTRY-US, V37, P5258, DOI 10.1021/bi972521d; Schick C, 1997, J BIOL CHEM, V272, P1849, DOI 10.1074/jbc.272.3.1849; SCHNEIDER SS, 1995, P NATL ACAD SCI USA, V92, P3147, DOI 10.1073/pnas.92.8.3147; Shi GP, 1999, IMMUNITY, V10, P197, DOI 10.1016/S1074-7613(00)80020-5; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; Stennicke HR, 2002, TRENDS BIOCHEM SCI, V27, P94, DOI 10.1016/S0968-0004(01)02045-X; Suminami Y, 2000, BRIT J CANCER, V82, P981, DOI 10.1054/bjoc.1999.1028; TAKEDA A, 1995, FEBS LETT, V359, P78, DOI 10.1016/0014-5793(94)01456-B; Ye S, 2001, CURR OPIN STRUC BIOL, V11, P740, DOI 10.1016/S0959-440X(01)00275-5; Yuyama N, 2002, CYTOKINE, V19, P287, DOI 10.1006/cyto.2002.1972; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	31	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45296	45304		10.1074/jbc.M307741200	http://dx.doi.org/10.1074/jbc.M307741200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12949073	hybrid			2022-12-25	WOS:000186452300031
J	van't Slot, KAE; van den Burg, HA; Kloks, CPAM; Hilbers, CW; Knogge, W; Papavoine, CHM				van't Slot, KAE; van den Burg, HA; Kloks, CPAM; Hilbers, CW; Knogge, W; Papavoine, CHM			Solution structure of the plant disease resistance-triggering protein NIP1 from the fungus Rhynchosporium secalis shows a novel beta-sheet fold	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PATHOGEN CLADOSPORIUM-FULVUM; AVIRULENCE GENE-PRODUCT; RACE-SPECIFIC ELICITOR; COUPLING-CONSTANTS; SECONDARY STRUCTURE; BARLEY PATHOGEN; TOMATO; AVR9; PEPTIDES; CLEAVAGE	Activation of the disease resistance response in a host plant frequently requires the interaction of a plant resistance gene product with a corresponding, pathogen-derived signal encoded by an avirulence gene. The products of resistance genes from diverse plant species show remarkable structural similarity. However, due to the general paucity of information on pathogen avirulence genes the recognition process remains in most cases poorly understood. NIP1, a small protein secreted by the fungal barley pathogen Rhynchosporium secalis, is one of only a few fungal avirulence proteins identified and characterized to date. The defense-activating activity of NIP1 is mediated by barley resistance gene Rrs1. In addition, a role of the protein in fungal virulence is suggested by its nonspecific toxicity in leaf tissues of host and non-host cereals as well as its resistance gene-independent stimulatory effect on the plant plasma membrane H+-ATPase. Four naturally occurring NIP1 isoforms are characterized by single amino acid alterations that affect the different activities in a similar way. As a step toward unraveling the signal perception/transduction mechanism, the solution structure of NIP1 was determined. The protein structure is characterized by a novel fold. It consists of two parts containing beta-sheets of two and three anti-parallel strands, respectively. Five intramolecular disulfide bonds, comprising a novel disulfide bond pattern, stabilize these parts and their position with respect to each other. A comparative analysis of the protein structure with the properties of the NIP1 isoforms suggests two loop regions to be crucial for the resistance-triggering activity of NIP1.	Univ Adelaide, Sch Agr & Wine, Glen Osmond, SA 5064, Australia; AstraZeneca R&D, Med Chem, S-43183 Molndal, Sweden; Univ Wageningen & Res Ctr, Dept Plant Sci, Phytopathol Lab, NL-6709 PD Wageningen, Netherlands; Univ Wageningen & Res Ctr, Dept Biomol Sci, Biochem Lab, NL-6703 HA Wageningen, Netherlands; Univ Nijmegen, NSR Ctr, Dept Biophys Chem, NL-6500 HC Nijmegen, Netherlands	University of Adelaide; AstraZeneca; Wageningen University & Research; Wageningen University & Research; Radboud University Nijmegen	Knogge, W (corresponding author), Univ Adelaide, Sch Agr & Wine, Glen Osmond, SA 5064, Australia.	wolfgang.knogge@adelaide.edu.au		van den Burg, Harrold/0000-0003-4142-374X				BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; Cohn J, 2001, CURR OPIN IMMUNOL, V13, P55, DOI 10.1016/S0952-7915(00)00182-5; Creighton TE, 1983, PROTEINS STRUCTURES; Dangl JL, 2001, NATURE, V411, P826, DOI 10.1038/35081161; DEGANI Y, 1974, BIOCHEMISTRY-US, V13, P1, DOI 10.1021/bi00698a001; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Fiegen M, 2002, PHYSIOL MOL PLANT P, V61, P299, DOI 10.1006/pmpp.2002.0442; Galan JE, 1999, SCIENCE, V284, P1322, DOI 10.1126/science.284.5418.1322; Gierlich A, 1999, PROTEIN EXPRES PURIF, V17, P64, DOI 10.1006/prep.1999.1098; Gooley PR, 1998, J BIOMOL NMR, V12, P523, DOI 10.1023/A:1008395001008; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; HAHN M, 1993, MOL PLANT MICROBE IN, V6, P745, DOI 10.1094/MPMI-6-745; Jia Y, 2000, EMBO J, V19, P4004, DOI 10.1093/emboj/19.15.4004; KAY LE, 1990, J MAGN RESON, V86, P110, DOI 10.1016/0022-2364(90)90215-U; KoomanGersmann M, 1996, PLANT CELL, V8, P929, DOI 10.1105/tpc.8.5.929; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Lauge R, 1998, FUNGAL GENET BIOL, V24, P285, DOI 10.1006/fgbi.1998.1076; Luderer R, 2001, MOL PLANT MICROBE IN, V14, P867, DOI 10.1094/MPMI.2001.14.7.867; Mackey D, 2002, CELL, V108, P743, DOI 10.1016/S0092-8674(02)00661-X; PALMER AG, 1991, J AM CHEM SOC, V113, P4371, DOI 10.1021/ja00012a001; Perl D, 2000, NAT STRUCT BIOL, V7, P380; REES DC, 1982, J MOL BIOL, V160, P475, DOI 10.1016/0022-2836(82)90309-6; Rivas S, 2002, PLANT CELL, V14, P689, DOI [10.1105/tpc.010357, 10.​1105/​tpc.​010357]; ROHE M, 1995, EMBO J, V14, P4168, DOI 10.1002/j.1460-2075.1995.tb00090.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SZYPERSKI T, 1992, J MAGN RESON, V99, P552, DOI 10.1016/0022-2364(92)90209-P; van den Hooven HW, 2001, BIOCHEMISTRY-US, V40, P3458, DOI 10.1021/bi0023089; van der Biezen EA, 1998, TRENDS BIOCHEM SCI, V23, P454, DOI 10.1016/S0968-0004(98)01311-5; van't Slot KAE, 2002, CRIT REV PLANT SCI, V21, P229, DOI 10.1080/0735-260291044223; Vervoort J, 1997, FEBS LETT, V404, P153, DOI 10.1016/S0014-5793(97)00117-8; VUISTER GW, 1992, J BIOMOL NMR, V2, P401, DOI 10.1007/BF01874818; WEVELSIEP L, 1993, PLANT PHYSIOL, V101, P297, DOI 10.1104/pp.101.1.297; WEVELSIEP L, 1991, PHYSIOL MOL PLANT P, V39, P471, DOI 10.1016/0885-5765(91)90013-8; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Wu J, 1998, ANAL BIOCHEM, V258, P268, DOI 10.1006/abio.1998.2596; Wu J, 1997, PROTEIN SCI, V6, P391; Wu J, 1996, ANAL BIOCHEM, V235, P161, DOI 10.1006/abio.1996.0108; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Xia YL, 2000, J MAGN RESON, V146, P228, DOI 10.1006/jmre.2000.2140	40	18	18	0	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45730	45736		10.1074/jbc.M308304200	http://dx.doi.org/10.1074/jbc.M308304200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12944393	hybrid			2022-12-25	WOS:000186452300083
J	Vemula, M; Kandasamy, P; Oh, CS; Chellappa, R; Gonzalez, CI; Martin, CE				Vemula, M; Kandasamy, P; Oh, CS; Chellappa, R; Gonzalez, CI; Martin, CE			Maintenance and regulation of mRNA stability of the Saccharomyces cerevisiae OLE1 gene requires multiple elements within the transcript that act through translation-independent mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID DESATURASE; SACCHAROMYCES-CEREVISIAE; HYPOXIC INDUCTION; BINDING PROTEIN; YEAST; TURNOVER; DECAY; OLE1; DEADENYLATION; IDENTIFICATION	The Saccharomyces cerevisiae OLE1 gene encodes a membrane-bound Delta-9 fatty acid desaturase, whose expression is regulated by unsaturated fatty acids through both transcriptional and mRNA stability controls. In fatty acid-free medium, the mRNA has a half-life of 10+/-1.5 min (basal stability) that drops to 2+/-1.5 min when cells are exposed to unsaturated fatty acids (regulated stability). A deletion analysis of elements within the transcript revealed that the sequences within the protein-coding region that encode transmembrane sequences and a part of the cytochrome b(5) domain are essential for the basal stability of the transcript. Deletion of any of the three essential elements produced unstable transcripts and loss of regulated instability. By contrast, substitution of the 3'-untranslated region with that of the stable PGK1 gene did not affect the basal stability of the transcript and did not block regulated decay. Given that Ole1p is a membrane-bound protein whose activities are a major determinant of membrane fluidity, we asked whether membrane-associated translation of the protein was essential for basal and regulated stability. Insertion of stop codons within the transcript that blocked either translation of the entire protein or parts of the protein required for co-translation insertion of Ole1p had no effect. We conclude that the basal and regulated stability of the OLE1 transcript is resistant to the nonsense-mediated decay pathway and that the essential protein-encoding elements for basal stability act cooperatively as stabilizing sequences through RNA-protein interactions via a translation-independent mechanism.	Rutgers State Univ, Dept Cell Biol & Neurosci, Div Life Sci, Nelson Labs, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick	Martin, CE (corresponding author), Rutgers State Univ, Dept Cell Biol & Neurosci, Div Life Sci, Nelson Labs, 604 Allison Rd, Piscataway, NJ 08854 USA.	martin@biology.Rutgers.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045768] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45768] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allmang C, 1999, GENE DEV, V13, P2148, DOI 10.1101/gad.13.16.2148; Anderson JSJ, 1998, EMBO J, V17, P1497, DOI 10.1093/emboj/17.5.1497; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; BOSSIE MA, 1989, J BACTERIOL, V171, P6409, DOI 10.1128/jb.171.12.6409-6413.1989; Bousquet-Antonelli C, 2000, CELL, V102, P765, DOI 10.1016/S0092-8674(00)00065-9; CAPONIGRO G, 1993, MOL CELL BIOL, V13, P5141, DOI 10.1128/MCB.13.9.5141; CEREGHINO GP, 1995, MOL BIOL CELL, V6, P1125, DOI 10.1091/mbc.6.9.1125; Chellappa R, 2001, J BIOL CHEM, V276, P43548, DOI 10.1074/jbc.M107845200; Choi JY, 1996, J BIOL CHEM, V271, P3581; DECKER CJ, 1993, GENE DEV, V7, P1632, DOI 10.1101/gad.7.8.1632; Gonzalez CI, 1996, J BIOL CHEM, V271, P25801, DOI 10.1074/jbc.271.42.25801; HAGAN KW, 1995, MOL CELL BIOL, V15, P809; HE F, 1993, P NATL ACAD SCI USA, V90, P7034, DOI 10.1073/pnas.90.15.7034; HEATON B, 1992, NUCLEIC ACIDS RES, V20, P5365, DOI 10.1093/nar/20.20.5365; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Jiang YD, 2001, MOL CELL BIOL, V21, P6161, DOI 10.1128/MCB.21.18.6161-6169.2001; LaGrandeur T, 1999, RNA, V5, P420, DOI 10.1017/S1355838299981748; LOMBARDO A, 1992, MOL CELL BIOL, V12, P2941, DOI 10.1128/MCB.12.7.2941; Mitchell AG, 1997, J BIOL CHEM, V272, P28281, DOI 10.1074/jbc.272.45.28281; Mitchell P, 2000, CURR OPIN GENET DEV, V10, P193, DOI 10.1016/S0959-437X(00)00063-0; Mitchell P, 2001, CURR OPIN CELL BIOL, V13, P320, DOI 10.1016/S0955-0674(00)00214-3; MUHLRAD D, 1992, GENE DEV, V6, P2100, DOI 10.1101/gad.6.11.2100; MUHLRAD D, 1995, MOL CELL BIOL, V15, P2145; Prieto S, 2000, J BIOL CHEM, V275, P14155, DOI 10.1074/jbc.275.19.14155; Ruiz-Echevarria MJ, 2000, CELL, V101, P741, DOI 10.1016/S0092-8674(00)80886-7; Ruiz-Echevarria MJ, 1998, EMBO J, V17, P575, DOI 10.1093/emboj/17.2.575; Ruiz-Echevarria MJ, 2001, J BIOL CHEM, V276, P30995, DOI 10.1074/jbc.M010833200; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; Schwartz DC, 2000, MOL CELL BIOL, V20, P7933, DOI 10.1128/MCB.20.21.7933-7942.2000; Schwartz DC, 1999, MOL CELL BIOL, V19, P5247; Steiger M, 2003, RNA, V9, P231, DOI 10.1261/rna.2151403; STUKEY JE, 1989, J BIOL CHEM, V264, P16537; STUKEY JE, 1990, J BIOL CHEM, V265, P20144; van Hoof A, 1999, CELL, V99, P347, DOI 10.1016/S0092-8674(00)81520-2; Vasconcelles MJ, 2001, J BIOL CHEM, V276, P14374, DOI 10.1074/jbc.M009546200; Vasudevan S, 2001, MOL CELL, V7, P1191, DOI 10.1016/S1097-2765(01)00279-9; YEN TJ, 1988, NATURE, V334, P580, DOI 10.1038/334580a0	38	14	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45269	45279		10.1074/jbc.M308812200	http://dx.doi.org/10.1074/jbc.M308812200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12947098	hybrid			2022-12-25	WOS:000186452300028
J	Aon, MA; Cortassa, S; Marban, E; O'Rourke, B				Aon, MA; Cortassa, S; Marban, E; O'Rourke, B			Synchronized whole cell oscillations in mitochondrial metabolism triggered by a local release of reactive oxygen species in cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY TRANSITION PORE; ADENINE-NUCLEOTIDE CARRIER; DEPENDENT ANION CHANNEL; BENZODIAZEPINE-RECEPTOR; HEART-MITOCHONDRIA; ENERGY-METABOLISM; HYDROGEN-PEROXIDE; SUPEROXIDE ANION; SINGLE MITOCHONDRIA; ION CHANNELS	Reactive oxygen species (ROS) and/or Ca2+ overload can trigger depolarization of mitochondrial inner membrane potential (DeltaPsi(m)) and cell injury. Little is known about how loss of DeltaPsi(m) in a small number of mitochondria might influence the overall function of the cell. Here we employ the narrow focal excitation volume of the two-photon microscope to examine the effect of local mitochondrial depolarization in guinea pig ventricular myocytes. Remarkably, a single local laser flash triggered synchronized and self-sustained oscillations in DeltaPsi(m), NADH, and ROS after a delay of similar to40s, in more than 70% of the mitochondrial population. Oscillations were initiated only after a specific threshold level of mitochondrially produced ROS was exceeded, and did not involve the classical permeability transition pore or intracellular Ca2+ overload. The synchronized transitions were abolished by several respiratory inhibitors or a superoxide dismutase mimetic. Anion channel inhibitors potentiated matrix ROS accumulation in the flashed region, but blocked propagation to the rest of the myocyte, suggesting that an inner membrane, super-oxide-permeable, anion channel opens in response to free radicals. The transitions in mitochondrial energetics were tightly coupled to activation of sarcolemmal K-ATP currents, causing oscillations in action potential duration, and thus might contribute to catastrophic arrhythmias during ischemia-reperfusion injury.	Johns Hopkins Univ, Inst Mol Cardiobiol, Baltimore, MD 21205 USA	Johns Hopkins University	O'Rourke, B (corresponding author), Johns Hopkins Univ, Inst Mol Cardiobiol, 720 Rutland Ave,844 Ross Bldg, Baltimore, MD 21205 USA.	bor@jhmi.edu	Marban, Eduardo/GWC-8514-2022; Aon, Miguel Antonio/A-6564-2008; Cortassa, Sonia/AAO-1633-2020	Aon, Miguel Antonio/0000-0002-4355-5431; Cortassa, Sonia/0000-0001-7224-9858; O'Rourke, Brian/0000-0002-5548-4853	NHLBI NIH HHS [R01HL54598, R37HL36957] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL036957, R01HL054598] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aon MA., 1997, DYNAMIC BIOL ORG FUN, V1st edn; Baines CP, 1997, J MOL CELL CARDIOL, V29, P207, DOI 10.1006/jmcc.1996.0265; Beavis AD, 1996, J BIOENERG BIOMEMBR, V28, P207, DOI 10.1007/BF02110652; BEAVIS AD, 1992, J BIOENERG BIOMEMBR, V24, P77, DOI 10.1007/BF00769534; BEAVIS AD, 1989, J BIOL CHEM, V264, P1508; BOVERIS A, 1972, BIOCHEM J, V128, P617, DOI 10.1042/bj1280617; CADENAS E, 1977, ARCH BIOCHEM BIOPHYS, V180, P248, DOI 10.1016/0003-9861(77)90035-2; CADENAS E, 1980, BIOCHEM J, V188, P31, DOI 10.1042/bj1880031; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHANCE B, 1965, BIOCHEM Z, V341, P357; Cortassa S, 2003, BIOPHYS J, V84, P2734, DOI 10.1016/S0006-3495(03)75079-6; Crompton M, 1999, BIOCHEM SOC SYMP, V66, P167, DOI 10.1042/bss0660167; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Duchen MR, 1999, J PHYSIOL-LONDON, V516, P1, DOI 10.1111/j.1469-7793.1999.001aa.x; FAULKNER KM, 1994, J BIOL CHEM, V269, P23471; Freeman FM, 2000, PHARMACOL BIOCHEM BE, V67, P355, DOI 10.1016/S0091-3057(00)00373-7; Gardner PR, 1996, ARCH BIOCHEM BIOPHYS, V325, P20, DOI 10.1006/abbi.1996.0003; HALLIWELL B, 1997, INTRO FREE RADICALS, P1; Han D, 2003, J BIOL CHEM, V278, P5557, DOI 10.1074/jbc.M210269200; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Huser J, 1999, BIOCHEM J, V343, P311, DOI 10.1042/0264-6021:3430311; Huser J, 1998, BIOPHYS J, V74, P2129, DOI 10.1016/S0006-3495(98)77920-2; Ichas F, 1997, CELL, V89, P1145, DOI 10.1016/S0092-8674(00)80301-3; JosephLiauzun E, 1997, J BIOL CHEM, V272, P28102, DOI 10.1074/jbc.272.44.28102; KINNALLY KW, 1993, P NATL ACAD SCI USA, V90, P1374, DOI 10.1073/pnas.90.4.1374; KORETSUNE Y, 1990, AM J PHYSIOL, V258, pH9, DOI 10.1152/ajpheart.1990.258.1.H9; Korshunov SS, 1997, FEBS LETT, V416, P15, DOI 10.1016/S0014-5793(97)01159-9; Kowaltowski AJ, 1996, FEBS LETT, V378, P150, DOI 10.1016/0014-5793(95)01449-7; Kowaltowski AJ, 1999, FREE RADICAL BIO MED, V26, P463, DOI 10.1016/S0891-5849(98)00216-0; Kushnareva Y, 2002, BIOCHEM J, V368, P545, DOI 10.1042/BJ20021121; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; LOEW LM, 1993, BIOPHYS J, V65, P2396, DOI 10.1016/S0006-3495(93)81318-3; MCENERY MW, 1992, P NATL ACAD SCI USA, V89, P3170, DOI 10.1073/pnas.89.8.3170; MIYATA H, 1991, AM J PHYSIOL, V261, pH1123, DOI 10.1152/ajpheart.1991.261.4.H1123; Murphy MP, 2001, BBA-BIOENERGETICS, V1504, P1, DOI 10.1016/S0005-2728(00)00234-6; Nicholls D.G., 1992, BIOENERGETICS, V2, P22; O'Rourke B, 2000, J PHYSIOL-LONDON, V529, P23, DOI 10.1111/j.1469-7793.2000.00023.x; O'Rourke B, 1999, CURR TOP MEMBR, V46, P449; OROURKE B, 1994, SCIENCE, V265, P962, DOI 10.1126/science.8052856; Plas DR, 2002, TRENDS ENDOCRIN MET, V13, P74; Raha S, 2000, FREE RADICAL BIO MED, V29, P170, DOI 10.1016/S0891-5849(00)00338-5; Romashko DN, 1998, P NATL ACAD SCI USA, V95, P1618, DOI 10.1073/pnas.95.4.1618; Saks VA, 2001, BIOCHEM J, V356, P643, DOI 10.1042/0264-6021:3560643; SIEMENS A, 1982, P NATL ACAD SCI-BIOL, V79, P466, DOI 10.1073/pnas.79.2.466; SORGATO MC, 1987, NATURE, V330, P498, DOI 10.1038/330498a0; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; SZABO I, 1991, J BIOL CHEM, V266, P3376; TAKAHASHI MA, 1983, ARCH BIOCHEM BIOPHYS, V226, P558, DOI 10.1016/0003-9861(83)90325-9; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; Tsien Roger Y., 1995, P267; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; Vanden Hoek TL, 1998, J BIOL CHEM, V273, P18092, DOI 10.1074/jbc.273.29.18092; VandenHoek TL, 1997, J MOL CELL CARDIOL, V29, P2571, DOI 10.1006/jmcc.1997.0497; Xie ZJ, 1999, J BIOL CHEM, V274, P19323, DOI 10.1074/jbc.274.27.19323; Xu C, 1996, P NATL ACAD SCI USA, V93, P10763, DOI 10.1073/pnas.93.20.10763; Xu L, 1999, J BIOL CHEM, V274, P32680, DOI 10.1074/jbc.274.46.32680; Zorov DB, 2000, J EXP MED, V192, P1001, DOI 10.1084/jem.192.7.1001	60	407	425	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44735	44744		10.1074/jbc.M302673200	http://dx.doi.org/10.1074/jbc.M302673200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12930841	hybrid			2022-12-25	WOS:000186306700107
J	Gardoni, F; Mauceri, D; Fiorentini, C; Bellone, C; Missale, C; Cattabeni, F; Di Luca, M				Gardoni, F; Mauceri, D; Fiorentini, C; Bellone, C; Missale, C; Cattabeni, F; Di Luca, M			CaMKII-dependent phosphorylation regulates SAP97/NR2A interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-II; NMDA RECEPTOR SUBUNITS; SYNAPSE-ASSOCIATED PROTEIN-97; POSTSYNAPTIC DENSITY; PSD-95; BINDING; NR2A; MOTIFS; DLG	Synapse-associated protein 97 (SAP97), a member of membrane-associated guanylate kinase protein family, has been implicated in the processes of targeting ionotropic glutamate receptors at postsynaptic sites. Here we show that SAP97 is enriched at the postsynaptic density where it co-localizes with both ionotropic glutamate receptors and downstream signaling proteins such as Ca2+/calmodulin-dependent protein kinase II (CaMKII). SAP97 and alphaCaMKII display a high co-localization pattern in hippocampal neurons as well as in transfected COS-7 cells. Metabolic labeling of hippocampal cultures reveals that N-methyl-D-aspartic acid (NMDA) receptor activation induces CaMKII-dependent phosphorylation of SAP97; co-incubation with the CaMKII-specific inhibitor KN-93 reduces SAP97 phosphorylation to basal levels. Our results show that SAP97 directly interacts with the NR2A subunit of NMDA receptor both in an in vitro "pull-out" assay and in coimmunoprecipitation experiments from homogenates and synaptosomes purified from hippocampal rat tissue. Interestingly, in the postsynaptic density fraction, SAP97 fails to co-precipitate with NR2A. We show here that SAP97 is directly associated with NR2A through its PDZ1 domain, and CaMKII-dependent phosphorylation of SAP97-Ser-232 disrupts NR2A interaction both in an in vitro pull-out assay and in transfected COS-7 cells. Moreover, expression of SAP97(S232D) mutant has effects similar to those observed upon constitutively activating CaMKII. Our findings suggest that SAP97/NR2A interaction is regulated by CaMKII-dependent phosphorylation and provide a novel mechanism for the regulation of synaptic targeting of NMDA receptor subunits.	Univ Milan, Ctr Excellence Neurodegenerat Dis, I-20133 Milan, Italy; Univ Milan, Dept Pharmacol Sci, I-20133 Milan, Italy; Univ Brescia, Dept Biomed Sci & Biotechnol, Div Pharmacol, I-25124 Brescia, Italy	University of Milan; University of Milan; University of Brescia	Gardoni, F (corresponding author), Univ Milan, Ctr Excellence Neurodegenerat Dis, Via Balzaretti 9, I-20133 Milan, Italy.	Fabrizio.Gardoni@unimi.it	Missale, Mariacristina/E-6600-2010; Mauceri, Daniela/C-4969-2014; Gardoni, Fabrizio/A-3135-2009; DiLuca, Monica/A-7632-2012	Mauceri, Daniela/0000-0003-1225-4633; Gardoni, Fabrizio/0000-0003-4598-5563; DiLuca, Monica/0000-0003-2298-615X; bellone, camilla/0000-0002-6774-6275				Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; Bassand P, 1999, EUR J NEUROSCI, V11, P2031, DOI 10.1046/j.1460-9568.1999.00611.x; Cai C, 2002, J BIOL CHEM, V277, P31484, DOI 10.1074/jbc.M204354200; CARLIN RK, 1980, J CELL BIOL, V86, P831, DOI 10.1083/jcb.86.3.831; Chetkovich DM, 2002, J NEUROSCI, V22, P6415; Gardoni F, 1999, FEBS LETT, V456, P394, DOI 10.1016/S0014-5793(99)00985-0; Gardoni F, 1998, J NEUROCHEM, V71, P1733; Gardoni F, 2002, EUR J NEUROSCI, V16, P777, DOI 10.1046/j.1460-9568.2002.02141.x; Gardoni F, 2001, J NEUROSCI, V21, P1501, DOI 10.1523/JNEUROSCI.21-05-01501.2001; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; Goslin K., 1991, CULTURING NERVE CELL, P251; Koh YH, 1999, CELL, V98, P353, DOI 10.1016/S0092-8674(00)81964-9; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Lisman J, 2002, NAT REV NEUROSCI, V3, P175, DOI 10.1038/nrn753; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Niethammer M, 1996, J NEUROSCI, V16, P2157; Sans N, 2001, J NEUROSCI, V21, P7506, DOI 10.1523/JNEUROSCI.21-19-07506.2001; Sheng M, 2001, P NATL ACAD SCI USA, V98, P7058, DOI 10.1073/pnas.111146298; Tejedor FJ, 1997, J NEUROSCI, V17, P152, DOI 10.1523/JNEUROSCI.17-01-00152.1997; Valtschanoff JG, 2000, EUR J NEUROSCI, V12, P3605, DOI 10.1046/j.1460-9568.2000.00256.x; Wenthold RJ, 2003, ANNU REV PHARMACOL, V43, P335, DOI 10.1146/annurev.pharmtox.43.100901.135803; White RR, 1998, J BIOL CHEM, V273, P3166, DOI 10.1074/jbc.273.6.3166; Yoshimura Y, 2002, BIOCHEM BIOPH RES CO, V290, P948, DOI 10.1006/bbrc.2001.6320; Yoshimura Y, 2000, MOL BRAIN RES, V81, P118, DOI 10.1016/S0169-328X(00)00170-4	24	86	89	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44745	44752		10.1074/jbc.M303576200	http://dx.doi.org/10.1074/jbc.M303576200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12933808	hybrid			2022-12-25	WOS:000186306700108
J	Mahdi, F; Shariat-Madar, Z; Schmaier, AH				Mahdi, F; Shariat-Madar, Z; Schmaier, AH			The relative priority of Prekallikrein and factors XI/XIa assembly on cultured endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT KININOGEN; PLASMINOGEN-ACTIVATOR RECEPTOR; FACTOR-XI; CONSOLIDATION PHASE; FACTOR-IX; BINDING; PLATELETS; PLASMA; IDENTIFICATION; EXPRESSION	Investigations determined the relative preference of prekallikrein (PK) or factor XI/XIa (FXI/FXIa) binding to endothelial cells (HUVECs). In microtiter plates, biotinylated high molecular weight kininogen (biotin-HK) or biotin-FXI binding to HUVEC monolayers or their matrix proteins, but not fibronectin-coated plastic microtiter plate wells, was specifically blocked by antibodies to each of the receptors of HK, uPAR, gC1qR, or cytokeratin 1. Fluorescein isothiocyanate (FITC)-PK specifically bound to HUVEC suspensions without added Zn2+, whereas FITC-FXI or -FXIa binding to HUVEC suspensions required 10 muM added Zn2+ to support specific binding. Plasma concentrations of FXI did not block FITC-PK binding to HUVECs in the absence or presence of 10 muM Zn2+. In the absence of HK, the level of FITC-FXI or -FXIa binding was half that seen in its presence. At physiologic concentrations, PK (450 nM) abolished FITC-FXI or -FXIa binding to HUVEC suspensions in the absence or presence of HK in the presence of 10 muM Zn2+. Released Zn2+ from 2-8x10(8) collagen-activated platelets/ml supported biotin-FXI binding to HUVEC monolayers, but platelet activation was not necessary to support biotin-PK binding to HUVECs. At physiologic concentrations, PK also abolished FXI binding to HUVECs in the presence of activated platelets, but FXI did not influence PK binding. PK in the presence or absence of HK preferentially bound to HUVECs over FXI or FXIa. Elevated Zn2+ concentrations are required for FXI but not PK binding, but the presence of physiologic concentrations of PK and HK also prevented FXI binding. PK preferential binding to endothelial cells contributes to their anticoagulant nature.	Univ Michigan, Dept Internal Med, Div Hematol & Oncol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Schmaier, AH (corresponding author), Univ Michigan, Dept Internal Med & Pathol, Div Hematol & Oncol, 5301 MSRB 3,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	aschmaie@umich.edu	Schmaier, Alvin/AAM-1063-2020	Schmaier, Alvin/0000-0002-3884-6234	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052779] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52779] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baird TR, 2003, J BIOL CHEM, V278, P20618, DOI 10.1074/jbc.M300224200; Baird TR, 2002, J BIOL CHEM, V277, P28498, DOI 10.1074/jbc.M203427200; Baird TR, 2002, J BIOL CHEM, V277, P38462, DOI 10.1074/jbc.M205902200; Bax CMR, 1997, BIOL TRACE ELEM RES, V56, P255, DOI 10.1007/BF02785298; BERRETTINI M, 1992, J BIOL CHEM, V267, P19833; GORODETSKY R, 1993, AM J HEMATOL, V42, P278, DOI 10.1002/ajh.2830420307; GREENGARD JS, 1986, BIOCHEMISTRY-US, V25, P3884, DOI 10.1021/bi00361a022; Han ED, 2002, J CLIN INVEST, V109, P1057, DOI 10.1172/JCI200214211; Hasan AAK, 2003, AM J PHYSIOL-HEART C, V285, pH183, DOI 10.1152/ajpheart.00490.2002; HASAN AAK, 1995, BLOOD, V85, P3134, DOI 10.1182/blood.V85.11.3134.bloodjournal85113134; Ho DH, 2000, J BIOL CHEM, V275, P25139, DOI 10.1074/jbc.M001890200; Ho DH, 2000, BIOCHEMISTRY-US, V39, P316, DOI 10.1021/bi991851q; ICHINOSE A, 1986, J BIOL CHEM, V261, P3486; LENICH C, 1995, THROMB HAEMOSTASIS, V74, P698; Mahdi F, 2002, BLOOD, V99, P3585, DOI 10.1182/blood.V99.10.3585; Mahdi F, 2001, BLOOD, V97, P2342, DOI 10.1182/blood.V97.8.2342; Moreira CR, 2002, FEBS LETT, V523, P167, DOI 10.1016/S0014-5793(02)02980-0; Motta G, 2001, THROMB HAEMOSTASIS, V86, P840; Motta G, 1998, BLOOD, V91, P516, DOI 10.1182/blood.V91.2.516.516_516_528; Renne T, 2002, J BIOL CHEM, V277, P4892, DOI 10.1074/jbc.M105221200; Rojkjaer R, 1997, EUR J BIOCHEM, V247, P491, DOI 10.1111/j.1432-1033.1997.00491.x; Rojkjaer R, 1998, THROMB HAEMOSTASIS, V80, P74, DOI 10.1055/s-0037-1615142; SCHLEEF RR, 1990, J CELL BIOL, V110, P155, DOI 10.1083/jcb.110.1.155; SCHMAIER AH, 1988, J BIOL CHEM, V263, P16327; Shariat-Madar Z, 2002, INT IMMUNOPHARMACOL, V2, P1841, DOI 10.1016/S1567-5769(02)00178-9; Shariat-Madar Z, 2002, J BIOL CHEM, V277, P17962, DOI 10.1074/jbc.M106101200; Shariat-Madar Z, 2001, THROMB HAEMOSTASIS, V85, P544, DOI 10.1055/s-0037-1615619; Shariat-Madar Z, 1999, J BIOL CHEM, V274, P7137, DOI 10.1074/jbc.274.11.7137; Sheng N, 2000, BLOOD, V95, P3788; SINHA D, 1984, J CLIN INVEST, V73, P1550, DOI 10.1172/JCI111361; VANIWAARDEN F, 1988, J BIOL CHEM, V263, P4698; WHITEHOUSE RC, 1982, CLIN CHEM, V28, P475; Zhao YQ, 2001, AM J PHYSIOL-HEART C, V280, pH1821, DOI 10.1152/ajpheart.2001.280.4.H1821	33	24	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					43983	43990		10.1074/jbc.M304239200	http://dx.doi.org/10.1074/jbc.M304239200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12944405	hybrid			2022-12-25	WOS:000186306700013
J	Marsin, S; Vidal, AE; Sossou, M; Menissier-de Murcia, J; Le Page, F; Boiteux, S; de Murcia, G; Radicella, JP				Marsin, S; Vidal, AE; Sossou, M; Menissier-de Murcia, J; Le Page, F; Boiteux, S; de Murcia, G; Radicella, JP			Role of XRCC1 in the coordination and stimulation of oxidative DNA damage repair initiated by the DNA glycosylase hOGG1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; STRAND BREAK REPAIR; POLYMERASE-BETA; LIGASE III; POLY(ADP-RIBOSE) POLYMERASE; SUBSTRATE-SPECIFICITY; AP-ENDONUCLEASE; PROTEIN XRCC1; GENE; POLYMORPHISMS	XRCC1 participates in DNA single strand break and base excision repair (BER) to preserve genetic stability in mammalian cells. XRCC1 participation in these pathways is mediated by its interactions with several of the acting enzymes. Here, we report that XRCC1 interacts physically and functionally with hOGG1, the human DNA glycosylase that initiates the repair by BER of the mutagenic oxidized base 8-oxoguanine. This interaction leads to a 2- to 3-fold stimulation of the DNA glycosylase activity of hOGG1. XRCC1 stimulates the formation of the hOGG1 Schiff-base DNA intermediate without interfering with the endonuclease activity of APE1, the second enzyme in the pathway. On the contrary, the stimulation in the appearance of the incision product seems to reflect the addition of the effects of XRCC1 on the two first enzymes of the pathway. The data presented support a model by which XRCC1 will pass on the DNA intermediate from hOGG1 to the endonuclease APE1. This results in an acceleration of the overall repair process of oxidized purines to yield an APE1-cleaved abasic site, which can be used as a substrate by DNA polymerase beta. More importantly, the results unveil a highly coordinated mechanism by which XRCC1, through its multiple protein-protein interactions, extends its orchestrating role from the base excision step to the resealing of the repaired DNA strand.	Commissariat Energie Atom, UMR 217 CNRS, Dept Radiobiol & Radiopathol, F-92265 Fontenay Aux Roses, France; Univ Strasbourg 1, UPR 9003 CNRS, Ecole Super Biotechnol Strasbourg, F-67412 Illkirch Graffenstaden, France	CEA; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Radicella, JP (corresponding author), Commissariat Energie Atom, UMR 217 CNRS, Dept Radiobiol & Radiopathol, BP6, F-92265 Fontenay Aux Roses, France.	jpradicella@cea.fr	Radicella, J. Pablo/AAU-3178-2020; Vidal, Antonio/ABE-5693-2020	Radicella, J. Pablo/0000-0002-8807-7226; Vidal, Antonio/0000-0001-9491-8901; MARSIN, Stephanie/0000-0002-7074-7818				Allinson SL, 2001, EMBO J, V20, P6919, DOI 10.1093/emboj/20.23.6919; Audebert M, 2002, DNA REPAIR, V1, P497, DOI 10.1016/S1568-7864(02)00034-4; Audebert M, 2000, NUCLEIC ACIDS RES, V28, P2672, DOI 10.1093/nar/28.14.2672; Boiteux S, 1999, NATO ADV SCI I A-LIF, V302, P35; Caldecott KW, 1996, NUCLEIC ACIDS RES, V24, P4387, DOI 10.1093/nar/24.22.4387; Caldecott KW, 2001, BIOESSAYS, V23, P447, DOI 10.1002/bies.1063; CALDECOTT KW, 1994, MOL CELL BIOL, V14, P68, DOI 10.1128/MCB.14.1.68; Caldecott KW, 1995, NUCLEIC ACIDS RES, V23, P4836, DOI 10.1093/nar/23.23.4836; Callebaut I, 1997, CELL MOL LIFE SCI, V53, P621, DOI 10.1007/s000180050082; Chen SQ, 2002, CARCINOGENESIS, V23, P1321, DOI 10.1093/CARCIN/23.8.1321; Dantzer F, 2000, BIOCHEMISTRY-US, V39, P7559, DOI 10.1021/bi0003442; Fortini P, 1999, J BIOL CHEM, V274, P15230, DOI 10.1074/jbc.274.21.15230; Hill JW, 2001, NUCLEIC ACIDS RES, V29, P430, DOI 10.1093/nar/29.2.430; Hu JJ, 2002, ENVIRON MOL MUTAGEN, V39, P208, DOI 10.1002/em.10058; Kubota Y, 2003, DNA REPAIR, V2, P407, DOI 10.1016/S1568-7864(02)00242-2; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; Ladiges W, 2003, MECH AGEING DEV, V124, P27, DOI 10.1016/S0047-6374(02)00166-5; Le Page F, 2003, J BIOL CHEM, V278, P18471, DOI 10.1074/jbc.M212905200; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; Marintchev A, 1999, NAT STRUCT BIOL, V6, P884; Marintchev A, 2000, NUCLEIC ACIDS RES, V28, P2049, DOI 10.1093/nar/28.10.2049; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; Miller J. H., 1982, EXPT MOL GENETICS; Nash HM, 1997, CHEM BIOL, V4, P693, DOI 10.1016/S1074-5521(97)90225-8; Nash RA, 1997, BIOCHEMISTRY-US, V36, P5207, DOI 10.1021/bi962281m; Prasad R, 2001, J BIOL CHEM, V276, P32411, DOI 10.1074/jbc.C100292200; Rice PA, 1999, NAT STRUCT BIOL, V6, P805, DOI 10.1038/12257; Rothwell DG, 2000, NUCLEIC ACIDS RES, V28, P2207, DOI 10.1093/nar/28.11.2207; Schreiber V, 2002, J BIOL CHEM, V277, P23028, DOI 10.1074/jbc.M202390200; Seedhouse C, 2002, BLOOD, V100, P3761, DOI 10.1182/blood-2002-04-1152; Smith TR, 2003, CANCER LETT, V190, P183, DOI 10.1016/S0304-3835(02)00595-5; Stern MC, 2002, CANCER EPIDEM BIOMAR, V11, P939; Taylor RM, 2000, MOL CELL BIOL, V20, P735, DOI 10.1128/MCB.20.2.735-740.2000; Taylor RM, 1998, CURR BIOL, V8, P877, DOI 10.1016/S0960-9822(07)00350-8; Tebbs RS, 1999, DEV BIOL, V208, P513, DOI 10.1006/dbio.1999.9232; THOMPSON LH, 1990, MOL CELL BIOL, V10, P6160, DOI 10.1128/MCB.10.12.6160; Thompson LH, 2000, MUTAT RES-DNA REPAIR, V459, P1, DOI 10.1016/S0921-8777(99)00058-0; van Gils CH, 2002, CANCER EPIDEM BIOMAR, V11, P1279; Vidal AE, 2001, EMBO J, V20, P6530, DOI 10.1093/emboj/20.22.6530; Vidal AE, 2001, NUCLEIC ACIDS RES, V29, P1285, DOI 10.1093/nar/29.6.1285; Whitehouse CJ, 2001, CELL, V104, P107, DOI 10.1016/S0092-8674(01)00195-7; Wilson SH, 2000, NAT STRUCT BIOL, V7, P176; Zharkov DO, 2000, J BIOL CHEM, V275, P28607, DOI 10.1074/jbc.M002441200	43	202	209	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44068	44074		10.1074/jbc.M306160200	http://dx.doi.org/10.1074/jbc.M306160200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12933815	hybrid			2022-12-25	WOS:000186306700023
J	Fan, XL; Liu, Y; Chen, JJ				Fan, XL; Liu, Y; Chen, JJ			Activation of c-Myc contributes to bovine papillomavirus type 1 E7-induced cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPEN READING FRAME; DIHYDROFOLATE-REDUCTASE PROMOTER; RETINOBLASTOMA FAMILY PROTEINS; CYCLE PROGRESSION; TRANSFORMING GENE; E7 PROTEINS; INHIBITOR P27(KIP1); DEPENDENT KINASES; GROWTH-REGULATION; PRB/E2F PATHWAY	Inactivation of the tumor suppressor pRB by the human papillomavirus (HPV) oncoprotein E7 is a mechanism by which HPV promotes cell growth. The bovine papillomavirus type 1 (BPV-1) E7 does not bind pRB efficiently yet is required for full transformation of murine cells by BPV-1. In the present study, we investigated the mechanism of BPV-1 E7-induced cell proliferation. Our studies indicate that expression of BPV-1 E7 induces DNA synthesis and stimulates cells to enter S phase in quiescent cells. The induction of cell proliferation by BPV-1 E7 can occur in the retinoblastoma gene (Rb)-null cells, suggesting an Rb-independent mechanism. Consistent with this observation, BPV-1 E7 does not efficiently activate the transcription of the E2F family of transcription factors (E2F)-responsive promoters. Notably, c-Myc is able to induce cells to enter S phase in quiescent cells through an Rb/E2F-independent pathway. Significantly, c-Myc levels are increased in BPV-1 E7-expressing cells. Moreover, expression of a dominant negative c-Myc mutant inhibited BPV-1 E7-induced DNA synthesis. Consistent with the notion that c-Myc could down-regulate p27 and activate Cdk2, p27 level is decreased while both cyclin A and cyclin E-associated kinase activities are up-regulated in BPV-1 E7-expressing cells. These studies indicate an important role for c-Myc in BPV-1 E7-induced cell proliferation.	Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Chen, JJ (corresponding author), Univ Massachusetts, Sch Med, Dept Med, NRB Rm 323,364 Plantat St, Worcester, MA 01605 USA.				PHS HHS [F32] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; Armstrong DJ, 1997, VIROLOGY, V239, P238, DOI 10.1006/viro.1997.8885; Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; Berezutskaya E, 1997, CELL GROWTH DIFFER, V8, P1277; Berns K, 2000, ONCOGENE, V19, P4822, DOI 10.1038/sj.onc.1203879; Berns K, 1997, ONCOGENE, V15, P1347, DOI 10.1038/sj.onc.1201280; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Classon M, 2001, EXP CELL RES, V264, P135, DOI 10.1006/excr.2000.5135; DIMAIO D, 1986, P NATL ACAD SCI USA, V83, P1797, DOI 10.1073/pnas.83.6.1797; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Gewin L, 2001, J VIROL, V75, P7198, DOI 10.1128/JVI.75.15.7198-7201.2001; GROFF DE, 1986, VIROLOGY, V150, P221, DOI 10.1016/0042-6822(86)90281-3; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; Hiraiwa A, 1996, VIRUS GENES, V12, P27, DOI 10.1007/BF00369998; Howley M. P., 1996, FIELDS VIROLOGY, P2045; JAREBORG N, 1992, J VIROL, V66, P4957, DOI 10.1128/JVI.66.8.4957-4965.1992; Jiang W, 1998, BIOTECHNIQUES, V24, P349; Katich SC, 2001, ONCOGENE, V20, P543, DOI 10.1038/sj.onc.1204130; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Leng XH, 1997, CURR BIOL, V7, P709, DOI 10.1016/S0960-9822(06)00301-0; Liu Y, 2000, J BIOL CHEM, V275, P30894, DOI 10.1074/jbc.M000640200; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; McArthur GA, 2002, MOL CELL BIOL, V22, P3014, DOI 10.1128/MCB.22.9.3014-3023.2002; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; Morozov A, 1997, J VIROL, V71, P3451, DOI 10.1128/JVI.71.5.3451-3457.1997; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; MUNGER K, 1991, J VIROL, V65, P3943; NEARY K, 1989, J VIROL, V63, P259, DOI 10.1128/JVI.63.1.259-266.1989; Nguyen DX, 2002, J VIROL, V76, P619, DOI 10.1128/JVI.76.2.619-632.2002; PATRICK DR, 1994, J BIOL CHEM, V269, P6842; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; Santoni-Rugiu E, 2000, MOL CELL BIOL, V20, P3497, DOI 10.1128/MCB.20.10.3497-3509.2000; SCHILLER JT, 1984, P NATL ACAD SCI-BIOL, V81, P7880, DOI 10.1073/pnas.81.24.7880; SCHILLER JT, 1986, J VIROL, V57, P1; SCHLEGEL R, 1986, SCIENCE, V233, P464, DOI 10.1126/science.3014660; SEDMAN SA, 1992, J VIROL, V66, P4201, DOI 10.1128/JVI.66.7.4201-4208.1992; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; STOREY A, 1990, J GEN VIROL, V71, P165, DOI 10.1099/0022-1317-71-1-165; VANDEPOL SB, 1995, J VIROL, V69, P395, DOI 10.1128/JVI.69.1.395-402.1995; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; VOUSDEN KH, 1988, ONCOGENE RES, V3, P167; WADE M, 1992, MOL CELL BIOL, V12, P4364, DOI 10.1128/MCB.12.10.4364; Wang SY, 1998, J CELL PHYSIOL, V176, P456, DOI 10.1002/(SICI)1097-4652(199809)176:3<456::AID-JCP2>3.0.CO;2-N; Yang W, 2001, ONCOGENE, V20, P1688, DOI 10.1038/sj.onc.1204245; ZerfassThome K, 1996, ONCOGENE, V13, P2323; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	54	8	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43163	43168		10.1074/jbc.M306008200	http://dx.doi.org/10.1074/jbc.M306008200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12937171	hybrid			2022-12-25	WOS:000186157000057
J	Hikino, M; Mikami, T; Faissner, A; Vilela-Silva, ACES; Pavao, MSG; Sugahara, K				Hikino, M; Mikami, T; Faissner, A; Vilela-Silva, ACES; Pavao, MSG; Sugahara, K			Oversulfated dermatan sulfate exhibits neurite outgrowth-promoting activity toward embryonic mouse hippocampal neurons - Implications of dermatan sulfate in neuritogenesis in the brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-ASSOCIATED MOLECULE; PHOSPHATASE ZETA/RPTP-BETA; AMYLOID PRECURSOR PROTEIN; HEPARIN COFACTOR-II; CHONDROITIN-SULFATE; IN-VITRO; HB-GAM; HEXASACCHARIDE SEQUENCES; ANTICOAGULANT ACTIVITY; INHIBITORY MOLECULES	Brain-specific chondroitin sulfate (CS) proteoglycan (PG) DSD-1-PG/6B4-PG/phosphacan isolated from neonatal mouse brains exhibits neurite outgrowth-promoting activity toward embryonic rat and mouse hippocampal neurons in vitro through the so-called DSD-1 epitope embedded in its glycosaminoglycan side chains. Oversulfated CS variants, CS-D from shark cartilage and CS-E from squid cartilage, also possess similar activities. We have proposed that the neuritogenic property of the DSD-1 epitope may be attributable to a distinct CS structure characterized by the disulfated D disaccharide unit [GlcUA(2S)-GalNAc(6S)]. In this study, we assessed neuritogenic potencies of various oversulfated dermatan sulfate (DS) preparations purified from hagfish notochord, the bodies of two kinds of ascidians and embryonic sea urchin, which are characterized by the predominant disulfated disaccharide units of [IdoUA-GalNAc(4S,6S)] (68%), [IdoUA(2S)-GalNAc(4S)](66%) plus [IdoUA(2S)-GalNAc(6S)](5%), [IdoUA(2S)-GalNAc (6S)] (>90%), and [IdoUA-GalNAc(4S,6S)] (74%), respectively. They exerted marked neurite outgrowth-promoting activities, resulting in distinct morphological features depending on the individual structural features. Such activities were not observed for a less sulfated DS preparation derived from porcine skin, which has a monosulfated disaccharide unit [IdoUA-GalNAc(4S)] as a predominant unit. The neurite outgrowth-promoting activities of these oversulfated DS preparations and DSD-1-PG were eliminated by the specific enzymatic cleavage of GalNAc-IdoUA linkages characteristic of DS using chondroitinase B. In addition, chemical analysis of the glycosaminoglycan side chains of DSD-1-PG revealed the DS-type structures. These observations suggest potential novel neurobiological functions of oversulfated DS structures and may reflect the physiological neuritogenesis during brain development by mammalian oversulfated DS structures exemplified by the DSD-1 epitope.	Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan; Ruhr Univ Bochum, Dept Cell Morphol & Mol Neurobiol, D-44801 Bochum, Germany; Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Bioquim,Lab Tecido Conjunt, Hosp Univ Clementino Fraga Filho, BR-21941590 Rio De Janeiro, Brazil	Kobe Pharmaceutical University; Ruhr University Bochum; Universidade Federal do Rio de Janeiro	Sugahara, K (corresponding author), Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, 4-19-1 Motoyamakita Machi, Kobe, Hyogo 6588558, Japan.		Pavao, Mauro Sergio Goncalves/B-1979-2010; Faissner, Andreas/A-5314-2008	Pavao, Mauro Sergio Goncalves/0000-0002-1336-4271; Faissner, Andreas/0000-0002-2211-8259				ANNO K, 1971, BIOCHIM BIOPHYS ACTA, V237, P173, DOI 10.1016/0304-4165(71)90046-8; Bandtlow CE, 2000, PHYSIOL REV, V80, P1267, DOI 10.1152/physrev.2000.80.4.1267; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; CACERES A, 1986, J NEUROSCI, V6, P714; CHAMAK B, 1989, DEVELOPMENT, V106, P483; Clement AM, 1999, NEUROSCI LETT, V269, P125, DOI 10.1016/S0304-3940(99)00432-2; Clement AM, 1998, J BIOL CHEM, V273, P28444, DOI 10.1074/jbc.273.43.28444; Davies SJA, 1997, NATURE, V390, P680, DOI 10.1038/37776; DEBUS E, 1983, DIFFERENTIATION, V25, P193, DOI 10.1111/j.1432-0436.1984.tb01355.x; Deepa SS, 2002, J BIOL CHEM, V277, P43707, DOI 10.1074/jbc.M207105200; Elefteriou F, 2001, FEBS LETT, V495, P44, DOI 10.1016/S0014-5793(01)02361-4; FAISSNER A, 1995, GLIA, V13, P233, DOI 10.1002/glia.440130402; FAISSNER A, 1994, J CELL BIOL, V126, P783, DOI 10.1083/jcb.126.3.783; FernaudEspinosa I, 1996, J NEUROBIOL, V30, P410, DOI 10.1002/(SICI)1097-4695(199607)30:3<410::AID-NEU9>3.0.CO;2-7; Garwood J, 1999, J NEUROSCI, V19, P3888; HIKINO M, 2002, SEIKAGAKU, V74, P734; Huston JP, 2000, NEUROSCIENCE, V100, P355, DOI 10.1016/S0306-4522(00)00270-0; Kaneda N, 1996, J BIOCHEM-TOKYO, V119, P1150; Kappler J, 1997, EUR J NEUROSCI, V9, P306, DOI 10.1111/j.1460-9568.1997.tb01401.x; Kawashima H, 2002, J BIOL CHEM, V277, P12921, DOI 10.1074/jbc.M200396200; Kim BT, 2001, P NATL ACAD SCI USA, V98, P7176, DOI 10.1073/pnas.131188498; Kinoshita A, 1997, J BIOL CHEM, V272, P19656, DOI 10.1074/jbc.272.32.19656; Kinoshita A, 1999, ANAL BIOCHEM, V269, P367, DOI 10.1006/abio.1999.4027; Kitagawa H, 1997, J BIOL CHEM, V272, P31377, DOI 10.1074/jbc.272.50.31377; Kobayashi M, 1999, J BIOL CHEM, V274, P10474, DOI 10.1074/jbc.274.15.10474; Koops A, 1996, MOL BRAIN RES, V41, P65, DOI 10.1016/0169-328X(96)00067-8; LAFONT F, 1992, DEVELOPMENT, V114, P17; LAFONT F, 1994, DEV BIOL, V165, P453, DOI 10.1006/dbio.1994.1267; Lander A D, 1993, Curr Opin Neurobiol, V3, P716, DOI 10.1016/0959-4388(93)90143-M; LOCHTER A, 1993, J NEUROSCI, V13, P3986; Lyon M, 1998, J BIOL CHEM, V273, P271, DOI 10.1074/jbc.273.1.271; MAEDA N, 1992, DEV BIOL, V151, P564, DOI 10.1016/0012-1606(92)90194-L; Maeda N, 2003, J BIOL CHEM, V278, P35805, DOI 10.1074/jbc.M305530200; Maeda N, 1996, J BIOL CHEM, V271, P21446, DOI 10.1074/jbc.271.35.21446; Maeda N, 1998, J CELL BIOL, V142, P203, DOI 10.1083/jcb.142.1.203; MAIMONE MM, 1990, J BIOL CHEM, V265, P18263; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; MURAMATSU H, 1991, BIOCHEM BIOPH RES CO, V177, P652, DOI 10.1016/0006-291X(91)91838-4; Muramatsu T, 2001, TRENDS GLYCOSCI GLYC, V13, P563, DOI 10.4052/tigg.13.563; Nadanaka S, 1998, J BIOL CHEM, V273, P3296, DOI 10.1074/jbc.273.6.3296; Niederost BP, 1999, J NEUROSCI, V19, P8979, DOI 10.1523/JNEUROSCI.19-20-08979.1999; Oohira A, 2000, ARCH BIOCHEM BIOPHYS, V374, P24, DOI 10.1006/abbi.1999.1598; Oohira A, 2000, ARCH BIOCHEM BIOPHYS, V378, P78, DOI 10.1006/abbi.2000.1775; Pavao MSG, 1995, J BIOL CHEM, V270, P31027, DOI 10.1074/jbc.270.52.31027; Pavao MSG, 1998, J BIOL CHEM, V273, P27848, DOI 10.1074/jbc.273.43.27848; Pizzorusso T, 2002, SCIENCE, V298, P1248, DOI 10.1126/science.1072699; POOLE AR, 1986, BIOCHEM J, V236, P1; PROCHIANTZ A, 1995, NEURON, V15, P743, DOI 10.1016/0896-6273(95)90164-7; Rauvala H, 2000, MATRIX BIOL, V19, P377, DOI 10.1016/S0945-053X(00)00084-6; RAUVALA H, 1989, EMBO J, V8, P2933, DOI 10.1002/j.1460-2075.1989.tb08443.x; ROSEN L, 1980, BIOCH GLYCOPROTEINS, P491; ROUSSELET A, 1990, DEV BIOL, V137, P33, DOI 10.1016/0012-1606(90)90005-4; SAIGO K, 1970, J NEUROCHEM, V17, P633, DOI 10.1111/j.1471-4159.1970.tb00543.x; Salinero O, 2000, J NEUROSCI RES, V60, P87, DOI 10.1002/(SICI)1097-4547(20000401)60:1<87::AID-JNR9>3.0.CO;2-C; SCULLY MF, 1988, BIOCHEM J, V254, P547, DOI 10.1042/bj2540547; SMITHTHOMAS LC, 1995, J CELL SCI, V108, P1307; SUGAHARA K, 1995, J BIOL CHEM, V270, P7204, DOI 10.1074/jbc.270.13.7204; Sugahara K, 1996, J BIOL CHEM, V271, P26745, DOI 10.1074/jbc.271.43.26745; Sugahara K, 2000, CURR OPIN STRUC BIOL, V10, P518, DOI 10.1016/S0959-440X(00)00125-1; Sugahara K, 2000, TRENDS GLYCOSCI GLYC, V12, P321, DOI 10.4052/tigg.12.321; Trowbridge JM, 2002, J BIOL CHEM, V277, P42815, DOI 10.1074/jbc.M204959200; Tsuchida K, 2001, J BIOL CHEM, V276, P37155, DOI 10.1074/jbc.M105818200; Uchimura K, 2002, J BIOL CHEM, V277, P1443, DOI 10.1074/jbc.M104719200; Ueoka C, 2000, J BIOL CHEM, V275, P37407, DOI 10.1074/jbc.M002538200; Ueoka C, 1999, GLYCOCONJUGATE J, V16, P291, DOI 10.1023/A:1007022229813; Vilela-Silva ACES, 2001, GLYCOBIOLOGY, V11, P433, DOI 10.1093/glycob/11.6.433; Yoshida K., 1993, DERMATAN SULFATE PRO, P55; Zou P, 2003, GLYCOBIOLOGY, V13, P35, DOI 10.1093/glycob/cwg001	68	104	108	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43744	43754		10.1074/jbc.M308169200	http://dx.doi.org/10.1074/jbc.M308169200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12917413	hybrid			2022-12-25	WOS:000186157000124
J	McCarthy, TL; Chang, WZ; Liu, Y; Centrella, M				McCarthy, TL; Chang, WZ; Liu, Y; Centrella, M			Runx2 integrates estrogen activity in osteoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; FETAL-RAT BONE; TRANSCRIPTION FACTOR CBFA1; I RECEPTOR PROMOTER; CELL-CULTURES; COLLAGEN-SYNTHESIS; GENE-EXPRESSION; BINDING DOMAIN; CROSS-TALK; GLUCOCORTICOID RECEPTOR	Steroids significantly effect skeletal integrity. For example, bone mass decreases with glucocorticoid excess or with estrogen depletion after menopause. Glucocorticoid suppresses gene expression by an essential skeletal tissue transcription factor, Runx2, in rat osteoblasts. We now report that estrogen enhances Runx2 activity in dose- and estrogen receptor-dependent ways independently of changes in Runx2 levels or its DNA binding potential. Estrogen receptor and Runx2 can be collected by co-immunoprecipitation. By two-hybrid gene expression analysis, high affinity complex formation involves portions of Runx2 outside of its own DNA binding domain and the DNA binding domain of the estrogen receptor. Consistent with this interaction, the stimulatory effect of estrogen on Runx2 activity is lost when the DNA binding domain of the estrogen receptor is eliminated. Unlike the stimulatory effect of estrogen and the inhibitory effect of glucocorticoid, androgen fails to increase Runx2 activity, whereas Runx2 potently suppresses gene expression induced by all three steroids. Finally, estrogen increases gene transcription by the transforming growth factor-beta type I receptor gene promoter, which contains several Runx binding sequences, and enhances Smad dependent gene expression by transforming growth factor-beta in osteoblasts. These results reveal that Runx2 can integrate complex effects on gene transcription in hormone-, growth factor-, and tissue-restricted ways.	Yale Univ, Sch Med, Dept Surg, New Haven, CT 06520 USA	Yale University	McCarthy, TL (corresponding author), 333 Cedar St,POB 208041, New Haven, CT 06520 USA.	thomas.mccarthy@yale.edu			NIAMS NIH HHS [AR 39201] Funding Source: Medline; NIDDK NIH HHS [DK 56310] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039201, R29AR039201] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056310] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adya N, 2000, SEMIN CELL DEV BIOL, V11, P361, DOI 10.1006/scdb.2000.0189; Amanatullah D F, 2002, Minerva Endocrinol, V27, P7; Aubin JE, 1999, J CELL BIOCHEM, V72, P396, DOI 10.1002/(SICI)1097-4644(19990301)72:3<396::AID-JCB9>3.3.CO;2-Y; Batra GS, 2003, J PATHOL, V200, P65, DOI 10.1002/path.1332; Beavan S, 2001, J BONE MINER RES, V16, P1496, DOI 10.1359/jbmr.2001.16.8.1496; Bijlsma JWJ, 1999, ANN NY ACAD SCI, V876, P366, DOI 10.1111/j.1749-6632.1999.tb07659.x; Bjornstrom L, 2002, J BIOL CHEM, V277, P48479, DOI 10.1074/jbc.C200570200; Bodine PVN, 1998, ENDOCRINOLOGY, V139, P2048, DOI 10.1210/en.139.4.2048; Bonnelye E, 2002, J BONE MINER RES, V17, P1392, DOI 10.1359/jbmr.2002.17.8.1392; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Carpenter TO, 1998, ENDOCRINOLOGY, V139, P35, DOI 10.1210/en.139.1.35; Cato A., 2002, SCI STKE; Centrella M, 1997, J CELL BIOCHEM, V67, P528, DOI 10.1002/(SICI)1097-4644(19971215)67:4<528::AID-JCB10>3.3.CO;2-5; CENTRELLA M, 1994, ENDOCRINOLOGY, V135, P1611, DOI 10.1210/en.135.4.1611; CENTRELLA M, 1989, ENDOCRINOLOGY, V125, P199, DOI 10.1210/endo-125-1-199; Centrella M, 1996, ANN NY ACAD SCI, V785, P224, DOI 10.1111/j.1749-6632.1996.tb56267.x; CENTRELLA M, 1987, J BIOL CHEM, V262, P2869; Chang DJ, 1998, J BIOL CHEM, V273, P4892, DOI 10.1074/jbc.273.9.4892; Chen TK, 1996, MOL CARCINOGEN, V15, P215, DOI 10.1002/(SICI)1098-2744(199603)15:3<215::AID-MC7>3.0.CO;2-G; Gohel A, 1999, ENDOCRINOLOGY, V140, P5339, DOI 10.1210/en.140.11.5339; Greenfield EM, 1999, LIFE SCI, V65, P1087, DOI 10.1016/S0024-3205(99)00156-3; Hsiao PW, 2002, BIOCHEM CELL BIOL, V80, P343, DOI 10.1139/O02-082; Ireland DC, 2002, J CELL BIOCHEM, V86, P251, DOI 10.1002/jcb.10228; Ito Y, 1999, GENES CELLS, V4, P685, DOI 10.1046/j.1365-2443.1999.00298.x; Jakacka M, 2002, MOL ENDOCRINOL, V16, P2188, DOI 10.1210/me.2001-0174; Javed A, 2001, MOL CELL BIOL, V21, P2891, DOI 10.1128/MCB.21.8.2891-2905.2001; Ji CH, 1996, J CELL BIOCHEM, V63, P478; Ji CH, 1997, J BIOL CHEM, V272, P21260, DOI 10.1074/jbc.272.34.21260; Ji CH, 1998, J CELL BIOCHEM, V69, P353, DOI 10.1002/(SICI)1097-4644(19980601)69:3<353::AID-JCB12>3.3.CO;2-W; Ji CH, 2001, ENDOCRINOLOGY, V142, P3873, DOI 10.1210/en.142.9.3873; Karsenty G, 2000, SEMIN CELL DEV BIOL, V11, P343, DOI 10.1006/scdb.2000.0188; Katzburg S, 1999, BONE, V25, P667, DOI 10.1016/S8756-3282(99)00225-2; Katzburg S, 2001, J ENDOCRINOL INVEST, V24, P166, DOI 10.1007/BF03343837; Kellendonk C, 1999, J STEROID BIOCHEM, V69, P253, DOI 10.1016/S0960-0760(99)00041-2; Kelly MJ, 2001, TRENDS ENDOCRIN MET, V12, P152, DOI 10.1016/S1043-2760(01)00377-0; Komori T, 2000, BIOCHEM BIOPH RES CO, V276, P813, DOI 10.1006/bbrc.2000.3460; Kousteni S, 2002, SCIENCE, V298, P843, DOI 10.1126/science.1074935; Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(01)00268-9; Leboy PS, 2001, J BONE JOINT SURG AM, V83A, pS15; Lee SK, 1998, MOL ENDOCRINOL, V12, P1184, DOI 10.1210/me.12.8.1184; Liu YM, 2002, ONCOGENE, V21, P7680, DOI 10.1038/sj.onc.1205883; Lutterbach B, 2000, J BIOL CHEM, V275, P651, DOI 10.1074/jbc.275.1.651; Masi L, 2001, Q J NUCL MED, V45, P2; Matsuda T, 2001, J BIOL CHEM, V276, P42908, DOI 10.1074/jbc.M105316200; McCarthy TL, 2000, ENDOCRINOLOGY, V141, P127, DOI 10.1210/en.141.1.127; McCarthy TL, 2000, J BIOL CHEM, V275, P21746, DOI 10.1074/jbc.M002291200; McCarthy TL, 1997, J BIOL CHEM, V272, P18132, DOI 10.1074/jbc.272.29.18132; MCCARTHY TL, 1988, J BONE MINER RES, V3, P401; McLarrent FW, 2001, J BIOL CHEM, V276, P1578, DOI 10.1074/jbc.M007629200; Ning YM, 1999, J BIOL CHEM, V274, P30624, DOI 10.1074/jbc.274.43.30624; Nishimura J, 2000, J BONE MINER METAB, V18, P350, DOI 10.1007/s007740070008; Nuttall ME, 2000, AM J PHYSIOL-CELL PH, V279, pC1550, DOI 10.1152/ajpcell.2000.279.5.C1550; Olsen BR, 2000, ANNU REV CELL DEV BI, V16, P191, DOI 10.1146/annurev.cellbio.16.1.191; Pereira RMR, 2001, BONE, V28, P484, DOI 10.1016/S8756-3282(01)00422-7; Pike ACW, 1999, EMBO J, V18, P4608, DOI 10.1093/emboj/18.17.4608; Plant A, 2002, J CELL BIOCHEM, V84, P285, DOI 10.1002/jcb.10021; Raisz LG, 1999, OSTEOARTHR CARTILAGE, V7, P419, DOI 10.1053/joca.1998.0230; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Rosen CJ, 2000, BEST PRACT RES CL EN, V14, P181, DOI 10.1053/beem.2000.0068; Sadowski I, 1995, Genet Eng (N Y), V17, P119; Schuur ER, 2001, J BIOL CHEM, V276, P33554, DOI 10.1074/jbc.M105555200; Selvamurugan N, 2000, J BIOL CHEM, V275, P5037, DOI 10.1074/jbc.275.7.5037; Simoncini T, 2002, STEROIDS, V67, P935, DOI 10.1016/S0039-128X(02)00040-5; Simoncini T, 2003, EUR J ENDOCRINOL, V148, P281, DOI 10.1530/eje.0.1480281; Suda T, 1997, J BONE MINER RES, V12, P869, DOI 10.1359/jbmr.1997.12.6.869; Sutter-Dub MT, 2002, STEROIDS, V67, P77, DOI 10.1016/S0039-128X(01)00142-8; Taranta A, 2002, BONE, V30, P368, DOI 10.1016/S8756-3282(01)00685-8; Tintut Y, 1999, J BIOL CHEM, V274, P28875, DOI 10.1074/jbc.274.41.28875; Tou LQ, 2001, MOL CELL ENDOCRINOL, V183, P71, DOI 10.1016/S0303-7207(01)00594-9; Uht RM, 1997, ENDOCRINOLOGY, V138, P2900, DOI 10.1210/en.138.7.2900; Viereck V, 2002, J CELL BIOCHEM, V86, P348, DOI 10.1002/jcb.10220; Walters MR, 2002, J BIOL CHEM, V277, P1669, DOI 10.1074/jbc.M109320200; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Wiren KM, 2002, J ENDOCRINOL, V175, P683, DOI 10.1677/joe.0.1750683; Yamamoto T, 2002, ENDOCRINOLOGY, V143, P2635, DOI 10.1210/en.143.7.2635; Zhou S, 2001, J CELL BIOCHEM, P144	76	97	102	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43121	43129		10.1074/jbc.M306531200	http://dx.doi.org/10.1074/jbc.M306531200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12951324	hybrid			2022-12-25	WOS:000186157000052
J	Rosonina, E; Bakowski, MA; McCracken, S; Blencowe, BJ				Rosonina, E; Bakowski, MA; McCracken, S; Blencowe, BJ			Transcriptional activators control splicing and 3 '-end cleavage levels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; PRE-MESSENGER-RNA; CARBOXY-TERMINAL DOMAIN; LARGEST SUBUNIT; ENHANCER; COMPLEX; BINDING; COACTIVATOR; ELONGATION; HOLOENZYME	We have investigated whether transcriptional activators influence the efficiency of constitutive splicing and 3'-end formation, in addition to transcription levels. Remarkably, strong activators result in higher levels of splicing and 3'-cleavage than weak activators and can control the efficiency of these steps in pre-mRNA processing separately. The pre-mRNA processing stimulatory property of activators is dependent on their binding to promoters, but is not an indirect consequence of the levels of transcripts produced. Moreover, stimulation of splicing and cleavage by a strong activator operates by a mechanism that requires the carboxyl-terminal domain of RNA polymerase II. The splicing stimulatory property of activators was observed for unrelated transcripts and for separate introns within a transcript, indicating a possible general role for strong activators in facilitating pre-mRNA processing levels. The results suggest that the efficiency of constitutive splicing and 3'-end cleavage is closely coordinated with transcription levels by promoter-bound activators.	Univ Toronto, Charles H Best Inst, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5G 1L6, Canada	University of Toronto; University of Toronto	Blencowe, BJ (corresponding author), Univ Toronto, Charles H Best Inst, Banting & Best Dept Med Res, 112 Coll St,Rm 410, Toronto, ON M5G 1L6, Canada.			Rosonina, Emanuel/0000-0001-6861-3143				ALLISON LA, 1989, P NATL ACAD SCI USA, V86, P2794, DOI 10.1073/pnas.86.8.2794; ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; Auboeuf D, 2002, SCIENCE, V298, P416, DOI 10.1126/science.1073734; Blau J, 1996, MOL CELL BIOL, V16, P2044; Calvo O, 2001, MOL CELL, V7, P1013, DOI 10.1016/S1097-2765(01)00236-2; Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; Corden JL, 1997, TRENDS BIOCHEM SCI, V22, P413, DOI 10.1016/S0968-0004(97)01125-0; CORDEN JL, 1985, P NATL ACAD SCI USA, V82, P7934, DOI 10.1073/pnas.82.23.7934; Cramer P, 2001, FEBS LETT, V498, P179, DOI 10.1016/S0014-5793(01)02485-1; Cramer P, 1999, MOL CELL, V4, P251, DOI 10.1016/S1097-2765(00)80372-X; Dantonel JC, 1997, NATURE, V389, P399, DOI 10.1038/38763; Eldridge AG, 1999, P NATL ACAD SCI USA, V96, P6125, DOI 10.1073/pnas.96.11.6125; Emili A, 2002, RNA, V8, P1102, DOI 10.1017/S1355838202025037; Flaherty SM, 1997, P NATL ACAD SCI USA, V94, P11893, DOI 10.1073/pnas.94.22.11893; Ge H, 1998, MOL CELL, V2, P751, DOI 10.1016/S1097-2765(00)80290-7; GERBER HP, 1995, NATURE, V374, P660, DOI 10.1038/374660a0; Hirose Y, 1998, NATURE, V395, P93, DOI 10.1038/25786; Hirose Y, 1999, GENE DEV, V13, P1234, DOI 10.1101/gad.13.10.1234; Hirose Y, 2000, GENE DEV, V14, P1415; INOUE K, 1992, P NATL ACAD SCI USA, V89, P8092, DOI 10.1073/pnas.89.17.8092; IZAURRALDE E, 1994, CELL, V78, P657, DOI 10.1016/0092-8674(94)90530-4; Kadener S, 2002, P NATL ACAD SCI USA, V99, P8185, DOI 10.1073/pnas.122246099; Kadener S, 2001, EMBO J, V20, P5759, DOI 10.1093/emboj/20.20.5759; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; Lai MC, 1999, J BIOL CHEM, V274, P11832, DOI 10.1074/jbc.274.17.11832; LIAO SM, 1991, GENE DEV, V5, P2431, DOI 10.1101/gad.5.12b.2431; Liu JH, 2001, CELL, V104, P353, DOI 10.1016/S0092-8674(01)00223-9; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; McCracken S, 2002, MOL CELL BIOL, V22, P148, DOI 10.1128/MCB.22.1.148-160.2002; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; Monsalve M, 2000, MOL CELL, V6, P307, DOI 10.1016/S1097-2765(00)00031-9; Nguyen VT, 1996, NUCLEIC ACIDS RES, V24, P2924, DOI 10.1093/nar/24.15.2924; Nogues G, 2002, J BIOL CHEM, V277, P43110, DOI 10.1074/jbc.M208418200; OSSIPOW V, 1995, CELL, V83, P137, DOI 10.1016/0092-8674(95)90242-2; Pan GH, 1997, J BIOL CHEM, V272, P24563, DOI 10.1074/jbc.272.39.24563; Robert F, 2002, J BIOL CHEM, V277, P9302, DOI 10.1074/jbc.M110516200; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; TIAN M, 1992, SCIENCE, V256, P237, DOI 10.1126/science.1566072; WALKER S, 1993, MOL CELL BIOL, V13, P5233, DOI 10.1128/MCB.13.9.5233; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2; Yeakley JM, 1996, P NATL ACAD SCI USA, V93, P7582, DOI 10.1073/pnas.93.15.7582; Zeng CQ, 2000, MOL CELL BIOL, V20, P8290, DOI 10.1128/MCB.20.21.8290-8301.2000	45	54	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43034	43040		10.1074/jbc.M307289200	http://dx.doi.org/10.1074/jbc.M307289200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12939267	hybrid			2022-12-25	WOS:000186157000040
J	Sakato, M; King, SM				Sakato, M; King, SM			Calcium regulates ATP-sensitive microtubule binding by Chlamydomonas outer arm dynein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRITON-EXTRACTED MODELS; LIGHT-CHAIN; HEAVY-CHAIN; ALPHA-BETA; FLAGELLAR DYNEINS; DIVALENT-CATIONS; GAMMA-SUBUNIT; MOTOR DOMAIN; MUTANT; COMPLEX	The Chlamydomonas outer dynein arm contains three distinct heavy chains (alpha, beta, and gamma) that exhibit different motor properties. The LC4 protein, which binds 1 - 2 Ca2+ with K-Ca = 3 x 10(-5) M, is associated with the gamma heavy chain and has been proposed to act as a sensor to regulate dynein motor function in response to alterations in intraflagellar Ca2+ levels. Here we genetically dissect the outer arm to yield subparticles containing different motor unit combinations and assess the microtubule-binding properties of these complexes both prior to and following preincubation with tubulin and ATP, which was used to inhibit ATP-insensitive ( structural) microtubule binding. We observed that the gamma heavy chain exhibits a dominant Ca2+-independent ATP-sensitive MT binding activity in vitro that is inhibited by attachment of tubulin to the structural microtubule-binding domain. Furthermore, we show that ATP-sensitive microtubule binding by a dynein subparticle containing only the beta and gamma heavy chains does not occur at Ca2+ concentrations below pCa 6 but is maximally activated above pCa 5. This activity was not observed in mutant dyneins containing small deletions in the microtubule-binding region of the beta heavy chain or in dyneins that lack both the alpha heavy chain and the motor domain of the beta heavy chain. These findings strongly suggest that Ca2+ binding directly to a component of the dynein complex regulates ATP-sensitive interactions between the beta heavy chain and microtubules and lead to a model for how individual motor units are controlled within the outer dynein arm.	Univ Connecticut, Ctr Hlth, Dept Biochem, Farmington, CT 06030 USA	University of Connecticut	King, SM (corresponding author), Univ Connecticut, Ctr Hlth, Dept Biochem, 263 Farmington Ave, Farmington, CT 06030 USA.	steve@king2.uchc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051293] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51293] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Benashski SE, 1999, BIOCHEMISTRY-US, V38, P7253, DOI 10.1021/bi990466y; BESSEN M, 1980, J CELL BIOL, V86, P446, DOI 10.1083/jcb.86.2.446; BROKAW CJ, 1974, BIOCHEM BIOPH RES CO, V58, P795, DOI 10.1016/S0006-291X(74)80487-0; Casey DM, 2003, MOL BIOL CELL, V14, P3650, DOI 10.1091/mbc.E03-01-0057; DiBella LM, 2001, INT REV CYTOL, V210, P227; GIBBONS BH, 1984, NATURE, V309, P560, DOI 10.1038/309560a0; GOLDSTEIN DA, 1979, BIOPHYS J, V26, P235, DOI 10.1016/S0006-3495(79)85247-9; HAIMO LT, 1988, CELL MOTIL CYTOSKEL, V9, P129, DOI 10.1002/cm.970090205; Harrison A, 1998, J CELL BIOL, V140, P1137, DOI 10.1083/jcb.140.5.1137; Harrison A, 2002, CELL MOTIL CYTOSKEL, V52, P131, DOI 10.1002/cm.10044; HUANG B, 1982, CELL, V28, P115, DOI 10.1016/0092-8674(82)90381-6; KAMIYA R, 1984, J CELL BIOL, V98, P97, DOI 10.1083/jcb.98.1.97; KAMIYA R, 1985, J CELL SCI, V74, P181; KING SM, 1995, J CELL SCI, V108, P3757; KING SM, 1994, J BIOL CHEM, V269, P5452; KING SM, 1991, J BIOL CHEM, V266, P8401; KING SM, 1985, P NATL ACAD SCI USA, V82, P4717, DOI 10.1073/pnas.82.14.4717; LINDEMANN CB, 1988, CELL MOTIL CYTOSKEL, V10, P420, DOI 10.1002/cm.970100309; MITCHELL DR, 1985, J CELL BIOL, V100, P1228, DOI 10.1083/jcb.100.4.1228; MITCHELL DR, 1994, J CELL SCI, V107, P635; MOSS AG, 1992, J CELL BIOL, V118, P1189, DOI 10.1083/jcb.118.5.1189; MOSS AG, 1992, J CELL BIOL, V118, P1177, DOI 10.1083/jcb.118.5.1177; MOSS AG, 1999, MICROSC ANAL, V34, P7; NAITOH Y, 1973, J EXP BIOL, V58, P657; NAITOH Y, 1972, SCIENCE, V176, P523, DOI 10.1126/science.176.4034.523; Nakamura K, 1997, CELL MOTIL CYTOSKEL, V37, P338; PFISTER KK, 1982, CELL MOTIL CYTOSKEL, V2, P525, DOI 10.1002/cm.970020604; PFISTER KK, 1984, J BIOL CHEM, V259, P2072; PIPERNO G, 1981, CELL, V27, P331, DOI 10.1016/0092-8674(81)90416-5; PIPERNO G, 1992, J CELL BIOL, V118, P1455, DOI 10.1083/jcb.118.6.1455; PORTER ME, 1994, J CELL BIOL, V126, P1495, DOI 10.1083/jcb.126.6.1495; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Sakakibara H, 1998, J CELL SCI, V111, P1155; SAKAKIBARA H, 1991, J CELL BIOL, V113, P615, DOI 10.1083/jcb.113.3.615; SAKAKIBARA H, 1993, J CELL BIOL, V122, P653, DOI 10.1083/jcb.122.3.653; Sillen L.G., 1971, STABILITY CONSTANTS; TAKADA S, 1994, J CELL BIOL, V126, P737, DOI 10.1083/jcb.126.3.737; Wakabayashi K, 1997, CELL MOTIL CYTOSKEL, V38, P22, DOI 10.1002/(SICI)1097-0169(1997)38:1<22::AID-CM3>3.0.CO;2-J; WITMAN GB, 1986, METHOD ENZYMOL, V134, P280; Witman George B., 1993, Trends in Cell Biology, V3, P403, DOI 10.1016/0962-8924(93)90091-E; Wu HW, 2000, NAT STRUCT BIOL, V7, P575; Yang PF, 2001, J CELL BIOL, V153, P1315, DOI 10.1083/jcb.153.6.1315	42	32	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43571	43579		10.1074/jbc.M305894200	http://dx.doi.org/10.1074/jbc.M305894200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12923201	hybrid			2022-12-25	WOS:000186157000104
J	Babenko, AP; Bryan, J				Babenko, AP; Bryan, J			SUR domains that associate with and gate K-ATP pores define a novel gatekeeper	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE POTASSIUM CHANNELS; SULFONYLUREA RECEPTOR; ABC TRANSPORTER; INSULIN-SECRETION; CRYSTAL-STRUCTURE; MOLECULAR-BASIS; SUBUNIT; TRAFFICKING; INHIBITION; CONDUCTION	Structure-function analyses of K+ channels identify a common pore architecture whose gating depends on diverse signal sensing elements. The "gatekeepers" of the long, ATP-inhibited K(IR)6.0 pores of K-ATP channels are ABC proteins, SURs, receptors for channel opening and closing drugs. Several competing models for SUR/K-IR coupling exist. We show that SUR TMD0, the N-terminal bundle of five transmembrane helices, specifically associates with K(IR)6.2, forcing nearly silent pores to burst like native KATP channels and enhancing surface expression. Inclusion of adjacent submembrane residues of L0, the linker between TMD0 and the stimulatory nucleotide- and drug-binding ABC core, generates constitutively active channels, whereas additional cytoplasmic residues counterbalance this activation establishing a relationship between the mean open and burst times of intact pores. SUR fragments, lacking TMD0, fail to modulate K-IR. TMD0 is thus the domain that anchors SUR to the K-IR pore. Consistent with data on chimeric ABCC/K(IR)s and a modeled channel structure, we propose that interactions of TMD0-L0 with the outer helix and N terminus of K-IR bidirectionally modulate gating. The results explain and predict pathologies associated with alteration of the 5' ends of clustered ABCC8 (9)/KCNJ11 (8) genes.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine	Babenko, AP (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza,112C, Houston, TX 77030 USA.				NIDDK NIH HHS [DK 44311] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044311] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aguilar-Bryan L, 1999, ENDOCR REV, V20, P101, DOI 10.1210/er.20.2.101; AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Armstrong C.M., 2003, SCI STKE, V2003, pre10; Babenko AP, 1998, ANNU REV PHYSIOL, V60, P667, DOI 10.1146/annurev.physiol.60.1.667; Babenko AP, 1999, J BIOL CHEM, V274, P11587, DOI 10.1074/jbc.274.17.11587; Babenko AP, 1999, FEBS LETT, V445, P131, DOI 10.1016/S0014-5793(99)00102-7; Babenko AP, 2002, J BIOL CHEM, V277, P43997, DOI 10.1074/jbc.M208085200; Babenko AP, 2001, J BIOL CHEM, V276, P49083, DOI 10.1074/jbc.M108763200; Babenko AP, 1999, BIOCHEM BIOPH RES CO, V255, P231, DOI 10.1006/bbrc.1999.0172; Babenko AP, 1999, FEBS LETT, V459, P367, DOI 10.1016/S0014-5793(99)01215-6; Bakos E, 2000, J CELL SCI, V113, P4451; Chang G, 2003, J MOL BIOL, V330, P419, DOI 10.1016/S0022-2836(03)00587-4; Cortes DM, 2001, J GEN PHYSIOL, V117, P165, DOI 10.1085/jgp.117.2.165; Dean M, 2001, GENOME RES, V11, P1156, DOI 10.1101/gr.GR-1649R; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Giblin JP, 1999, J BIOL CHEM, V274, P22652, DOI 10.1074/jbc.274.32.22652; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; Kuo AL, 2003, SCIENCE, V300, P1922, DOI 10.1126/science.1085028; Lu Z, 2001, NATURE, V413, P809, DOI 10.1038/35101535; Ma DK, 2001, SCIENCE, V291, P316, DOI 10.1126/science.291.5502.316; Mikhailov MV, 2000, FEBS LETT, V482, P59, DOI 10.1016/S0014-5793(00)02035-4; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; Nishida M, 2002, CELL, V111, P957, DOI 10.1016/S0092-8674(02)01227-8; Perozo E, 1999, SCIENCE, V285, P73, DOI 10.1126/science.285.5424.73; Schwanstecher C, 2002, DIABETES, V51, P875, DOI 10.2337/diabetes.51.3.875; Schwappach B, 2000, NEURON, V26, P155, DOI 10.1016/S0896-6273(00)81146-0; Sharma N, 1999, J BIOL CHEM, V274, P20628, DOI 10.1074/jbc.274.29.20628; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	31	119	121	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41577	41580		10.1074/jbc.C300363200	http://dx.doi.org/10.1074/jbc.C300363200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12941953	hybrid			2022-12-25	WOS:000185989500002
J	Saporita, AJ; Zhang, QH; Navai, N; Dincer, Z; Hahn, JH; Cai, XY; Wang, Z				Saporita, AJ; Zhang, QH; Navai, N; Dincer, Z; Hahn, JH; Cai, XY; Wang, Z			Identification and characterization of a ligand-regulated nuclear export signal in androgen receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING DOMAIN; GLUCOCORTICOID RECEPTOR; LIVING CELLS; LOCALIZATION; DNA; TRAFFICKING; SEQUENCES; DYNAMICS; PROTEINS; MOVEMENT	Androgen receptor (AR) belongs to the steroid receptor superfamily that regulates gene expression in a ligand-dependent fashion. AR is localized to the cytoplasm in the absence of androgen and translocates into the nuclei to activate gene expression in the presence of ligand. Regulation of AR nuclear import and export represents an essential step in androgen action. A nuclear localization signal (NLS) has been identified in the DNA-binding domain and hinge region of AR and other steroid receptors. Studies on nuclear export of AR, however, are limited, and what might be the underlying mechanism regulating the intracellular localization of steroid receptors is unclear. Our studies have identified a leptomycin B-insensitive nuclear export signal (NESAR) in the ligand-binding domain of AR, which is active in the absence of androgen and repressed upon ligand binding. Consistent with its androgen-sensitivity, NESAR contains amino acid residues in the immediate vicinity of the bound ligand. NESAR is necessary for AR nuclear export and is dominant over the NLS in the DNA-binding domain and hinge region in the absence of hormone. Our findings suggest that androgen can regulate NESAR and, subsequently, the NLS of the AR, providing a mechanism by which androgen regulates AR nuclear/cytoplasmic shuttling. Estrogen receptor alpha and mineralocorticoid receptor also contain functional NES, suggesting that this ligand-regulated NES is conserved among steroid receptors.	Northwestern Univ, Freinberg Sch Med, Dept Urol, Chicago, IL 60611 USA; Northwestern Univ, Freinberg Sch Med, Dept Mol Pharmacol & Biol Chem, Chicago, IL 60611 USA; Northwestern Univ, Freinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center	Wang, Z (corresponding author), Northwestern Univ, Freinberg Sch Med, Dept Urol, 303 E Chicago Ave, Chicago, IL 60611 USA.		Dincer, Zehra/U-6023-2019		NCI NIH HHS [P50 CA 90386, T32 CA 80621] Funding Source: Medline; NIDDK NIH HHS [R01 DK 51193] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA080621, P50CA090386] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051193] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Black BE, 2001, CURR BIOL, V11, P1749, DOI 10.1016/S0960-9822(01)00537-1; CHANG CS, 1988, P NATL ACAD SCI USA, V85, P7211, DOI 10.1073/pnas.85.19.7211; Georget V, 1997, MOL CELL ENDOCRINOL, V129, P17, DOI 10.1016/S0303-7207(97)04034-3; GUIOCHONMANTEL A, 1994, P NATL ACAD SCI USA, V91, P7179, DOI 10.1073/pnas.91.15.7179; Holaska JM, 2001, J CELL BIOL, V152, P127, DOI 10.1083/jcb.152.1.127; JENSTER G, 1992, J STEROID BIOCHEM, V41, P671, DOI 10.1016/0960-0760(92)90402-5; JENSTER G, 1993, BIOCHEM J, V293, P761, DOI 10.1042/bj2930761; Liu JM, 2000, MOL ENDOCRINOL, V14, P40, DOI 10.1210/me.14.1.40; MAINWARING W, 1977, MECHAMISM ACTION AND, P10; Marte B, 2001, NAT CELL BIOL, V3, pE135, DOI 10.1038/35078596; Matias PM, 2000, J BIOL CHEM, V275, P26164, DOI 10.1074/jbc.M004571200; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; Poukka H, 2000, J CELL SCI, V113, P2991; Roy AK, 2001, ANN NY ACAD SCI, V949, P44; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tyagi RK, 1998, MOL ENDOCRINOL, V12, P1684, DOI 10.1210/me.12.11.1684; Tyagi RK, 2000, MOL ENDOCRINOL, V14, P1162, DOI 10.1210/me.14.8.1162; WEN W, 1994, J BIOL CHEM, V269, P32214; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; ZHOU ZX, 1994, RECENT PROG HORM RES, V49, P249; ZHOU ZX, 1994, J BIOL CHEM, V269, P13115	23	133	135	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41998	42005		10.1074/jbc.M302460200	http://dx.doi.org/10.1074/jbc.M302460200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12923188	hybrid			2022-12-25	WOS:000185989500143
J	Xu, L; Alarcon, X; Col, S; Massague, J				Xu, L; Alarcon, X; Col, S; Massague, J			Distinct domain utilization by Smad3 and Smad4 for nucleoporin interaction and nuclear import	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA RECEPTOR; NUCLEOCYTOPLASMIC TRANSPORT; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; PROTEIN; IDENTIFICATION; RECOGNITION; CYTOPLASM; SYSTEM; SARA	Smad proteins undergo rapid nuclear translocation upon stimulation by transforming growth factor-beta (TGFbeta) and in so doing transduce the signal into the nucleus. In this report we unraveled nuclear import mechanisms of Smad3 and Smad4 that are dependent on their interaction with FG-repeat-containing nucleoporins such as CAN/Nup214, without the involvement of importin molecules that are responsible for most of the known nuclear import events. A surface hydrophobic corridor within the MH2 domain of Smad3 is critical for association with CAN/Nup214 and nuclear import, whereas Smad4 interaction with CAN/Nup214, and nuclear import requires structural elements present only in the full-length Smad4. As exemplified by the different susceptibility to inhibition of import by cytoplasmic retention factor SARA ( Smad anchor for receptor activation), such utilization of distinct domains for nuclear import of Smad3 and Smad4 suggests that nuclear transport of Smad3 and Smad4 is subject to control by different retention factors.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	Massague, J (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, Box 116,1275 York Ave, New York, NY 10021 USA.	j-massague@ski.mskcc.org		Massague, Joan/0000-0001-9324-8408	NCI NIH HHS [CA 34610] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA034610, R01CA034610] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAM SA, 1992, METHOD ENZYMOL, V219, P97; Bayliss R, 2000, CELL, V102, P99, DOI 10.1016/S0092-8674(00)00014-3; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Cingolani G, 1999, NATURE, V399, P221, DOI 10.1038/20367; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Durocher D, 2000, MOL CELL, V6, P1169, DOI 10.1016/S1097-2765(00)00114-3; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Inman GJ, 2002, MOL CELL, V10, P283, DOI 10.1016/S1097-2765(02)00585-3; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; Jakel S, 2002, EMBO J, V21, P377, DOI 10.1093/emboj/21.3.377; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Kurisaki A, 2001, MOL BIOL CELL, V12, P1079, DOI 10.1091/mbc.12.4.1079; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; Pierreux CE, 2000, MOL CELL BIOL, V20, P9041, DOI 10.1128/MCB.20.23.9041-9054.2000; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; Qin B, 1999, STRUCTURE, V7, P1493, DOI 10.1016/S0969-2126(00)88340-9; Qin BY, 2002, GENE DEV, V16, P1950, DOI 10.1101/gad.1002002; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Watanabe M, 2000, EMBO REP, V1, P176, DOI 10.1093/embo-reports/kvd029; Weis K, 2003, CELL, V112, P441, DOI 10.1016/S0092-8674(03)00082-5; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Wu G, 2000, SCIENCE, V287, P92, DOI 10.1126/science.287.5450.92; Wu JW, 2001, MOL CELL, V8, P1277, DOI 10.1016/S1097-2765(01)00421-X; Xiao Z, 2000, J BIOL CHEM, V275, P23425, DOI 10.1074/jbc.C000345200; Xiao Z, 2003, ONCOGENE, V22, P1057, DOI 10.1038/sj.onc.1206212; Xu L, 2002, MOL CELL, V10, P271, DOI 10.1016/S1097-2765(02)00586-5; Xu L, 2000, NAT CELL BIOL, V2, P559, DOI 10.1038/35019649; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1	37	93	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42569	42577		10.1074/jbc.M307601200	http://dx.doi.org/10.1074/jbc.M307601200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12917407	hybrid			2022-12-25	WOS:000185989500122
J	Wu, HY; Windmiller, DA; Wang, L; Backer, JM				Wu, HY; Windmiller, DA; Wang, L; Backer, JM			YXXM motifs in the PDGF-beta receptor serve dual roles as phosphoinositide 3-kinase binding motifs and tyrosine-based endocytic sorting signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; HAMSTER OVARY CELLS; PHOSPHATIDYLINOSITOL 3-PHOSPHATE; MEMBRANE-TRANSPORT; KINASE; PROTEIN; CBL; TRAFFICKING; DOMAIN; UBIQUITINATION	Phosphoinositide 3-kinases (PI 3-kinases) are important regulators of endocytic trafficking. Previous studies have shown that mutant human platelet-derived growth factor-beta receptors (PDGFR), which contain Phe in place of Tyr at the two p85/p110 PI 3-kinase binding sites (PDGFR-F/F), are defective for both p85 binding and ligand-stimulated degradation. This suggested that p85/p110 regulates PDGFR trafficking. However, more recent work has identified hVPS34, and not p85/p110, as the major PI 3-kinase regulating the movement of receptors through the endosomal system. To reconcile this discrepancy, we hypothesized that YXXM motifs in the PDGFR might play a second role as Tyr-based lysosomal sorting motifs (YXXPhi). To test this, we replaced both YXXM motifs with a motif from LAMP-1, YQTI. This mutant PDGFR (PDGFR-YQTI) still underwent PDGF-stimulated autophosphorylation but did not bind p85. In CHO cells, both wild-type and YQTI receptors showed PDGF-stimulated turnover, whereas F/F receptors did not. In addition, uptake and degradation of cell surface-labeled YXXM and YQTI receptors was fast relative to F/F receptors. We also constructed chimeras containing extracellular and membrane-spanning domains from CD25 (Tac) and cytoplasmic tails containing the YQTI motif, two YXXM motifs, or two mutant FXXM motifs. The YXXM and YQTI chimeras mediated lysosomal delivery of fluorescein isothiocyanate-labeled anti-CD25 antibodies, whereas the F/F chimera was defective. Thus, YQTI motifs can target PDGFR for degradation in the absence of p85/p110 binding, and the p85/p110 binding motifs from PDGFR are sufficient to target Tac chimeras to the lysosome. These data suggest that the YXXM motifs in the PDGFR serve two distinct functions: PI 3-kinase recruitment and lysosomal targeting.	Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Backer, JM (corresponding author), Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.				NIGMS NIH HHS [GM55692] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Backer Jonathan M., 2000, Molecular Cell Biology Research Communications, V3, P193, DOI 10.1006/mcbr.2000.0202; Bilodeau PS, 2002, NAT CELL BIOL, V4, P534, DOI 10.1038/ncb815; Burke P, 2001, MOL BIOL CELL, V12, P1897, DOI 10.1091/mbc.12.6.1897; Christoforidis S, 1999, NAT CELL BIOL, V1, P249, DOI 10.1038/12075; Chuang E, 1997, J IMMUNOL, V159, P144; Clague MJ, 2001, J CELL SCI, V114, P3075; Corvera S, 1999, CURR OPIN CELL BIOL, V11, P460, DOI 10.1016/S0955-0674(99)80066-0; DUAN L, 2003, J BIOL CHEM; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; Gary JD, 1998, J CELL BIOL, V143, P65, DOI 10.1083/jcb.143.1.65; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Haj FG, 2002, SCIENCE, V295, P1708, DOI 10.1126/science.1067566; Hausdorff SF, 1999, J BIOL CHEM, V274, P24677, DOI 10.1074/jbc.274.35.24677; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; JADOT M, 1992, J BIOL CHEM, V267, P11069; JOLY M, 1995, J BIOL CHEM, V270, P13225, DOI 10.1074/jbc.270.22.13225; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341; McEwen RK, 1999, J BIOL CHEM, V274, P33905, DOI 10.1074/jbc.274.48.33905; MCGRAW TE, 1987, J CELL BIOL, V105, P207, DOI 10.1083/jcb.105.1.207; Meng WY, 1999, NATURE, V398, P84, DOI 10.1038/18050; METZELAAR MJ, 1991, J BIOL CHEM, V266, P3239; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; MORI S, 1994, J BIOL CHEM, V269, P4917; Mosesson Y, 2003, J BIOL CHEM, V278, P21323, DOI 10.1074/jbc.C300096200; Owen DJ, 1999, CELL, V97, P805, DOI 10.1016/S0092-8674(00)80791-6; Patki V, 1997, P NATL ACAD SCI USA, V94, P7326, DOI 10.1073/pnas.94.14.7326; PETERS C, 1990, EMBO J, V9, P3497, DOI 10.1002/j.1460-2075.1990.tb07558.x; POLLARD JW, 1979, J CELL PHYSIOL, V98, P571, DOI 10.1002/jcp.1040980315; Prasad SVN, 2002, J CELL BIOL, V158, P563, DOI 10.1083/jcb.200202113; Rapoport I, 1997, EMBO J, V16, P2240, DOI 10.1093/emboj/16.9.2240; Roggo L, 2002, EMBO J, V21, P1673, DOI 10.1093/emboj/21.7.1673; ROSENWALD AG, 1992, BIOCHEMISTRY-US, V31, P3581, DOI 10.1021/bi00129a005; Sbrissa D, 1999, J BIOL CHEM, V274, P21589, DOI 10.1074/jbc.274.31.21589; Shiratori T, 1997, IMMUNITY, V6, P583, DOI 10.1016/S1074-7613(00)80346-5; Siddhanta U, 1998, J CELL BIOL, V143, P1647, DOI 10.1083/jcb.143.6.1647; STACK JH, 1994, J BIOL CHEM, V269, P31552; Stenmark H, 1999, J CELL SCI, V112, P4175; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; Virbasius JV, 2001, P NATL ACAD SCI USA, V98, P12908, DOI 10.1073/pnas.221352898; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2; Yokouchi M, 1999, ONCOGENE, V18, P759, DOI 10.1038/sj.onc.1202326; Zheng B, 2001, SCIENCE, V294, P1939, DOI 10.1126/science.1064757	45	30	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40425	40428		10.1074/jbc.C300225200	http://dx.doi.org/10.1074/jbc.C300225200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12941951	hybrid			2022-12-25	WOS:000185847200002
J	Rothenberger, S; Burns, K; Rousseaux, M; Tschopp, J; Bron, C				Rothenberger, S; Burns, K; Rousseaux, M; Tschopp, J; Bron, C			Ubiquitination of the Epstein-Barr virus-encoded latent membrane protein 1 depends on the integrity of the TRAF binding site	ONCOGENE			English	Article						LMP1; ubiquitin; TRAF3; lipid rafts	LIPID RAFTS; SIGNAL-TRANSDUCTION; PROTEIN; CELLS; DEGRADATION; LMP1; TRANSFORMATION; RECOGNITION; ASSOCIATION; ACTIVATION	The latent membrane protein 1 (LMP1) encoded by the Epstein-Barr virus functions as a constitutively activated receptor of the tumor necrosis factor receptor family. LMP1 is a short-lived protein that is ubiquitinated and degraded by the proteasome. We have previously shown that LMP1 recruits the adapter protein tumor necrosis factor receptor-associated factor 3 (TRAF3) to lipid rafts. To test if TRAFs are involved in LMP1's ubiquitination, we have mutated the LMP1 CTAR1 site that has been identified as a TRAF binding site. We show that the CTAR1 mutant (CTAR1(-)) is expressed after transfection at a similar level to wild-type LMP1, and behaves as wild-type LMP1 with respect to membrane localization. However, CTAR1(-) does not bind TRAF3. We demonstrate that ubiquitination of CTAR1(-) is significantly reduced when compared to wild-type LMP1. In addition, the expression of wild-type LMP1 induces the ubiquitination, an effect that is significantly reduced when the CTAR1(-) is expressed. Taken together, our results suggest that TRAF proteins are involved in the ubiquitination of LMP1, and that their binding to LMP1 may facilitate their own ubiquitination.	Univ Lausanne, Inst Biochem, CH-1066 Epalinges, Switzerland	University of Lausanne	Rothenberger, S (corresponding author), Univ Lausanne, Inst Biochem, Ch Boveresses 155, CH-1066 Epalinges, Switzerland.	Sylvia.RothenbergerAubert@ib.unil.ch		Rothenberger, Sylvia/0000-0001-8633-2994				Aviel S, 2000, J BIOL CHEM, V275, P23491, DOI 10.1074/jbc.M002052200; BAICHWAL VR, 1988, ONCOGENE, V2, P461; BAICHWAL VR, 1987, J VIROL, V61, P866, DOI 10.1128/JVI.61.3.866-875.1987; Bradley JR, 2001, ONCOGENE, V20, P6482, DOI 10.1038/sj.onc.1204788; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Brown KD, 2001, J EXP MED, V193, P943, DOI 10.1084/jem.193.8.943; Cherukuri A, 2001, IMMUNITY, V14, P657, DOI 10.1016/S1074-7613(01)00156-X; Chung JY, 2002, J CELL SCI, V115, P679; Ciechanover A, 2000, J CELL BIOCHEM, P40; Clausse B, 1997, VIROLOGY, V228, P285, DOI 10.1006/viro.1996.8380; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; HAMMARSKJOLD ML, 1992, J VIROL, V66, P6496; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Higuchi M, 2001, P NATL ACAD SCI USA, V98, P4675, DOI 10.1073/pnas.081075298; Hofmann RM, 2001, J BIOL CHEM, V276, P27936, DOI 10.1074/jbc.M103378200; Ilangumaran S, 2000, IMMUNOL TODAY, V21, P2, DOI 10.1016/S0167-5699(99)01494-2; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Kulwichit W, 1998, P NATL ACAD SCI USA, V95, P11963, DOI 10.1073/pnas.95.20.11963; Lafont F, 2001, P NATL ACAD SCI USA, V98, P3180, DOI 10.1073/pnas.051003498; Li XM, 2002, NATURE, V416, P345, DOI 10.1038/416345a; MANN KP, 1987, J VIROL, V61, P2100, DOI 10.1128/JVI.61.7.2100-2108.1987; MARTIN J, 1991, J VIROL, V65, P3246, DOI 10.1128/JVI.65.6.3246-3258.1991; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Polekhina G, 2002, NAT STRUCT BIOL, V9, P68, DOI 10.1038/nsb743; Rothenberger S, 2002, CELL MOL LIFE SCI, V59, P171, DOI 10.1007/s00018-002-8413-y; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Strous GJ, 1999, J CELL SCI, V112, P1417; Wajant H, 2001, CELL SIGNAL, V13, P389, DOI 10.1016/S0898-6568(01)00160-7; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; Ye H, 1999, MOL CELL, V4, P321, DOI 10.1016/S1097-2765(00)80334-2	31	14	16	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2003	22	36					5614	5618		10.1038/sj.onc.1206497	http://dx.doi.org/10.1038/sj.onc.1206497			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944909				2022-12-25	WOS:000184865900010
J	Monti, P; Campomenosi, P; Ciribilli, Y; Iannone, R; Aprile, A; Inga, A; Tada, M; Menichini, P; Abbondandolo, A; Fronza, G				Monti, P; Campomenosi, P; Ciribilli, Y; Iannone, R; Aprile, A; Inga, A; Tada, M; Menichini, P; Abbondandolo, A; Fronza, G			Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	ONCOGENE			English	Article						P73 beta; P53 mutants; yeast; functional assay	WILD-TYPE P53; KINASE C-ABL; DNA-DAMAGE; APOPTOTIC RESPONSE; INDUCE APOPTOSIS; TUMOR-SUPPRESSOR; GENE FAMILY; P73; MUTATIONS; P63	p53 is the most frequently altered tumor suppressor gene in a wide spectrum of human tumors. The large majority of p53 mutations observed in tumors are missense mutations. The p73 gene, encoding a protein with significant sequence similarity to p53, expresses multiple transcription-competent spliced variants, or transcription-incompetent forms (i.e. DeltaNp73). It was clearly shown that p73 transactivation from a p53-responsive promoter is inhibited by some tumor-derived p53 mutants in eucaryotic cells. In this study, we adapted a yeast-based p53 functional assay for the analysis of the influences of different p53 mutants on the activity of one of the p73 isoforms, namely p73beta. We determined the ability of a panel of 61 p53 mutants to inhibit p73beta activity following the net transcription of the ADE2 color (red/white) reporter gene driven by a p53-responsive promoter. By analysing a large number of mutants, we could conclude that interference: (a) is a quite frequent phenomenon (more than 70% of p53 mutants analysed are interfering); (b) is not confined to p53 mutations located in particular topological regions of the DNA binding domain; (c) does not appear to be dependent on the kind of side chains introduced at a specific position; (d) appears to significantly correlate with evolutionary conservation of the mutated p53 codon, frequency of occurrence of the mutation in tumors. The influence of a common R/P polymorphism at codon 72 on the ability of p53 mutants to interfere with p73beta was also studied. Two sets of polymorphic variants (R and P) for 14 mutants were constructed and analysed. In all cases, the R/P 72 polymorphism was phenotypically irrelevant. In conclusion, our results suggest that the interpretation of the biological effects of p53 mutants should take into consideration the possibility that p53 mutants show loss or gain of function also through the interference with p53 family members.	Natl Canc Res Inst IST, Mutagenesis Lab, I-16132 Genoa, Italy; Univ Insubria, Dept Struct & Funct Biol, Human Genet Lab, Varese, Italy; Hokkaido Univ, Inst Med Genet, Div Canc Related Genes, Sapporo, Hokkaido, Japan; Univ Genoa, Dept Oncol Biol & Genet, Genoa, Italy	University of Insubria; Hokkaido University; University of Genoa	Fronza, G (corresponding author), Natl Canc Res Inst IST, Mutagenesis Lab, Lgo R Benzi 10, I-16132 Genoa, Italy.		Monti, Paola/Y-1118-2019; Inga, Alberto/AAC-3815-2022; Fronza, Gilberto/AAG-8735-2019; Campomenosi, Paola/C-9729-2011; Menichini, Paola/K-9422-2016; Ciribilli, Yari/K-2751-2018	Monti, Paola/0000-0002-1978-4998; Inga, Alberto/0000-0002-8767-1637; Fronza, Gilberto/0000-0003-3722-553X; Campomenosi, Paola/0000-0002-8853-1134; Ciribilli, Yari/0000-0001-9231-379X; Menichini, Paola/0000-0003-0057-6184				Agami R, 1999, NATURE, V399, P809; Campomenosi P, 2001, ONCOGENE, V20, P3573, DOI 10.1038/sj.onc.1204468; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; Davison TS, 1999, J BIOL CHEM, V274, P18709, DOI 10.1074/jbc.274.26.18709; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Flaman JM, 1998, ONCOGENE, V16, P1369, DOI 10.1038/sj.onc.1201889; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Fontemaggi G, 2002, J BIOL CHEM, V277, P43359, DOI 10.1074/jbc.M205573200; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gong JG, 1999, NATURE, V399, P806; Inga A, 1997, CARCINOGENESIS, V18, P2019, DOI 10.1093/carcin/18.10.2019; Inga A, 1997, ONCOGENE, V14, P1307, DOI 10.1038/sj.onc.1200952; Inga A, 1999, CANCER RES, V59, P689; Inga A, 1998, CARCINOGENESIS, V19, P741, DOI 10.1093/carcin/19.5.741; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Kaelin WG, 1999, J NATL CANCER I, V91, P594, DOI 10.1093/jnci/91.7.594; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kelly JD, 1999, J BIOL CHEM, V274, P18327, DOI 10.1074/jbc.274.26.18327; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Monti P, 2002, ONCOGENE, V21, P1641, DOI 10.1038/sj.onc.1205250; Monti P, 2000, MUTAGENESIS, V15, P127, DOI 10.1093/mutage/15.2.127; Nozaki M, 2001, BRAIN PATHOL, V11, P296; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Prives C, 1999, J PATHOL, V187, P112; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; Stiewe T, 2002, CELL DEATH DIFFER, V9, P237, DOI 10.1038/sj.cdd.4400995; Tada M, 2001, CARCINOGENESIS, V22, P515, DOI 10.1093/carcin/22.3.515; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zaika AI, 2002, J EXP MED, V196, P765, DOI 10.1084/jem.20020179	39	37	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 14	2003	22	34					5252	5260		10.1038/sj.onc.1206511	http://dx.doi.org/10.1038/sj.onc.1206511			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JB	12917626	Green Published			2022-12-25	WOS:000184734900004
J	Delgado, M; Ganea, D				Delgado, M; Ganea, D			Vasoactive intestinal peptide prevents activated microglia-induced neurodegeneration under inflammatory conditions: potential therapeutic role in brain trauma	FASEB JOURNAL			English	Article						VIP; inflammation; endotoxin; cytokines; neuropeptides	TUMOR-NECROSIS-FACTOR; SPINAL-CORD-INJURY; MESSENGER-RNA; FACTOR-ALPHA; RAT-BRAIN; CHEMOKINE PRODUCTION; TNF-ALPHA; IN-VITRO; KAPPA-B; PITUITARY	In most neurodegenerative disorders, including multiple sclerosis, Parkinson's disease, and Alzheimer's disease, a massive neuronal cell death occurs as a consequence of an uncontrolled inflammatory response, where activated microglia and its cytotoxic agents play a crucial pathologic role. Because current treatments for these diseases are not effective, several regulatory molecules termed "microglia-deactivating factors" recently have been the focus of considerable research. Vasoactive intestinal peptide ( VIP) is a neuropeptide with a potent antiinflammatory effect, which has been found to protect from other inflammatory disorders, such as endotoxic shock and rheumatoid arthritis. In the present study, we investigate the effect of VIP on inflammation-mediated neurodegeneration in vitro and in vivo as well as on the putative neuroprotective effect of VIP on experimental pathological conditions in which central nervous system (CNS) inflammation is involved, such as brain trauma. The involvement of activated microglia and their derived cytotoxic products is also studied. VIP has a clear neuroprotective effect on inflammatory conditions by inhibiting the production of microglia-derived proinflammatory factors (tumor necrosis factor alpha, interleukin-1beta, nitric oxide). In this sense, VIP prevents neuronal cell death following brain trauma by reducing the inflammatory response of neighboring microglia. Therefore, VIP emerges as a valuable neuroprotective agent for the treatment of pathologic conditions of the CNS where inflammation-induced neurodegeneration occurs.	CSIC, Inst Parasitol & Biomed Lopez Neyra, Granada 18001, Spain; Rutgers State Univ, Dept Biol Sci, Newark, NJ 07102 USA	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN); Rutgers State University Newark; Rutgers State University New Brunswick	Delgado, M (corresponding author), CSIC, Inst Parasitol & Biomed Lopez Neyra, Granada 18001, Spain.	mdelgado@ipb.csic.es	Delgado, Mario/P-1524-2016	Delgado, Mario/0000-0003-1893-5982				Bartholdi D, 1997, EUR J NEUROSCI, V9, P1422, DOI 10.1111/j.1460-9568.1997.tb01497.x; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; CHAO CC, 1992, J IMMUNOL, V149, P2736; DAVID S, 1990, NEURON, V5, P463, DOI 10.1016/0896-6273(90)90085-T; de Yebenes EG, 1999, J NEUROCHEM, V73, P812, DOI 10.1046/j.1471-4159.1999.0730812.x; Delgado M, 1998, J BIOL CHEM, V273, P31427, DOI 10.1074/jbc.273.47.31427; Delgado M, 1999, J IMMUNOL, V162, P4685; Delgado M, 1999, J IMMUNOL, V162, P2358; Delgado M, 1999, J NEUROIMMUNOL, V96, P167, DOI 10.1016/S0165-5728(99)00023-5; Delgado M, 2003, FASEB J, V17, P944, DOI 10.1096/fj.02-0799fje; Delgado M, 2003, J LEUKOCYTE BIOL, V73, P155, DOI 10.1189/jlb.0702372; Delgado M, 1999, J IMMUNOL, V162, P1200; Delgado M, 2002, GLIA, V39, P148, DOI 10.1002/glia.10098; Delgado M, 2001, J IMMUNOL, V167, P966, DOI 10.4049/jimmunol.167.2.966; FRANK M, 1996, GLIA, V7, P146; Ganea D, 2001, MICROBES INFECT, V3, P141, DOI 10.1016/S1286-4579(00)01361-7; GIULIAN D, 1989, J NEUROSCI, V9, P4416; Gomariz RP, 2001, CURR PHARM DESIGN, V7, P89, DOI 10.2174/1381612013398374; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; Gourlet P, 1997, PEPTIDES, V18, P1539, DOI 10.1016/S0196-9781(97)00228-3; Gressens P, 1997, J CLIN INVEST, V100, P390, DOI 10.1172/JCI119545; HALL ED, 1982, SURG NEUROL, V18, P320, DOI 10.1016/0090-3019(82)90140-9; Harmar AJ, 1998, PHARMACOL REV, V50, P265; HIRSCHBERG DL, 1994, J NEUROIMMUNOL, V50, P9, DOI 10.1016/0165-5728(94)90209-7; Kim WG, 2000, J NEUROSCI, V20, P6309, DOI 10.1523/JNEUROSCI.20-16-06309.2000; KNO JY, 1987, J NEUROSCI, V20, P83; Lawrence CB, 1998, EUR J NEUROSCI, V10, P1188, DOI 10.1046/j.1460-9568.1998.00136.x; LAWSON LJ, 1990, NEUROSCIENCE, V39, P151, DOI 10.1016/0306-4522(90)90229-W; LIPTON JM, 1993, NEUROBIOLOGY CYTOK B, P61; MORENOFLORES MT, 1993, GLIA, V7, P146, DOI 10.1002/glia.440070204; Moro O, 1997, J BIOL CHEM, V272, P966, DOI 10.1074/jbc.272.2.966; Nadeau S, 2000, J NEUROSCI, V20, P3456, DOI 10.1523/JNEUROSCI.20-09-03456.2000; Offen D, 2000, BRAIN RES, V854, P257, DOI 10.1016/S0006-8993(99)02375-6; Pozo D, 2000, IMMUNOL TODAY, V21, P7, DOI 10.1016/S0167-5699(99)01525-X; Quan N, 1998, NEUROSCIENCE, V83, P281, DOI 10.1016/S0306-4522(97)00350-3; Rajora N, 1997, J NEUROSCI, V17, P2181; SAID SI, 1991, AM REV RESPIR DIS, V143, pS22, DOI 10.1164/ajrccm/143.3_Pt_2.S22; SAWADA M, 1990, BRAIN RES, V509, P119, DOI 10.1016/0006-8993(90)90317-5; SAWADA M, 1989, BRAIN RES, V491, P394, DOI 10.1016/0006-8993(89)90078-4; Schwartz M, 1999, TRENDS NEUROSCI, V22, P295, DOI 10.1016/S0166-2236(99)01405-8; SHER PK, 1990, GLIA, V3, P350, DOI 10.1002/glia.440030506; Streit WJ, 1998, EXP NEUROL, V152, P74, DOI 10.1006/exnr.1998.6835; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; WHITFIELD HJ, 1990, CELL MOL NEUROBIOL, V10, P145, DOI 10.1007/BF00733641; Xia MG, 1997, J PHARMACOL EXP THER, V281, P629; [No title captured]	46	96	101	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1922	+		10.1096/fj.02-1029fje	http://dx.doi.org/10.1096/fj.02-1029fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12923064				2022-12-25	WOS:000185345100006
J	Cheng, SL; Shao, JS; Charlton-Kachigian, N; Loewy, AP; Towler, DA				Cheng, SL; Shao, JS; Charlton-Kachigian, N; Loewy, AP; Towler, DA			Msx2 promotes osteogenesis and suppresses adipogenic differentiation of multipotent mesenchymal progenitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-2; MARROW STROMAL CELLS; VASCULAR CALCIFICATION; ARTERIAL CALCIFICATION; GENE-EXPRESSION; DEFICIENT MICE; TRANSCRIPTION; GROWTH; PROLIFERATION; OSTEOBLASTS	In the aorta, diabetes activates an osteogenic program that includes expression of bone morphogenetic protein-2 (BMP2) and the osteoblast homeoprotein Msx2. To evaluate BMP2-Msx2 signaling in vascular calcification, we studied primary aortic myofibroblasts. These cells express vascular smooth muscle cell (VSMC) markers, respond to BMP2 by up-regulating Msx2, and undergo osteogenic differentiation with BMP2 treatment or transduction with a virus encoding Msx2. The osteoblast factor osterix (Osx) is up-regulated 10-fold by Msx2, but Runx2 mRNA is unchanged; the early osteoblast marker alkaline phosphatase increases 50-fold with mineralized nodule formation enhanced 30-fold. Adipocyte markers are concomitantly suppressed. To better understand Msx2 actions on osteogenesis versus adipogenesis, mechanistic studies were extended to C3H10T1/2 mesenchymal cells. Msx2 enhances osteogenic differentiation in synergy with BMP2. Osteogenic actions depend upon intrinsic Msx2 DNA binding; the gain-of-function variant Msx2(P148H) directs enhanced mineralization, whereas the binding-deficient variant Msx2(T147A) is inactive. Adipogenesis ( lipid accumulation, Pparg expression) is inhibited by Msx2. By contrast, suppression of adipogenesis does not require Msx2 DNA binding; inhibition occurs in part via protein-protein interactions with C/EBPalpha that control Pparg transcription. Thus, Msx2 regulates osteogenic versus adipogenic differentiation of aortic myofibroblasts. Myofibroblasts capable of both fates can be diverted to the osteogenic lineage by BMP2-Msx2 signaling and contribute to vascular calcification.	Washington Univ, Med Ctr,Sch Med, Div Bone & Mineral Dis, Dept Med, St Louis, MO 63110 USA	Washington University (WUSTL)	Towler, DA (corresponding author), Washington Univ, Med Ctr,Sch Med, Div Bone & Mineral Dis, Dept Med, Barnes Jewish Hosp N Campus,216 S Kingshighway Bl, St Louis, MO 63110 USA.			Towler, Dwight/0000-0003-2107-7923	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069229] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043731, P01AR032087] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL69229] Funding Source: Medline; NIAMS NIH HHS [P01-AR032087, R01-AR43731] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AHRENS M, 1993, DNA CELL BIOL, V12, P871, DOI 10.1089/dna.1993.12.871; Bidder M, 2002, J BIOL CHEM, V277, P44485, DOI 10.1074/jbc.M206235200; BOSTROM K, 1993, J CLIN INVEST, V91, P1800, DOI 10.1172/JCI116391; Bostrom K, 2000, CRIT REV EUKAR GENE, V10, P151; Demer LL, 2002, CURR OPIN NEPHROL HY, V11, P437, DOI 10.1097/00041552-200207000-00011; Dennis JE, 2002, CELLS TISSUES ORGANS, V170, P73, DOI 10.1159/000046182; Doherty MJ, 1998, J BONE MINER RES, V13, P828, DOI 10.1359/jbmr.1998.13.5.828; Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0; Hirschi KK, 1998, J CELL BIOL, V141, P805, DOI 10.1083/jcb.141.3.805; Hu GZ, 2001, DEVELOPMENT, V128, P2373; Ishimura E, 2002, DIABETOLOGIA, V45, P1446, DOI 10.1007/s00125-002-0920-8; Kalajzic I, 2001, VIROLOGY, V284, P37, DOI 10.1006/viro.2001.0903; Katagiri T, 1997, EXP CELL RES, V230, P342, DOI 10.1006/excr.1996.3432; Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089; Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200; Lecanda F, 1997, J CELL BIOCHEM, V67, P386, DOI 10.1002/(SICI)1097-4644(19971201)67:3<386::AID-JCB10>3.3.CO;2-5; Lehto S, 1996, ARTERIOSCL THROM VAS, V16, P978, DOI 10.1161/01.ATV.16.8.978; Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092-8674(01)00622-5; Newberry EP, 1997, BIOCHEMISTRY-US, V36, P10451, DOI 10.1021/bi971008x; Newberry EP, 1997, J BIOL CHEM, V272, P29607, DOI 10.1074/jbc.272.47.29607; Odelberg SJ, 2000, CELL, V103, P1099, DOI 10.1016/S0092-8674(00)00212-9; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Parhami F, 1997, CURR OPIN LIPIDOL, V8, P312, DOI 10.1097/00041433-199710000-00010; PARK JC, 1993, AM HEART J, V125, P344, DOI 10.1016/0002-8703(93)90010-7; Patel MS, 2002, NEW ENGL J MED, V346, P1572, DOI 10.1056/NEJM200205163462011; Rifas L, 1997, P NATL ACAD SCI USA, V94, P7549, DOI 10.1073/pnas.94.14.7549; Rosen ED, 2000, GENE DEV, V14, P1293; Satokata I, 2000, NAT GENET, V24, P391, DOI 10.1038/74231; Shi S, 2003, J BONE MINER RES, V18, P696, DOI 10.1359/jbmr.2003.18.4.696; Shi XM, 2000, J CELL BIOCHEM, V76, P518, DOI 10.1002/(SICI)1097-4644(20000301)76:3<518::AID-JCB18>3.0.CO;2-M; Sirard C, 2000, J BIOL CHEM, V275, P2063, DOI 10.1074/jbc.275.3.2063; Thomas T, 1999, ENDOCRINOLOGY, V140, P5036, DOI 10.1210/en.140.11.5036; Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; Towler DA, 1998, J BIOL CHEM, V273, P30427, DOI 10.1074/jbc.273.46.30427; Tyson KL, 2003, ARTERIOSCL THROM VAS, V23, P489, DOI 10.1161/01.ATV.0000059406.92165.31; Willert Jennifer, 2002, BMC Dev Biol, V2, P8, DOI 10.1186/1471-213X-2-8; Willis DM, 2002, J BIOL CHEM, V277, P37280, DOI 10.1074/jbc.M206482200; Zebboudj AF, 2002, J BIOL CHEM, V277, P4388, DOI 10.1074/jbc.M109683200; Zhou YL, 2000, J BIOL CHEM, V275, P29066, DOI 10.1074/jbc.M002031200; Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a	41	279	295	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45969	45977		10.1074/jbc.M306972200	http://dx.doi.org/10.1074/jbc.M306972200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12925529	hybrid			2022-12-25	WOS:000186452300111
J	Rowlinson, SW; Kiefer, JR; Prusakiewicz, JJ; Pawlitz, JL; Kozak, KR; Kalgutkar, AS; Stallings, WC; Kurumbail, RG; Marnett, LJ				Rowlinson, SW; Kiefer, JR; Prusakiewicz, JJ; Pawlitz, JL; Kozak, KR; Kalgutkar, AS; Stallings, WC; Kurumbail, RG; Marnett, LJ			A novel mechanism of cyclooxygenase-2 inhibition involving interactions with Ser-530 and Tyr-385	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PROSTAGLANDIN G/H SYNTHASE-2; X-RAY-DIFFRACTION; SELECTIVE-INHIBITION; CRYSTAL-STRUCTURES; ARACHIDONIC-ACID; STRUCTURAL BASIS; NSAID BINDING; ACTIVE-SITE; H SYNTHASE	A variety of drugs inhibit the conversion of arachidonic acid to prostaglandin G(2) by the cyclooxygenase (COX) activity of prostaglandin endoperoxide synthases. Several modes of inhibitor binding in the COX active site have been described including ion pairing of carboxylic acid containing inhibitors with Arg-120 of COX-1 and COX-2 and insertion of arylsulfonamides and sulfones into the COX-2 side pocket. Recent crystallographic evidence suggests that Tyr-385 and Ser-530 chelate polar or negatively charged groups in arachidonic acid and aspirin. We tested the generality of this binding mode by analyzing the action of a series of COX inhibitors against site-directed mutants of COX-2 bearing changes in Arg-120, Tyr-355, Tyr-348, and Ser-530. Interestingly, diclofenac inhibition was unaffected by the mutation of Arg-120 to alanine but was dramatically attenuated by the S530A mutation. Determination of the crystal structure of a complex of diclofenac with murine COX-2 demonstrates that diclofenac binds to COX-2 in an inverted conformation with its carboxylate group hydrogen-bonded to Tyr-385 and Ser-530. This finding represents the first experimental demonstration that the carboxylate group of an acidic non-steroidal anti-inflammatory drug can bind to a COX enzyme in an orientation that precludes the formation of a salt bridge with Arg-120. Mutagenesis experiments suggest Ser-530 is also important in time-dependent inhibition by nimesulide and piroxicam.	Vanderbilt Univ, Sch Med,Dept Biochem, Vanderbilt Ingram Canc Ctr,Ctr Mol Toxicol, Vanderbilt Inst Chem Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med,Dept Chem, Vanderbilt Ingram Canc Ctr,Ctr Mol Toxicol, Vanderbilt Inst Chem Biol, Nashville, TN 37232 USA; Pfizer Inc, St Louis Res Labs, Chesterfield, MO 63017 USA	Vanderbilt University; Vanderbilt University; Pfizer	Kurumbail, RG (corresponding author), Pfizer Inc, St Louis Res Labs, Chesterfield, MO 63017 USA.	rgkuru@pfizer.com; marnett@toxicology.mc.vanderbilt.edu	ID, IMCACAT/D-5867-2014	Kiefer, James/0000-0001-6317-0902	NCI NIH HHS [CA68485, CA89450] Funding Source: Medline; NIEHS NIH HHS [ES00267] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485, R01CA089450] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bhattacharyya DK, 1996, J BIOL CHEM, V271, P2179, DOI 10.1074/jbc.271.4.2179; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Cromlish WA, 1996, BIOCHEM PHARMACOL, V52, P1777, DOI 10.1016/S0006-2952(96)00599-0; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; Fabiola GF, 1998, BIOORGAN MED CHEM, V6, P2337, DOI 10.1016/S0968-0896(98)80012-6; Garcia-Nieto R, 1999, RHEUMATOLOGY, V38, P14, DOI 10.1093/rheumatology/38.suppl_1.14; GIERSE JK, 1995, BIOCHEM J, V305, P479, DOI 10.1042/bj3050479; Greig GM, 1997, MOL PHARMACOL, V52, P829, DOI 10.1124/mol.52.5.829; Guo QP, 1996, J BIOL CHEM, V271, P19134, DOI 10.1074/jbc.271.32.19134; Guo QP, 1997, ARCH BIOCHEM BIOPHYS, V344, P150, DOI 10.1006/abbi.1997.0192; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P345, DOI 10.1073/pnas.71.2.345; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; Hochgesang GP, 2000, J AM CHEM SOC, V122, P6514, DOI 10.1021/ja0003932; Houtzager V, 1996, BIOCHEMISTRY-US, V35, P10974, DOI 10.1021/bi960053m; JIANG JS, 1994, J MOL BIOL, V243, P100, DOI 10.1006/jmbi.1994.1633; Kalgutkar AS, 2000, J MED CHEM, V43, P2860, DOI 10.1021/jm000004e; Kiefer JR, 2000, NATURE, V405, P97, DOI 10.1038/35011103; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; Kurumbail RG, 2001, CURR OPIN STRUC BIOL, V11, P752, DOI 10.1016/S0959-440X(01)00277-9; Llorens O, 2002, J MOL GRAPH MODEL, V20, P359, DOI 10.1016/S1093-3263(01)00135-8; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; Malkowski MG, 2000, SCIENCE, V289, P1933, DOI 10.1126/science.289.5486.1933; Mancini JA, 1997, MOL PHARMACOL, V51, P52, DOI 10.1124/mol.51.1.52; MANCINI JA, 1995, J BIOL CHEM, V270, P29372, DOI 10.1074/jbc.270.49.29372; MARKEY CM, 1987, J BIOL CHEM, V262, P6266; NUGTEREN DH, 1973, BIOCHIM BIOPHYS ACTA, V326, P448, DOI 10.1016/0005-2760(73)90145-8; ODENWALLER R, 1990, METHOD ENZYMOL, V187, P479; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; Rowlinson SW, 1999, J BIOL CHEM, V274, P23305, DOI 10.1074/jbc.274.33.23305; Selinsky BS, 2001, BIOCHEMISTRY-US, V40, P5172, DOI 10.1021/bi010045s; Simon LS, 1998, ARTHRITIS RHEUM-US, V41, P1591, DOI 10.1002/1529-0131(199809)41:9<1591::AID-ART9>3.0.CO;2-J; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Warner TD, 1999, P NATL ACAD SCI USA, V96, P7563, DOI 10.1073/pnas.96.13.7563	36	234	243	1	37	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45763	45769		10.1074/jbc.M305481200	http://dx.doi.org/10.1074/jbc.M305481200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12925531	hybrid			2022-12-25	WOS:000186452300087
J	Vernell, R; Helin, K; Muller, H				Vernell, R; Helin, K; Muller, H			Identification of target genes of the p16(INK4A)-pRB-E2F pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P16(INK4A)-MEDIATED GROWTH SUPPRESSION; E2F TRANSCRIPTION FACTORS; CELL-CYCLE; TGF-BETA; RETINOBLASTOMA-PROTEIN; C-MYC; LYMPHOCYTE DEVELOPMENT; MICROARRAY ANALYSIS; SIGNALING PATHWAYS; TUMOR-SUPPRESSOR	Deregulation of the retinoblastoma protein (pRB) pathway is a hallmark of human cancer. The core members of this pathway include the tumor suppressor protein, pRB, which through binding to a number of cellular proteins, most notably members of the E2F transcription factor family, regulates progression through the cell division cycle. With the aim of identifying transcriptional changes provoked by deregulation of the pRB pathway, we have used cell lines that conditionally express a constitutively active phosphorylation site mutant of pRB (pRBDeltaCDK) or p16(INK4A) (p16). The expression of pRBDeltaCDK and p16 resulted in significant repression and activation of a large number of genes as measured by high density oligonucleotide array analysis. Transcriptional changes were found in genes that are essential for DNA replication and cell proliferation. In agreement with previous results, we found a high degree of overlap between genes regulated by p16 and pRB. Data we have obtained previously for E2F family members showed that 74 of the genes repressed by pRB and p16 were induced by the E2Fs and 23 genes that were induced by pRB and p16 were repressed by the E2Fs. Thus, we have identified 97 genes as physiological targets of the pRB pathway, and the further characterization of these genes should provide insights into how this pathway controls proliferation. We show that Gibbs sampling detects enrichment of several sequence motifs, including E2F consensus binding sites, in the upstream regions of these genes and use this enrichment in an in silico filtering process to refine microarray derived gene lists.	European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; FIRC Inst Mol Oncol, I-20139 Milan, Italy	IRCCS European Institute of Oncology (IEO); IFOM - FIRC Institute of Molecular Oncology	Helin, K (corresponding author), European Inst Oncol, Dept Expt Oncol, Via Ripamonti 435, I-20141 Milan, Italy.	khelin@ieo.it	Helin, Kristian/HDM-8306-2022; Helin, Kristian/K-2526-2019	Helin, Kristian/0000-0003-1975-6097; Muller, Heiko/0000-0001-9873-3146				Altaba AR, 2002, NAT REV CANCER, V2, P361, DOI 10.1038/nrc796; Aplan PD, 1997, EMBO J, V16, P2408, DOI 10.1093/emboj/16.9.2408; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; BASCH RS, 1975, CELL IMMUNOL, V20, P218, DOI 10.1016/0008-8749(75)90099-4; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Cho RJ, 2001, NAT GENET, V27, P48, DOI 10.1038/83751; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Cortes U, 2000, MOL CARCINOGEN, V27, P57, DOI 10.1002/(SICI)1098-2744(200002)27:2<57::AID-MC1>3.3.CO;2-9; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; D'Andrea AD, 2003, NAT REV CANCER, V3, P23, DOI 10.1038/nrc970; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; Feng XH, 2002, MOL CELL, V9, P133, DOI 10.1016/S1097-2765(01)00430-0; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; Freeman M, 2000, NATURE, V408, P313, DOI 10.1038/35042500; Geng Y, 1996, ONCOGENE, V12, P1173; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Hughes JD, 2000, J MOL BIOL, V296, P1205, DOI 10.1006/jmbi.2000.3519; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Izraeli S, 1999, NATURE, V399, P691, DOI 10.1038/21429; Jiang H, 1998, MOL CELL BIOL, V18, P5284, DOI 10.1128/MCB.18.9.5284; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kel AE, 2001, J MOL BIOL, V309, P99, DOI 10.1006/jmbi.2001.4650; Koziczak M, 2000, MOL CELL BIOL, V20, P2014, DOI 10.1128/MCB.20.6.2014-2022.2000; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Lessnick SL, 2002, CANCER CELL, V1, P393, DOI 10.1016/S1535-6108(02)00056-9; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Lukas J, 1996, MOL CELL BIOL, V16, P1047; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Lukas J, 1999, ONCOGENE, V18, P3930, DOI 10.1038/sj.onc.1202777; Markey MP, 2002, CANCER RES, V62, P6587; Matsuda S, 2001, FEBS LETT, V497, P67, DOI 10.1016/S0014-5793(01)02436-X; Matsui T, 2002, J BIOL CHEM, V277, P36167, DOI 10.1074/jbc.M203184200; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; McArthur GA, 1998, COLD SPRING HARB SYM, V63, P423, DOI 10.1101/sqb.1998.63.423; Milech N, 2001, GENE CHROMOSOME CANC, V32, P275, DOI 10.1002/gcc.1190; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Nishimori H, 2002, ONCOGENE, V21, P8302, DOI 10.1038/sj.onc.1206025; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861; Polager S, 2002, ONCOGENE, V21, P437, DOI 10.1038/sj.onc.1205102; Rathmell JC, 2002, CELL, V109, pS97, DOI 10.1016/S0092-8674(02)00704-3; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Roth FP, 1998, NAT BIOTECHNOL, V16, P939, DOI 10.1038/nbt1098-939; SCHLESINGER DH, 1975, CELL, V5, P367, DOI 10.1016/0092-8674(75)90055-0; Schlisio S, 2002, EMBO J, V21, P5775, DOI 10.1093/emboj/cdf577; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; See MS, 1999, GENE, V240, P165, DOI 10.1016/S0378-1119(99)00415-1; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Stanelle J, 2002, NUCLEIC ACIDS RES, V30, P1859, DOI 10.1093/nar/30.8.1859; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; van de Wetering M, 2002, CELL, V109, pS13, DOI 10.1016/S0092-8674(02)00709-2; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; Wells J, 2003, ONCOGENE, V22, P1445, DOI 10.1038/sj.onc.1206264; Wong AKC, 2000, CANCER RES, V60, P6171; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	70	100	102	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					46124	46137		10.1074/jbc.M304930200	http://dx.doi.org/10.1074/jbc.M304930200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12923195	hybrid			2022-12-25	WOS:000186452300130
J	Mizoguchi, Y; Kanematsu, T; Hirata, M; Nabekura, J				Mizoguchi, Y; Kanematsu, T; Hirata, M; Nabekura, J			A rapid increase in the total number of cell surface functional GABA(A) receptors induced by brain-derived neurotrophic factor in rat visual cortex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR CA2+ ELEVATION; CRITICAL-PERIOD; DOWN-REGULATION; MESSENGER-RNA; NEURONS; BDNF; CURRENTS; INHIBITION; POTENTIATION; EXPRESSION	The number of postsynaptic gamma-aminobutyric acid type A (GABA(A)) receptors is a fundamental determinant of the variability of inhibitory synaptic responses in the central nervous system. In rat visual cortex, [H-3] SR-95531 binding assays revealed that brain-derived neurotrophic factor (BDNF), one of the neurotrophins, induced a rapid increase in the total number of cell surface GABA(A) receptors, through the activation of Trk B receptor tyrosine kinases. We also demonstrated that BDNF rapidly induced a sustained potentiation of GABA(A) receptor-mediated currents, using nystatin-perforated patch clamp recordings, in visual cortical layer 5 pyramidal neurons freshly isolated from P14 rats. The potentiation was caused by the activation of Trk B receptor tyrosine kinase and phospholipase C-gamma. In addition, intracellular Ca2+ was important for the potentiation of GABA(A) responses induced by BDNF. The selective increase in mean miniature inhibitory postsynaptic (mIPSC) current amplitude without effects on mIPSC time courses supports the idea that BDNF rapidly induces an increase in the total number of cell surface functional GABA(A) receptors in visual cortical pyramidal neurons. These results suggest that BDNF could alter the number of cell surface GABA(A) receptors in a region-specific manner.	Kyushu Univ, Grad Sch Med Sci, Fukuoka 8128582, Japan; Kyushu Univ, Fac Dent Sci, Lab Mol & Cellular Biochem, Fukuoka 8128582, Japan; Kyushu Univ, Stn Collaborat Res, Fukuoka 8128582, Japan	Kyushu University; Kyushu University; Kyushu University	Nabekura, J (corresponding author), Kyushu Univ, Grad Sch Med Sci, Fukuoka 8128582, Japan.	nabekura@mailserver.med.kyushu-u.ac.jp						Aguayo LG, 1998, PFLUG ARCH EUR J PHY, V435, P382, DOI 10.1007/s004240050527; Akaike N, 2003, TRENDS PHARMACOL SCI, V24, P44, DOI 10.1016/S0165-6147(02)00010-X; ALICKE B, 1995, J NEUROCHEM, V65, P2808; Bedford FK, 2001, NAT NEUROSCI, V4, P908, DOI 10.1038/nn0901-908; BERNINGER B, 1993, NEUROREPORT, V4, P1303, DOI 10.1097/00001756-199309150-00004; BOURGUIGNON JJ, 1985, PHARMACOLOGIST, V27, P518; BOZZI Y, 1995, NEUROSCIENCE, V69, P1133, DOI 10.1016/0306-4522(95)00321-9; Brunig I, 2001, EUR J NEUROSCI, V13, P1320, DOI 10.1046/j.0953-816x.2001.01506.x; Cabelli RJ, 1997, NEURON, V19, P63, DOI 10.1016/S0896-6273(00)80348-7; Capsoni S, 1999, NEUROSCIENCE, V93, P1033, DOI 10.1016/S0306-4522(99)00240-7; Cellerino A, 1996, EUR J NEUROSCI, V8, P1190, DOI 10.1111/j.1460-9568.1996.tb01287.x; CHEN QX, 1990, J PHYSIOL-LONDON, V420, P207, DOI 10.1113/jphysiol.1990.sp017908; Cheng Q, 2003, J PHYSIOL-LONDON, V548, P711, DOI 10.1113/jphysiol.2002.037846; Cherubini E, 2001, TRENDS NEUROSCI, V24, P155, DOI 10.1016/S0166-2236(00)01724-0; Fagiolini M, 2000, NATURE, V404, P183, DOI 10.1038/35004582; Feldman DE, 2000, NAT NEUROSCI, V3, P303, DOI 10.1038/73849; FELDMAN ML, 1978, J COMP NEUROL, V179, P761, DOI 10.1002/cne.901790406; FRERKING M, 1995, NEURON, V15, P885, DOI 10.1016/0896-6273(95)90179-5; GUNTHER U, 1995, P NATL ACAD SCI USA, V92, P7749, DOI 10.1073/pnas.92.17.7749; Hajos N, 2000, EUR J NEUROSCI, V12, P810, DOI 10.1046/j.1460-9568.2000.00964.x; Hashimoto T, 1996, J PHYSIOL-LONDON, V497, P611, DOI 10.1113/jphysiol.1996.sp021794; Hata Y, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-03-j0002.2000; Hensch TK, 1998, SCIENCE, V282, P1504, DOI 10.1126/science.282.5393.1504; Huang ZJ, 1999, CELL, V98, P739, DOI 10.1016/S0092-8674(00)81509-3; HUETTNER JE, 1986, J NEUROSCI, V6, P3044; INOUE M, 1986, NATURE, V324, P156, DOI 10.1038/324156a0; Kakazu Y, 2000, J NEUROPHYSIOL, V84, P281, DOI 10.1152/jn.2000.84.1.281; Kakazu Y, 1999, J NEUROSCI, V19, P2843; Kano M, 1996, P NATL ACAD SCI USA, V93, P13351, DOI 10.1073/pnas.93.23.13351; Katz LC, 1999, CELL, V99, P673, DOI 10.1016/S0092-8674(00)81665-7; Keller AF, 2001, J NEUROSCI, V21, P7871, DOI 10.1523/JNEUROSCI.21-20-07871.2001; Kilman V, 2002, J NEUROSCI, V22, P1328, DOI 10.1523/JNEUROSCI.22-04-01328.2002; Kittler JT, 2000, J NEUROSCI, V20, P7972; KNUSEL B, 1992, J NEUROCHEM, V59, P1987; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; MICHAELS RL, 1990, J NEUROSCI, V10, P283; Mizoguchi Y, 2003, NEUROREPORT, V14, P1481, DOI 10.1097/00001756-200308060-00015; Mizoguchi Y, 2003, J PHYSIOL-LONDON, V548, P703, DOI 10.1113/jphysiol.2003.038935; Mizoguchi Y, 2002, EUR J NEUROSCI, V16, P1417, DOI 10.1046/j.1460-9568.2002.02198.x; MURASE K, 1990, BRAIN RES, V525, P84, DOI 10.1016/0006-8993(90)91323-9; Nabekura J, 1996, J NEUROPHYSIOL, V76, P2447, DOI 10.1152/jn.1996.76.4.2447; Nabekura J, 2002, J NEUROSCI, V22, P4412, DOI 10.1523/JNEUROSCI.22-11-04412.2002; OTIS TS, 1994, P NATL ACAD SCI USA, V91, P7698, DOI 10.1073/pnas.91.16.7698; Patapoutian A, 2001, CURR OPIN NEUROBIOL, V11, P272, DOI 10.1016/S0959-4388(00)00208-7; Perrais D, 1999, J NEUROSCI, V19, P578; PETERS A, 1985, J COMP NEUROL, V234, P218, DOI 10.1002/cne.902340208; Rhee JS, 1999, J NEUROCHEM, V72, P800, DOI 10.1046/j.1471-4159.1999.0720800.x; ROGERS CJ, 1994, J PHYSIOL-LONDON, V475, P69, DOI 10.1113/jphysiol.1994.sp020050; Smart TG, 1997, CURR OPIN NEUROBIOL, V7, P358, DOI 10.1016/S0959-4388(97)80063-3; Tanaka T, 1997, J NEUROSCI, V17, P2959; TAPLEY P, 1992, ONCOGENE, V7, P371; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; Tropea D, 2001, EUR J NEUROSCI, V13, P709, DOI 10.1046/j.0953-816x.2000.01436.x; Wan Q, 1997, NATURE, V388, P686, DOI 10.1038/41792; WIDMER HR, 1993, J NEUROCHEM, V60, P2111, DOI 10.1111/j.1471-4159.1993.tb03496.x; YULE DI, 1992, J BIOL CHEM, V267, P13830; ZIVIN JA, 1982, LIFE SCI, V30, P1407, DOI 10.1016/0024-3205(82)90554-9	59	51	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44097	44102		10.1074/jbc.M305872200	http://dx.doi.org/10.1074/jbc.M305872200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12941963	hybrid			2022-12-25	WOS:000186306700027
J	Miranda, KC; Joseph, SR; Yap, AS; Teasdale, RD; Stow, JL				Miranda, KC; Joseph, SR; Yap, AS; Teasdale, RD; Stow, JL			Contextual binding of p120(ctn) to E-cadherin at the basolateral plasma membrane in polarized epithelia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DARBY CANINE KIDNEY; DI-LEUCINE MOTIF; CELL-ADHESION; P120 CATENIN; MDCK CELLS; CYTOPLASMIC TAIL; BETA-CATENIN; PROTEIN; COMPLEX; ENDOCYTOSIS	E-cadherin-catenin complexes mediate cell-cell adhesion on the basolateral membrane of epithelial cells. The cytoplasmic tail of E-cadherin supports multiple protein interactions, including binding of beta-catenin at the C terminus and of p120(ctn) to the juxtamembrane domain. The temporal assembly and polarized trafficking of the complex or its individual components to the basolateral membrane are not fully understood. In Madin-Darby canine kidney cells at steady state and after treatment with cycloheximide or temperature blocks, E-cadherin and beta-catenin localized to the Golgi complex, but p120ctn was found only at the basolateral plasma membrane. We previously identified a dileucine sorting motif (Leu(586)-Leu(587), termed S1) in the juxtamembrane domain of E-cadherin and now show that it is required to target full-length E-cadherin to the basolateral membrane. Removal of S1 resulted in missorting of E-cadherin mutants (EcadDeltaS1) to the apical membrane; beta-catenin was simultaneously missorted and appeared at the apical membrane. p120(ctn) was not mistargeted with EcadDeltaS1, but could be recruited to the E-cadherin-catenin complex only at the basolateral membrane. These findings help define the temporal assembly and sorting of the E-cadherin-catenin complex and show that membrane recruitment of p120(ctn) in polarized cells is contextual and confined to the basolateral membrane.	Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia; Univ Queensland, Sch Mol & Microbial Sci, Brisbane, Qld 4072, Australia	University of Queensland; University of Queensland; University of Queensland	Stow, JL (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.	j.stow@imb.uq.edu.au	Teasdale, Rohan/AAD-6698-2019; Teasdale, Rohan D/B-2538-2009; Joseph, Shannon/F-9844-2011; Stow, Jennifer L/I-4723-2013; Yap, Alpha S./J-1554-2014	Teasdale, Rohan/0000-0001-7455-5269; Teasdale, Rohan D/0000-0001-7455-5269; Stow, Jennifer L/0000-0002-5409-9101; Yap, Alpha S./0000-0002-1038-8956				Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637, DOI 10.1038/35023588; Baki L, 2001, P NATL ACAD SCI USA, V98, P2381, DOI 10.1073/pnas.041603398; Bello V, 2001, MOL BIOL CELL, V12, P3004, DOI 10.1091/mbc.12.10.3004; Ben-Ze'ev A, 2000, EXP CELL RES, V261, P75, DOI 10.1006/excr.2000.5045; Brieher WM, 1996, J CELL BIOL, V135, P487, DOI 10.1083/jcb.135.2.487; Chen YT, 1999, J CELL BIOL, V144, P687, DOI 10.1083/jcb.144.4.687; Craig HM, 2000, VIROLOGY, V271, P9, DOI 10.1006/viro.2000.0277; Daniel JM, 1999, MOL CELL BIOL, V19, P3614; DECURTIS I, 1988, EXP CELL RES, V175, P248, DOI 10.1016/0014-4827(88)90190-5; El Nemer W, 1999, J BIOL CHEM, V274, P31903, DOI 10.1074/jbc.274.45.31903; Fujita H, 1999, BIOCHEM BIOPH RES CO, V255, P54, DOI 10.1006/bbrc.1998.0140; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; GALLOWAY CJ, 1988, METHOD ENZYMOL, V157, P601; Grosheva I, 2001, J CELL SCI, V114, P695; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; Holsinger LJ, 2002, ONCOGENE, V21, P7067, DOI 10.1038/sj.onc.1205858; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115; Izawa I, 2002, GENES CELLS, V7, P475, DOI 10.1046/j.1365-2443.2002.00533.x; Jaulin-Bastard F, 2002, J BIOL CHEM, V277, P2869, DOI 10.1074/jbc.M109652200; Keilhack H, 2000, J BIOL CHEM, V275, P26376, DOI 10.1074/jbc.M001315200; KOOY J, 1992, J BIOL CHEM, V267, P20255; Kovacs EM, 2002, CURR BIOL, V12, P379, DOI 10.1016/S0960-9822(02)00661-9; Laura RP, 2002, J BIOL CHEM, V277, P12906, DOI 10.1074/jbc.M200818200; Le TL, 2002, AM J PHYSIOL-CELL PH, V283, pC489, DOI 10.1152/ajpcell.00566.2001; Le TL, 1999, J CELL BIOL, V146, P219, DOI 10.1083/jcb.146.1.219; LEBIVIC A, 1990, J CELL BIOL, V110, P1533, DOI 10.1083/jcb.110.5.1533; Lecuit M, 1999, EMBO J, V18, P3956, DOI 10.1093/emboj/18.14.3956; LEVINE E, 1994, DEVELOPMENT, V120, P901; Meigs TE, 2001, P NATL ACAD SCI USA, V98, P519, DOI 10.1073/pnas.021350998; Miranda KC, 2001, J BIOL CHEM, V276, P22565, DOI 10.1074/jbc.M101907200; MOSTOV KE, 1986, CELL, V46, P613, DOI 10.1016/0092-8674(86)90887-1; NELSON WJ, 1990, J CELL BIOL, V110, P349, DOI 10.1083/jcb.110.2.349; OZAWA M, 1992, J CELL BIOL, V116, P989, DOI 10.1083/jcb.116.4.989; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; Sambrook J., 1989, MOL CLONING LAB MANU, V2; STAPPERT J, 1994, CELL ADHES COMMUN, V2, P319, DOI 10.3109/15419069409014207; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; Wahl JK, 2003, J BIOL CHEM, V278, P17269, DOI 10.1074/jbc.M211452200; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; Yap AS, 1998, J CELL BIOL, V141, P779, DOI 10.1083/jcb.141.3.779; Zondag GCM, 2000, J BIOL CHEM, V275, P11264, DOI 10.1074/jbc.275.15.11264	46	50	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43480	43488		10.1074/jbc.M305525200	http://dx.doi.org/10.1074/jbc.M305525200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12923199	hybrid			2022-12-25	WOS:000186157000093
J	Murakami, M; Yamamura, H; Suzuki, T; Kang, MG; Ohya, S; Murakami, A; Miyoshi, I; Sasano, H; Muraki, K; Hano, T; Kasai, N; Nakayama, S; Campbell, KP; Flockerzi, V; Imaizumi, Y; Yanagisawa, T; Iijima, T				Murakami, M; Yamamura, H; Suzuki, T; Kang, MG; Ohya, S; Murakami, A; Miyoshi, I; Sasano, H; Muraki, K; Hano, T; Kasai, N; Nakayama, S; Campbell, KP; Flockerzi, V; Imaizumi, Y; Yanagisawa, T; Iijima, T			Modified cardiovascular L-type channels in mice lacking the voltage-dependent Ca2+ channel beta 3 subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; CALCIUM-CHANNEL; FUNCTIONAL EXPRESSION; INACTIVATION; ALPHA(1); HEART	The beta subunits of voltage-dependent calcium channels are known to modify calcium channel currents through pore-forming alpha(1) subunits. Of the four beta subunits reported to date, the beta3 subunit is highly expressed in smooth muscle cells and is thought to consist of L-type calcium channels. To determine the role of the beta3 subunit in the voltage-dependent calcium channels of the cardiovascular system in situ, we performed a series of experiments in beta-null mice. Western blot analysis indicated a significant reduction in expression of the alpha(1) subunit in the plasma membrane of beta3-null mice. Dihydropyridine binding experiments also revealed a significant decrease in the calcium channel population in the aorta. Electrophysiological analyses indicated a 30% reduction in Ca2+ channel current density, a slower inactivation rate, and a decreased dihydropyridine-sensitive current in beta3-null mice. The reductions in the peak current density and inactivation rate were reproduced in vitro by co-expression of the calcium channel subunits in Chinese hamster ovary cells. Despite the reduced channel population, beta3-null mice showed normal blood pressure, whereas a significant reduction in dihydropyridine responsiveness was observed. A high salt diet significantly elevated blood pressure only in the beta3-null mice and resulted in hypertrophic changes in the aortic smooth muscle layer and cardiac enlargement. In conclusion, this study demonstrates the involvement and importance of the beta3 subunit of voltage-dependent calcium channels in the cardiovascular system and in regulating channel populations and channel properties in vascular smooth muscle cells.	Akita Univ, Sch Med, Dept Pharmacol, Akita 0108543, Japan; Nagoya City Univ, Grad Sch Pharmaceut Sci, Dept Mol & Cellular Pharmacol, Nagoya, Aichi 4678603, Japan; Tohoku Univ, Sch Med, Dept Pathol, Sendai, Miyagi 9808575, Japan; Tohoku Univ, Sch Med, Inst Anim Experimentat, Sendai, Miyagi 9808575, Japan; Tohoku Univ, Sch Med, Dept Mol Pharmacol, Sendai, Miyagi 9808575, Japan; Wakayama Med Coll, Dept Med, Div Cardiol, Wakayama 6418509, Japan; Nagoya Univ, Grad Sch Med, Dept Cell Physiol, Nagoya, Aichi 4668550, Japan; Univ Iowa, Howard Hughes Med Inst, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Univ Saarland, Inst Pharmakol & Toxikol, D-66421 Homburg, Germany	Akita University; Nagoya City University; Tohoku University; Tohoku University; Tohoku University; Wakayama Medical University; Nagoya University; Howard Hughes Medical Institute; University of Iowa; Saarland University	Murakami, A (corresponding author), Akita Univ, Sch Med, Dept Pharmacol, 1-1-1 Hondou, Akita 0108543, Japan.	manabumurakami@excite.co.jp	Ohya, Susumu/AAB-3618-2020; Imaizumi, Yuji/AAF-6585-2020	Ohya, Susumu/0000-0002-5765-0667; Kang, Myoung-Goo/0000-0003-2649-219X; Campbell, Kevin/0000-0003-2066-5889				Aoyama M, 2003, BIOPHYS J, V84, P709, DOI 10.1016/S0006-3495(03)74890-5; Bichet D, 2000, NEURON, V25, P177, DOI 10.1016/S0896-6273(00)80881-8; BOSSE E, 1992, EMBO J, V11, P2033, DOI 10.1002/j.1460-2075.1992.tb05260.x; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; COLLIN T, 1994, EUR J BIOCHEM, V220, P257, DOI 10.1111/j.1432-1033.1994.tb18621.x; DEWAARD M, 1995, J BIOL CHEM, V270, P12056, DOI 10.1074/jbc.270.20.12056; HOFMANN F, 1994, ANNU REV NEUROSCI, V17, P399, DOI 10.1146/annurev.neuro.17.1.399; Hullin R, 2003, J BIOL CHEM, V278, P21623, DOI 10.1074/jbc.M211164200; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; IMAIZUMI Y, 1990, J PHYSIOL-LONDON, V427, P301, DOI 10.1113/jphysiol.1990.sp018173; Jaggar JH, 2000, AM J PHYSIOL-CELL PH, V278, pC235, DOI 10.1152/ajpcell.2000.278.2.C235; JOHN SWM, 1995, SCIENCE, V267, P679, DOI 10.1126/science.7839143; Kang MG, 2001, J BIOL CHEM, V276, P32917, DOI 10.1074/jbc.M100787200; LACINOVA L, 1995, J PHARMACOL EXP THER, V274, P54; Murakami M, 2002, J BIOL CHEM, V277, P40342, DOI 10.1074/jbc.M203425200; Murakami M, 2000, J CARDIOVASC PHARM, V36, pS69, DOI 10.1097/00005344-200000006-00015; NEELY A, 1993, SCIENCE, V262, P575, DOI 10.1126/science.8211185; NEHER E, 1992, METHOD ENZYMOL, V207, P123; NISHIMURA S, 1993, FEBS LETT, V324, P283, DOI 10.1016/0014-5793(93)80135-H; Ohi Y, 2001, J PHYSIOL-LONDON, V534, P313, DOI 10.1111/j.1469-7793.2001.t01-3-00313.x; Perez-Reyes E, 1998, NATURE, V391, P896, DOI 10.1038/36110; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; STRIESSNIG J, 1986, FEBS LETT, V197, P204, DOI 10.1016/0014-5793(86)80327-1; Tareilus E, 1997, P NATL ACAD SCI USA, V94, P1703, DOI 10.1073/pnas.94.5.1703; VARADI G, 1991, NATURE, V352, P159, DOI 10.1038/352159a0; WELLING A, 1993, J PHYSIOL-LONDON, V471, P749, DOI 10.1113/jphysiol.1993.sp019926; WELLING A, 1995, PFLUG ARCH EUR J PHY, V429, P400, DOI 10.1007/BF00374156; WITCHER DR, 1993, SCIENCE, V261, P486, DOI 10.1126/science.8392754	29	41	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43261	43267		10.1074/jbc.M211380200	http://dx.doi.org/10.1074/jbc.M211380200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12920136	hybrid, Green Submitted			2022-12-25	WOS:000186157000068
J	Rodriguez, CI; Girones, N; Fresno, M				Rodriguez, CI; Girones, N; Fresno, M			Cha, a basic helix-loop-helix transcription factor involved in the regulation of upstream stimulatory factor activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; PROTEIN-KINASE-C; T-CELL; GENE-EXPRESSION; MAMMALIAN-CELLS; FACTOR-BINDING; USF FAMILY; ACTIVATION; CD2; PROMOTER	We report here the characterization of Cha, a transcription factor of the basic helix-loop-helix (bHLH) family. The basic region of Cha shares DNA-interacting amino acids with members of class C bHLH transcription factors. In addition, the HLH region of Cha presents a Myc-type dimerization domain signature required for heterodimer formation between members of this class. Cha protein and mRNA were ubiquitously expressed in many human tissues. Electrophoretic mobility shift assays showed that Cha and upstream stimulatory factor (USF)-1 formed a complex that specifically bound to E-box DNA elements. Moreover, pull-down and co-immunoprecipitation experiments showed an interaction between Cha and USF-1. Cha did not bind to E-box DNA elements and required USF-1 for protein-DNA complex formation. Moreover, Cha inhibited USF-1-stimulated transcription of CD2 (a USF-1-dependent gene) and E-box promoter reporter plasmids. Chromatin immunoprecipitation assays showed that Cha occupied the CD2 promoter in resting, but not in mitogen-stimulated, T cells. Finally, Cha mRNA and protein expression were high in resting T cells and absent in mitogen-activated T cells and inversely correlated with CD2 expression. Contrarily, overexpression of Cha in T cells significantly reduced CD2 expression. In summary, our results indicated that Cha is a new bHLH transcription factor that negatively regulates USF-dependent transcription.	Univ Autonoma Madrid, CSIC, Ctr Biol Mol, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Fresno, M (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Biol Mol, E-28049 Madrid, Spain.		Rodríguez, Clara/E-4835-2012; Rodriguez, Clara I./E-5402-2012; Girones, Nuria/L-7865-2017; Gironès, Núria/AAR-7436-2020	Rodriguez, Clara I./0000-0002-6749-6288; Girones, Nuria/0000-0002-8130-2750; Gironès, Núria/0000-0002-8130-2750; Girones Pujol, Nuria/0000-0002-0932-5018; Fresno Escudero, Manuel/0000-0002-9223-5477				ALCONADA A, 1994, J BIOL CHEM, V269, P13670; Andrews GK, 2000, BIOCHEM PHARMACOL, V59, P95, DOI 10.1016/S0006-2952(99)00301-9; Bachmann MF, 1999, J EXP MED, V190, P1383, DOI 10.1084/jem.190.10.1383; Boyd KE, 1999, MOL CELL BIOL, V19, P8393; Brownlie P, 1997, STRUCTURE, V5, P509, DOI 10.1016/S0969-2126(97)00207-4; BUCKINGHAM M, 1992, TRENDS GENET, V8, P144, DOI 10.1016/0168-9525(92)90373-C; CANTRELL DA, 1988, EUR J IMMUNOL, V18, P1391, DOI 10.1002/eji.1830180914; Casado M, 1999, J BIOL CHEM, V274, P2009, DOI 10.1074/jbc.274.4.2009; DANG CV, 1992, P NATL ACAD SCI USA, V89, P599, DOI 10.1073/pnas.89.2.599; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FRENCH BA, 1991, MOL CELL BIOL, V11, P2439, DOI 10.1128/MCB.11.5.2439; Giannola DM, 2000, J EXP MED, V192, P1479, DOI 10.1084/jem.192.10.1479; Girones N, 2001, J CLIN INVEST, V107, P985, DOI 10.1172/JCI10734; HAHN WC, 1993, J IMMUNOL, V150, P2607; Heckert LL, 2001, MOL ENDOCRINOL, V15, P704, DOI 10.1210/me.15.5.704; Henrion AA, 1996, MAMM GENOME, V7, P803, DOI 10.1007/s003359900241; Howcroft TK, 1999, MOL CELL BIOL, V19, P4788; KOSKINEN PJ, 1993, SEMIN CANCER BIOL, V4, P3; Krones A, 2001, ENDOCRINOLOGY, V142, P2707, DOI 10.1210/en.142.6.2707; LARSSON LG, 1994, ONCOGENE, V9, P1247; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; Luo X, 1996, P NATL ACAD SCI USA, V93, P1308, DOI 10.1073/pnas.93.3.1308; Luscher B, 1999, ONCOGENE, V18, P2955, DOI 10.1038/sj.onc.1202750; Martin AG, 2000, J BIOL CHEM, V275, P24383, DOI 10.1074/jbc.M909396199; Maruyama O, 1998, CYTOGENET CELL GENET, V82, P41, DOI 10.1159/000015061; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MONOSTORI E, 1990, J IMMUNOL, V144, P1010; Moon YS, 2000, J BIOL CHEM, V275, P10121, DOI 10.1074/jbc.275.14.10121; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NEUHOLD LA, 1993, CELL, V74, P1033, DOI 10.1016/0092-8674(93)90725-6; Nicolas G, 2001, P NATL ACAD SCI USA, V98, P8780, DOI 10.1073/pnas.151179498; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; OUTRAM SV, 1994, J BIOL CHEM, V269, P26525; Peters MA, 1997, MOL CELL BIOL, V17, P1037, DOI 10.1128/MCB.17.3.1037; PIMENTELMUINOS FX, 1994, J BIOL CHEM, V269, P24424; Sambrook J., 2002, MOL CLONING LAB MANU; Sasada T, 2001, J IMMUNOL, V166, P2394, DOI 10.4049/jimmunol.166.4.2394; Sirito M, 1998, P NATL ACAD SCI USA, V95, P3758, DOI 10.1073/pnas.95.7.3758; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; Sirito Mario, 1992, Gene Expression, V2, P231; Smih F, 2002, DIABETES, V51, P293, DOI 10.2337/diabetes.51.2.293; Tibaldi EV, 2002, P NATL ACAD SCI USA, V99, P7582, DOI 10.1073/pnas.112212699; Vallet VS, 1997, J BIOL CHEM, V272, P21944, DOI 10.1074/jbc.272.35.21944; Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3	48	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43135	43145		10.1074/jbc.M300053200	http://dx.doi.org/10.1074/jbc.M300053200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12923186	hybrid			2022-12-25	WOS:000186157000054
J	Zhao, RX; Fu, XQ; Teng, LR; Li, QS; Zhao, ZHJ				Zhao, RX; Fu, XQ; Teng, LR; Li, QS; Zhao, ZHJ			Blocking the function of tyrosine phosphatase SHP-2 by targeting its Src homology 2 domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; HEMATOPOIETIC-CELL DEVELOPMENT; ACTIVATED PROTEIN-KINASE; CRYSTAL-STRUCTURE; NOONAN-SYNDROME; PTPN11 MUTATIONS; SH2 DOMAINS; SH-PTP2; INSULIN; PURIFICATION	SHP-2 is an Src homology 2 (SH2) domain-containing tyrosine phosphatase with crucial functions in cell signaling and major pathological implications. It stays inactive in the cytosol and is activated by binding through its SH2 domains to tyrosine-phosphorylated receptors on the cell surface. One such cell surface protein is PZR, which contains two tyrosine-based inhibition motifs responsible for binding of SHP-2. We have generated a glutathione S-transferase fusion protein carrying the tandem tyrosine-based inhibition motifs of PZR, and the protein was tyrosine-phosphorylated by co-expressing c-Src in Escherichia coli cells. The purified phosphoprotein displays a strong binding to SHP-2 and causes its activation in vitro. However, when introduced into NIH 3T3 cells by using a protein delivery reagent, it effectively inhibited the activation of ERK1/2 induced by growth factors and serum but not by phorbol ester, in reminiscence of the effects caused by expression of dominant negative SHP-2 mutants and deletion of functional SHP-2. The data suggest that the exogenously introduced PZR protein specifically binds SHP-2, blocks its translocation, and renders it functionally incompetent. This is further supported by the fact that the phosphorylated PZR protein had no inhibitory effects on fibroblasts derived from mice expressing only a mutant SHP-2 protein lacking most of the N-terminal SH2 domain. This study thus provides a novel and highly specific method to interrupt the function of SHP-2 in cells.	Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Dept Med, Div Hematol Oncol, Nashville, TN 37232 USA; Jilin Univ, Coll Life Sci, Key Lab Mol Enzymol & Engn, Minist Educ, Changchun 130023, Peoples R China	Vanderbilt University; Jilin University	Zhao, ZHJ (corresponding author), 777,PRB,2220 Pierce Ave, Nashville, TN 37232 USA.				NCI NIH HHS [CA75218] Funding Source: Medline; NHLBI NIH HHS [HL57393] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075218] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057393] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bennett AM, 1996, MOL CELL BIOL, V16, P1189; Dunican DJ, 2001, BIOPOLYMERS, V60, P45, DOI 10.1002/1097-0282(2001)60:1<45::AID-BIP1003>3.3.CO;2-0; Feng GS, 1999, EXP CELL RES, V253, P47, DOI 10.1006/excr.1999.4668; Hawiger J, 1999, CURR OPIN CHEM BIOL, V3, P89, DOI 10.1016/S1367-5931(99)80016-7; Higashi H, 2002, SCIENCE, V295, P683, DOI 10.1126/science.1067147; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; Maheshwari M, 2002, HUM MUTAT, V20, P298, DOI 10.1002/humu.10129; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; Qu CK, 2001, BLOOD, V97, P911, DOI 10.1182/blood.V97.4.911; Qu CK, 1997, MOL CELL BIOL, V17, P5499, DOI 10.1128/MCB.17.9.5499; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; Rojas M, 1998, NAT BIOTECHNOL, V16, P370, DOI 10.1038/nbt0498-370; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Shi ZQ, 2000, MOL CELL BIOL, V20, P1526, DOI 10.1128/MCB.20.5.1526-1536.2000; Shi ZQ, 1998, J BIOL CHEM, V273, P4904, DOI 10.1074/jbc.273.9.4904; Streuli M, 1996, CURR OPIN CELL BIOL, V8, P182, DOI 10.1016/S0955-0674(96)80064-0; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; Tartaglia M, 2001, NAT GENET, V29, P465, DOI 10.1038/ng772; Tartaglia M, 2002, AM J HUM GENET, V70, P1555, DOI 10.1086/340847; TOMIC S, 1995, J BIOL CHEM, V270, P21277, DOI 10.1074/jbc.270.36.21277; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; XIAO S, 1994, J BIOL CHEM, V269, P21244; Xu MJ, 2000, J BIOL CHEM, V275, P17440, DOI 10.1074/jbc.M001313200; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; Yang J, 2003, J BIOL CHEM, V278, P6516, DOI 10.1074/jbc.M210430200; Yang J, 1998, J BIOL CHEM, V273, P28199, DOI 10.1074/jbc.273.43.28199; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; Zhao RX, 2000, J BIOL CHEM, V275, P5453, DOI 10.1074/jbc.275.8.5453; Zhao RX, 1999, BIOCHEM J, V338, P35, DOI 10.1042/0264-6021:3380035; Zhao RX, 2002, J BIOL CHEM, V277, P7882, DOI 10.1074/jbc.M111914200; ZHAO ZH, 1993, P NATL ACAD SCI USA, V90, P4251, DOI 10.1073/pnas.90.9.4251; ZHAO ZZ, 1994, J BIOL CHEM, V269, P8780; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765; ZHAO ZZ, 1993, J BIOL CHEM, V268, P2816	38	18	18	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42893	42898		10.1074/jbc.M306136200	http://dx.doi.org/10.1074/jbc.M306136200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12913007	hybrid			2022-12-25	WOS:000186157000021
J	Kim, SJ; Martinson, HG				Kim, SJ; Martinson, HG			Poly(A)-dependent transcription termination - Continued communication of the poly(A) signal with the polymerase is required long after extrusion in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; B-CELL DIFFERENTIATION; DOUBLE-STRANDED-RNA; SACCHAROMYCES-CEREVISIAE; DOWNSTREAM ELEMENT; POLYADENYLATION; ELONGATION; MECHANISM; CSTF-64; SITE	Genes encoding polyadenylated mRNAs depend on their poly(A) signals for termination of transcription. An unsolved problem is how the poly(A) signal triggers the polymerase to terminate. A popular model is that this occurs during extrusion of the poly(A) signal, at which time it interacts with factors on the transcription complex. To test this idea we used cis-antisense inhibition in vivo to probe the temporal relationship between poly(A) signal extrusion and the commitment of the polymerase to terminate. Our rationale was to inactivate the poly(A) signal at increasing times post-extrusion to determine the point beyond which it is no longer required for termination. We found that communication with the polymerase is not temporally restricted to the time of poly(A) signal extrusion, but is ongoing and perhaps random. Some polymerases terminate almost immediately. Others have yet to receive their termination instructions from the poly(A) signal even 500 bp downstream, as indicated by the ability of an antisense at this distance to block termination. Thus, the poly(A) signal can functionally interact with the polymerase at considerable distances down the template. This is consistent with the emerging picture of a processing apparatus that assembles and matures while riding with the polymerase.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Martinson, HG (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050863] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 50863] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aranda A, 2001, MOL CELL, V7, P1003, DOI 10.1016/S1097-2765(01)00235-0; Aranda A, 1998, RNA, V4, P303; Artsimovitch I, 2000, P NATL ACAD SCI USA, V97, P7090, DOI 10.1073/pnas.97.13.7090; Artsimovitch I, 2002, CELL, V109, P193, DOI 10.1016/S0092-8674(02)00724-9; BAGGA PS, 1995, NUCLEIC ACIDS RES, V23, P1625, DOI 10.1093/nar/23.9.1625; Barilla D, 2001, P NATL ACAD SCI USA, V98, P445, DOI 10.1073/pnas.021545298; Bentley D, 2002, CURR OPIN CELL BIOL, V14, P336, DOI 10.1016/S0955-0674(02)00333-2; Calvo O, 2001, MOL CELL, V7, P1013, DOI 10.1016/S1097-2765(01)00236-2; Canadillas JMP, 2003, EMBO J, V22, P2821, DOI 10.1093/emboj/cdg259; Chao LC, 1999, MOL CELL BIOL, V19, P5588; CHODCHOY N, 1991, MOL CELL BIOL, V11, P497, DOI 10.1128/MCB.11.1.497; Colgan DF, 1997, GENE DEV, V11, P2755, DOI 10.1101/gad.11.21.2755; Condit RC, 2002, BBA-GENE STRUCT EXPR, V1577, P325, DOI 10.1016/S0167-4781(02)00461-X; Cramer P, 2000, SCIENCE, V288, P640, DOI 10.1126/science.288.5466.640; Dantonel JC, 1997, NATURE, V389, P399, DOI 10.1038/38763; Dichtl B, 2002, EMBO J, V21, P4125, DOI 10.1093/emboj/cdf390; Fish RN, 2002, BBA-GENE STRUCT EXPR, V1577, P287, DOI 10.1016/S0167-4781(02)00459-1; Fong N, 2001, GENE DEV, V15, P1783, DOI 10.1101/gad.889101; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; Gu XH, 1996, NUCLEIC ACIDS RES, V24, P3797, DOI 10.1093/nar/24.19.3797; HAGLER J, 1994, J BIOL CHEM, V269, P10050; Hirose Y, 2000, GENE DEV, V14, P1415; Liang XH, 2003, P NATL ACAD SCI USA, V100, P7521, DOI 10.1073/pnas.1332001100; LIU Z, 1994, P NATL ACAD SCI USA, V91, P4258, DOI 10.1073/pnas.91.10.4258; LOGAN J, 1987, P NATL ACAD SCI USA, V84, P8306, DOI 10.1073/pnas.84.23.8306; LUTZ CS, 1994, GENE DEV, V8, P576, DOI 10.1101/gad.8.5.576; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; Medlin JE, 2003, EMBO J, V22, P925, DOI 10.1093/emboj/cdg077; Mette MF, 2000, EMBO J, V19, P5194, DOI 10.1093/emboj/19.19.5194; Mohamed MR, 2003, J BIOL CHEM, V278, P11794, DOI 10.1074/jbc.M213263200; Mooney RA, 1998, J BACTERIOL, V180, P3265, DOI 10.1128/JB.180.13.3265-3275.1998; Orozco IJ, 2002, J BIOL CHEM, V277, P42899, DOI 10.1074/jbc.M207415200; Osheim YN, 1999, MOL CELL, V3, P379, DOI 10.1016/S1097-2765(00)80465-7; PROUDFOOT NJ, 1989, TRENDS BIOCHEM SCI, V14, P105, DOI 10.1016/0968-0004(89)90132-1; Proudfoot NJ, 2002, CELL, V108, P501, DOI 10.1016/S0092-8674(02)00617-7; ROHRMANN G, 1986, CELL, V46, P1029, DOI 10.1016/0092-8674(86)90702-6; Sadowski M, 2003, EMBO J, V22, P2167, DOI 10.1093/emboj/cdg200; Sanders SL, 2002, MOL CELL BIOL, V22, P4723, DOI 10.1128/MCB.22.13.4723-4738.2002; Takagaki Y, 2000, MOL CELL BIOL, V20, P1515, DOI 10.1128/MCB.20.5.1515-1525.2000; Takagaki Y, 1998, MOL CELL, V2, P761, DOI 10.1016/S1097-2765(00)80291-9; Takagaki Y, 1996, CELL, V87, P941, DOI 10.1016/S0092-8674(00)82000-0; Tran DP, 2001, MOL CELL BIOL, V21, P7495, DOI 10.1128/MCB.21.21.7495-7508.2001; Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973; Yankulov K, 1999, MOL CELL BIOL, V19, P6154; Yeung G, 1998, MOL CELL BIOL, V18, P276, DOI 10.1128/MCB.18.1.276; Yonaha M, 2000, EMBO J, V19, P3770, DOI 10.1093/emboj/19.14.3770; Zhao J, 1999, MICROBIOL MOL BIOL R, V63, P405, DOI 10.1128/MMBR.63.2.405-445.1999	48	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41691	41701		10.1074/jbc.M306304200	http://dx.doi.org/10.1074/jbc.M306304200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12933817				2022-12-25	WOS:000185989500019
J	Kok, T; Hulzebos, CV; Wolters, H; Havinga, R; Agellon, LB; Stellaard, F; Shan, B; Schwarz, M; Kuipers, F				Kok, T; Hulzebos, CV; Wolters, H; Havinga, R; Agellon, LB; Stellaard, F; Shan, B; Schwarz, M; Kuipers, F			Enterohepatic circulation of bile salts in farnesoid x receptor-deficient mice - Efficient intestinal bile salt absorption in the absence of ileal bile acid-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEGATIVE FEEDBACK-REGULATION; BILIARY CHOLESTEROL SECRETION; NUCLEAR RECEPTOR; ACTIVATED RECEPTOR; CHOLIC-ACID; EXPORT PUMP; GENE; EXPRESSION; TRANSPORTERS; DISRUPTION	The bile salt-activated farnesoid X receptor (FXR; NR1H4) controls expression of several genes considered crucial in maintenance of bile salt homeostasis. We evaluated the physiological consequences of FXR deficiency on bile formation and on the kinetics of the enterohepatic circulation of cholate, the major bile salt species in mice. The pool size, fractional turnover rate, synthesis rate, and intestinal absorption of cholate were determined by stable isotope dilution and were related to expression of relevant transporters in the livers and intestines of FXR-deficient (Fxr(-/-)) mice. Fxr(-/-) mice showed only mildly elevated plasma bile salt concentrations associated with a 2.4-fold higher biliary bile salt output, whereas hepatic mRNA levels of the bile salt export pump were decreased. Cholate pool size and total bile salt pool size were increased by 67 and 39%, respectively, in Fxr(-/-) mice compared with wild-type mice. The cholate synthesis rate was increased by 85% in Fxr(-/-) mice, coinciding with a 2.5-fold increase in cholesterol 7alpha-hydroxylase (Cyp7a1) and unchanged sterol 12alpha-hydroxylase (Cyp8b1) expression in the liver. Despite a complete absence of ileal bile acid-binding protein mRNA and protein, the fractional turnover rate and cycling time of the cholate pool were not affected. The calculated amount of cholate reabsorbed from the intestine per day was similar to2-fold higher in Fxr(-/-) mice than in wild-type mice. Thus, the absence of FXR in mice is associated with defective feedback inhibition of hepatic cholate synthesis, which leads to enlargement of the circulating cholate pool with an unaltered fractional turnover rate. The absence of ileal bile acid-binding protein does not negatively interfere with the enterohepatic circulation of cholate in mice.	Univ Groningen, Univ Groningen Hosp, Ctr Liver Digest & Metab Dis,Inst Drug Explorat, Pediat Lab, NL-9713 GZ Groningen, Netherlands; Univ Alberta, Canadian Inst Hlth Res Grp Mol & Cell Biol Lipids, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada; Tularik Inc, San Francisco, CA 94080 USA	University of Groningen; University of Alberta; University of Alberta	Kok, T (corresponding author), Univ Groningen, Univ Groningen Hosp, Ctr Liver Digest & Metab Dis,Inst Drug Explorat, Pediat Lab, CMC 4,Rm Y2-163,Hanzeplein 1, NL-9713 GZ Groningen, Netherlands.	T.Kok@med.rug.nl	Hulzebos, Christian Victor/AAY-6803-2021	Hulzebos, Christian Victor/0000-0002-8159-7501; Kuipers, Folkert/0000-0003-2518-737X				Ananthanarayanan M, 2001, J BIOL CHEM, V276, P28857, DOI 10.1074/jbc.M011610200; BALLATORI N, 1992, AM J PHYSIOL, V263, pG617, DOI 10.1152/ajpgi.1992.263.5.G617; Bull LN, 1998, NAT GENET, V18, P219, DOI 10.1038/ng0398-219; Chen F, 2003, J BIOL CHEM, V278, P19909, DOI 10.1074/jbc.M207903200; Chiang JYL, 2002, ENDOCR REV, V23, P443, DOI 10.1210/er.2000-0035; Claudel T, 2002, J CLIN INVEST, V109, P961; Denson LA, 2001, GASTROENTEROLOGY, V121, P140, DOI 10.1053/gast.2001.25503; DUANE WC, 1995, J LIPID RES, V36, P96; ELFERINK RPJO, 1995, J CLIN INVEST, V95, P31, DOI 10.1172/JCI117658; Gerloff T, 1998, J BIOL CHEM, V273, P10046, DOI 10.1074/jbc.273.16.10046; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Grober J, 1999, J BIOL CHEM, V274, P29749, DOI 10.1074/jbc.274.42.29749; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hofmann AF, 1999, NEWS PHYSIOL SCI, V14, P24, DOI 10.1152/physiologyonline.1999.14.1.24; Hulzebos CV, 2003, J PHARMACOL EXP THER, V304, P356, DOI 10.1124/jpet.102.041640; Hulzebos CV, 2001, J LIPID RES, V42, P1923; Kast HR, 2002, J BIOL CHEM, V277, P2908, DOI 10.1074/jbc.M109326200; Kast HR, 2001, MOL ENDOCRINOL, V15, P1720, DOI 10.1210/me.15.10.1720; Kerr TA, 2002, DEV CELL, V2, P713, DOI 10.1016/S1534-5807(02)00154-5; Kok T, 2003, BIOCHEM J, V369, P539, DOI 10.1042/BJ20020981; Kosters A, 2003, J HEPATOL, V38, P710, DOI 10.1016/S0168-8278(03)00093-X; KUIPERS F, 1988, J CLIN INVEST, V81, P1593, DOI 10.1172/JCI113493; KUIPERS F, 1985, GASTROENTEROLOGY, V88, P403, DOI 10.1016/0016-5085(85)90499-8; Kuipers F, 1996, HEPATOLOGY, V24, P241; Kullak-Ublick GA, 2000, SEMIN LIVER DIS, V20, P273, DOI 10.1055/s-2000-9426; Labonte ED, 2003, PROTEIN EXPRES PURIF, V28, P25, DOI 10.1016/S1046-5928(02)00561-2; Lambert G, 2003, J BIOL CHEM, V278, P2563, DOI 10.1074/jbc.M209525200; Landrier JF, 2002, MOL CELL BIOCHEM, V239, P149, DOI 10.1023/A:1020557502795; Li-Hawkins J, 2002, J CLIN INVEST, V110, P1191, DOI 10.1172/JCI200216309; Lin YG, 1996, HEPATOLOGY, V23, P218; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu TT, 2001, J BIOL CHEM, V276, P37735, DOI 10.1074/jbc.R100035200; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; MASHIGE F, 1976, CLIN CHIM ACTA, V70, P79, DOI 10.1016/0009-8981(76)90007-3; Meier PJ, 2002, ANNU REV PHYSIOL, V64, P635, DOI 10.1146/annurev.physiol.64.082201.100300; Miyake JH, 2001, J BIOL CHEM, V276, P23304, DOI 10.1074/jbc.M101853200; PARMENTIER G, 1978, J CHROMATOGR, V152, P285, DOI 10.1016/S0021-9673(00)85370-4; Paulusma CC, 1996, SCIENCE, V271, P1126, DOI 10.1126/science.271.5252.1126; Pircher PC, 2003, J BIOL CHEM, V278, P27703, DOI 10.1074/jbc.M302128200; Plass JRM, 2002, HEPATOLOGY, V35, P589, DOI 10.1053/jhep.2002.31724; Plosch T, 2002, J BIOL CHEM, V277, P33870, DOI 10.1074/jbc.M206522200; Russell DW, 2003, ANNU REV BIOCHEM, V72, P137, DOI 10.1146/annurev.biochem.72.121801.161712; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; SCHMITZ J, 1973, BIOCHIM BIOPHYS ACTA, V323, P98, DOI 10.1016/0005-2736(73)90434-3; Schuetz EG, 2001, J BIOL CHEM, V276, P39411, DOI 10.1074/jbc.M106340200; SETCHELL KD, 1988, BILE ACIDS CHEM PHYS, P457; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; STELLAARD F, 1984, J LIPID RES, V25, P1313; Torchia EC, 2001, BMC BIOCHEM, V2, DOI 10.1186/1471-2091-2-11; VERKADE HJ, 1995, HEPATOLOGY, V21, P1174; Wang L, 2002, DEV CELL, V2, P721, DOI 10.1016/S1534-5807(02)00187-9; Wolters H, 2002, J HEPATOL, V37, P556, DOI 10.1016/S0168-8278(02)00247-7; Yu LQ, 2002, P NATL ACAD SCI USA, V99, P16237, DOI 10.1073/pnas.252582399; Yu LQ, 2002, J CLIN INVEST, V110, P671, DOI [10.1172/JCI200216001, 10.1172/JCI0216001]	55	168	171	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41930	41937		10.1074/jbc.M306309200	http://dx.doi.org/10.1074/jbc.M306309200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12917447	hybrid			2022-12-25	WOS:000185989500047
J	Metz, TO; Alderson, NL; Chachich, ME; Thorpe, SR; Baynes, JW				Metz, TO; Alderson, NL; Chachich, ME; Thorpe, SR; Baynes, JW			Pyridoxamine traps intermediates in lipid peroxidation reactions in vivo - Evidence on the role of lipids in chemical modification of protein and development of diabetic complications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADVANCED GLYCATION REACTIONS; POST-AMADORI; INHIBITOR PYRIDOXAMINE; OXIDATIVE STRESS; MAILLARD REACTION; END-PRODUCTS; RISK-FACTORS; LIPOXIDATION; QUANTIFICATION; GLYCOXIDATION	Maillard or browning reactions between reducing sugars and protein lead to formation of advanced glycation end products (AGEs) and are thought to contribute to the pathogenesis of diabetic complications. AGE inhibitors such as aminoguanidine and pyridoxamine (PM) inhibit both the formation of AGEs and development of complications in animal models of diabetes. PM also inhibits the chemical modification of protein by advanced lipoxidation end products (ALEs) during lipid peroxidation reactions in vitro. We show here that several PM adducts, formed in incubations of PM with linoleate and arachidonate in vitro, are also excreted in the urine of PM-treated animals. The PM adducts N-nonanedioyl-PM (derived from linoleate), N-pentanedioyl-PM, N-pyrrolo-PM, and N-(2-formyl)-pyrrolo-PM (derived from arachidonate), and N-formyl-PM and N- hexanoyl-PM (derived from both fatty acids) were quantified by liquid chromatography-mass spectrometry analysis of rat urine. Levels of these adducts were increased 5-10-fold in the urine of PM-treated diabetic and hyperlipidemic rats, compared with control animals. We conclude that the PM functions, at least in part, by trapping intermediates in AGE/ALE formation and propose a mechanism for PM inhibition of AGE/ALE formation involving cleavage of alpha-dicarbonyl intermediates in glycoxidation and lipoxidation reactions. We also conclude that ALEs derived from polyunsaturated fatty acids are increased in diabetes and hyperlipidemia and may contribute to development of long term renal and vascular pathology in these diseases.	Univ S Carolina, Dept Chem & Biochem, Grad Sci Res Ctr, Columbia, SC 29208 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Baynes, JW (corresponding author), Univ S Carolina, Dept Chem & Biochem, Grad Sci Res Ctr, 631 Sumter St, Columbia, SC 29208 USA.	john.baynes@sc.edu		Metz, Tom/0000-0001-6049-3968	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019971, R37DK019971] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 19971] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alderson NL, 2003, KIDNEY INT, V63, P2123, DOI 10.1046/j.1523-1755.2003.00027.x; BATTISTI WP, 2003, IN PRESS CLIN CHEM L; Baynes JW, 1999, DIABETES, V48, P1, DOI 10.2337/diabetes.48.1.1; Baynes JW, 2000, FREE RADICAL BIO MED, V28, P1708, DOI 10.1016/S0891-5849(00)00228-8; Booth AA, 1997, J BIOL CHEM, V272, P5430, DOI 10.1074/jbc.272.9.5430; Ceriello A, 2003, DIABETES CARE, V26, P1589, DOI 10.2337/diacare.26.5.1589; Chaturvedi N, 2001, KIDNEY INT, V60, P219, DOI 10.1046/j.1523-1755.2001.00789.x; Chew E Y, 1997, Curr Opin Ophthalmol, V8, P59, DOI 10.1097/00055735-199706000-00011; CULL C, 1993, DIABETOLOGIA, V36, P1021; D'Silva C, 1998, J ORG CHEM, V63, P6715, DOI 10.1021/jo971365d; Degenhardt TP, 2002, KIDNEY INT, V61, P939, DOI 10.1046/j.1523-1755.2002.00207.x; Fu MX, 1996, J BIOL CHEM, V271, P9982, DOI 10.1074/jbc.271.17.9982; Glomb MA, 2001, J BIOL CHEM, V276, P41638, DOI 10.1074/jbc.M103557200; Halliwell B., 1999, FREE RADICAL BIO MED, Vthird, P246; HAYASE F, 1985, AGR BIOL CHEM TOKYO, V49, P467, DOI 10.1080/00021369.1985.10866744; Kato Y, 1999, J BIOL CHEM, V274, P20406, DOI 10.1074/jbc.274.29.20406; Khalifah RG, 1996, BIOCHEMISTRY-US, V35, P4645, DOI 10.1021/bi9525942; Khalifah RG, 1999, BIOCHEM BIOPH RES CO, V257, P251, DOI 10.1006/bbrc.1999.0371; Kreisberg RA, 1998, AM J CARDIOL, V82, p67U, DOI 10.1016/S0002-9149(98)00848-0; Miyata T, 2000, J AM SOC NEPHROL, V11, P1744, DOI 10.1681/ASN.V1191744; Miyata T, 1999, KIDNEY INT, V55, P389, DOI 10.1046/j.1523-1755.1999.00302.x; Miyata TR, 1998, KIDNEY INT, V54, P1290, DOI 10.1046/j.1523-1755.1998.00093.x; Muntner P, 2000, KIDNEY INT, V58, P293, DOI 10.1046/j.1523-1755.2000.00165.x; Nagaraj RH, 2002, ARCH BIOCHEM BIOPHYS, V402, P110, DOI 10.1016/S0003-9861(02)00067-X; Newman JW, 2002, J LIPID RES, V43, P1563, DOI 10.1194/jlr.D200018-JLR200; Onorato JM, 2000, J BIOL CHEM, V275, P21177, DOI 10.1074/jbc.M003263200; Requena JR, 1997, BIOCHEM J, V322, P317, DOI 10.1042/bj3220317; Spiteller G, 2001, EXP GERONTOL, V36, P1425, DOI 10.1016/S0531-5565(01)00131-0; Stitt A, 2002, DIABETES, V51, P2826, DOI 10.2337/diabetes.51.9.2826; Thorpe SR, 1996, DRUG AGING, V9, P69, DOI 10.2165/00002512-199609020-00001; Ulrich P, 2001, RECENT PROG HORM RES, V56, P1, DOI 10.1210/rp.56.1.1; van Leiden HA, 2002, DIABETES CARE, V25, P1320, DOI 10.2337/diacare.25.8.1320; Viberti G, 2003, J HYPERTENS, V21, pS3; Voziyan PA, 2002, J BIOL CHEM, V277, P3397, DOI 10.1074/jbc.M109935200; YAMADA H, 1975, YAKUGAKU ZASSHI, V95, P487, DOI 10.1248/yakushi1947.95.5_487	35	95	99	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42012	42019		10.1074/jbc.M304292200	http://dx.doi.org/10.1074/jbc.M304292200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12923193	hybrid			2022-12-25	WOS:000185989500056
J	Alsheikh, MK; Heyen, BJ; Randall, SK				Alsheikh, MK; Heyen, BJ; Randall, SK			Ion binding properties of the dehydrin ERD14 are dependent upon phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARABIDOPSIS-THALIANA L; DHN/LEA/RAB-LIKE GENES; ENDOPLASMIC-RETICULUM; DEHYDRATION STRESS; LOW-TEMPERATURE; CALCIUM; PROTEIN; COLD; EXPRESSION; PLANTS	The ERD14 protein ( early response to dehydration) is a member of the dehydrin family of proteins which accumulate in response to dehydration-related environmental stresses. Here we show the Arabidopsis dehydrin, ERD14, possesses ion binding properties. ERD14 is an in vitro substrate of casein kinase II; the phosphorylation resulting both in a shift in apparent molecular mass on SDS-PAGE gels and increased calcium binding activity. The phosphorylated protein bound significantly more calcium than the nonphosphorylated protein, with a dissociation constant of 120 muM and 2.86 mol of calcium bound per mol of protein. ERD14 is phosphorylated by extracts of cold-treated tissues, suggesting that the phosphorylation status of this protein might be modulated by cold-regulated kinases or phosphatases. Calcium binding properties of ERD14 purified from Arabidopsis extracts were comparable with phosphorylated Escherichia coli-expressed ERD14. Approximately 2 mol of phosphate were incorporated per mol of ERD14, indicating a minimum of two phosphorylation sites. Western blot analyses confirmed that threonine and serine are possible phosphorylation sites on ERD14. Utilizing matrix assisted laser desorption ionization-time of flight/ mass spectrometry we identified five phosphorylated peptides that were present in both in vivo and in vitro phosphorylated ERD14. Our results suggest that the polyserine ( S) domain is most likely the site of phosphorylation in ERD14 responsible for the activation of calcium binding.	Indiana Univ Purdue Univ, Dept Biol, Indianapolis, IN 46202 USA; Tabor Coll, Dept Biol, Hillsboro, KS 67063 USA; Tabor Coll, Dept Chem, Hillsboro, KS 67063 USA	Indiana University System; Indiana University-Purdue University Indianapolis	Randall, SK (corresponding author), Indiana Univ Purdue Univ, Dept Biol, 723 W Michigan St, Indianapolis, IN 46202 USA.	srandal@iupui.edu		Randall, Stephen/0000-0002-8637-9407				BIERMANN BJ, 1994, J BIOL CHEM, V269, P25251; BUSH DS, 1993, PLANT PHYSIOL, V103, P7, DOI 10.1104/pp.103.1.7; BUSH DS, 1995, ANNU REV PLANT PHYS, V46, P95, DOI 10.1146/annurev.pp.46.060195.000523; CECCARDI TL, 1994, PROTEIN EXPRES PURIF, V5, P266, DOI 10.1006/prep.1994.1040; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CLOSE TJ, 1993, PLANT MOL BIOL, V23, P279, DOI 10.1007/BF00029004; Close TJ, 1997, PHYSIOL PLANTARUM, V100, P291, DOI 10.1034/j.1399-3054.1997.1000210.x; Close TJ, 1993, CUR TOP PL, V10, P104; Corbett EF, 2000, TRENDS BIOCHEM SCI, V25, P307, DOI 10.1016/S0968-0004(00)01588-7; DING JP, 1993, PLANT J, V3, P713, DOI 10.1111/j.1365-313X.1993.00713.x; Dure L, 1993, CUR TOP PL, V10, P91; Garay-Arroyo A, 2000, J BIOL CHEM, V275, P5668, DOI 10.1074/jbc.275.8.5668; GILMOUR SJ, 1992, PLANT MOL BIOL, V18, P13, DOI 10.1007/BF00018452; HEPLER PK, 1985, ANNU REV PLANT PHYS, V36, P397, DOI 10.1146/annurev.pp.36.060185.002145; Heyen BJ, 2002, PLANT PHYSIOL, V130, P675, DOI 10.1104/pp.002550; Ingram J, 1996, ANNU REV PLANT PHYS, V47, P377, DOI 10.1146/annurev.arplant.47.1.377; Jensen AB, 1998, PLANT J, V13, P691, DOI 10.1046/j.1365-313X.1998.00069.x; Kaye C., 1995, Science Progress, V78, P271; Kim KN, 2003, PLANT CELL, V15, P411, DOI 10.1105/tpc.006858; Kitta K, 2001, BIOCHEM J, V359, P375, DOI 10.1042/0264-6021:3590375; KIYOSUE T, 1994, PLANT CELL PHYSIOL, V35, P225; KIYOSUE T, 1994, PLANT MOL BIOL, V25, P791, DOI 10.1007/BF00028874; Knight H, 1998, PLANT J, V16, P681, DOI 10.1046/j.1365-313x.1998.00332.x; Knight H, 1996, PLANT CELL, V8, P489, DOI 10.1105/tpc.8.3.489; Knight H, 1997, PLANT J, V12, P1067, DOI 10.1046/j.1365-313X.1997.12051067.x; Koag MC, 2003, PLANT PHYSIOL, V131, P309, DOI 10.1104/pp.011171; Kruger C, 2002, J BIOL CHEM, V277, P25062, DOI 10.1074/jbc.M201896200; Lewis BD, 1997, PLANT PHYSIOL, V114, P1327, DOI 10.1104/pp.114.4.1327; Li XH, 1998, PLANT CELL, V10, P119, DOI 10.1105/tpc.10.1.119; MINORSKY PV, 1989, PLANT CELL ENVIRON, V12, P137, DOI 10.1111/j.1365-3040.1989.tb01925.x; MINORSKY PV, 1989, PLANT CELL ENVIRON, V12, P119, DOI 10.1111/j.1365-3040.1989.tb01924.x; Nelson DE, 1997, PLANT PHYSIOL, V114, P29, DOI 10.1104/pp.114.1.29; NIGAM SK, 1994, J BIOL CHEM, V269, P1744; Nylander M, 2001, PLANT MOL BIOL, V45, P263, DOI 10.1023/A:1006469128280; Palva E. T., 2002, JIRCAS Working Report, P9; Persson S, 2001, PLANT PHYSIOL, V126, P1092, DOI 10.1104/pp.126.3.1092; PETERSON JR, 1995, MOL BIOL CELL, V6, P1173, DOI 10.1091/mbc.6.9.1173; PLANA M, 1991, J BIOL CHEM, V266, P22510; Polisensky DH, 1996, PLANT PHYSIOL, V111, P1271, DOI 10.1104/pp.111.4.1271; Rivedal E, 2001, CARCINOGENESIS, V22, P1543, DOI 10.1093/carcin/22.9.1543; Sanders D, 1999, PLANT CELL, V11, P691, DOI 10.1105/tpc.11.4.691; Sedbrook JC, 1996, PLANT PHYSIOL, V111, P243, DOI 10.1104/pp.111.1.243; Shinozaki K, 1996, CURR OPIN BIOTECH, V7, P161, DOI 10.1016/S0958-1669(96)80007-3; Svensson J, 2000, PROTEIN EXPRES PURIF, V20, P169, DOI 10.1006/prep.2000.1297; Sze H, 2000, ANNU REV PLANT PHYS, V51, P433, DOI 10.1146/annurev.arplant.51.1.433; Tompa P, 2002, TRENDS BIOCHEM SCI, V27, P527, DOI 10.1016/S0968-0004(02)02169-2; VILARDELL J, 1990, PLANT MOL BIOL, V14, P423, DOI 10.1007/BF00028778; WELIN BV, 1995, PLANT MOL BIOL, V29, P391, DOI 10.1007/BF00043662; WELIN BV, 1994, PLANT MOL BIOL, V26, P131, DOI 10.1007/BF00039526; XING T, 1994, PROTOPLASMA, V179, P158, DOI 10.1007/BF01403954	50	159	177	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40882	40889		10.1074/jbc.M307151200	http://dx.doi.org/10.1074/jbc.M307151200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12917402	hybrid			2022-12-25	WOS:000185847200058
J	Shao, JY; Prince, T; Hartson, SD; Matts, RL				Shao, JY; Prince, T; Hartson, SD; Matts, RL			Phosphorylation of serine 13 is required for the proper function of the Hsp90 co-chaperone, Cdc37	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATED EIF2-ALPHA KINASE; HEAT-SHOCK PROTEIN; ASSOCIATION; CONFORMATION; RECEPTOR; DOMAIN	The Hsp90 co-chaperone Cdc37 provides an essential function for the biogenesis and support of numerous protein kinases. In this report, we demonstrate that mammalian Cdc37 is phosphorylated on Ser(13) in situ in rabbit reticulocyte lysate and in cultured K562 cells and that casein kinase II is capable of quantitatively phosphorylating recombinant Cdc37 at this site. Mutation of Ser(13) to either Ala or Glu compromises the recruitment of Cdc37 to Hsp90-kinase complexes but has only modest effects on its basal (client-free) binding to Hsp90. Furthermore, Cdc37 containing the complementing Ser to Glu mutation showed altered interactions with Hsp90-kinase complexes consistent with compromised Cdc37 modulation of the Hsp90 ATP-driven reaction cycle. Thus, the data indicate that phosphorylation of Cdc37 on Ser(13) is critical for its ability to coordinate Hsp90 nucleotide-mediated conformational switching and kinase binding.	Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA	Oklahoma State University System; Oklahoma State University - Stillwater	Matts, RL (corresponding author), Oklahoma State Univ, Dept Biochem & Mol Biol, 246 NRC, Stillwater, OK 74078 USA.							Bandhakavi S, 2003, J BIOL CHEM, V278, P2829, DOI 10.1074/jbc.M206662200; Clauser KR, 1999, ANAL CHEM, V71, P2871, DOI 10.1021/ac9810516; Fliss AE, 1997, MOL BIOL CELL, V8, P2501, DOI 10.1091/mbc.8.12.2501; Hartson SD, 1999, BIOCHEMISTRY-US, V38, P3837, DOI 10.1021/bi983027s; Hartson SD, 2000, BIOCHEMISTRY-US, V39, P7631, DOI 10.1021/bi000315r; HARTSON SD, 1994, BIOCHEMISTRY-US, V33, P8912, DOI 10.1021/bi00196a008; KREIG PA, 1984, NUCLEIC ACIDS RES, V12, P7057; MATTS RL, 1989, J BIOL CHEM, V264, P15542; Neckers L, 2002, TRENDS MOL MED, V8, pS55, DOI 10.1016/S1471-4914(02)02316-X; Pearl LH, 2002, ADV PROTEIN CHEM, V59, P157; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; Picard D, 2002, CELL MOL LIFE SCI, V59, P1640, DOI 10.1007/PL00012491; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Richter K, 2001, J CELL PHYSIOL, V188, P281, DOI 10.1002/jcp.1131; Shao J, 2002, BIOCHEMISTRY-US, V41, P6770, DOI 10.1021/bi025737a; Shao J, 2001, J BIOL CHEM, V276, P206, DOI 10.1074/jbc.M007583200; Uma S, 1997, J BIOL CHEM, V272, P11648; Uma S, 2000, EUR J BIOCHEM, V267, P498, DOI 10.1046/j.1432-1327.2000.01021.x	18	88	92	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38117	38120		10.1074/jbc.C300330200	http://dx.doi.org/10.1074/jbc.C300330200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12930845	hybrid			2022-12-25	WOS:000185575100004
J	Xu, QY; Karouji, Y; Kobayashi, M; Ihara, S; Konishi, H; Fukui, Y				Xu, QY; Karouji, Y; Kobayashi, M; Ihara, S; Konishi, H; Fukui, Y			The PI 3-kinase-Rac-p38 MAP kinase pathway is involved in the formation of signet-ring cell carcinoma	ONCOGENE			English	Article						PI3-kinase; signet-ring cell carcinoma; cell-cell contact; p38 MAP kinase; MUC1	ACTIVATED PROTEIN-KINASE; SIGNALING PATHWAY; EXPRESSION; ADHESION; STRESS; FAMILY; PHOSPHORYLATION; IDENTIFICATION; DOWNSTREAM; DYNAMICS	Signet-ring cell carcinoma is classified in poorly differentiated adenocarcinoma with an aggressive nature and a poor prognosis. We have shown that the activation of PI 3-kinase in highly differentiated adenocarcinomas induces loss of cell-cell contact and formation of vacuoles, giving phenotypes similar to those of signet-ring cell lines. SB203580, a potent p38 MAP kinase inhibitor, blocked this transition, and expression of an active form of MKK6 (MKK6DA), an activator of p38 MAP kinase, gave effects similar to those induced by expression of the active form of PI 3-kinase (BD110), although formation of large vacuoles was not induced. Activation of MKK3, another activator of p38 MAP kinase, was activated in native signet-ring carcinoma cell lines. Anchorage-independent growth of signet-ring cell lines was inhibited by LY294002 or SB203580. These results suggest that p38 MAP kinase is functioning downstream of PI 3-kinase in signaling of the malignant phenotype. Secretion of mucins was enhanced in BD110-expressing cells, but not in MKK6DA-expressing cells, suggesting that secretion of mucins is independent of the MKK6-p38 MAP kinase cascade. Thus, there may be at least two pathways, p38 MAP kinase-dependent and -independent, which are involved in regulation of cell-cell contact and the protein secretion system, respectively.	Univ Tokyo, Fac Agr & Life Sci, Grad Sch Agr & Life Sci, Dept Appl Biol Chem,Lab Biol Chem,Bunkyo Ku, Tokyo 1138657, Japan	University of Tokyo	Fukui, Y (corresponding author), Univ Tokyo, Fac Agr & Life Sci, Grad Sch Agr & Life Sci, Dept Appl Biol Chem,Lab Biol Chem,Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan.	ayfukui@mail.ecc.u-tokyo.ac.jp	Fukui, Yasuhisa/E-8806-2010					AKIYAMA S, 1988, JPN J SURG, V18, P438, DOI 10.1007/BF02471470; Braga V, 2000, EXP CELL RES, V261, P83, DOI 10.1006/excr.2000.5050; Cassimeris L, 2002, CURR OPIN CELL BIOL, V14, P18, DOI 10.1016/S0955-0674(01)00289-7; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Desprez PY, 1998, MOL CELL BIOL, V18, P4577, DOI 10.1128/MCB.18.8.4577; DUANE GB, 1985, ACTA CYTOL, V29, P211; Fronsdal K, 2000, PROSTATE, V43, P111, DOI 10.1002/(SICI)1097-0045(20000501)43:2<111::AID-PROS5>3.0.CO;2-4; Gavet O, 1998, J CELL SCI, V111, P3333; Gimmi CD, 1996, NAT MED, V2, P1367, DOI 10.1038/nm1296-1367; Guay J, 1997, J CELL SCI, V110, P357; Hilkens J, 1995, BIOCHEM SOC T, V23, P822, DOI 10.1042/bst0230822; Jamora C, 2002, NAT CELL BIOL, V4, pE101, DOI 10.1038/ncb0402-e101; Kameda H, 2001, MOL CELL BIOL, V21, P6895, DOI 10.1128/MCB.21.20.6895-6905.2001; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; Kita Y, 1998, J CELL SCI, V111, P907; Kobayashi M, 1999, P NATL ACAD SCI USA, V96, P4874, DOI 10.1073/pnas.96.9.4874; Kobayashi M, 2003, ONCOGENE, V22, P1294, DOI 10.1038/sj.onc.1206256; KUFE D, 1984, HYBRIDOMA, V3, P223, DOI 10.1089/hyb.1984.3.223; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; Laffargue M, 1999, J BIOL CHEM, V274, P32835, DOI 10.1074/jbc.274.46.32835; Landry J, 1995, BIOCHEM CELL BIOL, V73, P703, DOI 10.1139/o95-078; Maeno Y, 1999, AM J PATHOL, V154, P1323, DOI 10.1016/S0002-9440(10)65385-0; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; ODA T, 1994, P NATL ACAD SCI USA, V91, P1858, DOI 10.1073/pnas.91.5.1858; Parker CG, 1998, BIOCHEM BIOPH RES CO, V249, P791, DOI 10.1006/bbrc.1998.9250; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Tahara E, 1989, Gan To Kagaku Ryoho, V16, P2149; vom Dahl S, 2001, BIOCHEM J, V354, P31, DOI 10.1042/0264-6021:3540031; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X; YAMAMOTO R, 1990, VIRCHOWS ARCH B, V59, P26, DOI 10.1007/BF02899383; Yonezawa S, 1997, PATHOL INT, V47, P813, DOI 10.1111/j.1440-1827.1997.tb03713.x; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	36	17	18	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2003	22	36					5537	5544		10.1038/sj.onc.1206796	http://dx.doi.org/10.1038/sj.onc.1206796			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944900				2022-12-25	WOS:000184865900001
J	Argani, P; Lui, MY; Couturier, J; Bouvier, R; Fournet, JC; Ladanyi, M				Argani, P; Lui, MY; Couturier, J; Bouvier, R; Fournet, JC; Ladanyi, M			A novel CLTC-TFE3 gene fusion in pediatric renal adenocarcinoma with t(X;17)(p11.2;q23)	ONCOGENE			English	Article						chromosome translocation; carcinoma; pediatric; kidney	SOFT PART SARCOMA; CELL CARCINOMA; TFE3 GENE; NUCLEAR-LOCALIZATION; TUBEROUS SCLEROSIS; CLATHRIN; PRCC; ALK; KINASE; IMMUNOREACTIVITY	A distinctive subset of renal carcinomas is associated with Xp11.2 translocations and resulting TFE3 gene fusions (PRCC-TFE3, PSF-TFE3, NONO-TFE3, ASPL-TFE3), encoding related aberrant transcription factors. We report the cloning of a novel clathrin heavy-chain gene (CLTC)-TFE3 gene fusion resulting from a t(X;l7)(p11.2;q23) in a renal carcinoma arising in a 14-year-old boy. The fusion transcript joined the 5' exons of CLTC on chromosome band 17q23 to the 3' exons of TFE3. CLTC encodes a major subunit of clathrin, a multimeric protein on cytoplasmic organelles, and is a known recurrent fusion partner of the ALK tyrosine kinase gene in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumors. The predicted CLTC-TFE3 product retains the nuclear localization and DNA-binding domains of TFE3, but lacks the multimerization domain of CLTC. The present renal tumor demonstrated morphologic and immunohistochemical features of both PRCC-TFE3 and ASPL-TFE3 carcinomas, including strong nuclear immunoreactivity for the TFE3 C-terminal and only minimal expression of epithelial proteins. However, unlike most renal carcinomas, it also focally expressed melanocytic proteins. The present report highlights the promiscuity of certain genes involved in chromosomal translocations. Further analysis of the shared features of CLTC and other TFE3 fusion partners may shed light on the essential biology of TFE3 fusion proteins.	Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA; Inst Curie, F-75248 Paris 05, France; Hop Edouard Herriot, F-69437 Lyon 3, France; Hop St Justine, Montreal, PQ H3T 1C5, Canada	Memorial Sloan Kettering Cancer Center; Johns Hopkins University; Johns Hopkins Medicine; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; CHU Lyon; Universite de Montreal	Ladanyi, M (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Pathol, Room S-801,1275 York Ave, New York, NY 10021 USA.	ladanyim@mskcc.org	Ladanyi, Marc/AAG-8585-2019		NCI NIH HHS [R01CA95785] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095785] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Argani P, 2002, AM J SURG PATHOL, V26, P1553, DOI 10.1097/00000478-200212000-00003; Argani P, 2003, AM J SURG PATHOL, V27, P750, DOI 10.1097/00000478-200306000-00005; Argani P, 2001, AM J PATHOL, V159, P179, DOI 10.1016/S0002-9440(10)61684-7; Argani P, 2001, AM J PATHOL, V158, P2089, DOI 10.1016/S0002-9440(10)64680-9; Avery AK, 2000, AM J SURG PATHOL, V24, P203, DOI 10.1097/00000478-200002000-00006; Bjornsson J, 1996, AM J PATHOL, V149, P1201; Bridge JA, 2001, AM J PATHOL, V159, P411, DOI 10.1016/S0002-9440(10)61711-7; Clark J, 1997, ONCOGENE, V15, P2233, DOI 10.1038/sj.onc.1201394; Cools J, 2002, GENE CHROMOSOME CANC, V34, P354, DOI 10.1002/gcc.10033; Davis IJ, 2003, P NATL ACAD SCI USA, V100, P6051, DOI 10.1073/pnas.0931430100; Heimann P, 2001, CANCER RES, V61, P4130; Kirchhausen T, 2000, ANNU REV BIOCHEM, V69, P699, DOI 10.1146/annurev.biochem.69.1.699; Kovacs G, 1997, J PATHOL, V183, P131, DOI 10.1002/(SICI)1096-9896(199710)183:2<131::AID-PATH931>3.0.CO;2-G; Ladanyi M, 2000, AM J PATHOL, V157, P341, DOI 10.1016/S0002-9440(10)64545-2; Ladanyi M, 2001, ONCOGENE, V20, P48, DOI 10.1038/sj.onc.1204074; Pea M, 1998, AM J SURG PATHOL, V22, P180, DOI 10.1097/00000478-199802000-00005; PEROT C, 2003, IN PRESS CANC GENET; Sidhar SK, 1996, HUM MOL GENET, V5, P1333, DOI 10.1093/hmg/5.9.1333; Skalsky YM, 2001, ONCOGENE, V20, P178, DOI 10.1038/sj.onc.1204056; Smith CJ, 1999, TRENDS CELL BIOL, V9, P335, DOI 10.1016/S0962-8924(99)01631-1; Storkel S, 1997, CANCER, V80, P987, DOI 10.1002/(SICI)1097-0142(19970901)80:5<987::AID-CNCR24>3.0.CO;2-R; Takebayashi K, 1996, MOL CELL BIOL, V16, P1203; Touriol C, 2000, BLOOD, V95, P3204, DOI 10.1182/blood.V95.10.3204.010k04_3204_3207; Weterman MAJ, 1996, P NATL ACAD SCI USA, V93, P15294, DOI 10.1073/pnas.93.26.15294; Weterman MAJ, 2000, ONCOGENE, V19, P69, DOI 10.1038/sj.onc.1203255; Weterman MAJ, 2001, P NATL ACAD SCI USA, V98, P13808, DOI 10.1073/pnas.241304198; Ybe JA, 1998, EMBO J, V17, P1297, DOI 10.1093/emboj/17.5.1297; Ybe JA, 1999, NATURE, V399, P371, DOI 10.1038/20708	28	201	213	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2003	22	34					5374	5378		10.1038/sj.onc.1206686	http://dx.doi.org/10.1038/sj.onc.1206686			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JB	12917640				2022-12-25	WOS:000184734900018
J	Qu, ZQ; Wei, RW; Mann, W; Hartzell, HC				Qu, ZQ; Wei, RW; Mann, W; Hartzell, HC			Two bestrophins cloned from Xenopus laevis oocytes express Ca2+-activated Cl- currents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLORIDE CONDUCTANCE MEDIATOR; GLYCINE RECEPTOR-CHANNEL; MACULAR DYSTROPHY; ELECTRO-OCULOGRAPHY; PERMEATION PATHWAY; INNER SEGMENTS; MUTATIONS; MEMBRANE; PROTEIN; ANION	Ca2+-activated Cl- channels play important diverse roles from fast block to polyspermy to olfactory transduction, but their molecular identity has not been firmly established. By searching sequence databases with the M2 pore domain of ligand-gated anion channels, we identified potential Ca2+-activated Cl- channels, which included members of the bestrophin family. We cloned two bestrophins from Xenopus oocytes, which express high levels of Ca2+-activated Cl- channels. The Xenopus bestrophins were expressed in a variety of tissues. We predict that bestrophin has six transmembrane domains with the conserved RFP domain playing an integral part in ionic selectivity. When Xenopus bestrophins were heterologously expressed in human embryonic kidney-293 cells, large Ca2+-activated Cl- currents were observed. The currents are voltage- and time-independent, do not rectify, have a K-d for Ca2+ of similar to210 nM, and exhibit a permeability ratio of I- > Br- > Cl- >> aspartate. The W93C and G299E mutations produce non-functional channels that exert a dominant negative effect on wild type channels. We conclude that bestrophins are the first molecularly identified Cl- channels that are dependent on intracellular Ca2+ in a physiological range.	Emory Univ, Sch Med, Dept Cell Biol, Atlanta, GA 30322 USA	Emory University	Hartzell, HC (corresponding author), Emory Univ, Sch Med, Dept Cell Biol, 535 Whitehead Biomed Res Bldg,615 Michael St, Atlanta, GA 30322 USA.	criss@cellbio.emory.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060448] Funding Source: NIH RePORTER; NEI NIH HHS [EY01452] Funding Source: Medline; NIGMS NIH HHS [GM-60448] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BADER CR, 1982, J PHYSIOL-LONDON, V331, P253, DOI 10.1113/jphysiol.1982.sp014372; Bakall B, 1999, HUM GENET, V104, P383, DOI 10.1007/s004390050972; BARNES S, 1989, J GEN PHYSIOL, V94, P719, DOI 10.1085/jgp.94.4.719; Cunningham SA, 1995, J BIOL CHEM, V270, P31016, DOI 10.1074/jbc.270.52.31016; DEUTMAN AF, 1969, ARCH OPHTHALMOL-CHIC, V81, P305, DOI 10.1001/archopht.1969.00990010307001; FRANCOIS J, 1967, ARCH OPHTHALMOL-CHIC, V77, P726; Fuller CM, 2002, CALCIUM ACTIVATED CH; GALLEMORE R, 1998, RETINAL PIGMENT EPIT; Gruber AD, 1999, AM J PHYSIOL-CELL PH, V276, pC1261; Gruber AD, 1998, GENOMICS, V54, P200, DOI 10.1006/geno.1998.5562; Hille B., 1992, ION CHANNELS EXCITAB; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Jentsch TJ, 2002, PHYSIOL REV, V82, P503, DOI 10.1152/physrev.00029.2001; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; Keramidas A, 2000, BIOPHYS J, V79, P247, DOI 10.1016/S0006-3495(00)76287-4; Keramidas A, 2002, J GEN PHYSIOL, V119, P393, DOI 10.1085/jgp.20028552; Kuruma A, 2000, J GEN PHYSIOL, V115, P59, DOI 10.1085/jgp.115.1.59; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANGOSCH D, 1994, EMBO J, V13, P4223, DOI 10.1002/j.1460-2075.1994.tb06742.x; LESTER HA, 1992, ANNU REV BIOPH BIOM, V21, P267, DOI 10.1146/annurev.bb.21.060192.001411; Loewen ME, 2002, AM J PHYSIOL-CELL PH, V283, pC412, DOI 10.1152/ajpcell.00477.2001; Loewen ME, 2002, BIOCHEM BIOPH RES CO, V298, P531, DOI 10.1016/S0006-291X(02)02498-1; MACHACA K, 2002, CALCIUM ACTIVATED CH; Marmorstein AD, 2000, P NATL ACAD SCI USA, V97, P12758, DOI 10.1073/pnas.220402097; Morgans CW, 1998, J NEUROSCI, V18, P2467; Nilius B, 1997, PROG BIOPHYS MOL BIO, V68, P69, DOI 10.1016/S0079-6107(97)00021-7; Papassotiriou J, 2001, PFLUG ARCH EUR J PHY, V442, P273; Petrukhin K, 1998, NAT GENET, V19, P241, DOI 10.1038/915; Qu ZQ, 2000, J GEN PHYSIOL, V116, P825, DOI 10.1085/jgp.116.6.825; Qu ZQ, 2001, J BIOL CHEM, V276, P18423, DOI 10.1074/jbc.M101264200; Romio L, 1999, GENE, V228, P181, DOI 10.1016/S0378-1119(98)00620-9; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sun H, 2002, P NATL ACAD SCI USA, V99, P4008, DOI 10.1073/pnas.052692999; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; White K, 2000, HUM MUTAT, V15, P301, DOI 10.1002/(SICI)1098-1004(200004)15:4<301::AID-HUMU1>3.0.CO;2-N; Xu M, 1996, J GEN PHYSIOL, V107, P195, DOI 10.1085/jgp.107.2.195; YAGI T, 1994, J NEUROPHYSIOL, V71, P656, DOI 10.1152/jn.1994.71.2.656	38	138	139	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	2003	278	49					49563	49572		10.1074/jbc.M308414200	http://dx.doi.org/10.1074/jbc.M308414200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	747WL	12939260	hybrid			2022-12-25	WOS:000186829000127
J	Brunner, C; Laumen, H; Nielsen, PJ; Kraut, N; Wirth, T				Brunner, C; Laumen, H; Nielsen, PJ; Kraut, N; Wirth, T			Expression of the aldehyde dehydrogenase 2-like gene is controlled by BOB.1/OBF.1 in B lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SPECIFIC COACTIVATOR; NF-KAPPA-B; OCA-B; TRANSCRIPTION FACTORS; VITAMIN-A; DIFFERENTIAL TRANSACTIVATION; FUNCTIONAL-CHARACTERIZATION; MURINE HOMOLOG; MICE LACKING; BINDING	BOB.1/OBF.1 is a lymphocyte-restricted transcriptional coactivator. It binds to the Oct1 and Oct2 transcription factors and increases their transactivation potential. Targeted gene disruption experiments revealed that BOB.1/OBF.1 is critical at different stages of B cell development. A large number of genes expressed in B cells contain octamer motifs in their regulatory regions. However, only few genes have been described so far whose expression is dependent on BOB.1/OBF.1. To understand the molecular basis of BOB.1/OBF.1 function in B cell development, we searched for BOB.1/OBF.1 target genes by expression profiling. We have identified genes both induced and repressed by BOB.1/OBF.1. Using different genetic systems, we demonstrate regulation of a selection of these genes. Identified targets included genes encoding Ahd2-like, AKR1C13, Rbp1, Sdh, Idh2, protocadherin gamma, alpha-catenin, Ptprs, Id3, and Creg. Classification of BOB.1/OBF.1 target genes by function suggests that they affect various aspects of B cell physiology such as cellular metabolism, cell adhesion, and differentiation. To better understand the mechanism of BOB.1/OBF.1 action, we cloned the promoter of the gene encoding Ahd2-like, the gene showing the strongest regulation by BOB.1/OBF.1. This promoter indeed contains a perfect octamer motif. Furthermore, the motif was recognized by the Oct transcription factors as well as BOB.1/OBF.1 in vitro and in vivo, as shown by electromobility shift and chromatin immunoprecipitation assays. Transient transfections confirm that this promoter is activated by BOB.1/OBF.1. Our observations suggest that by regulating genes in different functional pathways, BOB.1/OBF.1 has a widespread effect on B cell development and function.	Boehringer Ingelheim Austria GmbH, R&D Vienna Exploratory Res, A-1121 Vienna, Austria; Univ Ulm, Dept Physiol Chem, D-89081 Ulm, Germany; Max Planck Inst Immunol, D-79108 Freiburg, Germany	Boehringer Ingelheim; Ulm University; Max Planck Society	Kraut, N (corresponding author), Boehringer Ingelheim Austria GmbH, R&D Vienna Exploratory Res, Dr Boehringer Gasse 5-11, A-1121 Vienna, Austria.	norbert.kraut@vie.boehringer-ngelheim.com; thomas.wirth@medizin.uni.ulm.de	Laumen, Helmut/M-5140-2013; Brunner, Cornelia/H-8893-2018; Wirth, Thomas/X-7172-2019; Brunner, Cornelia/L-1291-2013	Laumen, Helmut/0000-0002-5885-5242; Brunner, Cornelia/0000-0002-6456-5508; 				ANNWEILER A, 1992, MOL CELL BIOL, V12, P3107, DOI 10.1128/MCB.12.7.3107; Babb R, 1997, MOL CELL BIOL, V17, P7295, DOI 10.1128/MCB.17.12.7295; Boehm J, 2001, EMBO J, V20, P4153, DOI 10.1093/emboj/20.15.4153; BOND SL, 1994, BIOCHEM MED METAB B, V52, P155, DOI 10.1006/bmmb.1994.1048; Buchanan KL, 1997, J IMMUNOL, V159, P1247; BUCK J, 1990, J EXP MED, V171, P1613, DOI 10.1084/jem.171.5.1613; BUCK J, 1991, SCIENCE, V254, P1654, DOI 10.1126/science.1749937; BUCK J, 1993, J EXP MED, V178, P675, DOI 10.1084/jem.178.2.675; Casellas R, 2002, CELL, V110, P575, DOI 10.1016/S0092-8674(02)00911-X; Cepek KL, 1996, GENE DEV, V10, P2079, DOI 10.1101/gad.10.16.2079; Chasman D, 1999, GENE DEV, V13, P2650, DOI 10.1101/gad.13.20.2650; Damm K, 2001, EMBO J, V20, P6958, DOI 10.1093/emboj/20.24.6958; DeGregori J, 2002, BBA-REV CANCER, V1602, P131, DOI 10.1016/S0304-419X(02)00051-3; DOUER D, 1982, J CLIN INVEST, V69, P1039, DOI 10.1172/JCI110507; Duester G, 2000, EUR J BIOCHEM, V267, P4315, DOI 10.1046/j.1432-1327.2000.01497.x; Duester G, 1996, BIOCHEMISTRY-US, V35, P12221, DOI 10.1021/bi961176+; Ghatpande S, 2002, BLOOD, V99, P2379, DOI 10.1182/blood.V99.7.2379; Greiner A, 2000, AM J PATHOL, V156, P501, DOI 10.1016/S0002-9440(10)64754-2; Gstaiger M, 1996, TRENDS GENET, V12, P393, DOI 10.1016/S0168-9525(96)90096-7; GSTAIGER M, 1995, NATURE, V373, P360, DOI 10.1038/373360a0; HAHNE M, 1994, J EXP MED, V179, P1391, DOI 10.1084/jem.179.4.1391; Hess J, 2001, MOL CELL BIOL, V21, P1531, DOI 10.1128/MCB.21.5.1531-1539.2001; Kim U, 1996, NATURE, V383, P542, DOI 10.1038/383542a0; KONIG H, 1995, GENE DEV, V9, P1598, DOI 10.1101/gad.9.13.1598; Kuwata T, 2000, BLOOD, V95, P3349, DOI 10.1182/blood.V95.11.3349; Laumen H, 2000, EUR J IMMUNOL, V30, P458, DOI 10.1002/1521-4141(200002)30:2<458::AID-IMMU458>3.0.CO;2-5; LERNBECHER T, 1993, NATURE, V365, P767, DOI 10.1038/365767a0; LIBERMANN TA, 1991, HORMONAL REGULATION, P385; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; LUO Y, 1995, MOL CELL BIOL, V15, P4115; Malone CS, 2002, J IMMUNOL, V168, P3369, DOI 10.4049/jimmunol.168.7.3369; Moriuchi M, 2001, J BIOL CHEM, V276, P8639, DOI 10.1074/jbc.M008391200; Nielsen PJ, 1996, EUR J IMMUNOL, V26, P3214, DOI 10.1002/eji.1830261255; Pfisterer P, 1996, MOL CELL BIOL, V16, P6160; PFISTERER P, 1994, EMBO J, V13, P1654, DOI 10.1002/j.1460-2075.1994.tb06429.x; PFISTERER P, 1995, J BIOL CHEM, V270, P29870, DOI 10.1074/jbc.270.50.29870; PIERANI A, 1990, MOL CELL BIOL, V10, P6204, DOI 10.1128/MCB.10.12.6204; Purton LE, 2000, BLOOD, V95, P470, DOI 10.1182/blood.V95.2.470; Purton LE, 1999, BLOOD, V94, P483, DOI 10.1182/blood.V94.2.483.414k12_483_495; Qin XF, 1998, EMBO J, V17, P5066, DOI 10.1093/emboj/17.17.5066; Quadro L, 1999, EMBO J, V18, P4633, DOI 10.1093/emboj/18.17.4633; Remenyi A, 2001, MOL CELL, V8, P569, DOI 10.1016/S1097-2765(01)00336-7; Rempel RE, 2000, MOL CELL, V6, P293, DOI 10.1016/S1097-2765(00)00030-7; Sauter P, 1998, MOL CELL BIOL, V18, P7397, DOI 10.1128/MCB.18.12.7397; SCHAFFNER W, 1989, TRENDS GENET, V5, P37, DOI 10.1016/0168-9525(89)90017-6; Schubart DB, 1996, NUCLEIC ACIDS RES, V24, P1913, DOI 10.1093/nar/24.10.1913; Schubart DB, 1996, NATURE, V383, P538, DOI 10.1038/383538a0; Schubart DB, 2000, J IMMUNOL, V164, P18, DOI 10.4049/jimmunol.164.1.18; Schubart K, 2001, NAT IMMUNOL, V2, P69, DOI 10.1038/83190; Shore P, 2002, NUCLEIC ACIDS RES, V30, P1767, DOI 10.1093/nar/30.8.1767; SMITH WC, 1991, EMBO J, V10, P2223, DOI 10.1002/j.1460-2075.1991.tb07758.x; STAUDT LM, 1991, ANNU REV IMMUNOL, V9, P373; Stevens S, 2000, J IMMUNOL, V164, P6372, DOI 10.4049/jimmunol.164.12.6372; Stevens S, 2000, J IMMUNOL, V164, P5306, DOI 10.4049/jimmunol.164.10.5306; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; Tang H, 1999, IMMUNITY, V11, P517, DOI 10.1016/S1074-7613(00)80127-2; Tiedt R, 2001, EMBO J, V20, P4143, DOI 10.1093/emboj/20.15.4143; Tomilin A, 2000, CELL, V103, P853, DOI 10.1016/S0092-8674(00)00189-6; Veal E, 1998, MOL CELL BIOL, V18, P5032, DOI 10.1128/MCB.18.9.5032; VERRIJZER CP, 1993, BIOCHIM BIOPHYS ACTA, V1173, P1, DOI 10.1016/0167-4781(93)90237-8; Webb CF, 1997, MOL IMMUNOL, V34, P743, DOI 10.1016/S0161-5890(97)00084-9; WIRTH T, 1988, EMBO J, V7, P3109, DOI 10.1002/j.1460-2075.1988.tb03177.x; WIRTH T, 1987, NATURE, V329, P174, DOI 10.1038/329174a0; Wolf I, 1998, J BIOL CHEM, V273, P28831, DOI 10.1074/jbc.273.44.28831; Yamasaki L, 1999, BBA-REV CANCER, V1423, pM9, DOI 10.1016/S0304-419X(99)00003-7; Yeh KC, 2000, GENE, V254, P163, DOI 10.1016/S0378-1119(00)00274-2; Yu X, 2001, IMMUNITY, V14, P157, DOI 10.1016/S1074-7613(09)00090-9; Zile MH, 2001, J NUTR, V131, P705, DOI 10.1093/jn/131.3.705; Zwilling S, 1997, SCIENCE, V277, P221, DOI 10.1126/science.277.5323.221	70	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45231	45239		10.1074/jbc.M302539200	http://dx.doi.org/10.1074/jbc.M302539200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12947107	hybrid			2022-12-25	WOS:000186452300024
J	Hou, SH; Guan, HC; Ricciardi, RP				Hou, SH; Guan, HC; Ricciardi, RP			Phosphorylation of serine 337 of NF-kappa B p50 is critical for DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOVIRUS-TYPE-12 TUMORIGENIC CELLS; UBIQUITIN-PROTEASOME PATHWAY; CLASS-I TRANSCRIPTION; KINASE COMPLEX; P65 SUBUNIT; COUP-TFII; ALPHA; ACTIVATION; HOMODIMER; REL	It has been demonstrated that phosphorylation of the p50 subunit of NF-kappaB is required for efficient DNA binding, yet the specific phospho-residues of p50 have not been determined. In this study, we substituted all of the serine and conserved threonine residues in the p50 Rel homology domain and identified three serine residues, Ser(65), Ser(337), and Ser(342), as critical for DNA binding without affecting dimerization. Although substitution with negatively charged aspartic acid at each of these positions failed to restore DNA binding, substitution with threonine, a potential phospho-acceptor, retained DNA binding for residues 65 and 337. In particular, Ser(337), in a consensus site for protein kinase A (PKA) and other kinases, was shown to be phosphorylated both in vitro and in vivo. Importantly, phosphorylation of Ser(337) by PKA in vitro dramatically increased DNA binding of p50. This study shows for the first time that the DNA binding ability of NF-kappaB p50 subunit is regulated through phosphorylation of residue Ser(337), which has implications for both positive and negative control of NF-kappaB transcription.	Univ Penn, Sch Dent Med, Dept Microbiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Biochem & Mol Biophys, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Ricciardi, RP (corresponding author), Univ Penn, Sch Dent Med, Dept Microbiol, Philadelphia, PA 19104 USA.				NCI NIH HHS [CA29797] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA029797] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Chen FE, 1999, ONCOGENE, V18, P6845, DOI 10.1038/sj.onc.1203224; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Chen YQ, 1998, NAT STRUCT BIOL, V5, P67, DOI 10.1038/nsb0198-67; Chen YQ, 2000, STRUCT FOLD DES, V8, P419, DOI 10.1016/S0969-2126(00)00123-4; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; Drier EA, 1999, GENE DEV, V13, P556, DOI 10.1101/gad.13.5.556; Ghoda L, 1997, J BIOL CHEM, V272, P21281, DOI 10.1074/jbc.272.34.21281; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; HAYASHI T, 1993, J BIOL CHEM, V268, P26790; Hou SH, 2002, J VIROL, V76, P3212, DOI 10.1128/JVI.76.7.3212-3220.2002; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KRALLI A, 1992, J VIROL, V66, P6979, DOI 10.1128/JVI.66.12.6979-6988.1992; Kushner DB, 1999, MOL CELL BIOL, V19, P2169; LI CCH, 1994, BIOCHEM J, V303, P499, DOI 10.1042/bj3030499; LI CCH, 1994, J BIOL CHEM, V269, P30089; Li J, 1998, J BIOL CHEM, V273, P30736, DOI 10.1074/jbc.273.46.30736; May MJ, 1997, SEMIN CANCER BIOL, V8, P63, DOI 10.1006/scbi.1997.0057; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pereira DS, 1996, ONCOGENE, V13, P445; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Smirnov DA, 2001, VIROLOGY, V284, P13, DOI 10.1006/viro.2001.0913; Wang D, 2000, J BIOL CHEM, V275, P32592, DOI 10.1074/jbc.M001358200; WHALEN AM, 1993, J CELL BIOL, V123, P523, DOI 10.1083/jcb.123.3.523; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	46	76	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45994	45998		10.1074/jbc.M307971200	http://dx.doi.org/10.1074/jbc.M307971200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12947093	hybrid			2022-12-25	WOS:000186452300114
J	Sharma, SK; Kapoor, M; Ramya, TNC; Kumar, S; Kumar, G; Modak, R; Sharma, S; Surolia, N; Surolia, A				Sharma, SK; Kapoor, M; Ramya, TNC; Kumar, S; Kumar, G; Modak, R; Sharma, S; Surolia, N; Surolia, A			Identification, characterization, and inhibition of Plasmodium falciparum beta-hydroxyacyl-acyl carrier protein dehydratase (FabZ)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROXYDECANOYL THIOESTER DEHYDRASE; FATTY-ACID BIOSYNTHESIS; ENOYL-ACP REDUCTASE; ESCHERICHIA-COLI; AUTOMATED DOCKING; FREE-ENERGY; MALARIA; MODEL; TRICLOSAN; MECHANISM	The emergence of drug-resistant forms of Plasmodium falciparum emphasizes the need to develop new antimalarials. In this context, the fatty acid biosynthesis (FAS) pathway of the malarial parasite has recently received a lot of attention. Due to differences in the fatty acid biosynthesis systems of Plasmodium and man, this pathway is a good target for the development of new and selective therapeutic drugs directed against malaria. In continuation of these efforts we report cloning and overexpression of P. falciparum beta-hydroxyacyl-acyl carrier protein (ACP) dehydratase (PffabZ) gene that codes for a 17-kDa protein. The enzyme catalyzes the dehydration of beta-hydroxyacyl-ACP to trans-2-acyl-ACP, the third step in the elongation phase of the FAS cycle. It has a K-m of 199 muM and k(cat)/K-m of 80.4 M-1 s(-1) for the substrate analog beta-hydroxybutyryl-CoA but utilizes crotonoyl-CoA, the product of the reaction, more efficiently (K-m=86 muM, k(cat)/K-m=220 M-1 s(-1)). More importantly, we also identify inhibitors (NAS-91 and NAS-21) for the enzyme. Both the inhibitors prevented the binding of crotonoyl-CoA to PfFabZ in a competitive fashion. Indeed these inhibitors compromised the growth of P. falciparum in cultures and inhibited the parasite fatty acid synthesis pathway both in cell-free extracts as well as in situ. We modeled the structure of PfFabZ using Escherichia coli beta-hydroxydecanoyl thioester dehydratase (EcFabA) as a template. We also modeled the inhibitor complexes of PfFabZ to elucidate the mode of binding of these compounds to FabZ. The discovery of the inhibitors of FabZ, reported for the first time against any member of this family of enzymes, essential to the type II FAS pathway opens up new avenues for treating a number of infectious diseases including malaria.	Jawaharlal Nehru Ctr Adv Sci Res, Mol Biol & Genet Unit, Bangalore 560064, Karnataka, India; Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India	Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR); Indian Institute of Science (IISC) - Bangalore	Surolia, N (corresponding author), Jawaharlal Nehru Ctr Adv Sci Res, Mol Biol & Genet Unit, Bangalore 560064, Karnataka, India.	surolia@jncasr.ac.in; surolia@mbu.iisc.ernet.in	Chakravarthy, Ramya T. N./AAJ-7507-2021; Chakravarthy, Ramya/F-8924-2010; Kumar, Gyanendra/B-1751-2009; SUROLIA, AVADESHA/C-5442-2009	Kumar, Gyanendra/0000-0001-7593-0737; Modak, Rahul/0000-0002-1717-4627				Ancelin ML, 1998, BLOOD, V91, P1426, DOI 10.1182/blood.V91.4.1426; Arnot DE, 1998, ANN TROP MED PARASIT, V92, P361, DOI 10.1080/00034989859357; ASINDI AA, 1993, TROP GEOGR MED, V45, P110; Bebernitz GR, 2001, J MED CHEM, V44, P2601, DOI 10.1021/jm010032c; Bergler H, 1996, EUR J BIOCHEM, V242, P689, DOI 10.1111/j.1432-1033.1996.0689r.x; BROCK DJH, 1967, J BIOL CHEM, V242, P4432; Campbell JW, 2001, ANNU REV MICROBIOL, V55, P305, DOI 10.1146/annurev.micro.55.1.305; *CHEM COMP GROUP I, 2001, MOL OP ENV MOE VERS; CHICHE L, 1990, P NATL ACAD SCI USA, V87, P3240, DOI 10.1073/pnas.87.8.3240; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEBUYSERE MS, 1983, ANAL BIOCHEM, V133, P373, DOI 10.1016/0003-2697(83)90097-0; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; GASTEIGER J, 1980, TETRAHEDRON, V36, P3219, DOI 10.1016/0040-4020(80)80168-2; Goodsell DS, 1996, J MOL RECOGNIT, V9, P1, DOI 10.1002/(SICI)1099-1352(199601)9:1<1::AID-JMR241>3.0.CO;2-6; Goodstadt L, 2001, BIOINFORMATICS, V17, P845, DOI 10.1093/bioinformatics/17.9.845; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HEATH RJ, 1995, J BIOL CHEM, V270, P26538, DOI 10.1074/jbc.270.44.26538; Heath RJ, 1996, J BIOL CHEM, V271, P27795, DOI 10.1074/jbc.271.44.27795; Heath RJ, 2002, APPL MICROBIOL BIOT, V58, P695, DOI 10.1007/s00253-001-0918-z; Heath RJ, 2000, J BIOL CHEM, V275, P40128, DOI 10.1074/jbc.M005611200; Hoang TT, 1997, J BACTERIOL, V179, P5326, DOI 10.1128/jb.179.17.5326-5332.1997; Kapoor M, 2001, BIOCHEM BIOPH RES CO, V289, P832, DOI 10.1006/bbrc.2001.6061; KASS LR, 1968, J BIOL CHEM, V243, P3223; Lakowicz J.R., 1983, PRINCIPLES FLUORESCE, P44; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; Leesong M, 1996, STRUCTURE, V4, P253, DOI 10.1016/S0969-2126(96)00030-5; Marrakchi H, 2002, BIOCHEM SOC T, V30, P1050, DOI 10.1042/bst0301050; Marrakchi H, 2002, J BIOL CHEM, V277, P44809, DOI 10.1074/jbc.M208920200; McMurry LM, 1998, FEMS MICROBIOL LETT, V166, P305, DOI 10.1016/S0378-1097(98)00347-4; MEHLER EL, 1991, PROTEIN ENG, V4, P903, DOI 10.1093/protein/4.8.903; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; MULVEY RS, 1974, BIOCHEMISTRY-US, V13, P782, DOI 10.1021/bi00701a021; Penning TD, 1997, J MED CHEM, V40, P1347, DOI 10.1021/jm960803q; RAMYA TNC, 2002, CURR SCI, V83, P101; Rock CO, 1996, BBA-LIPID LIPID MET, V1302, P1, DOI 10.1016/0005-2760(96)00056-2; SCHWAB JM, 1986, J AM CHEM SOC, V108, P5309, DOI 10.1021/ja00277a041; SHERMAN IW, 1998, MALARIA; Suarez JE, 2000, MEM I OSWALDO CRUZ, V95, P495, DOI 10.1590/S0074-02762000000400009; Surolia N, 2002, BIOESSAYS, V24, P192, DOI 10.1002/bies.10042; Surolia N, 2001, NAT MED, V7, P167, DOI 10.1038/84612; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; Waller RF, 2000, EMBO J, V19, P1794, DOI 10.1093/emboj/19.8.1794; Waller RF, 1998, P NATL ACAD SCI USA, V95, P12352, DOI 10.1073/pnas.95.21.12352; Ward WHJ, 1999, BIOCHEMISTRY-US, V38, P12514, DOI 10.1021/bi9907779; WEEKS G, 1968, J BIOL CHEM, V243, P1180; WHO, 1999, WORLD HLTH REP 1999, P49	47	89	91	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45661	45671		10.1074/jbc.M304283200	http://dx.doi.org/10.1074/jbc.M304283200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12930838	hybrid			2022-12-25	WOS:000186452300075
J	Kitamura, K; Tanaka, H; Nishimune, Y				Kitamura, K; Tanaka, H; Nishimune, Y			Haprin, a novel haploid germ cell-specific RING finger protein involved in the acrosome reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; MAMMALIAN SPERM; ZONA-PELLUCIDA; MOUSE; MEMBRANE; IDENTIFICATION; EXPRESSION; FUSION; CDNA; ACID	The acrosome reaction (i.e. the exocytosis of the sperm vesicle) is a prerequisite for fertilization, but its molecular mechanism is largely unknown. We have identified a cDNA clone for a gene named haprin, which encodes a haploid germ cell-specific RING finger protein. This protein is a novel member of the RBCC (RING finger, B-box type zinc finger, and coiled-coil domain) motif family that has roles in several cellular processes, such as exocytosis. It is transcribed exclusively in testicular germ cells after meiotic division. Western blot and immunohistochemical analyses showed the molecular weight of Haprin protein to be M-r similar to 82,000. It was localized in the acrosomal region of elongated spermatids and mature sperm and was not present in acrosome-reacted sperm. The specific antibody against the RING finger domain of Haprin inhibited the acrosome reaction in permeabilized sperm. These results indicated that the novel RBCC protein Haprin plays a key role in the acrosome reaction and fertilization.	Osaka Univ, Microbial Dis Res Inst, Dept Sci Lab Anim Experimentat, Suita, Osaka 5650871, Japan	Osaka University	Nishimune, Y (corresponding author), Osaka Univ, Microbial Dis Res Inst, Dept Sci Lab Anim Experimentat, 3-1 Yamadaoka, Suita, Osaka 5650871, Japan.	nishimun@biken.osaka-u.ac.jp	Kitamura, Kouichi/L-3654-2015	Kitamura, Kouichi/0000-0001-9692-8724				Abou-Haila A, 2000, ARCH BIOCHEM BIOPHYS, V379, P173, DOI 10.1006/abbi.2000.1880; Baker SS, 2002, BIOL REPROD, V66, P57, DOI 10.1095/biolreprod66.1.57; Borden KLB, 2000, J MOL BIOL, V295, P1103, DOI 10.1006/jmbi.1999.3429; Breitbart H, 1997, MOL HUM REPROD, V3, P195, DOI 10.1093/molehr/3.3.195; de Carvalho CE, 2002, BIOL REPROD, V66, P785, DOI 10.1095/biolreprod66.3.785; Diaz A, 1996, ANDROLOGIA, V28, P21; El-Husseini AE, 1999, J BIOL CHEM, V274, P19771, DOI 10.1074/jbc.274.28.19771; Fujii T, 1999, GENOMICS, V57, P94, DOI 10.1006/geno.1998.5738; Fujii T, 2002, EMBO REP, V3, P367, DOI 10.1093/embo-reports/kvf073; Hsu SC, 1996, NEURON, V17, P1209, DOI 10.1016/S0896-6273(00)80251-2; HUGO F, 1986, INFECT IMMUN, V54, P641, DOI 10.1128/IAI.54.3.641-645.1986; Hutt DM, 2002, BIOL REPROD, V66, P50, DOI 10.1095/biolreprod66.1.50; Iguchi N, 1999, FEBS LETT, V456, P315, DOI 10.1016/S0014-5793(99)00967-9; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; Johnson LR, 1999, BIOL REPROD, V60, P683, DOI 10.1095/biolreprod60.3.683; Kierszenbaum AL, 2000, MOL REPROD DEV, V57, P309, DOI 10.1002/1098-2795(200012)57:4&lt;309::AID-MRD1&gt;3.0.CO;2-W; Koga M, 2000, BIOL REPROD, V63, P1601, DOI 10.1095/biolreprod63.6.1601; Koga M, 1998, BIOL REPROD, V58, P261, DOI 10.1095/biolreprod58.1.261; Li YK, 2001, J BIOL CHEM, V276, P40824, DOI 10.1074/jbc.M106141200; LIU DY, 1994, HUM REPROD, V9, P1694, DOI 10.1093/oxfordjournals.humrep.a138776; Liu DY, 2001, HUM REPROD, V16, P1185, DOI 10.1093/humrep/16.6.1185; MartinMoutot N, 1996, J BIOL CHEM, V271, P6567, DOI 10.1074/jbc.271.12.6567; Michaut M, 2001, DEV BIOL, V235, P521, DOI 10.1006/dbio.2001.0316; MISHIMA K, 1993, J BIOL CHEM, V268, P8801; MORTIMER D, 1987, J REPROD FERTIL, V81, P127; Nakamura Y, 2002, BIOL REPROD, V67, P1, DOI 10.1095/biolreprod67.1.1; Ponting C, 1997, TRENDS BIOCHEM SCI, V22, P193, DOI 10.1016/S0968-0004(97)01049-9; Ramalho-Santos J, 2000, DEV BIOL, V223, P54, DOI 10.1006/dbio.2000.9745; Ramalho-Santos J, 2002, BIOL REPROD, V67, P1043, DOI 10.1095/biolreprod67.4.1043; Ramalho-Santos J, 2001, EXP CELL RES, V267, P45, DOI 10.1006/excr.2000.5119; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Spitzfaden C, 1997, J MOL BIOL, V265, P565, DOI 10.1006/jmbi.1996.0736; Tanaka H, 1999, J BIOL CHEM, V274, P17049, DOI 10.1074/jbc.274.24.17049; TANAKA H, 1994, FEBS LETT, V355, P4, DOI 10.1016/0014-5793(94)01155-9; Tanaka H, 2003, BIOL REPROD, V69, P475, DOI 10.1095/biolreprod.103.015867; Tanaka H, 2002, E SCHERING RES FDN W, P55; Tomes CN, 2002, DEV BIOL, V243, P326, DOI 10.1006/dbio.2002.0567; Tosaka Y, 2000, GENES CELLS, V5, P265, DOI 10.1046/j.1365-2443.2000.00324.x; Venturini L, 1999, ONCOGENE, V18, P1209, DOI 10.1038/sj.onc.1202655; Visconti PE, 1997, DEV BIOL, V192, P351, DOI 10.1006/dbio.1997.8768; Yanagimachi R., 1994, P189; Yoda Y., 1971, JAPANESE J ANIM REPR, V16, P147, DOI [DOI 10.1262/JRD1955.16.147, 10.1262/jrd1955.16.147]	44	43	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44417	44423		10.1074/jbc.M304306200	http://dx.doi.org/10.1074/jbc.M304306200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12917430	hybrid			2022-12-25	WOS:000186306700068
J	Liu, CQ; Goshu, E; Wells, A; Fan, CM				Liu, CQ; Goshu, E; Wells, A; Fan, CM			Identification of the downstream targets of SIM1 and ARNT2, a pair of transcription factors essential for neuroendocrine cell differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; 2 MURINE HOMOLOGS; CNS MIDLINE; EXPRESSION PATTERNS; MOUSE HYPOTHALAMUS; FACTOR BRN-2; DNA-BINDING; GENE; OBESITY; DOMAIN	SIM1 and ARNT2 are two basic helix-loop-helix/PAS ((P) under bar er-(A) under bar rnt-(S) under bar im) transcription factors that control the differentiation of neuroendocrine lineages in the mouse hypothalamus. Heterozygous Sim1 mice also develop early onset obesity, possibly due to hypodevelopment of the hypothalamus. Although SIM1 and ARNT2 form heterodimers to direct the same molecular pathway, knowledge of this pathway is limited. To facilitate the identification of their downstream genes, we combined an inducible gene expression system in a neuronal cell line with microarray analysis to screen for their transcriptional targets. This method identified 268 potential target genes of SIM1/ARNT2 that displayed >1.7-fold induced expression. 15 of these genes were subjected to Northern analysis, and a high percentage of them were confirmed to be up-regulated. In vivo, several of these genes showed neuroendocrine hypothalamic expression correlating with that of Sim1. Furthermore, we found that expression of two of these potential targets, the Jak2 and thyroid hormone receptor beta(2) genes, was lost in the neuroendocrine hypothalamus of the Sim1 mutant. The expression and predicted functions of many of these genes provide new insight into both the Sim1/Arnt2 action in neuroendocrine hypothalamus development and the molecular basis for the Sim1 haplo-insufficient obesity phenotype.	Carnegie Inst Washington, Dept Embryol, Baltimore, MD 21210 USA	Carnegie Institution for Science	Fan, CM (corresponding author), Carnegie Inst Washington, Dept Embryol, 115 W Univ Pkwy, Baltimore, MD 21210 USA.		Liu, Chunqiao/O-3391-2013	Liu, Chunqiao/0000-0002-0299-7401	NICHD NIH HHS [R01HD35596] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD035596] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Auerbach A, 1998, J GEN PHYSIOL, V112, P181, DOI 10.1085/jgp.112.2.181; Bjorbaek C, 2002, VITAM HORM, V65, P281, DOI 10.1016/S0083-6729(02)65068-X; Burbach JPH, 2001, PHYSIOL REV, V81, P1197, DOI 10.1152/physrev.2001.81.3.1197; Butler AA, 2000, ENDOCRINOLOGY, V141, P3518, DOI 10.1210/en.141.9.3518; Cheng A, 2002, DEV CELL, V2, P497, DOI 10.1016/S1534-5807(02)00149-1; Crews ST, 1999, CURR OPIN GENET DEV, V9, P580, DOI 10.1016/S0959-437X(99)00003-9; Ema M, 1996, MOL CELL BIOL, V16, P5865; Epstein DJ, 2000, DEVELOPMENT, V127, P4701; Faivre L, 2002, J MED GENET, V39, P594, DOI 10.1136/jmg.39.8.594; Fan CM, 1996, MOL CELL NEUROSCI, V7, P1, DOI 10.1006/mcne.1996.0001; Feng W, 2002, J BIOL CHEM, V277, P44722, DOI 10.1074/jbc.M207675200; FRANKS RG, 1994, MECH DEVELOP, V45, P269, DOI 10.1016/0925-4773(94)90013-2; Hirose K, 1996, MOL CELL BIOL, V16, P1706; Holder JL, 2000, HUM MOL GENET, V9, P101; Hosoya T, 2001, GENES CELLS, V6, P361, DOI 10.1046/j.1365-2443.2001.00421.x; KANDEL ER, 1991, PRINCIPLE NEUROSCIEN; KARIM MA, 1980, J ANAT, V130, P341; Kasai Y, 1998, GENE EXPRESSION, V7, P171; Keith B, 2001, P NATL ACAD SCI USA, V98, P6692, DOI 10.1073/pnas.121494298; Langlois MF, 1997, J BIOL CHEM, V272, P24927, DOI 10.1074/jbc.272.40.24927; Lee YS, 2002, J CLIN ENDOCR METAB, V87, P1423, DOI 10.1210/jc.87.3.1423; LI P, 1993, GENE DEV, V7, P2483, DOI 10.1101/gad.7.12b.2483; Michaud JL, 2000, MECH DEVELOP, V90, P253, DOI 10.1016/S0925-4773(99)00328-7; Michaud JL, 1998, GENE DEV, V12, P3264, DOI 10.1101/gad.12.20.3264; Michaud JL, 2001, HUM MOL GENET, V10, P1465, DOI 10.1093/hmg/10.14.1465; Moffett P, 2000, FEBS LETT, V466, P80, DOI 10.1016/S0014-5793(99)01750-0; Nakai S, 1995, GENE DEV, V9, P3109, DOI 10.1101/gad.9.24.3109; OKAMURA H, 1983, DEV BRAIN RES, V9, P223, DOI 10.1016/0165-3806(83)90055-X; Probst MR, 1997, J BIOL CHEM, V272, P4451, DOI 10.1074/jbc.272.7.4451; Ramkumar T, 1999, MOL ENDOCRINOL, V13, P1237, DOI 10.1210/me.13.8.1237; Reick M, 2001, SCIENCE, V293, P506, DOI 10.1126/science.1060699; Satoh T, 1999, MOL CELL ENDOCRINOL, V154, P137, DOI 10.1016/S0303-7207(99)00032-5; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Schonemann MD, 1995, GENE DEV, V9, P3122, DOI 10.1101/gad.9.24.3122; Semenza GL, 1997, KIDNEY INT, V51, P553, DOI 10.1038/ki.1997.77; Sonnenfeld M, 1997, DEVELOPMENT, V124, P4571; Suzuki M, 2003, J BIOL CHEM, V278, P14640, DOI 10.1074/jbc.M300239200; Uchino S, 1997, NEUROREPORT, V8, P445, DOI 10.1097/00001756-199701200-00014; Wallenius V, 2002, NAT MED, V8, P75, DOI 10.1038/nm0102-75; WHARTON KA, 1994, DEVELOPMENT, V120, P3563; Zabolotny JM, 2002, DEV CELL, V2, P489, DOI 10.1016/S1534-5807(02)00148-X	41	34	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44857	44867		10.1074/jbc.M304489200	http://dx.doi.org/10.1074/jbc.M304489200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12947113	hybrid			2022-12-25	WOS:000186306700121
J	Murai, N; Murakami, Y; Matsufuji, S				Murai, N; Murakami, Y; Matsufuji, S			Identification of nuclear export signals in antizyme-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORNITHINE-DECARBOXYLASE-ANTIZYME; TISSUE-CULTURE CELLS; AMINO-ACID-SEQUENCE; EXPRESSION; POLYAMINES; PROTEINS; CRM1; LOCALIZATION; RECEPTOR; COMPLEX	Antizyme-1 (AZ1) is a protein that negatively regulates polyamine synthesis by inhibiting the key synthetic enzyme ornithine decarboxylase and targeting it for degradation by the 26 S proteasome. Recent work shows that antizyme protein translocates to the nucleus during mouse development (Gritli-Linde, A., Nilssom, J., Bohlooly, Y.M., Heby, O., and Linde, A. (2001) Dev. Dyn. 220, 259-275). However, the significance and mechanism of this phenomenon remain unclear. In this study, we expressed AZ1 fused with enhanced green fluorescent protein (EGFP) to study its localization in a living cell. We found that EGFP-AZ1 was predominantly localized in the cytoplasm and that treatment with leptomycin B, a specific inhibitor of chromosomal region maintenance 1 (CRM1) induced nuclear accumulation of EGFP-AZ1 in Chinese hamster ovary and NIH3T3 cells. Two independent nuclear export signal (NES) sequences, each containing essential hydrophobic residues, were identified in the 50 N-terminal amino acid residues and in the central part of AZ1. The activity of the second NES was inhibited by an N-terminal adjacent region and was only revealed in N-terminal truncated constructs. Both NESs were active when fused to an artificial nuclear protein SV40-NLS-EGFP-EGFP. The ability of AZ1 to shuttle between the nucleus and the cytoplasm suggests that it has a novel function in the nucleus.	Jikei Univ, Sch Med, Dept Biochem 2, Minato Ku, Tokyo 1058461, Japan; LTT Biopharma Co Ltd, Minato Ku, Tokyo 1056201, Japan	Jikei University	Murai, N (corresponding author), Jikei Univ, Sch Med, Dept Biochem 2, Minato Ku, 3-25-8 Nishi Shinbashi, Tokyo 1058461, Japan.	nmurai@jikei.ac.jp	MURAI, NORIYUKI/V-5747-2018	MURAI, NORIYUKI/0000-0002-1552-5104				DAVIS LI, 1995, ANNU REV BIOCHEM, V64, P865, DOI 10.1146/annurev.bi.64.070195.004245; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2; Engel K, 1998, EMBO J, V17, P3363, DOI 10.1093/emboj/17.12.3363; Fasken MB, 2000, J BIOL CHEM, V275, P1878, DOI 10.1074/jbc.275.3.1878; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; FONG WF, 1976, BIOCHIM BIOPHYS ACTA, V428, P456, DOI 10.1016/0304-4165(76)90054-4; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Gandre S, 2003, MITOCHONDRION, V2, P245, DOI 10.1016/S1567-7249(02)00105-8; Gritli-Linde A, 2001, DEV DYNAM, V220, P259, DOI 10.1002/1097-0177(20010301)220:3<259::AID-DVDY1100>3.0.CO;2-#; Gruendler C, 2001, J BIOL CHEM, V276, P46533, DOI 10.1074/jbc.M105500200; HELLER JS, 1976, P NATL ACAD SCI USA, V73, P1858, DOI 10.1073/pnas.73.6.1858; Huber J, 1998, EMBO J, V17, P4114, DOI 10.1093/emboj/17.14.4114; ICHIBA T, 1994, BIOCHEM BIOPH RES CO, V200, P1721, DOI 10.1006/bbrc.1994.1651; Ivanov IP, 2000, P NATL ACAD SCI USA, V97, P4808, DOI 10.1073/pnas.070055897; Ivanov IP, 2000, NUCLEIC ACIDS RES, V28, P3185, DOI 10.1093/nar/28.17.3185; Ivanov IP, 2000, EMBO J, V19, P1907, DOI 10.1093/emboj/19.8.1907; Jullien D, 1999, EMBO J, V18, P4348, DOI 10.1093/emboj/18.15.4348; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; LI XQ, 1994, MOL CELL BIOL, V14, P87, DOI 10.1128/MCB.14.1.87; Lin Y, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-15; MATSUFUJI S, 1995, CELL, V80, P51, DOI 10.1016/0092-8674(95)90450-6; MITCHELL JLA, 1994, BIOCHEM J, V299, P19, DOI 10.1042/bj2990019; Mitchell JLA, 1998, BIOCHEM J, V329, P453; Mitchell JLA, 1998, BIOCHEM SOC T, V26, P591, DOI 10.1042/bst0260591; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; MURAKAMI Y, 1992, J BIOL CHEM, V267, P13138; Murphy R, 1996, NATURE, V383, P357, DOI 10.1038/383357a0; Pante N, 1995, J CELL SCI, P1; ROM E, 1994, P NATL ACAD SCI USA, V91, P3959, DOI 10.1073/pnas.91.9.3959; Sekimoto T, 1997, EMBO J, V16, P7067, DOI 10.1093/emboj/16.23.7067; SUZUKI T, 1994, P NATL ACAD SCI USA, V91, P8930, DOI 10.1073/pnas.91.19.8930; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; Tosaka Y, 2000, GENES CELLS, V5, P265, DOI 10.1046/j.1365-2443.2000.00324.x; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2	37	35	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44791	44798		10.1074/jbc.M308059200	http://dx.doi.org/10.1074/jbc.M308059200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12941943	hybrid			2022-12-25	WOS:000186306700113
J	Robert, F; Brakier-Gingras, L				Robert, F; Brakier-Gingras, L			A functional interaction between ribosomal proteins S7 and S11 within the bacterial ribosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION COMPLEX-FORMATION; TRANSFER-RNA-BINDING; MESSENGER-RNA; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; TRANSLATIONAL ACCURACY; ANGSTROM RESOLUTION; ATOMIC-RESOLUTION; CROSS-LINKING; 70S RIBOSOME	In this study, we used site-directed mutagenesis to disrupt an interaction that had been detected between ribosomal proteins S7 and S11 in the crystal structure of the bacterial 30 S subunit. This interaction, which is located in the E site, connects the head of the 30 S subunit to the platform and is involved in the formation of the exit channel through which passes the 30 S-bound messenger RNA. Neither mutations in S7 nor mutations in S11 prevented the incorporation of the proteins into the 30 S subunits but they perturbed the function of the ribosome. In vivo assays showed that ribosomes with either mutated S7 or S11 were altered in the control of translational fidelity, having an increased capacity for frameshifting, readthrough of a nonsense codon and codon misreading. Toeprinting and filter-binding assays showed that 30 S subunits with either mutated S7 or S11 have an enhanced capacity to bind mRNA. The effects of the S7 and S11 mutations can be related to an increased flexibility of the head of the 30 S, to an opening of the mRNA exit channel and to a perturbation of the proposed allosteric coupling between the A and E sites. Altogether, our results demonstrate that S7 and S11 interact in a functional manner and support the notion that protein-protein interactions contribute to the dynamics of the ribosome.	Univ Montreal, Dept Biochim, Montreal, PQ H3C 3J7, Canada	Universite de Montreal	Brakier-Gingras, L (corresponding author), Univ Montreal, Dept Biochim, Montreal, PQ H3C 3J7, Canada.	lea.brakier.gingras@umontreal.ca						Agrawal RK, 1999, INT J BIOCHEM CELL B, V31, P243, DOI 10.1016/S1357-2725(98)00149-6; Agrawal RK, 1999, NAT STRUCT BIOL, V6, P643, DOI 10.1038/10695; ANDERSSON DI, 1982, MOL GEN GENET, V187, P467, DOI 10.1007/BF00332630; Belanger F, 2002, J MOL BIOL, V320, P979, DOI 10.1016/S0022-2836(02)00550-8; BRETSCHER MS, 1968, NATURE, V220, P1088, DOI 10.1038/2201088a0; Brimacombe R, 2000, STRUCTURE, V8, pR195, DOI 10.1016/S0969-2126(00)00510-4; Brodersen DE, 2002, J MOL BIOL, V316, P725, DOI 10.1006/jmbi.2001.5359; BROUDE NE, 1983, EUR J BIOCHEM, V132, P139, DOI 10.1111/j.1432-1033.1983.tb07338.x; Brunelle MN, 1999, NUCLEIC ACIDS RES, V27, P4783, DOI 10.1093/nar/27.24.4783; Carter AP, 2001, SCIENCE, V291, P498, DOI 10.1126/science.1057766; Carter AP, 2000, NATURE, V407, P340, DOI 10.1038/35030019; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Cooperman BS, 1995, BIOCHEM CELL BIOL, V73, P1087, DOI 10.1139/o95-117; Culver GM, 2001, STRUCTURE, V9, P751, DOI 10.1016/S0969-2126(01)00649-9; Dahlberg AE, 2001, SCIENCE, V292, P868, DOI 10.1126/science.1061513; Dallas A, 2001, MOL CELL, V8, P855, DOI 10.1016/S1097-2765(01)00356-2; Davies C, 1998, J MOL BIOL, V279, P873, DOI 10.1006/jmbi.1998.1780; Diedrich G, 2000, EMBO J, V19, P5241, DOI 10.1093/emboj/19.19.5241; DORING T, 1994, EMBO J, V13, P2677, DOI 10.1002/j.1460-2075.1994.tb06558.x; Farabaugh PJ, 1999, EMBO J, V18, P1427, DOI 10.1093/emboj/18.6.1427; Feinberg JS, 2001, P NATL ACAD SCI USA, V98, P11120, DOI 10.1073/pnas.211184098; Frank J, 2000, NATURE, V406, P318, DOI 10.1038/35018597; Frank J, 2003, BIOPOLYMERS, V68, P223, DOI 10.1002/bip.10210; Frank J, 2001, COLD SPRING HARB SYM, V66, P67, DOI 10.1101/sqb.2001.66.67; Fredrick K, 2000, J MOL BIOL, V298, P379, DOI 10.1006/jmbi.2000.3563; Green R, 1997, ANNU REV BIOCHEM, V66, P679, DOI 10.1146/annurev.biochem.66.1.679; Greuer B, 1999, RNA, V5, P1521, DOI 10.1017/S1355838299991550; GREUER B, 1987, NUCLEIC ACIDS RES, V15, P3241, DOI 10.1093/nar/15.8.3241; Grill S, 2000, EMBO J, V19, P4101, DOI 10.1093/emboj/19.15.4101; GUALERZI C, 1977, BIOCHEMISTRY-US, V16, P1684, DOI 10.1021/bi00627a025; Gualerzi CO, 2000, RIBOSOME: STRUCTURE, FUNCTION, ANTIBIOTICS, AND CELLULAR INTERACTIONS, P477; Gualerzi CO, 2001, COLD SPRING HARB SYM, V66, P363, DOI 10.1101/sqb.2001.66.363; HARTZ D, 1988, METHOD ENZYMOL, V164, P419; Herr AJ, 2001, J MOL BIOL, V309, P1029, DOI 10.1006/jmbi.2001.4717; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Joseph S, 1998, EMBO J, V17, P3478, DOI 10.1093/emboj/17.12.3478; Joseph S, 2003, RNA, V9, P160, DOI 10.1261/rna.2163103; Karimi R, 1999, MOL CELL, V3, P601, DOI 10.1016/S1097-2765(00)80353-6; Khaitovich P, 1999, P NATL ACAD SCI USA, V96, P85, DOI 10.1073/pnas.96.1.85; Komarova AV, 2002, RNA, V8, P1137, DOI 10.1017/S1355838202029990; Maguire BA, 2001, CELL, V104, P813, DOI 10.1016/S0092-8674(01)00278-1; Marquez V, 2002, BIOCHEM SOC T, V30, P133, DOI 10.1042/BST0300133; McCutcheon JP, 1999, P NATL ACAD SCI USA, V96, P4301, DOI 10.1073/pnas.96.8.4301; Moore PB, 2002, NATURE, V418, P229, DOI 10.1038/418229a; Moore PB, 2001, BIOCHEMISTRY-US, V40, P3243, DOI 10.1021/bi0029402; NIERHAUS KH, 1990, BIOCHEMISTRY-US, V29, P4997, DOI 10.1021/bi00473a001; Noller HF, 2002, BIOCHEM SOC T, V30, P1159, DOI 10.1042/BST0301159; Noller HF, 2002, FEBS LETT, V514, P11, DOI 10.1016/S0014-5793(02)02327-X; Ogle JM, 2002, CELL, V111, P721, DOI 10.1016/S0092-8674(02)01086-3; Ogle JM, 2001, SCIENCE, V292, P897, DOI 10.1126/science.1060612; PIEPERSBERG W, 1979, MOL GEN GENET, V171, P23, DOI 10.1007/BF00274011; PINARD R, 1995, BIOCHEMISTRY-US, V34, P9611, DOI 10.1021/bi00029a038; Ramakrishnan V, 2002, CELL, V108, P557, DOI 10.1016/S0092-8674(02)00619-0; Robert F, 2000, RNA, V6, P1649, DOI 10.1017/S1355838200001199; Robert F, 2001, NUCLEIC ACIDS RES, V29, P677, DOI 10.1093/nar/29.3.677; Rodnina MV, 2002, BIOCHIMIE, V84, P745, DOI 10.1016/S0300-9084(02)01409-8; SAITO K, 1994, J MOL BIOL, V235, P111, DOI 10.1016/S0022-2836(05)80020-8; Schluenzen F, 2000, CELL, V102, P615, DOI 10.1016/S0092-8674(00)00084-2; Sengupta J, 2001, P NATL ACAD SCI USA, V98, P11991, DOI 10.1073/pnas.211266898; SPEDDING G, 1993, J MOL BIOL, V229, P609, DOI 10.1006/jmbi.1993.1067; SPEDDING G, 1990, RIBOSOMES PROTEIN SY, P1; Stahl G, 2002, TRENDS BIOCHEM SCI, V27, P178, DOI 10.1016/S0968-0004(02)02064-9; Stark H, 2000, CELL, V100, P301, DOI 10.1016/S0092-8674(00)80666-2; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; Viviani VR, 2002, PHOTOCHEM PHOTOBIOL, V76, P538, DOI 10.1562/0031-8655(2002)076&lt;0538:TIOAGA&gt;2.0.CO;2; Wilson KS, 2000, NAT STRUCT BIOL, V7, P866, DOI 10.1038/82818; Wimberly BT, 2000, NATURE, V407, P327, DOI 10.1038/35030006; WOWER J, 1993, EMBO J, V12, P617, DOI 10.1002/j.1460-2075.1993.tb05694.x; Yonath A, 2002, ANNU REV BIOPH BIOM, V31, P257, DOI 10.1146/annurev.biophys.31.082901.134439; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089; Yusupova GZ, 2001, CELL, V106, P233, DOI 10.1016/S0092-8674(01)00435-4	72	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44913	44920		10.1074/jbc.M306534200	http://dx.doi.org/10.1074/jbc.M306534200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12937172	hybrid			2022-12-25	WOS:000186306700127
J	Zufferey, R; Allen, S; Barron, T; Sullivan, DR; Denny, PW; Almeida, IC; Smith, DF; Turco, SJ; Ferguson, MAJ; Beverley, SM				Zufferey, R; Allen, S; Barron, T; Sullivan, DR; Denny, PW; Almeida, IC; Smith, DF; Turco, SJ; Ferguson, MAJ; Beverley, SM			Ether phospholipids and glycosylinositolphospholipids are not required for amastigote virulence or for inhibition of macrophage activation by Leishmania major	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTOZOAN PARASITE LEISHMANIA; PROTEIN-KINASE-C; DIHYDROXYACETONE-PHOSPHATE SYNTHASE; NITRIC-OXIDE SYNTHASE; GLYCOSYLPHOSPHATIDYLINOSITOL BIOSYNTHESIS; DONOVANI LIPOPHOSPHOGLYCAN; TRYPANOSOMA-BRUCEI; MURINE MACROPHAGES; GLYCOINOSITOL PHOSPHOLIPIDS; MEXICANA PROMASTIGOTES	Ether phospholipids are major components of the membranes of humans and Leishmania. In protozoan parasites they occur separately or as part of the glycosylphosphatidylinositol (GPI) anchor of molecules implicated in virulence, such as lipophosphoglycan (LPG), smaller glycosylinositolphospholipids (GIPLs), and GPI-anchored proteins. We generated null mutants of the Leishmania major alkyldihydroxyacetonephosphate synthase ( ADS), the first committed step of ether lipid synthesis. Enzymatic analysis and comprehensive mass spectrometric analysis showed that ads1(-) knock-outs lacked all ether phospholipids, including plasmalogens, LPG, and GIPLs. Leishmania ads1(-) thus represents the first ether lipid- synthesizing eukaryote for which a completely null mutant could be obtained. Remarkably ads1(-) grew well and maintained lipid rafts (detergent-resistant membranes). In virulence tests it closely resembled LPG-deficient L. major, including sensitivity to complement and an inability to survive the initial phase of macrophage infection. Likewise it retained the ability to inhibit host cell signaling and to form infectious amastigotes from the few parasites surviving the establishment defect. These findings counter current proposals that GIPLs are required for amastigote survival in the mammalian host or that parasite lyso-alkyl or alkylacyl-GPI anchors are solely responsible for inhibition of macrophage activation.	Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA; Univ Dundee, Wellcome Trust Bioctr, Dundee DD1 4HN, Scotland; Univ Kentucky, Med Ctr, Dept Biochem, Lexington, KY 40506 USA; Univ London Imperial Coll Sci Technol & Med, Wellcome Trust Labs Mol Parasitol, Dept Biol Sci, London SW7 1AZ, England; Univ Sao Paulo, Dept Parasitol, BR-05508900 Sao Paulo, Brazil	Washington University (WUSTL); University of Dundee; University of Kentucky; Imperial College London; Universidade de Sao Paulo	Beverley, SM (corresponding author), Washington Univ, Sch Med, Dept Mol Microbiol, Campus Box 8230,660 S Euclid Ave, St Louis, MO 63110 USA.	beverley@borcim.wustl.edu	Almeida, Igor C./AAF-9409-2019; Ferguson, Michael A. J./F-7829-2010; Denny, Paul/B-8431-2013	Almeida, Igor C./0000-0002-2443-8213; Ferguson, Michael A. J./0000-0003-1321-8714; Denny, Paul/0000-0002-5051-1613; Beverley, Stephen/0000-0001-5319-0811	Wellcome Trust [061343] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BEACH DH, 1979, J PARASITOL, V65, P203, DOI 10.2307/3280147; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Chawla M, 2003, J LIPID RES, V44, P594, DOI 10.1194/jlr.M200296-JLR200; Clayton CE, 2002, EMBO J, V21, P1881, DOI 10.1093/emboj/21.8.1881; Croft SL, 2003, MOL BIOCHEM PARASIT, V126, P165, DOI 10.1016/S0166-6851(02)00283-9; CRUZ A, 1991, P NATL ACAD SCI USA, V88, P7170, DOI 10.1073/pnas.88.16.7170; Denny PW, 2001, FEBS LETT, V491, P148, DOI 10.1016/S0014-5793(01)02172-X; Ferguson MAJ, 1997, PHILOS T ROY SOC B, V352, P1295, DOI 10.1098/rstb.1997.0113; Garami A, 2001, EMBO J, V20, P3657, DOI 10.1093/emboj/20.14.3657; Garami A, 2001, MOL CELL BIOL, V21, P8168, DOI 10.1128/MCB.21.23.8168-8183.2001; GLASER PE, 1995, BIOCHEMISTRY-US, V34, P12193, DOI 10.1021/bi00038a013; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Ha DS, 1996, MOL BIOCHEM PARASIT, V77, P57, DOI 10.1016/0166-6851(96)02580-7; Heise N, 1997, MOL BIOCHEM PARASIT, V89, P61, DOI 10.1016/S0166-6851(97)00101-1; Ilgoutz SC, 1999, EMBO J, V18, P2746, DOI 10.1093/emboj/18.10.2746; Ilgoutz SC, 2001, INT J PARASITOL, V31, P899, DOI 10.1016/S0020-7519(01)00197-7; JARDIM A, 1991, J IMMUNOL, V147, P3538; JOSHI PB, 1995, GENE, V156, P145, DOI 10.1016/0378-1119(95)00042-5; KAPLER GM, 1990, MOL CELL BIOL, V10, P1084, DOI 10.1128/MCB.10.3.1084; KARP CL, 1991, J IMMUNOL, V147, P680; KATAKURA K, 1988, INFECT IMMUN, V56, P2856, DOI 10.1128/IAI.56.11.2856-2860.1988; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lux H, 2000, MOL BIOCHEM PARASIT, V111, P1, DOI 10.1016/S0166-6851(00)00278-4; McConville MJ, 2002, MICROBIOL MOL BIOL R, V66, P122, DOI 10.1128/MMBR.66.1.122-154.2002; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P7385; MCCONVILLE MJ, 1992, EMBO J, V11, P3593, DOI 10.1002/j.1460-2075.1992.tb05443.x; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P19611; MCCONVILLE MJ, 1989, J BIOL CHEM, V264, P757; MCNEELY TB, 1989, BIOCHEM J, V259, P601, DOI 10.1042/bj2590601; Mengeling BJ, 1997, GLYCOBIOLOGY, V7, P873, DOI 10.1093/glycob/7.7.873-c; Mensa-Wilmot K, 1999, MOL BIOCHEM PARASIT, V99, P103, DOI 10.1016/S0166-6851(99)00003-1; MOODY SF, 1993, J BIOL CHEM, V268, P18457; Nagan N, 2001, PROG LIPID RES, V40, P199, DOI 10.1016/S0163-7827(01)00003-0; Ohvo-Rekila H, 2002, PROG LIPID RES, V41, P66, DOI 10.1016/S0163-7827(01)00020-0; OPPERDOES FR, 1993, BIOCHIMIE, V75, P231, DOI 10.1016/0300-9084(93)90081-3; ORLANDI PA, 1987, J BIOL CHEM, V262, P10384; Pike LJ, 2002, BIOCHEMISTRY-US, V41, P2075, DOI 10.1021/bi0156557; PIMENTA PFP, 1991, EXP PARASITOL, V72, P191, DOI 10.1016/0014-4894(91)90137-L; PROUDFOOT L, 1995, BIOCHEM J, V308, P45, DOI 10.1042/bj3080045; PROUDFOOT L, 1995, EUR J IMMUNOL, V25, P745, DOI 10.1002/eji.1830250318; Proudfoot L, 1996, P NATL ACAD SCI USA, V93, P10984, DOI 10.1073/pnas.93.20.10984; Racoosin EL, 1997, EXP PARASITOL, V85, P283, DOI 10.1006/expr.1996.4139; Ralton JE, 1998, J BIOL CHEM, V273, P4245, DOI 10.1074/jbc.273.7.4245; Ralton JE, 2002, BIOCHEM J, V363, P365, DOI 10.1042/0264-6021:3630365; RYAN KA, 1993, GENE, V131, P145, DOI 10.1016/0378-1119(93)90684-U; RYU EK, 1979, J LIPID RES, V20, P561; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHNEIDER P, 1994, BIOCHEM J, V304, P603, DOI 10.1042/bj3040603; SCHNEIDER P, 1993, BIOCHEM J, V295, P555, DOI 10.1042/bj2950555; Schneiter R, 1999, J CELL BIOL, V146, P741, DOI 10.1083/jcb.146.4.741; SCHRAKAMP G, 1985, J LIPID RES, V26, P867; SERRANO AA, 1995, J BIOL CHEM, V270, P27244, DOI 10.1074/jbc.270.45.27244; Shakarian AM, 1997, GENE, V196, P127, DOI 10.1016/S0378-1119(97)00218-7; Shakarian AM, 2000, EXP PARASITOL, V95, P79, DOI 10.1006/expr.2000.4511; Shih S, 1998, J BIOL CHEM, V273, P1534, DOI 10.1074/jbc.273.3.1534; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SINGH BN, 1988, BIOCHEM BIOPH RES CO, V157, P1239, DOI 10.1016/S0006-291X(88)81007-6; Smith TK, 2002, J BIOL CHEM, V277, P37147, DOI 10.1074/jbc.M203371200; SOMMER JM, 1994, ANNU REV MICROBIOL, V48, P105, DOI 10.1146/annurev.mi.48.100194.000541; Spath GF, 2000, P NATL ACAD SCI USA, V97, P9258, DOI 10.1073/pnas.160257897; Spath GF, 2003, SCIENCE, V301, P1241, DOI 10.1126/science.1087499; Spath GF, 2003, P NATL ACAD SCI USA, V100, P9536, DOI 10.1073/pnas.1530604100; Spath GF, 2001, EXP PARASITOL, V99, P97, DOI 10.1006/expr.2001.4656; Tachado SD, 1999, PARASITE IMMUNOL, V21, P609, DOI 10.1046/j.1365-3024.1999.00268.x; Tachado SD, 1996, J IMMUNOL, V156, P1897; Thai TP, 2001, HUM MOL GENET, V10, P127, DOI 10.1093/hmg/10.2.127; TITUS RG, 1985, PARASITE IMMUNOL, V7, P545, DOI 10.1111/j.1365-3024.1985.tb00098.x; TOLSON DL, 1989, MOL BIOCHEM PARASIT, V35, P109, DOI 10.1016/0166-6851(89)90113-8; Turco SJ, 1999, PARASITE IMMUNOL, V21, P597, DOI 10.1046/j.1365-3024.1999.00266.x; Turco SJ, 2001, TRENDS PARASITOL, V17, P223, DOI 10.1016/S1471-4922(01)01895-5; vandenBosch H, 1997, BBA-LIPID LIPID MET, V1348, P35, DOI 10.1016/S0005-2760(97)00107-0; WASSEF MK, 1985, LIPIDS, V20, P108, DOI 10.1007/BF02534216; Watanabe R, 1998, EMBO J, V17, P877, DOI 10.1093/emboj/17.4.877; Wilson IBH, 1999, MOL BIOCHEM PARASIT, V100, P207, DOI 10.1016/S0166-6851(99)00061-4; Zomer AWM, 1999, MOL BIOCHEM PARASIT, V104, P55, DOI 10.1016/S0166-6851(99)00141-3	76	87	90	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44708	44718		10.1074/jbc.M308063200	http://dx.doi.org/10.1074/jbc.M308063200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12944391	hybrid			2022-12-25	WOS:000186306700104
J	Constantinescu, SN; Keren, T; Russ, WP; Ubarretxena-Belandia, I; Malka, Y; Kubatzky, KF; Engelman, DM; Lodish, HF; Henis, YI				Constantinescu, SN; Keren, T; Russ, WP; Ubarretxena-Belandia, I; Malka, Y; Kubatzky, KF; Engelman, DM; Lodish, HF; Henis, YI			The erythropoietin receptor transmembrane domain mediates complex formation with viral anemic and polycythemic gp55 proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCUS-FORMING VIRUS; FACTOR-BETA RECEPTORS; SIGNAL-TRANSDUCTION; FRIEND-VIRUS; ENVELOPE GLYCOPROTEIN; INDEPENDENT GROWTH; ENDOPLASMIC-RETICULUM; HELIX ASSOCIATION; TYROSINE KINASE; TRUNCATED FORM	Erythropoietin receptor (EpoR) activation is crucial for mature red blood cell production. The murine EpoR can also be activated by the envelope protein of the polycythemic (P) spleen focus forming virus (SFFV), gp55-P. Due to differences in the TM sequence, gp55 of the anemic (A) strain SFFV, gp55-A, cannot efficiently activate the EpoR. Using antibody-mediated immunofluorescence co-patching, we show that the majority of EpoR forms hetero-oligomers at the cell surface with gp55-P and, surprisingly, with gp55-A. The EpoR TM domain is targeted by gp55-P and -A, as only chimeric receptors containing EpoR TM sequences oligomerized with gp55 proteins. Both gp55-P and gp55-A are homodimers on the cell surface, as shown by co-patching. However, when the homomeric interactions of the isolated TM domains were assayed by TOXCAT bacterial reporter system, only the TM sequence of gp55-P was dimerized. Thus, homo-oligomerization of gp55 proteins is insufficient for full EpoR activation, and a correct conformation of the dimer in the TM region is required. This is supported by the failure of gp55-A3P, a mutant protein whose TM domain can homo-oligomerize, to fully activate EpoR. As unliganded EpoR forms TM-dependent but inactive homodimers, we propose that the EpoR can be activated to different extents by homodimeric gp55 proteins, depending on the conformation of the gp55 protein dimer in the TM region.	Ludwig Inst Canc Res, B-1200 Brussels, Belgium; Catholic Univ Louvain, B-1200 Brussels, Belgium; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Ludwig Institute for Cancer Research; Universite Catholique Louvain; Massachusetts Institute of Technology (MIT); Whitehead Institute; Tel Aviv University; Yale University; Massachusetts Institute of Technology (MIT)	Constantinescu, SN (corresponding author), Ludwig Inst Canc Res, B-1200 Brussels, Belgium.	stefan.constantinescu@bru.licr.org; henis@post.tau.ac.il	Ubarretxena-Belandia, Iban/A-8389-2009; Constantinescu, Stefan N/E-5277-2012; Ubarretxena-Belandia, Iban/AAA-8939-2019	Constantinescu, Stefan N./0000-0002-8599-2699; Henis, Yoav/0000-0002-1408-3877	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL032262] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL32262] Funding Source: Medline; NIGMS NIH HHS [GM54160] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; CASADEVALL N, 1991, J BIOL CHEM, V266, P16015; CHUNG SW, 1989, P NATL ACAD SCI USA, V86, P7957, DOI 10.1073/pnas.86.20.7957; Constantinescu SN, 1999, EMBO J, V18, P3334, DOI 10.1093/emboj/18.12.3334; Constantinescu SN, 1999, TRENDS ENDOCRIN MET, V10, P18, DOI 10.1016/S1043-2760(98)00101-5; Constantinescu SN, 1998, BLOOD, V91, P1163, DOI 10.1182/blood.V91.4.1163; Constantinescu SN, 2001, MOL CELL, V7, P377, DOI 10.1016/S1097-2765(01)00185-X; Constantinescu SN, 2001, P NATL ACAD SCI USA, V98, P4379, DOI 10.1073/pnas.081069198; Dawson JP, 2002, J MOL BIOL, V316, P799, DOI 10.1006/jmbi.2001.5353; DUSANTERFOURT I, 1994, EMBO J, V13, P2583, DOI 10.1002/j.1460-2075.1994.tb06548.x; Fang C, 1998, VIROLOGY, V252, P46, DOI 10.1006/viro.1998.9453; FERRO FE, 1993, J BIOL CHEM, V268, P5741; Finkelstein LD, 2002, ONCOGENE, V21, P3562, DOI 10.1038/sj.onc.1205442; FRIEND C, 1957, J EXP MED, V105, P307, DOI 10.1084/jem.105.4.307; Gent J, 2002, P NATL ACAD SCI USA, V99, P9858, DOI 10.1073/pnas.152294299; Gilboa L, 1998, J CELL BIOL, V140, P767, DOI 10.1083/jcb.140.4.767; Gilboa L, 2000, MOL BIOL CELL, V11, P1023, DOI 10.1091/mbc.11.3.1023; Gurezka R, 2001, J BIOL CHEM, V276, P45580, DOI 10.1074/jbc.M105362200; Gurezka R, 1999, J BIOL CHEM, V274, P9265, DOI 10.1074/jbc.274.14.9265; HANKINS WD, 1980, CELL, V22, P693; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; HOATLIN ME, 1990, P NATL ACAD SCI USA, V87, P9985, DOI 10.1073/pnas.87.24.9985; Huang LJS, 2001, MOL CELL, V8, P1327, DOI 10.1016/S1097-2765(01)00401-4; KABAT D, 1989, CURR TOP MICROBIOL, V148, P1; KILPATRICK DR, 1989, J BIOL CHEM, V264, P10732; KOLMAR H, 1995, EMBO J, V14, P3895, DOI 10.1002/j.1460-2075.1995.tb00061.x; KOZAK SL, 1993, J VIROL, V67, P2611, DOI 10.1128/JVI.67.5.2611-2620.1993; Kubatzky KF, 2001, CURR BIOL, V11, P110, DOI 10.1016/S0960-9822(01)00018-5; Leeds JA, 2001, J MOL BIOL, V313, P181, DOI 10.1006/jmbi.2001.5007; LEMMON MA, 1994, NAT STRUCT BIOL, V1, P157, DOI 10.1038/nsb0394-157; LEMMON MA, 1992, BIOCHEMISTRY-US, V31, P12719, DOI 10.1021/bi00166a002; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; Liu XD, 2000, ANAL BIOCHEM, V280, P20, DOI 10.1006/abio.2000.4478; Livnah O, 1998, NAT STRUCT BIOL, V5, P993, DOI 10.1038/2965; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131; Mendrola JM, 2002, J BIOL CHEM, V277, P4704, DOI 10.1074/jbc.M108681200; MIRAND EA, 1968, P SOC EXP BIOL MED, V128, P844; MOREAUGACHELIN F, 1990, LEUKEMIA, V4, P20; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Nishigaki K, 2001, J VIROL, V75, P7893, DOI 10.1128/JVI.75.17.7893-7903.2001; Persons DA, 1999, NAT GENET, V23, P159, DOI 10.1038/13787; POPOT JL, 1990, BIOCHEMISTRY-US, V29, P4031, DOI 10.1021/bi00469a001; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; RUSCETTI SK, 1990, J VIROL, V64, P1057, DOI 10.1128/JVI.64.3.1057-1062.1990; RUSCETTI SK, 1995, BAILLIERE CLIN HAEM, V8, P225, DOI 10.1016/S0950-3536(05)80239-2; Russ WP, 1999, P NATL ACAD SCI USA, V96, P863, DOI 10.1073/pnas.96.3.863; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; SHOWERS MO, 1993, MOL CELL BIOL, V13, P739, DOI 10.1128/MCB.13.2.739; SMITH SO, 1995, P NATL ACAD SCI USA, V92, P488, DOI 10.1073/pnas.92.2.488; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; TAMBOURIN PE, 1979, LEUKEMIA RES, V3, P117, DOI 10.1016/0145-2126(79)90009-2; Tarr K, 1997, J BIOL CHEM, V272, P9099; TUCKER SP, 1991, VIROLOGY, V185, P710, DOI 10.1016/0042-6822(91)90542-J; Watowich SS, 1996, ANNU REV CELL DEV BI, V12, P91, DOI 10.1146/annurev.cellbio.12.1.91; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; WOLFF L, 1985, SCIENCE, V228, P1549, DOI 10.1126/science.2990034; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139; ZON LI, 1992, MOL CELL BIOL, V12, P2949, DOI 10.1128/MCB.12.7.2949	59	24	28	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43755	43763		10.1074/jbc.M302974200	http://dx.doi.org/10.1074/jbc.M302974200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12930840	hybrid			2022-12-25	WOS:000186157000125
J	Hahn, D; Pischitzis, A; Roesmann, S; Hansen, MK; Leuenberger, B; Luginbuehl, U; Sterchi, EE				Hahn, D; Pischitzis, A; Roesmann, S; Hansen, MK; Leuenberger, B; Luginbuehl, U; Sterchi, EE			Phorbol 12-myristate 13-acetate-induced ectodomain shedding and phosphorylation of the human meprin beta metalloprotease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; AMINOBENZOIC ACID HYDROLASE; AMYLOID PRECURSOR PROTEIN; NON-PANCREATIC HYDROLYSIS; NECROSIS-FACTOR-ALPHA; GROWTH-FACTOR-ALPHA; PABA-PEPTIDE; COLORECTAL-CANCER; MEDIATED RELEASE; MEMBRANE	Shedding of proteins localized at the cell surface is an important regulatory step in the function of many of these proteins. Human meprin (N-benzoyl-L-tyrosyl-paminobenzoic acid hydrolase, PPH, EC 3.4.24.18) a zinc-metalloendopeptidase of the astacin family is an oligomeric protein complex of alpha- and beta-subunits and is expressed abundantly in the intestine and kidney as well as in leukocytes of the lamina propria and in cancer cells. In transfected cells intracellular proteolytic removal of the membrane anchor results in the secretion of the meprin alpha-subunit. In rats and mice, the beta-subunit exists in a membrane-anchored form. In contrast, human meprinbeta is constitutively converted into a secretable form. We now show that phorbol 12-myristate 13-acetate (PMA) stimulates an increased release of hmeprinbeta from transfected COS-1 cells, whereas hme-prinalpha secretion is not influenced. This stimulatory effect is inhibited by the protein kinase C (PKC) inhibitor staurosporine, suggesting that activation of PKC mediates PMA-induced hmeprinbeta shedding. The use of different protease inhibitors shows that two different metalloprotease activities are responsible for the constitutive and the PMA-stimulated hmeprinbeta shedding. We identified tumor necrosis factor alpha-converting enzyme (TACE or ADAM17) as the protease that mediates the PMA-induced release. We also demonstrate that hmeprinbeta is phosphorylated by PMA treatment on Ser(687) within a PKC consensus sequence in the cytosolic domain of the protein. This phosphorylation of hmeprinbeta is not, however, implicated in the enhanced secretion by PMA treatment.	Univ Bern, Inst Biochem & Mol Biol, CH-3012 Bern, Switzerland; Univ Bern, Dept Pediat, CH-3012 Bern, Switzerland	University of Bern; University of Bern	Sterchi, EE (corresponding author), Univ Bern, Inst Biochem & Mol Biol, Buhlstr 28, CH-3012 Bern, Switzerland.	erwin.sterchi@mci.unibe.ch						Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; ARRIBAS J, 1995, J CELL BIOL, V128, P433, DOI 10.1083/jcb.128.3.433; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Bauvois B, 2001, J LEUKOCYTE BIOL, V70, P11; Bertenshaw GP, 2001, J BIOL CHEM, V276, P13248, DOI 10.1074/jbc.M011414200; BEYNON RJ, 1981, BIOCHEM J, V199, P591, DOI 10.1042/bj1990591; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; CROWE PD, 1993, J IMMUNOL, V151, P6882; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DUMERMUTH E, 1993, FEBS LETT, V335, P367, DOI 10.1016/0014-5793(93)80421-P; EHLERS MRW, 1995, BIOCHEM BIOPH RES CO, V206, P541, DOI 10.1006/bbrc.1995.1077; Eldering JA, 1997, EUR J BIOCHEM, V247, P920, DOI 10.1111/j.1432-1033.1997.00920.x; Garton KJ, 2001, J BIOL CHEM, V276, P37993; GORBEA CM, 1993, J BIOL CHEM, V268, P21035; GORBEA CM, 1991, ARCH BIOCHEM BIOPHYS, V290, P549, DOI 10.1016/0003-9861(91)90580-C; GRUNBERG J, 1993, FEBS LETT, V335, P376, DOI 10.1016/0014-5793(93)80422-Q; Gutwein P, 2000, J BIOL CHEM, V275, P15490, DOI 10.1074/jbc.275.20.15490; Hahn D, 1997, EUR J BIOCHEM, V247, P933, DOI 10.1111/j.1432-1033.1997.00933.x; HANSEN HP, 1995, INT J CANCER, V63, P750, DOI 10.1002/ijc.2910630524; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; Hofmann J, 1997, FASEB J, V11, P649, DOI 10.1096/fasebj.11.8.9240967; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; JOHNSON GD, 1994, J BIOL CHEM, V269, P7682; KAUSHAL GP, 1994, J CELL BIOL, V126, P1319, DOI 10.1083/jcb.126.5.1319; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KENNY AJ, 1987, BIOCHEM J, V245, P515, DOI 10.1042/bj2450515; KIMMEL AR, 1987, METHOD ENZYMOL, V152, P307; Kohler D, 2000, FEBS LETT, V465, P2, DOI 10.1016/S0014-5793(99)01712-3; LEUENBERGER B, 2003, BIOCHEM J, V369, P1; Liu JP, 1996, MOL CELL ENDOCRINOL, V116, P1, DOI 10.1016/0303-7207(95)03706-3; Lottaz D, 1999, CANCER RES, V59, P1127; Lottaz D, 1999, EUR J BIOCHEM, V259, P496, DOI 10.1046/j.1432-1327.1999.00071.x; Mahon TM, 1997, BIOCHEM J, V325, P39; MARCHAND P, 1994, J BIOL CHEM, V269, P15388; MARCHAND P, 1995, J BIOL CHEM, V270, P5449, DOI 10.1074/jbc.270.10.5449; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; Matters GL, 1999, MOL CARCINOGEN, V25, P169, DOI 10.1002/(SICI)1098-2744(199907)25:3<169::AID-MC3>3.0.CO;2-Y; McLaughlin M, 1999, J NEUROCHEM, V72, P273, DOI 10.1046/j.1471-4159.1999.0720273.x; MILHIET PE, 1994, BIOCHEM J, V300, P37, DOI 10.1042/bj3000037; Mufson RA, 1997, FASEB J, V11, P37, DOI 10.1096/fasebj.11.1.9034164; MULLBERG J, 1993, EUR J IMMUNOL, V23, P473, DOI 10.1002/eji.1830230226; Mullberg J, 1997, FEBS LETT, V401, P235, DOI 10.1016/S0014-5793(96)01480-9; MULLBERG J, 1995, J IMMUNOL, V155, P5198; MULLBERG J, 1992, BIOCHEM BIOPH RES CO, V189, P794, DOI 10.1016/0006-291X(92)92272-Y; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Pischitzis A, 1999, EUR J BIOCHEM, V261, P421, DOI 10.1046/j.1432-1327.1999.00268.x; RAMCHANDRAN R, 1994, J BIOL CHEM, V269, P2125; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; Rosmann S, 2002, J BIOL CHEM, V277, P40650, DOI 10.1074/jbc.M206203200; SHENOLIKAR S, 1988, FASEB J, V2, P2753, DOI 10.1096/fasebj.2.12.2842213; SLATER SJ, 1994, J BIOL CHEM, V269, P17160; SLATER SJ, 1995, J BIOL CHEM, V270, P6639, DOI 10.1074/jbc.270.12.6639; STERCHI EE, 1983, J PEDIATR GASTR NUTR, V2, P539, DOI 10.1097/00005176-198302030-00024; STERCHI EE, 1982, CLIN SCI, V62, P557, DOI 10.1042/cs0620557; STERCHI EE, 1988, ARCH BIOCHEM BIOPHYS, V265, P119, DOI 10.1016/0003-9861(88)90377-3; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; Tang J, 1998, ARCH BIOCHEM BIOPHYS, V349, P192, DOI 10.1006/abbi.1997.0453; Tzivion G, 2001, ONCOGENE, V20, P6331, DOI 10.1038/sj.onc.1204777; Yaffe MB, 2001, STRUCTURE, V9, pR33, DOI 10.1016/S0969-2126(01)00580-9; Yaffe MB, 2001, CURR OPIN CELL BIOL, V13, P131, DOI 10.1016/S0955-0674(00)00189-7; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X; Zhu GZ, 2001, J CELL SCI, V114, P1787	68	49	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42829	42839		10.1074/jbc.M211169200	http://dx.doi.org/10.1074/jbc.M211169200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12941954	hybrid			2022-12-25	WOS:000186157000014
J	Vanwetswinkel, S; Kriek, J; Andersen, GR; Guntert, P; Dijk, J; Canters, GW; Siegal, G				Vanwetswinkel, S; Kriek, J; Andersen, GR; Guntert, P; Dijk, J; Canters, GW; Siegal, G			Solution structure of the 162 residue C-terminal domain of human elongation factor 1B gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION PROFILE; TRANSFER RNA-SYNTHETASE; TORSION ANGLE DYNAMICS; NUCLEOTIDE EXCHANGE; RESONANCE ASSIGNMENTS; MESSENGER-RNA; PROTEIN-SYNTHESIS; FACTOR 1-BETA; COMPLEX; C-13	The multisubunit elongation factor 1 (eEF1) is required for the elongation step of eukaryotic protein synthesis. The eEF1 complex consists of four subunits: eEF1A, a G-protein that shuttles aminoacylated tRNAs to the ribosome; eEF1Balpha and eEF1Bbeta, two guanine nucleotide exchange factors, and eEF1Bgamma. Although its exact function remains unknown, this latter subunit is present in all eukaryotes. Recombinant human eEF1Bgamma has been purified and shown to consist of two independent domains. We have utilized high resolution NMR to determine the three-dimensional structure of the 19 kDa C-terminal fragment (domain 2). The structure consists of a five-stranded anti-parallel beta-sheet surrounded by alpha-helices and resembles a contact lens. Highly conserved residues are mainly located on the concave face, suggesting thereby that this side of the molecule might be involved in some biologically relevant interface(s). Although the isolated domain 2 appears to be mostly monomeric in solution, biochemical and structural data indicate a potential homodimer. The proposed dimer model can be further positioned within the quaternary arrangement of the whole eEF1 assembly.	Leiden Univ, Leiden Inst Chem, Gorlaeus Lab, NL-2333 CC Leiden, Netherlands; Sylvius Lab, Dept Mol Cell Biol, NL-2333 AL Leiden, Netherlands; Univ Aarhus, Inst Mol & Struct Biol, DK-8000 Aarhus C, Denmark; RIKEN, Genom Sci Ctr, Yokohama, Kanagawa 2300045, Japan	Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC; Aarhus University; RIKEN	Siegal, G (corresponding author), Leiden Univ, Leiden Inst Chem, Gorlaeus Lab, Einsteinweg 55, NL-2333 CC Leiden, Netherlands.	g.siegal@chem.leidenuniv.nl	Güntert, Peter/L-5577-2013	Güntert, Peter/0000-0002-2911-7574; Andersen, Gregers Rom/0000-0001-6292-3319				Al-Maghrebi M, 2002, NUCLEIC ACIDS RES, V30, P5017, DOI 10.1093/nar/gkf656; Andersen GR, 2000, MOL CELL, V6, P1261, DOI 10.1016/S1097-2765(00)00122-2; Andersen GR, 2001, NAT STRUCT BIOL, V8, P531, DOI 10.1038/88598; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; BEC G, 1994, J BIOL CHEM, V269, P2086; BURLEY SK, 1986, FEBS LETT, V203, P139, DOI 10.1016/0014-5793(86)80730-X; Cavanagh J., 1993, ANNU REP NMR SPECTRO, V27, P1; CHI KF, 1992, GASTROENTEROLOGY, V103, P98, DOI 10.1016/0016-5085(92)91101-9; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; GRZESIEK S, 1992, J AM CHEM SOC, V114, P6291, DOI 10.1021/ja00042a003; GRZESIEK S, 1993, J BIOMOL NMR, V3, P185; Guntert P, 2000, J BIOMOL NMR, V18, P129, DOI 10.1023/A:1008318805889; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JANSSEN GMC, 1991, J BIOL CHEM, V266, P14885; JANSSEN GMC, 1988, EUR J BIOCHEM, V171, P119, DOI 10.1111/j.1432-1033.1988.tb13766.x; JANSSEN GMC, 1994, J BIOL CHEM, V269, P31410; Kamiie K, 2002, BIOSCI BIOTECH BIOCH, V66, P558, DOI 10.1271/bbb.66.558; KAY LE, 1993, J MAGN RESON SER B, V101, P333, DOI 10.1006/jmrb.1993.1053; KINZY TG, 1994, NUCLEIC ACIDS RES, V22, P2703, DOI 10.1093/nar/22.13.2703; Kobayashi S, 2001, BIOCHEM BIOPH RES CO, V288, P509, DOI 10.1006/bbrc.2001.5799; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Koradi R, 2000, COMPUT PHYS COMMUN, V124, P139, DOI 10.1016/S0010-4655(99)00436-1; Kozlov G, 2000, J BIOMOL NMR, V17, P187, DOI 10.1023/A:1008363304977; KUMABE T, 1992, NUCLEIC ACIDS RES, V20, P2598, DOI 10.1093/nar/20.10.2598; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; Lee CK, 2000, NAT GENET, V25, P294, DOI 10.1038/77046; LEVITT M, 1988, J MOL BIOL, V201, P751, DOI 10.1016/0022-2836(88)90471-8; Mansilla F, 2002, BIOCHEM J, V365, P669, DOI 10.1042/BJ20011681; Merrick WC, 2000, COLD SPRING HARBOR M, V39, P89; MIMORI K, 1995, CANCER, V75, P1446, DOI 10.1002/1097-0142(19950315)75:6+<1446::AID-CNCR2820751509>3.0.CO;2-P; Minella O, 1998, BIOSCIENCE REP, V18, P119, DOI 10.1023/A:1020140527930; Monnier A, 2001, NUCLEIC ACIDS RES, V29, P1453, DOI 10.1093/nar/29.7.1453; MOTORIN YA, 1988, FEBS LETT, V238, P262, DOI 10.1016/0014-5793(88)80492-7; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; NEGRUTSKII BS, 1991, P NATL ACAD SCI USA, V88, P4991, DOI 10.1073/pnas.88.11.4991; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; PASCAL SM, 1994, J MAGN RESON SER B, V103, P197, DOI 10.1006/jmrb.1994.1031; Perez JMJ, 1999, STRUCTURE, V7, P217, DOI 10.1016/S0969-2126(99)80027-6; Prompers JJ, 1997, PROTEIN SCI, V6, P2375; Sheu GT, 1999, MOL CELL BIOCHEM, V191, P181, DOI 10.1023/A:1006802125856; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VANDAMME H, 1991, EUR J BIOCHEM, V197, P505, DOI 10.1111/j.1432-1033.1991.tb15938.x; VANDAMME HTF, 1990, BIOCHIM BIOPHYS ACTA, V1050, P241, DOI 10.1016/0167-4781(90)90174-Z; Vanwetswinkel S, 2003, J BIOMOL NMR, V26, P189, DOI 10.1023/A:1023504611632; VUISTER GW, 1992, J MAGN RESON, V98, P428, DOI 10.1016/0022-2364(92)90144-V; WANG AC, 1994, J MAGN RESON SER B, V105, P196, DOI 10.1006/jmrb.1994.1123; Wilkie GS, 2003, TRENDS BIOCHEM SCI, V28, P182, DOI 10.1016/S0968-0004(03)00051-3; WITTEKIND M, 1993, J MAGN RESON SER B, V101, P201, DOI 10.1006/jmrb.1993.1033	52	11	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43443	43451		10.1074/jbc.M306031200	http://dx.doi.org/10.1074/jbc.M306031200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12920118	hybrid			2022-12-25	WOS:000186157000089
J	Ko, J; Na, M; Kim, S; Lee, JR; Kim, E				Ko, J; Na, M; Kim, S; Lee, JR; Kim, E			Interaction of the ERC family of RIM-binding proteins with the liprin-alpha family of multidomain proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRESYNAPTIC ACTIVE ZONES; TYROSINE-PHOSPHATASE; TRANSPORT; CYTOMATRIX; PICCOLO; ASSOCIATION; VESICLE; BASSOON; MOTOR; FORMS	Liprin-alpha/SYD-2 is a family of multidomain proteins with four known isoforms. One of the reported functions of liprin-alpha is to regulate the development of presynaptic active zones, but the underlying mechanism is poorly understood. Here we report that liprin-alpha directly interacts with the ERC (ELKS-Rab6-interacting protein-CAST) family of proteins, members of which are known to bind RIMs, the active zone proteins that regulate neurotransmitter release. In vitro results indicate that ERC2/CAST, an active zone-specific isoform, interacts with all of the known isoforms of liprin-alpha and that liprin-alpha1 associates with both ERC2 and ERC1b, a splice variant of ERC1 that distributes to both cytosolic and active zone regions. ERC2 colocalizes with liprin-alpha1 in cultured neurons and forms a complex with liprin-alpha1 in brain. Liprin-alpha1, when expressed alone in cultured neurons, shows a partial synaptic localization. When coexpressed with ERC2, however, liprin-alpha1 is redistributed to synaptic sites. Moreover, roughly the first half of ERC2, which contains the liprin-alpha-binding region, is sufficient for the synaptic localization of liprin-alpha1 while the second half is not. These results suggest that the interaction between ERC2 and liprin-alpha may be involved in the presynaptic localization of liprin-alpha and the molecular organization of presynaptic active zones.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; Korea Adv Inst Sci & Technol, Natl Creat Res Initiat Ctr Synaptogenesis, Taejon 305701, South Korea	Korea Advanced Institute of Science & Technology (KAIST); Korea Advanced Institute of Science & Technology (KAIST)	Kim, E (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea.		Kim, Eunjoon/C-1566-2011					Ahmari SE, 2000, NAT NEUROSCI, V3, P445, DOI 10.1038/74814; CasesLanghoff C, 1996, EUR J CELL BIOL, V69, P214; Castillo PE, 2002, NATURE, V415, P327, DOI 10.1038/415327a; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; Choi J, 2002, J BIOL CHEM, V277, P12359, DOI 10.1074/jbc.M200528200; Dresbach T, 2001, CELL MOL LIFE SCI, V58, P94, DOI 10.1007/PL00000781; Fenster SD, 2000, NEURON, V25, P203, DOI 10.1016/S0896-6273(00)80883-1; Garner CC, 2000, CURR OPIN NEUROBIOL, V10, P321, DOI 10.1016/S0959-4388(00)00093-3; Goslin  K., 1991, CULTURING NERVE CELL, P339; Hernandez-Deviez DJ, 2002, NAT NEUROSCI, V5, P623, DOI 10.1038/nn865; Kaufmann N, 2002, NEURON, V34, P27, DOI 10.1016/S0896-6273(02)00643-8; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kim S, 2003, J BIOL CHEM, V278, P6291, DOI 10.1074/jbc.M212287200; Ko J, 2003, J NEUROSCI, V23, P1667; Koushika SP, 2001, NAT NEUROSCI, V4, P997, DOI 10.1038/nn732; Mok H, 2002, J NEUROSCI, V22, P5253; Monier S, 2002, TRAFFIC, V3, P289, DOI 10.1034/j.1600-0854.2002.030406.x; Naisbitt S, 1999, NEURON, V23, P569, DOI 10.1016/S0896-6273(00)80809-0; Nakata T, 1999, GENE CHROMOSOME CANC, V25, P97, DOI 10.1002/(SICI)1098-2264(199906)25:2<97::AID-GCC4>3.0.CO;2-L; Ohtsuka T, 2002, J CELL BIOL, V158, P577, DOI 10.1083/jcb.200202083; OKADA Y, 1995, CELL, V81, P769, DOI 10.1016/0092-8674(95)90538-3; Schoch S, 2002, NATURE, V415, P321, DOI 10.1038/415321a; Serra-Pages C, 1998, J BIOL CHEM, V273, P15611, DOI 10.1074/jbc.273.25.15611; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; Shapira M, 2003, NEURON, V38, P237, DOI 10.1016/S0896-6273(03)00207-1; Shin H, 2003, J BIOL CHEM, V278, P11393, DOI 10.1074/jbc.M211874200; TIXIERVIDAL A, 1993, J CELL SCI, V105, P935; Turner CE, 2001, CURR OPIN CELL BIOL, V13, P593, DOI 10.1016/S0955-0674(00)00256-8; Wang XL, 1999, J CELL BIOL, V147, P151, DOI 10.1083/jcb.147.1.151; Wang Y, 1997, NATURE, V388, P593, DOI 10.1038/41580; Wang Y, 2002, P NATL ACAD SCI USA, V99, P14464, DOI 10.1073/pnas.182532999; Wang Y, 2000, J BIOL CHEM, V275, P20033, DOI 10.1074/jbc.M909008199; Wyszynski M, 1999, J NEUROSCI, V19, P6528; Wyszynski M, 1998, NEUROPHARMACOLOGY, V37, P1335, DOI 10.1016/S0028-3908(98)00120-8; Wyszynski M, 2002, NEURON, V34, P39, DOI 10.1016/S0896-6273(02)00640-2; Zhai RG, 2001, NEURON, V29, P131, DOI 10.1016/S0896-6273(01)00185-4; Zhen M, 1999, NATURE, V401, P371, DOI 10.1038/43886	38	122	129	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42377	42385		10.1074/jbc.M307561200	http://dx.doi.org/10.1074/jbc.M307561200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12923177	hybrid			2022-12-25	WOS:000185989500100
J	Oe, T; Arora, JS; Lee, SH; Blair, IA				Oe, T; Arora, JS; Lee, SH; Blair, IA			A novel lipid hydroperoxide-derived cyclic covalent modification to histone H4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINOLEIC-ACID; INDUCED DECOMPOSITION; PEROXIDATION; ADDUCTS; PRODUCT; SUBSTRATE; PEPTIDES; DIFFERENTIATION; METHYLATION; EXPRESSION	Previous studies have established that 4-hydroxy-2-nonenal is a lipid hydroperoxide-derived aldehydic bifunctional electrophile that reacts with DNA and proteins. However, it has now been recognized that 4-oxo-2- nonenal is also a major product of lipid hydroperoxide decomposition. Furthermore, 4-oxo-2-nonenal is more reactive than 4-hydroxy-2-nonenal toward the DNAbases 2'-deoxyguanosine, 2'-deoxyadenosine, and 2'-deoxycytidine and proteins. The formation of 4-oxo-2-nonenal can be induced through vitamin C-mediated or transition metal ion-mediated homolytic decomposition of polyunsaturated omega-3 lipid hydroperoxides such as 13(S)-hydroperoxyoctadecadienoic acid. We have discovered that synthetic 4-oxo-nonenal or 4-oxo-2-nonenal-generated from 13(S)-hydroperoxyoctadecadienoic acid recognizes the specific amino acid motifs of His(75), Ala(76), and Lys(77) in bovine histone H4. Reaction of the histidine and lysine residues with 4-oxo-2-nonenal results in the formation of a novel cyclic structure within the protein. The cyclic structure incorporates the histidine imidazole ring and a newly formed pyrrole derived from the lysine. The cyclic imidazole-pyrrole derivative that is formed from the small Nalpha-acetyl-His-Ala-Lys peptide exists as a mixture of two atropisomers that interconvert upon heating. Such lipid hydroperoxide-derived modifications could potentially modulate transcriptional activation in vivo. Furthermore, the ability to synthesize cyclic peptides using 4-oxo-2-nonenal will facilitate the preparation of novel structural analogs with potential biological activity.	Univ Penn, Ctr Canc Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Blair, IA (corresponding author), Univ Penn, Ctr Canc Pharmacol, 1254 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.		Oe, Tomoyuki/AAE-1514-2019; Blair, Ian A/B-3320-2010	Oe, Tomoyuki/0000-0002-3893-0815; Lee, Seon Hwa/0000-0003-1095-5516	NATIONAL CANCER INSTITUTE [R01CA095586] Funding Source: NIH RePORTER; NCI NIH HHS [CA 95586] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bannister AJ, 2002, CELL, V109, P801, DOI 10.1016/S0092-8674(02)00798-5; Blair IA, 2001, EXP GERONTOL, V36, P1473, DOI 10.1016/S0531-5565(01)00133-4; Boiadjiev SE, 2002, MONATSH CHEM, V133, P1469, DOI 10.1007/s00706-002-0512-9; Brash AR, 1999, J BIOL CHEM, V274, P23679, DOI 10.1074/jbc.274.34.23679; Chung FL, 2000, CANCER RES, V60, P1507; DELANGE RJ, 1973, J BIOL CHEM, V248, P3261; Doorn JA, 2002, CHEM RES TOXICOL, V15, P1445, DOI 10.1021/tx025590o; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; Feng Q, 2002, CURR BIOL, V12, P1052, DOI 10.1016/S0960-9822(02)00901-6; HAMBERG M, 1967, J BIOL CHEM, V242, P5336; Hamberg M, 1998, ARCH BIOCHEM BIOPHYS, V349, P376, DOI 10.1006/abbi.1997.0443; JOHNSON RS, 1987, ANAL CHEM, V59, P2621, DOI 10.1021/ac00148a019; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Kamitani H, 1998, J BIOL CHEM, V273, P21569, DOI 10.1074/jbc.273.34.21569; Kawai Y, 2002, CARCINOGENESIS, V23, P485, DOI 10.1093/carcin/23.3.485; LANEUVILLE O, 1995, J BIOL CHEM, V270, P19330, DOI 10.1074/jbc.270.33.19330; Lee SH, 2001, SCIENCE, V292, P2083, DOI 10.1126/science.1059501; Lee SH, 2000, CHEM RES TOXICOL, V13, P698, DOI 10.1021/tx000101a; Lee SH, 2000, CHEM RES TOXICOL, V13, P565, DOI 10.1021/tx000057z; Lee SH, 2002, CHEM RES TOXICOL, V15, P300, DOI 10.1021/tx010147j; Lee SH, 2001, TRENDS CARDIOVAS MED, V11, P148, DOI 10.1016/S1050-1738(01)00094-9; LI P, 2002, CURR TOP MED CHEM, V3, P325; Liu ZF, 2003, CHEM RES TOXICOL, V16, P901, DOI 10.1021/tx0300030; Lloyd-Williams P, 2001, CHEM SOC REV, V30, P145, DOI 10.1039/b001971m; Picklo MJ, 2002, TOXICOL APPL PHARM, V184, P187, DOI 10.1006/taap.2002.9506; Pollack M, 2003, CHEM RES TOXICOL, V16, P893, DOI 10.1021/tx030009p; PORTER NA, 1995, LIPIDS, V30, P277, DOI 10.1007/BF02536034; Rindgen D, 1999, CHEM RES TOXICOL, V12, P1195, DOI 10.1021/tx990034o; Rindgen D, 2000, CHEM RES TOXICOL, V13, P846, DOI 10.1021/tx0000771; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; Schneider C, 2000, J BIOL CHEM, V275, P4743, DOI 10.1074/jbc.275.7.4743; Schneider C, 2001, J BIOL CHEM, V276, P20831, DOI 10.1074/jbc.M101821200; Spiteller P, 2001, BBA-MOL CELL BIOL L, V1531, P188, DOI 10.1016/S1388-1981(01)00100-7; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; Zhang WH, 2003, CHEM RES TOXICOL, V16, P512, DOI 10.1021/tx020105a	35	65	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42098	42105		10.1074/jbc.M308167200	http://dx.doi.org/10.1074/jbc.M308167200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12930824	hybrid, Green Published			2022-12-25	WOS:000185989500067
J	Razzaq, TM; Bass, R; Vines, DJ; Werner, F; Whawell, SA; Ellis, V				Razzaq, TM; Bass, R; Vines, DJ; Werner, F; Whawell, SA; Ellis, V			Functional regulation of tissue plasminogen activator on the surface of vascular smooth muscle cells by the type-II transmembrane protein p63 (CKAP4)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOLGI INTERMEDIATE COMPARTMENT; GROWTH-FACTOR-BETA; ENDOPLASMIC-RETICULUM; MATRIX METALLOPROTEINASES; UROKINASE-TYPE; CELLULAR-BINDING; ANNEXIN-II; RECEPTOR; GENERATION; MIGRATION	We have demonstrated that tissue plasminogen activator (tPA) binds specifically to human vascular smooth muscle cells (VSMC) in a functionally relevant manner, both increasing plasminogen activation and decreasing tPA inhibition (Ellis, V., and Whawell, S. A. ( 1997) Blood 90, 2312-2322; Werner, F., Razzaq, T. M., and Ellis, V. ( 1999) J. Biol. Chem. 274, 21555-21561). To further understand this system we have now identified and characterized the protein responsible for this binding. Rat VSMC were surface-labeled with I-125, and cell lysates were subjected to an affinity chromatography scheme based on the previously identified tPA binding characteristics. A single radiolabeled protein of 63 kDa bound specifically and was eluted at low pH. This protein was isolated from large scale preparations of VSMC and unambiguously identified as the rat homologue of the human type-II transmembrane protein p63 (CKAP4) by matrix-assisted laser desorption ionization and nano-electrospray tandem mass spectrometry of tryptic fragments. In confirmation of this, a monoclonal antibody raised against authentic human p63 recognized the isolated protein in Western blotting. Immunofluorescence microscopy demonstrated that p63 was located principally in the endoplasmic reticulum but was also detected in significant quantities on the surface of human VSMC. In support of the hypothesis that p63 is the functional tPA binding site on VSMC, an anti-p63 monoclonal antibody was found to block tPA binding. Furthermore, heterologous expression of an N-terminally truncated mutant of p63, which targets exclusively to the plasma membrane, led to an increase in tPA-catalyzed plasminogen activation. Therefore, p63 on the surface of VSMC may contribute to the functional regulation of the plasminogen activation system in the vessel wall.	Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England	University of East Anglia	Ellis, V (corresponding author), Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England.		Ellis, Vincent/D-1860-2009; Bass, Rosemary A/A-5328-2009	Ellis, Vincent/0000-0003-1956-073X; Bass, Rosemary A/0000-0003-4997-5207; Werner, Finn/0000-0002-3930-3821				Bass R, 2002, BIOCHEM SOC T, V30, P189, DOI 10.1042/BST0300189; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; BOCHATONPIALLAT ML, 1992, DIFFERENTIATION, V49, P175, DOI 10.1111/j.1432-0436.1992.tb00665.x; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; Carmeliet P, 1997, NAT GENET, V17, P439, DOI 10.1038/ng1297-439; CESARMAN GM, 1994, J BIOL CHEM, V269, P21198; CLOWES AW, 1990, CIRC RES, V67, P61, DOI 10.1161/01.RES.67.1.61; Drew AF, 2000, CIRC RES, V87, P133, DOI 10.1161/01.RES.87.2.133; Dudani AK, 1996, BRIT J HAEMATOL, V95, P168, DOI 10.1046/j.1365-2141.1996.7482367.x; ELLIS V, 1991, J BIOL CHEM, V266, P12752; Ellis V, 1997, TRENDS CARDIOVAS MED, V7, P227, DOI 10.1016/S1050-1738(97)00084-4; ELLIS V, 1989, J BIOL CHEM, V264, P2185; Ellis V, 2001, FEBS LETT, V506, P1, DOI 10.1016/S0014-5793(01)02845-9; Ellis V, 1997, BLOOD, V90, P2312, DOI 10.1182/blood.V90.6.2312.2312_2312_2322; FELEZ J, 1993, BLOOD, V82, P2433, DOI 10.1182/blood.V82.8.2433.bloodjournal8282433; Galis ZS, 2002, CIRC RES, V90, P251, DOI 10.1161/res.90.3.251; GRAINGER DJ, 1994, NATURE, V370, P460, DOI 10.1038/370460a0; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; Hembrough TA, 1996, BIOCHEM J, V317, P763, DOI 10.1042/bj3170763; Kenagy RD, 1996, ARTERIOSCL THROM VAS, V16, P1373, DOI 10.1161/01.ATV.16.11.1373; Klopfenstein DR, 2001, J CELL BIOL, V153, P1287, DOI 10.1083/jcb.153.6.1287; Klopfenstein DRC, 1998, EMBO J, V17, P6168, DOI 10.1093/emboj/17.21.6168; Kranenburg O, 2002, CURR BIOL, V12, P1833, DOI 10.1016/S0960-9822(02)01224-1; Levi M, 2001, CIRCULATION, V103, P2014; Libby P, 2001, CIRCULATION, V104, P365, DOI 10.1161/01.CIR.104.3.365; LIND SE, 1991, J BIOL CHEM, V266, P17673; LUPU F, 1995, ARTERIOSCL THROM VAS, V15, P1444, DOI 10.1161/01.ATV.15.9.1444; Machovich R, 1997, FEBS LETT, V407, P93, DOI 10.1016/S0014-5793(97)00303-7; MILES LA, 1991, BIOCHEMISTRY-US, V30, P1682, DOI 10.1021/bi00220a034; Newby AC, 1999, CARDIOVASC RES, V41, P345, DOI 10.1016/S0008-6363(98)00286-7; Okazaki Y, 2000, J BIOL CHEM, V275, P35751, DOI 10.1074/jbc.M007476200; PADRO T, 1995, ARTERIOSCL THROM VAS, V15, P893, DOI 10.1161/01.ATV.15.7.893; Pignolo RJ, 1998, EXP CELL RES, V240, P305, DOI 10.1006/excr.1998.4009; REUNING U, 1994, BLOOD, V84, P3700, DOI 10.1182/blood.V84.11.3700.bloodjournal84113700; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; Schafer K, 2002, CIRCULATION, V106, P1847, DOI 10.1161/01.CIR.0000031162.80988.2B; SCHWEIZER A, 1995, J CELL SCI, V108, P2477; SCHWEIZER A, 1994, J CELL BIOL, V126, P25, DOI 10.1083/jcb.126.1.25; SCHWEIZER A, 1993, EUR J CELL BIOL, V60, P366; SCHWEIZER A, 1993, J CELL SCI, V104, P685; Steins MB, 1999, ATHEROSCLEROSIS, V145, P173, DOI 10.1016/S0021-9150(99)00030-1; Tran H, 2002, J CELL SCI, V115, P2031; Ueba H, 1997, ARTERIOSCL THROM VAS, V17, P1512, DOI 10.1161/01.ATV.17.8.1512; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Werner F, 1999, J BIOL CHEM, V274, P21555, DOI 10.1074/jbc.274.31.21555; Wittmann T, 2001, J CELL SCI, V114, P3795; Yakovlev S, 2000, BIOCHEMISTRY-US, V39, P15730, DOI 10.1021/bi001847a	47	46	48	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42679	42685		10.1074/jbc.M305695200	http://dx.doi.org/10.1074/jbc.M305695200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12913003	hybrid			2022-12-25	WOS:000185989500134
J	Iliakis, G; Wang, Y; Guan, J; Wang, HC				Iliakis, G; Wang, Y; Guan, J; Wang, HC			DNA damage checkpoint control in cells exposed to ionizing radiation	ONCOGENE			English	Review						checkpoints; DNA repair; DNA double-strand breaks; ionizing radiation	DEPENDENT PROTEIN-KINASE; S-PHASE CHECKPOINT; DOUBLE-STRAND BREAKS; TELANGIECTASIA GENE-PRODUCT; POLO-LIKE KINASE-1; HUMAN CYCLIN-A; ATAXIA-TELANGIECTASIA; HOMOLOGOUS RECOMBINATION; INDUCED PHOSPHORYLATION; FISSION YEAST	Damage induced in the DNA after exposure of cells to ionizing radiation activates checkpoint pathways that inhibit progression of cells through the G1 and G2 phases and induce a transient delay in the progression through S phase. Checkpoints together with repair and apoptosis are integrated in a circuitry that determines the ultimate response of a cell to DNA damage. Checkpoint activation typically requires sensors and mediators of DNA damage, signal transducers and effectors. Here, we review the current state of knowledge regarding mechanisms of checkpoint activation and proteins involved in the different steps of the process. Emphasis is placed on the role of ATM and ATR, as well on CHK1 and CHK2 kinases in checkpoint response. The roles of downstream effectors, such as P53 and the CDC25 family of proteins, are also described, and connections between repair and checkpoint activation are attempted. The role of checkpoints in genomic stability and the potential of improving the treatment of cancer by DNA damage inducing agents through checkpoint abrogation are also briefly outlined.	Univ Essen Med Sch, Inst Med Radiat Biol, D-45122 Essen, Germany; Thomas Jefferson Univ, Jefferson Med Coll, Dept Radiat Oncol, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	University of Duisburg Essen; Jefferson University	Iliakis, G (corresponding author), Univ Essen Med Sch, Inst Med Radiat Biol, Hufelanstr 55, D-45122 Essen, Germany.	Georg.Iliakis@uni-essen.de			NCI NIH HHS [2P01 CA56690, CA42026, CA56706, CA76203] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA056690, R29CA076203, R01CA056706, R01CA042026] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; Anderson CW, 1996, CURR TOP MICROBIOL, V217, P91; Anderson L, 2001, MOL CELL BIOL, V21, P1719, DOI 10.1128/MCB.21.5.1719-1729.2001; Ando T, 2001, J BIOL CHEM, V276, P42971, DOI 10.1074/jbc.M106460200; Asaad NA, 2000, ONCOGENE, V19, P5788, DOI 10.1038/sj.onc.1203953; ATCHLEY WR, 1995, P NATL ACAD SCI USA, V92, P10217, DOI 10.1073/pnas.92.22.10217; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bao SD, 2001, NATURE, V411, P969, DOI 10.1038/35082110; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Bermudez VP, 2003, P NATL ACAD SCI USA, V100, P1633, DOI 10.1073/pnas.0437927100; BERNHARD EJ, 1995, RADIAT ENVIRON BIOPH, V34, P79, DOI 10.1007/BF01275210; Bernhard EJ, 1999, CANCER J SCI AM, V5, P194; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Booher RN, 1997, J BIOL CHEM, V272, P22300, DOI 10.1074/jbc.272.35.22300; Brown EJ, 2000, GENE DEV, V14, P397; BRUSH GS, 1996, MECH REPLICATION DNA; Bulavin DV, 2002, CURR OPIN GENET DEV, V12, P92, DOI 10.1016/S0959-437X(01)00270-2; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chan DW, 2000, J BIOL CHEM, V275, P7803, DOI 10.1074/jbc.275.11.7803; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chan TA, 2000, GENE DEV, V14, P1584; CLEAVER JE, 1990, RADIAT RES, V124, P294, DOI 10.2307/3577842; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Costanzo V, 2000, MOL CELL, V6, P649, DOI 10.1016/S1097-2765(00)00063-0; Crawford DF, 2001, J BIOL CHEM, V276, P37166, DOI 10.1074/jbc.M103414200; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; DePamphilis ML, 1999, BIOESSAYS, V21, P5, DOI 10.1002/(SICI)1521-1878(199901)21:1<5::AID-BIES2>3.0.CO;2-6; Desai-Mehta A, 2001, MOL CELL BIOL, V21, P2184, DOI 10.1128/MCB.21.6.2184-2191.2001; DeSimone JN, 2003, RADIAT RES, V159, P72, DOI 10.1667/0033-7587(2003)159[0072:COTMOI]2.0.CO;2; Dibiase SJ, 2000, CANCER RES, V60, P1245; Donaldson AD, 2001, CURR BIOL, V11, pR979, DOI 10.1016/S0960-9822(01)00579-6; DOTTO GP, 2000, BIOCHIM BIOPHYS ACTA, V1471, P43; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; Eckstein J., 1997, BIOCHIM BIOPHYS ACTA, V1332, P53; Edwards RJ, 1999, NAT CELL BIOL, V1, P393, DOI 10.1038/15623; EISENMAN RN, 1995, NATURE, V378, P438, DOI 10.1038/378438a0; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Furnari B, 1999, MOL BIOL CELL, V10, P833, DOI 10.1091/mbc.10.4.833; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Gatei M, 2000, CANCER RES, V60, P3299; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; Goldberg M, 2003, NATURE, V421, P952, DOI 10.1038/nature01445; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Green CM, 2000, CURR BIOL, V10, P39, DOI 10.1016/S0960-9822(99)00263-8; GRIFFITHS DJF, 1995, EMBO J, V14, P5812, DOI 10.1002/j.1460-2075.1995.tb00269.x; Guan J, 2000, NUCLEIC ACIDS RES, V28, P1183, DOI 10.1093/nar/28.5.1183; Guo CY, 1999, RADIAT RES, V151, P125, DOI 10.2307/3579762; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Hagting A, 1998, EMBO J, V17, P4127, DOI 10.1093/emboj/17.14.4127; HARPER JW, 1993, CELL, V75, P805; Harris EER, 1998, CANC TREAT, V93, P169; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hickman ES, 2002, CURR OPIN GENET DEV, V12, P60, DOI 10.1016/S0959-437X(01)00265-9; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; HOULDSWORTH J, 1980, NUCLEIC ACIDS RES, V8, P3709, DOI 10.1093/nar/8.16.3709; HWANG A, 1995, J BIOL CHEM, V270, P28419; Iliakis G, 1997, SEMIN ONCOL, V24, P602; ILIAKIS G, 1988, INT J RADIAT BIOL, V53, P541, DOI 10.1080/09553008814550901; Jackson SP, 2002, CARCINOGENESIS, V23, P687, DOI 10.1093/carcin/23.5.687; Jeggo PA, 1997, MUTAT RES-DNA REPAIR, V384, P1, DOI 10.1016/S0921-8777(97)00009-8; Jeggo PA, 1998, ADV GENET, V38, P185, DOI 10.1016/S0065-2660(08)60144-3; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; Kang DM, 2002, J CELL BIOL, V156, P249, DOI 10.1083/jcb.200108016; Kao GD, 1999, J BIOL CHEM, V274, P34779, DOI 10.1074/jbc.274.49.34779; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Kastan MB, 2001, NATURE, V410, P766, DOI 10.1038/35071218; Kawabe T, 2002, ONCOGENE, V21, P1717, DOI 10.1038/sj.onc.1205229; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; LAMB JR, 1989, INT J RADIAT BIOL, V56, P125, DOI 10.1080/09553008914551271; Larner JM, 1999, NUCLEIC ACIDS RES, V27, P803, DOI 10.1093/nar/27.3.803; Larner JM, 1997, CANCER SURV, V29, P25; Larson JS, 1997, CANCER RES, V57, P3351; LAVIN MF, 1988, MUTAT RES, V193, P193, DOI 10.1016/0167-8817(88)90030-2; Lee CH, 2001, J BIOL CHEM, V276, P30537, DOI 10.1074/jbc.M104414200; Lee HY, 1997, P NATL ACAD SCI USA, V94, P526, DOI 10.1073/pnas.94.2.526; Lee J, 2001, MOL BIOL CELL, V12, P551, DOI 10.1091/mbc.12.3.551; LEE M, 1988, TRENDS GENET, V4, P287, DOI 10.1016/0168-9525(88)90171-0; LeesMiller SP, 1996, BIOCHEM CELL BIOL, V74, P503, DOI 10.1139/o96-054; LEHMANN AR, 1986, INT J RADIAT BIOL, V49, P639; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; LI JK, 1995, MOL BIOL CELL, V6, P1111, DOI 10.1091/mbc.6.9.1111; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Lindsey-Boltz LA, 2001, P NATL ACAD SCI USA, V98, P11236, DOI 10.1073/pnas.201373498; Liu F, 1997, MOL CELL BIOL, V17, P571, DOI 10.1128/MCB.17.2.571; Liu QH, 2000, GENE DEV, V14, P1448; Lopez-Girona A, 2001, CURR BIOL, V11, P50, DOI 10.1016/S0960-9822(00)00026-9; Lou ZK, 2003, NATURE, V421, P957, DOI 10.1038/nature01447; LUCKEHUHLE C, 1982, RADIAT RES, V89, P298, DOI 10.2307/3575776; Lukas C, 2001, CANCER RES, V61, P4990; Lupardus PJ, 2002, GENE DEV, V16, P2327, DOI 10.1101/gad.1013502; LYDALL D, 1995, SCIENCE, V270, P1488, DOI 10.1126/science.270.5241.1488; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; MAITY A, 1994, RADIOTHER ONCOL, V31, P1, DOI 10.1016/0167-8140(94)90408-1; Maity A, 1996, ONCOGENE, V13, P1647; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Maser RS, 2001, MOL CELL BIOL, V21, P6006, DOI 10.1128/MCB.21.17.6006-6016.2001; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MCKENNA WG, 1991, RADIAT RES, V125, P283, DOI 10.2307/3578111; MCKENNA WG, 1995, 37 ANN M AM SOC THER; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; METZGER L, 1991, INT J RADIAT BIOL, V59, P1325, DOI 10.1080/09553009114551201; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MUSCHEL RJ, 1992, RADIAT RES, V132, P153, DOI 10.2307/3578520; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Nurse P, 1997, CELL, V91, P865, DOI 10.1016/S0092-8674(00)80476-6; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; Paciotti V, 2000, GENE DEV, V14, P2046; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PAINTER RB, 1981, MUTAT RES, V84, P183, DOI 10.1016/0027-5107(81)90061-0; PAINTER RB, 1986, INT J RADIAT BIOL, V49, P771; Parker AE, 1998, J BIOL CHEM, V273, P18332, DOI 10.1074/jbc.273.29.18332; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Petrini JHJ, 2000, CURR OPIN CELL BIOL, V12, P293, DOI 10.1016/S0955-0674(00)00091-0; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1995, SEMIN CANCER BIOL, V6, P63, DOI 10.1006/scbi.1995.0009; Piwnica-Worms H, 1999, NATURE, V401, P535, DOI 10.1038/44029; POWELL SN, 1995, CANCER RES, V55, P1643; Rhind N, 2000, J CELL SCI, V113, P3889; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; Rotman G, 1998, HUM MOL GENET, V7, P1555, DOI 10.1093/hmg/7.10.1555; Rouse J, 2000, EMBO J, V19, P5801, DOI 10.1093/emboj/19.21.5801; Sampath D, 2001, CURR OPIN ONCOL, V13, P484, DOI 10.1097/00001622-200111000-00011; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Santoni-Rugiu E, 2000, MOL CELL BIOL, V20, P3497, DOI 10.1128/MCB.20.10.3497-3509.2000; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Senderowicz AM, 2000, JNCI-J NATL CANCER I, V92, P376, DOI 10.1093/jnci/92.5.376; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Sheen JH, 2002, MOL CELL BIOL, V22, P1819, DOI 10.1128/MCB.22.6.1819-1833.2002; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Sillje HHW, 2003, SCIENCE, V299, P1190; SMEETS MFMA, 1994, RADIAT RES, V140, P153, DOI 10.2307/3578897; Smith A, 2001, J ASSOC PERS SEVERE, V26, P180, DOI 10.2511/rpsd.26.3.180; Smith GCM, 1999, P NATL ACAD SCI USA, V96, P11134, DOI 10.1073/pnas.96.20.11134; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Smits VAJ, 2001, BBA-GENE STRUCT EXPR, V1519, P1, DOI 10.1016/S0167-4781(01)00204-4; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Stewart GS, 2003, NATURE, V421, P961, DOI 10.1038/nature01446; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; Stokes MP, 2002, J CELL BIOL, V158, P863, DOI 10.1083/jcb.200204127; SU LN, 1993, RADIAT RES, V133, P73, DOI 10.2307/3578259; Suganuma M, 1999, CANCER RES, V59, P5887; Takai H, 2000, GENE DEV, V14, P1439; Taylor WR, 1999, ONCOGENE, V18, P283, DOI 10.1038/sj.onc.1202516; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; Thompson LH, 2002, MUTAT RES-FUND MOL M, V509, P49, DOI 10.1016/S0027-5107(02)00224-5; Thompson LH, 2001, MUTAT RES-FUND MOL M, V477, P131, DOI 10.1016/S0027-5107(01)00115-4; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; TOBEY RA, 1975, NATURE, V254, P245, DOI 10.1038/254245a0; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; van Vugt MATM, 2001, J BIOL CHEM, V276, P41656, DOI 10.1074/jbc.M101831200; Venkitaraman AR, 2001, J CELL SCI, V114, P3591; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Volkmer E, 1999, J BIOL CHEM, V274, P567, DOI 10.1074/jbc.274.2.567; Wakayama T, 2001, MOL CELL BIOL, V21, P755, DOI 10.1128/MCB.21.3.755-764.2001; WALTERS RA, 1974, BIOPHYS J, V14, P99, DOI 10.1016/S0006-3495(74)70002-9; Walworth NC, 2001, CURR OPIN GENET DEV, V11, P78, DOI 10.1016/S0959-437X(00)00160-X; Wang HC, 2003, RADIAT RES, V159, P420, DOI 10.1667/0033-7587(2003)159[0420:CCNESH]2.0.CO;2; Wang HC, 2001, CANCER RES, V61, P270; Wang HC, 2001, ONCOGENE, V20, P2212, DOI 10.1038/sj.onc.1204350; Wang JYJ, 2000, NATURE, V405, P404, DOI 10.1038/35013171; WANG X, 2003, IN PRESS RAD RES; Wang Y, 1999, J BIOL CHEM, V274, P22060, DOI 10.1074/jbc.274.31.22060; Wang Y, 2000, GENE DEV, V14, P927; WANG Y, 1995, RADIAT RES, V142, P169, DOI 10.2307/3579025; WEICHSELBAUM RR, 1978, NATURE, V271, P261, DOI 10.1038/271261a0; Wolkow TD, 2002, MOL BIOL CELL, V13, P480, DOI 10.1091/mbc.01-03-0104; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Xia F, 2001, P NATL ACAD SCI USA, V98, P8644, DOI 10.1073/pnas.151253498; Xie SQ, 2001, J BIOL CHEM, V276, P43305, DOI 10.1074/jbc.M106050200; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Yamane K, 2002, MOL CELL BIOL, V22, P555, DOI 10.1128/MCB.22.2.555-566.2002; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Zachos G, 2003, EMBO J, V22, P713, DOI 10.1093/emboj/cdg060; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342; Zhou XY, 2002, CANCER RES, V62, P1598; Ziegler M, 2001, BIOESSAYS, V23, P543, DOI 10.1002/bies.1074; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302	230	378	407	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 1	2003	22	37					5834	5847		10.1038/sj.onc.1206682	http://dx.doi.org/10.1038/sj.onc.1206682			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	717JV	12947390				2022-12-25	WOS:000185086100010
J	Lorentzen, E; Pohl, E; Zwart, P; Stark, A; Russell, RB; Knura, T; Hensel, R; Siebers, B				Lorentzen, E; Pohl, E; Zwart, P; Stark, A; Russell, RB; Knura, T; Hensel, R; Siebers, B			Crystal structure of an archaeal class I aldolase and the evolution of (beta alpha)(8) barrel proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MUSCLE ALDOLASE; FAMILY; MODEL; FRUCTOSE-1,6-BISPHOSPHATE; CRYSTALLOGRAPHY; RESOLUTION; SEQUENCES; ISOMERASE; MOLSCRIPT; PROGRAM	Fructose-1,6-bisphosphate aldolase (FBPA) catalyzes the reversible cleavage of fructose 1,6-bisphosphate to glyceraldehyde 3-phosphate and dihydroxyacetone phosphate in the glycolytic pathway. FBPAs from archaeal organisms have recently been identified and characterized as a divergent family of proteins. Here, we report the first crystal structure of an archaeal FBPA at 1.9-Angstrom resolution. The structure of this 280-kDa protein complex was determined using single wavelength anomalous dispersion followed by 10-fold non-crystallographic symmetry averaging and refined to an R-factor of 14.9% (R-free 17.9%). The protein forms a dimer of pentamers, consisting of subunits adopting the ubiquitous (betaalpha)(8) barrel fold. Additionally, a crystal structure of the archaeal FBPA covalently bound to dihydroxyacetone phosphate was solved at 2.1-Angstrom resolution. Comparison of the active site residues with those of classical FBPAs, which share no significant sequence identity but display the same overall fold, reveals a common ancestry between these two families of FBPAs. Structural comparisons, furthermore, establish an evolutionary link to the triosephosphate isomerases, a superfamily hitherto considered independent from the superfamily of aldolases.	European Mol Biol Lab, Hamburg Outstn, D-22603 Hamburg, Germany; European Mol Biol Lab, D-69012 Heidelberg, Germany; Univ Essen Gesamthsch, Dept Microbiol, D-45117 Essen, Germany	European Molecular Biology Laboratory (EMBL); European Molecular Biology Laboratory (EMBL); University of Duisburg Essen	Pohl, E (corresponding author), European Mol Biol Lab, Hamburg Outstn, Notkestr 85, D-22603 Hamburg, Germany.	ehmke@embl-hamburg.de	Russell, Rob/AAH-9145-2019; Lorentzen, Esben/AAX-8077-2020; Russell, Robert/GWU-6389-2022; Pohl, Ehmke/I-2408-2012; Stark, Alexander/D-1473-2012	Russell, Rob/0000-0002-1905-4717; Russell, Robert/0000-0002-7213-1398; Pohl, Ehmke/0000-0002-9949-4471; Stark, Alexander/0000-0003-2611-0841; Lorentzen, Esben/0000-0001-6493-7220; Siebers, Bettina/0000-0002-9905-541X				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BANNER DW, 1975, NATURE, V255, P609, DOI 10.1038/255609a0; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Choi KH, 2001, BIOCHEMISTRY-US, V40, P13868, DOI 10.1021/bi0114877; Copley RR, 2000, J MOL BIOL, V303, P627, DOI 10.1006/jmbi.2000.4152; Dalby A, 1999, PROTEIN SCI, V8, P291; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FARBER GK, 1990, TRENDS BIOCHEM SCI, V15, P228, DOI 10.1016/0968-0004(90)90035-A; Galperin MY, 2000, FEMS MICROBIOL LETT, V183, P259, DOI 10.1016/S0378-1097(99)00612-6; GAMBLIN SJ, 1990, FEBS LETT, V262, P282, DOI 10.1016/0014-5793(90)80211-Z; Jia J, 1996, STRUCTURE, V4, P715, DOI 10.1016/S0969-2126(96)00077-9; JONES S, 1995, PROG BIOPHYS MOL BIO, V63, P31, DOI 10.1016/0079-6107(94)00008-W; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kollman JM, 2000, J MOL EVOL, V51, P173, DOI 10.1007/s002390010078; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lazcano A, 1999, J MOL EVOL, V49, P424, DOI 10.1007/PL00006565; LEBHERZ HG, 1969, BIOCHEMISTRY-US, V8, P109, DOI 10.1021/bi00829a016; Lindqvist Y, 1997, CURR OPIN STRUC BIOL, V7, P422, DOI 10.1016/S0959-440X(97)80061-9; Lo Conte L, 2002, NUCLEIC ACIDS RES, V30, P264; MANDE SC, 1994, PROTEIN SCI, V3, P810, DOI 10.1002/pro.5560030510; MAVRIDIS IM, 1982, J MOL BIOL, V162, P419, DOI 10.1016/0022-2836(82)90536-8; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MORRIS AJ, 1993, J BIOL CHEM, V268, P1095; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; MURZIN AG, 1993, J MOL BIOL, V230, P689, DOI 10.1006/jmbi.1993.1186; Nagano N, 2002, J MOL BIOL, V321, P741, DOI 10.1016/S0022-2836(02)00649-6; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PACE NR, 1991, CELL, V65, P531, DOI 10.1016/0092-8674(91)90082-A; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Pohl E, 2001, J SYNCHROTRON RADIAT, V8, P1113, DOI 10.1107/S0909049501005891; Puchkaev AV, 2003, ARCH BIOCHEM BIOPHYS, V409, P52, DOI 10.1016/S0003-9861(02)00402-2; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; RUSSELL RB, 1992, PROTEINS, V14, P309, DOI 10.1002/prot.340140216; Sheldrick GM, 1998, NATO ADV SCI I C-MAT, V507, P401; Siebers B, 2001, J BIOL CHEM, V276, P28710, DOI 10.1074/jbc.M103447200; Stark A, 2003, J MOL BIOL, V326, P1307, DOI 10.1016/S0022-2836(03)00045-7; TENG TY, 1990, J APPL CRYSTALLOGR, V23, P387, DOI 10.1107/S0021889890005568; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Thomson GJ, 1998, BIOCHEM J, V331, P437, DOI 10.1042/bj3310437; Thorell S, 2002, J MOL BIOL, V319, P161, DOI 10.1016/S0022-2836(02)00258-9; Walden H, 2001, J MOL BIOL, V306, P745, DOI 10.1006/jmbi.2000.4433; WILMANNS M, 1991, BIOCHEMISTRY-US, V30, P9161, DOI 10.1021/bi00102a006; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987	49	45	47	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					47253	47260		10.1074/jbc.M305922200	http://dx.doi.org/10.1074/jbc.M305922200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12941964	hybrid			2022-12-25	WOS:000186569400126
J	Bell, JS; McCulloch, R				Bell, JS; McCulloch, R			Mismatch repair regulates homologous recombination, but has little influence on antigenic variation, in Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN EXPRESSION SITES; SACCHAROMYCES-CEREVISIAE MSH2; MONO-ALLELIC EXPRESSION; DOUBLE-STRAND BREAKS; GENETIC-RECOMBINATION; SALMONELLA-TYPHIMURIUM; AFRICAN TRYPANOSOMES; ESCHERICHIA-COLI; IN-VIVO; SEXUAL ISOLATION	Antigenic variation is critical in the life of the African trypanosome, as it allows the parasite to survive in the face of host immunity and enhance its transmission to other hosts. Much of trypanosome antigenic variation uses homologous recombination of variant surface glycoprotein (VSG)-encoding genes into specialized transcription sites, but little is known about the processes that regulate it. Here we describe the effects on VSG switching when two central mismatch repair genes, MSH2 and MLH1, are mutated. We show that disruption of the parasite mismatch repair system causes an increased frequency of homologous recombination, both between perfectly matched DNA molecules and between DNA molecules with divergent sequences. Mismatch repair therefore provides an important regulatory role in homologous recombination in this ancient eukaryote. Despite this, the mismatch repair system has no detectable role in regulating antigenic variation, meaning that VSG switching is either immune to mismatch selection or that mismatch repair acts in a subtle manner, undetectable by current assays.	Univ Glasgow, Wellcome Ctr Mol Parasitol, Anderson Coll, Glasgow G11 6NU, Lanark, Scotland	University of Glasgow	McCulloch, R (corresponding author), Univ Glasgow, Wellcome Ctr Mol Parasitol, Anderson Coll, 56 Dumbarton Rd, Glasgow G11 6NU, Lanark, Scotland.							Abdulkarim F, 1996, J MOL BIOL, V260, P506, DOI 10.1006/jmbi.1996.0418; ALANI E, 1994, GENETICS, V137, P19; Alsford NS, 2003, MOL MICROBIOL, V47, P277, DOI 10.1046/j.1365-2958.2003.03266.x; Augusto-Pinto L, 2003, GENETICS, V164, P117; Augusto-Pinto L, 2001, GENE, V272, P323, DOI 10.1016/S0378-1119(01)00549-2; Barnes DE, 2001, CURR BIOL, V11, pR455, DOI 10.1016/S0960-9822(01)00279-2; Barry JD, 2001, ADV PARASIT, V49, P1, DOI 10.1016/S0065-308X(01)49037-3; BIANCHI ME, 1983, CELL, V35, P511, DOI 10.1016/0092-8674(83)90185-X; Blundell PA, 1996, MOL BIOCHEM PARASIT, V76, P215, DOI 10.1016/0166-6851(95)02560-X; Borst P, 1996, ARCH MED RES, V27, P379; BORST P, 1982, CELL, V29, P291, DOI 10.1016/0092-8674(82)90146-5; Borst P, 1999, TRENDS GENET, V15, P95, DOI 10.1016/S0168-9525(98)01680-1; Chaves I, 1999, EMBO J, V18, P4846, DOI 10.1093/emboj/18.17.4846; Conway C, 2002, J BIOL CHEM, V277, P21269, DOI 10.1074/jbc.M200550200; Conway C, 2002, MOL MICROBIOL, V45, P1687, DOI 10.1046/j.1365-2958.2002.03122.x; Cross GAM, 1998, MOL BIOCHEM PARASIT, V91, P77, DOI 10.1016/S0166-6851(97)00186-2; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; Culligan KM, 2000, PLANT CELL, V12, P991, DOI 10.1105/tpc.12.6.991; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; Datta A, 1997, P NATL ACAD SCI USA, V94, P9757, DOI 10.1073/pnas.94.18.9757; de Wind N, 2001, CURR BIOL, V11, pR545, DOI 10.1016/S0960-9822(01)00338-4; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Donelson JE, 2003, ACTA TROP, V85, P391, DOI 10.1016/S0001-706X(02)00237-1; Durant ST, 1999, CURR BIOL, V9, P51, DOI 10.1016/S0960-9822(99)80047-5; Eisen JA, 1998, NUCLEIC ACIDS RES, V26, P4291, DOI 10.1093/nar/26.18.4291; Elliott B, 2001, MOL CELL BIOL, V21, P2671, DOI 10.1128/MCB.21.8.2671-2682.2001; Evans E, 2000, MOL CELL, V5, P789, DOI 10.1016/S1097-2765(00)80319-6; Evans E, 2000, MOL CELL BIOL, V20, P7839, DOI 10.1128/MCB.20.21.7839-7844.2000; Featherstone C, 1999, CURR BIOL, V9, pR759, DOI 10.1016/S0960-9822(00)80005-6; FISHMANLOBELL J, 1992, SCIENCE, V258, P480, DOI 10.1126/science.1411547; Gaud A, 1997, MOL BIOCHEM PARASIT, V87, P113, DOI 10.1016/S0166-6851(97)00048-0; Harfe BD, 2000, CURR BIOL, V10, P145, DOI 10.1016/S0960-9822(00)00314-6; Harfe BD, 2000, ANNU REV GENET, V34, P359, DOI 10.1146/annurev.genet.34.1.359; HIRUMI H, 1989, J PARASITOL, V75, P985, DOI 10.2307/3282883; Hsieh P, 2001, MUTAT RES-DNA REPAIR, V486, P71, DOI 10.1016/S0921-8777(01)00088-X; HUMBERT O, 1995, P NATL ACAD SCI USA, V92, P9052, DOI 10.1073/pnas.92.20.9052; Hunter N, 1996, EMBO J, V15, P1726, DOI 10.1002/j.1460-2075.1996.tb00518.x; KAMPER SM, 1992, MOL BIOCHEM PARASIT, V53, P33, DOI 10.1016/0166-6851(92)90004-4; Lin CT, 2001, NUCLEIC ACIDS RES, V29, P3304, DOI 10.1093/nar/29.16.3304; Lipkin SM, 2002, NAT GENET, V31, P385, DOI 10.1038/ng931; Majewski J, 1998, GENETICS, V148, P13; Majewski J, 2000, J BACTERIOL, V182, P1016, DOI 10.1128/JB.182.4.1016-1023.2000; Malik HS, 2000, TRENDS BIOCHEM SCI, V25, P414, DOI 10.1016/S0968-0004(00)01623-6; McCulloch R, 1997, MOL CELL BIOL, V17, P833, DOI 10.1128/MCB.17.2.833; McCulloch R, 1999, GENE DEV, V13, P2875, DOI 10.1101/gad.13.21.2875; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Navarro M, 2001, NATURE, V414, P759, DOI 10.1038/414759a; Navarro M, 1999, EMBO J, V18, P2265, DOI 10.1093/emboj/18.8.2265; Nicholson A, 2000, GENETICS, V154, P133; Papadopoulou B, 1997, NUCLEIC ACIDS RES, V25, P4278, DOI 10.1093/nar/25.21.4278; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; PAYS E, 1985, PROG NUCLEIC ACID RE, V32, P1, DOI 10.1016/S0079-6603(08)60344-X; PETIT MA, 1991, GENETICS, V129, P327; Porter G, 1996, GENETICS, V143, P755; RADMAN M, 1989, GENOME, V31, P68, DOI 10.1139/g89-014; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; Richardson AR, 2001, MOL MICROBIOL, V40, P645, DOI 10.1046/j.1365-2958.2001.02408.x; Roberts Michael S., 1993, Genetics, V134, P401; Robinson NP, 1999, MOL CELL BIOL, V19, P5839; Robinson NP, 2002, J BIOL CHEM, V277, P26185, DOI 10.1074/jbc.M203205200; Rosenberg SM, 2001, NAT REV GENET, V2, P504, DOI 10.1038/35080556; Saparbaev M, 1996, GENETICS, V142, P727; SHEN P, 1986, GENETICS, V112, P441; Shen SY, 2001, MOL BIOCHEM PARASIT, V113, P171, DOI 10.1016/S0166-6851(00)00383-2; SOGIN ML, 1986, P NATL ACAD SCI USA, V83, P1383, DOI 10.1073/pnas.83.5.1383; Sugawara N, 1997, P NATL ACAD SCI USA, V94, P9214, DOI 10.1073/pnas.94.17.9214; Tran H, 1997, MOL CELL BIOL, V17, P1027, DOI 10.1128/MCB.17.2.1027; Vanhamme L, 2001, TRENDS PARASITOL, V17, P338, DOI 10.1016/S1471-4922(01)01922-5; Vanhamme L, 2001, INT J PARASITOL, V31, P523, DOI 10.1016/S0020-7519(01)00143-6; Vanhamme L, 2000, MOL MICROBIOL, V36, P328, DOI 10.1046/j.1365-2958.2000.01844.x; Vulic M, 1997, P NATL ACAD SCI USA, V94, P9763, DOI 10.1073/pnas.94.18.9763; Wang TF, 1999, P NATL ACAD SCI USA, V96, P13914, DOI 10.1073/pnas.96.24.13914; WORTH L, 1994, P NATL ACAD SCI USA, V91, P3238, DOI 10.1073/pnas.91.8.3238; Yang W, 2000, MUTAT RES-DNA REPAIR, V460, P245, DOI 10.1016/S0921-8777(00)00030-6; ZAHRT TC, 1994, J BACTERIOL, V176, P1527, DOI 10.1128/jb.176.5.1527-1529.1994; ZAWADZKI P, 1995, GENETICS, V140, P917	77	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45182	45188		10.1074/jbc.M308123200	http://dx.doi.org/10.1074/jbc.M308123200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12933800	hybrid			2022-12-25	WOS:000186452300018
J	Chen, Y; Takizawa, N; Crowley, JL; Oh, SW; Gatto, CL; Kambara, T; Sato, O; Li, XD; Ikebe, M; Luna, EJ				Chen, Y; Takizawa, N; Crowley, JL; Oh, SW; Gatto, CL; Kambara, T; Sato, O; Li, XD; Ikebe, M; Luna, EJ			F-actin and myosin II binding domains in supervillin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY LIGHT-CHAINS; SMOOTH-MUSCLE MYOSIN; LIPID RAFTS; PLASMA-MEMBRANE; PROTEINS; SPECTRIN; GELSOLIN; SURFACE; LOCALIZATION; CALDESMON	Detergent-resistant membranes contain signaling and integral membrane proteins that organize cholesterol-rich domains called lipid rafts. A subset of these detergent-resistant membranes (DRM-H) exhibits a higher buoyant density (similar to1.16 g/ml) because of association with membrane skeleton proteins, including actin, myosin II, myosin 1G, fodrin, and an actin- and membrane-binding protein called supervillin (Nebl, T., Pestonjamasp, K. N., Leszyk, J. D., Crowley, J. L., Oh, S. W., and Luna, E. J. (2002) J. Biol. Chem. 277, 43399-43409). To characterize interactions among DRM-H cytoskeletal proteins, we investigated the binding partners of the novel supervillin N terminus, specifically amino acids 1-830. We find that the supervillin N terminus binds directly to myosin II, as well as to F-actin. Three F-actin-binding sites were mapped to sequences within amino acids similar to280-342, similar to344-422, and similar to700-830. Sequences with combinations of these sites promote F-actin cross-linking and/or bundling. Supervillin amino acids 1-174 specifically interact with the S2 domain in chicken gizzard myosin and nonmuscle myosin IIA (MYH-9) but exhibit little binding to skeletal muscle myosin II. Direct or indirect binding to filamin also was observed. Overexpression of supervillin amino acids 1-174 in COS7 cells disrupted the localization of myosin IIB without obviously affecting actin filaments. Taken together, these results suggest that supervillin may mediate actin and myosin II filament organization at cholesterol-rich membrane domains.	Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Program Cell Dynam, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Luna, EJ (corresponding author), Univ Massachusetts, Sch Med, Dept Cell Biol, Biotech 4,Ste 306,377 Plantat St, Worcester, MA 01605 USA.	Elizabeth.Luna@umassmed.edu	Luna, Elizabeth/B-4364-2012		NIAMS NIH HHS [AR41653] Funding Source: Medline; NIGMS NIH HHS [GM55834, GM33048, R01 GM033048] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041653] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033048] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AguadoVelasco C, 1997, P NATL ACAD SCI USA, V94, P9684, DOI 10.1073/pnas.94.18.9684; Anderson RGW, 2002, SCIENCE, V296, P1821, DOI 10.1126/science.1068886; Arhets P, 1998, MOL BIOL CELL, V9, P1537, DOI 10.1091/mbc.9.6.1537; BOURGUIGNON LYW, 1984, INT REV CYTOL, V87, P195, DOI 10.1016/S0074-7696(08)62443-2; BOURGUIGNON LYW, 1988, J CELL BIOCHEM, V37, P131, DOI 10.1002/jcb.240370202; BRAUN J, 1978, J CELL BIOL, V79, P409, DOI 10.1083/jcb.79.2.409; BURNS CG, 1995, P NATL ACAD SCI USA, V92, P8244, DOI 10.1073/pnas.92.18.8244; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; CHIA CP, 1991, CELL MOTIL CYTOSKEL, V18, P164, DOI 10.1002/cm.970180303; Cuff JA, 2000, PROTEINS, V40, P502, DOI 10.1002/1097-0134(20000815)40:3<502::AID-PROT170>3.0.CO;2-Q; DAHL SC, 1994, J CELL BIOL, V125, P1057, DOI 10.1083/jcb.125.5.1057; FERAMISCO JR, 1980, J BIOL CHEM, V255, P1194; FOWLER V, 1980, J CELL BIOL, V85, P361, DOI 10.1083/jcb.85.2.361; FOWLER VM, 1981, J CELL BIOL, V88, P388, DOI 10.1083/jcb.88.2.388; FUKUI Y, 1990, J CELL BIOL, V110, P367, DOI 10.1083/jcb.110.2.367; Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X; Gharahdaghi F, 1999, ELECTROPHORESIS, V20, P601, DOI 10.1002/(SICI)1522-2683(19990301)20:3<601::AID-ELPS601>3.0.CO;2-6; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Gomez-Mouton C, 2001, P NATL ACAD SCI USA, V98, P9642, DOI 10.1073/pnas.171160298; GRIFFITH LM, 1978, J CELL BIOL, V78, P958, DOI 10.1083/jcb.78.3.958; Gusev NB, 2001, BIOCHEMISTRY-MOSCOW+, V66, P1112, DOI 10.1023/A:1012480829618; HARTWIG JH, 1989, J CELL BIOL, V108, P467, DOI 10.1083/jcb.108.2.467; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; Holowka D, 2000, J CELL SCI, V113, P1009; Ikebe M, 1998, BIOCHEMISTRY-US, V37, P13285, DOI 10.1021/bi981130b; IKEBE M, 1984, J BIOL CHEM, V259, P1639; IKEBE M, 1985, J BIOL CHEM, V260, P3146; IKEBE M, 1985, BIOCHEMISTRY-US, V24, P2380, DOI 10.1021/bi00330a038; IKEBE M, 1988, J BIOL CHEM, V263, P3055; Janmey PA, 1998, CHEM BIOL, V5, pR81, DOI 10.1016/S1074-5521(98)90631-7; KHREBTUKOVA IA, 1991, EXP CELL RES, V194, P48, DOI 10.1016/0014-4827(91)90128-H; Kim M, 2001, EMBO J, V20, P6347, DOI 10.1093/emboj/20.22.6347; Kohama K, 1996, TRENDS PHARMACOL SCI, V17, P284, DOI 10.1016/0165-6147(96)10033-X; Kolega J, 1998, J CELL SCI, V111, P2085; Konishi K, 2001, J BIOCHEM-TOKYO, V129, P365, DOI 10.1093/oxfordjournals.jbchem.a002866; Kunst G, 2000, CIRC RES, V86, P51, DOI 10.1161/01.RES.86.1.51; Kwiatkowska K, 1999, BIOCHEM BIOPH RES CO, V259, P287, DOI 10.1006/bbrc.1999.0769; Kwiatkowski DJ, 1999, CURR OPIN CELL BIOL, V11, P103, DOI 10.1016/S0955-0674(99)80012-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Luna EJ, 1997, SOC GEN PHY, V52, P3; Luna EJ, 1998, METHOD ENZYMOL, V298, P32, DOI 10.1016/S0076-6879(98)98006-5; Mackay DJG, 1997, J CELL BIOL, V138, P927, DOI 10.1083/jcb.138.4.927; MACLEANFLETCHER S, 1980, BIOCHEM BIOPH RES CO, V96, P18, DOI 10.1016/0006-291X(80)91175-4; Manes S, 1999, EMBO J, V18, P6211, DOI 10.1093/emboj/18.22.6211; Morgan KG, 2001, J APPL PHYSIOL, V91, P953, DOI 10.1152/jappl.2001.91.2.953; Nebl T, 2002, J BIOL CHEM, V277, P43399, DOI 10.1074/jbc.M205386200; Oh SW, 2003, J CELL SCI, V116, P2261, DOI 10.1242/jcs.00422; Pappin D J, 1997, Methods Mol Biol, V64, P165; PASTERNAK C, 1989, NATURE, V341, P549, DOI 10.1038/341549a0; PESTONJAMASP K, 1995, MOL BIOL CELL, V6, P247, DOI 10.1091/mbc.6.3.247; Pestonjamasp KN, 1997, J CELL BIOL, V139, P1255, DOI 10.1083/jcb.139.5.1255; Pierini LM, 2003, J BIOL CHEM, V278, P10831, DOI 10.1074/jbc.M212386200; Pierini LM, 2001, P NATL ACAD SCI USA, V98, P9471, DOI 10.1073/pnas.181353098; Pike LJ, 2003, J LIPID RES, V44, P655, DOI 10.1194/jlr.R200021-JLR200; POLLARD TD, 1982, METHOD ENZYMOL, V85, P211; Pope RK, 1998, GENOMICS, V52, P342, DOI 10.1006/geno.1998.5466; Pradhan D, 2002, IMMUNITY, V17, P303, DOI 10.1016/S1074-7613(02)00396-5; Pralle A, 2000, J CELL BIOL, V148, P997, DOI 10.1083/jcb.148.5.997; Rizzo MA, 2001, J BIOL CHEM, V276, P34928, DOI 10.1074/jbc.M105918200; Saitoh T, 2001, FEBS LETT, V509, P365, DOI 10.1016/S0014-5793(01)03186-6; Sata M, 1996, J CLIN INVEST, V98, P2866, DOI 10.1172/JCI119115; SEIDEL JC, 1980, J BIOL CHEM, V255, P4355; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; SPECKART G, 1986, J QUANTITATIVE CRIMI, V0002; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STARR R, 1971, FEBS LETT, V15, P40, DOI 10.1016/0014-5793(71)80075-3; SWAFFIELD JC, 1996, CURRENT PROTOCOLS MO; Takizawa N, 2003, AM J PHYSIOL-CELL PH, V284, pC250, DOI 10.1152/ajpcell.00153.2002; Ting HJ, 2002, P NATL ACAD SCI USA, V99, P661, DOI 10.1073/pnas.022469899; VARMA M, 1988, MUTAT RES, V199, P437, DOI 10.1016/0027-5107(88)90220-5; von Haller PD, 2001, PROTEOMICS, V1, P1010; WACHSSTOCK DH, 1993, BIOPHYS J, V65, P205, DOI 10.1016/S0006-3495(93)81059-2; Wang CLA, 2001, CELL BIOCHEM BIOPHYS, V35, P275, DOI 10.1385/CBB:35:3:275; WAY M, 1989, J CELL BIOL, V109, P593, DOI 10.1083/jcb.109.2.593; WEEDS AG, 1977, J MOL BIOL, V111, P129, DOI 10.1016/S0022-2836(77)80119-8; Wulfkuhle JD, 1999, J CELL SCI, V112, P2125	76	55	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					46094	46106		10.1074/jbc.M305311200	http://dx.doi.org/10.1074/jbc.M305311200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12917436	hybrid			2022-12-25	WOS:000186452300127
J	Amoui, M; Baylink, DJ; Tillman, JB; Lau, KHW				Amoui, M; Baylink, DJ; Tillman, JB; Lau, KHW			Expression of a structurally unique osteoclastic protein-tyrosine phosphatase is driven by an alternative intronic, cell type-specific promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; TARGETED DISRUPTION; DIFFERENTIATION; OSTEOPETROSIS; GENE; DEFICIENCY; REPRESSOR; GLEPP1	An osteoclastic protein-tyrosine phosphatase ( PTP-oc), essential for osteoclast activity, shows sequence identity with the intracellular domain of GLEPP1, a renal receptor-like transmembrane PTP. PTP-oc has been assumed to be a truncated variant of GLEPP1, resulting from alternative splicing. However, the 5'-untranslated region sequence of PTP-oc mRNA contains 217 bp from an intron of GLEPP1. There are no splicing acceptor sites at the PTP-oc transcription site. The intronic sequence flanking the 5' end of the PTP-oc transcription start site contains potential promoter elements essential for transcriptional initiation. To test the hypothesis that the PTP-oc gene has an alternative, tissue-specific, intronic promoter, the promoter activity of a 1.3-kb PCR fragment covering the 5'-flanking region of the PTP-oc gene was measured. The putative PTP-oc promoter fragment showed strong promoter activity in U937 cells. Mutation of the putative TATA box within the PTP-oc promoter abolished 60 - 90% of its promoter activity. The PTP-oc promoter fragment showed strong promoter activity in cells that express PTP-oc ( U937 cells and RAW264.7 cells) but not in cells that do not express the enzyme ( skin fibroblasts, TE85 cells, and HEK293 cells). These findings strongly support the conclusion that the 1.3-kb intronic fragment contains the tissue-specific, PTP-oc proximal promoter. Deletion and functional analyses indicate that the proximal 5' sequence flanking the TATA box of the PTP-oc contains potential repressor elements. The removal of the putative repressor elements led to the apparent loss of tissue specificity. In summary, we conclude that an intronic promoter within the GLEPP1 gene drives the expression of the PTP-oc in a cell type-specific manner. This GLEPP1/PTP-oc gene system is one of the very few systems in which two important tissue-specific enzymes are derived from the same gene by the use of alternative intronic promoters.	Jerry L Pettis Mem Vet Affairs Med Ctr, Musculoskeletal Dis Ctr 151, Loma Linda, CA 92357 USA; Loma Linda Univ, Dept Med, Loma Linda, CA 92357 USA; Loma Linda Univ, Dept Biochem, Loma Linda, CA 92357 USA	Loma Linda University; Loma Linda University	Lau, KHW (corresponding author), Jerry L Pettis Mem Vet Affairs Med Ctr, Musculoskeletal Dis Ctr 151, 11201 Benton St, Loma Linda, CA 92357 USA.	laub@lom.med.va.gov		Tillman, John/0000-0003-2912-2370; Lau, Kin-Hing/0000-0003-1109-5052	NIDCR NIH HHS [R01DE13097] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013097] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aguiar RCT, 1999, BLOOD, V94, P2403, DOI 10.1182/blood.V94.7.2403.419k39_2403_2413; Barber MC, 1998, BIOCHEM J, V333, P17, DOI 10.1042/bj3330017; Dai XM, 2002, BLOOD, V99, P111, DOI 10.1182/blood.V99.1.111; Hotokezaka H, 2002, J BIOL CHEM, V277, P47366, DOI 10.1074/jbc.M208284200; Jones FS, 1999, BIOESSAYS, V21, P372, DOI 10.1002/(SICI)1521-1878(199905)21:5<372::AID-BIES3>3.0.CO;2-3; MATSUI T, 1995, MOL CELL BIOL, V15, P1961; Moroni E, 2000, J BIOL CHEM, V275, P10567, DOI 10.1074/jbc.275.14.10567; PIXLEY FJ, 1995, J BIOL CHEM, V270, P27339, DOI 10.1074/jbc.270.45.27339; RHIM JS, 1975, INT J CANCER, V15, P23, DOI 10.1002/ijc.2910150104; Schmidt A, 1996, P NATL ACAD SCI USA, V93, P3068, DOI 10.1073/pnas.93.7.3068; SEIMIYA H, 1995, ONCOGENE, V10, P1731; Seimiya H, 1998, J BIOL CHEM, V273, P21187, DOI 10.1074/jbc.273.33.21187; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Suhr SM, 2001, J BONE MINER RES, V16, P1795, DOI 10.1359/jbmr.2001.16.10.1795; Tagawa M, 1997, BIOCHEM J, V321, P865, DOI 10.1042/bj3210865; THOMAS PE, 1994, J BIOL CHEM, V269, P19953; Umeda S, 1999, AM J PATHOL, V155, P223, DOI 10.1016/S0002-9440(10)65116-4; Wang RX, 2000, KIDNEY INT, V57, P1847, DOI 10.1046/j.1523-1755.2000.00034.x; WERGEDAL JE, 1984, P SOC EXP BIOL MED, V176, P60; Wharram BL, 2000, J CLIN INVEST, V106, P1281, DOI 10.1172/JCI7236; WIGGINS RC, 1995, GENOMICS, V27, P174, DOI 10.1006/geno.1995.1021; Wu LW, 1996, BIOCHEM J, V316, P515, DOI 10.1042/bj3160515; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0	23	33	37	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44273	44280		10.1074/jbc.M303933200	http://dx.doi.org/10.1074/jbc.M303933200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12949066	hybrid			2022-12-25	WOS:000186306700048
J	Aracena, P; Sanchez, G; Donoso, P; Hamilton, SL; Hidalgo, C				Aracena, P; Sanchez, G; Donoso, P; Hamilton, SL; Hidalgo, C			S-glutathionylation decreases Mg2+ inhibition and S-nitrosylation enhances Ca2+ activation of RyR1 channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; MUSCLE SARCOPLASMIC-RETICULUM; JUN DNA-BINDING; SKELETAL-MUSCLE; RYANODINE RECEPTOR; HYDROGEN-PEROXIDE; NITRIC-OXIDE; REDOX SENSOR; CHANNEL/RYANODINE RECEPTOR; ENDOGENOUS EFFECTORS	We have analyzed the effects of the endogenous redoxactive agents S-nitrosoglutathione and glutathione disulfide, and the NO donor NOR-3, on calcium release kinetics mediated by ryanodine receptor channels. Incubation of triad-enriched sarcoplasmic reticulum vesicles isolated from mammalian skeletal muscle with these three agents elicits different responses. Glutathione disulfide significantly reduces the inhibitory effect of Mg2+ without altering Ca2+ activation of release kinetics, whereas NOR-3 enhances Ca2+ activation of release kinetics without altering Mg2+ inhibition. Incubation with S-nitrosoglutathione produces both effects; it significantly enhances Ca2+ activation of release kinetics and diminishes the inhibitory effect of Mg2+ on this process. Triad incubation with [S-35] nitrosoglutathione at pCa 5 promoted S-35 incorporation into 2.5 cysteine residues per channel monomer; this incorporation decreased significantly at pCa 9. These findings indicate that S-nitrosoglutathione supports S-glutathionylation as well as the reported S-nitrosylation of ryanodine receptor channels ( Sun, J., Xu, L., Eu, J. P., Stamler, J. S., and Meissner, G. ( 2003) J. Biol. Chem. 278, 8184 - 8189). The combined results suggest that S-glutathionylation of specific cysteine residues can modulate channel inhibition by Mg2+, whereas S-nitrosylation of different cysteines can modulate the activation of the channel by Ca2+. Possible physiological and pathological implications of the activation of skeletal Ca2+ release channels by endogenous redox species are discussed.	Univ Chile, Fac Med, Inst Ciencias Biomed, Programa Biol Celular & Mol, Santiago 7, Chile; Univ Chile, Fac Med, Ctr Fondo Invest Avanzada, Areas Prioritarias Estudios Mol Celula, Santiago 7, Chile; Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA	Universidad de Chile; Universidad de Chile; Baylor College of Medicine	Hidalgo, C (corresponding author), Univ Chile, Fac Med, Inst Ciencias Biomed, Programa Biol Celular & Mol, Casilla 70005, Santiago 7, Chile.		Aracena, Paula/A-5607-2012; HIDALGO, Cecilia/H-7107-2013	Aracena, Paula/0000-0002-2144-6875; Hamilton, Susan/0000-0003-0241-9369	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041802, R01AR044864] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR41802, AR44864] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABRAMSON JJ, 1995, J BIOL CHEM, V270, P29644; Aghdasi B, 1997, J BIOL CHEM, V272, P3739, DOI 10.1074/jbc.272.6.3739; ARACENA P, 2003, P 11 BIENN M SOC FRE, P221; Aslund F, 1999, P NATL ACAD SCI USA, V96, P6161, DOI 10.1073/pnas.96.11.6161; Balshaw DM, 2001, J BIOL CHEM, V276, P20144, DOI 10.1074/jbc.M010771200; Borges CR, 2002, J BIOL CHEM, V277, P48295, DOI 10.1074/jbc.M209042200; BULL R, 1989, BIOPHYS J, V56, P749, DOI 10.1016/S0006-3495(89)82722-5; Cancela JM, 2002, EMBO J, V21, P909, DOI 10.1093/emboj/21.5.909; Casagrande S, 2002, P NATL ACAD SCI USA, V99, P9745, DOI 10.1073/pnas.152168599; CLANCY RM, 1994, P NATL ACAD SCI USA, V91, P3680, DOI 10.1073/pnas.91.9.3680; Dalle-Donne I, 2003, FREE RADICAL BIO MED, V34, P23, DOI 10.1016/S0891-5849(02)01182-6; Donoso P, 1997, ARCH BIOCHEM BIOPHYS, V341, P295, DOI 10.1006/abbi.1997.9960; Donoso P, 2000, BIOPHYS J, V79, P279, DOI 10.1016/S0006-3495(00)76290-4; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Elferink JGR, 1999, GEN PHARMACOL, V33, P1, DOI 10.1016/S0306-3623(98)00258-4; Eu JP, 2000, CELL, V102, P499, DOI 10.1016/S0092-8674(00)00054-4; FAVERO TG, 1995, J BIOL CHEM, V270, P25557, DOI 10.1074/jbc.270.43.25557; Feng W, 2000, J BIOL CHEM, V275, P35902, DOI 10.1074/jbc.C000523200; Feng W, 2002, METHOD ENZYMOL, V353, P240; Fill M, 2002, PHYSIOL REV, V82, P893, DOI 10.1152/physrev.00013.2002; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; Fratelli M, 2002, P NATL ACAD SCI USA, V99, P3505, DOI 10.1073/pnas.052592699; Haarmann CS, 1999, BIOPHYS J, V77, P3010, DOI 10.1016/S0006-3495(99)77132-8; Hamilton SL, 2000, ANTIOXID REDOX SIGN, V2, P41, DOI 10.1089/ars.2000.2.1-41; Hardingham GE, 2001, NAT NEUROSCI, V4, P261, DOI 10.1038/85109; HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003-2697(72)90094-2; Hidalgo C, 2000, BIOL RES, V33, P113; HIDALGO C, 1993, J BIOL CHEM, V268, P15111; Hogg N, 2002, ANNU REV PHARMACOL, V42, P585, DOI 10.1146/annurev.pharmtox.42.092501.104328; Ji YB, 1999, ARCH BIOCHEM BIOPHYS, V362, P67, DOI 10.1006/abbi.1998.1013; KAPLAN RS, 1985, ANAL BIOCHEM, V150, P97, DOI 10.1016/0003-2697(85)90445-2; Kawakami M, 1998, MOL PHARMACOL, V53, P497, DOI 10.1124/mol.53.3.497; Klatt P, 1999, J BIOL CHEM, V274, P15857, DOI 10.1074/jbc.274.22.15857; Klatt P, 1999, FASEB J, V13, P1481, DOI 10.1096/fasebj.13.12.1481; Klatt P, 2000, EUR J BIOCHEM, V267, P4928, DOI 10.1046/j.1432-1327.2000.01601.x; KOSHITA M, 1993, EXPERIENTIA, V49, P282, DOI 10.1007/BF01923402; LAI FA, 1989, J BIOL CHEM, V264, P16776; LAU KHW, 1983, J BIOL CHEM, V258, P2321; LEE HB, 1994, J BIOL CHEM, V269, P13305; Lind C, 2002, ARCH BIOCHEM BIOPHYS, V406, P229, DOI 10.1016/S0003-9861(02)00468-X; LIU GH, 1994, J BIOL CHEM, V269, P33028; Lu YF, 2002, J NEUROPHYSIOL, V88, P1270, DOI 10.1152/jn.2002.88.3.1270; Mackrill JJ, 1999, BIOCHEM J, V337, P345, DOI 10.1042/0264-6021:3370345; Mallis RJ, 2001, BIOCHEM J, V355, P145, DOI 10.1042/bj3550145; Mallis RJ, 2000, ARCH BIOCHEM BIOPHYS, V383, P60, DOI 10.1006/abbi.2000.2048; Marengo JJ, 1998, BIOPHYS J, V74, P1263, DOI 10.1016/S0006-3495(98)77840-3; Marshall HE, 2000, FASEB J, V14, P1889, DOI 10.1096/fj.00.011rev; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; Oba T, 2000, AM J PHYSIOL-CELL PH, V279, pC1366, DOI 10.1152/ajpcell.2000.279.5.C1366; Oba T, 2002, AM J PHYSIOL-CELL PH, V282, pC684, DOI 10.1152/ajpcell.01273.2000; Padgett C. M., 1995, AM J PHYSIOL, V269, pC739; Padgett CM, 1998, ARCH BIOCHEM BIOPHYS, V358, P232, DOI 10.1006/abbi.1998.0859; Pessah IN, 2001, PEST MANAG SCI, V57, P941, DOI 10.1002/ps.391; PESSAH IN, 1991, MOL PHARMACOL, V39, P679; Pineda-Molina E, 2001, BIOCHEMISTRY-US, V40, P14134, DOI 10.1021/bi011459o; PORTER MC, 1999, J BIOL CHEM, V274, P36831; POSTERINO GS, 2003, J PHYSL, V347, P807; Rao RK, 2002, BIOCHEM BIOPH RES CO, V293, P610, DOI 10.1016/S0006-291X(02)00268-1; Reddy S, 2000, BIOCHEM J, V347, P821, DOI 10.1042/0264-6021:3470821; Reid MB, 2001, J APPL PHYSIOL, V90, P724, DOI 10.1152/jappl.2001.90.2.724; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; Rose CR, 2001, NEURON, V31, P519, DOI 10.1016/S0896-6273(01)00402-0; Rossi R, 1997, ANAL BIOCHEM, V254, P215, DOI 10.1006/abio.1997.2424; SALAMA G, 1992, J PHYSIOL-LONDON, V454, P389, DOI 10.1113/jphysiol.1992.sp019270; Sanchez G, 2003, BIOPHYS J, V84, P2319, DOI 10.1016/S0006-3495(03)75037-1; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; SCHUPPEKOISTINEN I, 1994, EUR J BIOCHEM, V221, P1033, DOI 10.1111/j.1432-1033.1994.tb18821.x; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; Suko J, 1998, BBA-MOL CELL RES, V1404, P435, DOI 10.1016/S0167-4889(98)00075-5; Suko J, 1999, BBA-MOL CELL RES, V1451, P271, DOI 10.1016/S0167-4889(99)00098-1; Sun JH, 2003, J BIOL CHEM, V278, P8184, DOI 10.1074/jbc.M211940200; Sun JH, 2001, J BIOL CHEM, V276, P15625, DOI 10.1074/jbc.M100083200; Sun JH, 2001, P NATL ACAD SCI USA, V98, P11158, DOI 10.1073/pnas.201289098; Suzuki YJ, 1998, FREE RADICAL BIO MED, V24, P318, DOI 10.1016/S0891-5849(97)00227-X; Svoboda K, 1999, NEURON, V22, P427, DOI 10.1016/S0896-6273(00)80698-4; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; Taylor ER, 2003, J BIOL CHEM, V278, P19603, DOI 10.1074/jbc.M209359200; TRIMM JL, 1986, J BIOL CHEM, V261, P6092; Viner RI, 1999, BIOCHEMISTRY-US, V38, P12408, DOI 10.1021/bi9909445; Wang W, 1998, PHARMACOL REV, V50, P335; Wu YL, 1997, J BIOL CHEM, V272, P25051, DOI 10.1074/jbc.272.40.25051; Xia RH, 2000, J BIOL CHEM, V275, P36556, DOI 10.1074/jbc.M007613200; Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234; Zable AC, 1997, J BIOL CHEM, V272, P7069, DOI 10.1074/jbc.272.11.7069; ZAIDI NF, 1989, J BIOL CHEM, V264, P21725; Zhang JZ, 1999, AM J PHYSIOL-CELL PH, V276, pC46; Zucchi R, 1997, PHARMACOL REV, V49, P1	87	106	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42927	42935		10.1074/jbc.M306969200	http://dx.doi.org/10.1074/jbc.M306969200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12920114	hybrid			2022-12-25	WOS:000186157000026
J	Goralska, M; Holley, BL; McGahan, MC				Goralska, M; Holley, BL; McGahan, MC			Identification of a mechanism by which lens epithelial cells limit accumulation of overexpressed ferritin H-chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPERFERRITINEMIA-CATARACT SYNDROME; IRON-RESPONSIVE ELEMENT; CANINE SERUM FERRITIN; TRANSCRIPTIONAL REGULATION; HELA-CELLS; L-SUBUNIT; GENE; MOUSE; LIVER; ALPHA	The primary cultures of canine lens epithelial cells were transiently transfected with cDNAs for dog ferritin H- or L-chains in order to study differential expression of these chains. By using chain-specific antibodies, we determined that at 48 h after transfection overexpression of L-chain was much higher (9-fold over control) than that of H-chain (1.7-fold). We discovered that differentially transfected cells secrete overexpressed chains as homopolymeric ferritin into the media. Forty-eight hours after transfection accumulation of H- ferritin in the media was much higher (3-fold) than that of L-ferritin. This resulted in lowering of the concentration of H- chain in the cytosol. Co-transfection of cells with both H- and L-chain cDNAs increased the intracellular levels of H- chain and eliminated secretion of H-ferritin to the media. We concluded that lens epithelial cells differentially regulate concentration of both ferritin chains in the cytosol. The overexpressed L-chain accumulated in the cytosol as predominantly homopolymeric L-ferritin. This is in contrast to H-chain, which is removed to the media unless there is an L-chain available to form heteropolymeric ferritin. These data indicate that the inability of cells to more strictly control cytosolic levels of L-chain may augment its accumulation in lenses of humans with hereditary hyperferritinemia cataract syndrome, which is caused by overexpression of L-chain due to mutation in the regulatory element in the untranslated region of the mRNA of the chain.	N Carolina State Univ, Dept Mol Biomed Sci, Raleigh, NC 27606 USA	University of North Carolina; North Carolina State University	Goralska, M (corresponding author), N Carolina State Univ, Dept Mol Biomed Sci, 4700 Hillsborough St, Raleigh, NC 27606 USA.							ADDISON JM, 1984, FEBS LETT, V175, P333, DOI 10.1016/0014-5793(84)80763-2; BEAUMONT C, 1989, J BIOL CHEM, V264, P7498; Brooks DG, 2002, INVEST OPHTH VIS SCI, V43, P1121; Cicilano M, 1999, HAEMATOLOGICA, V84, P489; Corsi B, 1998, BIOCHEM J, V330, P315, DOI 10.1042/bj3300315; Cozzi A, 2000, J BIOL CHEM, V275, P25122, DOI 10.1074/jbc.M003797200; Cozzi A, 2003, FEBS LETT, V537, P187, DOI 10.1016/S0014-5793(03)00114-5; Epsztejn S, 1999, BLOOD, V94, P3593, DOI 10.1182/blood.V94.10.3593.422k26_3593_3603; Fan HZ, 1996, FEBS LETT, V382, P145, DOI 10.1016/0014-5793(96)00143-3; Ferreira C, 2000, J BIOL CHEM, V275, P3021, DOI 10.1074/jbc.275.5.3021; GIRELLI D, 1995, BLOOD, V86, P4050, DOI 10.1182/blood.V86.11.4050.bloodjournal86114050; Goralska M, 2001, INVEST OPHTH VIS SCI, V42, P1721; Grace JE, 2000, ARCH BIOCHEM BIOPHYS, V384, P116, DOI 10.1006/abbi.2000.2068; HENTZE MW, 1987, SCIENCE, V238, P1570, DOI 10.1126/science.3685996; KWAK EL, 1995, J BIOL CHEM, V270, P15285, DOI 10.1074/jbc.270.25.15285; LUZZAGO A, 1993, GENE, V128, P51, DOI 10.1016/0378-1119(93)90152-S; Marziali G, 1997, MOL CELL BIOL, V17, P1387, DOI 10.1128/MCB.17.3.1387; Miyazaki E, 2002, GUT, V50, P413, DOI 10.1136/gut.50.3.413; Orino K, 2003, BIOMETALS, V16, P341, DOI 10.1023/A:1020659317564; Picard V, 1996, BLOOD, V87, P2057; Picard V, 1998, J BIOL CHEM, V273, P15382, DOI 10.1074/jbc.273.25.15382; Tsuji Y, 1999, J BIOL CHEM, V274, P7501, DOI 10.1074/jbc.274.11.7501; Watanabe K, 2000, BIOMETALS, V13, P319, DOI 10.1023/A:1009276323707	23	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42920	42926		10.1074/jbc.M305827200	http://dx.doi.org/10.1074/jbc.M305827200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12920121	hybrid			2022-12-25	WOS:000186157000025
J	Huggins, KW; Camarota, LM; Howles, PN; Hui, DY				Huggins, KW; Camarota, LM; Howles, PN; Hui, DY			Pancreatic triglyceride lipase deficiency minimally affects dietary fat absorption but dramatically decreases dietary cholesterol absorption in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA RATIO METHOD; ESTER HYDROLYSIS; INTESTINAL-CELLS; BILE SALTS; DIGESTION; TRANSPORT; TETRAHYDROLIPSTATIN; INHIBITOR; SITE; GENE	This study generated pancreatic triglyceride lipase (PTL)-null mice to test the hypothesis that PTL-mediated hydrolysis of dietary triglyceride is necessary for efficient dietary cholesterol absorption. The PTL-/- mice grew normally and displayed similar body weight as their PTL+/+ littermates. Plasma lipid levels between animals of various PTL genotypes were similar when they were maintained on either a basal low fat diet or a western-type high fat/high cholesterol diet. Although the lack of a functional PTL delayed fat absorption during the initial hour of feeding a bolus load of olive oil containing [H-3] triolein and [C-14] cholesterol, the rate of [H-3] triolein absorption was similar between PTL+/+ and PTL-/- mice after the initial 1-h period. Importantly, comparison of fecal fat content revealed similar overall fat absorption efficiency between PTL+/+ and PTL-/- mice. In contrast, the PTL-/- mice displayed significant decrease in both the rate and the amount of cholesterol absorbed after a single meal. The plasma appearance of [C-14] cholesterol was found to be 75% lower ( p < 0.0005) in PTL-/- mice compared with PTL+/+ mice after 4 h. The total amount of [C-14] cholesterol excreted in the feces was 45% higher ( p < 0.0004) in PTL-/- mice compared with PTL-/- mice over a 24-h period. These results indicate that the delayed fat digestion due to PTL deficiency results in a significant reduction in cholesterol absorption, although other enzymes in the digestive tract may compensate for the lack of PTL in PTL-/- mice in fat digestion and absorption.	Univ Cincinnati, Coll Med, Dept Pathol & Lab Med, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Hui, DY (corresponding author), Univ Cincinnati, Coll Med, Dept Pathol & Lab Med, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.	huidy@email.uc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK010065] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54504, DK10065] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AALTOSETALA K, 1992, J CLIN INVEST, V90, P1889, DOI 10.1172/JCI116066; BHAT SG, 1982, BIOCHEM BIOPH RES CO, V109, P486, DOI 10.1016/0006-291X(82)91747-8; BITMAN J, 1981, J LIQ CHROMATOGR, V4, P1007, DOI 10.1080/01483918108059601; BORGSTROM B, 1960, J CLIN INVEST, V39, P809, DOI 10.1172/JCI104100; BORGSTROM B, 1963, GASTROENTEROLOGY, V45, P229; BRANNON PM, 1990, ANNU REV NUTR, V10, P85, DOI 10.1146/annurev.nu.10.070190.000505; CAREY MC, 1983, ANNU REV PHYSIOL, V45, P651, DOI 10.1146/annurev.ph.45.030183.003251; D'Agostino D, 2002, J BIOL CHEM, V277, P7170, DOI 10.1074/jbc.M108328200; Dawson PA, 1999, CURR OPIN LIPIDOL, V10, P315, DOI 10.1097/00041433-199908000-00005; DIPERSIO LP, 1990, J BIOL CHEM, V265, P16801; FERNANDEZ E, 1989, BIOCHIM BIOPHYS ACTA, V1001, P249, DOI 10.1016/0005-2760(89)90107-0; FIGARELLA C, 1980, J PEDIATR-US, V96, P412, DOI 10.1016/S0022-3476(80)80683-4; GALLO LL, 1977, P SOC EXP BIOL MED, V156, P277; GRUNDY SM, 1968, J LIPID RES, V9, P374; HADVARY P, 1988, BIOCHEM J, V256, P357, DOI 10.1042/bj2560357; HAUPTMAN JB, 1992, AM J CLIN NUTR, V55, P309; HERNELL O, 1990, BIOCHEMISTRY-US, V29, P2041, DOI 10.1021/bi00460a012; HERNELL O, 1990, ACTA PAEDIATR SCAND, P20; Hernell O., 1992, SEMINARS GASTROINTES, V3, P189; HOGAN S, 1987, INT J OBESITY, V11, P35; HOLT PR, 1986, LIPIDS, V21, P444, DOI 10.1007/BF02536401; Homan R, 1998, J LIPID RES, V39, P1197; Howles PN, 1996, J BIOL CHEM, V271, P7196, DOI 10.1074/jbc.271.12.7196; Huggins KW, 2002, AM J PHYSIOL-ENDOC M, V283, pE994, DOI 10.1152/ajpendo.00110.2002; Hui DY, 1996, BBA-LIPID LIPID MET, V1303, P1, DOI 10.1016/0005-2760(96)00085-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIGUMSKY M, 1990, GUT, V31, P1416, DOI 10.1136/gut.31.12.1416; LOPEZCANDALES A, 1993, BIOCHEMISTRY-US, V32, P12085, DOI 10.1021/bi00096a019; Love MW, 1998, CURR OPIN LIPIDOL, V9, P225, DOI 10.1097/00041433-199806000-00007; LOWE ME, 1994, GASTROENTEROLOGY, V107, P1524, DOI 10.1016/0016-5085(94)90559-2; LOWE ME, 1989, J BIOL CHEM, V264, P20042; Lowe ME, 2002, J LIPID RES, V43, P2007, DOI 10.1194/jlr.R200012-JLR200; Lowe ME, 1998, J BIOL CHEM, V273, P31215, DOI 10.1074/jbc.273.47.31215; Lowe ME, 1999, METH MOL B, V109, P59; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mackay K, 1997, J BIOL CHEM, V272, P13380, DOI 10.1074/jbc.272.20.13380; Mardones P, 2001, J LIPID RES, V42, P170; Miled N, 2000, BIOCHIMIE, V82, P973, DOI 10.1016/S0300-9084(00)01179-2; PAYNE RM, 1994, AM J PHYSIOL, V266, pG914, DOI 10.1152/ajpgi.1994.266.5.G914; Richmond BL, 2001, GASTROENTEROLOGY, V120, P1193, DOI 10.1053/gast.2001.23254; ROSSI SS, 1987, J LIPID RES, V28, P589; Schwarz M, 1996, J BIOL CHEM, V271, P18024, DOI 10.1074/jbc.271.30.18017; SIMS HF, 1993, GENE, V131, P281, DOI 10.1016/0378-1119(93)90307-O; SWELL L, 1958, P SOC EXP BIOL MED, V98, P174, DOI 10.3181/00379727-98-23979; SYLVEN C, 1970, SCAND J GASTROENTERO, V5, P57; Tsuchiya T, 1996, AM J PHYSIOL-GASTR L, V271, pG681, DOI 10.1152/ajpgi.1996.271.4.G681; TURLEY SD, 1994, J LIPID RES, V35, P328; WANG CS, 1993, BIOCHIM BIOPHYS ACTA, V1166, P1, DOI 10.1016/0005-2760(93)90277-G; Wang DQH, 2003, J LIPID RES, V44, P1042, DOI 10.1194/jlr.D200041-JLR200; Young SC, 1999, BIOCHEM J, V339, P615, DOI 10.1042/0264-6021:3390615; ZILVERSMIT DB, 1974, J LIPID RES, V15, P465; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	52	41	41	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42899	42905		10.1074/jbc.M303422200	http://dx.doi.org/10.1074/jbc.M303422200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12915407	hybrid			2022-12-25	WOS:000186157000022
J	Murphy, GJ; Gottgens, B; Vegiopoulos, A; Sanchez, MJ; Leavitt, AD; Watson, SP; Green, AR; Frampton, J				Murphy, GJ; Gottgens, B; Vegiopoulos, A; Sanchez, MJ; Leavitt, AD; Watson, SP; Green, AR; Frampton, J			Manipulation of mouse hematopoietic progenitors by specific retroviral infection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A AVIAN-LEUKOSIS; GENE-TRANSFER; LEUKEMIA-VIRUS; VIVO EXPANSION; STEM-CELLS; RECEPTOR; VECTORS; MICE; LIGAND; SCL	Previous studies have identified an enhancer 3' of the scl gene that can direct transgene expression to hematopoietic progenitors and stem cells. Here we use this enhancer to restrict expression of the avian leukosis virus receptor, TVA, to hematopoietic stem cells and progenitors in bone marrow and fetal liver and demonstrate that retroviral infection can be used to specifically introduce exogenous sequences. We show that a majority of CFU-S-12 multipotential progenitor cells can be transduced in vitro. Uniquely, transduction of TVA(+) progenitors with a retrovirus encoding a puromycin resistance gene allows selection and expansion of a multipotential hematopoietic progenitor population that can be superinfected with high efficiency. Using this system we show for the first time that v-Myb oncoproteins expressed from avian viruses can induce a leukemic transformation in the mouse. The phenotype of the transformed cells is similar to that which is seen in the chicken and is likewise dependent on the particular structure of v-Myb. This implies that the basic mechanisms of action of mutated transcription factors in the etiology of leukemia are conserved between birds and mammals.	Univ Birmingham, Sch Med, Dept Anat, Birmingham B15 2TT, W Midlands, England; John Radcliffe Hosp, Weatherall Inst Mol Med, Oxford OX3 9DS, England; Cambridge Inst Med Res, Dept Haematol, Cambridge CB2 2XY, England; Univ Calif San Francisco, Dept Lab, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Internal Med, San Francisco, CA 94143 USA; Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England	University of Birmingham; University of Oxford; University of Cambridge; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Oxford	Frampton, J (corresponding author), Univ Birmingham, Sch Med, Dept Anat, Birmingham B15 2TT, W Midlands, England.	j.frampton@bham.ac.uk	Watson, Stephen P/Q-6292-2016; Sanchez, Maria Jose/P-4716-2016	Watson, Stephen P/0000-0002-7846-7423; Sanchez, Maria Jose/0000-0003-3464-6224; Gottgens, Berthold/0000-0001-6302-5705; Green, Anthony/0000-0002-9795-0218				BATES P, 1993, CELL, V74, P1043, DOI 10.1016/0092-8674(93)90726-7; Begley CG, 1999, BLOOD, V93, P2760; Coligan J, 1995, CURRENT PROTOCOLS IM; COSSET FL, 1995, J VIROL, V69, P6314, DOI 10.1128/JVI.69.10.6314-6322.1995; FEDERSPIEL MJ, 1994, P NATL ACAD SCI USA, V91, P11241, DOI 10.1073/pnas.91.23.11241; Federspiel MJ, 1997, METHOD CELL BIOL, V52, P179, DOI 10.1016/S0091-679X(08)60379-9; GRAF T, 1992, CELL, V70, P201, DOI 10.1016/0092-8674(92)90096-U; Heim DA, 2000, IMMUNOL REV, V178, P29, DOI 10.1034/j.1600-065X.2000.17802.x; HODGSON GS, 1979, NATURE, V281, P381, DOI 10.1038/281381a0; HOGAN B, 1986, MANIPULATING MOUSE E; Holland EC, 1998, P NATL ACAD SCI USA, V95, P1218, DOI 10.1073/pnas.95.3.1218; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; KASAHARA N, 1994, SCIENCE, V266, P1373, DOI 10.1126/science.7973726; Kobari L, 1998, BONE MARROW TRANSPL, V21, P759, DOI 10.1038/sj.bmt.1701199; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; Lin AH, 2001, HUM GENE THER, V12, P323, DOI 10.1089/10430340150503957; MILLER AD, 1997, DEV APPL RETROVIRAL; MILLER DG, 1990, MOL CELL BIOL, V10, P4239, DOI 10.1128/MCB.10.8.4239; MOSCOVICI MG, 1983, VIROLOGY, V129, P65, DOI 10.1016/0042-6822(83)90396-3; Murphy GJ, 1999, P NATL ACAD SCI USA, V96, P3065, DOI 10.1073/pnas.96.6.3065; Psarras K, 2000, CYTOKINE, V12, P786, DOI 10.1006/cyto.1999.0619; RUSCETTI S, 1992, J VIROL, V66, P20, DOI 10.1128/JVI.66.1.20-26.1992; Sanchez MJ, 1999, DEVELOPMENT, V126, P3891; Sanchez MJ, 2001, DEVELOPMENT, V128, P4815; Schwarzenberger P, 1996, BLOOD, V87, P472, DOI 10.1182/blood.V87.2.472.bloodjournal872472; SPANGRUDE GJ, 1995, BLOOD, V85, P1006, DOI 10.1182/blood.V85.4.1006.bloodjournal8541006; Stein CS, 2001, MOL THER, V3, P850, DOI 10.1006/mthe.2001.0325; TILL JE, 1961, RADIAT RES, V14, P213, DOI 10.2307/3570892; Veiby OP, 1996, J IMMUNOL, V157, P2953; Yajima T, 1998, HUM GENE THER, V9, P779, DOI 10.1089/hum.1998.9.6-779; YOUNG JAT, 1993, J VIROL, V67, P1811, DOI 10.1128/JVI.67.4.1811-1816.1993	31	12	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43556	43563		10.1074/jbc.M302717200	http://dx.doi.org/10.1074/jbc.M302717200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12928443	Green Published, hybrid			2022-12-25	WOS:000186157000102
J	He, YY; Huang, JL; Gentry, JB; Chignell, CF				He, YY; Huang, JL; Gentry, JB; Chignell, CF			Epidermal growth factor receptor down-regulation induced by UVA in human keratinocytes does not require the receptor kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; EGF RECEPTOR; C-CBL; MALIGNANT-MELANOMA; ULTRAVIOLET-LIGHT; RING FINGER; INTERNALIZATION; UBIQUITINATION; ACTIVATION; APOPTOSIS	Activation of the epidermal growth factor (EGF) receptor by EGF, its ligand, results in receptor internalization and down-regulation, which requires receptor kinase activity, phosphorylation, and ubiquitination. In contrast, we have found here in human HaCaT keratinocytes that exposure to UVA induces EGF receptor internalization and down-regulation without receptor phosphorylation and ubiquitination. The presence of the receptor kinase activity inhibitor AG1478 increased UVA-induced receptor down-regulation, whereas it inhibited EGF-induced receptor down-regulation. These observations demonstrate that, in contrast to EGF, receptor kinase activity is not required for receptor downregulation by UVA. Concurrent with receptor down-regulation, caspases were activated by UVA exposure. The presence of caspase inhibitors blocked receptor downregulation in a pattern similar to poly(ADP)-ribose polymerase cleavage. Much more receptor down-regulation was observed after UVA exposure in apoptotic detached cells in which caspase is activated completely. These results indicate that UVA-induced receptor downregulation is dependent on caspase activation. Similar to UVA, both UVB and UVC induced receptor downregulation, in which receptor kinase activity is not required, whereas caspase activation is involved. Inhibition of EGF receptor down-regulation increased receptor activation and activation of its downstream survival signaling ERK and AKT after UVA exposure. Preventing the activation of each of these pathways enhanced apoptosis induced by UVA. These findings suggest that EGF receptor down-regulation by UVA may play an important role in the execution of the cell suicide program by attenuating its anti-apoptotic function and thereby preventing cell transformation and tumorigenesis in vivo.	NIEHS, Lab Pharmacol & Chem, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	He, YY (corresponding author), NIEHS, Lab Pharmacol & Chem, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES050046, ZIAES050046] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Andl CD, 2003, J BIOL CHEM, V278, P1824, DOI 10.1074/jbc.M209148200; [Anonymous], 2002, FED REGISTER, V67, P77283; Aubin F, 2001, PRESSE MED, V30, P546; Authier F, 1999, J BIOL CHEM, V274, P33723, DOI 10.1074/jbc.274.47.33723; Bae SS, 2001, FEBS LETT, V491, P16, DOI 10.1016/S0014-5793(01)02167-6; Bao J, 2000, J BIOL CHEM, V275, P26178, DOI 10.1074/jbc.M002367200; BEGUINOT L, 1984, P NATL ACAD SCI-BIOL, V81, P2384, DOI 10.1073/pnas.81.8.2384; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; de Gruijl FR, 1999, EUR J CANCER, V35, P2003, DOI 10.1016/S0959-8049(99)00283-X; de Melker AA, 2001, J CELL SCI, V114, P2167; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; GalchevaGargova Z, 1995, ONCOGENE, V11, P2649; Gasparro FP, 1998, PHOTOCHEM PHOTOBIOL, V68, P243, DOI 10.1111/j.1751-1097.1998.tb09677.x; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GREENFIELD C, 1989, EMBO J, V8, P4115, DOI 10.1002/j.1460-2075.1989.tb08596.x; He YY, 2003, J BIOL CHEM, V278, P8058, DOI 10.1074/jbc.M207781200; HELDIN CH, 1979, NATURE, V282, P419, DOI 10.1038/282419a0; HELIN K, 1991, J BIOL CHEM, V266, P8363; Huang RP, 1996, J CELL BIOL, V133, P211, DOI 10.1083/jcb.133.1.211; Iordanov MS, 2002, MOL CELL BIOL, V22, P5380, DOI 10.1128/MCB.22.15.5380-5394.2002; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Kitagawa D, 2002, J BIOL CHEM, V277, P366, DOI 10.1074/jbc.M107110200; LAI WH, 1989, J CELL BIOL, V109, P2741, DOI 10.1083/jcb.109.6.2741; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Oksvold MP, 2002, J CELL SCI, V115, P793; OPRESKO LK, 1995, J BIOL CHEM, V270, P4325, DOI 10.1074/jbc.270.9.4325; Pathak Madhu A., 1996, Journal of Dermatology (Tokyo), V23, P783; Pourzand C, 1999, PHOTOCHEM PHOTOBIOL, V70, P380, DOI 10.1111/j.1751-1097.1999.tb08239.x; RENFREW CA, 1991, J BIOL CHEM, V266, P21265; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; RUNGER TM, 1995, HAUTARZT, V46, P394, DOI 10.1007/s001050050272; SETLOW RB, 1993, P NATL ACAD SCI USA, V90, P6666, DOI 10.1073/pnas.90.14.6666; SORKIN A, 1991, J BIOL CHEM, V266, P8355; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Wang SQ, 2001, J AM ACAD DERMATOL, V44, P837, DOI 10.1067/mjd.2001.114594; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707	42	42	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42457	42465		10.1074/jbc.M303376200	http://dx.doi.org/10.1074/jbc.M303376200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12930839	hybrid			2022-12-25	WOS:000185989500110
J	Pradip, D; Peng, XD; Durden, DL				Pradip, D; Peng, XD; Durden, DL			Rac2 specificity in macrophage integrin signaling - Potential role for Syk kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; TYROSINE KINASE; RHO GTPASES; MAST-CELLS; PROTOONCOGENE PRODUCT; FIBRONECTIN FRAGMENTS; HEMATOPOIETIC-CELLS; LIGAND RECOGNITION; OXIDASE ACTIVATION; ACTIN CYTOSKELETON	Herein we report that, despite the similarity of Rac2 to Rac1 (92% amino acid identity), macrophages derived from Rac2-/- mice, which continue to express Rac1, display a marked defect in alpha(v)beta(3)/alpha(v)beta(5) and alpha(4)beta(1) integrin-directed migration measured on vitronectin and fibronectin fragments (FN-H296), respectively. In contrast, mouse embryo fibroblasts derived from the Rac2 knockout mice utilize Rac1 for migration via alpha(v)beta(3)/alpha(v)beta(5) and alpha(4)beta(1). The genetic reconstitution of bone marrow-derived macrophages (BMMtheta) with Rac2 restores the integrin-dependent migration of Rac2-deficient macrophages on vitronectin (VN) and FN-H296. The levels of GTP-Rac2 generated upon specific integrin engagement in wild type macrophages parallels the phenotypic defect observed in Rac2-deficient macrophages; i.e. FN-H296, alpha(4)beta(1) > VN, alpha(v)beta(3)/alpha(v)beta(5) > FN-CH271, alpha(5)beta(1) > intact FN. In a COS7 cell system, the expression of Syk kinase alone is sufficient to convert the alpha(4)beta(1) migration response to Rac2 dependence. Therefore, we present the first evidence that the alpha(4)beta(1) receptor in blood cells has evolved a Syk-Rac2 signaling axis to transmit signals required for integrin-directed migration suggesting that Syk kinase in part encodes myeloid Rac2 specificity in vivo.	Indiana Univ, Sch Med,Sect Hematol Oncol, Dept Pediat Biochem & Mol Biol, Herman B Wells Ctr Pediat Res, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	Durden, DL (corresponding author), Indiana Univ, Sch Med,Sect Hematol Oncol, Dept Pediat Biochem & Mol Biol, Herman B Wells Ctr Pediat Res, 1044 W Walnut St, Indianapolis, IN 46202 USA.				NCI NIH HHS [CA 94233, CA 81403] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R56CA094233, P01CA081403, R01CA094233] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allen WE, 1997, J CELL SCI, V110, P707; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Borisy GG, 2000, CURR OPIN CELL BIOL, V12, P104, DOI 10.1016/S0955-0674(99)00063-0; Chu DH, 1998, IMMUNOL REV, V165, P167, DOI 10.1111/j.1600-065X.1998.tb01238.x; CLARK EA, 1994, J BIOL CHEM, V269, P28859; Cowan KJ, 2000, J BIOL CHEM, V275, P36423, DOI 10.1074/jbc.M004068200; de Curtis I, 2001, EMBO REP, V2, P277, DOI 10.1093/embo-reports/kve072; Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; Erdreich-Epstein A, 2000, CANCER RES, V60, P712; Fernandez JA, 1999, J BIOL CHEM, V274, P1401, DOI 10.1074/jbc.274.3.1401; Gotoh A, 1997, CELL GROWTH DIFFER, V8, P721; Gu Y, 2002, MOL CELL BIOL, V22, P7645, DOI 10.1128/MCB.22.21.7645-7657.2002; Haataja L, 1997, J BIOL CHEM, V272, P20384, DOI 10.1074/jbc.272.33.20384; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hall A, 2000, PHILOS T R SOC B, V355, P965, DOI 10.1098/rstb.2000.0632; Hanenberg H, 1996, NAT MED, V2, P876, DOI 10.1038/nm0896-876; Hong JJ, 2002, J BIOL CHEM, V277, P31703, DOI 10.1074/jbc.M201362200; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Humphries JD, 2000, J BIOL CHEM, V275, P20337, DOI 10.1074/jbc.M000568200; Jacinto E, 1998, IMMUNITY, V8, P31, DOI 10.1016/S1074-7613(00)80456-2; Jones GE, 1998, CELL ADHES COMMUN, V6, P237, DOI 10.3109/15419069809004479; Jordan MS, 2003, NAT IMMUNOL, V4, P110, DOI 10.1038/ni0203-110; Kapur R, 2001, BLOOD, V97, P1975, DOI 10.1182/blood.V97.7.1975; Kim C, 2001, J IMMUNOL, V166, P1223, DOI 10.4049/jimmunol.166.2.1223; Kim JS, 2002, BLOOD, V99, P694, DOI 10.1182/blood.V99.2.694; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Kyono WT, 1998, J IMMUNOL, V161, P5555; Law DA, 1999, NATURE, V401, P808, DOI 10.1038/44599; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; Mocsai A, 2003, BLOOD, V101, P4155, DOI 10.1182/blood-2002-07-2346; Mocsai A, 2002, IMMUNITY, V16, P547, DOI 10.1016/S1074-7613(02)00303-5; Mould AP, 2000, J BIOL CHEM, V275, P20324, DOI 10.1074/jbc.M000572200; MOULD AP, 1991, J BIOL CHEM, V266, P3579; Park RK, 1999, J IMMUNOL, V163, P6023; Piccolo E, 2002, ONCOGENE, V21, P6520, DOI 10.1038/sj.onc.1205821; Pollok KE, 1998, J VIROL, V72, P4882, DOI 10.1128/JVI.72.6.4882-4892.1998; QUINN MT, 1993, J BIOL CHEM, V268, P20983; Roberts AW, 1999, IMMUNITY, V10, P183, DOI 10.1016/S1074-7613(00)80019-9; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Schvartz I, 1999, INT J BIOCHEM CELL B, V31, P539, DOI 10.1016/S1357-2725(99)00005-9; Scita G, 2000, EMBO J, V19, P2393, DOI 10.1093/emboj/19.11.2393; Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0; Suen PW, 1999, J CELL SCI, V112, P4067; Suzuki T, 1998, J IMMUNOL, V161, P3694; Tao W, 2002, BLOOD, V100, P1679, DOI 10.1182/blood.V100.5.1679.h81702001679_1679_1688; Turner M, 2000, IMMUNOL TODAY, V21, P148, DOI 10.1016/S0167-5699(99)01574-1; VAN AL, 1997, GENE DEV, V11, P2295; van der Loo JCM, 1998, J CLIN INVEST, V102, P1051, DOI 10.1172/JCI3687; Williams DA, 2000, BLOOD, V96, P1646; Woodside DG, 2002, J BIOL CHEM, V277, P39401, DOI 10.1074/jbc.M207657200; Yang FC, 2000, IMMUNITY, V12, P557, DOI 10.1016/S1074-7613(00)80207-1; Yang FC, 2001, P NATL ACAD SCI USA, V98, P5614, DOI 10.1073/pnas.101546898; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281	56	40	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41661	41669		10.1074/jbc.M306491200	http://dx.doi.org/10.1074/jbc.M306491200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12917394	hybrid			2022-12-25	WOS:000185989500015
J	Vuocolo, S; Purev, E; Zhang, DM; Bartek, J; Hansen, K; Soprano, DR; Soprano, KJ				Vuocolo, S; Purev, E; Zhang, DM; Bartek, J; Hansen, K; Soprano, DR; Soprano, KJ			Protein phosphatase 2A associates with Rb2/p130 and mediates retinoic acid-induced growth suppression of ovarian carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA PROTEIN; CANCER STATISTICS; CYCLIN-A; P130; PHOSPHORYLATION; PRB; P107; PRB2/P130; FAMILY; DIFFERENTIATION	Levels of Rb2/p130 protein are increased 5-10-fold following all-trans-retinoic acid (ATRA) treatment of the retinoid-sensitive ovarian adenocarcinoma cell line CAOV3, but not the retinoid-resistant adenocarcinoma cell line SKOV3. We found that this increase in Rb2/p130 protein levels in ATRA-treated CAOV3 cells was the result of an increased protein stability. Moreover, Rb2/ p130 exhibited a decreased ubiquitination following ATRA treatment. Because phosphorylation frequently mediates ubiquitination of proteins, we examined the serine/threonine phosphatase activity in our CAOV3 cells following ATRA treatment. A significant increase in Ser/Thr phosphatase activity was found, which correlated with a rise in the level of protein phosphatase 2A (PP2A) catalytic subunit-alpha. In addition, co-immunoprecipitation and glutathione S-transferase pull- down studies demonstrated that PP2A and Rb2/ p130 associate. We have made use of a battery of Rb2/ p130 mutants to determine the sites dephosphorylated in response to ATRA treatment of CAOV3 cells. Obligate CDK4 phosphorylation sites seemed most important to the stability of the protein and are among the candidate sites that are dephosphorylated by PP2A following ATRA treatment. Finally, using both small interfering RNA specific to the catalytic subunit of PP2A and a variant of the SKOV3 cell line that overexpresses PP2A, we have shown that modulation of PP2A protein levels correlates with the ability of ATRA to inhibit growth of ovarian carcinoma cells. Our data suggest that ATRA mediates growth inhibition by stabilizing Rb2/p130 via a mechanism that involves induction of PP2A, an enzyme that can potentially dephosphorylate Rb2/p130, thereby protecting it from degradation by the proteasome.	Temple Univ, Sch Med, Dept Microbiol & Immunol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen, Denmark	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Danish Cancer Society	Soprano, KJ (corresponding author), Temple Univ, Sch Med, Dept Microbiol & Immunol, 3400 N Broad St, Philadelphia, PA 19140 USA.	sopranok@temple.edu	Bartek, Jiri/G-5870-2014	Hansen, Klaus/0000-0001-9657-8816	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000710] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013139] Funding Source: NIH RePORTER; NCI NIH HHS [CA 64965] Funding Source: Medline; NIAID NIH HHS [5T32 AI 0710] Funding Source: Medline; NIDCR NIH HHS [DE 13139] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BALDI A, 1995, J CELL BIOCHEM, V59, P402, DOI 10.1002/jcb.240590311; Borriello A, 2000, ONCOGENE, V19, P51, DOI 10.1038/sj.onc.1203231; Canhoto AJ, 2000, ONCOGENE, V19, P5116, DOI 10.1038/sj.onc.1203893; Chen MH, 2002, MECH DEVELOP, V114, P205, DOI 10.1016/S0925-4773(02)00066-7; Claudio PP, 1996, CANCER RES, V56, P2003; Corbeil HB, 1997, ONCOGENE, V15, P657, DOI 10.1038/sj.onc.1201224; Craiu A, 1997, J BIOL CHEM, V272, P13437, DOI 10.1074/jbc.272.20.13437; Daly M, 1998, SEMIN ONCOL, V25, P255; DeLuca A, 1997, J BIOL CHEM, V272, P20971, DOI 10.1074/jbc.272.34.20971; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Fukuchi K, 1999, BBA-MOL CELL RES, V1451, P206, DOI 10.1016/S0167-4889(99)00081-6; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; GUDAS LJ, 1992, CELL GROWTH DIFFER, V3, P655; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Hansen K, 2001, EMBO J, V20, P422, DOI 10.1093/emboj/20.3.422; Hershko A, 1997, CURR OPIN CELL BIOL, V9, P788, DOI 10.1016/S0955-0674(97)80079-8; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hoskins WJ, 1995, J CELL BIOCHEM, P189; Laidley CW, 1999, BIOORGAN MED CHEM, V7, P2937, DOI 10.1016/S0968-0896(99)00239-4; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Mayol X, 1997, Prog Cell Cycle Res, V3, P157; MAYOL X, 1995, ONCOGENE, V11, P801; Mayol Xavier, 1998, Frontiers in Bioscience, V3, pD11; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Naderi S, 1999, BLOOD, V94, P1348, DOI 10.1182/blood.V94.4.1348.416k29_1348_1358; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Paggi MG, 1996, J CELL BIOCHEM, V62, P418; Pandey AV, 2003, J BIOL CHEM, V278, P2837, DOI 10.1074/jbc.M209527200; SASAKI K, 1994, BIOCHEM J, V298, P259, DOI 10.1042/bj2980259; Sidle A, 1996, CRIT REV BIOCHEM MOL, V31, P237, DOI 10.3109/10409239609106585; Spinella MJ, 1999, J BIOL CHEM, V274, P22013, DOI 10.1074/jbc.274.31.22013; Stiegler P, 1999, ANAL QUANT CYTOL, V21, P363; Stiegler P, 1998, CANCER RES, V58, P5049; Sueoka N, 1999, CANCER RES, V59, P3838; TAWARA I, 1993, FEBS LETT, V321, P224, DOI 10.1016/0014-5793(93)80113-9; Teixeira C, 1997, MOL ENDOCRINOL, V11, P1191, DOI 10.1210/me.11.9.1191; Walsh AH, 1997, FEBS LETT, V416, P230, DOI 10.1016/S0014-5793(97)01210-6; Woo MSA, 1997, MOL CELL BIOL, V17, P3566, DOI 10.1128/MCB.17.7.3566; Wu SJ, 1998, ONCOGENE, V17, P2839, DOI 10.1038/sj.onc.1202208; Wu SJ, 1997, EXP CELL RES, V237, P118, DOI 10.1006/excr.1997.3769; Wu SJ, 1998, J CELL BIOCHEM, V68, P378, DOI 10.1002/(SICI)1097-4644(19980301)68:3<378::AID-JCB8>3.0.CO;2-R; Wu SJ, 1997, EXP CELL RES, V232, P277, DOI 10.1006/excr.1997.3495; Yan Y, 1999, J BIOL CHEM, V274, P31917, DOI 10.1074/jbc.274.45.31917; Zhang DM, 2001, ONCOGENE, V20, P7935, DOI 10.1038/sj.onc.1204971; Zhang DM, 2000, J CELL PHYSIOL, V185, P1, DOI 10.1002/1097-4652(200010)185:1<1::AID-JCP1>3.0.CO;2-O	51	37	39	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41881	41889		10.1074/jbc.M302715200	http://dx.doi.org/10.1074/jbc.M302715200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12915404	hybrid			2022-12-25	WOS:000185989500041
J	Kwak, JC; Ongusaha, PP; Ouchi, T; Lee, SW				Kwak, JC; Ongusaha, PP; Ouchi, T; Lee, SW			IFI16 as a negative regulator in the regulation of p53 and p21(Waf1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON-INDUCIBLE PROTEIN; CELL-PROLIFERATION; 204 GENE; IFI-16; EXPRESSION; GROWTH; CANCER; TRANSCRIPTION; DOMAIN; DEGRADATION	IFI16 is a member of the HIN-200 family ( hematopoietic interferon-inducible nuclear antigens with 200 amino acid repeats) that contains a DNA binding domain, a transcriptional regulatory domain, and DAPIN/ PAAD, a protein domain associated with interferon response. It can function as a transcription repressor and directly binds p53. Although the structural and biochemical properties of IFI16 are known, the physiological relevance of these properties in the cellular context is still elusive. Here we report that the inhibition of endogenous IFI16 expression by small interfering RNA ( siRNA) induces p21(Waf1) mRNA and protein expression through p53 but does not induce pro-apoptotic p53 target genes. This rapid induction of p21 was wild-type p53-dependent and resulted in cell cycle arrest along with a marked reduction of phosphorylated Rb in normally growing cells. We also showed that the repression of IFI16 affects p53 transcriptional activity at the p21 promoter as well as the protein stability of p53 and p21. Our findings identified a new role for IFI16 in modulating p53 function and its target gene regulation in the control of cell cycle regulation.	Harvard Univ, Sch Med, Inst Med, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Div Hematol & Oncol, Canc Biol Program, Boston, MA 02115 USA; Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Icahn School of Medicine at Mount Sinai	Lee, SW (corresponding author), Harvard Univ, Sch Med, Inst Med, 4 Blackfan Circle,Rm 921, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA078356, R01CA085214, R01CA085681] Funding Source: NIH RePORTER; NCI NIH HHS [CA85681, CA78356, CA85214] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Clarke CJP, 2003, J CELL BIOCHEM, V89, P80, DOI 10.1002/jcb.10475; Coleman ML, 2003, EMBO J, V22, P2036, DOI 10.1093/emboj/cdg189; DAWSON MJ, 1995, BIOCHEM BIOPH RES CO, V214, P152, DOI 10.1006/bbrc.1995.2269; DAWSON MJ, 1995, J CELL BIOCHEM, V57, P39, DOI 10.1002/jcb.240570106; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fang L, 1999, ONCOGENE, V18, P2789, DOI 10.1038/sj.onc.1202615; Gutterman JU, 1999, CELL GROWTH DIFFER, V10, P93; Hertel L, 2000, ONCOGENE, V19, P3598, DOI 10.1038/sj.onc.1203697; Johnstone RW, 1998, J BIOL CHEM, V273, P17172, DOI 10.1074/jbc.273.27.17172; Johnstone RW, 1998, BIOCHEMISTRY-US, V37, P11924, DOI 10.1021/bi981069a; Johnstone RW, 2000, ONCOGENE, V19, P6033, DOI 10.1038/sj.onc.1204005; Johnstone RW, 1999, MOL CELL BIOL, V19, P5833; Lembo M, 1998, ONCOGENE, V16, P1543, DOI 10.1038/sj.onc.1201677; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Meulmeester E, 2003, MOL CELL BIOL, V23, P4929, DOI 10.1128/MCB.23.14.4929-4938.2003; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Pawlowski K, 2001, TRENDS BIOCHEM SCI, V26, P85, DOI 10.1016/S0968-0004(00)01729-1; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Staub E, 2001, TRENDS BIOCHEM SCI, V26, P83, DOI 10.1016/S0968-0004(00)01717-5; TRAPANI JA, 1992, IMMUNOGENETICS, V36, P369; TRAPANI JA, 1994, IMMUNOGENETICS, V40, P415; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wei W, 2003, HISTOCHEM CELL BIOL, V119, P45, DOI 10.1007/s00418-002-0485-0; Yan DH, 1999, ONCOGENE, V18, P807, DOI 10.1038/sj.onc.1202369	31	44	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40899	40904		10.1074/jbc.M308012200	http://dx.doi.org/10.1074/jbc.M308012200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12925527	hybrid			2022-12-25	WOS:000185847200060
J	Song, OK; Wang, XR; Waterborg, JH; Sternglanz, R				Song, OK; Wang, XR; Waterborg, JH; Sternglanz, R			An N-alpha-acetyltransferase responsible for acetylation of the N-terminal residues of histones H4 and H2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; EUKARYOTIC PROTEINS; YEAST; IDENTIFICATION; REPRESSION; SEQUENCE; GENE	A yeast gene has been identified that encodes a novel, evolutionarily conserved N-alpha-acetyltransferase responsible for acetylation of the N-terminal residues of histones H4 and H2A. The gene has been named NAT4. Recombinant Nat4 protein acetylated a peptide corresponding to the N-terminal tail of H4, but not an H3 peptide nor the peptide adrenocorticotropin. H4 and H2A are N-terminally acetylated in all species from yeast to mammals and hence blocked from sequencing by Edman degradation. In contrast, H4 and H2A purified from a nat4 mutant were unacetylated and could be sequenced. Analysis of yeast histones by acid-urea gel electrophoresis showed that all the H4 and H2A from the mutant migrated more rapidly than the same histones from a wild type strain, consistent with the histones from the mutant having one extra positive charge due to one less acetylated amino group. A comparison of yeast proteins from wild type and a nat4 mutant by two-dimensional gel electrophoresis showed no evidence that other yeast proteins are substrates of this acetyltransferase. Thus, Nat4 may be dedicated specifically to the N-terminal acetylation of histones H4 and H2A. Surprisingly, nat4 mutants grow at a normal rate and have no readily observable phenotypes.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; Univ Missouri, Sch Biol Sci, Kansas City, MO 64110 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Missouri System; University of Missouri Kansas City	Sternglanz, R (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.		Waterborg, Jakob H./J-5479-2013	Waterborg, Jakob H./0000-0002-2881-4634; wang, isabel/0000-0003-3264-7071	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028220, R56GM028220] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28220] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRANDT WF, 1980, EUR J BIOCHEM, V110, P67, DOI 10.1111/j.1432-1033.1980.tb04841.x; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; DELANGE RJ, 1969, J BIOL CHEM, V244, P319; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; FASSLER JS, 1988, GENETICS, V118, P203; Krebs JE, 1999, GENE DEV, V13, P1412, DOI 10.1101/gad.13.11.1412; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; PARK EC, 1992, EMBO J, V11, P2087, DOI 10.1002/j.1460-2075.1992.tb05267.x; Polevoda B, 2000, J BIOL CHEM, V275, P36479, DOI 10.1074/jbc.R000023200; Polevoda B, 2003, J MOL BIOL, V325, P595, DOI 10.1016/S0022-2836(02)01269-X; Polevoda B, 1999, EMBO J, V18, P6155, DOI 10.1093/emboj/18.21.6155; Pollard KJ, 1997, MOL CELL BIOL, V17, P6212, DOI 10.1128/MCB.17.11.6212; TAKAKURA H, 1992, J BIOL CHEM, V267, P5442; TERCERO JC, 1992, J BIOL CHEM, V267, P20277; Waterborg JH, 2000, J BIOL CHEM, V275, P13007, DOI 10.1074/jbc.275.17.13007; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3	19	91	96	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38109	38112		10.1074/jbc.C300355200	http://dx.doi.org/10.1074/jbc.C300355200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12915400	hybrid			2022-12-25	WOS:000185575100002
J	Chen, LH; Chen, JD				Chen, LH; Chen, JD			MDM2-ARF complex regulates p53 sumoylation	ONCOGENE			English	Article						p53; mdm2; ARF; sumoylation	NUCLEOLAR-LOCALIZATION; NUCLEAR EXPORT; SUMO-1; MDM-2; UBIQUITINATION; ACTIVATION; P14(ARF); PIAS	The p53 tumor suppressor is regulated by MDM2-mediated ubiquitination and degradation. Ubiquitination of p53 is regulated by ARF, which binds to MDM2 and inhibits its E3 ligase function. P53 is also subjected to modification by conjugation of SUMO-1. We found that a p53 mutant deficient for MDM2 binding (p53(14Q19S)) is poorly sumoylated in vivo compared to wild-type p53. Overexpression of MDM2 increases the level of p53 sumoylation, which is further stimulated by expression of ARE Stimulation of p53 sumoylation requires a highly conserved region (102-116) encoded by exon 2 of ARF and correlates with the ability of ARF to target p53 to the nucleolus. An MDM2 deletion mutant (MDM2(Delta222-437)) with activated cryptic nucleolar localization signal also targets p53 to the nucleolus and efficiently promotes p53 sumoylation in the absence of ARE Direct targeting of p53 to the nucleolus enhances its sumoylation in an MDM2- and ARF-dependent fashion. These results show that p53 sumoylation is regulated by MDM2- and ARF-mediated nucleolar targeting.	H Lee Moffit Comprehens Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA		Chen, JD (corresponding author), H Lee Moffit Comprehens Canc Ctr & Res Inst, Mol Oncol Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.	jchen@moffitt.usf.edu						CHEN JD, 1995, MOL MED, V1, P142, DOI 10.1007/BF03401562; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Gong LM, 2000, J BIOL CHEM, V275, P3355, DOI 10.1074/jbc.275.5.3355; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Hochstrasser M, 2001, CELL, V107, P5, DOI 10.1016/S0092-8674(01)00519-0; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kobet E, 2000, P NATL ACAD SCI USA, V97, P12547, DOI 10.1073/pnas.97.23.12547; Kwek SSS, 2001, ONCOGENE, V20, P2587, DOI 10.1038/sj.onc.1204362; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lohrum MAE, 2000, NAT CELL BIOL, V2, P179, DOI 10.1038/35004057; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Melchior F, 2002, CELL CYCLE, V1, P243, DOI 10.4161/cc.1.4.131; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; Miyauchi Y, 2002, J BIOL CHEM, V277, P50131, DOI 10.1074/jbc.M208319200; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Prives C, 1999, J PATHOL, V187, P112; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Xirodimas DP, 2002, FEBS LETT, V528, P207, DOI 10.1016/S0014-5793(02)03310-0; Zhang YP, 2001, CELL GROWTH DIFFER, V12, P175; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; ZIRODIMAS D, 2002, ONCOGENE, V20, P4972	31	104	109	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2003	22	34					5348	5357		10.1038/sj.onc.1206851	http://dx.doi.org/10.1038/sj.onc.1206851			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JB	12917636				2022-12-25	WOS:000184734900014
J	Schavinsky-Khrapunsky, Y; Huleihel, M; Aboud, M; Torgeman, A				Schavinsky-Khrapunsky, Y; Huleihel, M; Aboud, M; Torgeman, A			Role of protein kinase C and the Sp1-p53 complex in activation of p21(WAF-1) expression by 12-O-tetradecanoylphorbol-13-acetate in human T cells	ONCOGENE			English	Article						p21(WAF-1); TPA; PKC; Sp1-p53 complex	LONG TERMINAL REPEAT; VIRUS TYPE-I; TRANSCRIPTION FACTOR SP1; CYCLIN-DEPENDENT KINASES; GROWTH-FACTOR-BETA; INHIBITOR P21(WAF1/CIP1); CARCINOMA CELLS; DNA-REPLICATION; FAMILY-MEMBERS; CDK INHIBITORS	Previous reports have shown that, in certain cell types, p21(WAF-1), which plays a central role in cell proliferation, can be activated by HTLV-I Tax protein and by TPA. Tax and TPA are also known to stimulate HTLV-I gene expression. Since cell proliferation has a major impact on HTLV-I replication, it was of interest to investigate their effect on p21(WAF-1) in human T cells, which are the main target of HTLV-I in human infection. This study demonstrates that p21(WAF-1) is activated in such cells by both factors, each acting through a different mechanism that does not influence the other. The effect of TPA is shown to require PKC activity. Notably, however, examination of different PKC isoforms revealed that PKC-alpha: and PKC-epsilon stimulated p21(WAF-1) expression, whereas PKC-eta was rather inhibitory and PKC-beta1 and beta2 were ineffective. All these isoforms were found to be activated by TPA in the employed T cells, but this apparent paradox was resolved by the observation that when coexpressed together in these cells, the stimulatory PKCs override the inhibitory isoform. Further experiments demonstrated that the PKC-induced p21(WAF-1) activation was mediated by binding of Sp1-p53 complex to the second most upstream of the six Sp1 recognition sites present in its promoter and that this effect did not require the cooperation of an p53-binding site.	Ben Gurion Univ Negev, Fac Hlth Sci, Dept Microbiol & Immunol, Canc Res Ctr, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Inst Appl Biosci, IL-84105 Beer Sheva, Israel	Ben Gurion University; Ben Gurion University	Aboud, M (corresponding author), Ben Gurion Univ Negev, Fac Hlth Sci, Dept Microbiol & Immunol, Canc Res Ctr, IL-84105 Beer Sheva, Israel.	aboud@bgumail.bgu.ac.il	HULEIHEL, MAHMOUD/F-1837-2012					Bellido T, 1998, J BIOL CHEM, V273, P21137, DOI 10.1074/jbc.273.33.21137; Biggs JR, 1999, J BIOL CHEM, V274, P36987, DOI 10.1074/jbc.274.52.36987; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Billon N, 1996, ONCOGENE, V13, P2047; Blatt NB, 2001, BIOORGAN MED CHEM, V9, P1371, DOI 10.1016/S0968-0896(01)00041-4; Boulaire J, 2000, PATHOL BIOL, V48, P190; Cereseto A, 1996, BLOOD, V88, P1551, DOI 10.1182/blood.V88.5.1551.bloodjournal8851551; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; De La Fuente C, 2000, J VIROL, V74, P7270, DOI 10.1128/JVI.74.16.7270-7283.2000; Decker SJ, 1995, J BIOL CHEM, V270, P30841, DOI 10.1074/jbc.270.52.30841; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; ELDAR H, 1990, J BIOL CHEM, V265, P13290; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Gervais JLM, 1998, J BIOL CHEM, V273, P19207, DOI 10.1074/jbc.273.30.19207; GITLIN SD, 1991, J VIROL, V65, P2612, DOI 10.1128/JVI.65.5.2612-2621.1991; Gorospe M, 1999, GENE EXPRESSION, V7, P377; Gorospe M, 1998, MOL CELL BIOL, V18, P1400, DOI 10.1128/MCB.18.3.1400; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; GUALBERTO A, 1995, J BIOL CHEM, V270, P19680, DOI 10.1074/jbc.270.34.19680; GUALBERTO A, 1995, MOL CELL BIOL, V15, P3450; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Hingorani R, 2000, J IMMUNOL, V164, P4032, DOI 10.4049/jimmunol.164.8.4032; Hobeika AC, 1997, ONCOGENE, V14, P1165, DOI 10.1038/sj.onc.1200939; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; Isonishi S, 2000, BRIT J CANCER, V82, P34, DOI 10.1054/bjoc.1999.0873; Jin YH, 2000, J BIOL CHEM, V275, P30256, DOI 10.1074/jbc.M001902200; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; Koutsodontis G, 2001, J BIOL CHEM, V276, P29116, DOI 10.1074/jbc.M104130200; Koutsodontis G, 2002, BIOCHEMISTRY-US, V41, P12771, DOI 10.1021/bi026141q; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Li JM, 1998, NUCLEIC ACIDS RES, V26, P2449, DOI 10.1093/nar/26.10.2449; Livneh E, 1996, ONCOGENE, V12, P1545; Lu S, 2000, MOL ENDOCRINOL, V14, P753, DOI 10.1210/me.14.5.753; Lu ZM, 1998, MOL CELL BIOL, V18, P839, DOI 10.1128/MCB.18.2.839; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; MorVaknin N, 1997, VIROLOGY, V232, P337, DOI 10.1006/viro.1997.8566; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; NAMBA H, 1995, CANCER RES, V55, P2075; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Owen GI, 1998, J BIOL CHEM, V273, P10696, DOI 10.1074/jbc.273.17.10696; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Revazova T, 1995, CELL MOL BIOL RES, V41, P377; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; Torgeman A, 2001, VIROLOGY, V281, P10, DOI 10.1006/viro.2000.0779; Torgeman A, 2001, EXP CELL RES, V271, P169, DOI 10.1006/excr.2001.5363; Torgeman A, 1999, VIROLOGY, V254, P279, DOI 10.1006/viro.1998.9556; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R; YANG S, 2003, TRENDS GENET, V19, P9; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zezula J, 1997, J BIOL CHEM, V272, P29967, DOI 10.1074/jbc.272.47.29967; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; Zhang YK, 1999, ONCOGENE, V18, P1131, DOI 10.1038/sj.onc.1202426	58	20	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2003	22	34					5315	5324		10.1038/sj.onc.1206782	http://dx.doi.org/10.1038/sj.onc.1206782			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JB	12917633	Bronze			2022-12-25	WOS:000184734900011
J	Cunchillos, C; Lecointre, G				Cunchillos, C; Lecointre, G			Evolution of amino acid metabolism inferred through cladistic analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLE; PARSIMONY; ORIGIN	Because free amino acids were most probably available in primitive abiotic environments, their metabolism is likely to have provided some of the very first metabolic pathways of life. What were the first enzymatic reactions to emerge? A cladistic analysis of metabolic pathways of the 16 aliphatic amino acids and 2 portions of the Krebs cycle was performed using four criteria of homology. The analysis is not based on sequence comparisons but, rather, on coding similarities in enzyme properties. The properties used are shared specific enzymatic activity, shared enzymatic function without substrate specificity, shared coenzymes, and shared functional family. The tree shows that the earliest pathways to emerge are not portions of the Krebs cycle but metabolisms of aspartate, asparagine, glutamate, and glutamine. The views of Horowitz (Horowitz, N. H. (1945) Proc. Natl. Acad. Sci. U. S. A. 31, 153-157) and Cordon (Cordon, F. (1990) Tratado Evolucionista de Biologia, Aguilar, Madrid, Spain), according to which the upstream reactions in the catabolic pathways and the downstream reactions in the anabolic pathways are the earliest in evolution, are globally corroborated; however, with some exceptions. These are due to later opportunistic connections of pathways ( actually already suggested by these authors). Earliest enzymatic functions are mostly catabolic; they were deaminations, transaminations, and decarboxylations. From the consensus tree we extracted four time spans for amino acid metabolism development. For some amino acids catabolism and biosynthesis occurred at the same time (Asp, Glu, Lys, Leu, Ala, Val, Ile, Pro, Arg). For others ultimate reactions that use amino acids as a substrate or as a product are distinct in time, with catabolism preceding anabolism for Asn, Gln, and Cys and anabolism preceding catabolism for Ser, Met, and Thr. Cladistic analysis of the structure of biochemical pathways makes hypotheses in biochemical evolution explicit and parsimonious.	Inst Charles Darwin Int, F-93230 Romainville, France; Museum Natl Hist Nat, CNRS, UMR 7138, Dept Systemat,Serv Systemat Mol, F-75231 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Museum National d'Histoire Naturelle (MNHN); UDICE-French Research Universities; Sorbonne Universite	Lecointre, G (corresponding author), Inst Charles Darwin Int, BP 70, F-93230 Romainville, France.	lecointr@mnhn.fr						[Anonymous], 1983, ADV CLADISTICS; CAVALIERSMITH T, 1987, COLD SPRING HARB SYM, V52, P805, DOI 10.1101/SQB.1987.052.01.089; Copley SD, 2000, TRENDS BIOCHEM SCI, V25, P261, DOI 10.1016/S0968-0004(00)01562-0; Cordon F., 1990, TRATADO EVOLUCIONIST; Cunchillos C, 2002, CR BIOL, V325, P119, DOI 10.1016/S1631-0691(02)01411-7; CUNCHILLOS C, 1997, DARWIN, P425; Cunchillos Chomin, 2000, Biosystema, V18, P87; DARLU P, 1993, RECONSTRUCTION PHYLO; DEPINNA MCC, 1991, CLADISTICS, V7, P367; FOREY PL, 1992, CLADISTICS PRACTICAL; Forst CV, 2001, J MOL EVOL, V52, P471, DOI 10.1007/s002390010178; FOTHERGILLGILMORE LA, 1993, PROG BIOPHYS MOL BIO, V59, P105, DOI 10.1016/0079-6107(93)90001-Z; GEST H, 1981, FEMS MICROBIOL LETT, V12, P209; GEST H, 1987, BIOCHEM SOC SYMP, P3; GOLOBOFF P, 1998, NONA COMPUTER PROGRA; Hennig W., 1950, GRUNDZUGE THEORIE PH; HENNIG W, 1999, PHYLOGENETIC SYSTEMA; HOLDEN JT, 1968, J THEOR BIOL, V21, P97, DOI 10.1016/0022-5193(68)90062-3; HOROWITZ NH, 1945, P NATL ACAD SCI USA, V31, P153, DOI 10.1073/pnas.31.6.153; JALLON JM, 1983, EVOLUTION PROTEINES, P92; JENSEN RA, 1976, ANNU REV MICROBIOL, V30, P409, DOI 10.1146/annurev.mi.30.100176.002205; Kluge AG, 2001, CLADISTICS, V17, P199, DOI 10.1111/j.1096-0031.2001.tb00117.x; KNOWLES JR, 1991, NATURE, V350, P121, DOI 10.1038/350121a0; Martin W, 1998, NATURE, V392, P37, DOI 10.1038/32096; MelendezHevia E, 1996, J MOL EVOL, V43, P293, DOI 10.1007/PL00006089; Michal G, 1999, BIOCH PATHWAYS; MILLER SL, 1953, SCIENCE, V117, P528, DOI 10.1126/science.117.3046.528; Nixon KC, 1999, CLADISTICS, V15, P407, DOI 10.1111/j.1096-0031.1999.tb00277.x; Nixon KC, 1999, WINCLADA BETA VERSIO; O'Brien PJ, 1999, CHEM BIOL, V6, pR91, DOI 10.1016/S1074-5521(99)80033-7; PETSKO GA, 1993, TRENDS BIOCHEM SCI, V18, P372, DOI 10.1016/0968-0004(93)90091-Z; PIERARD A, 1983, EVOLUTION PROTEINES, P53; SANDERSON MJ, 1996, HOMOPLASY; SCHOFFENIELS E, 1984, BIOCH COMP; SCHOFFENIELS E, 1981, CAHIERS BIOCH PARIS; Swofford D.L., 1999, PAUP PHYLOGENETIC AN; TAKIGUCHI M, 1989, BIOESSAYS, V10, P163, DOI 10.1002/bies.950100506; ZUCKERKANDL E, 1965, J THEOR BIOL, V8, P357, DOI 10.1016/0022-5193(65)90083-4	38	13	13	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					47960	47970		10.1074/jbc.M213028200	http://dx.doi.org/10.1074/jbc.M213028200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12949083	hybrid			2022-12-25	WOS:000186731400074
J	Jeong, HS; Lee, MH; Lee, KH; Park, SJ; Choi, SH				Jeong, HS; Lee, MH; Lee, KH; Park, SJ; Choi, SH			SmcR and cyclic AMP receptor protein coactivate Vibrio vulnificus vvpE encoding elastase through the RpoS-dependent promoter in a synergistic manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; GENE-EXPRESSION; HARVEYI LUXR; VIRULENCE DETERMINANTS; ELASTOLYTIC PROTEASE; SUICIDE VECTOR; TRANSCRIPTION; HOMOLOG; METALLOPROTEASE; PATHOGENESIS	The putative virulence factors of Vibrio vulnificus include an elastase, the gene product of vvpE. We previously demonstrated that vvpE expression is differentially directed by two different promoters in a growth phase-dependent manner. The activity of the stationary-phase promoter (promoter S (PS)) is dependent on RpoS and is also under the positive control of cyclic AMP receptor protein (CRP). In this study, primer extension analyses revealed that SmcR, the Vibrio harveyi LuxR homolog, is also involved in the regulation of vvpE transcription by activating PS. Although the influence of CRP on PS is mediated by SmcR, the level of PS activity observed when CRP and SmcR function together was found to be greater than the sum of the PS activities achieved by each activator alone. Western blot analyses demonstrated that the cellular levels of RpoS, CRP, and SmcR were not significantly affected by one other, indicating that CRP and SmcR function cooperatively to activate PS rather than sequentially in a regulatory cascade. The binding sites for CRP and SmcR were mapped based on a deletion analysis of the vvpE promoter region and confirmed by in vitro DNase I protection assays. The binding sites for CRP and SmcR were juxtapositioned and centered 220 and 198 bp upstream of the transcription start site of PS, respectively. Accordingly, these results reveal that CRP and SmcR function synergistically to coactivate the expression of vvpE by the RpoS-dependent promoter (PS) and that the activators exert their effect by directly binding to the promoter in the stationary phase.	Chonnam Natl Univ, Biotechnol Res Inst, Dept Food Sci & Technol, Kwangju 500757, South Korea; Chonnam Natl Univ, Biotechnol Res Inst, Dept Mol Biotechnol, Kwangju 500757, South Korea; Hankuk Univ Foreign Studies, Dept Environm Sci, Yongin 449791, Kyunggi Do, South Korea; Yonsei Univ, Coll Med, Dept Parasitol, Seoul 133791, South Korea	Chonnam National University; Chonnam National University; Hankuk University Foreign Studies; Yonsei University; Yonsei University Health System	Choi, SH (corresponding author), Chonnam Natl Univ, Biotechnol Res Inst, Dept Food Sci & Technol, Kwangju 500757, South Korea.			Park, Soon-Jung/0000-0002-0423-1944; Choi, Sang Ho/0000-0003-3865-1039				Adhya Sankar, 1996, P181; Busby S, 1999, J MOL BIOL, V293, P199, DOI 10.1006/jmbi.1999.3161; Busby Stephen, 1996, P255; Cheng JC, 1996, GENE, V183, P255, DOI 10.1016/S0378-1119(96)00488-X; Choi HK, 2002, J BIOL CHEM, V277, P47292, DOI 10.1074/jbc.M206893200; Choi SH, 2000, APPL ENVIRON MICROB, V66, P3911, DOI 10.1128/AEM.66.9.3911-3916.2000; Croxatto A, 2002, J BACTERIOL, V184, P1617, DOI 10.1128/JB.184.6.1617-1629.2002; DONNENBERG MS, 1991, INFECT IMMUN, V59, P4310, DOI 10.1128/IAI.59.12.4310-4317.1991; Estrem ST, 1998, P NATL ACAD SCI USA, V95, P9761, DOI 10.1073/pnas.95.17.9761; GOOSEN N, 1995, MOL MICROBIOL, V16, P1, DOI 10.1111/j.1365-2958.1995.tb02386.x; Jeong HS, 2001, J BIOL CHEM, V276, P13875, DOI 10.1074/jbc.M010567200; Jeong KC, 2000, INFECT IMMUN, V68, P5096, DOI 10.1128/IAI.68.9.5096-5106.2000; KEEN NT, 1988, GENE, V70, P191, DOI 10.1016/0378-1119(88)90117-5; Kim SY, 1999, J BIOL CHEM, V274, P25398, DOI 10.1074/jbc.274.36.25398; KOTHARY MH, 1987, J GEN MICROBIOL, V133, P1783; Kovacikova G, 2002, MOL MICROBIOL, V46, P1135, DOI 10.1046/j.1365-2958.2002.03229.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Linkous DA, 1999, FEMS MICROBIOL LETT, V174, P207, DOI 10.1111/j.1574-6968.1999.tb13570.x; McCarter LL, 1998, J BACTERIOL, V180, P3166, DOI 10.1128/JB.180.12.3166-3173.1998; McDougald D, 2001, J BACTERIOL, V183, P758, DOI 10.1128/JB.183.2.758-762.2001; McDougald D, 2000, GENE, V248, P213, DOI 10.1016/S0378-1119(00)00117-7; McLeod SM, 2000, J BACTERIOL, V182, P4180, DOI 10.1128/JB.182.15.4180-4187.2000; MEKALANOS JJ, 1992, J BACTERIOL, V174, P1; MILLER JF, 1989, SCIENCE, V243, P916, DOI 10.1126/science.2537530; MILLER VL, 1988, J BACTERIOL, V170, P2575, DOI 10.1128/JB.170.6.2575-2583.1988; Miyoshi S, 1997, J BACTERIOL, V179, P7606, DOI 10.1128/jb.179.23.7606-7609.1997; Miyoshi S, 2000, MICROBES INFECT, V2, P91, DOI 10.1016/S1286-4579(00)00280-X; Nagai S, 1998, VET MICROBIOL, V60, P227, DOI 10.1016/S0378-1135(98)00144-8; OBYRNE CP, 1994, J BACTERIOL, V176, P905, DOI 10.1128/jb.176.3.905-912.1994; OKA A, 1981, J MOL BIOL, V147, P217, DOI 10.1016/0022-2836(81)90438-1; OLIVER JD, 1986, DIAGN MICR INFEC DIS, V5, P99, DOI 10.1016/0732-8893(86)90112-4; Rhodius VA, 1998, CURR OPIN MICROBIOL, V1, P152, DOI 10.1016/S1369-5274(98)80005-2; SAMBROOK J, 2000, MOL CLONING LAB MANU; SCOTT S, 1995, MOL MICROBIOL, V18, P521, DOI 10.1111/j.1365-2958.1995.mmi_18030521.x; Shao CP, 2001, J BACTERIOL, V183, P1369, DOI 10.1128/JB.183.4.1369-1375.2001; Skorupski K, 1997, P NATL ACAD SCI USA, V94, P265, DOI 10.1073/pnas.94.1.265; Strom MS, 2000, MICROBES INFECT, V2, P177, DOI 10.1016/S1286-4579(00)00270-7; SWARTZMAN E, 1993, J BIOL CHEM, V268, P16706; Vicente M, 1999, MOL MICROBIOL, V33, P8, DOI 10.1046/j.1365-2958.1999.01445.x; Weyand NJ, 2001, MOL MICROBIOL, V39, P1504, DOI 10.1046/j.1365-2958.2001.02338.x; Williams P, 2000, PHILOS T R SOC B, V355, P667, DOI 10.1098/rstb.2000.0607	41	82	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45072	45081		10.1074/jbc.M308184200	http://dx.doi.org/10.1074/jbc.M308184200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12947096	hybrid			2022-12-25	WOS:000186452300006
J	Wagner, LE; Li, WH; Yule, DI				Wagner, LE; Li, WH; Yule, DI			Phosphorylation of type-1 inositol 1,4,5-trisphosphate receptors by cyclic nucleotide-dependent protein kinases - A mutational analysis of the functionally important sites in the S2(+) and S2(-) splice variants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECONSTITUTED LIPID VESICLES; PANCREATIC ACINAR-CELLS; VASCULAR SMOOTH-MUSCLE; LIGAND-BINDING SITE; INTACT RAT AORTA; TRISPHOSPHATE RECEPTOR; CA2+ RELEASE; MOLECULAR DETERMINANTS; SIGNALING COMPLEX; INSP3 RECEPTOR	Inositol 1,4,5-trisphosphate receptors (InsP(3)R) are the major route of intracellular calcium release in eukaryotic cells and as such are pivotal for stimulation of Ca2+-dependent effectors important for numerous physiological processes. Modulation of this release has important consequences for defining the particular spatio-temporal characteristics of Ca2+ signals. In this study, regulation of Ca2+ release by phosphorylation of type-1 InsP(3)R (InsP(3)R-1) by cAMP (PKA)- and cGMP (PKG)-dependent protein kinases was investigated in the two major splice variants of InsP(3)R-1. InsP(3)R-1 was expressed in DT-40 cells devoid of endogenous InsP3R. In cells expressing the neuronal, S2+ splice variant of the InsP(3)R-1, Ca2+ release was markedly enhanced when either PKA or PKG was activated. The sites of phosphorylation were investigated by mutation of serine residues present in two canonical phosphorylation sites present in the protein. Potentiated Ca2+ release was abolished when serine 1755 was mutated to alanine (S1755A) but was unaffected by a similar mutation of serine 1589 (S1589A). These data demonstrate that Ser-1755 is the functionally important residue for phosphoregulation by PKA and PKG in the neuronal variant of the InsP(3)R-1. Activation of PKA also resulted in potentiated Ca2+ release in cells expressing the non-neuronal, S2+ splice variant of the InsP(3)R-1. However, the PKA-induced potentiation was still evident in S1589A or S1755A InsP(3)R-1 mutants. The effect was abolished in the double (S1589A/S1755A) mutant, indicating both sites are phosphorylated and contribute to the functional effect. Activation of PKG had no effect on Ca2+ release in cells expressing the S2- variant of InsP(3)R-1. Collectively, these data indicate that phosphoregulation of InsP(3)R-1 has dramatic effects on Ca2+ release and defines the molecular sites phosphorylated in the major variants expressed in neuronal and peripheral tissues.	Univ Rochester, Dept Physiol & Pharmacol, Rochester, NY 14642 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	University of Rochester; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Yule, DI (corresponding author), Univ Rochester, Dept Physiol & Pharmacol, 601 Elmwood Ave, Rochester, NY 14642 USA.	David_yule@urmc.rochester.edu			NIDCR NIH HHS [R01-DE14756, P01-DE13539] Funding Source: Medline; NIDDK NIH HHS [R01-DK54568] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE014756] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE013539] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054568] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ammendola A, 2001, J BIOL CHEM, V276, P24153, DOI 10.1074/jbc.M101530200; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; Boehning D, 2001, J BIOL CHEM, V276, P13509, DOI 10.1074/jbc.C100094200; Bootman MD, 2001, SEMIN CELL DEV BIOL, V12, P3, DOI 10.1006/scdb.2000.0211; Bruce JIE, 2002, J BIOL CHEM, V277, P1340, DOI 10.1074/jbc.M106609200; Cavallini L, 1996, J BIOL CHEM, V271, P5545, DOI 10.1074/jbc.271.10.5545; COLBRAN JL, 1992, J BIOL CHEM, V267, P9589; DANOFF SK, 1991, P NATL ACAD SCI USA, V88, P2951, DOI 10.1073/pnas.88.7.2951; den Dekker E, 2002, ARTERIOSCL THROM VAS, V22, P179, DOI 10.1161/hq0102.101515; deSouza N, 2002, J BIOL CHEM, V277, P39397, DOI 10.1074/jbc.M207059200; EHRLICH BE, 1988, NATURE, V336, P583, DOI 10.1038/336583a0; FERRIS CD, 1991, BIOCHEM BIOPH RES CO, V175, P192, DOI 10.1016/S0006-291X(05)81219-7; FERRIS CD, 1991, P NATL ACAD SCI USA, V88, P2232, DOI 10.1073/pnas.88.6.2232; FURUICHI T, 1989, NUCLEIC ACIDS RES, V17, P5385, DOI 10.1093/nar/17.13.5385; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; Giovannucci DR, 2000, J BIOL CHEM, V275, P33704, DOI 10.1074/jbc.M004278200; Haug LS, 1999, J BIOL CHEM, V274, P7467, DOI 10.1074/jbc.274.11.7467; Houslay MD, 1997, TRENDS BIOCHEM SCI, V22, P217, DOI 10.1016/S0968-0004(97)01050-5; IINO M, 1991, J GEN PHYSIOL, V98, P681, DOI 10.1085/jgp.98.4.681; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; Jayaraman T, 1996, SCIENCE, V272, P1492, DOI 10.1126/science.272.5267.1492; JOSEPH SK, 1993, J BIOL CHEM, V268, P23059; KOGA T, 1994, J BIOL CHEM, V269, P11640; KOMALAVILAS P, 1994, J BIOL CHEM, V269, P8701; Komalavilas P, 1996, J BIOL CHEM, V271, P21933, DOI 10.1074/jbc.271.36.21933; Kubista H, 1998, BBA-MOL CELL RES, V1448, P299, DOI 10.1016/S0167-4889(98)00132-3; LeBeau AP, 1999, J GEN PHYSIOL, V113, P851, DOI 10.1085/jgp.113.6.851; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; MARANTO AR, 1994, J BIOL CHEM, V269, P1222; MICHIKAWA T, 1994, J BIOL CHEM, V269, P9184; MIGNERY GA, 1992, J BIOL CHEM, V267, P7450; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; Miyakawa T, 1999, EMBO J, V18, P1303, DOI 10.1093/emboj/18.5.1303; NAKADE S, 1994, J BIOL CHEM, V269, P6735; NAKAGAWA T, 1991, P NATL ACAD SCI USA, V88, P6244, DOI 10.1073/pnas.88.14.6244; Patel S, 1999, CELL CALCIUM, V25, P247, DOI 10.1054/ceca.1999.0021; Pieper AA, 2001, NEUROSCIENCE, V102, P433, DOI 10.1016/S0306-4522(00)00470-X; RAPOPORT RM, 1982, P NATL ACAD SCI-BIOL, V79, P6470, DOI 10.1073/pnas.79.21.6470; Schlossmann J, 2000, NATURE, V404, P197, DOI 10.1038/35004606; Straub SV, 2002, J BIOL CHEM, V277, P31949, DOI 10.1074/jbc.M204318200; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; Sugawara H, 1997, EMBO J, V16, P3078, DOI 10.1093/emboj/16.11.3078; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; Tang TS, 2003, J NEUROSCI, V23, P403, DOI 10.1523/JNEUROSCI.23-02-00403.2003; Tertyshnikova S, 1998, P NATL ACAD SCI USA, V95, P1613, DOI 10.1073/pnas.95.4.1613; Tertyshnikova X, 1998, J PHYSIOL-LONDON, V512, P89, DOI 10.1111/j.1469-7793.1998.089bf.x; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678; Wojcikiewicz RJH, 1998, J BIOL CHEM, V273, P5670, DOI 10.1074/jbc.273.10.5670; YAMADA M, 1995, BIOCHEM J, V308, P83, DOI 10.1042/bj3080083; Yoshikawa F, 1996, J BIOL CHEM, V271, P18277, DOI 10.1074/jbc.271.30.18277	52	83	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45811	45817		10.1074/jbc.M306270200	http://dx.doi.org/10.1074/jbc.M306270200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12939273	hybrid			2022-12-25	WOS:000186452300093
J	Adams, DJ; Beveridge, DJ; van der Weyden, L; Mangs, H; Leedman, PJ; Morris, BJ				Adams, DJ; Beveridge, DJ; van der Weyden, L; Mangs, H; Leedman, PJ; Morris, BJ			HADHB, HuR, and CP1 bind to the distal 3 '-untranslated region of human renin mRNA and differentially modulate renin expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AU-RICH ELEMENT; BETA-OXIDATION ENZYMES; 3' UNTRANSLATED REGION; PROTEIN-BINDING; GENE-EXPRESSION; IN-VITRO; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; POLY(C)-BINDING PROTEIN; GLUCOSE-TRANSPORTER; RESPONSIVE ELEMENT	Production of renin is critically dependent on modulation of REN mRNA stability. Here we sought to elucidate the molecular mechanisms involved. Transfections of renin-expressing Calu-6 cells with reporter constructs showed that a cis-acting 34-nucleotide AU-rich "renin stability regulatory element" in the REN 3'-untranslated region (3'-UTR) contributes to basal REN mRNA instability. Yeast three-hybrid screening with the REN 3/-UTR as bait isolated HADHB (hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase ( trifunctional protein) beta-subunit) as a novel REN mRNA-binding protein. Recombinant HADHB bound specifically to the 3'-UTR of REN mRNA, as did the known mRNA stabilizers HuR and CP1 ( poly( C)binding protein-1). This required the renin stability regulatory element. Forskolin, which augments REN mRNA stability in Calu-6 cells, increased binding of several proteins, including HuR and CP1, to the REN 3'-UTR, whereas 4-bromocrotonic acid, a specific thiolase inhibitor, decreased binding and elevated renin protein levels. Upon decreasing HADHB mRNA with RNA interference, renin protein and mRNA stability increased, whereas RNA interference against HuR caused these to decrease. Immunoprecipitation and reverse transcription-PCR of Calu-6 extracts confirmed that HADHB, HuR, and CP1 each associate with REN mRNA in vivo. Intracellular imaging revealed distinct localization of HADHB to mitochondria, HuR to nuclei, and CP1 throughout the cell. Immunohistochemistry demonstrated enrichment of HADHB in renin-producing renal juxtaglomerular cells. In conclusion, HADHB, HuR, and CP1 are novel REN mRNA-binding proteins that target a cis-element in the 3'-UTR of REN mRNA and regulate renin production. cAMP- mediated increased REN mRNA stability may involve stimulation of HuR and CP1, whereas REN mRNA decay may involve thiolase-dependent pathways.	Univ Sydney, Sch Med Sci, Basic & Clin Genom Lab, Sydney, NSW 2006, Australia; Univ Sydney, Inst Biomed Res, Sydney, NSW 2006, Australia; Univ Western Australia, Royal Perth Hosp, Western Australian Inst Med Res, Ctr Med Res,Sch Med & Pharmacol,Lab Canc Med, Perth, WA 6000, Australia	University of Sydney; University of Sydney; Royal Perth Hospital; University of Western Australia	Morris, BJ (corresponding author), Univ Sydney, Sch Med Sci, Basic & Clin Genom Lab, Bldg F13, Sydney, NSW 2006, Australia.		Leedman, Peter J/O-4044-2014; van der Weyden, Louise/AAV-5711-2021	van der Weyden, Louise/0000-0002-0645-1879; Adams, David/0000-0001-9490-0306				Adams DJ, 2001, J CELL BIOL, V154, P25, DOI 10.1083/jcb.200010059; Antic D, 1997, AM J HUM GENET, V61, P273, DOI 10.1086/514866; AOYAMA T, 1995, J CLIN INVEST, V95, P2465, DOI 10.1172/JCI117947; Balmer LA, 2001, MOL CELL BIOL, V21, P2070, DOI 10.1128/MCB.21.6.2070-2084.2001; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; Brennan LE, 1999, GENE, V228, P85, DOI 10.1016/S0378-1119(99)00003-7; Chen CYA, 2002, MOL CELL BIOL, V22, P7268, DOI 10.1128/MCB.22.20.7268-7278.2002; CHEN M, 1993, HYPERTENSION, V21, P36, DOI 10.1161/01.HYP.21.1.36; CHRZANOWSKALIGHTOWLERS ZMA, 1994, J BIOL CHEM, V269, P27322; Clausmeyer S, 1999, CIRC RES, V84, P337, DOI 10.1161/01.RES.84.3.337; Collier B, 1998, J BIOL CHEM, V273, P22648, DOI 10.1074/jbc.273.35.22648; CORNELIUS P, 1991, J CELL PHYSIOL, V146, P298, DOI 10.1002/jcp.1041460215; Czyzyk-Krzeska MF, 1999, BLOOD, V93, P2111, DOI 10.1182/blood.V93.6.2111.406k24_2111_2120; CzyzykKrzeska MF, 1996, J BIOL CHEM, V271, P3293, DOI 10.1074/jbc.271.6.3293; DONG Y, 1989, J BIOL CHEM, V264, P13679; Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Ford LP, 1999, GENE DEV, V13, P188, DOI 10.1101/gad.13.2.188; Gallouzi IE, 2000, P NATL ACAD SCI USA, V97, P3073, DOI 10.1073/pnas.97.7.3073; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Giles KM, 2003, J BIOL CHEM, V278, P2937, DOI 10.1074/jbc.M208439200; HAMILTON BJ, 1993, J BIOL CHEM, V268, P8881; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; Hollams EM, 2002, NEUROCHEM RES, V27, P957, DOI 10.1023/A:1020992418511; Huang S, 1996, J CELL BIOCHEM, V62, P191, DOI 10.1002/(SICI)1097-4644(199608)62:2<191::AID-JCB7>3.0.CO;2-N; IZAI K, 1992, J BIOL CHEM, V267, P1027; Jain RG, 1997, MOL CELL BIOL, V17, P954, DOI 10.1128/MCB.17.2.954; Joseph B, 1998, J BIOL CHEM, V273, P20511, DOI 10.1074/jbc.273.32.20511; KAMIJO T, 1993, J BIOL CHEM, V268, P26452; KAMIJO T, 1994, BIOCHEM BIOPH RES CO, V199, P818, DOI 10.1006/bbrc.1994.1302; KILEDJIAN M, 1995, EMBO J, V14, P4357, DOI 10.1002/j.1460-2075.1995.tb00110.x; Kiledjian M, 1999, METHODS, V17, P84, DOI 10.1006/meth.1998.0710; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; Lang JA, 1996, AM J PHYSIOL-RENAL, V271, pF94, DOI 10.1152/ajprenal.1996.271.1.F94; LEEDMAN PJ, 1995, MOL ENDOCRINOL, V9, P375, DOI 10.1210/me.9.3.375; Leedman PJ, 1996, J BIOL CHEM, V271, P12017, DOI 10.1074/jbc.271.20.12017; LEVINE TD, 1993, MOL CELL BIOL, V13, P3494, DOI 10.1128/MCB.13.6.3494; Li HW, 2002, J BIOL CHEM, V277, P44623, DOI 10.1074/jbc.M206187200; Lightowlers RN, 1996, BIOCHEM SOC T, V24, P527, DOI 10.1042/bst0240527; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; Makeyev AV, 2002, RNA, V8, P265, DOI 10.1017/S1355838202024627; Maurer F, 1999, NUCLEIC ACIDS RES, V27, P1664, DOI 10.1093/nar/27.7.1664; McGary EC, 1997, J BIOL CHEM, V272, P8628, DOI 10.1074/jbc.272.13.8628; Mintz PJ, 2000, J STRUCT BIOL, V129, P241, DOI 10.1006/jsbi.2000.4213; MIURA S, 1994, J BIOCHEM-TOKYO, V115, P1064, DOI 10.1093/oxfordjournals.jbchem.a124458; MORRIS BJ, 2000, HDB PHYSL 7, V3, P3; NAGAKAWA J, 1995, P NATL ACAD SCI USA, V92, P2051; Nagy E, 2000, BIOCHEM BIOPH RES CO, V275, P253, DOI 10.1006/bbrc.2000.3246; NAGY E, 1995, J BIOL CHEM, V270, P2755, DOI 10.1074/jbc.270.6.2755; NANBU R, 1993, J BIOCHEM-TOKYO, V114, P432, DOI 10.1093/oxfordjournals.jbchem.a124193; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; Park YW, 1999, BIOTECHNIQUES, V26, P1102, DOI 10.2144/99266st01; Paulding WR, 1999, J BIOL CHEM, V274, P2532, DOI 10.1074/jbc.274.4.2532; PELTZ S W, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P99; PREISS T, 1993, J BIOL CHEM, V268, P24523; Rouillard JM, 2000, MOL GEN GENET, V262, P1103, DOI 10.1007/PL00008653; SCHULZ H, 1987, LIFE SCI, V40, P1443, DOI 10.1016/0024-3205(87)90375-4; SenGupta DJ, 1996, P NATL ACAD SCI USA, V93, P8496, DOI 10.1073/pnas.93.16.8496; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SIGMUND CD, 1992, CIRC RES, V70, P1070, DOI 10.1161/01.RES.70.5.1070; Sinn PL, 1999, HYPERTENSION, V33, P900, DOI 10.1161/01.HYP.33.3.900; SMITH DL, 1994, BBA-GENE STRUCT EXPR, V1219, P465, DOI 10.1016/0167-4781(94)90073-6; SMITH DL, 1994, BIOCHEM BIOPH RES CO, V200, P320, DOI 10.1006/bbrc.1994.1451; Takami S, 1996, Hypertens Res, V19, P51, DOI 10.1291/hypres.19.51; Thomson AM, 2000, J BIOL CHEM, V275, P31609, DOI 10.1074/jbc.M002354200; Thomson AM, 1999, BIOTECHNIQUES, V27, P1032, DOI 10.2144/99275rr03; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; van der Weyden L, 2000, HYPERTENSION, V36, P1093, DOI 10.1161/01.HYP.36.6.1093; WANG XM, 1995, MOL CELL BIOL, V15, P1769; Yeap BB, 2002, J BIOL CHEM, V277, P27183, DOI 10.1074/jbc.M202883200; Ying LH, 1997, J BIOL CHEM, V272, P2412; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	74	52	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44894	44903		10.1074/jbc.M307782200	http://dx.doi.org/10.1074/jbc.M307782200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12933794	hybrid			2022-12-25	WOS:000186306700125
J	Hashimoto, M; Asai, Y; Ogawa, T				Hashimoto, M; Asai, Y; Ogawa, T			Treponemal phospholipids inhibit innate immune responses induced by pathogen-associated molecular patterns	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOPOLYSACCHARIDE-BINDING-PROTEIN; TOLL-LIKE RECEPTORS; NF-KAPPA-B; BORRELIA-BURGDORFERI LIPOPROTEINS; CYTOKINE GENE-EXPRESSION; HUMAN MONOCYTIC CELLS; ACUTE PHASE REACTANT; SOLUBLE CD14; ORAL TREPONEMES; PERITONEAL-MACROPHAGES	Host innate immune responses to microbial components, known as pathogen-associated molecular patterns (PAMPs), are regulated and modified by cellular receptors and serum proteins, including Toll-like receptors (TLRs), CD14, and LPS-binding protein (LBP). We demonstrated that a treponemal membrane lipid inhibited PAMPs-induced immune responses. The chemical structure of the lipid was elucidated as a phosphatidylglycerol ( PG) derivative, which is scarce in most mammalian tissues, but relatively abundant in treponemal membrane lipids. Natural and synthetic PG counterparts as well as related natural anionic phospholipids, phosphatidylinositol, phosphatidylserine, and cardiolipin, also demonstrated an inhibitory effect. Further, we noted that PG inhibited PAMPs-induced immune responses by blocking the binding of PAMPs with LBP and CD14. In addition, PG decreased proinflammatory cytokine production in serum of LPS-injected mice and depressed abscess formation in mice infected with treponemes. These results suggest that treponemal phospholipid interfere the function of LBP/CD14 and act as a modulator of innate immune responses.	Asahi Univ Sch Dent, Dept Oral Microbiol, Mizuho Ku, Gifu 5010296, Japan	Asahi University	Ogawa, T (corresponding author), Asahi Univ Sch Dent, Dept Oral Microbiol, Mizuho Ku, 1851-1 Hozumi, Gifu 5010296, Japan.	tomo527@dent.asahi-u.ac.jp	Eckhardt, Erik/G-1567-2010					Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Akashi S, 2000, J IMMUNOL, V164, P3471, DOI 10.4049/jimmunol.164.7.3471; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Asai Y, 2003, INFECT IMMUN, V71, P717, DOI 10.1128/IAI.71.2.717-725.2003; Asai Y, 2002, J CLIN MICROBIOL, V40, P3334, DOI 10.1128/JCM.40.9.3334-3340.2002; BELISLE JT, 1994, J BACTERIOL, V176, P2151, DOI 10.1128/JB.176.8.2151-2157.1994; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bochkov VN, 2002, NATURE, V419, P77, DOI 10.1038/nature01023; Cunningham MD, 1996, INFECT IMMUN, V64, P3601, DOI 10.1128/IAI.64.9.3601-3608.1996; Dziarski R, 1998, J BIOL CHEM, V273, P8680, DOI 10.1074/jbc.273.15.8680; EHLERS S, 1992, J IMMUNOL, V149, P3016; Fraser CM, 1998, SCIENCE, V281, P375, DOI 10.1126/science.281.5375.375; HAILMAN E, 1994, J EXP MED, V179, P269, DOI 10.1084/jem.179.1.269; HARRIS EN, 1988, J INFECT DIS, V157, P23, DOI 10.1093/infdis/157.1.23; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Iwaki D, 2002, J BIOL CHEM, V277, P24315, DOI 10.1074/jbc.M107057200; JOHNSON R C, 1970, Infection and Immunity, V2, P606; Kesavalu L, 1997, INFECT IMMUN, V65, P5096, DOI 10.1128/IAI.65.12.5096-5102.1997; Lamping N, 1996, J IMMUNOL, V157, P4648; Lien E, 1999, J BIOL CHEM, V274, P33419, DOI 10.1074/jbc.274.47.33419; LIVERMORE BP, 1974, J BACTERIOL, V120, P1268, DOI 10.1128/JB.120.3.1268-1273.1974; Luk JM, 1995, ANAL BIOCHEM, V232, P217, DOI 10.1006/abio.1995.0010; MARTIN TR, 1992, J CLIN INVEST, V90, P2209, DOI 10.1172/JCI116106; Matsumoto K, 2001, MOL MICROBIOL, V39, P1427, DOI 10.1046/j.1365-2958.2001.02320.x; MATTHEWS HM, 1980, J BACTERIOL, V143, P1151, DOI 10.1128/JB.143.3.1151-1155.1980; MATTHEWS HM, 1980, BIOCHIM BIOPHYS ACTA, V618, P273, DOI 10.1016/0005-2760(80)90033-8; McCormack FX, 2002, J CLIN INVEST, V109, P707, DOI 10.1172/JCI200215293; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; MONTGOMERY RA, 1991, J IMMUNOL, V147, P554; MORRISON DC, 1976, IMMUNOCHEMISTRY, V13, P813, DOI 10.1016/0019-2791(76)90181-6; MUTA T, 1993, METHOD ENZYMOL, V223, P336; Norgard MV, 1996, INFECT IMMUN, V64, P3845, DOI 10.1128/IAI.64.9.3845-3852.1996; Norris SJ, 2001, J MOL MICROB BIOTECH, V3, P37; OGAWA T, 1982, INFECT IMMUN, V38, P817, DOI 10.1128/IAI.38.3.817-824.1982; Opitz B, 2001, J BIOL CHEM, V276, P22041, DOI 10.1074/jbc.M010481200; Paster BJ, 2001, J BACTERIOL, V183, P3770, DOI 10.1128/JB.183.12.3770-3783.2001; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; RADOLF JD, 1989, P NATL ACAD SCI USA, V86, P2051, DOI 10.1073/pnas.86.6.2051; RADOLF JD, 1988, INFECT IMMUN, V56, P490, DOI 10.1128/IAI.56.2.490-498.1988; Rosen G, 1999, INFECT IMMUN, V67, P1180, DOI 10.1128/IAI.67.3.1180-1186.1999; Salez L, 2001, J IMMUNOL, V166, P6376, DOI 10.4049/jimmunol.166.10.6376; Sano H, 2000, J BIOL CHEM, V275, P22442, DOI 10.1074/jbc.M001107200; Schroder NW, 2001, J BIOL CHEM, V276, P9713, DOI 10.1074/jbc.M008954200; Schroder NWJ, 2000, J IMMUNOL, V165, P2683, DOI 10.4049/jimmunol.165.5.2683; Schultz CP, 1998, J BIOL CHEM, V273, P15661, DOI 10.1074/jbc.273.25.15661; Schumann RR, 2000, CHEM IMMUNOL, V74, P42; Scott MG, 2000, J IMMUNOL, V164, P549, DOI 10.4049/jimmunol.164.2.549; Sela MN, 2001, CRIT REV ORAL BIOL M, V12, P399, DOI 10.1177/10454411010120050301; Sela MN, 1997, J PERIODONTAL RES, V32, P455, DOI 10.1111/j.1600-0765.1997.tb00558.x; Sellati TJ, 1999, J IMMUNOL, V163, P2049; Singh AE, 1999, CLIN MICROBIOL REV, V12, P187, DOI 10.1128/CMR.12.2.187; Stelter F, 2000, CHEM IMMUNOL, V74, P25; Sugiyama T, 2001, J IMMUNOL, V166, P826, DOI 10.4049/jimmunol.166.2.826; TAKAYAMA K, 1994, J BIOL CHEM, V269, P2241; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; TOBIAS PS, 1986, J EXP MED, V164, P777, DOI 10.1084/jem.164.3.777; TOBIAS PS, 1989, J BIOL CHEM, V264, P10867; TOBIAS PS, 1995, J BIOL CHEM, V270, P10482, DOI 10.1074/jbc.270.18.10482; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; Umemoto T, 1997, INT J SYST BACTERIOL, V47, P67, DOI 10.1099/00207713-47-1-67; Underhill DM, 2002, CURR OPIN IMMUNOL, V14, P103, DOI 10.1016/S0952-7915(01)00304-1; Vance D., 1996, BIOCH LIPIDS LIPOPRO, V31, P1; Veldhuizen R, 1998, BBA-MOL BASIS DIS, V1408, P90, DOI 10.1016/S0925-4439(98)00061-1; WRIGHT SD, 1995, J IMMUNOL, V155, P6; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Wurfel MM, 1997, J IMMUNOL, V158, P3925; Yu B, 1997, J CLIN INVEST, V99, P315, DOI 10.1172/JCI119160	67	46	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44205	44213		10.1074/jbc.M306735200	http://dx.doi.org/10.1074/jbc.M306735200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12947124	hybrid			2022-12-25	WOS:000186306700040
J	Lee, SJ; Kim, SJ; Kim, IK; Ko, J; Jeong, CS; Kim, GH; Park, C; Kang, SO; Suh, PG; Lee, HS; Cha, SS				Lee, SJ; Kim, SJ; Kim, IK; Ko, J; Jeong, CS; Kim, GH; Park, C; Kang, SO; Suh, PG; Lee, HS; Cha, SS			Crystal structures of human DJ-1 and Escherichia coli Hsp31, which share an evolutionarily conserved domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONSET PARKINSONS-DISEASE; UBIQUITIN-PROTEIN LIGASE; YEDU GENE-PRODUCT; MOLECULAR CHAPERONE; ANDROGEN RECEPTOR; TRICORN PROTEASE; ALPHA-SYNUCLEIN; DEGRADATION; SUPPRESSION; DROSOPHILA	Human DJ-1 and Escherichia coli Hsp31 belong to ThiJ/PfpI family, whose members contain a conserved domain. DJ-1 is associated with autosomal recessive early onset parkinsonism and Hsp31 is a molecular chaperone. Structural comparisons between DJ-1, Hsp31, and an Archaea protease, a member of ThiJ/PfpI family, lead to the identification of the chaperone activity of DJ-1 and the proteolytic activity of Hsp31. Moreover, the comparisons provide insights into how the functional diversity is realized in proteins that share an evolutionarily conserved domain. On the basis of the chaperone activity the possible role of DJ-1 in the pathogenesis of Parkinson's disease is discussed.	Pohang Accelerator Lab, Beamline Div, Pohang 790784, Kyungbuk, South Korea; Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, South Korea; Seoul Natl Univ, Biophys Lab, Sch Biol Sci, Seoul 151742, South Korea; Seoul Natl Univ, Inst Microbiol, Seoul 151742, South Korea; Korea Adv Inst Sci & Technol, Dept Biol Sci, Natl Creat Res Initiat Ctr Behav Genet, Taejon 305710, South Korea	Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH); Seoul National University (SNU); Seoul National University (SNU); Korea Advanced Institute of Science & Technology (KAIST)	Cha, SS (corresponding author), Pohang Accelerator Lab, Beamline Div, Pohang 790784, Kyungbuk, South Korea.		Park, Chankyu/C-1936-2011; Suh, Pann-Ghill/F-3610-2010; Cha, Sun Shin/B-7370-2009	Cha, Sun-Shin/0000-0002-0913-8706				Auluck PK, 2002, SCIENCE, V295, P865, DOI 10.1126/science.1067389; Bateman A, 1999, NUCLEIC ACIDS RES, V27, P260, DOI 10.1093/nar/27.1.260; Bitto E, 2002, STRUCTURE, V10, P1489, DOI 10.1016/S0969-2126(02)00877-8; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; Bonini NM, 2002, P NATL ACAD SCI USA, V99, P16407, DOI 10.1073/pnas.152330499; BRAVO J, 1995, STRUCTURE, V3, P491, DOI 10.1016/S0969-2126(01)00182-4; Cookson MR, 2003, NEURON, V37, P7, DOI 10.1016/S0896-6273(02)01166-2; de Nobel H, 2001, YEAST, V18, P1413, DOI 10.1002/yea.793; Du XL, 2000, P NATL ACAD SCI USA, V97, P14079, DOI 10.1073/pnas.260503597; Fernandez-Funez P, 2000, NATURE, V408, P101, DOI 10.1038/35040584; Giasson BI, 2002, FREE RADICAL BIO MED, V32, P1264, DOI 10.1016/S0891-5849(02)00804-3; Griffiths SW, 2002, J BIOL CHEM, V277, P25486, DOI 10.1074/jbc.M203089200; Hod Y, 1999, J CELL BIOCHEM, V72, P435, DOI 10.1002/(SICI)1097-4644(19990301)72:3<435::AID-JCB12>3.3.CO;2-8; HOLMAN CM, 1994, BIOCHEMISTRY-US, V33, P2672, DOI 10.1021/bi00175a041; Honbou K, 2003, J BIOL CHEM, V278, P31380, DOI 10.1074/jbc.M305878200; Horvath MM, 2001, PROTEINS, V42, P230, DOI 10.1002/1097-0134(20010201)42:2<230::AID-PROT100>3.3.CO;2-A; Huai Q, 2003, FEBS LETT, V549, P171, DOI 10.1016/S0014-5793(03)00764-6; Jakob U, 1999, CELL, V96, P341, DOI 10.1016/S0092-8674(00)80547-4; Kazemi-Esfarjani P, 2000, SCIENCE, V287, P1837, DOI 10.1126/science.287.5459.1837; Kim OG, 2002, ACTA CRYSTALLOGR D, V58, P1217, DOI 10.1107/S0907444902007369; Kim SJ, 2001, NAT STRUCT BIOL, V8, P459, DOI 10.1038/87639; Kobayashi Y, 2000, J BIOL CHEM, V275, P8772, DOI 10.1074/jbc.275.12.8772; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lotharius J, 2002, NAT REV NEUROSCI, V3, P932, DOI 10.1038/nrn983; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; Malki A, 2003, BIOCHEM BIOPH RES CO, V301, P430, DOI 10.1016/S0006-291X(02)03053-X; Mitsumoto A, 2001, FREE RADICAL RES, V35, P885, DOI 10.1080/10715760100301381; Mitsumoto A, 2001, FREE RADICAL RES, V35, P301, DOI 10.1080/10715760100300831; Mouradian MM, 2002, NEUROLOGY, V58, P179, DOI 10.1212/WNL.58.2.179; Nagakubo D, 1997, BIOCHEM BIOPH RES CO, V231, P509, DOI 10.1006/bbrc.1997.6132; Oh HJ, 1997, J BIOL CHEM, V272, P31636, DOI 10.1074/jbc.272.50.31636; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; Quigley PM, 2003, P NATL ACAD SCI USA, V100, P3137, DOI 10.1073/pnas.0530312100; Sastry MSR, 2002, J BIOL CHEM, V277, P46026, DOI 10.1074/jbc.M205800200; Satyal SH, 2000, P NATL ACAD SCI USA, V97, P5750, DOI 10.1073/pnas.100107297; Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Takahashi K, 2001, J BIOL CHEM, V276, P37556, DOI 10.1074/jbc.M101730200; Tamura N, 1998, CELL, V95, P637, DOI 10.1016/S0092-8674(00)81634-7; Tamura T, 1996, SCIENCE, V274, P1385, DOI 10.1126/science.274.5291.1385; Tao X, 2003, J BIOL CHEM, V278, P31372, DOI 10.1074/jbc.M304221200; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Wagenfeld A, 2000, J ANDROL, V21, P954; Warrick JM, 1999, NAT GENET, V23, P425, DOI 10.1038/70532; Wilson MA, 2003, P NATL ACAD SCI USA, V100, P9256, DOI 10.1073/pnas.1133288100; Xu ZH, 2000, NAT STRUCT BIOL, V7, P1172, DOI 10.1038/82040; Zalkin H, 1993, Adv Enzymol Relat Areas Mol Biol, V66, P203; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797	50	187	194	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44552	44559		10.1074/jbc.M304517200	http://dx.doi.org/10.1074/jbc.M304517200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12939276	hybrid			2022-12-25	WOS:000186306700084
J	Scacco, S; Petruzzella, V; Budde, S; Vergari, R; Tamborra, R; Panelli, D; van den Heuvel, LP; Smeitink, JA; Papa, S				Scacco, S; Petruzzella, V; Budde, S; Vergari, R; Tamborra, R; Panelli, D; van den Heuvel, LP; Smeitink, JA; Papa, S			Pathological mutations of the human NDUFS4 gene of the 18-kDa (AQDQ) subunit of complex I affect the expression of the protein and the assembly and function of the complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADH DEHYDROGENASE; RESPIRATORY-CHAIN; RNA SURVEILLANCE; MAMMALIAN-CELLS; NUCLEAR GENES; AAA PROTEASES; CAMP CASCADE; MITOCHONDRIA; OXIDOREDUCTASE; DEFICIENCY	Presented is a study of the impact on the structure and function of human complex I of three different homozygous mutations in the NDUFS4 gene coding for the 18-kDa subunit of respiratory complex I, inherited by autosomal recessive mode in three children affected by a fatal neurological Leigh-like syndrome. The mutations consisted, respectively, of a AAGTC duplication at position 466 - 470 of the coding sequence, a single base deletion at position 289/290, and a G44A nonsense mutation in the first exon of the gene. All three mutations were found to be associated with a defect of the assembly of a functional complex in the inner mitochondrial membrane. In all the mutations, in addition to destruction of the carboxyl-terminal segment of the 18-kDa subunit, the amino-terminal segment of the protein was also missing. In the mutation that was expected to produce a truncated subunit, the disappearance of the protein was associated with an almost complete disappearance of the NDUFS4 transcript. These observations show the essential role of the NDUFS4 gene in the structure and function of complex I and give insight into the pathogenic mechanism of NDUFS4 gene mutations in a severe defect of complex I.	Univ Bari, Dept Med Biochem & Mol Biol, I-70124 Bari, Italy; Univ Med Ctr Nijmegen, Dept Pediat, Nijmegen Ctr Mitochondrial Disorders, NL-6500 HB Nijmegen, Netherlands; Italian Res Council, Inst Biomembranes & Bioenerget, I-70126 Bari, Italy	Universita degli Studi di Bari Aldo Moro; Radboud University Nijmegen	Papa, S (corresponding author), Univ Bari, Dept Med Biochem & Biol, Piazza G Cesare, I-70124 Bari, Italy.		petruzzella, vittoria/K-8863-2016; van den Heuvel, L.P.W.J./H-8044-2014; van den Heuvel, Lambertus/AAM-1772-2021; Scacco, Salvatore/AAC-7406-2022; Smeitink, Jan/C-1351-2013	petruzzella, vittoria/0000-0001-8771-6033; van den Heuvel, L.P.W.J./0000-0003-3917-6727; van den Heuvel, Lambertus/0000-0003-3917-6727; Scacco, Salvatore/0000-0003-2717-2489; Papa, Sergio/0000-0002-4417-1763				Bai YD, 1998, EMBO J, V17, P4848, DOI 10.1093/emboj/17.16.4848; Boffoli D, 1996, BBA-MOL BASIS DIS, V1315, P66, DOI 10.1016/0925-4439(95)00107-7; Budde SMS, 2000, BIOCHEM BIOPH RES CO, V275, P63, DOI 10.1006/bbrc.2000.3257; Carroll J, 2003, MOL CELL PROTEOMICS, V2, P117, DOI 10.1074/mcp.M300014-MCP200; Carroll J, 2002, J BIOL CHEM, V277, P50311, DOI 10.1074/jbc.M209166200; CHOMYN A, 1986, SCIENCE, V234, P614, DOI 10.1126/science.3764430; COOPERSTEIN SJ, 1951, J BIOL CHEM, V189, P665; Culbertson MR, 1999, TRENDS GENET, V15, P74, DOI 10.1016/S0168-9525(98)01658-8; GOPALAKRISHNAN L, 1994, J BIOL CHEM, V269, P105; HOFHAUS G, 1993, EMBO J, V12, P3043, DOI 10.1002/j.1460-2075.1993.tb05973.x; Iborra FJ, 2001, SCIENCE, V293, P1139, DOI 10.1126/science.1061216; Janssen R, 2002, HUM GENET, V110, P264, DOI 10.1007/s00439-001-0673-3; Langer T, 2001, BIOCHEM SOC T, V29, P431, DOI 10.1042/BST0290431; Lenaz G, 1998, BIOFACTORS, V8, P195, DOI 10.1002/biof.5520080305; Leonhard K, 2000, MOL CELL, V5, P629, DOI 10.1016/S1097-2765(00)80242-7; Mitchell P, 2001, CURR OPIN CELL BIOL, V13, P320, DOI 10.1016/S0955-0674(00)00214-3; Murray J, 2003, J BIOL CHEM, V278, P13619, DOI 10.1074/jbc.C300064200; Papa S, 2002, BBA-BIOENERGETICS, V1555, P147, DOI 10.1016/S0005-2728(02)00270-0; Papa S, 2002, J BIOENERG BIOMEMBR, V34, P1, DOI 10.1023/A:1013863018115; Papa S, 1996, FEBS LETT, V379, P299, DOI 10.1016/0014-5793(95)01532-9; Papa S, 2001, FEBS LETT, V489, P259, DOI 10.1016/S0014-5793(00)02334-6; Petruzzella V, 2002, GENE, V286, P149, DOI 10.1016/S0378-1119(01)00810-1; Petruzzella V, 2001, HUM MOL GENET, V10, P529, DOI 10.1093/hmg/10.5.529; Scacco S, 2000, J BIOL CHEM, V275, P17578, DOI 10.1074/jbc.M001174200; Schapira AHV, 1998, BBA-BIOENERGETICS, V1364, P261, DOI 10.1016/S0005-2728(98)00032-2; Schulte U, 2001, J BIOENERG BIOMEMBR, V33, P205, DOI 10.1023/A:1010730919074; Signorile A, 2002, FEBS LETT, V512, P91, DOI 10.1016/S0014-5793(02)02226-3; Smeitink J, 1999, AM J HUM GENET, V64, P1505, DOI 10.1086/302432; Smeitink JAM, 1998, HUM MOL GENET, V7, P1573, DOI 10.1093/hmg/7.10.1573; van den Heuvel L, 1998, AM J HUM GENET, V62, P262, DOI 10.1086/301716; Wagner E, 2002, J CELL SCI, V115, P3033; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X; Yadava N, 2002, J BIOL CHEM, V277, P21221, DOI 10.1074/jbc.M202016200; Yagi T, 2003, BIOCHEMISTRY-US, V42, P2266, DOI 10.1021/bi027158b; Zerbetto E, 1997, ELECTROPHORESIS, V18, P2059, DOI 10.1002/elps.1150181131; Zhang J, 1997, EMBO J, V16, P826, DOI 10.1093/emboj/16.4.826	36	108	108	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44161	44167		10.1074/jbc.M307615200	http://dx.doi.org/10.1074/jbc.M307615200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12944388	Green Published, hybrid			2022-12-25	WOS:000186306700035
J	Maehashi, E; Sato, C; Ohta, K; Harada, Y; Matsuda, T; Hirohashi, N; Lennarz, WJ; Kitajima, K				Maehashi, E; Sato, C; Ohta, K; Harada, Y; Matsuda, T; Hirohashi, N; Lennarz, WJ; Kitajima, K			Identification of the sea urchin 350-kDa sperm-binding protein as a new sialic acid-binding lectin that belongs to the heat shock protein 110 family - Implication of its binding to gangliosides in sperm lipid rafts in fertilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGG RECEPTOR; VITELLINE LAYER; LOW-DENSITY; MEMBRANE; FRACTION; GAMETE; HSP70; GLYCOPROTEIN; SEQUENCE; LIGANDS	The 350-kDa sperm-binding protein (SBP), a species-specific sperm-binding protein, is localized in the vitelline layer of sea urchin eggs. In this study, we have shown for the first time that sperm gangliosides are ligands for the intact glycosylated SBP. Using recombinant fragments of the SBP, the N-terminal heat shock protein 110-like domain was shown to be responsible for the binding. The intact SBP could bind various gangliosides, and the binding was sialidase-sensitive and inhibited by sialyllactose, thus indicating that it is the sialic acid-binding protein. Calcium and magnesium ions were not required but they did enhance the binding activity of SBP. The observation that bacterially expressed recombinant SBP and the sialidase-treated intact glycosylated SBP lost divalent cation-dependent enhancement of binding activity suggests that the sialylated carbohydrate moieties of the SBP may be involved in this property. Furthermore, the SBP was shown to bind sperm lipid rafts, in which gangliosides are enriched, and this binding was lost upon sialidase treatment of the lipid rafts. Finally, liposomes containing the ganglioside specifically inhibited fertilization. Taken together, these results allow us to identify SBP as a member of a new class of sialic acid-binding lectin belonging to the Hsp110 family, and indicate that SBP may be involved in interaction of sperm with the vitelline layer of the egg.	Nagoya Univ, Grad Sch Agr Sci, Nagoya, Aichi 4648601, Japan; Nagoya Univ, Biosci & Biotechnol Ctr, Nagoya, Aichi 4648601, Japan; Nagoya Univ, Inst Adv Res, Nagoya, Aichi 4648601, Japan; SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA	Nagoya University; Nagoya University; Nagoya University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Kitajima, K (corresponding author), Nagoya Univ, Grad Sch Agr Sci, Nagoya, Aichi 4648601, Japan.	kitajima@agr.nagoya-u.ac.jp	Naganawa, Shinji/I-1572-2012; SATO, Chihiro/B-7396-2014	Naganawa, Shinji/0000-0002-0214-613X; 				Ahnonkitpanit V, 1999, BIOL REPROD, V61, P749, DOI 10.1095/biolreprod61.3.749; Cameron RA, 1996, DEV BIOL, V180, P348, DOI 10.1006/dbio.1996.0307; Crocker PR, 2001, TRENDS IMMUNOL, V22, P337, DOI 10.1016/S1471-4906(01)01930-5; DHUME ST, 1995, GLYCOBIOLOGY, V5, P11, DOI 10.1093/glycob/5.1.11; FOLTZ KR, 1993, SCIENCE, V259, P1421, DOI 10.1126/science.8383878; Fuchizawa S, 1998, BIOCHEM BIOPH RES CO, V248, P505, DOI 10.1006/bbrc.1998.9002; Giusti AF, 1997, DEV BIOL, V184, P10, DOI 10.1006/dbio.1997.8507; HARA S, 1986, J CHROMATOGR, V377, P111, DOI 10.1016/S0378-4347(00)80766-5; Hirohashi N, 1998, DEV BIOL, V201, P270, DOI 10.1006/dbio.1998.8984; Hirohashi N, 1998, DEV BIOL, V204, P305, DOI 10.1006/dbio.1998.9015; Hirohashi N, 2001, DEV GROWTH DIFFER, V43, P247, DOI 10.1046/j.1440-169x.2001.00571.x; Ijuin T, 1996, GLYCOCONJUGATE J, V13, P401, DOI 10.1007/BF00731473; Just ML, 1997, DEV BIOL, V184, P25, DOI 10.1006/dbio.1997.8504; Kitazume S, 1996, J BIOL CHEM, V271, P6694, DOI 10.1074/jbc.271.12.6694; KitazumeKawaguchi S, 1997, P NATL ACAD SCI USA, V94, P3650, DOI 10.1073/pnas.94.8.3650; LEEYOON D, 1995, J BIOL CHEM, V270, P15725, DOI 10.1074/jbc.270.26.15725; LINGWOOD CA, 1985, CAN J BIOCHEM CELL B, V63, P1077, DOI 10.1139/o85-134; Mamelak D, 2001, J BIOL CHEM, V276, P449, DOI 10.1074/jbc.M006732200; Mamelak D, 2001, BIOCHEMISTRY-US, V40, P3572, DOI 10.1021/bi001643u; Mengerink KJ, 2001, GLYCOBIOLOGY, V11, p37R, DOI 10.1093/glycob/11.4.37R; NAGAI Y, 1975, BIOCHIM BIOPHYS ACTA, V388, P146; Nagai Y., 1995, BIOL SIALIC ACIDS, P197; OHLENDIECK K, 1994, J CELL BIOL, V125, P817, DOI 10.1083/jcb.125.4.817; OHLENDIECK K, 1993, J CELL BIOL, V122, P887, DOI 10.1083/jcb.122.4.887; OHLENDIECK K, 1994, DEV BIOL, V165, P53, DOI 10.1006/dbio.1994.1233; Ohta K, 1999, BIOCHEM BIOPH RES CO, V258, P616, DOI 10.1006/bbrc.1999.0686; Ohta K, 2000, GLYCOCONJUGATE J, V17, P205, DOI 10.1023/A:1026589223811; OHTA K, 1999, GLYCOCONJUGATE J, V16, pS63; OKUMURA Y, 1994, BBA-BIOMEMBRANES, V1194, P335, DOI 10.1016/0005-2736(94)90316-6; Renkonen R, 1998, ADV EXP MED BIOL, V435, P63; Sato C, 1998, ANAL BIOCHEM, V261, P191, DOI 10.1006/abio.1998.2718; Sharon N., 1997, GLYCOSCIENCES STATUS, P133; SHIMODA Y, 1994, BIOCHEMISTRY-US, V33, P1202, DOI 10.1021/bi00171a020; Stears RL, 1997, DEV BIOL, V187, P200, DOI 10.1006/dbio.1997.8608; TANPHAICHITR N, 1993, DEV BIOL, V156, P164, DOI 10.1006/dbio.1993.1067; VACQUIER VD, 1977, P NATL ACAD SCI USA, V74, P2456, DOI 10.1073/pnas.74.6.2456; Varki A, 1997, FASEB J, V11, P248, DOI 10.1096/fasebj.11.4.9068613; White D, 2000, BIOL REPROD, V63, P147, DOI 10.1095/biolreprod63.1.147; Yu S, 2002, P NATL ACAD SCI USA, V99, P2854, DOI 10.1073/pnas.052707599; YU S, 1995, GLYCOBIOLOGY, V5, P207	40	51	52	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42050	42057		10.1074/jbc.M307493200	http://dx.doi.org/10.1074/jbc.M307493200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12917406	hybrid			2022-12-25	WOS:000185989500061
J	Mirzayans, R; Pollock, S; Scott, A; Gao, CQ; Murray, D				Mirzayans, R; Pollock, S; Scott, A; Gao, CQ; Murray, D			Metabolic labeling of human cells with tritiated nucleosides results in activation of the ATM-dependent p53 signaling pathway and acceleration of DNA repair	ONCOGENE			English	Article						radiolabeled nucleosides; growth arrest; nucleotide excision repair; CPDs; UV; p53; p21(WAF1)	NUCLEOTIDE EXCISION-REPAIR; NORMAL HUMAN FIBROBLASTS; GLOBAL GENOMIC REPAIR; LI-FRAUMENI SYNDROME; WILD-TYPE P53; ULTRAVIOLET-LIGHT; GROWTH ARREST; PYRIMIDINE DIMERS; PROTEIN-LEVELS; EXPRESSION	We investigated the effects of metabolic labeling with [H-3]thymidine, [H-3]uridine, and [C-14]thymidine on human cells in terms of cell growth, p53 signaling, and nucleotide excision repair. Labeling with [H-3] nucleosides resulted in growth inhibition by both p53-dependent and -independent mechanisms. Tritium labeling also led to nuclear accumulation of p53 and induction of the p53-regulated gene p2(WAF1) and its encoded protein (p21). ATM-deficient cells, however, did not increase their p53 and p21 protein levels in response to radiolabeling. Thus, labeling of human cells with tritiated nucleosides activates the radiation-responsive, ATM-dependent, DNA-damage surveillance network. Labeling of normal cells with [H-3]thymidine significantly accelerated the repair of ultraviolet (UV) light-induced cyclobutane pyrimidine dimers, as monitored by a sensitive immunofluorescence assay. Unlike [(3H]) labeling, [C-14] labeling did not produce any impact on proliferation, p53 signaling, or DNA repair. In the light of these findings, the validity of results obtained with nucleic acid synthesis and DNA repair assays that involve [H-3] and [C-14] labeling is discussed. Our immunofluorescence approach detected pyrimidine dimers after exposure to UV fluences as low as 1 J/m(2) (the lowest fluence examined). This approach may prove particularly useful for monitoring DNA damage and its repair following exposure to extremely low levels of genotoxic agents.	Univ Alberta, Cross Canc Inst, Dept Oncol, Edmonton, AB T6G 1Z2, Canada	University of Alberta	Mirzayans, R (corresponding author), Univ Alberta, Cross Canc Inst, Dept Oncol, Edmonton, AB T6G 1Z2, Canada.							ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; Barley RDC, 1998, ONCOGENE, V17, P533, DOI 10.1038/sj.onc.1202271; BICKAR D, 1992, ANAL BIOCHEM, V203, P109, DOI 10.1016/0003-2697(92)90049-D; Bond JA, 1999, ONCOGENE, V18, P3788, DOI 10.1038/sj.onc.1202733; Bowman KK, 2000, MOL CARCINOGEN, V29, P17, DOI 10.1002/1098-2744(200009)29:1<17::AID-MC3>3.3.CO;2-5; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chang BD, 2000, P NATL ACAD SCI USA, V97, P4291, DOI 10.1073/pnas.97.8.4291; DOVER R, 1994, J CELL SCI, V107, P1181; Enns L, 2000, PHOTOCHEM PHOTOBIOL, V72, P562, DOI 10.1562/0031-8655(2000)072<0562:LOCBDS>2.0.CO;2; Enns L, 1998, RADIAT RES, V150, P11, DOI 10.2307/3579639; Enns L, 1999, BRIT J CANCER, V81, P959, DOI 10.1038/sj.bjc.6690793; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; Gaitonde SV, 2001, CELL GROWTH DIFFER, V12, P19; GALLOWAY AM, 1994, J BIOL CHEM, V269, P974; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Hu VW, 2001, FASEB J, V15, P1562, DOI 10.1096/fj.01-0102com; Hu VW, 2000, FASEB J, V14, P448, DOI 10.1096/fasebj.14.3.448; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; MIRZAYANS R, 1992, INT J RADIAT BIOL, V62, P417, DOI 10.1080/09553009214552301; Mirzayans R, 1999, CARCINOGENESIS, V20, P941, DOI 10.1093/carcin/20.6.941; MIRZAYANS R, 1995, ONCOGENE, V11, P1597; Mirzayans R, 1996, CARCINOGENESIS, V17, P691, DOI 10.1093/carcin/17.4.691; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; SMITH ML, 1995, ONCOGENE, V10, P1053; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; Suzuki A, 2000, ONCOGENE, V19, P1346, DOI 10.1038/sj.onc.1203429; Wakasugi M, 2002, J BIOL CHEM, V277, P1637, DOI 10.1074/jbc.C100610200; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; YEARGIN J, 1995, CURR BIOL, V5, P423, DOI 10.1016/S0960-9822(95)00083-2	29	18	18	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2003	22	36					5562	5571		10.1038/sj.onc.1206514	http://dx.doi.org/10.1038/sj.onc.1206514			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944903				2022-12-25	WOS:000184865900004
J	Henriksen, J; Aagesen, TH; Maelandsmo, GM; Lothe, RA; Myklebost, O; Forus, A				Henriksen, J; Aagesen, TH; Maelandsmo, GM; Lothe, RA; Myklebost, O; Forus, A			Amplification and overexpression of COPS3 in osteosarcomas potentially target TP53 for proteasome-mediated degradation	ONCOGENE			English	Article						COP9 signalosome; chromosome 17; mdm2; sarcoma; CSN3; CGH	COMPARATIVE GENOMIC HYBRIDIZATION; MDM2 GENE AMPLIFICATION; SMITH-MAGENIS-SYNDROME; ADIPOSE-TISSUE TUMORS; HUMAN SARCOMAS; CYTOGENETIC FINDINGS; SIGNAL-TRANSDUCTION; DNA-SEQUENCES; REGION; IDENTIFICATION	In sarcomas, the TP53 tumour suppressor pathway may be altered either by TP53 mutations or by amplification of MDM2, encoding a protein that inhibits TP53 and targets it for 26S-proteasome degradation. However, in the majority of the analysed clinical samples, neither of these types of aberrations are found, suggesting that additional mechanisms are involved. The present study shows that COPS3, located in 17p11 and encoding a component of the proteasome pathway, is more frequently amplified in osteosarcomas (OS) than is MDM2. We present detailed analysis of TP53 mutations and MDM2 and COPS3 expression levels in a set of 23 OS. Our results show that none of the tumours with COPS3 amplification had MDM2 amplification nor TP53 mutations, consistent with the hypothesis that one of the three aberrations is sufficient. The results suggest that inactivation of otherwise intact TP53 by aberrations in the proteasome pathway may contribute to the characteristic aneuploidy observed in OS.	Norwegian Radium Hosp, Inst Canc Res, Dept Tumor Biol, N-0310 Oslo, Norway; Norwegian Radium Hosp, Inst Canc Res, Dept Genet, N-0310 Oslo, Norway	University of Oslo; University of Oslo	Myklebost, O (corresponding author), Norwegian Radium Hosp, Inst Canc Res, Dept Tumor Biol, N-0310 Oslo, Norway.	olam@radium.uio.no	Myklebost, Ola/E-9335-2010	Myklebost, Ola/0000-0002-2866-3223; Lothe, Ragnhild A./0000-0002-1693-1032				Bech-Otschir D, 2001, EMBO J, V20, P1630, DOI 10.1093/emboj/20.7.1630; Bech-Otschir D, 2002, J CELL SCI, V115, P467; Berner JM, 1996, GENE CHROMOSOME CANC, V17, P254, DOI 10.1002/(SICI)1098-2264(199612)17:4<254::AID-GCC7>3.0.CO;2-2; Bridge JA, 1997, CANCER GENET CYTOGEN, V95, P74, DOI 10.1016/S0165-4608(96)00306-8; Bridge JA, 1994, CYTOGENETICS BONE SO; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; El-Rifai W, 1998, AM J PATHOL, V153, P985, DOI 10.1016/S0002-9440(10)65640-4; Elsea SH, 1999, AM J MED GENET, V87, P342, DOI 10.1002/(SICI)1096-8628(19991203)87:4<342::AID-AJMG12>3.3.CO;2-1; FLETCHER JA, 1994, CANCER GENET CYTOGEN, V77, P81, DOI 10.1016/0165-4608(94)90154-6; FLORENES VA, 1994, J NATL CANCER I, V86, P1297, DOI 10.1093/jnci/86.17.1297; FORUS A, 1995, GENE CHROMOSOME CANC, V14, P15, DOI 10.1002/gcc.2870140104; FORUS A, 1993, CELL GROWTH DIFFER, V4, P1065; FORUS A, 1995, GENE CHROMOSOME CANC, V14, P8, DOI 10.1002/gcc.2870140103; Hansen DV, 2002, ONCOGENE, V21, P6209, DOI 10.1038/sj.onc.1205824; HUANG LS, 1985, P NATL ACAD SCI USA, V82, P6825, DOI 10.1073/pnas.82.20.6825; Hulsebos TJM, 1997, GENE CHROMOSOME CANC, V18, P279, DOI 10.1002/(SICI)1098-2264(199704)18:4<279::AID-GCC5>3.0.CO;2-Y; LADANYI M, 1993, CANCER RES, V53, P16; LINK MP, 1993, CANC PRINCIPLES PRAC, P1534; Lothe RA, 2001, GENE CHROMOSOME CANC, V30, P202, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1079>3.3.CO;2-X; MERTENS F, 1993, INT J CANCER, V55, P44, DOI 10.1002/ijc.2910550109; NAKAYAMA T, 1995, INT J CANCER, V64, P342, DOI 10.1002/ijc.2910640511; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Pedeutour F, 1999, GENE CHROMOSOME CANC, V24, P30, DOI 10.1002/(SICI)1098-2264(199901)24:1<30::AID-GCC5>3.0.CO;2-P; Potocki L, 1999, GENOMICS, V57, P180, DOI 10.1006/geno.1998.5748; Simons A, 2000, CANCER GENET CYTOGEN, V118, P89, DOI 10.1016/S0165-4608(99)00178-8; Stock C, 2000, GENE CHROMOSOME CANC, V28, P329, DOI 10.1002/1098-2264(200007)28:3<329::AID-GCC11>3.0.CO;2-F; Szymanska J, 1996, GENE CHROMOSOME CANC, V15, P89, DOI 10.1002/(SICI)1098-2264(199602)15:2<89::AID-GCC2>3.0.CO;2-#; TARKKANEN M, 1993, CANCER GENET CYTOGEN, V68, P1, DOI 10.1016/0165-4608(93)90068-W; TARKKANEN M, 1995, CANCER RES, V55, P1334; Weiss SW, 1994, WHO HISTOLOGICAL CLA, V2nd; Wolf M, 1999, INT J CANCER, V82, P329, DOI 10.1002/(SICI)1097-0215(19990730)82:3<329::AID-IJC4>3.0.CO;2-1	31	43	46	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2003	22	34					5358	5361		10.1038/sj.onc.1206671	http://dx.doi.org/10.1038/sj.onc.1206671			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JB	12917637				2022-12-25	WOS:000184734900015
J	Ma, CL; Lin, H; Leonard, SS; Shi, XL; Ye, JP; Luo, J				Ma, CL; Lin, H; Leonard, SS; Shi, XL; Ye, JP; Luo, J			Overexpression of ErbB2 enhances ethanol-stimulated intracellular signaling and invasion of human mammary epithelial and breast cancer cells in vitro	ONCOGENE			English	Article						alcohol; growth factors; metastasis; reactive oxygen species; signal transduction	N-TERMINAL KINASE; RECEPTOR TYROSINE KINASES; EPIDERMAL-GROWTH-FACTOR; ALCOHOL-CONSUMPTION; ESTROGEN-RECEPTOR; PC12 CELLS; REGULATED KINASE; OXIDATIVE STRESS; CARCINOMA-CELLS; RAT HEPATOCYTES	Both epidemiological and experimental studies indicate that ethanol is a tumor promoter and may promote metastasis of breast cancer. However, the molecular mechanisms underlying ethanol-mediated tumor promotion remain unknown. Overexpression of ErbB proteins in breast cancer patients is generally associated with poor prognosis. The ErbB proteins are a family of receptor kinases that include four closely related members: epidermal growth factor receptor (EGFR/ErbB1), ErbB2/neu, ErbB3, and ErbB4. Particularly, ErbB2 plays a pivotal role in ErbB-mediated activities. Here we demonstrated that amplification of ErbB2 expression sensitized a specific cellular response to ethanol. Human breast cancer cells or mammary epithelial cells with a high expression of ErbB2 exhibited an enhanced response to ethanol-stimulated cell invasion in vitro. Ethanol also stimulated cell proliferation; however, this stimulation was independent of ErbB2 levels. Ethanol triggered divergent intracellular signaling among cells expressing different ErbB2 levels. In the cells overexpressing ErbB2, ethanol was more effective in the activation of c-Jun NH2 terminal protein kinases (JNKs) and p38 mitogen-activated protein kinase (p38 MAPK) as well as the induction of reactive oxygen species (ROS) than the cells with normal ErbB2 expression. Blockage of either JNKs or p38 MAPK activation eliminated ethanol-mediated cell invasion. In contrast, the reduction of hydrogen peroxide concentration by catalase exposure had little effect on ethanol-induced cell invasion. These results indicated that ethanol-induced cell invasion was primarily mediated by JNKs and p38 MAPK, whereas the involvement of ROS formation might be minimal. Our study suggests that overexpression of ErbB2 may augment ethanol-elicited signaling and promote ethanol-stimulated tumor metastasis.	W Virginia Univ, Sch Med, Robert C Byrd Hlth Sci Ctr, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA; Xijing Hosp, Dept Dermatol, Xian 710032, Peoples R China; NIOSH, Pathol & Physiol Res Branch, Morgantown, WV 26505 USA; Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA	West Virginia University; Air Force Military Medical University; Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center	Luo, J (corresponding author), W Virginia Univ, Sch Med, Robert C Byrd Hlth Sci Ctr, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA.		Ye, Jianping/N-1998-2017; Shi, Xianglin/B-8588-2012; Luo, Jia/E-4674-2012	Ye, Jianping/0000-0003-3875-365X; Luo, Jia/0000-0002-6968-3618	NATIONAL CANCER INSTITUTE [R01CA090385] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R03AA012968] Funding Source: NIH RePORTER; NCI NIH HHS [CA90385] Funding Source: Medline; NIAAA NIH HHS [AA12968] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Alford D, 1998, J CELL SCI, V111, P521; Bailey SM, 1998, HEPATOLOGY, V28, P1318, DOI 10.1002/hep.510280521; Bowers G, 2001, ONCOGENE, V20, P1388, DOI 10.1038/sj.onc.1204255; Bowlin SJ, 1997, INT J EPIDEMIOL, V26, P915, DOI 10.1093/ije/26.5.915; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; Castro GD, 2001, TOXICOLOGY, V160, P11, DOI 10.1016/S0300-483X(00)00433-9; Chen YR, 2001, ONCOGENE, V20, P367, DOI 10.1038/sj.onc.1204105; Denkert C, 2002, CLIN EXP METASTAS, V19, P79, DOI 10.1023/A:1013857325012; Dhar A, 2002, MOL CELL BIOCHEM, V234, P185, DOI 10.1023/A:1015948505117; Doll R, 1981, J NATL CANCER I, V66, P1192; Duffy MJ, 2000, BREAST CANCER RES, V2, P252, DOI 10.1186/bcr65; Fan SJ, 2000, CANCER RES, V60, P5635; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Hauck CR, 2001, CANCER RES, V61, P7079; HIATT RA, 1990, MED ONCOL TUMOR PHAR, V7, P143; Hoek JB, 2002, ALCOHOL, V27, P63, DOI 10.1016/S0741-8329(02)00215-X; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Izevbigie EB, 2002, EXP BIOL MED, V227, P260, DOI 10.1177/153537020222700406; Jurgensmeier JM, 1997, INT J CANCER, V70, P587; KELSEY JL, 1993, EPIDEMIOL REV, V15, P7, DOI 10.1093/oxfordjournals.epirev.a036118; Kulisz A, 2002, AM J PHYSIOL-LUNG C, V282, pL1324, DOI 10.1152/ajplung.00326.2001; Kuper H, 2000, BRIT J CANCER, V83, P949, DOI 10.1054/bjoc.2000.1360; LACROIX H, 1989, ONCOGENE, V4, P145; Lakka SS, 2000, CLIN EXP METASTAS, V18, P245, DOI 10.1023/A:1006724826083; Li YX, 2001, FREE RADICAL BIO MED, V30, P389, DOI 10.1016/S0891-5849(00)00484-6; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; LONGNECKER MP, 1994, CANCER CAUSE CONTROL, V5, P73, DOI 10.1007/BF01830729; Luo J, 1999, J NEUROSCI, V19, P10014, DOI 10.1523/jneurosci.19-22-10014.1999; Luo J, 2003, J BIOL CHEM, V278, P4542, DOI 10.1074/jbc.M208295200; Luo J, 1997, ALCOHOL CLIN EXP RES, V21, P1186, DOI 10.1111/j.1530-0277.1997.tb04436.x; Luo J, 1999, ALCOHOL CLIN EXP RES, V23, P644, DOI 10.1111/j.1530-0277.1999.tb04166.x; Luo J, 2000, BREAST CANCER RES TR, V63, P61, DOI 10.1023/A:1006436315284; Mansat-De Mas V, 1999, MOL PHARMACOL, V56, P867, DOI 10.1124/mol.56.5.867; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCCANN A, 1989, IRISH J MED SCI, V158, P137, DOI 10.1007/BF02943053; Meng QH, 2000, BIOCHEM BIOPH RES CO, V273, P448, DOI 10.1006/bbrc.2000.2942; MUFTI SI, 1993, J CANCER RES CLIN, V119, P304, DOI 10.1007/BF01212730; Olayioye MA, 1998, MOL CELL BIOL, V18, P5042, DOI 10.1128/MCB.18.9.5042; Olayioye MA, 2001, EXP CELL RES, V267, P81, DOI 10.1006/excr.2001.5242; PANTEL K, 1993, JNCI-J NATL CANCER I, V85, P1419, DOI 10.1093/jnci/85.17.1419; Park MJ, 2002, J NEUROSURG, V97, P112, DOI 10.3171/jns.2002.97.1.0112; PATERSON MC, 1991, CANCER RES, V51, P556; PLANT ML, 1992, INT J ADDICT, V27, P107, DOI 10.3109/10826089209068733; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; QIU MS, 1991, NEURON, V7, P937, DOI 10.1016/0896-6273(91)90339-2; Reinke LA, 2002, FREE RADICAL BIO MED, V32, P953, DOI 10.1016/S0891-5849(02)00795-5; Reunanen N, 2002, J BIOL CHEM, V277, P32360, DOI 10.1074/jbc.M204296200; ROSENBERG L, 1993, EPIDEMIOL REV, V15, P133, DOI 10.1093/oxfordjournals.epirev.a036097; Sano M, 2001, CIRC RES, V89, P661, DOI 10.1161/hh2001.098873; Schmidt-Ullrich RK, 1999, RADIAT ONCOL INVESTI, V7, P321, DOI 10.1002/(SICI)1520-6823(1999)7:6<321::AID-ROI2>3.0.CO;2-Q; SHI XL, 1991, ARCH BIOCHEM BIOPHYS, V289, P355, DOI 10.1016/0003-9861(91)90423-G; Shin EY, 2001, EXP MOL MED, V33, P276, DOI 10.1038/emm.2001.45; Shin M, 2002, BBA-MOL CELL RES, V1589, P311, DOI 10.1016/S0167-4889(02)00195-7; Simon C, 2001, EXP CELL RES, V271, P344, DOI 10.1006/excr.2001.5374; Singletary K, 1997, ALCOHOL CLIN EXP RES, V21, P334; Singletary KW, 2001, JAMA-J AM MED ASSOC, V286, P2143, DOI 10.1001/jama.286.17.2143; Singletary KW, 2001, CANCER LETT, V165, P131, DOI 10.1016/S0304-3835(01)00419-0; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; Smith-Warner SA, 1998, JAMA-J AM MED ASSOC, V279, P535, DOI 10.1001/jama.279.7.535; Spencer KSR, 2000, J CELL BIOL, V148, P385, DOI 10.1083/jcb.148.2.385; Sun YB, 2002, J CELL PHYSIOL, V192, P225, DOI 10.1002/jcp.10132; Swanson CA, 1997, EPIDEMIOLOGY, V8, P231, DOI 10.1097/00001648-199705000-00001; Talvensaari-Mattila A, 1998, CANCER-AM CANCER SOC, V83, P1153, DOI 10.1002/(SICI)1097-0142(19980915)83:6<1153::AID-CNCR14>3.0.CO;2-4; Tan M, 1997, CANCER RES, V57, P1199; TAUCHI K, 1989, VIRCHOWS ARCH A, V416, P65, DOI 10.1007/BF01606471; Tombes RM, 1998, BIOCHEM J, V330, P1451; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Vaeth PAC, 1998, ALCOHOL CLIN EXP RES, V22, P928; Verma M, 1999, Cancer Biochem Biophys, V17, P1; Watabiki T, 2000, ALCOHOL CLIN EXP RES, V24, p117S, DOI 10.1111/j.1530-0277.2000.tb00025.x; Weiss HA, 1996, BRIT J CANCER, V73, P1298, DOI 10.1038/bjc.1996.248; Wright RM, 1999, FREE RADICAL BIO MED, V26, P348, DOI 10.1016/S0891-5849(98)00204-4; Ye JP, 1996, MOL CELL BIOL, V16, P6178; Zhu YF, 2001, BREAST CANCER RES TR, V69, P29, DOI 10.1023/A:1012293507534; Zhu YF, 2001, INT J ONCOL, V18, P1299	76	47	50	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 14	2003	22	34					5281	5290		10.1038/sj.onc.1206675	http://dx.doi.org/10.1038/sj.onc.1206675			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JB	12917629				2022-12-25	WOS:000184734900007
J	Robenek, MJ; Schlattmann, K; Zimmer, KP; Plenz, G; Troyer, D; Robenek, H				Robenek, MJ; Schlattmann, K; Zimmer, KP; Plenz, G; Troyer, D; Robenek, H			Cholesterol transporter caveolin-1 transits the lipid bilayer during intracellular cycling	FASEB JOURNAL			English	Article						intracellular transport; membrane leaflet; endocytotic pathway; lipid droplets	PROTEIN TRANSLOCATION; MEMBRANE; DOMAINS; IDENTIFICATION; COMPLEX; MEDIATE	Caveolin-1, a major protein of cell surface invaginations called caveolae, is currently believed to cycle between the plasma membrane and intracellular compartments via the endocytotic pathway, at least for part of its itinerary. We studied the distribution of caveolin-1 in cell membranes, using ultrathin cryosections and freeze-fracture immunolabeling and found this protein not only in the cytoplasmic leaflet of the plasma membrane, but also in the exoplasmic leaflet of all intracellular membranes. This sidedness implies that caveolin-1 switches from one membrane leaflet to the other somewhere on its way through the cell and rules out the classic mechanism of endocytotic membrane budding and fusion for caveolin-1 intracellular trafficking. Underlying the sidedness of caveolin-1 may be a fundamental, hitherto unrecognized, mechanism by which proteins transit membranes.	Univ Munster, Inst Arteriosclerosis Res, Dept Cell Biol & Ultrastruct Res, D-48149 Munster, Germany; Univ Munster, Univ Childrens Hosp, D-4400 Munster, Germany; Univ Munster, Dept Thorac & Cardiovasc Surg, D-4400 Munster, Germany; Univ Munster, Dept Cardiol & Angiol, D-4400 Munster, Germany	University of Munster; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munster; University of Munster; University of Munster	Robenek, MJ (corresponding author), Univ Munster, Inst Arteriosclerosis Res, Dept Cell Biol & Ultrastruct Res, Domagkstr 3, D-48149 Munster, Germany.	robenek@uni-muenster.de	Zimmer, Klaus-Peter/AAY-9261-2020; Zimmer, Klaus-Peter/AAY-9351-2020					Agarraberes FA, 2001, BBA-BIOMEMBRANES, V1513, P1, DOI 10.1016/S0304-4157(01)00005-3; BRANTON D, 1975, SCIENCE, V190, P54, DOI 10.1126/science.1166299; CONRAD PA, 1995, J CELL BIOL, V131, P1421, DOI 10.1083/jcb.131.6.1421; Couet J, 2001, ADV DRUG DELIVER REV, V49, P223, DOI 10.1016/S0169-409X(01)00139-9; Das K, 1999, J BIOL CHEM, V274, P18721, DOI 10.1074/jbc.274.26.18721; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; FUJIMOTO K, 1995, J CELL SCI, V108, P3443; Ikonen E, 2000, TRAFFIC, V1, P212, DOI 10.1034/j.1600-0854.2000.010303.x; Liu PS, 1999, NAT CELL BIOL, V1, P369, DOI 10.1038/14067; Liu PS, 2002, J BIOL CHEM, V277, P41295, DOI 10.1074/jbc.R200020200; Machleidt T, 2000, J CELL BIOL, V148, P17, DOI 10.1083/jcb.148.1.17; Matveev S, 2001, ADV DRUG DELIVER REV, V49, P237, DOI 10.1016/S0169-409X(01)00138-7; Nichols BJ, 2002, NAT CELL BIOL, V4, P374, DOI 10.1038/ncb787; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Ostermeyer AG, 2001, J CELL BIOL, V152, P1071, DOI 10.1083/jcb.152.5.1071; Rapoport TA, 1999, BIOL CHEM, V380, P1143, DOI 10.1515/BC.1999.145; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Scheiffele P, 1998, J CELL BIOL, V140, P795, DOI 10.1083/jcb.140.4.795; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; Schlegel A, 2000, J BIOL CHEM, V275, P21605, DOI 10.1074/jbc.M002558200; SHOTTON DM, 1995, RAPID FREEZING FREEZ, P1; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Thyberg J, 2002, J HISTOCHEM CYTOCHEM, V50, P185, DOI 10.1177/002215540205000206; TOKUYASU KT, 1980, HISTOCHEM J, V12, P381, DOI 10.1007/BF01011956; Uittenbogaard A, 1998, J BIOL CHEM, V273, P6525, DOI 10.1074/jbc.273.11.6525; van Deurs B, 2003, TRENDS CELL BIOL, V13, P92, DOI 10.1016/S0962-8924(02)00039-9; van Meer G, 2001, J CELL BIOL, V152, pF29, DOI 10.1083/jcb.152.5.F29	27	21	21	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1940	+		10.1096/fj.03-0008fje	http://dx.doi.org/10.1096/fj.03-0008fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12923065				2022-12-25	WOS:000185345100015
J	Nishikubo, S; Ohara, M; Ueno, Y; Ikura, M; Kurihara, H; Komatsuzawa, H; Oswald, E; Sugai, M				Nishikubo, S; Ohara, M; Ueno, Y; Ikura, M; Kurihara, H; Komatsuzawa, H; Oswald, E; Sugai, M			An N-terminal segment of the active component of the bacterial genotoxin cytolethal distending toxin B (CDTB) directs CDTB into the nucleus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE ARREST; AGROBACTERIUM VIRD2; LOCALIZATION SIGNAL; MAMMALIAN-CELLS; PROTEIN IMPORT; VIRE2 PROTEINS; HELA-CELLS; BINDING; RECOGNITION; TRANSPORT	Cytolethal distending toxin (CDT), produced by Actinobacillus actinomycetemcomitans, is a putative virulence factor in the pathogenesis of periodontal diseases. It is a cell cycle specific inhibitor at the G(2)/M transition. CDTB, one of the subunits of the CDT holotoxin, is implicated in a genotoxic role after entering the target cells, whereby chromosomal damage induces checkpoint phosphorylation cascades. CDTB microinjected into the cytoplasm was shown to localize in the nucleus and induce chromatin collapse. To investigate the molecular mechanism involved in nuclear transport of CDTB, we used transient expression and microinjection of a CDTB-green fluorescent protein (GFP) fusion protein. After microinjection, His-tagged CDTB-GFP entered the nucleus in 3-4 h. Leptomycin B did not increase the speed of entry of the fusion protein, suggesting that the relatively slow entry of the fusion protein is not due to the CRM1-dependent nuclear export of the protein. Nuclear localization of the CDTB-GFP was temperature-dependent. An in vitro transport assay demonstrated that the nuclear localization of CDTB is mediated by active transport. An assay using transient expression of a series of truncated CDTB-GFP fusion proteins revealed that residues 48-124 constitute the minimum region involved in nuclear transport of CDTB. A domain swapping experiment of the region involved in nuclear transport of CDTB with an SV40 T nuclear localization signal indicated that CDTB is composed of two domains, an N-terminal domain for nuclear transport and a C-terminal active domain. Our results strongly suggest that nuclear localization of CDTB is required for the holotoxin to induce cytodistension and cell cycle block. This is the first demonstration that a bacterial toxin possessing a unique domain for nuclear transport is transferred to the animal cell nucleus by active transport.	Hiroshima Univ, Grad Sch Biomed Sci, Dept Bacteriol, Minami Ku, Hiroshima 7348553, Japan; Hiroshima Univ, Grad Sch Biomed Sci, Dept Periodontal Med, Minami Ku, Hiroshima 7348553, Japan; Ecole Natl Vet Toulouse, Inst Natl Rech Agron Interact Hotes Agents Pathog, UMR 1225, F-31076 Toulouse, France	Hiroshima University; Hiroshima University; INRAE; Universite de Toulouse; Ecole Nationale Veterinaire de Toulouse	Sugai, M (corresponding author), Hiroshima Univ, Grad Sch Biomed Sci, Dept Bacteriol, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348553, Japan.	sugai@hiroshima-u.ac.jp	Komatsuzawa, Hitoshi/AAC-7731-2019	Oswald, Eric/0000-0002-3017-0081; Nishikubo, Shuichi/0000-0002-9060-2974				ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; CITOVSKY V, 1994, P NATL ACAD SCI USA, V91, P3210, DOI 10.1073/pnas.91.8.3210; CITOVSKY V, 1992, SCIENCE, V256, P1802, DOI 10.1126/science.1615325; Comayras C, 1997, INFECT IMMUN, V65, P5088, DOI 10.1128/IAI.65.12.5088-5095.1997; Corbett AH, 1997, MICROBIOL MOL BIOL R, V61, P193, DOI 10.1128/.61.2.193-211.1997; Cortes-Bratti X, 1999, J CLIN INVEST, V103, P107, DOI 10.1172/JCI3831; Cortes-Bratti X, 2000, INFECT IMMUN, V68, P6903, DOI 10.1128/IAI.68.12.6903-6911.2000; De Rycke J, 2000, EUR J CELL BIOL, V79, P192, DOI 10.1078/S0171-9335(04)70022-9; Deng KP, 2001, BIOCHEM BIOPH RES CO, V285, P609, DOI 10.1006/bbrc.2001.5223; Elwell C, 2001, INFECT IMMUN, V69, P3418, DOI 10.1128/IAI.69.5.3418-3422.2001; Elwell CA, 2000, MOL MICROBIOL, V37, P952, DOI 10.1046/j.1365-2958.2000.02070.x; Escalas N, 2000, EXP CELL RES, V257, P206, DOI 10.1006/excr.2000.4878; Gelvin SB, 1998, J BACTERIOL, V180, P4300, DOI 10.1128/JB.180.16.4300-4302.1998; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Hassane DC, 2003, INFECT IMMUN, V71, P541, DOI 10.1128/IAI.71.1.541-545.2003; HERRERAESTRELLA A, 1990, P NATL ACAD SCI USA, V87, P9534, DOI 10.1073/pnas.87.24.9534; JOHNSON WM, 1988, MICROB PATHOGENESIS, V4, P115, DOI 10.1016/0882-4010(88)90053-8; JOHNSON WM, 1988, MICROB PATHOGENESIS, V4, P103, DOI 10.1016/0882-4010(88)90052-6; Jullien D, 1999, EMBO J, V18, P4348, DOI 10.1093/emboj/18.15.4348; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Lara-Tejero M, 2000, SCIENCE, V290, P354, DOI 10.1126/science.290.5490.354; Li LQ, 2002, CELL MICROBIOL, V4, P87, DOI 10.1046/j.1462-5822.2002.00174.x; Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001; Miyamoto Y, 1997, J BIOL CHEM, V272, P26375, DOI 10.1074/jbc.272.42.26375; MOROIANU J, 1995, P NATL ACAD SCI USA, V96, P12542; Nagoshi E, 2001, MOL CELL BIOL, V21, P2779, DOI 10.1128/MCB.21.8.2779-2789.2001; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; Peres SY, 1997, MOL MICROBIOL, V24, P1095, DOI 10.1046/j.1365-2958.1997.4181785.x; PICKETT CL, 1994, INFECT IMMUN, V62, P1046, DOI 10.1128/IAI.62.3.1046-1051.1994; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; Sert V, 1999, ONCOGENE, V18, P6296, DOI 10.1038/sj.onc.1203007; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; SHURVINTON CE, 1992, P NATL ACAD SCI USA, V89, P11837, DOI 10.1073/pnas.89.24.11837; Sugai M, 1998, INFECT IMMUN, V66, P5008, DOI 10.1128/IAI.66.10.5008-5019.1998; Szurek B, 2001, PLANT J, V26, P523, DOI 10.1046/j.0960-7412.2001.01046.x; VandenAckerveken G, 1996, CELL, V87, P1307, DOI 10.1016/S0092-8674(00)81825-5; Weis K, 2002, CURR OPIN CELL BIOL, V14, P328, DOI 10.1016/S0955-0674(02)00337-X; Weis K, 1998, TRENDS BIOCHEM SCI, V23, P185, DOI 10.1016/S0968-0004(98)01204-3; Whitehouse CA, 1998, INFECT IMMUN, V66, P1934, DOI 10.1128/IAI.66.5.1934-1940.1998; WORNIAK RW, 1998, TRENDS CELL BIOL, V8, P184; Yoneda Y, 2000, GENES CELLS, V5, P777, DOI 10.1046/j.1365-2443.2000.00366.x; ZAMBRYSKI P, 1988, ANNU REV GENET, V22, P1, DOI 10.1146/annurev.ge.22.120188.000245	43	75	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 12	2003	278	50					50671	50681		10.1074/jbc.M305062200	http://dx.doi.org/10.1074/jbc.M305062200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751LH	12947116	hybrid, Green Published			2022-12-25	WOS:000187068200123
J	Basran, J; Harris, RJ; Sutcliffe, MJ; Scrutton, NS				Basran, J; Harris, RJ; Sutcliffe, MJ; Scrutton, NS			H-tunneling in the multiple H-transfers of the catalytic cycle of morphinone reductase and in the reductive half-reaction of the homologous pentaerythritol tetranitrate reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTEROBACTER-CLOACAE PB2; PSEUDOMONAS-PUTIDA M10; BARRIER HYDROGEN-BOND; OLD YELLOW ENZYME; PROTON-TRANSFER; ALCOHOL-DEHYDROGENASE; BIOLOGICAL CATALYSIS; CRYSTAL-STRUCTURE; PROTEIN DYNAMICS; MECHANISM	The mechanism of flavin reduction in morphinone reductase (MR) and pentaerythritol tetranitrate (PETN) reductase, and flavin oxidation in MR, has been studied by stopped-flow and steady-state kinetic methods. The temperature dependence of the primary kinetic isotope effect for flavin reduction in MR and PETN reductase by nicotinamide coenzyme indicates that quantum mechanical tunneling plays a major role in hydride transfer. In PETN reductase, the kinetic isotope effect (KIE) is essentially independent of temperature in the experimentally accessible range, contrasting with strongly temperature-dependent reaction rates, consistent with a tunneling mechanism from the vibrational ground state of the reactive C-H/D bond. In MR, both the reaction rates and the KIE are dependent on temperature, and analysis using the Eyring equation suggests that hydride transfer has a major tunneling component, which, unlike PETN reductase, is gated by thermally induced vibrations in the protein. The oxidative half-reaction of MR is fully rate-limiting in steady-state turnover with the substrate 2-cyclohexenone and NADH at saturating concentrations. The KIE for hydride transfer from reduced flavin to the alpha/beta unsaturated bond of 2-cyclohexenone is independent of temperature, contrasting with strongly temperature-dependent reaction rates, again consistent with ground-state tunneling. A large solvent isotope effect (SIE) accompanies the oxidative half-reaction, which is also independent of temperature in the experimentally accessible range. Double isotope effects indicate that hydride transfer from the flavin N5 atom to 2-cyclohexenone, and the protonation of 2-cyclohexenone, are concerted and both the temperature-independent KIE and SIE suggest that this reaction also proceeds by ground-state quantum tunneling. Our results demonstrate the importance of quantum tunneling in the reduction of flavins by nicotinamide coenzymes. This is the first observation of (i) three H-nuclei in an enzymic reaction being transferred by tunneling and (ii) the utilization of both passive and active dynamics within the same native enzyme.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Univ Leicester, Dept Chem, Leicester LE1 7RH, Leics, England	University of Leicester; University of Leicester	Scrutton, NS (corresponding author), Univ Leicester, Dept Biochem, Univ Rd, Leicester LE1 7RH, Leics, England.			Sutcliffe, Mike/0000-0003-0414-1700				Antoniou D, 1999, J CHEM PHYS, V110, P7359, DOI 10.1063/1.478667; Antoniou D, 1999, J CHEM PHYS, V110, P465, DOI 10.1063/1.478107; Antoniou D, 1997, P NATL ACAD SCI USA, V94, P12360, DOI 10.1073/pnas.94.23.12360; Antoniou D, 2002, EUR J BIOCHEM, V269, P3103, DOI 10.1046/j.1432-1033.2002.03021.x; BAHNSON BJ, 1995, METHOD ENZYMOL, V249, P373; Bahnson BJ, 1997, P NATL ACAD SCI USA, V94, P12797, DOI 10.1073/pnas.94.24.12797; BAHNSON BJ, 1993, BIOCHEMISTRY-US, V32, P5503, DOI 10.1021/bi00072a003; Barna T, 2002, J BIOL CHEM, V277, P30976, DOI 10.1074/jbc.M202846200; Barna TM, 2001, J MOL BIOL, V310, P433, DOI 10.1006/jmbi.2001.4779; Basran J, 2001, J BIOL CHEM, V276, P24581, DOI 10.1074/jbc.M101178200; Basran J, 2001, J BIOL CHEM, V276, P6234, DOI 10.1074/jbc.M008141200; Basran J, 1999, BIOCHEMISTRY-US, V38, P3218, DOI 10.1021/bi982719d; Bell R. P., 1980, TUNNEL EFFECT CHEM, P51; Binks PR, 1996, APPL ENVIRON MICROB, V62, P1214, DOI 10.1128/AEM.62.4.1214-1219.1996; BOCANEGRA JA, 1993, BIOCHEMISTRY-US, V32, P2737, DOI 10.1021/bi00062a001; Borgis D, 1996, J PHYS CHEM-US, V100, P1118, DOI 10.1021/jp9522324; BRUNO WJ, 1992, BIOPHYS J, V63, P689, DOI 10.1016/S0006-3495(92)81654-5; Buckman J, 1998, BIOCHEMISTRY-US, V37, P14326, DOI 10.1021/bi981106y; Cameron CE, 1997, BIOCHEMISTRY-US, V36, P15792, DOI 10.1021/bi9716231; Cannon WR, 1998, J BIOL CHEM, V273, P26257, DOI 10.1074/jbc.273.41.26257; Cannon WR, 1996, NAT STRUCT BIOL, V3, P821, DOI 10.1038/nsb1096-821; Cleland W. W., 1991, ENZYME MECH ISOTOPE, P247; CLELAND WW, 1994, SCIENCE, V264, P1887, DOI 10.1126/science.8009219; Cleland WW, 1998, J BIOL CHEM, V273, P25529, DOI 10.1074/jbc.273.40.25529; Craig DH, 1998, BIOCHEMISTRY-US, V37, P7598, DOI 10.1021/bi980345i; Craig DH, 2001, BIOCHEM J, V359, P315, DOI 10.1042/0264-6021:3590315; Faulder PF, 2001, J AM CHEM SOC, V123, P8604, DOI 10.1021/ja016219a; FOX KM, 1994, STRUCTURE, V2, P1089, DOI 10.1016/S0969-2126(94)00111-1; FRENCH CE, 1994, BIOCHEM J, V301, P97, DOI 10.1042/bj3010097; French CE, 1996, J BACTERIOL, V178, P6623, DOI 10.1128/jb.178.22.6623-6627.1996; FREY PA, 1994, SCIENCE, V264, P1927, DOI 10.1126/science.7661899; GAO J, 1998, METHODS APPL COMBINE; GERLT JA, 1993, BIOCHEMISTRY-US, V32, P11943, DOI 10.1021/bi00096a001; GIBSON QH, 1964, J BIOL CHEM, V239, P3927; Harris RJ, 2000, BIOCHEMISTRY-US, V39, P1189, DOI 10.1021/bi991941v; Jonsson T, 1996, J AM CHEM SOC, V118, P10319, DOI 10.1021/ja961827p; Khan H, 2002, J BIOL CHEM, V277, P21906, DOI 10.1074/jbc.M200637200; Knapp MJ, 2002, J AM CHEM SOC, V124, P3865, DOI 10.1021/ja012205t; Knapp MJ, 2002, EUR J BIOCHEM, V269, P3113, DOI 10.1046/j.1432-1033.2002.03022.x; Kohen A, 1999, NATURE, V399, P496, DOI 10.1038/20981; KRAUT J, 1988, SCIENCE, V242, P533, DOI 10.1126/science.3051385; Kuznetsov AM, 1999, CAN J CHEM, V77, P1085, DOI 10.1139/cjc-77-5-6-1085; Lad C, 2003, P NATL ACAD SCI USA, V100, P5607, DOI 10.1073/pnas.0631607100; MASSEY V, 1986, J BIOL CHEM, V261, P1215; MELMON K, 1972, CLIN PHARM BASIC PRI; Mincer JS, 2003, J PHYS CHEM B, V107, P366, DOI 10.1021/jp027017j; Moffat A.C, 1986, CLARKES ISOLATION ID, DOI DOI 10.1002/JPS.2600760520; Neet KE, 1998, J BIOL CHEM, V273, P25527, DOI 10.1074/jbc.273.40.25527; Pollock VV, 2001, BIOCHEMISTRY-US, V40, P1430, DOI 10.1021/bi001842d; Rajagopalan PTR, 2002, BIOCHEMISTRY-US, V41, P12618, DOI 10.1021/bi026369d; SCRUTTON NS, 1990, NATURE, V343, P38, DOI 10.1038/343038a0; Sutcliffe MJ, 2002, EUR J BIOCHEM, V269, P3096, DOI 10.1046/j.1432-1033.2002.03020.x; VIOLA RE, 1979, ANAL BIOCHEM, V96, P334, DOI 10.1016/0003-2697(79)90590-6; Warshel A, 1998, J BIOL CHEM, V273, P27035, DOI 10.1074/jbc.273.42.27035	54	87	90	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					43973	43982		10.1074/jbc.M305983200	http://dx.doi.org/10.1074/jbc.M305983200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12941965	hybrid			2022-12-25	WOS:000186306700012
J	Carter, JM; Waite, KA; Campenot, RB; Vance, JE; Vance, DE				Carter, JM; Waite, KA; Campenot, RB; Vance, JE; Vance, DE			Enhanced expression and activation of CTP : phosphocholine cytidylyltransferase beta 2 during neurite outgrowth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; PHOSPHOLIPASE-C; PC12 CELLS; RAT-BRAIN; TRANSCRIPTION; GENE; DIACYLGLYCEROL; IDENTIFICATION; DEPHOSPHORYLATION	During differentiation neurons increase phospholipid biosynthesis to provide new membrane for neurite growth. We studied the regulation of phosphatidylcholine ( PC) biosynthesis during differentiation of two neuronal cell lines: PC12 cells and Neuro2a cells. We hypothesized that in PC12 cells nerve growth factor (NGF) would up-regulate the activity and expression of the rate-limiting enzyme in PC biosynthesis, CTP: phosphocholine cytidylyltransferase (CT). During neurite outgrowth, NGF doubled the amount of cellular PC and CT activity. CTbeta2 mRNA increased within 1 day of NGF application, prior to the formation of visible neurites, and continued to increase during neurite growth. When neurites retracted in response to NGF withdrawal, CTbeta2 mRNA, protein, and CT activity decreased. NGF specifically activated CTbeta2 by promoting its translocation from cytosol to membranes. In contrast, NGF did not alter CTalpha expression or translocation. The increase in both CTbeta2 mRNA and CT activity was inhibited by U0126, an inhibitor of mitogen-activated kinase/extracellular signal-regulated kinase kinase 1/2 (MEK1/2). In Neuro2a cells, retinoic acid significantly increased CT activity (by 54%) and increased CTbeta2 protein, coincident with neurite outgrowth but did not change CTalpha expression. Together, these data suggest that the CTbeta2 isoform of CT is specifically up-regulated and activated during neuronal differentiation to increase PC biosynthesis for growing neurites.	Univ Alberta, Canadian Inst Hlth Res Grp Mol & Cell Biol Lipids, Dept Biochem, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Canadian Inst Hlth Res Grp Mol & Cell Biol Lipids, Dept Cell Biol, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Canadian Inst Hlth Res Grp Mol & Cell Biol Lipids, Dept Med, Edmonton, AB T6G 2S2, Canada	University of Alberta; University of Alberta; University of Alberta	Vance, DE (corresponding author), Univ Alberta, Canadian Inst Hlth Res Grp Mol & Cell Biol Lipids, Dept Biochem, Edmonton, AB T6G 2S2, Canada.			Carter, Jodi/0000-0002-5973-0732				Araki W, 1997, P NATL ACAD SCI USA, V94, P11946, DOI 10.1073/pnas.94.22.11946; Bakovic M, 2000, J LIPID RES, V41, P583; Bakovic M, 2003, J BIOL CHEM, V278, P14753, DOI 10.1074/jbc.M300162200; Barrie AP, 1997, J BIOL CHEM, V272, P19666, DOI 10.1074/jbc.272.32.19666; Bodennec J, 2002, FASEB J, V16, P1814, DOI 10.1096/fj.02-0149fje; DECHAVES EP, 1995, J CELL BIOL, V128, P913, DOI 10.1083/jcb.128.5.913; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HOUWELING M, 1994, J BIOL CHEM, V269, P7544; Kano Y, 2002, NEUROCHEM RES, V27, P1655, DOI 10.1023/A:1021639128120; Karim M, 2003, BBA-MOL CELL BIOL L, V1633, P1, DOI 10.1016/S1388-1981(03)00067-2; Lykidis A, 1999, J BIOL CHEM, V274, P26992, DOI 10.1074/jbc.274.38.26992; PELECH SL, 1981, J BIOL CHEM, V256, P8283; Prinetti A, 1999, J BIOL CHEM, V274, P20916, DOI 10.1074/jbc.274.30.20916; SHEA TB, 1985, DEV BRAIN RES, V21, P307, DOI 10.1016/0165-3806(85)90220-2; SHIRATORI Y, 1995, J BIOL CHEM, V270, P29894; SLACK BE, 1991, J BIOL CHEM, V266, P24503; SLEIGHT R, 1980, J BIOL CHEM, V255, P644; STROSZNAJDER J, 1979, BIOCHIM BIOPHYS ACTA, V574, P48, DOI 10.1016/0005-2760(79)90083-3; TANAKA T, 1987, BIOCHIM BIOPHYS ACTA, V922, P85, DOI 10.1016/0005-2760(87)90248-7; Torocsik B, 2002, J NEUROSCI, V22, P8971; UTAL AK, 1991, J BIOL CHEM, V266, P24084; VANCE D, 2003, BIOCH LIPIDS LIPOPRO, P205; VANCE DE, 1984, TRENDS BIOCHEM SCI, V9, P17, DOI 10.1016/0968-0004(84)90041-0; VANCE JE, 1991, J CELL BIOL, V115, P1061, DOI 10.1083/jcb.115.4.1061; Vaudry D, 2002, SCIENCE, V296, P1648, DOI 10.1126/science.1071552; WANG YL, 1995, J BIOL CHEM, V270, P17843, DOI 10.1074/jbc.270.30.17843; WANG YL, 1995, J BIOL CHEM, V270, P354, DOI 10.1074/jbc.270.1.354; WIESPRECHT M, 1994, FEBS LETT, V353, P221; Xiong Y, 2000, NEUROSCI LETT, V283, P129, DOI 10.1016/S0304-3940(00)00929-0; Zhou AW, 1997, PEPTIDES, V18, P1179, DOI 10.1016/S0196-9781(97)00184-8	31	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44988	44994		10.1074/jbc.M307336200	http://dx.doi.org/10.1074/jbc.M307336200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12928431	hybrid			2022-12-25	WOS:000186306700135
J	Osborne, A; Teng, QC; Miles, EW; Phillips, RS				Osborne, A; Teng, QC; Miles, EW; Phillips, RS			Detection of open and closed conformations of tryptophan synthase by N-15-heteronuclear single-quantum coherence nuclear magnetic resonance of bound 1-N-15-L-tryptophan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIENZYME COMPLEX; BETA-SUBUNIT; ALPHA(2)BETA(2) COMPLEX; SALMONELLA-TYPHIMURIUM; ESCHERICHIA-COLI; 3-DIMENSIONAL STRUCTURE; SUBSTRATE-SPECIFICITY; ALLOSTERIC REGULATION; ALPHA-SUBUNIT; ACTIVE-SITES	1-N-15-L-Tryptophan (1-N-15-L-Trp) was synthesized from N-15-aniline by a Sandmeyer reaction, followed by cyclization to isatin, reduction to indole with LiAlH4, and condensation of the N-15-indole with L-serine, catalyzed by tryptophan synthase. 1-N-15-L-Trp was complexed with wild-type tryptophan synthase and beta-subunit mutants, betaK87T, betaD305A, and betaE109D, in the absence or presence of the allosteric ligands sodium chloride and disodium alpha-glycerophosphate. The enzyme complexes were observed by N-15-heteronuclear single-quantum coherence nuclear magnetic resonance (N-15-HSQC NMR) spectroscopy for the presence of 1-N-15-L-Trp bound to the beta- active site. No N-15-HSQC signal was detected for 1-N-15-L-Trp in 10 mM triethanolamine hydrochloride buffer at pH 8.1-N-15-L-Trp in the presence of wild-type tryptophan synthase in the absence or presence of 50 mM sodium chloride showed a cross peak at 10.25 ppm on the H-1 axis and 129 ppm on the N-15 axis as a result of reduced solvent exchange for the bound 1-N-15-L-Trp, consistent with formation of a closed conformation of the active site. The addition of disodium alpha-glycerophosphate produced a signal twice as intense, suggesting that the equilibrium favors the closed conformation. 15N-HSQC NMR spectra of betaK87T and betaE109D mutant Trp synthase with 1-N-15-L-Trp showed a similar cross peak either in the presence or absence of disodium alpha-glycerophosphate, indicating the preference for a closed conformation for these mutant proteins. In contrast, the betaD305A Trp synthase mutant only showed a N-15-HSQC signal in the presence of disodium alpha-glycerophosphate. Thus, this mutant Trp synthase favored an open conformation in the absence of disodium alpha-glycerophosphate but was able to form a closed conformation in the presence of disodium alpha-glycerophosphate. Our results demonstrate that the N-15-HSQC NMR spectra of 1-N-15-L-Trp bound to Trp synthase can be used to determine the conformational state of mutant forms in solution rapidly. In contrast, UV-visible spectra of wild-type and mutant Trp synthase in the presence of L-Trp with NaCl and/or disodium alpha-glycerophosphate are more difficult to interpret in terms of altered conformational equilibria.	Univ Georgia, Dept Chem, Athens, GA 30602 USA; Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA; Univ Georgia, Ctr Metalloenzyme Studies, Athens, GA 30602 USA; NIDDKD, NIH, Bethesda, MD 20892 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Phillips, RS (corresponding author), Univ Georgia, Dept Chem, Athens, GA 30602 USA.	rsphillips@chem.uga.edu		Phillips, Robert/0000-0001-8710-562X	NIGMS NIH HHS [GM42588-13] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMED SA, 1991, J BIOL CHEM, V266, P21548; ANDERSON KS, 1991, J BIOL CHEM, V266, P8020; BANIK U, 1995, BIOCHEMISTRY-US, V34, P12704, DOI 10.1021/bi00039a029; BRZOVIC PS, 1992, BIOCHEMISTRY-US, V31, P1180, DOI 10.1021/bi00119a030; CREIGHTO.TE, 1970, EUR J BIOCHEM, V13, P1, DOI 10.1111/j.1432-1033.1970.tb00892.x; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DEMOSS JA, 1962, BIOCHIM BIOPHYS ACTA, V62, P279, DOI 10.1016/0006-3002(62)90041-0; DUNN MF, 1990, BIOCHEMISTRY-US, V29, P8598, DOI 10.1021/bi00489a015; Ferrari D, 2003, BIOCHEMISTRY-US, V42, P7807, DOI 10.1021/bi034291a; Ferrari D, 2001, BIOCHEMISTRY-US, V40, P7421, DOI 10.1021/bi002892l; GIOVANNI E, 1957, HELV CHIM ACTA, V161, P1552; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; HOUBEN KF, 1990, BIOCHEMISTRY-US, V29, P2421, DOI 10.1021/bi00461a028; HYDE CC, 1988, J BIOL CHEM, V263, P17857; KIRSCHNER K, 1975, EUR J BIOCHEM, V60, P513, DOI 10.1111/j.1432-1033.1975.tb21030.x; KIRSCHNER K, 1991, BIOCHEMISTRY-US, V30, P472, DOI 10.1021/bi00216a024; Kirschner K., 1975, PROTEIN LIGAND INTER, P27, DOI [10.1515/9783110830811-006, DOI 10.1515/9783110830811-006]; LU ZC, 1993, J BIOL CHEM, V268, P8727; Marvel C. S., 1941, ORG SYNTH, V1, P327; MATCHETT WH, 1974, J BIOL CHEM, V249, P4041; MCDOWELL LM, 1995, J AM CHEM SOC, V117, P12352, DOI 10.1021/ja00154a045; Miles E W, 1995, Subcell Biochem, V24, P207; Miles E W, 1979, Adv Enzymol Relat Areas Mol Biol, V49, P127; MILES EW, 1986, BIOCHEMISTRY-US, V25, P4240, DOI 10.1021/bi00363a011; MILES EW, 1989, J BIOL CHEM, V264, P6280; MILES EW, 1991, ADV ENZYMOL RAMB, V64, P93; PERACCHI A, 1995, BIOCHEMISTRY-US, V34, P9459, DOI 10.1021/bi00029a022; Peracchi A, 1996, BIOCHEMISTRY-US, V35, P1872, DOI 10.1021/bi951889c; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Rhee S, 1997, BIOCHEMISTRY-US, V36, P7664, DOI 10.1021/bi9700429; Rhee S, 1996, BIOCHEMISTRY-US, V35, P4211, DOI 10.1021/bi952506d; RUVINOV SB, 1995, J BIOL CHEM, V270, P17333, DOI 10.1074/jbc.270.29.17333; Sandmeyer T, 1919, HELV CHIM ACTA, V2, P234, DOI 10.1002/hlca.19190020125; Schneider TR, 1998, BIOCHEMISTRY-US, V37, P5394, DOI 10.1021/bi9728957; UNKEFER CJ, 1991, J LABELLED COMPD RAD, V29, P1247, DOI 10.1002/jlcr.2580291109; VANDENBERG EMM, 1988, RECL TRAV CHIM PAY B, V107, P73; VUISTER GW, 1992, J MAGN RESON, V98, P428, DOI 10.1016/0022-2364(92)90144-V; Weber-Ban E, 2001, BIOCHEMISTRY-US, V40, P3497, DOI 10.1021/bi002690p; WEYLAND M, 1999, BIOCHEMISTRY-US, V38, P16469; Yang LH, 1996, PROTEIN EXPRES PURIF, V8, P126, DOI 10.1006/prep.1996.0082; YANOFSKY C, 1958, BIOCHIM BIOPHYS ACTA, V28, P640, DOI 10.1016/0006-3002(58)90533-X; YANOFSKY C, 1972, ENZYMES, V3, P1; YUAN SS, 1982, TETRAHEDRON, V38, P2051, DOI 10.1016/0040-4020(82)85150-8; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413	44	22	22	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44083	44090		10.1074/jbc.M308276200	http://dx.doi.org/10.1074/jbc.M308276200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12939261	hybrid			2022-12-25	WOS:000186306700025
J	Patel, M; Morrow, J; Maxfield, FR; Strickland, DK; Greenberg, S; Tabas, I				Patel, M; Morrow, J; Maxfield, FR; Strickland, DK; Greenberg, S; Tabas, I			The cytoplasmic domain of the low density lipoprotein (LDL) receptor-related protein, but not that of the LDL receptor, triggers phagocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATHEROSCLEROTIC LESION FORMATION; SMOOTH-MUSCLE-CELLS; TYROSINE PHOSPHORYLATION; MACROPHAGE UPTAKE; MEDIATED PHAGOCYTOSIS; APOPTOTIC CELLS; ADAPTER PROTEIN; BINDING; INTERNALIZATION; MATRIX	The macrophage LDL receptor and LDL receptor-related protein (LRP, CD91) mediate the phagocytic-like uptake of atherogenic lipoproteins and apoptotic cells, yet the structural basis of their phagocytic functions is not known. To address this issue, we transfected macrophages with chimeric proteins containing the cytoplasmic tails and transmembrane regions of the LDL receptor or LRP and the ectodomain of CD2, which can bind non-opsonized sheep red blood cells (SRBCs). Macrophages expressing receptors containing the LDL receptor domains were able to bind but not internalize SRBCs. In contrast, macrophages expressing receptors containing the cytoplasmic tail of LRP were able to bind and internalize SRBCs. Chimeras in which the LRP cytoplasmic tail was mutated in two di-leucine motifs and a tyrosine in an NPXYXXL motif were able to endocytose anti-CD2 antibody and bind SRBCs, but SRBC phagocytosis was decreased by 70%. Thus, the phagocytic-like functions of LRP, but not those of the LDL receptor, can be explained by the ability of the LRP cytoplasmic tail to trigger phagocytosis. These findings have important implications for atherogenesis and apoptotic cell clearance and for a fundamental cell biological understanding of how the LDL receptor and LRP function in internalization processes.	Columbia Univ, Dept Med, New York, NY 10032 USA; Columbia Univ, Dept Pharmacol, New York, NY 10032 USA; Columbia Univ, Dept Anat & Cell Biol, New York, NY 10032 USA; Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY 10021 USA; Amer Red Cross, Jerome H Holland Lab Biomed Sci, Dept Vasc Biol, Rockville, MD 20855 USA	Columbia University; Columbia University; Columbia University; Cornell University; American Red Cross	Tabas, I (corresponding author), Columbia Univ, Dept Med, 630 W 168th St, New York, NY 10032 USA.		Maxfield, Fred/A-1718-2011; Maxfield, Fred/M-6747-2019	Maxfield, Fred/0000-0003-4396-8866; Morrow, John/0000-0002-9264-5273	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056984, R01HL054164, R01HL057560, P01HL054710] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-54710, HL-54164, HL-57560, HL-56984] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barnes H, 2003, ONCOGENE, V22, P3589, DOI 10.1038/sj.onc.1206504; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Boucher P, 2002, J BIOL CHEM, V277, P15507, DOI 10.1074/jbc.M200428200; Buton X, 1999, J BIOL CHEM, V274, P32112, DOI 10.1074/jbc.274.45.32112; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; Cox D, 1997, J EXP MED, V186, P1487, DOI 10.1084/jem.186.9.1487; Cox D, 1999, J BIOL CHEM, V274, P1240, DOI 10.1074/jbc.274.3.1240; Cox D, 2001, J EXP MED, V193, P61, DOI 10.1084/jem.193.1.61; DAUGHERTY A, 1994, ARTERIOSCLER THROMB, V14, P2017, DOI 10.1161/01.ATV.14.12.2017; Garcia CK, 2001, SCIENCE, V292, P1394, DOI 10.1126/science.1060458; Goretzki L, 1998, BIOCHEM J, V336, P381, DOI 10.1042/bj3360381; Greenberg S, 1996, P NATL ACAD SCI USA, V93, P1103, DOI 10.1073/pnas.93.3.1103; GREENBERG S, 1999, INFLAMMATION BASIC P, P681; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Herijgers N, 2000, ARTERIOSCL THROM VAS, V20, P1961, DOI 10.1161/01.ATV.20.8.1961; Hiltunen TP, 1998, ATHEROSCLEROSIS, V137, pS81, DOI 10.1016/S0021-9150(97)00307-9; HOFF HF, 1991, LAB INVEST, V64, P254; HOFF HF, 1990, EUR HEART J, V11, P105, DOI 10.1093/eurheartj/11.suppl_E.105; HUTCHINSON MJ, 1995, EUR J IMMUNOL, V25, P481, DOI 10.1002/eji.1830250226; INDIK ZK, 1995, IMMUNOL LETT, V44, P133, DOI 10.1016/0165-2478(94)00204-5; ISHIKAWA Y, 1991, Journal of Biomaterials Science Polymer Edition, V2, P53, DOI 10.1163/156856291X00052; KHOO JC, 1988, ARTERIOSCLEROSIS, V8, P348, DOI 10.1161/01.ATV.8.4.348; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; Koval M, 1998, EXP CELL RES, V242, P265, DOI 10.1006/excr.1998.4110; KRUSKAL BA, 1992, J EXP MED, V176, P1673, DOI 10.1084/jem.176.6.1673; Kruth HS, 2002, CURR OPIN LIPIDOL, V13, P483, DOI 10.1097/00041433-200210000-00003; KUBOTA Y, 1983, Journal of Toxicological Sciences, V8, P189; Li YS, 2000, J BIOL CHEM, V275, P37187, DOI 10.1074/jbc.M000490200; Linton MF, 1999, J BIOL CHEM, V274, P19204, DOI 10.1074/jbc.274.27.19204; Llorente-Cortes V, 2000, ARTERIOSCL THROM VAS, V20, P1572, DOI 10.1161/01.ATV.20.6.1572; Loukinova E, 2002, J BIOL CHEM, V277, P15499, DOI 10.1074/jbc.M200427200; LUND H, 1989, P NATL ACAD SCI USA, V86, P9318, DOI 10.1073/pnas.86.23.9318; LUPU F, 1994, ARTERIOSCLER THROMB, V14, P1438, DOI 10.1161/01.ATV.14.9.1438; Misra UK, 1999, ARCH BIOCHEM BIOPHYS, V372, P238, DOI 10.1006/abbi.1999.1521; Morris SM, 2001, TRAFFIC, V2, P111, DOI 10.1034/j.1600-0854.2001.020206.x; Ogden CA, 2001, J EXP MED, V194, P781, DOI 10.1084/jem.194.6.781; PRATTEN MK, 1986, BIOCHIM BIOPHYS ACTA, V881, P307, DOI 10.1016/0304-4165(86)90020-6; Sakr SW, 2001, J BIOL CHEM, V276, P37649, DOI 10.1074/jbc.M105129200; Su HP, 2002, J BIOL CHEM, V277, P11772, DOI 10.1074/jbc.M109336200; SUITS AG, 1989, P NATL ACAD SCI USA, V86, P2713, DOI 10.1073/pnas.86.8.2713; TABAS I, 1993, J BIOL CHEM, V268, P20419; Tabas I, 1999, ANNU REV NUTR, V19, P123, DOI 10.1146/annurev.nutr.19.1.123; Tridandapani S, 2002, J IMMUNOL, V169, P4370, DOI 10.4049/jimmunol.169.8.4370; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Tse SML, 2003, J BIOL CHEM, V278, P3331, DOI 10.1074/jbc.M207966200; Vandivier RW, 2002, J IMMUNOL, V169, P3978, DOI 10.4049/jimmunol.169.7.3978; VanNhieu GT, 1996, J BIOL CHEM, V271, P7665, DOI 10.1074/jbc.271.13.7665; WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551; XU XX, 1991, J BIOL CHEM, V266, P24849	49	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44799	44807		10.1074/jbc.M308982200	http://dx.doi.org/10.1074/jbc.M308982200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12941948	hybrid			2022-12-25	WOS:000186306700114
J	Sathish, HA; Stein, RA; Yang, GY; Mchaourab, HS				Sathish, HA; Stein, RA; Yang, GY; Mchaourab, HS			Mechanism of chaperone function in small heat-shock proteins - Fluorescence studies of the conformations of T4 lysozyme bound to alpha B-crystallin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONE; A-CRYSTALLIN; SUBUNIT EXCHANGE; SECONDARY STRUCTURE; MISSENSE MUTATION; 2-MODE BINDING; EXCITED-STATES; IN-VITRO; SPECTROSCOPY; DYNAMICS	To further develop the mechanistic understanding of small heat-shock protein ( sHSP) chaperone activity, we investigate the nature of the intermediate states recognized by alpha-crystallin and the conformations that are stably bound. The model substrates consist of a set of well characterized, destabilized T4 Lysozyme (T4L) mutants that have been shown to differentially bind alpha-crystallin in a manner that reflects their free-energy of unfolding. A new approach for the detection of complex formation is introduced based on the conformational sensitivity of the fluorescent probe bimane, site-specifically introduced in T4L. Emission spectra of bimanelabeled T4L reveal two distinct patterns of intensity changes upon binding that depend on the molar ratio of alpha-crystallin to T4L. This directly demonstrates the two-mode nature of the binding process by the alpha-crystallins. Biphasic binding isotherms, obtained and analyzed over a wide range of T4L concentrations, demonstrate a substantially quenched bimane fluorescence in the low affinity-bound T4L that is similar to the quenching level observed due to denaturant unfolding. Furthermore, the pattern of intensity changes that occur upon binding of a T4L variant, bimane-labeled at an alternative solvent-exposed site, establishes a direct correlation between the quenching level observed in binding and unfolding. The results can be interpreted in terms of a model where alpha-crystallin binds at least two conformationally distinct non-native states of T4L, one of which is substantially unfolded and is bound with low affinity. A high affinity binding mode to compact states may be relevant to chaperone function in the lens, where protein damage is unlikely to cause global unfolding.	Vanderbilt Univ, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Vanderbilt University	Mchaourab, HS (corresponding author), Vanderbilt Univ, Dept Mol Physiol & Biophys, 741 Light Hall, Nashville, TN 37232 USA.	hassane.mchaourab@vanderbilt.edu			NEI NIH HHS [EY-R0112683] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY012683] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BAI YW, 1995, SCIENCE, V269, P192, DOI 10.1126/science.7618079; Bova MP, 2000, J BIOL CHEM, V275, P1035, DOI 10.1074/jbc.275.2.1035; Bova MP, 2002, J BIOL CHEM, V277, P38468, DOI 10.1074/jbc.M205594200; Carver JA, 2002, J MOL BIOL, V318, P815, DOI 10.1016/S0022-2836(02)00144-4; Cobb BA, 2002, BIOCHEMISTRY-US, V41, P483, DOI 10.1021/bi0112457; Das BK, 1997, CURR EYE RES, V16, P303, DOI 10.1076/ceyr.16.4.303.10691; Das KP, 1999, J BIOL CHEM, V274, P33209, DOI 10.1074/jbc.274.47.33209; DAS KP, 1995, FEBS LETT, V369, P321, DOI 10.1016/0014-5793(95)00775-5; Das KP, 1996, J BIOL CHEM, V271, P10449, DOI 10.1074/jbc.271.18.10449; Ehrnsperger M, 1999, J BIOL CHEM, V274, P14867, DOI 10.1074/jbc.274.21.14867; Englander SW, 1998, TRENDS BIOCHEM SCI, V23, P378, DOI 10.1016/S0968-0004(98)01281-X; Giese KC, 2002, J BIOL CHEM, V277, P46310, DOI 10.1074/jbc.M208926200; Grantcharova V, 2001, CURR OPIN STRUC BIOL, V11, P70, DOI 10.1016/S0959-440X(00)00176-7; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Horwitz J, 2000, SEMIN CELL DEV BIOL, V11, P53, DOI 10.1006/scdb.1999.0351; Kappe G, 2003, CELL STRESS CHAPERON, V8, P53, DOI 10.1379/1466-1268(2003)8<53:THGECS>2.0.CO;2; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; Koteiche HA, 2003, J BIOL CHEM, V278, P10361, DOI 10.1074/jbc.M211851200; Koteiche HA, 1998, BIOCHEMISTRY-US, V37, P12681, DOI 10.1021/bi9814078; Koteiche HA, 1999, J MOL BIOL, V294, P561, DOI 10.1006/jmbi.1999.3242; LEE GJ, 1995, J BIOL CHEM, V270, P10432, DOI 10.1074/jbc.270.18.10432; Litt M, 1998, HUM MOL GENET, V7, P471, DOI 10.1093/hmg/7.3.471; MacRae TH, 2000, CELL MOL LIFE SCI, V57, P899, DOI 10.1007/PL00000733; Mansoor SE, 2002, BIOCHEMISTRY-US, V41, P2475, DOI 10.1021/bi011198i; Mansoor SE, 1999, BIOCHEMISTRY-US, V38, P16383, DOI 10.1021/bi991331v; Matthews BW, 1996, FASEB J, V10, P35, DOI 10.1096/fasebj.10.1.8566545; Mchaourab HS, 1996, BIOCHEMISTRY-US, V35, P7692, DOI 10.1021/bi960482k; Mchaourab HS, 2002, J BIOL CHEM, V277, P40557, DOI 10.1074/jbc.M206250200; Mulder FAA, 2001, NAT STRUCT BIOL, V8, P932, DOI 10.1038/nsb1101-932; Pace CN, 2000, PROTEINS, P1; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; Sobott F, 2002, J BIOL CHEM, V277, P38921, DOI 10.1074/jbc.M206060200; Van Montfort R, 2002, ADV PROTEIN CHEM, V59, P105; van Montfort RLM, 2001, NAT STRUCT BIOL, V8, P1025, DOI 10.1038/nsb722; Verschuure P, 2002, J MOL CELL CARDIOL, V34, P117, DOI 10.1006/jmcc.2001.1493; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; Wang ZX, 1996, FEBS LETT, V392, P245, DOI 10.1016/0014-5793(96)00818-6; Xu ZH, 1998, J STRUCT BIOL, V124, P129, DOI 10.1006/jsbi.1998.4060	38	50	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44214	44221		10.1074/jbc.M307578200	http://dx.doi.org/10.1074/jbc.M307578200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12928430	hybrid			2022-12-25	WOS:000186306700041
J	Benko, S; Love, JD; Beladi, M; Schwabe, JWR; Nagy, L				Benko, S; Love, JD; Beladi, M; Schwabe, JWR; Nagy, L			Molecular determinants of the balance between co-repressor and co-activator recruitment to the retinoic acid receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR HORMONE-RECEPTORS; LIGAND-BINDING DOMAIN; THYROID-HORMONE; ESTROGEN-RECEPTOR; TRANSCRIPTIONAL REPRESSION; HISTONE ACETYLTRANSFERASE; INTERACTING DOMAINS; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; COMPLEX	The repressive and activating states of nuclear hormone receptors are achieved through the recruitment of cofactor proteins. The binding of co-repressors and coactivators is believed to be mutually exclusive and principally regulated by ligand binding. To understand the molecular determinants of the switch induced by ligand in the retinoic acid receptor and in particular the intrinsic role of the ligand binding domain (LBD) in cofactor binding and release, we carried out extensive mutational analysis of surface residues of the LBD. As seen previously we found that co-repressor and co-activator molecules bind to overlapping docking sites on the surface of the retinoic acid receptor alpha LBD. Perturbation of this surface impaired both co- activator and co- repressor association resulting in a transcriptionally inert receptor. Unexpectedly mutation of two residues, Trp-225 and Ala-392, which lie outside the docking site, had opposite effects on co- activator and co- repressor binding. W225A was a constitutive repressor that failed to bind co- activator and exhibited an increased, and ligand-insensitive, interaction with co- repressor. A392R, on the other hand, had reduced affinity for co- repressors and increased affinity for co- activators and behaved as a constitutive, but still ligand-inducible, activator. Analysis of known structures showed that these mutations lie in the proximity of helix 12 (H12), and their effects are likely to be the result of perturbations in the behavior of H12. These data suggest that residues in the close vicinity of H12 regulate cofactor affinity and determine the basal activity of receptors.	Univ Debrecen, Med & Hlth Sci Ctr, Res Ctr Mol Med, Dept Biochem & Mol Biol, H-4012 Debrecen, Hungary; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	University of Debrecen; MRC Laboratory Molecular Biology	Nagy, L (corresponding author), Univ Debrecen, Med & Hlth Sci Ctr, Res Ctr Mol Med, Dept Biochem & Mol Biol, Nagyerdei Krt 98, H-4012 Debrecen, Hungary.		Nagy, Laszlo/A-3814-2008; Schwabe, John WR/A-9132-2008	Nagy, Laszlo/0000-0001-6653-2155; Schwabe, John WR/0000-0003-2865-4383				BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; Barroso I, 1999, NATURE, V402, P880, DOI 10.1038/47254; Berger J, 2002, ANNU REV MED, V53, P409, DOI 10.1146/annurev.med.53.082901.104018; Bourguet W, 2000, MOL CELL, V5, P289, DOI 10.1016/S1097-2765(00)80424-4; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Cohen RN, 2001, MOL ENDOCRINOL, V15, P1049, DOI 10.1210/me.15.7.1049; Collingwood TN, 1999, J MOL ENDOCRINOL, V23, P255, DOI 10.1677/jme.0.0230255; Collins SJ, 2002, LEUKEMIA, V16, P1896, DOI 10.1038/sj.leu.2402718; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; DELESCLUSE C, 1991, MOL PHARMACOL, V40, P556; Gelman L, 1999, CELL MOL LIFE SCI, V55, P932, DOI 10.1007/s000180050345; Ghosh JC, 2002, P NATL ACAD SCI USA, V99, P5842, DOI 10.1073/pnas.092043399; Glass CK, 2000, GENE DEV, V14, P121; Gottlicher M, 1998, J MOL MED-JMM, V76, P480, DOI 10.1007/s001090050242; Hansen LA, 2000, CARCINOGENESIS, V21, P1271, DOI 10.1093/carcin/21.7.1271; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hellal-Levy C, 2000, MOL ENDOCRINOL, V14, P1210, DOI 10.1210/me.14.8.1210; Hermanson O, 2002, TRENDS ENDOCRIN MET, V13, P55, DOI 10.1016/S1043-2760(01)00527-6; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Johnson BA, 2000, J MOL BIOL, V298, P187, DOI 10.1006/jmbi.2000.3636; Kallenberger BC, 2003, NAT STRUCT BIOL, V10, P136, DOI 10.1038/nsb892; Lee WY, 2002, BIOCHEMISTRY-US, V41, P2500, DOI 10.1021/bi011764+; Li H, 1997, MOL ENDOCRINOL, V11, P2025, DOI 10.1210/me.11.13.2025; Lin BC, 1997, MOL CELL BIOL, V17, P6131, DOI 10.1128/MCB.17.10.6131; Malloy PJ, 2002, MOL ENDOCRINOL, V16, P2538, DOI 10.1210/me.2002-0152; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MANGELSDORF DJ, 1994, NUTR REV, V52, P32; Marimuthu A, 2002, MOL ENDOCRINOL, V16, P271, DOI 10.1210/me.16.2.271; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; Nagy L, 1999, GENE DEV, V13, P3209, DOI 10.1101/gad.13.24.3209; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; Pike ACW, 2000, BIOCHEM SOC T, V28, P396, DOI 10.1042/0300-5127:0280396; Rachez C, 2000, MOL CELL BIOL, V20, P2718, DOI 10.1128/MCB.20.8.2718-2726.2000; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; Robyr D, 2000, MOL ENDOCRINOL, V14, P329, DOI 10.1210/me.14.3.329; Sande S, 1996, MOL ENDOCRINOL, V10, P813, DOI 10.1210/me.10.7.813; Seol W, 1996, MOL ENDOCRINOL, V10, P1646, DOI 10.1210/me.10.12.1646; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Shibata H, 1997, RECENT PROG HORM RES, V52, P141; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Xu HE, 2002, NATURE, V415, P813, DOI 10.1038/415813a; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Zhang JS, 1999, MOL CELL BIOL, V19, P6448	58	28	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43797	43806		10.1074/jbc.M306199200	http://dx.doi.org/10.1074/jbc.M306199200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12917445	hybrid, Green Published			2022-12-25	WOS:000186157000130
J	Yanaka, N; Imai, Y; Kawai, E; Akatsuka, H; Wakimoto, K; Nogusa, Y; Kato, N; Chiba, H; Kotani, E; Omori, K; Sakurai, N				Yanaka, N; Imai, Y; Kawai, E; Akatsuka, H; Wakimoto, K; Nogusa, Y; Kato, N; Chiba, H; Kotani, E; Omori, K; Sakurai, N			Novel membrane protein containing glycerophosphodiester phosphodiesterase motif is transiently expressed during osteoblast differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARREST; GENE; PHOSPHORYLATION; PROLIFERATION; BINDING; CULTURE; SYSTEM; SHAPE; CBFA1; CELLS	Osteoblast maturation is a multistep series of events characterized by an integrated cascade of gene expression that are accompanied by specific phenotypic alterations. To find new osteoblast-related genes we cloned differentially expressed cDNAs characteristic of specific differentiation stages in the mouse osteoblast-like MC3T3-E1 cells by a differential display method. We identified a novel cDNA encoding a putative glycerophosphodiester phosphodiesterase, GDE3, which specifically was expressed at the stage of matrix maturation. Interestingly, the deduced amino acid sequence contains 539 amino acids including seven putative transmembrane domains and a glycerophosphodiester phosphodiesterase region in one of the extracellular loops. Northern blot analysis revealed that GDE3 was also expressed in spleen as well as primary calvarial osteoblasts and femur. We next transfected HEK293T cells with GDE3 with green fluorescent protein fused to the C terminus. The green fluorescent protein-fused protein accumulated at the cell periphery, and the transfected cells overexpressing the protein changed from a spread form to rounded form with disappearance of actin filaments. Immunofluorescence staining with GDE3 antibody and phalloidin in MC3T3-E1 cells indicated that endogenous GDE3 might be co-localized with the actin cytoskeleton. To identify a role for GDE3 in osteoblast differentiation, MC3T3-E1 cells stably expressing the full-length protein were constructed. Expression of GDE3 showed morphological changes, resulting in dramatic increases in alkaline phosphatase activity and calcium deposit. These results suggest that GDE3 might be a novel seven-transmembrane protein with a GP-PDE-like extracellular motif expressed during the osteoblast differentiation that dramatically accelerates the program of osteoblast differentiation and is involved in the morphological change of cells.	Tanabe Seiyaku Co Ltd, Discovery Res Lab, Toda, Saitama 3358305, Japan; Tanabe Seiyaku Co Ltd, Discovery Res Lab, Yodogawa Ku, Osaka 5328505, Japan; Hiroshima Univ, Grad Sch Biosphere Sci, Dept Mol & Appl Biosci, Higashihiroshima 7398528, Japan	Mitsubishi Tanabe Pharma Corporation; Mitsubishi Tanabe Pharma Corporation; Hiroshima University	Imai, Y (corresponding author), Tanabe Seiyaku Co Ltd, Discovery Res Lab, 2-50 Kawagishi 2 Chome, Toda, Saitama 3358305, Japan.		Yanaka, Noriyuki/P-9096-2016					Aubin JE, 1999, J CELL BIOCHEM, V72, P396, DOI 10.1002/(SICI)1097-4644(19990301)72:3<396::AID-JCB9>3.3.CO;2-Y; Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Fan X, 2001, MOL MICROBIOL, V41, P1029, DOI 10.1046/j.1365-2958.2001.02571.x; Guardavaccaro D, 2000, MOL CELL BIOL, V20, P1797, DOI 10.1128/MCB.20.5.1797-1815.2000; Hagiwara H, 1996, AM J PHYSIOL-CELL PH, V270, pC1311, DOI 10.1152/ajpcell.1996.270.5.C1311; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; JONES SJ, 1976, CELL TISSUE RES, V169, P449; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MILLER SS, 1976, SCIENCE, V192, P1340, DOI 10.1126/science.1273593; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MUNSON RS, 1993, J BACTERIOL, V175, P4569, DOI 10.1128/JB.175.14.4569-4571.1993; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Raouf A, 2002, BONE, V30, P463, DOI 10.1016/S8756-3282(01)00699-8; RODAN GA, 1981, CALCIFIED TISSUE INT, V33, P349, DOI 10.1007/BF02409454; Sakurai N, 2002, J BONE MINER RES, V17, pS194; STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; Tanaka-Kamioka K, 1998, J BONE MINER RES, V13, P1555, DOI 10.1359/jbmr.1998.13.10.1555; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; TOMMASSEN J, 1991, MOL GEN GENET, V226, P321, DOI 10.1007/BF00273621; Tsuda M, 1997, J NEUROSCI, V17, P6678; Yang RS, 1998, BONE, V22, P629, DOI 10.1016/S8756-3282(98)00055-6; Yuasa K, 2000, J BIOL CHEM, V275, P4897, DOI 10.1074/jbc.275.7.4897; Zheng B, 2003, P NATL ACAD SCI USA, V100, P1745, DOI 10.1073/pnas.0337605100; Zheng B, 2000, P NATL ACAD SCI USA, V97, P3999, DOI 10.1073/pnas.97.8.3999	27	36	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43595	43602		10.1074/jbc.M302867200	http://dx.doi.org/10.1074/jbc.M302867200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12933806	hybrid			2022-12-25	WOS:000186157000107
J	Vasiljeva, L; Merits, A; Golubtsov, A; Sizemskaja, V; Kaariainen, L; Ahola, T				Vasiljeva, L; Merits, A; Golubtsov, A; Sizemskaja, V; Kaariainen, L; Ahola, T			Regulation of the sequential processing of Semliki Forest virus replicase polyprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND RNA-SYNTHESIS; SINDBIS VIRUS; NONSTRUCTURAL POLYPROTEIN; CRYSTAL-STRUCTURE; PROTEIN NSP2; TEMPORAL REGULATION; MINUS-STRAND; CLEAVAGE; SITE; COMPLEXES	The replication of most positive-strand RNA viruses and retroviruses is regulated by proteolytic processing. Alphavirus replicase proteins are synthesized as a polyprotein, called P1234, which is cleaved into nsP1, nsP2, nsP3, and nsP4 by the carboxyl-terminal protease domain of nsP2. The cleavage intermediate P123 + nsP4 synthesizes minus-strand copies of the viral RNA genome, whereas the completely processed complex is required for plus-strand synthesis. To understand the mechanisms responsible for this sequential proteolysis, we analyzed in vitro translated Semliki Forest virus polyproteins containing noncleavable processing sites or various deletions. Processing of each of the three sites in vitro required a different type of activity. Site 3/4 was cleaved in trans by nsP2, its carboxyl-terminal fragment Pro39, and by all polyprotein proteases. Site 1/2 was cleaved in cis with a half-life of about 20-30 min. Site 2/3 was cleaved rapidly in trans but only after release of nsP1 from the polyprotein exposing an "activator" sequence present in the amino terminus of nsP2. Deletion of amino-terminal amino acids of nsP2 or addition of extra amino acid residues to its amino terminus specifically inhibited the protease activity that processes the 2/3 site. This sequence of delayed processing of P1234 would explain the accumulation of P123 plus nsP4, the early short-lived minus-strand replicase. The polyprotein stage would allow correct assembly and membrane association of the RNA-polymerase complex. Late in infection free nsP2 would cleave at site 2/3 yielding P12 and P34, the products of which, nsP1-4, are distributed to the plasma membrane, nucleus, cytoplasmic aggregates, and proteasomes, respectively.	Univ Helsinki, Viikki Bioctr, Inst Biotechnol, Program Cellular Biotechnol, FIN-00014 Helsinki, Finland; Estonian Bioctr, EE-51010 Tartu, Estonia; Inst Mol & Cellular Biol, EE-51010 Tartu, Estonia	University of Helsinki; Estonian Biocentre	Kaariainen, L (corresponding author), Univ Helsinki, Viikki Bioctr, Inst Biotechnol, Program Cellular Biotechnol, POB 56, FIN-00014 Helsinki, Finland.		Merits, Andres/H-3125-2015; Lulla, Valeria/W-1994-2019	Merits, Andres/0000-0001-8193-0071; Lulla, Valeria/0000-0002-6605-0727; Golubtsov, Andrey/0000-0002-1418-7692; Vasiljeva, Lidia/0000-0002-1244-8772				Ahola T, 1999, EMBO J, V18, P3164, DOI 10.1093/emboj/18.11.3164; BARTENSCHLAGER R, 1994, J VIROL, V68, P5045, DOI 10.1128/JVI.68.8.5045-5055.1994; de Cedron MG, 1999, FEBS LETT, V448, P19, DOI 10.1016/S0014-5793(99)00321-X; DEGROOT RJ, 1990, EMBO J, V9, P2631, DOI 10.1002/j.1460-2075.1990.tb07445.x; DEGROOT RJ, 1991, P NATL ACAD SCI USA, V88, P8967, DOI 10.1073/pnas.88.20.8967; DING MX, 1989, VIROLOGY, V171, P280, DOI 10.1016/0042-6822(89)90539-4; FROSHAUER S, 1988, J CELL BIOL, V107, P2075, DOI 10.1083/jcb.107.6.2075; Griffin D.E., 2001, FIELDS VIROLOGY, P917; HARDY WR, 1989, J VIROL, V63, P4653, DOI 10.1128/JVI.63.11.4653-4664.1989; Kaariainen L, 2002, PROG NUCLEIC ACID RE, V71, P187, DOI 10.1016/S0079-6603(02)71044-1; KERANEN S, 1983, J VIROL, V47, P505; Kim JL, 1996, CELL, V87, P343, DOI 10.1016/S0092-8674(00)81351-3; Kujala P, 2001, J VIROL, V75, P3873, DOI 10.1128/JVI.75.8.3873-3884.2001; LACHMI BE, 1976, P NATL ACAD SCI USA, V73, P1936, DOI 10.1073/pnas.73.6.1936; LEHTOVAARA P, 1980, EUR J BIOCHEM, V112, P461; Lemm JA, 1998, J VIROL, V72, P6546, DOI 10.1128/JVI.72.8.6546-6553.1998; LEMM JA, 1993, J VIROL, V67, P1905, DOI 10.1128/JVI.67.4.1905-1915.1993; LEMM JA, 1993, J VIROL, V67, P1916, DOI 10.1128/JVI.67.4.1916-1926.1993; LEMM JA, 1994, EMBO J, V13, P2925, DOI 10.1002/j.1460-2075.1994.tb06587.x; LIN C, 1994, J VIROL, V68, P8147, DOI 10.1128/JVI.68.12.8147-8157.1994; LINDENBACH BD, 2001, FIELDS VIROLOGY, P991; Love RA, 1996, CELL, V87, P331, DOI 10.1016/S0092-8674(00)81350-1; Merits A, 2001, J GEN VIROL, V82, P765, DOI 10.1099/0022-1317-82-4-765; PERANEN J, 1995, VIROLOGY, V208, P610, DOI 10.1006/viro.1995.1192; PERANEN J, 1990, J VIROL, V64, P1888; RIKKONEN M, 1994, J VIROL, V68, P5804, DOI 10.1128/JVI.68.9.5804-5810.1994; Salonen A, 2003, J VIROL, V77, P1691, DOI 10.1128/JVI.77.3.1691-1702.2003; Schlesinger S, 2001, EXPERT OPIN BIOL TH, V1, P177, DOI 10.1517/14712598.1.2.177; SHIRAKO Y, 1990, VIROLOGY, V177, P54, DOI 10.1016/0042-6822(90)90459-5; SHIRAKO Y, 1994, J VIROL, V68, P1874, DOI 10.1128/JVI.68.3.1874-1885.1994; Smerdou C, 1999, CURR OPIN MOL THER, V1, P244; STRAUSS EG, 1992, VIROLOGY, V191, P932, DOI 10.1016/0042-6822(92)90268-T; TAKKINEN K, 1991, J GEN VIROL, V72, P1627, DOI 10.1099/0022-1317-72-7-1627; Vasiljeva L, 2001, J BIOL CHEM, V276, P30786, DOI 10.1074/jbc.M104786200; Vasiljeva L, 2000, J BIOL CHEM, V275, P17281, DOI 10.1074/jbc.M910340199; WANG YF, 1994, J VIROL, V68, P6466, DOI 10.1128/JVI.68.10.6466-6475.1994; Weston J, 2002, J VIROL, V76, P6155, DOI 10.1128/JVI.76.12.6155-6163.2002; Yao NH, 1999, STRUCTURE, V7, P1353, DOI 10.1016/S0969-2126(00)80025-8; Yao NH, 1997, NAT STRUCT BIOL, V4, P463, DOI 10.1038/nsb0697-463	39	74	76	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41636	41645		10.1074/jbc.M307481200	http://dx.doi.org/10.1074/jbc.M307481200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12917405	hybrid			2022-12-25	WOS:000185989500012
J	Roucou, X; Guo, Q; Zhang, Y; Goodyer, CG; LeBlanc, AC				Roucou, X; Guo, Q; Zhang, Y; Goodyer, CG; LeBlanc, AC			Cytosolic prion protein is not toxic and protects against Bax-mediated cell death in human primary neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRPSC-LIKE CONFORMATION; DE-NOVO GENERATION; CONVERSION; PROTEASOME; APOPTOSIS; MITOCHONDRIA; DEGRADATION; SUPPRESSES; STABILITY; TRANSPORT	Recently, it was observed that reverse-translocated cytosolic PrP and PrP expressed in the cytosol induce rapid death in neurons (Ma, J., Wollmann, R., and Lindquist, S. ( 2002) Science 298, 1781 - 1785). In this study, we investigated whether accumulation of prion protein ( PrP) in the cytosol is toxic to human neurons in primary culture. We show that in these neurons, a single PrP isoform lacking signal peptide accumulates in the cytosol of neurons treated with epoxomicin, a specific proteasome inhibitor. Therefore, endogenously expressed PrP is subject to the endoplasmic reticulum-associated degradation (ERAD) pathway and is degraded by the proteasome in human primary neurons. In contrast to its toxicity in N2a cells, reverse-translocated PrP (ERAD-PrP) is not toxic even when neurons are microinjected with cDNA constructs to overexpress either wild-type PrP or mutant PrPD178N. We found that ERAD-PrP in human neurons remains detergent-soluble and proteinase K-sensitive, in contrast to its detergent-insoluble and proteinase K-resistant state in N2a cells. Furthermore, not only is microinjection of a cDNA construct expressing CyPrP not toxic, it protects these neurons against Bax-mediated cell death. We conclude that in human neurons, ERAD-PrP is not converted naturally into a form reminiscent of scrapie PrP and that PrP located in the cytosol retains its protective function against Bax. Thus, it is unlikely that simple accumulation of PrP in the cytosol can cause neurodegeneration in prion diseases.	McGill Univ, Sir Mortimer B Davis Jewish Gen Hosp, Lady Davis Inst Med Res, Bloomfield Ctr Res Aging, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Neurol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Neurosurg, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University; McGill University; McGill University	LeBlanc, AC (corresponding author), McGill Univ, Sir Mortimer B Davis Jewish Gen Hosp, Lady Davis Inst Med Res, Bloomfield Ctr Res Aging, 3755 Ch Cote Ste Catherine, Montreal, PQ H3T 1E2, Canada.	andrea.leblanc@mcgill.ca						BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; Bounhar Y, 2001, J BIOL CHEM, V276, P39145, DOI 10.1074/jbc.C100443200; Brown DR, 1999, BIOCHEM J, V344, P1, DOI 10.1042/0264-6021:3440001; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; Chen SZ, 2003, MOL CELL NEUROSCI, V22, P227, DOI 10.1016/S1044-7431(02)00014-3; Chiarini LB, 2002, EMBO J, V21, P3317, DOI 10.1093/emboj/cdf324; DebBurman SK, 1997, P NATL ACAD SCI USA, V94, P13938, DOI 10.1073/pnas.94.25.13938; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Drisaldi B, 2003, J BIOL CHEM, V278, P21732, DOI 10.1074/jbc.M213247200; Edenhofer F, 1996, J VIROL, V70, P4724, DOI 10.1128/JVI.70.7.4724-4728.1996; Guo B, 2003, NATURE, V423, P456, DOI 10.1038/nature01627; Hall GF, 2001, AM J PATHOL, V158, P235, DOI 10.1016/S0002-9440(10)63962-4; Harris CA, 2001, J BIOL CHEM, V276, P37754; Jin TC, 2000, J BIOL CHEM, V275, P38699, DOI 10.1074/jbc.M005543200; Keller JN, 2002, AGEING RES REV, V1, P279, DOI 10.1016/S1568-1637(01)00006-X; KURSCHNER C, 1995, MOL BRAIN RES, V30, P165, DOI 10.1016/0169-328X(95)00013-I; Kuwahara C, 1999, NATURE, V400, P225, DOI 10.1038/22241; LeBlanc A, 1995, J NEUROSCI, V15, P7837; LEBLANC A, 1998, HDB AGING BRAIN, P201; Lei K, 2002, MOL CELL BIOL, V22, P4929, DOI 10.1128/MCB.22.13.4929-4942.2002; Ma JY, 2002, SCIENCE, V298, P1781, DOI 10.1126/science.1073725; Ma JY, 2002, SCIENCE, V298, P1785, DOI 10.1126/science.1073619; Ma JY, 1999, NAT CELL BIOL, V1, P358, DOI 10.1038/14053; Ma JY, 2001, P NATL ACAD SCI USA, V98, P14955, DOI 10.1073/pnas.011578098; Maiti NR, 2001, J BIOL CHEM, V276, P2427, DOI 10.1074/jbc.M007862200; McLean PJ, 2001, NEUROSCIENCE, V104, P901, DOI 10.1016/S0306-4522(01)00113-0; Meng LH, 1999, P NATL ACAD SCI USA, V96, P10403, DOI 10.1073/pnas.96.18.10403; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; Sawada M, 2003, NAT CELL BIOL, V5, P320, DOI 10.1038/ncb950; Stockel J, 2001, J MOL BIOL, V313, P861, DOI 10.1006/jmbi.2001.5085; Swietnicki W, 1997, J BIOL CHEM, V272, P27517, DOI 10.1074/jbc.272.44.27517; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Xu QL, 1998, MOL CELL, V1, P337, DOI 10.1016/S1097-2765(00)80034-9; Yedidia Y, 2001, EMBO J, V20, P5383, DOI 10.1093/emboj/20.19.5383; YOST CS, 1990, NATURE, V343, P669, DOI 10.1038/343669a0; Zanata SM, 2002, EMBO J, V21, P3307, DOI 10.1093/emboj/cdf325; Zanusso G, 1999, J BIOL CHEM, V274, P23396, DOI 10.1074/jbc.274.33.23396; Zhang Y, 2002, APOPTOSIS TECHNIQUES, P83; Zou WQ, 2002, J BIOL CHEM, V277, P43942, DOI 10.1074/jbc.M203611200	40	134	140	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40877	40881		10.1074/jbc.M306177200	http://dx.doi.org/10.1074/jbc.M306177200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12917444	hybrid			2022-12-25	WOS:000185847200057
J	Waltermann, A; Kartasheva, NN; Dobbelstein, M				Waltermann, A; Kartasheva, NN; Dobbelstein, M			Differential regulation of p63 and p73 expression	ONCOGENE			English	Article						p53; p63; p73; E2F; TGF beta; cell density	GROWTH-FACTOR-BETA; P53 HOMOLOG P63; LARGE T-ANTIGEN; CELL-DENSITY; TRANSCRIPTION ANALYSES; P53-RELATED PROTEIN; VIRAL ONCOPROTEINS; SPONTANEOUS TUMORS; E1B 55-KILODALTON; E4ORF6 PROTEINS	Two homologs of the tumor suppressor p53, named p63 and p 73, are each expressed from at least two start sites of mRNA synthesis, yielding full-length, transactivating (TA) isoforms, and also aminoterminally truncated (DeltaN) isoforms that act as antagonists to p53. The expression of TAp73-transcripts is induced by E2F and negatively regulated by transforming growth factor beta (TGFbeta). The DeltaNp73 promoter is induced by p53, resulting in negative feedback to control p53 activity. Here, we have analysed the expression of p63 in comparison with p73. In contrast to the induction of DeltaNp73, the expression of DeltaNp63 was reduced by p53 particularly in human keratinocytes, at the mRNA and protein levels. Accordingly, the 3' promoter of p73, but not that of p63, was activated by p53 in reporter assays. DeltaNp73 mRNA and DeltaNp73 protein, but not the p63 gene products, also accumulated when HaCat cells (lacking functional p53) were grown to high density. TAp73, but not TAp63, expression was suppressed by TGFbeta in these cells, and the TAp73, but not the TAp63, promoter was induced by E2F-1. Thus, in contrast to the functional similarities of their respective products, the expression levels of p63 and p 73 are regulated by different mechanisms. This might be responsible for the discordant biological roles of p63 and p73 in development, as well as their deviant expression characteristics in cancer.	Univ Marburg, Inst Virol, D-35037 Marburg, Germany; Russian Acad Sci, Inst Mol Genet, Moscow 123182, Russia	Philipps University Marburg; Russian Academy of Sciences	Dobbelstein, M (corresponding author), Univ Marburg, Inst Virol, Robert Koch Str 17, D-35037 Marburg, Germany.			Dobbelstein, Matthias/0000-0001-5052-3967				Capone A, 2000, CELL GROWTH DIFFER, V11, P607; Contente A, 2002, NAT GENET, V30, P315, DOI 10.1038/ng836; Cviko A, 2000, HUM PATHOL, V31, P740, DOI 10.1053/hupa.2000.8232; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; De Laurenzi V, 2000, BIOCHEM BIOPH RES CO, V273, P342, DOI 10.1006/bbrc.2000.2932; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Dietrich C, 2002, BIOCHEM BIOPH RES CO, V292, P195, DOI 10.1006/bbrc.2002.6625; Dobbelstein M, 1998, J GEN VIROL, V79, P3079, DOI 10.1099/0022-1317-79-12-3079; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Douc-Rasy S, 2002, AM J PATHOL, V160, P631, DOI 10.1016/S0002-9440(10)64883-3; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Hagiwara K, 1999, CANCER RES, V59, P4165; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Higashino F, 1998, P NATL ACAD SCI USA, V95, P15683, DOI 10.1073/pnas.95.26.15683; Hoh J, 2002, P NATL ACAD SCI USA, V99, P8467, DOI 10.1073/pnas.132268899; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kartasheva NN, 2002, ONCOGENE, V21, P4715, DOI 10.1038/sj.onc.1205584; KATO M, 1995, J BIOL CHEM, V270, P12373, DOI 10.1074/jbc.270.21.12373; Koch P, 2001, CANCER RES, V61, P5941; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Liefer KM, 2000, CANCER RES, V60, P4016; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Mai M, 1998, CANCER RES, V58, P2347; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Nakagawa T, 2002, MOL CELL BIOL, V22, P2575, DOI 10.1128/MCB.22.8.2575-2585.2002; Nishi H, 1999, INT J ONCOL, V15, P1149; Nomoto S, 1998, CANCER RES, V58, P1380; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Pellegrini G, 2001, P NATL ACAD SCI USA, V98, P3156, DOI 10.1073/pnas.061032098; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Prabhu NS, 1998, INT J ONCOL, V13, P5; Quade BJ, 2001, GYNECOL ONCOL, V80, P24, DOI 10.1006/gyno.2000.5953; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Ratovitski EA, 2001, P NATL ACAD SCI USA, V98, P1817, DOI 10.1073/pnas.98.4.1817; Reichelt M, 1999, ARCH VIROL, V144, P621, DOI 10.1007/s007050050530; Roth J, 1997, J VIROL, V71, P8933, DOI 10.1128/JVI.71.11.8933-8939.1997; Roth J, 1998, J VIROL, V72, P8510, DOI 10.1128/JVI.72.11.8510-8516.1998; Roth J, 1999, J GEN VIROL, V80, P3251, DOI 10.1099/0022-1317-80-12-3251; Seelan RS, 2002, NEOPLASIA, V4, P195, DOI 10.1038/sj.neo.7900237; Steegenga WT, 1999, MOL CELL BIOL, V19, P3885; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; STIEWE T, 2002, J BIOL CHEM, V13, P13; Takahashi H, 1998, CANCER RES, V58, P2076; Tokuchi Y, 1999, BRIT J CANCER, V80, P1623, DOI 10.1038/sj.bjc.6690572; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang TY, 2001, HUM PATHOL, V32, P479, DOI 10.1053/hupa.2001.24324; Weigel S, 2000, J VIROL, V74, P764, DOI 10.1128/JVI.74.2.764-772.2000; Wienzek S, 2000, J VIROL, V74, P193, DOI 10.1128/JVI.74.1.193-202.2000; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zaika A, 2001, J BIOL CHEM, V276, P11310, DOI 10.1074/jbc.M005737200; Zaika AI, 1999, CANCER RES, V59, P3257; Zaika AI, 2002, J EXP MED, V196, P765, DOI 10.1084/jem.20020179; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x	61	50	53	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2003	22	36					5686	5693		10.1038/sj.onc.1206859	http://dx.doi.org/10.1038/sj.onc.1206859			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944917				2022-12-25	WOS:000184865900018
J	Bae, SH; Cheong, HK; Cheong, C; Kang, SH; Hwang, DS; Choi, BS				Bae, SH; Cheong, HK; Cheong, C; Kang, SH; Hwang, DS; Choi, BS			Structure and dynamics of hemimethylated GATC sites Implications for DNA-SeqA recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI CHROMOSOME; NUCLEIC-ACID CONFORMATIONS; ADENINE METHYLATION; PROTON-EXCHANGE; DAM METHYLASE; AMINO-GROUPS; REPLICATION; STABILITY; SEQUENCE; INITIATION	DNA methylation occurs in most organisms from bacteria to mammals and provides a mechanism for epigenetic control of a variety of cellular processes. In Escherichia coli, most of the N-6 positions in adenines found in the sequence GATC are methylated by DNA adenine methyltransferase. After DNA replication, the GATC sites exist transiently in the hemimethylated state, and the specific recognition of these hemimethylated GATC sites is essential for several processes, including sequestration of the site of replication initiation by the SeqA protein, strand discrimination in DNA mismatch repair by the MutH protein, and transcription of several genes. Here, we characterize the solution structure and dynamics of two dodecamer DNA duplexes that each contains a single GATC site in either unmethylated or hemimethylated state. We found that the N-6-methylated adenine of a hemimethylated GATC site undergoes a slow trans-cis interconversion. The release of a tightly bound cation from hemimethylated DNA explains the instability of this structure. In addition, quantitative structural analysis revealed that hemimethylated DNA has unusual backbone structures and a remarkably narrow major groove. These dynamic and structural features provide insights into the specific recognition of hemimethylated GATC sites by the SeqA protein.	Korea Adv Inst Sci & Technol, Dept Chem, Taejon 305701, South Korea; Korea Adv Inst Sci & Technol, Natl Creat Res Initiat Ctr, Taejon 305701, South Korea; Korea Basic Sci Inst, Magnet Resonance Team, Taejon 305333, South Korea; Seoul Natl Univ, Dept Microbiol, Seoul 151742, South Korea	Korea Advanced Institute of Science & Technology (KAIST); Korea Advanced Institute of Science & Technology (KAIST); Korea Basic Science Institute (KBSI); Seoul National University (SNU)	Choi, BS (corresponding author), Korea Adv Inst Sci & Technol, Dept Chem, 373-1 Guseong Dong, Taejon 305701, South Korea.	byongseok.choi@kaist.ac.kr	Cheong, Chaejoon/GWC-3135-2022; Choi, Byong-Seok/C-1937-2011	Kang, Sukhyun/0000-0002-7567-0231				Bae SH, 2001, P NATL ACAD SCI USA, V98, P10602, DOI 10.1073/pnas.191268798; BAIKALOV I, 1993, J MOL BIOL, V231, P768, DOI 10.1006/jmbi.1993.1325; BARRAS F, 1988, NUCLEIC ACIDS RES, V16, P9821, DOI 10.1093/nar/16.20.9821; BORGIAS BA, 1989, METHOD ENZYMOL, V176, P169; Brendler T, 1999, EMBO J, V18, P2304, DOI 10.1093/emboj/18.8.2304; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHUPRINA VP, 1991, P NATL ACAD SCI USA, V88, P9087, DOI 10.1073/pnas.88.20.9087; ENGEL JD, 1974, BIOCHEMISTRY-US, V13, P4143, DOI 10.1021/bi00717a013; ENGEL JD, 1978, J BIOL CHEM, V253, P927; FAZAKERLEY GV, 1985, BIOCHEMISTRY-US, V24, P4540, DOI 10.1021/bi00338a009; FAZAKERLEY GV, 1987, EUR J BIOCHEM, V167, P397, DOI 10.1111/j.1432-1033.1987.tb13351.x; FoltaStogniew E, 1996, BIOCHEMISTRY-US, V35, P8439, DOI 10.1021/bi952932z; GEEK H, 1991, J MAGN RESON, V93, P93; Guarne A, 2002, NAT STRUCT BIOL, V9, P839, DOI 10.1038/nsb857; Gueron M, 1995, METHOD ENZYMOL, V261, P383; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Guo Q, 1995, BIOCHEMISTRY-US, V34, P16359, DOI 10.1021/bi00050a016; Hud NV, 1998, J AM CHEM SOC, V120, P6403, DOI 10.1021/ja9811039; Jeltsch A, 2002, CHEMBIOCHEM, V3, P275, DOI 10.1002/1439-7633(20020402)3:4<274::AID-CBIC274>3.0.CO;2-S; Kang S, 1999, J BIOL CHEM, V274, P11463, DOI 10.1074/jbc.274.17.11463; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LACKS S, 1977, J MOL BIOL, V114, P153, DOI 10.1016/0022-2836(77)90289-3; Lavery R., 1997, CURVES 5 2 HELICAL A; LEONARD GA, 1993, J MOL BIOL, V234, P198, DOI 10.1006/jmbi.1993.1574; Lingbeck J, 1996, BIOCHEMISTRY-US, V35, P719, DOI 10.1021/bi951364k; Lu XJ, 2000, J MOL BIOL, V300, P819, DOI 10.1006/jmbi.2000.3690; MARINUS MG, 1985, MOL GEN GENET, V200, P185, DOI 10.1007/BF00383334; Michalczyk R, 1999, BIOPHYS J, V76, P2679, DOI 10.1016/S0006-3495(99)77420-5; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; OGDEN GB, 1988, CELL, V54, P127, DOI 10.1016/0092-8674(88)90186-9; Pastor N, 2000, J MOL BIOL, V304, P55, DOI 10.1006/jmbi.2000.4173; RASZKA M, 1974, BIOCHEMISTRY-US, V13, P4616, DOI 10.1021/bi00719a023; RINKEL LJ, 1987, EUR J BIOCHEM, V163, P275, DOI 10.1111/j.1432-1033.1987.tb10798.x; ROBERTS D, 1985, CELL, V43, P117, DOI 10.1016/0092-8674(85)90017-0; RUSSELL DW, 1987, CELL, V50, P1071, DOI 10.1016/0092-8674(87)90173-5; Stancheva I, 1999, EMBO J, V18, P6542, DOI 10.1093/emboj/18.22.6542; STERNGLANZ H, 1973, SCIENCE, V182, P833, DOI 10.1126/science.182.4114.833; THEISEN PW, 1993, MOL MICROBIOL, V10, P575, DOI 10.1111/j.1365-2958.1993.tb00929.x; Varnai P, 2002, NUCLEIC ACIDS RES, V30, P5398, DOI 10.1093/nar/gkf680	39	19	19	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45987	45993		10.1074/jbc.M306038200	http://dx.doi.org/10.1074/jbc.M306038200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12944412	hybrid			2022-12-25	WOS:000186452300113
J	Jongstra-Bilen, J; Harrison, R; Grinstein, S				Jongstra-Bilen, J; Harrison, R; Grinstein, S			Fc gamma-receptors induce Mac-1 (CD11b/CD18) mobilization and accumulation in the phagocytic cup for optimal phagocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT RECEPTOR; PHOSPHOLIPASE C-GAMMA-1; MEDIATED PHAGOCYTOSIS; HUMAN-NEUTROPHILS; TYROSINE PHOSPHORYLATION; MONOCLONAL-ANTIBODIES; LEUKOCYTE INTEGRINS; LECTIN SITE; I-DOMAIN; ADHESION	Functional interactions between Fcgamma-receptors (FcgammaR) and the beta(2) integrin Mac-1 (CD11b/CD18) have been described, but the molecular basis of this relationship remains unclear. Although the glycosylphosphatidylinositol-linked receptor FcgammaRIIIB of human neutrophils is constitutively associated with Mac-1, we found no evidence for direct physical association between Mac-1 and the FcgammaR of mouse macrophages, which are transmembrane proteins. Nevertheless, Mac-1 accumulated in the phagocytic cup following engagement of FcgammaR by IgG-opsonized particles. Blocking the CD18 chains of beta(2) integrins by using specific antibodies reduced Mac-1 accumulation in the cup. These antibodies or the addition of the recombinant CD11b I-domain inhibited the ingestion of IgG-opsonized particles. FcgammaR cross-linking stimulated cell adhesion to surfaces coated with Mac-1 ligands and in addition enabled macrophages to bind C3bi-opsonized particles, indicating that FcgammaR-derived signals induce activation of Mac-1. Measurements of fluorescence recovery after photobleaching revealed that whereas most (>80%) of Mac-1 is immobile in resting cells, stimulation of FcgammaR markedly increases the mobile fraction of the integrin. Activation of Mac-1 by FcgammaR required the activity of Src family tyrosine kinases, phosphatidylinositol 3-kinase and phospholipase C, with the release of diacylglycerol and stimulation of protein kinase C. Because elevated cytosolic Ca2+ was not required, we suggest that novel protein kinase C isoforms are involved in Mac-1 activation. These results suggest that FcgammaR stimulation promotes Mac-1 clustering into high avidity complexes in phagocytic cups by releasing the integrin from cytoskeletal constraints and enhancing its lateral diffusion. FcgammaR can enhance host defense by activating Mac-1 (and possibly other integrins), having a synergistic effect on pathogen engulfment and promoting the adherence of phagocytes at sites of infection.	Univ Toronto, Hosp Sick Children, Cell Biol Program, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5G 1X8, Canada; Univ Toronto, Univ Hlth Network, Toronto Western Res Inst, Div Cell & Mol Biol, Toronto, ON M5T 2S8, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5T 2S8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Grinstein, S (corresponding author), Univ Toronto, Hosp Sick Children, Cell Biol Program, Toronto, ON M5G 1X8, Canada.							Allen LAH, 1996, J EXP MED, V184, P627, DOI 10.1084/jem.184.2.627; ANDERSSON T, 1988, FEBS LETT, V239, P371, DOI 10.1016/0014-5793(88)80954-2; AZZONI L, 1992, J EXP MED, V176, P1745, DOI 10.1084/jem.176.6.1745; BELLER DI, 1982, J EXP MED, V156, P1000, DOI 10.1084/jem.156.4.1000; Berrier AL, 2000, J CELL BIOL, V151, P1549, DOI 10.1083/jcb.151.7.1549; Booth JW, 2002, EMBO J, V21, P251, DOI 10.1093/emboj/21.3.251; Botelho RJ, 2000, J CELL BIOL, V151, P1353, DOI 10.1083/jcb.151.7.1353; BROWN EJ, 1988, J CLIN INVEST, V81, P365, DOI 10.1172/JCI113328; Caron E, 2000, CURR BIOL, V10, P974, DOI 10.1016/S0960-9822(00)00641-2; Chan JR, 2000, J IMMUNOL, V164, P746, DOI 10.4049/jimmunol.164.2.746; Constantin G, 2000, IMMUNITY, V13, P759, DOI 10.1016/S1074-7613(00)00074-1; Coxon A, 2001, IMMUNITY, V14, P693, DOI 10.1016/S1074-7613(01)00150-9; Coxon A, 1996, IMMUNITY, V5, P653, DOI 10.1016/S1074-7613(00)80278-2; Dewitt S, 2002, J CELL BIOL, V159, P181, DOI 10.1083/jcb.200206089; DRANSFIELD I, 1989, EMBO J, V8, P3759, DOI 10.1002/j.1460-2075.1989.tb08552.x; Ehlers MRW, 2000, MICROBES INFECT, V2, P289, DOI 10.1016/S1286-4579(00)00299-9; Etzioni A, 1999, BLOOD, V94, P3281, DOI 10.1182/blood.V94.10.3281.422k37_3281_3288; Gessner JE, 1998, ANN HEMATOL, V76, P231, DOI 10.1007/s002770050396; GRAHAM IL, 1989, J IMMUNOL, V142, P2352; GRESHAM HD, 1991, J CLIN INVEST, V88, P588, DOI 10.1172/JCI115343; Hogg N, 2001, J LEUKOCYTE BIOL, V69, P893; Hughes PE, 1998, TRENDS CELL BIOL, V8, P359, DOI 10.1016/S0962-8924(98)01339-7; Jones SL, 1998, J BIOL CHEM, V273, P10556, DOI 10.1074/jbc.273.17.10556; Kim MK, 2001, CLIN IMMUNOL, V98, P125, DOI 10.1006/clim.2000.4955; Kolanus W, 1997, CURR OPIN CELL BIOL, V9, P725, DOI 10.1016/S0955-0674(97)80127-5; Kucik DF, 1996, J CLIN INVEST, V97, P2139, DOI 10.1172/JCI118651; KUSUNOKI T, 1994, J LEUKOCYTE BIOL, V55, P735, DOI 10.1002/jlb.55.6.735; Kwiatkowska K, 1999, BIOESSAYS, V21, P422, DOI 10.1002/(SICI)1521-1878(199905)21:5<422::AID-BIES9>3.0.CO;2-#; Larsen EC, 2000, J IMMUNOL, V165, P2809, DOI 10.4049/jimmunol.165.5.2809; Li M, 1996, J EXP MED, V183, P1259, DOI 10.1084/jem.183.3.1259; LIAO F, 1992, P NATL ACAD SCI USA, V89, P3659, DOI 10.1073/pnas.89.8.3659; METLAY JP, 1990, J EXP MED, V171, P1753, DOI 10.1084/jem.171.5.1753; Morrissette NS, 1999, J CELL SCI, V112, P4705; Orchekowski RP, 2000, J LEUKOCYTE BIOL, V68, P641; POO H, 1995, J MOL BIOL, V247, P597; RAVETCH JV, 1989, J EXP MED, V170, P481, DOI 10.1084/jem.170.2.481; Reynolds LF, 2002, J EXP MED, V195, P1103, DOI 10.1084/jem.20011663; ROSEN H, 1987, J EXP MED, V166, P1685, DOI 10.1084/jem.166.6.1685; Ross GD, 2000, CRIT REV IMMUNOL, V20, P197; ROSS GD, 1992, J LEUKOCYTE BIOL, V51, P109, DOI 10.1002/jlb.51.2.109; Tan SM, 2000, J IMMUNOL, V165, P2574, DOI 10.4049/jimmunol.165.5.2574; Tang T, 1997, J EXP MED, V186, P1853, DOI 10.1084/jem.186.11.1853; Thornton BP, 1996, J IMMUNOL, V156, P1235; Todd RF, 1997, J LAB CLIN MED, V129, P492, DOI 10.1016/S0022-2143(97)90003-2; Ustinov VA, 2002, J BIOL CHEM, V277, P18769, DOI 10.1074/jbc.M110242200; van Kooyk Y, 2000, CURR OPIN CELL BIOL, V12, P542, DOI 10.1016/S0955-0674(00)00129-0; Vetvicka V, 1996, J CLIN INVEST, V98, P50, DOI 10.1172/JCI118777; ZHANG F, 1995, FEBS LETT, V376, P77, DOI 10.1016/0014-5793(95)01249-X; Zhang FH, 2001, INT IMMUNOPHARMACOL, V1, P1375, DOI 10.1016/S1567-5769(01)00069-8; ZHOU MJ, 1993, J IMMUNOL, V150, P3030; Zhou XM, 2000, J BIOL CHEM, V275, P20217, DOI 10.1074/jbc.M909129199	51	100	103	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45720	45729		10.1074/jbc.M303704200	http://dx.doi.org/10.1074/jbc.M303704200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12941957	hybrid			2022-12-25	WOS:000186452300082
J	Kozlov, G; Lee, J; Elias, D; Gravel, M; Gutierrez, P; Ekiel, I; Braun, PE; Gehring, K				Kozlov, G; Lee, J; Elias, D; Gravel, M; Gutierrez, P; Ekiel, I; Braun, PE; Gehring, K			Structural evidence that brain cyclic nucleotide phosphodiesterase is a member of the 2H phosphodiesterase superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEIN; MYELIN-ASSOCIATED ENZYME; CARBONIC-ANHYDRASE-II; RNA TRAFFICKING; BASIC-PROTEIN; MESSENGER-RNA; 3-PHOSPHODIESTERASE; 3'-PHOSPHODIESTERASE; LOCALIZATION; DOMAIN	2',3'-Cyclic-nucleotide 3'-phosphodiesterase (CNP) is an enzyme abundantly present in the central nervous system of mammals and some vertebrates. In vitro, CNP specifically catalyzes the hydrolysis of 2',3'-cyclic nucleotides to produce 2'-nucleotides, but the physiologically relevant in vivo substrate remains obscure. Here, we report the medium resolution NMR structure of the catalytic domain of rat CNP with phosphate bound and describe its binding to CNP inhibitors. The structure has a bilobal arrangement of two modules, each consisting of a four-stranded beta-sheet and two alpha-helices. The beta-sheets form a large cavity containing a number of positively charged and aromatic residues. The structure is similar to those of the cyclic phosphodiesterase from Arabidopsis thaliana and the 2'-5' RNA ligase from Thermus thermophilus, placing CNP in the superfamily of 2H phosphodiesterases that contain two tetrapeptide HX(T/S)X motifs. NMR titrations of the CNP catalytic domain with inhibitors and kinetic studies of site-directed mutants reveal a protein conformational change that occurs upon binding.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; Natl Res Council Canada, Biotechnol Res Inst, Hlth Sector, Montreal, PQ H4P 2R2, Canada	McGill University; National Research Council Canada	Gehring, K (corresponding author), McGill Univ, Dept Biochem, 3655 Promenade Sir William Osler, Montreal, PQ H3G 1Y6, Canada.	kalle.gehring@bri.nrc.ca	Gehring, Kalle/I-4403-2013; Gehring, Kalle/N-2945-2019	Gehring, Kalle/0000-0001-6500-1184; Gehring, Kalle/0000-0001-6500-1184				Arn EA, 1998, COLD SPRING HARBOR M, P695; Ballestero RP, 1997, J BIOL CHEM, V272, P11479; BALLESTERO RP, 1995, P NATL ACAD SCI USA, V92, P8621, DOI 10.1073/pnas.92.19.8621; Barbarese E, 1999, J NEUROCYTOL, V28, P263, DOI 10.1023/A:1007097226688; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; Bifulco M, 2002, P NATL ACAD SCI USA, V99, P1807, DOI 10.1073/pnas.042678799; BRAUN PE, 1988, J NEUROSCI, V8, P3057; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carson J H, 2001, Results Probl Cell Differ, V34, P69; Carson JH, 1998, CURR OPIN NEUROBIOL, V8, P607, DOI 10.1016/S0959-4388(98)80088-3; Chini EN, 2002, AM J PHYSIOL-CELL PH, V282, pC1191, DOI 10.1152/ajpcell.00475.2001; CULVER GM, 1993, SCIENCE, V261, P206, DOI 10.1126/science.8392224; DEANGELIS DA, 1994, J NEUROSCI RES, V39, P386, DOI 10.1002/jnr.490390405; DeAngelis DA, 1996, J NEUROCHEM, V66, P2523; DYER CA, 1989, J NEUROSCI RES, V24, P201, DOI 10.1002/jnr.490240211; Genschik P, 1997, J BIOL CHEM, V272, P13211, DOI 10.1074/jbc.272.20.13211; GHANDOUR MS, 1991, GLIA, V4, P1, DOI 10.1002/glia.440040102; Gravel M, 1996, MOL CELL NEUROSCI, V7, P453, DOI 10.1006/mcne.1996.0033; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; Hofmann A, 2002, BIOCHEM BIOPH RES CO, V291, P875, DOI 10.1006/bbrc.2002.6527; Hofmann A, 2002, J BIOL CHEM, V277, P1419, DOI 10.1074/jbc.M107889200; Hofmann A, 2000, EMBO J, V19, P6207, DOI 10.1093/emboj/19.22.6207; Kato M, 2003, J MOL BIOL, V329, P903, DOI 10.1016/S0022-2836(03)00448-0; Kim T, 1999, J NEUROCYTOL, V28, P281, DOI 10.1023/A:1007001427597; KOONIN EV, 1990, FEBS LETT, V268, P231, DOI 10.1016/0014-5793(90)81015-G; Kozlov G, 2002, J BIOMOL NMR, V22, P99, DOI 10.1023/A:1013898222817; Kurihara T., 1992, MYELIN BIOL CHEM; Lappe-Siefke C, 2003, NAT GENET, V33, P366, DOI 10.1038/ng1095; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lee J, 2001, J BIOL CHEM, V276, P14804, DOI 10.1074/jbc.M009434200; LOPRESTI P, 1995, P NATL ACAD SCI USA, V92, P10369, DOI 10.1073/pnas.92.22.10369; Mazumder R, 2002, NUCLEIC ACIDS RES, V30, P5229, DOI 10.1093/nar/gkf645; McFerran BW, 1997, J CELL SCI, V110, P2979; Nasr F, 2000, NUCLEIC ACIDS RES, V28, P1676, DOI 10.1093/nar/28.8.1676; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nilges M, 1997, J MOL BIOL, V269, P408, DOI 10.1006/jmbi.1997.1044; Pons JL, 1996, J BIOMOL NMR, V8, P445, DOI 10.1007/BF00228146; SOGIN DC, 1976, J NEUROCHEM, V27, P1333, DOI 10.1111/j.1471-4159.1976.tb02612.x; SPRINKLE TJ, 1987, BIOCHEM BIOPH RES CO, V145, P686, DOI 10.1016/0006-291X(87)91019-9; SPRINKLE TJ, 1989, CRIT REV NEUROBIOL, V4, P235; Tansey FA, 1996, NEUROCHEM RES, V21, P411, DOI 10.1007/BF02527704; TRAPP BD, 1988, J NEUROCHEM, V51, P859, DOI 10.1111/j.1471-4159.1988.tb01822.x; TYC K, 1987, J BIOL CHEM, V262, P12994; Varani G, 1998, ANNU REV BIOPH BIOM, V27, P407, DOI 10.1146/annurev.biophys.27.1.407; VOGEL US, 1988, J NEUROCHEM, V50, P1667, DOI 10.1111/j.1471-4159.1988.tb02461.x; XU Q, 1990, BIOCHEMISTRY-US, V29, P6132, DOI 10.1021/bi00478a004; Yin X, 1997, J NEUROSCI RES, V50, P238, DOI 10.1002/(SICI)1097-4547(19971015)50:2<238::AID-JNR12>3.0.CO;2-4	47	31	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					46021	46028		10.1074/jbc.M305176200	http://dx.doi.org/10.1074/jbc.M305176200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12947117	hybrid			2022-12-25	WOS:000186452300118
J	Tanowitz, M; von Zastrow, M				Tanowitz, M; von Zastrow, M			A novel endocytic recycling signal that distinguishes the membrane trafficking of naturally occurring opioid receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEASE-ACTIVATED RECEPTOR-1; EXCHANGER REGULATORY FACTOR; C-TERMINAL TAIL; DOWN-REGULATION; COUPLED RECEPTORS; BETA(2)-ADRENERGIC RECEPTOR; BETA-2-ADRENERGIC RECEPTOR; MU; UBIQUITINATION; DESENSITIZATION	delta and mu opioid receptors are homologous G protein-coupled receptors that are differentially sorted between divergent degradative and recycling membrane pathways following agonist-induced endocytosis. Whereas delta opioid receptors are selectively sorted to lysosomes, mu opioid receptors recycle rapidly to the plasma membrane by a process that has been proposed to occur via bulk membrane flow. We have observed that mu opioid receptors do not recycle by default and have defined a specific sequence present in the cytoplasmic tail of the cloned mu opioid receptor that is both necessary and sufficient for rapid recycling of internalized receptors. This sequence is completely distinct from a sequence shown previously to be required for recycling of the beta(2) adrenergic receptor yet is functionally interchangeable when tested in chimeric mutant receptors. These results indicate that signal-dependent recycling is a more common property of G protein-coupled receptors than previously appreciated and demonstrate that such a modular recycling signal distinguishes the regulation of homologous receptors that are naturally co-expressed.	Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Tanowitz, M (corresponding author), Univ Calif San Francisco, Dept Psychiat, N-216 Genentech Hall,600 16th St, San Francisco, CA 94143 USA.	mbt2m@itsa.ucsf.edu						Anborgh PH, 2000, MOL ENDOCRINOL, V14, P2040, DOI 10.1210/me.14.12.2040; Beland B, 2001, PAIN, V90, P143, DOI 10.1016/S0304-3959(00)00397-3; Cahill CM, 2001, J NEUROSCI, V21, P7598, DOI 10.1523/JNEUROSCI.21-19-07598.2001; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Chaturvedi K, 2001, J BIOL CHEM, V276, P12345, DOI 10.1074/jbc.M008054200; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cheng PY, 1997, BRAIN RES, V778, P367, DOI 10.1016/S0006-8993(97)00891-3; Cong M, 2001, J BIOL CHEM, V276, P45145, DOI 10.1074/jbc.M106087200; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; Ferguson SSG, 1998, LIFE SCI, V62, P1561, DOI 10.1016/S0024-3205(98)00107-6; Finn AK, 2001, NEURON, V32, P829, DOI 10.1016/S0896-6273(01)00517-7; Gage RM, 2001, J BIOL CHEM, V276, P44712, DOI 10.1074/jbc.M107417200; Galet C, 2003, MOL ENDOCRINOL, V17, P411, DOI 10.1210/me.2002-0161; Goodman O B Jr, 1998, Adv Pharmacol, V42, P429; Gruenberg J, 2001, NAT REV MOL CELL BIO, V2, P721, DOI 10.1038/35096054; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Innamorati G, 1998, P NATL ACAD SCI USA, V95, P2222, DOI 10.1073/pnas.95.5.2222; KAUFMAN DL, 1995, J BIOL CHEM, V270, P15877, DOI 10.1074/jbc.270.26.15877; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Kishi M, 2001, MOL ENDOCRINOL, V15, P1624, DOI 10.1210/me.15.9.1624; KOBILKA BK, 1987, P NATL ACAD SCI USA, V84, P46, DOI 10.1073/pnas.84.1.46; Koenig JA, 1997, TRENDS PHARMACOL SCI, V18, P276, DOI 10.1016/S0165-6147(97)01091-2; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; Law PY, 1999, J PHARMACOL EXP THER, V289, P607; Lee MC, 2002, SYNAPSE, V43, P102, DOI 10.1002/syn.10014; Lefkowitz R J, 1998, Adv Pharmacol, V42, P416; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Li J, 2001, MOL PHARMACOL, V60, P1064, DOI 10.1124/mol.60.5.1064; Li JG, 2002, J BIOL CHEM, V277, P27545, DOI 10.1074/jbc.M200058200; Marchese A, 2001, J BIOL CHEM, V276, P45509, DOI 10.1074/jbc.C100527200; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; Paasche JD, 2001, J BIOL CHEM, V276, P34041, DOI 10.1074/jbc.M103243200; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Shih SC, 2002, NAT CELL BIOL, V4, P389, DOI 10.1038/ncb790; Tanowitz M, 2002, J BIOL CHEM, V277, P50219, DOI 10.1074/jbc.C200536200; Tao PL, 1998, EUR J PHARMACOL, V344, P137, DOI 10.1016/S0014-2999(97)01596-3; Trejo J, 1999, J BIOL CHEM, V274, P2216, DOI 10.1074/jbc.274.4.2216; Trejo J, 1998, P NATL ACAD SCI USA, V95, P13698, DOI 10.1073/pnas.95.23.13698; Tsao P, 2000, CURR OPIN NEUROBIOL, V10, P365, DOI 10.1016/S0959-4388(00)00096-9; Tsao PI, 2000, J BIOL CHEM, V275, P11130, DOI 10.1074/jbc.275.15.11130; Wang YJ, 2002, MOL BIOL CELL, V13, P1965, DOI 10.1091/mbc.E01-11-0131; Whistler JL, 2002, SCIENCE, V297, P615, DOI 10.1126/science.1073308; Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157	45	142	146	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45978	45986		10.1074/jbc.M304504200	http://dx.doi.org/10.1074/jbc.M304504200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12939277	hybrid			2022-12-25	WOS:000186452300112
J	Hong, R; Chakravarti, D				Hong, R; Chakravarti, D			The human proliferating cell nuclear antigen regulates transcriptional coactivator p300 activity and promotes transcriptional repression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE-BINDING-PROTEIN; RECEPTOR COACTIVATOR; DNA-REPLICATION; MUSCLE DIFFERENTIATION; FACTOR PCNA; COMPLEX; REPAIR; ACETYLATION; CHROMATIN; CBP	Chromatin structure plays an important role in DNA replication, repair, and transcription. p300 is a transcriptional coactivator with protein acetyltransferase activity, and proliferating cell nuclear antigen (PCNA) plays important roles in DNA replication and repair. It has been shown recently that p300 is necessary for DNA synthesis and repair. However, it is not known whether human PCNA, in a reciprocal manner, can regulate the enzymatic activity and transcriptional regulatory properties of p300. Here we show that human PCNA associates with p300 and potently inhibits the acetyltransferase activity and transcriptional activation properties of p300. Surprisingly, PCNA fails to inhibit p300/CBP-associated factor (PCAF) acetyltransferase function as well as PCAF-dependent transcription. Additionally, PCNA potently represses transcription when targeted to chromatin in vivo. Consistent with these observations, using chromatin immunoprecipitation assays, we demonstrate that PCNA recruitment to promoters causes hypoacetylation of chromatin. Together, our results demonstrate for the first time a novel role for human PCNA in transcriptional repression and in modulating chromatin modification. The reciprocal modulation of p300 and PCNA activities by each other provides an example of integrative regulatory cross-talk among chromatin-based processes such as DNA transcription, repair, and synthesis.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania	Chakravarti, D (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, 810 BRB2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.			Chakravarti, Debabrata/0000-0001-8446-8599	NIDDK NIH HHS [R01-DK57079, P30-DK50306, R01 DK057079] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057079, P30DK050306] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; Ait-Si-Ali S, 1999, BIOCHEM BIOPH RES CO, V262, P157, DOI 10.1006/bbrc.1999.1132; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; Assy N, 1997, J HEPATOL, V26, P945, DOI 10.1016/S0168-8278(97)80266-8; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Chakravarti D, 2003, CELL, V112, P589, DOI 10.1016/S0092-8674(03)00151-X; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Cheung WL, 2000, CURR OPIN CELL BIOL, V12, P326, DOI 10.1016/S0955-0674(00)00096-X; Cho H, 1998, MOL CELL BIOL, V18, P5355, DOI 10.1128/MCB.18.9.5355; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Elias JM, 1997, BIOTECH HISTOCHEM, V72, P78, DOI 10.3109/10520299709082216; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; HALL PA, 1995, ONCOGENE, V10, P2427; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Hasan S, 2001, MOL CELL, V7, P1221, DOI 10.1016/S1097-2765(01)00272-6; Hasan S, 2001, NATURE, V410, P387, DOI 10.1038/35066610; HENDERSON DS, 1994, EMBO J, V13, P1450, DOI 10.1002/j.1460-2075.1994.tb06399.x; Hong W, 2002, MOL CELL BIOL, V22, P3729, DOI 10.1128/MCB.22.11.3729-3743.2002; Hosfield DJ, 1998, CELL, V95, P135, DOI 10.1016/S0092-8674(00)81789-4; Ishizuka T, 2003, MOL CELL BIOL, V23, P5122, DOI 10.1128/MCB.23.15.5122-5131.2003; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kraus WL, 1999, MOL CELL BIOL, V19, P8123; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Li FS, 2002, J BIOL CHEM, V277, P45004, DOI 10.1074/jbc.M205259200; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; MATHEWS MB, 1984, NATURE, V309, P374, DOI 10.1038/309374a0; Meijer M, 1999, BIOESSAYS, V21, P596, DOI 10.1002/(SICI)1521-1878(199907)21:7<596::AID-BIES8>3.0.CO;2-5; Milutinovic S, 2002, J BIOL CHEM, V277, P20974, DOI 10.1074/jbc.M202504200; Mizzen CA, 2000, SCIENCE, V289, P2290, DOI 10.1126/science.289.5488.2290; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Perlmann T, 1997, CELL, V90, P391, DOI 10.1016/S0092-8674(00)80498-5; Polesskaya A, 2001, EMBO J, V20, P6816, DOI 10.1093/emboj/20.23.6816; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; REEVES R, 1985, NUCLEIC ACIDS RES, V13, P3599, DOI 10.1093/nar/13.10.3599; Schiltz RL, 1999, J BIOL CHEM, V274, P1189, DOI 10.1074/jbc.274.3.1189; Seo SB, 2002, J BIOL CHEM, V277, P14005, DOI 10.1074/jbc.M112455200; Seo SB, 2001, CELL, V104, P119, DOI 10.1016/S0092-8674(01)00196-9; Shibahara K, 1999, CELL, V96, P575, DOI 10.1016/S0092-8674(00)80661-3; SHIVJI MKK, 1995, BIOCHEMISTRY-US, V34, P5011, DOI 10.1021/bi00015a012; Stoilov L, 2000, INT J RADIAT BIOL, V76, P1485, DOI 10.1080/09553000050176243; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Tini M, 2002, MOL CELL, V9, P265, DOI 10.1016/S1097-2765(02)00453-7; Tsurimoto T, 1998, BBA-GENE STRUCT EXPR, V1443, P23, DOI 10.1016/S0167-4781(98)00204-8; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Vairapandi M, 1996, ONCOGENE, V12, P2579; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Zhang QH, 2000, MOL CELL BIOL, V20, P4970, DOI 10.1128/MCB.20.14.4970-4978.2000; Zhang ZG, 2000, NATURE, V408, P221, DOI 10.1038/35041601	60	40	41	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44505	44513		10.1074/jbc.M303138200	http://dx.doi.org/10.1074/jbc.M303138200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12937166	hybrid			2022-12-25	WOS:000186306700079
J	McBryant, SJ; Park, YJ; Abernathy, SM; Laybourn, PJ; Nyborg, JK; Luger, K				McBryant, SJ; Park, YJ; Abernathy, SM; Laybourn, PJ; Nyborg, JK; Luger, K			Preferential binding of the histone (H3-H4)(2) tetramer by NAP1 is mediated by the amino-terminal histone tails	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSOME ASSEMBLY PROTEIN-1; RNA-POLYMERASE-II; TRANSCRIPTIONAL ACTIVATION; CORE PARTICLE; CRYSTAL-STRUCTURE; ANGSTROM RESOLUTION; MOLECULAR-CLONING; DNA-REPLICATION; H2A/H2B DIMER; HUMAN-CELLS	The yeast nucleosome assembly protein 1 (yNAP1) participates in many diverse activities, such as the assembly of newly synthesized DNA into chromatin and the rearrangement of nucleosomes during transcriptional activation. yNAP1 does not require ATP hydrolysis to perform these functions and is a valuable tool for in vitro chromatin assembly. Using recombinant histone complexes, we show that yNAP1 has a preference for binding the (H3-H4)(2) tetramer over the (H2A-H2B) dimer. We find that the loss of the histone tails abrogates this preference for H3 and H4, and we demonstrate a direct interaction between yNAP1 and the amino-terminal tails of H3 and H4. yNAP1 binds to one histone fold domain, thus specifying the stoichiometry of the complexes formed with the histone dimer and tetramer. Finally, we provide evidence that the acidic carboxyl-terminal region of yNAP1, although dispensable for nucleosome assembly in vitro, contributes to binding via structure-independent electrostatic interactions. Our results are consistent with recent mechanistic investigations of NAP1 and expand our understanding of the histone chaperone family of assembly factors.	Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA	Colorado State University	Luger, K (corresponding author), Colorado State Univ, Dept Biochem & Mol Biol, 316 MRB, Ft Collins, CO 80523 USA.		Park, Young-Jun/AAF-6249-2021	Park, Young-Jun/0000-0003-2901-6949; SCHNIZER-LUGER, KAROLINE/0000-0001-5136-5331	NCI NIH HHS [R01 CA080002, R01 CA080002-05, CA80002] Funding Source: Medline; NIGMS NIH HHS [R01 GM067777, GM067777] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080002] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067777] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akey CW, 2003, CURR OPIN STRUC BIOL, V13, P6, DOI 10.1016/S0959-440X(03)00002-2; Altman R, 1997, J CELL BIOL, V138, P119, DOI 10.1083/jcb.138.1.119; An WJ, 2002, MOL CELL, V9, P811, DOI 10.1016/S1097-2765(02)00497-5; ARENTS G, 1995, P NATL ACAD SCI USA, V92, P11170, DOI 10.1073/pnas.92.24.11170; ARENTS G, 1991, P NATL ACAD SCI USA, V88, P10148, DOI 10.1073/pnas.88.22.10148; Asahara H, 2002, MOL CELL BIOL, V22, P2974, DOI 10.1128/MCB.22.9.2974-2983.2002; AUSIO J, 1989, J MOL BIOL, V206, P451, DOI 10.1016/0022-2836(89)90493-2; BAER BW, 1983, NATURE, V301, P482, DOI 10.1038/301482a0; BOHM L, 1984, BIOSCIENCE REP, V4, P365, DOI 10.1007/BF01122502; Carruthers LM, 2000, J BIOL CHEM, V275, P37285, DOI 10.1074/jbc.M006801200; Chang L, 1997, BIOCHEMISTRY-US, V36, P469, DOI 10.1021/bi962069i; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; Croston G.E., 1991, Protein Expression and Purification, V2, P162, DOI 10.1016/1046-5928(91)90066-R; Davey CA, 2002, J MOL BIOL, V319, P1097, DOI 10.1016/S0022-2836(02)00386-8; Dorigo B, 2003, J MOL BIOL, V327, P85, DOI 10.1016/S0022-2836(03)00025-1; Dutta S, 2001, MOL CELL, V8, P841, DOI 10.1016/S1097-2765(01)00354-9; DYER PN, 2003, IN PRESS METHODS ENZ; EARNSHAW WC, 1980, CELL, V21, P373, DOI 10.1016/0092-8674(80)90474-2; EICKBUSH TH, 1978, BIOCHEMISTRY-US, V17, P4955, DOI 10.1021/bi00616a016; FUJIINAKATA T, 1992, J BIOL CHEM, V267, P20980; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Georges SA, 2002, MOL CELL BIOL, V22, P127, DOI 10.1128/MCB.22.1.127-137.2002; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Iizuka M, 2003, CURR OPIN GENET DEV, V13, P154, DOI 10.1016/S0959-437X(03)00020-0; ISHIMI Y, 1984, EUR J BIOCHEM, V142, P431, DOI 10.1111/j.1432-1033.1984.tb08305.x; ISHIMI Y, 1987, EUR J BIOCHEM, V162, P19, DOI 10.1111/j.1432-1033.1987.tb10535.x; ISHIMI Y, 1991, J BIOL CHEM, V266, P7025; Ito T, 2000, GENE DEV, V14, P1899; Ito T, 1997, GENES CELLS, V2, P593, DOI 10.1046/j.1365-2443.1997.1500348.x; Ito T, 1996, MOL CELL BIOL, V16, P3112; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kimura H, 2001, J CELL BIOL, V153, P1341, DOI 10.1083/jcb.153.7.1341; Kireeva ML, 2002, MOL CELL, V9, P541, DOI 10.1016/S1097-2765(02)00472-0; Krude T, 2001, CELL MOL LIFE SCI, V58, P665, DOI 10.1007/PL00000890; Luger K, 1997, J MOL BIOL, V272, P301, DOI 10.1006/jmbi.1997.1235; Luger K, 1998, CURR OPIN STRUC BIOL, V8, P33, DOI 10.1016/S0959-440X(98)80007-9; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Luger K, 1999, METH MOL B, V119, P1; Luger K, 1998, CURR OPIN GENET DEV, V8, P140, DOI 10.1016/S0959-437X(98)80134-2; McQuibban GA, 1998, J BIOL CHEM, V273, P6582, DOI 10.1074/jbc.273.11.6582; Nakagawa T, 2001, J BIOL CHEM, V276, P27384, DOI 10.1074/jbc.M101331200; Namboodiri VMH, 2003, STRUCTURE, V11, P175, DOI 10.1016/S0969-2126(03)00007-8; Nishiyama N, 2001, GENE, V280, P107, DOI 10.1016/S0378-1119(01)00778-8; PAZIN MJ, 1994, SCIENCE, V266, P2007, DOI 10.1126/science.7801129; Philpott A, 2000, SEMIN CELL DEV BIOL, V11, P7, DOI 10.1006/scdb.1999.0346; Pilon J, 1997, PROTEIN EXPRES PURIF, V10, P132, DOI 10.1006/prep.1996.0716; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; Rodriguez P, 2000, J MOL BIOL, V298, P225, DOI 10.1006/jmbi.2000.3674; Shikama N, 2000, MOL CELL BIOL, V20, P8933, DOI 10.1128/MCB.20.23.8933-8943.2000; SMITH RM, 1989, J BIOL CHEM, V264, P10574; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Terrell AR, 2002, J BIOL CHEM, V277, P31038, DOI 10.1074/jbc.M204662200; Thiriet C, 2001, GENE DEV, V15, P2048, DOI 10.1101/gad.910201; Tyler JK, 2002, EUR J BIOCHEM, V269, P2268, DOI 10.1046/j.1432-1033.2002.02890.x; Tyler JK, 1999, NATURE, V402, P555, DOI 10.1038/990147; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; WALTER PP, 1995, MOL CELL BIOL, V15, P6178; White CL, 2001, EMBO J, V20, P5207, DOI 10.1093/emboj/20.18.5207; Widlund HR, 2000, BIOCHEMISTRY-US, V39, P3835, DOI 10.1021/bi991957l; Yoon HW, 1995, MOL GEN GENET, V249, P465, DOI 10.1007/BF00290572; Zheng CY, 2003, BIOPOLYMERS, V68, P539, DOI 10.1002/bip.10303; Zimmerman ZA, 2001, MOL BIOL CELL, V12, P201, DOI 10.1091/mbc.12.1.201	63	88	88	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44574	44583		10.1074/jbc.M305636200	http://dx.doi.org/10.1074/jbc.M305636200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12928440	hybrid			2022-12-25	WOS:000186306700087
J	Wu, JH; Peppel, K; Nelson, CD; Lin, FT; Kohout, TA; Miller, WE; Exum, ST; Freedman, NJ				Wu, JH; Peppel, K; Nelson, CD; Lin, FT; Kohout, TA; Miller, WE; Exum, ST; Freedman, NJ			The adaptor protein beta-arrestin2 enhances endocytosis of the low density lipoprotein receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REVERSE-TURN CONFORMATION; BETA-ADRENERGIC-RECEPTOR; LDL RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; MEDIATED ENDOCYTOSIS; ANGIOTENSIN-II; CYTOPLASMIC DOMAIN; COUPLED RECEPTORS; CLATHRIN ADAPTER; KINASE-C	Endocytosis of the low density lipoprotein (LDL) receptor ( LDLR) in coated pits employs the clathrin adaptor protein ARH. Similarly, agonist-dependent endocytosis of heptahelical receptors in coated pits employs the clathrin adaptor beta-arrestin proteins. In mice fed a high fat diet, we found that homozygous deficiency of beta-arrestin2 increased total and LDL plus intermediate-density lipoprotein cholesterol levels by 23 and 53%, respectively ( p < 0.05), but had no effect on high density lipoprotein cholesterol levels. We therefore tested whether &beta;-arrestins could affect the constitutive endocytosis of the LDLR. When overexpressed in cells, &beta;-arrestin1 and &beta;-arrestin2 each associated with the LDLR, as judged by co-immunoprecipitation, and augmented LDLR endocytosis by &SIM; 70%, as judged by uptake of fluorescent LDL. However, physiologic expression levels of only &beta;-arrestin2, and not &beta;-arrestin1, enhanced endogenous LDLR endocytosis ( by 65%) in stably transfected &beta;-arrestin1/&beta;-arrestin2 double-knockout mouse embryonic fibroblasts (MEFs). Concordantly, when RNA interference was used to suppress expression of &beta;-arrestin2, but not &beta;-arrestin1, LDLR endocytosis was reduced. Moreover, &beta;-arrestin2(-/-) MEFs demonstrated LDLR endocytosis that was 50% less than cognate wild type MEFs. In fusion protein pull-down assays, &beta;-arrestin2 bound to the LDLR cytoplasmic tail stoichiometrically, and binding was abolished by mutation of LDLR Tyr(807) to Ala. Mutation of LDLR cytoplasmic tail Ser(833) to Asp enhanced both the affinity of LDLR fusion protein binding to &beta;-arrestin2, and the efficiency of LDLR endocytosis in cells expressing &beta;-arrestin2 physiologically. We conclude that &beta;-arrestin2 can bind to and enhance endocytosis of the LDLR, both in vitro and in vivo, and may thereby influence lipoprotein metabolism.	Duke Univ, Med Ctr, Dept Med Cardiol, Durham, NC 27710 USA	Duke University	Freedman, NJ (corresponding author), Duke Univ, Med Ctr, Dept Med Cardiol, Box 3187, Durham, NC 27710 USA.				NHLBI NIH HHS [HL64744, HL63288] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063288, R01HL064744] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahn S, 2003, P NATL ACAD SCI USA, V100, P1740, DOI 10.1073/pnas.262789099; ANDERSON RGW, 1982, J CELL BIOL, V93, P523, DOI 10.1083/jcb.93.3.523; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; Bohn LM, 1999, SCIENCE, V286, P2495, DOI 10.1126/science.286.5449.2495; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHUNG BH, 1986, METHOD ENZYMOL, V128, P181; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DUELAND S, 1993, J LIPID RES, V34, P923; Freedman NJ, 1997, J BIOL CHEM, V272, P17734, DOI 10.1074/jbc.272.28.17734; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; Garcia CK, 2001, SCIENCE, V292, P1394, DOI 10.1126/science.1060458; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Haddad G, 1997, REGUL PEPTIDES, V68, P111, DOI 10.1016/S0167-0115(96)02112-X; He GC, 2002, J BIOL CHEM, V277, P44044, DOI 10.1074/jbc.M208539200; Hein L, 1997, MOL ENDOCRINOL, V11, P1266, DOI 10.1210/me.11.9.1266; Innerarity T L, 1986, Methods Enzymol, V129, P542; KESANIEMI YA, 1983, J CLIN INVEST, V71, P950, DOI 10.1172/JCI110849; Kibbey RG, 1998, J CELL BIOL, V142, P59, DOI 10.1083/jcb.142.1.59; KINGSLEY DM, 1984, P NATL ACAD SCI-BIOL, V81, P5454, DOI 10.1073/pnas.81.17.5454; KISHIMOTO A, 1987, J BIOL CHEM, V262, P9367; KISHIMOTO A, 1987, J BIOL CHEM, V262, P1344; Knouff C, 1999, J CLIN INVEST, V103, P1579, DOI 10.1172/JCI6172; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; Laporte SA, 2000, J BIOL CHEM, V275, P23120, DOI 10.1074/jbc.M002581200; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Lin FT, 1997, J BIOL CHEM, V272, P31051, DOI 10.1074/jbc.272.49.31051; Lin FT, 2002, BIOCHEMISTRY-US, V41, P10692, DOI 10.1021/bi025705n; MEHTA KD, 1991, J BIOL CHEM, V266, P10406; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; Miller WE, 2000, J BIOL CHEM, V275, P11312, DOI 10.1074/jbc.275.15.11312; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4; Rohlmann A, 1998, J CLIN INVEST, V101, P689, DOI 10.1172/JCI1240; Sambrook J, 2001, MOL CLONING LAB MANU, V3rd; VON ZM, 1992, J BIOL CHEM, V267, P3530; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0; YOKODE M, 1992, J CELL BIOL, V117, P39, DOI 10.1083/jcb.117.1.39	46	43	46	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44238	44245		10.1074/jbc.M309450200	http://dx.doi.org/10.1074/jbc.M309450200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12944399	hybrid			2022-12-25	WOS:000186306700044
J	Head, JF; Mealy, TR; McCormack, FX; Seaton, BA				Head, JF; Mealy, TR; McCormack, FX; Seaton, BA			Crystal structure of trimeric carbohydrate recognition and neck domains of surfactant protein A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE-BINDING PROTEINS; HELICAL COILED-COIL; PULMONARY SURFACTANT; INNATE IMMUNITY; PHOSPHOLIPID AGGREGATION; SPECIFICALLY BINDS; LECTIN DOMAINS; HUMAN LUNG; PHOSPHATIDYLINOSITOL; LIPOPOLYSACCHARIDE	Surfactant protein A (SP-A), one of four proteins associated with pulmonary surfactant, binds with high affinity to alveolar phospholipid membranes, positioning the protein at the first line of defense against inhaled pathogens. SP-A exhibits both calcium-dependent carbohydrate binding, a characteristic of the collectin family, and specific interactions with lipid membrane components. The crystal structure of the trimeric carbohydrate recognition domain and neck domain of SP-A was solved to 2.1-Angstrom resolution with multiwavelength anomalous dispersion phasing from samarium. Two metal-binding sites were identified, one in the highly conserved lectin site and the other 8.5 Angstrom away. The interdomain carbohydrate recognition domain-neck angle is significantly less in SP-A than in the homologous collectins, surfactant protein D, and mannose-binding protein. This conformational difference may endow the SP-A trimer with a more extensive hydrophobic surface capable of binding lipophilic membrane components. The appearance of this surface suggests a putative binding region for membrane-derived SP-A ligands such as phosphatidylcholine and lipid A, the endotoxic lipid component of bacterial lipopolysaccharide that mediates the potentially lethal effects of Gram-negative bacterial infection.	Boston Univ, Sch Med, Dept Physiol & Biophys, Boston, MA 02118 USA; Univ Cincinnati, Dept Internal Med, Div Pulm Crit Care Med, Cincinnati, OH 45267 USA	Boston University; University System of Ohio; University of Cincinnati	Seaton, BA (corresponding author), Boston Univ, Sch Med, Dept Physiol & Biophys, Boston, MA 02118 USA.		McCormack, Francis X./ABE-8398-2020	McCormack, Francis X./0000-0001-7168-9464; Head, James/0000-0002-6226-4146; Seaton, Barbara/0000-0003-4654-7709				BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; COCKSHUTT AM, 1990, BIOCHEMISTRY-US, V29, P8424, DOI 10.1021/bi00488a032; CROUCH E, 1994, J BIOL CHEM, V269, P17311; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; Drickamer K, 1999, CURR OPIN STRUC BIOL, V9, P585, DOI 10.1016/S0959-440X(99)00009-3; Epstein J, 1996, CURR OPIN IMMUNOL, V8, P29, DOI 10.1016/S0952-7915(96)80101-4; Feinberg H, 2001, SCIENCE, V294, P2163, DOI 10.1126/science.1066371; Ferguson AD, 1998, SCIENCE, V282, P2215, DOI 10.1126/science.282.5397.2215; Ferguson AD, 2000, STRUCTURE, V8, P585; Goerke J., 1986, HDB PHYSL RESP SYSTE, P247; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HAAGSMAN HP, 1990, BIOCHEMISTRY-US, V29, P8894, DOI 10.1021/bi00490a003; Hakansson K, 1999, STRUCTURE, V7, P255, DOI 10.1016/S0969-2126(99)80036-7; Hakansson K, 2000, PROTEIN SCI, V9, P1607, DOI 10.1110/ps.9.9.1607; HOPPE HJ, 1994, PROTEIN SCI, V3, P1143, DOI 10.1002/pro.5560030801; JONES TA, 1992, O MANUAL; KALINA M, 1995, AM J PHYSIOL-LUNG C, V268, pL144, DOI 10.1152/ajplung.1995.268.1.L144; KING RJ, 1973, AM J PHYSIOL, V224, P788, DOI 10.1152/ajplegacy.1973.224.4.788; Korfhagen TR, 1996, P NATL ACAD SCI USA, V93, P9594, DOI 10.1073/pnas.93.18.9594; Kovacs H, 2002, J BIOMOL NMR, V24, P89, DOI 10.1023/A:1020980006628; KUROKI Y, 1994, J BIOL CHEM, V269, P29793; KUROKI Y, 1991, J BIOL CHEM, V266, P3068; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LeVine AM, 1997, J IMMUNOL, V158, P4336; McCormack FX, 1997, BIOCHEMISTRY-US, V36, P8092, DOI 10.1021/bi970313f; McCormack FX, 1997, BIOCHEMISTRY-US, V36, P13963, DOI 10.1021/bi970745q; McCormack FX, 2002, J CLIN INVEST, V109, P707, DOI 10.1172/JCI200215293; MCCORMACK FX, 1994, J BIOL CHEM, V269, P29801; McCormack FX, 1999, J BIOL CHEM, V274, P3173, DOI 10.1074/jbc.274.5.3173; Ng KKS, 1998, BIOCHEMISTRY-US, V37, P17965, DOI 10.1021/bi981972a; Ng KKS, 1998, BIOCHEMISTRY-US, V37, P17977, DOI 10.1021/bi9819733; Ng KKS, 2002, J BIOL CHEM, V277, P16088, DOI 10.1074/jbc.M200493200; Nielsen BB, 1997, FEBS LETT, V412, P388, DOI 10.1016/S0014-5793(97)00664-9; Ochs M, 2002, AM J RESP CELL MOL, V26, P91, DOI 10.1165/ajrcmb.26.1.4570; OGASAWARA Y, 1995, J BIOL CHEM, V270, P14725, DOI 10.1074/jbc.270.24.14725; OGASAWARA Y, 1992, J BIOL CHEM, V267, P21244; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Palaniyar N, 1998, J STRUCT BIOL, V122, P297, DOI 10.1006/jsbi.1998.4004; Palaniyar N, 2000, BIOCHEMISTRY-US, V39, P6310, DOI 10.1021/bi992793b; Pattanajitvilai S, 1998, J BIOL CHEM, V273, P5702, DOI 10.1074/jbc.273.10.5702; PERSSON AV, 1992, BIOCHEMISTRY-US, V31, P12183, DOI 10.1021/bi00163a030; Radaev S, 2001, IMMUNITY, V15, P1039, DOI 10.1016/S1074-7613(01)00241-2; Sahly H, 2002, J IMMUNOL, V169, P3267, DOI 10.4049/jimmunol.169.6.3267; SUZUKI Y, 1989, AM REV RESPIR DIS, V140, P75, DOI 10.1164/ajrccm/140.1.75; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; VANIWAARDEN JF, 1994, BIOCHEM J, V303, P407, DOI 10.1042/bj3030407; Veldhuizen RAW, 1996, BIOCHEM J, V313, P835, DOI 10.1042/bj3130835; VOSS T, 1988, J MOL BIOL, V201, P219, DOI 10.1016/0022-2836(88)90448-2; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; WEIS WI, 1994, STRUCTURE, V2, P1227, DOI 10.1016/S0969-2126(94)00124-3; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; Zhang M, 1998, BIOCHEMISTRY-US, V37, P16481, DOI 10.1021/bi9817966; Zhang PN, 2001, J BIOL CHEM, V276, P19862, DOI 10.1074/jbc.M100597200	54	89	92	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43254	43260		10.1074/jbc.M305628200	http://dx.doi.org/10.1074/jbc.M305628200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12913002	hybrid			2022-12-25	WOS:000186157000067
J	Bist, P; Rao, DN				Bist, P; Rao, DN			Identification and mutational analysis of Mg2+ binding site in EcoP15I DNA methyltransferase - Involvement in target base eversion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FE2+-MEDIATED OXIDATIVE CLEAVAGE; RESTRICTION-ENDONUCLEASE; ACTIVE-SITE; MODIFICATION METHYLASE; RECOGNITION SEQUENCE; CATALYTIC PROPERTIES; ESCHERICHIA-COLI; ENZYMES; CALCIUM; PURIFICATION	EcoP15I DNA methyltransferase catalyzes the transfer of the methyl group of S-adenosyl-L-methionine to the N-6 position of the second adenine within the double-stranded DNA sequence 5'-CAGCAG-3'. To achieve catalysis, the enzyme requires a magnesium ion. Binding of magnesium to the enzyme induces significant conformational changes as monitored by circular dichroism spectroscopy. EcoP15I DNA methyltransferase was rapidly inactivated by micromolar concentrations of ferrous sulfate in the presence of ascorbate at pH 8.0. The inactivated enzyme was cleaved into two fragments with molecular masses of 36 and 35 kDa. Using this affinity cleavage assay, we have located the magnesium binding-like motif to amino acids 355 - 377 of EcoP15I DNA methyltransferase. Sequence homology comparisons between EcoP15I DNA methyltransferase and other restriction endonucleases allowed us to identify a PD(X)(n)(D/E) XK-like sequence as the putative magnesium ion binding site. Point mutations generated in this region were analyzed for their role in methyltransferase activity, metal coordination, and substrate binding. Although the mutant methyltransferases bind DNA and S-adenosyl-L-methionine as well as the wild-type enzyme does, they are inactive primarily because of their inability to flip the target base. Collectively, these data are consistent with the fact that acidic amino acid residues of the region 355 - 377 in EcoP15I DNA methyltransferase are important for the critical positioning of magnesium ions for catalysis. This is the first example of metal-dependent function of a DNA methyltransferase. These findings provide impetus for exploring the role(s) of metal ions in the structure and function of DNA methyltransferases.	Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Rao, DN (corresponding author), Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India.	dnrao@biochem.iisc.ernet.in	BIST, PRADEEP/AAG-7986-2019					AHAMD I, 1994, J MOL BIOL, V242, P378, DOI 10.1006/jmbi.1994.1588; Ahmad I, 1996, CRIT REV BIOCHEM MOL, V31, P361, DOI 10.3109/10409239609108722; Ahmad I, 1996, J MOL BIOL, V259, P229, DOI 10.1006/jmbi.1996.0315; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bujnicki JM, 2001, J MOL MICROB BIOTECH, V3, P69; Cao WG, 1998, J BIOL CHEM, V273, P33002, DOI 10.1074/jbc.273.49.33002; Cesnaviciene E, 2001, J MOL BIOL, V314, P205, DOI 10.1006/jmbi.2001.5049; CHENG XD, 1995, ANNU REV BIOPH BIOM, V24, P293, DOI 10.1146/annurev.bb.24.060195.001453; COX JA, 1981, BIOCHEMISTRY-US, V20, P5430, DOI 10.1021/bi00522a012; DYDEN DTF, 1999, S ADENOSYLMETHIONINE, P283; Enzlin JH, 2002, EMBO J, V21, P2045, DOI 10.1093/emboj/21.8.2045; Fenton H., 1894, J CHEM SOC T, V65, P899, DOI [10.1039/CT8946500899, DOI 10.1039/CT8946500899]; HADI SM, 1983, J MOL BIOL, V165, P19, DOI 10.1016/S0022-2836(83)80240-X; Hlavaty JJ, 2000, BIOCHEMISTRY-US, V39, P3097, DOI 10.1021/bi992268c; HUMBELIN M, 1988, J MOL BIOL, V200, P23, DOI 10.1016/0022-2836(88)90330-0; JANULAITIS A, 1992, NUCLEIC ACIDS RES, V20, P6043, DOI 10.1093/nar/20.22.6043; Jose TJ, 1999, J BIOL INORG CHEM, V4, P814, DOI 10.1007/s007750050355; Kim DR, 1999, GENE DEV, V13, P3070, DOI 10.1101/gad.13.23.3070; Kong HM, 1997, NUCLEIC ACIDS RES, V25, P3687, DOI 10.1093/nar/25.18.3687; KRETSINGER RH, 1973, J BIOL CHEM, V248, P3313; KUMAR S, 1994, NUCLEIC ACIDS RES, V22, P1, DOI 10.1093/nar/22.1.1; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lagunavicius A, 2003, J MOL BIOL, V326, P1051, DOI 10.1016/S0022-2836(03)00020-2; LAUTENBERGER JA, 1972, J BIOL CHEM, V247, P6176; MALONE T, 1995, J MOL BIOL, V253, P618, DOI 10.1006/jmbi.1995.0577; Marks P, 2003, NUCLEIC ACIDS RES, V31, P2803, DOI 10.1093/nar/gkg399; MEISEL A, 1991, NUCLEIC ACIDS RES, V19, P3997, DOI 10.1093/nar/19.14.3997; MILOS M, 1986, BIOCHEMISTRY-US, V25, P6279, DOI 10.1021/bi00368a067; Pingoud A, 2001, NUCLEIC ACIDS RES, V29, P3705, DOI 10.1093/nar/29.18.3705; Raghavendra NK, 2003, NUCLEIC ACIDS RES, V31, P1888, DOI 10.1093/nar/gkg275; RAO DN, 1989, J MOL BIOL, V209, P599, DOI 10.1016/0022-2836(89)90597-4; Reddy YVR, 1998, J BIOL CHEM, V273, P23866, DOI 10.1074/jbc.273.37.23866; Reddy YVR, 2000, J MOL BIOL, V298, P597, DOI 10.1006/jmbi.2000.3673; Roberts RJ, 1998, ANNU REV BIOCHEM, V67, P181, DOI 10.1146/annurev.biochem.67.1.181; Roberts RJ, 2003, NUCLEIC ACIDS RES, V31, P1805, DOI 10.1093/nar/gkg274; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Soundararajan M, 2002, J BIOL CHEM, V277, P887, DOI 10.1074/jbc.M109100200; Tucholski J, 1998, GENE, V223, P293, DOI 10.1016/S0378-1119(98)00450-8; Vanamee ES, 2001, J MOL BIOL, V309, P69, DOI 10.1006/jmbi.2001.4635; Viadiu H, 1998, NAT STRUCT BIOL, V5, P910, DOI 10.1038/2352; VIPOND IB, 1995, BIOCHEMISTRY-US, V34, P1113, DOI 10.1021/bi00004a002	42	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41837	41848		10.1074/jbc.M307053200	http://dx.doi.org/10.1074/jbc.M307053200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12917398	hybrid			2022-12-25	WOS:000185989500036
J	Brumaghim, JL; Li, Y; Henle, E; Linn, S				Brumaghim, JL; Li, Y; Henle, E; Linn, S			Effects of hydrogen peroxide upon nicotinamide nucleotide metabolism in Escherichia coli - Changes in enzyme levels and nicotinamide nucleotide pools and studies of the oxidation of NAD(P)H by Fe(III)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEHYDROGENASE-DEFICIENT ERYTHROCYTES; DNA-DAMAGE; ENCODING GLUCOSE-6-PHOSPHATE-DEHYDROGENASE; DIPHOSPHOPYRIDINE NUCLEOTIDE; 3-DIMENSIONAL STRUCTURE; GLUTATHIONE-PEROXIDASE; SUPEROXIDE-DISMUTASE; STRESS RESPONSES; GALLIUM COMPLEX; FENTON REACTION	DNA is damaged in vivo by the Fenton reaction mediated by Fe2+ and cellular reductants such as NADH, which reduce Fe3+ to Fe2+ and allow the recycling of iron. To study the response of Escherichia coli to such cycling, the activities of several enzymes involved in nicotinamide nucleotide metabolism were measured following an H2O2 challenge. NADPH-dependent peroxidase, NADH/NADP(+) transhydrogenase, and glucose-6-phosphate dehydrogenase were most strongly induced, increasing 2.5-3-fold. In addition, the cellular ratios of NADPH to NADH increased 6- or 92-fold 15 min after exposure to 0.5 or 5 mM H2O2, respectively. In vitro, NADH was oxidized by Fe3+ up to 16-fold faster than NADPH, despite their identical reduction potentials. To understand this rate difference, the interactions of Fe3+ and Ga3+ with NAD(P) H were examined by H-1, C-13, and P-31 NMR spectroscopy. Association with NADH occurred primarily with adenine at N7 and the amino group, but for NADPH, strong metal interactions also occurred at the 2'-phosphate group. Interaction of M3+ (Fe3+ or Ga3+) with the adenine ring would bring it into close proximity to the redox-active nicotinamide ring in the folded form of NAD( P) H, but interaction of M3+ with the 2'-phosphate group would avoid this close contact. In addition, as determined by absorbance spectroscopy, the energy of the charge-transfer species was significantly higher for the Fe3+.NADPH complex than for the Fe3+.NADH complex. We therefore suggest that upon exposure to H2O2 the NADH pool is depleted, and NADPH, which is less reactive with Fe3+, functions as the major nicotinamide nucleotide reductant.	Univ Calif Berkeley, Div Biochem & Mol Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Linn, S (corresponding author), Univ Calif Berkeley, Div Biochem & Mol Biol, Barker Hall, Berkeley, CA 94720 USA.	slinn@socrates.berkeley.edu		Brumaghim, Julia/0000-0002-9274-014X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007075] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019020] Funding Source: NIH RePORTER; NIEHS NIH HHS [T32 ES 07075, P30 ES 01986] Funding Source: Medline; NIGMS NIH HHS [R01 GM 19020] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATKINSON RA, 1988, BIOCHEMISTRY-US, V37, P15965; BAES CF, 1976, HYDROLYSIS CATIONS, P27; BARBIERI JT, 1989, J BACTERIOL, V171, P4362, DOI 10.1128/JB.171.8.4362-4369.1989; Barja G, 2002, AGEING RES REV, V1, P397, DOI 10.1016/S1568-1637(02)00008-9; BOCHNER BR, 1982, J BIOL CHEM, V257, P9759; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAGG PD, 1972, BIOCHEM BIOPH RES CO, V47, P1248, DOI 10.1016/0006-291X(72)90969-2; CAVARI BZ, 1968, J BACTERIOL, V96, P751, DOI 10.1128/JB.96.3.751-759.1968; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CLAIBORNE A, 1979, J BIOL CHEM, V254, P4245; COVES J, 1991, BIOCHEM BIOPH RES CO, V178, P54, DOI 10.1016/0006-291X(91)91778-B; Cusumano M, 1997, J INORG BIOCHEM, V65, P137, DOI 10.1016/S0162-0134(96)00100-6; DEMPLE B, 1991, CELL, V67, P837, DOI 10.1016/0092-8674(91)90355-3; Du F, 2001, J INORG BIOCHEM, V83, P101, DOI 10.1016/S0162-0134(00)00185-9; ELMAHDAOUI L, 1995, J BIOMOL STRUCT DYN, V13, P69, DOI 10.1080/07391102.1995.10508822; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; GERLI GC, 1982, SCAND J HAEMATOL, V29, P135; Goth L, 2000, LANCET, V356, P1820, DOI 10.1016/S0140-6736(00)03238-4; GREENBERG JT, 1986, J BACTERIOL, V168, P1026, DOI 10.1128/jb.168.2.1026-1029.1986; GUTMAN M, 1968, BIOCHEMISTRY-US, V7, P2778, DOI 10.1021/bi00848a012; GUTMAN M, 1973, BIOCHEMISTRY-US, V12, P2314, DOI 10.1021/bi00736a020; Gutteridge JMC, 2000, ANN NY ACAD SCI, V899, P136, DOI 10.1111/j.1749-6632.2000.tb06182.x; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; Halliwell B, 2001, DRUG AGING, V18, P685, DOI 10.2165/00002512-200118090-00004; HILLAR A, 1994, BIOCHEM J, V300, P531, DOI 10.1042/bj3000531; HUGICLEARY D, 1987, J AM CHEM SOC, V109, P4444, DOI 10.1021/ja00249a003; IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616; IMLAY JA, 1988, SCIENCE, V240, P640, DOI 10.1126/science.2834821; IMLAY JA, 1987, J BACTERIOL, V169, P2967, DOI 10.1128/jb.169.7.2967-2976.1987; Kapinos LE, 2001, INORG CHEM, V40, P2500, DOI 10.1021/ic0009775; Kersting B, 1996, J AM CHEM SOC, V118, P5712, DOI 10.1021/ja953545f; KIRKMAN HN, 1984, P NATL ACAD SCI-BIOL, V81, P4343, DOI 10.1073/pnas.81.14.4343; KLAIDMAN LK, 1995, ANAL BIOCHEM, V228, P312, DOI 10.1006/abio.1995.1356; Kong J, 2000, J COMPUT CHEM, V21, P1532, DOI 10.1002/1096-987X(200012)21:16<1532::AID-JCC10>3.0.CO;2-W; KORNBERG A, 1950, J BIOL CHEM, V182, P763; LEE CP, 1964, BIOCHIM BIOPHYS ACTA, V81, P187, DOI 10.1016/0926-6569(64)90353-0; Lee SM, 2002, FREE RADICAL BIO MED, V32, P1185, DOI 10.1016/S0891-5849(02)00815-8; Liu GD, 2001, ANAL SCI, V17, P1031, DOI 10.2116/analsci.17.1031; Lloyd RV, 1997, FREE RADICAL BIO MED, V22, P885, DOI 10.1016/S0891-5849(96)00432-7; LUNDQUIST R, 1971, J BIOL CHEM, V246, P1107; Markesbery WR, 1999, BRAIN PATHOL, V9, P133; MCKIE JH, 1991, FEBS LETT, V279, P5, DOI 10.1016/0014-5793(91)80236-V; MEZZETTI A, 1990, J MOL CELL CARDIOL, V22, P935, DOI 10.1016/0022-2828(90)91033-4; NOGAE I, 1990, GENE, V96, P161, DOI 10.1016/0378-1119(90)90248-P; NORLAND S, 1987, MICROBIAL ECOL, V13, P95, DOI 10.1007/BF02011246; NUNOSHIBA T, 1992, J BACTERIOL, V174, P6054, DOI 10.1128/JB.174.19.6054-6060.1992; Obrey SJ, 2000, J CHEM CRYSTALLOGR, V30, P61, DOI 10.1023/A:1009502317489; OLIVERA BM, 1967, P NATL ACAD SCI USA, V57, P1700, DOI 10.1073/pnas.57.6.1700; OLSINKI R, 2002, FREE RADIC BIOL MED, V33, P192; OPPENHEIMER NJ, 1978, BIOCHEMISTRY-US, V17, P2613, DOI 10.1021/bi00606a024; OPPENHEIMER NJ, 1987, PYRIDINE NUCLEOTIDE, VA, P185; PANDOLFI PP, 1995, EMBO J, V14, P5209, DOI 10.1002/j.1460-2075.1995.tb00205.x; PARK UE, 1989, J BACTERIOL, V171, P2173, DOI 10.1128/jb.171.4.2173-2180.1989; Peskin AV, 1996, FREE RADICAL BIO MED, V20, P313, DOI 10.1016/0891-5849(96)02053-9; PRIETOALAMO MJ, 1993, CARCINOGENESIS, V14, P237, DOI 10.1093/carcin/14.2.237; Qian SY, 1999, FREE RADICAL BIO MED, V26, P1447, DOI 10.1016/S0891-5849(99)00002-7; Rai P, 2001, J MOL BIOL, V312, P1089, DOI 10.1006/jmbi.2001.5010; RIZZO V, 1987, PYRIDINE NUCLEOTIDE, VA, P99; SCOTT MD, 1993, BIOCHIM BIOPHYS ACTA, V1181, P163, DOI 10.1016/0925-4439(93)90106-B; SCOTT MD, 1991, BLOOD, V77, P2059; SHANNON RD, 1976, ACTA CRYSTALLOGR A, V32, P751, DOI 10.1107/S0567739476001551; SINHA BK, 1989, CANCER RES, V49, P3844; Slekar KH, 1996, J BIOL CHEM, V271, P28831, DOI 10.1074/jbc.271.46.28831; Sorokin VA, 1997, J MOL STRUCT, V408, P233, DOI 10.1016/S0022-2860(96)09724-4; STEPHAN H, 1993, LIEBIGS ANN CHEM, P43; STORZ G, 1990, TRENDS GENET, V6, P363, DOI 10.1016/0168-9525(90)90278-E; STRYER L, 1988, BIOCHEMISTRY-US, P400; TYRRELL RM, 1989, PHOTOCHEM PHOTOBIOL, V49, P407, DOI 10.1111/j.1751-1097.1989.tb09187.x; Wasielewski E, 2002, BIOCHEMISTRY-US, V41, P12488, DOI 10.1021/bi025990a; Woodmansee AN, 2002, J BIOL CHEM, V277, P34055, DOI 10.1074/jbc.M203977200; WORTHINGTON CC, 1988, WORTHINGTON MANUAL E; ZEREZ CR, 1987, J BACTERIOL, V169, P184, DOI 10.1128/jb.169.1.184-188.1987; Zheng M, 2001, J BACTERIOL, V183, P4562, DOI 10.1128/JB.183.15.4562-4570.2001	74	73	73	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42495	42504		10.1074/jbc.M306251200	http://dx.doi.org/10.1074/jbc.M306251200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12913009	hybrid			2022-12-25	WOS:000185989500114
J	Carrillo, JJ; Pediani, J; Milligan, G				Carrillo, JJ; Pediani, J; Milligan, G			Dimers of class A G protein-coupled receptors function via agonist-mediated trans-activation of associated G proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; HORMONE RECEPTOR; SIGNAL-TRANSDUCTION; SPLICE VARIANT; CELL-SURFACE; HETERODIMERIZATION; OLIGOMERIZATION; ACTIVATION; FUSION; EXPRESSION	The histamine H1 receptor and the alpha(1b)-adrenoreceptor are G protein-coupled receptors that elevate intracellular [Ca2+] via activation of G(q)/G(11). Assessed by coimmunoprecipitation and time-resolved fluorescence resonance energy transfer they both exist as homodimers. The addition of the G protein G(11)alpha to the C terminus of these receptors did not prevent dimerization. Agonists produced a large stimulation of guanosine 5'-3-O-([S-35] thio) triphosphate ([S-35] GTPgammaS) binding to receptor-G protein fusions containing wild type forms of both polypeptides. For both receptors this was abolished by incorporation of G208AG(11)alpha into the fusions. Mutation of a highly conserved leucine in intracellular loop 2 of each receptor also eliminated agonist function but not binding. Co-expression of the two non-functional but complementary fusion constructs reconstituted agonist-mediated binding of [S-35] GTPgammaS in membranes of HEK293 cells and elevation of [Ca2+](i) in mouse embryo fibroblasts lacking both G(q) and G(11). Co-expression of the histamine H1 receptor- and the alpha(1b)-adrenoreceptor-G(11)alpha fusions allowed detection of functional hetero- dimeric complexes, whereas co-expression of histamine H1 receptor-G(11)alpha with increasing amounts of L151Dalpha(1b)-adrenoreceptor resulted in decreasing levels of histamine-stimulated [S-35] GTPgammaS binding. Co-expression of the alpha(1b)-adrenoreceptor with a fusion protein incorporating the N-terminal domain and transmembrane helix 1 of the alpha(1b)-adrenoreceptor and G(11)alpha did not result in agonist activation of the G protein but did indicate a role for transmembrane helix 1 in dimerization. These data demonstrate that dimers of these class A receptors function via trans-activation of associated G proteins.	Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Mol Pharmacol Grp, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow	Milligan, G (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Mol Pharmacol Grp, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	g.milligan@bio.gla.ac.uk	Milligan, Graeme/F-9426-2011; Pediani, John/F-2708-2019	Milligan, Graeme/0000-0002-6946-3519; Pediani, John/0000-0001-6615-537X				AbdAlla S, 2000, NATURE, V407, P94, DOI 10.1038/35024095; Baneres JL, 2003, J MOL BIOL, V329, P815, DOI 10.1016/S0022-2836(03)00439-X; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Burt AR, 1998, J BIOL CHEM, V273, P10367, DOI 10.1074/jbc.273.17.10367; Carrillo JJ, 2002, J PHARMACOL EXP THER, V302, P1080, DOI 10.1124/jpet.102.035501; Devi LA, 2001, TRENDS PHARMACOL SCI, V22, P532, DOI 10.1016/S0165-6147(00)01799-5; Duthey B, 2002, J BIOL CHEM, V277, P3236, DOI 10.1074/jbc.M108900200; Faber JE, 2001, J PHARMACOL EXP THER, V298, P441; Filizola M, 2002, BIOPOLYMERS, V66, P317, DOI 10.1002/bip.10311; Filizola M, 2002, PROTEIN ENG, V15, P881, DOI 10.1093/protein/15.11.881; Fotiadis D, 2003, NATURE, V421, P127, DOI 10.1038/421127a; Fredriksson R, 2003, MOL PHARMACOL, V63, P1256, DOI 10.1124/mol.63.6.1256; George SR, 2002, NAT REV DRUG DISCOV, V1, P808, DOI 10.1038/nrd913; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; Gouldson PR, 2001, PROTEIN ENG, V14, P759, DOI 10.1093/protein/14.10.759; Greasley PJ, 2001, J BIOL CHEM, V276, P46485, DOI 10.1074/jbc.M105791200; Grosse R, 1997, MOL ENDOCRINOL, V11, P1305, DOI 10.1210/me.11.9.1305; Guo W, 2003, J BIOL CHEM, V278, P4385, DOI 10.1074/jbc.C200679200; Guzzi F, 2001, BIOCHEM J, V355, P323, DOI 10.1042/0264-6021:3550323; HERBERT TE, 1996, J BIOL CHEM, V271, P16384; Ji IH, 2002, MOL ENDOCRINOL, V16, P1299, DOI 10.1210/me.16.6.1299; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Karpa KD, 2000, MOL PHARMACOL, V58, P677, DOI 10.1124/mol.58.4.677; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Klco JM, 2003, J BIOL CHEM, V278, P35345, DOI 10.1074/jbc.M305606200; Lee CW, 2002, J BIOL CHEM, V277, P15795, DOI 10.1074/jbc.M111818200; Lee SP, 2000, MOL PHARMACOL, V58, P120, DOI 10.1124/mol.58.1.120; Lee TW, 1999, BIOCHEMISTRY-US, V38, P13801, DOI 10.1021/bi9908282; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; Liu S, 2002, J BIOL CHEM, V277, P25707, DOI 10.1074/jbc.M201015200; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; Margeta-Mitrovic M, 2001, P NATL ACAD SCI USA, V98, P14649, DOI 10.1073/pnas.251554498; McVey M, 2001, J BIOL CHEM, V276, P14092, DOI 10.1074/jbc.M008902200; Mellado M, 2001, EMBO J, V20, P2497, DOI 10.1093/emboj/20.10.2497; Mercier JF, 2002, J BIOL CHEM, V277, P44925, DOI 10.1074/jbc.M205767200; Milligan G, 2003, TRENDS PHARMACOL SCI, V24, P87, DOI 10.1016/S0165-6147(02)00027-5; Milligan G, 2000, TRENDS PHARMACOL SCI, V21, P24, DOI 10.1016/S0165-6147(99)01404-2; Milligan G, 2002, METHOD ENZYMOL, V343, P260; Milligan G, 2001, J CELL SCI, V114, P1265; MITCHELL FM, 1993, BIOCHEM J, V293, P495, DOI 10.1042/bj2930495; Molinari P, 2003, J BIOL CHEM, V278, P15778, DOI 10.1074/jbc.M300731200; Offermanns S, 2001, ONCOGENE, V20, P1635, DOI 10.1038/sj.onc.1204189; Offermanns S, 1998, EMBO J, V17, P4304, DOI 10.1093/emboj/17.15.4304; Osuga Y, 1997, J BIOL CHEM, V272, P25006, DOI 10.1074/jbc.272.40.25006; Overton MC, 2002, J BIOL CHEM, V277, P41463, DOI 10.1074/jbc.M205368200; Parmentier ML, 2002, TRENDS PHARMACOL SCI, V23, P268, DOI 10.1016/S0165-6147(02)02016-3; Pfeiffer M, 2001, J BIOL CHEM, V276, P14027, DOI 10.1074/jbc.M006084200; Ramsay D, 2002, BIOCHEM J, V365, P429, DOI 10.1042/BJ20020251; Robbins MJ, 2001, J NEUROSCI, V21, P8043, DOI 10.1523/JNEUROSCI.21-20-08043.2001; Rocheville M, 2000, SCIENCE, V288, P154, DOI 10.1126/science.288.5463.154; Rodriguez-Frade JM, 1999, P NATL ACAD SCI USA, V96, P3628, DOI 10.1073/pnas.96.7.3628; Salim K, 2002, J BIOL CHEM, V277, P15482, DOI 10.1074/jbc.M201539200; Stevens PA, 2001, J BIOL CHEM, V276, P35883, DOI 10.1074/jbc.M103816200; TAKAGISHI T, 1995, AM J PATHOL, V146, P981; Vassilatis DK, 2003, P NATL ACAD SCI USA, V100, P4903, DOI 10.1073/pnas.0230374100; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Yu R, 1999, J BIOL CHEM, V274, P15745, DOI 10.1074/jbc.274.22.15745	58	108	112	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42578	42587		10.1074/jbc.M306165200	http://dx.doi.org/10.1074/jbc.M306165200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12920117	hybrid			2022-12-25	WOS:000185989500123
J	Yamaguchi, J; Gamble, MV; Conlon, D; Liang, JS; Ginsberg, HN				Yamaguchi, J; Gamble, MV; Conlon, D; Liang, JS; Ginsberg, HN			The conversion of apoB100 low density lipoprotein/high density lipoprotein particles to apoB100 very low density lipoproteins in response to oleic acid occurs in the endoplasmic reticulum and not in the Golgi in McA RH7777 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; APOLIPOPROTEIN-B; INTRACELLULAR DEGRADATION; BREFELDIN-A; APO-B; SECRETION; LIVER; APOPROTEIN; B100; TRIACYLGLYCEROL	The site where bulk lipid is added to apoB100 low density lipoproteins (LDL)/high density lipoproteins (HDL) particles to form triglyceride-enriched very low density lipoproteins (VLDL) has not been identified definitively. We employed several strategies to address this question. First, McA RH7777 cells were pulse-labeled for 20 min with [S-35]methionine/cysteine and chased for 1 h (Chase I) to allow study of newly synthesized apoB100 LDL/HDL remaining in the endoplasmic reticulum (ER). After Chase I, cells were incubated for another hour (C2) with/without brefeldin A (BFA) and nocodazole (Noc) (to block ER to Golgi trafficking) and with/without oleic acid (OA). OA treatment alone during C2 increased VLDL secretion. This was prevented by the addition of BFA/Noc in C2. When C2 media were replaced by control media for another 1-h chase (C3), VLDL formed during OA treatment in C2 were secreted into C3 medium. Thus, OA-induced conversion of apoB100 LDL/HDL to VLDL during C2 occurred in the ER. Next, newly synthesized apoB100 lipoproteins were trapped in the Golgi by treatment with Noc and monensin during Chase I (C1), and C2 was carried out in the presence of BFA/Noc with/without OA and without monensin. Under these conditions, OA treatment during C2 did not stimulate VLDL secretion. The same pulse/chase protocols were followed by iodixanol subcellular fractionation, extraction of lipoproteins from ER and Golgi, and sucrose gradient separation of extracted lipoproteins. Cells treated with BFA/Noc and OA in C2 had VLDL in the ER. In the absence of OA, only LDL/HDL were present in the ER. The density of Golgi lipoproteins in these cells was not affected by OA. Similar results were obtained when ER were immuno-isolated with anti-calnexin antibodies. In conclusion, apoB100 bulk lipidation, resulting in conversion of LDL/HDL to VLDL, can occur in the ER, but not in the Golgi, in McA RH7777 cells.	Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA	Columbia University	Ginsberg, HN (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, PH 10-305,630 W 168th St, New York, NY 10032 USA.	hng1@columbia.edu	Adiels, Martin/C-9278-2011	Conlon, Donna/0000-0002-9471-3081	NHLBI NIH HHS [HL 55368] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEXANDER CA, 1976, J CELL BIOL, V69, P241, DOI 10.1083/jcb.69.2.241; Asp L, 2000, J BIOL CHEM, V275, P26285, DOI 10.1074/jbc.M003520200; BAMBERGER MJ, 1990, P NATL ACAD SCI USA, V87, P2390, DOI 10.1073/pnas.87.7.2390; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BOREN J, 1994, J BIOL CHEM, V269, P25879; Cartwright IJ, 2001, J BIOL CHEM, V276, P48048, DOI 10.1074/jbc.M104229200; DIXON JL, 1991, J BIOL CHEM, V266, P5080; Fisher EA, 2002, J BIOL CHEM, V277, P17377, DOI 10.1074/jbc.R100068200; FURUKAWA S, 1992, J BIOL CHEM, V267, P22630; GINSBERG HN, 1995, CURR OPIN LIPIDOL, V6, P275, DOI 10.1097/00041433-199510000-00006; GLAUMANN H, 1975, J CELL BIOL, V64, P356, DOI 10.1083/jcb.64.2.356; Gordon DA, 2000, BBA-MOL CELL BIOL L, V1486, P72, DOI 10.1016/S1388-1981(00)00049-4; HIGGINS JA, 1988, FEBS LETT, V232, P405, DOI 10.1016/0014-5793(88)80780-4; Kulinski A, 2002, J BIOL CHEM, V277, P31516, DOI 10.1074/jbc.M202015200; Liang JS, 1998, J BIOL CHEM, V273, P35216, DOI 10.1074/jbc.273.52.35216; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Mitchell DM, 1998, P NATL ACAD SCI USA, V95, P14733, DOI 10.1073/pnas.95.25.14733; Olofsson SO, 2000, TRENDS CARDIOVAS MED, V10, P338, DOI 10.1016/S1050-1738(01)00071-8; Pan MH, 2002, J BIOL CHEM, V277, P4413, DOI 10.1074/jbc.M107460200; Pariyarath R, 2001, J BIOL CHEM, V276, P541, DOI 10.1074/jbc.M007944200; Raabe M, 1999, J CLIN INVEST, V103, P1287, DOI 10.1172/JCI6576; RUSINOL A, 1993, J BIOL CHEM, V268, P3555; RUSTAEUS S, 1995, J BIOL CHEM, V270, P28879, DOI 10.1074/jbc.270.48.28879; Rustaeus S, 1998, J BIOL CHEM, V273, P5196, DOI 10.1074/jbc.273.9.5196; Rustaeus S, 1999, J NUTR, V129, p463S, DOI 10.1093/jn/129.2.463S; Stillemark P, 2000, J BIOL CHEM, V275, P10506, DOI 10.1074/jbc.275.14.10506; SWIFT LL, 1995, J LIPID RES, V36, P395; Swift LL, 2001, J LIPID RES, V42, P218; Wang YW, 1997, J BIOL CHEM, V272, P12272, DOI 10.1074/jbc.272.19.12272; Wang YW, 1999, J BIOL CHEM, V274, P27793, DOI 10.1074/jbc.274.39.27793; Zhou MY, 1998, J BIOL CHEM, V273, P24649, DOI 10.1074/jbc.273.38.24649	31	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42643	42651		10.1074/jbc.M306920200	http://dx.doi.org/10.1074/jbc.M306920200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12917397	hybrid			2022-12-25	WOS:000185989500130
J	Yokota, S; Yokosawa, N; Kubota, T; Okabayashi, T; Arata, S; Fujii, N				Yokota, S; Yokosawa, N; Kubota, T; Okabayashi, T; Arata, S; Fujii, N			Suppression of thermotolerance in mumps virus-infected cells is caused by lack of HSP27 induction contributed by STAT-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; V-PROTEIN; TRANSCRIPTIONAL ACTIVATION; SIGNALING PATHWAY; ALPHA-INTERFERON; CYTOSOLIC CHAPERONIN; ANTIVIRAL ACTIONS; GAMMA-INTERFERON; RECEPTOR COMPLEX; C-PROTEINS	Viral infection modulates the regulation of apoptosis in host cells. Here, we report a novel mechanism by which human cells infected with mumps virus become susceptible to apoptosis caused by extracellular stresses. Mumps virus stimulates proteasome-dependent degradation of STAT-1 by action of viral accessory protein V, resulting in a severe decrease in STAT-1 protein in infected cells. We exposed mumps virus-infected and uninfected cells to heat and chemical stress. The infected cells failed to acquire resistance to apoptotic stimuli (thermotolerance) after exposure to these mild stresses. The induction of HSP27 by stress exposure was dramatically suppressed in the infected cells, but HSP70 induction was not affected. STAT-1 was required for transcriptional activation of the HSP27 gene, but not for the HSP70 gene, and cDNA transfection of STAT-1 in mumps virus-infected cells restored thermotolerance. Phosphorylated heat shock factor-1 (HSF-1) and STAT-1 phosphorylated on neither tyrosine nor serine residues were co-transported to the nucleus in response to stress. Furthermore, overexpression of unphosphorylatable mutants of STAT-1 also restored thermotolerance in mumps virus-infected cells. These lines of evidence indicate that the induction of HSP27 by stress requires STAT-1 in addition to the activated HSF-1. Furthermore, STAT-1 required for the induction of HSP27 worked independent to its phosphorylation. Thus, HSP27-dependent thermotolerance is suppressed by mumps virus infection through the destruction of STAT-1. The lack of thermotolerance should allow the infected cells to be eliminated by apoptosis and might be a host defense against viral infection.	Sapporo Med Univ, Sch Med, Dept Microbiol, Chuo Ku, Sapporo, Hokkaido 0608556, Japan; Showa Univ, Ctr Biotechnol, Tokyo 1428555, Japan	Sapporo Medical University; Showa University	Fujii, N (corresponding author), Sapporo Med Univ, Sch Med, Dept Microbiol, Chuo Ku, Sapporo, Hokkaido 0608556, Japan.		Yokota, Shin-ichi/K-8139-2019	Yokota, Shin-ichi/0000-0002-0831-3429				Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; Alcami A, 2000, IMMUNOL TODAY, V21, P447, DOI 10.1016/S0167-5699(00)01699-6; Barber GN, 2001, CELL DEATH DIFFER, V8, P113, DOI 10.1038/sj.cdd.4400823; Battle T. E., 2002, Current Molecular Medicine (Hilversum), V2, P381, DOI 10.2174/1566524023362456; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Creagh EM, 2000, LEUKEMIA, V14, P1161, DOI 10.1038/sj.leu.2401841; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Didcock L, 1999, J VIROL, V73, P9928, DOI 10.1128/JVI.73.12.9928-9933.1999; FUJII N, 1988, J GEN VIROL, V69, P2085, DOI 10.1099/0022-1317-69-8-2085; FUJII N, 1990, J GEN VIROL, V71, P3071, DOI 10.1099/0022-1317-71-12-3071; Fujii N, 1994, Prog Mol Subcell Biol, V14, P150; Fujimoto I, 2000, J VIROL, V74, P3399, DOI 10.1128/JVI.74.7.3399-3403.2000; GAESTEL M, 1993, GENE, V128, P279, DOI 10.1016/0378-1119(93)90575-N; Gao J, 2001, J VIROL, V75, P1124, DOI 10.1128/JVI.75.3.1124-1131.2001; Garcin D, 1999, J VIROL, V73, P6559, DOI 10.1128/JVI.73.8.6559-6565.1999; GERNER EW, 1975, NATURE, V256, P500, DOI 10.1038/256500a0; Goh KC, 1999, EMBO J, V18, P5601, DOI 10.1093/emboj/18.20.5601; Goodbourn S, 2000, J GEN VIROL, V81, P2341, DOI 10.1099/0022-1317-81-10-2341; Gotoh B, 2002, REV MED VIROL, V12, P337, DOI 10.1002/rmv.357; Gotoh B, 2001, MICROBIOL IMMUNOL, V45, P787, DOI 10.1111/j.1348-0421.2001.tb01315.x; Hariya Y, 1999, J INTERF CYTOK RES, V19, P479, DOI 10.1089/107999099313929; Hariya Y, 2000, MICROBIOL IMMUNOL, V44, P537, DOI 10.1111/j.1348-0421.2000.tb02531.x; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HENLE KJ, 1978, CANCER RES, V38, P1843; HICKEY E, 1986, NUCLEIC ACIDS RES, V14, P4127, DOI 10.1093/nar/14.10.4127; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; Jaattela M, 1999, ANN MED, V31, P261, DOI 10.3109/07853899908995889; Kato A, 2001, J VIROL, V75, P3802, DOI 10.1128/JVI.75.8.3802-3810.2001; Komatsu T, 2000, J VIROL, V74, P2477, DOI 10.1128/JVI.74.5.2477-2480.2000; Kovarik P, 1999, P NATL ACAD SCI USA, V96, P13956, DOI 10.1073/pnas.96.24.13956; Kubota T, 2002, J VIROL, V76, P12676, DOI 10.1128/JVI.76.24.12676-12682.2002; Kubota T, 2001, BIOCHEM BIOPH RES CO, V283, P255, DOI 10.1006/bbrc.2001.4764; LANDRY J, 1982, CANCER RES, V42, P2457; Latchman David S, 2002, Prog Mol Subcell Biol, V28, P253; LI GC, 1991, P NATL ACAD SCI USA, V88, P1681, DOI 10.1073/pnas.88.5.1681; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; McMillan DR, 1998, J BIOL CHEM, V273, P7523, DOI 10.1074/jbc.273.13.7523; MORIMOTO RI, 1993, SCIENCE, V259, P1409, DOI 10.1126/science.8451637; Mowen KA, 2001, CELL, V104, P731, DOI 10.1016/S0092-8674(02)08085-6; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; Nishio M, 2001, J VIROL, V75, P9165, DOI 10.1128/JVI.75.19.9165-9176.2001; Parisien JP, 2001, VIROLOGY, V283, P230, DOI 10.1006/viro.2001.0856; Samali A, 1998, CELL STRESS CHAPERON, V3, P228, DOI 10.1054/csac.1998.0129; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; SEN GC, 1993, ADV VIRUS RES, V42, P57, DOI 10.1016/S0065-3527(08)60083-4; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Stephanou A, 1998, BIOCHEM J, V330, P189, DOI 10.1042/bj3300189; Stephanou A, 1999, J BIOL CHEM, V274, P1723, DOI 10.1074/jbc.274.3.1723; Stephanou A, 1999, HANDB EXP PHARM, V136, P153; SUBJECK JR, 1982, BRIT J RADIOL, V55, P579, DOI 10.1259/0007-1285-55-656-579; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Xanthoudakis S, 2000, NAT CELL BIOL, V2, pE163, DOI 10.1038/35023643; Yokosawa N, 2002, J VIROL, V76, P12683, DOI 10.1128/JVI.76.24.12683-12690.2002; Yokosawa N, 1998, ARCH VIROL, V143, P1985, DOI 10.1007/s007050050434; Yokota S, 2000, EUR J BIOCHEM, V267, P1658, DOI 10.1046/j.1432-1327.2000.01157.x; Yokota S, 2003, VIROLOGY, V306, P135, DOI 10.1016/S0042-6822(02)00026-0; Yokota S, 2001, VIROLOGY, V286, P119, DOI 10.1006/viro.2001.0941; Yokota S, 1999, J BIOL CHEM, V274, P37070, DOI 10.1074/jbc.274.52.37070; Yonekura N, 2003, CELL DEATH DIFFER, V10, P313, DOI 10.1038/sj.cdd.4401169; Yonekura Noriyuki, 2000, Tumor Research, V35, P25	60	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41654	41660		10.1074/jbc.M305701200	http://dx.doi.org/10.1074/jbc.M305701200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12917439	hybrid			2022-12-25	WOS:000185989500014
J	Pawar, A; Botolin, D; Mangelsdorf, DJ; Jump, DB				Pawar, A; Botolin, D; Mangelsdorf, DJ; Jump, DB			The role of liver X receptor-alpha in the fatty acid regulation of hepatic gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN-1C; S14 GENE; CHOLESTEROL 7-ALPHA-HYDROXYLASE; TRANSCRIPTION FACTOR; NUCLEAR RECEPTORS; RESPONSE ELEMENT; PPAR-ALPHA; RAT-LIVER; SUPPRESSION; METABOLISM	Liver X receptors (LXR) alpha and beta play an important role in regulating the expression of genes involved in hepatic bile and fatty acid synthesis, glucose metabolism, as well as sterol efflux. Studies with human embryonic kidney 293 cells indicate that unsaturated fatty acids interfere with oxysterols binding to LXR and antagonize oxysterol-induced LXRalpha activity. In this report, we evaluated the effects of unsaturated fatty acids on LXR-regulated hepatic gene expression. The LXR agonist, T1317, induced mRNAs encoding sterol regulatory element-binding protein 1c (SREBP-1c) and two SREBP-1c-regulated lipogenic genes, e. g. fatty-acid synthase and the S14 protein in primary hepatocytes. Treatment of hepatocytes with eicosapentaenoic acid (20:5n-3) suppressed these mRNAs in the absence and presence of T1317. The cis-regulatory elements targeted by T1317 were not required for fatty-acid suppression of FAS or S14 promoter activity. In contrast to SREBP-1-regulated lipogenic genes, 20: 5n-3 had no effect on the T1317 induction of ABCG5 or ABCG8 in the rat hepatoma cell line, FTO-2B. These two genes require LXR but not SREBP-1c for their expression. Feeding rats a diet supplemented with fish oil suppressed hepatic SREBP-1c-regulated genes and induced PPARalpha-regulated genes but had no effect on the LXR-regulated transcripts, CYP7A1, ABCG5, or ABCG8. Transfection studies, using either full-length hLXRalpha or a chimera containing only the LXRalpha ligand binding domain, indicate that a wide array of unsaturated fatty acids had little effect on LXRalpha activity in primary hepatocytes or FTO-2B. These studies suggest that LXRalpha is not a target for unsaturated fatty acid regulation in primary rat hepatocytes or in liver. Thus, oxysterol/LXR-mediated regulation of transcripts involved in bile acid synthesis or sterol efflux appear insensitive to dietary unsaturated fatty acids. The unsaturated fatty acid suppression of SREBP-1 and its targeted lipogenic genes is independent of LXRalpha.	Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA; Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA; Michigan State Univ, Dept Mol Biol, E Lansing, MI 48824 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA	Michigan State University; Michigan State University; Michigan State University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Jump, DB (corresponding author), Michigan State Univ, Dept Physiol, 3165 Biomed & Phys Sci Bldg, E Lansing, MI 48824 USA.		Pawar, Anjali/AAT-8945-2020	Pawar, Anjali/0000-0002-2133-8663; Mangelsdorf, David/0000-0002-4355-0796	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043220] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43220, R01 DK043220] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Azzout-Marniche D, 2000, BIOCHEM J, V350, P389, DOI 10.1042/0264-6021:3500389; Botolin D, 2003, J BIOL CHEM, V278, P6959, DOI 10.1074/jbc.M212846200; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Chan DC, 2002, EUR J CLIN INVEST, V32, P429, DOI 10.1046/j.1365-2362.2002.01001.x; Cheema SK, 1997, J LIPID RES, V38, P315; Cheema SK, 1999, J NUTR, V129, P1718, DOI 10.1093/jn/129.9.1718; Cheema SK, 2000, J BIOL CHEM, V275, P12530, DOI 10.1074/jbc.275.17.12530; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; Hannah VC, 2001, J BIOL CHEM, V276, P4365, DOI 10.1074/jbc.M007273200; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; JELINEK DF, 1990, J BIOL CHEM, V265, P8190; Joseph SB, 2002, J BIOL CHEM, V277, P11019, DOI 10.1074/jbc.M111041200; JUMP DB, 1993, P NATL ACAD SCI USA, V90, P8454, DOI 10.1073/pnas.90.18.8454; Jump DB, 1997, J BIOL CHEM, V272, P27778, DOI 10.1074/jbc.272.44.27778; Jump DB, 2002, CURR OPIN LIPIDOL, V13, P155, DOI 10.1097/00041433-200204000-00007; Jump DB, 2001, J BIOL CHEM, V276, P34419, DOI 10.1074/jbc.M105471200; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Kim JH, 2001, J BIOL CHEM, V276, P24667, DOI 10.1074/jbc.M010793200; Koo SH, 2000, J BIOL CHEM, V275, P5200, DOI 10.1074/jbc.275.7.5200; Koo SH, 2001, J BIOL CHEM, V276, P9437, DOI 10.1074/jbc.M010029200; Laffitte BA, 2003, P NATL ACAD SCI USA, V100, P5419, DOI 10.1073/pnas.0830671100; Laffitte BA, 2003, MOL CELL BIOL, V23, P2182, DOI 10.1128/MCB.23.6.2182-2191.2003; Lewin TM, 2001, ARCH BIOCHEM BIOPHYS, V396, P119, DOI 10.1006/abbi.2001.2604; Liang GS, 2002, J BIOL CHEM, V277, P9520, DOI 10.1074/jbc.M111421200; Lu TT, 2001, J BIOL CHEM, V276, P37735, DOI 10.1074/jbc.R100035200; Mater MK, 1999, J BIOL CHEM, V274, P32725, DOI 10.1074/jbc.274.46.32725; Mater MK, 1999, J LIPID RES, V40, P1045; Nordoy A, 2001, NUTR METAB CARDIOVAS, V11, P7; Ou JF, 2001, P NATL ACAD SCI USA, V98, P6027, DOI 10.1073/pnas.111138698; Pan DA, 2000, J LIPID RES, V41, P742; Pawar A, 2003, J BIOL CHEM, V278, P35931, DOI 10.1074/jbc.M306238200; Pawar A, 2002, J BIOL CHEM, V277, P39243, DOI 10.1074/jbc.M206170200; Ren B, 1997, J BIOL CHEM, V272, P26827, DOI 10.1074/jbc.272.43.26827; Repa JJ, 2002, J BIOL CHEM, V277, P18793, DOI 10.1074/jbc.M109927200; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; SHIH HM, 1992, J BIOL CHEM, V267, P13222; Tobin KAR, 2002, J BIOL CHEM, V277, P10691, DOI 10.1074/jbc.M109771200; Wang XJ, 2002, J BIOL CHEM, V277, P15697, DOI 10.1074/jbc.M112068200; Worgall TS, 2002, J BIOL CHEM, V277, P3878, DOI 10.1074/jbc.M102393200; Xu J, 1999, J BIOL CHEM, V274, P23577, DOI 10.1074/jbc.274.33.23577; Xu J, 2001, J BIOL CHEM, V276, P9800, DOI 10.1074/jbc.M008973200; Yahagi N, 1999, J BIOL CHEM, V274, P35840, DOI 10.1074/jbc.274.50.35840; Yoshikawa T, 2002, J BIOL CHEM, V277, P1705, DOI 10.1074/jbc.M105711200; Zhang Y, 2001, J BIOL CHEM, V276, P43018, DOI 10.1074/jbc.M107823200; Zvibel I, 1998, DIFFERENTIATION, V63, P215, DOI 10.1111/j.1432-0436.1998.00215.x	45	120	124	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40736	40743		10.1074/jbc.M307973200	http://dx.doi.org/10.1074/jbc.M307973200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12917410	hybrid			2022-12-25	WOS:000185847200040
J	Phillips, RM; Six, DA; Dennis, EA; Ghosh, P				Phillips, RM; Six, DA; Dennis, EA; Ghosh, P			In vivo phospholipase activity of the Pseudomonas aeruginosa cytotoxin ExoU and protection of mammalian cells with phospholipase A(2) inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; EXOENZYME-S; CYSTIC-FIBROSIS; ARACHIDONIC-ACID; EPITHELIAL-CELLS; SECRETION; PNEUMONIA; MACROPHAGES; EXPRESSION; CLONING	A number of clinical isolates of Pseudomonas aeruginosa are cytotoxic to mammalian cells due to the action of the 74-kDa protein ExoU, which is secreted into host cells by the type III secretion system and whose function is unknown. Here we report that the swift and profound cytotoxicity induced by purified ExoU or by an ExoU-expressing strain of P. aeruginosa is blocked by various inhibitors of cytosolic (cPLA(2)) and Ca2+-independent (iPLA(2)) phospholipase A(2) enzymes. In contrast, no cytoprotection is offered by inhibitors of secreted phospholipase A(2) enzymes or by a number of inhibitors of signal transduction pathways. This suggests that phospholipase A(2) inhibitors may represent a novel mode of treatment for acute P. aeruginosa infections. We find that 300 - 600 molecules of ExoU/cell are required to achieve half-maximal cell killing and that ExoU localizes to the host cell plasma membrane in punctate fashion. We also show that ExoU interacts in vitro with an inhibitor of cPLA(2) and iPLA(2) enzymes and contains a putative serine-aspartate catalytic dyad homologous to those found in cPLA(2) and iPLA(2) enzymes. Mutation of either the serine or the aspartate renders ExoU non-cytotoxic. Although no phospholipase or esterase activity is detected in vitro, significant phospholipase activity is detected in vivo, suggesting that ExoU requires one or more host cell factors for activation as a membrane-lytic and cytotoxic phospholipase.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Ghosh, P (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, Mail Code 0314,9500 Gilman Dr, La Jolla, CA 92093 USA.		Dennis, Edward A./M-5554-2019; Six, David A/D-6523-2011	Dennis, Edward A./0000-0003-3738-3140; Six, David A/0000-0002-9013-1711; DuBois, Rebecca/0000-0003-4185-5673	NCI NIH HHS [T32 CA09523] Funding Source: Medline; NIDDK NIH HHS [DK07202] Funding Source: Medline; NIGMS NIH HHS [GM20501, GM64611] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009523] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007202] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064611] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Afessa B, 2000, CHEST, V117, P1017, DOI 10.1378/chest.117.4.1017; Allewelt M, 2000, INFECT IMMUN, V68, P3998, DOI 10.1128/IAI.68.7.3998-4004.2000; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Balsinde J, 1996, EUR J BIOCHEM, V235, P480, DOI 10.1111/j.1432-1033.1996.00480.x; Balsinde J, 1999, ANNU REV PHARMACOL, V39, P175, DOI 10.1146/annurev.pharmtox.39.1.175; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; Brennan AL, 2002, CURR OPIN INFECT DIS, V15, P175, DOI 10.1097/00001432-200204000-00013; CLARKE MSF, 1992, J CELL SCI, V102, P533; CondeFrieboes K, 1996, J AM CHEM SOC, V118, P5519, DOI 10.1021/ja953553w; Dessen A, 1999, CELL, V97, P349, DOI 10.1016/S0092-8674(00)80744-8; Evans DJ, 1998, INFECT IMMUN, V66, P1453, DOI 10.1128/IAI.66.4.1453-1459.1998; Feltman H, 2001, MICROBIOL-SGM, V147, P2659, DOI 10.1099/00221287-147-10-2659; Finck-Barbancon V, 1998, J BACTERIOL, V180, P6224; Finck-Barbancon V, 2001, J BACTERIOL, V183, P4330, DOI 10.1128/JB.183.14.4330-4344.2001; FinckBarbancon V, 1997, MOL MICROBIOL, V25, P547, DOI 10.1046/j.1365-2958.1997.4891851.x; Frank DW, 1997, MOL MICROBIOL, V26, P621, DOI 10.1046/j.1365-2958.1997.6251991.x; FU H, 1993, P NATL ACAD SCI USA, V90, P2320, DOI 10.1073/pnas.90.6.2320; Garrity-Ryan L, 2000, INFECT IMMUN, V68, P7100, DOI 10.1128/IAI.68.12.7100-7113.2000; Geiser TK, 2001, CELL MICROBIOL, V3, P223, DOI 10.1046/j.1462-5822.2001.00107.x; Girod A, 2002, J GEN VIROL, V83, P973, DOI 10.1099/0022-1317-83-5-973; Goehring UM, 1999, J BIOL CHEM, V274, P36369, DOI 10.1074/jbc.274.51.36369; Hauser AR, 1999, INFECT IMMUN, V67, P5530, DOI 10.1128/IAI.67.10.5530-5537.1999; Hauser AR, 1998, MOL MICROBIOL, V27, P807, DOI 10.1046/j.1365-2958.1998.00727.x; Hauser AR, 2002, CRIT CARE MED, V30, P521, DOI 10.1097/00003246-200203000-00005; Hirschberg HJHB, 2001, EUR J BIOCHEM, V268, P5037, DOI 10.1046/j.0014-2956.2001.02411.x; Kazmierczak BI, 2002, INFECT IMMUN, V70, P2198, DOI 10.1128/IAI.70.4.2198-2205.2002; Knight DA, 1997, INFECT IMMUN, V65, P3304, DOI 10.1128/IAI.65.8.3304-3309.1997; Kokotos G, 2002, J MED CHEM, V45, P2891, DOI 10.1021/jm025538p; Krall R, 2000, INFECT IMMUN, V68, P6066, DOI 10.1128/IAI.68.10.6066-6068.2000; Kurahashi K, 1999, J CLIN INVEST, V104, P743, DOI 10.1172/JCI7124; Leidich SD, 1998, J BIOL CHEM, V273, P26078, DOI 10.1074/jbc.273.40.26078; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; Lyczak JB, 2000, MICROBES INFECT, V2, P1051, DOI 10.1016/S1286-4579(00)01259-4; Lyczak JB, 2002, CLIN MICROBIOL REV, V15, P194, DOI 10.1128/CMR.15.2.194-222.2002; Moss J, 2001, INFECT IMMUN, V69, P1185, DOI 10.1128/IAI.69.2.1185-1188.2001; OJCIUS DM, 1995, INFECT IMMUN, V63, P3069, DOI 10.1128/IAI.63.8.3069-3072.1995; Ono T, 2002, BIOCHEM J, V363, P727, DOI 10.1042/0264-6021:3630727; Pickard RT, 1996, J BIOL CHEM, V271, P19225, DOI 10.1074/jbc.271.32.19225; Pickard RT, 1999, J BIOL CHEM, V274, P8823, DOI 10.1074/jbc.274.13.8823; Roy-Burman A, 2001, J INFECT DIS, V183, P1767, DOI 10.1086/320737; Sawa T, 1999, NAT MED, V5, P392, DOI 10.1038/7391; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; Tevzadze GG, 2000, CHROMOSOMA, V109, P72, DOI 10.1007/s004120050414; van Tienhoven M, 2002, J BIOL CHEM, V277, P20942, DOI 10.1074/jbc.M200330200; WANG LX, 1992, J BIOL CHEM, V267, P18983; Yahr TL, 1998, P NATL ACAD SCI USA, V95, P13899, DOI 10.1073/pnas.95.23.13899; Yang HC, 1999, ANAL BIOCHEM, V269, P278, DOI 10.1006/abio.1999.4053; Zadori Z, 2001, DEV CELL, V1, P291, DOI 10.1016/S1534-5807(01)00031-4	49	135	139	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41326	41332		10.1074/jbc.M302472200	http://dx.doi.org/10.1074/jbc.M302472200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12915403	hybrid, Green Published			2022-12-25	WOS:000185847200112
J	Sokolowski, F; Modler, AJ; Masuch, R; Zirwer, D; Baier, M; Lutsch, G; Moss, DA; Gast, K; Naumann, D				Sokolowski, F; Modler, AJ; Masuch, R; Zirwer, D; Baier, M; Lutsch, G; Moss, DA; Gast, K; Naumann, D			Formation of critical oligomers is a key event during conformational transition of recombinant Syrian hamster prion protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFRARED-SPECTROSCOPY; SECONDARY STRUCTURE; ALZHEIMERS-DISEASE; BETA-SHEETS; SCRAPIE; CONVERSION; AGGREGATION; MECHANISM; RIBONUCLEASE-T1; DIFFERENTIATION	We have investigated the conformational transition and aggregation process of recombinant Syrian hamster prion protein (SHaPrP(90-232)) by Fourier transform infrared spectroscopy, circular dichroism spectroscopy, light scattering, and electron microscopy under equilibrium and kinetic conditions. SHaPrP(90-232) showed an infrared absorbance spectrum typical of proteins with a predominant alpha-helical structure both at pH 7.0 and at pH 4.2 in the absence of guanidine hydrochloride. At pH 4.2 and destabilizing conditions (0.3 - 2 M guanidine hydrochloride), the secondary structure of SHaPrP(90-232) was transformed to a strongly hydrogen- bonded, most probably intermolecularly arranged antiparallel beta-sheet structure as indicated by dominant amide I band components at 1620 and 1691 cm(-1). Kinetic analysis of the transition process showed that the decrease in alpha-helical structures and the increase in beta-sheet structures occurred concomitantly according to a bimolecular reaction. However, the concentration dependence of the corresponding rate constant pointed to an apparent third order reaction. No beta-sheet structure was formed within the dead time ( 190 ms) of the infrared experiments. Light scattering measurements revealed that the structural transition of SHaPrP(90-232) was accompanied by formation of oligomers, whose size was linearly dependent on protein concentration. Extrapolation to zero protein concentration yielded octamers as the smallest oligomers, which are considered as "critical oligomers." The small oligomers showed spherical and annular shapes in electron micrographs. Critical oligomers seem to play a key role during the transition and aggregation process of SHaPrP(90-232). A new model for the structural transition and aggregation process of the prion protein is described.	Robert Koch Inst, D-13353 Berlin, Germany; Free Univ Berlin, Fachbereich Biol, D-14195 Berlin, Germany; Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; Humboldt Univ, Inst Biol, D-10115 Berlin, Germany; Forschungszentrum Karlsruhe, D-76344 Eggenstein Leopoldshafen, Germany	Robert Koch Institute; Free University of Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Humboldt University of Berlin; Helmholtz Association; Karlsruhe Institute of Technology	Sokolowski, F (corresponding author), Robert Koch Inst, Nordufer 20, D-13353 Berlin, Germany.							Alvarez-Martinez MT, 2003, BBA-PROTEINS PROTEOM, V1645, P228, DOI 10.1016/S1570-9639(02)00536-8; Barth A, 2002, Q REV BIOPHYS, V35, P369, DOI 10.1017/S0033583502003815; Barth A, 2000, PROG BIOPHYS MOL BIO, V74, P141, DOI 10.1016/S0079-6107(00)00021-3; Baskakov IV, 2002, J BIOL CHEM, V277, P21140, DOI 10.1074/jbc.M111402200; Baskakov IV, 2000, BIOCHEMISTRY-US, V39, P2792, DOI 10.1021/bi9923353; Baskakov IV, 2001, J BIOL CHEM, V276, P19687, DOI 10.1074/jbc.C100180200; Callahan NA, 2001, J BIOL CHEM, V276, P28022, DOI 10.1074/jbc.M103629200; Caughey B, 1998, J BIOL CHEM, V273, P32230, DOI 10.1074/jbc.273.48.32230; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; Chiesa R, 2001, NEUROBIOL DIS, V8, P743, DOI 10.1006/nbdi.2001.0433; Chitnumsub P, 1999, BIOORGAN MED CHEM, V7, P39, DOI 10.1016/S0968-0896(98)00222-3; FABIAN H, 2002, HDB VIBRATIONAL SPEC, V5, P3399; Gast K, 1997, EUR BIOPHYS J BIOPHY, V25, P211, DOI 10.1007/s002490050033; Glockshuber R, 2001, ADV PROTEIN CHEM, V57, P83; HENRY ER, 1992, METHOD ENZYMOL, V210, P129; Hornemann S, 1997, FEBS LETT, V413, P277, DOI 10.1016/S0014-5793(97)00921-6; Hornemann S, 1998, P NATL ACAD SCI USA, V95, P6010, DOI 10.1073/pnas.95.11.6010; Jackson GS, 1999, BBA-PROTEIN STRUCT M, V1431, P1, DOI 10.1016/S0167-4838(99)00038-2; JACKSON M, 1995, CRIT REV BIOCHEM MOL, V30, P95, DOI 10.3109/10409239509085140; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; KOPPEL DE, 1972, J CHEM PHYS, V57, P4814, DOI 10.1063/1.1678153; KRIMM S, 1986, ADV PROTEIN CHEM, V38, P181, DOI 10.1016/S0065-3233(08)60528-8; Kubelka J, 2001, J AM CHEM SOC, V123, P12048, DOI 10.1021/ja0116627; Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a; Lu BY, 2002, BIOCHEM J, V364, P81, DOI 10.1042/bj3640081; Ma JY, 2002, SCIENCE, V298, P1781, DOI 10.1126/science.1073725; MASUCH R, 2003, IN PRESS APPL SPECTR, V57; MAUSER H, 1974, FORMALE KINETIK; Mehlhorn I, 1996, BIOCHEMISTRY-US, V35, P5528, DOI 10.1021/bi952965e; Modler AJ, 2003, J MOL BIOL, V325, P135, DOI 10.1016/S0022-2836(02)01175-0; Morillas M, 2001, BIOCHEMISTRY-US, V40, P6982, DOI 10.1021/bi010232q; Moritz R, 2002, BIOPOLYMERS, V67, P145, DOI 10.1002/bip.10083; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P229, DOI 10.1016/0010-4655(82)90174-6; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Reinstadler D, 1999, PROTEINS, V34, P303, DOI 10.1002/(SICI)1097-0134(19990215)34:3<303::AID-PROT4>3.0.CO;2-H; Sanghera N, 2002, J MOL BIOL, V315, P1241, DOI 10.1006/jmbi.2001.5322; SAVITZKY A, 1964, ANAL CHEM, V36, P1627, DOI 10.1021/ac60214a047; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Serio TR, 2000, SCIENCE, V289, P1317, DOI 10.1126/science.289.5483.1317; Swietnicki W, 2000, BIOCHEMISTRY-US, V39, P424, DOI 10.1021/bi991967m; Swietnicki W, 1997, J BIOL CHEM, V272, P27517, DOI 10.1074/jbc.272.44.27517; Vanik DL, 2002, J BIOL CHEM, V277, P49065, DOI 10.1074/jbc.M207511200; Volles MJ, 2002, BIOCHEMISTRY-US, V41, P4595, DOI 10.1021/bi0121353; Wille H, 2002, P NATL ACAD SCI USA, V99, P3563, DOI 10.1073/pnas.052703499; Wisniewski T, 1998, AMYLOID, V5, P212; Wuthrich K, 2001, ADV PROTEIN CHEM, V57, P55; Xiong LW, 2001, J NEUROCHEM, V79, P669, DOI 10.1046/j.1471-4159.2001.00606.x; Yamada N, 1998, J AM CHEM SOC, V120, P12192, DOI 10.1021/ja981363q; Zahn R, 2000, P NATL ACAD SCI USA, V97, P145, DOI 10.1073/pnas.97.1.145; Zahn R, 1997, FEBS LETT, V417, P400, DOI 10.1016/S0014-5793(97)01330-6; Zhang H, 1997, BIOCHEMISTRY-US, V36, P3543, DOI 10.1021/bi961965r	55	119	121	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40481	40492		10.1074/jbc.M304391200	http://dx.doi.org/10.1074/jbc.M304391200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12917432	hybrid			2022-12-25	WOS:000185847200009
J	Grassme, H; Cremesti, A; Kolesnick, R; Gulbins, E				Grassme, H; Cremesti, A; Kolesnick, R; Gulbins, E			Ceramide-mediated clustering is required for CD95-DISC formation	ONCOGENE			English	Article						receptor aggregation; ceramide; acid sphingomyelinase; CD95; apoptosis	FAS-INDUCED APOPTOSIS; RICH MEMBRANE RAFTS; ACID SPHINGOMYELINASE; T-LYMPHOCYTES; CELL-DEATH; SIGNALING PATHWAY; CD95; ACTIVATION; RECEPTOR; FADD	Early events required for induction of apoptosis by CD95 are preassociation of CD95, the formation of the death-inducing signaling complex (DISC) and clustering of CD95 in distinct membrane domains. Here, we identify the molecular ordering of these events and show that the acid sphingomyelinase (ASM) functions upstream of the DISC to mediate CD95 clustering in ceramide-enriched membrane platforms, an event that is required for DISC formation. Experiments in ASM-deficient cells revealed that CD95 ligation, in the absence of ceramide generation, triggers <1% of full caspase 8 activation at the receptor. This event, however, is both necessary and sufficient to trigger translocation of ASM onto the outer leaflet of the plasma membrane, ASM activation and ceramide release, but insufficient for apoptosis induction. Ceramide-mediated CD95 clustering then amplifies the primary CD95 signaling and drives the second step of CD95 signaling, that is, formation of the DISC yielding 100% caspase activity and apoptosis. These studies suggest that the most parsimonious interpretation of the molecular ordering of the earliest events in CD95 signaling, at least in some cells, is: CD95 ligation&RARR;1% of maximum caspase 8 activation&RARR;ASM translocation&RARR;ceramide generation&RARR;CD95 clustering&RARR;DISC formation&RARR;100% of maximum caspase 8 activation&RARR;apoptosis.	Univ Duisburg Essen, Dept Mol Biol, D-45122 Essen, Germany; Mem Sloan Kettering Canc Ctr, Lab Signal Transduct, New York, NY 10021 USA	University of Duisburg Essen; Memorial Sloan Kettering Cancer Center	Gulbins, E (corresponding author), Univ Duisburg Essen, Dept Mol Biol, Hufelandstr 55, D-45122 Essen, Germany.		Gulbins, Erich/L-6989-2014	Gulbins, Erich/0000-0002-3117-1342	NCI NIH HHS [CA 21765, CA 85704] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085704, P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Algeciras-Schimnich A, 2002, MOL CELL BIOL, V22, P207, DOI 10.1128/MCB.22.1.207-220.2002; Altman A, 1994, Semin Immunol, V6, P9, DOI 10.1006/smim.1994.1003; Belka C, 2003, ONCOGENE, V22, P176, DOI 10.1038/sj.onc.1206103; Birbes H, 2001, FASEB J, V15, P2669, DOI 10.1096/fj.01-0539com; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Brenner B, 1998, CELL DEATH DIFFER, V5, P29, DOI 10.1038/sj.cdd.4400307; Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Cremesti A, 2001, J BIOL CHEM, V276, P23954, DOI 10.1074/jbc.M101866200; Desbarats J, 1999, P NATL ACAD SCI USA, V96, P8104, DOI 10.1073/pnas.96.14.8104; FANZO JC, 2003, UNPUB MCB; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Grassme H, 2003, NAT MED, V9, P322, DOI 10.1038/nm823; Grassme H, 1997, CELL, V91, P605, DOI 10.1016/S0092-8674(00)80448-1; Grassme H, 2002, J IMMUNOL, V168, P298, DOI 10.4049/jimmunol.168.1.298; Grassme H, 2001, BIOCHEM BIOPH RES CO, V284, P1016, DOI 10.1006/bbrc.2001.5045; Grassme H, 2001, J BIOL CHEM, V276, P20589, DOI 10.1074/jbc.M101207200; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Grullich C, 2000, J BIOL CHEM, V275, P8650, DOI 10.1074/jbc.275.12.8650; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; Gulbins E, 1996, J BIOL CHEM, V271, P26389, DOI 10.1074/jbc.271.42.26389; HIRSCHBERG K, 1993, BIOCHEM J, V290, P751, DOI 10.1042/bj2900751; Hueber AO, 2002, EMBO REP, V3, P190, DOI 10.1093/embo-reports/kvf022; ITOH N, 1993, J BIOL CHEM, V268, P10932; Kirschnek S, 2000, J BIOL CHEM, V275, P27316; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Paris F, 2001, J BIOL CHEM, V276, P8297, DOI 10.1074/jbc.M008732200; Parlato S, 2000, EMBO J, V19, P5123, DOI 10.1093/emboj/19.19.5123; Peter ME, 1998, CURR OPIN IMMUNOL, V10, P545, DOI 10.1016/S0952-7915(98)80222-7; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Rudner J, 2001, J CELL SCI, V114, P4161; Sakata K, 1998, EUR J IMMUNOL, V28, P2648, DOI 10.1002/(SICI)1521-4141(199809)28:09<2648::AID-IMMU2648>3.0.CO;2-M; SAMELSON LE, 1986, NATURE, V324, P674, DOI 10.1038/324674a0; Sawada M, 2002, EXP CELL RES, V273, P157, DOI 10.1006/excr.2001.5437; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; Schwandner R, 1998, J BIOL CHEM, V273, P5916, DOI 10.1074/jbc.273.10.5916; SHIMENO H, 1995, BIOL PHARM BULL, V18, P1335; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Smith KGC, 1996, EMBO J, V15, P5167, DOI 10.1002/j.1460-2075.1996.tb00901.x; Villunger A, 2000, J IMMUNOL, V165, P1337, DOI 10.4049/jimmunol.165.3.1337; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; Wiegmann K, 1999, J BIOL CHEM, V274, P5267, DOI 10.1074/jbc.274.9.5267	45	217	225	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 21	2003	22	35					5457	5470		10.1038/sj.onc.1206540	http://dx.doi.org/10.1038/sj.onc.1206540			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JC	12934106				2022-12-25	WOS:000184735000011
J	Sanchez-Carbayo, M; Schwarz, K; Charytonowicz, E; Cordon-Cardo, C; Mundel, P				Sanchez-Carbayo, M; Schwarz, K; Charytonowicz, E; Cordon-Cardo, C; Mundel, P			Tumor suppressor role for myopodin in bladder cancer: loss of nuclear expression of myopodin is cell-cycle dependent and predicts clinical outcome	ONCOGENE			English	Article						bladder cancer; tissue microarrays; myopodin; cell-cycle	GENETIC ALTERATIONS; PARTIAL ALLELOTYPE; PROTEIN; ACTIN; P53; SYNAPTOPODIN; CARCINOMA; PATHWAY; ZYXIN	Myopodin is a dual compartment protein that displays actin-bundling activity and redistributes between the nucleus and the cytoplasm in a differentiation-dependent and stress-induced fashion. We evaluated myopodin expression in initiation and progression of bladder cancer. Normal urothelium expresses myopodin in the cytoplasm and nuclei. Invasive bladder tumors showed decreased nuclear myopodin expression as compared to superficial lesions. This loss of nuclear myopodin expression was significantly associated with histopathological stage, tumor grade and overall patient survival in bladder tumors contained in tissue microarrays. We identified a differential nuclear expression for myopodin among bladder cancer cell lines during cell-cycle. Myopodin was present in the nucleus during G1/S in cells derived from superficial and low-grade lesions but not in those derived from invasive tumors. Loss of nuclear myopodin expression could classify bladder tumors and bladder cancer cell lines based on their histopathology. Most importantly, patients with preserved nuclear myopodin expression showed a longer survival. Nuclear myopodin expression in the context of cell-cycle progression may prove useful for staging bladder tumors and suggest a tumor suppressor role of myopodin in bladder cancer.	Mem Sloan Kettering Canc Ctr, Div Mol Pathol, New York, NY 10021 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA	Memorial Sloan Kettering Cancer Center; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Sanchez-Carbayo, M (corresponding author), Mem Sloan Kettering Canc Ctr, Div Mol Pathol, 1270 York Ave, New York, NY 10021 USA.		Schwarz, Karin/AAO-2819-2020	Schwarz, Karin/0000-0002-7328-1427				*AM JOINT COMM CAN, 1988, MAN STAG CANC, P194; American Cancer Society, 2000, CANC FACTS FIG; CordonCardo C, 1997, CANCER RES, V57, P1217; CRAWFORD AW, 1992, J CELL BIOL, V116, P1381, DOI 10.1083/jcb.116.6.1381; DALBAGNI G, 1993, LANCET, V342, P469, DOI 10.1016/0140-6736(93)91595-D; Dawson-Saunders B., 1994, BASIC CLIN BIOSTATIS; El-Rifai W, 2000, AM J PATHOL, V156, P871, DOI 10.1016/S0002-9440(10)64956-5; Giroldi LA, 1999, INT J CANCER, V82, P70, DOI 10.1002/(SICI)1097-0215(19990702)82:1<70::AID-IJC13>3.0.CO;2-#; Hoos A, 2001, AM J PATHOL, V158, P1245, DOI 10.1016/S0002-9440(10)64075-8; Koo SH, 1999, CANCER GENET CYTOGEN, V110, P87, DOI 10.1016/S0165-4608(98)00193-9; Lin F, 2001, AM J PATHOL, V159, P1603, DOI 10.1016/S0002-9440(10)63006-4; Lu ML, 2002, CLIN CANCER RES, V8, P171; Markl IDC, 1998, CANCER RES, V58, P5348; McShane LM, 2000, CLIN CANCER RES, V6, P1854; Mostofi FK, 1973, HISTOLOGICAL TYPING; Mundel P, 1997, J CELL BIOL, V139, P193, DOI 10.1083/jcb.139.1.193; Nix DA, 1997, J CELL BIOL, V138, P1139, DOI 10.1083/jcb.138.5.1139; Popov Z, 2000, BRIT J CANCER, V83, P209; REUTER VE, 1989, DIAGNOSTIC SURG PATH, P1355; REZNIKOFF CA, 1994, GENE DEV, V8, P2227, DOI 10.1101/gad.8.18.2227; ROSIN MP, 1995, CANCER RES, V55, P5213; SAHLAS DJ, 1993, J CELL SCI, V105, P347; Shaw ME, 1999, INT J CANCER, V80, P656, DOI 10.1002/(SICI)1097-0215(19990301)80:5&lt;656::AID-IJC4&gt;3.0.CO;2-A; Simon R, 2000, INT J ONCOL, V17, P1025; Simon R, 1998, J PATHOL, V185, P345; WANG Y, 2000, BIOCHIM BIOPHYS ACTA, V1538, P260; Weins A, 2001, J CELL BIOL, V155, P393, DOI 10.1083/jcb.200012039	27	42	44	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 14	2003	22	34					5298	5305		10.1038/sj.onc.1206616	http://dx.doi.org/10.1038/sj.onc.1206616			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JB	12917631				2022-12-25	WOS:000184734900009
J	Moccia, F; Lim, D; Nusco, GA; Ercolano, E; Santella, L				Moccia, F; Lim, D; Nusco, GA; Ercolano, E; Santella, L			NAADP activates a Ca2+ current that is dependent on F-actin cytoskeleton	FASEB JOURNAL			English	Article						Ca2+ imaging; electrophysiology; nicotinic acid adenine dinucleotide phosphate	ADENINE-DINUCLEOTIDE PHOSPHATE; CYCLIC ADP-RIBOSE; PANCREATIC BETA-CELLS; INOSITOL TRISPHOSPHATE; STARFISH OOCYTES; INTRACELLULAR CA2+; ASCIDIAN OOCYTES; CALCIUM-RELEASE; FERTILIZATION; CHANNELS	Nicotinic acid adenine dinucleotide phosphate (NAADP) is involved in the Ca2+ response observed at fertilization in several species, including starfish. In this study, we have employed Ca2+ imaging and the single-electrode voltage-clamp technique to investigate whether the NAADP-mediated Ca2+ entry discovered in our laboratory in starfish oocytes was underlain by a membrane current and whether the response to NAADP required an intact cytoskeleton. Uncaging of preinjected NAADP evoked a cortical Ca2+ flash that was followed by the spreading of the wave to the remainder of the cell. No Ca2+ increase was detected in Ca2+-free sea water. Under voltage-clamp conditions, the photoliberation of NAADP activated an inward rectifying membrane current, which reversed at potentials more positive than + 50 mV and was abolished by removal of Ca2+ but not of Na+. The current was affected by preincubation with verapamil, SK& F 96356, and thapsigargin but not by preinjection of heparin, 8-NH2- cyclic ADP-ribose, or both antagonists. The membrane current and the Ca2+ wave were inhibited by latrunculin-A and jasplakinolide, which depolymerize and stabilize actin cytoskeleton, respectively. These data offer the first demonstration that NAADP initiates a Ca2+ sweep by activating a Ca2+-permeable membrane current that requires an intact F-actin cytoskeleton as other Ca2+-permeable currents, such as I-CRAC and I-ARC.	Staz Zool Anton Dohrn, Cell Biol Lab, I-80121 Naples, Italy	Stazione Zoologica Anton Dohrn di Napoli	Santella, L (corresponding author), Staz Zool Anton Dohrn, Cell Biol Lab, Villa Comunale, I-80121 Naples, Italy.	santella@szn.it	Santella, Luigia/AAM-3524-2020; Moccia, Francesco/AAX-6447-2020; Lim, Dmitry/H-9101-2012	Santella, Luigia/0000-0001-7159-0499; Moccia, Francesco/0000-0003-0010-0098; 				Albrieux M, 1998, J BIOL CHEM, V273, P14566, DOI 10.1074/jbc.273.23.14566; Bak J, 2002, BIOCHEM BIOPH RES CO, V295, P806, DOI 10.1016/S0006-291X(02)00761-1; Bak J, 2001, CURR BIOL, V11, P987, DOI 10.1016/S0960-9822(01)00269-X; Baumann O, 2001, NEUROSCI LETT, V306, P181, DOI 10.1016/S0304-3940(01)01900-0; Berg I, 2000, J CELL BIOL, V150, P581, DOI 10.1083/jcb.150.3.581; Berridge G, 2002, J BIOL CHEM, V277, P43717, DOI 10.1074/jbc.M203224200; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Billington RA, 2002, J PHYSIOL-LONDON, V544, P107, DOI 10.1113/jphysiol.2002.030098; Bozem M, 2000, CELL CALCIUM, V28, P73, DOI 10.1054/ceca.2000.0133; Brailoiu E, 2001, MOL PHARMACOL, V60, P718; Cancela JM, 1999, NATURE, V398, P74, DOI 10.1038/18032; Cancela JM, 2000, EMBO J, V19, P2549, DOI 10.1093/emboj/19.11.2549; Carafoli E, 2001, CRIT REV BIOCHEM MOL, V36, P107, DOI 10.1080/20014091074183; Carlier MF, 1997, J MOL BIOL, V269, P459, DOI 10.1006/jmbi.1997.1062; Churchill GC, 2003, CURR BIOL, V13, P125, DOI 10.1016/S0960-9822(03)00002-2; Churchill GC, 2001, EMBO J, V20, P2666, DOI 10.1093/emboj/20.11.2666; Churchill GC, 2002, CELL, V111, P703, DOI 10.1016/S0092-8674(02)01082-6; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Genazzani AA, 1997, BRIT J PHARMACOL, V121, P1489, DOI 10.1038/sj.bjp.0701295; Gerasimenko J, 2003, BIOCHEM SOC T, V31, P76, DOI 10.1042/bst0310076; Glogauer M, 1997, J CELL SCI, V110, P11; Hille B., 1992, IONIC CHANNELS EXCIT; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; Inoue I, 2002, J PHYSIOL-LONDON, V541, P769, DOI 10.1113/jphysiol.2002.019638; JOHNSON BD, 1993, NEURON, V10, P797, DOI 10.1016/0896-6273(93)90196-X; Johnson JD, 2002, P NATL ACAD SCI USA, V99, P14566, DOI 10.1073/pnas.222099799; Lader AS, 1999, AM J PHYSIOL-CELL PH, V277, pC1277, DOI 10.1152/ajpcell.1999.277.6.C1277; LANSMAN JB, 1983, J PHYSIOL-LONDON, V345, P353, DOI 10.1113/jphysiol.1983.sp014982; LEE HC, 1995, J BIOL CHEM, V270, P2152, DOI 10.1074/jbc.270.5.2152; Lee HC, 2000, J CELL SCI, V113, P4413; Lim D, 2002, FASEB J, V16, P1050, DOI 10.1096/fj.02-0021com; Lim D, 2001, FASEB J, V15, P2257, DOI 10.1096/fj.01-0157com; Mignen O, 2003, J BIOL CHEM, V278, P10174, DOI 10.1074/jbc.M212536200; Mignen O, 2000, J BIOL CHEM, V275, P9114, DOI 10.1074/jbc.275.13.9114; Mitchell KJ, 2003, J BIOL CHEM, V278, P11057, DOI 10.1074/jbc.M210257200; MIYAZAKI S, 1979, DEV BIOL, V70, P327, DOI 10.1016/0012-1606(79)90031-9; MIYAZAKI SI, 1975, J PHYSIOL-LONDON, V246, P55, DOI 10.1113/jphysiol.1975.sp010880; MOCCIA F, 2003, IN PRESS PFLUGERS AR; Nusco GA, 2002, BIOCHEM BIOPH RES CO, V290, P1015, DOI 10.1006/bbrc.2001.6286; Patel S, 2003, BIOESSAYS, V25, P430, DOI 10.1002/bies.10276; Ribeiro CMP, 1997, J BIOL CHEM, V272, P26555, DOI 10.1074/jbc.272.42.26555; Rosado JA, 2000, TRENDS CARDIOVAS MED, V10, P327, DOI 10.1016/S1050-1738(01)00073-1; Rueckschloss U, 2001, J PHYSIOL-LONDON, V537, P363, DOI 10.1111/j.1469-7793.2001.00363.x; Sabala P, 2002, BIOCHEM BIOPH RES CO, V296, P484, DOI 10.1016/S0006-291X(02)00893-8; Santella L, 2000, J BIOL CHEM, V275, P8301, DOI 10.1074/jbc.275.12.8301; Vazquez G, 2002, EMBO J, V21, P4531, DOI 10.1093/emboj/cdf467; Wang YJ, 2002, BIOCHEM J, V363, P117, DOI 10.1042/0264-6021:3630117; Wilding M, 1998, AM J PHYSIOL-CELL PH, V275, pC1277, DOI 10.1152/ajpcell.1998.275.5.C1277	48	58	61	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1907	+		10.1096/fj.03-0178fje	http://dx.doi.org/10.1096/fj.03-0178fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12923070				2022-12-25	WOS:000185345100004
J	Sturniolo, MT; Dashti, SR; Deucher, A; Rorke, EA; Broome, AM; Chandraratna, RAS; Keepers, T; Eckert, RL				Sturniolo, MT; Dashti, SR; Deucher, A; Rorke, EA; Broome, AM; Chandraratna, RAS; Keepers, T; Eckert, RL			A novel tumor suppressor protein promotes keratinocyte terminal differentiation via activation of type I transglutaminase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN EPIDERMAL-KERATINOCYTES; RADIATION-INDUCED APOPTOSIS; CROSS-LINKING; BIOLOGICAL-ACTIVITY; CORNIFIED ENVELOPE; DOWN-REGULATION; CELL-DEATH; GENE; IDENTIFICATION; INVOLUCRIN	Tazarotene-induced protein 3 (TIG3) is a recently discovered regulatory protein that is expressed in the suprabasal epidermis. In the present study, we show that TIG3 regulates keratinocyte viability and proliferation. TIG3-dependent reduction in keratinocyte viability is accompanied by a substantial increase in the number of sub-G(1) cells, nuclear shrinkage, and increased formation of cornified envelope-like structures. TIG3 localizes to the membrane fraction, and TIG3- dependent differentiation is associated with increased type I transglutaminase activity. Microscopic localization and isopeptide cross-linking studies suggest that TIG3 and type I transglutaminase co-localize in membranes. Markers of apoptosis, including caspases and poly( ADP-ribose) polymerase, are not activated by TIG3, and caspase inhibitors do not stop the TIG3- dependent reduction in cell viability. Truncation of the carboxyl-terminal membrane-anchoring domain results in a complete loss of TIG3 activity. The morphology of the TIG3- positive cells and the effects on cornified envelope formation suggest that TIG3 is an activator of terminal keratinocyte differentiation. Our studies suggest that TIG3 facilitates the terminal stages in keratinocyte differentiation via activation of type I transglutaminase.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Dermatol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Reprod Biol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Oncol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Environm Hlth Sci, Cleveland, OH 44106 USA; Allergan Pharmaceut Inc, Dept Chem, Irvine, CA 92713 USA; Allergan Pharmaceut Inc, Dept Biol, Irvine, CA 92713 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; AbbVie; Allergan; AbbVie; Allergan	Eckert, RL (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Rm E532,2109 Adelbert Rd, Cleveland, OH 44106 USA.	rle2@po.cwru.edu		Broome, Ann-Marie/0000-0002-2384-5212; Dashti, Shervin/0000-0002-1552-9738	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041456, R55AR041456] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007250] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR41456] Funding Source: Medline; NIGMS NIH HHS [T32GM07250] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akiyama H, 1999, J BIOL CHEM, V274, P32192, DOI 10.1074/jbc.274.45.32192; Assefa Z, 2000, J BIOL CHEM, V275, P21416, DOI 10.1074/jbc.M002634200; Autuori F, 1998, Adv Biochem Eng Biotechnol, V62, P129, DOI 10.1007/BFb0102308; BENINATI S, 1995, BIOCHEM J, V305, P725, DOI 10.1042/bj3050725; Bouchard WJ, 2003, EXP HEMATOL, V31, P446, DOI 10.1016/S0301-472X(03)00083-3; Denning MF, 1998, J BIOL CHEM, V273, P29995, DOI 10.1074/jbc.273.45.29995; Deucher A, 2000, INT J ONCOL, V17, P1195; DiSepio D, 1998, P NATL ACAD SCI USA, V95, P14811, DOI 10.1073/pnas.95.25.14811; Duvic M, 2000, CLIN CANCER RES, V6, P3249; Eckert RL, 1997, PHYSIOL REV, V77, P397, DOI 10.1152/physrev.1997.77.2.397; Eckhart L, 2000, BIOCHEM BIOPH RES CO, V277, P655, DOI 10.1006/bbrc.2000.3698; Fesus L, 1996, EXPERIENTIA, V52, P942, DOI 10.1007/BF01920102; Gandarillas A, 2000, EXP GERONTOL, V35, P53, DOI 10.1016/S0531-5565(99)00088-1; Gentile V, 1998, ARCH BIOCHEM BIOPHYS, V352, P314, DOI 10.1006/abbi.1998.0592; GOLDSMITH LA, 1983, J INVEST DERMATOL, V80, pS39, DOI 10.1111/1523-1747.ep12537077; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HAJNAL A, 1994, ONCOGENE, V9, P479; Huang SL, 2000, MOL CELL ENDOCRINOL, V159, P15, DOI 10.1016/S0303-7207(99)00207-5; Husmann K, 1998, ONCOGENE, V17, P1305, DOI 10.1038/sj.onc.1202060; KIM IG, 1994, J INVEST DERMATOL, V103, P137, DOI 10.1111/1523-1747.ep12392470; LaCelle PT, 1998, SKIN PHARMACOL APPL, V11, P214, DOI 10.1159/000029830; Lippens S, 2000, CELL DEATH DIFFER, V7, P1218, DOI 10.1038/sj.cdd.4400785; Nicoletti VG, 2003, NEUROCHEM RES, V28, P187, DOI 10.1023/A:1022316914492; Oliverio S, 1999, J BIOL CHEM, V274, P34123, DOI 10.1074/jbc.274.48.34123; PHILLIPS MA, 1993, BIOCHEMISTRY-US, V32, P11057, DOI 10.1021/bi00092a015; Piacentini M, 2002, J NEUROCHEM, V81, P1061; Rice R H, 1988, Adv Exp Med Biol, V231, P51; RICE RH, 1977, CELL, V11, P417, DOI 10.1016/0092-8674(77)90059-9; Robinson NA, 1998, J BIOL CHEM, V273, P2721, DOI 10.1074/jbc.273.5.2721; Robinson NA, 1996, J INVEST DERMATOL, V107, P101, DOI 10.1111/1523-1747.ep12298323; Robinson NA, 1997, J BIOL CHEM, V272, P12035, DOI 10.1074/jbc.272.18.12035; RORKE EA, 1995, EXP CELL RES, V216, P65, DOI 10.1006/excr.1995.1008; Sers C, 1997, J CELL BIOL, V136, P935, DOI 10.1083/jcb.136.4.935; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Shimizu H, 1999, J INVEST DERMATOL, V112, P769, DOI 10.1046/j.1523-1747.1999.00582.x; Sitailo LA, 2002, J BIOL CHEM, V277, P19346, DOI 10.1074/jbc.M200401200; Steinert P M, 1995, Cell Death Differ, V2, P33; Steinert PM, 1996, J BIOL CHEM, V271, P26242, DOI 10.1074/jbc.271.42.26242; Takahashi H, 1999, EXP CELL RES, V249, P291, DOI 10.1006/excr.1999.4476; Teraki Y, 1999, EUR J DERMATOL, V9, P413; Tucholski J, 2002, J NEUROCHEM, V81, P780, DOI 10.1046/j.1471-4159.2002.00859.x; YUSPA SH, 1982, J BIOL CHEM, V257, P9906	42	59	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48066	48073		10.1074/jbc.M307215200	http://dx.doi.org/10.1074/jbc.M307215200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12928434	hybrid			2022-12-25	WOS:000186731400086
J	Basbous, J; Arpin, C; Gaudray, G; Piechaczyk, M; Devaux, C; Mesnard, JM				Basbous, J; Arpin, C; Gaudray, G; Piechaczyk, M; Devaux, C; Mesnard, JM			The HBZ factor of human T-cell leukemia virus type I dimerizes with transcription factors JunB and c-Jun and modulates their transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN-CONTAINING PROTEIN; DNA-BINDING; TAX PROTEIN; PROMOTER TRANSACTIVATION; ACTIVATES TRANSCRIPTION; CONSTITUTIVE EXPRESSION; FOS-JUN; K-BZIP; GENE; AP-1	The human T-cell leukemia virus type I (HTLV-I)-encoded Tax protein activates transcription from the viral promoter via association with the cellular basic leucine zipper factor cAMP-response element-binding protein-2. Tax is also able to induce cellular transformation of T lymphocytes probably by modulating transcriptional activity of cellular factors, including nuclear factor-kappaB, E2F, activator protein-1 (AP-1), and p53. Recently, we characterized in HTLV-I-infected cells the presence of a novel viral protein, HBZ, encoded by the complementary strand of the HTLV-I RNA genome (Gaudray, G., Gachon, F., Basbous, J., Biard-Piechaczyk, M., Devaux, C., and Mesnard, J.-M. (2002) J. Virol. 76, 12813-12822). HBZ is a nuclear basic leucine zipper protein that downregulates Tax-dependent viral transcription by inhibiting the binding of cAMP-response element-binding protein-2 to the HTLV-I promoter. In searching for other cellular targets of HBZ, we identified two members of the Jun family, JunB and c-Jun. Co-immunoprecipitation and cellular colocalization confirmed that HBZ interacts in vivo with JunB and c-Jun. When transiently introduced into CEM cells with a reporter gene containing the AP-1 site from the collagenase promoter, HBZ suppressed transactivation by c-Jun. On the other hand, the combination of HBZ with Jun-B had higher transcriptional activity than JunB alone. Consistent with the structure of its basic domain, we demonstrate that HBZ decreases the DNA-binding activity of c-Jun and JunB. Last, we show that c-Jun is no longer capable of activating the basal expression of the HTLV-I promoter in the presence of HBZ in vivo. Our results support the hypothesis that HBZ could be a negative modulator of the Tax effect by controlling Tax expression at the transcriptional level and by attenuating activation of AP-1 by Tax.	Univ Montpellier I, CNRS, Lab Infect Retrovirales & Signalisat Cellulaire, Inst Biol,UMR 5121,Inst Federat Rech 122, F-34960 Montpellier 2, France; Inst Genet Mol, UMR 5535, F-34293 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB)	Mesnard, JM (corresponding author), Univ Montpellier I, CNRS, Lab Infect Retrovirales & Signalisat Cellulaire, Inst Biol,UMR 5121,Inst Federat Rech 122, 4 Blvd Henri 4,CS 89508, F-34960 Montpellier 2, France.	jean-michel.mesnard@univ-montp1.fr	Basbous, Jihane/AAQ-2040-2021; PIECHACZYK, Marc/E-7896-2013	Basbous, Jihane/0000-0002-3943-627X; PIECHACZYK, Marc/0000-0003-1367-2597; Mesnard, Jean-Michel/0000-0003-3344-5367				ALEXANDRE C, 1991, ONCOGENE, V6, P543; BASBOUS J, 2002, RECENT RES DEV MOL C, V3, P155; Chen BPC, 1996, MOL CELL BIOL, V16, P1157, DOI 10.1128/mcb.16.3.1157; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; COHEN DR, 1990, ONCOGENE, V5, P929; Curtiss VE, 1996, MOL CELL BIOL, V16, P3567; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1991, ONCOGENE, V6, P1023; Gachon F, 2002, VIROLOGY, V299, P271, DOI 10.1006/viro.2002.1501; Gachon F, 2001, FEBS LETT, V502, P57, DOI 10.1016/S0014-5793(01)02646-1; Gachon F, 1998, J VIROL, V72, P8332, DOI 10.1128/JVI.72.10.8332-8337.1998; Gachon F, 2000, MOL CELL BIOL, V20, P3470, DOI 10.1128/MCB.20.10.3470-3481.2000; Gaudray G, 2002, J VIROL, V76, P12813, DOI 10.1128/JVI.76.24.12813-12822.2002; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; Georges SA, 2002, MOL CELL BIOL, V22, P127, DOI 10.1128/MCB.22.1.127-137.2002; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HOOPER WC, 1991, BIOCHEM BIOPH RES CO, V181, P976, DOI 10.1016/0006-291X(91)92032-F; Iwai K, 2001, VIROLOGY, V279, P38, DOI 10.1006/viro.2000.0669; Izumiya Y, 2003, J VIROL, V77, P1441, DOI 10.1128/JVI.77.2.1441-1451.2003; JEANG KT, 1991, VIROLOGY, V181, P218, DOI 10.1016/0042-6822(91)90487-V; KERPPOLA TK, 1994, ONCOGENE, V9, P675; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LAROCCA D, 1989, BIOCHEM BIOPH RES CO, V163, P1006, DOI 10.1016/0006-291X(89)92322-X; Lemasson I, 1998, J BIOL CHEM, V273, P23598, DOI 10.1074/jbc.273.36.23598; Lemasson I, 2002, J BIOL CHEM, V277, P49459, DOI 10.1074/jbc.M209566200; Liao W, 2003, J VIROL, V77, P3809, DOI 10.1128/JVI.77.6.3809-3815.2003; Liu XD, 1999, J GEN VIROL, V80, P3073, DOI 10.1099/0022-1317-80-12-3073; MACGREGOR PF, 1990, ONCOGENE, V5, P451; Mechta-Grigoriou F, 2001, ONCOGENE, V20, P2378, DOI 10.1038/sj.onc.1204381; Mesnard JM, 1999, VIROLOGY, V257, P277, DOI 10.1006/viro.1999.9685; Mori N, 1998, CANCER RES, V58, P3993; Mori N, 2000, BLOOD, V95, P3915; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NAKABEPPU Y, 1989, EMBO J, V8, P3833, DOI 10.1002/j.1460-2075.1989.tb08561.x; RANSONE LJ, 1990, MOL CELL BIOL, V10, P4565, DOI 10.1128/MCB.10.9.4565; RANSONE LJ, 1989, GENE DEV, V3, P770, DOI 10.1101/gad.3.6.770; Reddy TR, 1997, ONCOGENE, V14, P2785, DOI 10.1038/sj.onc.1201119; Renard P, 2001, Nucleic Acids Res, V29, pE21, DOI 10.1093/nar/29.4.e21; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; RYSECK RP, 1991, ONCOGENE, V6, P533; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Sok J, 1999, MOL CELL BIOL, V19, P495; Suzuki T, 1999, ONCOGENE, V18, P4137, DOI 10.1038/sj.onc.1202766; Thebault S, 2000, EUR J CELL BIOL, V79, P834, DOI 10.1078/0171-9335-00111; Thebault S, 2000, J BIOL CHEM, V275, P4848, DOI 10.1074/jbc.275.7.4848; THEBAULT S, 2001, RRD VIROLOGY I, V3, P151; TSUCHIYA H, 1993, J VIROL, V67, P7001, DOI 10.1128/JVI.67.12.7001-7007.1993; Ubeda M, 1996, MOL CELL BIOL, V16, P1479; UCHIJIMA M, 1994, J BIOL CHEM, V269, P14946; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; Wells SI, 2000, EMBO J, V19, P5762, DOI 10.1093/emboj/19.21.5762; Xiao GT, 2001, EMBO J, V20, P6805, DOI 10.1093/emboj/20.23.6805; Yamagata T, 1997, MOL CELL BIOL, V17, P4272, DOI 10.1128/MCB.17.8.4272	61	149	158	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43620	43627		10.1074/jbc.M307275200	http://dx.doi.org/10.1074/jbc.M307275200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12937177	Green Published, hybrid			2022-12-25	WOS:000186157000110
J	Ohashi, K; Osuga, J; Tozawa, R; Kitamine, T; Yagyu, H; Sekiya, M; Tomita, S; Okazaki, H; Tamura, Y; Yahagi, N; Iizuka, Y; Harada, K; Gotoda, T; Shimano, H; Yamada, N; Ishibashi, S				Ohashi, K; Osuga, J; Tozawa, R; Kitamine, T; Yagyu, H; Sekiya, M; Tomita, S; Okazaki, H; Tamura, Y; Yahagi, N; Iizuka, Y; Harada, K; Gotoda, T; Shimano, H; Yamada, N; Ishibashi, S			Early embryonic lethality caused by targeted disruption of the 3-hydroxy-3-methylglutaryl-CoA reductase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A-REDUCTASE; HMG-COA REDUCTASE; IMPLANTATION MOUSE EMBRYOS; RECEPTOR KNOCKOUT MICE; 3-HYDROXY-3-METHYGLUTARYL COENZYME; CHOLESTEROL-BIOSYNTHESIS; ENDOPLASMIC-RETICULUM; FEEDBACK-REGULATION; LIPID-METABOLISM; PREGNANT RATS	The endoplasmic reticulum (ER) enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, which converts HMG-CoA to mevalonate, catalyzes the rate-limiting step in cholesterol biosynthesis. Because this mevalonate pathway also produces several non-sterol isoprenoid compounds, the level of HMG-CoA reductase activity may coordinate many cellular processes and functions. We used gene targeting to knock out the mouse HMG-CoA reductase gene. The heterozygous mutant mice (Hmgcr +/-) appeared normal in their development and gross anatomy and were fertile. Although HMG-CoA reductase activities were reduced in Hmgcr +/- embryonic fibroblasts, the enzyme activities and cholesterol biosynthesis remained unaffected in the liver from Hmgcr +/ - mice, suggesting that the haploid amount of Hmgcr gene is not rate-limiting in the hepatic cholesterol homeostasis. Consistently, plasma lipoprotein profiles were similar between Hmgcr +/- and Hmgcr +/+ mice. In contrast, the embryos homozygous for the Hmgcr mutant allele were recovered at the blastocyst stage, but not at E8.5, indicating that HMG-CoA reductase is crucial for early development of the mouse embryos. The lethal phenotype was not completely rescued by supplementing the dams with mevalonate. Although it has been postulated that a second, peroxisome-specific HMG-CoA reductase could substitute for the ER reductase in vitro, we speculate that the putative peroxisomal reductase gene, if existed, does not fully compensate for the lack of the ER enzyme at least in embryogenesis.	Jichi Med Sch, Dept Internal Med, Div Endocrinol & Metab, Minami Kawachi, Tochigi 3290498, Japan; Univ Tokyo, Fac Med, Dept Metab Dis, Tokyo 1138655, Japan; Tokyo Womens Med Univ Sch Med, Ctr Diabet, Tokyo 1620054, Japan; Univ Tsukuba, Inst Clin Med, Tsukuba, Ibaraki 3058575, Japan	Jichi Medical University; University of Tokyo; Tokyo Women's Medical University; University of Tsukuba	Ishibashi, S (corresponding author), Jichi Med Sch, Dept Internal Med, Div Endocrinol & Metab, 3311-1 Yakushiji, Minami Kawachi, Tochigi 3290498, Japan.		Shimano, Hitoshi/V-1761-2019; Yahagi, Naoya/D-2360-2014; Shimano, Hitoshi/AAI-5648-2020	Shimano, Hitoshi/0000-0002-5562-5572; Yahagi, Naoya/0000-0002-1823-1865; 				Aboushadi N, 2000, BIOCHEMISTRY-US, V39, P237, DOI 10.1021/bi9916325; BASSON ME, 1986, P NATL ACAD SCI USA, V83, P5563, DOI 10.1073/pnas.83.15.5563; Breitling R, 2002, J LIPID RES, V43, P2031, DOI 10.1194/jlr.R200010-JLR200; BREWER LM, 1993, TERATOLOGY, V47, P137, DOI 10.1002/tera.1420470206; BROWN MS, 1980, J LIPID RES, V21, P505; CARR BR, 1985, J CLIN INVEST, V76, P1946, DOI 10.1172/JCI112192; Chan KA, 2000, LANCET, V355, P2185, DOI 10.1016/S0140-6736(00)02400-4; Crouse JR, 1998, ATHEROSCLEROSIS, V138, P11, DOI 10.1016/S0021-9150(98)00014-8; DOSTAL LA, 1994, TERATOLOGY, V50, P387, DOI 10.1002/tera.1420500604; Eisele B, 1997, J LIPID RES, V38, P564; Engfelt WH, 1998, J LIPID RES, V39, P2182; Engfelt WH, 1997, J BIOL CHEM, V272, P24579, DOI 10.1074/jbc.272.39.24579; ENGSTROM W, 1987, ANTICANCER RES, V7, P337; Feingold K R, 1980, Metabolism, V29, P285; FELDMAN B, 1995, SCIENCE, V267, P246, DOI 10.1126/science.7809630; GERTLER FB, 1988, MOL CELL BIOL, V8, P2713, DOI 10.1128/MCB.8.7.2713; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Hoffmann GF, 1997, PEDIATR RES, V41, P541, DOI 10.1203/00006450-199704000-00014; HOFFMANN GF, 1993, PEDIATRICS, V91, P915; HRAB RV, 1994, TERATOLOGY, V50, P19, DOI 10.1002/tera.1420500104; HWA JJ, 1992, J LIPID RES, V33, P711; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; Istvan ES, 2000, BBA-MOL CELL BIOL L, V1529, P9, DOI 10.1016/S1388-1981(00)00134-7; Jick H, 2000, LANCET, V356, P1627, DOI 10.1016/S0140-6736(00)03155-X; KANEKO I, 1978, EUR J BIOCHEM, V87, P313; KITA T, 1980, J CLIN INVEST, V66, P1094, DOI 10.1172/JCI109938; LEONARD S, 1988, BIOCHIM BIOPHYS ACTA, V947, P101, DOI 10.1016/0304-4157(88)90021-4; LISCUM L, 1985, J BIOL CHEM, V260, P522; Marek KW, 1999, GLYCOBIOLOGY, V9, P1263; MINSKER DH, 1983, TERATOLOGY, V28, P449, DOI 10.1002/tera.1420280316; MOSLEY ST, 1983, J BIOL CHEM, V258, P3875; Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; Nwokoro NA, 2001, MOL GENET METAB, V74, P105, DOI 10.1006/mgme.2001.3226; Osuga J, 1998, J CLIN INVEST, V102, P386, DOI 10.1172/JCI1124; Porter FD, 2002, J CLIN INVEST, V110, P715, DOI 10.1172/JCI200216386; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; PRATT HPM, 1982, DEV BIOL, V89, P101, DOI 10.1016/0012-1606(82)90298-6; Rao S, 1999, P NATL ACAD SCI USA, V96, P7797, DOI 10.1073/pnas.96.14.7797; REYNOLDS GA, 1984, CELL, V38, P275, DOI 10.1016/0092-8674(84)90549-X; SHAPIRO DJ, 1969, BIOCHEM BIOPH RES CO, V37, P867, DOI 10.1016/0006-291X(69)90972-3; SURANI MAH, 1983, J EMBRYOL EXP MORPH, V75, P205; Takemoto M, 2001, ARTERIOSCL THROM VAS, V21, P1712, DOI 10.1161/hq1101.098486; Tozawa R, 1999, J BIOL CHEM, V274, P30843, DOI 10.1074/jbc.274.43.30843; VAN AL, 1997, GENE DEV, V11, P2295; Van Doren M, 1998, NATURE, V396, P466, DOI 10.1038/24871; von Keutz E, 1998, AM J CARDIOL, V82, p11J, DOI 10.1016/S0002-9149(98)00424-X; Wagner AH, 2002, ARTERIOSCL THROM VAS, V22, P1784, DOI 10.1161/01.ATV.0000037098.20829.31; Weitz-Schmidt G, 2001, NAT MED, V7, P687, DOI 10.1038/89058; WISE L D, 1990, Oyo Yakuri, V39, P143; Wolozin B, 2000, ARCH NEUROL-CHICAGO, V57, P1439, DOI 10.1001/archneur.57.10.1439; WOODWARD HD, 1988, J BIOL CHEM, V263, P2513; YOKODE M, 1990, SCIENCE, V250, P1273, DOI 10.1126/science.2244210	53	81	82	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42936	42941		10.1074/jbc.M307228200	http://dx.doi.org/10.1074/jbc.M307228200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12920113	hybrid			2022-12-25	WOS:000186157000027
J	Rafiee, P; Shi, Y; Pritchard, KA; Ogawa, H; Eis, ALW; Komorowski, RA; Fitzpatrick, CM; Tweddell, JS; Litwin, SB; Mussatto, K; Jaquiss, RD; Baker, JE				Rafiee, P; Shi, Y; Pritchard, KA; Ogawa, H; Eis, ALW; Komorowski, RA; Fitzpatrick, CM; Tweddell, JS; Litwin, SB; Mussatto, K; Jaquiss, RD; Baker, JE			Cellular redistribution of inducible hsp70 protein in the human and rabbit heart in response to the stress of chronic hypoxia - Role of protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOCK TRANSCRIPTION FACTOR-1; NITRIC-OXIDE SYNTHASE; SIZE IN-VIVO; GENE-EXPRESSION; HEME OXYGENASE-1; ISCHEMIC-INJURY; MESSENGER-RNAS; CELLS; PROTECTION; HEAT-SHOCK-PROTEIN-70	Many infants who undergo cardiac surgery have a congenital cyanotic defect where the heart is chronically perfused with hypoxemic blood. Infant hearts adapt to chronic hypoxemia by activation of intracellular protein kinase signal transduction pathways. However, the involvement of heat shock protein 70 in adaptation to chronic hypoxemia and its role in protein kinase signaling pathways is unknown. We determined expression of message and subcellular protein distribution for inducible (Hsp70i) and constitutive heat shock protein 70 (Hsc70) in chronically hypoxic and normoxic infant human and rabbit hearts and their relationship to protein kinases. In chronically hypoxic human and rabbit hearts message levels for Hsp70i were elevated 4- to 5-fold compared with normoxic hearts, Hsp70i protein was redistributed from the particulate to the cytosolic fraction. In normoxic infants Hsp70i protein was distributed almost equally between the cytosolic and particulate fractions. Hsc70 message and subcellular distribution of Hsc70 protein were unaffected by chronic hypoxia. We then determined if protein kinases influence Hsp70i protein subcellular distribution. In rabbit hearts SB203580 and chelerythrine reduced Hsp70i message levels, whereas SB203580, chelerythrine, and curcumin reversed the subcellular redistribution of Hsp70i protein caused by chronic hypoxia, with no effect in normoxic hearts, indicating regulation of Hsp70i message and subcellular distribution of Hsp70i protein in chronically hypoxic rabbit hearts is influenced by protein kinase C and mitogen-activated protein kinases, specifically p38 MAPK and JNK. We conclude the Hsp70 signal transduction pathway plays an important role in adaptation of infant human and rabbit hearts to chronic hypoxemia.	Med Coll Wisconsin, Div Pediat Surg, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Div Gastroenterol, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Pediat, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Pathol, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Div Cardiothorac Surg, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Childrens Hosp Wisconsin, Sect Cardiothorac Surg, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; Children's Hospital of Wisconsin; Medical College of Wisconsin	Baker, JE (corresponding author), Med Coll Wisconsin, Div Pediat Surg, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.		Baker, John/V-8897-2019	Baker, John/0000-0001-7899-3266	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054075, P50HL065203] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL65203, HL61414, HL54075] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMRANI M, 1994, ANN THORAC SURG, V57, P157, DOI 10.1016/0003-4975(94)90385-9; ANG D, 1991, J BIOL CHEM, V266, P24233; Baker JE, 1999, CIRCULATION, V99, P1249, DOI 10.1161/01.CIR.99.9.1249; Bellmann K, 2000, J BIOL CHEM, V275, P18172, DOI 10.1074/jbc.M000340200; Benjamin IJ, 1998, CIRC RES, V83, P117, DOI 10.1161/01.RES.83.2.117; Das DK, 1998, ANN NY ACAD SCI, V851, P129, DOI 10.1111/j.1749-6632.1998.tb08986.x; Di YP, 1997, J CELL PHYSIOL, V172, P44, DOI 10.1002/(SICI)1097-4652(199707)172:1<44::AID-JCP5>3.0.CO;2-D; ERDOS G, 1994, BIOCHEM BIOPH RES CO, V202, P476, DOI 10.1006/bbrc.1994.1953; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Grabellus F, 2002, J PATHOL, V197, P230, DOI 10.1002/path.1106; Hung JJ, 1998, J BIOL CHEM, V273, P31924, DOI 10.1074/jbc.273.48.31924; Hutter JJ, 1996, CIRCULATION, V94, P1408, DOI 10.1161/01.CIR.94.6.1408; JAATTELA M, 1989, EUR J IMMUNOL, V19, P1413, DOI 10.1002/eji.1830190810; Kiemer AK, 2003, ENDOCRINOLOGY, V144, P802, DOI 10.1210/en.2002-220610; Kukreja RC, 1999, MOL CELL BIOCHEM, V195, P123, DOI 10.1023/A:1006977311448; LARRICK JW, 1990, FASEB J, V4, P3215, DOI 10.1096/fasebj.4.14.2172061; LEE YJ, 1994, BIOCHEM BIOPH RES CO, V199, P714, DOI 10.1006/bbrc.1994.1287; Lewis ML, 2000, J CELL BIOCHEM, V77, P127, DOI 10.1002/(SICI)1097-4644(20000401)77:1<127::AID-JCB13>3.3.CO;2-S; Li F, 2000, Acta Anaesthesiol Sin, V38, P207; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; MARBER MS, 1995, J CLIN INVEST, V95, P1446, DOI 10.1172/JCI117815; MARGULIS BA, 1991, DIABETES, V40, P1418, DOI 10.2337/diabetes.40.11.1418; Martin JL, 1997, CIRCULATION, V96, P4343; McMillan DR, 1998, J BIOL CHEM, V273, P7523, DOI 10.1074/jbc.273.13.7523; Mestril R, 1996, J MOL CELL CARDIOL, V28, P2351, DOI 10.1006/jmcc.1996.0228; Morimoto RI, 1998, NAT BIOTECHNOL, V16, P833, DOI 10.1038/nbt0998-833; Ohnishi K, 1999, MOL CELL BIOCHEM, V197, P129, DOI 10.1023/A:1006937513154; Okubo S, 2001, CIRCULATION, V103, P877, DOI 10.1161/01.CIR.103.6.877; Ping PP, 1997, CIRC RES, V81, P404, DOI 10.1161/01.RES.81.3.404; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; Rafiee P, 2002, CIRCULATION, V106, P239, DOI 10.1161/01.CIR.0000022018.68965.6D; Sheikh-Hamad D, 1998, J BIOL CHEM, V273, P1832, DOI 10.1074/jbc.273.3.1832; Shi Y, 2000, FREE RADICAL BIO MED, V29, P695, DOI 10.1016/S0891-5849(00)00364-6; Snoeckx LHEH, 2001, PHYSIOL REV, V81, P1461, DOI 10.1152/physrev.2001.81.4.1461; Trost SU, 1998, J CLIN INVEST, V101, P855, DOI 10.1172/JCI265; Uehara T, 1999, BRAIN RES, V823, P226, DOI 10.1016/S0006-8993(99)01178-6; Xiao XZ, 1999, EMBO J, V18, P5943, DOI 10.1093/emboj/18.21.5943; Zhao MJ, 2002, J BIOL CHEM, V277, P44539, DOI 10.1074/jbc.M208408200; ZHAO Y, 1995, MOL CELL BIOCHEM, V148, P1, DOI 10.1007/BF00929496	39	44	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43636	43644		10.1074/jbc.M212993200	http://dx.doi.org/10.1074/jbc.M212993200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12937165	hybrid			2022-12-25	WOS:000186157000112
J	Vines, CM; Revankar, CM; Maestas, DC; LaRusch, LL; Cimino, DF; Kohout, TA; Lefkowitz, RJ; Prossnitz, ER				Vines, CM; Revankar, CM; Maestas, DC; LaRusch, LL; Cimino, DF; Kohout, TA; Lefkowitz, RJ; Prossnitz, ER			N-formyl peptide receptors internalize but do not recycle in the absence of arrestins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA-ARRESTINS; DEPENDENT ENDOCYTOSIS; AGONIST AFFINITY; TRAFFICKING; DESENSITIZATION; PHOSPHORYLATION; IDENTIFICATION; KINASES; SRC	Arrestins mediate phosphorylation-dependent desensitization, internalization, and initiation of signaling cascades for the majority of G protein-coupled receptors (GPCRs). Many GPCRs undergo agonist-mediated internalization through arrestin-dependent mechanisms, wherein arrestin serves as an adapter between the receptor and endocytic proteins. To understand the role of arrestins in N-formyl peptide receptor (FPR) trafficking, we stably expressed the FPR in a mouse embryonic fibroblast cell line (MEF) that lacked endogenous arrestin 2 and arrestin 3 (arrestin-deficient). We compared FPR internalization and recycling kinetics in these cells to congenic wild type MEF cell lines. Internalization of the FPR was not altered in the absence of arrestins. Since the FPR remains associated with arrestins following internalization, we investigated whether the rate of FPR recycling was altered in arrestin-deficient cells. While the FPR was able to recycle in the wild type cells, receptor recycling was largely absent in the arrestin double knockout cells. Reconstitution of the arrestin-deficient line with either arrestin 2 or arrestin 3 restored receptor recycling. Confocal fluorescence microscopy studies demonsrated that in arrestin-deficient cells the FPR may become trapped in the perinuclear recycling compartment. These observations indicate that, although the FPR can internalize in the absence of arrestins, recycling of internalized receptors to the cell surface is prevented. Our results suggest a novel role for arrestins in the post-endocytic trafficking of GPCRs.	Univ New Mexico, Hlth Sci Ctr, Canc Res & Treatment Ctr, Dept Cell Biol & Physiol, Albuquerque, NM 87131 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	University of New Mexico; University of New Mexico's Health Sciences Center; Duke University; Howard Hughes Medical Institute; Duke University; Duke University	Prossnitz, ER (corresponding author), Univ New Mexico, Hlth Sci Ctr, Canc Res & Treatment Ctr, Dept Cell Biol & Physiol, Albuquerque, NM 87131 USA.		Lefkowitz, Robert/AAW-2649-2021; Prossnitz, Eric/I-4599-2019; Prossnitz, Eric R./B-4543-2008	Prossnitz, Eric/0000-0001-9190-8302; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037, R01HL070631] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036357, R01AI043932, R29AI036357, T32AI007538] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 70631, HL 16037] Funding Source: Medline; NIAID NIH HHS [AI 36357, AI 43932, T32 AI 007538] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anborgh PH, 2000, MOL ENDOCRINOL, V14, P2040, DOI 10.1210/me.14.12.2040; Bennett TA, 2000, J BIOL CHEM, V275, P24590, DOI 10.1074/jbc.C000314200; Bennett TA, 2001, J BIOL CHEM, V276, P49195, DOI 10.1074/jbc.M106414200; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; DeGraff JL, 1999, J BIOL CHEM, V274, P11253, DOI 10.1074/jbc.274.16.11253; Gaborik Z, 2001, MOL PHARMACOL, V59, P239, DOI 10.1124/mol.59.2.239; Gilbert TL, 2001, BIOCHEMISTRY-US, V40, P3467, DOI 10.1021/bi001320y; Imamura T, 2001, J BIOL CHEM, V276, P43663, DOI 10.1074/jbc.M105364200; Innamorati G, 2001, J BIOL CHEM, V276, P13096, DOI 10.1074/jbc.M009780200; Key TA, 2003, J BIOL CHEM, V278, P4041, DOI 10.1074/jbc.M204687200; Key TA, 2001, J BIOL CHEM, V276, P49204, DOI 10.1074/jbc.M109475200; Kim KM, 2001, J BIOL CHEM, V276, P37409, DOI 10.1074/jbc.M106728200; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Maestes DC, 1999, J BIOL CHEM, V274, P29791, DOI 10.1074/jbc.274.42.29791; McDonald PH, 1999, J BIOL CHEM, V274, P10677, DOI 10.1074/jbc.274.16.10677; McDonald PH, 2001, CELL SIGNAL, V13, P683, DOI 10.1016/S0898-6568(01)00203-0; Miller WE, 2000, J BIOL CHEM, V275, P11312, DOI 10.1074/jbc.275.15.11312; Miller WE, 2001, J BIOL CHEM, V276, P27770, DOI 10.1074/jbc.M102264200; Mundell SJ, 2000, BIOCHEMISTRY-US, V39, P12828, DOI 10.1021/bi0010928; Orsini MJ, 1999, J BIOL CHEM, V274, P31076, DOI 10.1074/jbc.274.43.31076; Paing MM, 2002, J BIOL CHEM, V277, P1292, DOI 10.1074/jbc.M109160200; Pan L, 2003, J BIOL CHEM, V278, P11623, DOI 10.1074/jbc.M209532200; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PROSSNITZ ER, 1991, BIOCHEM BIOPH RES CO, V179, P471, DOI 10.1016/0006-291X(91)91394-R; Prossnitz ER, 1997, PHARMACOL THERAPEUT, V74, P73, DOI 10.1016/S0163-7258(96)00203-3; Rosenfeld JL, 2002, RECEPTOR CHANNEL, V8, P87, DOI 10.1080/10606820212398; Scott MGH, 2002, J BIOL CHEM, V277, P37693, DOI 10.1074/jbc.M207552200	33	85	87	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41581	41584		10.1074/jbc.C300291200	http://dx.doi.org/10.1074/jbc.C300291200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12947104	hybrid			2022-12-25	WOS:000185989500003
J	Fernandez, FR; Morales, E; Rashid, AJ; Dunn, RJ; Turner, RW				Fernandez, FR; Morales, E; Rashid, AJ; Dunn, RJ; Turner, RW			Inactivation of Kv3.3 potassium channels in heterologous expression systems	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIPPOCAMPAL PYRAMIDAL NEURONS; K+ CHANNELS; DROSOPHILA MUSCLE; BURST DISCHARGE; PROTEIN-KINASE; MESSENGER-RNA; RAT-BRAIN; TRANSLATION; INITIATION; EUKARYOTES	Kv3.3 K+ channels are believed to incorporate an NH2-terminal domain to produce an intermediate rate of inactivation relative to the fast inactivating K+ channels Kv3.4 and Kv1.4. The rate of Kv3.3 inactivation has, however, been difficult to establish given problems in obtaining consistent rates of inactivation in expression systems. This study characterized the properties of AptKv3.3, the teleost homologue of Kv3.3, when expressed in Chinese hamster ovary (CHO) or human embryonic kidney (HEK) cells. We show that the properties of AptKv3.3 differ significantly between CHO and HEK cells, with the largest difference occurring in the rate and voltage dependence of inactivation. While AptKv3.3 in CHO cells showed a fast and voltage-dependent rate of inactivation consistent with N-type inactivation, currents in HEK cells showed rates of inactivation that were voltage-independent and more consistent with a slower C-type inactivation. Examination of the mRNA sequence revealed that the first methionine start site had a weak Kozak consensus sequence, suggesting that the lack of inactivation in HEK cells could be due to translation at a second methionine start site downstream of the NH2-terminal coding region. Mutating the nucleotide sequence surrounding the first methionine start site to one more closely resembling a Kozak consensus sequence produced currents that inactivated with a fast and voltage-dependent rate of inactivation in both CHO and HEK cells. These results indicate that under the appropriate conditions Kv3.3 channels can exhibit fast and reliable inactivation that approaches that more typically expected of "A"-type K+ currents.	Univ Calgary, Neurosci Res Grp, Calgary, AB T2N 4N1, Canada; Montreal Gen Hosp, Neurosci Res Ctr, Montreal, PQ H3G 1A4, Canada; McGill Univ, Dept Neurol, Montreal, PQ H3G 1A4, Canada; McGill Univ, Dept Biol, Montreal, PQ H3G 1A4, Canada	University of Calgary; McGill University; McGill University; McGill University	Turner, RW (corresponding author), Univ Calgary, Neurosci Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.		Fernandez, Fernando/G-9398-2018	Fernandez, Fernando/0000-0001-9308-3594				ALDRICH RW, 1983, NATURE, V306, P436, DOI 10.1038/306436a0; Coetzee WA, 1999, ANN NY ACAD SCI, V868, P233, DOI 10.1111/j.1749-6632.1999.tb11293.x; CONNOR JA, 1971, J PHYSIOL-LONDON, V213, P21, DOI 10.1113/jphysiol.1971.sp009365; COVARRUBIAS M, 1994, NEURON, V13, P1403, DOI 10.1016/0896-6273(94)90425-1; CRITZ SD, 1993, J NEUROCHEM, V60, P1175, DOI 10.1111/j.1471-4159.1993.tb03273.x; DEMIERA EV, 1994, HDB MEMBRANE CHANNEL, P41; DEMIERA EV, 1992, P ROY SOC LOND B BIO, V248, P9, DOI [DOI 10.1098/RSPB.1992.0036, 10.1098/rspb.1992.0036]; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Doiron B, 2001, J NEUROPHYSIOL, V86, P1523, DOI 10.1152/jn.2001.86.4.1523; DRAIN P, 1994, NEURON, V12, P1097, DOI 10.1016/0896-6273(94)90317-4; Franqueza L, 1999, CARDIOVASC RES, V41, P212, DOI 10.1016/S0008-6363(98)00220-X; Hashimoto Y, 2000, J BIOL CHEM, V275, P9358, DOI 10.1074/jbc.275.13.9358; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HOSHI T, 1991, NEURON, V7, P547, DOI 10.1016/0896-6273(91)90367-9; Jiang B, 2002, MOL CELL BIOCHEM, V238, P69, DOI 10.1023/A:1019907104763; Johnston D, 2000, J PHYSIOL-LONDON, V525, P75, DOI 10.1111/j.1469-7793.2000.00075.x; Jonas EA, 1996, CURR OPIN NEUROBIOL, V6, P318, DOI 10.1016/S0959-4388(96)80114-0; Kentros C., 1992, Society for Neuroscience Abstracts, V18, P1093; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; Kozak M, 2001, MOL CELL BIOL, V21, P1899, DOI 10.1128/MCB.21.6.1899-1907.2001; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; Lee TE, 1996, J MEMBRANE BIOL, V151, P225, DOI 10.1007/s002329900073; MACKINNON R, 1993, SCIENCE, V262, P757, DOI 10.1126/science.7694359; Martina M, 2003, J NEUROSCI, V23, P5698; Migliore M, 1999, J COMPUT NEUROSCI, V7, P5, DOI 10.1023/A:1008906225285; Negulescu D, 1998, J BIOL CHEM, V273, P20109, DOI 10.1074/jbc.273.32.20109; Noonan L, 2003, J NEUROSCI, V23, P1524, DOI 10.1523/JNEUROSCI.23-04-01524.2003; Petersen KR, 1999, PFLUG ARCH EUR J PHY, V437, P381, DOI 10.1007/s004240050792; Rae JL, 2000, EXP EYE RES, V70, P339, DOI 10.1006/exer.1999.0796; Rashid AJ, 2001, J COMP NEUROL, V441, P234, DOI 10.1002/cne.1409; Rashid AJ, 2001, J NEUROSCI, V21, P125, DOI 10.1523/JNEUROSCI.21-01-00125.2001; RETTIG J, 1992, EMBO J, V11, P2473, DOI 10.1002/j.1460-2075.1992.tb05312.x; Roeper J, 1997, J NEUROSCI, V17, P3379; Rudy B, 2001, TRENDS NEUROSCI, V24, P517, DOI 10.1016/S0166-2236(00)01892-0; Rudy B, 1999, ANN NY ACAD SCI, V868, P304, DOI 10.1111/j.1749-6632.1999.tb11295.x; RUPPERSBERG JP, 1991, NATURE, V352, P711, DOI 10.1038/352711a0; Velasco I, 1998, Neurobiology (Bp), V6, P23; Watanabe S, 2002, P NATL ACAD SCI USA, V99, P8366, DOI 10.1073/pnas.122210599; ZAGOTTA WN, 1990, J GEN PHYSIOL, V95, P29, DOI 10.1085/jgp.95.1.29; ZAGOTTA WN, 1989, P NATL ACAD SCI USA, V86, P7243, DOI 10.1073/pnas.86.18.7243	40	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40890	40898		10.1074/jbc.M304235200	http://dx.doi.org/10.1074/jbc.M304235200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12923191	hybrid			2022-12-25	WOS:000185847200059
J	Suriano, G; Mulholland, D; de Wever, O; Ferreira, P; Mateus, AR; Bruyneel, E; Nelson, CC; Mareel, MM; Yokota, J; Huntsman, D; Seruca, R				Suriano, G; Mulholland, D; de Wever, O; Ferreira, P; Mateus, AR; Bruyneel, E; Nelson, CC; Mareel, MM; Yokota, J; Huntsman, D; Seruca, R			The intracellular E-cadherin germline mutation V832 M lacks the ability to mediate cell-cell adhesion and to suppress invasion	ONCOGENE			English	Article						E-cadherin; hereditary diffuse gastric cancer; mutations; cell-cell adhesion; invasion; TCF-LEF	GASTRIC-CANCER FAMILIES	E-cadherin germline missense mutations have been shown to be responsible for significant loss of protein activity. A new cytoplasmic E-cadherin germline missense mutation (V832 M) was recently identified in a hereditary diffuse gastric cancer (HDGC) Japanese family. This E-cadherin mutant was cloned in a Chinese hamster ovary cell model system and functionally characterized, in terms of aggregation and invasion. Cells expressing the germline V832M mutant fail to aggregate and invade into collagen, supporting the pathogenic role of this germline missense mutation in gastric cancer. We also tested the ability of this mutation to activate the TCF-LEF trascriptional activity, in comparison with three other E-cadherin missense mutations (T340A, A634V and A617T), associated to loss of E-cadherin function. All the E-cadherin mutants reduced TCF-LEF activation to a similar extent as the wild-type protein, suggesting that the oncogenic effect of the E-cadherin mutants is unlikely to be transmitted through a beta-catenin-dependent activation of the WNT pathway.	Univ Porto IPATIMUP, Inst Patol & Imunol Mol, P-4200 Oporto, Portugal; Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada; UZG, Expt Cancerol Lab, B-9000 Ghent, Belgium; Natl Canc Ctr, Res Inst, Tokyo 104, Japan; Hosp Sao Joao, Fac Med, P-4200 Oporto, Portugal	Universidade do Porto; University of British Columbia; National Cancer Center - Japan; Sao Joao Hospital; Universidade do Porto	Seruca, R (corresponding author), Univ Porto IPATIMUP, Inst Patol & Imunol Mol, P-4200 Oporto, Portugal.	rseruca@ipatimup.pt	de wever, olivier/J-3094-2013; Huntsman, David/ABE-6082-2020; seruca, raquel/F-8187-2011	de wever, olivier/0000-0002-5453-760X; Seruca, Raquel/0000-0002-8851-4166				Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637, DOI 10.1038/35023588; BECKER KF, 1994, CANCER RES, V54, P3845; Becker KF, 1999, AM J PATHOL, V155, P1803, DOI 10.1016/S0002-9440(10)65497-1; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; Berx G, 1998, HUM MUTAT, V12, P226, DOI 10.1002/(SICI)1098-1004(1998)12:4<226::AID-HUMU2>3.0.CO;2-D; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; BOTERBERG T, 2000, METASTASIS RES PROTO, P35; BRACKE ME, 2000, METASTASIS RES PROTO, P81; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cavallaro U, 2002, CANCER LETT, V176, P123, DOI 10.1016/S0304-3835(01)00759-5; Chausovsky A, 2000, NAT CELL BIOL, V2, P797, DOI 10.1038/35041037; Chen HY, 1997, J CELL SCI, V110, P345; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Gayther SA, 1998, CANCER RES, V58, P4086; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Handschuh G, 2001, J MOL BIOL, V314, P445, DOI 10.1006/jmbi.2001.5143; Huber AH, 2001, CELL, V105, P391, DOI 10.1016/S0092-8674(01)00330-0; Machado JC, 2001, ONCOGENE, V20, P1525, DOI 10.1038/sj.onc.1204234; Oliveira C, 2003, EXPERT REV MOL DIAGN, V3, P201; Oliveira C, 2002, HUM MUTAT, V19, P510, DOI 10.1002/humu.10068; Pertz O, 1999, EMBO J, V18, P1738, DOI 10.1093/emboj/18.7.1738; Polakis P, 2000, GENE DEV, V14, P1837; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; SHORE EM, 1991, J BIOL CHEM, V266, P19672; Suriano G, 2003, HUM MOL GENET, V12, P575, DOI 10.1093/hmg/ddg048; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Van Aken E, 2001, VIRCHOWS ARCH, V439, P725, DOI 10.1007/S004280100516; van de Wetering M, 2001, CANCER RES, V61, P278; Vecsey-Semjen B, 2002, ONCOGENE, V21, P4646, DOI 10.1038/sj.onc.1205577; Yabuta T, 2002, INT J CANCER, V101, P434, DOI 10.1002/ijc.10633	31	65	69	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2003	22	36					5716	5719		10.1038/sj.onc.1206672	http://dx.doi.org/10.1038/sj.onc.1206672			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944922				2022-12-25	WOS:000184865900023
J	Ludwig, L; Kessler, H; Hoang-Vu, C; Dralle, H; Adler, G; Boehm, BO; Schmid, RM				Ludwig, L; Kessler, H; Hoang-Vu, C; Dralle, H; Adler, G; Boehm, BO; Schmid, RM			Grap-2, a novel RET binding protein, is involved in RET mitogenic signaling	ONCOGENE			English	Article						RET; Grb2-related adaptors; mitogenic signaling	CELL-LINE; CARCINOMA; PROTOONCOGENE; SYSTEM; SLP-76; GADS	Signal transduction of the RET receptor tyrosine kinase is involved in developmental processes as well as in neoplastic transformation. Activation of RET initiates receptor autophosphorylation on specific tyrosines that act as docking sites for downstream signaling molecules. Using the cytoplasmatic part of RET as bait in a yeast two-hybrid screen, we identified a novel SH2 and SH3 domain containing adaptor protein previously termed Grap-2/Grf40/GrpL/GRID) and its murine homologue as Gads/Mona, respectively. This protein, predominantly expressed in cells of hematopoietic origin, is involved in signaling downstream of the T-cell receptor and the receptor for monocyte colony-stimulating factor. Here, we show that Grap-2 is also expressed in neuroendocrine tumors and cell lines known to bear mutated forms of RET. Endogenously expressed RET and Grap-2 coimmunoprecipitate from lysates of a medullary thyroid carcinoma cell line. Grap-2 directly associates with RET in pull-down experiments using in vitro translated proteins. Overexpression of Grap-2 inhibits RET-induced NF-kappaB activation, and cotransfection of Grap-2 significantly reduces focus formation induced by oncogenic RET in NIH 3T3 cells. Taken together, these results suggest that besides being involved in tyrosine kinase signaling in hematopoietic cells, Grap-2 plays a tissue-specific role as an inhibitor of RET mitogenic signaling.	Tech Univ Munich, Klinikum Rechts Isar, Med Klin, D-81675 Munich, Germany; Univ Ulm, Dept Internal Med 1, D-89081 Ulm, Germany; Univ Halle Wittenberg, Dept Surg 1, D-06097 Halle Saale, Germany	Technical University of Munich; Ulm University; Martin Luther University Halle Wittenberg	Schmid, RM (corresponding author), Tech Univ Munich, Klinikum Rechts Isar, Med Klin, Ismaninger Str 22, D-81675 Munich, Germany.		Boehm, Bernhard Otto/F-8750-2015					Baloh RH, 2000, CURR OPIN NEUROBIOL, V10, P103, DOI 10.1016/S0959-4388(99)00048-3; Bourette RP, 1998, EMBO J, V17, P7273, DOI 10.1093/emboj/17.24.7273; CARLOMAGNO F, 1995, BIOCHEM BIOPH RES CO, V207, P1022, DOI 10.1006/bbrc.1995.1287; EVERS BM, 1994, ANN NY ACAD SCI, V733, P393, DOI 10.1111/j.1749-6632.1994.tb17289.x; Hansford JR, 2000, J MED GENET, V37, P817, DOI 10.1136/jmg.37.11.817; Jhiang SM, 2000, ONCOGENE, V19, P5590, DOI 10.1038/sj.onc.1203857; Liu SK, 1999, CURR BIOL, V9, P67, DOI 10.1016/S0960-9822(99)80017-7; Liu SKW, 2001, ONCOGENE, V20, P6284, DOI 10.1038/sj.onc.1204771; Ludwig L, 2001, CANCER RES, V61, P4526; LUNDQVIST M, 1991, EUR J CANCER, V27, P1663, DOI 10.1016/0277-5379(91)90441-F; Qiu MS, 1998, BIOCHEM BIOPH RES CO, V253, P443, DOI 10.1006/bbrc.1998.9795; Schedl A, 2000, CURR OPIN GENET DEV, V10, P543, DOI 10.1016/S0959-437X(00)00125-8; Taraviras S, 1999, CURR OPIN GENET DEV, V9, P321, DOI 10.1016/S0959-437X(99)80048-3; Yoder J, 2001, SCIENCE, V291, P1987, DOI 10.1126/science.1057176	14	8	10	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 14	2003	22	34					5362	5366		10.1038/sj.onc.1206517	http://dx.doi.org/10.1038/sj.onc.1206517			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JB	12917638				2022-12-25	WOS:000184734900016
J	Maneg, O; Ludwig, B; Malatesta, F				Maneg, O; Ludwig, B; Malatesta, F			Different interaction modes of two cytochrome-c oxidase soluble Cu-A fragments with their substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARACOCCUS-DENITRIFICANS; THERMUS-THERMOPHILUS; SUBUNIT-II; ELECTRON-TRANSFER; ESCHERICHIA-COLI; SITE; C(552); PROTEIN; DOMAIN; DOCKING	Cytochrome-c oxidase is the terminal enzyme in the respiratory chains of mitochondria and many bacteria and catalyzes the formation of water by reduction of dioxygen. The first step in the cytochrome oxidase reaction is the bimolecular electron transfer from cytochrome c to the homobinuclear mixed-valence Cu-A center of subunit II. In Thermus thermophilus a soluble cytochrome c(552) acts as the electron donor to ba(3) cytochrome-c oxidase, an interaction believed to be mainly hydrophobic. In Paracoccus denitrificans, electrostatic interactions appear to play a major role in the electron transfer process from the membrane-spanning cytochrome c552. In the present study, soluble fragments of the CuA domains and their respective cytochrome c electron donors were analyzed by stopped-flow spectroscopy to further characterize the interaction modes. The forward and the reverse electron transfer reactions were studied as a function of ionic strength and temperature, in all cases yielding monoexponential time-dependent reaction profiles in either direction. From the apparent second-order rate constants, equilibrium constants were calculated, with values of 4.8 and of 0.19, for the T. thermophilus and P. denitrificans c552 and CuA couples, respectively. Ionic strength strongly affects the electron transfer reaction in P. denitrificans indicating that about five charges on the protein interfaces control the interaction, when analyzed according to the Bronsted equation, whereas in the T. thermophilus only 0.5 charges are involved. Overall the results indicate that the soluble CuA domains are excellent models for the initial electron transfer processes in cytochrome-c oxidases.	Univ Aquila, Dipartimento Biol Base & Applicata, I-67010 Coppito, Laquila, Italy; Goethe Univ Frankfurt, Biozentrum, D-60439 Frankfurt, Germany	University of L'Aquila; Goethe University Frankfurt	Malatesta, F (corresponding author), Univ Aquila, Dipartimento Biol Base & Applicata, Via Vetoio, I-67010 Coppito, Laquila, Italy.	malatest@univaq.it	Malatesta, Francesco/AAT-4757-2020					ALAYASH AI, 1979, BIOCHEM J, V177, P641, DOI 10.1042/bj1770641; ANTALIS TM, 1982, J BIOL CHEM, V257, P6194; Arslan E, 1998, BIOCHEM BIOPH RES CO, V251, P744, DOI 10.1006/bbrc.1998.9549; ATKINS PW, 1990, PHYSICAL CHEM, P851; Baker SC, 1998, MICROBIOL MOL BIOL R, V62, P1046, DOI 10.1128/MMBR.62.4.1046-1078.1998; BERRY EA, 1985, J BIOL CHEM, V260, P2458; Bronsted JN, 1924, J AM CHEM SOC, V46, P555, DOI 10.1021/ja01668a006; Crowley PB, 2001, J AM CHEM SOC, V123, P10444, DOI 10.1021/ja0112700; DETHMERS JK, 1979, J BIOL CHEM, V254, P1973; Drosou V, 2002, EUR J BIOCHEM, V269, P2980, DOI 10.1046/j.1432-1033.2002.02979.x; Drosou V, 2002, BIOCHEMISTRY-US, V41, P10629, DOI 10.1021/bi020094k; DROSOU V, 2002, THESIS U FRANKFURT F; Fee JA, 2000, PROTEIN SCI, V9, P2074, DOI 10.1110/ps.9.11.2074; Flock D, 2002, PROTEINS, V47, P75, DOI 10.1002/prot.10066; Giuffre A, 1999, BIOCHEMISTRY-US, V38, P1057, DOI 10.1021/bi9815389; Harrenga A, 2000, J MOL BIOL, V295, P667, DOI 10.1006/jmbi.1999.3382; Hart SE, 2003, BIOCHEMISTRY-US, V42, P4829, DOI 10.1021/bi020674h; HONNAMI K, 1977, J BIOCHEM, V82, P769, DOI 10.1093/oxfordjournals.jbchem.a131753; INMOOS C, 1996, J BIOL INORG CHEM, V1, P529; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; Kapust RB, 2000, PROTEIN EXPRES PURIF, V19, P312, DOI 10.1006/prep.2000.1251; LAPPALAINEN P, 1993, J BIOL CHEM, V268, P26416; MYER YP, 1980, J BIOL CHEM, V255, P9666; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Reincke B, 1999, BBA-BIOENERGETICS, V1411, P114, DOI 10.1016/S0005-2728(99)00037-7; Salgado J, 1998, BIOCHEMISTRY-US, V37, P7378, DOI 10.1021/bi9728598; SCHNEIDER M, 2000, THESIS U FRANKFURT F; Schultz BE, 2001, ANNU REV BIOPH BIOM, V30, P23, DOI 10.1146/annurev.biophys.30.1.23; Slutter CE, 1996, BIOCHEMISTRY-US, V35, P3387, DOI 10.1021/bi9525839; Soulimane T, 2000, EMBO J, V19, P1766, DOI 10.1093/emboj/19.8.1766; Soulimane T, 1997, BIOCHEM BIOPH RES CO, V237, P572, DOI 10.1006/bbrc.1997.7041; STEINRUCKE P, 1987, EUR J BIOCHEM, V167, P431, DOI 10.1111/j.1432-1033.1987.tb13356.x; Szundi I, 2001, BIOCHEMISTRY-US, V40, P2186, DOI 10.1021/bi002341v; Than ME, 1997, J MOL BIOL, V271, P629, DOI 10.1006/jmbi.1997.1181; TURBA A, 1995, EUR J BIOCHEM, V231, P259, DOI 10.1111/j.1432-1033.1995.0259f.x; TURBA A, 1993, THESIS U FRANKFURT F; VONWACHENFELDT C, 1994, FEBS LETT, V340, P109, DOI 10.1016/0014-5793(94)80182-7; Wienk H, 2003, BIOCHEMISTRY-US, V42, P6005, DOI 10.1021/bi027198f; Wingfield P. T., 1998, CURRENT PROTOCOLS PR; Witt H, 1998, J BIOL CHEM, V273, P5132, DOI 10.1074/jbc.273.9.5132; Witt H, 1998, EUR J BIOCHEM, V251, P367, DOI 10.1046/j.1432-1327.1998.2510367.x	41	42	42	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46734	46740		10.1074/jbc.M307594200	http://dx.doi.org/10.1074/jbc.M307594200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12937163	hybrid			2022-12-25	WOS:000186569400064
J	Nishi, J; Sheikh, J; Mizuguchi, K; Luisi, B; Burland, V; Boutin, A; Rose, DJ; Blattner, FR; Nataro, JP				Nishi, J; Sheikh, J; Mizuguchi, K; Luisi, B; Burland, V; Boutin, A; Rose, DJ; Blattner, FR; Nataro, JP			The export of coat protein from enteroaggregative Escherichia coli by a specific ATP-binding cassette transporter system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE PROTEIN; GRAM-NEGATIVE BACTERIA; STRUCTURE PREDICTION; MULTIDRUG EFFLUX; DNA-SEQUENCE; HEP-2 CELLS; ADHERENCE; VIRULENCE; SECRETION; FAMILIES	Enteroaggregative Escherichia coli (EAEC) is an emerging enteric pathogen characterized by aggregative adherence (AA) to cultured human mucosal epithelium cells. We have recently characterized a 10.2-kDa protein, called dispersin, which is exported from the bacteria and which promotes dispersal of EAEC across the intestinal mucosa. Here, we present evidence that dispersin is exported by a putative ABC transporter complex, which is encoded by a genetic locus of the EAEC virulence plasmid pAA2. We demonstrate that the locus comprises a cluster of five genes (designated aat-PABCD), including homologs of an inner-membrane permease (AatP), an ATP-binding cassette protein (AatC) and the outer membrane protein TolC (AatA). We show that, like TolC, AatA localizes to the outer membrane independently of its ABC partner. Dispersin appears to require the Aat complex for outer membrane translocation but not for secretion across the inner membrane. We also show that, like the dispersin gene, transcription of the aat cluster is dependent on AggR, a regulator of virulence genes in EAEC. We propose that the aat cluster encodes a specialized ABC transporter, which plays a role in the pathogenesis of EAEC by transporting dispersin out of the bacterial cell.	Univ Maryland, Sch Med, Ctr Vaccine Dev, Dept Pediat, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Ctr Vaccine Dev, Dept Med, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Ctr Vaccine Dev, Dept Microbiol & Immunol, Baltimore, MD 21201 USA; Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England; Univ Wisconsin, Lab Mol & Computat Genom, Madison, WI 53706 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University of Cambridge; University of Wisconsin System; University of Wisconsin Madison	Nishi, J (corresponding author), Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Pediat, Sakuragaoka 8-35-1, Kagoshima 8908520, Japan.		Mizuguchi, Kenji/GVS-5857-2022	Mizuguchi, Kenji/0000-0003-3021-7078	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033096, U01AI044387, R29AI033096, R01AI044387] Funding Source: NIH RePORTER; NIAID NIH HHS [AI44387, AI33096] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Amako K, 1996, MICROBIOL IMMUNOL, V40, P749, DOI 10.1111/j.1348-0421.1996.tb01136.x; Bao QY, 2002, GENOME RES, V12, P689, DOI 10.1101/gr.219302; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; BAUDRY B, 1990, J INFECT DIS, V161, P1249, DOI 10.1093/infdis/161.6.1249; Bernier C, 2002, INFECT IMMUN, V70, P4302, DOI 10.1128/IAI.70.8.4302-4311.2002; Binet R, 1997, GENE, V192, P7, DOI 10.1016/S0378-1119(96)00829-3; BORODOVSKY M, 1993, COMPUT CHEM, V17, P123, DOI 10.1016/0097-8485(93)85004-V; BURLAND V, 1993, GENOMICS, V16, P551, DOI 10.1006/geno.1993.1230; Calladine CR, 2001, J MOL BIOL, V305, P603, DOI 10.1006/jmbi.2000.4320; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Czeczulin JR, 1997, INFECT IMMUN, V65, P4135, DOI 10.1128/IAI.65.10.4135-4145.1997; Czeczulin JR, 1999, INFECT IMMUN, V67, P2692, DOI 10.1128/IAI.67.6.2692-2699.1999; Elias WP, 1999, J BACTERIOL, V181, P1779, DOI 10.1128/JB.181.6.1779-1785.1999; Eslava C, 1998, INFECT IMMUN, V66, P3155, DOI 10.1128/IAI.66.7.3155-3163.1998; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Harlow E, 1998, ANTIBODIES LAB MANUA; Henderson IR, 1999, INFECT IMMUN, V67, P5338, DOI 10.1128/IAI.67.10.5338-5344.1999; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Holland IB, 1999, J MOL BIOL, V293, P381, DOI 10.1006/jmbi.1999.2993; Johnson JM, 1999, J MOL BIOL, V287, P695, DOI 10.1006/jmbi.1999.2630; Koronakis V, 2000, NATURE, V405, P914, DOI 10.1038/35016007; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Letoffe S, 1996, EMBO J, V15, P5804, DOI 10.1002/j.1460-2075.1996.tb00967.x; Linton KJ, 1998, MOL MICROBIOL, V28, P5, DOI 10.1046/j.1365-2958.1998.00764.x; Mahillon J, 1998, GENE, V223, P47, DOI 10.1016/S0378-1119(98)00365-5; Marti-Renom MA, 2000, ANNU REV BIOPH BIOM, V29, P291, DOI 10.1146/annurev.biophys.29.1.291; MERITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869; Mizuguchi K, 1998, PROTEIN SCI, V7, P2469, DOI 10.1002/pro.5560071126; Mizuguchi K, 1998, BIOINFORMATICS, V14, P617, DOI 10.1093/bioinformatics/14.7.617; NAKAI K, 1991, PROTEINS, V11, P95, DOI 10.1002/prot.340110203; NATARO JP, 1994, J BACTERIOL, V176, P4691, DOI 10.1128/JB.176.15.4691-4699.1994; NATARO JP, 1985, J INFECT DIS, V152, P560, DOI 10.1093/infdis/152.3.560; Nataro JP, 1998, CLIN MICROBIOL REV, V11, P403; Nataro JP, 1996, INFECT IMMUN, V64, P4761, DOI 10.1128/IAI.64.11.4761-4768.1996; Nataro JP, 1998, EMERG INFECT DIS, V4, P251, DOI 10.3201/eid0402.980212; NATARO JP, 1992, INFECT IMMUN, V60, P2297, DOI 10.1128/IAI.60.6.2297-2304.1992; NATARO JP, 1987, PEDIATR INFECT DIS J, V6, P829, DOI 10.1097/00006454-198709000-00008; NATARO JP, 1995, J INFECT DIS, V171, P465, DOI 10.1093/infdis/171.2.465; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Okeke I N, 2001, Lancet Infect Dis, V1, P304, DOI 10.1016/S1473-3099(01)00144-X; Okeke IN, 2000, J INFECT DIS, V181, P252, DOI 10.1086/315204; PENFOLD RJ, 1992, GENE, V118, P145, DOI 10.1016/0378-1119(92)90263-O; Piva IC, 2003, J CLIN MICROBIOL, V41, P1827, DOI 10.1128/JCM.41.5.1827-1832.2003; Sambrook J, 2001, MOL CLONING LAB MANU, V3rd; SCHMIDT H, 1995, J CLIN MICROBIOL, V33, P701, DOI 10.1128/JCM.33.3.701-705.1995; Servant Florence, 2002, Brief Bioinform, V3, P246, DOI 10.1093/bib/3.3.246; Sharff A, 2001, EUR J BIOCHEM, V268, P5011, DOI 10.1046/j.0014-2956.2001.02442.x; Sheikh J, 2002, J CLIN INVEST, V110, P1329, DOI 10.1172/JCI200216172; Sheikh J, 2001, MOL MICROBIOL, V41, P983, DOI 10.1046/j.1365-2958.2001.02512.x; Shi JY, 2001, J MOL BIOL, V310, P243, DOI 10.1006/jmbi.2001.4762; Skare JT, 1996, J BACTERIOL, V178, P4909, DOI 10.1128/jb.178.16.4909-4918.1996; Steiner TS, 1998, J INFECT DIS, V177, P88, DOI 10.1086/513809; Thanabalu T, 1998, EMBO J, V17, P6487, DOI 10.1093/emboj/17.22.6487; Thorstenson YR, 1997, J BACTERIOL, V179, P5333, DOI 10.1128/jb.179.17.5333-5339.1997; TZIPORI S, 1992, INFECT IMMUN, V60, P5302, DOI 10.1128/IAI.60.12.5302-5306.1992; WANDERSMAN C, 1990, P NATL ACAD SCI USA, V87, P4776, DOI 10.1073/pnas.87.12.4776; [No title captured]	59	132	139	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 14	2003	278	46					45680	45689		10.1074/jbc.M306413200	http://dx.doi.org/10.1074/jbc.M306413200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	741HH	12933818	hybrid			2022-12-25	WOS:000186452300077
J	Dahl, NK; Jiang, LW; Chernova, MN; Stuart-Tilley, AK; Shmukler, BE; Alper, SL				Dahl, NK; Jiang, LW; Chernova, MN; Stuart-Tilley, AK; Shmukler, BE; Alper, SL			Deficient HCO3- transport in an AE1 mutant with normal Cl- transport can be rescued by carbonic anhydrase II presented on an adjacent AE1 protomer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL TUBULAR-ACIDOSIS; ANION-EXCHANGER BAND-3; RED-BLOOD-CELLS; SOUTHEAST-ASIAN OVALOCYTES; XENOPUS-OOCYTES; GLYCOPHORIN-A; FUNCTIONAL CONSEQUENCES; ERYTHROCYTE-MEMBRANE; AUTOSOMAL-DOMINANT; CL-/HCO3-EXCHANGER	Cl-/HCO3- exchange activity mediated by the AE1 anion exchanger is reduced by carbonic anhydrase II (CA2) inhibition or by prevention of CA2 binding to the AE1 C-terminal cytoplasmic tail. This type of AE1 inhibition is thought to represent reduced metabolic channeling of HCO3- to the intracellular HCO3- binding site of AE1. To test the hypothesis that CA2 binding might itself allosterically activate AE1 in Xenopus oocytes, we compared Cl-/Cl- and Cl-/HCO3- exchange activities of AE1 polypeptides with truncation and missense mutations in the C-terminal tail. The distal renal tubular acidosis-associated AE1 901X mutant exhibited both Cl-/Cl- and Cl-/HCO3- exchange activities. In contrast, AE1 896X, 891X, and AE1 missense mutants in the CA2 binding site were inactive as Cl-/HCO3- exchangers despite exhibiting normal Cl-/Cl- exchange activities. Co-expression of CA2 enhanced wild-type AE1-mediated Cl-/HCO3- exchange, but not Cl-/Cl- exchange. CA2 co-expression could not rescue Cl-/HCO3- exchange activity in AE1 mutants selectively impaired in Cl-/HCO3- exchange. However, co-expression of transport-incompetent AE1 mutants with intact CA2 binding sites completely rescued Cl-/HCO3- exchange by an AE1 missense mutant devoid of CA2 binding, with activity further enhanced by CA2 co-expression. The same transport-incompetent AE1 mutants failed to rescue Cl-/HCO3- exchange by the AE1 truncation mutant 896X, despite preservation of the latter's core CA2 binding site. These data increase the minimal extent of a functionally defined CA2 binding site in AE1. The inter-protomeric rescue of HCO3- transport within the AE1 dimer shows functional proximity of the C-terminal cytoplasmic tail of one protomer to the anion translocation pathway in the adjacent protomer within the AE1 heterodimer. The data strongly support the hypothesis that an intact transbilayer anion translocation pathway is completely contained within an AE1 monomer.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Mol Med Unit, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Renal Unit, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Alper, SL (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Mol Med Unit, RW763 E,330 Brookline Ave, Boston, MA 02215 USA.		Dahl, Neera/AAI-7380-2021; Dahl, Neera/AAV-4856-2021		NIDDK NIH HHS [T32DK007199, DK43495] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043495, R37DK043495, T32DK007199] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alper SL, 2002, J NEPHROL, V15, pS41; Alper SL, 2002, ANNU REV PHYSIOL, V64, P899, DOI 10.1146/annurev.physiol.64.092801.141759; ARONSSON G, 1995, BIOCHEMISTRY-US, V34, P2153, DOI 10.1021/bi00007a008; Bruce LJ, 2000, BIOCHEM J, V350, P41, DOI 10.1042/0264-6021:3500041; BRUCE LJ, 1994, BLOOD, V84, P916; Bruce LJ, 2002, BLOOD, V100, P1878, DOI 10.1182/blood-2002-03-0706; Bruce LJ, 1997, J CLIN INVEST, V100, P1693, DOI 10.1172/JCI119694; Brunati AM, 2000, BLOOD, V96, P1550, DOI 10.1182/blood.V96.4.1550.h8001550_1550_1557; Cheidde L, 2002, J AM SOC NEPHROL, V13, p575A; Chernova MN, 1997, BBA-BIOMEMBRANES, V1329, P111, DOI 10.1016/S0005-2736(97)00090-4; CHERNOVA MN, 1995, J MEMBRANE BIOL, V148, P203; Chernova MN, 1997, J GEN PHYSIOL, V109, P345, DOI 10.1085/jgp.109.3.345; Chishti A H, 1998, Curr Opin Hematol, V5, P116; COUSIN JL, 1976, J PHYSIOL-LONDON, V256, P61, DOI 10.1113/jphysiol.1976.sp011311; Cowan CA, 2000, NEURON, V26, P417, DOI 10.1016/S0896-6273(00)81174-5; Devonald MAJ, 2002, J AM SOC NEPHROL, V13, p57A; DOLDER M, 1993, J MOL BIOL, V231, P119, DOI 10.1006/jmbi.1993.1261; FIERKE CA, 1991, BIOCHEMISTRY-US, V30, P11054, DOI 10.1021/bi00110a007; Gross E, 2002, J PHYSIOL-LONDON, V544, P679, DOI 10.1113/jphysiol.2002.029777; GROVES JD, 1994, J MEMBRANE BIOL, V140, P81; GROVES JD, 1994, MOL MEMBR BIOL, V11, P31, DOI 10.3109/09687689409161027; GROVES JD, 1995, J BIOL CHEM, V270, P9097, DOI 10.1074/jbc.270.16.9097; GROVES JD, 1992, J BIOL CHEM, V267, P22163; Groves JD, 1999, BIOCHEM J, V344, P699, DOI 10.1042/0264-6021:3440699; GROVES JD, 1993, FEBS LETT, V330, P186, DOI 10.1016/0014-5793(93)80270-5; Jarolim P, 1998, J BIOL CHEM, V273, P6380, DOI 10.1074/jbc.273.11.6380; JENNINGS ML, 1995, BIOCHEMISTRY-US, V34, P3588, DOI 10.1021/bi00011a013; Jiang LW, 1997, AM J PHYSIOL-CELL PH, V272, pC191, DOI 10.1152/ajpcell.1997.272.1.C191; Karet FE, 1998, P NATL ACAD SCI USA, V95, P6337, DOI 10.1073/pnas.95.11.6337; Kere J, 1999, AM J PHYSIOL-GASTR L, V276, pG7, DOI 10.1152/ajpgi.1999.276.1.G7; Knauf PA, 2002, P NATL ACAD SCI USA, V99, P10861, DOI 10.1073/pnas.162402399; Knauf PA, 2002, IMA VOL MATH APPL, V129, P85; Ko SBH, 2002, EMBO J, V21, P5662, DOI 10.1093/emboj/cdf580; Kuma H, 2002, BIOCHEMISTRY-US, V41, P3311, DOI 10.1021/bi011678+; Li XJ, 2002, J BIOL CHEM, V277, P36085, DOI 10.1074/jbc.M111952200; LINDENTHAL S, 1991, P NATL ACAD SCI USA, V88, P6540, DOI 10.1073/pnas.88.15.6540; Liu DS, 1996, BIOCHEMISTRY-US, V35, P15228, DOI 10.1021/bi961443b; LOW PS, 1986, BIOCHIM BIOPHYS ACTA, V864, P145, DOI 10.1016/0304-4157(86)90009-2; Nakhoul NL, 1998, AM J PHYSIOL-CELL PH, V274, pC543, DOI 10.1152/ajpcell.1998.274.2.C543; Peters LL, 1999, J CLIN INVEST, V103, P1527, DOI 10.1172/JCI5766; Quilty JA, 2002, BIOCHEM J, V368, P895, DOI 10.1042/BJ20020574; Quilty JA, 2002, AM J PHYSIOL-RENAL, V282, pF810, DOI 10.1152/ajprenal.00216.2001; Reithmeier RAF, 2001, BLOOD CELL MOL DIS, V27, P85, DOI 10.1006/bcmd.2000.0353; Salhany JM, 2003, BIOCHEMISTRY-US, V42, P1589, DOI 10.1021/bi0205294; SALHANY JM, 1978, BIOCHEMISTRY-US, V17, P3354, DOI 10.1021/bi00609a028; SARABIA VE, 1993, J BIOL CHEM, V268, P10676; SCHNELL KF, 1984, PFLUG ARCH EUR J PHY, V402, P197, DOI 10.1007/BF00583335; SCHOFIELD AE, 1992, NATURE, V355, P836, DOI 10.1038/355836a0; SCHWARTZ GJ, 1993, AM J PHYSIOL, V265, pF764, DOI 10.1152/ajprenal.1993.265.6.F764; Scozzafava A, 2002, BIOORG MED CHEM LETT, V12, P1177, DOI 10.1016/S0960-894X(02)00121-X; Spitzer KW, 2002, J PHYSIOL-LONDON, V541, P159, DOI 10.1113/jphysiol.2001.013268; Sterling D, 2002, BIOCHEM CELL BIOL, V80, P483, DOI 10.1139/O02-152; Sterling D, 2001, J BIOL CHEM, V276, P47886, DOI 10.1074/jbc.M105959200; Sterling D, 2002, AM J PHYSIOL-CELL PH, V283, pC1522, DOI 10.1152/ajpcell.00115.2002; Stewart AK, 2002, J GEN PHYSIOL, V120, P707, DOI 10.1085/jgp.20028641; Tanner MJA, 2002, CURR OPIN HEMATOL, V9, P133, DOI 10.1097/00062752-200203000-00009; Tanphaichitr VS, 1998, J CLIN INVEST, V102, P2173, DOI 10.1172/JCI4836; Taylor AM, 2001, BIOCHEM J, V359, P661, DOI 10.1042/0264-6021:3590661; Toye AM, 2002, BLOOD, V99, P342, DOI 10.1182/blood.V99.1.342; Tsuganezawa H, 2001, J BIOL CHEM, V276, P8180, DOI 10.1074/jbc.M004513200; Vince JW, 2000, BIOCHEMISTRY-US, V39, P5527, DOI 10.1021/bi992564p; Vince JW, 2000, BIOCHEMISTRY-US, V39, P13344, DOI 10.1021/bi0015111; Vince JW, 1998, J BIOL CHEM, V273, P28430, DOI 10.1074/jbc.273.43.28430; Wang ZH, 2002, AM J PHYSIOL-GASTR L, V282, pG573, DOI 10.1152/ajpgi.00338.2001; Zhang DC, 2000, BLOOD, V96, P2925; Zhang Y, 1996, J BIOL CHEM, V271, P5741, DOI 10.1074/jbc.271.10.5741; Zhu QS, 2003, J BIOL CHEM, V278, P3112, DOI 10.1074/jbc.M207797200; Zolotarev AS, 1999, BIOCHEMISTRY-US, V38, P8521, DOI 10.1021/bi990337h	68	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44949	44958		10.1074/jbc.M308660200	http://dx.doi.org/10.1074/jbc.M308660200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12933803	hybrid			2022-12-25	WOS:000186306700131
J	Espeli, O; Lee, C; Marians, KJ				Espeli, O; Lee, C; Marians, KJ			A physical and functional interaction between Escherichia coli FtsK and topoisomerase IV	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC RECOMBINATION; DNA-REPLICATION; CELL-DIVISION; CHROMOSOME SEGREGATION; PROTEIN; LOCALIZATION; RESOLUTION; DIF; DECATENATION; POLYMERASE	FtsK and topoisomerase (Topo) IV are both involved in chromosome segregation in Escherichia coli. The former protein resides at the septal ring and is required for resolution of chromosome dimers. The latter protein is the chromosomal decatenase. We have demonstrated recently that Topo IV activity is concentrated at the septal proximal regions of the nucleoids late in the cell cycle. Here we demonstrate that FtsK and Topo IV physically and functionally interact. Topo IV was recovered in immunoprecipitates of FtsK. Two-hybrid analysis and immunoblotting showed that this interaction was mediated by the ParC subunit of Topo IV. In addition, we show that the C-terminal motor domain of FtsK stimulates the decatenation activity of Topo IV but not that of DNA gyrase, the other type II topoisomerase in the cell. Topo IV and FtsK appear to cooperate in the cell as well. Rescue of a parE temperature-sensitive mutation by overproduction of DnaX, which leads to stabilization of the temperature-sensitive Topo IV, required both the C-terminal domain of FtsK and dif, whereas rescue by overproduction of Topo III, which bypasses Topo IV function, did not. The interaction between FtsK and Topo IV may provide a means for concentrating the latter enzyme at the cell center.	Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Marians, KJ (corresponding author), Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA.		espeli, olivier/A-6337-2009	espeli, olivier/0000-0003-2804-2192	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034558] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34558] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS DE, 1992, CELL, V71, P277, DOI 10.1016/0092-8674(92)90356-H; Aussel L, 2002, CELL, V108, P195, DOI 10.1016/S0092-8674(02)00624-4; Barre FX, 2000, GENE DEV, V14, P2976, DOI 10.1101/gad.188700; BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; Brendler T, 2000, EMBO J, V19, P6249, DOI 10.1093/emboj/19.22.6249; CONWAY TW, 1964, P NATL ACAD SCI USA, V52, P1462, DOI 10.1073/pnas.52.6.1462; DIEDERICH L, 1994, BIOTECHNIQUES, V16, P916; Draper GC, 1998, J BACTERIOL, V180, P4621, DOI 10.1128/JB.180.17.4621-4627.1998; Dworkin J, 2002, P NATL ACAD SCI USA, V99, P14089, DOI 10.1073/pnas.182539899; Espeli O, 2003, MOL CELL, V11, P189, DOI 10.1016/S1097-2765(03)00013-3; Hendricks EC, 2000, MOL MICROBIOL, V36, P973, DOI 10.1046/j.1365-2958.2000.01920.x; Hiasa H, 1996, J BIOL CHEM, V271, P21529, DOI 10.1074/jbc.271.35.21529; Hojgaard A, 1999, MOL MICROBIOL, V33, P1027, DOI 10.1046/j.1365-2958.1999.01545.x; KATO J, 1990, CELL, V63, P393, DOI 10.1016/0092-8674(90)90172-B; KATO JI, 1988, J BACTERIOL, V170, P3967, DOI 10.1128/jb.170.9.3967-3977.1988; Koppes LJH, 1999, BIOCHIMIE, V81, P803, DOI 10.1016/S0300-9084(00)87163-1; KRASNOW MA, 1982, J BIOL CHEM, V257, P2687; Lemon KP, 2001, GENE DEV, V15, P2031, DOI 10.1101/gad.913301; Lemon KP, 1998, SCIENCE, V282, P1516, DOI 10.1126/science.282.5393.1516; Lemon KP, 2000, MOL CELL, V6, P1321, DOI 10.1016/S1097-2765(00)00130-1; LESLIE NR, 1995, EMBO J, V14, P1561, DOI 10.1002/j.1460-2075.1995.tb07142.x; Levine C, 1998, J BACTERIOL, V180, P1232, DOI 10.1128/JB.180.5.1232-1240.1998; Li YF, 2002, MOL MICROBIOL, V46, P985, DOI 10.1046/j.1365-2958.2002.03234.x; Liu GW, 1998, MOL MICROBIOL, V29, P893, DOI 10.1046/j.1365-2958.1998.00986.x; Lowe J, 1998, NATURE, V391, P203, DOI 10.1038/34472; MARIANS KJ, 1987, J BIOL CHEM, V262, P10362; Nurse P, 2003, J BIOL CHEM, V278, P8653, DOI 10.1074/jbc.M211211200; Ohsumi K, 2001, MOL MICROBIOL, V40, P835, DOI 10.1046/j.1365-2958.2001.02447.x; PENG H, 1993, P NATL ACAD SCI USA, V90, P8571, DOI 10.1073/pnas.90.18.8571; PENG H, 1993, J BIOL CHEM, V268, P24481; Recchia GD, 1999, EMBO J, V18, P5724, DOI 10.1093/emboj/18.20.5724; Sherratt DJ, 2001, CURR OPIN MICROBIOL, V4, P653, DOI 10.1016/S1369-5274(01)00265-X; Steiner W, 1999, MOL MICROBIOL, V31, P579, DOI 10.1046/j.1365-2958.1999.01198.x; Ullsperger C, 1996, J BIOL CHEM, V271, P31549, DOI 10.1074/jbc.271.49.31549; WU LJ, 1995, GENE DEV, V9, P1316, DOI 10.1101/gad.9.11.1316	35	94	95	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44639	44644		10.1074/jbc.M308926200	http://dx.doi.org/10.1074/jbc.M308926200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12939258	hybrid			2022-12-25	WOS:000186306700095
J	Hafez, I; Stolpe, A; Lindau, M				Hafez, I; Stolpe, A; Lindau, M			Compound exocytosis and cumulative fusion in eosinophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITANCE MEASUREMENTS; SCHISTOSOMA-MANSONI; GRANULE MEMBRANES; CELL; DEGRANULATION; SECRETION; RESOLUTION; MECHANISM; PROTEINS; PH	Focal release of cytotoxic proteins by eosinophils onto the target surface plays an important role in parasite killing. Degranulation was stimulated by intracellular application of calcium and guanosine 5'-3-O-(thio)triphosphate via the recording patch pipette or via streptolysin-O permeabilization. Exocytotic fusion was monitored by capacitance measurements, whereas release of fluorescent weak bases, which accumulate selectively within eosinophil granules, was followed by fluorescence imaging. Several distinct types of granule fusion events were directly observed by simultaneous capacitance and fluorescence measurements. These are fusion of a single granule with the plasma membrane, intracellular granule-granule fusion, fusion of large compounds of pre-fused granules with the plasma membrane ( compound exocytosis), and sequential fusion of granules to granules previously fused to the plasma membrane. Extensive granule-granule fusion was also observed by electron microscopy of permeabilized cells. All these fusion mechanisms contribute to focal release. The coexistence of distinct modes of exocytosis suggests that their regulation may modulate effector functions of eosinophils during helminth infection and allergic response.	Cornell Univ, Sch Appl & Engn Phys, Ithaca, NY 14853 USA	Cornell University	Lindau, M (corresponding author), Cornell Univ, Sch Appl & Engn Phys, Ithaca, NY 14853 USA.	ml95@cornell.edu	Lindau, Manfred/ABD-3449-2021	Lindau, Manfred/0000-0002-5722-9557	NINDS NIH HHS [R01 NS038200-01A2, R01NS38200, R01 NS038200, R01 NS038200-03, R01 NS038200-02] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038200] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Albillos A, 1997, NATURE, V389, P509, DOI 10.1038/39081; Angleson JK, 1999, NAT NEUROSCI, V2, P440, DOI 10.1038/8107; BRECKENRIDGE LJ, 1987, P NATL ACAD SCI USA, V84, P1945, DOI 10.1073/pnas.84.7.1945; Butterworth A E, 1977, Curr Top Microbiol Immunol, V77, P127; Cochilla AJ, 2000, J CELL BIOL, V150, P839, DOI 10.1083/jcb.150.4.839; DETOLEDO GA, 1993, NATURE, V363, P554, DOI 10.1038/363554a0; DVORAK AM, 1981, LAB INVEST, V44, P174; GLAUERT AM, 1978, J CELL SCI, V34, P173, DOI 10.1007/BF01944659; Guo ZH, 1998, CELL, V94, P537, DOI 10.1016/S0092-8674(00)81594-9; Hartmann J, 2003, J BIOL CHEM, V278, P44929, DOI 10.1074/jbc.M306014200; HENDERSON WR, 1985, J CELL SCI, V73, P33; HENDERSON WR, 1983, AM J PATHOL, V111, P341; Hoffmann HJ, 2001, BIOCHEM BIOPH RES CO, V282, P194, DOI 10.1006/bbrc.2001.4499; Kurashima K, 1996, LAB INVEST, V75, P689; Lacy P, 2001, J ALLERGY CLIN IMMUN, V107, P671, DOI 10.1067/mai.2001.113562; Lacy P, 2001, CURR OPIN ALLERGY CL, V1, P79, DOI 10.1097/00130832-200102000-00014; LAWSON D, 1978, J CELL BIOL, V79, P394, DOI 10.1083/jcb.79.2.394; LINDAU M, 1994, ANN NY ACAD SCI, V710, P232, DOI 10.1111/j.1749-6632.1994.tb26631.x; LINDAU M, 1988, PFLUG ARCH EUR J PHY, V411, P137, DOI 10.1007/BF00582306; Logan MR, 2002, J ALLERGY CLIN IMMUN, V109, P299, DOI 10.1067/mai.2002.121453; Mair N, 1999, AM J PHYSIOL-LUNG C, V276, pL376, DOI 10.1152/ajplung.1999.276.2.L376; MCLAREN DJ, 1977, CLIN EXP IMMUNOL, V30, P105; Meeusen ENT, 2000, PARASITOL TODAY, V16, P95, DOI 10.1016/S0169-4758(99)01607-5; Nemoto T, 2001, NAT CELL BIOL, V3, P253, DOI 10.1038/35060042; Niemeyer BA, 2000, J CELL SCI, V113, P4055; NUSSE O, 1990, J EXP MED, V171, P775, DOI 10.1084/jem.171.3.775; SCEPEK S, 1993, EMBO J, V12, P1811, DOI 10.1002/j.1460-2075.1993.tb05829.x; SCEPEK S, 1994, PARASITOL TODAY, V10, P276, DOI 10.1016/0169-4758(94)90146-5; TAI PC, 1981, BRIT J HAEMATOL, V49, P219, DOI 10.1111/j.1365-2141.1981.tb07218.x; Thompson RE, 2001, BIOPHYS J, V81, P937, DOI 10.1016/S0006-3495(01)75752-9; Walsh GM, 1999, CRIT REV CL LAB SCI, V36, P453, DOI 10.1080/10408369991239277; Yoo SH, 1996, J BIOL CHEM, V271, P1558	32	59	61	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44921	44928		10.1074/jbc.M306013200	http://dx.doi.org/10.1074/jbc.M306013200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12923203	Green Published, hybrid			2022-12-25	WOS:000186306700128
J	Babu, E; Kanai, Y; Chairoungdua, A; Kim, DK; Iribe, Y; Tangtrongsup, S; Jutabha, P; Li, YW; Ahmed, N; Sakamoto, S; Anzai, N; Nagamori, S; Endou, H				Babu, E; Kanai, Y; Chairoungdua, A; Kim, DK; Iribe, Y; Tangtrongsup, S; Jutabha, P; Li, YW; Ahmed, N; Sakamoto, S; Anzai, N; Nagamori, S; Endou, H			Identification of a novel system L amino acid transporter structurally distinct from heterodimeric amino acid transporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY GLUTAMATE TRANSPORTER; ORGANIC ANION TRANSPORTER; 4F2 HEAVY-CHAIN; FUNCTIONAL-CHARACTERIZATION; EXPRESSION CLONING; SUBSTRATE SELECTIVITY; MOLECULAR-BIOLOGY; MEMBRANE-PROTEIN; LIVER-CELL; RAT-LIVER	A cDNA that encodes a novel Na+-independent neutral amino acid transporter was isolated from FLC4 human hepatocarcinoma cells by expression cloning. When expressed in Xenopus oocytes, the encoded protein designated LAT3 (L-type amino acid transporter 3) transported neutral amino acids such as L-leucine, L-isoleucine, L-valine, and L-phenylalanine. The LAT3-mediated transport was Na+-independent and inhibited by 2-aminobicyclo[ 2.2.1] heptane-2-carboxylic acid, consistent with the properties of system L. Distinct from already known system L transporters LAT1 and LAT2, which form heterodimeric complex with 4F2 heavy chain, LAT3 was functional by itself in Xenopus oocytes. The deduced amino acid sequence of LAT3 was identical to the gene product of POV1 reported as a prostate cancer-upregulated gene whose function was not determined, whereas it did not exhibit significant similarity to already identified transporters. The Eadie-Hofstee plots of LAT3-mediated transport were curvilinear, whereas the low affinity component is predominant at physiological plasma amino acid concentration. In addition to amino acid substrates, LAT3 recognized amino acid alcohols. The transport of L-leucine was electroneutral and mediated by a facilitated diffusion. In contrast, L-leucinol, L-valinol, and L-phenylalaninol, which have a net positive charge induced inward currents under voltage clamp, suggesting these compounds are transported by LAT3. LAT3-mediated transport was inhibited by the pretreatment with N-ethylmaleimide, consistent with the property of system L2 originally characterized in hepatocyte primary culture. Based on the substrate selectivity, affinity, and N-ethylmaleimide sensitivity, LAT3 is proposed to be a transporter subserving system L2. LAT3 should denote a new family of organic solute transporters.	Kyorin Univ, Sch Med, Dept Gen Med, Tokyo 1818611, Japan; Kyorin Univ, Sch Med, Dept Pharmacol & Toxicol, Tokyo 1818611, Japan; Chiba Univ, Sch Med, Dept Urol, Chuo Ku, Chiba 2608670, Japan; Chosun Univ, Coll Dent, Dept Oral Physiol, Gwangju 501759, South Korea	Kyorin University; Kyorin University; Chiba University; Chosun University	Kanai, Y (corresponding author), Kyorin Univ, Sch Med, Dept Gen Med, 6-20-2 Shinkawa, Tokyo 1818611, Japan.		Jutabha, Promsuk/AAE-9872-2022; ANZAI, NAOHIKO/K-9492-2017; Jutabha, Promsuk/AFF-4363-2022; Tangtrongsup, Sahatchai/U-6745-2019	ANZAI, NAOHIKO/0000-0003-0605-0458; Tangtrongsup, Sahatchai/0000-0001-9417-7736				Aoki Y, 1998, VIROLOGY, V250, P140, DOI 10.1006/viro.1998.9361; Asghar M, 2002, AM J PHYSIOL-RENAL, V283, pF350, DOI 10.1152/ajprenal.00361.2001; BELL GI, 1993, J BIOL CHEM, V268, P19161; Chairoungdua A, 2001, J BIOL CHEM, V276, P49390, DOI 10.1074/jbc.M107517200; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; CHRISTENSEN HN, 1975, CURRENT TOPICS MEMBR, V6, P227; Cole KA, 1998, GENOMICS, V51, P282, DOI 10.1006/geno.1998.5359; COONS DM, 1995, J BACTERIOL, V177, P3251, DOI 10.1128/jb.177.11.3251-3258.1995; Fukasawa Y, 2000, J BIOL CHEM, V275, P9690, DOI 10.1074/jbc.275.13.9690; Gallardo MA, 1996, J MEMBRANE BIOL, V152, P57, DOI 10.1007/s002329900085; GUIDOTTI GG, 1978, BIOCHIM BIOPHYS ACTA, V515, P329, DOI 10.1016/0304-4157(78)90009-6; Kanai Y, 1998, J BIOL CHEM, V273, P23629, DOI 10.1074/jbc.273.37.23629; Kanai Y, 2000, J BIOL CHEM, V275, P20787, DOI 10.1074/jbc.M000634200; KANAI Y, 1995, J BIOL CHEM, V270, P16561, DOI 10.1074/jbc.270.28.16561; Kanai Y, 2001, CURR DRUG METAB, V2, P339, DOI 10.2174/1389200013338324; KANAI Y, 1994, J BIOL CHEM, V269, P20599; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; Kanai Y, 1997, CURR OPIN CELL BIOL, V9, P565, DOI 10.1016/S0955-0674(97)80035-X; Kim D, 2002, BBA-BIOMEMBRANES, V1565, P112, DOI 10.1016/S0005-2736(02)00516-3; Kim DK, 2001, J BIOL CHEM, V276, P17221, DOI 10.1074/jbc.M009462200; KUBAR J, 1990, CELL SIGNAL, V2, P587, DOI 10.1016/0898-6568(90)90081-K; LEEBLUNDBERG LMF, 1985, P NATL ACAD SCI USA, V82, P5651, DOI 10.1073/pnas.82.17.5651; Mannion BA, 1998, J BIOL CHEM, V273, P33127, DOI 10.1074/jbc.273.50.33127; Mastroberardino L, 1998, NATURE, V395, P288, DOI 10.1038/26246; Matsuo H, 2002, J BIOL CHEM, V277, P21017, DOI 10.1074/jbc.M200019200; Meier C, 2002, EMBO J, V21, P580, DOI 10.1093/emboj/21.4.580; MITSUMOTO Y, 1986, J BIOL CHEM, V261, P4549; Mizoguchi K, 2001, KIDNEY INT, V59, P1821, DOI 10.1046/j.1523-1755.2001.0590051821.x; Nagamori S, 2000, J GASTROENTEROL, V35, P493, DOI 10.1007/s005350070071; Nakamura E, 1999, J BIOL CHEM, V274, P3009, DOI 10.1074/jbc.274.5.3009; NOVAK DA, 1994, BIOCHEM J, V301, P671, DOI 10.1042/bj3010671; OXENDER DL, 1963, NATURE, V197, P765, DOI 10.1038/197765a0; Pineda M, 1999, J BIOL CHEM, V274, P19738, DOI 10.1074/jbc.274.28.19738; Reig N, 2002, EMBO J, V21, P4906, DOI 10.1093/emboj/cdf500; Romero MF, 1998, METHOD ENZYMOL, V296, P17; Rossier G, 1999, J BIOL CHEM, V274, P34948, DOI 10.1074/jbc.274.49.34948; SALTER M, 1986, BIOCHEM J, V233, P499, DOI 10.1042/bj2330499; Segawa H, 1999, J BIOL CHEM, V274, P19745, DOI 10.1074/jbc.274.28.19745; Sekine T, 2000, PFLUG ARCH EUR J PHY, V440, P337, DOI 10.1007/s004240000297; Sekine T, 1998, AM J PHYSIOL-RENAL, V275, pF298, DOI 10.1152/ajprenal.1998.275.2.F298; Sekine T, 1997, J BIOL CHEM, V272, P18526, DOI 10.1074/jbc.272.30.18526; Skotheim RI, 2002, CANCER RES, V62, P2359; STEVENS BR, 1982, J MEMBRANE BIOL, V66, P213, DOI 10.1007/BF01868496; Uchino H, 2002, MOL PHARMACOL, V61, P729, DOI 10.1124/mol.61.4.729; UtsunomiyaTate N, 1996, J BIOL CHEM, V271, P14883, DOI 10.1074/jbc.271.25.14883; Verrey F, 2000, PFLUG ARCH EUR J PHY, V440, P503, DOI 10.1007/s004240050001; Verrey F, 1999, J MEMBRANE BIOL, V172, P181, DOI 10.1007/s002329900595; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; WEISSBACH L, 1982, J BIOL CHEM, V257, P2006; Yanagida O, 2001, BBA-BIOMEMBRANES, V1514, P291, DOI 10.1016/S0005-2736(01)00384-4	51	185	193	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43838	43845		10.1074/jbc.M305221200	http://dx.doi.org/10.1074/jbc.M305221200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12930836	hybrid			2022-12-25	WOS:000186157000134
J	Seo, SJ; Cheon, HM; Sun, JX; Sappington, TW; Raikhel, AS				Seo, SJ; Cheon, HM; Sun, JX; Sappington, TW; Raikhel, AS			Tissue- and stage-specific expression of two lipophorin receptor variants with seven and eight ligand-binding repeats in the adult mosquito	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; LYSOSOMAL ASPARTIC PROTEASE; MESSENGER-RNA DEGRADATION; CHICKEN OOCYTE RECEPTOR; GENE FAMILY-MEMBER; FAT-BODY CELLS; VITELLOGENIN RECEPTORS; LDL-RECEPTOR; MOLECULAR CHARACTERIZATION; AEDES-AEGYPTI	We identified two splice variants of lipophorin receptor (LpR) gene products specific to the mosquito fat body (AaLpRfb) and ovary ( AaLpRov) with respective molecular masses of 99.3 and 128.9 kDa. Each LpR variant encodes a member of the low density lipoprotein receptor family with five characteristic domains: 1) ligand recognition, 2) epidermal growth factor precursor, 3) putative O-linked sugar, 4) single membrane-spanning domains, and 5) the cytoplasmic tail with a highly conserved internalization signal FDNPVY. Proposed phylogenetic relationships among low density lipoprotein receptor superfamily members suggest that the LpRs of insects are more closely related to vertebrate low density lipoprotein receptors and very low density lipoprotein receptor/vitellogenin receptor than to insect vitellogenin receptor/yolk protein receptors. Two mosquito LpR isoforms differ in their amino termini, the ligand-binding domains, and O-linked sugar domains, which are generated by differential splicing. Polymerase chain reaction and Southern blot hybridization analyses show that these two transcripts originated from a single gene. Significantly, the putative ligand-binding domain consists of seven and eight complement-type, cysteine-rich repeats in AaLpRfb and AaLRov, respectively. Seven cysteine-rich repeats in AaLpRfb are identical to the second through eighth repeats of AaLpRov. Previous analyses ( 1) have indicated that the AaLpRov transcript is present exclusively in ovarian germ-line cells, nurse cells, and oocytes throughout the previtellogenic and vitellogenic stages, with the peak at 24 - 30 h after blood meal, coincident with the peak of yolk protein uptake. In contrast, the fat body-specific AaLpRfb transcript expression is restricted to the postvitellogenic period, during which yolk protein production is terminated and the fat body is transformed to a storage depot of lipid, carbohydrate, and protein.	Univ Calif Riverside, Dept Entomol, Riverside, CA 92521 USA; Gyeongsang Natl Univ, Coll Nat Sci, Div Life Sci, Jinju 660701, Gyeongnam, South Korea; Michigan State Univ, Dept Entomol, E Lansing, MI 48824 USA; Iowa State Univ, USDA ARS, Ames, IA 50011 USA	University of California System; University of California Riverside; Gyeongsang National University; Michigan State University; Iowa State University; United States Department of Agriculture (USDA)	Raikhel, AS (corresponding author), Univ Calif Riverside, Dept Entomol, Riverside, CA 92521 USA.	alexander.raikhel@ucr.edu	Sun, Jianxin/B-5866-2008		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI024716, R01AI036959, R01AI024716] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI024716, AI 024716, AI 36959] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arrese EL, 2001, INSECT BIOCHEM MOLEC, V31, P7, DOI 10.1016/S0965-1748(00)00102-8; BAUERFEIND R, 1992, J INSECT PHYSIOL, V38, P185, DOI 10.1016/0022-1910(92)90067-N; BOROVSKY D, 1985, ARCH INSECT BIOCHEM, V2, P333, DOI 10.1002/arch.940020402; BUJO H, 1995, P NATL ACAD SCI USA, V92, P9905, DOI 10.1073/pnas.92.21.9905; BUJO H, 1995, J BIOL CHEM, V270, P23546, DOI 10.1074/jbc.270.40.23546; BUJO H, 1994, EMBO J, V13, P5165, DOI 10.1002/j.1460-2075.1994.tb06847.x; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Cheon HM, 2001, INSECT BIOCHEM MOLEC, V31, P753, DOI 10.1016/S0965-1748(01)00068-6; Cho WL, 1999, J BIOL CHEM, V274, P13311, DOI 10.1074/jbc.274.19.13311; CHO WL, 1992, J BIOL CHEM, V267, P21823; CHO WL, 1991, P NATL ACAD SCI USA, V88, P10821, DOI 10.1073/pnas.88.23.10821; CHO WL, 1991, INSECT BIOCHEM, V21, P165, DOI 10.1016/0020-1790(91)90047-I; Cho WL, 2001, INSECT BIOCHEM MOLEC, V31, P283, DOI 10.1016/S0965-1748(00)00175-2; Dantuma NP, 1999, J LIPID RES, V40, P973; Dantuma NP, 1997, J LIPID RES, V38, P254; Dantuma NP, 1998, J LIPID RES, V39, P1877; DAVIS CG, 1986, J BIOL CHEM, V261, P2828; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DECKER CJ, 1994, TRENDS BIOCHEM SCI, V19, P336, DOI 10.1016/0968-0004(94)90073-6; DEITSCH KW, 1993, INSECT MOL BIOL, V242, P205; DHADIALLA TS, 1994, PERSPECTIVES IN COMPARATIVE ENDOCRINOLOGY, P275; Gliemann J, 1998, BIOL CHEM, V379, P951; HAYS AR, 1990, ROUX ARCH DEV BIOL, V199, P114, DOI 10.1007/BF02029559; HIESBERGER T, 1995, J BIOL CHEM, V270, P18219, DOI 10.1074/jbc.270.31.18219; Hussain MM, 1999, ANNU REV NUTR, V19, P141, DOI 10.1146/annurev.nutr.19.1.141; JACOBSEN L, 1995, J BIOL CHEM, V270, P6468, DOI 10.1074/jbc.270.12.6468; KAWOOYA JK, 1988, J BIOL CHEM, V263, P8740; Kokoza VA, 1997, J BIOL CHEM, V272, P1164, DOI 10.1074/jbc.272.2.1164; LAW JH, 1989, J BIOL CHEM, V264, P16335; Lee CS, 2003, INSECT BIOCHEM MOLEC, V33, P761, DOI 10.1016/S0965-1748(03)00066-3; Lindstedt KA, 1997, DNA CELL BIOL, V16, P35, DOI 10.1089/dna.1997.16.35; Magrane J, 1998, J LIPID RES, V39, P2172; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MEHTA KD, 1991, J BIOL CHEM, V266, P10406; MEOLA R, 1972, J MED ENTOMOL, V9, P99, DOI 10.1093/jmedent/9.1.99; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; NIMPF J, 2000, BIOCHIM BIOPHYS ACTA, V1259, P287; OCHMAN H, 1988, GENETICS, V120, P621; OKA K, 1994, EUR J BIOCHEM, V224, P975, DOI 10.1111/j.1432-1033.1994.00975.x; POLVINO WJ, 1992, SOMAT CELL MOLEC GEN, V18, P443, DOI 10.1007/BF01233084; RAIKHEL AS, 1992, ANNU REV ENTOMOL, V42, P527; Ryan RO, 2000, ANNU REV ENTOMOL, V45, P233, DOI 10.1146/annurev.ento.45.1.233; SAKAI J, 1994, J BIOL CHEM, V269, P2173; SAMBROOK J, 1989, MOL LAB MANUAL; Sappington TW, 1996, P NATL ACAD SCI USA, V93, P8934, DOI 10.1073/pnas.93.17.8934; Sappington TW, 1998, INSECT BIOCHEM MOLEC, V28, P277, DOI 10.1016/S0965-1748(97)00110-0; Sappington TW, 1998, J MOL EVOL, V46, P476, DOI 10.1007/PL00006328; Schneider WJ, 1996, INT REV CYTOL, V166, P103, DOI 10.1016/S0074-7696(08)62507-3; SCHONBAUM CP, 1995, P NATL ACAD SCI USA, V92, P1485, DOI 10.1073/pnas.92.5.1485; STOECKLIN G, 1994, J BIOL CHEM, V269, P28591; Sun JX, 2000, INSECT BIOCHEM MOLEC, V30, P1161, DOI 10.1016/S0965-1748(00)00093-X; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; TELFER WH, 1991, INSECT BIOCHEM, V21, P653, DOI 10.1016/0020-1790(91)90036-E; TSUCHIDA K, 1990, J BIOL CHEM, V265, P5761; Van Hoof D, 2003, J LIPID RES, V44, P1431, DOI 10.1194/jlr.M300022-JLR200; WEBB JC, 1994, HUM MOL GENET, V3, P531, DOI 10.1093/hmg/3.4.531; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0	57	38	41	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41954	41962		10.1074/jbc.M308200200	http://dx.doi.org/10.1074/jbc.M308200200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12917414	hybrid, Green Submitted			2022-12-25	WOS:000185989500050
J	Saito, H; Dhanasekaran, P; Baldwin, F; Weisgraber, KH; Phillips, MC; Lund-Katz, S				Saito, H; Dhanasekaran, P; Baldwin, F; Weisgraber, KH; Phillips, MC; Lund-Katz, S			Effects of polymorphism on the lipid interaction of human apolipoprotein E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL DOMAIN; LDL RECEPTOR-BINDING; HUMAN PLASMA-LIPOPROTEINS; LOW-DENSITY LIPOPROTEINS; E ISOFORMS; EXCHANGEABLE APOLIPOPROTEIN; ALZHEIMERS-DISEASE; CONFORMATIONAL-CHANGES; APOLIPOPHORIN-III; AQUEOUS-SOLUTION	ApoE exists as three common isoforms, apoE2, apoE3, and apoE4; apoE2 and apoE3 preferentially bind to high density lipoproteins, whereas apoE4 prefers very low density lipoproteins ( VLDL). To understand the molecular basis for the different lipoprotein distributions of these isoforms in human plasma, we examined the lipid- binding properties of the apoE isoforms and some mutants using lipid emulsions. With both large ( 120 nm) and small ( 35 nm) emulsion particles, the binding affinity of apoE4 was much higher than that of apoE2 and apoE3, whereas the maximal binding capacities were similar among the three isoforms. The 22-kDa N-terminal fragment of apoE4 displayed a much higher binding capacity than did apoE2 and apoE3. The apoE4(E255A) mutant, which has no electrostatic interaction between Arg(61) and Glu(255), showed binding behavior similar to that of apoE3, indicating that N- and C-terminal domain interaction in apoE4 is responsible for its high affinity for lipid. In addition, the apoE3( P267A) mutant, which is postulated to contain a long alpha-helix in the C-terminal domain, had significantly decreased binding capacities for both sizes of emulsion particle, suggesting that the apoE4 preference for VLDL is not due to a stabilized long alpha-helical structure. Isothermal titration calorimetry measurements showed that there is no significant difference in thermodynamic parameters for emulsion binding among the apoE isoforms. However, fluorescence measurements of 8-anilino-1-naphthalenesulfonic acid binding to apoE indicated that apoE4 has more exposed hydrophobic surface compared with apoE3 mainly due to the different tertiary organization of the C-terminal domain. The less organized structure in the C-terminal domain of apoE4 leads to the higher affinity for lipid, contributing to its preferential association with VLDL. In fact, we found that apoE4 binds to VLDL with higher affinity compared with apoE3.	Univ Penn, Childrens Hosp Philadelphia, Sch Med, Joseph Stokes Jr Res Inst,Abramson Res Ctr, Philadelphia, PA 19104 USA; Natl Inst Hlth Sci, Osaka Branch, Osaka 5400006, Japan; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94141 USA; Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, Inst Cardiovasc Res, San Francisco, CA 94141 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; National Institute of Health Sciences - Japan; University of California System; University of California San Francisco; University of California System; University of California San Francisco; The J David Gladstone Institutes	Lund-Katz, S (corresponding author), Univ Penn, Childrens Hosp Philadelphia, Sch Med, Joseph Stokes Jr Res Inst,Abramson Res Ctr, Abramson Res Bldg,Suite 302,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.			Phillips, Michael/0000-0002-7147-8007	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056083] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG020235] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56083] Funding Source: Medline; NIA NIH HHS [AG20235] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Acharya P, 2002, BBA-MOL CELL BIOL L, V1584, P9, DOI 10.1016/S1388-1981(02)00263-9; AGGERBECK LP, 1988, J BIOL CHEM, V263, P6249; AlHaideri M, 1997, BIOCHEMISTRY-US, V36, P12766, DOI 10.1021/bi9631024; Boyle KE, 1999, BBA-PROTEIN STRUCT M, V1430, P302, DOI 10.1016/S0167-4838(99)00009-6; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; deKnijff P, 1996, CURR OPIN LIPIDOL, V7, P59, DOI 10.1097/00041433-199604000-00002; DEPAUW M, 1995, BIOCHEMISTRY-US, V34, P10953, DOI 10.1021/bi00034a030; DERKSEN A, 1989, BIOCHEMISTRY-US, V28, P900, DOI 10.1021/bi00428a074; Dong J, 2000, J LIPID RES, V41, P1783; DONG LM, 1994, J BIOL CHEM, V269, P22358; Dong LM, 1996, J BIOL CHEM, V271, P19053, DOI 10.1074/jbc.271.32.19053; Fisher CA, 1999, J LIPID RES, V40, P93; Fisher CA, 2000, J BIOL CHEM, V275, P33601, DOI 10.1074/jbc.M002643200; Gong JS, 2002, J BIOL CHEM, V277, P29919, DOI 10.1074/jbc.M203934200; Huang YD, 2001, P NATL ACAD SCI USA, V98, P8838, DOI 10.1073/pnas.151254698; INNERARITY TL, 1979, J BIOL CHEM, V254, P4186; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu B, 2000, J BIOL CHEM, V275, P20775, DOI 10.1074/jbc.M003508200; Lund-Katz S, 2000, J BIOL CHEM, V275, P34459, DOI 10.1074/jbc.M005265200; Lund-Katz S, 2001, J LIPID RES, V42, P894; LUNDKATZ S, 1993, J BIOL CHEM, V268, P23008; Mahley RW, 1999, J LIPID RES, V40, P1933; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Massey JB, 1998, BIOPHYS J, V74, P869, DOI 10.1016/S0006-3495(98)74010-X; Morrow JA, 2000, BIOCHEMISTRY-US, V39, P11657, DOI 10.1021/bi000099m; Morrow JA, 2002, J BIOL CHEM, V277, P50380, DOI 10.1074/jbc.M204898200; Morrow JA, 1999, PROTEIN EXPRES PURIF, V16, P224, DOI 10.1006/prep.1999.1069; Narayanaswami V, 2001, J BIOL CHEM, V276, P37853; Narayanaswami V, 2000, BBA-MOL CELL BIOL L, V1483, P15, DOI 10.1016/S1388-1981(99)00176-6; Perugini MA, 2000, J BIOL CHEM, V275, P36758, DOI 10.1074/jbc.M005565200; Perugini MA, 2002, EUR J BIOCHEM, V269, P5939, DOI 10.1046/j.1432-1033.2002.03319.x; Pillot T, 1999, J NEUROCHEM, V72, P230, DOI 10.1046/j.1471-4159.1999.0720230.x; Raussens V, 1998, J BIOL CHEM, V273, P25825, DOI 10.1074/jbc.273.40.25825; Rogers DP, 1997, BIOCHEMISTRY-US, V36, P288, DOI 10.1021/bi961876e; Saito H, 1997, J LIPID RES, V38, P287; Saito H, 2003, J BIOL CHEM, V278, P14782, DOI 10.1074/jbc.M213207200; Saito H, 2001, LANGMUIR, V17, P2528, DOI 10.1021/la001583t; Saito H, 2001, J BIOL CHEM, V276, P40949, DOI 10.1074/jbc.M106337200; Segall ML, 2002, J LIPID RES, V43, P1688, DOI 10.1194/jlr.M200157-JLR200; SEGREST JP, 1992, J LIPID RES, V33, P141; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; Soulages JL, 1998, BIOCHEMISTRY-US, V37, P10203, DOI 10.1021/bi980622l; STRITTMATTER WJ, 1995, P NATL ACAD SCI USA, V92, P4725, DOI 10.1073/pnas.92.11.4725; Weers PMM, 2003, BIOPHYS CHEM, V100, P481, DOI 10.1016/S0301-4622(02)00300-9; Weers PMM, 2001, BIOCHEMISTRY-US, V40, P7754, DOI 10.1021/bi010410f; Weers PMM, 2001, EUR J BIOCHEM, V268, P3728, DOI 10.1046/j.1432-1327.2001.02282.x; WEISGRABER KH, 1990, J LIPID RES, V31, P1503; WEISGRABER KH, 1981, J BIOL CHEM, V256, P9077; Weisgraber KH, 1996, FASEB J, V10, P1485, DOI 10.1096/fasebj.10.13.8940294; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WESTERLUND JA, 1993, J BIOL CHEM, V268, P15745; WETTERAU JR, 1988, J BIOL CHEM, V263, P6240; WILSON C, 1994, STRUCTURE, V2, P713, DOI 10.1016/S0969-2126(00)00072-1; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; YOKOYAMA S, 1985, J BIOL CHEM, V260, P6375	55	70	77	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40723	40729		10.1074/jbc.M304814200	http://dx.doi.org/10.1074/jbc.M304814200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12917433	hybrid			2022-12-25	WOS:000185847200038
J	Frese, S; Pirnia, F; Miescher, D; Krajewski, S; Borner, MM; Reed, JC; Schmid, RA				Frese, S; Pirnia, F; Miescher, D; Krajewski, S; Borner, MM; Reed, JC; Schmid, RA			PG490-mediated sensitization of lung cancer cells to Apo2L/TRAIL-induced apoptosis requires activation of ERK2	ONCOGENE			English	Article						lung cancer; resistance to apoptosis; tumor necrosis factor-related apoptosis-inducing ligand; mitogen-activated protein kinase; primary culture	TRAIL-INDUCED APOPTOSIS; SIGNAL-REGULATED KINASE; MAP KINASE; IN-VIVO; TRAIL/APO2L-INDUCED APOPTOSIS; CHEMOTHERAPEUTIC-AGENTS; INHIBITORY PROTEIN; ANTITUMOR-ACTIVITY; TUMOR-CELLS; LIGAND	Tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) belongs to the family of programmed cell death-inducing cytokines. Apo2L/TRAIL induces apoptosis in a wide variety of tumor cells. Tumor cells that are resistant to Apo2L/TRAIL-induced apoptosis can be sensitized by chemotherapeutic drugs and other agents via an unknown mechanism. Here we report that PG490 (triptolide), a diterpene triepoxide extracted from the Chinese herb Tripterygium wilfordii and used in traditional Chinese medicine, sensitizes lung cancer but not normal human bronchial epithelial cells to Apo2L/TRAIL-induced apoptosis. Sensitization was accompanied by caspase-3 and caspase-8 activation, whereas no cleavage of caspase-9 was observed. Determination of cell surface receptors by flow cytometry demonstrated no difference in Apo2L/TRAIL-R1 and -R2 expression, the two receptors with functional death domains, between resistant and sensitized cells. In cells treated with the combination of Apo2L/TRAIL and PG490, we observed activation of ERK2, a member of the mitogen-activated protein kinase family. Furthermore, sensitization could be blocked by the ERK inhibitor U0126 but not the p38 inhibitor SB203580, suggesting that activation of ERK2 is required for this effect. In addition, sensitization of lung cancer cells was also seen in ex vivo culture of lung cancer tissue from four patients who underwent surgery. Immunohistochemical staining showed a clear reduction in proliferation cell nuclear antigen (PCNA) in tissue treated with Apo2L/TRAIL and PG490. In conclusion, apoptosis induced by the combination of Apo2L/TRAIL and PG490 warrants further evaluation as a potential new strategy for the treatment of lung cancer.	Univ Hosp Bern, Dept Clin Res, Div Gen Thorac Surg, CH-3010 Bern, Switzerland; Univ Hosp Bern, Inst Med Oncol, CH-3010 Bern, Switzerland; Burnham Inst, La Jolla, CA 92037 USA	University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern; Sanford Burnham Prebys Medical Discovery Institute	Frese, S (corresponding author), Univ Hosp Bern, Dept Clin Res, Div Gen Thorac Surg, Murtenstr 35,Room C807, CH-3010 Bern, Switzerland.	steffen.frese@email.de	Frese, Steffen/AAL-4573-2021; Borner, Markus/B-7583-2011	Schmid, Ralph Alexander/0000-0003-0699-079X	NCI NIH HHS [CA 69381] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA069381] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chang WT, 2001, J BIOL CHEM, V276, P2221, DOI 10.1074/jbc.M009713200; Cottom J, 2003, J BIOL CHEM, V278, P7167, DOI 10.1074/jbc.M203901200; English J, 1999, EXP CELL RES, V253, P255, DOI 10.1006/excr.1999.4687; Evdokiou A, 2002, INT J CANCER, V99, P491, DOI 10.1002/ijc.10376; Faul JL, 2000, AM J RESP CRIT CARE, V162, P2252, DOI 10.1164/ajrccm.162.6.2002018; Frese S, 2002, J THORAC CARDIOV SUR, V123, P168, DOI 10.1067/mtc.2002.119694; Gliniak B, 1999, CANCER RES, V59, P6153; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Griffith TS, 2002, CANCER RES, V62, P3093; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; Huynh PN, 2000, J ANDROL, V21, P689; Ishiwata N, 2000, ANTICANCER RES, V20, P1445; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Krajewska M, 1997, CANCER RES, V57, P1605; Lee KY, 2002, EXP MOL MED, V34, P462, DOI 10.1038/emm.2002.64; Lee KY, 1999, J BIOL CHEM, V274, P13451, DOI 10.1074/jbc.274.19.13451; Lee MW, 2002, FEBS LETT, V512, P313, DOI 10.1016/S0014-5793(02)02225-1; Lee YJ, 2001, ONCOGENE, V20, P1476, DOI 10.1038/sj.onc.1204225; Leverkus M, 2000, CANCER RES, V60, P553; MacKeigan JP, 2000, J BIOL CHEM, V275, P38953, DOI 10.1074/jbc.C000684200; McCullagh P, 1989, MONOGRAPHS STAT APPL, V2nd; Nam SY, 2002, ONCOGENE, V21, P337, DOI 10.1038/sj.onc.1205068; Nesterov A, 2002, ONCOGENE, V21, P1135, DOI 10.1038/sj.onc.1205151; Rohn TA, 2001, ONCOGENE, V20, P4128, DOI 10.1038/sj.onc.1204534; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Stadheim TA, 2001, CANCER RES, V61, P1533; Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xiang H, 2002, ONCOGENE, V21, P3611, DOI 10.1038/sj.onc.1205449; Yang YL, 1998, IMMUNOPHARMACOLOGY, V40, P139, DOI 10.1016/S0162-3109(98)00036-8; Zhang XD, 1999, CANCER RES, V59, P2747	40	84	96	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2003	22	35					5427	5435		10.1038/sj.onc.1206842	http://dx.doi.org/10.1038/sj.onc.1206842			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JC	12934102				2022-12-25	WOS:000184735000007
J	Nilsen, H; Stamp, G; Andersen, S; Hrivnak, G; Krokan, HE; Lindahl, T; Barnes, DE				Nilsen, H; Stamp, G; Andersen, S; Hrivnak, G; Krokan, HE; Lindahl, T; Barnes, DE			Gene-targeted mice lacking the Ung uracil-DNA glycosylase develop B-cell lymphomas	ONCOGENE			English	Article						uracil-DNA glycosylase; B-cell lymphoma; gene-targeted mice; antibody diversity	BASE EXCISION-REPAIR; CYTIDINE DEAMINASE AID; SOMATIC HYPERMUTATION; IMMUNOGLOBULIN GENES; DEFICIENCY CAUSES; MISINCORPORATION; MUTATIONS; TUMORIGENESIS; ACCUMULATION; SUPPRESSION	Mice deficient in the Ung uracil-DNA glycosylase have an increased level of uracil in their genome, consistent with a major role of Ung counteracting U:A base pairs arising by misincorporation of dUMP during DNA replication. A complementary uracil-excising activity apparently acts on premutagenic U:G lesions resulting from deamination of cytosine throughout the genome. However, Ung specifically processes U:G lesions targeted to immunoglobulin variable (V) genes during somatic hypermutation and class-switch recombination. Gene-targeted Ung(-/-) null mice remained tumour-free and showed no overt pathological phenotype up to similar to12 months of age. We have monitored a large cohort of ageing Ung(-/-) mice and, beyond 18 months of age, they had a higher morbidity than Ung(+/+) controls. Post-mortem analyses revealed pathological changes in lymphoid organs, abnormal lymphoproliferation, and a greatly increased incidence of B-cell lymphomas in older Ung-deficient mice. These are the first data reporting the development of spontaneous malignancies in mice due to deficiency in a DNA glycosylase. Furthermore, they support a specific role for Ung in the immune system, with lymphomagenesis being related to perturbed processing of antibody genes in germinal centre B cells.	Imperial Canc Res Fund, Clare Hall Labs, Canc Res UK, London Res Inst, S Mimms EN6 3LD, Herts, England; Univ London Imperial Coll Sci Technol & Med, Dept Histopathol, Fac Med, London W12 0NN, England; Norwegian Univ Sci & Technol, Inst Canc Res & Mol Biol, Fac Med, N-7489 Trondheim, Norway	Cancer Research UK; Imperial College London; Norwegian University of Science & Technology (NTNU)	Lindahl, T (corresponding author), Imperial Canc Res Fund, Clare Hall Labs, Canc Res UK, London Res Inst, S Mimms EN6 3LD, Herts, England.	lindahl@cancer.org.uk	Nilsen, Hilde/F-6432-2014	Nilsen, Hilde/0000-0003-2115-2663				Aravind L, 2000, GENOME BIOL, V1, P1, DOI DOI 10.1186/GB-2000-1-4-RESEARCH0007; Blount BC, 1997, P NATL ACAD SCI USA, V94, P3290, DOI 10.1073/pnas.94.7.3290; Di Noia J, 2002, NATURE, V419, P43, DOI 10.1038/nature00981; Elder RH, 1998, MOL CELL BIOL, V18, P5828, DOI 10.1128/MCB.18.10.5828; Elder RH, 2002, J BIOL CHEM, V277, P50487, DOI 10.1074/jbc.M208153200; Engelward BP, 1997, P NATL ACAD SCI USA, V94, P13087, DOI 10.1073/pnas.94.24.13087; Faili A, 2002, NATURE, V419, P944, DOI 10.1038/nature01117; GOULIAN M, 1980, P NATL ACAD SCI-BIOL, V77, P1956, DOI 10.1073/pnas.77.4.1956; Haushalter KA, 1999, CURR BIOL, V9, P174, DOI 10.1016/S0960-9822(99)80087-6; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; Kuppers R, 2001, ONCOGENE, V20, P5580, DOI 10.1038/sj.onc.1204640; Kvaloy K, 2001, MUTAT RES-DNA REPAIR, V461, P325, DOI 10.1016/S0921-8777(00)00063-X; Lindahl T, 2000, MUTAT RES-REV MUTAT, V462, P129, DOI 10.1016/S1383-5742(00)00024-7; Martin A, 2002, P NATL ACAD SCI USA, V99, P12304, DOI 10.1073/pnas.192442899; MCDONALD JP, 2003, IN PRESS J EXP MED; Millar CB, 2002, SCIENCE, V297, P403, DOI 10.1126/science.1073354; Minowa O, 2000, P NATL ACAD SCI USA, V97, P4156, DOI 10.1073/pnas.050404497; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Nilsen H, 2000, MOL CELL, V5, P1059, DOI 10.1016/S1097-2765(00)80271-3; Nilsen H, 2001, EMBO J, V20, P4278, DOI 10.1093/emboj/20.15.4278; Ocampo MTA, 2002, MOL CELL BIOL, V22, P6111, DOI 10.1128/MCB.22.17.6111-6121.2002; Otterlei M, 1999, EMBO J, V18, P3834, DOI 10.1093/emboj/18.13.3834; Pasqualucci L, 2001, NATURE, V412, P341, DOI 10.1038/35085588; Peters A, 1996, IMMUNITY, V4, P57, DOI 10.1016/S1074-7613(00)80298-8; Petersen-Mahrt SK, 2002, NATURE, V418, P99, DOI 10.1038/nature00862; Rada C, 2002, CURR BIOL, V12, P1748, DOI 10.1016/S0960-9822(02)01215-0; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; Sakumi K, 2003, CANCER RES, V63, P902; Scharer OD, 2001, BIOESSAYS, V23, P270, DOI 10.1002/1521-1878(200103)23:3<270::AID-BIES1037>3.0.CO;2-J; Sieber OM, 2003, NEW ENGL J MED, V348, P791, DOI 10.1056/NEJMoa025283; Stevenson FK, 2001, ADV CANCER RES, V83, P81, DOI 10.1016/S0065-230X(01)83004-9; Takao M, 2002, EMBO J, V21, P3486, DOI 10.1093/emboj/cdf350; VERRI A, 1990, NUCLEIC ACIDS RES, V18, P5775, DOI 10.1093/nar/18.19.5775; Wong E, 2002, P NATL ACAD SCI USA, V99, P14937, DOI 10.1073/pnas.232579299; Wright BE, 2002, CANCER RES, V62, P5641	35	122	125	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2003	22	35					5381	5386		10.1038/sj.onc.1206860	http://dx.doi.org/10.1038/sj.onc.1206860			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JC	12934097				2022-12-25	WOS:000184735000002
J	Bianchi, V; Spychala, J				Bianchi, V; Spychala, J			Mammalian 5 '-nucleotidases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							CYTOSOLIC 5'-NUCLEOTIDASE; PYRIMIDINE 5'-NUCLEOTIDASE; ADENOSINE FORMATION; ESCHERICHIA-COLI; 5-NUCLEOTIDASE; CLONING; IMP; OVEREXPRESSION; CELLS; 5'(3')-DEOXYRIBONUCLEOTIDASE		Univ Padua, Dept Biol, I-35131 Padua, Italy; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of Padua; University of North Carolina; University of North Carolina Chapel Hill	Bianchi, V (corresponding author), Univ Padua, Dept Biol, I-35131 Padua, Italy.	vbianchi@mail.bio.unipd.it			NCI NIH HHS [R01 CA 34085] Funding Source: Medline; Telethon [GP0140Y01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA034085] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Telethon(Fondazione Telethon); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allegrin S, 2001, J BIOL CHEM, V276, P33526, DOI 10.1074/jbc.M104088200; Amici A, 2000, BLOOD, V96, P1596, DOI 10.1182/blood.V96.4.1596.h8001596_1596_1598; Amici A, 1997, FEBS LETT, V419, P263, DOI 10.1016/S0014-5793(97)01464-6; CARSON DA, 1991, BIOCHIM BIOPHYS ACTA, V1091, P22, DOI 10.1016/0167-4889(91)90216-K; Gallinaro L, 2002, J BIOL CHEM, V277, P35080, DOI 10.1074/jbc.M203755200; Galmarini CM, 2003, BRIT J HAEMATOL, V122, P53, DOI 10.1046/j.1365-2141.2003.04386.x; Galmarini CM, 2001, LEUKEMIA, V15, P875, DOI 10.1038/sj.leu.2402114; Garvey EP, 1998, BIOCHEMISTRY-US, V37, P9043, DOI 10.1021/bi980209d; Gazziola C, 2001, J BIOL CHEM, V276, P6185, DOI 10.1074/jbc.M007623200; Gazziola C, 1999, EXP CELL RES, V253, P474, DOI 10.1006/excr.1999.4681; Hansen KR, 1995, GENE, V167, P307, DOI 10.1016/0378-1119(95)00574-9; HOGLUND L, 1990, J BIOL CHEM, V265, P6589; Hunsucker SA, 2001, J BIOL CHEM, V276, P10498, DOI 10.1074/jbc.M011218200; ITOH R, 1993, COMP BIOCHEM PHYS B, V105, P13, DOI 10.1016/0305-0491(93)90163-Y; JOHNSON MA, 1989, MOL PHARMACOL, V36, P291; KELLER PM, 1985, J BIOL CHEM, V260, P8664; Knofel T, 1999, NAT STRUCT BIOL, V6, P448; Knofel T, 2001, J MOL BIOL, V309, P239, DOI 10.1006/jmbi.2001.4656; Lahiri SD, 2003, SCIENCE, V299, P2067, DOI 10.1126/science.1082710; LEWIS W, 1995, NAT MED, V1, P417, DOI 10.1038/nm0595-417; Marinaki AM, 2001, BLOOD, V97, P3327, DOI 10.1182/blood.V97.11.3327; Mazzon C, 2003, BIOCHEM PHARMACOL, V66, P471, DOI 10.1016/S0006-2952(03)00290-9; MISUMI Y, 1990, EUR J BIOCHEM, V191, P563, DOI 10.1111/j.1432-1033.1990.tb19158.x; OKA J, 1994, BIOCHEM BIOPH RES CO, V205, P917, DOI 10.1006/bbrc.1994.2752; PESI R, 1994, ARCH BIOCHEM BIOPHYS, V312, P75, DOI 10.1006/abbi.1994.1282; PIEC G, 1991, BIOCHEM J, V273, P409, DOI 10.1042/bj2730409; Rampazzo C, 2000, J BIOL CHEM, V275, P5409, DOI 10.1074/jbc.275.8.5409; Rampazzo C, 2002, BIOCHEM BIOPH RES CO, V293, P258, DOI 10.1016/S0006-291X(02)00206-1; Rampazzo C, 2000, P NATL ACAD SCI USA, V97, P8239, DOI 10.1073/pnas.97.15.8239; Rampazzo C, 1999, EUR J BIOCHEM, V261, P689, DOI 10.1046/j.1432-1327.1999.00320.x; Rees DC, 2003, BRIT J HAEMATOL, V120, P375, DOI 10.1046/j.1365-2141.2003.03980.x; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; Resta R, 1998, IMMUNOL REV, V161, P95, DOI 10.1111/j.1600-065X.1998.tb01574.x; Rinaldo-Matthis A, 2002, NAT STRUCT BIOL, V9, P779, DOI 10.1038/nsb846; Sala-Newby GB, 1999, J BIOL CHEM, V274, P17789, DOI 10.1074/jbc.274.25.17789; Sala-Newby GB, 2003, AM J PHYSIOL-HEART C, V285, pH991, DOI 10.1152/ajpheart.00053.2003; Sala-Newby GB, 2001, BBA-GENE STRUCT EXPR, V1521, P12, DOI 10.1016/S0167-4781(01)00278-0; Sala-Newby GB, 2000, J BIOL CHEM, V275, P11666, DOI 10.1074/jbc.275.16.11666; SKLADANOWSKI AC, 1989, BIOCHEM J, V262, P203, DOI 10.1042/bj2620203; Spychala J, 1999, J BIOL CHEM, V274, P22705, DOI 10.1074/jbc.274.32.22705; Spychala J, 1999, EUR J BIOCHEM, V259, P851, DOI 10.1046/j.1432-1327.1999.00099.x; Spychala J, 2000, PHARMACOL THERAPEUT, V87, P161, DOI 10.1016/S0163-7258(00)00053-X; SPYCHALA J, 1988, J BIOL CHEM, V263, P18759; WORKU Y, 1982, BIOCHEM J, V205, P503, DOI 10.1042/bj2050503; Yegutkin GG, 2002, BIOCHEM J, V367, P121, DOI 10.1042/BJ20020439; ZIMMERMANN H, 1992, BIOCHEM J, V285, P345, DOI 10.1042/bj2850345	46	175	177	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46195	46198		10.1074/jbc.R300032200	http://dx.doi.org/10.1074/jbc.R300032200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12947102	hybrid, Green Published			2022-12-25	WOS:000186569400001
J	Harper, N; Hughes, MA; Farrow, SN; Cohen, GM; MacFarlane, M				Harper, N; Hughes, MA; Farrow, SN; Cohen, GM; MacFarlane, M			Protein kinase C modulates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by targeting the apical events of death receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TRAIL-INDUCED APOPTOSIS; FAS-MEDIATED APOPTOSIS; P55 TNF RECEPTOR; CYTOCHROME-C; HUMAN-MELANOMA; CD95-MEDIATED APOPTOSIS; MITOCHONDRIAL RELEASE; DOWN-REGULATION; CD95 FAS/APO-1	We have further examined the mechanism by which phorbol ester-mediated protein kinase C (PKC) activation protects against tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced cytotoxicity. We now report that activation of PKC targets death receptor signaling complex formation. Pre-treatment with 12-O-tetradecanoylphorbol-13-acetate (PMA) led to inhibition of TRAIL-induced apoptosis in HeLa cells, which was characterized by a reduction in phosphatidylserine (PS) externalization, decreased caspase-8 processing, and incomplete maturation and activation of caspase-3. These effects of PMA were completely abrogated by the PKC inhibitor, bisindolylmaleimide I (Bis I), clearly implicating PKC in the protective effect of PMA. TRAIL-induced mitochondrial release of the apoptosis mediators cytochrome c and Smac was blocked by PMA. This, together with the observed decrease in Bid cleavage, suggested that PKC activation modulates apical events in TRAIL signaling upstream of mitochondria. This was confirmed by analysis of TRAIL death-inducing signaling complex formation, which was disrupted in PMA-treated cells as evidenced by a marked reduction in Fas-associated death domain protein (FADD) recruitment, an effect that could not be explained by any change in FADD phosphorylation state. In an in vitro binding assay, the intracellular domains of both TRAIL-R1 and TRAIL-R2 bound FADD: activation of PKC significantly inhibited this interaction suggesting that PKC may be targeting key apical components of death receptor signaling. Significantly, this effect was not confined to TRAIL, because isolation of the native TNF receptor signaling complex revealed that PKC activation also inhibited TNF receptor-associated death domain protein recruitment to TNF-R1 and TNF-induced phosphorylation of IkappaB-alpha. Taken together, these results show that PKC activation specifically inhibits the recruitment of key obligatory death domain-containing adaptor proteins to their respective membrane-associated signaling complexes, thereby modulating TRAIL-induced apoptosis and TNF-induced NF-kappaB activation, respectively.	Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England; Glaxo SmithKline Med Res Ctr, Stevenage SG1 2NY, Herts, England	University of Leicester; GlaxoSmithKline	MacFarlane, M (corresponding author), Univ Leicester, MRC, Toxicol Unit, Hodgkin Bldg,POB 138,Lancaster Rd, Leicester LE1 9HN, Leics, England.	mm21@le.ac.uk	Cohen, Gerald M/A-1687-2008					AGGARWAL BB, 1987, J BIOL CHEM, V262, P16450; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; BOLDIN MP, 1995, FEBS LETT, V367, P39, DOI 10.1016/0014-5793(95)00534-G; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chen GQ, 2002, MOL CELL, V9, P401, DOI 10.1016/S1097-2765(02)00450-1; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Ekert PG, 2001, J CELL BIOL, V152, P483, DOI 10.1083/jcb.152.3.483; Frankel SK, 2001, BIOCHEM BIOPH RES CO, V288, P313, DOI 10.1006/bbrc.2001.5761; Gomez-Angelats M, 2000, J BIOL CHEM, V275, P19609, DOI 10.1074/jbc.M909563199; Gomez-Angelats M, 2001, J BIOL CHEM, V276, P44944, DOI 10.1074/jbc.M104919200; Griffith TS, 1998, J IMMUNOL, V161, P2833; Griffith TS, 1999, J IMMUNOL, V162, P2597; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Harper N, 2001, J BIOL CHEM, V276, P34743, DOI 10.1074/jbc.M105693200; Harper N, 2003, J BIOL CHEM, V278, P25534, DOI 10.1074/jbc.M303399200; HAVELL EA, 1988, J EXP MED, V167, P1067, DOI 10.1084/jem.167.3.1067; Holmstrom TH, 1999, MOL CELL BIOL, V19, P5991; Holmstrom TH, 2000, EMBO J, V19, P5418, DOI 10.1093/emboj/19.20.5418; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hu WH, 1999, J BIOL CHEM, V274, P30603, DOI 10.1074/jbc.274.43.30603; Jeremias I, 1998, BLOOD, V91, P4624, DOI 10.1182/blood.V91.12.4624.412k19_4624_4631; Juo P, 1999, CELL GROWTH DIFFER, V10, P797; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kennedy NJ, 1998, J IMMUNOL, V160, P4881; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Leverkus M, 2000, CANCER RES, V60, P553; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li SC, 2002, J BIOL CHEM, V277, P26912, DOI 10.1074/jbc.M200726200; Li Y, 2000, INT J CANCER, V87, P473, DOI 10.1002/1097-0215(20000815)87:4<473::AID-IJC3>3.0.CO;2-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; MacFarlane M, 2002, ONCOGENE, V21, P6809, DOI 10.1038/sj.onc.1205853; MacFarlane M, 2000, BIOCHEM J, V348, P93, DOI 10.1042/0264-6021:3480093; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; McFarlane SM, 2002, FEBS LETT, V515, P119, DOI 10.1016/S0014-5793(02)02450-X; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Meng XW, 2002, J BIOL CHEM, V277, P3776, DOI 10.1074/jbc.M107218200; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Roth W, 1999, BIOCHEM BIOPH RES CO, V265, P479, DOI 10.1006/bbrc.1999.1693; Ruiz-Ruiz C, 1999, J IMMUNOL, V163, P4737; Ryu SW, 2003, J BIOL CHEM, V278, P24003, DOI 10.1074/jbc.M302200200; Sarker M, 2002, ONCOGENE, V21, P4323, DOI 10.1038/sj.onc.1205523; Sarker M, 2001, CELL DEATH DIFFER, V8, P172, DOI 10.1038/sj.cdd.4400791; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Scaffidi C, 2000, J IMMUNOL, V164, P1236, DOI 10.4049/jimmunol.164.3.1236; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Sun XM, 2002, J BIOL CHEM, V277, P11345, DOI 10.1074/jbc.M109893200; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200; UNGLAUB R, 1987, J EXP MED, V166, P1788, DOI 10.1084/jem.166.6.1788; Varadhachary AS, 2001, J IMMUNOL, V166, P6564, DOI 10.4049/jimmunol.166.11.6564; Vassilev A, 1999, J BIOL CHEM, V274, P1646, DOI 10.1074/jbc.274.3.1646; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Willems F, 2000, BLOOD, V95, P3478, DOI 10.1182/blood.V95.11.3478.011k10_3478_3482; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1; Zhang XD, 2000, J IMMUNOL, V164, P3961, DOI 10.4049/jimmunol.164.8.3961; Zhang XD, 1999, CANCER RES, V59, P2747; Zhang XD, 2001, CANCER RES, V61, P7339; Zhou T, 1999, NAT MED, V5, P42, DOI 10.1038/4723	82	81	86	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44338	44347		10.1074/jbc.M307376200	http://dx.doi.org/10.1074/jbc.M307376200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12920112	hybrid			2022-12-25	WOS:000186306700057
J	Malli, R; Frieden, M; Osibow, K; Zoratti, C; Mayer, M; Demaurex, N; Graier, WF				Malli, R; Frieden, M; Osibow, K; Zoratti, C; Mayer, M; Demaurex, N; Graier, WF			Sustained Ca2+ transfer across mitochondria is essential for mitochondrial Ca2+ buffering, store-operated Ca2+ entry, and Ca2+ store refilling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; VASCULAR ENDOTHELIAL-CELLS; GREEN FLUORESCENT PROTEINS; ACTIVATED CALCIUM CURRENT; ENDOPLASMIC-RETICULUM; INTACT-CELLS; FEEDBACK INHIBITION; PLASMA-MEMBRANE; T-LYMPHOCYTES; HOMEOSTASIS	Mitochondria have been found to sequester and release Ca2+ during cell stimulation with inositol 1,4,5-triphosphate-generating agonists, thereby generating subplasmalemmal microdomains of low Ca2+ that sustain activity of capacitative Ca2+ entry (CCE). Procedures that prevent mitochondrial Ca2+ uptake inhibit local Ca2+ buffering and CCE, but it is not clear whether Ca2+ has to transit through or remains trapped in the mitochondria. Thus, we analyzed the contribution of mitochondrial Ca2+ efflux on the ability of mitochondria to buffer subplasmalemmal Ca2+, to maintain CCE, and to facilitate endoplasmic reticulum (ER) refilling in endothelial cells. Upon the addition of histamine, the initial mitochondrial Ca2+ transient, monitored with ratio-metric-pericam-mitochondria, was largely independent of extracellular Ca2+. However, subsequent removal of extracellular Ca2+ produced a reversible decrease in [Ca2+](mito), indicating that Ca2+ was continuously taken up and released by mitochondria, although [Ca2+](mito) had returned to basal levels. Accordingly, inhibition of the mitochondrial Na+/Ca2+ exchanger with CGP 37157 increased [Ca2+](mito) and abolished the ability of mitochondria to buffer subplasmalemmal Ca2+, resulting in an increased activity of BKCa channels and a decrease in CCE. Hence, CGP 37157 also reversibly inhibited ER refilling during cell stimulation. These effects of CGP 37157 were mimicked if mitochondrial Ca2+ uptake was prevented with oligomycin/antimycin A. Thus, during cell stimulation a continuous Ca2+ flux through mitochondria underlies the ability of mitochondria to generate subplasmalemmal microdomains of low Ca2+, to facilitate CCE, and to relay Ca2+ from the plasma membrane to the ER.	Graz Univ, Dept Med Biochem & Med Mol Biol, A-8010 Graz, Austria; Univ Geneva, Dept Physiol, CH-1211 Geneva 4, Switzerland	University of Graz; University of Geneva	Graier, WF (corresponding author), Graz Univ, Dept Med Biochem & Med Mol Biol, Harrachgasse 21-3, A-8010 Graz, Austria.		Malli, Roland/B-7369-2008; Graier, Wolfgang F./B-7052-2008	Graier, Wolfgang F./0000-0003-1871-3298; Malli, Roland/0000-0001-6327-8729; Demaurex, Nicolas/0000-0002-9933-6772; Osibow, Karin/0000-0002-9703-595X; Frieden, Maud/0000-0001-7135-0874				Arnaudeau S, 2001, J BIOL CHEM, V276, P29430, DOI 10.1074/jbc.M103274200; Babcock DF, 1998, CURR OPIN NEUROBIOL, V8, P398, DOI 10.1016/S0959-4388(98)80067-6; Babcock DF, 1997, J CELL BIOL, V136, P833, DOI 10.1083/jcb.136.4.833; Bowser DN, 2002, FASEB J, V16, P1105, DOI 10.1096/fj.01-0828fje; Broad LM, 1999, J BIOL CHEM, V274, P32881, DOI 10.1074/jbc.274.46.32881; Collins TJ, 2001, J BIOL CHEM, V276, P26411, DOI 10.1074/jbc.M101101200; COX DA, 1993, J CARDIOVASC PHARM, V21, P595, DOI 10.1097/00005344-199304000-00013; Duchen MR, 2000, CELL CALCIUM, V28, P339, DOI 10.1054/ceca.2000.0170; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; Encabo A, 1996, BRIT J PHARMACOL, V119, P702, DOI 10.1111/j.1476-5381.1996.tb15729.x; Frieden M, 2002, J PHYSIOL-LONDON, V540, P73, DOI 10.1113/jphysiol.2002.017053; Gilabert JA, 2000, EMBO J, V19, P6401, DOI 10.1093/emboj/19.23.6401; Gilabert JA, 2001, EMBO J, V20, P2672, DOI 10.1093/emboj/20.11.2672; Glitsch MD, 2002, J PHYSIOL-LONDON, V539, P93, DOI 10.1113/jphysiol.2001.012826; Glitsch MD, 2002, EMBO J, V21, P6744, DOI 10.1093/emboj/cdf675; Hofer AM, 1998, EMBO J, V17, P1986, DOI 10.1093/emboj/17.7.1986; Hoth M, 1997, J CELL BIOL, V137, P633, DOI 10.1083/jcb.137.3.633; Hoth M, 2000, P NATL ACAD SCI USA, V97, P10607, DOI 10.1073/pnas.180143997; Johnson PR, 2002, CELL CALCIUM, V32, P59, DOI 10.1016/S0143-4160(02)00091-X; JOUAVILLE LS, 1995, NATURE, V377, P438, DOI 10.1038/377438a0; Landolfi B, 1998, J CELL BIOL, V142, P1235, DOI 10.1083/jcb.142.5.1235; Ma HT, 2001, J BIOL CHEM, V276, P18888, DOI 10.1074/jbc.M100944200; Malli R, 2003, J BIOL CHEM, V278, P10807, DOI 10.1074/jbc.M212971200; Miyawaki A, 1999, P NATL ACAD SCI USA, V96, P2135, DOI 10.1073/pnas.96.5.2135; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Nagai T, 2001, P NATL ACAD SCI USA, V98, P3197, DOI 10.1073/pnas.051636098; Pacher P, 2001, BIOL SIGNAL RECEPT, V10, P200; Parekh AB, 1998, J BIOL CHEM, V273, P14925, DOI 10.1074/jbc.273.24.14925; Parekh AB, 2003, J PHYSIOL-LONDON, V547, P333, DOI 10.1113/jphysiol.2002.034140; Park KS, 2002, PFLUG ARCH EUR J PHY, V443, P344, DOI 10.1007/s004240100703; Petersen OH, 2002, BIOL RES, V35, P177, DOI 10.4067/S0716-97602002000200008; Pozzan T, 2000, CELL CALCIUM, V28, P279, DOI 10.1054/ceca.2000.0166; Putney J W Jr, 1991, Adv Pharmacol, V22, P251, DOI 10.1016/S1054-3589(08)60037-X; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Putney JW, 2001, J CELL SCI, V114, P2223; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1994, J CELL BIOL, V126, P1183, DOI 10.1083/jcb.126.5.1183; Rizzuto R, 1999, CELL CALCIUM, V26, P193, DOI 10.1054/ceca.1999.0076; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; Rizzuto R, 2000, J PHYSIOL-LONDON, V529, P37, DOI 10.1111/j.1469-7793.2000.00037.x; Robert V, 2001, EMBO J, V20, P4998, DOI 10.1093/emboj/20.17.4998; SCHILLING WP, 1992, BIOCHEM J, V284, P521, DOI 10.1042/bj2840521; Sedova M, 2000, J BIOL CHEM, V275, P35402, DOI 10.1074/jbc.M006058200; Szabadkai G, 2003, J BIOL CHEM, V278, P15153, DOI 10.1074/jbc.M300180200; Thyagarajan B, 2002, BRIT J PHARMACOL, V137, P821, DOI 10.1038/sj.bjp.0704949; Tinel H, 1999, EMBO J, V18, P4999, DOI 10.1093/emboj/18.18.4999; Yu R, 2000, J BIOL CHEM, V275, P23648, DOI 10.1074/jbc.M002684200	47	147	152	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44769	44779		10.1074/jbc.M302511200	http://dx.doi.org/10.1074/jbc.M302511200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12941956	Green Published, hybrid			2022-12-25	WOS:000186306700111
J	Sachs, RK; Halverson, KM; Barry, BA				Sachs, RK; Halverson, KM; Barry, BA			Specific isotopic labeling and photooxidation-linked structural changes in the manganese-stabilizing subunit of photosystem II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN-EVOLVING COMPLEX; DIFFERENCE FT-IR; S-STATE CYCLE; ELECTRON-PARAMAGNETIC-RES; WATER-OXIDIZING COMPLEX; KDA EXTRINSIC PROTEIN; AMINO-ACID-SEQUENCES; ESCHERICHIA-COLI; SECONDARY STRUCTURE; 33-KDA POLYPEPTIDE	Photosystem II (PSII) oxidizes water to molecular oxygen; the catalytic site is a cluster of four manganese ions. The catalytic site undergoes four sequential light-driven oxidation steps to form oxygen; these sequentially oxidized states are referred to as the S-n states, where n refers to the number of oxidizing equivalents stored. The extrinsic manganese stabilizing protein (MSP) of PSII influences the efficiency and stability of the manganese cluster, as well as the rates of the S state transitions. To understand how MSP influences photosynthetic water oxidation, we have employed isotope editing and difference Fourier transform infrared spectroscopy. MSP was expressed in Escherichia coli under conditions in which MSP aspartic and glutamic acid residues label at yields of 65 and 41%, respectively. Asparagine and glutamine were also labeled by this approach. GC/MS analysis was consistent with minimal scrambling of label into other amino acid residues and with no significant scrambling into the peptide bond. Selectively labeled MSP was then reconstituted to PSII, which had been stripped of native MSP. Difference Fourier transform infrared spectroscopy was used to probe the S(1)Q(A) to S(2)Q(A)(-) transition at 200 K, as well as the S(1)Q(B) to S(2)Q(B)(-) transition at 277 K. These experiments show that aspargine, glutamine, and glutamate residues in MSP are perturbed by photooxidation of manganese during the S-1 to S-2 transition.	Univ Minnesota, Dept Biochem Mol Biol & Biophys, St Paul, MN 55108 USA; Colorado Coll, Dept Chem, Colorado Springs, CO 80903 USA; Messiah Coll, Dept Chem & Biochem, Grantham, PA 17027 USA	University of Minnesota System; University of Minnesota Twin Cities; Colorado College	Barry, BA (corresponding author), Georgia Inst Technol, Sch Chem & Biochem, Atlanta, GA 30332 USA.	barry@cbs.umn.edu						AHMED A, 1995, FEBS LETT, V363, P65, DOI 10.1016/0014-5793(95)00282-E; Anderson LB, 2000, J BIOL CHEM, V275, P4920, DOI 10.1074/jbc.275.7.4920; ARNSTEIN HRV, 1978, INT REV BIOCH, V18; BARRY BA, 1995, METHOD ENZYMOL, V258, P303; Barry BA, 2000, PHOTOSYNTH RES, V65, P197, DOI 10.1023/A:1006466531431; BERTHOLD DA, 1981, FEBS LETT, V134, P231, DOI 10.1016/0014-5793(81)80608-4; Betts SD, 1996, BBA-BIOENERGETICS, V1274, P135, DOI 10.1016/0005-2728(96)00023-0; Betts SD, 1998, BIOCHEMISTRY-US, V37, P14230, DOI 10.1021/bi981305h; BETTS SD, 1994, PLANT MOL BIOL, V26, P117, DOI 10.1007/BF00039525; Bricker TM, 2002, PHOTOSYNTH RES, V72, P131, DOI 10.1023/A:1016128715865; BRICKER TM, 1992, BIOCHEMISTRY-US, V31, P4623, DOI 10.1021/bi00134a012; Bricker TM, 1998, PHOTOSYNTH RES, V56, P157, DOI 10.1023/A:1006068615220; BRITT RD, 1996, OXYGENIC PHOTOSYNTHE, V4, P137; De Las Rivas J, 1999, PHOTOSYNTH RES, V61, P11, DOI 10.1023/A:1006265816104; DEPAULA JC, 1985, BIOCHEMISTRY-US, V24, P8114, DOI 10.1021/bi00348a042; DISMUKES GC, 1981, P NATL ACAD SCI-BIOL, V78, P274, DOI 10.1073/pnas.78.1.274; EATONRYE JJ, 1989, BIOCHIM BIOPHYS ACTA, V977, P219, DOI 10.1016/S0005-2728(89)80075-1; Enami I, 1998, J BIOL CHEM, V273, P4629, DOI 10.1074/jbc.273.8.4629; FARINEAU J, 1985, BIOCHIM BIOPHYS ACTA, V808, P103, DOI 10.1016/0005-2728(85)90032-5; Frankel LK, 1999, BIOCHEMISTRY-US, V38, P14271, DOI 10.1021/bi991366v; GRIFFEY RH, 1985, BIOCHEMISTRY-US, V24, P817, DOI 10.1021/bi00325a001; Halverson KM, 2003, BIOPHYS J, V85, P2581, DOI 10.1016/S0006-3495(03)74680-3; Halverson KM, 2003, BIOPHYS J, V85, P1317, DOI 10.1016/S0006-3495(03)74566-4; Hillier W, 2001, BIOCHEMISTRY-US, V40, P1503, DOI 10.1021/bi002436x; Hutchison RS, 1998, BIOCHEMISTRY-US, V37, P5643, DOI 10.1021/bi9724467; Hutchison RS, 1999, J BIOL CHEM, V274, P31987, DOI 10.1074/jbc.274.45.31987; Joliot P., 1975, BIOENERG PHOTOSYNTH, P388; Kamiya N, 2003, P NATL ACAD SCI USA, V100, P98, DOI 10.1073/pnas.0135651100; Kim SY, 1998, BIOPHYS J, V74, P2588, DOI 10.1016/S0006-3495(98)77965-2; Kitson F. G., 1996, GAS CHROMATOGRAPHY M, P3; KRIMM S, 1986, ADV PROTEIN CHEM, V38, P181, DOI 10.1016/S0065-3233(08)60528-8; Lydakis-Simantiris N, 1999, BIOCHEMISTRY-US, V38, P404, DOI 10.1021/bi981847z; Lydakis-Simantiris N, 1999, BIOCHEMISTRY-US, V38, P15528, DOI 10.1021/bi991599m; MACDONALD GM, 1995, J BIOL CHEM, V270, P8420, DOI 10.1074/jbc.270.15.8420; MACDONALD GM, 1992, BIOCHEMISTRY-US, V31, P9848, DOI 10.1021/bi00155a043; MACDONALD GM, 1993, P NATL ACAD SCI USA, V90, P11024, DOI 10.1073/pnas.90.23.11024; MIYAO M, 1983, FEBS LETT, V164, P375, DOI 10.1016/0014-5793(83)80320-2; MIYAO M, 1984, FEBS LETT, V170, P350, DOI 10.1016/0014-5793(84)81342-3; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; NANBA O, 1987, P NATL ACAD SCI USA, V84, P109, DOI 10.1073/pnas.84.1.109; Noguchi T, 2003, BIOCHEMISTRY-US, V42, P6035, DOI 10.1021/bi0341612; Noguchi T, 2001, BIOCHEMISTRY-US, V40, P1497, DOI 10.1021/bi0023807; NOGUCHI T, 1995, BIOCHIM BIOPHYS ACTA, V1232, P65; ODOM WR, 1992, BIOCHEMISTRY-US, V31, P5616, DOI 10.1021/bi00139a027; OETTMEIER W, 1983, BIOCHIM BIOPHYS ACTA, V724, P287, DOI 10.1016/0005-2728(83)90147-0; OHOKA H, 1986, FEBS LETT, V197, P63, DOI 10.1016/0014-5793(86)80299-X; ONO TA, 1983, FEBS LETT, V164, P255, DOI 10.1016/0014-5793(83)80297-X; PATTERSON BW, 1993, BIOL MASS SPECTROM, V22, P518, DOI 10.1002/bms.1200220905; Pazos F, 2001, PROTEINS, V45, P372, DOI 10.1002/prot.10012; Popelkova H, 2003, PHOTOSYNTH RES, V77, P21, DOI 10.1023/A:1024970926655; Popelkova H, 2003, BIOCHEMISTRY-US, V42, P6193, DOI 10.1021/bi0207115; Popelkova H, 2002, BIOCHEMISTRY-US, V41, P2702, DOI 10.1021/bi0118761; Popelkova H, 2002, BIOCHEMISTRY-US, V41, P10038, DOI 10.1021/bi020228u; RAMESH V, 1994, EUR J BIOCHEM, V225, P601, DOI 10.1111/j.1432-1033.1994.00601.x; Ramirez FJ, 1998, J PHYS CHEM B, V102, P6290, DOI 10.1021/jp981831i; Roelofs TA, 1996, P NATL ACAD SCI USA, V93, P3335, DOI 10.1073/pnas.93.8.3335; SEIDLER A, 1990, EMBO J, V9, P1743, DOI 10.1002/j.1460-2075.1990.tb08298.x; Seidler A, 1996, BBA-BIOENERGETICS, V1277, P35, DOI 10.1016/S0005-2728(96)00102-8; Shutova T, 1997, BIOCHEMISTRY-US, V36, P6350, DOI 10.1021/bi963115h; Steenhuis JJ, 1996, J AM CHEM SOC, V118, P11927, DOI 10.1021/ja961691v; Steenhuis JJ, 1999, J BIOL CHEM, V274, P14609, DOI 10.1074/jbc.274.21.14609; Steenhuis JJ, 1998, J PHYS CHEM B, V102, P4, DOI 10.1021/jp9730609; Steenhuis JJ, 1997, J PHYS CHEM B, V101, P6652, DOI 10.1021/jp971260e; STYRING S, 1988, BIOCHIM BIOPHYS ACTA, V933, P378, DOI 10.1016/0005-2728(88)90046-1; Svensson B, 2002, J PHYS CHEM B, V106, P8485, DOI 10.1021/jp0258199; Tohri A, 2002, PLANT CELL PHYSIOL, V43, P429, DOI 10.1093/pcp/pcf053; Waugh DS, 1996, J BIOMOL NMR, V8, P184; WILSON NA, 1995, BIOCHEMISTRY-US, V34, P8931, DOI 10.1021/bi00028a001; XU Q, 1994, BBA-BIOENERGETICS, V1188, P427, DOI 10.1016/0005-2728(94)90065-5; Zhang HM, 1998, BIOCHEMISTRY-US, V37, P5511, DOI 10.1021/bi971787h; Zouni A, 2001, NATURE, V409, P739, DOI 10.1038/35055589; Zubrzycki IZ, 1998, BIOCHEMISTRY-US, V37, P13553, DOI 10.1021/bi981469y	72	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44222	44229		10.1074/jbc.M307148200	http://dx.doi.org/10.1074/jbc.M307148200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12941934	hybrid			2022-12-25	WOS:000186306700042
J	Cherian, PP; Cheng, BX; Gu, SM; Sprague, E; Bonewald, LF; Jiang, JX				Cherian, PP; Cheng, BX; Gu, SM; Sprague, E; Bonewald, LF; Jiang, JX			Effects of mechanical strain on the function of gap junctions in osteocytes are mediated through the prostaglandin EP2 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPRESSION; FETAL-RAT CALVARIAE; CYCLIC-AMP; INTERCELLULAR COMMUNICATION; FLUID-FLOW; BONE-CELLS; PROSTANOID RECEPTORS; OSTEOCLAST FORMATION; SMOOTH-MUSCLE; PROTEIN	Osteocytes embedded in the matrix of bone are thought to be mechanosensory cells that translate mechanical strain into biochemical signals that regulate bone modeling and remodeling. We have shown previously that fluid flow shear stress dramatically induces prostaglandin release and COX-2 mRNA expression in osteocyte-like MLO-Y4 cells, and that prostaglandin E-2 (PGE(2)) released by these cells functions in an autocrine manner to regulate gap junction function and connexin 43 (Cx43) expression. Here we show that fluid flow regulates gap junctions through the PGE(2) receptor EP2 activation of cAMP-dependent protein kinase A (PKA) signaling. The expression of the EP2 receptor, but not the subtypes EP1, EP3, and EP4, increased in response to fluid flow. Application of PGE(2) or conditioned medium from fluid flow-treated cells to non-stressed MLO-Y4 cells increased expression of the EP2 receptor. The EP2 receptor antagonist, AH6809, suppressed the stimulatory effects of PGE(2) and fluid flow-conditioned medium on the expression of the EP2 receptor, on Cx43 protein expression, and on gap junction-mediated intercellular coupling. In contrast, the EP2 receptor agonist butaprost, not the E-1/E-3 receptor agonist sulprostone, stimulated the expression of Cx43 and gap junction function. Fluid flow conditioned medium and PGE(2) stimulated cAMP production and PKA activity suggesting that PGE(2) released by mechanically stimulated cells is responsible for the activation of cAMP and PKA. The adenylate cyclase activators, forskolin and 8-bromo-cAMP, enhanced intercellular connectivity, the number of functional gap junctions, and Cx43 protein expression, whereas the PKA inhibitor, H89, inhibited the stimulatory effect of PGE(2) on gap junctions. These studies suggest that the EP2 receptor mediates the effects of autocrine PGE(2) on the osteocyte gap junction in response to fluid flow-induced shear stress. These data support the hypothesis that the EP2 receptor, cAMP, and PKA are critical components of the signaling cascade between mechanical strain and gap junction-mediated communication between osteocytes.	Univ Texas, Hlth Sci Ctr, Dept Biochem, MSC 7760, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Radiol, San Antonio, TX 78229 USA; Univ Missouri, Sch Dent, Dept Oral Biol, Kansas City, MO 64108 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Missouri System; University of Missouri Kansas City	Jiang, JX (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, MSC 7760, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	jiangj@uthscsa.edu	Bonewald, Lynda/Q-3638-2019	Jiang, Jean/0000-0002-2185-5716	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR046798] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR46798] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ajubi NE, 1996, BIOCHEM BIOPH RES CO, V225, P62, DOI 10.1006/bbrc.1996.1131; ATKINSON MM, 1995, J CELL SCI, V108, P3079; AZARNIA R, 1981, J MEMBRANE BIOL, V63, P133, DOI 10.1007/BF01969454; BASTIEN L, 1994, J BIOL CHEM, V269, P11873; Baylink TM, 1996, J BONE MINER RES, V11, P1413; BENNETT MVL, 1978, NEUROSCI RES PROG B, V16, P377; BEYER EC, 1987, J CELL BIOL, V105, P2621, DOI 10.1083/jcb.105.6.2621; BEYER EC, 1988, GAP JUNCTIONS, P167; Boie Y, 1997, EUR J PHARMACOL, V340, P227, DOI 10.1016/S0014-2999(97)01383-6; Bonewald LF, 2000, J BONE MINER RES, V15, pS502; Breyer RM, 2001, ANNU REV PHARMACOL, V41, P661, DOI 10.1146/annurev.pharmtox.41.1.661; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; Cass LA, 1999, MOL CELL BIOL, V19, P5882; Cheng BX, 2001, ENDOCRINOLOGY, V142, P3464, DOI 10.1210/en.142.8.3464; Cheng BX, 2001, J BONE MINER RES, V16, P249, DOI 10.1359/jbmr.2001.16.2.249; Civitelli R, 1998, J CELL BIOCHEM, V68, P8, DOI 10.1002/(SICI)1097-4644(19980101)68:1<8::AID-JCB2>3.0.CO;2-#; COLEMAN RA, 1989, BRIT J PHARMACOL, V96, P688, DOI 10.1111/j.1476-5381.1989.tb11869.x; COLLINS DA, 1992, J BONE MINER RES, V7, P555; COLLINS DA, 1991, J BONE MINER RES, V6, P157; COWIN SC, 1991, J BIOMECH ENG-T ASME, V113, P191, DOI 10.1115/1.2891234; Del Toro F, 2000, J CELL PHYSIOL, V182, P196, DOI 10.1002/(SICI)1097-4652(200002)182:2<196::AID-JCP8>3.0.CO;2-E; Donahue HJ, 1998, CALCIFIED TISSUE INT, V62, P85, DOI 10.1007/s002239900398; DOTY SB, 1981, CALCIFIED TISSUE INT, V33, P509, DOI 10.1007/BF02409482; ELFOULY MH, 1987, EXP CELL RES, V168, P422, DOI 10.1016/0014-4827(87)90014-0; FISCH A, 1995, EUR J PHARM-MOLEC PH, V289, P455, DOI 10.1016/0922-4106(95)90154-X; FLANAGAN AM, 1992, ENDOCRINOLOGY, V130, P443, DOI 10.1210/en.130.1.443; FROST HM, 1987, ANAT RECORD, V219, P1, DOI 10.1002/ar.1092190104; Frost HM, 1996, ANAT RECORD, V244, P139, DOI 10.1002/(SICI)1097-0185(199602)244:2<139::AID-AR1>3.0.CO;2-X; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; Grima J, 2000, BIOL REPROD, V63, P1648, DOI 10.1095/biolreprod63.6.1648; GRIMSTON SK, 1993, MED SCI SPORT EXER, V25, P1293; He DS, 1999, P NATL ACAD SCI USA, V96, P6495, DOI 10.1073/pnas.96.11.6495; JEE WSS, 1990, BONE, V11, P253, DOI 10.1016/8756-3282(90)90078-D; JEE WSS, 1985, CALCIFIED TISSUE INT, V37, P148, DOI 10.1007/BF02554834; JONES SJ, 1993, ANAT EMBRYOL, V187, P343; JULIANI MH, 1990, J BIOL CHEM, V265, P9077; Kaji H, 1996, J BONE MINER RES, V11, P62; Kato Y, 1997, J BONE MINER RES, V12, P2014, DOI 10.1359/jbmr.1997.12.12.2014; KATSUYAMA M, 1995, FEBS LETT, V372, P151, DOI 10.1016/0014-5793(95)00966-D; KEERY RJ, 1988, BRIT J PHARMACOL, V94, P745, DOI 10.1111/j.1476-5381.1988.tb11584.x; KELLER J, 1993, ACTA ORTHOP SCAND, V64, P59, DOI 10.3109/17453679308994530; Kiriyama M, 1997, BRIT J PHARMACOL, V122, P217, DOI 10.1038/sj.bjp.0701367; KLEINNULEND J, 1995, FASEB J, V9, P441, DOI 10.1096/fasebj.9.5.7896017; KleinNulend J, 1997, J BONE MINER RES, V12, P45, DOI 10.1359/jbmr.1997.12.1.45; Mason DJ, 1996, J BONE MINER RES, V11, P350; MEHTA PP, 1992, MOL BIOL CELL, V3, P839, DOI 10.1091/mbc.3.8.839; MERY PF, 1993, J BIOL CHEM, V268, P26286; Michael LF, 2000, MOL CELL BIOL, V20, P1596, DOI 10.1128/MCB.20.5.1596-1603.2000; NAGATA T, 1994, CALCIFIED TISSUE INT, V55, P451, DOI 10.1007/BF00298559; PALUMBO C, 1990, BONE, V11, P401, DOI 10.1016/8756-3282(90)90134-K; Paulson AF, 2000, J CELL SCI, V113, P3037; PICO C, 1994, BIOCHEM J, V302, P81, DOI 10.1042/bj3020081; PONTECORVI A, 1988, EMBO J, V7, P1489, DOI 10.1002/j.1460-2075.1988.tb02967.x; PRASAD ARS, 1993, CIRC RES, V72, P827, DOI 10.1161/01.RES.72.4.827; RAISZ LG, 1990, ENDOCRINOLOGY, V126, P1654, DOI 10.1210/endo-126-3-1654; RAISZ LG, 1993, ENDOCRINOLOGY, V133, P1504, DOI 10.1210/en.133.4.1504; RAKOVSKA A, 1984, ARCH INT PHARMACOD T, V268, P59; REGAN JW, 1994, MOL PHARMACOL, V46, P213; REICH KM, 1990, J CELL PHYSIOL, V143, P100, DOI 10.1002/jcp.1041430113; Romanello M, 2001, BIOCHEM BIOPH RES CO, V282, P1138, DOI 10.1006/bbrc.2001.4710; SAEZ JC, 1986, P NATL ACAD SCI USA, V83, P2473, DOI 10.1073/pnas.83.8.2473; SCHILLER PC, 1992, MOL ENDOCRINOL, V6, P1433, DOI 10.1210/me.6.9.1433; TenBroek EM, 2001, J CELL BIOL, V155, P1307, DOI 10.1083/jcb.200102017; TURNER CH, 1994, FASEB J, V8, P875, DOI 10.1096/fasebj.8.11.8070637; TURNER CH, 1995, BONE, V16, P283, DOI 10.1016/8756-3282(94)00052-2; WATABE A, 1993, J BIOL CHEM, V268, P20175; WEINBAUM S, 1994, J BIOMECH, V27, P339, DOI 10.1016/0021-9290(94)90010-8; WHITE TW, 1992, MOL BIOL CELL, V3, P711, DOI 10.1091/mbc.3.7.711; WOODWARD DF, 1995, BIOCHEM PHARMACOL, V50, P1731, DOI 10.1016/0006-2952(95)02035-7; Yellowley CE, 2000, J BONE MINER RES, V15, P209, DOI 10.1359/jbmr.2000.15.2.209	70	146	158	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43146	43156		10.1074/jbc.M302993200	http://dx.doi.org/10.1074/jbc.M302993200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12939279	hybrid			2022-12-25	WOS:000186157000055
J	Wang, N; Lan, D; Gerbod-Giannone, M; Linsel-Nitschke, P; Jehle, AW; Chen, WG; Martinez, LO; Tall, AR				Wang, N; Lan, D; Gerbod-Giannone, M; Linsel-Nitschke, P; Jehle, AW; Chen, WG; Martinez, LO; Tall, AR			ATP-binding cassette transporter A7 (ABCA7) binds apolipoprotein A-I and mediates cellular phospholipid but not cholesterol efflux	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TANGIER-DISEASE; MUTATIONS; RECEPTOR; IDENTIFICATION; MECHANISMS; SECRETION; PROMOTER; CELLS; LIVER	ATP-binding cassette transporter 1 (ABCA1), the defective transporter in Tangier disease, binds and promotes cellular cholesterol and phospholipid efflux to apolipoprotein I (apoA-I). Based on a high degree of sequence homology between ABCA1 and ABCA7, a transporter of unknown function, we investigated the possibility that ABCA7 might be involved in apolipoprotein binding and lipid efflux. Similarly to cells expressing ABCA1, HEK293 cells overexpressing ABCA7 showed specific binding and cross-linking of lipid-poor apoA-I. ABCA7 expression increased cellular phosphatidylcholine and sphingomyelin efflux to apoA-I in a manner similar to ABCA1 but had no effect on cholesterol efflux. Western analysis showed a high protein level of ABCA7 in mouse spleen, lung, adrenal, and brain but low expression in liver. In contrast to ABCA1, ABCA7 showed moderate basal mRNA and protein levels in macrophages and lymphocytes but no induction by liver X receptor activation. These studies show that ABCA7 has the ability to bind apolipoproteins and promote efflux of cellular phospholipids without cholesterol, and they suggest a possible role of ABCA7 in cellular phospholipid metabolism in peripheral tissues.	Columbia Univ, Dept Med, Div Mol Med, New York, NY 10032 USA	Columbia University	Tall, AR (corresponding author), Columbia Univ, Dept Med, Div Mol Med, New York, NY 10032 USA.	nw30@columbia.edu	Tall, Alan/AAT-8528-2021; Martinez, Laurent O./ABD-6880-2020; Martinez, Laurent O/B-8343-2015	Martinez, Laurent O./0000-0002-0985-3152; Martinez, Laurent O/0000-0002-0985-3152	NHLBI NIH HHS [HL22682, HL54591] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL022682, R01HL022682, P01HL054591] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Borst P, 2002, ANNU REV BIOCHEM, V71, P537, DOI 10.1146/annurev.biochem.71.102301.093055; Bortnick AE, 2000, J BIOL CHEM, V275, P28634, DOI 10.1074/jbc.M003407200; Broccardo C, 2001, CYTOGENET CELL GENET, V92, P264, DOI 10.1159/000056914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Bungert S, 2001, J BIOL CHEM, V276, P23539, DOI 10.1074/jbc.M101902200; Chen WG, 2000, J BIOL CHEM, V275, P30794, DOI 10.1074/jbc.M004552200; Clee SM, 2000, J CLIN INVEST, V106, P1263, DOI 10.1172/JCI10727; Costet P, 2000, J BIOL CHEM, V275, P28240; Fitzgerald ML, 2002, J BIOL CHEM, V277, P33178, DOI 10.1074/jbc.M204996200; Gerber SH, 2002, DIABETES, V51, pS3, DOI 10.2337/diabetes.51.2007.S3; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; Jahraus A, 1998, J BIOL CHEM, V273, P30379, DOI 10.1074/jbc.273.46.30379; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Kaminski WE, 2000, BIOCHEM BIOPH RES CO, V273, P532, DOI 10.1006/bbrc.2000.2954; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; PHILLIPS MC, 1987, BIOCHIM BIOPHYS ACTA, V906, P223, DOI 10.1016/0304-4157(87)90013-X; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Sasaki M, 2003, BIOCHEM BIOPH RES CO, V304, P777, DOI 10.1016/S0006-291X(03)00659-4; SCHAEFER EJ, 1980, ANN INTERN MED, V93, P261, DOI 10.7326/0003-4819-93-2-261; Small DM, 2003, P NATL ACAD SCI USA, V100, P4, DOI 10.1073/pnas.0237205100; Smith JD, 2002, J BIOL CHEM, V277, P17797, DOI 10.1074/jbc.M201594200; Tall AR, 2000, J CLIN INVEST, V106, P1205, DOI 10.1172/JCI11538; Vaughan AM, 2003, J LIPID RES, V44, P1373, DOI 10.1194/jlr.M300078-JLR200; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Wang N, 2003, ARTERIOSCL THROM VAS, V23, P1178, DOI 10.1161/01.ATV.0000075912.83860.26; Wang N, 2001, J BIOL CHEM, V276, P23742, DOI 10.1074/jbc.M102348200; Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9; Yancey PG, 2003, ARTERIOSCL THROM VAS, V23, P712, DOI 10.1161/01.ATV.0000057572.97137.DD	31	149	159	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					42906	42912		10.1074/jbc.M307831200	http://dx.doi.org/10.1074/jbc.M307831200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12917409	hybrid			2022-12-25	WOS:000186157000023
J	Araki, T; Nawa, H; Neel, BG				Araki, T; Nawa, H; Neel, BG			Tyrosyl phosphorylation of Shp2 is required for normal ERK activation in response to some, but not all, growth factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTOR-BETA; SRC FAMILY KINASES; PHOSPHOTYROSINE PHOSPHATASE SYP; PROTEIN-KINASE; PTP-ALPHA; SIGNAL-TRANSDUCTION; BINDING-SITE; IN-VIVO; CELL; CORKSCREW	The protein-tyrosine phosphatase Shp2 is required for normal activation of the ERK mitogen-activated protein kinase in multiple receptor tyrosine kinase signaling pathways. In fibroblasts, Shp2 undergoes phosphorylation at two C-terminal tyrosyl residues in response to some (fibroblast growth factor and platelet-derived growth factor (PDGF)) but not all (epidermal growth factor and insulin-like growth factor) growth factors. Whereas the catalytic activity of Shp2 is required for all Shp2 actions, the effect of tyrosyl phosphorylation on Shp2 function has been controversial. To clarify the role of Shp2 tyrosyl phosphorylation, we infected Shp2-mutant fibroblasts with retroviruses expressing wild type Shp2 or mutants of either (Y542F or Y580F) or both (Y542F, Y580F) C-terminal tyrosines. Compared with wild type cells, ERK activation was decreased in Y542F- or Y580F-infected cells in response to fibroblast growth factor and PDGF but not the epidermal growth factor. Mutation of both phosphorylation sites resulted in a further decrease in growth factor-evoked ERK activation, although not to the level of the vector control. Immunoblot analyses confirm that Tyr-542 and Tyr-580 are the major sites of Shp2 tyrosyl phosphorylation and that Tyr-542 is the major Grb2 binding site. However, studies with antibodies specific for individual Shp2 phosphorylation sites reveal unexpected complexity in the mechanism of Shp2 tyrosyl phosphorylation by different receptor tyrosine kinases. Moreover, because Y580F mutants retain nearly wild type Grb2-binding ability, yet exhibit defective PDGF-evoked ERK activation, our results show that the association of Grb2 with Shp2 is not sufficient for promoting full ERK activation in response to these growth factors, thereby arguing strongly against the "Grb2-adapter" model of Shp2 action.	Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med,Dept Med, Canc Biol Program,Div Hematol Oncol, Boston, MA 02215 USA; Niigata Univ, Brain Res Inst, Dept Mol Neurobiol, Niigata 9518585, Japan	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Niigata University	Araki, T (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med,Dept Med, Canc Biol Program,Div Hematol Oncol, Boston, MA 02215 USA.	taraki@bidmc.harvard.edu		Araki, Toshiyuki/0000-0002-1179-4534	NCI NIH HHS [R01 CA 49152] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA049152] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; Allard JD, 1998, J BIOL CHEM, V273, P13129, DOI 10.1074/jbc.273.21.13129; Araki T, 2000, J NEUROCHEM, V74, P659, DOI 10.1046/j.1471-4159.2000.740659.x; Barford D, 1998, STRUCTURE, V6, P249, DOI 10.1016/S0969-2126(98)00027-6; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; Duckworth BC, 1997, J BIOL CHEM, V272, P27665, DOI 10.1074/jbc.272.44.27665; Feng GS, 1999, EXP CELL RES, V253, P47, DOI 10.1006/excr.1999.4668; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; GERLACH MS, 1995, J BIOL CHEM, V270, P24635, DOI 10.1074/jbc.270.42.24635; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Hakak Y, 2000, ONCOGENE, V19, P3164, DOI 10.1038/sj.onc.1203655; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; Keegan K, 1996, ONCOGENE, V12, P1537; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; Lu W, 2001, MOL CELL, V8, P759, DOI 10.1016/S1097-2765(01)00369-0; Miller AT, 2002, CURR OPIN IMMUNOL, V14, P331, DOI 10.1016/S0952-7915(02)00345-X; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; O'Reilly AM, 1998, MOL CELL BIOL, V18, P161, DOI 10.1128/MCB.18.1.161; Oh ES, 1999, MOL CELL BIOL, V19, P3205; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Qu CK, 1998, MOL CELL BIOL, V18, P6075, DOI 10.1128/MCB.18.10.6075; Qu CK, 1997, MOL CELL BIOL, V17, P5499, DOI 10.1128/MCB.17.9.5499; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schwaller J, 1998, EMBO J, V17, P5321, DOI 10.1093/emboj/17.18.5321; Shi ZQ, 2000, MOL CELL BIOL, V20, P1526, DOI 10.1128/MCB.20.5.1526-1536.2000; Shi ZQ, 1998, J BIOL CHEM, V273, P4904, DOI 10.1074/jbc.273.9.4904; SU J, 1994, J BIOL CHEM, V269, P18731; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Van Vactor D, 1998, CURR OPIN GENET DEV, V8, P112, DOI 10.1016/S0959-437X(98)80070-1; Vogel W, 1996, CELL GROWTH DIFFER, V7, P1589; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Zhang SQ, 2002, MOL CELL BIOL, V22, P4062, DOI 10.1128/MCB.22.12.4062-4072.2002; Zheng XM, 2000, EMBO J, V19, P964, DOI 10.1093/emboj/19.5.964; Zheng XM, 2001, EMBO J, V20, P6037, DOI 10.1093/emboj/20.21.6037	53	166	170	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41677	41684		10.1074/jbc.M306461200	http://dx.doi.org/10.1074/jbc.M306461200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12923167	hybrid			2022-12-25	WOS:000185989500017
J	Ren, XH; Mody, I				Ren, XH; Mody, I			gamma-hydroxybutyrate reduces mitogen-activated protein kinase phosphorylation via GABA(B) receptor activation in mouse frontal cortex and hippocampus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE; IN-VIVO; DOPAMINE NEURONS; MAP KINASE; RAT-BRAIN; POSTSYNAPTIC POTENTIALS; AMINOBUTYRIC-ACID; COUPLED RECEPTORS; ABSENCE SEIZURES; BINDING-SITES	Hydroxybutyrate (GHB) naturally occurs in the brain, but its exogenous administration induces profound effects on the central nervous system in animals and humans. The intracellular signaling mechanisms underlying its actions remain unclear. In the present study, the effects of GHB on the activation (phosphorylation) of mitogen-activated protein kinases (MAP kinases), extracellular signal-regulated kinase 1 and 2 (ERK1/2), were investigated. Acute administration of GHB (500 mg/kg, intraperitoneal) induced a fast and long lasting inhibition of MAP kinase phosphorylation in both frontal cortex and hippocampus. The reduced MAP kinase phosphorylation was observed in the CA1 and CA3 areas but not in the dentate gyrus. Pretreatment with the specific gamma-aminobutyric acid, type B (GABA(B)), receptor antagonist CGP56999A (20 mg/kg, intraperitoneal) prevented the action of GHB, and the effect of GHB was mimicked by baclofen, a selective GABAB receptor agonist, whereas the high affinity GHB receptor antagonist NCS-382 (200 mg/kg, intraperitoneal) had no effect on GHB-inhibited MAP kinase phosphorylation. Moreover, the GHB dehydrogenase inhibitor valproate (500 mg/kg, intraperitoneal), which inhibits the conversion of GHB into GABA, failed to block the effect of GHB on MAP kinase phosphorylation. Altogether, these data suggest that GHB, administered in vivo, reduces MAP kinase phosphorylation via a direct activation of GABAB receptors by GHB. In contrast, GHB (10 mM for 15 min) was found ineffective on MAP kinase phosphorylation in brain slices, indicating important differences in the conditions required for the second messenger activating action of GHB.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Mody, I (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, RNRC 3-155,710 Westwood Plaza, Los Angeles, CA 90095 USA.				NIDA NIH HHS [DA 14947] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA014947] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Agell N, 2002, CELL SIGNAL, V14, P649, DOI 10.1016/S0898-6568(02)00007-4; BANERJEE PK, 1993, NEUROSCIENCE, V56, P11, DOI 10.1016/0306-4522(93)90557-V; Barbaccia ML, 2002, NEUROPHARMACOLOGY, V42, P782, DOI 10.1016/S0028-3908(02)00026-6; Bernasconi R, 1999, TRENDS PHARMACOL SCI, V20, P135, DOI 10.1016/S0165-6147(99)01341-3; Berton F, 1999, EUR J PHARMACOL, V380, P109, DOI 10.1016/S0014-2999(99)00515-4; Bowery NG, 2002, PHARMACOL REV, V54, P247, DOI 10.1124/pr.54.2.247; Brunzell DH, 2003, J NEUROCHEM, V84, P1431, DOI 10.1046/j.1471-4159.2003.01640.x; Carai MAM, 2001, EUR J PHARMACOL, V428, P315, DOI 10.1016/S0014-2999(01)01334-6; Cash CD, 1999, BIOCHEM PHARMACOL, V58, P1815, DOI 10.1016/S0006-2952(99)00265-8; Choe ES, 2002, NEUROPSYCHOPHARMACOL, V27, P565; Cook CD, 2002, PSYCHOPHARMACOLOGY, V160, P99, DOI 10.1007/s00213-001-0951-8; Cousins MS, 2002, DRUG ALCOHOL DEPEN, V65, P209, DOI 10.1016/S0376-8716(01)00163-6; Derkinderen P, 2003, J NEUROSCI, V23, P2371; ENGBERG G, 1993, N-S ARCH PHARMACOL, V348, P491; Erhardt S, 1998, N-S ARCH PHARMACOL, V357, P611, DOI 10.1007/PL00005215; Ferraro L, 2001, J NEUROCHEM, V78, P929, DOI 10.1046/j.1471-4159.2001.00530.x; GALLIMBERTI L, 1989, LANCET, V2, P787; Galloway GP, 1997, ADDICTION, V92, P89, DOI 10.1111/j.1360-0443.1997.tb03640.x; Gobaille S, 1999, J PHARMACOL EXP THER, V290, P303; Grewal SS, 1999, CURR OPIN NEUROBIOL, V9, P544, DOI 10.1016/S0959-4388(99)00010-0; Guan KL, 2000, J BIOL CHEM, V275, P27354; Hafen E, 1998, SCIENCE, V280, P1212, DOI 10.1126/science.280.5367.1212; Hechler V, 1997, J PHARMACOL EXP THER, V281, P753; Hu RQ, 2000, NEUROPHARMACOLOGY, V39, P427, DOI 10.1016/S0028-3908(99)00152-5; ITO Y, 1995, J NEUROCHEM, V65, P75; Jensen K, 2001, CEREB CORTEX, V11, P424, DOI 10.1093/cercor/11.5.424; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Joyal JL, 1997, J BIOL CHEM, V272, P28183, DOI 10.1074/jbc.272.45.28183; Kalluri HSG, 2002, EUR J PHARMACOL, V439, P53, DOI 10.1016/S0014-2999(01)01599-0; Kanterewicz BI, 1998, J NEUROCHEM, V70, P1009; KAUFMAN EE, 1990, BIOCHEM PHARMACOL, V40, P2637, DOI 10.1016/0006-2952(90)90581-5; Kleinschmidt S, 1999, EUR J ANAESTH, V16, P23, DOI 10.1046/j.1365-2346.1999.00393.x; Koob GF, 1998, NEURON, V21, P467, DOI 10.1016/S0896-6273(00)80557-7; Kyosseva SV, 2001, NEUROPSYCHOPHARMACOL, V24, P267, DOI 10.1016/S0893-133X(00)00180-9; Licata SC, 2003, J NEUROCHEM, V85, P14, DOI 10.1046/j.1471-4159.2003.01662.x; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Madden TE, 1998, J PHARMACOL EXP THER, V287, P261; Maitre M, 1997, PROG NEUROBIOL, V51, P337, DOI 10.1016/S0301-0082(96)00064-0; MAMELAK M, 1986, SLEEP, V9, P285, DOI 10.1093/sleep/9.1.285; Martin KC, 1997, NEURON, V18, P899, DOI 10.1016/S0896-6273(00)80330-X; Mathivet P, 1997, EUR J PHARMACOL, V321, P67, DOI 10.1016/S0014-2999(96)00916-8; McLean HA, 1996, J NEUROPHYSIOL, V76, P1036, DOI 10.1152/jn.1996.76.2.1036; Nava F, 2001, EUR J PHARMACOL, V430, P261, DOI 10.1016/S0014-2999(01)01163-3; Nestler EJ, 2002, NAT NEUROSCI, V5, P1076, DOI 10.1038/nn945; Nicholson KL, 2001, DRUG ALCOHOL DEPEN, V63, P1, DOI 10.1016/S0376-8716(00)00191-5; Nissbrandt H, 1996, J NEURAL TRANSM, V103, P1255, DOI 10.1007/BF01271186; Okun MS, 2001, J PHARM PHARM SCI, V4, P167; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Rosen MI, 1996, NEUROPSYCHOPHARMACOL, V14, P187, DOI 10.1016/0893-133X(95)00087-T; Schulz S, 1998, EUR J NEUROSCI, V10, P1196, DOI 10.1046/j.1460-9568.1998.00103.x; SHUMATE JS, 1979, RES COMMUN CHEM PATH, V25, P241; SNEAD OC, 1994, BRAIN RES, V659, P147, DOI 10.1016/0006-8993(94)90874-5; Snead OC, 2000, J NEUROCHEM, V75, P1986, DOI 10.1046/j.1471-4159.2000.0751986.x; SNEAD OC, 1978, NEUROLOGY, V28, P636, DOI 10.1212/WNL.28.7.636; SNEAD OC, 1976, NEUROLOGY, V26, P51, DOI 10.1212/WNL.26.1.51; SNEAD OC, 1980, NEUROPHARMACOLOGY, V19, P47, DOI 10.1016/0028-3908(80)90165-3; Sweatt JD, 2001, J NEUROCHEM, V76, P1, DOI 10.1046/j.1471-4159.2001.00054.x; Takaki M, 2001, J NEUROCHEM, V79, P679, DOI 10.1046/j.1471-4159.2001.00615.x; Timby N, 2000, AM J MED, V108, P518, DOI 10.1016/S0002-9343(99)00468-4; TREMBLAY E, 1995, J NEUROCHEM, V65, P863; Vanhoose AM, 2002, J BIOL CHEM, V277, P9049, DOI 10.1074/jbc.M108309200; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; XIE XM, 1992, EUR J PHARMACOL, V212, P291, DOI 10.1016/0014-2999(92)90347-7; XIE XM, 1992, EUR J PHARMACOL, V223, P193, DOI 10.1016/0014-2999(92)94839-N; Yuan PX, 2001, J BIOL CHEM, V276, P31674, DOI 10.1074/jbc.M104309200	65	31	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42006	42011		10.1074/jbc.M304238200	http://dx.doi.org/10.1074/jbc.M304238200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12923192	hybrid			2022-12-25	WOS:000185989500055
J	Ota, J; Yamashita, Y; Okawa, K; Kisanuki, H; Fujiwara, S; Ishikawa, M; Choi, YL; Ueno, S; Ohki, R; Koinuma, K; Wada, T; Compton, D; Kadoya, T; Mano, H				Ota, J; Yamashita, Y; Okawa, K; Kisanuki, H; Fujiwara, S; Ishikawa, M; Choi, YL; Ueno, S; Ohki, R; Koinuma, K; Wada, T; Compton, D; Kadoya, T; Mano, H			Proteomic analysis of hematopoietic stem cell-like fractions in leukemic disorders	ONCOGENE			English	Article						acute myeloid leukemia; proteome; AC133; NuMA	MYELOID DIFFERENTIATION PROGRAM; DNA MICROARRAY ANALYSIS; S-TRANSFERASE-PI; GENE-EXPRESSION; CANCER-CELLS; PROTEINS; NUMA; IDENTIFICATION; PARKINSONISM; ORGANIZATION	DNA microarray analysis has been applied to identify molecular markers of human hematological malignancies. However, the relatively low correlation between the abundance of a given mRNA and that of the encoded protein makes it important to characterize the protein profile directly, or 'proteome,' of malignant cells in addition to the 'transcriptome.' To identify proteins specifically expressed in leukemias, here we isolated AC133(+) hematopoietic stem cell-like fractions from the bone marrow of 13 individuals with various leukemic disorders, and compared their protein profiles by two-dimensional electrophoresis. A total of 11 differentially expressed protein spots corresponding to 10 independent proteins were detected, and peptide fingerprinting combined with mass spectrometry of these proteins revealed them to include NuMA (nuclear protein that associates with the mitotic apparatus), heat shock proteins, and redox regulators. The abundance of NuMA in the leukemic blasts was significantly related to the presence of complex karyotype anomalies. Conditional expression of NuMA in a mouse myeloid cell line resulted in the induction of aneuploidy, cell cycle arrest in G(2)-M phases, and apoptosis. These results demonstrate the potential of proteome analysis with background-matched cell fractions obtained from fresh clinical specimens to provide insight into the mechanism of human leukemogenesis.	Jichi Med Sch, Div Funct Genom, Tochigi 3290498, Japan; Kirin Brewery Co Ltd, Div Pharmaceut, Pharmaceut Res Labs, Takasaki, Gumma 3701925, Japan; Jichi Med Sch, Div Hematol, Tochigi 3290498, Japan; Jichi Med Sch, Div Cardiol, Tochigi 3290498, Japan; Jichi Med Sch, Dept Surg, Tochigi 3290498, Japan; Jichi Med Sch, Dept Gynecol, Tochigi 3290498, Japan; Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Biochem, Hanover, NH 03755 USA; Kirin Brewery Co Ltd, Div Pharmaceut, Prod Dept, R&D Ctr, Maebashi, Gumma 3710853, Japan	Jichi Medical University; Kirin Brewery Company Limited; Jichi Medical University; Jichi Medical University; Jichi Medical University; Jichi Medical University; Dartmouth College; Kirin Brewery Company Limited	Mano, H (corresponding author), Jichi Med Sch, Div Funct Genom, 3311-1 Yakushiji, Tochigi 3290498, Japan.	hmano@jichi.ac.jp		Compton, Duane/0000-0002-4445-9118				Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; COMPTON DA, 1993, J CELL BIOL, V120, P947, DOI 10.1083/jcb.120.4.947; Davis W, 2001, J PHARMACOL EXP THER, V296, P1; Du QS, 2001, NAT CELL BIOL, V3, P1069, DOI 10.1038/ncb1201-1069; Duggan DJ, 1999, NAT GENET, V21, P10, DOI 10.1038/4434; GAGLIO T, 1995, J CELL BIOL, V131, P693, DOI 10.1083/jcb.131.3.693; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; Jaattela M, 1999, ANN MED, V31, P261, DOI 10.3109/07853899908995889; Kaul SC, 1998, ONCOGENE, V17, P907, DOI 10.1038/sj.onc.1202017; KAUL SC, 1995, FEBS LETT, V361, P269, DOI 10.1016/0014-5793(95)00177-B; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lian Z, 2002, BLOOD, V100, P3209, DOI 10.1182/blood-2002-03-0850; Lian Z, 2001, BLOOD, V98, P513, DOI 10.1182/blood.V98.3.513; Makishima H, 2002, BRIT J HAEMATOL, V118, P462, DOI 10.1046/j.1365-2141.2002.03646.x; Matsumine H, 1997, AM J HUM GENET, V60, P588; Miyazato A, 2001, BLOOD, V98, P422, DOI 10.1182/blood.V98.2.422; Ohmine K, 2001, ONCOGENE, V20, P8249, DOI 10.1038/sj.onc.1205029; OKUYAMA T, 1994, CANCER, V74, P1230, DOI 10.1002/1097-0142(19940815)74:4<1230::AID-CNCR2820740409>3.0.CO;2-0; Pang XP, 1997, ONCOL RES, V9, P623; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; ShimodaMatsubayashi S, 1997, NEUROLOGY, V49, P1257, DOI 10.1212/WNL.49.5.1257; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; VOLM M, 1992, CANCER, V70, P764, DOI 10.1002/1097-0142(19920815)70:4<764::AID-CNCR2820700408>3.0.CO;2-M; Watarai H, 2000, ELECTROPHORESIS, V21, P460, DOI 10.1002/(SICI)1522-2683(20000101)21:2<460::AID-ELPS460>3.0.CO;2-P; Yamashita Y, 1996, JPN J CANCER RES, V87, P1106, DOI 10.1111/j.1349-7006.1996.tb03118.x	29	40	43	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2003	22	36					5720	5728		10.1038/sj.onc.1206855	http://dx.doi.org/10.1038/sj.onc.1206855			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944923				2022-12-25	WOS:000184865900024
J	Ohira, M; Morohashi, A; Inuzuka, H; Shishikura, T; Kawamoto, T; Kageyama, H; Nakamura, Y; Isogai, E; Takayasu, H; Sakiyama, S; Suzuki, Y; Sugano, S; Goto, T; Sato, S; Nakagawara, A				Ohira, M; Morohashi, A; Inuzuka, H; Shishikura, T; Kawamoto, T; Kageyama, H; Nakamura, Y; Isogai, E; Takayasu, H; Sakiyama, S; Suzuki, Y; Sugano, S; Goto, T; Sato, S; Nakagawara, A			Expression profiling and characterization of 4200 genes cloned from primary neuroblastomas: identification of 305 genes differentially expressed between favorable and unfavorable subsets	ONCOGENE			English	Article						neuroblastoma; expression profile; oligo-capping cDNA library; differentiation; regression; MYCN	N-MYC AMPLIFICATION; NEUROTROPHIC FACTOR; MOLECULAR-CLONING; NEURO-BLASTOMA; RNA; ASSOCIATION; PROTEINS; LOCUS; GAIN; ONCOGENE	Neuroblastoma (NBL), one of the most common childhood solid tumors, has a distinct nature in different prognostic subgroups: NBL in patients under I year of age usually regresses spontaneously, whereas that in patients over 1 year of age often grows aggressively and eventually kills the patient. To understand the molecular mechanism of biology and tumorigenesis of NBL, we decided to perform a comprehensive approach to unveil the gene expression profiles among the NBL subsets. We constructed the subset-specific oligo-capping cDNA libraries from the primary NBL tissues with favorable (F: stage 1, high expression of TrkA and a single copy of MYCN) and unfavorable (UF: stage 3 or 4, decreased expression of TrkA and MYCN amplification) characteristics and randomly cloned 4654 cDNAs. Among 4243 cDNAs sequenced successfully, 1799 (42.4%) were the genes with unknown function. Excluding the housekeeping genes, an expression profile of each subset was extremely different. To determine the genes expressed differentially between F and UF subsets, we performed semiquantitative reverse transcriptase (RT)-PCR for each of the 1842 independent genes using RNA obtained from 16 F and 16 UF NBLs as template. This revealed that 278 genes were highly expressed in the F subset as compared to the UF one, while, surprisingly, only 27 genes were expressed at higher levels in the UF rather than the F subset. These differentially expressed genes included 194 genes with unknown function. Many of the genes expressed at high levels in the F subset were related to catecholamine biosynthesis, small GTPases, synapse formation, synaptic vesicle transport, and transcription factors regulating differentiation of the neural crest-derived cells. On the other hand, the genes expressed at high levels in the UF subset included transcription factors and/or receptors that might regulate neuronal growth and differentiation. The chromosomal mapping of those genes showed some clusters. Thus, our mass-identification and characterization of the differentially expressed genes between the subsets may become a powerful tool for finding the important genes of NBL as well as developing new diagnostic and therapeutic strategies against aggressive NBL.	Chiba Canc Ctr Res Inst, Div Biochem, Chiba 2608717, Japan; Univ Tokyo, Dept Canc Virol, Inst Med Sci, Tokyo 1088639, Japan; Hisamitsu Co Inc, Chiyoda Ku, Tokyo 100622, Japan	Chiba Cancer Center; University of Tokyo	Nakagawara, A (corresponding author), Chiba Canc Ctr Res Inst, Div Biochem, 666-2 Nitona, Chiba 2608717, Japan.							Abe A, 1999, J CLIN MICROBIOL, V37, P2899, DOI 10.1128/JCM.37.9.2899-2903.1999; Amler LC, 1996, GENE CHROMOSOME CANC, V15, P134, DOI 10.1002/(SICI)1098-2264(199602)15:2<134::AID-GCC9>3.0.CO;2-4; ANDERSON DJ, 1985, CELL, V42, P649, DOI 10.1016/0092-8674(85)90122-9; BARTRAM CR, 1987, EUR J PEDIATR, V146, P162, DOI 10.1007/BF02343225; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Bown N, 1999, NEW ENGL J MED, V340, P1954, DOI 10.1056/NEJM199906243402504; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; BRODEUR GM, 1992, AM J PEDIAT HEMATOL, V14, P111; CARON H, 1995, HUM MOL GENET, V4, P535, DOI 10.1093/hmg/4.4.535; Hamajima N, 1996, GENE, V180, P157, DOI 10.1016/S0378-1119(96)00445-3; Hirai M, 1999, GENE CHROMOSOME CANC, V25, P261, DOI 10.1002/(SICI)1098-2264(199907)25:3<261::AID-GCC8>3.0.CO;2-#; HIRANO S, 1987, J CELL BIOL, V105, P2501, DOI 10.1083/jcb.105.6.2501; Hishiki T, 1998, CANCER RES, V58, P2158; Ichimiya S, 1999, ONCOGENE, V18, P1061, DOI 10.1038/sj.onc.1202390; Inoue K, 1999, J HEPATOL, V30, P801, DOI 10.1016/S0168-8278(99)80132-9; Kawamoto T, 2003, INT J ONCOL, V22, P815; LOOK AT, 1991, J CLIN ONCOL, V9, P581, DOI 10.1200/JCO.1991.9.4.581; MARUYAMA K, 1994, GENE, V138, P171; MATSUMOTO K, 1995, CANCER RES, V55, P1798; MCCLELLAND M, 1995, TRENDS GENET, V11, P242, DOI 10.1016/S0168-9525(00)89058-7; MCCONNELL JE, 1995, DEV BIOL, V169, P218, DOI 10.1006/dbio.1995.1139; Mitsuya K, 1999, HUM MOL GENET, V8, P1209, DOI 10.1093/hmg/8.7.1209; NAKAGAWARA A, 1987, J PEDIATR SURG, V22, P895, DOI 10.1016/S0022-3468(87)80583-3; NAKAGAWARA A, 1995, CANCER RES, V55, P1792; NAKAGAWARA A, 1992, CANCER RES, V52, P1364; NAKAGAWARA A, 1994, MOL CELL BIOL, V14, P759, DOI 10.1128/MCB.14.1.759; NAKAGAWARA A, 1988, J PEDIATR SURG, V23, P346, DOI 10.1016/S0022-3468(88)80204-5; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; NAKAGAWARA A, 1990, SURGERY, V107, P43; Nakagawara A, 1998, Hum Cell, V11, P115; Noguchi T, 1996, GENE CHROMOSOME CANC, V15, P129, DOI 10.1002/(SICI)1098-2264(199602)15:2<129::AID-GCC8>3.3.CO;2-M; OKUBO K, 1992, NAT GENET, V2, P173, DOI 10.1038/ng1192-173; Okutsu T, 2000, J BIOCHEM-TOKYO, V127, P475, DOI 10.1093/oxfordjournals.jbchem.a022630; Ono R, 2001, GENOMICS, V73, P232, DOI 10.1006/geno.2001.6494; Plantaz D, 1997, AM J PATHOL, V150, P81; SAWADA T, 1984, LANCET, V2, P271; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SLAVC I, 1990, CANCER RES, V50, P1459; STUDLER JM, 1993, EUR J NEUROSCI, V5, P614, DOI 10.1111/j.1460-9568.1993.tb00527.x; Suzuki Y, 1997, GENE, V200, P149, DOI 10.1016/S0378-1119(97)00411-3; Svensson EC, 1999, P NATL ACAD SCI USA, V96, P956, DOI 10.1073/pnas.96.3.956; Taguchi A, 1996, MOL BRAIN RES, V35, P31, DOI 10.1016/0169-328X(95)00178-U; Takita J, 1997, CANCER RES, V57, P907; Tevosian SG, 1999, P NATL ACAD SCI USA, V96, P950, DOI 10.1073/pnas.96.3.950; Velculescu VE, 2000, TRENDS GENET, V16, P423, DOI 10.1016/S0168-9525(00)02114-4	46	64	75	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 21	2003	22	35					5525	5536		10.1038/sj.onc.1206853	http://dx.doi.org/10.1038/sj.onc.1206853			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JC	12934113				2022-12-25	WOS:000184735000018
